Also O O
, O O
the O O
potential O O
for O O
hepatic O O
injury O O
should O O
be O O
considered O O
when O O
Rebif B-brand B-brand
is O O
used O O
in O O
combination O O
with O O
other O O
products O O
associated O O
with O O
hepatic O O
injury O O
, O O
or O O
when O O
new O O
agents O O
are O O
added O O
to O O
the O O
regimen O O
of O O
patients O O
already O O
on O O
Rebif B-brand B-brand
. O O

- O O
a O O
steroid B-group B-group
medicine I-group O
such O O
as O O
prednisone B-drug B-drug
( O O
Deltasone B-brand B-drug
, O O
Orasone B-brand B-brand
, O O
others O O
) O O
, O O
methylprednisolone B-drug B-drug
( O O
Medrol B-brand B-brand
, O O
others O O
) O O
, O O
prednisolone B-drug B-drug
( O O
Prelone B-brand B-brand
, O O
Pediapred B-brand B-brand
, O O
others O O
) O O
, O O
and O O
others O O
; O O

also O O
, O O
concurrent O O
use O O
of O O
this O O
medication O O
may O O
antagonise O O
the O O
anti-glaucoma O O
and O O
miotic O O
actions O O
of O O
ophthalmic O B-group
cholinesterase B-group I-group
inhibitors I-group I-group
. O O

If O O
any O O
signs O O
or O O
symptoms O O
occur O O
physicians O O
should O O
consider O O
discontinuation O O
of O O
either O O
one O O
or O O
both O O
agents O O
( O O
ZYVOX B-brand B-brand
or O O
concomitant O O
serotonergic B-group B-group
agents I-group I-group
) O O
. O O

This O O
time O O
window O O
is O O
different O O
than O O
for O O
other O O
oral O O
formulations O O
of O O
ciprofloxacin B-drug B-drug
, O O
which O O
are O O
usually O O
administered O O
2 O O
hours O O
before O O
or O O
6 O O
hours O O
after O O
antacids B-group B-group
. O O

Lithium B-drug B-drug
: O O
NSAIDs B-group B-group
have O O
produced O O
an O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
levels O O
and O O
a O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
. O O

No O O
pharmacokinetic O O
data O O
are O O
available O O
. O O

pregnancies O O
have O O
been O O
reported O O
. O O

On O O
the O O
basis O O
of O O
the O O
estimated O O
number O O
of O O
regular O O
users O O
of O O
intravenous O O
amphetamine B-drug B-drug
in O O
Ontario O O
, O O
the O O
mortality O O
rate O O
in O O
such O O
users O O
is O O
at O O
least O O
four O O
times O O
as O O
high O O
as O O
in O O
the O O
general O O
population O O
of O O
the O O
same O O
age O O
, O O
and O O
is O O
comparable O O
to O O
that O O
in O O
alcoholics O B-group
and O O
heroin B-drug_n B-drug
addicts O O
. O O

The O O
effects O O
of O O
L-CCG-1 B-drug_n B-drug_n
were O O
not O O
so O O
strong O O
. O O

A O O
400 O O
mg O O
once-daily O O
dose O O
was O O
not O O
studied O O
but O O
would O O
be O O
expected O O
to O O
increase O O
aliskiren B-drug B-drug
blood O O
levels O O
further O O
. O O

SSRIs B-group B-group
: O O
Weakness O O
hyperreflexia O O
, O O
and O O
incoordination O O
have O O
been O O
reported O O
rarely O O
when O O
5-HT1 B-group B-group
agonists I-group I-group
have O O
been O O
co-administered O O
with O O
SSRIs B-group B-group
( O O
e. O O
g O O
. O O

Because O O
moderate O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
diltiazem B-drug B-drug
) O O
result O O
in O O
2-fold O O
increase O O
in O O
plasma O O
concentrations O O
of O O
aprepitant B-drug B-drug
, O O
concomitant O O
administration O O
should O O
also O O
be O O
approached O O
with O O
caution O O
. O O

Exemestane B-drug B-drug
is O O
extensively O O
metabolized O O
by O O
CYP O O
3A4 O O
, O O
but O O
coadministration O O
of O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
CYP O O
3A4 O O
, O O
has O O
no O O
significant O O
effect O O
on O O
exemestane B-drug B-drug
pharmacokinetics O O
. O O

Phenytoin B-drug B-drug
: O O
Altered O O
serum O O
levels O O
of O O
phenytoin B-drug B-drug
( O O
increased O O
and O O
decreased O O
) O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
concomitant O O
ciprofloxacin B-drug B-drug
. O O

Since O O
iloprost B-drug B-drug
inhibits O O
platelet O O
function O O
, O O
there O O
is O O
a O O
potential O O
for O O
increased O O
risk O O
of O O
bleeding O O
, O O
particularly O O
in O O
patients O O
maintained O O
on O O
anticoagulants B-group B-group
. O O

Therefore O O
, O O
caution O O
is O O
advised O O
if O O
the O O
concomitant O O
administration O O
of O O
loxapine B-drug B-drug
and O O
CNS-active O O
drugs O O
is O O
required O O
. O O

Consequently O O
, O O
drugs O O
with O O
a O O
low O O
therapeutic O O
margin O O
, O O
such O O
as O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
, O O
phenytoin B-drug B-drug
, O O
and O O
theophylline B-drug B-drug
, O O
could O O
have O O
a O O
delayed O O
elimination O O
and O O
increases O O
in O O
their O O
serum O O
half-life O O
leading O O
to O O
a O O
toxic O O
level O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
using O O
these O O
drugs O O
together O O

Phenytoin B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenytoin B-drug B-drug
; O O

Anticoagulants B-group B-group
: O O
Flurbiprofen B-drug B-drug
like O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
has O O
been O O
shown O O
to O O
affect O O
bleeding O O
parameters O O
in O O
patients O O
receiving O O
anti-coagulants B-group B-group
, O O
and O O
serious O O
clinical O O
bleeding O O
has O O
been O O
reported O O
. O O

propranolol B-drug B-drug
to O O
healthy O O
volunteers O O
under O O
steady-state O O
conditions O O
had O O
no O O
relevant O O
effect O O
on O O
either O O
drug O O
s O O
bioavailability O O
, O O
AUC O O
and O O
Cmax O O
, O O
differences O O
were O O
20 O O
% O O
between O O
isradipine B-drug B-drug
given O O
singly O O
and O O
in O O
combination O O
with O O
propranolol B-drug B-drug
, O O
and O O
between O O
propranolol B-drug B-drug
given O O
singly O O
and O O
in O O
combination O O
with O O
isradipine B-drug B-drug
. O O

ocular O O
effects O O
; O O

The O O
concomitant O O
administration O O
of O O
bosentan B-drug B-drug
and O O
cyclosporine B-drug B-drug
A I-drug O
is O O
contraindicated O O
. O O

This O O
oxidation O O
, O O
which O O
is O O
catalyzed O O
by O O
xanthine O O
oxidase O O
, O O
inactivates O O
mercaptopurine B-drug B-drug
. O O

Ethinyl B-drug B-drug
estradiol I-drug I-drug
: O O
Substrate O O
of O O
CYP3A4 O O
( O O
major O O
) O O
, O O
3A5-7 O O
( O O
minor O O
) O O
; O O

4 O O
. O O

The O O
mean O O
clearances O O
of O O
dofetilide B-drug B-drug
were O O
16 O O
% O O
and O O
15 O O
% O O
lower O O
in O O
patients O O
on O O
thiazide B-group B-group
diuretics I-group I-group
and O O
inhibitors O O
of O O
tubular O O
organic O O
cation O O
transport O O
, O O
respectively O O
. O O

In O O
addition O O
, O O
levetiracetam B-drug B-drug
does O O
not O O
affect O O
the O O
in O O
vitro O O
glucuronidation O O
of O O
valproic B-drug B-drug
acid I-drug I-drug
. O O

Specifically O O
, O O
they O O
have O O
focused O O
on O O
aspects O O
of O O
learning O O
and O O
memory O O
that O O
are O O
impaired O O
( O O
vs. O O
spared O O
) O O
by O O
lesions O O
of O O
the O O
hippocampal O O
formation O O
. O O

The O O
concentrations O O
of O O
SN38 B-drug_n B-drug_n
, O O
the O O
active O O
metabolite O O
of O O
irinotecan B-drug B-drug
, O O
were O O
on O O
average O O
33 O O
% O O
higher O O
in O O
patients O O
receiving O O
bolus-IFL O O
in O O
combination O O
with O O
AVASTIN B-brand B-brand
when O O
compared O O
with O O
bolus-IFL O O
alone O O
. O O

All O O
vasopressors B-group B-group
should O O
be O O
used O O
cautiously O O
in O O
patients O O
taking O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
. O O

If O O
an O O
alternative O O
treatment O O
is O O
unavailable O O
, O O
a O O
TARCEVA B-brand B-brand
dose O O
greater O O
than O O
150 O O
mg O O
should O O
be O O
considered O O
for O O
NSCLC O O
patients O O
, O O
and O O
greater O O
than O O
100 O O
mg O O
considered O O
for O O
pancreatic O O
cancer O O
patients O O
. O O

Vitamin B-group B-group
D I-group I-group
: O O
The O O
coadministration O O
of O O
any O O
of O O
the O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
should O O
be O O
avoided O O
as O O
this O O
could O O
create O O
possible O O
additive O O
effects O O
and O O
hypercalcemia O O
. O O

Check O O
serum O O
potassium O O
levels O O
at O O
frequent O O
intervals O O
; O O

Twenty-four O O
healthy O O
male O O
subjects O O
were O O
randomized O O
to O O
one O O
of O O
two O O
cohorts O O
. O O

Androgens B-group B-group
may O O
increase O O
sensitivity O O
to O O
oral O O
anticoagulahts O O
. O O

The O O
serum O O
concentration O O
of O O
phenytoin B-drug B-drug
increased O O
dramatically O O
from O O
16.6 O O
to O O
49.1 O O
microg/mL O O
when O O
fluvoxamine B-drug B-drug
was O O
coadministered O O
, O O
although O O
the O O
daily O O
dosage O O
of O O
phenytoin B-drug B-drug
and O O
other O O
drugs B-drug O
had O O
not O O
changed O O
. O O

Acetazolamide B-drug B-drug
may O O
increase O O
the O O
effects O O
of O O
other O O
folic B-group B-group
acid I-group I-group
antagonists I-group I-group
. O O

If O O
replacing O O
clonidine B-drug B-drug
by O O
beta-blocker B-group B-group
therapy O O
, O O
the O O
introduction O O
of O O
beta B-group B-group
blockers I-group I-group
should O O
be O O
delayed O O
for O O
several O O
days O O
after O O
clonidine B-drug B-drug
administration O O
has O O
stopped O O
. O O

Grapefruit O O
juice O O
Co-administration O O
of O O
felodipine B-drug B-drug
with O O
grapefruit O O
juice O O
resulted O O
in O O
more O O
than O O
2-fold O O
increase O O
in O O
the O O
AUC O O
and O O
Cmax O O
, O O
but O O
no O O
prolongation O O
in O O
the O O
half- O O
life O O
of O O
felodipine B-drug B-drug
. O O

Renal O O
clearance O O
measurements O O
of O O
PAH B-drug B-drug
can O O
not O O
be O O
made O O
with O O
any O O
significant O O
accuracy O O
in O O
patients O O
receiving O O
sulfonamides B-group B-group
, O O
procaine B-drug B-drug
, O O
or O O
thiazolesulfone B-drug B-drug
. O O

Co-administration O O
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
CYP O O
3A4 O O
( O O
e.g. O O
, O O
indinavir B-drug B-drug
, O O
erythromycin B-drug B-drug
) O O
may O O
increase O O
their O O
clearance O O
, O O
resulting O O
in O O
decreased O O
plasma O O
concentration O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
As O O
a O O
result O O
of O O
administration O O
of O O
Keflex B-brand B-brand
, O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
. O O

Marked O O
symptomatic O O
orthostatic O O
hypotension O O
has O O
been O O
reported O O
when O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
and O O
organic O B-group
nitrates B-group I-group
were O O
used O O
in O O
combination O O
. O O

There O O
were O O
no O O
clinically O O
relevant O O
alterations O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

MAO B-group B-group
inhibitors I-group I-group
: O O
MAOI B-group B-group
antidepressants I-group I-group
, O O
as O O
well O O
as O O
a O O
metabolite O O
of O O
furazolidone B-drug B-drug
, O O
slow O O
amphetamine B-group B-drug
metabolism O O
. O O

A O O
host O O
of O O
other O O
medical O O
considerations O O
are O O
discussed O O
in O O
chapter O O
8 O O
, O O
including O O
persistent O O
ovarian O O
follicles O O
; O O

Aprepitant B-drug B-drug
increased O O
the O O
AUC O O
of O O
midazolam B-drug B-drug
by O O
25 O O
% O O
on O O
Day O O
4 O O
and O O
decreased O O
the O O
AUC O O
of O O
midazolam B-drug B-drug
by O O
19 O O
% O O
on O O
Day O O
8 O O
relative O O
to O O
the O O
dosing O O
of O O
Aprepitant B-drug B-drug
on O O
Days O O
1 O O
through O O
3 O O
. O O

1 O O
. O O

Drug O O
Interactions O O
: O O
a O O
. O O
Drugs O O
Enhancing O O
Heparin B-drug B-drug
Effect O O
: O O
Oral O O
anticoagulants B-group B-group
: O O
Heparin B-drug B-drug
sodium I-drug I-drug
may O O
prolong O O
the O O
one-stage O O
prothrombin O O
time O O
. O O

Seventeen O O
percent O O
of O O
CHOP-HAART O O
patients O O
developed O O
severe O O
autonomic O O
neurotoxicity O O
, O O
whereas O O
none O O
of O O
the O O
CHOP O O
patients O O
developed O O
neurotoxicity O O
( O O
P O O
= O O
0.002 O O
) O O
. O O

metabolic O O
interference O O
has O O
sometimes O O
been O O
observed O O
and O O
the O O
behaviour O O
of O O
the O O
biological O O
indicators O O
differs O O
from O O
what O O
would O O
be O O
expected O O
. O O

The O O
different O O
responses O O
in O O
locomotor O O
activity O O
induced O O
by O O
cocaine B-drug B-drug
suggest O O
that O O
genetic O O
factors O O
may O O
play O O
a O O
role O O
in O O
determining O O
the O O
magnitude O O
of O O
response O O
to O O
this O O
drug O O
. O O

Acetylcysteine B-drug B-drug
interference O O
with O O
urine O O
ketone O O
test O O
. O O

Patients O O
with O O
renal O O
insufficiency O O
or O O
renal O O
failure O O
may O O
be O O
at O O
risk O O
for O O
further O O
kidney O O
damage O O
as O O
well O O
as O O
complications O O
related O O
to O O
interactions O O
of O O
herbal O O
remedies O O
with O O
complex O O
renal O O
therapy O O
regimens O O
. O O

nitrosourea B-group B-group
AUC O O
, O O
with O O
the O O
extent O O
of O O
the O O
reduction O O
depending O O
on O O
the O O
minimum O O
effective O O
concentration O O
( O O
MEC O O
) O O
chosen O O
. O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
interferes O O
with O O
renal O O
tubular O O
secretion O O
of O O
ciprofloxacin B-drug B-drug
and O O
produces O O
an O O
increase O O
in O O
the O O
level O O
of O O
ciprofloxacin B-drug B-drug
in O O
serum O O
. O O

Cholinesterase B-group B-group
Inhibitors I-group I-group
: O O
Dipyridamole B-drug B-drug
may O O
counteract O O
the O O
anticholinesterase O O
effect O O
of O O
cholinesterase B-group B-group
inhibitors I-group I-group
, O O
thereby O O
potentially O O
aggravating O O
myasthenia O O
gravis O O
. O O

At O O
steady O O
state O O
, O O
VIOXX B-brand B-brand
50 O O
mg O O
once O O
daily O O
had O O
no O O
effect O O
on O O
the O O
anti-platelet O O
activity O O
of O O
low-dose O O
( O O
81 O O
mg O O
once O O
daily O O
) O O
aspirin B-brand B-brand
, O O
as O O
assessed O O
by O O
ex O O
vivo O O
platelet O O
aggregation O O
and O O
serum O O
TXB2 O O
generation O O
in O O
clotting O O
blood O O
. O O

Cardiovascular O O
: O O
Hypotension O O
( O O
0-9 O O
% O O
) O O
. O O

antihistamines B-group B-group
; O O

No O O
significant O O
drug-drug O O
pharmacokinetic O O
( O O
or O O
pharmacodynamic O O
) O O
interactions O O
have O O
been O O
found O O
in O O
interaction O O
studies O O
with O O
hydrochlorothiazide B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
and O O
nifedipine B-drug B-drug
. O O

WelChol B-brand B-brand
decreased O O
the O O
Cmax O O
and O O
AUC O O
of O O
sustained-release O O
verapamil B-drug B-drug
( O O
Calan B-brand B-brand
SR I-brand O
) O O
by O O
approximately O O
31 O O
% O O
and O O
11 O O
% O O
, O O
respectively O O
. O O

Pharmacokinetic O O
profile O O
of O O
etodolac B-drug B-drug
in O O
special O O
populations O O
. O O

- O O
Lithium B-drug B-drug
: O O
Lithium B-drug B-drug
should O O
generally O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
( O O
such O O
as O O
bumetanide B-drug B-drug
) O O
because O O
they O O
reduce O O
its O O
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Alternatives O O
to O O
clarithromycin B-drug B-drug
, O O
such O O
as O O
azithromycin B-drug B-drug
, O O
should O O
be O O
considered O O
. O O

Administration O O
of O O
eplerenone B-drug B-drug
with O O
other O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
erythromycin B-drug B-drug
500 O O
mg O O
BID O O
, O O
verapamil B-drug B-drug
240 O O
mg O O
QD O O
, O O
saquinavir B-drug B-drug
1200 O O
mg O O
TID O O
, O O
fluconazole B-drug B-drug
200 O O
mg O O
QD O O
) O O
resulted O O
in O O
increases O O
in O O
Cmax O O
of O O
eplerenone B-drug B-drug
ranging O O
from O O
1.4- O O
to O O
1.6- O O
fold O O
and O O
AUC O O
from O O
2.0- O O
to O O
2.9- O O
fold O O
. O O

These O O
alterations O O
in O O
digoxin B-drug B-drug
pharmacokinetics O O
produced O O
by O O
amiodarone B-drug B-drug
explain O O
the O O
increase O O
in O O
serum O O
digoxin B-drug B-drug
level O O
that O O
has O O
been O O
observed O O
when O O
this O O
drug O O
combination O O
has O O
been O O
used O O
clinically O O
. O O

co-administration O O
of O O
phenobarbital B-drug B-drug
may O O
produce O O
a O O
synergistic O O
anticonvulsant O O
action O O
. O O

Carbamazepine B-drug B-drug
: O O
Steady-state O O
trough O O
plasma O O
carbamazepine B-drug B-drug
and O O
carbamazepine B-drug_n B-drug
10 I-drug_n O
, I-drug_n O
11 I-drug_n O
epoxide I-drug_n O
concentrations O O
were O O
not O O
affected O O
by O O
concomitant O O
gabapentin B-drug B-drug
( O O
400 O O
mg O O
TID O O
; O O

Restoration O O
of O O
female O O
fertility O O
to O O
values O O
similar O O
to O O
controls O O
was O O
evident O O
following O O
a O O
29-day O O
withdrawal O O
period O O
after O O
dosing O O
at O O
2 O O
mg/kg/day O O
( O O
twice O O
the O O
human O O
dose O O
based O O
on O O
BSA O O
) O O
. O O

Cardiac B-group B-group
glycosides I-group I-group
could O O
exaggerate O O
the O O
depression O O
of O O
AV O O
nodal O O
conduction O O
observed O O
with O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
. O O

The O O
harmonic O O
mean O O
elimination O O
half-life O O
was O O
45.7 O O
and O O
43.4 O O
hours O O
for O O
rofecoxib B-drug B-drug
+ O O
digoxin B-drug B-drug
and O O
placebo O O
+ O O
digoxin B-drug B-drug
treatments O O
, O O
respectively O O
. O O

Most O O
who O O
take O O
EPA B-drug B-drug
supplements O O
and O O
the O O
above O O
drugs O O
or O O
herbs O O
do O O
not O O
suffer O O
from O O
these O O
problems O O
and O O
if O O
they O O
occur O O
, O O
they O O
are O O
rare O O
. O O

Rifampin B-drug B-drug
: O O
Coadministration O O
of O O
rifampin B-drug B-drug
and O O
VIRACEPT B-brand B-brand
resulted O O
in O O
an O O
82 O O
% O O
decrease O O
in O O
nelfinavir B-drug B-drug
plasma O O
A.C O O
. O O

Animal O O
studies O O
also O O
suggest O O
an O O
increased O O
potential O O
for O O
seizures O O
when O O
these O O
two O O
drugs O O
are O O
given O O
concomitantly O O
. O O

and O O
overdose O O
. O O

Tadalafil B-drug B-drug
dose O O
should O O
not O O
exceed O O
a O O
maximum O O
of O O
10 O O
mg O O
in O O
a O O
72- O O
hour O O
period O O
in O O
patients O O
receiving O O
concomitant O O
indinavir B-drug B-drug
therapy O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
be O O
used O O
. O O

The O O
uptake O O
inhibitors O O
cocaine B-drug B-drug
and O O
desipramine B-drug B-drug
( O O
3 O O
mumol/liter O O
) O O
potentiated O O
the O O
positive O O
inotropic O O
effects O O
of O O
norepinephrine B-drug B-drug
in O O
nonfailing O O
myocardium O O
( O O
p O O
< O O
0.05 O O
) O O
but O O
not O O
in O O
functional O O
class O O
IV O O
myocardium O O
. O O

In O O
clinical O O
studies O O
performed O O
with O O
Fondaparinux B-drug B-drug
, O O
the O O
concomitant O O
use O O
of O O
oral O O
anticoagulants B-group B-group
( O O
warfarin B-drug B-drug
) O O
, O O
platelet B-group B-group
inhibitors I-group I-group
( O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
) O O
, O O
NSAIDs B-group B-group
( O O
piroxicam B-drug B-drug
) O O
, O O
and O O
digoxin B-drug B-drug
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics/pharmacodynamics O O
of O O
fondaparinux B-drug B-drug
sodium I-drug I-drug
. O O

The O O
half-life O O
of O O
ketamine B-drug B-drug
in O O
plasma O O
and O O
brain O O
was O O
longer O O
in O O
the O O
presence O O
of O O
halothane B-drug B-drug
than O O
when O O
ketamine B-drug B-drug
was O O
given O O
alone O O
. O O

Tacrolimus B-drug O
: O O
Co-administration O O
of O O
tacrolimus B-drug B-drug
and O O
bosentan B-drug B-drug
has O O
not O O
been O O
studied O O
in O O
man O O
. O O

Animal O O
studies O O
indicate O O
that O O
dobutamine B-drug B-drug
may O O
be O O
ineffective O O
if O O
the O O
patient O O
has O O
recently O O
received O O
a O O
b-blocking B-group B-group
drug I-group I-group
. O O

Avoid O O
dong O O
quai O O
and O O
black O O
cohosh O O
( O O
have O O
estrogen O O
activity O O
) O O
. O O

Administration O O
of O O
reserpine B-drug B-drug
during O O
therapy O O
with O O
a O O
tricyclic B-group B-group
antidepressant I-group I-group
has O O
been O O
shown O O
to O O
produce O O
a O O
stimulating O O
effect O O
in O O
some O O
depressed O O
patients O O
. O O

Nonetheless O O
, O O
they O O
have O O
been O O
observed O O
with O O
macrolide B-group B-group
products I-group I-group
. O O

Drugs O O
That O O
Should O O
Not O O
Be O O
Coadministered O O
with O O
CRIXIVAN B-brand B-brand

Nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
other O O
cephalosporins B-group B-group
with O I-group
potent O I-group
diuretics B-group I-group
such O O
as O O
furosemide B-drug B-drug
. O O

Drug/Laboratory O O
Interactions O O
No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
Campath B-brand B-brand
. O O

Drug O O
interaction O O
studies O O
were O O
performed O O
with O O
azithromycin B-drug B-drug
and O O
other O O
drugs O O
likely O O
to O O
be O O
co-administered O O
. O O

No O O
dosage O O
adjustment O O
of O O
either O O
drug O O
is O O
recommended O O
when O O
azithromycin B-drug B-drug
is O O
co O O
administered O O
with O O
any O O
of O O
the O O
above O O
agents O O
. O O

Naproxen B-drug B-drug
, O O
naproxen B-drug B-drug
sodium I-drug I-drug
and O O
other O O
NSAIDs B-group B-group
have O O
been O O
reported O O
to O O
reduce O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-drug B-drug
in O O
an O O
animal O O
model O O
, O O
possibly O O
increasing O O
the O O
toxicity O O
of O O
methotrexate B-drug B-drug
. O O

Adrenergic B-group B-group
blockers I-group I-group
: O O
Adrenergic B-group B-group
blockers I-group I-group
are O O
inhibited O O
by O O
amphetamines B-group B-group
. O O

+109 O O
% O O

Warfarin B-drug B-drug
: O O
A O O
single O O
125-mg O O
dose O O
of O O
Aprepitant B-drug B-drug
was O O
administered O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
and O O
3 O O
to O O
healthy O O
subjects O O
who O O
were O O
stabilized O O
on O O
chronic O O
warfarin B-drug B-drug
therapy O O
. O O

RESULTS O O
: O O
Bombesin B-drug_n B-brand
significantly O O
increased O O
the O O
incidence O O
of O O
intestinal O O
tumors O O
and O O
cancer O O
metastasis O O
to O O
the O O
peritoneum O O
. O O

The O O
gastrointestinal O O
absorption O O
of O O
digoxin B-drug B-drug
also O O
appears O O
to O O
be O O
inhibited O O
. O O

. O O

The O O
physician O O
should O O
be O O
cautious O O
when O O
administering O O
flurbiprofen B-drug B-drug
to O O
patients O O
taking O O
anticoagulants B-group B-group
. O O

Interactions O O
may O O
occur O O
with O O
the O O
following O O
: O O
adrenocorticoids O B-group
( O O
cortisone-like O B-group
medicine O O
) O O
, O O
anticoagulants B-group B-group
( O O
blood B-group B-group
thinners O I-group
) O O
, O O
carbamazepine B-drug B-drug
, O O
corticotropin B-drug B-drug
( O O
barbiturates B-group B-group
may O O
decrease O O
the O O
effects O O
of O O
these O O
medicines O O
) O O
, O O
central B-group B-group
nervous I-group I-group
system I-group I-group
( I-group I-group
CNS I-group I-group
) I-group I-group
depressants I-group I-group
( O O
using O O
these O O
medicines O O
with O O
barbiturates B-group B-group
may O O
result O O
in O O
increased O O
CNS O O
depressant O O
effects O O
) O O
, O O
divalproex B-drug B-drug
sodium I-drug I-drug
, O O
valproic B-drug B-drug
acid I-drug I-drug
( O O
using O O
these O O
medicines O O
with O O
barbiturates B-group B-group
may O O
change O O
the O O
amount O O
of O O
either O O
medicine O O
that O O
you O O
need O O
to O O
take O O
) O O
, O O
and O O
oral O O
contraceptives B-group B-group
containing O O
estrogens B-group B-group
( O O
barbiturates B-group B-group
may O O
decrease O O
the O O
effectiveness O O
of O O
these O O
oral O O
contraceptives B-group B-group
, O O
and O O
you O O
may O O
need O O
to O O
change O O
to O O
a O O
different O O
type O O
of O O
birth O O
control O O
) O O
. O O

Other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
( O O
e.g O O
. O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
opioids B-group B-group
and O O
general O O
anesthetics B-group B-group
) O O
have O O
additive O O
or O O
potentiating O O
effects O O
with O O
INAPSINE B-brand B-brand
. O O

Because O O
of O O
the O O
small O O
effect O O
on O O
half-life O O
, O O
the O O
coadministration O O
with O O
probenecid B-drug B-drug
to O O
extend O O
the O O
half-life O O
of O O
ertapenem B-drug B-drug
is O O
not O O
recommended O O
. O O

[ O O
The O O
effect O O
of O O
sandimmune B-brand B-drug_n
on O O
the O O
activity O O
of O O
mixed-function O O
mono-oxidases O O
in O O
the O O
liver O O
microsomes O O
] O O
The O O
effects O O
of O O
the O O
immunodepressant B-group O
-- O O
the O O
drug O O
sandimmune B-brand B-drug
-- O O
on O O
hepatic O O
microsomal O O
monooxygenase O O
activities O O
were O O
studied O O
. O O

In O O
large O O
, O O
well O O
controlled O O
trials O O
in O O
patients O O
with O O
schizophrenia O O
or O O
related O O
psychoses O O
, O O
olanzapine B-drug B-drug
5 O O
to O O
20 O O
mg/day O O
was O O
significantly O O
superior O O
to O O
haloperidol B-drug B-drug
5 O O
to O O
20 O O
mg/day O O
in O O
overall O O
improvements O O
in O O
psychopathology O O
rating O O
scales O O
and O O
in O O
the O O
treatment O O
of O O
depressive O O
and O O
negative O O
symptoms O O
, O O
and O O
was O O
comparable O O
in O O
effects O O
on O O
positive O O
psychotic O O
symptoms O O
. O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
the O O
metabolism O O
of O O
docetaxel B-drug B-drug
may O O
be O O
modified O O
by O O
the O O
concomitant O O
administration O O
of O O
compounds O O
that O O
induce O O
, O O
inhibit O O
, O O
or O O
are O O
metabolized O O
by O O
cytochrome O O
P450 O O
3A4 O O
, O O
such O O
as O O
cyclosporine B-drug B-drug
, O O
terfenadine B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
and O O
troleandomycin B-drug B-drug
. O O

Maximal O O
exercise O O
testing O O
, O O
a O O
maneuver O O
often O O
applied O O
to O O
cardiac O O
patients O O
, O O
does O O
not O O
significantly O O
alter O O
the O O
serum O O
digoxin B-drug B-drug
level O O
. O O

Potential O O
interactions O O
between O O
TAXOL B-brand B-brand
, O O
a O O
substrate O O
of O O
CYP3A4 O O
, O O
and O O
protease B-group B-group
inhibitors I-group I-group
( O O
ritonavir B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
and O O
nelfinavir B-drug B-drug
) O O
, O O
which O O
are O O
substrates O O
and/or O O
inhibitors O O
of O O
CYP3A4 O O
, O O
have O O
not O O
been O O
evaluated O O
in O O
clinical O O
trials O O
. O O

( O O
41 O O
) O O
but O O
returned O O
to O O
normal O O
levels O O
when O O
the O O
nerves O O
were O O
rewarmed O O
. O O

Animal O O
experience O O
indicates O O
that O O
clorazepate B-drug B-drug
dipotassium I-drug I-drug
prolongs O O
the O O
sleeping O O
time O O
after O O
hexobarbital B-drug B-drug
or O O
after O O
ethyl B-drug B-drug
alcohol I-drug I-drug
, O O
increases O O
the O O
inhibitory O O
effects O O
of O O
chlorpromazine B-drug B-drug
, O O
but O O
does O O
not O O
exhibit O O
monoamine O O
oxidase O O
inhibition O O
. O O

and O O
calcium B-group B-group
channel I-group I-group
antagonists I-group I-group
e.g. O O
, O O
verapamil B-drug B-drug
) O O
, O O
CYP1A2 O O
inducers O O
( O O
omeprazole B-drug B-drug
) O O
and O O
CYP1A2 O B-group
inhibitors O I-group
( O O
furafylline B-drug B-drug
and O O
clarithromycin B-drug B-drug
) O O
. O O

Digoxin B-drug B-drug
and O O
verapamil B-drug B-drug
use O O
may O O
be O O
rarely O O
associated O O
with O O
ventricular O O
fibrillation O O
when O O
combined O O
with O O
Adenocard B-brand B-brand
. O O

Nelfinavir B-drug B-drug
steady-state O O
Cmax O O
, O O
A.C. O O
and O O
Cmin O O
were O O
increased O O
by O O
12 O O
% O O
, O O
15 O O
% O O
, O O
and O O
14 O O
% O O
, O O
respectively O O
, O O
by O O
concomitant O O
amprenavir B-drug B-drug
. O O

Phase O O
II O O
clinical O O
trial O O
data O O
, O O
where O O
IRESSA B-brand B-brand
and O O
vinorelbine B-drug B-drug
have O O
been O O
used O O
concomitantly O O
, O O
indicate O O
that O O
IRESSA B-brand B-brand
may O O
exacerbate O O
the O O
neutropenic O O
effect O O
of O O
vinorelbine B-drug B-drug
. O O

Weak O O
inhibitory O O
effects O O
toward O O
other O O
isoforms O O
( O O
CYP2C8 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
3A4 O O
) O O
were O O
found O O
, O O
but O O
Ki O O
values O O
were O O
in O O
excess O O
of O O
plasma O O
concentrations O O
achieved O O
following O O
dosing O O
. O O

- O O
Drugs O O
that O O
may O O
decrease O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
include O O
: O O
carbamazepine B-drug B-drug
, O O
chronic O O
alcohol B-drug B-drug
abuse O O
, O O
reserpine B-drug B-drug

The O O
majority O O
of O O
patients O O
in O O
RA O O
clinical O O
studies O O
received O O
one O O
or O O
more O O
of O O
the O O
following O O
concomitant O O
medications O O
with O O
ORENCIA B-brand B-brand
: O O
MTX B-drug B-drug
, O O
NSAIDs B-group B-group
, O O
corticosteroids B-group B-group
, O O
TNF B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
azathioprine B-drug B-drug
, O O
chloroquine B-drug B-drug
, O O
gold B-drug B-drug
, O O
hydroxychloroquine B-drug B-drug
, O O
leflunomide B-drug B-drug
, O O
sulfasalazine B-drug B-drug
, O O
and O O
anakinra B-drug B-drug
. O O

Indinavir B-drug B-drug
steady-state O O
Cmax O O
, O O
A.C. O O
and O O
Cmin O O
were O O
decreased O O
by O O
22 O O
% O O
, O O
38 O O
% O O
, O O
and O O
27 O O
% O O
, O O
respectively O O
, O O
by O O
concomitant O O
amprenavir B-drug B-drug
. O O

In O O
contrast O O
, O O
the O O
potency O O
of O O
norepinephrine B-drug B-drug
was O O
increased O O
in O O
failing O O
hearts O O
( O O
New O O
York O O
Heart O O
Association O O
functional O O
class O O
IV O O
) O O
in O O
relation O O
to O O
the O O
concentrations O O
producing O O
50 O O
% O O
of O O
the O O
maximal O O
effect O O
( O O
EC50 O O
) O O
. O O

No O O
clinically O O
significant O O
adverse O O
interactions O O
with O O
commonly O O
used O O
preanesthetic O B-group
drugs O I-group
, O O
or O O
drugs O O
used O O
during O O
anesthesia O O
( O O
muscle B-group B-group
relaxants I-group I-group
, O O
intravenous O O
agents O O
, O O
and O O
local O O
anesthetic B-group B-group
agents I-group I-group
) O O
were O O
reported O O
in O O
clinical O O
trials O O
. O O

Monitor O O
prothrombin O O
levels O O
and O O
adjust O O
anticoagulant B-group B-group
dosage O O
accordingly O O
. O O

Further O O
, O O
if O O
guanfacine B-drug B-drug
is O O
to O O
be O O
discontinued O O
in O O
such O O
patients O O
, O O
careful O O
tapering O O
of O O
the O O
dosage O O
may O O
be O O
necessary O O
in O O
order O O
to O O
avoid O O
rebound O O
phenomena O O
. O O

Activation O O
of O O
an O O
effector O O
immediate-early O O
gene O O
arc O O
by O O
methamphetamine B-drug B-drug
. O O

CYP450 O O
Metabolized O O
Drugs O O
Results O O
from O O
in O O
vitro O O
and O O
in O O
vivo O O
studies O O
suggest O O
that O O
enfuvirtide B-drug B-drug
is O O
unlikely O O
to O O
have O O
significant O O
drug O O
interactions O O
with O O
concomitantly O O
administered O O
drugs O O
metabolized O O
by O O
CYP450 O O
enzymes O O
. O O

The O O
antihypertensive O O
effects O O
of O O
methyldopa B-drug B-drug
, O O
mecamylamine B-drug B-drug
, O O
reserpine B-drug B-drug
, O O
and O O
veratrum B-drug B-group
alkaloids I-drug I-group
may O O
be O O
reduced O O
by O O
sympathomimetics B-group B-group
. O O

The O O
clinical O O
relevance O O
of O O
these O O
increases O O
is O O
not O O
known O O
. O O

Omeprazole B-drug B-drug
should O O
be O O
taken O O
as O O
directed O O
and O O
Proquin B-brand B-brand
XR I-brand I-brand
should O O
be O O
taken O O
with O O
a O O
main O O
meal O O
of O O
the O O
day O O
, O O
preferably O O
the O O
evening O O
meal.. O O

Certain O O
drugs O O
, O O
including O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
( O O
NSAIDs B-group B-group
) O O
, O O
salicylates B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
and O O
non-selective B-group B-group
beta-adrenergic-blocking I-group I-group
agents I-group I-group
may O O
potentiate O O
the O O
hypoglycemic O O
action O O
of O O
Starlix B-brand B-brand
and O O
other O O
oral O O
antidiabetic B-group B-group
drugs I-group I-group
. O O

Corticosteroids B-group B-group
: O O
Concomitant O O
administration O O
with O O
aspirin B-brand B-brand
may O O
increase O O
the O O
risk O O
of O O
gastrointestinal O O
ulceration O O
and O O
may O O
reduce O O
serum O O
salicylate O B-group
levels O O
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA O B-group
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

Concomitant O O
treatment O O
with O O
potassium-sparing B-group B-group
diuretics I-group I-group
may O O
be O O
associated O O
with O O
increased O O
serum O O
potassium O O
levels O O
. O O

Valproate B-drug B-drug
500 O O
mg O O
twice O O
daily O O
did O O
not O O
modify O O
the O O
rate O O
or O O
extent O O
of O O
levetiracetam B-drug B-drug
absorption O O
or O O
its O O
plasma O O
clearance O O
or O O
urinary O O
excretion O O
. O O

However O O
, O O
in O O
a O O
follow-up O O
study O O
in O O
normal O O
subjects O O
, O O
single-dose O O
administration O O
of O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
and O O
propranolol B-drug B-drug
and O O
twice-a-day O O
administration O O
for O O
5 O O
days O O
of O O
both O O
agents O O
did O O
not O O
affect O O
the O O
extent O O
of O O
propranolol B-drug B-drug
absorption O O
, O O
but O O
had O O
a O O
small O O
yet O O
statistically O O
significant O O
effect O O
on O O
its O O
rate O O
of O O
absorption O O
; O O

Sexual O O
intercourse O O
with O O
a O O
steady O O
partner O O
causes O O
no O O
more O O
cardiovascular O O
risk O O
than O O
normal O O
daily O O
activities O O
such O O
as O O
ironing O B-drug
, O O
2 O O
kilometers O O
of O O
walking O O
without O O
climbing O O
, O O
paperhanging O O
, O O
playing O O
golf O O
or O O
gardening O O
. O O

Probenecid B-drug B-drug
may O O
decrease O O
renal O O
tubular O O
secretion O O
of O O
cephalosporins B-group B-group
when O O
used O O
concurrently O O
, O O
resulting O O
in O O
increased O O
and O O
more O O
prolonged O O
cephalosporin B-group B-group
blood O O
levels O O
. O O

Warfarin B-drug B-drug
: O O
In O O
subjects O O
receiving O O
warfarin B-drug B-drug
, O O
no O O
significant O O
change O O
in O O
clotting O O
time O O
was O O
observed O O
when O O
grepafloxacin B-drug B-drug
was O O
coadministered O O
. O O

Bismuth B-drug B-drug
: O O
Bismuth B-drug B-drug
subsalicylate I-drug I-drug
, O O
given O O
concomitantly O O
with O O
enoxacin B-drug B-drug
or O O
60 O O
minutes O O
following O O
enoxacin B-drug B-drug
administration O O
, O O
decreased O O
enoxacin B-drug B-drug
bioavailability O O
by O O
approximately O O
25 O O
% O O
. O O

hepatotoxic O O
drugs O O
; O O

For O O
the O O
calcium-entry B-group B-group
blocking I-group I-group
agents I-group I-group
now O O
available O O
in O O
the O O
United O O
States O O
( O O
verapamil B-drug B-drug
, O O
nifedipine B-drug B-drug
and O O
diltiazem B-drug B-drug
) O O
, O O
these O O
data O O
appeared O O
well O O
after O O
clinical O O
patterns O O
of O O
use O O
evolved O O
. O O

However O O
, O O
prudent O O
evaluation O O
of O O
individual O O
cases O O
is O O
warranted O O
in O O
the O O
clinical O O
setting O O
. O O

When O O
used O O
concurrently O O
with O O
such O O
drugs O O
, O O
the O O
dose O O
of O O
butorphanol B-drug B-drug
should O O
be O O
the O O
smallest O O
effective O O
dose O O
and O O
the O O
frequency O O
of O O
dosing O O
reduced O O
as O O
much O O
as O O
possible O O
when O O
administered O O
concomitantly O O
with O O
drugs O O
that O O
potentiate O O
the O O
action O O
of O O
opioids B-group B-group
. O O

Most O O
events O O
were O O
reported O O
to O O
occur O O
when O O
contrast O O
media O O
was O O
given O O
within O O
4 O O
weeks O O
after O O
the O O
last O O
dose O O
of O O
interleukin-2 B-drug B-drug
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
fosfomycin B-drug B-drug
when O O
coadministered O O
with O O
MONUROL B-brand B-brand
. O O

C57BL/6N O O
demonstrated O O
large O O
numbers O O
of O O
two O O
of O O
the O O
three O O
types O O
of O O
liver O O
tumors O O
seen O O
in O O
livers O O
of O O
genetically O O
predisposed O O
mice O O
, O O
one O O
of O O
which O O
required O O
the O O
additional O O
stimulus O O
of O O
dietary O O
phenobarbital B-drug B-drug
for O O
growth O O
. O O

May O O
interact O O
with O O
thyroid O B-group
medication O I-group
( O O
e.g. O O
, O O
levothyroxine B-drug B-drug
) O O
, O O
iodine-containing B-drug B-drug
products O O
, O O
antacids B-group B-group
, O O
H2-antagonists B-group B-group
( O O
e.g. O O
, O O
famotidine B-drug B-drug
, O O
ranitidine B-drug B-drug
) O O
, O O
and O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
( O O
e.g. O O
, O O
lansoprazole B-drug B-drug
, O O
omeprazole B-drug B-drug
) O O
. O O

Photic O O
evoked O O
potentials O O
were O O
recorded O O
from O O
the O O
visual O O
cortex O O
of O O
chronically O O
implanted O O
albino O O
rats O O
. O O

SETTING O O
: O O
Clinical O O
research O O
center O O
. O O

Concomitant O O
medications O O
were O O
grouped O O
as O O
ACE B-group B-group
inhibitors I-group I-group
, O O
oral O O
anticoagulants B-group B-group
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
beta B-group B-group
blockers I-group I-group
, O O
cardiac B-group B-group
glycosides I-group I-group
, O O
inducers O O
of O O
CYP3A4 O O
, O O
substrates O O
and O O
inhibitors O O
of O O
CYP3A4 O O
, O O
substrates O O
and O O
inhibitors O O
of O O
P-glycoprotein O O
, O O
nitrates B-group B-group
, O O
sulphonylureas B-group B-group
, O O
loop B-group B-group
diuretics I-group I-group
, O O
potassium B-group B-group
sparing I-group I-group
diuretics I-group I-group
, O O
thiazide B-group B-group
diuretics I-group I-group
, O O
substrates O O
and O O
inhibitors O O
of O O
tubular O O
organic O O
cation O O
transport O O
, O O
and O O
QTc-prolonging O O
drugs O O
. O O

Recombinant O O
shuttle O O
vectors O O
containing O O
a O O
vanH O O
promoter-vanA O O
antisense O O
gene O O
cassette O O
fully O O
restored O O
vancomycin B-drug B-drug
susceptibility O O
through O O
a O O
combined O O
transcriptional O O
activator O O
binding O O
domain O O
decoy O O
and O O
inducible O O
vanA O O
antisense O O
RNA O O
effect O O
. O O

3 O O
. O O

A O O
single O O
tonic O O
convulsion O O
was O O
seen O O
in O O
each O O
of O O
2 O O
male O O
dogs O O
( O O
one O O
treated O O
at O O
10 O O
mg/kg/day O O
and O O
one O O
at O O
120 O O
mg/kg/day O O
) O O
in O O
a O O
2-year O O
study O O
. O O

+82 O O
% O O

Gemfibrozil B-drug B-drug
Other O O
fibrates B-group B-group
Niacin B-drug B-drug
( O O
nicotinic B-drug B-drug
acid I-drug I-drug
) O O
( O O
=1 O O
g/day O O
) O O

Angiomax B-brand B-brand
does O O
not O O
exhibit O O
binding O O
to O O
plasma O O
proteins O O
( O O
other O O
than O O
thrombin O O
) O O
or O O
red O O
blood O O
cells O O
. O O

therefore O O
, O O
doses O O
greater O O
than O O
the O O
normal O O
antiasthmatic O O
dose O O
of O O
beta-agonist B-group B-group
bronchodilator I-group I-group
drugs I-group I-group
may O O
be O O
required O O
. O O

Co-administration O O
of O O
ketoconazole B-drug B-drug
, O O
a O O
strong O O
inhibitor O O
of O O
CYP3A4 O O
, O O
increased O O
cinacalcet B-drug B-drug
exposure O O
following O O
a O O
single O O
90 O O
mg O O
dose O O
of O O
Sensipar B-brand B-brand
by O O
2.3 O O
fold O O
. O O

If O O
resumed O O
during O O
captopril B-drug B-drug
therapy O O
, O O
such O O
agents O O
should O O
be O O
administered O O
cautiously O O
, O O
and O O
perhaps O O
at O O
lower O O
dosage O O
. O O

allopurinol B-drug B-drug
; O O

Certain O O
antibiotic B-group B-group
, O O
cisplatin B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
diuretic B-group B-group
, O O
foscarnet B-drug B-drug
, O O
and O O
vaccines B-group B-group
. O O

With O O
some O O
agents O O
, O O
the O O
metabolism O O
may O O
be O O
induced O O
, O O
resulting O O
in O O
decreased O O
concentrations O O
. O O

Beta-blockers B-group B-group
, O O
clonidine B-drug B-drug
, O O
lithium B-drug B-drug
salts O O
, O O
and O O
alcohol B-drug B-drug
may O O
either O O
potentiate O O
or O O
weaken O O
the O O
blood-glucose-lowering O O
effect O O
of O O
insulin B-drug B-drug
. O O

Antimicrobial O O
activity O O
of O O
Ganoderma B-drug_n O
lucidum I-drug_n O
extract I-drug_n O
alone O O
and O O
in O O
combination O O
with O O
some O O
antibiotics B-group B-group
. O O

Alcohol B-drug B-drug
, O O
in O O
particular O O
, O O
has O O
been O O
found O O
to O O
exhibit O O
additive O O
effects O O
of O O
this O O
variety O O
. O O

Due O O
to O O
the O O
possibility O O
of O O
antagonism O O
in O O
vivo O O
, O O
particularly O O
when O O
bactericidal O O
activity O O
is O O
desired O O
, O O
this O O
drug O O
combination O O
should O O
be O O
avoided O O
. O O

If O O
this O O
is O O
not O O
possible O O
, O O
the O O
starting O O
dose O O
should O O
be O O
reduced O O
and O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
several O O
hours O O
following O O
an O O
initial O O
dose O O
and O O
until O O
blood O O
pressure O O
has O O
stabilized O O
( O O
see O O
DOSAGE O O
AND O O
ADMINISTRATION O O
. O O
) O O

Cyclosporin B-drug B-drug
: O O
Reports O O
indicate O O
that O O
cyclosporine B-drug B-drug
levels O O
may O O
be O O
increased O O
during O O
concomitant O O
treatment O O
with O O
allopurinol B-drug B-drug
sodium I-drug I-drug
for O O
injection O O
. O O

Adequate O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
concentrations O O
should O O
be O O
considered O O
when O O
therapy O O
with O O
VIOXX B-brand B-brand
is O O
initiated O O
or O O
changed O O
in O O
patients O O
receiving O O
theophylline B-drug B-drug
. O O

If O O
midazolam B-drug B-drug
is O O
administered O O
parenterally O O
, O O
special O O
precaution O O
is O O
required O O
since O O
the O O
sedative O O
effect O O
may O O
be O O
prolonged O O
. O O

The O O
effect O O
of O O
Keppra B-brand B-brand
on O O
probenecid B-drug B-drug
was O O
not O O
studied O O
. O O

Lopinavir/ritonavir B-drug B-drug

It O O
is O O
structurally O O
distinct O O
from O O
the O O
other O O
currently O O
available O O
HMGCoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
( O O
lovastatin B-drug B-drug
, O O
simvastatin B-drug B-drug
, O O
and O O
pravastatin B-drug B-drug
) O O
, O O
leading O O
to O O
unique O O
biopharmaceutical O O
properties O O
relative O O
to O O
the O O
other O O
agents O O
of O O
this O O
class O O
. O O

Digoxin B-drug B-drug
: O O
In O O
patients O O
with O O
hypercholesterolemia O O
, O O
concomitant O O
administration O O
of O O
lovastatin B-drug B-drug
and O O
digoxin B-drug B-drug
resulted O O
in O O
no O O
effect O O
on O O
digoxin B-drug B-drug
plasma O O
concentrations O O
. O O

There O O
have O O
been O O
isolated O O
reports O O
of O O
patients O O
experiencing O O
increases O O
in O O
their O O
prothrombin O O
times O O
when O O
etidronate B-drug B-drug
was O O
added O O
to O O
warfarin B-drug B-drug
therapy O O
. O O

ulcerans O O
infection O O
. O O

isoflurane B-drug B-drug
; O O

INDOCIN B-brand B-brand
has O O
been O O
reported O O
to O O
decrease O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-drug B-drug
and O O
to O O
potentiate O O
its O O
toxicity O O
. O O

The O O
mean O O
minimum O O
lithium B-drug B-drug
concentration O O
increased O O
15 O O
% O O
and O O
the O O
renal O O
clearance O O
was O O
decreased O O
by O O
approximately O O
20 O O
% O O
. O O

The O O
behavioral O O
changes O O
of O O
mice O O
induced O O
by O O
acute O O
and O O
repeated O O
i.p O O
. O O

An O O
intravenous O O
injection O O
of O O
perchlorate B-drug_n B-drug
given O O
later O O
also O O
produces O O
a O O
complete O O
and O O
immediately O O
beginning O O
depletion O O
of O O
pertechnetate B-drug B-drug
already O O
accumulated O O
in O O
the O O
thyroid O O
, O O
within O O
a O O
period O O
of O O
195 O O
min O O
after O O
99m-TcO-4-injection O B-drug
with O O
a O O
corresponding O O
increase O O
in O O
blood O O
levels O O
. O O

The O O
development O O
of O O
clinical O O
vancomycin-resistant O O
strains O O
of O O
enterococci O O
( O O
VRE O O
) O O
is O O
a O O
major O O
cause O O
for O O
concern O O
. O O

In O O
human O O
heart O O
failure O O
, O O
there O O
is O O
a O O
presynaptic O O
defect O O
in O O
the O O
sympathetic O O
nervous O O
system O O
, O O
leading O O
to O O
reduced O O
uptake-1 O O
activity O O
. O O

Administering O O
InsP B-drug_n B-drug_n
( I-drug_n O
3 I-drug_n O
) I-drug_n O
together O O
with O O
RR B-drug_n B-drug_n
( O O
100-500 O O
microM O O
) O O
inhibited O O
InsP O B-drug_n
( O I-drug_n
3 O I-drug_n
) O I-drug_n
-induced O O
responses O O
( O O
both O O
Ca O O
( O O
2+ O O
) O O
and O O
current O O
responses O O
) O O
in O O
a O O
dose-dependent O O
fashion O O
. O O

Therefore O O
, O O
the O O
potential O O
exists O O
for O O
interaction O O
between O O
carbamazepine B-drug B-drug
and O O
any O O
agent O O
metabolized O O
by O O
one O O
( O O
or O O
more O O
) O O
of O O
these O O
enzymes O O
. O O

Seizure O O
, O O
associated O O
with O O
increased O O
lidocaine B-drug B-drug
concentrations O O
, O O
has O O
been O O
reported O O
with O O
concomitant O O
administration O O
of O O
intravenous O O
amiodarone B-drug B-drug
. O O

Evaluation O O
of O O
its O O
efficacy O O
and O O
toxicity O O
. O O

Azithromycin B-drug B-drug
did O O
not O O
affect O O
the O O
prothrombin O O
time O O
response O O
to O O
a O O
single O O
dose O O
of O O
warfarin B-drug B-drug
. O O

Preliminary O O
investigations O O
indicate O O
that O O
icodextrin B-drug B-drug
and O O
its O O
metabolites O O
interfere O O
with O O
enzymatic-based O O
amylase O O
assays O O
, O O
resulting O O
in O O
inaccurately O O
low O O
values O O
. O O

Drugs O O
That O O
Inhibit O O
CYP3A4 O O
CYP3A4 O O
is O O
a O O
minor O O
metabolic O O
pathway O O
for O O
the O O
elimination O O
of O O
zaleplon B-drug B-drug
because O O
the O O
sum O O
of O O
desethylzaleplon O B-drug
( O O
formed O O
via O O
CYP3A4 O O
in O O
vitro O O
) O O
and O O
its O O
metabolites O O
, O O
5-oxo-desethylzaleplon B-drug_n B-drug_n
and O O
5-oxo-desethylzaleplon B-drug_n B-drug_n
glucuronide I-drug_n I-drug_n
, O O
account O O
for O O
only O O
9 O O
% O O
of O O
the O O
urinary O O
recovery O O
of O O
a O O
zaleplon B-drug B-drug
dose O O
. O O

Blood O O
samples O O
also O O
were O O
taken O O
before O O
morning O O
doses O O
on O O
the O O
3rd O O
, O O
4th O O
, O O
and O O
5th O O
days O O
of O O
phases O O
1 O O
and O O
3 O O
. O O

Elevated O O
International O O
Normalized O O
Ratio O O
and O O
Potential O O
Bleeding O O
International O O
Normalized O O
Ratio O O
( O O
INR O O
) O O
elevations O O
and O O
infrequent O O
reports O O
of O O
bleeding O O
events O O
including O O
gastrointestinal O O
and O O
non-gastrointestinal O O
bleedings O O
have O O
been O O
reported O O
in O O
clinical O O
studies O O
, O O
some O O
associated O O
with O O
concomitant O O
warfarin B-drug B-drug
administration O O
. O O

Cimetidine B-drug B-drug
has O O
been O O
shown O O
to O O
increase O O
the O O
bioavailability O O
of O O
labetalol B-drug B-drug
HCl I-drug I-drug
. O O

indomethacin B-drug B-drug
; O O

- O O
In O O
isolated O O
cases O O
, O O
a O O
pronounced O O
though O O
reversible O O
, O O
impairment O O
of O O
renal O O
function O O
( O O
accompanied O O
by O O
a O O
corresponding O O
increase O O
in O O
the O O
serum O O
creatinine O O
level O O
) O O
has O O
been O O
reported O O
in O O
organ O O
transplant O O
patients O O
receiving O O
immuno-suppressant B-group B-group
therapy O O
and O O
concomitant O O
bezafibrate B-drug B-drug
. O O

Methadonea O O

Patients O O
taking O O
disopyramide B-drug B-drug
phosphate I-drug I-drug
and O O
hepatic O O
enzyme O O
inhibitors O O
concomitantly O O
should O O
be O O
closely O O
monitored O O
. O O

Observe O O
the O O
patient O O
for O O
possible O O
diminished O O
effect O O
of O O
steroid B-group B-group
and O O
increase O O
the O O
steroid B-group B-group
dosage O O
accordingly O O
. O O

This O O
defect O O
is O O
not O O
related O O
to O O
acute O O
insulin O B-drug
release O O
or O O
the O O
presence O O
of O O
glucose B-drug O
. O O

In O O
vitro O O
studies O O
have O O
demonstrated O O
that O O
efavirenz B-drug B-drug
inhibits O O
2C9 O O
, O O
2C19 O O
, O O
and O O
3A4 O O
isozymes O O
in O O
the O O
range O O
of O O
observed O O
efavirenz B-drug B-drug
plasma O O
concentrations O O
. O O

At O O
a O O
higher O O
dose O O
and O O
a O O
shorter O O
withdrawal O O
period O O
( O O
20 O O
mg/kg O O
, O O
daily O O
for O O
7 O O
days O O
followed O O
by O O
a O O
3-day O O
withdrawal O O
) O O
, O O
the O O
SST O O
mice O O
showed O O
behavioral O O
sensitization O O
similar O O
to O O
the O O
RBC O O
mice O O
, O O
but O O
the O O
LST O O
mice O O
did O O
not O O
develop O O
sensitization O O
. O O

the O O
fourth O O
group O O
served O O
as O O
control O O
and O O
received O O
an O O
equivalent O O
volume O O
of O O
an O O
isocaloric O O
solution O O
of O O
dextrose B-drug B-drug
. O O

When O O
the O O
dose O O
of O O
picrotoxin B-drug_n B-drug_n
is O O
minimized O O
to O O
0.5 O O
mg/kg O O
such O O
an O O
effect O O
is O O
not O O
observed O O
. O O

They O O
should O O
be O O
observed O O
closely O O
, O O
particularly O O
if O O
renal O O
function O O
is O O
impaired O O
. O O

In O O
addition O O
, O O
the O O
frequency O O
of O O
monitoring O O
serum O O
lithium B-drug B-drug
concentration O O
should O O
be O O
increased O O
at O O
the O O
outset O O
of O O
such O O
combination O O
drug O O
treatment O O
. O O

Dose-response O O
curves O O
( O O
derived O O
from O O
the O O
results O O
of O O
using O O
the O O
tablets O O
as O O
well O O
as O O
pure O O
powders O O
) O O
showed O O
that O O
tripelennamine B-drug B-drug
was O O
responsible O O
for O O
the O O
inhibitory O O
activity O O
, O O
which O O
was O O
partially O O
antagonized O O
by O O
pentazocine B-drug B-drug
. O O

When O O
CANCIDAS B-brand B-brand
is O O
co-administered O O
with O O
inducers O O
of O O
drug O O
clearance O O
, O O
such O O
as O O
efavirenz B-drug B-drug
, O O
nevirapine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
dexamethasone B-drug B-drug
, O O
or O O
carbamazepine B-drug B-drug
, O O
use O O
of O O
a O O
daily O O
dose O O
of O O
70 O O
mg O O
of O O
CANCIDAS B-brand B-brand
should O O
be O O
considered O O

Antidiabetics B-group B-group
: O O
Because O O
corticosteroids B-group B-group
may O O
increase O O
blood O O
glucose O O
concentrations O O
, O O
dosage O O
adjustments O O
of O O
antidiabetic B-group B-group
agents I-group I-group
may O O
be O O
required O O
. O O

Sulfapyridine B-drug B-drug
may O O
interact O O
with O O
any O O
of O O
the O O
following O O
: O O
- O O
Acetaminophen B-drug B-drug
( O O
e.g. O O
, O O
Tylenol B-brand B-brand
) O O
( O O
with O O
long-term O O
, O O
high-dose O O
use O O
) O O
or O O

Patients O O
receiving O O
beta-blockers B-group B-group
should O O
be O O
warned O O
of O O
this O O
potential O O
hazard O O
. O O

Diltiazem B-drug B-drug
is O O
both O O
a O O
substrate O O
and O O
an O O
inhibitor O O
of O O
the O O
cytochrome O O
P-450 O O
3A4 O O
enzyme O O
system O O
. O O

Recommendations O O
were O O
to O O
avoid O O
administration O O
of O O
diffusible O O
anti-helminthic B-group O
treatment O O
during O O
the O O
cure O O
, O O
and O O
to O O
improve O O
the O O
general O O
conditions O O
of O O
patients O O
before O O
the O O
cure O O
of O O
melarsoprol B-drug B-drug
. O O

Estrogen-containing B-group B-group
therapies O O
should O O
not O O
be O O
used O O
with O O
ARIMIDEX B-brand B-brand
as O O
they O O
may O O
diminish O O
its O O
pharmacologic O O
action O O
. O O

If O O
CEFOTAN B-brand B-brand
and O O
an O O
aminoglycoside B-group B-group
are O O
used O O
concomitantly O O
, O O
renal O O
function O O
should O O
be O O
carefully O O
monitored O O
, O O
because O O
nephrotoxicity O O
may O O
be O O
potentiated O O
. O O

Anticoagulants B-group B-group
: O O
Coagulation O O
parameters O O
should O O
be O O
tested O O
more O O
frequently O O
and O O
monitored O O
regularly O O
during O O
simultaneous O O
administration O O
of O O
high O O
doses O O
of O O
heparin B-drug B-drug
, O O
oral O O
anticoagulants B-group B-group
, O O
or O O
other O O
drugs O O
that O O
may O O
affect O O
the O O
blood O O
coagulation O O
system O O
or O O
the O O
thrombocyte O O
function O O
. O O

Amprenavir B-drug B-drug
significantly O O
increased O O
the O O
area O O
under O O
the O O
curve O O
at O O
steady O O
state O O
( O O
AUC O O
( O O
ss O O
) O O
) O O
of O O
rifabutin B-drug B-drug
by O O
2.93-fold O O
and O O
the O O
AUC O O
( O O
ss O O
) O O
of O O
25-O-desacetylrifabutin B-drug_n B-drug_n
by O O
13.3-fold O O
. O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
cardiac O O
arrhythmias O O
. O O

The O O
concomitant O O
administration O O
of O O
Exjade B-brand B-brand
and O O
aluminum-containing B-drug B-drug
antacid B-group B-group
preparations I-group I-group
has O O
not O O
been O O
formally O O
studied O O
. O O

Clinical O O
experience O O
in O O
the O O
concurrent O O
administration O O
of O O
ECT O O
and O O
antidepressant B-group B-group
drugs I-group I-group
is O O
limited O O
. O O

Pharmacokinetic O O
Interaction O O
between O O
amprenavir B-drug B-drug
and O O
rifabutin B-drug B-drug
or O O
rifampin B-drug B-drug
in O O
healthy O O
males O O
. O O

Therefore O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
biocytin O O
inclusion O O
on O O
opioid B-group O
responses O O
and O O
other O O
membrane O O
properties O O
during O O
whole-cell O O
, O O
tight O O
seal O O
recordings O O
of O O
these O O
neurons O O
. O O

Probenecid B-drug B-drug
: O O
May O O
decrease O O
renal O O
tubular O O
secretion O O
of O O
ampicillin B-drug B-drug
resulting O O
in O O
increased O O
blood O O
levels O O
and/or O O
ampicillin B-drug B-drug
toxicity O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
may O O
potentiate O O
the O O
cardiovascular O O
effects O O
of O O
adreneric O B-group
agents O I-group
. O O

4 O O
. O O

Many O O
drugs O O
used O O
in O O
dentistry O O
can O O
not O O
be O O
taken O O
concomitantly O O
with O O
these O O
medications O O
. O O

Fluvastatin B-drug B-drug
is O O
the O O
first O O
synthetic B-group O
3-hydroxy-3-methylglutaryl I-group O
coenzyme I-group O
A I-group O
( I-group O
HMGCoA I-group B-group
) I-group I-group
reductase I-group I-group
inhibitor I-group I-group
to O O
be O O
approved O O
for O O
clinical O O
use O O
, O O
and O O
has O O
been O O
studied O O
extensively O O
in O O
humans O O
since O O
1986 O O
. O O

Endogenous O O
respiration O O
was O O
unaffected O O
by O O
the O O
drug O O
at O O
a O O
concentration O O
as O O
high O O
as O O
100 O O
mug/ml O O
, O O
whereas O O
exogenous O O
respiration O O
was O O
markedly O O
sensitive O O
and O O
inhibited O O
to O O
an O O
extent O O
of O O
85 O O
% O O
. O O

Nonsteroidal B-group B-group
Anti-Inflammatory I-group I-group
Drugs I-group I-group
: O O
The O O
administration O O
of O O
diflunisal B-drug B-drug
to O O
normal O O
volunteers O O
receiving O O
indomethacin B-drug B-drug
decreased O O
the O O
renal O O
clearance O O
and O O
significantly O O
increased O O
the O O
plasma O O
levels O O
of O O
indomethacin B-drug B-drug
. O O

Analgesic/anti-inflammatory B-group O
( O O
e.g. O O
, O O
acetaminophen B-drug B-drug
, O O
aspirin B-brand B-brand
, O O
codeine B-drug B-drug
and O O
codeine B-drug B-drug
combinations O O
, O O
ibuprofen B-drug B-drug
, O O
indomethacin B-drug B-drug
) O O
. O O

Drugs O O
which O O
induce O O
CYP3A4 O O
activity O O
( O O
eg O O
, O O
phenobarbital B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
rifabutin B-drug B-drug
) O O
would O O
be O O
expected O O
to O O
increase O O
the O O
clearance O O
of O O
efavirenz B-drug B-drug
resulting O O
in O O
lowered O O
plasma O O
concentrations O O
. O O

Amiodarone B-drug B-drug
taken O O
concomitantly O O
with O O
digoxin B-drug B-drug
increases O O
the O O
serum O O
digoxin B-drug B-drug
concentration O O
by O O
70 O O
% O O
after O O
one O O
day O O
. O O

Haloperidol B-drug B-drug
reduced O O
or O O
eliminated O O
the O O
increases O O
in O O
FI O O
responding O O
produced O O
by O O
intermediate O O
doses O O
of O O
either O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
or O O
PCP B-drug_n B-drug_n
in O O
pigeons O O
, O O
but O O
did O O
not O O
antagonize O O
the O O
decreases O O
in O O
FI O O
or O O
FR O O
responding O O
produced O O
by O O
high O O
doses O O
of O O
PCP O B-drug_n
or O O
either O O
stereoisomer O O
of O O
NANM B-drug_n B-drug_n
. O O

WelChol B-brand B-brand
has O O
been O O
studied O O
in O O
several O O
human O O
drug O O
interaction O O
studies O O
in O O
which O O
it O O
was O O
administered O O
with O O
a O O
meal O O
and O O
the O O
test O O
drug O O
. O O

Propoxyphene B-drug B-drug
: O O
In O O
cases O O
of O O
propoxyphene B-drug B-drug
overdosage O O
, O O
amphetamine B-group B-drug
CNS O O
stimulation O O
is O O
potentiated O O
and O O
fatal O O
convulsions O O
can O O
occur O O
. O O

No O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
for O O
COLAZAL B-brand B-brand
, O O
however O O
the O O
use O O
of O O
orally O O
administered O O
antibiotics B-group B-group
could O O
, O O
theoretically O O
, O O
interfere O O
with O O
the O O
release O O
of O O
mesalamine B-drug B-drug
in O O
the O O
colon O O
. O O

T3 O O
resin O O
uptake O O
is O O
decreased O O
, O O
reflecting O O
the O O
elevated O O
TBG O O
. O O

Local O O
and O O
some O O
general O O
anesthetics B-group B-group
, O O
antiarrhythmic B-group B-group
agents I-group I-group
and O O
other O O
drugs O O
that O O
interfere O O
with O O
neuromuscular O O
transmission O O
should O O
be O O
used O O
cautiously O O
, O O
if O O
at O O
all O O
, O O
in O O
patients O O
with O O
myasthenia O O
gravis O O
; O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
not O O
clear O O
. O O

If O O
intravenous O O
pentamidine B-drug B-drug
is O O
required O O
to O O
treat O O
Pneumocystis O O
carinii O O
pneumonia O O
, O O
treatment O O
with O O
HIVID B-drug B-drug
should O O
be O O
interrupted O O
. O O

Both O O
ibogaine B-drug_n B-drug_n
and O O
18-MC B-drug_n B-drug_n
block O O
morphine-induced B-drug B-drug
and O O
nicotine-induced B-drug B-drug
dopamine O I-drug
release O O
in O O
the O O
nucleus O O
accumbens O O
; O O

Tetracyclines B-group B-group
: O O
Since O O
both O O
acitretin B-drug B-drug
and O O
tetracyclines B-group B-group
can O O
cause O O
increased O O
intracranial O O
pressure O O
, O O
their O O
combined O O
use O O
is O O
contraindicated O O
. O O

In O O
vitro O O
, O O
buspirone B-drug B-drug
may O O
displace O O
less O O
firmly O O
bound O O
drugs O O
like O O
digoxin B-drug B-drug
. O O

Death O O
in O O
amphetamine B-drug B-drug
users O O
: O O
causes O O
and O O
rates O O
. O O

The O O
following O O
drug O O
interactions O O
have O O
been O O
reported O O
with O O
erythromycin B-drug B-drug
products O O
. O O

The O O
goal O O
of O O
enhancing O O
selective O O
tumor O O
cell O O
killing O O
relative O O
to O O
the O O
normal O O
cells O O
that O O
are O O
dose O O
limiting O O
may O O
be O O
achieved O O
either O O
by O O
overcoming O O
tumor O O
cell O O
resistance O O
or O O
by O O
protecting O O
normal O O
cells O O
. O O

this O O
phenomenon O O
was O O
not O O
observed O O
in O O
North O O
American O O
clinical O O
trials O O
. O O

Acetazolamide B-drug B-drug
reduces O O
urinary O O
excretion O O
of O O
quinidine B-drug B-drug
and O O
may O O
enhance O O
its O O
effect O O
. O O

Agents O O
that O O
may O O
enhance O O
the O O
risk O O
of O O
hemorrhage O O
should O O
be O O
discontinued O O
prior O O
to O O
initiation O O
of O O
Fondaparinux B-drug B-drug
therapy O O
. O O

The O O
absorption O O
of O O
lymecycline B-drug B-drug
may O O
be O O
affected O O
by O O
the O O
simultaneous O O
administration O O
of O O
indigestion O O
remedies O O
, O O
iron B-drug B-drug
or O O
zinc B-drug B-drug
supplements O O
. O O

RESULTS O O
: O O
Sildenafil B-drug B-drug
has O O
demonstrated O O
effectiveness O O
in O O
men O O
with O O
erectile O O
dysfunction O O
associated O O
with O O
prostatectomy O O
, O O
radiation O O
therapy O O
, O O
diabetes O O
mellitus O O
, O O
certain O O
neurologic O O
disorders O O
, O O
and O O
drug O O
therapy O O
( O O
eg O O
, O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
[ O O
SSRIs B-group B-group
] O O
) O O
. O O

Beta-Blockers B-group B-group
: O O
In O O
controlled O O
clinical O O
studies O O
, O O
adrenergic B-group B-group
beta-receptor I-group I-group
blockers I-group I-group
have O O
been O O
frequently O O
administered O O
concomitantly O O
with O O
nicardipine B-drug B-drug
HCl I-drug I-drug
. O O

Metoprolol B-drug B-drug
- O O
Administration O O
of O O
20 O O
mg/day O O
LEXAPRO B-brand B-brand
for O O
21 O O
days O O
in O O
healthy O O
volunteers O O
resulted O O
in O O
a O O
50 O O
% O O
increase O O
in O O
Cmax O O
and O O
82 O O
% O O
increase O O
in O O
AUC O O
of O O
the O O
beta-adrenergic B-group B-group
blocker I-group I-group
metoprolol B-drug B-drug
( O O
given O O
in O O
a O O
single O O
dose O O
of O O
100 O O
mg O O
) O O
. O O

Histamine B-group B-group
H2-receptor I-group I-group
antagonists I-group I-group
: O O
Histamine B-group B-group
H2-receptor I-group I-group
antagonists I-group I-group
appear O O
to O O
have O O
no O O
significant O O
effect O O
on O O
the O O
bioavailability O O
of O O
ciprofloxacin B-drug B-drug
. O O

( O O
200 O O
mg O O
Q12h O O
) O O

Usually O O
, O O
such O O
inactivation O O
of O O
the O O
aminoglycoside B-group B-group
is O O
clinically O O
significant O O
only O O
in O O
patients O O
with O O
severely O O
impaired O O
renal O O
function.. O O

Liver O O
Function O O
Tests O O
: O O
Elevations O O
of O O
AST O O
( O O
SGOT O O
) O O
, O O
ALT O O
( O O
SGPT O O
) O O
or O O
LDH O O
were O O
experienced O O
by O O
approximately O O
1 O O
in O O
3 O O
patients O O
treated O O
with O O
Soriatane B-brand B-drug
. O O

Phenytoin B-drug B-drug

Concomitant O O
administration O O
of O O
Robinul B-brand B-brand
Injection O O
and O O
potassium B-drug B-drug
chloride I-drug I-drug
in O O
a O O
wax O O
matrix O O
may O O
increase O O
the O O
severity O O
of O O
potassium O B-drug
chloride-induced O I-drug
gastrointestinal O O
lesions O O
as O O
a O O
result O O
of O O
a O O
slower O O
gastrointestinal O O
transit O O
time O O
. O O

There O O
are O O
no O O
significant O O
effects O O
on O O
cefdinir B-drug B-drug
pharmacokinetics O O
if O O
the O O
antacid B-group B-group
is O O
administered O O
2 O O
hours O O
before O O
or O O
2 O O
hours O O
after O O
cefdinir B-drug B-drug
. O O

Acarbose B-drug B-drug
has O O
been O O
shown O O
to O O
change O O
the O O
bioavailabillty O O
digoxin B-drug B-drug
when O O
they O O
are O O
co-administered O O
, O O
which O O
may O O
require O O
digoxin B-drug B-drug
dose O O
adjustment O O
. O O

In O O
such O O
cases O O
, O O
the O O
unbound O O
( O O
free O O
) O O
hormone O O
should O O
be O O
measured O O
. O O

- O O
Procainamide B-drug B-drug
( O O
e.g. O O
, O O
Pronestyl B-brand B-brand
) O O
or O O

4 O O
microg O O
mL O O
( O O
-1 O O
) O O
in O O
the O O
presence O O
of O O
galangin B-drug B-drug
( O O
12.5 O O
microg O O
mL O O
( O O
-1 O O
) O O
) O O
or O O
3,7-dihydroxyflavone O O
( O O
6.25 O O
microg O O
mL O O
( O O
-1 O O
) O O
) O O
. O O

Aspirin B-brand B-brand
: O O
CELEBREX B-brand B-brand
can O O
be O O
used O O
with O O
low O O
dose O O
aspirin B-brand B-brand
. O O

however O O
, O O
no O O
deleterious O O
interactions O O
were O O
seen O O
when O O
ROMAZICON B-brand B-brand
was O O
administered O O
after O O
narcotics B-group B-group
, O O
inhalational O B-group
anesthetics B-group I-group
, O O
muscle B-group B-group
relaxants I-group I-group
and O O
muscle O B-group
relaxant O I-group
antagonists O I-group
administered O O
in O O
conjunction O O
with O O
sedation O O
or O O
anesthesia O O
. O O

Opioid B-group B-group
analgesics I-group I-group
Decreased O O
antinociceptive O O
action O O

Both O O
digoxin B-drug B-drug
and O O
COREG B-brand B-brand
slow O O
AV O O
conduction O O
. O O

Patients O O
with O O
HACA O B-drug
titers O O
may O O
have O O
allergic O O
or O O
hypersensitivity O O
reactions O O
when O O
treated O O
with O O
other O O
diagnostic B-group O
or O O
therapeutic B-group O
monoclonal I-group O
antibodies I-group O
. O O

Acute O O
dosing O O
with O O
clozapine B-drug B-drug
failed O O
to O O
alter O O
the O O
behavioral O O
effects O O
of O O
PCP B-drug_n B-drug_n
in O O
either O O
procedure O O
even O O
when O O
tested O O
up O O
to O O
doses O O
that O O
produced O O
pharmacological O O
effects O O
alone O O
. O O

Pharmacodynamic O O
Interactions O O
: O O
The O O
CNS-depressant O O
action O O
of O O
the O O
benzodiazepine B-group B-group
class I-group I-group
of O O
drugs O O
may O O
be O O
potentiated O O
by O O
alcohol B-drug B-drug
, O O
narcotics B-group B-group
, O O
barbiturates B-group B-group
, O O
nonbarbiturate B-group B-group
hypnotics I-group I-group
, O O
antianxiety B-group B-group
agents I-group I-group
, O O
the O O
phenothiazines O B-group
, O O
thioxanthene O B-drug
and O O
butyrophenone B-group B-drug
classes I-group O
of I-group O
antipsychotic I-group B-group
agents I-group I-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
and O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
and O O
by O O
other O O
anticonvulsant B-group B-group
drugs I-group I-group
. O O

Massive O O
seizures O O
may O O
be O O
encountered O O
with O O
this O O
combination O O
. O O

This O O
article O O
reviews O O
the O O
impact O O
of O O
renal O O
disease O O
on O O
the O O
pharmacokinetics O O
of O O
cardiovascular O O
drugs O O
and O O
identifies O O
clinically O O
important O O
interactions O O
between O O
these O O
and O O
other O O
drugs O O
commonly O O
used O O
in O O
the O O
management O O
of O O
chronic O O
renal O O
disease O O
. O O

In O O
diabetic O O
patients O O
, O O
the O O
metabolic O O
effects O O
of O O
androgens B-group B-group
may O O
decrease O O
blood O O
glucose O O
and O O
therefore O O
, O O
insulin B-drug B-drug
requirements O O
. O O

Some O O
early O O
studies O O
indicated O O
that O O
EPA B-drug B-drug
supplements O O
might O O
have O O
detrimental O O
effects O O
in O O
those O O
groups O O
. O O

Exacerbation O O
or O O
the O O
initial O O
presentation O O
of O O
a O O
number O O
of O O
autoimmune O O
and O O
inflammatory O O
disorders O O
has O O
been O O
observed O O
following O O
concurrent O O
use O O
of O O
interferon-alfa B-drug B-drug
and O O
PROLEUKIN B-brand B-brand
, O O
including O O
crescentic O O
IgA O O
glomerulonephritis O O
, O O
oculo-bulbar O O
myasthenia O O
gravis O O
, O O
inflammatory O O
arthritis O O
, O O
thyroiditis O O
, O O
bullous O O
pemphigoid O O
, O O
and O O
Stevens-Johnson O O
syndrome O O
. O O

3 O O
. O O

In O O
female O O
rats O O
, O O
fulvestrant B-drug B-drug
administered O O
at O O
doses O O
0.01 O O
mg/kg/day O O
( O O
approximately O O
one-hundredth O O
of O O
the O O
human O O
recommended O O
dose O O
based O O
on O O
body O O
surface O O
area O O
[ O O
BSA O O
] O O
, O O
for O O
2 O O
weeks O O
prior O O
to O O
and O O
for O O
1 O O
week O O
following O O
mating O O
, O O
caused O O
a O O
reduction O O
in O O
fertility O O
and O O
embryonic O O
survival O O
. O O

indinavir I-drug I-drug
concentration O O

DOXIL B-brand B-brand
may O O
interact O O
with O O
drugs O O
known O O
to O O
interact O O
with O O
the O O
conventional O O
formulation O O
of O O
doxorubicin B-drug B-drug
HCl I-drug I-drug
. O O

Ethosuximide B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
ethosuximide B-drug B-drug
. O O

In O O
situations O O
in O O
which O O
concurrent O O
therapy O O
is O O
necessary O O
, O O
careful O O
patient O O
monitoring O O
is O O
essential O O
. O O

This O O
interference O O
has O O
resulted O O
in O O
significant O O
increases O O
in O O
half-life O O
and O O
AUC O O
. O O

suppression O O
of O O
midcycle O O
gonadotropin O O
peaks O O
; O O

However O O
, O O
caution O O
should O O
be O O
used O O
when O O
administering O O
CELEBREX B-brand B-brand
with O O
warfarin B-drug B-drug
since O O
these O O
patients O O
are O O
at O O
increased O O
risk O O
of O O
bleeding O O
complications O O
. O O

Gentamicin B-drug B-drug
- O O
Methionine B-drug B-drug
may O O
protect O O
against O O
the O O
ototoxic O O
effects O O
of O O
gentamicin B-drug B-drug
. O O

Atracurium B-drug B-drug
was O O
again O O
given O O
by O O
infusion O O
to O O
maintain O O
40 O O
% O O
twitch O O
for O O
a O O
second O O
hour O O
, O O
then O O
2 O O
mg O O
gentamycin/kg B-drug B-drug
bwt O O
were O O
given O O
i.v O O
. O O

conversely O O
, O O
diethylpropion B-drug O
may O O
interfere O O
with O O
antihypertensive B-group B-group
drugs I-group I-group
( O O
i.e. O O
, O O
guanethidine B-drug B-drug
, O O
a-methyldopa B-drug B-drug
) O O
. O O

Co-treatment O O
with O O
the O O
potent O O
CYP3A4 O O
inhibitor O O
ketoconazole B-drug B-drug
increases O O
erlotinib B-drug B-drug
AUC O O
by O O
2/3 O O
. O O

Platelet B-group B-group
inhibitors I-group I-group
: O O
Drugs O O
such O O
as O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
dextran B-drug B-drug
, O O
phenylbutazone B-drug B-drug
, O O
ibuprofen B-drug B-drug
, O O
indomethacin B-drug B-drug
, O O
dipyridamole B-drug B-drug
, O O
hydroxychloroquine B-drug B-drug
and O O
others O O
that O O
interfere O O
with O O
platelet-aggregation O O
reactions O O
( O O
the O O
main O O
hemostatic O O
defense O O
of O O
heparinized O O
patients O O
) O O
may O O
induce O O
bleeding O O
and O O
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
heparin B-drug B-drug
sodium I-drug I-drug
. O O

It O O
is O O
not O O
known O O
whether O O
the O O
concurrent O O
use O O
of O O
these O O
agents O O
with O O
apraclonidine B-drug B-drug
can O O
lead O O
to O O
a O O
reduction O O
in O O
IOP O O
lowering O O
effect O O
. O O

The O O
approach O O
is O O
applicable O O
across O O
a O O
wide O O
variety O O
of O O
settings O O
commonly O O
associated O O
with O O
joint O O
action O O
data O O
, O O
including O O
continuous O O
and O O
discrete O O
responses O O
, O O
alternative O O
error O O
structures O O
, O O
and O O
nonzero O O
background O O
response O O
. O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
cardiac O O
arrhythmias O O
. O O

Methotrexate B-drug B-drug
: O O
Ibuprofen B-drug B-drug
, O O
as O O
well O O
as O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
probably O O
reduces O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-drug B-drug
based O O
on O O
in O O
vitro O O
studies O O
in O O
rabbit O O
kidney O O
slices O O
. O O

Inducers O O
of O O
CYP3A4 O O

Because O O
of O O
the O O
potential O O
for O O
additive O O
or O O
synergistic O O
depressant O O
effects O O
on O O
the O O
SA O O
and O O
AV O O
nodes O O
, O O
however O O
, O O
Adenocard B-brand B-brand
should O O
be O O
used O O
with O O
caution O O
in O O
the O O
presence O O
of O O
these O O
agents O O
. O O

Food O O
: O O
Isoniazid B-drug B-drug
should O O
not O O
be O O
administered O O
with O O
food O O
. O O

Postoperatively O O
, O O
45 O O
patients O O
were O O
randomly O O
assigned O O
in O O
a O O
double-blind O O
fashion O O
to O O
receive O O
ADL B-drug B-drug
8-2698 I-drug I-drug
( O O
4 O O
mg O O
) O O
or O O
placebo O O
and O O
intravenous O O
morphine B-drug B-drug
( O O
0.15 O O
mg/kg O O
) O O
or O O
to O O
receive O O
oral O O
and O O
intravenous O O
placebo O O
. O O

No O O
information O O
available O O
. O O

An O O
increased O O
incidence O O
of O O
benign O O
ovarian O O
granulosa O O
cell O O
tumors O O
and O O
testicular O O
Leydig O O
cell O O
tumors O O
was O O
evident O O
, O O
in O O
females O O
dosed O O
at O O
10 O O
mg/rat/15 O O
days O O
and O O
males O O
dosed O O
at O O
15 O O
mg/rat/30 O O
days O O
, O O
respectively O O
. O O

Behavioral O O
responses O O
to O O
repeated O O
cocaine B-drug B-drug
exposure O O
in O O
mice O O
selectively O O
bred O O
for O O
differential O O
sensitivity O O
to O O
pentobarbital B-drug B-drug
. O O

Such O O
individuals O O
are O O
referred O O
to O O
as O O
poor O O
metabolizers O O
of O O
drugs O O
such O O
as O O
debrisoquin B-drug B-drug
, O O
dextromethorphan B-drug B-drug
, O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
and O O
clozapine B-drug B-drug
. O O

Steady-state O O
plasma O O
felbamate B-drug B-drug
concentrations O O
were O O
found O O
to O O
be O O
29 O O
% O O
lower O O
than O O
the O O
mean O O
concentrations O O
of O O
a O O
group O O
of O O
newly O O
diagnosed O O
subjects O O
with O O
epilepsy O O
also O O
receiving O O
2400 O O
mg O O
of O O
felbamate B-drug B-drug
a O O
day O O
. O O

Cevimeline B-drug B-drug
should O O
be O O
used O O
with O O
caution O O
in O O
individuals O O
known O O
or O O
suspected O O
to O O
be O O
deficient O O
in O O
CYP2D6 O O
activity O O
, O O
based O O
on O O
previous O O
experience O O
, O O
as O O
they O O
may O O
be O O
at O O
a O O
higher O O
risk O O
of O O
adverse O O
events O O
. O O

see O O
DOSAGE O O
AND O O
ADMINISTRATION O O
) O O
. O O

Dasatinib B-drug B-drug
and O O
its O O
metabolites O O
are O O
minimally O O
excreted O O
via O O
the O O
kidney O O
. O O

Other O O
CYP3A4 O O
inducers O O
include O O
, O O
but O O
are O O
not O O
limited O O
to O O
, O O
rifabutin B-drug B-drug
, O O
rifapentine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
and O O
St. O O
Johns O O
Wort O O
. O O

. O O

Co-medications O O
that O O
induce O O
CYP O O
3A4 O O
( O O
e.g. O O
, O O
rifampicin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
or O O
St. O O
John O O
s O O
wort O O
) O O
may O O
significantly O O
decrease O O
exposure O O
to O O
exemestane B-drug B-drug
. O O

Among O O
the O O
risk O O
factors O O
studied O O
, O O
two O O
appear O O
to O O
increase O O
the O O
risk O O
of O O
ARE O O
: O O
the O O
prescription O O
of O O
thiabendazole B-drug B-drug
to O O
treat O O
strongyloidiasis O O
during O O
the O O
melarsoprol B-drug B-drug
cure O O
and O O
the O O
bad O O
general O O
clinical O O
conditions O O
of O O
patients O O
. O O

The O O
effects O O
of O O
nonbenzodiazepine O B-group
agonists O I-group
at O O
benzodiazepine O B-group
receptors O O
, O O
such O O
as O O
zopiclone B-drug B-drug
, O O
triazolopyridazines O B-group
and O O
others O O
, O O
are O O
also O O
blocked O O
by O O
ROMAZICON B-brand B-brand
. O O

. O O

When O O
administered O O
with O O
food O O
or O O
milk O O
, O O
there O O
is O O
more O O
rapid O O
absorption O O
; O O

Read O O
circulars O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
concomitant O O
therapy O O
. O O

indinavir I-drug I-drug
concentration O O

= O O
decrease O O

No O O
change O O
in O O
dose O O
of O O
either O O
drug O O
is O O
recommended O O
. O O

INH B-drug O
( O O
Isoniazid B-drug B-drug
) O O
is O O
also O O
reported O O
to O O
affect O O
ketoconazole B-drug B-drug
concentrations O O
adversely O O
. O O

In O O
vitro O O
studies O O
demonstrated O O
that O O
the O O
plasma O O
protein O O
binding O O
of O O
des-ciclesonide B-drug B-drug
was O O
not O O
affected O O
by O O
warfarin B-drug B-drug
or O O
salicylic B-drug B-drug
acid I-drug I-drug
, O O
indicating O O
no O O
potential O O
for O O
protein O O
binding-based O O
drug O O
interactions O O
. O O

The O O
following O O
drug O O
interactions O O
have O O
been O O
identified O O
involving O O
NIZORAL B-brand B-brand
Tablets O O
and O O
other O O
drugs O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
: O O
Ketoconazole B-drug B-drug
tablets O O
inhibit O O
the O O
metabolism O O
of O O
terfenadine B-drug B-drug
, O O
resulting O O
in O O
an O O
increased O O
plasma O O
concentration O O
of O O
terfenadine B-drug B-drug
and O O
a O O
delay O O
in O O
the O O
elimination O O
of O O
its O O
acid O O
metabolite O O
. O O

Cmax O O
and O O
t1/2 O B-drug
were O O
increased O O
1.4-fold O O
and O O
1.3-fold O O
, O O
respectively O O
. O O

Pharmacokinetic O O
interactions O O
between O O
nisoldipine B-drug B-drug
and O O
beta-blockers B-group B-group
( O O
atenolol B-drug B-drug
, O O
propranolol B-drug B-drug
) O O
were O O
variable O O
and O O
not O O
significant O O
. O O

Theophylline-related B-drug O
adverse O O
effects O O
have O O
occurred O O
in O O
patients O O
when O O
theophylline B-drug B-drug
and O O
enoxacin B-drug B-drug
were O O
coadministered O O
. O O

Certain O O
drugs O O
tend O O
to O O
produce O O
hyperglycemia O O
and O O
may O O
lead O O
to O O
loss O O
of O O
control O O
. O O

Example O O
inhibitors O B-group
include O O
azole B-group B-group
antifungals I-group I-group
, O O
ciprofloxacin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
diclofenac B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
imatinib B-drug B-drug
, O O
isoniazid B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
nicardipine B-drug B-drug
, O O
propofol B-drug B-drug
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
quinidine B-drug B-drug
, O O
and O O
verapamil B-drug B-drug
. O O

Effect O O
of O O
diazepam B-drug B-drug
and O O
midazolam B-drug B-drug
on O O
the O O
antinociceptive O O
effect O O
of O O
morphine B-drug B-drug
, O O
metamizol B-drug B-drug
and O O
indomethacin B-drug B-drug
in O O
mice O O
. O O

When O O
encountered O O
, O O
such O O
arrhythmias O O
may O O
respond O O
to O O
administration O O
of O O
a O O
beta-adrenergic B-group B-group
blocking I-group I-group
drug I-group I-group
. O O

The O O
clinical O O
significance O O
is O O
unknown O O
. O O

Cytochrome O O
P-450 O O
inducers O O
, O O
such O O
as O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
and O O
phenobarbital B-drug B-drug
, O O
induce O O
clonazepam B-drug B-drug
metabolism O O
, O O
causing O O
an O O
approximately O O
30 O O
% O O
decrease O O
in O O
plasma O O
clonazepam B-drug B-drug
levels O O
. O O

Binding O O
to O O
plasma O O
protein O O
is O O
not O O
significantly O O
altered O O
by O O
diazepam B-drug B-drug
, O O
diphenylhydantoin B-drug B-drug
, O O
or O O
phenylbutazone B-drug B-drug
. O O

Immunogenicity/Re-exposure O O
: O O
In O O
in O O
vitro O O
studies O O
, O O
Angiomax B-brand B-brand
exhibited O O
no O O
platelet O O
aggregation O O
response O O
against O O
sera O O
from O O
patients O O
with O O
a O O
history O O
of O O
HIT/HITTS O O
. O O

Concomitant O O
administration O O
of O O
other O O
sympathomimetic B-group B-group
agents I-group I-group
may O O
potentiate O O
the O O
undesirable O O
effects O O
of O O
FORADIL B-brand B-brand
. O O

Doxylamine B-drug B-drug
may O O
enhance O O
the O O
effects O O
of O O
epinephrine B-drug B-drug
. O O

Rare O O
instances O O
of O O
dyspnea O O
, O O
palpitation O O
, O O
chest O O
pain O O
, O O
syncope O O
. O O

Nevertheless O O
, O O
the O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
test O O
should O O
be O O
monitored O O
when O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
and O O
enoxacin B-drug B-drug
are O O
given O O
concomitantly O O
. O O

These O O
agents O O
should O O
not O O
be O O
taken O O
within O O
4 O O
hours O O
before O O
or O O
4 O O
hours O O
after O O
grepafloxacin B-drug B-drug
administration O O
. O O

Amiodarone B-drug B-drug
taken O O
concomitantly O O
with O O
quinidine B-drug B-drug
increases O O
quinidine B-drug B-drug
serum O O
concentration O O
by O O
33 O O
% O O
after O O
two O O
days O O
. O O

If O O
antacid B-group B-group
therapy O O
is O O
needed O O
, O O
the O O
antacid O B-group
dose O O
should O O
be O O
administered O O
at O O
least O O
2 O O
hours O O
prior O O
to O O
or O O
2 O O
hours O O
after O O
the O O
dose O O
of O O
SPRYCEL B-brand B-brand
. O O

Although O O
17-hydroxy-corticosteroid O O
measurements O O
( O O
Porter-Silber O O
test O O
) O O
do O O
not O O
appear O O
to O O
be O O
artifactually O O
altered O O
, O O
it O O
is O O
suggested O O
that O O
therapy O O
with O O
naproxen B-drug B-drug
be O O
temporarily O O
discontinued O O
72 O O
hours O O
before O O
adrenal O O
function O O
tests O O
are O O
performed O O
if O O
the O O
Porter-Silber O O
test O O
is O O
to O O
be O O
used O O
. O O

Rifampin B-drug B-drug
, O O
an O O
inducer O O
of O O
drug O O
metabolism O O
, O O
decreased O O
the O O
concentrations O O
of O O
losartan B-drug B-drug
and O O
its O O
active O O
metabolite O O
. O O

Drugs O O
Whose O O
Absorption O O
Can O O
Be O O
Affected O O
by O O
the O O
Level O O
of O O
Acidity O O
in O O
the O O
Stomach O O
: O O
Drugs O O
such O O
as O O
ketoconazole B-drug B-drug
and O O
itraconazole B-drug B-drug
should O O
be O O
administered O O
at O O
least O O
2 O O
hours O O
prior O O
to O O
dosing O O
with O O
VIDEX B-brand B-brand
. O O

Vaccinations O O
with O O
attenuated O O
live O O
bacteria O O
should O O
therefore O O
be O O
completed O O
at O O
least O O
3 O O
days O O
before O O
the O O
first O O
dose O O
of O O
Mefloquine B-drug B-drug
. O O

Additional O O
reductions O O
in O O
blood O O
pressure O O
may O O
occur O O
when O O
FLOLAN B-brand B-brand
is O O
administered O O
with O O
diuretics B-group B-group
, O O
antihypertensive B-group B-group
agents I-group I-group
, O O
or O O
other O O
vasodilators B-group B-group
. O O

The O O
inhibitor O O
, O O
on O O
the O O
other O O
hand O O
, O O
promoted O O
significant O O
decrease O O
of O O
nucleolin/C23 O O
in O O
NIH-3T3 O O
cells O O
during O O
serum O O
deprivation O O
. O O

Candida O O
albicans O O
, O O
one O O
of O O
the O O
pathogenic O O
species O O
, O O
was O O
totally O O
inhibited O O
at O O
a O O
concentration O O
of O O
approximately O O
10 O O
mug/ml O O
. O O

certain O O
antibiotics B-group B-group
, O O
especially O O
the O O
aminoglycosides B-group B-group
and O O
polymyxins B-group B-group
; O O

The O O
extent O O
to O O
which O O
SSRI-TCA B-group B-group
interactions O O
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

The O O
AUC O O
of O O
eszopiclone B-drug B-drug
was O O
increased O O
2.2-fold O O
by O O
coadministration O O
of O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
CYP3A4 O O
, O O
400 O O
mg O O
daily O O
for O O
5 O O
days O O
. O O

Lopinavir I-drug B-drug

Particular O O
caution O O
is O O
necessary O O
when O O
using O O
ROMAZICON B-brand B-brand
in O O
cases O O
of O O
mixed O O
drug O O
overdosage O O
since O O
the O O
toxic O O
effects O O
( O O
such O O
as O O
convulsions O O
and O O
cardiac O O
dysrhythmias O O
) O O
of O O
other O O
drugs O O
taken O O
in O O
overdose O O
( O O
especially O O
cyclic B-group B-group
antidepressants I-group I-group
) O O
may O O
emerge O O
with O O
the O O
reversal O O
of O O
the O O
benzodiazepine B-group B-group
effect O O
by O O
flumazenil B-drug B-drug
. O O

The O O
second O O
response O O
is O O
due O O
to O O
a O O
release O O
of O O
norepinephrine O B-drug
from O O
nerves O O
and O O
was O O
potentiated O O
by O O
ouabain B-drug B-drug
through O O
the O O
increase O O
in O O
the O O
norepinephrine O O
release O O
, O O
whereas O O
the O O
first O O
response O O
was O O
not O O
due O O
to O O
the O O
norepinephrine O B-drug
release O O
but O O
presumably O O
to O O
a O O
direct O O
action O O
on O O
smooth O O
muscle O O
cell O O
and O O
was O O
inhibited O O
by O O
ouabain B-drug B-drug
. O O

Oral O O
contraceptives B-group B-group
and O O
other O O
hormonalmethods O O
of O O
birth O O
control O O
should O O
not O O
be O O
usedas O O
the O O
sole O O
method O O
of O O
contraception O O
inwomen O O
taking O O
nevirapine B-drug B-drug
, O O
since O O
nevirapinemay O O
lower O O
the O O
plasma O O
levels O O
of O O
thesemedications O O
. O O

Therefore O O
, O O
the O O
potential O O
for O O
such O O
drug O O
interactions O O
should O O
be O O
considered O O
in O O
patients O O
receiving O O
dorzolamide B-drug B-drug
. O O

Human I-drug O
growth I-drug O
hormone I-drug O
- O O
Concomitant O O
use O O
of O O
L-glutamine B-drug B-drug
and O O
human B-drug O
growth I-drug O
hormone I-drug O
may O O
enhance O O
nutrient O O
absorption O O
in O O
those O O
with O O
severe O O
short O O
bowel O O
syndrome O O
. O O

No O O
effects O O
on O O
plasma O O
concentrations O O
of O O
cimetidine B-drug B-drug
or O O
ketoconazole B-drug B-drug
were O O
observed O O
. O O

amphotericin B-drug B-drug
B I-drug I-drug
, O O
however O O
, O O
is O O
useful O O
in O O
therapy O O
of O O
human O O
fungal O O
infections O O
because O O
it O O
is O O
less O O
toxic O O
. O O

Administration O O
of O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
concomitantly O O
with O O
cyclosporine B-drug B-drug
has O O
been O O
associated O O
with O O
an O O
increase O O
in O O
cyclosporine-induced B-drug B-drug
toxicity O O
, O O
possibly O O
due O O
to O O
decreased O O
synthesis O O
of O O
renal O O
prostacyclin O O
. O O

No O O
studies O O
have O O
been O O
performed O O
with O O
other O O
NNRTIs B-group B-group
. O O

Nicotine B-drug B-drug
: O O
Nicotine B-drug B-drug
may O O
provoke O O
vasoconstriction O O
in O O
some O O
patients O O
, O O
predisposing O O
to O O
a O O
greater O O
ischemic O O
response O O
to O O
ergot B-drug B-group
therapy O O
. O O

8 O O
. O O

Because O O
of O O
the O O
broadening O O
indications O O
for O O
immunosuppressive B-group B-group
drugs I-group I-group
, O O
and O O
the O O
prolonged O O
survival O O
in O O
conditions O O
for O O
which O O
they O O
are O O
being O O
used O O
, O O
many O O
patients O O
on O O
immunosuppression O O
are O O
now O O
cared O O
for O O
in O O
the O O
community O O
or O O
seen O O
in O O
non-specialist O O
hospitals O O
, O O
usually O O
in O O
close O O
collaboration O O
with O O
a O O
specialist O O
. O O

A O O
causal O O
relationship O O
has O O
not O O
been O O
established O O

Therefore O O
, O O
there O O
is O O
a O O
potential O O
for O O
an O O
in O O
vivo O O
drug O O
interaction O O
with O O
drugs O O
that O O
are O O
metabolized O O
by O O
P450 O O
2D6 O O
. O O

Verapamil B-drug B-drug
: O O
Concomitant O O
use O O
of O O
verapamil B-drug B-drug
is O O
contraindicated O O
. O O

( O O
500 O O
mg O O
Q8h O O
) O O

Duloxetine B-drug B-drug
May O O
Have O O
a O O
Clinically O O
Important O O
Interaction O O
with O O
the O O
Following O O
Other O O
Drugs O O
: O O
Alcohol B-drug B-drug
: O O
When O O
Duloxetine B-drug B-drug
and O O
ethanol B-drug B-drug
were O O
administered O O
several O O
hours O O
apart O O
so O O
that O O
peak O O
concentrations O O
of O O
each O O
would O O
coincide O O
, O O
Duloxetine B-drug B-drug
did O O
not O O
increase O O
the O O
impairment O O
of O O
mental O O
and O O
motor O O
skills O O
caused O O
by O O
alcohol B-drug B-drug
. O O

On O O
the O O
basis O O
of O O
the O O
metabolism O O
of O O
bexarotene B-drug B-drug
by O O
cytochrome O O
P450 O O
3A4 O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
gemfibrozil B-drug B-drug
, O O
grapefruit O O
juice O O
, O O
and O O
other O O
inhibitors O O
of O O
cytochrome O O
P450 O O
3A4 O O
would O O
be O O
expected O O
to O O
lead O O
to O O
an O O
increase O O
in O O
plasma O O
bexarotene B-drug B-drug
concentrations O O
. O O

- O O
Decreased O O
pregnanediol O B-drug
excretion O O

The O O
incidence O O
of O O
upper O O
gastrointestinal O O
events O O
in O O
patients O O
concomitantly O O
taking O O
aspirin B-brand B-brand
or O O
NSAIDs B-group B-group
was O O
similar O O
in O O
patients O O
taking O O
ibandronate B-drug B-drug
2.5 O O
mg O O
daily O O
( O O
21.7 O O
% O O
) O O
and O O
150 O O
mg O O
once O O
monthly O O
( O O
22.0 O O
% O O
) O O
. O O

Oral O O
Contraceptive B-group B-group
: O O
Based O O
on O O
AUC O O
and O O
half-life O O
, O O
multiple-dose O O
pharmacokinetic O O
profiles O O
of O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
following O O
administration O O
of O O
tablets O O
containing O O
2.5 O O
mg O O
of O O
norethindrone B-drug B-drug
acetate I-drug I-drug
and O O
50 O O
mcg O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
were O O
similar O O
with O O
and O O
without O O
coadministration O O
of O O
gabapentin B-drug B-drug
( O O
400 O O
mg O O
TID O O
; O O

Drugs O O
That O O
Are O O
Mainly O O
Metabolized O O
by O O
CYP3A4 O O

Elevated O O
plasma O O
levels O O
of O O
theophylline B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
quinolone B-group B-group
use O O
. O O

Because O O
lithium B-drug B-drug
may O O
enhance O O
the O O
serotonergic O O
effects O O
of O O
escitalopram B-drug B-drug
, O O
caution O O
should O O
be O O
exercised O O
when O O
LEXAPRO B-brand B-brand
and O O
lithium B-drug B-drug
are O O
coadministered O O
. O O

Drugs O O
That O O
Should O O
Not O O
Be O O
Coadministered O O
With O O
VIRACEPT B-brand B-brand
Antiarrhythmics B-group B-group
: O O
amiodarone B-drug B-drug
, O O
quinidine B-drug B-drug
Antihistamines B-group B-group
: O O
astemizole B-drug B-drug
, O O
terfenadine B-drug B-drug
Antimigraine O I-drug
: O O
ergot B-group B-group
derivatives I-group I-group
Antimycobacterial I-group I-group
agents I-group I-group
: O O
rifampin B-drug B-drug
Benzodiazepines B-group B-group
midazolam B-drug B-drug
, O O
triazolam B-drug B-drug
GI O O
motility O O
agents O O
: O O
cisapride B-drug B-drug

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

Cercarial O B-brand
encystment O O
at O O
concentrations O O
of O O
25000 O O
microg/l O O
or O O
higher O O
was O O
significantly O O
impaired O O
by O O
all O O
test O O
metals O O
; O O

Hyperpyrexia O O
has O O
been O O
reported O O
when O O
amitriptyline B-drug B-drug
HCl I-drug I-drug
is O O
administered O O
with O O
anticholinergic B-drug B-group
agents O I-group
or O O
with O O
neuroleptic B-drug B-group
drugs O I-group
, O O
particularly O O
during O O
hot O O
weather O O
. O O

Some O O
clinicians O O
have O O
noted O O
that O O
these O O
reactions O O
resemble O O
the O O
immediate O O
side O O
effects O O
caused O O
by O O
interleukin-2 B-drug B-drug
administration O O
, O O
however O O
the O O
cause O O
of O O
contrast O O
reactions O O
after O O
interleukin-2 O B-drug
therapy O O
is O O
unknown O O
. O O

The O O
anxiogenic O O
effects O O
of O O
theophylline B-drug B-drug
were O O
reduced O O
by O O
pretreatment O O
with O O
CGS B-drug_n B-drug
21680 I-drug_n I-drug
, O O
an O O
A2-selective O O
agonist O O
, O O
but O O
not O O
by O O
N6-cyclopentyladenosine B-drug_n B-drug_n
( O O
CPA B-drug_n B-drug_n
) O O
, O O
an O O
A1-selective O B-group
agonist O I-group
. O O

CNS O O
vascular O O
lesions O O
, O O
characterized O O
by O O
perivascular O O
hemorrhages O O
, O O
edema O O
, O O
and O O
mononuclear O O
cell O O
infiltration O O
of O O
perivascular O O
spaces O O
, O O
have O O
been O O
observed O O
in O O
dogs O O
treated O O
with O O
other O O
members O O
of O O
this O O
class O O
. O O

Ketamine B-drug B-drug
is O O
clinically O O
compatible O O
with O O
the O O
commonly O O
used O O
general O O
and O O
local O O
anesthetic B-group B-group
agents I-group I-group
when O O
an O O
adequate O O
respiratory O O
exchange O O
is O O
maintained O O
. O O

Erythromycin B-drug B-drug

increased O O
plasminogen O O
antigen O O
and O O
activity O O
. O O

Although O O
there O O
was O O
no O O
clinical O O
evidence O O
in O O
the O O
vehicle-controlled O O
studies O O
of O O
drug O O
interactions O O
with O O
systemic O B-group
antiretroviral B-group I-group
agents I-group I-group
, O O
including O O
protease B-group B-group
inhibitors I-group I-group
, O O
macrolide B-group B-group
antibiotics I-group I-group
, O O
and O O
azole B-group B-group
antifungals I-group I-group
, O O
the O O
effect O O
of O O
Panretin B-brand B-brand
gel O O
on O O
the O O
steady-state O O
concentrations O O
of O O
these O O
drugs O O
is O O
not O O
known O O
. O O

In O O
contrast O O
, O O
acute O O
toxicity O O
tests O O
showed O O
that O O
oral O O
CCNU B-drug B-drug
was O O
1.45 O O
times O O
less O O
toxic O O
to O O
normal O O
tissue O O
, O O
although O O
the O O
dose-limiting O O
organ O O
may O O
be O O
different O O
for O O
the O O
two O O
routes O O
. O O

Levodopa B-drug B-drug
and O O
Amantadine B-drug B-drug
: O O
Limited O O
clinical O O
data O O
suggest O O
a O O
higher O O
incidence O O
of O O
adverse O O
experiences O O
in O O
patients O O
receiving O O
bupropion B-drug B-drug
concurrently O O
with O O
either O O
levodopa B-drug B-drug
or O O
amantadine B-drug B-drug
. O O

In O O
patients O O
receiving O O
another O O
serotonin B-group B-group
reuptake I-group I-group
inhibitor I-group I-group
drug I-group I-group
in O O
combination O O
with O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
( O O
MAOI B-group B-group
) O O
, O O
there O O
have O O
been O O
reports O O
of O O
serious O O
, O O
sometimes O O
fatal O O
, O O
reactions O O
including O O
hyperthermia O O
, O O
rigidity O O
, O O
myoclonus O O
, O O
autonomic O O
instability O O
with O O
possible O O
rapid O O
fluctuations O O
of O O
vital O O
signs O O
, O O
and O O
mental O O
status O O
changes O O
that O O
include O O
extreme O O
agitation O O
progressing O O
to O O
delirium O O
and O O
coma O O
. O O

In O O
addition O O
, O O
several O O
AED B-group B-group
s O O
that O O
are O O
cytochrome O O
P450 O O
inducers O O
can O O
decrease O O
plasma O O
concentrations O O
of O O
oxcarbazepine B-drug B-drug
and O O
MHD B-drug_n B-drug_n
. O O

Administer O O
LEVSIN B-brand B-brand
before O O
meals O O
; O O

No O O
studies O O
have O O
been O O
conducted O O
at O O
intermediate O O
doses O O
of O O
cimetidine B-drug B-drug
. O O

Inhibition O O
of O O
metabolism O O
may O O
produce O O
significant O O
increases O O
in O O
circulating O O
phenytoin B-drug B-drug
concentrations O O
and O O
enhance O O
the O O
risk O O
of O O
drug O O
toxicity O O
. O O

The O O
mechanism O O
for O O
this O O
interaction O O
is O O
not O O
known O O
. O O

In O O
ewes O O
given O O
40 O O
mg O O
of O O
phenobarbital B-drug B-drug
sodium/kg O I-drug
for O O
5 O O
days O O
intraperitoneally O O
( O O
IP O O
) O O
, O O
the O O
anticholinesterase O O
effect O O
of O O
4 O O
mg O O
of O O
coumaphos/kg B-drug_n B-drug_n
was O O
significantly O O
reduced O O
and O O
signs O O
of O O
toxicity O O
were O O
not O O
present O O
. O O

There O O
also O O
was O O
no O O
effect O O
on O O
exposure O O
to O O
and O O
the O O
excretion O O
of O O
the O O
primary O O
metabolite O O
, O O
ucb O O
L057 O O
. O O

Chlorthalidone B-drug B-drug
may O O
add O O
to O O
or O O
potentiate O O
the O O
action O O
of O O
other O O
antihypertensive B-group B-group
drugs I-group I-group
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
. O O

OBJECTIVE O O
: O O
Our O O
objective O O
was O O
to O O
characterize O O
the O O
steady-state O O
pharmacokinetics O O
of O O
everolimus B-drug B-drug
and O O
cyclosporine B-drug B-drug
( O O
INN O O
, O O
ciclosporin B-drug B-drug
) O O
when O O
coadministered O O
in O O
de O O
novo O O
kidney O O
allograft O O
recipients O O
during O O
the O O
first O O
year O O
after O O
transplantation O O
. O O

Adrenocorticoids O B-group
: O O
Metabolic O O
clearance O O
of O O
adrenocorticoids O B-group
is O O
decreased O O
in O O
hypothyroid O O
patients O O
and O O
increased O O
in O O
hyperthyroid O O
patients O O
, O O
and O O
may O O
therefore O O
change O O
with O O
changing O O
thyroid O O
status O O
. O O

The O O
physician O O
should O O
be O O
notified O O
immediately O O
if O O
any O O
of O O
the O O
following O O
situations O O
occur O O
, O O
which O O
may O O
be O O
a O O
sign O O
of O O
seriously O O
worsening O O
asthma O O
: O O
Decreased O O
effectiveness O O
of O O
short-acting B-group O
, I-group O
inhaled I-group O
beta2-agonists I-group B-group
; O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
propafenone B-drug B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

The O O
steady-state O O
Cmin O O
concentration O O
increased O O
to O O
17.8 O O
micrograms/mL O O
when O O
2400 O O
mg/day O O
of O O
felbamate B-drug B-drug
was O O
coadministered O O
for O O
one O O
week O O
. O O

Lithium B-drug B-drug
- O O
Coadministration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
40 O O
mg/day O O
for O O
10 O O
days O O
) O O
and O O
lithium B-drug B-drug
( O O
30 O O
mmol/day O O
for O O
5 O O
days O O
) O O
had O O
no O O
significant O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
citalopram B-drug B-drug
or O O
lithium B-drug B-drug
. O O

Avoid O O
the O O
use O O
of O O
preparations O O
such O O
as O O
decongestants B-group B-group
and O O
local O O
anesthetics B-group B-group
which O O
contain O O
any O O
sympathomimetic B-group B-group
amine I-group I-group
( O O
e.g. O O
, O O
epinephrine B-drug B-drug
, O O
norepinephrine B-drug B-drug
) O O
, O O
since O O
it O O
has O O
been O O
reported O O
that O O
tricyclic B-group B-group
antidepressants I-group I-group
can O O
potentiate O O
the O O
effects O O
of O O
catecholamines O B-group
. O O

The O O
para-aminobenzoic O O
acid O O
metabolite O O
of O O
chloroprocaine O B-drug
inhibits O O
the O O
action O O
of O O
sulfonamides B-group B-group
. O O

Lithium B-drug B-drug
: O O
Increased O O
serum O O
lithium B-drug B-drug
levels O O
and O O
symptoms O O
of O O
lithium B-drug B-drug
toxicity O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
ACE B-group B-group
inhibitors I-group I-group
during O O
therapy O O
with O O
lithium B-drug B-drug
. O O

Use O O
with O O
caution O O
and O O
be O O
prepared O O
to O O
treat O O
hypertension O O
, O O
if O O
necessary O O
. O O

Gastrointestinal O B-group
agents O I-group
( O O
e.g. O O
, O O
antacids B-group B-group
) O O
. O O

- O O
Daunorubicin B-drug B-drug
( O O
e.g. O O
, O O
Cerubidine B-brand B-brand
) O O
or O O

Pediatric O O
Use O O
The O O
safety O O
and O O
effectiveness O O
of O O
PEGASYS B-brand B-brand
, O O
alone O O
or O O
in O O
combination O O
with O O
COPEGUS B-brand B-brand
in O O
patients O O
below O O
the O O
age O O
of O O
18 O O
years O O
have O O
not O O
been O O
established O O
. O O

Prolonged O O
menstrual O O
cycles O O
and/or O O
amenorrhea O O
were O O
observed O O
in O O
female O O
cynomolgus O O
monkeys O O
given O O
sc O O
injections O O
of O O
600 O O
m O O
g/kg/dose O O
( O O
7200 O O
m O O
g/m2/dose O O
) O O
of O O
PEGASYS B-brand B-brand
every O O
other O O
day O O
for O O
one O O
month O O
, O O
at O O
approximately O O
180 O O
times O O
the O O
recommended O O
weekly O O
human O O
dose O O
for O O
a O O
60 O O
kg O O
person O O
( O O
based O O
on O O
body O O
surface O O
area O O
) O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
using O O
these O O
drugs O O
together O O
. O O

Alternatives O O
to O O
rifampin B-drug B-drug
should O O
be O O
considered O O
during O O
the O O
course O O
of O O
PCP O B-drug_n
treatment O O
with O O
MEPRON B-brand B-brand
. O O

Component O O
P2 O O
, O O
however O O
, O O
was O O
increased O O
in O O
amplitude O O
. O O

In O O
utero O O
, O O
serum O O
levels O O
of O O
exposure O O
in O O
these O O
monkeys O O
were O O
23 O O
% O O
of O O
maternal O O
serum O O
levels O O
. O O

Patients O O
on O O
thyroid O O
replacement O O
therapy O O
may O O
require O O
higher O O
doses O O
of O O
thyroid B-group B-group
hormone I-group I-group
. O O

Coadministration O O
of O O
LEXAPRO B-brand B-brand
and O O
metoprolol B-drug B-drug
had O O
no O O
clinically O O
significant O O
effects O O
on O O
blood O O
pressure O O
or O O
heart O O
rate O O
. O O

NaCMC B-drug_n B-drug_n
at O O
1 O O
% O O
( O O
m/v O O
) O O
in O O
the O O
presence O O
of O O
free O O
cysteine B-drug B-drug
had O O
no O O
significant O O
effect O O
on O O
the O O
R-value O O
of O O
NaFlu B-drug B-drug
compared O O
to O O
NaCMC B-drug_n B-drug_n
alone O O
. O O

It O O
is O O
recommended O O
that O O
these O O
tests O O
be O O
performed O O
prior O O
to O O
initiation O O
of O O
Soriatane B-brand B-brand
therapy O O
, O O
at O O
1- O O
to O O
2-week O O
intervals O O
until O O
stable O O
and O O
thereafter O O
at O O
intervals O O
as O O
clinically O O
indicated O O
. O O

24.9 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
4.5 O O
) O O
were O O
PICR O O
, O O
detected O O
in O O
11.7 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
2.5 O O
) O O
of O O
the O O
MAC O O
. O O

Data O O
beyond O O
10 O O
days O O
are O O
not O O
available O O
. O O

Each O O
month O O
of O O
therapy O O
, O O
the O O
patient O O
must O O
have O O
a O O
negative O O
result O O
from O O
a O O
urine O O
or O O
serum O O
pregnancy O O
test O O
. O O

When O O
intravenous O O
morphine B-drug B-drug
and O O
BREVIBLOC B-brand B-brand
were O O
concomitantly O O
administered O O
in O O
normal O O
subjects O O
, O O
no O O
effect O O
on O O
morphine B-drug B-drug
blood O O
levels O O
was O O
seen O O
, O O
but O O
BREVIBLOC B-brand B-brand
steady-state O O
blood O O
levels O O
were O O
increased O O
by O O
46 O O
% O O
in O O
the O O
presence O O
of O O
morphine B-drug B-drug
. O O

Because O O
of O O
the O O
pronounced O O
intersubject O O
variability O O
in O O
the O O
extent O O
of O O
the O O
sirolimus-diltiazem B-drug B-drug
interaction O O
, O O
whole O O
blood O O
sirolimus B-drug B-drug
concentrations O O
should O O
be O O
monitored O O
closely O O
in O O
patients O O
treated O O
with O O
the O O
two O O
drugs O O
. O O

Effect O O

Therefore O O
, O O
patients O O
receiving O O
probenecid B-drug B-drug
will O O
have O O
erroneously O O
low O O
ERPF O O
and O O
Tm O O
PAH B-drug O
values O O
. O O

Drug-Drug O O
Interactions O O
: O O
No O O
clinically O O
significant O O
drug O O
interactions O O
have O O
been O O
found O O
with O O
theophylline B-drug B-drug
at O O
a O O
low O O
dose O O
, O O
azithromycin B-drug B-drug
, O O
pseudoephedrine B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
or O O
erythromycin B-drug B-drug
. O O

Drug O O
and O O
Laboratory O O
Test O O
Interactions O O
1 O O
. O O

Drug O O
interactions O O
with O O
SUSTIVA B-brand B-brand
are O O
summarized O O
in O O
Table O O
5 O O
. O O

Since O O
blood O O
level O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
will O O
be O O
reduced O O
, O O
higher O O
doses O O
of O O
Rocaltrol B-brand B-brand
may O O
be O O
necessary O O
if O O
these O O
drugs O O
are O O
administered O O
simultaneously O O
. O O

Inhibitors O O
of O O
the O O
CYP3A4 O O
isoenzyme O O
could O O
increase O O
systemic O O
dofetilide B-drug B-drug
exposure O O
. O O

Furosemide B-drug B-drug
has O O
a O O
tendency O O
to O O
antagonize O O
the O O
skeletal O O
muscle O O
relaxing O O
effect O O
of O O
tubocurarine B-drug B-drug
and O O
may O O
potentiate O O
the O O
action O O
of O O
succinylcholine B-drug B-drug
. O O

The O O
concomitant O O
use O O
of O O
diflunisal B-drug B-drug
tablets O O
and O O
other O O
NSAIDs B-group B-group
is O O
not O O
recommended O O
due O O
to O O
the O O
increased O O
possibility O O
of O O
gastrointestinal O O
toxicity O O
, O O
with O O
little O O
or O O
no O O
increase O O
in O O
efficacy O O
. O O

Therefore O O
, O O
a O O
slower O O
onset O O
can O O
be O O
anticipated O O
if O O
STADOL B-brand B-brand
NS I-brand I-brand
is O O
administered O O
concomitantly O O
with O O
, O O
or O O
immediately O O
following O O
, O O
a O O
nasal B-group B-group
vasoconstrictor I-group I-group
. O O

Smokers O O
have O O
an O O
increased O O
clearance O O
of O O
benzodiazepines B-group B-group
as O O
compared O O
to O O
nonsmokers O O
; O O

In O O
post-marketing O O
experience O O
there O O
have O O
been O O
reports O O
of O O
increases O O
in O O
plasma O O
lithium B-drug B-drug
levels O O
. O O

periodic O O
monitoring O O
of O O
anticonvulsant B-group B-group
plasma O O
levels O O
should O O
be O O
conducted O O
. O O

Patients O O
receiving O O
azathioprine B-drug B-drug
and O O
allopurinol B-drug B-drug
concomitantly O O
should O O
have O O
a O O
dose O O
reduction O O
of O O
azathioprine B-drug B-drug
, O O
to O O
approximately O O
1/3 O O
to O O
1/4 O O
the O O
usual O O
dose O O
. O O

These O O
stimulants O O
are O O
commonly O O
found O O
in O O
coffee O O
and O O
tea O B-drug
, O O
respectively O O
. O O

The O O
pharmacodynamic O O
effects O O
can O O
be O O
explained O O
by O O
a O O
combination O O
of O O
the O O
increase O O
in O O
dofetilide B-drug B-drug
exposure O O
and O O
the O O
reductions O O
in O O
serum O O
potassium O O
. O O

In O O
about O O
30 O O
% O O
of O O
patients O O
, O O
the O O
dose O O
of O O
cyclosporine B-drug B-drug
had O O
to O O
be O O
reduced O O
in O O
order O O
to O O
maintain O O
cyclosporine B-drug B-drug
concentrations O O
within O O
the O O
therapeutic O O
range O O
, O O
while O O
in O O
the O O
remainder O O
no O O
adjustment O O
was O O
needed O O
. O O

The O O
pharmacokinetics O O
of O O
fluvastatin B-drug B-drug
have O O
also O O
been O O
assessed O O
in O O
various O O
demographic O O
groups O O
. O O

Potential O O
drug O O
interactions O O
between O O
Mentax B-brand B-brand
( O O
butenafine B-drug B-drug
HCl I-drug I-drug
cream O O
) O O
Cream O O
, O O
1 O O
% O O
, O O
and O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

( O O
Thiazides B-group B-group
may O O
decrease O O
arterial O O
responsiveness O O
to O O
norepinephrine B-drug B-drug
. O O

Nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
cephalosporins B-group B-group
with O O
aminoglycoside B-group B-group
antibiotics I-group I-group
or O O
potent O O
diuretics B-group B-group
such O O
as O O
furosemide B-drug B-drug
. O O

. O O

Lithium-A B-drug O
drug O O
interaction O O
study O O
of O O
eplerenone B-drug B-drug
with O O
lithium B-drug B-drug
has O O
not O O
been O O
conducted O O
. O O

The O O
acid-catalyzed O O
ethanol-drug B-drug O
reaction O O
is O O
a O O
relatively O O
unexplored O O
area O O
and O O
may O O
alter O O
the O O
pharmacological O O
action O O
of O O
some O O
drugs O O
. O O

Immunosuppressants B-group B-group

Intestinal B-group O
adsorbents I-group O
( O O
e. O O
g. O O
, O O
charcoal B-drug B-drug
) O O
and O O
digestive B-group O
enzyme I-group O
preparations I-group O
containing O O
carbohydrate-splitting O O
enzymes O O
( O O
e. O O
g. O O
, O O
amylase B-drug O
, O O
pancreatin B-drug O
) O O
may O O
reduce O O
the O O
effect O O
of O O
Acarbose B-drug B-drug
and O O
should O O
not O O
be O O
taken O O
concomitantly O O
. O O

The O O
augmentation O O
persisted O O
even O O
after O O
carbachol B-drug B-drug
was O O
washed O O
out O O
and O O
was O O
resistant O O
to O O
chelated O O
extracellular O O
Ca O O
( O O
2+ O O
) O O
and O O
to O O
inhibitors O O
of O O
either O O
protein O O
kinase O O
C O O
or O O
calmodulin O B-drug
kinase O I-drug
II O I-drug
. O O

Much O O
higher O O
changes O O
were O O
observed O O
in O O
liver O O
, O O
increasing O O
from O O
a O O
level O O
of O O
60 O O
% O O
at O O
4 O O
h O O
up O O
to O O
nearly O O
4 O O
times O O
the O O
control O O
at O O
24 O O
h O O
for O O
single O O
dose O O
. O O

BACKGROUND O O
: O O
The O O
effects O O
of O O
combined O O
administration O O
of O O
bombesin B-drug_n B-drug_n
and O O
verapamil B-drug B-drug
hydrochloride I-drug I-drug
( O O
verapamil B-drug B-drug
) O O
, O O
a O O
calcium B-group B-group
channel I-group I-group
blocker I-group I-group
, O O
on O O
the O O
incidence O O
of O O
peritoneal O O
metastasis O O
of O O
intestinal O O
adenocarcinomas O O
induced O O
by O O
azoxymethane B-drug_n B-drug_n
( O O
AOM B-drug_n B-drug_n
) O O
and O O
the O O
labeling O O
index O O
of O O
intestinal O O
cancers O O
were O O
investigated O O
in O O
male O O
Wistar O O
rats O O
. O O

Exjade B-brand B-brand
tablets O O
for O O
oral O O
suspension O O
can O O
be O O
dispersed O O
in O O
water O O
, O O
orange O O
juice O O
, O O
or O O
apple O O
juice O O
. O O

Since O O
apraclonidine B-drug B-drug
may O O
reduce O O
pulse O O
and O O
blood O O
pressure O O
, O O
caution O O
in O O
using O O
drugs O O
such O O
as O O
beta-blockers B-group B-group
( O O
ophthalmic O O
and O O
systemic O O
) O O
, O O
antihypertensives B-group B-group
, O O
and O O
cardiac B-group B-group
glycosides I-group I-group
is O O
advised O O
. O O

The O O
administration O O
of O O
lower O O
doses O O
of O O
Vardenafil B-drug B-drug
with O O
alpha-blockers B-group B-group
has O O
not O O
been O O
completely O O
evaluated O O
to O O
determine O O
if O O
they O O
can O O
be O O
safely O O
administered O O
together O O
. O O

Ascorbic B-drug B-drug
acid I-drug I-drug
: O O
Doses O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
( O O
vitamin B-drug B-drug
C I-drug I-drug
) O O
1 O O
g/day O O
have O O
been O O
reported O O
to O O
increase O O
plasma O O
concentration O O
of O O
synthetic B-group B-group
estrogens I-group I-group
by O O
~47 O O
% O O
, O O
possibly O O
by O O
inhibiting O O
conjugation O O
; O O

In O O
patients O O
with O O
impaired O O
cardiac O O
function O O
, O O
simultaneous O O
use O O
should O O
be O O
avoided O O
altogether O O
. O O

Investigations O O
into O O
the O O
effect O O
of O O
acitretin B-drug B-drug
on O O
the O O
protein O O
binding O O
of O O
anticoagulants B-group B-group
of I-group O
the I-group O
coumarin I-group B-group
type I-group I-group
( O O
warfarin B-drug B-drug
) O O
revealed O O
no O O
interaction O O
. O O

In O O
order O O
to O O
avoid O O
lithium B-drug B-drug
intoxication O O
, O O
lithium B-drug B-drug
plasma O O
levels O O
should O O
be O O
monitored O O
closely O O
. O O

2 O O
. O O

THE O O
DOSAGE O O
OF O O
THE O O
ANTICOAGULANTS B-group B-group
SHOULD O O
BE O O
REDUCED O O
TO O O
MAINTAIN O O
THE O O
PROTHROMBIN O O
TIME/INR O O
AT O O
THE O O
DESIRED O O
LEVEL O O
TO O O
PREVENT O O
BLEEDING O O
COMPLICATIONS O O
. O O

The O O
literature O O
provides O O
considerable O O
evidence O O
indicating O O
that O O
several O O
, O O
but O O
not O O
all O O
antihistaminics B-group B-group
, O O
are O O
indeed O O
analgesic B-group B-group
agents I-group I-group
and O O
some O O
are O O
analgesic B-group B-group
adjuvants I-group I-group
as O O
well O O
. O O

Two O O
of O O
16 O O
subjects O O
dosed O O
simultaneously O O
with O O
Vardenafil B-drug B-drug
10 O O
mg O O
and O O
tamsulosin B-drug B-drug
0.4 O O
mg O O
experienced O O
a O O
standing O O
systolic O O
blood O O
pressure O O
below O O
85 O O
mm O O
Hg O O
. O O

Thirty O O
male O O
rats O O
of O O
the O O
Fischer-344 O O
strain O O
were O O
divided O O
into O O
three O O
equal O O
groups O O
and O O
were O O
given O O
injections O O
of O O
trimethyl B-drug_n B-drug
lead I-drug_n I-drug
( O O
TML B-drug_n B-drug_n
) O O
( O O
8.0 O O
or O O
17.0 O O
mg/kg/ml O O
SC O O
) O O
or O O
the O O
saline O O
vehicle O O
. O O

Antacids B-group B-group
and O O
sucralfate B-drug B-drug
: O O
Sucralfate B-drug B-drug
and O O
antacids B-group B-group
containing O O
magnesium B-drug B-drug
or O O
aluminum B-drug B-drug
, O O
as O O
well O O
as O O
formulations O O
containing O O
divalent O O
and O O
trivalent O O
cations O O
such O O
as O O
Videx B-brand B-brand
( O O
didanosine B-drug B-drug
) O O
, O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
can O O
form O O
chelation O O
complexes O O
with O O
lomefloxacin B-drug B-drug
and O O
interfere O O
with O O
its O O
bioavailability O O
. O O

Flecainide B-drug B-drug
is O O
not O O
extensively O O
bound O O
to O O
plasma O O
proteins O O
. O O

In O O
well-controlled O O
patients O O
undergoing O O
concurrent O O
therapy O O
with O O
cimetidine B-drug B-drug
, O O
a O O
decrease O O
in O O
the O O
steady-state O O
serum O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
occur O O
when O O
cime-tidine O B-drug
therapy O O
is O O
discontinued O O
. O O

When O O
such O O
combined O O
therapy O O
is O O
contemplated O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

Other O O
: O O
Concomitant O O
alcohol B-drug B-drug
or O O
hot O O
drinks O O
may O O
increase O O
the O O
side O O
effects O O
of O O
flushing O O
and O O
pruritus O O
and O O
should O O
be O O
avoided O O
at O O
the O O
time O O
of O O
drug O O
ingestion O O
. O O

Furosemide B-drug B-drug
: O O
TORADOL B-brand B-brand
IV/IM O O
reduced O O
the O O
diuretic B-group B-group
response O O
to O O
furosemide B-drug B-drug
in O O
normovolemic O B-drug
healthy O O
subjects O O
by O O
approximately O O
20 O O
% O O
( O O
mean O O
sodium O O
and O O
urinary O O
output O O
decreased O O
17 O O
% O O
) O O
. O O

After O O
the O O
coadministration O O
of O O
200 O O
mg O O
oral O O
ketoconazole B-drug B-drug
twice O O
daily O O
and O O
one O O
20 O O
mg O O
dose O O
of O O
loratadine B-drug B-drug
to O O
11 O O
subjects O O
, O O
the O O
AUC O O
and O O
Cmax O O
of O O
loratadine B-drug B-drug
averaged O O
302 O O
% O O
( O O
142 O O
S.D O O
. O O
) O O
and O O
251 O O
% O O
( O O
68 O O
S.D O O
. O O
) O O
, O O
respectively O O
, O O
of O O
those O O
obtained O O
after O O
co-treatment O O
with O O
placebo O O
. O O

Warfarin B-drug B-drug
: O O
Atorvastatin B-drug B-drug
had O O
no O O
clinically O O
significant O O
effect O O
on O O
prothrombin O O
time O O
when O O
administered O O
to O O
patients O O
receiving O O
chronic O O
warfarin B-drug B-drug
treatment O O
. O O

The O O
combination O O
is O O
well O O
tolerated O O
. O O

Acetazolamide B-drug B-drug
decreases O O
urinary O O
excretion O O
of O O
amphetamine B-drug B-drug
and O O
may O O
enhance O O
the O O
magnitude O O
and O O
duration O O
of O O
their O O
effect O O
. O O

Theoretically O O
, O O
fenoprofen B-drug B-drug
could O O
likewise O O
be O O
displaced O O
. O O

Oral O O
Contraceptives B-group B-group

It O O
is O O
concluded O O
that O O
ketamine B-drug B-drug
is O O
not O O
a O O
short-acting O O
drug O O
and O O
that O O
concomitant O O
use O O
with O O
halothane B-drug B-drug
would O O
be O O
expected O O
to O O
prolong O O
further O O
the O O
duration O O
of O O
its O O
action O O
on O O
the O O
central O O
nervous O O
system O O
. O O

therefore O O
it O O
is O O
not O O
expected O O
to O O
affect O O
the O O
plasma O O
concentrations O O
of O O
other O O
drugs O O
metabolized O O
by O O
CYP3A4 O O
. O O

However O O
, O O
since O O
aspirin B-brand B-brand
, O O
NSAIDs B-group B-group
, O O
and O O
bisphosphonates B-group B-group
are O O
all O O
associated O O
with O O
gastrointestinal O O
irritation O O
, O O
caution O O
should O O
be O O
exercised O O
in O O
the O O
concomitant O O
use O O
of O O
aspirin B-brand B-brand
or O O
NSAIDs B-group B-group
with O O
Ibandronate B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
Quinolones B-group B-group
have O O
been O O
reported O O
to O O
enhance O O
the O O
effects O O
of O O
the O O
oral O O
anticoagulant B-group B-group
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

No O O
clinically O O
significant O O
effect O O
of O O
famotidine B-drug B-drug
, O O
valproate B-drug B-drug
, O O
or O O
lithium B-drug B-drug
was O O
seen O O
on O O
the O O
pharmacokinetics O O
of O O
aripiprazole B-drug B-drug
( O O
see O O
CLINICAL O O
PHARMACOLOGY O O
: O O
Drug- O O
Drug O O
Interactions O O
) O O
. O O

Carbamazepine B-drug B-drug
: O O
Coadministration O O
of O O
carbamazepine B-drug B-drug
( O O
200 O O
mg O O
BID O O
) O O
, O O
a O O
potent O O
CYP3A4 O O
inducer O O
, O O
with O O
aripiprazole B-drug B-drug
( O O
30 O O
mg O O
QD O O
) O O
resulted O O
in O O
an O O
approximate O O
70 O O
% O O
decrease O O
in O O
Cmax O O
and O O
AUC O O
values O O
of O O
both O O
aripiprazole B-drug B-drug
and O O
its O O
active O O
metabolite O O
, O O
dehydro-aripiprazole B-drug_n B-drug_n
. O O

Certain O O
antibiotics B-group B-group
, O O
especially O O
neomycin B-drug B-drug
, O O
streptomycin B-drug B-drug
and O O
kanamycin B-drug B-drug
, O O
have O O
a O O
mild O O
but O O
definite O O
nondepolarizing O O
blocking O O
action O O
which O O
may O O
accentuate O O
neuromuscular O O
block O O
. O O

Loratadine B-drug B-drug
Descarboethoxyloratadine I-drug I-drug

. O O

Drug/Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
known O O
interactions O O
between O O
APOKYN B-brand B-brand
and O O
laboratory O O
tests O O
. O O

as O O
such O O
it O O
may O O
impair O O
intestinal O O
absorption O O
of O O
any O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

In O O
one O O
study O O
, O O
following O O
chronic O O
administration O O
of O O
bupropion B-drug B-drug
, O O
100 O O
mg O O
3 O O
times O O
daily O O
to O O
8 O O
healthy O O
male O O
volunteers O O
for O O
14 O O
days O O
, O O
there O O
was O O
no O O
evidence O O
of O O
induction O O
of O O
its O O
own O O
metabolism O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
Cetrotide B-brand B-drug
. O O

Since O O
hydroxyurea B-drug B-drug
may O O
raise O O
the O O
serum O O
uric O O
acid O O
level O O
, O O
dosage O O
adjustment O O
of O O
uricosuric B-group O
medication I-group O
may O O
be O O
necessary O O

Physiological O O
changes O O
resulting O O
from O O
smoking O O
cessation O O
, O O
with O O
or O O
without O O
nicotine B-drug B-drug
replacement O O
, O O
may O O
alter O O
the O O
pharmacokinetics O O
of O O
certain O O
concomitant O O
medications O O
, O O
such O O
as O O
tricyclic B-group B-group
antidepressants I-group I-group
and O O
theophylline B-drug B-drug
. O O

The O O
effect O O
of O O
administering O O
different O O
botulinum B-group B-group
neurotoxin I-group I-group
serotypes O O
at O O
the O O
same O O
time O O
or O O
within O O
less O O
than O O
4 O O
months O O
of O O
each O O
other O O
is O O
unknown O O
. O O

Established O O
Drug O O
Interactions O O

Non-nucleoside B-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitors I-group I-group

Lithium B-drug B-drug
toxicity O O
was O O
usually O O
reversible O O
upon O O
discontinuation O O
of O O
lithium B-drug B-drug
and O O
the O O
ACE B-group B-group
inhibitor I-group I-group
. O O

The O O
in O O
vitro O O
anti-cryptosporidial O O
activity O O
of O O
buforin B-drug_n B-drug_n
II I-drug_n I-drug_n
alone O O
and O O
in O O
combination O O
with O O
azithromycin B-drug B-drug
and O O
minocycline B-drug B-drug
was O O
investigated O O
. O O

Although O O
this O O
effect O O
was O O
noted O O
even O O
when O O
cholestyramine B-drug B-drug
was O O
given O O
4 O O
hours O O
prior O O
to O O
fluvastatin B-drug B-drug
, O O
this O O
regimen O O
did O O
not O O
result O O
in O O
diminished O O
efficacy O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Cephalosporins B-group B-group
are O O
known O O
to O O
occasionally O O
induce O O
a O O
positive O O
direct O O
Coombs O O
test O O
. O O

Perioperative O O
administration O O
of O O
drugs O O
affecting O O
hepatic O O
blood O O
flow O O
or O O
enzyme O O
function O O
may O O
reduce O O
plasma O O
clearance O O
and O O
prolong O O
recovery O O
. O O

CONCLUSIONS O O
: O O
Macrolide B-group B-group
antibiotics I-group I-group
inhibit O O
the O O
metabolism O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
that O O
are O O
metabolized O O
by O O
CYP3A4 O O
( O O
i.e. O O
, O O
atorvastatin B-drug B-drug
, O O
cerivastatin B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
simvastatin B-drug B-drug
) O O
. O O

CNS O O
depression O O
producing O O
medications O O
- O O
concurrent O O
use O O
may O O
potentiate O O
the O O
effects O O
of O O
either O O
these O O
medications O O
or O O
diphenidol B-drug B-drug
; O O

Nicardipine B-drug B-drug
HCl I-drug I-drug
usually O O
does O O
not O O
alter O O
the O O
plasma O O
levels O O
of O O
digoxin B-drug B-drug
, O O
however O O
, O O
serum O O
digoxin B-drug B-drug
levels O O
should O O
be O O
evaluated O O
after O O
concomitant O O
therapy O O
with O O
nicardipine B-drug B-drug
HCl I-drug I-drug
is O O
initiated O O
. O O

Sirolimus B-drug B-drug
works O O
differently O O
from O O
the O O
immunosuppressants B-group B-group
currently O O
available O O
, O O
and O O
except O O
for O O
increased O O
lipid O O
levels O O
, O O
the O O
adverse O O
reaction O O
profile O O
of O O
sirolimus B-drug B-drug
does O O
not O O
appear O O
to O O
overlap O O
to O O
any O O
great O O
extent O O
with O O
that O O
associated O O
with O O
cyclosporine B-drug B-drug
or O O
tacrolimus B-drug B-drug
. O O

When O O
carbamazepine B-drug B-drug
is O O
withdrawn O O
from O O
the O O
combination O O
therapy O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
then O O
be O O
reduced O O
. O O

A O O
common O O
phenotypic O O
subset O O
of O O
the O O
serotype O O
O11 O O
strains O O
from O O
drug O O
addicts O O
was O O
especially O O
resistant O O
to O O
the O O
inhibitory O O
effects O O
. O O

Because O O
there O O
are O O
no O O
data O O
on O O
the O O
compatibility O O
of O O
NovoLog B-brand B-brand
and O O
crystalline O O
zinc B-drug B-drug
insulin I-drug I-drug
preparations O O
, O O
NovoLog B-brand B-brand
should O O
not O O
be O O
mixed O O
with O O
these O O
preparations O O
. O O

In O O
this O O
paper O O
lists O O
of O O
multiple O O
exposure O O
in O O
which O O
the O O
doses O O
of O O
the O O
substances O O
, O O
the O O
types O O
of O O
interferences O O
and O O
the O O
behaviour O O
of O O
the O O
biological O O
levels O O
have O O
been O O
drawn O O
up O O
and O O
proposed O O
as O O
a O O
tool O O
for O O
easy O O
consultation O O
. O O

Administration O O
of O O
WELLBUTRIN B-brand B-brand
Tablets O O
to O O
patients O O
receiving O O
either O O
levodopa B-drug B-drug
or O O
amantadine B-drug B-drug
concurrently O O
should O O
be O O
undertaken O O
with O O
caution O O
, O O
using O O
small O O
initial O O
doses O O
and O O
small O O
gradual O O
dose O O
increases O O
. O O

consideration O O
should O O
be O O
given O O
to O O
possible O O
CNS O O
and O O
other O O
effects O O
of O O
alcohol B-drug B-drug
. O O

Agents O O
Causing O O
Renin O O
Release O O
: O O
The O O
antihypertensive O O
effect O O
of O O
enalapril B-drug B-drug
and O O
enalapril B-drug B-drug
IV O O
is O O
augmented O O
by O O
antihypertensive B-group B-group
agents I-group I-group
that O O
cause O O
renin O O
release O O
( O O
e.g. O O
, O O
diuretics B-group B-group
) O O
. O O

Serum O O
lithium B-drug B-drug
levels O O
should O O
be O O
monitored O O
frequently O O
if O O
INSPRA B-brand B-brand
is O O
administered O O
concomitantly O O
with O O
lithium B-drug B-drug
. O O

Increased O O
hepatotoxicity O O
of O O
acetaminophen B-drug B-drug
by O O
concomitant O O
administration O O
of O O
caffeine B-drug B-drug
in O O
the O O
rat O O
. O O

Digoxin B-drug B-drug
: O O
Supraventricular O O
arrhythmias O O
may O O
mask O O
the O O
cardiotoxicity O O
associated O O
with O O
excessive O O
digoxin B-drug B-drug
levels O O
. O O

Since O O
falsely O O
elevated O O
glucose O O
levels O O
have O O
been O O
observed O O
with O O
blood O O
glucose O O
monitoring O O
devices O O
and O O
test O O
strips O O
that O O
use O O
glucose O O
dehydrogenase O O
pyrroloquinolinequinone O B-drug_n
( O O
GDH O O
PQQ O O
) O O
-based O O
methods O O
, O O
GDH O O
PQQ-based O O
methods O O
should O O
not O O
be O O
used O O
to O O
measure O O
glucose O O
levels O O
in O O
patients O O
administered O O
EXTRANEAL.. B-brand B-brand

Both O O
the O O
magnitude O O
and O O
duration O O
of O O
central O O
nervous O O
system O O
and O O
cardiovascular O O
effects O O
may O O
be O O
enhanced O O
when O O
ALFENTA B-brand B-brand
is O O
administered O O
in O O
combination O O
with O O
other O O
CNS B-group B-group
depressants I-group I-group
such O O
as O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
opioids B-group B-group
, O O
or O O
inhalation O O
general O O
anesthetics B-group B-group
. O O

However O O
, O O
co O O
administration O O
of O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
with O O
either O O
ketoconazole B-drug B-drug
or O O
erythromycin B-drug B-drug
led O O
to O O
increased O O
plasma O O
concentrations O O
of O O
fexofenadine B-drug B-drug
. O O

A O O
single O O
dose O O
of O O
pravastatin B-drug B-drug
had O O
no O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
fenofibric B-drug_n B-drug_n
acid I-drug_n I-drug_n
. O O

The O O
drug O O
interaction O O
studies O O
with O O
valdecoxib B-drug B-drug
were O O
performed O O
both O O
with O O
valdecoxib B-drug B-drug
and O O
a O O
rapidly O O
hydrolyzed O O
intravenous O O
prodrug O O
form O O
. O O

Usually O O
, O O
severe O O
abdominal O O
symptoms O O
appear O O
before O O
there O O
is O O
such O O
a O O
fall O O
in O O
the O O
blood O O
pressure O O
. O O

Determinations O O
of O O
serum O O
digoxin B-drug B-drug
levels O O
utilizing O O
commercially O O
available O O
kits O O
with O O
an O O
125I-labelled O O
antigen O O
were O O
precise O O
and O O
not O O
materially O O
different O O
from O O
results O O
obtained O O
with O O
a O O
3H-labelled O O
antigen O O
. O O

At O O
least O O
3 O O
weeks O O
should O O
elapse O O
between O O
discontinuation O O
of O O
dexfenfluramine B-drug B-drug
and O O
initiation O O
of O O
treatment O O
with O O
a O O
MAO B-group B-group
inhibitor I-group I-group
. O O

The O O
lower O O
rate O O
of O O
absorption O O
in O O
the O O
groups O O
receiving O O
446 O O
mg O O
Fe B-drug B-drug
instead O O
of O O
48 O O
mg O O
of O O
Fe B-drug B-drug
per O O
kg O O
diet O O
resulted O O
in O O
a O O
decreased O O
renal O O
excretion O O
of O O
cobalt B-drug B-drug
. O O

Etofibrate B-drug B-drug
elicited O O
62 O O
% O O
enhancement O O
of O O
post-heparin B-drug O
lipolytic O O
activity O O
and O O
100 O O
% O O
increase O O
of O O
3H-triglyceride O B-drug_n
fractional O O
clearance O O
rate O O
compared O O
with O O
placebo O O
treatment O O
. O O

Recovery O O
from O O
50 O O
% O O
twitch O O
to O O
75 O O
% O O
fade O O
recovery O O
took O O
13.8 O O
+/- O O
0.8 O O
min O O
for O O
atracurium B-drug B-drug
alone O O
and O O
13.7 O O
+/- O O
1.2 O O
min O O
for O O
atracurium B-drug B-drug
plus O O
gentamycin B-drug B-drug
. O O

This O O
increase O O
is O O
due O O
to O O
the O O
inhibition O O
of O O
celecoxib B-drug B-drug
metabolism O O
via O O
P450 O O
2C9 O O
by O O
fluconazole B-drug B-drug
( O O
see O O
CLINICAL O O
PHARMACOLOGY O O
- O O
Pharmacokinetics O O
: O O
Metabolism O O
) O O
. O O

Non-pegylated B-drug B-drug
interferon I-drug I-drug
alfa-2a I-drug I-drug
treatment O O
of O O
pregnant O O
Rhesus O O
monkeys O O
at O O
approximately O O
20 O O
to O O
500 O O
times O O
the O O
human O O
weekly O O
dose O O
resulted O O
in O O
a O O
statistically O O
significant O O
increase O O
in O O
abortions O O
. O O

In O O
monkeys O O
, O O
the O O
effects O O
of O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
, O O
but O O
not O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
or O O
PCP B-drug_n B-drug_n
, O O
were O O
antagonized O O
by O O
naloxone B-drug B-drug
; O O

In O O
monkeys O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
was O O
about O O
10 O O
times O O
more O O
potent O O
than O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
in O O
decreasing O O
responding O O
, O O
whereas O O
in O O
pigeons O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
was O O
about O O
equipotent O O
with O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
. O O

Increased O O
toxicity O O
( O O
CNS O O
depression O O
) O O
: O O
CNS B-group B-group
depressants I-group I-group
, O O
MAO B-group B-group
inhibitors I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
phenothiazines B-group B-group
. O O

Transient O O
delirium O O
has O O
been O O
reported O O
in O O
patients O O
who O O
were O O
treated O O
with O O
one O O
gram O O
of O O
ethchlorvynol B-drug B-drug
and O O
75 O O
- O O
150 O O
mg O O
of O O
amitriptyline B-drug B-drug
HCl I-drug I-drug
. O O

In O O
such O O
patients O O
, O O
the O O
mean O O
area O O
under O O
the O O
felodipine B-drug B-drug
plasma O O
concentration-time O O
curve O O
was O O
also O O
reduced O O
to O O
approximately O O
6 O O
% O O
of O O
that O O
observed O O
in O O
healthy O O
volunteers O O
. O O

Several O O
clinically O O
important O O
interactions O O
have O O
previously O O
been O O
reported O O
for O O
other O O
immunosuppressive B-group B-group
drugs I-group I-group
that O O
are O O
metabolized O O
by O O
the O O
same O O
enzyme O O
and O O
for O O
calcium B-group B-group
antagonists I-group I-group
. O O

Clarithromycin B-drug B-drug

Alteration O O
of O O
pH O O
may O O
affect O O
absorption O O
of O O
certain O O
drugs O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
) O O
. O O

Both O O
the O O
toxicity O O
of O O
filipin B-drug_n B-drug_n
and O O
the O O
therapeutic O O
value O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
can O O
be O O
rationalized O O
at O O
the O O
cellular O O
and O O
molecular O O
level O O
by O O
the O O
following O O
observations O O
: O O
( O O
i O O
) O O
these O O
polyene B-group B-group
antibiotics I-group I-group
showed O O
differential O O
effects O O
on O O
cells O O
; O O

Multivitamins B-group B-group
, O O
or O O
other O O
products O O
containing O O
iron B-drug B-drug
or O O
zinc B-drug B-drug
, O O
antacids B-group B-group
or O O
sucralfate B-drug B-drug
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
, O O
or O O
within O O
2 O O
hours O O
of O O
, O O
the O O
administration O O
of O O
norfloxacin B-drug B-drug
, O O
because O O
they O O
may O O
interfere O O
with O O
absorption O O
resulting O O
in O O
lower O O
serum O O
and O O
urine O O
levels O O
of O O
norfloxacin B-drug B-drug
. O O

In O O
addition O O
, O O
under O O
the O O
influence O O
of O O
sympatholytic O B-group
medicinal O O
products O O
such O O
as O O
beta-blockers B-group B-group
, O O
clonidine B-drug B-drug
, O O
guanethidine B-drug B-drug
, O O
and O O
reserpine B-drug B-drug
, O O
the O O
signs O O
of O O
hypoglycemia O O
may O O
be O O
reduced O O
or O O
absent O O
. O O

Valproic B-drug B-drug
acid I-drug I-drug

May O O
lead O O
to O O
loss O O
of O O
virologic O O
response O O
and O O
possible O O
resistance O O
to O O
CRIXIVAN B-brand B-brand
or O O
to O O
the O O
class O O
of O O
protease B-group B-group
inhibitors I-group I-group
or O O
other O O
coadministered O O
antiretroviral B-group B-group
agents I-group I-group
. O O

The O O
risk O O
of O O
myopathy O O
during O O
treatment O O
with O O
drugs O O
of O O
this O O
class O O
is O O
increased O O
with O O
concurrent O O
administration O O
of O O
cyclosporine B-drug B-drug
, O O
fibric B-group B-group
acid I-group I-group
derivatives I-group I-group
, O O
niacin B-drug B-drug
( O O
nicotinic B-drug B-drug
acid I-drug I-drug
) O O
, O O
erythromycin B-drug B-drug
, O O
azole B-group B-group
antifungals I-group I-group
. O O

In O O
this O O
formal O O
interaction O O
study O O
, O O
TAMBOCOR B-brand B-brand
and O O
propranolol B-drug B-drug
were O O
each O O
found O O
to O O
have O O
negative O O
inotropic O O
effects O O
; O O

This O O
slowing O O
potentiates O O
amphetamines B-group B-group
, O O
increasing O O
their O O
effect O O
on O O
the O O
release O O
of O O
norepinephrine O B-drug
and O O
other O O
monoamines O O
from O O
adrenergic O O
nerve O O
endings O O
; O O

Physiological O O
oral O O
magnesium B-drug B-drug
supplementation O O
( O O
5 O O
mg/kg/day O O
) O O
is O O
easy O O
and O O
can O O
be O O
carried O O
out O O
in O O
the O O
diet O O
or O O
with O O
magnesium B-drug B-drug
salts O O
, O O
with O O
practically O O
only O O
one O O
contra-indication O O
: O O
overt O O
renal O O
failure O O
. O O

Rifampin B-drug B-drug

Influence O O
of O O
AED B-group B-group
On O O
MHD B-drug_n B-drug_n
Concentration O O
( O O
Mean O O
change O O
, O O
90 O O
% O O
Confidence O O
Interval O O
) O O

- O O
Drugs O O
with O O
nephrotoxic O O
potential O O
: O O
There O O
has O O
been O O
no O O
experience O O
on O O
the O O
concurrent O O
use O O
of O O
bumetanide B-drug B-drug
with O O
drugs O O
known O O
to O O
have O O
a O O
nephrotoxic O O
potential O O
. O O

In O O
this O O
setting O O
, O O
cardioselective B-group B-group
beta-blockers I-group I-group
could O O
be O O
considered O O
, O O
although O O
they O O
should O O
be O O
administered O O
with O O
caution O O
. O O

Before O O
taking O O
glimepiride B-drug B-drug
, O O
tell O O
your O O
doctor O O
if O O
you O O
are O O
taking O O
any O O
of O O
the O O
following O O
medicines O O
: O O
- O O
aspirin B-brand B-brand
or O O
another O O
salicylate B-group B-group
such O O
as O O
magnesium/choline B-drug B-drug
salicylate I-drug B-group
( O O
Trilisate B-brand B-brand
) O O
, O O
salsalate B-drug B-group
( O O
Disalcid B-brand B-brand
, O O
others O O
) O O
, O O
choline B-drug B-drug
salicylate I-drug I-drug
( O O
Arthropan B-drug B-brand
) O O
, O O
magnesium B-drug B-drug
salicylate I-drug I-drug
( O O
Magan B-brand B-drug
) O O
, O O
or O O
bismuth B-drug B-drug
subsalicylate I-drug I-drug
( O O
Pepto-Bismol B-brand B-drug
) O O
; O O

It O O
is O O
postulated O O
that O O
some O O
of O O
the O O
observed O O
training-induced O O
neurobiological O O
alterations O O
might O O
reflect O O
the O O
interaction O O
between O O
two O O
( O O
or O O
more O O
) O O
competing O O
memory O O
systems O O
at O O
the O O
hippocampal O O
level O O
. O O

These O O
effects O O
have O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
by O O
the O O
NSAID B-group B-group
. O O

Many O O
people O O
use O O
both O O
alcohol B-drug B-drug
and O O
nicotine B-drug B-drug
( O O
i.e. O O
, O O
cigarettes O O
and O O
other O O
tobacco O O
products O O
) O O
. O O

In O O
addition O O
, O O
reduced O O
kidney O O
and O O
liver O O
function O O
secondary O O
to O O
PROLEUKIN B-brand B-brand
treatment O O
may O O
delay O O
elimination O O
of O O
concomitant O O
medications O O
and O O
increase O O
the O O
risk O O
of O O
adverse O O
events O O
from O O
those O O
drugs O O
. O O

Drugs O O
That O O
Induce O O
CYP3A4 O O
Rifampin B-drug B-drug
: O O
CYP3A4 O B-drug
is O O
ordinarily O O
a O O
minor O O
metabolizing O O
enzyme O O
of O O
zaleplon B-drug B-drug
. O O

Atovaquone B-drug B-drug
is O O
highly O O
bound O O
to O O
plasma O O
protein O O
( O O
99.9 O O
% O O
) O O
. O O

and O O
Videx B-brand B-brand
, O O
( O O
Didanosine B-drug B-drug
) O O
, O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
may O O
substantially O O
interfere O O
with O O
the O O
absorption O O
of O O
quinolones B-group B-group
, O O
resulting O O
in O O
systemic O O
levels O O
considerably O O
lower O O
than O O
desired O O
. O O

No O O
specific O O
pharmacokinetic O O
or O O
other O O
formal O O
drug O O
interaction O O
studies O O
were O O
conducted O O
. O O

Methylprednisolone B-drug B-drug

Vaccines B-group B-group
neurological O O
complications O O
and O O
lack O O
of O O
antibody O O
response O O
. O O

Because O O
of O O
reports O O
of O O
prolongation O O
of O O
the O O
prothrombin O O
time O O
beyond O O
the O O
therapeutic O O
range O O
in O O
patients O O
taking O O
concurrent O O
levamisole B-drug B-drug
and O O
warfarin B-drug B-drug
sodium I-drug I-drug
, O O
it O O
is O O
suggested O O
that O O
the O O
prothrombin O O
time O O
be O O
monitored O O
carefully O O
, O O
and O O
the O O
dose O O
of O O
warfarin B-drug B-drug
sodium I-drug I-drug
or O O
other O O
coumarin-like B-group B-group
drugs O I-group
should O O
be O O
adjusted O O
accordingly O O
, O O
in O O
patients O O
taking O O
both O O
drugs O O
. O O

Therefore O O
, O O
it O O
can O O
prolong O O
bleeding O O
time O O
by O O
approximately O O
3 O O
to O O
4 O O
minutes O O
from O O
baseline O O
values O O
. O O

Time O O
to O O
reach O O
Cmax O O
is O O
also O O
prolonged O O
by O O
1 O O
hour O O
. O O

There O O
may O O
remain O O
some O O
indications O O
of O O
the O O
laxative O B-group
and O O
antacid O B-group
properties O O
of O O
non O O
soluble O O
magnesium B-drug B-drug
, O O
particularly O O
during O O
intermittent O O
haemodialysis O O
. O O

Increased O O
plasma O O
levels O O
of O O
diazepam B-drug B-drug
were O O
observed O O
12 O O
hours O O
after O O
dosing O O
and O O
onwards O O
. O O

Because O O
of O O
possible O O
clinical O O
significance O O
, O O
these O O
two O O
drugs O O
should O O
not O O
be O O
administered O O
concurrently O O
. O O

increased O O
thyroid O O
binding O O
globulin O O
( O O
TBG O O
) O O
leading O O
to O O
increased O O
circulating O O
total O O
thyroid O O
hormone O O
, O O
as O O
measured O O
by O O
PBI O O
, O O
T4 O O
by O O
column O O
, O O
or O O
T4 O O
by O O
radioimmunoassay O O
. O O

Whether O O
an O O
alteration O O
in O O
norepinephrine B-drug B-drug
uptake-1 O O
occurs O O
is O O
still O O
unresolved O O
. O O

The O O
possibility O O
of O O
altered O O
safety O O
and O O
efficacy O O
should O O
be O O
considered O O
when O O
Ponstel B-brand B-brand
is O O
used O O
concomitantly O O
with O O
these O O
drugs O O
. O O

Interactions O O
for O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
( O O
Vitamin B-drug B-drug
D2 I-drug I-drug
, O O
Vitamin B-drug B-drug
D3 I-drug I-drug
, O O
Calcitriol B-drug B-drug
, O O
and O O
Calcidiol B-drug B-drug
) O O
: O O
Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
has O O
been O O
reported O O
to O O
reduce O O
intestinal O O
absorption O O
of O O
fat B-group B-group
soluble I-group I-group
vitamins I-group I-group
; O O

Reported O O
examples O O
of O O
this O O
interaction O O
include O O
the O O
following O O
: O O
Immunosuppressives B-drug B-group
: O O
Cyclosporine B-drug B-drug
( O O
CYP3A4 B-drug B-drug
substrate O O
) O O
administered O O
in O O
combination O O
with O O
oral O O
amiodarone B-drug B-drug
has O O
been O O
reported O O
to O O
produce O O
persistently O O
elevated O O
plasma O O
concentrations O O
of O O
cyclosporine B-drug B-drug
resulting O O
in O O
elevated O O
creatinine O O
, O O
despite O O
reduction O O
in O O
dose O O
of O O
cyclosporine B-drug B-drug
. O O

In O O
addition O O
, O O
results O O
from O O
regression O O
analyses O O
of O O
patient O O
pharmacokinetic O O
data O O
suggest O O
that O O
co-administration O O
of O O
other O O
inducers O O
of O O
drug O O
clearance O O
( O O
efavirenz B-drug B-drug
, O O
nevirapine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
dexamethasone B-drug B-drug
, O O
or O O
carbamazepine B-drug B-drug
) O O
with O O
CANCIDAS B-brand B-brand
may O O
result O O
in O O
clinically O O
meaningful O O
reductions O O
in O O
caspofungin B-drug B-drug
concentrations O O
. O O

Concomitant O O
administration O O
of O O
drugs O O
known O O
to O O
inhibit O O
the O O
activity O O
of O O
cytochrome O O
P450 O O
isozymes O O
may O O
increase O O
the O O
plasma O O
levels O O
of O O
clozapine B-drug B-drug
. O O

Insulin O B-drug
parameters O O
were O O
not O O
affected O O
. O O

Specific O O
and O O
aspecific O O
treatments O O
of O O
magnesium B-drug B-drug
depletion O O
are O O
tricky O O
using O O
for O O
example O O
magnesium B-group B-drug
sparing I-group O
diuretics I-group B-group
, O O
pharmacological O O
doses O O
of O O
vitamin B-drug B-drug
B6 I-drug I-drug
, O O
physiological O O
doses O O
of O O
vitamin B-group B-group
D I-group I-group
and O O
of O O
selenium B-drug B-drug
. O O

Therefore O O
, O O
precaution O O
should O O
be O O
taken O O
when O O
coadministration O O
is O O
necessary O O
. O O

The O O
effects O O
of O O
Mefloquineuine O B-drug
on O O
the O O
compromised O O
cardiovascular O O
system O O
have O O
not O O
been O O
evaluated O O
. O O

The O O
clinical O O
relevance O O
of O O
this O O
difference O O
is O O
unknown O O
. O O

Caution O O
is O O
therefore O O
advised O O
in O O
the O O
coadministration O O
of O O
ATROVENT B-brand B-brand
Inhalation O O
Aerosol O O
with O O
other O O
anticholinergic-containing B-group B-group
drugs O I-group
. O O

Amphotericin B-drug B-drug
B I-drug I-drug
injection O O
and O O
potassium-depleting O B-group
agents O I-group
: O O
When O O
corticosteroids B-group B-group
are O O
administered O O
concomitantly O O
with O O
potassium-depleting O B-group
agents O I-group
( O O
e.g. O O
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
diuretics B-group B-group
) O O
, O O
patients O O
should O O
be O O
observed O O
closely O O
for O O
development O O
of O O
hypokalemia O O
. O O

No O O
clinically O O
relevant O O
pharmacokinetic O O
interactions O O
between O O
anagrelide B-drug B-drug
and O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
were O O
observed O O
. O O

SETTING O O
: O O
Rural O O
primary O O
care O O
centre O O
. O O

Cyclosporine B-drug B-drug
: O O
Elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
use O O
of O O
cyclosporine B-drug B-drug
with O O
other O O
members O O
of O O
the O O
quinolone B-group B-group
class I-group I-group
. O O

Wait O O
2 O O
weeks O O
after O O
stopping O O
an O O
MAO B-group B-group
inhibitor I-group I-group
before O O
starting O O
escitalopram B-drug B-drug
. O O

Tolbutamide B-drug B-drug
: O O
Aprepitant B-drug B-drug
, O O
when O O
given O O
as O O
125 O O
mg O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
and O O
3 O O
, O O
decreased O O
the O O
AUC O O
of O O
tolbutamide B-drug B-drug
( O O
a O O
CYP2C9 O O
substrate O O
) O O
by O O
23 O O
% O O
on O O
Day O O
4 O O
, O O
28 O O
% O O
on O O
Day O O
8 O O
, O O
and O O
15 O O
% O O
on O O
Day O O
15 O O
, O O
when O O
a O O
single O O
dose O O
of O O
tolbutamide B-drug B-drug
500 O O
mg O O
was O O
admini O O
, O O
stered O O
orally O O
prior O O
to O O
the O O
administration O O
of O O
the O O
3-day O O
regimen O O
of O O
Aprepitant B-drug B-drug
and O O
on O O
Days O O
4,8 O O
, O O
and O O
15 O O
. O O

increased O O
factors O O
II O O
, O O
VII O O
antigen O O
, O O
VIII O O
antigen O O
, O O
VIII O O
coagulant O O
activity O O
, O O
IX O O
, O O
X O O
, O O
XII O O
, O O
VII-X O O
complex O O
, O O
II-VII-X O O
complex O O
, O O
and O O
beta-thromboglobulin O O
; O O

There O O
is O O
one O O
report O O
of O O
cardiopulmonary O O
arrest O O
, O O
with O O
full O O
recovery O O
, O O
in O O
a O O
patient O O
who O O
was O O
taking O O
a O O
beta B-group B-group
blocker I-group I-group
( O O
propranolol B-drug B-drug
) O O
. O O

Such O O
agents O O
must O O
be O O
discontinued O O
at O O
least O O
seven O O
days O O
prior O O
to O O
starting O O
therapy O O
with O O
VISTIDE B-brand B-brand
. O O

Ephedrine B-drug B-drug
: O O
Ephedrine B-drug B-drug
may O O
enhance O O
the O O
metabolic O O
clearance O O
of O O
corticosteroids B-group B-group
, O O
resulting O O
in O O
decreased O O
blood O O
levels O O
and O O
lessened O O
physiologic O O
activity O O
, O O
thus O O
requiring O O
an O O
increase O O
in O O
corticosteroid B-group B-group
dosage O O
. O O

- O O
Anabolic B-group B-group
steroids I-group I-group
( O O
nandrolone B-drug B-drug
[ O O
e.g. O O
, O O
Anabolin B-brand B-brand
] O O
, O O
oxandrolone B-drug B-drug
[ O O
e.g. O O
, O O
Anavar B-brand B-brand
] O O
, O O
oxymetholone B-drug B-drug
[ O O
e.g. O O
, O O
Anadrol B-brand B-brand
] O O
, O O
stanozolol B-drug B-drug
[ O O
e.g. O O
, O O
Winstrol B-brand B-brand
] O O
) O O
or O O

When O O
given O O
concomitantly O O
with O O
felodipine B-drug B-drug
, O O
the O O
tacrolimus B-drug B-drug
blood O O
concentration O O
should O O
be O O
followed O O
and O O
the O O
tacrolimus O B-drug
dose O O
may O O
need O O
to O O
be O O
adjusted O O
. O O

Increased O O
anticoagulation O O
effects O O
due O O
to O O
a O O
drug O O
interaction O O
with O O
erythromycin B-drug B-drug
may O O
be O O
more O O
pronounced O O
in O O
the O O
elderly O O
. O O

A O O
specific O O
treatment O O
for O O
extravasation O O
reactions O O
is O O
unknown O O
at O O
this O O
time O O
. O O

An O O
interval O O
of O O
at O O
least O O
two O O
hours O O
between O O
intake O O
of O O
this O O
agent O O
and O O
chloroquine B-drug B-drug
should O O
be O O
observed O O
. O O

Amphetamines B-group B-group
may O O
decrease O O
the O O
hypotensive O O
effect O O
of O O
antihypertensives B-group B-group
. O O

Although O O
one O O
study O O
tentatively O O
supports O O
the O O
hypothesis O O
that O O
such O O
doses O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
may O O
be O O
efficacious O O
, O O
a O O
second O O
study O O
by O O
the O O
same O O
group O O
did O O
not O O
confirm O O
the O O
significant O O
findings O O
, O O
and O O
no O O
clear O O
, O O
reproducible O O
pattern O O
of O O
efficacy O O
has O O
emerged O O
from O O
the O O
review O O
of O O
all O O
the O O
evidence O O
. O O

This O O
has O O
been O O
observed O O
with O O
Benedict O O
s O O
and O O
Fehling O O
s O O
solutions O O
and O O
also O O
with O O
Clinitest O O
tablets O O
. O O

Therefore O O
, O O
dose O O
adjustments O O
of O O
concomitant O O
medications O O
that O O
are O O
predominantly O O
metabolized O O
by O O
CYP2D6 O O
and O O
have O O
a O O
narrow O O
therapeutic O O
index O O
( O O
e.g. O O
, O O
flecainide B-drug B-drug
, O O
vinblastine B-drug B-drug
, O O
thioridazine B-drug B-drug
and O O
most O O
tricyclic B-group B-group
antidepressants I-group I-group
) O O
may O O
be O O
required O O
. O O

Plasma O O
concentrations O O
of O O
quinolone B-group B-group
antibiotics I-group I-group
are O O
decreased O O
when O O
administered O O
with O O
antacids B-group B-group
containing O O
magnesium B-drug B-drug
, O O
calcium B-drug B-drug
, O O
or O O
aluminum B-drug B-drug
. O O

However O O
, O O
patients O O
receiving O O
infusions O O
of O O
FLOLAN B-brand B-brand
in O O
clinical O O
trials O O
were O O
maintained O O
on O O
anticoagulants B-group B-group
without O O
evidence O O
of O O
increased O O
bleeding O O
. O O

Monitoring O O
of O O
cyclosporine B-drug B-drug
levels O O
and O O
possible O O
adjustment O O
of O O
cyclosporine B-drug B-drug
dosage O O
should O O
be O O
considered O O
when O O
these O O
drugs O O
are O O
co-administered O O
. O O

Since O O
amiodarone B-drug B-drug
is O O
a O O
substrate O O
for O O
CYP3A4 B-drug O
, O O
there O O
is O O
the O O
potential O O
that O O
the O O
use O O
of O O
St. O O
John O O
s O O
Wort O O
in O O
patients O O
receiving O O
amiodarone B-drug B-drug
could O O
result O O
in O O
reduced O O
amiodarone B-drug B-drug
levels O O
. O O

However O O
, O O
decreases O O
in O O
exposure O O
were O O
as O O
much O O
as O O
56 O O
% O O
and O O
66 O O
% O O
, O O
respectively O O
, O O
in O O
individual O O
subjects O O
. O O

Drug O O
Class O O

High O O
concentrations O O
of O O
cefoxitin B-drug B-drug
in O O
the O O
urine O O
may O O
interfere O O
with O O
measurement O O
of O O
urinary O O
17-hydroxy-corticosteroids O O
by O O
the O O
Porter-Silber O O
reaction O O
, O O
and O O
produce O O
false O O
increases O O
of O O
modest O O
degree O O
in O O
the O O
levels O O
reported O O
. O O

Based O O
on O O
total O O
ertapenem B-drug B-drug
concentrations O O
, O O
probenecid B-drug B-drug
increased O O
the O O
AUC O O
by O O
25 O O
% O O
and O O
reduced O O
the O O
plasma O O
and O O
renal O O
clearances O O
by O O
20 O O
% O O
and O O
35 O O
% O O
, O O
respectively O O
. O O

CASE O O
SUMMARY O O
: O O
A O O
64-year-old O O
African-American O O
man O O
was O O
admitted O O
to O O
the O O
hospital O O
for O O
worsening O O
renal O O
failure O O
, O O
elevated O O
creatine O O
phosphokinase O O
, O O
diffuse O O
muscle O O
pain O O
, O O
and O O
severe O O
muscle O O
weakness O O
. O O

Allopurinol B-drug B-drug
: O O
Increased O O
possibility O O
of O O
skin O O
rash O O
, O O
particularly O O
in O O
hyperuricemic O O
patients O O
may O O
occur O O
. O O

Effects O O
of O O
xanthine B-group O
derivatives I-group O
in O O
a O O
light/dark O O
test O O
in O O
mice O O
and O O
the O O
contribution O O
of O O
adenosine O O
receptors O O
. O O

Therefore O O
, O O
patients O O
on O O
propranolol B-drug B-drug
should O O
be O O
observed O O
when O O
COLESTID B-brand B-brand
Tablets O O
are O O
either O O
added O O
or O O
deleted O O
from O O
a O O
therapeutic O O
regimen O O
. O O

Phenothiazines B-group B-group
and O O
butyrophenones B-group B-group
may O O
reduce O O
or O O
reverse O O
the O O
pressor O O
effect O O
of O O
epinephrine B-drug B-drug
. O O

There O O
were O O
no O O
reports O O
of O O
skeletal O O
myopathy O O
in O O
a O O
placebo-controlled O O
Phase O O
I O O
trial O O
in O O
which O O
10 O O
healthy O O
subjects O O
on O O
stable O O
simvastatin B-drug B-drug
therapy O O
were O O
treated O O
concurrently O O
with O O
daptomycin B-drug B-drug
( O O
4 O O
mg/kg O O
once O O
every O O
24 O O
hours O O
) O O
for O O
14 O O
days O O
. O O

METHODS O O
: O O
We O O
carried O O
out O O
two O O
different O O
3-way O O
crossover O O
studies O O
in O O
healthy O O
subjects O O
( O O
each O O
, O O
n O O
= O O
9 O O
) O O
. O O

In O O
addition O O
, O O
under O O
the O O
influence O O
of O O
sympatholytic O B-group
medicinal O O
products O O
such O O
as O O
beta-blockers B-group B-group
, O O
clonidine B-drug B-drug
, O O
guanethidine B-drug B-drug
, O O
and O O
reserpine B-drug B-drug
, O O
the O O
signs O O
of O O
hypoglycemia O O
may O O
be O O
reduced O O
or O O
absent O O
. O O

Since O O
barbiturates B-group B-group
are O O
potentiated O O
by O O
the O O
anticholinesterases B-group B-group
, O O
they O O
should O O
be O O
used O O
cautiously O O
in O O
the O O
treatment O O
of O O
convulsions O O
. O O

Patients O O
receiving O O
medications O O
that O O
interfere O O
with O O
platelet O O
function O O
or O O
coagulation O O
should O O
have O O
more O O
frequent O O
laboratory O O
monitoring O O
for O O
thrombocytopenia O O
. O O

Pre-treatment O O
with O O
the O O
CYP3A4 O O
inducer O O
rifampicin B-drug B-drug
decreased O O
erlotinib B-drug B-drug
AUC O O
by O O
about O O
2/3 O O
. O O

These O O
doses O O
are O O
lower O O
than O O
the O O
therapeutic O O
doses O O
for O O
both O O
drugs O O
. O O

Should O O
not O O
be O O
used O O
as O O
sole O B-group
protease B-group I-group
inhibitor I-group I-group
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
. O O

In O O
vitro O O
studies O O
: O O
Studies O O
in O O
human O O
liver O O
microsomes O O
showed O O
that O O
vardenafil B-drug B-drug
is O O
metabolized O O
primarily O O
by O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
isoforms O O
3A4/5 O O
, O O
and O O
to O O
a O O
lesser O O
degree O O
by O O
CYP2C9 O B-drug
. O O

Careful O O
observation O O
is O O
required O O
when O O
amantadine B-drug B-drug
is O O
administered O O
concurrently O O
with O O
central B-group B-group
nervous I-group I-group
system I-group I-group
stimulants I-group I-group
. O O

Accutane B-brand B-brand
use O O
is O O
associated O O
with O O
depression O O
in O O
some O O
patients O O
. O O

Antiretroviral B-group B-group
regimens O O
consisted O O
of O O
two O O
reverse B-group B-group
transcriptase I-group I-group
inhibitors I-group I-group
and O O
one O O
protease B-group B-group
inhibitor I-group I-group
. O O

If O O
concomitant O O
treatment O O
with O O
AXERT B-brand B-brand
and O O
an O O
SSRI B-group B-group
is O O
clinically O O
warranted O O
, O O
appropriate O O
observation O O
of O O
the O O
patient O O
is O O
advised O O
. O O

Fenbufen B-drug B-drug
is O O
not O O
approved O O
in O O
the O O
United O O
States O O
at O O
this O O
time O O
. O O

weaker O B-group
inhibitors O I-group
( O O
erythromycin B-drug B-drug
, O O
grapefruit O O
juice O O
) O O
have O O
not O O
been O O
studied O O
. O O

The O O
risk O O
of O O
using O O
loxapine B-drug B-drug
in O O
combination O O
with O O
CNS-active O O
drugs O O
has O O
not O O
been O O
systematically O O
evaluated O O
. O O

In O O
practice O O
, O O
the O O
greatest O O
value O O
of O O
the O O
thioether O O
assay O O
appears O O
to O O
lie O O
in O O
its O O
signal O O
function O O
. O O

Renal O O
clearance O O
of O O
ucb O O
L057 O O
in O O
the O O
presence O O
of O O
probenecid B-drug B-drug
decreased O O
60 O O
% O O
, O O
probably O O
related O O
to O O
competitive O O
inhibition O O
of O O
tubular O O
secretion O O
of O O
ucb O O
L057 O O
. O O

Fat O O
redistribution O O
: O O
Redistribution/accumulation O O
of O O
body O O
fat O O
including O O
central O O
obesity O O
, O O
dorsocervical O O
fat O O
enlargement O O
( O O
buffalo O O
hump O O
) O O
, O O
peripheral O O
wasting O O
, O O
facial O O
wasting O O
, O O
breast O O
enlargement O O
, O O
and O O
cushingoid O O
appearance O O
have O O
been O O
observed O O
in O O
patients O O
receiving O O
antiretroviral B-group B-group
therapy O O
. O O

In O O
patients O O
with O O
chronic O O
hepatitis O O
C O O
treated O O
with O O
PEGASYS B-brand B-brand
in O O
combination O O
with O O
COPEGUS B-brand B-brand
, O O
PEGASYS B-brand B-brand
treatment O O
did O O
not O O
affect O O
ribavirin B-drug B-drug
distribution O O
or O O
clearance O O
. O O

In O O
addition O O
, O O
several O O
cardiovascular O O
drugs O O
directly O O
affect O O
renal O O
function O O
and O O
the O O
management O O
of O O
patients O O
with O O
renal O O
disease O O
. O O

FREQUENT O O
PROTHROMBIN O O
TIME/INR O O
DETERMINATIONS O O
ARE O O
ADVISABLE O O
UNTIL O O
IT O O
HAS O O
BEEN O O
DEFINITELY O O
DETERMINED O O
THAT O O
THE O O
PROTHROMBIN O O
TIME/INR O O
HAS O O
STABILIZED O O
. O O

PEGASYS B-brand B-brand
and O O
COPEGUS B-brand B-brand
are O O
excreted O O
by O O
the O O
kidney O O
, O O
and O O
the O O
risk O O
of O O
toxic O O
reactions O O
to O O
this O O
therapy O O
may O O
be O O
greater O O
in O O
patients O O
with O O
impaired O O
renal O O
function O O
. O O

Volatile O B-group
Anesthetic B-drug I-group
Agents O I-group
: O O
. O O

Lansoprazole B-drug B-drug
is O O
metabolized O O
through O O
the O O
cytochrome O O
P450 O O
system O O
, O O
specifically O O
through O O
the O O
CYP3A O O
and O O
CYP2C19 O O
isozymes O O
. O O

Cholinergic O O
role O O
in O O
alcohol B-drug B-drug
's O O
effects O O
on O O
evoked O O
potentials O O
in O O
visual O O
cortex O O
of O O
the O O
albino O O
rat O O
. O O

alopecia O O

Use O O
in O O
Ambulatory O O
Patients O O
The O O
effects O O
of O O
ROMAZICON B-brand B-brand
may O O
wear O O
off O O
before O O
a O O
long-acting B-group O
benzodiazepine I-group B-group
is O O
completely O O
cleared O O
from O O
the O O
body O O
. O O

Therefore O O
, O O
it O O
is O O
critically O O
important O O
for O O
women O O
of O O
childbearing O O
potential O O
to O O
select O O
and O O
commit O O
to O O
use O O
2 O O
forms O O
of O O
effective O O
contraception O O
simultaneously O O
, O O
at O O
least O O
1 O O
of O O
which O O
must O O
be O O
a O O
primary O O
form O O
, O O
unless O O
absolute O O
abstinence O O
is O O
the O O
chosen O O
method O O
, O O
or O O
the O O
patient O O
has O O
undergone O O
a O O
hysterectomy O O

Pharmacokinetics O O
were O O
assessed O O
in O O
two O O
of O O
these O O
trials O O
. O O

increased O O
serum O O
digoxin B-drug B-drug
concentrations O O
may O O
result O O
. O O

monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
; O O

There O O
does O O
not O O
appear O O
to O O
be O O
an O O
increase O O
in O O
adverse O O
events O O
in O O
subjects O O
who O O
received O O
oral O O
contraceptives B-group B-group
and O O
loratadine B-drug B-drug
. O O

However O O
, O O
numerous O O
potentiation O O
effects O O
have O O
frequently O O
been O O
reported O O
for O O
combined O O
exposure O O
to O O
substances O O
of O O
widespread O O
use O O
. O O

Because O O
of O O
its O O
lack O O
of O O
platelet O O
effects O O
, O O
VIOXX B-brand B-brand
is O O
not O O
a O O
substitute O O
for O O
aspirin B-brand B-brand
for O O
cardiovascular O O
prophylaxis O O
. O O

Monoamine B-drug B-group
Oxidase I-drug I-group
Inhibitors I-drug I-group
: O O
Guanethidine B-drug B-drug
or O O
similarly O O
acting O O
compounds O O
; O O

Since O O
blood O O
level O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
will O O
be O O
reduced O O
, O O
higher O O
doses O O
of O O
Rocaltrol B-brand B-brand
may O O
be O O
necessary O O
if O O
these O O
drugs O O
are O O
administered O O
simultaneously O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
post-marketing O O
observations O O
, O O
have O O
shown O O
that O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
taking O O
this O O
medicine O O
certain O O
antibiotics B-group B-group
, O O
such O O
as O O
erythromycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
or O O
azithromycin B-drug B-drug
. O O

Drugs O O
Metabolized O O
by O O
Cytochrome O O
P450IID6 O O
( O O
CYP2D6 O O
) O O
: O O
Many O O
drugs O O
, O O
including O O
most O O
antidepressants B-group B-group
( O O
SSRIs O B-group
, O O
many O O
tricyclics B-group B-group
) O O
, O O
beta-blockers B-group B-group
, O O
antiarrhythmics B-drug B-group
, O O
and O O
antipsychotics B-group B-group
are O O
metabolized O O
by O O
the O O
CYP2D6 O O
isoenzyme O O
. O O

Moreover O O
, O O
each O O
task O O
induced O O
significant O O
alterations O O
in O O
hippocampal O O
adenylate O O
cyclase O O
activity O O
but O O
in O O
opposite O O
directions O O
. O O

Registered O O
trademark O O
of O O
Ames O O
Company O O
, O O
Division O O
of O O
Miles O O
Laboratories O O
, O O
Inc O O
. O O

Twenty O O
four O O
male O O
Wistar O O
rats O O
were O O
divided O O
into O O
four O O
groups O O
. O O

Quinidine B-drug B-drug
: O O
Immediate O O
Release O O
Capsules O O
: O O
There O O
have O O
been O O
rare O O
reports O O
of O O
an O O
interaction O O
between O O
quinidine B-drug B-drug
and O O
nifedipine B-drug B-drug
( O O
with O O
a O O
decreased O O
plasma O O
level O O
of O O
quinidine B-drug B-drug
) O O
. O O

There O O
is O O
no O O
known O O
drug O O
interference O O
with O O
standard O O
clinical O O
laboratory O O
tests O O
. O O

The O O
absorption O O
of O O
oral O O
gemifloxacin B-drug B-drug
is O O
significantly O O
reduced O O
by O O
the O O
concomitant O O
administration O O
of O O
an O O
antacid B-group B-group
containing O O
aluminum B-drug B-drug
and O O
magnesium B-drug B-drug
. O O

- O O
Phenytoin B-drug B-drug
( O O
e.g. O O
, O O
Dilantin B-brand B-brand
) O O
Use O O
of O O
phenytoin B-drug B-drug
with O O
sulfapyridine B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O
and/or O O
the O O
side O O
effects O O
of O O
phenytoin B-drug B-drug

Multivalent O O
Cation-Containing O O
Products O O
: O O
Concurrent O O
administration O O
of O O
a O O
quinolone B-group B-group
, O O
including O O
ciprofloxacin B-drug B-drug
, O O
with O O
multivalent O B-group
cation-containing O I-group
products O I-group
such O O
as O O
magnesium B-drug B-drug
or O O
aluminum B-drug B-drug
antacids B-group B-group
, O O
sucralfate B-drug B-drug
, O O
VIDEX B-brand B-brand
chewable/buffered O O
tablets O O
or O O
pediatric O O
powder O O
, O O
or O O
products O O
containing O O
calcium B-drug B-drug
, O O
iron B-drug B-drug
, O O
or O O
zinc B-drug B-drug
may O O
substantially O O
decrease O O
the O O
absorption O O
of O O
ciprofloxacin B-drug B-drug
, O O
resulting O O
in O O
serum O O
and O O
urine O O
levels O O
considerably O O
lower O O
than O O
desired O O
. O O

Compounds O O
that O O
have O O
been O O
tested O O
in O O
man O O
include O O
antipyrine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
and O O
no O O
clinically O O
meaningful O O
interactions O O
were O O
found O O
. O O

There O O
are O O
no O O
adequate O O
and O O
well-controlled O O
studies O O
of O O
PEGASYS B-brand B-brand
in O O
pregnant O O
women O O
. O O

cholestyramine B-drug B-drug
; O O

cases O O
of O O
rhabdomyolysis O O
have O O
been O O
reported O O
in O O
seriously O O
ill O O
patients O O
. O O

There O O
have O O
been O O
reports O O
of O O
theophylline-related B-drug B-drug
side O O
effects O O
in O O
patients O O
on O O
concomitant O O
therapy O O
with O O
quinolones B-group B-group
and O O
theophylline B-drug B-drug
. O O

. O O

Use O O
with O O
Other O O
Agents O O
Affecting O O
Myelopoesis O O
: O O
Drugs O O
which O O
may O O
affect O O
leukocyte O O
production O O
, O O
including O O
co-trimoxazole B-brand B-drug
, O O
may O O
lead O O
to O O
exaggerated O O
leukopenia O O
, O O
especially O O
in O O
renal O O
transplant O O
recipients O O
. O O

Together O O
with O O
previous O O
findings O O
, O O
these O O
results O O
suggest O O
that O O
the O O
hippocampus O O
is O O
involved O O
in O O
both O O
the O O
so-called O O
" O O
hippocampal-dependent O O
" O O

A O O
clinical O O
interaction O O
study O O
was O O
also O O
conducted O O
with O O
alosetron B-drug B-drug
and O O
the O O
CYP3A4 O O
substrate O O
cisapride B-drug B-drug
. O O

In O O
addition O O
, O O
drugs O O
that O O
are O O
actively O O
secreted O O
via O O
this O O
route O O
( O O
e.g. O O
, O O
triamterene B-drug B-drug
, O O
metformin B-drug B-drug
and O O
amiloride B-drug B-drug
) O O
should O O
be O O
co-administered O O
with O O
care O O
as O O
they O O
might O O
increase O O
dofetilide B-drug B-drug
levels O O
. O O

Endothelium-intact O O
aortic O O
rings O O
from O O
high-estradiol B-drug O
rats O O
were O O
supersensitive O O
to O O
noradrenaline B-drug B-drug
when O O
compared O O
to O O
vehicle- O O
, O O
progesterone- B-drug O
and O O
progesterone B-drug B-drug
+ O O
high-estradiol-treated O O
rats O O
( O O
pD2 O O
values O O
= O O
7.77+/-0.12 O O
, O O
7.21+/-0.13 O O
, O O
6.93+/-0.04 O O
and O O
7.22+/-0.18 O O
, O O
respectively O O
) O O
. O O

A O O
potential O O
interaction O O
between O O
oral O O
miconazole B-drug B-drug
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
leading O O
to O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
. O O

as O O
such O O
it O O
may O O
impair O O
intestinal O O
absorption O O
of O O
any O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

Elevated O O
plasma O O
levels O O
of O O
theophylline B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
use O O
of O O
some O O
quinolones B-group B-group
. O O

The O O
drug O O
interaction O O
data O O
described O O
in O O
this O O
section O O
were O O
obtained O O
from O O
controlled O O
clinical O O
trials O O
and O O
studies O O
involving O O
otherwise O O
healthy O O
adults O O
with O O
epilepsy O O
. O O

decreased O O
antithrombin B-drug B-drug
3 I-drug O
; O O

The O O
hypoglycemic O O
action O O
of O O
sulfonylureas B-group B-group
may O O
be O O
potentiated O O
by O O
certain O O
drugs O O
including O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
and O O
other O O
drugs O O
that O O
are O O
highly O O
protein O O
bound O O
, O O
salicylates B-group B-group
, O O
sulfonamides B-group B-group
, O O
chloramphenicol B-drug B-drug
, O O
probenecid B-drug B-drug
, O O
coumarins B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
and O O
beta B-group B-group
adrenergic I-group I-group
blocking I-group I-group
agents I-group I-group
. O O

The O O
AUC O O
and O O
Cmax O O
of O O
both O O
the O O
( O O
R O O
) O O
and O O
( O O
S O O
) O O
isomers O O
of O O
warfarin B-drug B-drug
were O O
unaffected O O
by O O
concurrent O O
dosing O O
of O O
0.3 O O
mg O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
. O O

Clinical O O
studies O O
with O O
celecoxib B-drug B-drug
have O O
identified O O
potentially O O
significant O O
interactions O O
with O O
fluconazole B-drug B-drug
and O O
lithium B-drug B-drug
. O O

Rifabutin B-drug B-drug

Digitalis B-group B-group

Coadministration O O
of O O
digoxin B-drug B-drug
did O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
. O O

The O O
mechanism O O
and O O
long-term O O
consequences O O
of O O
these O O
events O O
are O O
currently O O
unknown O O
. O O

- O O
Estrogens B-group B-group
( O O
female O O
hormones O B-group
) O O
or O O

Administration O O
of O O
phenytoin B-drug B-drug
to O O
patients O O
receiving O O
dopamine B-drug B-drug
HCl I-drug I-drug
has O O
been O O
reported O O
to O O
lead O O
to O O
hypotension O O
and O O
bradycardia O O
. O O

As O O
immediate-early O O
genes O O
( O O
IEGs O O
) O O
are O O
thought O O
to O O
play O O
a O O
critical O O
role O O
in O O
mediating O O
stimulus-induced O O
neural O O
plasticity O O
, O O
IEG O O
response O O
induced O O
by O O
methamphetamine B-drug B-drug
( O O
METH B-drug B-drug
) O O
has O O
been O O
characterized O O
to O O
define O O
the O O
changes O O
in O O
gene O O
expression O O
that O O
may O O
underlie O O
its O O
long-lasting O O
behavioral O O
effects O O
. O O

In O O
seven O O
experiments O O
reactions O O
to O O
norepinephrine B-drug B-drug
and O O
oxytocin B-drug B-drug
were O O
PGF2alpha B-drug B-drug
. O O

Both O O
itraconazole B-drug B-drug
and O O
its O O
major O O
metabolite O O
, O O
hydroxyitraconazole B-drug_n B-drug_n
, O O
are O O
inhibitors O O
of O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
. O O

Prothrombin O O
times O O
were O O
measured O O
four O O
times O O
weekly O O
during O O
five O O
long-term O O
experiments O O
. O O

Caution O O
should O O
be O O
used O O
when O O
alosetron B-drug B-drug
and O O
ketoconazole B-drug B-drug
are O O
administered O O
concomitantly O O
. O O

Caution O O
is O O
therefore O O
advised O O
when O O
administering O O
PEGANONE B-brand B-brand
to O O
patients O O
receiving O O
coumarin B-group B-group
anticoagulants I-group I-group
. O O

In O O
vitro O O
studies O O
indicate O O
CYP3A4 O O
isoform O O
and O O
CYP1A2 O O
isoform O O
mediate O O
the O O
metabolism O O
of O O
levobupivacaine B-drug B-drug
to O O
desbutyl B-drug_n O
levobupivacaine I-drug_n B-drug
and O O
3-hydroxy B-drug_n O
levobupivacaine I-drug_n B-drug
, O O
respectively O O
. O O

3 O O
. O O

Venlafaxine B-drug B-drug
: O O
Coadministration O O
of O O
a O O
single O O
dose O O
of O O
zaleplon B-drug B-drug
10 O O
mg O O
and O O
multiple O O
doses O O
of O O
venlafaxine B-drug B-drug
ER O O
( O O
extended O O
release O O
) O O
150 O O
mg O O
did O O
not O O
result O O
in O O
any O O
significant O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
zaleplon B-drug B-drug
or O O
venlafaxine B-drug B-drug
. O O

Amprenavir B-drug B-drug
does O O
not O O
inhibit O O
CYP2D6 O O
, O O
CYP1A2 O O
, O O
CYP2C9 O B-drug
, O O
CYP2C19 O O
, O O
CYP2E1 O O
, O O
or O O
uridine O O
glucuronosyltransferase O O
( O O
UDPGT O O
) O O
. O O

Co-administration O O
of O O
single O O
25-mg O O
dose O O
warfarin B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
total O O
lenalidomide B-drug B-drug
. O O

Advantages O O
offered O O
by O O
this O O
class O O
of O O
antibiotics B-group B-group
include O O
optimal O O
pharmacokinetics O O
, O O
effectiveness O O
against O O
multidrug-resistant O O
organisms O O
, O O
and O O
oral O O
administration O O
even O O
when O O
parenteral O B-group
antibiotics B-drug I-group
are O O
generally O O
used O O
. O O

- O O
Amiodarone B-drug B-drug
( O O
e.g. O O
, O O
Cordarone B-brand B-brand
) O O
or O O

Coadministration O O
of O O
Itraconazole B-drug B-drug
with O O
oral O O
midazolam B-drug B-drug
or O O
triazolam B-drug B-drug
has O O
resulted O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
the O O
latter O O
two O O
drugs O O
. O O

Ritonavir B-drug B-drug
( O O
600 O O
mg O O
b.i.d O O
. O O
) O O
co-administered O O
with O O
Vardenafil B-drug B-drug
5 O O
mg O O
resulted O O
in O O
a O O
49-fold O O
increase O O
in O O
vardenafil B-drug B-drug
AUC O O
and O O
a O O
13-fold O O
increase O O
in O O
vardenafil B-drug B-drug
Cmax O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
administration O O
of O O
ceftazidime B-drug B-drug
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
when O O
using O O
CLINITEST O O
tablets O O
, O O
Benedicts O O
solution O O
, O O
or O O
Fehlings O O
solution O O
. O O

In O O
addition O O
, O O
olanzapine B-drug B-drug
is O O
not O O
associated O O
with O O
a O O
risk O O
of O O
agranulocytosis O O
as O O
seen O O
with O O
clozapine B-drug B-drug
or O O
clinically O O
significant O O
hyperprolactinaemia O O
as O O
seen O O
with O O
risperidone B-drug B-drug
or O O
prolongation O O
of O O
the O O
QT O O
interval O O
. O O

Ethinyl I-drug B-drug
estradiol I-drug I-drug
Norethindrone I-drug I-drug

Clinical O O
trials O O
have O O
indicated O O
that O O
Pulmozyme B-brand B-brand
can O O
be O O
effectively O O
and O O
safely O O
used O O
in O O
conjunction O O
with O O
standard O B-group
cystic O I-group
fibrosis O I-group
therapies O O
including O O
oral O O
, O O
inhaled O O
and/or O O
parenteral O O
antibiotics B-group B-group
, O O
bronchodilators B-group B-group
, O O
enzyme O O
supplements O O
, O O
vitamins B-group B-group
, O O
oral O O
or O O
inhaled O O
corticosteroids B-group B-group
, O O
and O O
analgesics B-group B-group
. O O

Drug/Laboratory O O
Test O O
Interaction O O
Captopril B-drug B-drug
may O O
cause O O
a O O
false-positive O O
urine O O
test O O
for O O
acetone O B-drug
. O O

Tolbutamide B-drug B-drug
: O O
In O O
in O O
vitro O O
studies O O
, O O
M1 O O
was O O
shown O O
to O O
cause O O
increases O O
ranging O O
from O O
13 O O
- O O
50 O O
% O O
in O O
the O O
free O O
fraction O O
of O O
tolbutamide B-drug B-drug
at O O
concentrations O O
in O O
the O O
clinical O O
range O O
. O O

Interactions O O
between O O
COPAXONE B-brand B-brand
and O O
other O O
drugs O O
have O O
not O O
been O O
fully O O
evaluated O O
. O O

Therefore O O
, O O
patients O O
without O O
a O O
functioning O O
thyroid B-group O
gland O O
who O O
are O O
on O O
thyroid O O
replacement O O
therapy O O
may O O
need O O
to O O
increase O O
their O O
thyroid O B-group
dose O O
if O O
estrogens B-group B-group
or O O
estrogen-containing B-group B-group
oral O O
contraceptives B-group B-group
are O O
given O O
. O O

These O O
drugs O O
should O O
be O O
coadministered O O
with O O
caution O O
, O O
and O O
frequent O O
monitoring O O
of O O
serum O O
lithium B-drug B-drug
levels O O
is O O
recommended O O
. O O

Serum O O
samples O O
from O O
patients O O
treated O O
with O O
cefoxitin B-drug B-drug
should O O
not O O
be O O
analyzed O O
for O O
creatinine O O
if O O
withdrawn O O
within O O
2 O O
hours O O
of O O
drug O O
administration O O
. O O

- O O
Gold B-drug B-group
salts O I-group
( O O
medicine O O
for O O
arthritis O O
) O O
or O O

Calcium B-group B-group
channel I-group I-group
blockers I-group I-group
may O O
also O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
TENORMIN B-brand B-brand
. O O

Fluvoxamine B-drug B-drug
has O O
also O O
been O O
shown O O
to O O
inhibit O O
P450 O O
1A2 O O
, O O
an O O
isoform O O
also O O
involved O O
in O O
TCAmetabolism B-group O
. O O

Coadminstration O O
with O O
agents O O
that O O
induce O O
3A4 O O
activity O O
may O O
reduce O O
the O O
efficacy O O
of O O
DURAGESIC B-brand B-brand
. O O

1 O O
. O O

Antiarrhythmics B-group B-group
: O O
amiodarone B-drug B-drug

Digitalis B-group B-group
: O O
Vitamin B-group B-group
D I-group I-group
dosage O O
must O O
be O O
determined O O
with O O
care O O
in O O
patients O O
undergoing O O
treatment O O
with O O
digitalis B-group B-group
, O O
as O O
hypercalcemia O O
in O O
such O O
patients O O
may O O
precipitate O O
cardiac O O
arrhythmias O O
. O O

Administration O O
of O O
0.1-mg/kg O O
( O O
2 O O
x O O
ED95 O O
) O O
NIMBEX B-brand B-brand
at O O
10 O O
% O O
or O O
95 O O
% O O
recovery O O
following O O
an O O
intubating O O
dose O O
of O O
succinylcholine B-drug B-drug
( O O
1 O O
mg/kg O O
) O O
produced O O
95 O O
% O O
neuromuscular O O
block O O
. O O

There O O
have O O
been O O
reports O O
of O O
interactions O O
of O O
erythromycin B-drug B-drug
with O O
carbamazepine B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
hexobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
alfentanil B-drug B-drug
, O O
cisapride B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
bromocriptine B-drug B-drug
, O O
valproate B-drug B-drug
, O O
terfenadine B-drug B-drug
, O O
and O O
astemizole B-drug B-drug
. O O

( O O
SGOT O O
) O O
, O O
ALT O O
( O O
SGPT O O
) O O

However O O
, O O
10 O O
patients O O
who O O
switched O O
from O O
therapy O O
with O O
Interferon B-drug B-drug
beta I-drug I-drug
to O O
COPAXONE B-brand B-brand
did O O
not O O
report O O
any O O
serious O O
and O O
unexpected O O
adverse O O
reactions O O
thought O O
to O O
be O O
related O O
to O O
treatment O O
. O O

Therefore O O
, O O
esomeprazole B-drug B-drug
may O O
interfere O O
with O O
the O O
absorption O O
of O O
drugs O O
where O O
gastric O O
pH O O
is O O
an O O
important O O
determinant O O
of O O
bioavailability O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
, O O
iron B-drug B-drug
salts O O
and O O
digoxin B-drug B-drug
) O O
. O O

In O O
a O O
similar O O
study O O
, O O
attempting O O
to O O
replicate O O
this O O
finding O O
, O O
no O O
interactive O O
effect O O
on O O
hepatic O O
transaminases O O
was O O
identified O O
. O O

inhalation O O
anesthetics B-group B-group
; O O

Because O O
of O O
its O O
lack O O
of O O
platelet O O
effects O O
, O O
CELEBREX B-brand B-brand
is O O
not O O
a O O
substitute O O
for O O
aspirin B-brand B-brand
for O O
cardiovascular O O
prophylaxis O O
. O O

Paroxetine B-drug B-drug
( O O
20 O O
mg O O
QD O O
) O O
increased O O
the O O
concentration O O
of O O
duloxetine B-drug B-drug
( O O
40 O O
mg O O
QD O O
) O O
by O O
about O O
60 O O
% O O
, O O
and O O
greater O O
degrees O O
of O O
inhibition O O
are O O
expected O O
with O O
higher O O
doses O O
of O O
paroxetine B-drug B-drug
. O O

Thus O O
, O O
when O O
NSAIDs B-group B-group
and O O
lithium B-drug B-drug
are O O
administered O O
concurrently O O
, O O
subjects O O
should O O
be O O
observed O O
carefully O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

These O O
findings O O
suggest O O
that O O
intracellular O O
Ca O O
( O O
2+ O O
) O O
release O O
by O O
cholinergic O O
stimulation O O
is O O
critical O O
for O O
determining O O
synergism O O
with O O
cAMP O O
in O O
parietal O O
cell O O
activation O O
and O O
that O O
functional O O
coupling O O
between O O
the O O
Ca O O
( O O
2+ O O
) O O
store O O
and O O
the O O
receptor O O
is O O
maintained O O
by O O
actin O O
microfilaments O O
. O O

Dose O O
adjustments O O
of O O
either O O
class O O
of O O
agents O O
may O O
be O O
necessary O O
. O O

Serum O O
concentration O O
of O O
digoxin B-drug B-drug
and O O
digitoxin B-drug B-drug
may O O
increase O O
when O O
patients O O
take O O
antithyroid B-group B-group
agents I-group I-group
. O O

The O O
administration O O
of O O
naratriptan B-drug B-drug
with O O
other O O
5-HT1 B-group B-group
agonists I-group I-group
has O O
not O O
been O O
evaluated O O
in O O
migraine O O
patients O O
. O O

Molecular O O
basis O O
for O O
the O O
selective O O
toxicity O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
for O O
yeast O O
and O O
filipin B-drug_n B-drug_n
for O O
animal O O
cells O O
. O O

Estazolam B-drug B-drug
: O O
Interaction O O
with O O
Other O O
Drugs O O
that O O
are O O
Metabolized O O
by O O
Cytochrome O O
P450 O O
( O O
CYP O O
) O O
: O O
At O O
clinically O O
relevant O O
concentrations O O
, O O
in O O
vitro O O
studies O O
indicate O O
that O O
estazolam B-drug B-drug
( O O
0.6 O O
M O O
) O O
was O O
not O O
inhibitory O O
towards O O
the O O
major O O
cytochrome O O
P450 O O
isoforms O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
and O O
CYP3A O O
. O O

However O O
, O O
when O O
the O O
thioether O O
concentration O O
ranges O O
within O O
the O O
limits O O
of O O
the O O
normal O O
value O O
, O O
one O O
must O O
not O O
conclude O O
that O O
there O O
is O O
no O O
, O O
or O O
negligible O O
, O O
exposure O O
. O O

- O O
Naltrexone B-drug B-drug
( O O
e.g. O O
, O O
Trexan B-brand B-brand
) O O
( O O
with O O
long-term O O
, O O
high-dose O O
use O O
) O O
or O O

Drugs O O
that O O
reportedly O O
may O O
increase O O
oral O O
anticoagulant B-group B-group
response O O
, O O
ie O O
, O O
increased O O
prothrombin O O
response O O
, O O
in O O
man O O
include O O
: O O
alcohol* B-drug B-drug
; O O

Again O O
, O O
sertraline B-drug B-drug
neutralized O O
the O O
increase O O
in O O
glycemia O O
after O O
glucose B-drug O
overload O O
both O O
in O O
diabetic O O
and O O
non-diabetic O O
rats O O
. O O

Coadministration O O
of O O
phenytoin B-drug B-drug
with O O
40 O O
mg O O
SULAR B-brand B-brand
tablets O O
in O O
epileptic O O
patients O O
lowered O O
the O O
nisoldipine B-drug B-drug
plasma O O
concentrations O O
to O O
undetectable O O
levels O O
. O O

The O O
effects O O
of O O
coadministration O O
of O O
BARACLUDE B-brand B-brand
with O O
other O O
drugs O O
that O O
are O O
renally O O
eliminated O O
or O O
are O O
known O O
to O O
affect O O
renal O O
function O O
have O O
not O O
been O O
evaluated O O
, O O
and O O
patients O O
should O O
be O O
monitored O O
closely O O
for O O
adverse O O
events O O
when O O
BARACLUDE B-brand B-brand
is O O
coadministered O O
with O O
such O O
drugs O O
. O O

Garlic O O
Capsules O O
Garlic O O
capsules O O
should O O
not O O
be O O
used O O
while O O
taking O O
saquinavir B-drug B-drug
( O O
FORTOVASE B-brand B-brand
) O O
as O O
the O O
sole O B-group
protease B-group I-group
inhibitor I-group I-group
due O O
to O O
the O O
risk O O
of O O
decreased O O
saquinavir B-drug B-drug
plasma O O
concentrations O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
poor O O
metabolizers O O
. O O

Mylotarg B-brand B-brand
is O O
not O O
known O O
to O O
interfere O O
with O O
any O O
routine O O
diagnostic O O
tests O O
. O O

pyrazolones B-group B-group
; O O

. O O

Oral O O
Hypoglycemics B-group B-group
: O O
Bepridil B-drug B-drug
has O O
been O O
safely O O
used O O
in O O
diabetic O O
patients O O
without O O
significantly O O
lowering O O
their O O
blood O O
glucose O O
levels O O
or O O
altering O O
their O O
need O O
for O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

however O O
, O O
patients O O
with O O
moderate O O
to O O
severe O O
cardiovascular O O
disease O O
or O O
those O O
taking O O
nitrate B-group B-drug
therapy O O
are O O
at O O
increased O O
risk O O
for O O
potentially O O
serious O O
cardiovascular O O
adverse O O
effects O O
with O O
sildenafil B-drug B-drug
therapy O O
. O O

A O O
dose O O
increase O O
of O O
lopinavir/ritonavir B-drug B-drug
to O O
533/133 O O
mg O O
( O O
4 O O
capsules O O
or O O
6.5 O O
mL O O
) O O
twice O O
daily O O
taken O O
with O O
food O O
is O O
recommended O O
when O O
used O O
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
. O O

Systemic O B-group
antibiotic B-group I-group
agents I-group I-group
. O O

Currently O O
, O O
it O O
is O O
conceived O O
that O O
a O O
number O O
of O O
events O O
, O O
or O O
hits O O
, O O
are O O
required O O
for O O
the O O
induction O O
of O O
tumors O O
by O O
chemical O O
agents O O
. O O

In O O
contrast O O
, O O
in O O
Ontario O O
alone O O
, O O
in O O
1972 O O
and O O
1973 O O
there O O
were O O
26 O O
deaths O O
in O O
amphetamine B-drug B-drug
users O O
, O O
of O O
which O O
16 O O
were O O
due O O
to O O
accident O O
suicide O O
or O O
homicide O O
. O O

These O O
effects O O
have O O
been O O
observed O O
with O O
co-administration O O
of O O
itraconazole B-drug B-drug
( O O
a O O
potent O O
CYP3A4 B-drug O
inhibitor O O
) O O
. O O

Thus O O
patients O O
receiving O O
oral O O
anticoagulants B-group B-group
and O O
Fluvoxamine B-drug B-drug
Tablets O O
should O O
have O O
their O O
prothrombin O O
time O O
monitored O O
and O O
their O O
anticoagulant B-group B-group
dose O O
adjusted O O
accordingly O O
. O O

We O O
compared O O
indinavir B-drug B-drug
pharmacokinetics O O
and O O
gastric O O
pH O O
in O O
12 O O
human O O
immunodeficiency O O
virus-positive O O
patients O O
by O O
use O O
of O O
800 O O
mg O O
of O O
indinavir B-drug B-drug
alone O O
versus O O
800 O O
mg O O
of O O
indinavir B-drug B-drug
administered O O
1 O O
h O O
after O O
didanosine B-drug B-drug
administration O O
. O O

3 O O
. O O

The O O
possible O O
adverse O O
effects O O
of O O
ZINECARD B-brand B-brand
on O O
the O O
fertility O O
of O O
humans O O
and O O
experimental O O
animals O O
, O O
male O O
or O O
female O O
, O O
have O O
not O O
been O O
adequately O O
studied O O
. O O

Terfenadine B-drug B-drug
, O O
astemizole B-drug B-drug
and O O
cisapride B-drug B-drug
are O O
all O O
metabolized O O
by O O
the O O
cytochrome O O
P450IIIA4 O O
isozyme O O
, O O
and O O
it O O
has O O
been O O
demonstrated O O
that O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
IIIA4 O O
, O O
blocks O O
the O O
metabolism O O
of O O
these O O
drugs O O
, O O
resulting O O
in O O
increased O O
plasma O O
concentrations O O
of O O
parent O O
drug O O
. O O

Loperamide B-drug B-drug
and O O
morphine B-drug B-drug
( O O
0.1 O O
and O O
1.0 O O
mg/kg O O
, O O
s.c. O O
) O O
inhibited O O
the O O
dmPGE2 B-drug_n B-drug_n
( O O
0.3 O O
mg/kg O O
, O O
p.o O O
. O O
) O O
-induced O O
diarrhea O O
in O O
cecectomized O O
rats O O
. O O

In O O
geriatric O O
subjects O O
( O O
n=7 O O
) O O
there O O
was O O
a O O
reduction O O
in O O
the O O
rate O O
but O O
not O O
the O O
extent O O
of O O
flurbiprofen B-drug B-drug
absorption O O
. O O

Influence O O
of O O
coadministration O O
of O O
fluoxetine B-drug B-drug
on O O
cisapride B-drug B-drug
pharmacokinetics O O
and O O
QTc O O
intervals O O
in O O
healthy O O
volunteers O O
. O O

Coadministration O O
of O O
esomeprazole B-drug B-drug
30 O O
mg O O
and O O
diazepam B-drug B-drug
, O O
a O O
CYP2C19 O O
substrate O O
, O O
resulted O O
in O O
a O O
45 O O
% O O
decrease O O
in O O
clearance O O
of O O
diazepam B-drug B-drug
. O O

. O O

SIDE O O
EFFECTS O O
( O O
KEMSTRO B-brand B-brand
) O O
The O O
most O O
common O O
adverse O O
reaction O O
during O O
treatment O O
with O O
baclofen B-drug B-drug
is O O
transient O O
drowsiness O O
( O O
10-63 O O
% O O
) O O
. O O

Coadministration O O
of O O
CRIXIVAN B-brand B-brand
and O O
drugs O O
primarily O O
metabolized O O
by O O
CYP3A4 O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
other O O
drug O O
, O O
which O O
could O O
increase O O
or O O
prolong O O
its O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

The O O
relevance O O
of O O
this O O
finding O O
to O O
humans O O
is O O
not O O
known O O
at O O
this O O
time O O
. O O

Effect O O
of O O
Sensipar B-brand B-brand
on O O
other O O
drugs O O
: O O
Drugs O O
metabolized O O
by O O
cytochrome O O
P450 O O
2D6 O O
( O O
CYP2D6 O O
) O O
: O O
Sensipar B-brand B-brand
is O O
a O O
strong O O
in O O
vitro O O
inhibitor O O
of O O
CYP2D6 O O
. O O

This O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
pharmacokinetic O O
basis O O
of O O
this O O
interaction O O
in O O
10 O O
normal O O
subjects O O
. O O

In O O
uninfected O O
volunteers O O
, O O
46 O O
% O O
developed O O
rash O O
while O O
receiving O O
SUSTIVA B-brand B-brand
and O O
clarithromycin B-drug B-drug
. O O

Interactions O O
for O O
Vitamin B-drug B-drug
B3 I-drug I-drug
( O O
Niacin B-drug B-drug
) O O
: O O
Antihypertensive B-group B-group
Therapy O O
: O O
Nicotinic B-drug B-drug
acid I-drug I-drug
may O O
potentiate O O
the O O
effects O O
of O O
ganglionic B-group B-group
blocking I-group I-group
agents I-group I-group
and O O
vasoactive O B-group
drugs O I-group
resulting O O
in O O
postural O O
hypotension O O
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA O B-group
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

Following O O
oral O O
administration O O
of O O
two O O
150-mg O O
sustained-release O O
tablets O O
with O O
and O O
without O O
800 O O
mg O O
of O O
cimetidine B-drug B-drug
, O O
the O O
pharmacokinetics O O
of O O
bupropion B-drug B-drug
and O O
hydroxybupropion B-drug_n B-drug_n
were O O
unaffected O O
. O O

In O O
addition O O
, O O
most O O
macrolides B-group B-group
are O O
contraindicated O O
in O O
patients O O
receiving O O
terfenadine B-drug B-drug
therapy O O
who O O
have O O
pre-existing O O
cardiac O O
abnormalities O O
( O O
arrhythmia O O
, O O
bradycardia O O
, O O
QT O O
c O O
interval O O
prolongation O O
, O O
ischemic O O
heart O O
disease O O
, O O
congestive O O
heart O O
failure O O
, O O
etc O O
. O O
) O O
or O O
electrolyte O O
disturbances O O
. O O

OBJECTIVE O O
: O O
This O O
paper O O
reviews O O
recent O O
studies O O
of O O
the O O
efficacy O O
of O O
sildenafil B-drug B-drug
, O O
its O O
adverse O O
effects O O
and O O
drug O O
interactions O O
, O O
and O O
socioeconomic O O
factors O O
involved O O
in O O
its O O
use O O
, O O
with O O
a O O
focus O O
on O O
specific O O
patient O O
populations O O
( O O
prostate O O
cancer O O
, O O
diabetes O O
mellitus O O
, O O
ischemic O O
heart O O
disease O O
, O O
spinal O O
cord O O
injuries O O
, O O
neurologic O O
disorders O O
) O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
Measurement O O
of O O
serum O O
creatinine O O
levels O O
should O O
be O O
determined O O
by O O
the O O
Jaffe O O
reaction O O
, O O
since O O
Ancobon B-brand B-brand
does O O
not O O
interfere O O
with O O
the O O
determination O O
of O O
creatinine O O
values O O
by O O
this O O
method O O
. O O

Other O O
strong O O
selective O O
CYP3A4 O O
inhibitors O O
such O O
as O O
ketoconazole B-drug B-drug
can O O
also O O
be O O
expected O O
to O O
increase O O
the O O
exposure O O
of O O
zaleplon B-drug B-drug
. O O

Phenobarbital B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenobarbital B-drug B-drug
; O O

In O O
two O O
combined O O
12-week O O
placebo O O
controlled O O
trials O O
that O O
included O O
BROVANA B-brand B-brand
doses O O
of O O
15 O O
mcg O O
twice O O
daily O O
, O O
25 O O
mcg O O
twice O O
daily O O
, O O
and O O
50 O O
mcg O O
once O O
daily O O
, O O
54 O O
of O O
873 O O
BROVANA B-brand B-brand
-treated O O
subjects O O
received O O
concomitant O O
theophylline B-drug B-drug
at O O
study O O
entry O O
. O O

Limited O O
comparative O O
data O O
in O O
patients O O
with O O
high O O
viral O O
loads O O
treated O O
with O O
nevirapine- B-drug O
or O O
delavirdine-based B-drug O
regimens O O
currently O O
exist O O
. O O

Norepinephrine B-drug B-drug
: O O
Amphetamines B-group B-group
enhance O O
the O O
adrenergic O O
effect O O
of O O
norepinephrine B-drug B-drug
. O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
400 O O
mg O O
daily O O
did O O
not O O
have O O
any O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
rofecoxib B-drug B-drug
. O O

) O O

paraldehyde B-drug B-drug
; O O

*Not O O
administered O O
, O O
but O O
an O O
active O O
metabolite O O
of O O
carbamazepine B-drug B-drug
. O O

Clinical O O
studies O O
have O O
shown O O
increased O O
sedation O O
with O O
concurrent O O
hypnotic B-group B-group
medications I-group I-group
. O O

The O O
digoxin B-drug B-drug
median O O
tmax O O
was O O
0.5 O O
hours O O
for O O
both O O
treatments O O
. O O

No O O
pharmacokinetic O O
interactions O O
between O O
dexmedetomidine B-drug B-drug
and O O
isoflurane B-drug B-drug
, O O
propofol B-drug B-drug
, O O
alfentanil B-drug B-drug
, O O
and O O
midazolam B-drug B-drug
have O O
been O O
demonstrated O O
. O O

Close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
the O O
dosage O O
are O O
required O O
when O O
nortriptyline B-drug B-drug
hydrochloride I-drug I-drug
is O O
used O O
with O O
other O O
anticholinergic B-group B-group
drugs I-group I-group
or O O
sympathomimetic B-group B-group
drugs I-group I-group
. O O

Also O O
flucytosine B-drug B-drug
. O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCA B-group B-group
may O O
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Theophylline B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
and O O
appropriate O O
dose O O
adjustments O O
considered O O
for O O
patients O O
given O O
both O O
theophylline B-drug B-drug
and O O
PEGASYS B-brand B-brand
. O O

AXERT B-brand B-brand
is O O
not O O
known O O
to O O
interfere O O
with O O
commonly O O
employed O O
clinical O O
laboratory O O
tests O O
. O O

Bosentan B-drug B-drug
is O O
also O O
expected O O
to O O
reduce O O
plasma O O
concentrations O O
of O O
other O O
statins B-group B-group
that O O
have O O
significant O O
metabolism O O
by O O
CYP3A4 O O
, O O
such O O
as O O
lovastatin B-drug B-drug
and O O
atorvastatin B-drug B-drug
. O O

No O O
clinically O O
relevant O O
interactions O O
with O O
drugs O O
metabolized O O
by O O
these O O
CYP O O
enzymes O O
would O O
be O O
expected O O
. O O

therefore O O
, O O
nitroglycerin B-drug B-drug
or O O
other O O
nitrates B-group B-group
( O O
as O O
used O O
for O O
management O O
of O O
angina O O
) O O
or O O
other O O
drugs O O
having O O
vasodilator O O
activity O O
should O O
, O O
if O O
possible O O
, O O
be O O
discontinued O O
before O O
starting O O
captopril B-drug B-drug
. O O

( O O
Thiazide B-group B-group
drugs I-group I-group
may O O
increase O O
the O O
responsiveness O O
to O O
tubocurarine B-drug B-drug
. O O
) O O

DISULFIRAM B-drug B-drug
SHOULD O O
BE O O
USED O O
WITH O O
CAUTION O O
IN O O
THOSE O O
PATIENTS O O
REVEIVING O B-brand
PHENYTOIN B-drug B-drug
AND O O
ITS O O
CONGENERS O O
. O O

These O O
increased O O
exposures O O
of O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
should O O
be O O
taken O O
into O O
consideration O O
when O O
selecting O O
an O O
oral O O
contraceptive B-group B-group
for O O
women O O
taking O O
valdecoxib B-drug B-drug
. O O

Patients O O
receiving O O
narrow O O
therapeutic O O
ratio O O
drugs O O
or O O
other O O
drugs O O
that O O
require O O
careful O O
titration O O
should O O
be O O
followed O O
closely O O
; O O

Evidence O O
supporting O O
the O O
conclusion O O
that O O
it O O
is O O
inadvisable O O
to O O
co-administer O O
fluvoxamine B-drug B-drug
and O O
diazepam B-drug B-drug
is O O
derived O O
from O O
a O O
study O O
in O O
which O O
healthy O O
volunteers O O
taking O O
150 O O
mg/day O O
of O O
fluvoxamine B-drug B-drug
were O O
administered O O
a O O
single O O
oral O O
dose O O
of O O
10 O O
mg O O
of O O
diazepam B-drug B-drug
. O O

Inhibition O O
of O O
these O O
isoenzymes O O
may O O
increase O O
the O O
plasma O O
concentration O O
of O O
bosentan B-drug B-drug
. O O

These O O
results O O
are O O
consistent O O
with O O
the O O
in O O
vitro O O
finding O O
that O O
neither O O
isotretinoin B-drug B-drug
nor O O
its O O
metabolites O O
induce O O
or O O
inhibit O O
the O O
activity O O
of O O
the O O
CYP O O
2C9 O O
human O O
hepatic O O
P450 O O
enzyme O O
. O O

Although O O
clinical O O
studies O O
have O O
not O O
been O O
conducted O O
, O O
in O O
vitro O O
studies O O
of O O
iloprost B-drug B-drug
indicate O O
that O O
no O O
relevant O O
inhibition O O
of O O
cytochrome O O
P450 O O
drug O O
metabolism O O
would O O
be O O
expected O O
. O O

Quinolone B-group B-group
Antibiotics O I-group
: O O
VIDEX B-brand B-brand
should O O
be O O
administered O O
at O O
least O O
2 O O
hours O O
after O O
or O O
6 O O
hours O O
before O O
dosing O O
with O O
ciprofloxacin B-drug B-drug
because O O
plasma O O
concentrations O O
of O O
ciprofloxacin B-drug B-drug
are O O
decreased O O
when O O
administered O O
with O O
antacids B-group B-group
containing O O
magnesium B-drug B-drug
, O O
calcium B-drug B-drug
, O O
or O O
aluminum B-drug B-drug
. O O

Thyroid B-group B-group
administration O O
to O O
a O O
digitalized O O
, O O
hypothyroid O O
patient O O
may O O
increase O O
the O O
dose O O
requirement O O
of O O
digoxin B-drug B-drug
. O O

Similarly O O
, O O
diazepam B-drug B-drug
decreased O O
the O O
antinociceptive O O
effect O O
of O O
metamizol B-drug B-drug
( O O
only O O
in O O
the O O
tail-flick O O
test O O
) O O
and O O
indomethacin B-drug B-drug
. O O

The O O
following O O
are O O
examples O O
of O O
substances O O
that O O
may O O
increase O O
the O O
blood-glucose-lowering O O
effect O O
and O O
susceptibility O O
to O O
hypoglycemia O O
: O O
oral O O
antidiabetes O B-group
products O I-group
, O O
ACE B-group B-group
inhibitors I-group I-group
, O O
disopyramide B-drug B-drug
, O O
fibrates B-group B-group
, O O
fluoxetine B-drug B-drug
, O O
MAO B-group B-group
inhibitors I-group I-group
, O O
propoxyphene B-drug B-drug
, O O
salicylates B-group B-group
, O O
somatostatin B-group B-group
analog I-group I-group
( O O
e.g. O O
, O O
octreotide B-drug B-drug
) O O
, O O
sulfonamide B-group B-group
antibiotics I-group I-group
. O O

Patients O O
should O O
be O O
monitored O O
for O O
signs O O
of O O
withdrawal O O
and O O
their O O
methadone B-drug B-drug
dose O O
increased O O
as O O
required O O
to O O
alleviate O O
withdrawal O O
symptoms O O
. O O

Therefore O O
, O O
positive O O
test O O
results O O
in O O
patients O O
receiving O O
piperacillin B-drug B-drug
should O O
be O O
interpreted O O
cautiously O O
and O O
confirmed O O
by O O
other O O
diagnostic O O
methods O O
. O O

Concomitant O O
use O O
of O O
cimetidine B-drug B-drug
should O O
be O O
avoided O O
. O O

Antacids B-group B-group
: O O
Concomitant O O
administration O O
of O O
antacids B-group B-group
may O O
reduce O O
plasma O O
levels O O
of O O
diflunisal B-drug B-drug
. O O

In O O
patients O O
who O O
have O O
been O O
reported O O
to O O
be O O
well O O
controlled O O
on O O
tricyclic B-group B-group
antidepressants I-group I-group
receiving O O
concurrent O O
cimetidine B-drug B-drug
therapy O O
, O O
discontinuation O O
of O O
cimetidine B-drug B-drug
has O O
been O O
reported O O
to O O
decrease O O
established O O
steady-state O O
serum O O
tricyclic B-group B-group
antidepressant I-group I-group
levels O O
and O O
compromise O O
their O O
therapeutic O O
effects O O
. O O

Insulin B-drug B-drug
requirements O O
in O O
diabetic O O
patients O O
may O O
be O O
increased O O
, O O
decreased O O
, O O
or O O
unchanged O O
. O O

at O O
high O O
doses O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
decreased O O
FI O O
and O O
FR O O
responding O O
. O O

The O O
pharmacokinetics O O
of O O
terfenadine B-drug B-drug
and O O
its O O
acid O O
metabolite O O
and O O
the O O
electrocardiographic O O
QT O O
c O O
interval O O
were O O
measured O O
during O O
both O O
periods O O
: O O
with O O
terfenadine B-drug B-drug
alone O O
, O O
and O O
with O O
terfenadine B-drug B-drug
plus O O
dirithromycin B-drug B-drug
. O O

Thus O O
, O O
if O O
such O O
treatment O O
is O O
essential O O
, O O
the O O
possibility O O
of O O
increased O O
risk O O
relative O O
to O O
benefits O O
should O O
be O O
considered O O
. O O

In O O
10 O O
otherwise O O
healthy O O
subjects O O
with O O
epilepsy O O
ingesting O O
phenytoin B-drug B-drug
, O O
the O O
steadystate O O
trough O O
( O O
Cmin O O
) O O
phenytoin B-drug B-drug
plasma O O
concentration O O
was O O
17 O O
5 O O
micrograms/mL O O
. O O

Antiretroviral B-group B-group
Agents I-group I-group
: O O
No O O
drug O O
interactions O O
with O O
other O O
antiretroviral B-group B-group
medications I-group I-group
have O O
been O O
identified O O
that O O
would O O
warrant O O
alteration O O
of O O
either O O
the O O
enfuvirtide B-drug B-drug
dose O O
or O O
the O O
dose O O
of O O
the O O
other O O
antiretroviral B-group B-group
medication I-group I-group
. O O

Toxicology O O
studies O O
of O O
heroin-related B-drug_n B-drug_n
deaths O O
reveal O O
frequent O O
involvement O O
of O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
, O O
including O O
alcohol B-drug B-drug
, O O
benzodiazepines B-group B-group
such O O
as O O
diazepam B-drug B-drug
( O O
Valium B-brand B-brand
) O O
, O O
and O O
, O O
to O O
a O O
rising O O
degree O O
, O O
methadone B-drug B-drug
. O O

Aprepitant B-drug B-drug
has O O
been O O
shown O O
to O O
induce O O
the O O
metabolism O O
of O O
S B-drug B-drug
( I-drug I-drug
- I-drug I-drug
) I-drug I-drug
warfarin I-drug I-drug
and O O
tolbutamide B-drug B-drug
, O O
which O O
are O O
metabolized O O
through O O
CYP2C9 O O
. O O

5 O O
. O O

Although O O
increased O O
plasma O O
concentrations O O
( O O
C O O
max O O
and O O
AUC O O
0-24 O O
hrs O O
) O O
of O O
desloratadine B-drug B-drug
and O O
3-hydroxydesloratadine B-drug_n B-drug_n
were O O
observed O O
, O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
safety O O
profile O O
of O O
desloratadine B-drug B-drug
, O O
as O O
assessed O O
by O O
electrocardiographic O O
parameters O O
( O O
including O O
the O O
corrected O O
QT O O
interval O O
) O O
, O O
clinical O O
laboratory O O
tests O O
, O O
vital O O
signs O O
, O O
and O O
adverse O O
events O O
. O O

Plasma O O
exposure O O
of O O
diazepam B-drug B-drug
( O O
10 O O
mg O O
BID O O
) O O
was O O
increased O O
by O O
28 O O
% O O
following O O
administration O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
) O O
for O O
12 O O
days O O
, O O
while O O
plasma O O
exposure O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
) O O
was O O
not O O
substantially O O
increased O O
following O O
administration O O
of O O
diazepam B-drug B-drug
( O O
10 O O
mg O O
BID O O
) O O
for O O
12 O O
days O O
. O O

When O O
administered O O
concurrently O O
, O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
ampicillin B-drug B-drug
. O O

Concomitant O O
treatment O O
with O O
methylxanthines B-group B-group
( O O
aminophylline B-drug B-drug
, O O
theophylline B-drug B-drug
) O O
, O O
steroids B-group B-group
, O O
or O O
diuretics B-group B-group
may O O
potentiate O O
any O O
hypokalemic O O
effect O O
of O O
adrenergic B-group B-group
agonists I-group I-group
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
glipizide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Drug/LaboratoryTest O O
Interactions O O
Dactinomycin B-drug B-drug
may O O
interfere O O
with O O
bioassay O O
procedures O O
for O O
the O O
determination O O
of O O
antibacterial B-group B-group
drug I-group I-group
levels O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
p.o O O
. O O

Intravenous O O
Adenocard B-brand B-brand
( O O
adenosine B-drug B-drug
) O O
has O O
been O O
effectively O O
administered O O
in O O
the O O
presence O O
of O O
other O O
cardioactive O B-group
drugs O I-group
, O O
such O O
as O O
quinidine B-drug B-drug
, O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
calcium B-group B-group
channel I-group I-group
blocking I-group I-group
agents I-group I-group
, O O
and O O
angiotensin B-group B-group
converting I-group I-group
enzyme I-group I-group
inhibitors I-group I-group
, O O
without O O
any O O
change O O
in O O
the O O
adverse O O
reaction O O
profile O O
. O O

8 O O
. O O

At O O
24 O O
hours O O
postdose O O
, O O
a O O
similar O O
proportion O O
of O O
patients O O
treated O O
with O O
methotrexate B-drug B-drug
alone O O
( O O
94 O O
% O O
) O O
and O O
subsequently O O
treated O O
with O O
methotrexate B-drug B-drug
co-administered O O
with O O
75 O O
mg O O
of O O
rofecoxib B-drug B-drug
( O O
88 O O
% O O
) O O
had O O
methotrexate B-drug B-drug
plasma O O
concentrations O O
below O O
the O O
measurable O O
limit O O
( O O
5 O O
ng/mL O O
) O O
. O O

In O O
a O O
p53 O O
( O O
+/- O O
) O O
mouse O O
carcinogenicity O O
study O O
at O O
doses O O
up O O
to O O
the O O
maximum O O
tolerated O O
dose O O
of O O
100 O O
mg/kg/day O O
ribavirin B-drug B-drug
was O O
not O O
oncogenic O O
. O O

Results O O
of O O
studies O O
in O O
multiple O O
sclerosis O O
patients O O
taking O O
TYSABRI B-brand B-brand
and O O
concomitant O O
interferon B-drug B-drug
beta-1a I-drug I-drug
( O O
AVONEX B-brand B-brand
30 O O
mcg O O
IM O O
once O O
weekly O O
) O O
or O O
glatiramer B-drug O
acetate I-drug B-drug
were O O
inconclusive O O
with O O
regard O O
to O O
the O O
need O O
for O O
dose O O
adjustment O O
of O O
the O O
beta-interferon B-drug B-drug
or O O
glatiramer B-drug O
acetate I-drug B-drug
. O O

Laboratory O O
Test O O
Interactions O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
: O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
Caucasian O O
population O O
( O O
about O O
7-10 O O
% O O
of O O
Caucasians O O
are O O
so-called O O
poor O O
metabolizers O O
) O O
; O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
other O O
drugs O O
metabolized O O
by O O
cytochrome O O
P450IID6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

In O O
general O O
, O O
any O O
added O O
antiarrhythmic B-drug B-group
drug I-drug I-group
should O O
be O O
initiated O O
at O O
a O O
lower O O
than O O
usual O O
dose O O
with O O
careful O O
monitoring O O
. O O

There O O
have O O
been O O
rare O O
postmarketing O O
reports O O
of O O
rhabdomyolysis O O
, O O
some O O
associated O O
with O O
strenuous O O
physical O O
activity O O
. O O

The O O
effects O O
of O O
concomitant O O
administration O O
of O O
TAMBOCOR B-brand B-brand
and O O
propranolol B-drug B-drug
on O O
the O O
PR O O
interval O O
were O O
less O O
than O O
additive O O
. O O

Influence O O
of O O
calcium-channel B-group B-group
blockers I-group I-group
on O O
platelet O O
function O O
and O O
arachidonic O O
acid O O
metabolism O O
. O O

Amphetamines B-group B-group
may O O
interfere O O
with O O
urinary O O
steroid O O
determinations O O
. O O

Studies O O
have O O
shown O O
that O O
lansoprazole B-drug B-drug
does O O
not O O
have O O
clinically O O
significant O O
interactions O O
with O O
other O O
drugs O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
, O O
such O O
as O O
warfarin B-drug B-drug
, O O
antipyrine B-drug B-drug
, O O
indomethacin B-drug B-drug
, O O
ibuprofen B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
prednisone B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
or O O
terfenadine B-drug B-drug
in O O
healthy O O
subjects O O
. O O

We O O
report O O
the O O
case O O
of O O
an O O
adolescent O O
with O O
altered O O
consciousness O O
caused O O
by O O
carbamazepine B-drug B-drug
overdose O O
with O O
a O O
positive O O
tricyclic B-group B-group
antidepressant I-group I-group
level O O
to O O
alert O O
clinicians O O
to O O
the O O
cross-reactivity O O
of O O
carbamazepine B-drug B-drug
with O O
a O O
toxicology O O
screen O O
for O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

nc1 O O
18 O O
% O O
decrease O O
[ O O
CI O O
: O O
13 O O
% O O
decrease O O
, O O
40 O O
% O O
decrease O O
] O O

Trough O O
plasma O O
enoxacin B-drug B-drug
levels O O
were O O
also O O
20 O O
% O O
higher O O
when O O
caffeine B-drug B-drug
and O O
enoxacin B-drug B-drug
were O O
administered O O
concomitantly O O
. O O

In O O
contrast O O
, O O
preliminary O O
results O O
from O O
an O O
8-week O O
controlled O O
study O O
suggested O O
risperidone B-drug B-drug
2 O O
to O O
6 O O
mg/day O O
was O O
superior O O
to O O
olanzapine B-drug B-drug
5 O O
to O O
20 O O
mg/day O O
against O O
positive O O
and O O
anxiety/depressive O O
symptoms O O
( O O
p O O
< O O
0.05 O O
) O O
, O O
although O O
consistent O O
with O O
the O O
first O O
study O O
, O O
both O O
agents O O
demonstrated O O
similar O O
efficacy O O
on O O
measures O O
of O O
overall O O
psychopathology O O
. O O

The O O
goal O O
of O O
this O O
review O O
was O O
to O O
cite O O
primary O O
sources O O
for O O
virtually O O
all O O
research O O
specific O O
to O O
POPs O O
since O O
1975 O O
. O O

Then O O
, O O
the O O
effects O O
of O O
metabotropic O O
glutamate O O
receptor O O
( O O
mGluR O O
) O O
agonists O O
, O O
DCG-IV B-drug_n B-drug_n
and O O
L-CCG-1 B-drug_n B-drug_n
, O O
on O O
the O O
above O O
behavioral O O
changes O O
induced O O
by O O
PCP B-drug_n B-drug_n
were O O
found O O
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCA B-group B-group
plasma O O
levels O O
whenever O O
a O O
TCA B-group B-group
is O O
going O O
to O O
be O O
co-administered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
. O O

Patients O O
treated O O
with O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
and O O
warfarin B-drug B-drug
concomitantly O O
may O O
need O O
to O O
be O O
monitored O O
for O O
increases O O
in O O
INR O O
and O O
prothrombin O O
time O O
. O O

Both O O
hypo- O O
and O O
hyperglycemic O O
effects O O
have O O
been O O
reported O O
. O O

There O O
were O O
no O O
clinically O O
significant O O
changes O O
in O O
corrected O O
QT O O
intervals O O
during O O
administration O O
of O O
cisapride B-drug B-drug
alone O O
or O O
with O O
fluoxetine B-drug B-drug
. O O

A O O
rare O O
, O O
but O O
serious O O
, O O
constellation O O
of O O
symptoms O O
, O O
termed O O
serotonin O O
syndrome O O
, O O
has O O
been O O
reported O O
with O O
the O O
concomitant O O
use O O
of O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
and O O
agents O O
for O O
migraine O O
therapy O O
, O O
such O O
as O O
Imitrex B-brand B-brand
( O O
sumatriptan B-drug B-drug
succinate I-drug I-drug
) O O
and O O
dihydroergotamine B-drug B-drug
. O O

Concomitant O O
cyclophosphamide B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
vincristine B-drug B-drug
, O O
and O O
prednisone B-drug B-drug
chemotherapy O O
plus O O
highly B-group O
active I-group O
antiretroviral I-group B-group
therapy O O
in O O
patients O O
with O O
human O O
immunodeficiency O O
virus-related O O
, O O
non-Hodgkin O O
lymphoma O O
. O O

Most O O
automated O O
equipment O O
for O O
measurement O O
of O O
creatinine O O
makes O O
use O O
of O O
the O O
Jaffe O O
reaction O O
. O O

Some O O
quinolones B-group B-group
have O O
also O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

vii O O
. O O

No O O
inhibition O O
of O O
deferasirox B-drug B-drug
metabolism O O
by O O
hydroxyurea B-drug B-drug
is O O
expected O O
based O O
on O O
the O O
results O O
of O O
an O O
in O O
vitro O O
study O O
. O O

Since O O
aminotransferase O O
determinations O O
are O O
important O O
in O O
the O O
differential O O
diagnosis O O
of O O
myocardial O O
infarction O O
, O O
liver O O
disease O O
and O O
pulmonary O O
emboli O O
, O O
rises O O
that O O
might O O
be O O
caused O O
by O O
drugs O O
( O O
heparin B-drug B-drug
sodium I-drug I-drug
) O O
should O O
be O O
interpreted O O
with O O
caution O O
. O O

This O O
product O O
can O O
affect O O
the O O
results O O
of O O
certain O O
lab O O
tests O O
. O O

The O O
mean O O
QT O O
c O O
interval O O
( O O
msec O O
) O O
was O O
369 O O
with O O
terfenadine B-drug B-drug
alone O O
and O O
367 O O
with O O
terfenadine B-drug B-drug
plus O O
dirithromycin B-drug B-drug
. O O

Therefore O O
you O O
may O O
need O O
to O O
take O O
a O O
vitamin B-drug B-group
B12 I-drug I-group
supplement O O
while O O
taking O O
aminosalicylic B-drug B-drug
acid I-drug I-drug
. O O

Beta B-group B-group
Blockers I-group I-group

Atorvastatin B-drug B-drug
: O O
Atorvastatin B-drug B-drug
increases O O
the O O
AUC O O
for O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
. O O

Combinations O O
of O O
clindamycin B-drug B-drug
and O O
gentamicin B-drug B-drug
were O O
indifferent O O
for O O
29 O O
strains O O
and O O
synergistic O O
for O O
33 O O
strains O O
. O O

Agents O O
Causing O O
Renin O O
Release O O
Captopril B-drug B-drug
's O O
effect O O
will O O
be O O
augmented O O
by O O
antihypertensive B-group B-group
agents I-group I-group
that O O
cause O O
renin O O
release O O
. O O

Amprenavir B-drug B-drug
inhibits O O
the O O
ERMBT O O
, O O
and O O
rifampin B-drug B-drug
and O O
rifabutin B-drug B-drug
are O O
equipotent O O
inducers O O
of O O
the O O
ERMBT O O
. O O

Concomitant O O
use O O
of O O
zalcitabine B-drug B-drug
and O O
lamivudine B-drug B-drug
is O O
not O O
recommended O O
. O O

Although O O
activation O O
of O O
several O O
transcription O O
factor O O
IEGs O O
has O O
been O O
described O O
, O O
little O O
is O O
known O O
about O O
effector O O
IEGs O O
. O O

Clostridium B-drug_n B-drug_n
difficile I-drug_n I-drug_n
toxin I-drug_n I-drug_n
A I-drug_n I-drug_n
displays O O
both O O
cytotoxic O O
and O O
enterotoxic O O
activities O O
. O O

It O O
is O O
likely O O
that O O
experience O O
significantly O O
underestimates O O
the O O
degree O O
of O O
accumulation O O
that O O
might O O
occur O O
with O O
repealed O O
diazepam B-drug B-drug
administration O O
. O O

The O O
use O O
of O O
dexfenfluramine B-drug B-drug
with O O
other O O
CNS-active O O
drugs O O
has O O
not O O
been O O
systematically O O
evaluated O O
; O O

NSAIDs B-group B-group
may O O
decrease O O
the O O
hemodynamic O O
effects O O
of O O
hydralazine B-drug B-drug
; O O

therefore O O
, O O
close O O
monitoring O O
of O O
prothrombin O O
time O O
is O O
recommended O O
, O O
and O O
adjustment O O
of O O
the O O
anticoagulant B-group B-group
dose O O
may O O
be O O
necessary O O
when O O
Tagamet B-brand B-brand
is O O
administered O O
concomitantly O O
. O O

Genetic O O
variation O O
also O O
occurs O O
in O O
proteins O O
interacting O O
with O O
drugs O O
, O O
which O O
may O O
change O O
the O O
effect O O
of O O
e.g O O
. O O

Before O O
using O O
this O O
medication O O
, O O
tell O O
your O O
doctor O O
or O O
pharmacist O O
of O O
all O O
prescription O O
and O O
nonprescription O O
products O O
you O O
may O O
use O O
, O O
especially O O
of O O
: O O
aminoglycosides B-group B-group
( O O
e.g. O O
, O O
gentamicin B-drug B-drug
, O O
amikacin B-drug B-drug
) O O
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
cyclosporine B-drug B-drug
, O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs O I-group
( O O
e.g. O O
, O O
ibuprofen B-drug B-drug
) O O
, O O
tacrolimus B-drug B-drug
, O O
vancomycin B-drug B-drug
. O O

- O O
a O O
diuretic B-group B-group
( O O
water O O
pill O O
) O O
such O O
as O O
hydrochlorothiazide B-drug B-drug
( O O
HCTZ B-drug B-drug
, O O
Hydrodiuril B-brand B-drug
) O O
, O O
chlorothiazide B-drug B-drug
( O O
Diuril B-brand B-brand
) O O
, O O
and O O
others O O
; O O

Diuretics B-group B-group
: O O
Etodolac O B-drug
has O O
no O O
apparent O O
pharmacokinetic O O
interaction O O
when O O
administered O O
with O O
furosemide B-drug B-drug
or O O
hydrochlorothiazide B-drug B-drug
. O O

Interaction O O
studies O O
have O O
been O O
performed O O
with O O
fluvastatin B-drug B-drug
and O O
several O O
drugs O O
with O O
which O O
it O O
might O O
be O O
coadministered O O
. O O

As O O
with O O
other O O
antihypertensive B-group B-group
agents I-group I-group
, O O
the O O
antihypertensive O O
effect O O
of O O
losartan B-drug B-drug
may O O
be O O
blunted O O
by O O
the O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drug I-group I-group
indomethacin B-drug B-drug

Erythromycin O B-drug
Co-administration O O
of O O
felodipine B-drug B-drug
( O O
PLENDIL B-drug B-brand
) O O
with O O
erythromycin B-drug B-drug
resulted O O
in O O
approximately O O
2.5- O O
fold O O
increase O O
in O O
the O O
AUC O O
and O O
Cmax O O
, O O
and O O
about O O
2- O O
fold O O
prolongation O O
in O O
the O O
half- O O
life O O
of O O
felodipine B-drug B-drug
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
VELCADE B-brand B-brand
. O O

If O O
SPRYCEL B-brand B-brand
must O O
be O O
administered O O
with O O
a O O
CYP3A4 O O
inducer O O
, O O
a O O
dose O O
increase O O
in O O
SPRYCEL B-brand B-brand
should O O
be O O
considered O O
. O O

In O O
a O O
multiple-dose O O
study O O
, O O
enoxacin B-drug B-drug
caused O O
a O O
dose-related O O
increase O O
in O O
the O O
mean O O
elimination O O
half-life O O
of O O
caffeine B-drug B-drug
, O O
thereby O O
decreasing O O
the O O
clearance O O
of O O
caffeine B-drug B-drug
by O O
up O O
to O O
80 O O
% O O
and O O
leading O O
to O O
a O O
five-fold O O
increase O O
in O O
the O O
AUC O O
and O O
the O O
half-life O O
of O O
caffeine B-drug B-drug
. O O

Interaction O O
between O O
exogenous O O
and O O
endogenous O O
oxytocin B-drug B-drug
and O O
vasopressin O B-drug
was O O
found O O
to O O
affect O O
the O O
mechanism O O
of O O
milk O O
ejection O O
by O O
the O O
alveoli O O
of O O
the O O
mammary O O
gland O O
in O O
lactating O O
rats O O
. O O

Administration O O
of O O
ELLENCE B-brand B-brand
after O O
previous O O
radiation O O
therapy O O
may O O
induce O O
an O O
inflammatory O O
recall O O
reaction O O
at O O
the O O
site O O
of O O
the O O
irradiation O O
. O O

[ O O
The O O
effect O O
of O O
cimetidine B-drug B-drug
on O O
the O O
renal O O
excretion O O
of O O
verografin B-drug B-drug
and O O
iodamide B-drug B-drug
in O O
dogs O O
] O O
The O O
intravenous O O
injection O O
of O O
cimetidine B-drug B-drug
in O O
a O O
dose O O
of O O
20 O O
mg/kg O O
enhanced O O
verografine B-drug B-drug
and O O
iodamide B-drug B-drug
excretion O O
in O O
chronic O O
canine O O
experiments O O
. O O

An O O
adjustment O O
in O O
the O O
diltiazem B-drug B-drug
dose O O
may O O
be O O
warranted O O
. O O

The O O
concomitant O O
use O O
of O O
heparin B-drug B-drug
or O O
aspirin B-brand B-brand
during O O
the O O
first O O
24 O O
hours O O
following O O
symptom O O
onset O O
were O O
prohibited O O
in O O
The O O
NINDS O O
t-PA O O
Stroke O O
Trial O O
. O O

The O O
effects O O
of O O
concomitant O O
administration O O
of O O
cimetidine B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
bupropion B-drug B-drug
and O O
its O O
active O O
metabolites O O
were O O
studied O O
in O O
24 O O
healthy O O
young O O
male O O
volunteers O O
. O O

Gleevec B-brand B-brand
will O O
increase O O
plasmaconcentration O O
of O O
other O O
CYP3A4 O O
metabolized O O
drugs O O
( O O
e.g. O O
, O O
triazolo-benzodiazepines B-group B-group
, O O
dihydropyridine B-group B-group
calcium I-group I-group
channel I-group I-group
blockers I-group I-group
, O O
certain O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
, O O
etc O O
. O O
) O O
. O O

Pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
were O O
also O O
not O O
affected O O
by O O
phenytoin B-drug B-drug
. O O

Fulvestrant B-drug B-drug
is O O
metabolized O O
by O O
CYP O O
3A4 O O
in O O
vitro O O
. O O

The O O
results O O
of O O
assays O O
using O O
red O O
cells O O
from O O
healthy O O
subjects O O
to O O
determine O O
whether O O
ceftibuten B-drug B-drug
would O O
cause O O
direct O O
Coombs O O
reactions O O
in O O
vitro O O
showed O O
no O O
positive O O
reaction O O
at O O
ceftibuten B-drug B-drug
concentrations O O
as O O
high O O
as O O
40 O O
g/mL O O
. O O

Theophylline B-drug B-drug
: O O
Enoxacin B-drug B-drug
is O O
a O O
potent O O
inhibitor O O
of O O
the O O
cytochrome O O
P-450 O O
isozymes O O
responsible O O
for O O
the O O
metabolism O O
of O O
methylxanthines B-group B-group
. O O

Lithium B-drug B-drug
Reversible O O
increases O O
in O O
serum O O
lithium B-drug B-drug
concentrations O O
and O O
toxicity O O
have O O
been O O
reported O O
during O O
concomitant O O
administration O O
of O O
lithium B-drug B-drug
with O O
ACE B-group B-group
inhibitors I-group I-group
, O O
and O O
with O O
some O O
angiotensin B-group B-group
II I-group I-group
receptor I-group I-group
antagonists I-group I-group
. O O

Adjustment O O
of O O
adenosine B-drug B-drug
dosage O O
may O O
be O O
necessary O O
. O O

The O O
proposed O O
mechanisms O O
of O O
analgesic O O
action O O
of O O
antihistaminics B-group B-group
are O O
reviewed O O
and O O
discussed O O
. O O

PGF2alpha B-drug B-drug
produced O O
significantly O O
increased O O
vasoconstriction O O
after O O
a O O
single O O
administration O O
of O O
oxytocin B-drug B-drug
. O O

For O O
these O O
reasons O O
, O O
it O O
is O O
felt O O
that O O
, O O
in O O
most O O
subjects O O
who O O
have O O
had O O
an O O
unsatisfactory O O
lipid O O
response O O
to O O
either O O
drug O O
alone O O
, O O
the O O
possible O O
benefits O O
of O O
combined O O
therapy O O
with O O
lovastatin B-drug B-drug
and O O
a O O
fibrate B-group B-group
do O O
not O O
outweigh O O
the O O
risks O O
of O O
severe O O
myopathy O O
, O O
rhabdomyolysis O O
, O O
and O O
acute O O
renal O O
failure O O
. O O

The O O
risk O O
of O O
hypoglycemia O O
secondary O O
to O O
this O O
mechanism O O
may O O
be O O
increased O O
if O O
allopurinol B-drug B-drug
and O O
chlorpropamide B-drug B-drug
are O O
given O O
concomitantly O O
in O O
the O O
presence O O
of O O
renal O O
insufficiency O O
. O O

When O O
combined O O
therapy O O
is O O
contemplated O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

As O O
noted O O
below O O
, O O
a O O
sub- O O
for O O
fluvoxamine B-drug B-drug
in O O
combination O O
with O O
alprazolam B-drug B-drug
, O O
a O O
drug O O
that O O
is O O
known O O
to O O
be O O
metabolized O O
by O O
the O O
IIIA4 O O
isozyme O O
. O O

In O O
a O O
clinical O O
pharmacology O O
study O O
, O O
indomethacin B-drug B-drug
or O O
sulindac B-drug B-drug
was O O
administered O O
to O O
hypertensive O O
patients O O
receiving O O
VASOTEC B-brand B-brand
. O O

Concomitant O O
administration O O
of O O
alosetron B-drug B-drug
and O O
moderate O O
CYP1A2 O B-group
inhibitors O I-group
, O O
including O O
quinolone B-group B-group
antibiotics I-group I-group
and O O
cimetidine B-drug B-drug
, O O
has O O
not O O
been O O
evaluated O O
, O O
but O O
should O O
be O O
avoided O O
unless O O
clinically O O
necessary O O
because O O
of O O
similar O O
potential O O
drug O O
interactions O O
. O O

This O O
effect O O
may O O
be O O
mediated O O
by O O
the O O
ability O O
of O O
rifampin B-drug B-drug
to O O
induce O O
microsomal O O
enzymes O O
and O O
, O O
thus O O
, O O
the O O
catabolism O O
of O O
warfarin B-drug B-drug
. O O

NSAIDs B-group B-group
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
taking O O
cyclosporine B-drug B-drug
, O O
and O O
renal O O
function O O
should O O
be O O
carefully O O
monitored O O
. O O

The O O
reddish O O
color O O
is O O
due O O
to O O
the O O
formation O O
of O O
a O O
nonabsorbable O O
complex O O
between O O
cefdinir B-drug B-drug
or O O
its O O
breakdown O O
products O O
and O O
iron B-drug B-drug
in O O
the O O
gastrointestinal O O
tract O O
. O O

On O O
administration O O
of O O
oral O O
amiodarone B-drug B-drug
, O O
the O O
need O O
for O O
digitalis B-group B-group
therapy O O
should O O
be O O
reviewed O O
and O O
the O O
dose O O
reduced O O
by O O
approximately O O
50 O O
% O O
or O O
discontinued O O
. O O

Anagrelide B-drug B-drug
demonstrates O O
some O O
limited O O
inhibitory O O
activity O O
towards O O
CYP1A2 O O
which O O
may O O
present O O
a O O
theoretical O O
potential O O
for O O
interaction O O
with O O
other O O
coadministered O O
medicinal O O
products O O
sharing O O
that O O
clearance O O
mechanism O O
e.g O O
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
celecoxib B-drug B-drug
is O O
not O O
an O O
inhibitor O O
of O O
cytochrome O O
P450 O O
2C9 O O
, O O
2C19 O O
or O O
3A4 O O
. O O

The O O
metabolism O O
of O O
TAXOL B-brand B-brand
is O O
catalyzed O O
by O O
cytochrome O O
P450 O O
isoen-zymes O O
CYP2C8 O O
and O O
CYP3A4 O O
. O O

In O O
order O O
to O O
maintain O O
phenytoin B-drug B-drug
levels O O
, O O
limit O O
adverse O O
experiences O O
, O O
and O O
achieve O O
the O O
felbamate B-drug B-drug
dose O O
of O O
3600 O O
mg/day O O
, O O
a O O
phenytoin B-drug B-drug
dose O O
reduction O O
of O O
approximately O O
40 O O
% O O
was O O
necessary O O
for O O
eight O O
of O O
these O O
10 O O
subjects O O
. O O

Rare O O
cases O O
of O O
a O O
disulfiram-like O B-drug
reaction O O
to O O
alcohol B-drug B-drug
have O O
been O O
reported O O
. O O

Because O O
elderly O O
patients O O
are O O
more O O
likely O O
to O O
have O O
decreased O O
renal O O
function O O
, O O
care O O
should O O
be O O
taken O O
in O O
dose O O
selection O O
and O O
it O O
may O O
be O O
useful O O
to O O
monitor O O
renal O O
function O O
. O O

diet O O
high O O
in O O
vitamin B-group B-group
K I-group I-group
; O O

Oral O O
Contraceptives B-group B-group
: O O
Valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
) O O
did O O
not O O
induce O O
the O O
metabolism O O
of O O
the O O
combination O O
oral O O
contraceptive B-group B-group
norethindrone/ethinyl B-drug B-drug
estradiol I-drug I-drug
( O O
1 O O
mg O O
/35 O O
mcg O O
combination O O
, O O
Ortho-Novum B-brand B-brand
1/35 O O
) O O
. O O

Ketoconazole B-drug B-drug

In O O
vitro O O
studies O O
: O O
Vardenafil B-drug B-drug
and O O
its O O
metabolites O O
had O O
no O O
effect O O
on O O
CYP1A2 O O
, O O
2A6 O O
, O O
and O O
2E1 O O
( O O
Ki O O
100uM O O
) O O
. O O

MAO B-group B-group
inhibitors I-group I-group
MAOI I-group I-group
antidepressants I-group I-group
, O O
as O O
well O O
as O O
a O O
metabolite O O
of O O
furazolidone B-drug B-drug
, O O
slow O O
amphetamine B-drug B-drug
metabolism O O
. O O

Occasionally O O
TAXOL B-brand B-brand
infusions O O
must O O
be O O
interrupted O O
or O O
discontinued O O
because O O
of O O
initial O O
or O O
recurrent O O
hypertension O O
. O O

Because O O
their O O
vasospastic O O
effects O O
may O O
be O O
additive O O
, O O
coadministration O O
of O O
naratriptan B-drug B-drug
and O O
other O O
5-HT1 B-group B-group
agonists I-group I-group
within O O
24 O O
hours O O
of O O
each O O
other O O
is O O
not O O
recommended O O
. O O

Drugs O O
that O O
are O O
contraindicated O O
specifically O O
due O O
to O O
the O O
expected O O
magnitude O O
of O O
interaction O O
and O O
potential O O
for O O
serious O O
adverse O O
events O O
are O O
listed O O
CONTRAINDICATIONS O O
. O O

It O O
has O O
not O O
been O O
as O O
effective O O
in O O
women O O
with O O
sexual O O
dysfunction O O
, O O
with O O
the O O
exception O O
of O O
SSRI-associated B-group B-group
sexual O O
dysfunction O O
. O O

Corticosteroids B-group B-group
. O O

Ethopropazine B-drug B-drug
can O O
interact O O
with O O
chlorpromazine B-drug B-drug
, O O
increasing O O
the O O
metabolism O O
of O O
chlorpromazine B-drug B-drug
. O O

In O O
1992 O O
and O O
1993 O O
, O O
two O O
outbreaks O O
of O O
arsenical O O
reactive O O
encephalopathy O O
( O O
ARE O O
) O O
occurred O O
in O O
the O O
sleeping O O
sickness O O
center O O
of O O
Adjumani O B-brand
. O O

Herbal O O
products O O
: O O
St. O O
John O O
s O O
wort O O
( O O
Hypericum O O
perforatum O O
) O O

Selegiline B-drug B-drug
: O O
Combination B-group O
hormonal I-group B-group
contraceptives I-group I-group
may O O
increase O O
the O O
serum O O
concentration O O
of O O
selegiline B-drug B-drug
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
BEXTRA B-brand B-brand
concomitantly O O
with O O
ACE-inhibitors B-group B-group
. O O

Ventricular O O
tachycardia O O
induced O O
by O O
ouabain B-drug B-drug
was O O
generally O O
converted O O
to O O
sinus O O
rhythm O O
following O O
administration O O
of O O
Innovar B-brand B-brand
, O O
ketamine B-drug B-drug
, O O
or O O
droperidol B-drug B-drug
but O O
not O O
after O O
administration O O
of O O
fentayl B-drug B-brand
alone O O
or O O
after O O
pentobarbital B-drug B-drug
. O O

The O O
most O O
common O O
adverse O O
effects O O
reported O O
with O O
olanzapine B-drug B-drug
are O O
bodyweight O O
gain O O
, O O
somnolence O O
, O O
dizziness O O
, O O
anticholinergic O O
effects O O
( O O
constipation O O
and O O
dry O O
mouth O O
) O O
and O O
transient O O
asymptomatic O O
liver O O
enzyme O O
elevations O O
. O O

Lymphocytopenia O O
has O O
been O O
reported O O
in O O
patients O O
receiving O O
CAMPTOSAR B-brand B-brand
, O O
and O O
it O O
is O O
possible O O
that O O
the O O
administration O O
of O O
dexamethasone B-drug B-drug
as O O
antiemetic O B-group
prophylaxis O I-group
may O O
have O O
enhanced O O
the O O
likelihood O O
of O O
this O O
effect O O
. O O

Because O O
alosetron B-drug B-drug
is O O
metabolized O O
by O O
a O O
variety O O
of O O
hepatic O O
CYP O O
drug-metabolizing O O
enzymes O O
, O O
inducers O O
or O O
inhibitors O O
of O O
these O O
enzymes O O
may O O
change O O
the O O
clearance O O
of O O
alosetron B-drug B-drug
. O O

Dual O O
effect O O
of O O
ouabain B-drug B-drug
on O O
the O O
palytoxin-induced B-drug_n O
contraction O O
and O O
norepinephrine O B-drug
release O O
in O O
the O O
guinea-pig O O
vas O O
deferens O O
. O O

Aspirin B-brand B-brand
should O O
be O O
used O O
cautiously O O
in O O
conjunction O O
with O O
corticosteroids B-group B-group
in O O
hypoprothrombinemia O O
. O O

Antacids B-group B-group
: O O
Concomitant O O
administration O O
of O O
magnesium B-drug B-drug
hydroxide I-drug I-drug
and O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
does O O
not O O
interfere O O
with O O
the O O
rate O O
or O O
extent O O
of O O
the O O
absorption O O
of O O
ketoprofen B-drug B-drug
administered O O
as O O
Orudis B-brand B-brand
. O O

Clinically O O
significant O O
effects O O
have O O
been O O
reported O O
with O O
the O O
tricyclic B-drug B-group
antidepressants I-drug I-group
when O O
used O O
concomitantly O O
with O O
cimetidine B-drug B-drug
. O O

Sildenafil B-drug B-drug
citrate I-drug I-drug
: O O
a O O
therapeutic O O
update O O
. O O

Oral O O
doses O O
of O O
Antizol B-brand B-brand
( O O
10-20 O O
mg/kg O O
) O O
, O O
via O O
alcohol O B-drug
dehydrogenase O O
inhibition O O
, O O
significantly O O
reduced O O
the O O
rate O O
of O O
elimination O O
of O O
ethanol B-drug B-drug
( O O
by O O
approximately O O
40 O O
% O O
) O O
given O O
to O O
healthy O O
volunteers O O
in O O
moderate O O
doses O O
. O O

Monitor O O
salicylate B-group B-group
levels O O
or O O
the O O
therapeutic O O
effect O O
for O O
which O O
aspirin B-brand B-brand
is O O
given O O
; O O

The O O
interaction O O
was O O
pharmacodynamic O O
with O O
no O O
alteration O O
of O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
. O O

Cyclosporine O B-drug
, O O
Digoxin O B-drug
, O O
Methotrexate O B-drug
Lodine B-brand B-brand
, O O
like O O
other O O
NSAIDs B-group B-group
, O O
through O O
effects O O
on O O
renal O O
prostaglandins O O
, O O
may O O
cause O O
changes O O
in O O
the O O
elimination O O
of O O
these O O
drugs O O
leading O O
to O O
elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
and O O
increased O O
toxicity O O
. O O

Caution O O
should O O
be O O
used O O
when O O
NSAIDs B-group B-group
are O O
administered O O
concomitantly O O
with O O
methotrexate B-drug B-drug
. O O

If O O
the O O
dose O O
of O O
lovastatin B-drug B-drug
is O O
changed O O
, O O
the O O
same O O
procedure O O
should O O
be O O
repeated O O
. O O

Although O O
no O O
clinical O O
studies O O
have O O
been O O
conducted O O
, O O
it O O
is O O
likely O O
that O O
the O O
metabolism O O
of O O
levobupivacaine B-drug B-drug
may O O
be O O
affected O O
by O O
the O O
known O O
CYP3A4 O O
inducers O O
( O O
such O O
as O O
phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
rifampin B-drug B-drug
) O O
, O O
CYP3A4 O B-drug
inhibitors O O
( O O
azole O B-group
antimycotics O I-group
e.g. O O
, O O
ketoconazole B-drug B-drug
; O O

Salicylic B-drug B-drug
acid I-drug I-drug
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
increase O O
the O O
clearance O O
of O O
salicylic B-drug B-drug
acid I-drug I-drug
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
patients O O
receiving O O
Acarbose B-drug B-drug
in O O
combination O O
with O O
sulfonylureas B-group B-group
or O O
insulin B-drug B-drug
, O O
patients O O
should O O
be O O
observed O O
closely O O
for O O
any O O
evidence O O
of O O
hypoglycemia O O
. O O

Only O O
with O O
knowledge O O
of O O
the O O
interaction O O
can O O
the O O
therapeutic O O
regimen O O
be O O
altered O O
so O O
as O O
to O O
provide O O
therapeutic O O
levels O O
of O O
necessary O O
drugs O O
while O O
avoiding O O
toxicity O O
. O O

Reduced O O
efficacy O O
and O O
increased O O
incidence O O
of O O
breakthrough O O
bleeding O O
and O O
menstrual O O
irregularities O O
have O O
been O O
associated O O
with O O
concomitant O O
use O O
of O O
rifampin B-drug B-drug
. O O

Additionally O O
, O O
anti-malarial B-group B-group
drugs I-group I-group
, O O
such O O
as O O
chloroquine B-drug B-drug
and O O
mefloquine B-drug B-drug
, O O
may O O
antagonize O O
the O O
activity O O
of O O
carbamazepine B-drug B-drug
. O O

Whether O O
this O O
interaction O O
also O O
occurs O O
with O O
the O O
intravenous O O
, O O
topical O O
, O O
or O O
vaginal O O
preparations O O
of O O
miconazole B-drug B-drug
is O O
not O O
known O O
. O O

. O O

Agents O O
Increasing O O
Serum O O
Potassium O O
Since O O
captopril B-drug B-drug
decreases O O
aldosterone O O
production O O
, O O
elevation O O
of O O
serum O O
potassium O O
may O O
occur O O
. O O

In O O
the O O
first O O
double-blind O O
comparative O O
study O O
( O O
28-week O O
) O O
of O O
olanzapine B-drug B-drug
and O O
risperidone B-drug B-drug
, O O
olanzapine B-drug B-drug
10 O O
to O O
20 O O
mg/day O O
proved O O
to O O
be O O
significantly O O
more O O
effective O O
than O O
risperidone B-drug B-drug
4 O O
to O O
12 O O
mg/day O O
in O O
the O O
treatment O O
of O O
negative O O
and O O
depressive O O
symptoms O O
but O O
not O O
on O O
overall O O
psychopathology O O
symptoms O O
. O O

Secondary O O
prevention O O
of O O
atherosclerotic O O
risk O O
factors O O
is O O
also O O
important O O
: O O
regulation O O
of O O
blood O O
pressure O O
and O O
blood O O
sugar O O
level O O
, O O
hyperlipidaemia O O
and O O
obesity O O
, O O
as O O
well O O
as O O
a O O
change O O
of O O
lifestyle O O
( O O
giving O O
up O O
smoking O O
, O O
adapting O O
of O O
diet O O
and O O
more O O
physical O O
exertion O O
) O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
FROVA B-brand B-brand
is O O
not O O
known O O
to O O
interfere O O
with O O
commonly O O
employed O O
clinical O O
laboratory O O
tests O O
. O O

By O O
decreasing O O
the O O
gastrointestinal O O
absorption O O
of O O
primidone B-drug B-drug
, O O
DIAMOX B-brand B-brand
may O O
decrease O O
serum O O
concentrations O O
of O O
primidone B-drug B-drug
and O O
its O O
metabolites O O
, O O
with O O
a O O
consequent O O
possible O O
decrease O O
in O O
anticonvulsant O O
effect O O
. O O

Other O O
plasma O O
proteins O O
may O O
be O O
increased O O
( O O
angiotensinogen/renin O O
substrate O O
, O O
alpha-1-antitrypsin O O
, O O
ceruloplasmin O O
) O O
. O O

These O O
models O O
are O O
typically O O
nonlinear O O
in O O
the O O
parameters O O
, O O
and O O
as O O
such O O
, O O
a O O
nonlinear O O
weighted O O
least O O
squares O O
approach O O
can O O
be O O
employed O O
for O O
the O O
purpose O O
of O O
designing O O
experiments O O
. O O

Fluvoxamine B-drug B-drug
inhibits O O
the O O
CYP2C9 O O
catalyzed O O
biotransformation O O
of O O
tolbutamide B-drug B-drug
. O O

Norepinephrine B-drug B-drug

Oral O O
anticoagulants B-group B-group
decreased O O
prothrombin O O
time O O
response O O
. O O

No O O
adjustment O O
of O O
dosage O O
is O O
recommended O O
in O O
such O O
patients O O
. O O

In O O
a O O
placebo-controlled O O
trial O O
in O O
normal O O
volunteers O O
, O O
the O O
administration O O
of O O
a O O
single O O
1 O O
mg O O
dose O O
of O O
doxazosin B-drug B-drug
on O O
day O O
1 O O
of O O
a O O
four-day O O
regimen O O
of O O
oral O O
cimetidine B-drug B-drug
( O O
400 O O
mg O O
twice O O
daily O O
) O O
resulted O O
in O O
a O O
10 O O
% O O
increase O O
in O O
mean O O
AUC O O
of O O
doxazosin B-drug B-drug
( O O
p=0.006 O O
) O O
, O O
and O O
a O O
slight O O
but O O
not O O
statistically O O
significant O O
increase O O
in O O
mean O O
Cmax O O
and O O
mean O O
half-life O O
of O O
doxazosin B-drug B-drug
. O O

RESULTS O O
. O O

Similar O O
decreases O O
in O O
Cmax O O
and O O
AUC O O
were O O
seen O O
after O O
the O O
first O O
dose O O
. O O

No O O
in O O
vitro O O
metabolism O O
studies O O
were O O
performed O O
. O O

If O O
concomitant O O
treatment O O
with O O
naratriptan B-drug B-drug
and O O
an O O
SSRI B-group B-group
is O O
clinically O O
warranted O O
, O O
appropriate O O
observation O O
of O O
the O O
patient O O
is O O
advised O O
. O O

- O O
Other O O
anti-infectives B-group B-group
by O O
mouth O O
or O O
by O O
injection O O
( O O
medicine O O
for O O
infection O O
) O O
or O O

[ O O
Multiple O O
occupational O O
exposure O O
to O O
solvents O B-group
] O O
This O O
article O O
review O O
papers O O
published O O
over O O
the O O
last O O
20 O O
years O O
on O O
multiple O O
occupational O O
exposure O O
to O O
solvents O B-group
. O O

Drug O O
exposure O O
in O O
rodent O O
pups O O
from O O
fulvestrant-treated B-drug B-drug
lactating O O
dams O O
was O O
estimated O O
as O O
10 O O
% O O
of O O
the O O
administered O O
dose O O
. O O

If O O
rifampicin B-drug B-drug
therapy O O
is O O
required O O
, O O
isradipine B-drug B-drug
concentrations O O
and O O
therapeutic O O
effects O O
are O O
likely O O
to O O
be O O
markedly O O
reduced O O
or O O
abolished O O
as O O
a O O
consequence O O
of O O
increased O O
metabolism O O
and O O
higher O O
clearance O O
of O O
isradipine B-drug B-drug
. O O

Use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

Subsequent O O
adjustment O O
of O O
doses O O
of O O
mercaptopurine B-drug B-drug
or O O
azathioprine B-drug B-drug
should O O
be O O
made O O
on O O
the O O
basis O O
of O O
therapeutic O O
response O O
and O O
the O O
appearance O O
of O O
toxic O O
effects O O
. O O

All O O
drugs O O
were O O
injected O O
intraperitoneally O O
. O O

Glyburide B-drug B-drug
: O O
Etodolac B-drug B-drug
has O O
no O O
apparent O O
pharmacokinetic O O
interaction O O
when O O
administered O O
with O O
glyburide B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
fenofibrate B-drug B-drug
( O O
equivalent O O
to O O
145 O O
mg O O
TRICOR B-brand B-brand
) O O
with O O
atorvastatin B-drug B-drug
( O O
20 O O
mg O O
) O O
once O O
daily O O
for O O
10 O O
days O O
resulted O O
in O O
approximately O O
17 O O
% O O
decrease O O
( O O
range O O
from O O
67 O O
% O O
decrease O O
to O O
44 O O
% O O
increase O O
) O O
in O O
atorvastatin B-drug B-drug
AUC O O
values O O
in O O
22 O O
healthy O O
males O O
. O O

Drug/Food O O
Interactions O O
The O O
bioavailability O O
( O O
AUC O O
) O O
of O O
deferasirox B-drug B-drug
was O O
variably O O
increased O O
when O O
taken O O
with O O
a O O
meal O O
. O O

Pharmacokinetic O O
data O O
from O O
these O O
patients O O
demonstrated O O
a O O
decrease O O
in O O
paclitaxel B-drug B-drug
clearance O O
of O O
approximately O O
33 O O
% O O
when O O
TAXOL B-brand B-brand
was O O
administered O O
following O O
cisplatin B-drug B-drug
. O O

In O O
secretions O O
such O O
as O O
colostrum O O
, O O
IgA O O
is O O
the O O
only O O
protein O O
precipitated O O
by O O
jacalin B-drug_n B-drug_n
. O O

Trecator B-brand B-brand
has O O
been O O
found O O
to O O
temporarily O O
raise O O
serum O O
concentrations O O
of O O
isoniazid B-drug B-drug
. O O

Therefore O O
, O O
when O O
MIDAMOR B-brand B-brand
and O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O

Omeprazole B-drug B-drug
: O O
The O O
rate O O
and O O
extent O O
of O O
absorption O O
of O O
ciprofloxacin B-drug B-drug
was O O
bioequivalent O O
when O O
Proquin B-brand B-brand
XR I-brand I-brand
was O O
given O O
alone O O
or O O
when O O
Proquin B-brand B-brand
XR I-brand I-brand
was O O
given O O
2 O O
hours O O
after O O
omeprazole B-drug B-drug
at O O
the O O
dose O O
that O O
maximally O O
suppresses O O
gastric O O
acid O O
secretion O O
. O O

Chlorotrianisene B-drug B-drug
may O O
interact O O
with O O
antidepressants B-group B-group
, O O
aspirin B-brand B-brand
, O O
barbiturates B-group B-group
, O O
bromocriptine B-drug B-drug
, O O
calcium B-drug B-drug
supplements O O
, O O
corticosteroids B-group B-group
, O O
corticotropin B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
dantrolene B-drug B-drug
, O O
nicotine B-drug B-drug
, O O
somatropin B-drug B-drug
, O O
tamoxifen B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
. O O

Therefore O O
, O O
co-administration O O
of O O
clozapine B-drug B-drug
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isozyme O O
, O O
including O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
carbamazepine B-drug B-drug
, O O
and O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
( O O
e.g. O O
, O O
propafenone B-drug B-drug
, O O
flecainide B-drug B-drug
and O O
encainide B-drug B-drug
) O O
, O O
or O O
that O O
inhibit O O
this O O
enzyme O O
( O O
e.g. O O
, O O
quinidine B-drug B-drug
) O O
, O O
should O O
be O O
approached O O
with O O
caution O O
. O O

There O O
is O O
a O O
significant O O
increase O O
in O O
exposure O O
to O O
imatinib B-drug B-drug
when O O
Gleevec B-brand B-brand
is O O
coadministered O O
with O O
ketoconazole B-drug B-drug
( O O
CYP3A4 O O
inhibitor O O
) O O
. O O

There O O
is O O
one O O
report O O
suggesting O O
that O O
the O O
concomitant O O
use O O
of O O
trazodone B-drug B-drug
hydrochloride I-drug I-drug
( O O
Desyrel B-brand B-brand
) O O
and O O
buspirone B-drug B-drug
HCl I-drug I-drug
may O O
have O O
caused O O
3- O O
to O O
6-fold O O
elevations O O
on O O
SGPT O O
( O O
ALT O O
) O O
in O O
a O O
few O O
patients O O
. O O

An O O
alternative O O
or O O
additional O O
method O O
of O O
contraception O O
is O O
recommended O O
. O O

- O O
rifampin B-drug B-drug
( O O
Rifadin B-brand B-brand
, O O
Rifamate B-brand B-brand
) O O
; O O

ACE B-group B-group
inhibitors I-group I-group
: O O
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
Angiotensin B-group B-group
Converting I-group I-group
Enzyme I-group I-group
( I-group I-group
ACE I-group I-group
) I-group I-group
inhibitors I-group I-group
. O O

Cimetidine B-drug B-drug
: O O
Atorvastatin B-drug B-drug
plasma O O
concentrations O O
and O O
LDL-C O O
reduction O O
were O O
not O O
altered O O
by O O
coadministration O O
of O O
cimetidine B-drug B-drug
. O O

In O O
vivo O O
studies O O
: O O
Nitrates B-group B-group
: O O
The O O
blood O O
pressure O O
lowering O O
effects O O
of O O
sublingual O O
nitrates B-group B-group
( O O
0.4 O O
mg O O
) O O
taken O O
1 O O
and O O
4 O O
hours O O
after O O
vardenafil B-drug B-drug
and O O
increases O O
in O O
heart O O
rate O O
when O O
taken O O
at O O
1 O O
, O O
4 O O
and O O
8 O O
hours O O
were O O
potentiated O O
by O O
a O O
20 O O
mg O O
dose O O
of O O
Vardenafil B-drug B-drug
in O O
healthy O O
middle-aged O O
subjects O O
. O O

aeruginosa O O
serotype O O
O11 O O
strains O O
, O O
but O O
not O O
S O B-drug
. O O

Eprosartan B-drug B-drug
has O O
been O O
shown O O
to O O
have O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
and O O
the O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
and O O
glyburide B-drug B-drug
. O O

Neither O O
subject O O
demonstrated O O
clinical O O
evidence O O
of O O
allergic O O
or O O
anaphylactic O O
reactions O O
and O O
repeat O O
testing O O
was O O
not O O
performed O O
. O O

No O O
specific O O
information O O
available O O

METHODS O O
: O O
Healthy O O
subjects O O
who O O
were O O
20 O O
to O O
43 O O
years O O
old O O
participated O O
in O O
an O O
open O O
, O O
three-period O O
, O O
randomized O O
, O O
crossover O O
study O O
of O O
the O O
pharmacokinetics O O
of O O
a O O
single O O
10-mg O O
oral O O
dose O O
of O O
sirolimus B-drug B-drug
, O O
a O O
single O O
oral O O
120-mg O O
dose O O
of O O
diltiazem B-drug B-drug
, O O
and O O
the O O
two O O
drugs O O
given O O
together O O
. O O

These O O
lines O O
showed O O
variable O O
degrees O O
of O O
locomotor O O
activities O O
in O O
response O O
to O O
cocaine B-drug B-drug
. O O

An O O
adequate O O
period O O
of O O
observation O O
must O O
be O O
provided O O
for O O
any O O
patient O O
in O O
whom O O
either O O
long-acting B-group O
benzodiazepines I-group B-group
( O O
such O O
as O O
diazepam B-drug B-drug
) O O
or O O
large O O
doses O O
of O O
short-acting B-group B-group
benzodiazepines I-group I-group
( O O
such O O
as O O
10 O O
mg O O
of O O
midazolam B-drug B-drug
) O O
have O O
been O O
used O O
. O O

The O O
vasodilating O O
effects O O
of O O
isosorbide B-drug B-drug
dinitrate I-drug I-drug
may O O
be O O
additive O O
with O O
those O O
of O O
other O O
vasodilators B-group B-group
. O O

In O O
the O O
Duloxetine B-drug B-drug
clinical O O
trials O O
database O O
, O O
three O O
Duloxetine-treated B-drug B-drug
patients O O
had O O
liver O O
injury O O
as O O
manifested O O
by O O
ALT O O
and O O
total O O
bilirubin O O
elevations O O
, O O
with O O
evidence O O
of O O
obstruction O O
. O O

Stavudine B-drug B-drug
and O O
Zidovudine B-drug B-drug
Ribavirin I-drug I-drug
can O O
antagonize O O
the O O
in O O
vitro O O
antiviral O O
activity O O
of O O
stavudine B-drug B-drug
and O O
zidovudine B-drug B-drug
against O O
HIV O O
. O O

No O O
reported O O
interactions O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
investigate O O
the O O
effects O O
of O O
low O O
and O O
high O O
doses O O
of O O
estradiol B-drug B-drug
, O O
and O O
of O O
progesterone B-drug B-drug
on O O
the O O
response O O
to O O
noradrenaline B-drug B-drug
in O O
rat O O
thoracic O O
aorta O O
. O O

The O O
similarity O O
of O O
the O O
TYSABRI B-brand B-brand
-associated O O
adverse O O
event O O
profile O O
between O O
Study O O
1 O O
( O O
without O O
co-administered O O
AVONEX B-brand B-brand
) O O
and O O
Study O O
2 O O
( O O
with O O
co-administered O O
AVONEX B-brand B-brand
) O O
indicates O O
that O O
this O O
alteration O O
in O O
clearance O O
does O O
not O O
necessitate O O
reduction O O
of O O
the O O
TYSABRI B-brand B-brand
dose O O
to O O
maintain O O
safety O O
, O O
General O O
) O O
. O O

Haloperidol B-drug B-drug
: O O
Haloperidol B-drug B-drug
blocks O O
dopamine O O
and O O
norepinephrine O O
reuptake O O
, O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-group B-group
. O O

Patients O O
on O O
oral O O
antidiabetic B-group B-group
agents I-group I-group
receiving O O
VELCADE B-brand B-brand
treatment O O
may O O
require O O
close O O
monitoring O O
of O O
their O O
blood O O
glucose O O
levels O O
and O O
adjustment O O
of O O
the O O
dose O O
of O O
their O O
antidiabetic B-group B-group
medication I-group I-group
. O O

Concurrent O O
administration O O
of O O
cimetidine B-drug B-drug
and O O
tricyclic B-group B-group
antidepressants I-group I-group
can O O
produce O O
clinically O O
significant O O
increases O O
in O O
the O O
plasma O O
levels O O
of O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

Haemodynamic O O
effects O O
of O O
glucose B-drug B-drug
and O O
insulin B-drug B-drug
were O O
additive O O
when O O
somatostatin B-drug B-drug
was O O
co-administered O O
but O O
not O O
under O O
basal O O
conditions O O
. O O

Inhibits O O
CYP1A2 O O
( O O
weak O O
) O O
, O O
2B6 O O
( O O
weak O O
) O O
, O O
2C19 O O
( O O
weak O O
) O O
, O O
3A4 O O
( O O
weak O O
) O O
. O O

Subjects O O
who O O
do O O
not O O
metabolize O O
losartan B-drug B-drug
to O O
active O O
metabolite O O
have O O
been O O
shown O O
to O O
have O O
a O O
specific O O
, O O
rare O O
defect O O
in O O
cytochrome O O
P450 O O
2C9 O O
. O O

This O O
diminution O O
is O O
not O O
sufficient O O
to O O
preclude O O
effectiveness O O
of O O
the O O
pressor O O
agent O O
for O O
therapeutic O O
use O O
. O O

Thus O O
, O O
probenecid B-drug B-drug
should O O
not O O
be O O
administered O O
concurrently O O
with O O
bumetanide B-drug B-drug
. O O

A O O
3-fold O O
increase O O
was O O
seen O O
in O O
another O O
5 O O
patients O O
. O O

However O O
, O O
the O O
systemic O O
administration O O
of O O
some O O
quinolones B-group B-group
has O O
been O O
shown O O
to O O
elevate O O
plasma O O
concentrations O O
of O O
theophylline B-drug B-drug
, O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
, O O
and O O
enhance O O
the O O
effects O O
of O O
the O O
oral O O
anticoagulant B-group B-group
warfarin B-drug B-drug
and O O
its O O
derivatives O O
, O O
and O O
has O O
been O O
associated O O
with O O
transient O O
elevations O O
in O O
serum O O
creatinine O O
in O O
patients O O
receiving O O
systemic O O
cyclosporine B-drug B-drug
concomitantly O O
. O O

Other O O
Agents O O

Coumarin B-group B-group
Anticoagulants I-group I-group
: O O
There O O
have O O
been O O
rare O O
reports O O
of O O
increased O O
prothrombin O O
time O O
in O O
patients O O
taking O O
coumarin B-group B-group
anticoagulants I-group I-group
to O O
whom O O
nifedipine B-drug B-drug
was O O
administered O O
. O O

In O O
a O O
pharmacokinetic O O
study O O
, O O
40 O O
healthy O O
female O O
subjects O O
received O O
fluvoxamine B-drug B-drug
in O O
escalating O O
doses O O
from O O
50 O O
to O O
200 O O
mg O O
per O O
day O O
for O O
16 O O
days O O
, O O
with O O
coadministration O O
of O O
alosetron B-drug B-drug
1 O O
mg O O
on O O
the O O
last O O
day O O
. O O

Anakinra B-drug B-drug
: O O
Concurrent O O
administration O O
of O O
anakinra B-drug B-drug
( O O
an O O
interleukin-1 B-group B-group
antagonist I-group I-group
) O O
and O O
another O O
TNF-blocking B-group B-group
agent I-group I-group
has O O
been O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
serious O O
infections O O
, O O
an O O
increased O O
risk O O
of O O
neutropenia O O
and O O
no O O
additional O O
benefit O O
compared O O
to O O
these O O
medicinal O O
products O O
alone O O
. O O

Some O O
of O O
the O O
CNS O O
and O O
genitourinary O O
symptoms O O
may O O
be O O
related O O
to O O
the O O
underlying O O
disease O O
rather O O
than O O
to O O
drug O O
therapy O O
. O O

This O O
has O O
been O O
observed O O
with O O
Benedict O O
s O O
and O O
Fehling O O
s O O
solutions O O
but O O
not O O
with O O
the O O
glucose O O
enzymatic O O
test O O
. O O

If O O
co-administration O O
is O O
essential O O
, O O
conduct O O
close O O
clinical O O
and O O
laboratory O O
monitoring O O

Using O O
this O O
technique O O
, O O
it O O
was O O
possible O O
to O O
escalate O O
the O O
cisplatin B-drug B-drug
dose O O
to O O
225 O O
mg/m2 O O
before O O
dose-limiting O O
toxicities O O
were O O
encountered O O
. O O

Close O O
observation O O
of O O
the O O
patient O O
is O O
recommended O O
when O O
a O O
beta-blocker B-group B-group
is O O
administered O O
to O O
patients O O
receiving O O
catecholamine-depleting O O
drugs O O
such O O
as O O
reserpine B-drug B-drug
, O O
because O O
of O O
possible O O
additive O O
effects O O
and O O
the O O
production O O
of O O
hypotension O O
and/or O O
marked O O
bradycardia O O
, O O
which O O
may O O
produce O O
vertigo O O
, O O
syncope O O
or O O
postural O O
hypotension O O
. O O

primidone B-drug B-drug
; O O

Physiological O O
oral O O
magnesium B-drug B-drug
load O O
constitutes O O
the O O
best O O
tool O O
for O O
diagnosis O O
of O O
magnesium B-drug B-drug
deficiency O O
and O O
the O O
first O O
step O O
of O O
its O O
treatment O O
. O O

sildenafil I-drug B-drug
concentration O O

Concomitant O O
administration O O
of O O
Kerlone B-brand B-brand
with O O
the O O
oral O O
anticoagulant B-group B-group
warfarin B-drug B-drug
has O O
been O O
shown O O
not O O
to O O
potentiate O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-drug B-drug
. O O

Free O O
hormone O O
concentrations O O
may O O
be O O
decreased O O
. O O

2 O O
. O O

Diazepam B-drug B-drug
at O O
doses O O
of O O
0.25 O O
mg/kg O O
and O O
2.5 O O
mg/kg O O
injected O O
with O O
morphine B-drug B-drug
was O O
found O O
to O O
decrease O O
the O O
antinociceptive O O
effect O O
of O O
morphine B-drug B-drug
. O O

Mutagenesis O O
Impairment O O
of O O
Fertility O O
PEGASYS B-brand B-brand
may O O
impair O O
fertility O O
in O O
women O O
. O O

Caution O O
should O O
be O O
used O O
if O O
ibuprofen B-drug B-drug
is O O
administered O O
concomitantly O O
with O O
methotrexate B-drug B-drug
. O O

However O O
, O O
antacids B-group B-group
can O O
decrease O O
the O O
peak O O
concentration O O
reached O O
by O O
15 O O
% O O
to O O
20 O O
% O O
but O O
have O O
no O O
detectable O O
effect O O
on O O
the O O
time-to-peak O O
. O O

The O O
anesthesiologist O O
should O O
be O O
informed O O
when O O
a O O
patient O O
is O O
receiving O O
labetalol B-drug B-drug
HCl I-drug I-drug
. O O

Interactions O O
with O O
Other O O
Antiretroviral B-group B-group
Drugs I-group I-group
: O O
Significant O O
decreases O O
in O O
the O O
AUC O O
of O O
delavirdine B-drug B-drug
( O O
20 O O
% O O
) O O
and O O
indinavir B-drug B-drug
( O O
84 O O
% O O
) O O
occurred O O
following O O
simultaneous O O
administration O O
of O O
these O O
agents O O
with O O
VIDEX B-brand B-brand
. O O

Other O O
Drugs O O
: O O
Drugs O O
such O O
as O O
quinidine B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
phenothiazines B-group B-group
, O O
antihistamines B-group B-group
, O O
and O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
be O O
associated O O
with O O
QT-interval O O
prolongation O O
and O O
an O O
increased O O
risk O O
of O O
ventricular O O
arrhythmia O O
. O O

Cyclophosphamide B-drug B-drug
treatment O O
, O O
which O O
causes O O
a O O
marked O O
and O O
persistent O O
inhibition O O
of O O
cholinesterase O O
activity O O
, O O
potentiates O O
the O O
effect O O
of O O
succinylcholine B-drug B-drug
chloride I-drug I-drug
. O O

Chloral B-drug B-drug
hydrate I-drug I-drug
may O O
cause O O
an O O
increased O O
prothrombin O O
response O O
by O O
displacing O O
the O O
anticoagulant B-group B-group
from O O
protein O O
binding O O
sites O O
or O O
a O O
diminished O O
prothrombin O O
response O O
through O O
increased O O
metabolism O O
of O O
the O O
unbound O O
drug O O
by O O
hepatic O O
enzyme O O
induction O O
, O O
thus O O
leading O O
to O O
inter-patient O O
variation O O
in O O
ultimate O O
prothrombin O O
effect O O
. O O

The O O
plasma O O
concentration O O
of O O
imipramine B-drug B-drug
may O O
increase O O
when O O
the O O
drug O O
is O O
given O O
concomitantly O O
with O O
hepatic O O
enzyme O O
inhibitors O O
( O O
e.g. O O
, O O
cimetidine B-drug B-drug
, O O
fluoxetine B-drug B-drug
) O O
and O O
decrease O O
by O O
concomitant O O
administration O O
of O O
hepatic O O
enzyme O O
inducers O O
( O O
e.g. O O
, O O
barbiturates B-group B-group
, O O
phenytoin B-drug B-drug
) O O
, O O
and O O
adjustment O O
of O O
the O O
dosage O O
of O O
imipramine B-drug B-drug
may O O
therefore O O
be O O
necessary O O
. O O

Lomefloxacin B-drug B-drug
is O O
unlikely O O
to O O
have O O
a O O
significant O O
effect O O
on O O
phenytoin B-drug B-drug
metabolism O O
. O O

Hemodynamic O O
and O O
electrophysiologic O O
interactions O O
have O O
also O O
been O O
observed O O
after O O
concomitant O O
administration O O
with O O
propranolol B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
and O O
verapamil B-drug B-drug
. O O

Therefore O O
, O O
appropriate O O
dose O O
adjustments O O
may O O
be O O
necessary O O
for O O
these O O
drugs O O
. O O

- O O
Perhexiline B-drug B-drug
hydrogen I-drug I-drug
maleate I-drug I-drug
or O O
MAO-inhibitors B-group B-group
( O O
with O O
hepatotoxic O O
potential O O
) O O
must O O
not O O
be O O
administered O O
together O O
with O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
. O O

These O O
data O O
suggest O O
that O O
the O O
conversion O O
of O O
losartan B-drug B-drug
to O O
its O O
active O O
metabolite O O
is O O
mediated O O
primarily O O
by O O
P450 O O
2C9 O O
and O O
not O O
P450 O O
3A4 O O
. O O

Analgesia O O
and O O
pupil O O
constriction O O
were O O
measured O O
. O O

Effects O O
on O O
in O O
vitro O O
excystment O O
rates O O
over O O
a O O
2 O O
h O O
period O O
demonstrated O O
widespread O O
effects O O
for O O
cercariae-exposed O O
P O O
. O O

In O O
a O O
single O O
subject O O
given O O
one O O
dose O O
of O O
ciprofloxacin B-drug B-drug
2 O O
hours O O
after O O
a O O
dose O O
of O O
didanosine-placebo B-drug B-drug
tablets O O
, O O
a O O
greater O O
than O O
50 O O
% O O
reduction O O
in O O
the O O
AUC O O
of O O
ciprofloxacin B-drug B-drug
was O O
observed O O
. O O

If O O
you O O
are O O
also O O
using O O
a O O
steroid B-group B-group
inhaler O I-group
, O O
take O O
bitolterol B-drug B-drug
first O O
and O O
then O O
wait O O
about O O
15 O O
minutes O O
before O O
using O O
the O O
steroid B-group B-group
inhaler O I-group
. O O

Urinary O B-group
acidifying O I-group
agents O I-group
These O O
agents O O
( O O
ammonium B-drug B-drug
chloride I-drug I-drug
, O O
sodium B-drug B-drug
acid I-drug I-drug
phosphate I-drug I-drug
, O O
etc O O
. O O
) O O
increase O O
the O O
concentration O O
of O O
the O O
ionized O O
species O O
of O O
the O O
amphetamine B-drug B-drug
molecule O O
, O O
thereby O O
increasing O O
urinary O O
excretion O O
. O O

6 O O
. O O

In O O
vitro O O
, O O
nilutamide B-drug B-drug
has O O
been O O
shown O O
to O O
inhibit O O
the O O
activity O O
of O O
liver O O
cytochrome O O
P-450 O O
isoenzymes O O
and O O
therefore O O
, O O
may O O
reduce O O
the O O
metabolism O O
of O O
compounds O O
requiring O O
these O O
systems O O
. O O

Both O O
of O O
these O O
effects O O
were O O
endothelium-dependent O B-drug_n
. O O

Although O O
clinical O O
studies O O
have O O
not O O
established O O
a O O
cause O O
and O O
effect O O
relationship O O
, O O
physicians O O
should O O
be O O
aware O O
that O O
variable O O
effects O O
an O O
blood O O
coagulation O O
have O O
been O O
reported O O
very O O
rarely O O
in O O
patients O O
receiving O O
oral O O
anticoagulants B-group B-group
and O O
chlordiazepoxide B-drug B-drug
. O O

There O O
was O O
no O O
evidence O O
in O O
clinical O O
trials O O
of O O
drug O O
interactions O O
with O O
concurrent O O
medications O O
. O O

Erythromycin B-drug B-drug
use O O
in O O
patients O O
who O O
are O O
receiving O O
high O O
doses O O
of O O
theophylline B-drug B-drug
may O O
be O O
associated O O
with O O
an O O
increase O O
in O O
serum O O
theophylline B-drug B-drug
levels O O
and O O
potential O O
theophylline B-drug B-drug
toxicity O O
. O O

If O O
concomitant O O
use O O
can O O
not O O
be O O
avoided O O
, O O
serum O O
levels O O
of O O
theophylline B-drug B-drug
should O O
be O O
monitored O O
and O O
dosage O O
adjustments O O
made O O
as O O
appropriate O O
. O O

In O O
a O O
study O O
in O O
normal O O
volunteers O O
, O O
it O O
was O O
found O O
that O O
chronic O O
concurrent O O
administration O O
of O O
3.6 O O
g O O
of O O
aspirin B-brand B-brand
per O O
day O O
decreases O O
indomethacin B-drug B-drug
blood O O
levels O O
approximately O O
20 O O
% O O
. O O

The O O
safety O O
and O O
efficacy O O
of O O
concomitant O O
use O O
of O O
REVIA B-brand B-brand
and O O
disulfiram B-drug B-drug
is O O
unknown O O
, O O
and O O
the O O
concomitant O O
use O O
of O O
two O O
potentially O O
hepatotoxic O O
medications O O
is O O
not O O
ordinarily O O
recommended O O
unless O O
the O O
probable O O
benefits O O
outweigh O O
the O O
known O O
risks O O
. O O

Propranolol B-drug B-drug
increases O O
hydralazines B-drug B-group
serum O O
concentrations O O
. O O

Uricosuric B-group B-group
Agents I-group I-group
: O O
Since O O
the O O
excretion O O
of O O
oxipurinol B-drug B-drug
is O O
similar O O
to O O
that O O
of O O
urate O B-drug
, O O
uricosuric B-group O
agents I-group O
, O O
which O O
increase O O
the O O
excretion O O
of O O
urate O O
, O O
are O O
also O O
likely O O
to O O
increase O O
the O O
excretion O O
of O O
oxipurinol B-drug B-drug
and O O
thus O O
lower O O
the O O
degree O O
of O O
inhibition O O
of O O
xanthine O O
oxidase O O
. O O

No O O
data O O
for O O
delavirdine B-drug B-drug
; O O

All O O
elevations O O
resolved O O
, O O
2 O O
with O O
continuation O O
of O O
both O O
drugs O O
and O O
3 O O
after O O
discontinuation O O
of O O
leflunomide B-drug B-drug
. O O

Reports O O
of O O
fatal O O
hepatic O O
failure O O
, O O
as O O
well O O
as O O
peripheral O O
neuropathy O O
, O O
pancreatitis O O
, O O
and O O
symptomatic O O
hyperlactatemia/lactic O O
acidosis O O
have O O
been O O
reported O O
in O O
clinical O O
trials O O
. O O

There O O
is O O
thus O O
an O O
enhancement O O
effect O O

Systemic O O
exposure O O
to O O
substrates O O
of O O
CYP2D6 O O
is O O
expected O O
to O O
be O O
increased O O
when O O
coadministered O O
with O O
Gleevec O B-brand
. O O

If O O
chlorprothixene B-drug B-drug
is O O
given O O
concomitantly O O
with O O
opioids B-group B-group
, O O
the O O
opioid B-group B-group
dose O O
should O O
be O O
reduced O O
( O O
by O O
approx O O
. O O
50 O O
% O O
) O O
, O O
because O O
chlorprothixene B-drug B-drug
amplifies O I-drug
the O O
therapeutic O O
actions O O
and O O
side-effects O O
of O O
opioids B-group B-group
massively O O
. O O

Close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
dosage O O
is O O
required O O
when O O
this O O
drug O O
is O O
administered O O
concomitantly O O
with O O
anticholinergic B-group B-group
drugs I-group I-group
. O O

Sucralfate B-drug B-drug
and O O
antacids B-group B-group
: O O
Quinolones B-group B-group
form O O
chelates O O
with O O
metal O O
cations O O
. O O

These O O
doses O O
correspond O O
to O O
approximately O O
1- O O
, O O
3- O O
, O O
and O O
5-fold O O
( O O
in O O
females O O
) O O
and O O
1.3- O O
, O O
1.3- O O
, O O
and O O
1.6-fold O O
( O O
in O O
males O O
) O O
the O O
systemic O O
exposure O O
[ O O
AUC0-30 O O
days O O
] O O
] O O
achieved O O
in O O
women O O
receiving O O
the O O
recommended O O
dose O O
of O O
250 O O
mg/month O O
. O O

Antibiotics B-group B-group
: O O
Macrolide B-group B-group
antibiotics I-group I-group
have O O
been O O
reported O O
to O O
cause O O
a O O
significant O O
decrease O O
in O O
corticosteroid B-group B-group
clearance O O
. O O

Digoxin O B-drug
When O O
given O O
concomitantly O O
with O O
PLENDIL B-drug B-brand
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
in O O
patients O O
with O O
heart O O
failure O O
were O O
not O O
significantly O O
altered O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
( O O
such O O
as O O
Clinistix O O
or O O
Tes-Tape O O
) O O
be O O
used O O
. O O

Potassium-sparing B-group B-group
diuretics I-group I-group
( O O
spironolactone B-drug B-drug
, O O
amiloride B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
and O O
others O O
) O O
or O O
potassium B-drug B-drug
supplements O O
can O O
increase O O
the O O
risk O O
of O O
hyperkalemia O O
. O O

Valproate B-drug B-drug
: O O
Available O O
data O O
suggest O O
that O O
there O O
is O O
no O O
significant O O
effect O O
of O O
valproate B-drug B-drug
on O O
the O O
clearance O O
of O O
Felbatol B-brand B-brand
at O O
steady O O
state O O
, O O
Therefore O O
, O O
the O O
addition O O
of O O
valproate B-drug B-drug
is O O
not O O
expected O O
to O O
cause O O
a O O
clinically O O
important O O
effect O O
on O O
Felbatol B-brand B-brand
( O O
felbamate B-drug B-drug
) O O
plasma O O
concentrations O O
. O O

Ascorbic B-drug B-drug
acid I-drug I-drug
and O O
the O O
common O O
cold O O
. O O

CYP3A4 O O
Interactions O O

Methotrexate B-drug B-drug
: O O
Ketoprofen B-drug B-drug
, O O
like O O
other O O
NSAIDs B-group B-group
, O O
may O O
cause O O
changes O O
in O O
the O O
elimination O O
of O O
methotrexate B-drug B-drug
leading O O
to O O
elevated O O
serum O O
levels O O
of O O
the O O
drug O O
and O O
increased O O
toxicity O O
. O O

The O O
clinical O O
significance O O
of O O
these O O
observations O O
is O O
unknown O O
. O O

Antacids B-group B-group
containing O O
magnesium B-drug B-drug
, O O
aluminum B-drug B-drug
, O O
or O O
calcium B-drug B-drug
; O O

Tinnitus O O
and O O
decreased O O
hearing O O
have O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
Itraconazole B-drug B-drug
and O O
quinidine B-drug B-drug
. O O

No O O
significant O O
effects O O
were O O
noted O O
with O O
other O O
drug O O
combinations O O
or O O
with O O
the O O
addition O O
of O O
ethanol B-drug B-drug
. O O

Drug/Laboratory O O
Tests O O
Interactions O O
There O O
are O O
no O O
known O O
clinically O O
significant O O
interactions O O
of O O
CLOLAR B-brand B-brand
with O O
other O O
medications O O
or O O
laboratory O O
tests O O
. O O

Dicumarol B-drug B-drug
and O O
warfarin B-drug B-drug
may O O
decrease O O
hypoprothrombinemic O O
effect O O
. O O

apomorphine B-drug B-drug
- O O
prior O O
ingestion O O
of O O
diphenidol B-drug B-drug
may O O
decrease O O
the O O
emetic B-group O
response O O
to O O
apomorphine B-drug B-drug
in O O
the O O
treatment O O
of O O
poisoning O O
. O O

Dosing O O
recommendations O O
for O O
SUSTIVA B-brand B-brand
and O O
atazanavir B-drug B-drug
in O O
treatment-experienced O O
patients O O
have O O
not O O
been O O
established O O
. O O

Toxicity O O
associated O O
with O O
concomitant O O
use O O
of O O
aerosolized O O
pentamidine B-drug B-drug
has O O
not O O
been O O
reported O O
. O O

Lithium B-drug B-drug
carbonate I-drug I-drug
: O O
The O O
stimulatory O O
effects O O
of O O
amphetamines B-group B-group
may O O
be O O
inhibited O O
by O O
lithium B-drug B-drug
carbonate I-drug I-drug
. O O

The O O
treatment O O
of O O
depression O O
in O O
diabetic O O
patients O O
must O O
take O O
into O O
account O O
variations O O
of O O
glycemic O O
levels O O
at O O
different O O
times O O
and O O
a O O
comparison O O
of O O
the O O
available O O
antidepressant B-group B-group
agents I-group I-group
is O O
important O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
administering O O
ETOPOPHOS B-brand B-brand
with O O
drugs O O
that O O
are O O
known O O
to O O
inhibit O O
phosphatase O O
activities O O
( O O
e.g. O O
, O O
levamisole B-drug B-drug
hydrochloride I-drug I-drug
) O O
. O O

Because O O
there O O
is O O
a O O
theoretical O O
basis O O
that O O
these O O
effects O O
may O O
be O O
additive O O
, O O
use O O
of O O
ergotamine-containing B-drug B-drug
or O O
ergot-type B-group B-group
medications I-group I-group
( O O
like O O
dihydroergotamine B-drug B-drug
or O O
methysergide B-drug B-drug
) O O
and O O
naratriptan B-drug B-drug
within O O
24 O O
hours O O
is O O
contraindicated O O
. O O

This O O
suggests O O
that O O
interactions O O
between O O
the O O
two O O
elements O O
only O O
take O O
place O O
at O O
the O O
site O O
of O O
absorption O O
. O O

Aminoglycosides B-group B-group
: O O
The O O
mixing O O
of O O
piperacillin B-drug B-drug
with O O
an O O
aminoglycoside B-group B-group
in O O
vitro O O
can O O
result O O
in O O
substantial O O
inactivation O O
of O O
the O O
aminoglycoside B-group B-group
. O O

A O O
dose O O
adjustment O O
is O O
not O O
needed O O
when O O
zidovudine B-drug B-drug
is O O
administered O O
with O O
VIRACEPT B-brand B-brand
. O O

HIV B-group B-group
Protease I-group I-group
Inhibitors I-group I-group
: O O
Indinavir B-drug B-drug
( O O
800 O O
mg O O
t.i.d O O
. O O
) O O
co-administered O O
with O O
Vardenafil B-drug B-drug
10 O O
mg O O
resulted O O
in O O
a O O
16-fold O O
increase O O
in O O
vardenafil B-drug B-drug
AUC O O
, O O
a O O
7-fold O O
increase O O
in O O
vardenafil B-drug B-drug
Cmax O O
and O O
a O O
2-fold O O
increase O O
in O O
vardenafil B-drug B-drug
half-life O O
. O O

AED B-group B-group
Co-administered O O

Antiarrhythmic B-drug B-group
agents I-drug I-group
, I-drug O
class I-drug O
I I-drug O
( O O
such O O
as O O
flecainide B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
or O O
quinidine B-drug B-drug
) O O
: O O
concurrent O O
use O O
with O O
arbutamine B-drug B-drug
may O O
have O O
a O O
proarrhythmic O O
effect O O
. O O

Antitubercular O B-group
drugs O I-group
: O O
Serum O O
concentrations O O
of O O
isoniazid B-drug B-drug
may O O
be O O
decreased O O
. O O

No O O
information O O
available O O
. O O

Other O O
Potentially O O
Important O O
Drug O O
Interactions O O
: O O
Benzodiazepines B-group B-group
: O O
Benzodiazepines B-group B-group
metabolized O O
by O O
hepatic O O
oxidation O O
( O O
e.g. O O
, O O
alprazolam B-drug B-drug
, O O
midazolam B-drug B-drug
, O O
triazolam B-drug B-drug
elc O O
. O O
) O O
should O O
be O O
used O O
with O O
caution O O
because O O
the O O
clearance O O
of O O
these O O
drugs O O
is O O
likely O O
to O O
be O O
reduced O O
by O O
fluvoxamine B-drug B-drug
. O O

Fluoxetine B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
clonazepam B-drug B-drug
. O O

In O O
a O O
drug O O
interaction O O
study O O
, O O
co-administration O O
of O O
orally O O
inhaled O O
ciclesonide B-drug B-drug
and O O
oral O O
erythromycin B-drug B-drug
, O O
an O O
inhibitor O O
of O O
cytochrome O O
P450 O O
3A4 O O
, O O
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
either O O
des-ciclesonide B-drug B-drug
or O O
erythromycin B-drug B-drug
. O O

In O O
vitro O O
data O O
in O O
human O O
plasma O O
indicate O O
that O O
doxazosin B-drug B-drug
mesylate I-drug I-drug
has O O
no O O
effect O O
on O O
protein O O
binding O O
of O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
phenytoin B-drug B-drug
or O O
indomethacin B-drug B-drug
. O O

Herbal O O
Products O O
: O O
St. O O
John O O
s O O
wort O O
( O O
hypericum O O
perforatum O O
) O O
WARNING O O
coadministration O O
may O O
lead O O
to O O
loss O O
of O O
virologic O O
response O O
and O O
possible O O
resistance O O
to O O
INVIRASE B-brand B-brand
or O O
to O O
the O O
class O O
of O O
protease O B-group
inhibitors O I-group
. O O

The O O
action O O
of O O
nondepolarizing O B-group
relaxants O I-group
is O O
augmented O O
by O O
Enflurane B-drug B-drug
. O O

Theophylline B-drug B-drug
VIOXX B-brand B-brand
12.5 O O
, O O
25 O O
, O O
and O O
50 O O
mg O O
administered O O
once O O
daily O O
for O O
7 O O
days O O
increased O O
plasma O O
theophylline B-drug B-drug
concentrations O O
( O O
AUC O O
( O O
0- O O
) O O
) O O
by O O
38 O O
to O O
60 O O
% O O
in O O
healthy O O
subjects O O
administered O O
a O O
single O O
300-mg O O
dose O O
of O O
theophylline B-drug B-drug
. O O

If O O
bupropion B-drug B-drug
is O O
added O O
to O O
the O O
treatment O O
regimen O O
of O O
a O O
patient O O
already O O
receiving O O
a O O
drug O O
metabolized O O
by O O
CYP2D6 O O
, O O
the O O
need O O
to O O
decrease O O
the O O
dose O O
of O O
the O O
original O O
medication O O
should O O
be O O
considered O O
, O O
particularly O O
for O O
those O O
concomitant O O
medications O O
with O O
a O O
narrow O O
therapeutic O O
index O O
. O O

Consequently O O
, O O
TRACLEER B-brand B-brand
is O O
not O O
expected O O
to O O
increase O O
the O O
plasma O O
concentrations O O
of O O
drugs O O
metabolized O O
by O O
these O O
enzymes O O
. O O

Each O O
subject O O
received O O
an O O
individualized O O
fixed O O
daily O O
dose O O
of O O
warfarin B-drug B-drug
and O O
served O O
as O O
his O O
own O O
pre- O O
and O O
postsedative O O
treatment O O
control O O
. O O

Warfarin B-drug B-drug
: O O
Multiple O O
oral O O
doses O O
of O O
Sonata B-brand B-brand
( O O
20 O O
mg O O
q24h O O
for O O
13 O O
days O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
warfarin B-drug B-drug
( O O
R+ O O
) O O
- O O
or O O
( O O
S- O B-drug
) O O
-enantiomers O O
or O O
the O O
pharmacodynamics O O
( O O
prothrombin O O
time O O
) O O
following O O
a O O
single O O
25-mg O O
oral O O
dose O O
of O O
warfarin B-drug B-drug
. O O

The O O
hypoglycemic O O
action O O
of O O
sulfonylurea B-group B-group
may O O
be O O
potentiated O O
by O O
certain O O
drugs O O
including O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
and O O
other O O
drugs O O
that O O
are O O
highly O O
protein O O
bound O O
, O O
salicylates B-group B-group
, O O
sulfonamides B-group B-group
, O O
chloramphenicol B-drug B-drug
, O O
probenecid B-drug B-drug
, O O
coumarins B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
and O O
beta B-group B-group
adrenergic I-group I-group
blocking I-group I-group
agents I-group I-group
. O O

Rates O O
of O O
patients O O
with O O
maximum O O
potassium O O
levels O O
5.5 O O
mEq/L O O
were O O
similar O O
regardless O O
of O O
the O O
use O O
of O O
ACEI/ARB B-group B-group
. O O

SUBSEQUENT O O
TO O O
INITIATION O O
OF O O
DISULFIRAM B-drug B-drug
THERAPY O O
. O O

Lithium B-drug B-drug
: O O
Increased O O
serum O O
lithium B-drug B-drug
levels O O
and O O
symptoms O O
of O O
lithium B-drug B-drug
toxicity O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
ACE B-group B-group
inhibitors I-group I-group
during O O
therapy O O
with O O
lithium B-drug B-drug
. O O

Phenytoin B-drug B-drug
is O O
known O O
to O O
cause O O
osteomalacia O O
. O O

The O O
beneficial O O
effects O O
on O O
arterial O O
thrombus O O
formation O O
from O O
combined O O
therapy O O
with O O
antiplatelet O B-group
and O O
anticoagulant B-group B-group
medication I-group O
must O O
be O O
weighed O O
against O O
an O O
increased O O
risk O O
of O O
inducing O O
hemorrhage O O
. O O

Sulfacetamide B-drug B-drug
preparations O O
are O O
incompatible O O
with O O
silver B-drug O
preparations O O
. O O

antibody O O

Cimetidine B-drug B-drug
: O O
Albendazole B-drug B-drug
sulfoxide I-drug I-drug
concentrations O O
in O O
bile O O
and O O
cystic O O
fluid O O
were O O
increased O O
( O O
about O O
2-fold O O
) O O
in O O
hydatid O O
cyst O O
patients O O
treated O O
with O O
cimetidine B-drug B-drug
( O O
10 O O
mg/kg/day O O
) O O
( O O
n=7 O O
) O O
compared O O
with O O
albendazole B-drug B-drug
( O O
20 O O
mg/kg/day O O
) O O
alone O O
( O O
n=12 O O
) O O
. O O

Omeprazole B-drug B-drug
: O O
Omeprazole B-drug B-drug
is O O
a O O
CYP O O
3A4 O O
substrate O O
and O O
CYP O O
2C19 O O
substrate O O
and O O
inhibitor O O
. O O

It O O
was O O
observed O O
that O O
MPTP B-drug_n B-drug_n
induced O O
long O O
lasting O O
depletions O O
of O O
striatal O O
dopamine O O
concentrations O O
and O O
this O O
neurotoxic O O
effect O O
could O O
be O O
prevented O O
by O O
pargyline B-drug B-drug
pretreatment O O
. O O

Patients O O
treated O O
concurrently O O
with O O
BREVIBLOC B-brand B-brand
( O O
esmolol B-drug B-drug
HCl I-drug I-drug
) O O
and O O
a O O
catecholamine O O
depletor O O
should O O
therefore O O
be O O
closely O O
observed O O
for O O
evidence O O
of O O
hypotension O O
or O O
marked O O
bradycardia O O
, O O
which O O
may O O
result O O
in O O
vertigo O O
, O O
syncope O O
, O O
or O O
postural O O
hypotension O O
. O O

Other O O
Concomitant O O
Therapy O O
In O O
healthy O O
subjects O O
there O O
were O O
no O O
clinically O O
significant O O
interactions O O
when O O
felodipine B-drug B-drug
was O O
given O O
concomitantly O O
with O O
indomethacin B-drug B-drug
or O O
spironolactone B-drug B-drug
. O O

vasopressors B-group B-group
, O O
such O O
as O O
dopamine B-drug B-drug
and O O
isoproterenol B-drug B-drug
; O O

Decreasing O O
the O O
concentration O O
of O O
CMC-Cys B-drug_n B-drug_n
, O O
exhibiting O O
7.3 O O
% O O
( O O
m/m O O
) O O
of O O
immobilised O O
cysteine B-drug B-drug
( O O
CMC-Cys7.3 O B-brand
) O O
from O O
1 O O
% O O
( O O
m/v O O
) O O
to O O
0.5 O O
% O O
( O O
m/v O O
) O O
decreased O O
the O O
R-value O O
of O O
NaFlu B-drug B-drug
from O O
1.8 O O
to O O
1.2 O O
. O O

Antidepressants B-group B-group
, O O
tricyclic B-group B-group
Amphetamines I-group I-group
may O O
enhance O O
the O O
activity O O
of O O
tricyclic B-drug B-group
antidepressants I-drug I-group
or O O
sympathomimetic B-group B-group
agents I-group I-group
; O O

. O O

However O O
, O O
modification O O
abolished O O
the O O
'cold O O
' O O
binding O O
of O O
toxin O B-drug_n
to O O
bovine O O
thyroglobulin O O
in O O
an O O
ELISA O O
and O O
reduced O O
ligand O O
binding O O
activity O O
in O O
a O O
rabbit O O
erythrocyte O O
haemagglutination O O
assay O O
. O O

However O O
, O O
at O O
that O O
time O O
, O O
the O O
plasma O O
levels O O
of O O
diazepam B-drug B-drug
were O O
below O O
the O O
therapeutic O O
interval O O
, O O
and O O
thus O O
this O O
interaction O O
is O O
unlikely O O
to O O
be O O
of O O
clinical O O
relevance O O
. O O

In O O
simultaneous O O
treatment O O
with O O
imidazole B-group B-group
drugs I-group I-group
and O O
coumarin B-group B-group
drugs I-group I-group
, O O
the O O
anticoagulant O O
effect O O
should O O
be O O
carefully O O
titrated O O
and O O
monitored O O
. O O

There O O
was O O
no O O
evidence O O
of O O
drug O O
interactions O O
in O O
clinical O O
studies O O
in O O
which O O
dobutamine B-drug B-drug
was O O
administered O O
concurrently O O
with O O
other O O
drugs O O
, O O
including O O
digitalis B-group B-group
preparations I-group I-group
, O O
furosemide B-drug B-drug
, O O
spironolactone B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
glyceryl B-drug B-drug
trinitrate I-drug I-drug
, O O
isosorbide B-drug B-drug
dinitrate I-drug I-drug
, O O
morphine B-drug B-drug
, O O
atropine B-drug B-drug
, O O
heparin B-drug B-drug
, O O
protamine B-drug B-drug
, O O
potassium B-drug B-drug
chloride I-drug I-drug
, O O
folic B-drug B-drug
acid I-drug I-drug
, O O
and O O
acetaminophen B-drug B-drug
. O O

halothane B-drug B-drug
; O O

Olanzapine B-drug B-drug
: O O
an O O
updated O O
review O O
of O O
its O O
use O O
in O O
the O O
management O O
of O O
schizophrenia O O
. O O

We O O
assessed O O
the O O
ability O O
of O O
gene O O
transfer O O
to O O
reverse O O
vancomycin B-drug O
resistance O O
in O O
class O O
A O O
( O O
VanA O O
) O O
glycopeptide-resistant O O
Enterococcus O O
faecalis O O
. O O

Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
reported O O
laboratory O O
test O O
interactions O O
. O O

Cell O O
permeable O O
caspase-3 O O
inhibitor O O
added O O
in O O
the O O
medium O O
blocked O O
the O O
decrease O O
of O O
nucleophosmin/B23 O O
and O O
apoptosis O O
induced O O
by O O
serum O O
deprivation O O
in O O
NIH-3T3 O O
cells O O
. O O

Therefore O O
, O O
co-administration O O
of O O
Duloxetine B-drug B-drug
with O O
other O O
drugs O O
that O O
are O O
extensively O O
metabolized O O
by O O
this O O
isozyme O O
and O O
which O O
have O O
a O O
narrow O O
therapeutic O O
index O O
, O O
including O O
certain O O
antidepressants B-group B-group
( O O
tricyclic B-group B-group
antidepressants I-group I-group
[ O O
TCAs B-group B-group
] O O
, O O
such O O
as O O
nortriptyline B-drug B-drug
, O O
amitriptyline B-drug B-drug
, O O
and O O
imipramine B-drug B-drug
) O O
, O O
phenothiazines B-group B-group
and O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
( O O
e.g. O O
, O O
propafenone B-drug B-drug
, O O
flecainide B-drug B-drug
) O O
, O O
should O O
be O O
approached O O
with O O
caution O O
. O O

aureus O O
to O O
P O O
. O O

gestational O O
trophoblastic O O
disease O O
; O O

While O O
only O O
a O O
limited O O
number O O
of O O
in O O
vivo O O
drug-drug O O
interactions O O
with O O
amiodarone B-drug B-drug
have O O
been O O
reported O O
, O O
chiefly O O
with O O
the O O
oral O O
formulation O O
, O O
the O O
potential O O
for O O
other O O
interactions O O
should O O
be O O
anticipated O O
. O O

Discontinuing O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
could O O
pose O O
a O O
hazard O O
to O O
health O O
if O O
a O O
potentially O O
toxic O O
drug O O
that O O
is O O
significantly O O
bound O O
to O O
the O O
resin B-group B-group
has O O
been O O
titrated O O
to O O
a O O
maintenance O O
level O O
while O O
the O O
patient O O
was O O
taking O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
. O O

DEA O O
concentrations O O
were O O
not O O
affected O O
. O O

thrombocytopenia O O

Since O O
there O O
is O O
a O O
high O O
degree O O
of O O
variability O O
in O O
the O O
bioavailability O O
of O O
verapamil B-drug B-drug
, O O
the O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unclear O O
. O O

Nevirapine B-drug I-drug

Therefore O O
, O O
caffeine B-drug B-drug
has O O
the O O
potential O O
to O O
interact O O
with O O
drugs O O
that O O
are O O
substrates O O
for O O
CYP1A2 O O
, O O
inhibit O O
CYP1A2 O O
, O O
or O O
induce O O
CYP1A2 O O
. O O

Conversely O O
, O O
decreases O O
in O O
plasma O O
levels O O
of O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
upon O O
discontinuation O O
of O O
cimetidine B-drug B-drug
which O O
may O O
result O O
in O O
the O O
loss O O
of O O
the O O
therapeutic O O
efficacy O O
of O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
6 O O
. O O

Prothrombin O O
time O O
was O O
increased O O
by O O
5 O O
% O O
, O O
the O O
clinical O O
significance O O
of O O
which O O
is O O
unknown O O
. O O

Iron B-drug B-drug
salts O O
may O O
reduce O O
the O O
bioavailability O O
of O O
carbidopa B-drug B-drug
and O O
levodopa B-drug B-drug
. O O

Monoamine O B-group
Oxidase O I-group
Inhibition O O
: O O
Linezolid B-drug B-drug
is O O
a O O
reversible O O
, O O
nonselective O O
inhibitor O O
of O O
monoamine O B-group
oxidase O I-group
. O O

Patients O O
in O O
clinical O O
studies O O
were O O
prohibited O O
from O O
receiving O O
growth O O
factor O O
treatment O O
for O O
2 O O
weeks O O
prior O O
to O O
the O O
ZEVALIN B-brand B-brand
therapeutic O O
regimen O O
as O O
well O O
as O O
for O O
2 O O
weeks O O
following O O
completion O O
of O O
the O O
regimen O O
. O O

It O O
is O O
believed O O
that O O
the O O
toxicity O O
may O O
have O O
resulted O O
from O O
a O O
previously O O
unrecognized O O
interaction O O
between O O
isoniazid B-drug B-drug
and O O
acetaminophen B-drug B-drug
and O O
a O O
molecular O O
basis O O
for O O
this O O
interaction O O
has O O
been O O
proposed O O
. O O

Vesselinovitch O O
et O O
al O O
. O O

Patients O O
taking O O
these O O
drugs O O
with O O
LODOSYN B-brand B-brand
and O O
levodopa B-drug B-drug
or O O
carbidopa-levodopa B-drug B-drug
combination O O
products O O
should O O
be O O
carefully O O
observed O O
for O O
loss O O
of O O
therapeutic O O
response O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
p.o O O
. O O

Therefore O O
, O O
precaution O O
should O O
be O O
taken O O
when O O
coadministration O O
is O O
necessary O O
. O O

- O O
Drugs O O
with O O
ototoxic O O
potential O O
: O O
Especially O O
in O O
the O O
presence O O
of O O
impaired O O
renal O O
function O O
, O O
the O O
use O O
of O O
parenterally O O
administered O O
bumetanide B-drug B-drug
in O O
patients O O
to O O
whom O O
aminoglycoside B-group B-group
antibiotics I-group I-group
are O O
also O O
being O O
given O O
should O O
be O O
avoided O O
, O O
except O O
in O O
life-threatening O O
conditions O O
. O O

However O O
, O O
severe O O
reactions O O
, O O
such O O
as O O
hypotension O O
requiring O O
treatment O O
, O O
dyspnea O O
requiring O O
bronchodilators B-group B-group
, O O
angioedema O O
, O O
or O O
generalized O O
urticaria O O
require O O
immediate O O
discontinuation O O
of O O
TAXOL B-brand B-brand
and O O
aggressive O O
symptomatic O O
therapy O O
. O O

A O O
30 O O
to O O
45 O O
% O O
increase O O
in O O
AUC O O
and O O
Cmax O O
of O O
nisoldipine B-drug B-drug
was O O
observed O O
with O O
concomitant O O
administration O O
of O O
cimetidine B-drug B-drug
400 I-drug O
mg I-drug O
twice O O
daily O O
. O O

Drug O O
interaction O O
studies O O
with O O
other O O
anticonvulsants B-group B-group
have O O
not O O
been O O
conducted O O
. O O

In O O
the O O
same O O
study O O
it O O
was O O
shown O O
that O O
didanosine B-drug B-drug
and O O
stavudine B-drug B-drug
had O O
no O O
significant O O
effect O O
on O O
the O O
intracellular O O
phosphorylation O O
of O O
zalcitabine B-drug B-drug
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
. O O

A O O
study O O
of O O
interaction O O
between O O
BREVIBLOC B-brand B-brand
and O O
warfarin B-drug B-drug
showed O O
that O O
concomitant O O
administration O O
of O O
BREVIBLOC B-brand B-brand
and O O
warfarin B-drug B-drug
does O O
not O O
alter O O
warfarin B-drug B-drug
plasma O O
levels O O
. O O

In O O
a O O
study O O
involving O O
12 O O
adult O O
volunteers O O
, O O
TORADOLORAL O B-brand
was O O
coadministered O O
with O O
a O O
single O O
dose O O
of O O
25 O O
mg O O
warfarin B-drug B-drug
, O O
causing O O
no O O
significant O O
changes O O
in O O
pharmacokinetics O O
or O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
. O O

Patients O O
receiving O O
both O O
indomethacin B-drug B-drug
and O O
furosemide B-drug B-drug
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
diuretic O B-group
and/or O O
antihypertensive O O
effect O O
of O O
furosemide B-drug B-drug
is O O
achieved O O
. O O

Nonsteroidal B-group B-group
Anti-inflammatory I-group I-group
Drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
: O O
The O O
concomitant O O
administration O O
of O O
a O O
nonsteroidal B-group B-group
anti I-group I-group
inflammatory I-group I-group
drug I-group I-group
with O O
a O O
quinolone B-group B-group
may O O
increase O O
the O O
risks O O
of O O
CNS O O
stimulation O O
and O O
convulsions O O
. O O

The O O
effect O O
of O O
induction O O
or O O
inhibition O O
of O O
other O O
pathways O O
on O O
exposure O O
to O O
alosetron B-drug B-drug
and O O
its O O
metabolites O O
is O O
not O O
known O O
. O O

Drugs O O
such O O
as O O
troleandomycin B-drug B-drug
and O O
ketoconazole B-drug B-drug
may O O
inhibit O O
the O O
metabolism O O
of O O
corticosteroids B-group B-group
and O O
thus O O
decrease O O
their O O
clearance O O
. O O

In O O
some O O
patients O O
, O O
this O O
may O O
lead O O
to O O
reduced O O
clearance O O
, O O
prolongation O O
of O O
plasma O O
half-life O O
, O O
and O O
enhanced O O
effects O O
of O O
caffeine B-drug B-drug
and O O
theobromine B-drug B-drug
. O O

Effect O O
of O O
aprepitant B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
other O O
agents O O

Hydrochlorothiazide B-drug B-drug
( O O
HCTZ B-drug B-drug
) O O
Alone O O
or O O
in O O
Combination O O
with O O
Triamterene B-drug B-drug
: O O
Concomitant O O
use O O
of O O
HCTZ B-drug B-drug
alone O O
or O O
in O O
combination O O
with O O
triamterene B-drug B-drug
is O O
contraindicated O O
. O O

Salicylate B-group B-group
levels O O
have O O
been O O
found O O
to O O
be O O
falsely O O
elevated O O
with O O
some O O
assay O O
methods O O
. O O

Little O O
or O O
no O O
change O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
was O O
observed O O
when O O
VIRACEPT B-brand B-brand
was O O
coadministered O O
with O O
lamivudine B-drug B-drug
or O O
stavudine B-drug B-drug
. O O

Each O O
group O O
took O O
either O O
150 O O
mg O O
or O O
75 O O
mg O O
of O O
fluvoxamine B-drug B-drug
a O O
day O O
for O O
5 O O
days O O
( O O
day O O
-3 O O
to O O
day O O
2 O O
) O O
. O O

- O O
Chloroquine B-drug B-drug
( O O
e.g. O O
, O O
Aralen B-brand B-brand
) O O
or O O

Indinavir B-drug B-drug
has O O
been O O
shown O O
to O O
increase O O
plasma O O
levels O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
. O O

In O O
one O O
controlled O O
clinical O O
study O O
, O O
the O O
ureidopenicillins O B-group
, O O
including O O
piperacillin B-drug B-drug
, O O
were O O
reported O O
to O O
prolong O O
the O O
action O O
of O O
vecuronium B-drug B-drug
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA O B-group
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

Thalidomide B-drug B-drug
: O O
Co-administration O O
with O O
thalidomide B-drug B-drug
should O O
be O O
employed O O
cautiously O O
, O O
as O O
toxic O O
epidermal O O
necrolysis O O
has O O
been O O
reported O O
with O O
concomitant O O
use O O
. O O

In O O
addition O O
, O O
studies O O
in O O
healthy O O
volunteers O O
have O O
shown O O
that O O
TIKOSYN B-brand B-brand
does O O
not O O
affect O O
the O O
pharmacokinetics O O
or O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
, O O
or O O
the O O
pharmacokinetics O O
of O O
propranolol B-drug B-drug
( O O
40 O O
mg O O
twice O O
daily O O
) O O
, O O
phenytoin B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
or O O
oral O O
contraceptives B-group B-group
. O O

- O O
Medicinal O O
or O O
dietary O O
iodine B-group B-drug
interferes O O
with O O
all O O
in O O
vivo O O
tests O O
of O O
radio-iodine O B-drug
uptake O O
producing O O
low O O
uptakes O O
which O O
may O O
not O O
be O O
reflective O O
of O O
a O O
true O O
decrease O O
in O O
hormone O O
synthesis O O

The O O
pressor O O
effects O O
of O O
diethylpropion B-drug O
and O O
those O O
of O O
other O O
drugs O O
may O O
be O O
additive O O
when O O
the O O
drugs O O
are O O
used O O
concomitantly O O
; O O

Previous O O
studies O O
have O O
demonstrated O O
a O O
significant O O
reduction O O
in O O
the O O
oral O O
bioavailability O O
of O O
trovafloxacin B-drug B-drug
and O O
ciprofloxacin B-drug B-drug
when O O
administered O O
concomitantly O O
with O O
an O O
intravenous O O
opiate B-group B-group
such O O
as O O
morphine B-drug B-drug
. O O

Digoxin B-drug B-drug
volume O O
of O O
distribution O O
was O O
not O O
significantly O O
changed O O
. O O

free O O
T4 O O
concentration O O
is O O
unaltered O O

Serious O O
anticholinergic O O
symptoms O O
( O O
i.e. O O
, O O
severe O O
dry O O
mouth O O
, O O
urinary O O
retention O O
and O O
blurred O O
vision O O
) O O
have O O
been O O
associated O O
with O O
elevations O O
in O O
the O O
serum O O
levels O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
when O O
cimetidine B-drug B-drug
therapy O O
is O O
initiated O O
. O O

there O O
was O O
no O O
alteration O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
. O O

Patients O O
taking O O
disopyramide B-drug B-drug
phosphate I-drug I-drug
and O O
erythromycin B-drug B-drug
concomitantly O O
may O O
develop O O
increased O O
serum O O
concentrations O O
of O O
disopyramide B-drug B-drug
resulting O O
in O O
excessive O O
widening O O
of O O
the O O
QRS O O
complex O O
and/or O O
prolongation O O
of O O
the O O
Q-T O O
interval O O
. O O

Since O O
there O O
have O O
been O O
isolated O O
reports O O
of O O
patients O O
with O O
elevated O O
digoxin B-drug B-drug
levels O O
, O O
it O O
is O O
recommended O O
that O O
digoxin B-drug B-drug
levels O O
be O O
monitored O O
when O O
initiating O O
, O O
adjusting O O
, O O
and O O
discontinuing O O
nifedipine B-drug B-drug
to O O
avoid O O
possible O O
over- O O
or O O
under-digitalization O O
. O O

Valdecoxib B-drug B-drug
did O O
not O O
have O O
a O O
statistically O O
significant O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
phenytoin B-drug B-drug
( O O
a O O
CYP O O
2C9 O O
and O O
CYP O O
2C19 O O
substrate O O
) O O
. O O

certain O O
protease B-group B-group
inhibitors I-group I-group
e.g. O O
, O O
ritanovir O B-drug
; O O

Three O O
clinical O O
trials O O
have O O
investigated O O
Simulect B-brand B-brand
use O O
in O O
combination O O
with O O
triple-therapy O O
regimens O O
. O O

adjust O O
dosage O O
of O O
antidiabetic B-group B-group
drug I-group I-group
accordingly O O
. O O

Potent O O
inhibitors O O
of O O
CYP3A4 O O
( O O
below O O
) O O
increase O O
the O O
risk O O
of O O
myopathy O O
by O O
reducing O O
the O O
elimination O O
of O O
lovastatin B-drug B-drug
. O O

There O O
have O O
been O O
inconsistent O O
reports O O
regarding O O
the O O
effects O O
of O O
other O O
drugs O O
( O O
e.g. O O
, O O
quinine B-drug B-drug
, O O
penicillamine B-drug B-drug
) O O
on O O
serum O O
digoxin B-drug B-drug
concentration O O
. O O

Therefore O O
, O O
cyclosporine B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
and O O
appropriate O O
cyclosporine B-drug B-drug
dosage O O
adjustments O O
made O O
when O O
these O O
drugs O O
are O O
used O O
concomitantly O O
. O O

These O O
include O O
probenecid B-drug B-drug
, O O
cholestyramine B-drug B-drug
, O O
and O O
some O O
antibiotics B-group B-group
( O O
e.g O O
. O O
erythromycin B-drug B-drug
, O O
rifamipicin O B-drug
, O O
ampicillin B-drug B-drug
and O O
chloramphenicol B-drug B-drug
) O O
. O O

Thyroid O B-group
Physiology O O
: O O
The O O
following O O
agents O O
may O O
alter O O
thyroid O O
hormone O O
or O O
TSH O O
levels O O
, O O
generally O O
by O O
effects O O
on O O
thyroid O O
hormone O O
synthesis O O
, O O
secretion O O
, O O
distribution O O
, O O
metabolism O O
, O O
hormone O O
action O O
, O O
or O O
elimination O O
, O O
or O O
altered O O
TSH O O
secretion O O
: O O
aminoglutethimide B-drug B-drug
, O O
p-aminosalicylic B-drug O
acid I-drug O
, O O
amiodarone B-drug B-drug
, O O
androgens B-group B-group
and O O
related O O
anabolic O B-group
hormones O I-group
, O O
complex O O
anions O O
( O O
thiocyanate B-drug O
, O O
perchlorate B-drug B-drug
, O O
pertechnetate B-drug B-drug
) O O
, O O
antithyroid B-group B-group
drugs I-group I-group
, O O
b-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
carbamazepine B-drug B-drug
, O O
chloral B-drug B-drug
hydrate I-drug I-drug
, O O
diazepam B-drug B-drug
, O O
dopamine B-drug B-drug
and O O
dopamine B-group B-group
agonists I-group I-group
, O O
ethionamide B-drug B-drug
, O O
glucocorticoids B-group B-group
, O O
heparin B-drug B-drug
, O O
hepatic O O
enzyme O O
inducers O O
, O O
insulin B-drug B-drug
, O O
iodinated O B-group
cholestographic O I-group
agents O I-group
, O O
iodine-containing B-group B-drug
compounds I-group I-drug
, O O
levodopa B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
lithium B-drug B-drug
, O O
6-mercaptopurine B-drug B-drug
, O O
metoclopramide B-drug B-drug
, O O
mitotane B-drug B-drug
, O O
nitroprusside B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
resorcinol B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
somatostatin B-group B-drug
analogs I-group O
, O O
sulfonamides B-group B-group
, O O
sulfonylureas B-group B-group
, O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Given O O
the O O
possibility O O
of O O
extravasation O O
, O O
it O O
is O O
advisable O O
to O O
closely O O
monitor O O
the O O
infusion O O
site O O
for O O
possible O O
infiltration O O
during O O
drug O O
administration O O
. O O

Since O O
INVIRASE B-brand B-brand
is O O
coadministered O O
with O O
ritonavir B-drug B-drug
, O O
the O O
ritonavir B-drug B-drug
label O O
should O O
be O O
reviewed O O
for O O
additional O O
drugs O O
that O O
should O O
not O O
be O O
coadministered O O
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCA B-group B-group
plasma O O
levels O O
whenever O O
a O O
TCA B-group B-group
is O O
going O O
to O O
be O O
co-administered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
. O O

as O O
measured O O
by O O
PBI O O
, O O
T4 O O
by O O
column O O
, O O
or O O
T4 O O
by O O
radioimmunoassay O O
. O O

Sixty-two O O
( O O
94 O O
% O O
) O O
of O O
66 O O
strains O O
of O O
Enterobacteriaceae O O
and O O
Pseudomonas O O
aeruginosa O O
were O O
inhibited O O
by O O
6.2 O O
mug O O
or O O
less O O
of O O
gentamicin B-drug B-drug
per O O
ml O O
. O O

Anticonvulsants B-group B-group
: O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug

Resveratrol B-drug_n B-drug
has O O
been O O
shown O O
to O O
induce O O
vasorelaxation O O
. O O

prolonged B-group O
narcotics I-group B-group
; O O

Risk O O
of O O
Anaphylactic O O
Reaction O O
: O O
While O O
taking O O
beta-blockers B-group B-group
, O O
patients O O
with O O
a O O
history O O
of O O
severe O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
be O O
more O O
reactive O O
to O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
, O O
or O O
therapeutic O O
. O O

Epinephrine B-drug B-drug
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
other O O
sympathomimetic B-group B-group
drugs I-group I-group
( O O
such O O
as O O
isoproterenol B-drug B-drug
) O O
because O O
of O O
possible O O
additive O O
effects O O
and O O
increased O O
toxicity O O
. O O

Clinical O O
studies O O
have O O
shown O O
that O O
INDOCIN B-brand B-brand
does O O
not O O
influence O O
the O O
hypoprothrombinemia O O
produced O O
by O O
anticoagulants B-group B-group
. O O

Effect O O
of O O
other O O
drugs O O
on O O
Sensipar B-brand B-brand
: O O
Sensipar B-brand B-brand
is O O
metabolized O O
by O O
multiple O O
cytochrome O O
P450 O O
enzymes O O
, O O
primarily O O
CYP3A4 O O
, O O
CYP2D6 O O
, O O
and O O
CYP1A2 O O
. O O

therefore O O
, O O
drug O O
interactions O O
mediated O O
by O O
inhibition O O
of O O
hepatic O O
metabolism O O
are O O
not O O
expected O O
to O O
occur O O
. O O

In O O
rheumatoid O O
arthritis O O
, O O
concomitant O O
medications O O
besides O O
MTX B-drug B-drug
were O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
, O O
folic B-drug B-drug
acid I-drug I-drug
, O O
corticosteroids B-group B-group
and/or O O
narcotics B-group B-group
. O O

Therefore O O
, O O
when O O
Hydrochlorothiazide B-drug B-drug
and O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O

In O O
addition O O
, O O
steady O O
state O O
levels O O
of O O
racemic O O
citalopram B-drug B-drug
were O O
not O O
significantly O O
different O O
in O O
poor O O
metabolizers O O
and O O
extensive O O
CYP2D6 O O
metabolizers O O
after O O
multiple-dose O O
administration O O
of O O
citalopram B-drug B-drug
, O O
suggesting O O
that O O
coadministration O O
, O O
with O O
escitalopram B-drug B-drug
, O O
of O O
a O O
drug O O
that O O
inhibits O O
CYP2D6 O O
, O O
is O O
unlikely O O
to O O
have O O
clinically O O
significant O O
effects O O
on O O
escitalopram B-drug B-drug
metabolism O O
. O O

May O O
interact O O
anticoagulants B-group B-group
( O O
altered O O
hypo-prothrombinemic O O
effect O O
) O O
, O O
barbiturates B-group B-group
, O O
rifampin B-drug B-drug
and O O
other O O
inducers O O
of O O
hepatic O O
microsomal O O
enzyme O O
oxidation O O
system O O
( O O
decreased O O
effect O O
of O O
diethylstilbestrol B-drug B-drug
) O O
, O O
corticosteroids B-group B-group
( O O
increased O O
effect O O
of O O
corticosteroids B-group B-group
) O O
. O O

Effects O O
of O O
other O O
Antiepilepsy O O
Drugs O O
( O O
AEDs B-group B-group
) O O
on O O
GABITRIL B-brand B-brand
: O O
Carbamazepine B-drug B-drug
: O O
Population O O
pharmacokinetic O O
analyses O O
indicate O O
that O O
tiagabine B-drug B-drug
clearance O O
is O O
60 O O
% O O
greater O O
in O O
patients O O
taking O O
carbamazepine B-drug B-drug
with O O
or O O
without O O
other O O
enzyme- O O
inducing O O
AEDs B-group B-group
. O O

Diphenhydramine B-drug B-drug
: O O
Diphenhydramine B-drug B-drug
is O O
reported O O
to O O
be O O
a O O
weak O O
inhibitor O O
of O O
aldehyde O O
oxidase O O
in O O
rat O O
liver O O
, O O
but O O
its O O
inhibitory O O
effects O O
in O O
human O O
liver O O
are O O
not O O
known O O
. O O

Verapamil B-drug B-drug
produced O O
a O O
decrease O O
of O O
20 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
18-27 O O
] O O
of O O
the O O
plasma O O
levels O O
of O O
MHD B-drug_n B-drug_n
. O O

serum O O
magnesium O B-drug
levels O O
may O O
increase O O
in O O
uremic O O
patients O O
) O O
Serum O O
protein-bound O O
iodine O O
( O O
PBI O O
) O O
levels O O
( O O
may O O
be O O
decreased O O
) O O
Thiazides B-group B-group
should O O
be O O
discontinued O O
before O O
carrying O O
out O O
tests O O
for O O
parathyroid O O
function O O
. O O

It O O
is O O
not O O
known O O
if O O
fulvestrant B-drug B-drug
is O O
excreted O O
in O O
human O O
milk O O
. O O

Doses O O
of O O
vitamin B-drug B-drug
C I-drug I-drug
up O O
to O O
200 O O
mg O O
were O O
allowed O O
in O O
clinical O O
studies O O
without O O
negative O O
consequences O O
. O O

- O O
Drugs O O
whose O O
efficacy O O
is O O
impaired O O
by O O
phenytoin B-drug B-drug
include O O
: O O
anticoagulants B-group B-group
, O O
corticosteroids B-group B-group
, O O
coumarin B-group B-group
, O O
digitoxin B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
estrogens B-group B-group
, O O
furosemide B-drug B-drug
, O O
oral O O
contraceptives B-group B-group
, O O
rifampin B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
vitamin B-group B-group
D I-group I-group
. O O

Here O O
we O O
show O O
that O O
a O O
combination O O
of O O
galangin B-drug B-drug
or O O
3,7-dihydroxyflavone O B-drug_n
with O O
vancomycin B-drug B-drug
may O O
be O O
used O O
to O O
sensitize O O
resistant O O
strains O O
of O O
Enterococcus O O
faecalis O O
and O O
Enterococcus O O
faecium O O
to O O
the O O
level O O
of O O
vancomycin-sensitive O O
strains O O
. O O

In O O
vitro O O
studies O O
with O O
human O O
liver O O
microsomes O O
indicate O O
that O O
bortezomib B-drug B-drug
is O O
primarily O O
a O O
substrate O O
for O O
cytochrome O O
P450 O O
3A4 O O
, O O
2C19 O O
, O O
and O O
1A2 O O
. O O

Additionally O O
, O O
there O O
is O O
no O O
evidence O O
of O O
circulating O O
active O O
metabolites O O
or O O
accumulation O O
during O O
chronic O O
dosing O O
. O O

Therefore O O
, O O
there O O
is O O
a O O
potential O O
for O O
an O O
interaction O O
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
CYP O O
1A2 O O
( O O
e.g. O O
, O O
amitriptyline B-drug B-drug
, O O
tacrine B-drug B-drug
, O O
and O O
zileuton B-drug B-drug
) O O
. O O

In O O
vitro O O
activity O O
of O O
KRM-1648 B-drug_n B-drug_n
, O O
either O O
singly O O
or O O
in O O
combination O O
with O O
ofloxacin B-drug B-drug
, O O
against O O
Mycobacterium O O
ulcerans O O
. O O

Coadministration O O
of O O
ethoxzolamide B-drug B-drug
with O O
other O O
diuretics B-group B-group
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
and O O
corticosteroids B-group B-group
may O O
cause O O
hypokalemia O O
. O O

However O O
, O O
norepinephrine B-drug B-drug
may O O
still O O
be O O
used O O
effectively O O
. O O

haloperidol B-drug B-drug
; O O

Absorption O O
of O O
fluvastatin B-drug B-drug
is O O
virtually O O
complete O O
across O O
all O O
species O O
, O O
including O O
man O O
, O O
and O O
is O O
not O O
affected O O
by O O
the O O
presence O O
of O O
food O O
. O O

. O O

decreased O O
pregnanediol O B-drug
excretion O O
; O O

Use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

ritonavir I-drug B-drug
concentration O O

Patients O O
on O O
thyroid O O
replacement O O
therapy O O
may O O
require O O
higher O O
doses O O
of O O
thyroid B-group B-group
hormone I-group I-group
. O O

Enoxacin B-drug B-drug
interferes O O
with O O
the O O
metabolism O O
of O O
theophylline B-drug B-drug
resulting O O
in O O
a O O
42 O O
% O O
to O O
74 O O
% O O
dose-related O O
decrease O O
in O O
theophylline B-drug B-drug
clearance O O
and O O
a O O
subsequent O O
260 O O
% O O
to O O
350 O O
% O O
increase O O
in O O
serum O O
theophylline O B-drug
levels O O
. O O

Prostatic O O
epithelium O O
proliferates O O
in O O
a O O
defined O O
medium O O
consisting O O
of O O
basal O O
medium O O
RPMI1640 O O
containing O O
transferrin B-drug_n B-drug
( O O
1 O O
microgram/ml O O
) O O
, O O
EGF B-drug_n B-drug_n
( O O
10 O O
ng/ml O O
) O O
, O O
and O O
insulin B-drug B-drug
( O O
3.7 O O
micrograms/ml O O
or O O
0.1 O O
IU/ml O O
) O O
. O O

Amantadine B-drug B-drug
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
and O O
MAOIs B-group B-group
may O O
increase O O
anticholinergic O O
effect O O
of O O
clidinium B-drug B-drug
. O O

In O O
these O O
patients O O
whose O O
hypertension O O
was O O
controlled O O
with O O
nifedipine B-drug B-drug
, O O
Vardenafil B-drug B-drug
20 O O
mg O O
produced O O
mean O O
additional O O
supine O O
systolic/diastolic O O
blood O O
pressure O O
reductions O O
of O O
6/5 O O
mm O O
Hg O O
compared O O
to O O
placebo O O
. O O

- O O
Oral O O
contraceptives B-group B-group
( O O
birth O O
control O O
pills O O
) O O
containing O O
estrogen B-group B-group
or O O

meprobamate B-drug B-drug
; O O

Morphine B-drug B-drug
prolonged O O
gastrointestinal O O
transit O O
time O O
from O O
69 O O
to O O
103 O O
minutes O O
( O O
P O O
= O O
.005 O O
) O O
; O O

Hematopoietic O O

It O O
is O O
unknown O O
how O O
the O O
effect O O
seen O O
in O O
these O O
in O O
vitro O O
studies O O
translates O O
into O O
clinical O O
consequences O O
. O O

Corticosteroids B-group B-group
: O O
Dexamethasone B-drug B-drug
: O O
Aprepitant B-drug B-drug
, O O
when O O
given O O
as O O
a O O
regimen O O
of O O
125mg O O
with O O
dexamethasone B-drug B-drug
coadministered O O
orally O O
as O O
20 O O
mg O O
on O O
Day O O
1 O O
, O O
and O O
Aprepitant B-drug B-drug
when O O
given O O
as O O
80 O O
mg/day O O
with O O
dexamethasone B-drug B-drug
coadministered O O
orally O O
as O O
8 O O
mg O O
on O O
Days O O
2 O O
through O O
5 O O
, O O
increased O O
the O O
AUC O O
of O O
dexamethasone B-drug B-drug
, O O
a O O
CYP3A4 O O
substrate O O
by O O
2.2-fold O O
, O O
on O O
Days O O
1 O O
and O O
5 O O
. O O

ii O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
following O O
drugs O O
or O O
moieties O O
are O O
known O O
to O O
interfere O O
with O O
laboratory O O
tests O O
performed O O
in O O
patients O O
on O O
thyroid B-group B-group
hormone I-group I-group
therapy O O
: O O
androgens B-group B-group
, O O
corticosteroids B-group B-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
containing O O
estrogens B-group B-group
, O O
iodine-containing B-group B-drug
preparations O O
and O O
the O O
numerous O O
preparations O O
containing O O
salicylates B-group B-group
. O O

Ketamine B-drug B-drug
: O O
Marked O O
hypertension O O
and O O
tachycardia O O
have O O
been O O
reported O O
in O O
association O O
with O O
concomitant O O
administration O O
of O O
levothyroxine B-drug B-drug
sodium I-drug I-drug
and O O
ketamine B-drug B-drug
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-group B-group
concomitantly O O
with O O
ACE B-group B-group
inhibitors I-group I-group
. O O

There O O
have O O
been O O
greater O O
than O O
2-fold O O
increases O O
in O O
previously O O
stable O O
plasma O O
levels O O
of O O
other O O
antidepressants B-group B-group
, O O
including O O
nortriptyline B-drug B-drug
, O O
when O O
fluoxetine B-drug B-drug
hydrochloride I-drug I-drug
has O O
been O O
administered O O
in O O
combination O O
with O O
these O O
agents O O
. O O

No O O
confirmed O O
interactions O O
have O O
been O O
reported O O
between O O
ZOLADEX B-brand B-brand
and O O
other O O
drugs O O

Strong O O
inducers O O
of O O
cytochrome O O
P450 O O
enzymes O O
( O O
i.e O O
. O O
carbamazepine B-drug B-drug
, O O
phenytoin B-drug B-drug
and O O
phenobarbital B-drug B-drug
) O O
have O O
been O O
shown O O
to O O
decrease O O
the O O
plasma O O
levels O O
of O O
MHD B-drug_n B-drug_n
( O O
29-40 O O
% O O
) O O
. O O

Tolbutamides B-drug B-group
conversion O O
to O O
inactive O O
metabolites O O
has O O
been O O
shown O O
to O O
be O O
catalyzed O O
by O O
xanthine O O
oxidase O O
from O O
rat O O
liver O O
. O O

For O O
example O O
, O O
since O O
cholestyramine B-drug B-drug
may O O
reduce O O
the O O
gastrointestinal O O
absorption O O
of O O
both O O
the O O
oral O O
anticoagulants B-group B-group
and O O
vitamin B-group B-group
K I-group I-group
, O O
the O O
net O O
effects O O
are O O
unpredictable O O
. O O

It O O
is O O
recommended O O
that O O
if O O
CASODEX B-brand B-brand
is O O
started O O
in O O
patients O O
already O O
receiving O O
coumarin B-group B-group
anticoagulants I-group I-group
, O O
prothrombin O O
times O O
should O O
be O O
closely O O
monitored O O
and O O
adjustment O O
of O O
the O O
anticoagulant B-group B-group
dose O O
may O O
be O O
necessary O O
. O O

Anticonvulsants B-group B-group
( O O
Phenytoin B-drug B-drug
) O O
: O O
Steady O O
state O O
plasma O O
exposure O O
( O O
AUC O O
) O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
for O O
12 O O
days O O
) O O
was O O
decreased O O
by O O
27 O O
% O O
when O O
co-administered O O
with O O
multiple O O
doses O O
( O O
300 O O
mg O O
QD O O
for O O
12 O O
days O O
) O O
of O O
phenytoin B-drug B-drug
( O O
a O O
CYP O O
3A4 O O
inducer O O
) O O
. O O

Quinolones B-group B-group
, O O
including O O
norfloxacin B-drug B-drug
, O O
may O O
enhance O O
the O O
effects O O
of O O
oral O O
anticoagulants B-group B-group
, O O
including O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
or O O
similar O O
agents O O
. O O

Felbamate B-drug B-brand
treatment O O
resulted O O
in O O
a O O
42 O O
% O O
decrease O O
in O O
the O O
gestodene B-drug B-drug
AUC O O
0-24 O O
, O O
but O O
no O O
clinically O O
relevant O O
effect O O
was O O
observed O O
on O O
the O O
pharmacokinetic O O
parameters O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
As O O
with O O
cephalothin B-drug B-drug
, O O
high O O
concentrations O O
of O O
cefoxitin B-drug B-drug
( O O
100 O O
micrograms/mL O O
) O O
may O O
interfere O O
with O O
measurement O O
of O O
serum O O
and O O
urine O O
creatinine O O
levels O O
by O O
the O O
Jaff O O
reaction O O
, O O
and O O
produce O O
false O O
increases O O
of O O
modest O O
degree O O
in O O
the O O
levels O O
of O O
creatinine O O
reported O O
. O O

aureus O O
, O O
to O O
survive O O
in O O
pentazocine B-drug B-drug
and O O
tripelennamine B-drug B-drug
may O O
explain O O
in O O
part O O
a O O
shift O O
from O O
S O B-drug
. O O

In O O
addition O O
to O O
the O O
interactions O O
noted O O
above O O
, O O
chronic O O
( O O
2 O O
weeks O O
) O O
oral O O
Cordarone B-drug B-drug
administration O O
impairs O O
metabolism O O
of O O
phenytoin B-drug B-drug
, O O
dextromethorphan B-drug B-drug
, O O
and O O
methotrexate B-drug B-drug
. O O

. O O

A O O
review O O
is O O
presented O O
of O O
some O O
of O O
the O O
problems O O
that O O
may O O
arise O O
in O O
association O O
with O O
anaesthesia O O
for O O
epileptic O O
patients O O
. O O

Special O O
care O O
is O O
required O O
if O O
this O O
drug O O
is O O
given O O
to O O
patients O O
receiving O O
ganglion B-group B-group
blocking I-group I-group
compounds I-group I-group
because O O
a O O
critical O O
fall O O
in O O
blood O O
pressure O O
may O O
occur O O
. O O

Tetracyclines B-group B-group
: O O
Concomitant O O
treatment O O
with O O
Accutane B-brand B-brand
and O O
tetracyclines B-group B-group
should O O
be O O
avoided O O
because O O
Accutane B-brand B-brand
use O O
has O O
been O O
associated O O
with O O
a O O
number O O
of O O
cases O O
of O O
pseudotumor O O
cerebri O O
( O O
benign O O
intracranial O O
hypertension O O
) O O
, O O
some O O
of O O
which O O
involved O O
concomitant O O
use O O
of O O
tetracyclines B-group B-group

No O O
drug O O
interaction O O
data O O
are O O
available O O
on O O
concomitant O O
administration O O
of O O
Panretin B-brand B-brand
gel O O
and O O
systemic O B-group
anti-KS O I-group
agents O I-group
. O O

A O O
drug-drug O O
interaction O O
study O O
with O O
rifampin B-drug B-drug
in O O
healthy O O
volunteers O O
has O O
shown O O
a O O
30 O O
% O O
decrease O O
in O O
caspofungin B-drug B-drug
trough O O
concentrations O O
. O O

To O O
find O O
out O O
whether O O
this O O
observation O O
is O O
related O O
to O O
the O O
increased O O
regional O O
perfusion O O
in O O
diabetes O O
longitudinal O O
studies O O
on O O
patients O O
with O O
Type O O
I O O
( O O
insulin-dependent O O
) O O
diabetes O O
mellitus O O
are O O
needed O O
. O O

Carbamazepine B-drug B-drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
40 O O
mg/day O O
for O O
14 O O
days O O
) O O
and O O
carbamazepine B-drug B-drug
( O O
titrated O O
to O O
400 O O
mg/day O O
for O O
35 O O
days O O
) O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
carbamazepine B-drug B-drug
, O O
a O O
CYP3A4 O O
substrate O O
. O O

Levetiracetam B-drug B-drug
circulates O O
largely O O
unbound O O
( O O
10 O O
% O O
bound O O
) O O
to O O
plasma O O
proteins O O
; O O

Therefore O O
, O O
when O O
INSPRA B-brand B-brand
and O O
NSAIDs B-group B-group
are O O
used O O
concomitantly O O
, O O
patients O O
should O O
be O O
observed O O
to O O
determine O O
whether O O
the O O
desired O O
effect O O
on O O
blood O O
pressure O O
is O O
obtained O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
treating O O
patients O O
with O O
either O O
of O O
these O O
drugs O O
or O O
other O O
highly O O
protein-bound O O
drugs O O
and O O
Atromid-S B-brand B-brand
. O O

The O O
clinical O O
relevance O O
of O O
this O O
finding O O
is O O
unclear O O
. O O

Carbamazepine B-drug B-drug
: O O
Carbamazepine B-drug B-drug
causes O O
an O O
approximate O O
50 O O
% O O
increase O O
in O O
the O O
clearance O O
of O O
Felbatol B-brand B-brand
at O O
steady O O
state O O
and O O
, O O
therefore O O
, O O
the O O
addition O O
of O O
carbamazepine B-drug B-drug
results O O
in O O
an O O
approximate O O
40 O O
% O O
decrease O O
in O O
the O O
steady-state O O
trough O O
concentrations O O
of O O
Felbatol B-brand B-brand
as O O
compared O O
to O O
the O O
same O O
dose O O
of O O
Felbatol B-brand B-brand
given O O
as O O
monotherapy O O
. O O

Saquinavir B-drug B-drug

Less O O
than O O
the O O
usual O O
amounts O O
of O O
these O O
medicines O O
should O O
be O O
used O O
. O O

In O O
clinical O O
studies O O
, O O
Tilade B-brand B-brand
has O O
been O O
co-administered O O
with O O
other O O
anti-asthma O B-group
medications O I-group
, O O
including O O
inhaled O O
and O O
oral O O
bronchodilators B-group B-group
, O O
and O O
inhaled O O
corticosteroids B-group B-group
, O O
with O O
no O O
evidence O O
of O O
increased O O
frequency O O
of O O
adverse O O
events O O
or O O
laboratory O O
abnormalities O O
. O O

- O O
Methyldopa B-drug B-drug
( O O
e.g. O O
, O O
Aldomet B-brand B-brand
) O O
Use O O
of O O
methyldopa B-drug B-drug
with O O
sulfapyridine B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O
and/or O O
the O O
blood O O

Consideration O O
should O O
be O O
taken O O
in O O
patients O O
being O O
treated O O
with O O
antidiabetic B-drug B-group
agents O I-group
. O O

However O O
, O O
the O O
pharmacodynamic O O
effect O O
increased O O
by O O
197 O O
% O O
( O O
QTc O O
increase O O
over O O
time O O
) O O
and O O
by O O
95 O O
% O O
( O O
maximum O O
QTc O O
increase O O
) O O
. O O

No O O
drug/drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

Insulin B-drug B-drug
or O O
Oral O O
Hypoglycemics B-group B-group
: O O
Initiating O O
thyroid O B-group
replacement O O
therapy O O
may O O
cause O O
increases O O
in O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemic B-group B-group
requirements O O
. O O

Although O O
the O O
occurrence O O
has O O
not O O
been O O
reported O O
with O O
Cefizox B-brand B-brand
, O O
nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
other O O
cephalosporins B-group B-group
and O O
aminoglycosides B-group B-group
. O O

Serotonin O O
release O O
by O O
platelets O O
plays O O
an O O
important O O
role O O
in O O
hemostasis O O
. O O

. O O

Sumatriptan B-drug B-drug
- O O
There O O
have O O
been O O
rare O O
postmarketing O O
reports O O
describing O O
patients O O
with O O
weakness O O
, O O
hyperreflexia O O
, O O
and O O
incoordination O O
following O O
the O O
use O O
of O O
a O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitor I-group I-group
( O O
SSRI B-group B-group
) O O
and O O
sumatriptan B-drug B-drug
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

. O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCA B-group B-group
may O O
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Fluoxetine B-drug B-drug
and O O
moclobemide B-drug B-drug
increased O O
blood O O
glucose B-drug O
at O O
different O O
times O O
after O O
the O O
glucose O O
overload O O
. O O

Cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
and O O
digoxin B-drug B-drug
concentrations O O
should O O
be O O
monitored O O
at O O
the O O
initiation O O
of O O
Itraconazole B-drug B-drug
therapy O O
and O O
frequently O O
thereafter O O
, O O
and O O
the O O
dose O O
of O O
these O O
three O O
drug O O
products O O
adjusted O O
appropriately O O
. O O

Probenecid B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
TORADOL B-brand B-brand
ORAL O O
and O O
probenecid B-drug B-drug
resulted O O
in O O
decreased O O
clearance O O
of O O
ketorolac B-drug B-drug
and O O
significant O O
increases O O
in O O
ketorolac B-drug B-drug
plasma O O
levels O O
( O O
total O O
AUC O O
increased O O
approximately O O
threefold O O
from O O
5.4 O O
to O O
17.8 O O
m O O
g/h/mL O O
) O O
and O O
terminal O O
half-life O O
increased O O
approximately O O
twofold O O
from O O
6.6 O O
to O O
15.1 O O
hours O O
. O O

Therefore O O
, O O
it O O
is O O
advisable O O
to O O
be O O
particularly O O
cautious O O
in O O
patients O O
whose O O
plasma O O
digoxin B-drug B-drug
levels O O
are O O
above O O
or O O
suspected O O
to O O
be O O
above O O
the O O
usual O O
therapeutic O O
range O O
. O O

Pediatric O O
Use O O

Thus O O
, O O
the O O
interaction O O
observed O O
between O O
erythromycin B-drug B-drug
and O O
terfenadine B-drug B-drug
is O O
not O O
expected O O
for O O
dirithromycin B-drug B-drug
. O O

The O O
reported O O
dose O O
used O O
for O O
L-glutamine B-drug B-drug
was O O
21 O O
grams O O
daily O O
taken O O
in O O
divided O O
doses O O
three O O
times O O
a O O
day O O
. O O

Due O O
to O O
its O O
potential O O
to O O
cause O O
neutropenia O O
and O O
lymphopenia O O
, O O
proper O O
monitoring O O
of O O
patients O O
is O O
required O O
if O O
Rebif B-brand B-brand
is O O
given O O
in O O
combination O O
with O O
myelosuppressive O O
agents O O
. O O

Since O O
blood O O
level O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
will O O
be O O
reduced O O
, O O
higher O O
doses O O
of O O
Rocaltrol B-brand B-brand
may O O
be O O
necessary O O
if O O
these O O
drugs O O
are O O
administered O O
simultaneously O O
. O O

Most O O
of O O
the O O
above O O
effects O O
concerning O O
diuretics B-group B-group
have O O
been O O
attributed O O
, O O
at O O
least O O
in O O
part O O
, O O
to O O
mechanisms O O
involving O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
by O O
INDOCIN B-brand B-brand
. O O

Warfarin B-drug B-drug
- O O
Administration O O
of O O
40 O O
mg/day O O
racemic O O
citalopram B-drug B-drug
for O O
21 O O
days O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
warfarin B-drug B-drug
, O O
a O O
CYP3A4 O O
substrate O O
. O O

Concomitant O O
use O O
of O O
bromocriptine B-drug B-drug
mesylate I-drug I-drug
with O O
other O O
ergot B-group B-group
alkaloids I-group I-group
is O O
not O O
recommended O O
. O O

Antifungals B-group B-group
: O O
Itraconazole B-drug B-drug
Ketoconazole I-drug I-drug

Blood O O
samples O O
were O O
drawn O O
at O O
0 O O
, O O
0.5 O O
, O O
1 O O
, O O
1.5 O O
, O O
2 O O
, O O
3 O O
, O O
4 O O
, O O
6 O O
, O O
8 O O
, O O
12 O O
, O O
18 O O
, O O
and O O
24 O O
hours O O
for O O
Cmax O O
, O O
tmax O O
, O O
and O O
AUC O O
determinations O O
. O O

In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
a O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic B-group B-group
, I-group O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium-sparing O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

These O O
facts O O
should O O
be O O
considered O O
when O O
evaluating O O
plasma O O
renin O O
activity O O
in O O
hypertensive O O
patients O O
. O O

Onset O O
of O O
the O O
interaction O O
began O O
within O O
five O O
days O O
of O O
beginning O O
concurrent O O
therapy O O
. O O

Antacids B-group B-group
: O O
Enteric O O
Coated O O
Aspirin B-brand B-brand
should O O
not O O
be O O
given O O
concurrently O O
with O O
antacids B-group B-group
, O O
since O O
an O O
increase O O
in O O
the O O
pH O O
of O O
the O O
stomach O O
may O O
effect O O
the O O
enteric O O
coating O O
of O O
the O O
tablets O O
. O O

Naproxen B-drug B-drug
had O O
no O O
effect O O
on O O
plasma O O
levels O O
of O O
diflunisal B-drug B-drug
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCA B-group B-group
plasma O O
levels O O
whenever O O
a O O
TCA B-group B-group
is O O
going O O
to O O
be O O
coadministered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
. O O

To O O
study O O
the O O
pancreatic O O
effects O O
of O O
other O O
agents O O
, O O
dynamic O O
insulin O B-drug
and O O
glucagon O O
release O O
was O O
measured O O
from O O
the O O
in O O
vitro O O
perfused O O
pancreases O O
of O O
normal O O
and O O
diabetic O O
Chinese O O
hamsters O O
in O O
response O O
to O O
various O O
combinations O O
of O O
arginine B-drug B-drug
( O O
20mM O O
) O O
, O O
glucose B-drug B-drug
( O O
100 O O
or O O
150 O O
mg. O O
per O O
100 O O
ml O O
. O O
) O O
, O O
and O O
theophylline B-drug B-drug
( O O
10 O O
mM O O
) O O
. O O

MAO B-group B-group
Inhibitors I-group I-group
: O O
Studies O O
in O O
animals O O
demonstrate O O
that O O
the O O
acute O O
toxicity O O
of O O
bupropion B-drug B-drug
is O O
enhanced O O
by O O
the O O
MAO B-group B-group
inhibitor I-group I-group
phenelzine B-drug B-drug
. O O

Ethopropazine B-drug B-drug
may O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
, O O
causing O O
increased O O
sedative O O
effects O O
. O O

The O O
blood O O
pressure O O
effect O O
of O O
SULAR B-brand B-brand
tended O O
to O O
be O O
greater O O
in O O
patients O O
on O O
atenolol B-drug B-drug
than O O
in O O
patients O O
on O O
no O O
other O O
antihypertensive B-group B-group
therapy O O
. O O

Digoxin B-drug B-drug
: O O
In O O
controlled O O
studies O O
in O O
healthy O O
volunteers O O
, O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
either O O
had O O
no O O
effect O O
( O O
one O O
study O O
) O O
or O O
was O O
associated O O
with O O
modest O O
increases O O
, O O
about O O
30 O O
% O O
( O O
two O O
studies O O
) O O
in O O
steady-state O O
serum O O
digoxin B-drug B-drug
concentrations O O
. O O

Four O O
educational O O
messages O O
advise O O
on O O
over O O
60 O O
% O O
of O O
the O O
PICR O O
detected O O
. O O

Racemic O O
citalopram B-drug B-drug
did O O
not O O
alter O O
the O O
mean O O
AUC O O
or O O
Cmax O O
of O O
pimozide B-drug B-drug
. O O

Antigout B-group B-group
medications I-group I-group

Because O O
warfarin B-drug B-drug
is O O
metabolized O O
by O O
CYP2C9 O B-drug
and O O
CYP3A4 O O
, O O
patients O O
who O O
require O O
anticoagulation O O
should O O
receive O O
low-molecular O O
weight O O
or O O
standard O O
heparin B-drug B-drug
. O O

Lupus-like O O
syndrome O O

Other O O
binding O O
proteins O O
may O O
be O O
elevated O O
in O O
serum O O
, O O
i.e. O O
, O O
corticosteroid O O
binding O O
globulin O O
( O O
CBG O O
) O O
, O O
sex O O
hormone-binding O O
globulin O O
( O O
SHBG O O
) O O
, O O
leading O O
to O O
increased O O
total O O
circulating O O
corticosteroids B-group B-group
and O O
sex B-group B-group
steroids I-group I-group
, O O
respectively O O
. O O

Toxicity O O
of O O
cadmium O O
and O O
zinc B-drug B-drug
to O O
encystment O O
and O O
in O O
vitro O O
excystment O O
of O O
Parorchis O O
acanthus O O
( O O
Digenea O O
: O O
Philophthalmidae O O
) O O
. O O

Although O O
clinical O O
evidence O O
to O O
date O O
has O O
not O O
demonstrated O O
renal O O
precipitation O O
of O O
oxypurines O B-drug
in O O
patients O O
either O O
on O O
allopurinol B-drug B-drug
alone O O
or O O
in O O
combination O O
with O O
uricosuric B-group O
agents I-group O
, O O
the O O
possibility O O
should O O
be O O
kept O O
in O O
mind O O
. O O

( O O
Concurrent O O
use O O
with O O
thiazide B-group B-group
diuretics I-group I-group
may O O
intensify O O
electrolyte O O
imbalance O O
, O O
particularly O O
hypokalemia O O
. O O
) O O

Diphenoxylate B-drug B-drug
HCl I-drug I-drug
and O O
atropine B-drug B-drug
sulfate I-drug I-drug
may O O
interact O O
with O O
MAO B-group B-group
inhibitors I-group I-group
In O O
studies O O
with O O
male O O
rats O O
, O O
diphenoxylate B-drug B-drug
hydrochloride I-drug I-drug
was O O
found O O
to O O
inhibit O O
the O O
hepatic O O
microsomal O O
enzyme O O
system O O
at O O
a O O
dose O O
of O O
2 O O
mg/kg/day O O
. O O

The O O
following O O
similar O O
changes O O
may O O
be O O
expected O O
with O O
larger O O
doses O O
of O O
estrogen B-group B-group
: O O
- O O
Increased O O
sulfobromophthalein O O
retention O O

Corticosteroids B-group B-group
, O O
ACTH B-drug B-drug
: O O
intensified O O
electrolyte O O
depletion O O
, O O
particularly O O
hypokalemia O O
. O O

Flucytosine B-drug B-drug
: O O
while O O
a O O
synergistic O O
relationship O O
with O O
amphotericin B-drug B-drug
B I-drug I-drug
has O O
been O O
reported O O
, O O
concomitant O O
use O O
may O O
increase O O
the O O
toxicity O O
of O O
flucytosine B-drug B-drug
by O O
possibly O O
increasing O O
its O O
cellular O O
uptake O O
and/or O O
impairing O O
its O O
renal O O
excretion O O
. O O

reduced O O
response O O
to O O
metyrapone O O
test O O
; O O

Quinidine B-drug B-drug
, O O
verapamil B-drug B-drug
, O O
amiodarone B-drug B-drug
, O O
propafenone B-drug B-drug
, O O
indomethacin B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
alprazolam B-drug B-drug
, O O
and O O
spironolactone B-drug B-drug
raise O O
the O O
serum O O
digoxin B-drug B-drug
concentration O O
due O O
to O O
a O O
reduction O O
in O O
clearance O O
and/or O O
in O O
volume O O
of O O
distribution O O
of O O
the O O
drug O O
, O O
with O O
the O O
implication O O
that O O
digitalis B-group B-group
intoxication O O
may O O
result O O
. O O

Aminoglutethimide B-drug B-drug
: O O
May O O
increase O O
CYP O O
metabolism O O
of O O
progestins B-group B-group
leading O O
to O O
possible O O
decrease O O
in O O
contraceptive O O
effectiveness O O
. O O

There O O
are O O
case O O
reports O O
of O O
patients O O
who O O
developed O O
increased O O
BUN O O
, O O
serum O O
creatinine O O
and O O
serum O O
potassium O O
levels O O
, O O
and O O
weight O O
gain O O
when O O
furosemide B-drug B-drug
was O O
used O O
in O O
conjunction O O
with O O
NSAIDs B-group B-group
. O O

A O O
drug O O
interaction O O
study O O
was O O
performed O O
in O O
which O O
ERBITUX B-brand B-brand
was O O
administered O O
in O O
combination O O
with O O
irinotecan B-drug B-drug
. O O

Clinically O O
significant O O
effects O O
have O O
been O O
reported O O
with O O
the O O
warfarin B-group B-group
anticoagulants I-group I-group
; O O

Phenobarbital B-drug B-drug
or O O
Primidone B-drug B-drug
: O O
No O O
formal O O
pharmacokinetic O O
studies O O
have O O
been O O
performed O O
examining O O
the O O
addition O O
of O O
tiagabine B-drug B-drug
to O O
regimens O O
containing O O
phenobarbital B-drug B-drug
or O O
primidone B-drug B-drug
. O O

. O O

Interconversion O O
between O O
caffeine B-drug B-drug
and O O
theophylline B-drug B-drug
has O O
been O O
reported O O
in O O
preterm O O
neonates O O
. O O

therefore O O
, O O
the O O
use O O
of O O
dofetilide B-drug B-drug
does O O
not O O
necessitate O O
an O O
adjustment O O
in O O
digoxin B-drug B-drug
dose O O
to O O
maintain O O
therapeutic O O
digoxin O B-drug
levels O O
. O O

Spermine B-drug B-drug
promotes O O
the O O
translocation O O
of O O
phosphatidate O O
phosphohydrolase O O
from O O
the O O
cytosol O O
to O O
the O O
microsomal O O
fraction O O
of O O
rat O O
liver O O
and O O
it O O
enhances O O
the O O
effects O O
of O O
oleate O O
in O O
this O O
respect O O
. O O

The O O
steady O O
state O O
plasma O O
concentrations O O
of O O
imipramine B-drug B-drug
and O O
desipramine B-drug B-drug
have O O
been O O
reported O O
to O O
be O O
increased O O
an O O
average O O
of O O
31 O O
% O O
and O O
20 O O
% O O
, O O
respectively O O
, O O
by O O
the O O
concomitant O O
administration O O
of O O
alprazolam B-drug B-drug
tablets O O
in O O
doses O O
up O O
to O O
4 O O
mg/day O O
. O O

There O O
is O O
insufficient O O
experience O O
to O O
assess O O
the O O
safety O O
and O O
efficacy O O
of O O
ORENCIA B-brand B-brand
administered O O
concurrently O O
with O O
anakinra B-drug B-drug
, O O
and O O
therefore O O
such O O
use O O
is O O
not O O
recommended O O
. O O

however O O
, O O
it O O
adversely O O
affected O O
response O O
duration O O
suggesting O O
that O O
pyridoxine B-drug B-drug
should O O
not O O
be O O
administered O O
with O O
HEXALEN B-brand B-brand
and/or O O
cisplatin.1 B-drug B-drug

Nursing O O
Mothers O O
It O O
is O O
not O O
known O O
whether O O
peginterferon B-drug B-drug
or O O
ribavirin B-drug B-drug
or O O
its O O
components O O
are O O
excreted O O
in O O
human O O
milk O O
. O O

Antiretroviral B-group B-drug
plasma O O
and O O
urine O O
sampling O O
were O O
conducted O O
on O O
Days O O
1 O O
, O O
7 O O
, O O
and O O
21 O O
for O O
zidovudine B-drug B-drug
and O O
on O O
Days O O
7 O O
and O O
21 O O
for O O
dideoxyinosine B-drug B-drug
. O O

. O O

In O O
order O O
to O O
provide O O
information O O
for O O
the O O
appropriate O O
package O O
insert O O
labeling O O
of O O
progestin-only B-group B-group
oral I-group O
contraceptives I-group B-group
( O O
POC B-group B-group
) O O
in O O
the O O
US O O
, O O
a O O
comprehensive O O
review O O
was O O
made O O
of O O
norgestrel B-drug B-drug
( O O
0.075 O O
mg O O
) O O
and O O
norethindrone B-drug B-drug
( O O
0.35 O O
mg O O
) O O
, O O
with O O
the O O
clinical O O
differences O O
indicated O O
where O O
applicable O O
. O O

Drug-Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
known O O
interactions O O
between O O
ELLENCE B-brand B-brand
and O O
laboratory O O
tests O O
. O O

None O O
known O O
. O O

Valproate B-drug B-drug
: O O
The O O
addition O O
of O O
tiagabine B-drug B-drug
to O O
patients O O
taking O O
valproate B-drug B-drug
chronically O O
had O O
no O O
effect O O
on O O
tiagabine B-drug B-drug
pharmacokinetics O O
, O O
but O O
valproate B-drug B-drug
significantly O O
decreased O O
tiagabine B-drug B-drug
binding O O
in O O
vitro O O
from O O
96.3 O O
to O O
94.8 O O
% O O
, O O
which O O
resulted O O
in O O
an O O
increase O O
of O O
approximately O O
40 O O
% O O
in O O
the O O
free O O
tiagabine O B-drug
concentration O O
. O O

The O O
successive O O
application O O
of O O
glycine B-drug B-drug
( O O
5 O O
or O O
10 O O
mg/kg O O
egg O O
weight O O
( O O
e.w O O
. O O
) O O
and O O
glutamate B-drug B-drug
( O O
15 O O
mg/kg O O
e.w O O
. O O
) O O
in O O
a O O
10 O O
min O O
interval O O
significantly O O
increased O O
the O O
activation O O
of O O
spontaneous O O
motility O O
of O O
17-day-old O O
chick O O
embryos O O
in O O
comparison O O
with O O
the O O
effect O O
of O O
glutamate B-drug B-drug
alone O O
. O O

Propranolol B-drug B-drug
: O O
May O O
decrease O O
aspirins B-brand B-group
anti-inflammatory O I-group
action O O
by O O
competing O O
for O O
the O O
same O O
receptors O O
. O O

with O O
sucralfate B-drug B-drug
; O O

Some O O
quinolones B-group B-group
, O O
including O O
ciprofloxacin B-drug B-drug
, O O
have O O
been O O
associated O O
with O O
transient O O
elevations O O
in O O
serum O O
creatinine O O
in O O
patients O O
receiving O O
cyclosporine B-drug B-drug
concomitantly O O
. O O

twice O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
and O O
non-ossification O O
of O O
the O O
odontoid O O
and O O
ventral O O
tubercle O O
of O O
the O O
first O O
cervical O O
vertebra O O
at O O
doses O O
0.1 O O
mg/kg/day O O
IM O O
( O O
approximately O O
one-tenth O O
of O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
when O O
administered O O
during O O
the O O
period O O
of O O
organogenesis O O
. O O

Thus O O
there O O
was O O
a O O
tendency O O
toward O O
a O O
more O O
pronounced O O
inhibition O O
of O O
the O O
4-hydroxylation O O
during O O
treatment O O
with O O
150 O O
mg/d O O
of O O
fluvoxamine B-drug B-drug
compared O O
with O O
75 O O
mg/d O O
, O O
but O O
the O O
difference O O
was O O
not O O
statistically O O
significant O O
. O O

Amiodarone B-drug B-drug
is O O
also O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
CYP3A4 O O
. O O

Concomitant O O
administration O O
of O O
Mefloquine B-drug B-drug
and O O
other O O
related O O
compounds O O
( O O
eg O O
, O O
quinine B-drug B-drug
, O O
quinidine B-drug B-drug
and O O
chloroquine B-drug B-drug
) O O
may O O
produce O O
electrocardiographic O O
abnormalities O O
and O O
increase O O
the O O
risk O O
of O O
convulsions O O
. O O

Clinical O O
studies O O
of O O
the O O
effect O O
of O O
strong O O
CYP O O
3A4 O O
inhibitors O O
on O O
the O O
pharmacokinetics O O
of O O
fulvestrant B-drug B-drug
have O O
not O O
been O O
performed O O
. O O

The O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
has O O
been O O
reported O O
to O O
be O O
inhibited O O
by O O
some O O
drugs O O
of O O
this O O
class O O
. O O

Interference O O
of O O
biocytin O O
with O O
opioid-evoked B-group B-drug_n
hyperpolarization O O
and O O
membrane O O
properties O O
of O O
rat O O
spinal O O
substantia O O
gelatinosa O O
neurons O O
. O O

tricyclic B-group B-group
antidepressants I-group I-group
. O O

Coadministration O O
of O O
digoxin B-drug B-drug
did O O
not O O
have O O
effects O O
on O O
either O O
the O O
safety O O
or O O
efficacy O O
of O O
ibutilide B-drug B-drug
in O O
the O O
clinical O O
trials O O
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

In O O
an O O
effort O O
to O O
screen O O
compounds O O
for O O
antipsychotic O O
activity O O
, O O
preclinical O O
researchers O O
have O O
investigated O O
whether O O
these O O
compounds O O
block O O
PCP-induced B-drug_n B-drug_n
behaviors O O
in O O
animals O O
. O O

Other O O
compounds O O
that O O
are O O
substrates O O
of O O
CYP3A4 O O
may O O
have O O
decreased O O
plasma O O
concentrations O O
when O O
coadministered O O
with O O
SUSTIVA B-brand B-brand
( O O
efavirenz B-drug B-drug
) O O
. O O

Only O O
at O O
the O O
highest O O
concentration O O
tested O O
( O O
171 O O

No O O
carcinogenicity O O
or O O
fertility O O
studies O O
were O O
conducted O O
. O O

Estazolam B-drug B-drug
: O O
Interaction O O
with O O
Drugs O O
that O O
Inhibit O O
Metabolism O O
via O O
Cytochrome O O
P450 O O
3A O O
( O O
CYP3A O O
) O O
: O O
The O O
metabolism O O
of O O
estazolam B-drug B-drug
to O O
the O O
major O O
circulating O O
metabolite O O
4-hydroxy-estazolam B-drug_n B-drug_n
and O O
the O O
metabolism O O
of O O
other O O
triazolobenzodiazepines B-group B-group
is O O
catalyzed O O
by O O
CYP3A O O
. O O

A O O
daily O O
dose O O
of O O
2 O O
mg O O
of O O
coumaphos/kg B-drug_n B-drug_n
of O O
body O O
weight O O
for O O
6 O O
days O O
did O O
not O O
affect O O
the O O
plasma O O
enzymes O O
or O O
the O O
antiprothrombinemic O O
effect O O
of O O
bishydroxy-coumarin B-drug B-drug
in O O
wethers O O
. O O

The O O
incidence O O
of O O
cardiovascular O O
morbidity O O
and O O
mortality O O
is O O
not O O
higher O O
among O O
users O O
of O O
sildenafil B-drug B-drug
. O O

- O O
Primaquine B-drug B-drug
or O O

There O O
have O O
been O O
reports O O
of O O
theophylline-related B-drug B-drug
side O O
effects O O
in O O
patients O O
on O O
concomitant O O
therapy O O
with O O
norfloxacin B-drug B-drug
and O O
theophylline B-drug B-drug
. O O

Since O O
entecavir B-drug B-drug
is O O
primarily O O
eliminated O O
by O O
the O O
kidneys O O
, O O
coadministration O O
of O O
BARACLUDE B-brand B-brand
with O O
drugs O O
that O O
reduce O O
renal O O
function O O
or O O
compete O O
for O O
active O O
tubular O O
secretion O O
may O O
increase O O
serum O O
concentrations O O
of O O
either O O
entecavir B-drug B-drug
or O O
the O O
coadministered O O
drug O O
. O O

Naproxen B-drug B-drug
: O O
Coadministration O O
( O O
N=18 O O
) O O
of O O
naproxen B-drug B-drug
sodium I-drug I-drug
capsules O O
( O O
250 O O
mg O O
) O O
with O O
Neurontin B-brand B-brand
( O O
125 O O
mg O O
) O O
appears O O
to O O
increase O O
the O O
amount O O
of O O
gabapentin B-drug B-drug
absorbed O O
by O O
12 O O
% O O
to O O
15 O O
% O O
. O O

Therefore O O
, O O
COLESTlD B-brand B-brand
Tablets O O
may O O
delay O O
or O O
reduce O O
the O O
absorption O O
of O O
concomitant O O
oral O O
medication O O
. O O

PEGANONE B-brand B-brand
used O O
in O O
combination O O
with O O
other O O
drugs O O
known O O
to O O
adversely O O
affect O O
the O O
hematopoietic O O
system O O
should O O
be O O
avoided O O
if O O
possible O O
. O O

Drug O O
Interactions O O
with O O
Antacids B-group B-group
Administration O O
of O O
120 O O
mg O O
of O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
( O O
2 O O
x O O
60 O O
mg O O
capsule O O
) O O
within O O
15 O O
minutes O O
of O O
an O O
aluminum B-drug B-drug
and O O
magnesium B-drug B-drug
containing O O
antacid B-group B-group
( O O
Maalox B-brand B-brand
) O O
decreased O O
fexofenadine B-drug B-drug
AUC O O
by O O
41 O O
% O O
and O O
cmax O O
by O O
43 O O
% O O
. O O

Somatrem/Somatropin B-drug B-drug
: O O
Excessive O O
concurrent O O
use O O
of O O
thyroid B-group B-group
hormone I-group I-group
may O O
accelerate O O
epiphyseal O O
closure O O
. O O

Drugs O O
whose O O
absorption O O
is O O
sensitive O O
to O O
pH O O
may O O
be O O
negatively O O
impacted O O
by O O
concomitant O O
administration O O
of O O
omeprazole B-drug B-drug
and O O
valdecoxib B-drug B-drug
. O O

No O O
information O O
available O O
. O O

Arginine B-drug B-drug
, O O
in O O
the O O
absence O O
of O O
glucose B-drug B-drug
or O O
theophylline B-drug B-drug
, O O
caused O O
excessive O O
glucagon O O
release O O
in O O
the O O
diabetics O O
and O O
undetectable O O
insulin O O
release O O
in O O
either O O
diabetics O O
or O O
normals O O
. O O

These O O
agents O O
should O O
not O O
be O O
taken O O
for O O
8 O O
hours O O
before O O
or O O
for O O
2 O O
hours O O
after O O
enoxacin B-drug B-drug
administration O O
. O O

During O O
amiodarone B-drug B-drug
administration O O
, O O
systemic O O
clearance O O
of O O
digoxin B-drug B-drug
was O O
reduced O O
from O O
234 O O
+/- O O
72 O O
ml/min O O
( O O
mean O O
+/- O O
standard O O
deviation O O
) O O
to O O
172 O O
+/- O O
33 O O
ml/min O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
. O O

Drug O O
interactions O O
: O O
How O O
to O O
identify O O
them O O
. O O

. O O

injection O O
of O O
vehicle O O
( O O
corn O O
oil O B-drug
, O O
0.1 O O
mL/day O O
) O O
, O O
estradiol B-drug B-drug
( O O
10 O O
microg/kg/day O O
or O O
4 O O
mg/kg/day O O
) O O
and/or O O
progesterone B-drug B-drug
( O O
20 O O
mg/kg/day O O
) O O
, O O
for O O
eight O O
days O O
. O O

This O O
may O O
indicate O O
that O O
they O O
could O O
enhance O O
the O O
toxicity O O
of O O
methotrexate B-drug B-drug
. O O

Inhibitors O O
of O O
CYP3A4 O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
) O O
or O O
CYP2D6 O B-drug
( O O
eg O O
, O O
quinidine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
or O O
paroxetine B-drug B-drug
) O O
can O O
inhibit O O
aripiprazole B-drug B-drug
elimination O O
and O O
cause O O
increased O O
blood O O
levels O O
. O O

The O O
mechanism O O
underlying O O
many O O
of O O
these O O
events O O
is O O
unknown O O
, O O
but O O
may O O
represent O O
increased O O
hypotension O O
. O O

It O O
is O O
therefore O O
necessary O O
to O O
be O O
well O O
acquainted O O
with O O
the O O
clinical O O
and O O
paraclinical O O
pattern O O
of O O
magnesium B-drug B-drug
deficit O O
and O O
to O O
discriminate O O
between O O
magnesium B-drug B-drug
deficiency O O
due O O
to O O
an O O
insufficient O O
magnesium B-drug B-drug
intake O O
which O O
only O O
requires O O
oral O O
physiological O O
supplementation O O
and O O
magnesium B-drug B-drug
depletion O O
related O O
to O O
a O O
dysregulation O O
of O O
the O O
control O O
mechanisms O O
of O O
magnesium B-drug B-drug
status O O
which O O
requires O O
more O O
or O O
less O O
specific O O
regulation O O
of O O
its O O
causal O O
dysregulation O O
. O O

Therefore O O
, O O
the O O
concomitant O O
administration O O
of O O
TRACLEER B-brand B-brand
and O O
glyburide B-drug B-drug
is O O
contraindicated O O
, O O
and O O
alternative O O
hypoglycemic B-group B-group
agents I-group I-group
should O O
be O O
considered O O
. O O

Phenytoin B-drug B-drug
: O O
Serum O O
phenytoin B-drug B-drug
levels O O
may O O
be O O
increased O O
by O O
aspirin B-brand B-brand
. O O

Pharmacologic O O
studies O O
indicate O O
that O O
there O O
may O O
be O O
additive O O
effects O O
in O O
prolonging O O
AV O O
conduction O O
when O O
using O O
beta-blockers B-group B-group
or O O
digitalis B-group B-group
concomitantly O O
with O O
Tiazac B-brand B-brand
. O O

Amprenavir B-drug B-drug

No O O
abortifacient O O
or O O
teratogenic O O
effects O O
were O O
observed O O
in O O
cynomolgus O O
monkeys O O
following O O
intravenous O O
bolus O O
injections O O
of O O
AMEVIVE B-brand B-brand
administered O O
weekly O O
during O O
the O O
period O O
of O O
organogenesis O O
to O O
gestation O O
. O O

Therefore O O
, O O
concomitant O O
use O O
of O O
TORADOL B-brand B-brand
and O O
probenecid B-drug B-drug
is O O
contraindicated O O
. O O

( O O
54 O O
) O O
microtubules O O
per O O
axon O O
. O O

Primary O O
and O O
secondary O O
magnesium B-drug B-drug
deficiencies O O
constitute O O
the O O
sole O O
indication O O
of O O
physiological O O
oral O O
magnesium B-drug B-drug
therapy O O
. O O

Antacid B-group B-group
: O O
The O O
effect O O
of O O
an O O
aluminum B-drug B-drug
hydroxide- O O
and O O
magnesium B-drug B-drug
hydroxide-containing O O
antacid B-group B-group
( O O
Maalox B-brand B-brand
) O O
* O O
on O O
the O O
pharmacokinetics O O
of O O
capecitabine B-drug B-drug
was O O
investigated O O
in O O
12 O O
cancer O O
patients O O
. O O

Antacids B-group B-group
, O O
kaolin-pectin B-drug B-drug
, O O
sulfasalazine B-drug B-drug
, O O
neomycin B-drug B-drug
, O O
cholestyramine B-drug B-drug
, O O
certain O O
anticancer O B-group
drugs O I-group
, O O
and O O
metoclopramide B-drug B-drug
may O O
interfere O O
with O O
intestinal O O
digoxin B-drug B-drug
absorption O O
, O O
resulting O O
in O O
unexpectedly O O
low O O
serum O O
concentrations O O
. O O

Close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
dosage O O
are O O
required O O
when O O
this O O
drug O O
is O O
given O O
concomitantly O O
with O O
anticholinergic B-group B-group
or O O
sympathomimetic B-group B-group
drugs I-group I-group
. O O

Acetaminophen B-drug B-drug
diminished O O
the O O
binding O O
of O O
theophylline B-drug B-drug
to O O
human O O
serum O O
by O O
a O O
net O O
change O O
of O O
5.7 O O
% O O
( O O
percentage O O
increase O O
in O O
free O O
drug O O
fraction O O
[ O O
FDF O O
] O O
, O O
11.0 O O
% O O
) O O
at O O
662 O O
micromol/L O O
and O O
by O O
a O O
net O O
change O O
of O O
7.1 O O
% O O
( O O
percentage O O
increase O O
in O O
FDF O O
, O O
13.7 O O
% O O
) O O
at O O
1324 O O
micromol/L O O
. O O

This O O
paper O O
attempts O O
to O O
provide O O
a O O
basis O O
for O O
the O O
understanding O O
and O O
identifications O O
of O O
important O O
drug O O
interactions O O
. O O

Effects O O
of O O
etofibrate B-drug B-drug
upon O O
the O O
metabolism O O
of O O
chylomicron-like O O
emulsions O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

Hypersensitivity O O
Reactions O O
: O O
Patients O O
with O O
a O O
history O O
of O O
severe O O
hypersensitivity O O
reactions O O
to O O
products O O
containing O O
Cremophor O O
EL O O
( O O
eg O O
, O O
cyclosporin B-drug B-drug
for O O
injection O O
concentrate O O
and O O
teniposide B-drug B-drug
for O O
injection O O
concentrate O O
) O O
should O O
not O O
be O O
treated O O
with O O
TAXOL B-brand B-brand
. O O

Rare O O
reports O O
of O O
more O O
severe O O
events O O
such O O
as O O
phlebitis O O
, O O
cellulitis O O
, O O
induration O O
, O O
skin O O
exfoliation O O
, O O
necrosis O O
, O O
and O O
fibrosis O O
have O O
been O O
received O O
as O O
part O O
of O O
the O O
continuing O O
surveillance O O
of O O
TAXOL B-brand B-brand
safety O O
. O O

Cocaine B-drug B-drug
sometimes O O
proves O O
to O O
be O O
fatal O O
when O O
used O O
in O O
combination O O
with O O
heroin B-drug_n B-drug_n
. O O

Nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
aminoglycoside B-group B-group
antibiotics I-group I-group
and O O
cephalosporin B-group B-group
antibiotics I-group I-group
. O O

Of O O
the O O
229 O O
patients O O
who O O
had O O
potassium B-group B-group
depleting I-group I-group
diuretics I-group I-group
added O O
to O O
their O O
concomitant O O
medications O O
in O O
the O O
DIAMOND O O
trials O O
, O O
the O O
patients O O
on O O
TIKOSYN B-brand B-brand
had O O
a O O
non-significantly O O
reduced O O
relative O O
risk O O
for O O
death O O
of O O
0.68 O O
( O O
95 O O
% O O
CI O O
0.376 O O
, O O
1.230 O O
) O O
. O O

Azlocillin B-drug B-drug
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
amikacin B-drug B-drug
, O O
ciprofloxacin B-drug B-drug
, O O
gentamicin B-drug B-drug
, O O
netilmicin B-drug B-drug
, O O
or O O
tobramycin B-drug B-drug
. O O

Itraconazole B-drug B-drug
plasma O O
concentrations O O
should O O
be O O
monitored O O
when O O
Itraconazole B-drug B-drug
and O O
isoniazid B-drug B-drug
are O O
coadministered O O
. O O

Moreover O O
, O O
its O O
activity O O
was O O
enhanced O O
when O O
it O O
was O O
combined O O
with O O
either O O
azithromycin B-drug B-drug
or O O
minocycline B-drug B-drug
with O O
90 O O
% O O
parasite O O
reduction O O
at O O
the O O
highest O O
concentration O O
tested O O
. O O

Whether O O
abnormal O O
topoisomerase O O
quantity O O
and O O
specific O O
activity O O
are O O
associated O O
with O O
resistance O O
or O O
sensitivity O O
to O O
topoisomerase-targeted O O
chemotherapy O O
in O O
the O O
clinic O O
is O O
now O O
being O O
studied O O
. O O

Cardiac B-group B-group
glycosides I-group I-group

The O O
color O O
reverses O O
when O O
the O O
test O O
sample O O
is O O
acidified O O
in O O
vitro O O
to O O
a O O
pH O O
below O O
4 O O
. O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
propafenone B-drug B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

Amiodarone B-drug B-drug
or O O
Verapamil B-drug B-drug
: O O
The O O
risk O O
of O O
myopathy/rhabdomyolysis O O
is O O
increased O O
when O O
either O O
amiodarone B-drug B-drug
or O O
verapamil B-drug B-drug
is O O
used O O
concomitantly O O
with O O
a O O
closely O O
related O O
member O O
of O O
the O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitor I-group I-group
class I-group I-group
( O O
see O O
WARNINGS O O
, O O
Myopathy/Rhabdomyolysis O O
) O O
. O O

Lithium B-drug B-drug
: O O
Diclofenac B-drug B-drug
decreases O O
lithium B-drug B-drug
renal O O
clearance O O
and O O
increases O O
lithium B-drug B-drug
plasma O O
levels O O
. O O

- O O
Probenecid B-drug B-drug
: O O
Pretreatment O O
with O O
probenecid B-drug B-drug
reduces O O
both O O
the O O
natriuresis O O
and O O
hyperreninemia O O
produced O O
by O O
bumetanide B-drug B-drug
. O O

The O O
interaction O O
was O O
pharmacodynamic O O
; O O

Dose O O
of O O
AED B-group B-group
( O O
mg/day O O
) O O

Concomitantly O O
administered O O
iron-fortified B-drug_n B-drug_n
infant O O
formula O O
( O O
2.2 O O
mg O O
elemental O O
iron/6 B-drug_n B-drug_n
oz O O
) O O
has O O
no O O
significant O O
effect O O
on O O
cefdinir B-drug B-drug
pharmacokinetics O O
. O O

No O O
dosage O O
adjustment O O
is O O
required O O
for O O
Fluvoxamine B-drug B-drug
Tablets O O
. O O

Coadministration O O
of O O
Itraconazole B-drug B-drug
and O O
drugs O O
primarily O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
drugs O O
that O O
could O O
increase O O
or O O
prolong O O
both O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

Buforin B-drug_n B-drug_n
II I-drug_n I-drug_n
may O O
be O O
active O O
in O O
inhibiting O O
Cryptosporidium O O
parvum O O
growth O O
in O O
vitro O O
upon O O
combination O O
with O O
either O O
azithromycin B-drug B-drug
or O O
minocycline B-drug B-drug
. O O

Lovastatin B-drug B-drug
is O O
metabolized O O
by O O
CYP3A4 O O
but O O
has O O
no O O
CYP3A4 O O
inhibitory O O
activity O O
; O O

The O O
effects O O
of O O
chlordiazepoxide B-drug B-drug
, O O
amphetamine B-drug B-drug
and O O
cocaine B-drug B-drug
on O O
bar-press O O
behavior O O
in O O
normal O O
and O O
genetically O O
nervous O O
dogs O O
. O O

Hydrocodone B-drug B-drug
: O O
Coadministration O O
of O O
Neurontin B-brand B-brand
( O O
125 O O
to O O
500 O O
mg O O
; O O

There O O
are O O
a O O
number O O
of O O
steps O O
physicians O O
can O O
take O O
to O O
ensure O O
that O O
their O O
patients O O
are O O
not O O
being O O
undertreated O O
. O O

Digitalis B-group B-group
: O O
Thyroid B-group B-group
preparations I-group I-group
may O O
potentiate O O
the O O
toxic O O
effects O O
of O O
digitalis B-group B-group
. O O

Studies O O
with O O
ACE B-group B-group
inhibitors I-group I-group
in O O
combination O O
with O O
diuretics B-group B-group
indicate O O
that O O
the O O
dose O O
of O O
the O O
ACE B-group B-group
inhibitor I-group I-group
can O O
be O O
reduced O O
when O O
it O O
is O O
given O O
with O O
a O O
diuretic B-group B-group
. O O

Monitoring O O
of O O
liver O O
enzymes O O
is O O
recommended O O
when O O
SUSTIVA B-brand B-brand
is O O
used O O
in O O
combination O O
with O O
ritonavir B-drug B-drug
. O O

Severe O O
allergic O O
reactions O O
including O O
anaphylaxis O O
have O O
been O O
reported O O
in O O
patients O O
exposed O O
to O O
a O O
variety O O
of O O
allergens O O
either O O
by O O
repeated O O
challenge O O
, O O
or O O
accidental O O
contact O O
, O O
and O O
with O O
diagnostic O O
or O O
therapeutic O O
agents O O
while O O
receiving O O
beta-blockers B-group B-group
. O O

Ketoconazole B-drug B-drug
: O O
Sensipar B-brand B-brand
is O O
metabolized O O
in O O
part O O
by O O
CYP3A4 O O
. O O

Erythromycin B-drug B-drug
( O O
500 O O
mg O O
every O O
8 O O
hrs O O
) O O

In O O
the O O
present O O
study O O
, O O
evoked O O
potentials O O
were O O
recorded O O
at O O
5 O O
, O O
20 O O
, O O
and O O
40 O O
min O O
following O O
IP O O
injections O O
of O O
saline O O
, O O
ethanol B-drug B-drug
( O O
2.0 O O
g/kg O O
) O O
, O O
physostigmine B-drug B-drug
( O O
0.6 O O
mg/kg O O
) O O
or O O
atropine B-drug B-drug
( O O
15.0 O O
mg/kg O O
) O O
on O O
separate O O
days O O
. O O

There O O
is O O
little O O
if O O
any O O
clinically O O
significant O O
interaction O O
between O O
Acarbose B-drug B-drug
and O O
metformin B-drug B-drug
. O O

Edema O O
has O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
Itraconazole B-drug B-drug
and O O
dihydropyridine B-group B-group
calcium I-group I-group
channel I-group I-group
blockers I-group I-group
. O O

Thyroid O O
hormonal O O
replacement O O
increases O O
metabolic O O
rate O O
, O O
which O O
requires O O
an O O
increase O O
in O O
digitalis B-group B-group
dosage O O
. O O

No O O
dose O O
adjustment O O
is O O
necessary O O
. O O

Antihypertensives B-group B-group
: O O
Amphetamines B-group B-group
may O O
antagonize O O
the O O
hypotensive O O
effects O O
of O O
antihypertensives B-group B-group
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

Caution O O
should O O
be O O
exercised O O
if O O
LEUSTATIN B-brand B-brand
Injection O O
is O O
administered O O
before O O
, O O
after O O
, O O
or O O
in O O
conjunction O O
with O O
other O O
drugs O O
known O O
to O O
cause O O
immunosuppression O O
or O O
myelosuppression O O
. O O

As O O
a O O
false-negative O O
result O O
may O O
occur O O
in O O
the O O
ferricyanide O O
test O O
, O O
it O O
is O O
recommended O O
that O O
either O O
the O O
glucose O O
oxidase O O
or O O
hexokinase O O
method O O
be O O
used O O
to O O
determine O O
blood/plasma O O
glucose O O
levels O O
in O O
patients O O
receiving O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
. O O

No O O
significant O O
interactions O O
with O O
digoxin B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
hydralazine B-drug B-drug
, O O
sulfinpyrazone B-drug B-drug
, O O
oral O O
contraceptives B-group B-group
, O O
tolbutamide B-drug B-drug
, O O
or O O
warfarin B-drug B-drug
have O O
been O O
observed O O
. O O

The O O
high O O
acquisition O O
cost O O
of O O
olanzapine B-drug B-drug
is O O
offset O O
by O O
reductions O O
in O O
other O O
treatment O O
costs O O
( O O
inpatient O O
and/or O O
outpatient O O
services O O
) O O
of O O
schizophrenia O O
. O O

The O O
daily O O
dose O O
of O O
ENABLEX B-brand B-brand
should O O
not O O
exceed O O
7.5 O O
mg O O
when O O
coadministered O O
with O O
potent O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
clarithromycin B-drug B-drug
and O O
nefazadone O O
) O O
. O O

Treatment O O
of O O
the O O
glands O O
with O O
cytochalasin B-drug_n B-drug_n
D I-drug_n I-drug_n
redistributed O O
type O O
3 O O
inositol O O
1,4,5-trisphosphate O O
receptor O O
( O O
the O O
major O O
subtype O O
in O O
the O O
parietal O O
cell O O
) O O
from O O
the O O
fraction O O
containing O O
membranes O O
of O O
large O O
size O O
to O O
the O O
microsomal O O
fraction O O
, O O
suggesting O O
a O O
dissociation O O
of O O
the O O
store O O
from O O
the O O
plasma O O
membrane O O
. O O

diuretics* B-group B-group
; O O

It O O
is O O
presently O O
not O O
known O O
whether O O
these O O
same O O
drug O O
interactions O O
occur O O
with O O
dirithromycin B-drug B-drug
. O O

Doxazosin B-drug B-drug
mesylate I-drug I-drug
has O O
been O O
administered O O
without O O
any O O
evidence O O
of O O
an O O
adverse O O
drug O O
interaction O O
to O O
patients O O
receiving O O
thiazide B-group B-group
diuretics I-group I-group
, O O
beta-blocking B-group B-group
agents O I-group
, O O
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
. O O

Viable O O
counts O O
for O O
type O O
culture O O
E O O
. O O

The O O
concurrent O O
use O O
of O O
drugs O O
from O O
these O O
groups O O
is O O
decreasing O O
according O O
to O O
a O O
survey O O
of O O
200 O O
hospital O O
medical O O
records O O
. O O

Nephrotoxicity O O
associated O O
with O O
cyclosporine B-drug B-drug
may O O
also O O
be O O
enhanced O O
. O O

Pretreatment O O
of O O
megakaryocytes O O
with O O
extracellular O O
RR B-drug_n B-drug_n
( O O
50 O O
microM O O
) O O
also O O
inhibited O O
InsP B-drug_n B-drug_n
( I-drug_n I-drug_n
3 I-drug_n I-drug_n
) I-drug_n I-drug_n
-induced O O
responses O O
. O O

Dopamine B-group B-group
Antagonists I-group I-group
: O O
Since O O
apomorphine B-drug B-drug
is O O
a O O
dopamine B-group B-group
agonist I-group I-group
, O O
it O O
is O O
possible O O
that O O
dopamine B-group B-group
antagonists I-group I-group
, O O
such O O
as O O
the O O
neuroleptics B-group B-group
( O O
phenothiazines B-group B-group
, O O
butyrophenones B-group B-group
, O O
thioxanthenes B-group B-group
) O O
or O O
metoclopramide B-drug B-drug
, O O
may O O
diminish O O
the O O
effectiveness O O
of O O
APOKYN B-brand B-brand
. O O

If O O
such O O
drugs O O
are O O
needed O O
, O O
their O O
dose O O
should O O
be O O
reassessed O O
and O O
, O O
where O O
appropriate O O
, O O
plasma O O
concentration O O
measured O O
. O O

The O O
AUC O O
of O O
midazolam B-drug B-drug
on O O
Day O O
15 O O
was O O
similar O O
to O O
that O O
observed O O
at O O
baseline O O
. O O

5 O O
. O O

Appropriate O O
doses O O
for O O
this O O
combination O O
arenot O O
established O O
, O O
but O O
an O O
increase O O
in O O
thedosage O O
of O O
indinavir B-drug B-drug
may O O
be O O
required O O
. O O

They O O
are O O
part O O
of O O
the O O
treatment O O
of O O
patients O O
with O O
organ O O
transplants O O
, O O
malignancy O O
, O O
and O O
increasingly O O
those O O
with O O
conditions O O
such O O
as O O
psoriasis O O
, O O
rheumatoid O O
arthritis O O
, O O
and O O
liver O O
and O O
bowel O O
disease O O
in O O
which O O
inflammation O O
is O O
an O O
aetiological O O
factor O O
. O O

Phenytoin B-drug B-drug
: O O
Etodolac B-drug B-drug
has O O
no O O
apparent O O
pharmacokinetic O O
interaction O O
when O O
administered O O
with O O
phenytoin B-drug B-drug
. O O

Concomitant O O
use O O
of O O
HIVID B-drug B-drug
with O O
didanosine B-drug B-drug
is O O
not O O
recommended O O
. O O

Under O O
similar O O
conditions O O
, O O
bexarotene B-drug B-drug
concentrations O O
were O O
not O O
affected O O
by O O
concomitant O O
atorvastatin B-drug B-drug
administration O O
. O O

Increased O O
stability O O
of O O
nucleophosmin/B23 O O
in O O
anti-apoptotic O O
effect O O
of O O
ras O O
during O O
serum O O
deprivation O O
. O O

H2 B-group B-group
Receptor I-group I-group
Antagonists I-group I-group
: O O
Cimetidine B-drug B-drug
coadministration O O
leads O O
to O O
an O O
increased O O
peak O O
plasma O O
concentration O O
and O O
AUC O O
of O O
cisapride B-drug B-drug
, O O
there O O
is O O
no O O
effect O O
on O O
cisapride B-drug B-drug
absorption O O
when O O
it O O
is O O
coadministered O O
with O O
ranitidine B-drug B-drug
. O O

Pentamidine B-drug B-drug
may O O
cause O O
hypoglycemia O O
, O O
which O O
may O O
sometimes O O
be O O
followed O O
by O O
hyperglycemia O O
. O O

However O O
, O O
concomitant O O
administration O O
of O O
aspirin B-brand B-brand
with O O
CELEBREX B-brand B-brand
may O O
result O O
in O O
an O O
increased O O
rate O O
of O O
GI O O
ulceration O O
or O O
other O O
complications O O
, O O
compared O O
to O O
use O O
of O O
CELEBREX B-brand B-brand
alone O O
. O O

Another O O
investigator O O
found O O
no O O
increase O O
in O O
digoxin B-drug B-drug
levels O O
in O O
13 O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

If O O
additional O O
adrenergic B-group B-group
drugs I-group I-group
are O O
to O O
be O O
administered O O
by O O
any O O
route O O
, O O
they O O
should O O
be O O
used O O
with O O
caution O O
because O O
the O O
pharmacologically O O
predictable O O
sympathetic O O
effects O O
of O O
BROVANA B-brand B-brand
may O O
be O O
potentiated O O
. O O

Based O O
on O O
this O O
reported O O
activity O O
, O O
they O O
should O O
not O O
be O O
given O O
concomitantly O O
with O O
Coly-Mycin B-brand B-brand
M I-brand I-brand
Parenteral O O
except O O
with O O
the O O
greatest O O
caution O O
. O O

No O O
changes O O
were O O
observed O O
in O O
the O O
degree O O
of O O
anticoagulation O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

However O O
, O O
because O O
higher O O
doses O O
( O O
up O O
to O O
360 O O
mg O O
QD O O
) O O
of O O
omeprazole B-drug B-drug
are O O
tolerated O O
in O O
Zollinger-Ellison O O
( O O
ZE O O
) O O
patients O O
, O O
no O O
dose O O
adjustment O O
for O O
omeprazole B-drug B-drug
is O O
recommended O O
at O O
current O O
doses O O
. O O

After O O
14 O O
days O O
of O O
co-administration O O
, O O
mean O O
trough O O
concentrations O O
of O O
clozapine B-drug B-drug
and O O
its O O
metabolites O O
, O O
N-desmethylclozapine B-drug_n B-drug_n
and O O
clozapine B-drug_n B-drug_n
N-oxide I-drug_n I-drug_n
, O O
were O O
elevated O O
with O O
fluvoxamine B-drug B-drug
by O O
about O O
three-fold O O
compared O O
to O O
baseline O O
concentrations O O
. O O

In O O
a O O
study O O
involving O O
healthy O O
subjects O O
receiving O O
TAMBOCOR B-brand B-brand
and O O
propranolol B-drug B-drug
concurrently O O
, O O
plasma O O
flecainide B-drug B-drug
levels O O
were O O
increased O O
about O O
20 O O
% O O
and O O
propranolol B-drug B-drug
levels O O
were O O
increased O O
about O O
30 O O
% O O
compared O O
to O O
control O O
values O O
. O O

Because O O
of O O
its O O
lack O O
of O O
anti-platelet O O
effect O O
valdecoxib B-drug B-drug
is O O
not O O
a O O
substitute O O
for O O
aspirin B-brand B-brand
for O O
cardiovascular O O
prophylaxis O O
. O O

The O O
management O O
of O O
infection O O
is O O
dealt O O
with O O
as O O
a O O
separate O O
section O O
. O O

diuretics* B-group B-group
; O O

Patients O O
should O O
be O O
advised O O
against O O
the O O
simultaneous O O
use O O
of O O
other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
, O O
and O O
cautioned O O
that O O
the O O
effect O O
of O O
alcohol B-drug B-drug
may O O
be O O
increased O O
. O O

OTHER O O
CONCOMITANT O O
THERAPY O O
: O O
Although O O
specific O O
interaction O O
studies O O
were O O
not O O
performed O O
, O O
in O O
clinical O O
studies O O
, O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
was O O
used O O
concomitantly O O
with O O
angiotensin- B-group B-group
converting I-group I-group
enzyme I-group I-group
( I-group I-group
ACE I-group I-group
) I-group I-group
inhibitors I-group I-group
, O O
betablockers B-group B-group
, O O
calcium-channel B-group B-group
blockers I-group I-group
, O O
diuretics B-group B-group
, O O
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

Known O O
drug O O
interactions O O
include O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
and O O
alcohol B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
drugs O O
possessing O O
nephrotoxic O O
( O O
e.g. O O
, O O
aminoglycosides B-group B-group
, O O
indomethacin B-drug B-drug
) O O
, O O
myelotoxic O O
( O O
e.g. O O
, O O
cytotoxic B-group O
chemotherapy O O
) O O
, O O
cardiotoxic O O
( O O
e.g. O O
, O O
doxorubicin B-drug B-drug
) O O
or O O
hepatotoxic O O
( O O
e.g. O O
, O O
methotrexate B-drug B-drug
, O O
asparaginase B-drug B-brand
) O O
effects O O
with O O
PROLEUKIN B-brand B-brand
may O O
increase O O
toxicity O O
in O O
these O O
organ O O
systems O O
. O O

PCP B-drug_n B-drug_n
produced O O
distinctive O O
effects O O
in O O
each O O
task O O
: O O
it O O
substituted O O
for O O
the O O
training O O
dose O O
in O O
PCP B-drug_n B-drug_n
discrimination O O
and O O
it O O
increased O O
the O O
number O O
of O O
responses O O
with O O
short O O
( O O
< O O
3 O O
s O O
) O O
interresponse O O
times O O
as O O
well O O
as O O
increasing O O
overall O O
response O O
rates O O
in O O
the O O
DRL O O
schedule O O
. O O

Eprosartan B-drug B-drug
( O O
up O O
to O O
400 O O
mg O O
b.i.d O O
. O O
or O O
800 O O
mg O O
q.d O O
. O O
) O O
doses O O
have O O
been O O
safely O O
used O O
concomitantly O O
with O O
a O O
thiazide B-group B-group
diuretic I-group I-group
( O O
hydrochlorothiazide B-drug B-drug
) O O
. O O

clinical O O
significance O O
unknown O O
. O O

Because O O
candesartan B-drug B-drug
is O O
not O O
significantly O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
and O O
at O O
therapeutic O O
concentrations O O
has O O
no O O
effects O O
on O O
P450 O O
enzymes O O
, O O
interactions O O
with O O
drugs O O
that O O
inhibit O O
or O O
are O O
metabolized O O
by O O
those O O
enzymes O O
would O O
not O O
be O O
expected O O
. O O

The O O
AUC O O
and O O
Cmax O O
of O O
descarboethoxyloratadine B-drug_n B-drug_n
, O O
an O O
active O O
metabolite O O
, O O
averaged O O
155 O O
% O O
( O O
27 O O
S.D O O
. O O
) O O
and O O
141 O O
% O O
( O O
35 O O
S.D O O
. O O
) O O
, O O
respectively O O
. O O

No O O
significant O O
difference O O
was O O
found O O
between O O
the O O
mean O O
values O O
of O O
the O O
volume O O
of O O
distribution O O
of O O
cloxacillin B-drug B-drug
with O O
and O O
without O O
probenecid B-drug B-drug
( O O
13.0 O O
and O O
12.6 O O
liters O O
, O O
respectively O O
) O O
. O O

Toxicity O O
of O O
cadmium O O
and O O
zinc B-drug B-drug
to O O
miracidia O O
of O O
Schistosoma O O
mansoni O O
. O O

Rifampicin B-drug B-drug
: O O
In O O
a O O
study O O
in O O
healthy O O
volunteers O O
, O O
a O O
six-day O O
course O O
of O O
rifampicin B-drug B-drug
at O O
600 O O
mg/day O O
followed O O
by O O
a O O
single O O
5 O O
mg O O
dose O O
of O O
isradipine B-drug B-drug
resulted O O
in O O
a O O
reduction O O
in O O
isradipine B-drug B-drug
levels O O
to O O
below O O
detectable O O
limits O O
. O O

and O O
, O O
rarely O O
, O O
euphoria O O
, O O
excitement O O
, O O
depression O O
, O O
hallucinations O O
, O O
paresthesia O O
, O O
muscle O O
pain O O
, O O
tinnitus O O
, O O
slurred O O
speech O O
, O O
coordination O O
disorder O O
, O O
tremor O O
, O O
rigidity O O
, O O
dystonia O O
, O O
ataxia O O
, O O
blurred O O
vision O O
, O O
nystagmus O O
, O O
strabismus O O
, O O
miosis O O
, O O
mydriasis O O
, O O
diplopia O O
, O O
dysarthria O O
, O O
epileptic O O
seizure O O
. O O

Cholecystokinin O O
octapeptide O O
is O O
a O O
necessary O O
factor O O
for O O
realization O O
of O O
this O O
action O O
of O O
neuroleptics B-group B-group
. O O

Menstrual O O
cycle O O
irregularities O O
were O O
accompanied O O
by O O
both O O
a O O
decrease O O
and O O
delay O O
in O O
the O O
peak O O
17b O O
-estradiol O O
and O O
progesterone O O
levels O O
following O O
administration O O
of O O
PEGASYS B-brand B-brand
to O O
female O O
monkeys O O
. O O

HMG-CoA B-group B-group
Reductase I-group I-group
Inhibitors I-group I-group
: O O
Inhibitors B-group B-group
of I-group I-group
HMG-CoA I-group I-group
reductase I-group I-group
may O O
cause O O
myopathy O O
, O O
which O O
is O O
manifested O O
as O O
muscle O O
pain O O
or O O
weakness O O
associated O O
with O O
elevated O O
levels O O
of O O
CPK O O
. O O

Although O O
the O O
clinical O O
significance O O
of O O
these O O
effects O O
is O O
not O O
known O O
, O O
caution O O
is O O
advised O O
in O O
the O O
co-administration O O
of O O
beta-agonists B-group B-group
with O O
non-potassium B-group B-group
sparing I-group I-group
diuretics I-group I-group
. O O

Since O O
animal O O
studies O O
suggest O O
that O O
the O O
action O O
of O O
barbiturates B-group B-group
may O O
be O O
prolonged O O
by O O
therapy O O
with O O
chlorpropamide B-drug B-drug
, O O
barbiturates B-group B-group
should O O
be O O
employed O O
with O O
caution O O
. O O

Antihistamines B-group B-group
may O O
have O O
additive O O
effects O O
with O O
alcohol B-drug B-drug
and O O
other O O
CNS B-group B-group
depressants I-group I-group
, O O
e.g. O O
, O O
hypnotics B-group B-group
, O O
sedatives B-group B-group
, O O
tranquilizers B-group B-group
, O O
antianxiety B-group B-group
agents I-group I-group
. O O

Upon O O
administration O O
of O O
10 O O
mg O O
of O O
Vardenafil B-drug B-drug
with O O
800 O O
mg O O
TID O O
indinavir B-drug B-drug
, O O
the O O
Cmax O O
and O O
AUC O O
of O O
indinavir B-drug B-drug
were O O
reduced O O
by O O
40 O O
% O O
and O O
30 O O
% O O
, O O
respectively O O
. O O

Interaction O O
of O O
clindamycin B-drug B-drug
and O O
gentamicin B-drug B-drug
in O O
vitro O O
. O O

Anafranil B-brand B-brand
should O O
not O O
be O O
used O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Respiratory O O
depression O O
, O O
hypotension O O
, O O
and O O
profound O O
sedation O O
or O O
coma O O
may O O
occur O O
. O O

Therefore O O
, O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
levels O O
should O O
be O O
considered O O
and O O
dosage O O
of O O
theophylline B-drug B-drug
adjusted O O
as O O
required O O
. O O

These O O
results O O
suggest O O
that O O
oral O O
administration O O
of O O
dmPGE2 B-drug_n B-drug_n
induces O O
a O O
more O O
pronounced O O
secretory O O
diarrhea O O
in O O
cecectomized O O
than O O
in O O
control O O
rats O O
, O O
probably O O
due O O
to O O
the O O
lack O O
of O O
the O O
reservoir O O
function O O
of O O
the O O
cecum O O
in O O
the O O
operated O O
animals O O
. O O

Caution O O
should O O
be O O
used O O
when O O
CYP3A4 B-drug O
inhibitors O O
are O O
co-administered O O
with O O
felodipine B-drug B-drug
. O O

The O O
actions O O
of O O
the O O
benzodiazepines B-group B-group
may O O
be O O
potentiated O O
by O O
barbiturates B-group B-group
, O O
narcotics B-group B-group
, O O
phenothiazines B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
or O O
other O O
antidepressants B-group B-group
. O O

Effects O O
of O O
Erythromycin B-drug B-drug
on O O
Felbatol B-brand B-brand
The O O
coadministration O O
of O O
erythromycin B-drug B-drug
( O O
1000 O O
mg/day O O
) O O
for O O
10 O O
days O O
did O O
not O O
alter O O
the O O
pharmacokinetic O O
parameters O O
of O O
Cmax O O
, O O
Cmin O O
, O O
AUC O O
, O O
CI/kg O O
or O O
tmax O O
at O O
felbamate B-drug B-drug
daily O O
doses O O
of O O
3000 O O
or O O
3600 O O
mg/day O O
in O O
10 O O
otherwise O O
healthy O O
subjects O O
with O O
epilepsy O O
. O O

Small O O
differences O O
in O O
sensitivity O O
to O O
chemotherapy O O
can O O
have O O
a O O
dramatic O O
effect O O
on O O
cure O O
rates O O
, O O
and O O
therefore O O
subtle O O
cell O O
type-specific O O
differences O O
may O O
be O O
important O O
determinants O O
of O O
drug O O
sensitivity O O
. O O

Potassium O B-group
sparing O I-group
agents O I-group
should O O
generally O O
not O O
be O O
used O O
in O O
patients O O
with O O
heart O O
failure O O
who O O
are O O
receiving O O
PRINIVIL B-brand B-brand
. O O

Methotrexate B-drug B-drug
: O O
Valdecoxib B-drug B-drug
10 I-drug O
mg I-drug O
BID O O
did O O
not O O
show O O
a O O
significant O O
effect O O
on O O
the O O
plasma O O
exposure O O
or O O
renal O O
clearance O O
of O O
methotrexate B-drug B-drug
. O O

Medications O O
that O O
interfere O O
with O O
your O O
bodys O O
ability O O
to O O
use O O
folate O O
may O O
also O O
increase O O
the O O
need O O
for O O
this O O
vitamin B-group O
. O O

Effect O O
of O O
estradiol B-drug B-drug
on O O
endotoxin-induced B-drug_n B-drug_n
changes O O
in O O
steroid O O
hormone O O
levels O O
and O O
lethality O O
in O O
male O O
rats O O
. O O

In O O
noradrenaline-precontracted B-drug B-drug
arteries O O
from O O
dietary-obese O O
rats O O
, O O
responses O O
to O O
resveratrol B-drug_n B-drug_n
were O O
not O O
attenuated O O
by O O
endothelial O O
denudation O O
, O O
indicating O O
an O O
action O O
independent O O
of O O
the O O
endothelium O O
. O O

Nelfinavir I-drug B-drug
M8 O O

Drug/Laboratory O O
Test O O
Interactions O O

d-amphetamine B-drug B-drug
with O O
desipramine B-drug B-drug
or O O
protriptyline B-drug B-drug
and O O
possibly O O
other O O
tricyclics B-group B-group
cause O O
striking O O
and O O
sustained O O
increases O O
in O O
the O O
concentration O O
of O O
d-amphetamine B-drug B-drug
in O O
the O O
brain O O
; O O

In O O
vitro O O
studies O O
were O O
conducted O O
to O O
investigate O O
the O O
potential O O
of O O
gabapentin B-drug B-drug
to O O
inhibit O O
the O O
major O O
cytochrome O O
P450 O O
enzymes O O
( O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
and O O
CYP3A4 O O
) O O
that O O
mediate O O
drug O O
and O O
xenobiotic O O
metabolism O O
using O O
isoform O O
selective O O
marker O O
substrates O O
and O O
human O O
liver O O
microsomal O O
preparations O O
. O O

Careful O O
supervision O O
of O O
diabetic O O
patients O O
under O O
treatment O O
with O O
Soriatane B-brand B-brand
is O O
recommended O O
. O O

The O O
potential O O
for O O
clinically O O
significant O O
drug-drug O O
interactions O O
posed O O
by O O
dolasetron B-drug B-drug
and O O
hydrodolasetron B-drug_n B-drug_n
appears O O
to O O
be O O
low O O
for O O
drugs O O
commonly O O
used O O
in O O
chemotherapy O O
or O O
surgery O O
, O O
because O O
hydrodolasetron B-drug_n B-drug_n
is O O
eliminated O O
by O O
multiple O O
routes O O
. O O

Aspirin B-brand B-brand
: O O
Concomitant O O
aspirin B-brand B-brand
may O O
decrease O O
the O O
metabolic O O
clearance O O
of O O
nicotinic B-drug B-drug
acid I-drug I-drug
. O O

During O O
clinical O O
trials O O
, O O
hypoglycemia O O
and O O
hyperglycemia O O
were O O
reported O O
in O O
diabetic O O
patients O O
receiving O O
oral O O
hypoglycemics B-group B-group
. O O

use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

Administration O O
of O O
a O O
5 O O
g O O
bolus O O
followed O O
by O O
1 O O
to O O
1.25 O O
g/hr O O
should O O
achieve O O
and O O
sustain O O
plasma O O
levels O O
of O O
0.13 O O
mg/mL O O
. O O

Dose O O
reduction O O
of O O
CRIXIVAN B-brand B-brand
to O O
600 O O
mg O O
every O O
8 O O
hours O O
should O O
be O O
considered O O
. O O

Therefore O O
, O O
a O O
starting O O
daily O O
dose O O
of O O
25 O O
mg O O
of O O
VIOXX B-brand B-brand
should O O
be O O
considered O O
for O O
the O O
treatment O O
of O O
osteoarthritis O O
when O O
VIOXX B-brand B-brand
is O O
co-administered O O
with O O
potent O O
inducers O O
of O O
hepatic O O
metabolism O O
. O O

Influence O O
of O O
Trileptal B-brand B-brand
on O O
AED B-group B-group
Concentration O O
( O O
Mean O O
change O O
, O O
90 O O
% O O
Confidence O O
Interval O O
) O O

Although O O
these O O
results O O
do O O
not O O
indicate O O
a O O
significant O O
interaction O O
between O O
TORADOL B-brand B-brand
and O O
warfarin B-drug B-drug
or O O
heparin B-drug B-drug
, O O
the O O
administration O O
of O O
TORADOL B-brand B-brand
to O O
patients O O
taking O O
anticoagulants B-group B-group
should O O
be O O
done O O
extremely O O
cautiously O O
, O O
and O O
patients O O
should O O
be O O
closely O O
monitored O O
. O O

The O O
decision O O
to O O
prescribe O O
this O O
agent O O
should O O
include O O
such O O
considerations O O
as O O
the O O
cost-risk-benefit O O
balance O O
, O O
patient O O
access O O
, O O
drug O O
distribution O O
pathways O O
, O O
and O O
prescription O O
drug O O
coverage O O
. O O

Aspirin/Acetaminophen B-brand B-brand
: O O
Pharmacokinetic O O
or O O
pharmacodynamic O O
drug-drug O O
interactions O O
have O O
not O O
been O O
demonstrated O O
between O O
Argatroban B-drug B-drug
and O O
concomitantly O O
administered O O
aspirin B-brand B-brand
( O O
162.5 O O
mg O O
orally O O
given O O
26 O O
and O O
2 O O
hours O O
prior O O
to O O
initiation O O
of O O
Argatroban B-drug B-drug
1 O O
g/kg/min O O
. O O
over O O
4 O O
hours O O
) O O
or O O
acetaminophen B-drug B-drug
( O O
1000 O O
mg O O
orally O O
given O O
12 O O
, O O
6 O O
and O O
0 O O
hours O O
prior O O
to O O
, O O
and O O
6 O O
and O O
12 O O
hours O O
subsequent O O
to O O
, O O
initiation O O
of O O
Argatroban B-drug B-drug
1.5 O O
g/kg/min O O
. O O
over O O
18 O O
hours O O
) O O
. O O

Pregnancy O O
Pregnancy O O
: O O
Category O O
C O O
PEGASYS B-brand B-brand
has O O
not O O
been O O
studied O O
for O O
its O O
teratogenic O O
effect O O
. O O

Intravenous O O
ranitidine B-drug B-drug
was O O
shown O O
to O O
double O O
the O O
bioavailability O O
of O O
oral O O
alendronate B-drug B-drug
. O O

Caution O O
is O O
advised O O
if O O
patients O O
receive O O
large O O
doses O O
of O O
ethchlorvynol B-drug B-drug
concurrently O O
. O O

Chlorprothixene B-drug B-drug
may O O
increase O O
the O O
plasma-level O O
of O O
concomitantly O O
given O O
lithium B-drug B-drug
. O O

Genetic O O
variation O O
in O O
metabolism O O
may O O
result O O
in O O
high O O
concentrations O O
of O O
drugs O O
and O O
an O O
increased O O
risk O O
of O O
adverse O O
effects O O
in O O
slow O O
metabolizers O O
, O O
which O O
is O O
important O O
when O O
using O O
for O O
example O O
antidepressants B-group B-group
or O O
chemotherapy O O
. O O

Ampicillin/Amoxicillin B-drug B-drug
: O O
An O O
increase O O
in O O
the O O
frequency O O
of O O
skin O O
rash O O
has O O
been O O
reported O O
among O O
patients O O
receiving O O
ampicillin B-drug B-drug
or O O
amoxicillin B-drug B-drug
concurrently O O
with O O
allopurinol B-drug B-drug
compared O O
to O O
patients O O
who O O
are O O
not O O
receiving O O
both O O
drugs O O
. O O

Hyperglycemia O O
has O O
also O O
been O O
reported O O
in O O
patients O O
receiving O O
CAMPTOSAR B-brand B-brand
. O O

Until O O
further O O
data O O
are O O
developed O O
regarding O O
drug O O
interactions O O
when O O
azithromycin B-drug B-drug
and O O
these O O
drugs O O
are O O
used O O
concomitantly O O
, O O
careful O O
monitoring O O
of O O
patients O O
is O O
advised O O
: O O
Digoxin B-drug B-drug
elevated O O
digoxin B-drug B-drug
concentrations O O
. O O

Oral O O
Contraceptives B-group B-group
Multiple O O
doses O O
of O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
, O O
the O O
estrogenic O O
component O O
in O O
most O O
oral O O
contraceptives B-group B-group
. O O

When O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
is O O
used O O
at O O
the O O
same O O
time O O
as O O
other O O
medicines O O
or O O
substances O O
the O O
following O O
interactions O O
must O O
be O O
taken O O
into O O
account O O
: O O
- O O
Bezalip B-brand B-brand
and O O
Bezalip B-brand B-brand
retard I-brand I-brand
may O O
enhance O O
the O O
action O O
of O O
anticoagulants B-group B-group
of I-group I-group
the I-group I-group
coumarin I-group I-group
type I-group I-group
. O O

Oral O O
Contraceptives B-group B-group
: O O
The O O
effect O O
of O O
oral O O
contraceptives B-group B-group
on O O
the O O
pharmacokinetics O O
of O O
D.H.E B-brand B-brand
. I-brand I-brand
45 I-brand I-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
has O O
not O O
been O O
studied O O
. O O

Reduced O O
response O O
to O O
metyrapone O O
test O O
. O O

About O O
three O O
weeks O O
prior O O
to O O
admission O O
, O O
the O O
patient O O
was O O
started O O
on O O
clarithromycin B-drug B-drug
for O O
sinusitis O O
. O O

The O O
unrestricted O O
use O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
for O O
these O O
purposes O O
can O O
not O O
be O O
advocated O O
on O O
the O O
basis O O
of O O
the O O
evidence O O
currently O O
available O O
. O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
propafenone B-drug B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

Nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group

Drugs O O
that O O
have O O
been O O
reported O O
to O O
diminish O O
oral O O
anticoagulant B-group B-group
response O O
, O O
ie O O
, O O
decreased O O
prothrom-bin O O
time O O
response O O
, O O
in O O
man O O
significantly O O
include O O
: O O
adrenocortical B-group B-group
steroids I-group I-group
; O O
alcohol* B-drug B-drug
; O O
antacids B-group B-group
; O O
antihistamines B-group B-group
; O O
barbiturates B-group B-group
; O O
carbamazepine B-drug B-drug
; O O
chloral B-drug B-drug
hydrate* O O
; O O
chlordiazepoxide B-drug B-drug
; O O
cholestyramine B-drug B-drug
; O O
diet O O
high O O
in O O
vitamin B-group B-group
K I-group I-group
; O O
diuretics* B-group B-group
; O O
ethchlorvynol B-drug B-drug
; O O
glutethimide B-drug B-drug
; O O
griseofulvin B-drug B-drug
; O O
haloperidol B-drug B-drug
; O O
meprobamate B-drug B-drug
; O O
oral O O
contraceptives B-group B-group
; O O
paraldehyde B-drug B-drug
; O O
primidone B-drug B-drug
; O O
ranitidine* B-drug B-drug
; O O
rifampin B-drug B-drug
; O O
unreliable O O
prothrombin O O
time O O
determinations O O
; O O
vitamin B-drug B-drug
C I-drug I-drug
; O O
warfarin B-drug B-drug
sodium I-drug I-drug
under-dosage O O
. O O

This O O
transient O O
hypotensive O O
response O O
is O O
not O O
a O O
contraindication O O
to O O
further O O
doses O O
which O O
can O O
be O O
given O O
without O O
difficulty O O
once O O
the O O
blood O O
pressure O O
has O O
increased O O
after O O
volume O O
expansion O O
. O O

Human O O
pharmacokinetics O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-drug B-drug
potently O O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
resulting O O
in O O
an O O
eight-fold O O
increase O O
in O O
the O O
mean O O
AUC O O
of O O
cisapride B-drug B-drug
. O O

Increasing O O
the O O
felbamate B-drug B-drug
dose O O
to O O
1800 O O
mg/day O O
in O O
six O O
of O O
these O O
subjects O O
increased O O
the O O
steady-state O O
phenytoin B-drug B-drug
Cmin O O
to O O
25 O O
7 O O
micrograms/mL O O
. O O

Literature O O
reports O O
suggest O O
that O O
oral O O
calcium B-group B-group
antagonists I-group I-group
may O O
be O O
used O O
in O O
combination O O
with O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
when O O
heart O O
function O O
is O O
normal O O
, O O
but O O
should O O
be O O
avoided O O
in O O
patients O O
with O O
impaired O O
cardiac O O
function O O
. O O

The O O
effect O O
of O O
temperature O O
changes O O
on O O
the O O
number O O
of O O
microtubules O O
in O O
non-myelinated O O
axons O O
has O O
been O O
studied O O
in O O
cat O O
inferior O O
mesenteric O O
ganglion/hypogastric O O
nerve O O
preparations O O
incubated O O
at O O
various O O
temperatures O O
in O O
Eagles O O
minimal O O
essential O O
tissue O O
culture O O
medium O O
in O O
vitro O O
. O O

Administration O O
of O O
thiazide B-group B-group
diuretics I-group I-group
to O O
hypoparathyroid O O
patients O O
who O O
are O O
concurrently O O
being O O
treated O O
with O O
ergocalciferol B-drug B-drug
may O O
cause O O
hypercalcemia O O
. O O

Until O O
further O O
data O O
are O O
available O O
regarding O O
the O O
potential O O
interaction O O
of O O
dirithromycin B-drug B-drug
with O O
these O O
compounds O O
, O O
caution O O
should O O
be O O
used O O
during O O
coadministration O O
. O O

Restoration O O
of O O
vancomycin B-drug B-drug
susceptibility O O
in O O
Enterococcus O O
faecalis O O
by O O
antiresistance O O
determinant O O
gene O O
transfer O O
. O O

Other O O
common O O
adverse O O
reactions O O
are O O
dizziness O O
( O O
5-15 O O
% O O
) O O
, O O
weakness O O
( O O
5-15 O O
% O O
) O O
and O O
fatigue O O
( O O
2-4 O O
% O O
) O O
. O O

Interactions O O
with O O
other O O
drugs O O
metabolized O O
by O O
this O O
enzyme O O
could O O
potentially O O
occur O O
. O O

Further O O
, O O
designs O O
can O O
be O O
expressed O O
in O O
terms O O
of O O
proportionate O O
responses O O
associated O O
with O O
the O O
individual O O
compounds O O
rather O O
than O O
dose O O
levels O O
, O O
thereby O O
providing O O
for O O
results O O
that O O
are O O
applicable O O
across O O
compounds O O
. O O

therefore O O
, O O
the O O
disposition O O
of O O
zaleplon B-drug B-drug
is O O
not O O
expected O O
to O O
be O O
sensitive O O
to O O
alterations O O
in O O
protein O O
binding O O
. O O

The O O
potential O O
for O O
drug-drug O O
interaction O O
with O O
drugs O O
affected O O
by O O
cytochrome O O
P450 O O
enzymes O O
may O O
not O O
be O O
ruled O O
out O O
. O O

dermatitis O O

Lithium B-drug B-drug
: O O
In O O
a O O
study O O
conducted O O
in O O
healthy O O
subjects O O
, O O
mean O O
steady-state O O
lithium B-drug B-drug
plasma O O
levels O O
increased O O
approximately O O
17 O O
% O O
in O O
subjects O O
receiving O O
lithium B-drug B-drug
450 O O
mg O O
BID O O
with O O
CELEBREX B-brand B-brand
200 O O
mg O O
BID O O
as O O
compared O O
to O O
subjects O O
receiving O O
lithium B-drug B-drug
alone O O
. O O

In O O
situations O O
when O O
concurrent O O
therapy O O
is O O
necessary O O
, O O
careful O O
patient O O
monitoring O O
is O O
essential O O
. O O

Phosphate-Binding O O
Agents O O
: O O
Since O O
vitamin B-group B-group
D I-group I-group
also O O
has O O
an O O
effect O O
on O O
phosphate O O
transport O O
in O O
the O O
intestine O O
, O O
kidneys O O
and O O
bones O O
, O O
the O O
dosage O O
of O O
phosphate-binding O O
agents O O
must O O
be O O
adjusted O O
in O O
accordance O O
with O O
the O O
serum O O
phosphate O O
concentration O O
. O O

or O O
with O O
multivitamins B-group B-group
containing O O
zinc B-drug B-drug
may O O
substantially O O
interfere O O
with O O
drug O O
absorption O O
and O O
result O O
in O O
insufficient O O
plasma O O
and O O
tissue O O
quinolone B-group B-group
concentrations O O
. O O

Similarly O O
, O O
patients O O
receiving O O
the O O
drug O O
and O O
a O O
hydantoin B-group B-drug
, O O
sulfonamide B-group B-group
or O O
sulfonylurea B-group B-group
should O O
be O O
observed O O
for O O
signs O O
of O O
toxicity O O
to O O
these O O
drugs O O
. O O

Antipyrine B-drug B-drug
: O O
Antipyrine B-drug B-drug
pharmacokinetics O O
were O O
not O O
significantly O O
different O O
before O O
and O O
after O O
tiagabine B-drug B-drug
multiple-dose O O
regimens O O
. O O

Phenytoin B-drug B-drug
: O O
In O O
a O O
single O O
( O O
400 O O
mg O O
) O O
and O O
multiple O O
dose O O
( O O
400 O O
mg O O
TID O O
) O O
study O O
of O O
Neurontin B-brand B-brand
in O O
epileptic O O
patients O O
( O O
N=8 O O
) O O
maintained O O
on O O
phenytoin B-drug B-drug
monotherapy O O
for O O
at O O
least O O
2 O O
months O O
, O O
gabapentin B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
steady-state O O
trough O O
plasma O O
concentrations O O
of O O
phenytoin B-drug B-drug
and O O
phenytoin B-drug B-drug
had O O
no O O
effect O O
on O O
gabapentin B-drug B-drug
pharmacokinetics O O
. O O

Zidovudine B-drug B-drug
should O O
either O O
be O O
temporarily O O
discontinued O O
or O O
decreased O O
by O O
50 O O
% O O
when O O
coadministered O O
with O O
probenecid B-drug B-drug
on O O
the O O
day O O
of O O
VISTIDE B-brand B-brand
infusion O O
. O O

This O O
interaction O O
appears O O
to O O
be O O
related O O
both O O
to O O
pressor O O
activity O O
and O O
to O O
beta-adrenergic O O
stimulating O O
properties O O
of O O
these O O
catecholamines B-group O
and O O
may O O
produce O O
ventricular O O
arrhythmias O O
and O O
hypertension O O
. O O

Jacalin B-drug_n B-drug_n
: O O
an O O
IgA-binding O O
lectin O O
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCAplasma B-group B-group
levels O O
whenever O O
an O O
agent O O
of O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
class I-group I-group
including O O
Anafranil B-brand B-brand
is O O
going O O
to O O
be O O
co-administered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
( O O
and/or O O
P450 O O
1A2 O O
) O O
. O O

The O O
effect O O
of O O
cyclosporine B-drug B-drug
on O O
diltiazem B-drug B-drug
plasma O O
concentrations O O
has O O
not O O
been O O
evaluated O O
. O O

ERGAMISOL B-brand B-brand
( O O
levamisole B-drug B-drug
hydrochloride I-drug I-drug
) O O
has O O
been O O
reported O O
to O O
produce O O
ANTABUSE-like O O
side O O
effects O O
when O O
given O O
concomitantly O O
with O O
alcohol B-drug B-drug
. O O

During O O
the O O
above O O
experiments O O
we O O
noted O O
a O O
massive O O
precipitation O O
in O O
cell O O
cultures O O
stimulated O O
with O O
greater O O
than O O
or O O
equal O O
to O O
100 O O
micrograms O O
of O O
lectin O O
. O O

Other O O
drugs O O
metabolized O O
by O O
C.P.A O O
. O O

Cytochalasin B-drug_n B-drug_n
D I-drug_n I-drug_n
inhibited O O
the O O
carbachol-stimulated B-drug B-drug
intracellular O O
Ca O O
( O O
2+ O O
) O O
concentration O O
( O O
[ O O
Ca O O
( O O
2+ O O
) O O
] O O
( O O
i O O
) O O
) O O
increase O O
due O O
to O O
release O O
from O O
the O O
Ca O O
( O O
2+ O O
) O O
store O O
. O O

There O O
was O O
a O O
reduction O O
that O O
reached O O
borderline O O
statistical O O
significance O O
in O O
the O O
group O O
that O O
received O O
150 O O
mg/d O O
of O O
tolbutamide B-drug B-drug
. O O

Currently O O
, O O
there O O
are O O
no O O
safety O O
and O O
efficacy O O
data O O
available O O
from O O
the O O
use O O
of O O
this O O
combination O O
. O O

glutethimide B-drug B-drug
; O O

For O O
patients O O
receiving O O
both O O
therapies O O
, O O
standard O O
monitoring O O
of O O
tacrolimus B-drug B-drug
blood O O
concentrations O O
and O O
appropriate O O
tacrolimus B-drug B-drug
dosage O O
adjustments O O
are O O
recommended O O
. O O

Patients O O
on O O
rifampin B-drug B-drug
should O O
receive O O
70 O O
mg O O
of O O
CANCIDAS B-brand B-brand
daily O O
. O O

Sodium B-drug B-drug
Iodide I-drug I-drug
( O O
123I O O
and O O
131I O O
) O O
, O O
Sodium B-drug B-drug
Pertechnetate I-drug I-drug
Tc99m I-drug I-drug
: O O
Uptake O O
of O O
radiolabeled O O
ions O O
may O O
be O O
decreased O O
. O O

Nevirapine B-drug B-drug
is O O
principally O O
metabolized O O
by O O
the O O
liver O O
via O O
the O O
cytochrome O O
P450 O O
isoenzymes O O
, O O
3A4 O O
and O O
2B6 O O
. O O

CNS O O
Toxicity O O
Brain O O
hemorrhage O O
was O O
seen O O
in O O
a O O
female O O
dog O O
treated O O
for O O
3 O O
months O O
at O O
120 O O
mg/kg/day O O
. O O

This O O
allows O O
bitolterol B-drug B-drug
to O O
open O O
air O O
passages O O
, O O
increasing O O
the O O
effectiveness O O
of O O
the O O
steroid B-group B-group
. O O

It O O
is O O
known O O
that O O
CYP1A2 O O
is O O
inhibited O O
by O O
several O O
medicinal O O
products O O
, O O
including O O
fluvoxamine B-drug B-drug
, O O
and O O
such O O
medicinal O O
products O O
could O O
theoretically O O
adversely O O
influence O O
the O O
clearance O O
of O O
anagrelide B-drug B-drug
. O O

The O O
present O O
work O O
involved O O
the O O
administration O O
of O O
both O O
ethynyl B-drug B-drug
estradiol I-drug I-drug
and O O
levonorgestrel B-drug B-drug
to O O
groups O O
of O O
rats O O
, O O
followed O O
by O O
determination O O
of O O
the O O
homocysteine O O
excretion O O
rate O O
in O O
urine O O
. O O

Theoretically O O
, O O
the O O
naproxen B-drug B-drug
anion O O
itself O O
could O O
likewise O O
be O O
displaced O O
. O O

Indinavir B-drug B-drug
: O O
Coadministration O O
of O O
indinavir B-drug B-drug
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
an O O
83 O O
% O O
increase O O
in O O
nelfinavir B-drug B-drug
plasma O O
AUC O O
and O O
a O O
51 O O
% O O
increase O O
in O O
indinavir B-drug B-drug
plasma O O
A.C O O
. O O

Pharmacokinetics O O
of O O
calcium-entry B-group B-group
blockers I-group I-group
. O O

Coumarin-Type B-group B-group
Anticoagulants I-group I-group
: O O
Several O O
short-term O O
controlled O O
studies O O
failed O O
to O O
wshow O O
that O O
ibuprofen B-drug B-drug
significantly O O
affected O O
prothrombin O O
times O O
or O O
a O O
variety O O
of O O
other O O
clotting O O
factors O O
when O O
administered O O
to O O
individuals O O
on O O
coumarin-type B-group B-group
anticoagulants I-group I-group
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
glipizide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
control O O
. O O

Flavoridin B-drug_n B-drug_n
alone O O
was O O
found O O
to O O
have O O
no O O
effect O O
on O O
CAS O O
, O O
but O O
can O O
completely O O
block O O
contortrostatin-induced B-drug_n O
phosphorylation O O
of O O
this O O
protein O O
in O O
MDA-MB-435 O O
cells O O
. O O

If O O
a O O
patient O O
is O O
truly O O
hypothyroid O O
, O O
it O O
is O O
likely O O
that O O
a O O
reduction O O
in O O
anticoagulant B-group B-group
dosage O O
will O O
be O O
required O O
. O O

Methenamine B-drug B-drug

Therefore O O
, O O
OMNICEF B-brand B-brand
for O O
Oral O O
Suspension O O
can O O
be O O
administered O O
with O O
iron-fortified B-drug_n B-drug_n
infant O O
formula O O
. O O

Both O O
CRIXIVAN B-brand B-brand
and O O
atazanavir B-drug B-drug
are O O
associated O O
with O O
indirect O O
( O O
unconjugated O O
) O O
hyperbilirubinemia O O
. O O

Alkalinizing O O
agents O O
: O O
Gastrointestinal O O
alkalinizing O O
agents O O
( O O
sodium B-drug B-drug
bicarbonate I-drug I-drug
, O O
etc O O
. O O
) O O
increase O O
absorption O O
of O O
amphetamines B-drug B-group
. O O

Patients O O
taking O O
REVIA B-brand B-brand
may O O
not O O
benefit O O
from O O
opioid B-group B-group
containing O O
medicines O O
, O O
such O O
as O O
cough O O
and O O
cold O O
preparations O O
, O O
antidiarrheal O O
preparations O O
, O O
and O O
opioid B-group B-group
analgesics I-group I-group
. O O

Hormonal B-group B-group
Contraceptives I-group I-group
, O O
Including O O
Oral O O
, O O
Injectable O O
, O O
Transdermal O O
, O O
and O O
Implantable O O
Contraceptives B-group B-group
: O O
An O O
interaction O O
study O O
demonstrated O O
that O O
co-administration O O
of O O
bosentan B-drug B-drug
and O O
the O O
oral O O
hormonal B-group B-group
contraceptive I-group I-group
Ortho-Novum B-brand B-brand
produced O O
average O O
decreases O O
of O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
levels O O
of O O
14 O O
% O O
and O O
31 O O
% O O
, O O
respectively O O
. O O

macrolide B-group B-group
antibiotics I-group I-group
e.g. O O
, O O
erythromycin B-drug B-drug
; O O

Radioligand O O
binding O O
experiments O O
using O O
the O O
uptake O O
inhibitor O O
hydrogen-3 O O
mazindol B-drug B-drug
revealed O O
a O O
significant O O
decrease O O
by O O
approximately O O
30 O O
% O O
in O O
norepinephrine B-drug B-drug
uptake-1 O O
carrier O O
density O O
in O O
functional O O
classes O O
II O O
to O O
III O O
and O O
IV O O
myocardium O O
versus O O
nonfailing O O
myocardium O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

However O O
, O O
the O O
pharmacodynamics O O
of O O
coadministration O O
of O O
zaleplon B-drug B-drug
and O O
promethazine B-drug B-drug
have O O
not O O
been O O
evaluated O O
. O O

AIM O O
AND O O
BACKGROUND O O
: O O
The O O
pharmacokinetic O O
interaction O O
between O O
sirolimus B-drug B-drug
, O O
a O O
macrolide B-group B-group
immunosuppressant I-group I-group
metabolized O O
by O O
CYP3A4 O O
, O O
and O O
the O O
calcium B-group B-group
channel I-group I-group
blocker I-group I-group
diltiazem B-drug B-drug
was O O
studied O O
in O O
18 O O
healthy O O
subjects O O
. O O

only O O
ibogaine B-drug_n B-drug_n
enhances O O
cocaine-induced B-drug B-drug
increases O O
in O O
accumbal O O
dopamine O O
. O O

Behavioral O O
mechanisms O O
underlying O O
the O O
link O O
between O O
smoking O O
and O O
drinking O O
. O O

John O O
s O O
wort O O
) O O
may O O
increase O O
the O O
formation O O
of O O
dapsone B-drug_n B-drug_n
hydroxylamine I-drug_n I-drug_n
, O O
a O O
metabolite O O
of O O
dapsone B-drug B-drug
associated O O
with O O
hemolysis O O
. O O

Like O O
ibogaine B-drug_n B-drug_n
( O O
40 O O
mg/kg O O
) O O
, O O
18-MC B-drug_n B-drug_n
( O O
40 O O
mg/kg O O
) O O
decreases O O
the O O
intravenous O O
self-administration O O
of O O
morphine B-drug B-drug
and O O
cocaine B-drug B-drug
and O O
the O O
oral O O
self-administration O O
of O O
ethanol B-drug B-drug
and O O
nicotine B-drug B-drug
in O O
rats O O
; O O

increased O O
plasminogen O O
antigen O O
and O O
activity O O
. O O

Permeation O O
studies O O
were O O
performed O O
on O O
guinea O O
pig O O
small O O
intestinal O O
mucosa O O
mounted O O
in O O
Ussing-type O O
chamber O O
. O O

Other O O
macrolide B-group B-group
antibiotics I-group I-group
, O O
such O O
as O O
erythromycin B-drug B-drug
, O O
have O O
not O O
been O O
studied O O
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
. O O

Compounds O O
tested O O
in O O
man O O
include O O
warfarin B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
aminopyrine B-drug B-drug
and O O
antipyrine B-drug B-drug
. O O

Reported O O
examples O O
include O O
the O O
following O O
: O O
Protease B-group B-group
Inhibitors I-group I-group
: O O
Protease B-group B-group
inhibitors I-group I-group
are O O
known O O
to O O
inhibit O O
CYP3A4 O O
to O O
varying O O
degrees O O
. O O

therefore O O
, O O
patients O O
who O O
may O O
be O O
adversely O O
affected O O
by O O
such O O
an O O
action O O
should O O
be O O
carefully O O
observed O O
. O O

In O O
patients O O
given O O
very O O
high O O
doses O O
( O O
3900 O O
mg O O
) O O
of O O
aspirin B-brand B-brand
daily O O
, O O
increases O O
in O O
serum O O
salicylate B-group O
levels O O
were O O
seen O O
when O O
nizatidine B-drug B-drug
, O O
150 O O
mg O O
b.i.d. O O
, O O
was O O
administered O O
concurrently O O
. O O

Nicotine B-drug B-drug
Transdermal O O
System O O
: O O
. O O

Rabbits O O
failed O O
to O O
maintain O O
pregnancy O O
when O O
dosed O O
with O O
1 O O
mg/kg/day O O
fulvestrant B-drug B-drug
IM O O
( O O
twice O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
during O O
the O O
period O O
of O O
organogenesis O O
. O O

- O O
Other O O
antihypertensive B-group B-group
drugs I-group I-group
: O O
Additive O O
effect O O
or O O
potentiation O O

The O O
physician O O
is O O
advised O O
to O O
monitor O O
the O O
plasma O O
concentrations O O
of O O
itraconazole B-drug B-drug
when O O
any O O
of O O
these O O
drugs O O
is O O
taken O O
concurrently O O
, O O
and O O
to O O
increase O O
the O O
dose O O
of O O
Itraconazole B-drug B-drug
if O O
necessary O O
. O O

The O O
concurrent O O
administration O O
of O O
CAMPTOSAR B-brand B-brand
with O O
irradiation O O
has O O
not O O
been O O
adequately O O
studied O O
and O O
is O O
not O O
recommended O O
. O O

Indomethacin B-drug B-drug
- O O
Concomitant O O
use O O
of O O
L-glutamine B-drug B-drug
and O O
indomethacin B-drug B-drug
may O O
ameliorate O O
increased O O
intestinal O O
permeability O O
caused O O
by O O
indomethacin B-drug B-drug
. O O

Prospective O O
studies O O
on O O
the O O
potential O O
for O O
hydroxyurea B-drug B-drug
to O O
interact O O
with O O
other O O
drugs O O
have O O
not O O
been O O
performed O O
. O O

There O O
is O O
, O O
however O O
, O O
currently O O
no O O
data O O
on O O
the O O
effect O O
of O O
combined O O
hyperglycaemia O O
and O O
hyperinsulinaemia O O
on O O
the O O
renal O O
and O O
ocular O O
blood O O
flow O O
seen O O
in O O
diabetic O O
patients O O
on O O
insulin O B-drug
therapy O O
. O O

Animals O O
dosed O O
with O O
1,3-difluoroacetone B-drug_n B-drug_n
did O O
not O O
display O O
the O O
2-3 O O
hour O O
lag O O
phase O O
in O O
either O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
synthesis O O
or O O
in O O
citrate O O
and O O
fluoride O O
accumulation O O
characteristic O O
of O O
animals O O
dosed O O
with O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
. O O

In O O
clinical O O
trials O O
, O O
antacids B-group B-group
were O O
administered O O
concomitantly O O
with O O
lansoprazole B-drug B-drug
delayed-release O O
capsules O O
; O O

DISCUSSION O O
: O O
Clarithromycin B-drug B-drug
is O O
a O O
potent O O
inhibitor O O
of O O
CYP3A4 O O
, O O
the O O
major O O
enzyme O O
responsible O O
for O O
simvastatin B-drug B-drug
metabolism O O
. O O

Sodium B-drug B-drug
thiosulfate I-drug I-drug
is O O
a O O
neutralizing O O
agent O O
for O O
cisplatin B-drug B-drug
that O O
protects O O
against O O
renal O O
damage O O
. O O

Digitalis B-group B-group
glycosides I-group I-group
: O O
Patients O O
on O O
digitalis B-group B-group
glycosides I-group I-group
may O O
be O O
at O O
increased O O
risk O O
of O O
arrhythmias O O
due O O
to O O
hypokalemia O O
. O O

Phenytoin B-drug B-drug
: O O
Accutane B-brand B-brand
has O O
not O O
been O O
shown O O
to O O
alter O O
the O O
pharmacokinetics O O
of O O
phenytoin B-drug B-drug
in O O
a O O
study O O
in O O
seven O O
healthy O O
volunteers O O
. O O

The O O
average O O
increase O O
was O O
45 O O
% O O
. O O

There O O
was O O
an O O
increasing O O
incidence O O
of O O
transient O O
thrombocytopenia O O
( O O
or O O
=100 O O
x O O
10 O O
( O O
9 O O
) O O
/L O O
) O O
with O O
increasing O O
everolimus B-drug B-drug
AUC O O
( O O
P O O
= O O
.03 O O
) O O
. O O

MAO B-group B-group
Inhibitors I-group I-group
: O O
Serious O O
side O O
effects O O
and O O
even O O
death O O
have O O
been O O
reported O O
following O O
the O O
concomitant O O
use O O
of O O
certain O O
drugs O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

This O O
should O O
be O O
taken O O
into O O
account O O
when O O
evaluating O O
serum O O
amylase O O
levels O O
for O O
diagnosis O O
or O O
monitoring O O
of O O
pancreatitis O O
in O O
patients O O
using O O
EXTRANEAL B-brand B-brand
. O O

No O O
change O O
in O O
phase O O
was O O
detected O O
, O O
although O O
the O O
aerosol O O
particles O O
appeared O O
to O O
contain O O
residual O O
solvent B-group O
. O O

Sympathomimetic B-group B-group
amines I-group I-group
may O O
reduce O O
the O O
antihypertensive O O
effects O O
of O O
reserpine B-drug B-drug
, O O
veratrum B-group B-group
alkaloids I-group I-group
, O O
methyldopa B-drug B-drug
and O O
mecamylamine B-drug B-drug
. O O

CYP3A4 O O
and O O
-2C19 O O
Inhibitors O O
- O O
In O O
vitro O O
studies O O
indicated O O
that O O
CYP3A4 O O
and O O
-2C19 O O
are O O
the O O
primary O O
enzymes O O
involved O O
in O O
the O O
metabolism O O
of O O
escitalopram B-drug B-drug
. O O

this O O
can O O
cause O O
headaches O O
and O O
other O O
signs O O
of O O
hypertensive O O
crisis O O
. O O

Celecoxib B-drug B-drug
metabolism O O
is O O
predominantly O O
mediated O O
via O O
cytochrome O O
P450 O O
2C9 O O
in O O
the O O
liver O O
. O O

Digitalis B-group B-group
glycosides I-group I-group
: O O
amphotericin B-drug B-drug
B-induced O O
hypokalemia O O
may O O
potentiate O O
digitalis B-group B-group
toxicity O O
. O O

Potential O O
effect O O
on O O
anticoagulation O O
. O O

Androgens B-group B-group
may O O
increase O O
sensitivity O O
to O O
oral O O
anticoagulahts O O
. O O

SERUM O O
LEVELS O O
OF O O
PHENYTOIN B-drug B-drug
SHOULD O O
BE O O
DETERMINED O O
ON O O
DIFFERENT O O
DAYS O O
FOR O O
EVIDENCE O O
OF O O
AN O O
INCREASE O O
OR O O
FOR O O
A O O
CONTINUING O O
RISE O O
IN O O
LEVELS O O
. O O

Absorption O O
of O O
tetracyclines B-group B-group
is O O
impaired O O
by O O
antacids B-group B-group
containing O O
aluminum B-drug B-drug
, O O
calcium B-drug B-drug
, O O
or O O
magnesium B-drug B-drug
, O O
and O O
iron-containing B-drug B-drug
preparations O O
. O O

The O O
effects O O
of O O
adenosine B-drug B-drug
are O O
antagonized O O
by O O
methylxanthines B-group B-group
such O O
as O O
caffeine B-drug B-drug
and O O
theophylline B-drug B-drug
. O O

Oral O O
contraceptives B-group B-group
: O O
Aprepitant B-drug B-drug
, O O
when O O
given O O
once O O
daily O O
for O O
14 O O
days O O
as O O
a O O
100-mg O O
capsule O O
with O O
an O O
oral O O
contraceptive B-group B-group
containing O O
35 O O
mcg O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
1 O O
mg O O
of O O
norethindrone B-drug B-drug
, O O
decreased O O
the O O
AUC O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
by O O
43 O O
% O O
, O O
and O O
decreased O O
the O O
AUC O O
of O O
norethindrone B-drug B-drug
by O O
8 O O
% O O
; O O

Particular O O
caution O O
should O O
be O O
exercised O O
in O O
using O O
preparations O O
containing O O
sulfur B-drug B-drug
, O O
resorcinol B-drug B-drug
, O O
or O O
salicylic B-drug B-drug
acid I-drug I-drug
in O O
combination O O
with O O
DIFFERIN B-brand B-brand
Gel O O
. O O

Ketoconazole B-drug B-drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
40 O O
mg O O
) O O
and O O
ketoconazole B-drug B-drug
( O O
200 O O
mg O O
) O O
decreased O O
the O O
Cmax O O
and O O
AUC O O
of O O
ketoconazole B-drug B-drug
by O O
21 O O
% O O
and O O
10 O O
% O O
, O O
respectively O O
, O O
and O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
citalopram B-drug B-drug
. O O

Terfenadine B-drug B-drug
: O O
In O O
a O O
prospective O O
study O O
involving O O
six-healthy-male O O
volunteers O O
, O O
dirithromycin B-drug B-drug
did O O
not O O
affect O O
the O O
metabolism O O
of O O
terfenadine B-drug B-drug
. O O

The O O
existence O O
of O O
PI O O
was O O
related O O
to O O
the O O
number O O
of O O
drugs O O
prescribed O O
to O O
each O O
patient O O
( O O
p O O
< O O
0.01 O O
) O O
. O O

No O O
Information O O
Provided O O

. O O

Certain O O
other O O
antibiotics B-group B-group
( O O
aminoglycosides B-group B-group
and O O
polymyxin B-group B-group
) O O
have O O
also O O
been O O
reported O O
to O O
interfere O O
with O O
the O O
nerve O O
transmission O O
at O O
the O O
neuromuscular O O
junction O O
. O O

Likewise O O
, O O
gabapentin B-drug B-drug
pharmacokinetics O O
were O O
unaltered O O
by O O
carbamazepine B-drug B-drug
administration O O
. O O

atorvastatin I-drug B-drug
concentration O O

Controlled O O
and O O
uncontrolled O O
domestic O O
studies O O
suggest O O
that O O
concomitant O O
use O O
of O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
and O O
beta-blockers B-group B-group
is O O
usually O O
well O O
tolerated O O
, O O
but O O
available O O
data O O
are O O
not O O
sufficient O O
to O O
predict O O
the O O
effects O O
of O O
concomitant O O
treatment O O
in O O
patients O O
with O O
left O O
ventricular O O
dysfunction O O
or O O
cardiac O O
conduction O O
abnormalities O O
. O O

It O O
is O O
recommended O O
that O O
buspirone B-drug B-drug
hydrochloride I-drug I-drug
not O O
be O O
used O O
concomitantly O O
with O O
MAO B-group B-group
inhibitors I-group I-group
Because O O
the O O
effects O O
of O O
concomitant O O
administration O O
of O O
buspirone B-drug B-drug
HCl I-drug I-drug
with O O
most O O
other O O
psychotropic B-group B-group
drugs I-group I-group
have O O
not O O
been O O
studied O O
, O O
the O O
concomitant O O
use O O
of O O
buspirone B-drug B-drug
HCl I-drug I-drug
with O O
other O O
CNS-active O O
drugs O O
should O O
be O O
approached O O
with O O
caution O O
. O O

No O O
interaction O O
trials O O
have O O
been O O
conducted O O
with O O
MEPRON B-brand B-brand
and O O
rifabutin B-drug B-drug
. O O

Fluconazole B-drug B-drug
and O O
Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
and O O
fluconazole B-drug B-drug
are O O
predominantly O O
CYP O O
3A4 O O
and O O
2C9 O O
inhibitors O O
, O O
respectively O O
. O O

These O O
observations O O
strongly O O
suggest O O
that O O
the O O
homodimeric O O
structure O O
of O O
contortrostatin B-drug_n B-drug_n
functionally O O
distinguishes O O
it O O
from O O
other O O
monomeric O O
members O O
of O O
the O O
disintegrin O O
family O O
. O O

- O O
Impaired O O
glucose O O
tolerance O O

If O O
a O O
diuretic B-group B-group
is O O
also O O
used O O
, O O
it O O
may O O
increase O O
the O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

The O O
most O O
significant O O
drug O O
interactions O O
following O O
administration O O
of O O
Cerebyx B-brand B-brand
are O O
expected O O
to O O
occur O O
with O O
drugs O O
that O O
interact O O
with O O
phenytoin B-drug B-drug
. O O

Corticosteroids B-group B-group
: O O
A O O
relationship O O
of O O
functional O O
antagonism O O
exists O O
between O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
, O O
which O O
promote O O
calcium O O
absorption O O
, O O
and O O
corticosteroids B-group B-group
, O O
which O O
inhibit O O
calcium O O
absorption O O
. O O

Keys O O
to O O
maximizing O O
benefit O O
while O O
avoiding O O
adverse O O
drug O O
effects O O
. O O

When O O
given O O
concurrently O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Other O O
Drug O O
Interactions O O
: O O
No O O
pharmacokinetic O O
interactions O O
were O O
observed O O
between O O
vardenafil B-drug B-drug
and O O
the O O
following O O
drugs O O
: O O
glyburide B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
Maalox B-brand B-brand
, O O
and O O
ranitidine B-drug B-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
Amphetamines B-group B-group
can O O
cause O O
a O O
significant O O
elevation O O
in O O
plasma O O
corticosteroid B-group B-group
levels O O
. O O

When O O
cocaine B-drug B-drug
is O O
the O O
primary O O
addiction O O
, O O
after O O
withdrawal O O
the O O
most O O
effective O O
treatment O O
is O O
group O O
therapy O O
with O O
other O O
recovering O O
cocaine O B-drug
abusers O O
. O O

Today O O
pharmacological O O
magnesium B-drug B-drug
therapy O O
mainly O O
concerns O O
the O O
obstetrical O O
, O O
cardiological O O
and O O
anaesthesiological O O
fields O O
. O O

Compared O O
with O O
conventional B-group B-group
antipsychotics I-group I-group
, O O
it O O
has O O
greater O O
affinity O O
for O O
serotonin O O
5-HT2A O O
than O O
for O O
dopamine O O
D2 O O
receptors O O
. O O

Due O O
to O O
a O O
theoretical O O
risk O O
of O O
a O O
pharmacodynamic O O
interaction O O
, O O
use O O
of O O
ergotamine-containing B-drug B-drug
or O O
ergot-type B-group B-group
medications I-group I-group
( O O
like O O
dihydroergotamine B-drug B-drug
or O O
methysergide B-drug B-drug
) O O
and O O
FROVA B-brand B-brand
within O O
24 O O
hours O O
of O O
each O O
other O O
should O O
be O O
avoided O O
( O O
see O O
a O O
href= O O
frova_od.htm O O
# O O
CI O O
CONTRAINDICATIONS O O
) O O
. O O

Drug O O
Name O O

The O O
following O O
similar O O
changes O O
may O O
be O O
expected O O
with O O
larger O O
doses O O
of O O
estrogen B-group B-group
: O O
Increased O O
sulfobromophthalein O O
retention O O
; O O

Due O O
to O O
high O O
inter-patient O O
variability O O
and O O
limited O O
sampling O O
, O O
the O O
extent O O
of O O
the O O
increase O O
in O O
SN38 B-drug_n B-drug_n
levels O O
in O O
patients O O
receiving O O
concurrent O O
irinotecan B-drug B-drug
and O O
AVASTIN B-brand B-brand
is O O
uncertain O O
. O O

Hypoglycemics B-group B-group

http O O
: O O
//www.rxlist.com/cgi/generic3/guanethidine_od.htm O O

The O O
authors O O
examined O O
the O O
effect O O
of O O
the O O
cyclooxygenase-2 O O
( O O
COX-2 O O
) O O
inhibitor O O
, O O
rofecoxib B-drug B-drug
, O O
at O O
steady O O
state O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
following O O
a O O
single O O
dose O O
in O O
healthy O O
subjects O O
. O O

WelChol B-brand B-brand
was O O
found O O
to O O
have O O
no O O
significant O O
effect O O
on O O
the O O
bioavailability O O
of O O
digoxin B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
metoprolol B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
valproic B-drug B-drug
acid I-drug I-drug
, O O
and O O
warfarin B-drug B-drug
. O O

Such O O
interactions O O
might O O
be O O
manifested O O
by O O
increased O O
susceptibility O O
to O O
bruising O O
, O O
nosebleeds O O
, O O
hemoptysis O O
, O O
hematemesis O O
, O O
hematuria O O
and O O
blood O O
in O O
the O O
stool O O
. O O

There O O
is O O
a O O
single O O
case O O
report O O
, O O
which O O
suggests O O
that O O
sucralfate B-drug B-drug
may O O
interfere O O
with O O
anagrelide B-drug B-drug
absorption O O
. O O

Spontaneous O O
reports O O
of O O
serotonin O O
syndrome O O
associated O O
with O O
co-administration O O
of O O
ZYVOX B-brand B-brand
and O O
serotonergic B-group B-group
agents I-group I-group
, O O
including O O
antidepressants B-group B-group
such O O
as O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
have O O
been O O
reported O O
. O O

Therefore O O
, O O
4 O O
to O O
5 O O
hours O O
should O O
elapse O O
between O O
administration O O
of O O
cholestyramine B-drug B-drug
and O O
thyroid B-group B-group
hormones I-group I-group
. O O

It O O
is O O
not O O
known O O
whether O O
alosetron B-drug B-drug
might O O
induce O O
other O O
enzymes O O
. O O

The O O
use O O
of O O
ROMAZICON B-brand B-brand
is O O
not O O
recommended O O
in O O
epileptic O O
patients O O
who O O
have O O
been O O
receiving O O
benzodiazepine O B-group
treatment O O
for O O
a O O
prolonged O O
period O O
. O O

Caution O O
should O O
be O O
used O O
when O O
administering O O
or O O
taking O O
TARCEVA B-brand B-brand
with O O
ketoconazole B-drug B-drug
and O O
other O O
strong O O
CYP3A4 O O
inhibitors O O
such O O
as O O
, O O
but O O
not O O
limited O O
to O O
, O O
atazanavir B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
telithromycin B-drug B-drug
, O O
troleandomycin B-drug B-drug
( O O
TAO B-drug B-drug
) O O
, O O
and O O
voriconazole B-drug B-drug
. O O

The O O
clinical O O
significance O O
, O O
if O O
any O O
, O O
of O O
these O O
observations O O
is O O
unknown O O
. O O

Oral O O
Anticoagulants B-group B-group
: O O
Thyroid B-group B-group
hormones I-group I-group
appear O O
to O O
increase O O
catabolism O O
of O O
vitamin O O
K-dependent O O
clotting O O
factors O O
. O O

Medroxyprogesterone B-drug B-drug
Acetate I-drug I-drug
- O O
L-histidine B-drug B-drug
was O O
observed O O
to O O
enhance O O
( O O
in O O
tissue O O
culture O O
) O O
the O O
effect O O
of O O
medroxyprogesterone B-drug B-drug
acetate I-drug I-drug
in O O
reducing O O
the O O
number O O
of O O
human O O
breast O O
cancer O O
cells O O
that O O
were O O
in O O
the O O
S O O
phase O O
. O O

Other O O
Drugs O O
: O O
Based O O
on O O
the O O
results O O
of O O
drug O O
interaction O O
studies O O
, O O
no O O
dosage O O
adjustment O O
is O O
recommended O O
when O O
SUSTIVA B-brand B-brand
( O O
efavirenz B-drug B-drug
) O O
is O O
given O O
with O O
the O O
following O O
: O O
aluminum/magnesium B-group B-drug
hydroxide I-group B-group
antacids I-group I-group
, O O
azithromycin B-drug B-drug
, O O
cetirizine B-drug B-drug
, O O
famotidine B-drug B-drug
, O O
fluconazole B-drug B-drug
, O O
lamivudine B-drug B-drug
, O O
lorazepam B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
and O O
zidovudine B-drug B-drug
. O O

The O O
concurrent O O
use O O
of O O
intravenously O O
or O O
orally O O
administered O O
methylxanthines B-group B-group
( O O
e.g. O O
, O O
aminophylline B-drug B-drug
, O O
theophylline B-drug B-drug
) O O
by O O
patients O O
receiving O O
BROVANA B-brand B-brand
has O O
not O O
been O O
completely O O
evaluated O O
. O O

74.1 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
9.3 O O
) O O
of O O
the O O
total O O
PICR O O
could O O
be O O
avoided O O
by O O
simple O O
recommendations O O
; O O

The O O
data O O
do O O
not O O
suggest O O
the O O
need O O
for O O
dose O O
adjustment O O
of O O
either O O
HUMIRA B-brand B-brand
or O O
MTX B-drug B-drug
. O O

Diphenhydramine B-drug B-drug
hydrochloride I-drug I-drug
has O O
additive O O
effects O O
with O O
alcohol B-drug B-drug
and O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
hypnotics B-group B-group
, O O
sedatives B-group B-group
, O O
tranquilizers B-group B-group
, O O
etc O O
) O O
. O O

g/mL O O
; O O

If O O
the O O
treatment O O
is O O
continued O O
, O O
these O O
patients O O
should O O
be O O
particularly O O
carefully O O
monitored O O
for O O
adverse O O
effects O O
, O O
especially O O
conduction O O
disturbances O O
and O O
exacerbation O O
of O O
tachyarrhythmias O O
, O O
as O O
amiodarone B-drug B-drug
is O O
continued O O
. O O

Probenecid B-drug B-drug
Prolonged O O
action O O
of O O
etomidate B-drug B-drug

The O O
first O O
phase O O
of O O
this O O
sequence O O
, O O
initiation O O
, O O
is O O
considered O O
to O O
result O O
from O O
at O O
least O O
one O O
event O O
in O O
the O O
genetic O O
apparatus O O
. O O

Concomitant O O
use O O
of O O
prophylactic O O
low O O
dose O O
heparin B-drug B-drug
did O O
not O O
appear O O
to O O
affect O O
safety O O
, O O
however O O
, O O
its O O
effects O O
on O O
the O O
efficacy O O
of O O
Xigris B-brand B-brand
have O O
not O O
been O O
evaluated O O
in O O
an O O
adequate O O
and O O
well-controlled O O
clinical O O
trial O O
. O O

Amphotericin B-drug B-drug
B I-drug I-drug
or O O
potassium-depleting B-group B-group
diuretics I-group I-group
( O O
benzothiadiazines B-group B-group
and O O
related O O
drugs O O
, O O
ethacrynic B-drug B-drug
acid I-drug I-drug
and O O
furosemide B-drug B-drug
) O O
enhanced O O
hypokalemia O O
. O O

Aspirin B-brand B-brand
: O O
As O O
with O O
other O O
NSAIDs B-group B-group
, O O
concomitant O O
administration O O
of O O
Ponstel B-brand B-brand
and O O
aspirin B-brand B-brand
is O O
not O O
generally O O
recommended O O
because O O
of O O
the O O
potential O O
of O O
increased O O
adverse O O
effects O O
. O O

Calcium B-group B-group
Antagonists O I-group
: O O
After O O
repeated O O
co-administration O O
of O O
Trileptal B-brand B-brand
, O O
the O O
AUC O O
of O O
felodipine B-drug B-drug
was O O
lowered O O
by O O
28 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
20-33 O O
] O O
. O O

Patients O O
with O O
Crohn O O
s O O
disease O O
who O O
received O O
immunosuppressants B-group B-group
tended O O
to O O
experience O O
fewer O O
infusion O O
reactions O O
compared O O
to O O
patients O O
on O O
no O O
immunosuppressants B-group B-group
. O O

There O O
have O O
been O O
a O O
number O O
of O O
reports O O
in O O
the O O
post-marketing O O
experience O O
of O O
coma O O
and O O
death O O
associated O O
with O O
the O O
concomitant O O
intravenous O O
misuse O O
of O O
buprenorphine B-drug B-drug
and O O
benzodiazepines B-drug B-group
by O O
addicts O O
. O O

The O O
regulation O O
of O O
the O O
level O O
of O O
the O O
glucocorticoid-induced O O
gene O O
expression O O
by O O
the O O
antioxidative O O
gallates O O
is O O
of O O
great O O
interest O O
from O O
a O O
therapeutic O O
point O O
of O O
view O O
. O O

If O O
concomitant O O
treatment O O
with O O
frovatriptan B-drug B-drug
and O O
an O O
SSRI B-group B-group
is O O
clinically O O
warranted O O
, O O
appropriate O O
observation O O
of O O
the O O
patient O O
is O O
advised O O
. O O

Quinolones B-group B-group
form O O
chelates O O
with O O
alkaline O O
earth O O
and O O
transition O O
metals O O
. O O

Beta-adrenergic B-group B-group
Blocking I-group I-group
Agents I-group I-group
: O O
Experience O O
in O O
over O O
1400 O O
patients O O
in O O
a O O
non-comparative O O
clinical O O
trial O O
has O O
shown O O
that O O
concomitant O O
administration O O
of O O
nifedipine B-drug B-drug
and O O
beta-blocking B-group B-group
agents I-group I-group
is O O
usually O O
well O O
tolerated O O
, O O
but O O
there O O
have O O
been O O
occasional O O
literature O O
reports O O
suggesting O O
that O O
the O O
combination O O
may O O
increase O O
the O O
likelihood O O
of O O
congestive O O
heart O O
failure O O
, O O
severe O O
hypotension O O
or O O
exacerbation O O
of O O
angina O O
. O O

Moreover O O
, O O
as O O
noted O O
with O O
alprazolam B-drug B-drug
, O O
the O O
effect O O
of O O
fluvoxamine B-drug B-drug
may O O
even O O
be O O
more O O
pronounced O O
when O O
it O O
is O O
administered O O
at O O
higher O O
doses O O
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
ertapenem B-drug B-drug
does O O
not O O
inhibit O O
P-glycoprotein-mediated O O
transport O O
of O O
digoxin B-drug B-drug
or O O
vinblastine B-drug B-drug
and O O
that O O
ertapenem B-drug B-drug
is O O
not O O
a O O
substrate O O
for O O
P-glycoprotein-mediated O O
transport O O
. O O

Concurrent O O
administration O O
of O O
vasopressor B-group B-group
drugs I-group I-group
( O O
for O O
the O O
treatment O O
of O O
hypotension O O
related O O
to O O
obstetric O O
blocks O O
) O O
and O O
ergot-type B-group B-group
oxytocic I-group I-group
drugs I-group I-group
may O O
cause O O
severe O O
, O O
persistent O O
hypertension O O
or O O
cerebrovascular O O
accidents O O
. O O

Thus O O
, O O
when O O
NSAIDs B-group B-group
and O O
lithium B-drug B-drug
are O O
administered O O
concurrently O O
, O O
subjects O O
should O O
be O O
observed O O
carefully O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

( O O
Read O O
circulars O O
for O O
lithium B-drug B-drug
preparation O O
before O O
use O O
of O O
such O O
concurrent O O
therapy O O
) O O
. O O

When O O
atropine B-drug B-drug
and O O
pralidoxime B-drug B-drug
are O O
used O O
together O O
, O O
the O O
signs O O
of O O
atropinization O O
( O O
flushing O O
, O O
mydriasis O O
, O O
tachycardia O O
, O O
dryness O O
of O O
the O O
mouth O O
and O O
nose O O
) O O
may O O
occur O O
earlier O O
than O O
might O O
be O O
expected O O
than O O
when O O
atropine B-drug B-drug
is O O
used O O
alone O O
because O O
pralidoxime B-drug B-drug
may O O
potentiate O O
the O O
effect O O
of O O
atropine B-drug B-drug
. O O

Diuretic B-group B-group
agents I-group I-group
may O O
decrease O O
vascular O O
response O O
to O O
pressor O O
drugs O O
such O O
as O O
epinephrine B-drug B-drug
. O O

- O O
Nitrofurantoin B-drug B-drug
( O O
e.g. O O
, O O
Furadantin B-brand B-brand
) O O
or O O

Effect O O
of O O
AEDs B-group B-group
in O O
Pediatric O O
Patients O O
There O O
was O O
about O O
a O O
22 O O
% O O
increase O O
of O O
apparent O O
total O O
body O O
clearance O O
of O O
levetiracetam B-drug B-drug
when O O
it O O
was O O
co-administered O O
with O O
enzyme-inducing O O
AEDs B-group B-group
. O O

Disulfiram B-drug B-drug
appears O O
to O O
decrease O O
the O O
rate O O
at O O
which O O
certain O O
drugs O O
are O O
metabolized O O
and O O
therefore O O
may O O
increase O O
the O O
blood O O
levels O O
and O O
the O O
possibility O O
of O O
clinical O O
toxicity O O
of O O
drugs O O
given O O
concomitantly O O
. O O

Coadministration O O
of O O
thioridazine B-drug B-drug
has O O
been O O
reported O O
to O O
worsen O O
the O O
tremor O O
in O O
elderly O O
patients O O
with O O
Parkinsons O O
disease O O
; O O

Antihistamines B-group B-group
: O O
Amphetamines B-group B-group
may O O
counteract O O
the O O
sedative O O
effect O O
of O O
antihistamines B-group B-group
. O O

Changes O O
in O O
urinary O O
homocysteine O O
following O O
synthetic B-group B-group
steroidal I-group I-group
estrogen I-group I-group
and O O
progestogen O O
administration O O
to O O
rats O O
. O O

Plasma O O
concentrations O O
of O O
azole B-group B-group
antifungal I-group I-group
agents I-group I-group
are O O
reduced O O
when O O
given O O
concurrently O O
with O O
isoniazid B-drug B-drug
. O O

Hitherto O O
unrecognized O O
interactions O O
between O O
homopolyribonucleotides O O
and O O
complexes O O
thereof O O
are O O
suggested O O
by O O
interferon O O
induction O O
data O O
obtained O O
in O O
a O O
highly O O
sensitive O O
assay O O
system O O
of O O
primary O O
rabbit O O
kidney O O
cell O O
cultures O O
superinduced O O
by O O
metabolic O O
inhibitors O O
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reaction O O
. O O

Isoflurane B-drug B-drug
potentiates O O
the O O
muscle O O
relaxant O O
effect O O
of O O
all O O
muscle B-group B-group
relaxants I-group I-group
, O O
most O O
notably O O
nondepolarizing B-group B-group
muscle I-group I-group
relaxants I-group I-group
, O O
and O O
MAC O O
( O O
minimum O O
alveolar O O
concentration O O
) O O
is O O
reduced O O
by O O
concomitant O O
administration O O
of O O
N O O
2O O O
. O O

Concurrent O O
administration O O
of O O
etanercept B-drug B-drug
( O O
another O O
TNF O O
-blocking O O
agent O O
) O O
and O O
anakinra B-drug B-drug
( O O
an O O
interleukin-1 B-group B-group
antagonist I-group I-group
) O O
has O O
been O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
serious O O
infections O O
, O O
and O O
increased O O
risk O O
of O O
neutropenia O O
and O O
no O O
additional O O
benefit O O
compared O O
to O O
these O O
medicinal O O
products O O
alone O O
. O O

The O O
conversion O O
of O O
6-deoxy B-drug_n B-drug_n
penciclovir I-drug_n I-drug_n
to O O
penciclovir B-drug B-drug
is O O
catalyzed O O
by O O
aldehyde O O
oxidase O O
. O O

In O O
patients O O
receiving O O
coumarin-type B-group B-group
anticoagulants I-group I-group
, O O
the O O
addition O O
of O O
Nalfon B-brand B-brand
to O O
therapy O O
could O O
prolong O O
the O O
prothrombin O O
time O O
. O O

5 O O
. O O

. O O

Caution O O
is O O
advised O O
in O O
patients O O
receiving O O
concomitant O O
high-dose O O
aspirin B-brand B-brand
and O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitors I-group I-group
, O O
as O O
anorexia O O
, O O
tachypnea O O
, O O
lethargy O O
and O O
coma O O
have O O
been O O
rarely O O
reported O O
due O O
to O O
a O O
possible O O
drug O O
interaction O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
may O O
block O O
the O O
antihypertensive O O
action O O
of O O
guanethidine B-drug B-drug
and O O
similarly O O
acting O O
compounds O O
. O O

The O O
rats O O
treated O O
with O O
the O O
highest O O
dose O O
of O O
TML B-drug_n B-drug_n
manifested O O
significantly O O
longer O O
latencies O O
to O O
lose O O
the O O
righting O O
reflex O O
and O O
shorter O O
durations O O
of O O
sleep O O
than O O
did O O
controls O O
. O O

High-dose O O
cyclosporin B-drug B-drug
A I-drug O
resulting O O
in O O
concentrations O O
above O O
2000 O O
ng/mL O O
administered O O
with O O
oral O O
etoposide B-drug B-drug
has O O
led O O
to O O
an O O
80 O O
% O O
increase O O
in O O
etoposide B-drug B-drug
exposure O O
with O O
a O O
38 O O
% O O
decrease O O
in O O
total O O
body O O
clearance O O
of O O
etoposide B-drug B-drug
compared O O
to O O
etoposide B-drug B-drug
alone O O
. O O

Since O O
a O O
clinically O O
significant O O
interaction O O
may O O
be O O
anticipated O O
, O O
alternative O O
antihypertensive B-drug B-group
therapy O O
should O O
be O O
considered O O
in O O
these O O
patients O O
. O O

The O O
clinical O O
significance O O
of O O
these O O
changes O O
has O O
not O O
been O O
adequately O O
studied O O
. O O

It O O
is O O
suggested O O
that O O
there O O
is O O
a O O
minor O O
contribution O O
of O O
adenosine O O
receptors O O
to O O
these O O
effects O O
, O O
although O O
theophylline-induced B-drug B-drug
anxiogenic O O
effects O O
were O O
antagonized O O
by O O
an O O
A2 O O
receptor O O
agonist O O
. O O

Drug/ O O
Laboratory O O
Test O O
Interactions O O
: O O
It O O
is O O
not O O
known O O
if O O
MEPRON B-brand B-brand
interferes O O
with O O
clinical O O
laboratory O O
test O O
or O O
assay O O
results O O
. O O

These O O
levels O O
then O O
remained O O
stable O O
for O O
up O O
to O O
1 O O
year O O
of O O
therapy O O
. O O

Indomethacin B-drug B-drug
may O O
also O O
affect O O
plasma O O
renin O O
levels O O
, O O
aldosterone O O
excretion O O
, O O
and O O
renin O O
profile O O
evaluation O O
. O O

The O O
extent O O
of O O
interaction O O
depends O O
on O O
the O O
variability O O
of O O
effect O O
on O O
CYP2D6 O O
. O O

Drugs O O
that O O
Inhibit O O
Drug O O
Transport O O
Systems O O
Lapatinib B-drug B-drug
is O O
a O O
substrate O O
of O O
the O O
efflux O O
transporter O O
P-glycoprotein O O
( O O
Pgp O O
, O O
ABCB1 O O
) O O
. O O

Ultimately O O
however O O
, O O
up O O
to O O
80 O O
% O O
of O O
type O O
2 O O
diabetics O O
die O O
from O O
macrovascular O O
cardiovascular O O
disease O O
. O O

Furthermore O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
combining O O
digoxin B-drug B-drug
with O O
any O O
drug O O
that O O
may O O
cause O O
a O O
significant O O
deterioration O O
in O O
renal O O
function O O
, O O
since O O
a O O
decline O O
in O O
glomerular O O
filtration O O
or O O
tubular O O
secretion O O
may O O
impair O O
the O O
excretion O O
of O O
digoxin B-drug B-drug
. O O

Effect O O

CONCLUSION O O
: O O
Cisapride B-drug B-drug
can O O
be O O
administered O O
safely O O
to O O
patients O O
receiving O O
low O O
therapeutic O O
dosages O O
of O O
fluoxetine B-drug B-drug
. O O

The O O
optimal O O
dose O O
of O O
indinavir B-drug B-drug
, O O
when O O
given O O
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
, O O
is O O
not O O
known O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Cephalosporins B-group B-group
, O O
including O O
cefotaxime B-drug B-drug
sodium I-drug I-drug
, O O
are O O
known O O
to O O
occasionally O O
induce O O
a O O
positive O O
direct O O
Coombs O O
test O O
. O O

OBJECTIVES O O
. O O

Metoclopramide B-drug B-drug
: O O
Bioavailability O O
is O O
mildly O O
reduced O O
( O O
approximately O O
10 O O
% O O
) O O
when O O
zalcitabine B-drug B-drug
and O O
metoclopramide B-drug B-drug
are O O
coadministered O O
. O O

In O O
our O O
laboratory O O
, O O
preliminary O O
whole-cell O O
, O O
tight O O
seal O O
recordings O O
of O O
rat O O
spinal O O
substantia O O
gelatinosa O O
neurons O O
including O O
biocytin O O
in O O
the O O
patch O O
pipette O O
yielded O O
a O O
significantly O O
smaller O O
proportion O O
of O O
neurons O O
hyperpolarized O O
by O O
selective B-group B-group
opioid I-group I-group
agonists I-group I-group
compared O O
with O O
recordings O O
without O O
biocytin O O
. O O

Nonetheless O O
, O O
the O O
range O O
of O O
individual O O
Simulect B-brand B-brand
clearance O O
values O O
in O O
the O O
presence O O
of O O
azathioprine B-drug B-drug
( O O
12-57 O O
mL/h O O
) O O
or O O
mycophenolate B-drug B-drug
mofetil I-drug I-drug
( O O
7-54 O O
mL/h O O
) O O
did O O
not O O
extend O O
outside O O
the O O
range O O
observed O O
with O O
dual O O
therapy O O
( O O
10-78 O O
mL/h O O
) O O
. O O

In O O
vivo O O
interaction O O
studies O O
in O O
humans O O
have O O
demonstrated O O
that O O
digoxin B-drug B-drug
and O O
warfarin B-drug B-drug
do O O
not O O
affect O O
the O O
PK O O
properties O O
of O O
anagrelide B-drug B-drug
, O O
nor O O
does O O
anagrelide B-drug B-drug
affect O O
the O O
PK O O
properties O O
of O O
digoxin B-drug B-drug
or O O
warfarin B-drug B-drug
. O O

Diltiazem B-drug B-drug
plasma O O
levels O O
were O O
not O O
significantly O O
affected O O
by O O
lovastatin B-drug B-drug
or O O
pravastatin B-drug B-drug
. O O

Metabolism O O
of O O
dasatinib B-drug B-drug
is O O
mainly O O
hepatic O O
. O O

Cimetidine B-drug B-drug
, O O
Ranitidine B-drug B-drug
: O O
In O O
normal O O
volunteers O O
( O O
n=9 O O
) O O
, O O
pretreatment O O
with O O
cimetidine B-drug B-drug
or O O
ranitidine B-drug B-drug
did O O
not O O
affect O O
flurbiprofen B-drug B-drug
pharmacokinetics O O
except O O
that O O
a O O
small O O
( O O
13 O O
% O O
) O O
but O O
statistically O O
significant O O
increase O O
in O O
the O O
area O O
under O O
the O O
serum O O
concentration O O
curve O O
of O O
flurbiprofen B-drug B-drug
resulted O O
with O O
cimetidine B-drug B-drug
. O O

Using O O
in O O
situ O O
hybridization O O
, O O
we O O
observed O O
that O O
METH B-drug B-drug
caused O O
a O O
rapid O O
and O O
transient O O
dose-dependent O O
increase O O
in O O
arc O O
mRNA O O
level O O
in O O
the O O
striatum O O
and O O
cortex O O
that O O
was O O
abolished O O
by O O
pretreatment O O
with O O
the O O
specific O O
dopamine O O
D1 O O
receptor O O
antagonist O O
SCH-23390 B-drug_n B-drug_n
but O O
not O O
by O O
an O O
atypical B-group B-group
neuroleptic I-group I-group
clozapine B-drug B-drug
. O O

Consider O O
additive O O
sedative O O
effects O O
and O O
confusional O O
states O O
to O O
emerge O O
, O O
if O O
chlorprothixene B-drug B-drug
is O O
given O O
with O O
benzodiazepines B-group B-group
or O O
barbituates B-group B-group
. O O

Aminophylline B-drug B-drug
Etomidate I-drug I-drug
antagonism O O

Coumarin B-group B-group
Anticoagulants O I-group
: O O
In O O
a O O
small O O
clinical O O
trial O O
in O O
which O O
lovastatin B-drug B-drug
was O O
administered O O
to O O
warfarin B-drug B-drug
treated O O
patients O O
, O O
no O O
effect O O
on O O
prothrombin O O
time O O
was O O
detected O O
. O O

Coadministration O O
of O O
single O O
, O O
oral O O
doses O O
of O O
zaleplon B-drug B-drug
with O O
erythromycin B-drug B-drug
( O O
10 O O
mg O O
and O O
800 O O
mg O O
, O O
respectively O O
) O O
, O O
a O O
strong O O
, O O
selective O O
CYP3A4 O O
inhibitor O O
produced O O
a O O
34 O O
% O O
increase O O
in O O
zaleplons B-drug B-drug
maximal O O
plasma O O
concentrations O O
and O O
a O O
20 O O
% O O
increase O O
in O O
the O O
area O O
under O O
the O O
plasma O O
concentration-time O O
curve O O
. O O

Other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
( O O
e.g. O O
, O O
aspirin B-brand B-brand
) O O
may O O
also O O
have O O
this O O
effect O O
. O O

iii O O
. O O

The O O
clinical O O
relevance O O
is O O
unclear O O
. O O

alcohol* B-drug B-drug
; O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
fenoprofen B-drug B-drug
, O O
because O O
of O O
its O O
affinity O O
for O O
albumin O O
, O O
may O O
displace O O
from O O
their O O
binding O O
sites O O
other O O
drugs O O
that O O
are O O
also O O
albumin O O
bound O O
, O O
and O O
this O O
may O O
lead O O
to O O
drug O O
interaction O O
. O O

[ O O
A O O
pharmacological O O
analysis O O
of O O
the O O
effect O O
of O O
angiotensin B-drug_n B-drug_n
on O O
stimulated O O
gastric O O
secretion O O
] O O
Chronic O O
experiments O O
on O O
dogs O O
with O O
gastric O O
fistulas O O
were O O
carried O O
out O O
to O O
study O O
the O O
influence O O
of O O
angiotensin B-drug_n B-drug_n
1 I-drug_n I-drug_n
and O O
angiotensin B-drug_n B-drug_n
2 I-drug_n I-drug_n
on O O
pentagastrin- B-drug B-drug
and O O
histamine-induced B-drug B-drug
gastric O O
acid O O
secretion O O
. O O

changes O O
in O O
cervical O O
mucus O O
, O O
the O O
endometrium O O
, O O
and O O
the O O
fallopian O O
tubes O O
; O O

Anticoagulants B-group B-group
including O O
coumarin O B-group
derivatives O I-group
, O O
indandione O O
derivatives O O
, O O
and O O
platelet B-group B-group
aggregation I-group I-group
inhibitors I-group I-group
such O O
as O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
, O O
and O O
aspirin B-brand B-brand
may O O
increase O O
the O O
risk O O
of O O
bleeding O O
when O O
administered O O
concomitantly O O
with O O
ardeparin B-drug B-drug
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
( O O
10 O O
mg O O
BID O O
for O O
7 O O
days O O
) O O
with O O
glyburide B-drug B-drug
( O O
5 O O
mg O O
QD O O
or O O
10 O O
mg O O
BID O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
( O O
exposure O O
) O O
of O O
glyburide B-drug B-drug
. O O

Protein O O
Binding O O
In O O
vitro O O
, O O
diclofenac B-drug B-drug
interferes O O
minimally O O
or O O
not O O
at O O
all O O
with O O
the O O
protein O O
binding O O
of O O
salicylic B-drug B-drug
acid I-drug I-drug
( O O
20 O O
% O O
decrease O O
in O O
binding O O
) O O
, O O
tolbutamide B-drug B-drug
, O O
prednisolone B-drug B-drug
( O O
10 O O
% O O
decrease O O
in O O
binding O O
) O O
, O O
or O O
warfarin B-drug B-drug
. O O

injection O O
of O O
phencyclidine B-drug_n B-drug_n
( O O
PCP B-drug_n B-drug_n
) O O
were O O
observed O O
by O O
measuring O O
locomotor O O
activity O O
and O O
stereotyped O O
behavior O O
. O O

Thus O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
on O O
one O O
of O O
the O O
agents O O
in O O
this O O
category O O
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
treatment O O
with O O
EQUETROTM B-brand B-brand
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
adjustment O O
may O O
be O O
necessary O O
. O O

Repeated O O
injection O O
of O O
PCP B-drug_n B-drug_n
for O O
20 O O
days O O
into O O
mice O O
induced O O
lower O O
locomotor O O
activity O O
than O O
that O O
in O O
acutely O O
injected O O
mice O O
. O O

Ibogaine B-drug_n B-drug_n
, O O
but O O
not O O
18-MC B-drug_n B-drug_n
, O O
decreases O O
heart O O
rate O O
at O O
high O O
doses O O
. O O

Similar O O
effects O O
would O O
be O O
expected O O
with O O
other O O
potent O O
CYP2D6 O O
inhibitors O O
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
quinidine B-drug B-drug
) O O
. O O

The O O
following O O
medications O O
have O O
been O O
administered O O
in O O
clinical O O
trials O O
with O O
Simulect B-brand B-brand
with O O
no O O
increase O O
in O O
adverse O O
reactions O O
: O O
ATG/ALG O O
, O O
azathioprine B-drug B-drug
, O O
corticosteroids B-group B-group
, O O
cyclosporine B-drug B-drug
, O O
mycophenolate B-drug B-drug
mofetil I-drug I-drug
, O O
and O O
muromonab-CD3 B-drug B-drug
. O O

Therefore O O
, O O
it O O
is O O
recommended O O
that O O
Fluvoxamine B-drug B-drug
Tablets O O
not O O
be O O
used O O
in O O
combination O O
with O O
MAOIs B-group B-group
, O O
or O O
within O O
14 O O
days O O
of O O
discontinuing O O
treatment O O
with O O
a O O
MAOI B-group B-group
. O O

Midazolam B-drug B-drug
used O O
at O O
doses O O
of O O
1.25 O O
mg/kg O O
and O O
2.5 O O
mg/kg O O
decreased O O
the O O
antinociceptive O O
effect O O
of O O
morphine B-drug B-drug
, O O
metamizol B-drug B-drug
( O O
only O O
in O O
the O O
tail-flick O O
test O O
) O O
and O O
indomethacin B-drug B-drug
. O O

Oral O O
Contraceptives B-group B-group
Rofecoxib B-drug B-drug
did O O
not O O
have O O
any O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
norethindrone B-drug B-drug
. O O

The O O
continued O O
need O O
for O O
the O O
other O O
antiarrhythmic B-drug B-group
agent O I-group
should O O
be O O
reviewed O O
after O O
the O O
effects O O
of O O
amiodarone B-drug B-drug
have O O
been O O
established O O
, O O
and O O
discontinuation O O
ordinarily O O
should O O
be O O
attempted O O
. O O

Drug-lab O O
interactions O O
: O O
implications O O
for O O
nutrition O O
support O O
. O O

However O O
, O O
careful O O
attention O O
must O O
be O O
directed O O
to B-group O
cross O O
toxicity O O
and O O
possible O O
pharmacokinetic O O
interactions O O
between O O
antiretroviral O B-group
and O O
antineoplastic B-group B-group
drugs I-group I-group
. O O

Effect O O
of O O
other O O
agents O O
on O O
the O O
pharmacokinefics O O
of O O
aprepitant B-drug B-drug

Patients O O
who O O
require O O
the O O
use O O
of O O
one O O
of O O
these O O
drugs O O
with O O
HIVID B-drug B-drug
should O O
have O O
frequent O O
clinical O O
and O O
laboratory O O
monitoring O O
with O O
dosage O O
adjustment O O
for O O
any O O
significant O O
change O O
in O O
renal O O
function O O
. O O

however O O
, O O
150 O O
mg O O
of O O
ranitidine B-drug B-drug
q12h O O
for O O
3 O O
days O O
increased O O
the O O
ceftibuten B-drug B-drug
C O O
max O O
by O O
23 O O
% O O
and O O
ceftibuten B-drug B-drug
AUC O O
by O O
16 O O
% O O
. O O

Antacid B-group B-group
( O O
Maalox B-brand B-brand
) O O
: O O
Maalox B-brand B-brand
reduced O O
the O O
bioavailability O O
of O O
gabapentin B-drug B-drug
( O O
N=16 O O
) O O
by O O
about O O
20 O O
% O O
. O O

The O O
intensity O O
, O O
uniformity O O
and O O
time O O
course O O
of O O
anticoagulant B-group B-group
interference O O
by O O
phenobarbital B-drug B-drug
, O O
secobarbital B-drug B-drug
, O O
glutethimide B-drug B-drug
, O O
chloral B-drug B-drug
hydrate I-drug I-drug
and O O
methaqualone B-drug B-drug
were O O
systematically O O
investigated O O
in O O
16 O O
patients O O
receiving O O
coumarin B-group B-group
therapy O O
. O O

Warfarin-Vitamin B-drug B-drug
K B-group I-drug
can O O
antagonize O O
the O O
effect O O
of O O
warfarin B-drug B-drug

If O O
a O O
patient O O
has O O
been O O
treated O O
with O O
cyclophosphamide B-drug B-drug
within O O
10 O O
days O O
of O O
general O O
anesthesia O O
, O O
the O O
anesthesiologist O O
should O O
be O O
alerted O O
. O O

The O O
effect O O
of O O
alosetron B-drug B-drug
on O O
monoamine O O
oxidases O O
and O O
on O O
intestinal O O
first O O
pass O O
secondary O O
to O O
high O O
intraluminal O O
concentrations O O
have O O
not O O
been O O
examined O O
. O O

2 O O
. O O

Clinical O O
implications O O
of O O
warfarin B-drug B-drug
interactions O O
with O O
five O O
sedatives B-group B-group
. O O

Table O O
5a O O
: O O
Drugs O O
That O O
Should O O
Not O O
Be O O
Coadministered O O
With O O
SUSTIVA B-brand B-brand

Clonidine B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
clonidine B-drug B-drug
with O O
agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group I-group
may O O
potentiate O O
blood-pressure- O O
and O O
heart-rate-lowering O O
effects O O
. O O

Steady O O
state O O
plasma O O
digitoxin B-drug B-drug
concentrations O O
did O O
not O O
appear O O
to O O
change O O
. O O

CFUs O O
were O O
maintained O O
at O O
low O O
levels O O
( O O
10 O O
( O O
3 O O
) O O
CFU O O
mL O O
( O O
-1 O O
) O O
) O O
for O O
24 O O
h O O
by O O
vancomycin/flavone B-drug B-drug
combinations O O
. O O

Appropriate O O
doses O O
for O O
this O O
combination O O
are O O
not O O
established O O
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
other O O
drugs O O
is O O
withdrawn O O
from O O
cotherapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
may O O
be O O
required O O
. O O

Olanzapine B-drug B-drug
treatment O O
improves O O
quality O O
of O O
life O O
in O O
patients O O
with O O
schizophrenia O O
and O O
related O O
psychoses O O
to O O
a O O
greater O O
extent O O
than O O
haloperidol B-drug B-drug
, O O
and O O
to O O
broadly O O
the O O
same O O
extent O O
as O O
risperidone B-drug B-drug
. O O

Since O O
PLETAL B-brand B-brand
is O O
extensively O O
metabolized O O
by O O
cytochrome O O
P-450 O O
isoenzymes O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
PLETAL B-brand B-brand
is O O
coadministered O O
with O O
inhibitors O O
of O O
C.P.A O O
. O O
such O O
as O O
ketoconazole B-drug B-drug
and O O
erythromycin B-drug B-drug
or O O
inhibitors O O
of O O
CYP2C19 O O
such O O
as O O
omeprazole B-drug B-drug
. O O

On O O
the O O
average O O
for O O
the O O
group O O
, O O
the O O
dose O O
of O O
cyclosporine B-drug B-drug
was O O
reduced O O
about O O
20 O O
% O O
in O O
these O O
patients O O
. O O

In O O
vitro O O
studies O O
evaluating O O
the O O
minimum O O
inhibitory O O
concentration O O
( O O
MIC O O
) O O
of O O
vancomycin B-drug B-drug
, O O
cefazolin B-drug B-drug
, O O
ampicillin B-drug B-drug
, O O
ampicillin/flucoxacillin B-drug B-drug
, O O
ceftazidime B-drug B-drug
, O O
gentamicin B-drug B-drug
, O O
and O O
amphotericin B-drug B-drug
demonstrated O O
no O O
evidence O O
of O O
incompatibility O O
of O O
these O O
antibiotics B-group B-group
with O O
EXTRANEAL B-brand B-brand
. O O

Fulminant O O
rhabdomyolysis O O
has O O
been O O
seen O O
as O O
early O O
as O O
three O O
weeks O O
after O O
initiation O O
of O O
combined O O
therapy O O
with O O
another O O
fibrate B-group B-group
and O O
lovastatin B-drug B-drug
but O O
may O O
be O O
seen O O
after O O
several O O
months O O
. O O

Although O O
it O O
has O O
not O O
been O O
definitively O O
demonstrated O O
that O O
fluvoxamine B-drug B-drug
is O O
a O O
potent O O
IIIA4 O O
inhibitor O O
, O O
it O O
is O O
likely O O
to O O
be O O
, O O
given O O
the O O
substantial O O
interaction O O
of O O
fluvoxamine B-drug B-drug
with O O
alprazolam B-drug B-drug
. O O

Although O O
the O O
clinical O O
significance O O
is O O
not O O
known O O
, O O
it O O
is O O
not O O
recommended O O
that O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
be O O
taken O O
concomitantly O O
with O O
H2 B-group B-group
receptor I-group I-group
antagonists I-group I-group
. O O

The O O
administration O O
of O O
guanfacine B-drug B-drug
concomitantly O O
with O O
known O O
microsomal O O
enzyme O O
inducer O O
( O O
phenobarbital B-drug B-drug
or O O
phenytoin B-drug B-drug
) O O
to O O
two O O
patients O O
with O O
renal O O
impairment O O
reportedly O O
resulted O O
in O O
significant O O
reductions O O
in O O
elimination O O
half-life O O
and O O
plasma O O
concentration O O
. O O

These O O
antibiotics B-group B-group
should O O
be O O
used O O
in O O
the O O
myasthenic O O
patient O O
only O O
where O O
definitely O O
indicated O O
, O O
and O O
then O O
careful O O
adjustment O O
should O O
be O O
made O O
of O O
adjunctive O O
anticholinesterase B-group B-group
dosage O O
. O O

Both O O
18-MC B-drug_n B-drug_n
and O O
ibogaine B-drug_n B-drug_n
are O O
sequestered O O
in O O
fat O O
and O O
, O O
like O O
ibogaine B-drug_n B-drug_n
, O O
18-MC B-drug_n B-drug_n
probably O O
has O O
an O O
active O O
metabolite O O
. O O

Theophylline B-drug B-drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
40 O O
mg/day O O
for O O
21 O O
days O O
) O O
and O O
the O O
CYP1A2 O O
substrate O O
theophylline B-drug B-drug
( O O
single O O
dose O O
of O O
300 O O
mg O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
. O O

Digitalis B-group B-group
Glycosides I-group I-group
: O O
Therapeutic O O
effects O O
of O O
digitalis B-group B-group
glycosides I-group I-group
may O O
be O O
reduced O O
. O O

However O O
, O O
other O O
published O O
reports O O
describe O O
modest O O
elevations O O
( O O
less O O
than O O
two-fold O O
) O O
of O O
clozapine B-drug B-drug
and O O
metabolite O O
concentrations O O
when O O
clozapine B-drug B-drug
was O O
taken O O
with O O
paroxetine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
and O O
sertraline B-drug B-drug
. O O

These O O
results O O
suggest O O
that O O
D1 O O
receptors O O
are O O
coupled O O
to O O
activation O O
of O O
arc O O
gene O O
, O O
which O O
may O O
be O O
involved O O
in O O
functional O O
or O O
structural O O
alterations O O
underlying O O
neural O O
plasticity O O
triggered O O
by O O
METH B-drug B-drug
. O O

. O O

Close O O
monitoring O O
allows O O
physicians O O
to O O
minimize O O
risks O O
, O O
maximize O O
benefits O O
, O O
and O O
get O O
the O O
most O O
out O O
of O O
what O O
modern O O
medications O O
can O O
do O O
to O O
help O O
older O O
patients O O
. O O

Because O O
ritonavir B-drug B-drug
is O O
coadministered O O
, O O
prescribers O O
should O O
also O O
refer O O
to O O
the O O
prescribing O O
information O O
for O O
ritonavir B-drug B-drug
regarding O O
drug O O
interactions O O
associated O O
with O O
this O O
agent O O
. O O

Exogenous O O
estradiol B-drug B-drug
also O O
appeared O O
to O O
influence O O
the O O
percentage O O
of O O
endotoxin-induced B-drug_n B-drug_n
deaths O O
in O O
a O O
dose-dependent O O
manner O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
used O O
when O O
administering O O
MEPRON B-brand B-brand
concurrently O O
with O O
other O O
highly O O
plasma O O
protein- O O
bound O O
drugs O O
with O O
narrow O O
therapeutic O O
indices O O
, O O
as O O
competition O O
for O O
binding O O
sites O O
may O O
occur O O
. O O

Therefore O O
, O O
the O O
potential O O
for O O
such O O
drug O O
interaction O O
should O O
be O O
considered O O
in O O
patients O O
receiving O O
AZOPT B-brand B-brand
( O O
brinzolamide B-drug B-drug
ophthalmic O O
suspension O O
) O O
1 O O
% O O
. O O

When O O
administered O O
concurrently O O
, O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
adrenal B-group B-group
corticosteroids I-group I-group
. O O

forms O O
of O O
memory O O
. O O

Warfarin B-drug B-drug
, O O
Digoxin B-drug B-drug
, O O
Salicylate B-group B-group
, O O
and O O
Heparin B-drug B-drug
The O O
in O O
vitro O O
binding O O
of O O
warfarin B-drug B-drug
to O O
plasma O O
proteins O O
is O O
only O O
slightly O O
reduced O O
by O O
ketorolac B-drug B-drug
tromethamine I-drug I-drug
( O O
99.5 O O
% O O
control O O
vs O O
99.3 O O
% O O
) O O
when O O
ketorolac B-drug B-drug
plasma O O
concentrations O O
reach O O
5 O O
to10 O O
m O O
g/mL O O
. O O

Conversely O O
, O O
at O O
exposure O O
levels O O
close O O
to O O
the O O
" O O
limit O O
values O O
" O O

Reduced O O
response O O
to O O
metyrapone O O
test O O
. O O

Subjects O O
treated O O
with O O
200 O O
mg O O
of O O
dideoxyinosine B-drug B-drug
twice O O
daily O O
for O O
21 O O
days O O
received O O
1200 O O
mg O O
of O O
azithromycin B-drug B-drug
or O O
an O O
equivalent O O
amount O O
of O O
placebo/day O O
for O O
Days O O
8 O O
to O O
21 O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
used O O
in O O
concomitant O O
administration O O
. O O

Use O O
of O O
barrier O O
form O O
of O O
contraception O O
is O O
suggested O O
while O O
on O O
griseofulvin B-drug B-drug
therapy O O
. O O

With O O
drugs O O
inhibiting O O
CYP3A O O
to O O
a O O
lesser O O
, O O
but O O
still O O
significant O O
degree O O
, O O
estazolam B-drug B-drug
should O O
be O O
used O O
only O O
with O O
caution O O
and O O
consideration O O
of O O
appropriate O O
dosage O O
reduction O O
. O O

However O O
, O O
because O O
some O O
quinolones B-group B-group
have O O
been O O
reported O O
to O O
enhance O O
the O O
anticoagulant O O
effects O O
of O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
in O O
patients O O
, O O
the O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
test O O
should O O
be O O
closely O O
monitored O O
if O O
a O O
quinolone B-group B-group
antimicrobial I-group I-group
is O O
administered O O
concomitantly O O
with O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

Clinically O O
meaningful O O
drug O O
interactions O O
have O O
occurred O O
with O O
concomitant O O
medications O O
and O O
include O O
, O O
but O O
are O O
not O O
limited O O
to O O
the O O
following O O
: O O
Agents O O
Highly O O
Bound O O
to O O
Plasma O O
Protein O O
Carbamazepine B-drug B-drug
is O O
not O O
highly O O
bound O O
to O O
plasma O O
proteins O O
; O O

Clinical O O
Laboratory O O

Geriatric O O
Use O O
When O O
tumor O O
response O O
was O O
considered O O
by O O
age O O
, O O
objective O O
responses O O
were O O
seen O O
in O O
24 O O
% O O
and O O
22 O O
% O O
of O O
patients O O
under O O
65 O O
years O O
of O O
age O O
and O O
in O O
16 O O
% O O
and O O
11 O O
% O O
of O O
patients O O
65 O O
years O O
of O O
age O O
and O O
older O O
, O O
who O O
were O O
treated O O
with O O
FASLODEX B-brand B-brand
in O O
the O O
European O O
and O O
North O O
American O O
trials O O
, O O
respectively O O
. O O

Therefore O O
, O O
etodolac B-drug B-drug
can O O
generally O O
be O O
given O O
without O O
the O O
need O O
for O O
dosage O O
modifications O O
in O O
special O O
populations O O
such O O
as O O
uncompromised O O
elderly O O
patients O O
, O O
those O O
with O O
moderate O O
renal O O
impairment O O
, O O
and O O
patients O O
with O O
stable O O
hepatic O O
disease O O
. O O

Studies O O
of O O
the O O
effect O O
of O O
food O O
on O O
the O O
pharmacokinetics O O
of O O
fluvastatin B-drug B-drug
have O O
demonstrated O O
marked O O
reductions O O
in O O
the O O
rate O O
of O O
bioavailability O O
-- O O
from O O
40 O O
% O O
to O O
60 O O
% O O
; O O

In O O
a O O
patient O O
with O O
a O O
nonfunctioning O O
thyroid O O
gland O O
who O O
is O O
receiving O O
thyroid O O
replacement O O
therapy O O
, O O
free O O
levothyroxine B-drug B-drug
may O O
be O O
decreased O O
when O O
estrogens B-group B-group
are O O
started O O
thus O O
increasing O O
thyroid B-group O
requirements O O
. O O

In O O
patients O O
receiving O O
Nalfon B-brand B-brand
and O O
a O O
steroid B-group B-group
concomitantly O O
, O O
any O O
reduction O O
in O O
steroid B-group B-group
dosage O O
should O O
be O O
gradual O O
in O O
order O O
to O O
avoid O O
the O O
possible O O
complications O O
of O O
sudden O O
steroid B-group O
withdrawal O O
. O O

The O O
effect O O
of O O
foods O O
highly O O
fortified O O
with O O
elemental O O
iron B-drug_n B-drug_n
( O O
primarily O O
iron-fortified B-drug_n B-drug_n
breakfast O O
cereals O O
) O O
on O O
cefdinir B-drug B-drug
absorption O O
has O O
not O O
been O O
studied O O
. O O

As O O
plasma O O
protein O O
binding O O
of O O
decitabine B-drug B-drug
is O O
negligible O O
( O O
1 O O
% O O
) O O
, O O
interactions O O
due O O
to O O
displacement O O
of O O
more O O
highly O O
protein O O
bound O O
drugs O O
from O O
plasma O O
proteins O O
are O O
not O O
expected O O
. O O

Although O O
specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
ALPHAGAN B-brand B-brand
P I-brand I-brand
, O O
the O O
possibility O O
of O O
an O O
additive O O
or O O
potentiating O O
effect O O
with O O
CNS B-group B-group
depressants I-group I-group
( O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
opiates B-group B-group
, O O
sedatives B-group B-group
, O O
or O O
anesthetics B-group B-group
) O O
should O O
be O O
considered O O
. O O

Gabapentin B-drug B-drug
pharmacokinetic O O
parameters O O
without O O
and O O
with O O
probenecid B-drug B-drug
were O O
comparable O O
. O O

and O O
, O O
rarely O O
, O O
dry O O
mouth O O
, O O
anorexia O O
, O O
taste O O
disorder O O
, O O
abdominal O O
pain O O
, O O
vomiting O O
, O O
diarrhea O O
, O O
and O O
positive O O
test O O
for O O
occult O O
blood O O
in O O
stool O O
. O O

Plasma O O
levels O O
of O O
anticonvulsant B-group B-group
agents I-group I-group
may O O
become O O
subtherapeutic O O
during O O
cisplatin B-drug B-drug
therapy O O
. O O

Cardiovascular O O
agents O O
( O O
e.g. O O
, O O
atenolol B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
propranolol B-drug B-drug
) O O
. O O

+164 O O
% O O

vi O O
. O O

A O O
possible O O
interaction O O
between O O
glyburide B-drug B-drug
and O O
ciprofloxacin B-drug B-drug
, O O
a O O
fluoroquinolone B-group B-group
antibiotic I-group I-group
, O O
has O O
been O O
reported O O
, O O
resulting O O
in O O
a O O
potentiation O O
of O O
the O O
hypoglycemic O O
action O O
of O O
glyburide B-drug B-drug
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reaction O O
. O O

These O O
above O O
findings O O
are O O
summarized O O
in O O
TABLE O O
1 O O
. O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
, O O
because O O
of O O
its O O
affinity O O
for O O
protein O O
, O O
6MNA B-drug_n B-drug_n
may O O
displace O O
other O O
protein-bound O O
drugs O O
from O O
their O O
binding O O
site O O
. O O

The O O
effects O O
of O O
PEGASYS B-brand B-brand
on O O
male O O
fertility O O
have O O
not O O
been O O
studied O O
. O O

The O O
pressor O O
effects O O
of O O
catecholamines B-group O
such O O
as O O
dopamine B-drug B-drug
or O O
norepinephrine B-drug B-drug
are O O
enhanced O O
by O O
Bretylium B-drug B-drug
Tosylate I-drug I-drug
. O O

Because O O
dexfenfluramine B-drug B-drug
is O O
a O O
serotonin O O
releaser O O
and O O
reuptake O O
inhibitor O O
, O O
dexfenfluramine B-drug B-drug
should O O
not O O
be O O
used O O
concomitantly O O
with O O
a O O
MAO B-group B-group
inhibitor I-group I-group
. O O

CONCLUSIONS/INTERPRETATION O O
: O O
Glucose B-drug B-drug
and O O
insulin B-drug B-drug
can O O
exert O O
additive O O
vasodilator O O
properties O O
on O O
renal O O
and O O
ocular O O
circulation O O
. O O

Dexamethasone B-drug B-drug
at O O
10 O O
( O O
-10 O O
) O O
M O O
or O O
retinyl B-drug B-drug
acetate I-drug I-drug
at O O
about O O
3 O O
X O O
10 O O
( O O
-9 O O
) O O
M O O
inhibits O O
proliferation O O
stimulated O O
by O O
EGF B-drug_n B-drug_n
. O O

Therefore O O
, O O
concurrent O O
administration O O
of O O
drugs O O
that O O
induce O O
or O O
inhibit O O
this O O
enzyme O O
may O O
affect O O
quetiapine B-drug B-drug
pharmacokinetics O O
. O O

Our O O
results O O
indicate O O
important O O
relationships O O
among O O
ras O O
, O O
nucleophosmin/B23 O O
, O O
activation O O
of O O
caspase-3 O O
, O O
and O O
induction O O
of O O
apoptosis O O
. O O

Plasma O O
concentrations O O
increased O O
by O O
SUSTIVA B-brand B-brand
( O O
efavirenz B-drug B-drug
) O O
; O O

Coadministration O O
of O O
terfenadine B-drug B-drug
with O O
Itraconazole B-drug B-drug
has O O
led O O
to O O
elevated O O
plasma O O
concentrations O O
of O O
terfenadine B-drug B-drug
, O O
resulting O O
in O O
rare O O
instances O O
of O O
life- O O
threatening O O
cardiac O O
dysrhythmias O O
and O O
one O O
death O O
. O O

Agents O O
that O O
are O O
CYP O O
inducers O O
that O O
have O O
been O O
found O O
, O O
or O O
are O O
expected O O
, O O
to O O
decrease O O
plasma O O
levels O O
of O O
EQUETROTM B-brand B-brand
are O O
the O O
following O O
: O O
Cisplatin B-drug B-drug
, O O
doxorubicin B-drug B-drug
HCL I-drug I-drug
, O O
felbamate B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
Phenytoin B-drug B-drug
( O O
2 O O
) O O
, O O
primidone B-drug B-drug
, O O
methsuximide B-drug B-drug
, O O
and O O
theophylline B-drug B-drug
Thus O O
, O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
on O O
EQUETROTM B-brand B-brand
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
treatment O O
with O O
one O O
of O O
these O O
CYP3A4 O O
inducers O O
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
increase O O
for O O
EQUETROTM B-brand B-brand
may O O
be O O
necessary O O
. O O

The O O
Cmax O O
of O O
norethindrone B-drug B-drug
was O O
13 O O
% O O
higher O O
when O O
it O O
was O O
coadministered O O
with O O
gabapentin B-drug B-drug
; O O

The O O
effectiveness O O
of O O
norepinephrine B-drug B-drug
in O O
increasing O O
the O O
force O O
of O O
contraction O O
was O O
decreased O O
in O O
relation O O
to O O
the O O
degree O O
of O O
heart O O
failure O O
. O O

Cholestyramine B-drug B-drug
resin B-group B-group
may O O
delay O O
or O O
reduce O O
the O O
absorption O O
of O O
concomitant O O
oral O O
medication O O
such O O
as O O
phenylbutazone B-group B-drug
, O O
warfarin B-drug B-drug
, O O
thiazide B-group B-group
diuretics I-group I-group
( O O
acidic O O
) O O
or O O
propranolol B-drug B-drug
( O O
basic O O
) O O
, O O
as O O
well O O
as O O
tetracycline B-drug B-drug
penicillin I-drug I-drug
G I-drug I-drug
, O O
phenobarbital B-drug B-drug
, O O
thyroid O O
and O O
thyroxine B-drug B-group
preparations O I-group
, O O
estrogens B-group B-group
and O O
progestins B-group B-group
, O O
and O O
digitalis B-group B-group
. O O

- O O
Changes O O
in O O
TBg O O
concentration O O
should O O
be O O
taken O O
into O O
consideration O O
in O O
the O O
interpretation O O
of O O
T4 O O
and O O
T3 O O
values O O
. O O

14-OH O O
metabolite O O
concentration O O

No O O
data O O
from O O
prospective O O
clinical O O
trials O O
currently O O
exist O O
comparing O O
the O O
3 O O
approved O O
agents O O
( O O
efavirenz B-drug B-drug
, O O
nevirapine B-drug B-drug
or O O
delavirdine B-drug B-drug
) O O
. O O

A O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
. O O

Intracellular O O
and O O
extracellular O O
application O O
of O O
RR B-drug_n B-drug_n
reduced O O
ADP-induced O O
increases O O
in O O
[ O O
Ca O O
( O O
2+ O O
) O O
] O O
( O O
i O O
) O O
. O O

Imipramine B-drug B-drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
Sonata B-brand B-brand
20 O O
mg O O
and O O
imipramine B-drug B-drug
75 O O
mg O O
produced O O
additive O O
effects O O
on O O
decreased O O
alertness O O
and O O
impaired O O
psychomotor O O
performance O O
for O O
2 O O
to O O
4 O O
hours O O
after O O
administration O O
. O O

Total O O
body O O
clearance O O
of O O
Simulect B-brand B-brand
was O O
reduced O O
by O O
an O O
average O O
22 O O
% O O
and O O
51 O O
% O O
when O O
azathioprine B-drug B-drug
and O O
mycophenolate B-drug B-drug
mofetil I-drug I-drug
, O O
respectively O O
, O O
were O O
added O O
to O O
a O O
regimen O O
consisting O O
of O O
cyclosporine B-drug B-drug
, O O
USP O O
( O O
MODIFIED O O
) O O
and O O
corticosteroids B-group B-group
. O O

Of O O
the O O
1357 O O
patients O O
who O O
received O O
AMEVIVE B-brand B-brand
in O O
clinical O O
trials O O
, O O
a O O
total O O
of O O
100 O O
patients O O
were O O

Ibandronate B-drug B-drug
should O O
be O O
taken O O
at O O
least O O
60 O O
minutes O O
before O O
any O O
oral O O
medications O O
containing O O
multivalent O O
cations O O
( O O
including O O
antacids B-group B-group
, O O
supplements O O
or O O
vitamins B-group B-group
) O O
. O O

Frequent O O
prothrombin O O
determinations O O
are O O
advisable O O
until O O
it O O
has O O
been O O
determined O O
definitely O O
that O O
the O O
prothrombin O O
level O O
has O O
been O O
stabilized O O
. O O

The O O
risk O O
of O O
a O O
potential O O
interaction O O
between O O
NovoSeven B-brand B-brand
and O O
coagulation B-group B-group
factor I-group I-group
concentrates O I-group
has O O
not O O
been O O
adequately O O
evaluated O O
in O O
preclinical O O
or O O
clinical O O
studies O O
. O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
slows O O
the O O
renal O O
elimination O O
of O O
lome-floxacin O B-drug
. O O

Among O O
the O O
polyene B-group B-group
antibiotics I-group I-group
, O O
many O O
, O O
like O O
filipin B-drug_n B-drug_n
, O O
can O O
not O O
be O O
used O O
clinically O O
because O O
they O O
are O O
toxic O O
; O O

Patients O O
' O O
mean O O
age O O
was O O
69.1 O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
1.2 O O
) O O
. O O

Plasma O O
valproate B-drug B-drug
concentration O O
should O O
be O O
monitored O O
when O O
isoniazid B-drug B-drug
and O O
valproate B-drug B-drug
are O O
co O O
administered O O
, O O
and O O
appropriate O O
dosage O O
adjustments O O
of O O
valproate B-drug B-drug
should O O
be O O
made O O
. O O

Effective O O
use O O
of O O
drugs O O
in O O
therapy O O
depends O O
not O O
only O O
on O O
clinical O O
acumen O O
but O O
also O O
on O O
the O O
availability O O
of O O
relevant O O
pharmacokinetic O O
and O O
pharmacodynamic O O
data O O
. O O

Drug O O
Interactions O O
. O O

salicylates B-group B-group
; O O
sulfinpyrazone B-drug B-drug
; O O

No O O
adverse O O
effects O O
on O O
female O O
fertility O O
and O O
embryonic O O
survival O O
were O O
evident O O
in O O
female O O
animals O O
dosed O O
at O O
0.001 O O
mg/kg/day O O
( O O
approximately O O
one-thousandth O O
of O O
the O O
human O O
dose O O
based O O
on O O
BSA O O
) O O
. O O

These O O
agents O O
have O O
also O O
been O O
shown O O
to O O
decrease O O
platelet O O
nucleotide O O
release O O
and O O
thromboxane O O
A2 O O
generation O O
. O O

Do O O
not O O
start O O
or O O
stop O O
any O O
medicine O O
without O O
doctor O O
or O O
pharmacist O O
approval O O
. O O

Psychoactive B-group B-group
Drugs I-group I-group
: O O
Hallucinations O O
have O O
been O O
reported O O
when O O
TORADOL B-brand B-brand
was O O
used O O
in O O
patients O O
taking O O
psychoactive B-group B-group
drugs I-group I-group
( O O
fluoxetine B-drug B-drug
, O O
thiothixene B-drug B-drug
, O O
alprazolam B-drug B-drug
) O O
. O O

Use O O
caution O O
when O O
giving O O
these O O
drugs O O
together O O
, O O
especially O O
in O O
patients O O
with O O
hepatic O O
or O O
cardiac O O
disease O O
. O O

In O O
addition O O
, O O
Fondaparinux B-drug B-drug
neither O O
influenced O O
the O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
, O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
piroxicam B-drug B-drug
, O O
and O O
digoxin B-drug B-drug
, O O
nor O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
at O O
steady O O
state O O
. O O

Cypermethrin-induced B-drug B-drug
oxidative O O
stress O O
in O O
rat O O
brain O O
and O O
liver O O
is O O
prevented O O
by O O
vitamin B-drug B-drug
E I-drug I-drug
or O O
allopurinol B-drug B-drug
. O O

In O O
patients O O
taking O O
diclofenac B-drug B-drug
and O O
lithium B-drug B-drug
concomitantly O O
, O O
lithium B-drug B-drug
toxicity O O
may O O
develop O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
atypical B-group B-group
antipsychotic I-group I-group
clozapine B-drug B-drug
was O O
tested O O
in O O
combination O O
with O O
an O O
active O O
dose O O
of O O
PCP B-drug_n B-drug_n
in O O
two-lever O O
drug O O
discrimination O O
and O O
mixed O O
signalled-unsignalled O O
differential-reinforcement-of-low-rates O O
( O O
DRL O O
) O O
procedures O O
. O O

The O O
vasodilating O O
effects O O
of O O
isosorbide B-drug B-drug
mononitrate I-drug I-drug
may O O
be O O
additive O O
with O O
those O O
of O O
other O O
vasodilators B-group B-group
. O O

In O O
vitro O O
, O O
buspirone B-drug B-drug
does O O
not O O
displace O O
tightly O O
bound O O
drugs O O
like O O
phenytoin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
from O O
serum O O
proteins O O
. O O

No O O
evidence O O
of O O
fetal O O
toxicity O O
including O O
adverse O O
effects O O
on O O
immune O O
system O O
development O O
was O O
observed O O
in O O
any O O
of O O
these O O
animals O O
. O O

Efavirenz B-drug B-drug
has O O
demonstrated O O
superiority O O
over O O
nelfinavir B-drug B-drug
in O O
nucleoside-experienced O O
patients O O
, O O
although O O
combining O O
these O O
2 O O
agents O O
may O O
represent O O
the O O
best O O
approach O O
in O O
these O O
circumstances O O
. O O

Gold B-group B-drug
is O O
excreted O O
slowly O O
from O O
the O O
body O O
. O O

When O O
ertapenem B-drug B-drug
is O O
co-administered O O
with O O
probenecid B-drug B-drug
( O O
500 O O
mg O O
p.o O O
. O O
every O O
6 O O
hours O O
) O O
, O O
probenecid B-drug B-drug
competes O O
for O O
active O O
tubular O O
secretion O O
and O O
reduces O O
the O O
renal O O
clearance O O
of O O
ertapenem B-drug B-drug
. O O

METHODS O O
: O O
All O O
patients O O
were O O
enrolled O O
in O O
two O O
sequential O O
trials O O
performed O O
at O O
the O O
Aviano O O
Cancer O O
Center O O
, O O
Italy O O
, O O
from O O
April O O
1988 O O
to O O
December O O
1998 O O
. O O

There O O
was O O
no O O
effect O O
on O O
bleeding O O
time O O
, O O
PT O O
or O O
aPTT O O
. O O

The O O
potential O O
for O O
drug O O
interactions O O
with O O
EMTRIVA B-brand B-brand
has O O
been O O
studied O O
in O O
combination O O
with O O
indinavir B-drug B-drug
, O O
stavudine B-drug B-drug
, O O
famciclovir B-drug B-drug
, O O
and O O
tenofovir B-drug B-drug
disoproxil I-drug I-drug
fumarate I-drug I-drug
. O O

therefore O O
, O O
administration O O
of O O
these O O
agents O O
should O O
precede O O
lomefloxacin B-drug B-drug
dosing O O
by O O
4 O O
hours O O
or O O
follow O O
lomefloxacin B-drug B-drug
dosing O O
by O O
at O O
least O O
2 O O
hours O O
. O O

As O O
a O O
moderate O O
inhibitor O O
of O O
CYP3A4 O O
, O O
aprepitant B-drug B-drug
can O O
increase O O
plasma O O
concentrations O O
of O O
coadministered O O
medicinal O O
products O O
that O O
are O O
metabolized O O
through O O
CYP3A4 O O
. O O

Medications O O
can O O
interfere O O
with O O
folate O O
utilization O O
, O O
including O O
: O O
anticonvulsant B-group B-group
medications I-group I-group
( O O
such O O
as O O
phenytoin B-drug B-drug
, O O
and O O
primidone B-drug B-drug
) O O
metformin B-drug B-drug
( O O
sometimes O O
prescribed O O
to O O
control O O
blood O O
sugar O O
in O O
type O O
2 O O
diabetes O O
) O O
sulfasalazine B-drug B-drug
( O O
used O O
to O O
control O O
inflammation O O
associated O O
with O O
Crohns O O
disease O O
and O O
ulcerative O O
colitis O O
) O O
triamterene B-drug B-drug
( O O
a O O
diuretic B-group B-group
) O O
Methotrexate B-drug B-drug
There O O
has O O
been O O
concern O O
about O O
the O O
interaction O O
between O O
vitamin B-drug B-drug
B12 I-drug I-drug
and O O
folic B-drug B-drug
acid I-drug I-drug
. O O

Digoxin B-drug B-drug
: O O
Some O O
calcium B-group B-group
blockers I-group I-group
may O O
increase O O
the O O
concentration O O
of O O
digitalis B-group B-group
preparations I-group I-group
in O O
the O O
blood O O
. O O

The O O
mechanism O O
of O O
the O O
action O O
of O O
PTX B-drug_n B-drug_n
was O O
discussed O O
in O O
the O O
relation O O
with O O
Na O O
, O O
K-ATPase O O
. O O

Pregnancy O O
estrogens B-group B-group
and O O
estrogen-containing B-group B-group
oral O O
contraceptives B-group B-group
increase O O
TBg O O
concentrations O O
. O O

Reformed O O
microtubules O O
appeared O O
to O O
function O O
normally O O
with O O
respect O O
to O O
their O O
possible O O
role O O
in O O
the O O
transport O O
of O O
noradrenaline O O
storage O O
vesicles O O
along O O
the O O
axons O O
. O O

Free O O
hormone O O
concentrations O O
may O O
be O O
decreased O O
. O O

Exposed O O
histidines O O
on O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
are O O
available O O
for O O
zinc B-drug B-drug
chelation O O
, O O
and O O
these O O
have O O
been O O
exploited O O
in O O
the O O
development O O
of O O
a O O
novel O O
purification O O
protocol O O
for O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
using O O
zinc-chelating B-drug B-drug
chromatography O O
. O O

However O O
, O O
it O O
was O O
observed O O
that O O
the O O
pharmacokinetics O O
of O O
ENBREL B-brand B-brand
was O O
unaltered O O
by O O
concomitant O O
methotrexate B-drug B-drug
in O O
rheumatoid O O
arthritis O O
patients O O
. O O

Ketamine B-drug B-drug
: O O
When O O
administered O O
to O O
patients O O
on O O
a O O
thyroid B-group O
preparation I-group O
, O O
this O O
parenteral O O
anesthetic B-group B-group
may O O
cause O O
hypertension O O
and O O
tachycardia O O
. O O

Acetaminophen B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
and O O
valproic B-drug B-drug
acid I-drug I-drug
were O O
added O O
to O O
pooled O O
human O O
serum O O
at O O
therapeutic O O
concentrations O O
. O O

Metformin B-drug B-drug
: O O
In O O
healthy O O
subjects O O
given O O
single O O
500 O O
mg O O
doses O O
of O O
cephalexin B-drug B-drug
and O O
metformin B-drug B-drug
, O O
plasma O O
metformin B-drug B-drug
mean O O
cmax O O
and O O
AUC O O
increased O O
by O O
an O O
average O O
of O O
34 O O
% O O
and O O
24 O O
% O O
, O O
respectively O O
, O O
and O O
metformin B-drug B-drug
mean O O
renal O O
clearance O O
decreased O O
by O O
14 O O
% O O
. O O

Therefore O O
, O O
a O O
possible O O
lack O O
of O O
desired O O
effect O O
of O O
treatment O O
should O O
be O O
taken O O
into O O
consideration O O
before O O
such O O
drugs O O
are O O
given O O
concomitantly O O
with O O
lactulose B-drug B-drug
. O O

Nevertheless O O
, O O
clinical O O
studies O O
, O O
as O O
well O O
as O O
postmarketing O O
observations O O
have O O
shown O O
that O O
Lodine B-brand B-brand
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

MAO B-group B-group
inhibitors I-group I-group
, O O
narcotic B-group B-group
analgesics I-group I-group
( O O
e.g. O O
, O O
meperidine B-drug B-drug
) O O
, O O
nitrates B-group B-group
and O O
nitrites B-group B-group
, O O
sympathomimetic B-group B-group
agents I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
and O O
other O O
drugs O O
having O O
anticholinergic O O
activity O O
. O O

consequently O O
, O O
caution O O
is O O
advised O O
if O O
dexfenfluramine B-drug B-drug
and O O
such O O
drugs O O
are O O
prescribed O O
concurrently O O
. O O

( O O
Effects O O
may O O
be O O
potentiated O O
when O O
used O O
concurrently O O
with O O
thiazide B-group B-group
diuretics I-group I-group
; O O

The O O
effectiveness O O
of O O
progestin-only B-group B-group
pills O O
is O O
reduced O O
by O O
hepatic O O
enzyme-inducing O O
drugs O O
such O O
as O O
the O O
anticonvulsants B-group B-group
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
and O O
barbiturates B-group B-group
, O O
and O O
the O O
antituberculosis B-group B-group
drug I-group I-group
rifampin B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
indinavir B-drug B-drug
and O O
didanosine B-drug B-drug
significantly O O
reduces O O
the O O
level O O
of O O
exposure O O
to O O
indinavir B-drug B-drug
, O O
but O O
it O O
is O O
unclear O O
how O O
soon O O
after O O
didanosine B-drug B-drug
administration O O
indinavir B-drug B-drug
may O O
be O O
given O O
safely O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
DIABINESE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
control O O
. O O

Drug O O
interaction O O
studies O O
with O O
Xigris B-brand B-brand
have O O
not O O
been O O
performed O O
in O O
patients O O
with O O
severe O O
sepsis O O
. O O

Phenytoin B-drug B-drug
, O O
nicotine B-drug B-drug
, O O
and O O
rifampin B-drug B-drug
may O O
decrease O O
Clozapine B-drug B-drug
plasma O O
levels O O
, O O
resulting O O
in O O
a O O
decrease O O
in O O
effectiveness O O
of O O
a O O
previously O O
effective O O
Clozapine B-drug B-drug
dose O O
. O O

Concomitant O O
treatment O O
of O O
four O O
patients O O
in O O
the O O
United O O
Kingdom O O
with O O
FOSCAVIR B-brand B-brand
and O O
intravenous O O
pentamidine B-drug B-drug
may O O
have O O
caused O O
hypocalcemia O O
; O O

Tablets O O
Simultaneous O O
administration O O
of O O
sucralfate B-drug B-drug
and O O
furosemide B-drug B-drug
tablets O O
may O O
reduce O O
the O O
natriuretic O O
and O O
antihypertensive O O
effects O O
of O O
furosemide B-drug B-drug
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
( O O
day O O
1 O O
) O O
and O O
40 O O
mg O O
QD O O
( O O
days O O
2-7 O O
) O O
) O O
with O O
glyburide B-drug B-drug
( O O
5 O O
mg O O
QD O O
) O O
did O O
not O O
affect O O
either O O
the O O
pharmacokinetics O O
( O O
exposure O O
) O O
or O O
the O O
pharmacodynamics O O
( O O
blood O O
glucose O O
and O O
insulin O O
levels O O
) O O
of O O
glyburide B-drug B-drug
. O O

No O O
significant O O
effects O O
on O O
cisapride B-drug B-drug
metabolism O O
or O O
QT O O
interval O O
were O O
noted O O
. O O

This O O
study O O
demonstrates O O
that O O
concurrent O O
administration O O
of O O
thiosulfate B-drug B-drug
permits O O
at O O
least O O
a O O
twofold O O
increase O O
in O O
dose O O
and O O
total O O
exposure O O
to O O
cisplatin B-drug B-drug
. O O

Therefore O O
, O O
such O O
combined O O
treatment O O
should O O
be O O
approached O O
with O O
caution O O
and O O
patients O O
should O O
be O O
monitored O O
closely O O
when O O
Clozapine B-drug B-drug
is O O
combined O O
with O O
these O O
drugs O O
, O O
particularly O O
with O O
fluvoxamine B-drug B-drug
. O O

In O O
the O O
long-term O O
safety O O
studies O O
, O O
guanfacine B-drug B-drug
was O O
given O O
concomitantly O O
with O O
many O O
drugs O O
without O O
evidence O O
of O O
any O O
interactions O O
. O O

The O O
concurrent O O
use O O
of O O
Robinul B-brand B-brand
Injection O O
with O O
other O O
anticholinergics B-group B-group
or O O
medications O O
with O O
anticholinergic O O
activity O O
, O O
such O O
as O O
phenothiazines B-group B-group
, O O
antiparkinson B-group B-group
drugs I-group I-group
, O O
or O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
may O O
intensify O O
the O O
antimuscarinic O O
effects O O
and O O
may O O
result O O
in O O
an O O
increase O O
in O O
anticholinergic O O
side O O
effects O O
. O O

They O O
are O O
weak O O
inhibitors O O
of O O
CYP2C19 O O
and O O
CYP2A6 O O
, O O
and O O
mild-to-moderate O O
inhibitors O O
of O O
CYP2C9 O O
at O O
therapeutic O O
concentrations O O
. O O

Because O O
fluvoxamine B-drug B-drug
reduces O O
the O O
clearance O O
of O O
both O O
diazepam B-drug B-drug
and O O
its O O
active O O
metabolite O O
, O O
N-desmethyldiazepam B-drug_n B-drug_n
, O O
there O O
is O O
a O O
strong O O
likelihood O O
of O O
substantial O O
accumulation O O
of O O
both O O
species O O
during O O
chronic O O
co-administration O O
. O O

Antibiotics B-group B-group
: O O
No O O
human O O
drug O O
interaction O O
studies O O
with O O
antibiotics B-group B-group
were O O
conducted O O
. O O

There O O
have O O
been O O
greater O O
than O O
two-fold O O
increases O O
of O O
previously O O
stable O O
plasma O O
levels O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
when O O
fluoxetine B-drug B-drug
has O O
been O O
administered O O
in O O
combination O O
with O O
these O O
agents O O
. O O

No O O
formal O O
drug/laboratory O O
test O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
CLOLAR B-brand B-brand
. O O

In O O
patients O O
where O O
rifampin B-drug B-drug
or O O
other O O
CYP3A4 O O
inducers O O
are O O
indicated O O
, O O
alternative O O
therapeutic O O
agents O O
with O O
less O O
enzyme O O
induction O O
potential O O
should O O
be O O
considered O O
. O O

As O O
with O O
all O O
drugs O O
, O O
the O O
potential O O
exists O O
for O O
interaction O O
with O O
other O O
drugs O O
by O O
a O O
variety O O
of O O
mechanisms O O
. O O

The O O
amount O O
of O O
metformin B-drug B-drug
absorbed O O
while O O
taking O O
Acarbose B-drug B-drug
was O O
bioequivalent O O
to O O
the O O
amount O O
absorbed O O
when O O
taking O O
placebo O O
, O O
as O O
indicated O O
by O O
the O O
plasma O O
AUC O O
values O O
. O O

All O O
the O O
animals O O
were O O
killed O O
at O O
the O O
end O O
of O O
the O O
9th O O
week O O
of O O
the O O
experiment O O
. O O

The O O
pharmacokinetics O O
of O O
etodolac B-drug B-drug
in O O
healthy O O
normal O O
volunteers O O
has O O
been O O
extensively O O
studied O O
and O O
is O O
well O O
described O O
. O O

Patients O O
on O O
lithium B-drug B-drug
treatment O O
should O O
be O O
closely O O
monitored O O
when O O
CELEBREX B-brand B-brand
is O O
introduced O O
or O O
withdrawn O O
. O O

In O O
addition O O
, O O
administration O O
to O O
a O O
patient O O
population O O
with O O
hepatic O O
insufficiency O O
resulted O O
in O O
a O O
2.5-fold O O
increase O O
in O O
both O O
the O O
rate O O
and O O
extent O O
of O O
bioavailability O O
relative O O
to O O
controls O O
. O O

Hydrocodone B-drug B-drug
increases O O
gabapentin B-drug B-drug
AUC O O
values O O
by O O
14 O O
% O O
. O O

Therefore O O
, O O
Clozapine B-drug B-drug
should O O
not O O
be O O
used O O
with O O
other O O
agents O O
having O O
a O O
well-known O O
potential O O
to O O
suppress O O
bone O O
marrow O O
function O O
. O O

We O O
could O O
observe O O
that O O
ginsenosides B-drug_n B-drug_n
inhibited O O
high O O
threshold O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
currents O O
in O O
a O O
dose-dependent O O
manner O O
. O O

Selegiline B-drug B-drug
- O O
L-phenylalanine B-drug B-drug
and O O
the O O
selective B-group B-group
MAO I-group I-group
inhibitor I-group I-group
selegiline B-drug B-drug
may O O
have O O
synergistic O O
antidepressant O O
activity O O
if O O
used O O
concomitantly O O
. O O

As O O
the O O
primary O O
effect O O
of O O
adenosine B-drug B-drug
is O O
to O O
decrease O O
conduction O O
through O O
the O O
A-V O O
node O O
, O O
higher O O
degrees O O
of O O
heart O O
block O O
may O O
be O O
produced O O
in O O
the O O
presence O O
of O O
carbamazepine B-drug B-drug
. O O

The O O
effect O O
of O O
these O O
interactions O O
on O O
mean O O
AUCs O O
and O O
Cmin O O
are O O
summarized O O
in O O
Table O O
2 O O
: O O
Table O O
2 O O
: O O
Summary O O
of O O
AED O O
interactions O O
with O O
Trileptal B-brand B-brand

Drugs O O
and O O
other O O
substances O O
demonstrated O O
to O O
be O O
CYP O O
3A O O
inhibitors O O
on O O
the O O
basis O O
of O O
clinical O O
studies O O
involving O O
benzodiazepines B-group B-group
metabolized O O
similarly O O
to O O
alprazolam B-drug B-drug
or O O
on O O
the O O
basis O O
of O O
in O O
vitro O O
studies O O
with O O
alprazolam B-drug B-drug
or O O
other O O
benzodiazepines B-group B-group
( O O
caution O O
is O O
recommended O O
during O O
coadministration O O
with O O
alprazolam B-drug B-drug
) O O
: O O
Available O O
data O O
from O O
clinical O O
studies O O
of O O
benzodiazepines B-group B-group
other O O
than O O
alprazolam B-drug B-drug
suggest O O
a O O
possible O O
drug O O
interaction O O
with O O
alprazolam B-drug B-drug
for O O
the O O
following O O
: O O
diltiazem B-drug B-drug
, O O
isoniazid B-drug B-drug
, O O
macrolide B-group B-group
antibiotics I-group I-group
such O O
as O O
erythromycin B-drug B-drug
and O O
clarithromycin B-drug B-drug
, O O
and O O
grapefruit O O
juice O O
. O O

Ketorolac B-drug B-drug
does O O
not O O
alter O O
digoxin B-drug B-drug
protein O O
binding O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
may O O
enhance O O
the O O
seizure O O
risk O O
in O O
patients O O
taking O O
tramadol B-drug B-drug

Since O O
the O O
therapeutic O O
range O O
of O O
theophylline B-drug B-drug
is O O
narrow O O
theophylline B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
closely O O
, O O
and O O
appropriate O O
dosage O O
adjustments O O
of O O
theophylline B-drug B-drug
should O O
be O O
made O O
. O O

Combination O O
was O O
associated O O
with O O
a O O
higher O O
frequency O O
of O O
adverse O O
clinical O O
experiences O O
( O O
eg O O
, O O
dizziness O O
, O O
nausea O O
, O O
paresthesia O O
) O O
and O O
laboratory O O
abnormalities O O
( O O
elevated O O
liver O O
enzymes O O
) O O
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
has O O
been O O
demonstrated O O
to O O
interfere O O
with O O
the O O
elimination O O
of O O
other O O
quinolones B-group B-group
. O O

Antipyrine B-drug B-drug
: O O
Because O O
atorvastatin B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
antipyrine B-drug B-drug
, O O
interactions O O
with O O
other O O
drugs B-drug O
metabolized O O
via O O
the O O
same O O
cytochrome O O
isozymes O O
are O O
not O O
expected O O
. O O

Because O O
a O O
similar O O
interaction O O
is O O
likely O O
, O O
VIRACEPT B-brand B-brand
should O O
also O O
not O O
be O O
administered O O
concurrently O O
with O O
astemizole B-drug B-drug
. O O

Calcium B-group B-group
channel I-group I-group
blocking I-group I-group
agents I-group I-group
: O O
Coadministration O O
of O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
did O O
not O O
have O O
any O O
effect O O
on O O
either O O
the O O
safety O O
or O O
efficacy O O
of O O
ibutilide B-drug B-drug
in O O
the O O
clinical O O
trials O O
. O O

Anticoagulants B-drug B-group
: O O
Potentiation O O
of O O
warfarin-type B-drug B-drug
( O O
CYP2C9 B-drug O
and O O
CYP3A4 B-drug O
substrate O O
) O O
anticoagulant B-drug B-group
response O O
is O O
almost O O
always O O
seen O O
in O O
patients O O
receiving O O
amiodarone B-drug B-drug
and O O
can O O
result O O
in O O
serious O O
or O O
fatal O O
bleeding O O
. O O

The O O
use O O
of O O
MAO B-group B-group
inhibitors I-group I-group
or O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
hydrocodone B-drug B-drug
preparations O O
may O O
increase O O
the O O
effect O O
of O O
either O O
the O O
antidepressant B-group B-group
or O O
hydrocodone B-drug B-drug
. O O

It O O
has O O
recently O O
been O O
demonstrated O O
that O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
exerts O O
its O O
cytotoxic O O
effect O O
by O O
the O O
glucosylation O O
of O O
the O O
small O O
GTP-binding O O
proteins O O
of O O
the O O
Rho O O
family O O
. O O

Potentiation O O
occurs O O
with O O
ganglionic B-group B-group
peripheral I-group I-group
adrenergic I-group I-group
blocking I-group I-group
drugs I-group I-group
. O O

Also O O
, O O
in O O
vitro O O
experiments O O
demonstrated O O
a O O
lack O O
of O O
interaction O O
between O O
dirithromycin B-drug B-drug
and O O
terfenadine B-drug B-drug
. O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unknown O O
. O O

The O O
main O O
indications O O
are O O
eclampsia O O
, O O
some O O
dysrhythmias O O
( O O
torsades O O
de O O
pointe O O
particularly O O
) O O
and O O
myocardial O O
ischaemias O O
. O O

Also O O
, O O
there O O
were O O
no O O
clinically O O
significant O O
differences O O
in O O
adverse O O
events O O
when O O
loratadine B-drug B-drug
was O O
administered O O
with O O
or O O
without O O
ketoconazole B-drug B-drug
. O O

To O O
determine O O
whether O O
injection O O
of O O
thiosulfate B-drug B-drug
would O O
permit O O
larger O O
doses O O
of O O
cisplatin B-drug B-drug
to O O
be O O
administered O O
, O O
a O O
fixed O O
9.9-g/m2 O O
dose O O
of O O
thiosulfate B-drug B-drug
was O O
given O O
intravenously O O
over O O
three O O
hours O O
concurrently O O
with O O
escalating O O
doses O O
of O O
cisplatin B-drug B-drug
. O O

Cytochalasin B-drug_n B-drug_n
D I-drug_n I-drug_n
at O O
10 O O
microM O O
preferentially O O
blocked O O
the O O
secretory O O
effect O O
of O O
carbachol B-drug B-drug
and O O
its O O
synergism O O
with O O
cAMP O O
, O O
whereas O O
it O O
had O O
no O O
effect O O
on O O
histamine- O O
or O O
cAMP-stimulated O O
acid O O
secretion O O
within O O
15 O O
min O O
. O O

Omeprazole B-drug B-drug
: O O
No O O
clinically O O
significant O O
changes O O
in O O
lomefloxacin B-drug B-drug
pharmacokinetics O O
( O O
AUC O O
, O O
C O O
max O O
, O O
or O O
T O O
max O O
) O O
were O O
observed O O
when O O
a O O
single O O
dose O O
of O O
lomefloxacin B-drug B-drug
400 O O
mg O O
was O O
given O O
after O O
multiple O O
doses O O
of O O
omeprazole B-drug B-drug
( O O
20 O O
mg O O
qd O O
) O O
in O O
13 O O
healthy O O
volunteers O O
. O O

Caution O O
is O O
indicated O O
when O O
piperacillin B-drug B-drug
is O O
used O O
perioperatively O O
. O O

In O O
the O O
presence O O
of O O
phentolamine B-drug B-drug
( O O
10 O O
( O O
-6 O O
) O O
M O O
) O O
, O O
the O O
second O O
contraction O O
was O O
inhibited O O
selectively O O
. O O

Heparin B-drug B-drug
Sodium I-drug I-drug
Injection O O
should O O
not O O
be O O
mixed O O
with O O
doxorubicin B-drug B-drug
, O O
droperidol B-drug B-drug
, O O
ciprofloxacin B-drug B-drug
, O O
or O O
mitoxantrone B-drug B-drug
, O O
since O O
it O O
has O O
been O O
reported O O
that O O
these O O
drugs O O
are O O
incompatible O O
with O O
heparin B-drug B-drug
and O O
a O O
precipitate O O
may O O
form O O
. O O

The O O
intestinal O O
absorption O O
of O O
arsenate B-drug_n B-drug_n
( O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
) I-drug_n I-drug_n
has O O
been O O
investigated O O
in O O
the O O
chick O O
by O O
means O O
of O O
the O O
in O O
situ O O
ligated O O
duodenal O O
loop O O
technique O O
. O O

If O O
leprosy-associated O O
inflammatory O O
reactions O O
develop O O
in O O
patients O O
being O O
treated O O
with O O
dapsone B-drug B-drug
and O O
clofazimine B-drug B-drug
, O O
it O O
is O O
still O O
advisable O O
to O O
continue O O
treatment O O
with O O
both O O
drugs O O
. O O

Fexofenadine B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
either O O
erythromycin B-drug B-drug
or O O
ketoconazole B-drug B-drug
. O O

Dofetilide B-drug B-drug
is O O
metabolized O O
to O O
a O O
small O O
extent O O
by O O
the O O
CYP3A4 O O
isoenzyme O O
of O O
the O O
cytochrome O O
P450 O O
system O O
. O O

Because O O
the O O
risk O O
to O O
the O O
development O O
of O O
the O O
fetal O O
immune O O
system O O
and O O
postnatal O O
immune O O
function O O
in O O
humans O O
is O O
unknown O O
, O O
AMEVIVE B-brand B-brand
should O O
be O O
used O O
during O O
pregnancy O O
only O O
if O O
clearly O O
needed O O
. O O

Significant O O
pharmacokinetic O O
interactions O O
mediated O O
by O O
inhibition O O
of O O
CYP O O
isoenzymes O O
therefore O O
appear O O
unlikely O O
. O O

Tiagabine B-drug B-drug
has O O
shown O O
no O O
clinically O O
important O O
potentiation O O
of O O
the O O
pharmacodynamic O O
effects O O
of O O
triazo O O
lam O O
or O O
alcohol B-drug B-drug
. O O

metabolizers O O
. O O

Population O O
pharmacokinetic O O
analyses O O
were O O
conducted O O
on O O
plasma O O
concentration O O
data O O
from O O
1445 O O
patients O O
in O O
clinical O O
trials O O
to O O
examine O O
the O O
effects O O
of O O
concomitant O O
medications O O
on O O
clearance O O
or O O
volume O O
of O O
distribution O O
of O O
dofetilide B-drug B-drug
. O O

Isoproterenol B-drug B-drug
hydrochloride I-drug I-drug
injection O O
and O O
epinephrine B-drug B-drug
should O O
not O O
be O O
administered O O
simultaneously O O
because O O
both O O
drugs O O
are O O
direct O O
cardiac O O
stimulants O O
and O O
their O O
combined O O
effects O O
may O O
induce O O
serious O O
arrhythmias O O
. O O

Compared O O
with O O
lean O O
rats O O
, O O
arteries O O
from O O
dietary-obese O O
rats O O
showed O O
significant O O
( O O
P O O
< O O
0.001 O O
) O O
endothelial O O
dysfunction O O
, O O
as O O
indicated O O
by O O
a O O
decrease O O
( O O
> O O
20 O O
% O O
) O O
in O O
maximal O O
acetylcholine-induced O O
vasorelaxation O O
. O O

Suppression O O
by O O
verapamil B-drug B-drug
of O O
bombesin-enhanced B-drug_n B-drug_n
peritoneal O O
metastasis O O
of O O
intestinal O O
adenocarcinomas O O
induced O O
by O O
azoxymethane B-drug_n B-drug_n
in O O
wistar O O
rats O O
. O O

Glyburide B-drug B-drug
: O O
In O O
a O O
randomized O O
, O O
multiple-dose O O
crossover O O
study O O
, O O
patients O O
with O O
Type O O
2 O O
diabetes O O
were O O
administered O O
120 O O
mg O O
Starlix B-brand B-brand
three O O
times O O
a O O
day O O
before O O
meals O O
for O O
1 O O
day O O
in O O
combination O O
with O O
glyburide B-drug B-drug
10 O O
mg O O
daily O O
. O O

This O O
might O O
increase O O
the O O
risk O O
of O O
methotrexate B-drug B-drug
toxic O O
reactions O O
. O O

Since O O
the O O
arrival O O
of O O
oral O O
erection-supporting B-group B-group
medication I-group I-group
, O O
patients O O
want O O
to O O
know O O
how O O
safe O O
sexual O O
activity O O
is O O
in O O
cardiovascular O O
disease O O
in O O
general O O
and O O
during O O
use O O
of O O
erection-supporting B-group B-group
medication I-group I-group
in O O
particular O O
. O O

Bile B-group B-group
acid I-group I-group
sequestrants I-group I-group
have O O
been O O
shown O O
to O O
bind O O
other O O
drugs O O
given O O
concurrently O O
. O O

Allopurinol B-drug B-drug
: O O
In O O
a O O
study O O
of O O
healthy O O
male O O
volunteers O O
no O O
significant O O
pharmacokinetic O O
interaction O O
occurred O O
when O O
captopril B-drug B-drug
and O O
allopurinol B-drug B-drug
were O O
administered O O
concomitantly O O
for O O
6 O O
days O O
. O O

See O O
CLINICAL O O
PHARMACOLOGY O O
. O O

Inhibitory O O
effects O O
of O O
ruthenium B-drug_n B-drug_n
red I-drug_n O
on O O
inositol O O
1,4 O O
, O O
5-trisphosphate-induced O O
responses O O
in O O
rat O O
megakaryocytes O O
. O O

Drugs O O
That O O
Inhibit O O
Both O O
Aldehyde O O
Oxidase O O
and O O
CYP3A4 O O
Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
inhibits O O
both O O
aldehyde O O
oxidase O O
( O O
in O O
vitro O O
) O O
and O O
CYP3A4 O O
( O O
in O O
vitro O O
and O O
in O O
vivo O O
) O O
, O O
the O O
primary O O
and O O
secondary O O
enzymes O O
, O O
respectively O O
, O O
responsible O O
for O O
zaleplon B-drug B-drug
metabolism O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
No O O
laboratory O O
test O O
abnormalities O O
related O O
to O O
the O O
use O O
of O O
guanfacine B-drug B-drug
have O O
been O O
identified O O
. O O

These O O
increases O O
in O O
concentration O O
may O O
lead O O
to O O
increased O O
effects O O
, O O
( O O
lower O O
blood O O
pressure O O
and O O
increased O O
heart O O
rate O O
) O O
. O O

There O O
have O O
been O O
postmarketing O O
reports O O
of O O
drug O O
interactions O O
when O O
erythromycin B-drug B-drug
is O O
coadministered O O
with O O
cisapride B-drug B-drug
, O O
resulting O O
in O O
QT O O
prolongation O O
, O O
cardiac O O
arrythmias O O
, O O
ventricular O O
tachycardia O O
, O O
ventricular O O
fibrulation O O
, O O
and O O
torsades O O
de O O
pointes O O
, O O
most O O
like O O
due O O
to O O
inhibition O O
of O O
hepatic O O
metabolism O O
of O O
cisapride B-drug B-drug
by O O
erythromycin B-drug B-drug
. O O

There O O
are O O
3 O O
types O O
of O O
indications O O
: O O
specific O O
( O O
for O O
the O O
treatment O O
of O O
some O O
forms O O
of O O
magnesium B-drug B-drug
deficit O O
i.e O O
. O O
acute O O
) O O
, O O
pharmacological O O
( O O
i.e O O
. O O
without O O
alterations O O
of O O
magnesium B-drug B-drug
status O O
) O O
and O O
mixed O O
-- O O
pharmacological O O
and O O
aetiopathogenic O O
-- O O
( O O
for O O
example O O
complications O O
of O O
chronic O O
alcoholism O O
) O O
. O O

decreased O O
antithrombin O B-drug
3 O I-drug
; O O

Two O O
percent O O
of O O
patients O O
treated O O
concurrently O O
with O O
ENBREL B-brand B-brand
and O O
anakinra B-drug B-drug
developed O O
neutropenia O O
( O O
ANC O O
1 O O
x O O
109/L O O
) O O
. O O

Reported O O
examples O O
of O O
this O O
interaction O O
include O O
the O O
following O O
: O O
Antibiotics B-drug B-group
: O O
Rifampin B-drug B-drug
is O O
a O O
potent O O
inducer O O
of O O
CYP3A4 B-drug O
. O O

The O O
resulting O O
increase O O
in O O
free O O
drug O O
concentration O O
may O O
lead O O
to O O
enhanced O O
drug O O
effect O O
in O O
vivo O O
. O O

The O O
results O O
raise O O
the O O
possibility O O
that O O
the O O
ethanolysis O O
reaction O O
may O O
occur O O
in O O
the O O
stomach O O
of O O
people O O
who O O
consume O O
alcohol B-drug B-drug
and O O
3-hydroxy-1,4-benzodiazepine B-group B-drug_n
on O O
a O O
regular O O
basis O O
. O O

Patients O O
should O O
be O O
warned O O
of O O
the O O
potential O O
danger O O
of O O
the O O
intravenous O O
self-administration O O
of O O
benzodiazepines B-group B-group
while O O
under O O
treatment O O
with O O
SUBOXONE B-brand B-brand
or O O
SUBUTEX B-brand B-brand
. O O

In O O
vitro O O
studies O O
also O O
indicate O O
that O O
celecoxib B-drug B-drug
, O O
although O O
not O O
a O O
substrate O O
, O O
is O O
an O O
inhibitor O O
of O O
cytochrome O O
P450 O O
2D6 O O
. O O

Acute O O
symptoms O O
should O O
be O O
treated O O
with O O
a O O
short-acting O O
, O O
inhaled O O
beta2-agonist B-group B-group
such O O
as O O
salbutamol B-drug B-drug
( O O
the O O
physician O O
should O O
provide O O
the O O
patient O O
with O O
such O O
medication O O
and O O
instruct O O
the O O
patient O O
in O O
how O O
it O O
should O O
be O O
used O O
) O O
. O O

Drug O O
interaction O O
studies O O
of O O
mefenamic B-drug B-drug
acid I-drug I-drug
and O O
these O O
compounds O O
have O O
not O O
been O O
conducted O O
. O O

Cimetidine B-drug B-drug
is O O
reported O O
to O O
reduce O O
hepatic O O
metabolism O O
of O O
certain O O
tricyclic B-drug B-group
antidepressants I-drug I-group
, O O
thereby O O
delaying O O
elimination O O
and O O
increasing O O
steady-state O O
concentrations O O
of O O
these O O
drugs B-drug O
. O O

This O O
indicates O O
that O O
gabapentin B-drug B-drug
does O O
not O O
undergo O O
renal O O
tubular O O
secretion O O
by O O
the O O
pathway O O
that O O
is O O
blocked O O
by O O
probenecid B-drug B-drug
. O O

Induction O O
of O O
such O O
tumors O O
is O O
consistent O O
with O O
the O O
pharmacology-related O O
endocrine O O
feedback O O
alterations O O
in O O
gonadotropin O O
levels O O
caused O O
by O O
an O O
antiestrogen B-group B-group
. O O

Acid-catalyzed O O
ethanolysis O O
of O O
temazepam B-drug B-drug
in O O
anhydrous O O
and O O
aqueous O O
ethanol B-drug B-drug
solutions O O
. O O

Concomitant O O
use O O
of O O
calcium B-drug B-drug
supplements O O
and O O
L-lysine B-drug B-drug
may O O
increase O O
calcium B-drug B-drug
absorption O O

Monitor O O
serum O O
potassium O O
levels O O
; O O

Digoxin B-drug B-drug
: O O
In O O
a O O
study O O
in O O
12 O O
patients O O
with O O
congestive O O
heart O O
failure O O
where O O
ketoprofen B-drug B-drug
and O O
digoxin B-drug B-drug
were O O
concomitantly O O
administered O O
, O O
ketoprofen B-drug B-drug
did O O
not O O
alter O O
the O O
serum O O
levels O O
of O O
digoxin B-drug B-drug
. O O

Valproate B-drug B-drug
Keppra B-brand B-brand
( O O
1500 O O
mg O O
twice O O
daily O O
) O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
valproate B-drug B-drug
in O O
healthy O O
volunteers O O
. O O

If O O
you O O
are O O
50 O O
years O O
of O O
age O O
or O O
older O O
, O O
ask O O
your O O
physician O O
to O O
check O O
your O O
B12 O O
status O O
before O O
you O O
take O O
a O O
supplement O O
that O O
contains O O
folic B-drug B-drug
acid I-drug I-drug
. O O

Vancomycin O O
resistance O O
reversal O O
in O O
enterococci O O
by O O
flavonoids O O
. O O

route O O
. O O

Jacalin B-drug_n B-drug_n
is O O
a O O
D-Gal O O
binding O O
lectin O O
and O O
should O O
be O O
a O O
useful O O
tool O O
for O O
studying O O
of O O
serum O O
and O O
secretory O O
IgA O O
. O O

The O O
increase O O
of O O
phenobarbital B-drug B-drug
level O O
, O O
however O O
, O O
is O O
small O O
( O O
15 O O
% O O
) O O
when O O
given O O
with O O
Trileptal B-brand B-brand
. O O

therefore O O
, O O
periodic O O
liver O O
function O O
testing O O
( O O
transaminases O O
, O O
bilirubin O O
, O O
and O O
alkaline O O
phosphatase O O
) O O
should O O
be O O
considered O O
. O O

Until O O
specific O O
compatibility O O
data O O
are O O
available O O
, O O
it O O
is O O
not O O
recommended O O
that O O
DOXIL B-brand B-brand
be O O
mixed O O
with O O
other O O
drugs O O
. O O

Anticonvulsants B-group B-group

Pharmacokinetic-related O O
Interactions O O
: O O
Clozapine B-drug B-drug
is O O
a O O
substrate O O
for O O
many O O
CYP O O
450 O O
isozymes O O
, O O
in O O
particular O O
1A2 O O
, O O
2D6 O O
, O O
and O O
3A4 O O
. O O

Concomitant O O
use O O
of O O
Isocarboxazid B-drug B-drug
and O O
other O O
psychotropic B-group B-group
agents I-group I-group
is O O
generally O O
not O O
recommended O O
because O O
of O O
possible O O
potentiating O O
effects O O
. O O

Methadone B-drug B-drug

Table O O
9 O O

The O O
majority O O
of O O
adverse O O
events O O
with O O
NNRTIs B-group B-group
occur O O
within O O
the O O
first O O
month O O
, O O
and O O
are O O
predictable O O
and O O
manageable O O
without O O
therapy O O
interruption O O
. O O

administration O O
1 O O
hour O O
before O O
or O O
4 O O
hours O O
after O O
colestipol B-drug B-drug
is O O
recommended O O
. O O
) O O

Failure O O
of O O
neomycin B-drug B-drug
to O O
modify O O
ACTH B-group B-group
induced O O
hypertension O O
in O O
sheep O O
. O O

PATIENTS O O
: O O
Random O O
sample O O
of O O
626 O O
MAC O O
out O O
of O O
a O O
total O O
of O O
1306 O O
. O O

Monitor O O
for O O
symptoms O O
of O O
hyperglycemia O O
; O O

At O O
higher O O
than O O
recommended O O
doses O O
, O O
VIOXX B-brand B-brand
75 O O
mg O O
administered O O
once O O
daily O O
for O O
10 O O
days O O
increased O O
plasma O O
concentrations O O
by O O
23 O O
% O O
as O O
measured O O
by O O
AUC0-24hr O O
in O O
patients O O
receiving O O
methotrexate B-drug B-drug
7.5 O O
to O O
15 O O
mg/week O O
for O O
rheumatoid O O
arthritis O O
. O O

Acitretin B-drug B-drug
: O O
Interferes O O
with O O
the O O
contraceptive O O
effect O O
of O O
microdosed O O
progestin-containing B-group O
minipill O O
preparations O O
. O O

Co-administration O O
of O O
CYP3A4 O O
inhibitors O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
grapefruit O O
juice O O
, O O
cimetidine B-drug B-drug
) O O
with O O
felodipine B-drug B-drug
may O O
lead O O
to O O
several- O O
fold O O
increases O O
in O O
the O O
plasma O O
levels O O
of O O
felodipine B-drug B-drug
, O O
either O O
due O O
to O O
an O O
increase O O
in O O
bioavailability O O
or O O
due O O
to O O
a O O
decrease O O
in O O
metabolism O O
. O O

Differences O O
can O O
occur O O
in O O
therapeutic O O
effect O O
and O O
in O O
adverse O O
events O O
. O O

Conversely O O
, O O
adverse O O
effects O O
may O O
result O O
from O O
displacement O O
of O O
protein-bound O O
Anafranil B-brand B-brand
by O O
other O O
highly O O
bound O O
drugs O O
. O O

The O O
recommended O O
dosage O O
( O O
one O O
or O O
two O O
capsules O O
twice O O
daily O O
, O O
morning O O
and O O
evening O O
) O O
should O O
not O O
be O O
exceeded O O
. O O

Increases O O
in O O
sertraline B-drug B-drug
dose O O
should O O
be O O
guided O O
by O O
clinical O O
response O O
. O O

Pharmacokinetic O O
studies O O
have O O
demonstrated O O
that O O
omeprazole B-drug B-drug
and O O
erythromycin B-drug B-drug
significantly O O
increased O O
the O O
systemic O O
exposure O O
of O O
cilostazol B-drug B-drug
and/or O O
its O O
major O O
metabolites O O
. O O

Brain O O
hemorrhage O O
and O O
optic O O
nerve O O
vacuolation O O
were O O
seen O O
in O O
another O O
female O O
dog O O
that O O
was O O
sacrificed O O
in O O
moribund O O
condition O O
after O O
11 O O
weeks O O
of O O
escalating O O
doses O O
up O O
to O O
280 O O
mg/kg/day O O
. O O

Warning O O
signs O O
, O O
irrespective O O
of O O
cause O O
, O O
are O O
: O O
dryness O O
of O O
mouth O O
, O O
thirst O O
, O O
weakness O O
, O O
lethargy O O
, O O
drowsiness O O
, O O
restlessness O O
, O O
muscle O O
pains O O
or O O
cramps O O
, O O
muscular O O
fatigue O O
, O O
hypotension O O
, O O
oliguria O O
, O O
tachycardia O O
, O O
and O O
gastrointestinal O O
disturbances O O
such O O
as O O
nausea O O
and O O
vomiting O O
. O O

In O O
studies O O
in O O
normal O O
volunteers O O
, O O
there O O
was O O
no O O
pharmacodynamic O O
interaction O O
between O O
intravenous O O
iloprost B-drug B-drug
and O O
either O O
nifedipine B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
or O O
captopril B-drug B-drug
. O O

Expected O O
to O O
substantially O O
decrease O O
plasma O O
levels O O
of O O
efavirenz B-drug B-drug
; O O
has O O
not O O
been O O
studied O O
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
. O O

As O O
with O O
some O O
other O O
nondepolarizing B-group B-group
neuromuscular I-group I-group
blocking I-group I-group
agents I-group I-group
, O O
the O O
time O O
of O O
onset O O
of O O
neuromuscular O O
block O O
induced O O
by O O
NUROMAX B-brand B-brand
is O O
lengthened O O
and O O
the O O
duration O O
of O O
block O O
is O O
shortened O O
in O O
patients O O
receiving O O
phenytoin B-drug B-drug
or O O
carbamazepine B-drug B-drug
. O O

Uricosuric B-group B-group
drugs I-group I-group
, O O
such O O
as O O
probenecid B-drug B-drug
and O O
sulfinpyrazone B-drug B-drug
, O O
can O O
inhibit O O
renal O O
tubular O O
secretion O O
of O O
nitrofurantoin B-drug B-drug
. O O

Potential O O
for O O
ABILIFY B-brand B-brand
to O O
Affect O O
Other O O
Drugs O O
Aripiprazole B-drug B-drug
is O O
unlikely O O
to O O
cause O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
with O O
drugs O O
metabolized O O
by O O
cytochrome O O
P450 O O
enzymes O O
. O O

Antifungals B-group B-group
: O O
In O O
vitro O O
and/or O O
in O O
vivo O O
data O O
indicate O O
that O O
fluconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
and O O
oral O O
ketoconazole B-drug B-drug
markedly O O
inhibit O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
, O O
which O O
can O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
cisapride B-drug B-drug
levels O O
and O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

This O O
medicine O O
should O O
not O O
be O O
taken O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Drugs O O
that O O
inhibit O O
cytochrome O O
P450IID6 O O
, O O
such O O
as O O
quinidine B-drug B-drug
, O O
might O O
increase O O
the O O
plasma O O
concentrations O O
of O O
flecainide B-drug B-drug
in O O
patients O O
that O O
are O O
on O O
chronic O O
flecainide B-drug B-drug
therapy O O
; O O

Methotrexate B-drug B-drug
VIOXX B-brand B-brand
12.5 O O
, O O
25 O O
, O O
and O O
50 O O
mg O O
, O O
each O O
dose O O
administered O O
once O O
daily O O
for O O
7 O O
days O O
, O O
had O O
no O O
effect O O
on O O
the O O
plasma O O
concentration O O
of O O
methotrexate B-drug B-drug
as O O
measured O O
by O O
AUC0-24hr O O
in O O
patients O O
receiving O O
single O O
weekly O O
methotrexate B-drug B-drug
doses O O
of O O
7.5 O O
to O O
20 O O
mg O O
for O O
rheumatoid O O
arthritis O O
. O O

Antacids I-group B-group
: O O
Administration O O
of O O
flurbiprofen B-drug B-drug
to O O
volunteers O O
under O O
fasting O O
conditions O O
, O O
or O O
with O O
antacid B-group B-group
suspension O O
yielded O O
similar O O
serum O O
flurbiprofen B-drug B-drug
time O O
profiles O O
in O O
young O O
subjects O O
( O O
n=12 O O
) O O
. O O

Effects O O
on O O
the O O
absorption O O
of O O
other O O
beta-blockers B-group B-group
have O O
not O O
been O O
determined O O
. O O

Therefore O O
, O O
EXTREME O O
CAUTION O O
should O O
be O O
exercised O O
when O O
administering O O
dopamine B-drug B-drug
HCl I-drug I-drug
to O O
patients O O
receiving O O
cyclopropane B-drug B-drug
or O O
halogenated B-group B-group
hydrocarbon I-group I-group
anesthetics I-group I-group
. O O

Another O O
investigator O O
found O O
no O O
increase O O
in O O
digoxin B-drug B-drug
levels O O
in O O
12 O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

PEGASYS B-brand B-brand
is O O
to O O
be O O
used O O
during O O
pregnancy O O
only O O
if O O
the O O
potential O O
benefit O O
justifies O O
the O O
potential O O
risk O O
to O O
the O O
fetus O O
. O O

In O O
hematologic O O
studies O O
or O O
in O O
transfusion O O
cross-matching O O
procedures O O
when O O
anti-globulin O O
tests O O
are O O
performed O O
on O O
the O O
minor O O
side O O
or O O
in O O
Coombs O O
testing O O
of O O
newborns O O
whose O O
mothers O O
have O O
received O O
cephalosporin B-group B-group
antibiotics I-group I-group
before O O
parturition O O
, O O
it O O
should O O
be O O
recognized O O
that O O
a O O
positive O O
Coombs O O
test O O
may O O
be O O
due O O
to O O
the O O
drug O O
. O O

Anticoagulants B-group B-group
. O O

Tolbutamide B-drug B-drug
: O O
In O O
diabetic O O
patients O O
receiving O O
diflunisal B-drug B-drug
and O O
tolbutamide B-drug B-drug
, O O
no O O
significant O O
effects O O
were O O
seen O O
on O O
tolbutamide B-drug B-drug
plasma O O
levels O O
or O O
fasting O O
blood O O
glucose O O
. O O

There O O
is O O
limited O O
experience O O
with O O
concomitant O O
antihypertensive B-group B-group
agents I-group I-group
such O O
as O O
alpha-blockers B-group B-group
, O O
calcium B-group B-group
channel-blockers I-group I-group
, O O
ACE B-group B-group
inhibitors I-group I-group
, O O
and O O
diuretics B-group B-group
( O O
both O O
thiazide-like B-group B-group
and O O
loop O O
) O O
. O O

No O O
drug O O
, O O
nutritional O O
supplement O O
, O O
food O O
or O O
herb O O
interactions O O
have O O
yet O O
been O O
reported O O
. O O

Note O O
: O O
dissolution O O
of O O
aerosol O O
particles O O
of O O
budesonide B-drug B-drug
in O O
Survanta B-brand B-brand
, O O
a O O
model O O
lung B-group B-group
surfactant I-group I-group
. O O

If O O
TYKERB B-brand B-brand
is O O
administered O O
with O O
drugs O O
that O O
are O O
substrates O O
of O O
Pgp O O
, O O
increased O O
concentrations O O
of O O
the O O
substrate O O
drug O O
are O O
likely O O
, O O
and O O
caution O O
should O O
be O O
exercised O O
. O O

ETHANOL B-drug B-drug
/ O O
NUTRITION O O
/ O O
HERB O O
INTERACTIONS O O
: O O
Food O O
: O O
CNS O O
effects O O
of O O
caffeine B-drug B-drug
may O O
be O O
enhanced O O
if O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
are O O
used O O
concurrently O O
with O O
caffeine B-drug B-drug
. O O

If O O
antacids B-group B-group
are O O
required O O
during O O
OMNICEF B-brand B-brand
therapy O O
, O O
OMNICEF B-brand B-brand
should O O
be O O
taken O O
at O O
least O O
2 O O
hours O O
before O O
or O O
after O O
the O O
antacid B-group B-group
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA O O
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

It O O
is O O
not O O
known O O
if O O
the O O
effects O O
of O O
butorphanol B-drug B-drug
are O O
altered O O
by O O
concomitant O O
medications O O
that O O
affect O O
hepatic O O
metabolism O O
of O O
drugs O O
( O O
erythromycin B-drug B-drug
, O O
etc O O
. O O
) O O
, O O
but O O
physicians O O
should O O
be O O
alert O O
to O O
the O O
possibility O O
that O O
a O O
smaller O O
initial O O
dose O O
and O O
longer O O
intervals O O
between O O
doses O O
may O O
be O O
needed O O
. O O

The O O
mean O O
C O O
max O O
, O O
T O O
max O O
, O O
and O O
AUC O O
of O O
the O O
acid O O
metabolite O O
of O O
terfenadine B-drug B-drug
were O O
not O O
significantly O O
changed O O
. O O

Beta-blocking B-group B-group
Agents I-group I-group
: O O
The O O
concomitant O O
use O O
of O O
Bepridil B-drug B-drug
and O O
beta-blocking B-group B-group
agents I-group I-group
has O O
been O O
well O O
tolerated O O
in O O
patients O O
with O O
stable O O
angina O O
. O O

The O O
possibility O O
of O O
increased O O
interaction O O
should O O
be O O
kept O O
in O O
mind O O
when O O
Orudis B-brand B-brand
doses O O
greater O O
than O O
50 O O
mg O O
as O O
a O O
single O O
dose O O
or O O
200 O O
mg O O
of O O
ketoprofen B-drug B-drug
per O O
day O O
are O O
used O O
concomitantly O O
with O O
highly O O
bound O O
drugs O O
. O O

Results O O
showed O O
that O O
, O O
depending O O
on O O
the O O
task O O
considered O O
, O O
the O O
same O O
pharmacological O O
treatment O O
produced O O
either O O
a O O
facilitation O O
or O O
an O O
impairment O O
of O O
acquisition O O
. O O

Co-administration O O
of O O
nelfinavir B-drug B-drug
at O O
steady-state O O
with O O
a O O
single O O
dose O O
of O O
azithromycin B-drug B-drug
. O O

TABLE O O
1 O O
Effects O O
on O O
Plasma O O
Concentrations O O
( O O
AUC O O
0-24 O O
hrs O O
) O O
of O O
Loratadine B-drug B-drug
and O O
Descarboethoxyloratadine B-drug B-drug
After O O
10 O O
Days O O
of O O
Coadministration O O
( O O
Loratadine B-drug B-drug
10 O O
mg O O
) O O
in O O
Normal O O
Volunteers O O

Serum O O
infliximab B-drug B-drug
concentrations O O
appeared O O
to O O
be O O
unaffected O O
by O O
baseline O O
use O O
of O O
medications O O
for O O
the O O
treatment O O
of O O
Crohn O O
s O O
disease O O
including O O
corticosteroids B-group B-group
, O O
antibiotics B-group B-group
( O O
metronidazole B-drug B-drug
or O O
ciprofloxacin B-drug B-drug
) O O
and O O
aminosalicylates O O
. O O

Erythromycin B-drug B-drug
has O O
been O O
reported O O
to O O
decrease O O
the O O
clearance O O
of O O
triazolam B-drug B-drug
and O O
midazolam B-drug B-drug
and O O
thus O O
may O O
increase O O
the O O
pharmacologic O O
effect O O
of O O
these O O
benzodiazepines B-group B-group
. O O

Drugs O O
Associated O O
With O O
Peripheral O O
Neuropathy O O
: O O
The O O
concomitant O O
use O O
of O O
HIVID B-drug B-drug
with O O
drugs O O
that O O
have O O
the O O
potential O O
to O O
cause O O
peripheral O O
neuropathy O O
should O O
be O O
avoided O O
where O O
possible O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

Elevated O O
plasma O O
levels O O
of O O
theophylline B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
quinolone B-group B-group
use O O
. O O

HAART O O
was O O
included O O
with O O
combination O O
therapy O O
from O O
January O O
1997 O O
. O O

Consequently O O
, O O
estazolam B-drug B-drug
should O O
be O O
avoided O O
in O O
patients O O
receiving O O
ketoconazole B-drug B-drug
and O O
itraconazole B-drug B-drug
, O O
which O O
are O O
very O O
potent O O
inhibitors O O
of O O
CYP3A O O
. O O

trimethoprim/sulfamethoxazole B-drug B-drug
; O O

We O O
conclude O O
that O O
an O O
ability O O
of O O
some O O
P O O
. O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

Drug O O
interactions O O
caused O O
by O O
inhibition O O
of O O
P-glycoprotein-mediated O O
drug O O
clearance O O
or O O
CYP-mediated O O
drug O O
clearance O O
with O O
the O O
listed O O
isoforms O O
are O O
unlikely O O
. O O

Drugs O O
other O O
than O O
those O O
listed O O
here O O
may O O
also O O
interact O O
with O O
glimepiride B-drug B-drug
or O O
affect O O
your O O
condition O O
. O O

In O O
a O O
clinical O O
trial O O
of O O
217 O O
pediatric O O
patients O O
( O O
12 O O
to O O
17 O O
years O O
) O O
with O O
severe O O
recalcitrant O O
nodular O O
acne O O
, O O
transient O O
elevations O O
in O O
CPK O O
were O O
observed O O
in O O
12 O O
% O O
of O O
patients O O
, O O
including O O
those O O
undergoing O O
strenuous O O
physical O O
activity O O
in O O
association O O
with O O
reported O O
musculoskeletal O O
adverse O O
events O O
such O O
as O O
back O O
pain O O
, O O
arthralgia O O
, O O
limb O O
injury O O
, O O
or O O
muscle O O
sprain O O
. O O

Recent O O
, O O
better O O
designed O O
studies O O
have O O
not O O
reported O O
these O O
adverse O O
effects O O
. O O

Administration O O
of O O
doxapram B-drug B-drug
to O O
patients O O
who O O
are O O
receiving O O
sympathomimetic B-group B-group
or O O
monoamine B-group B-group
oxidase I-group I-group
inhibiting I-group I-group
drugs I-group I-group
may O O
result O O
in O O
an O O
additive O O
pressor O O
effect O O
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reactions O O
. O O

Therefore O O
, O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
should O O
be O O
taken O O
at O O
least O O
30 O O
minutes O O
prior O O
to O O
sucralfate B-drug B-drug
. O O

Potential O O
for O O
Interaction O O
with O O
Drugs O O
that O O
Affect O O
Gastric O O
Acidity O O
: O O
Duloxetine B-drug B-drug
has O O
an O O
enteric O O
coating O O
that O O
resists O O
dissolution O O
until O O
reaching O O
a O O
segment O O
of O O
the O O
gastrointestinal O O
tract O O
where O O
the O O
pH O O
exceeds O O
5.5 O O
. O O

Non-steroidal B-group B-group
Anti-inflammatory I-group I-group
Drugs I-group I-group
: O O
In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
a O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic O B-group
, O O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium-sparing O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
bupropion B-drug B-drug
is O O
primarily O O
metabolized O O
to O O
hydroxybupropion B-drug_n B-drug_n
by O O
the O O
CYP2B6 O O
isoenzyme O O
. O O

In O O
vitro O O
, O O
the O O
UDP-glucuronyl O O
transferase O O
level O O
was O O
increased O O
, O O
indicating O O
induction O O
of O O
this O O
enzyme O O
. O O

In O O
Study O O
1 O O
, O O
patients O O
with O O
colorectal O O
cancer O O
were O O
given O O
irinotecan/5-FU/leucovorin B-drug B-drug
( O O
bolus-IFL O O
) O O
with O O
or O O
without O O
AVASTIN B-brand B-brand
. O O

Avoid O O
saw O O
palmetto O O
, O O
red O O
clover O O
, O O
ginseng O O
. O O

. O O

phase O O
2 O O
( O O
days O O
14-44 O O
) O O
: O O
fluoxetine B-drug B-drug
20 O O
mg/day O O
; O O

In O O
study O O
one O O
, O O
hyperglycaemic O O
clamps O O
( O O
5.6 O O
mmol/l O O
, O O
11.1 O O
mmol/ O O
1 O O
, O O
16.7 O O
mmol/l O O
) O O
were O O
carried O O
out O O
during O O
placebo O O
or O O
insulin B-drug B-drug
( O O
dose O O
1 O O
: O O
1 O O
mU/kg/min O O
; O O
dose O O
2 O O
: O O
2 O O
mU/kg/min O O
) O O
infusion O O
. O O

Omniscan B-brand B-brand
interferes O O
with O O
serum O O
calcium O O
measurements O O
with O O
some O O
colorimetric O O
( O O
complexometric O O
) O O
methods O O
commonly O O
used O O
in O O
hospitals O O
, O O
resulting O O
in O O
serum O O
calcium O O
concentrations O O
lower O O
than O O
the O O
true O O
values O O
. O O

Appropriate O O
dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O

Drug/ O O
Laboratory O O
Tests O O
Interactions O O
Hyperaminotransferasemia O O
: O O
Significant O O
elevations O O
of O O
aminotransferase O O
( O O
SGOT O O
[ O O
S-AST O O
] O O
and O O
SGPT O O
[ O O
S-ALT O O
] O O
) O O
levels O O
have O O
occurred O O
in O O
a O O
high O O
percentage O O
of O O
patients O O
( O O
and O O
healthy O O
subjects O O
) O O
who O O
have O O
received O O
heparin B-drug B-drug
sodium I-drug I-drug
. O O

The O O
effect O O
of O O
clofarabine B-drug B-drug
on O O
the O O
metabolism O O
of O O
cytochrome O O
p450 O O
substrates O O
has O O
not O O
been O O
studied O O
. O O

The O O
effect O O
of O O
natural O O
and O O
synthetic O O
galloyl O O
esters O O
on O O
glucocorticoid-induced O O
gene O O
expression O O
was O O
evaluated O O
by O O
using O O
rat O O
fibroblast O O
3Y1 O O
cells O O
stably O O
transfected O O
with O O
a O O
luciferase O O
reporter O O
gene O O
under O O
the O O
transcriptional O O
regulation O O
of O O
the O O
mouse O O
mammary O O
tumor O O
virus O O
promoter B-drug O
. O O

The O O
ECG O O
changes O O
and/or O O
hypokalemia O O
that O O
may O O
result O O
from O O
the O O
administration O O
of O O
non-potassium B-group B-group
sparing I-group I-group
diuretics I-group I-group
( O O
such O O
as O O
loop O O
or O O
thiazide B-group B-group
diuretics I-group I-group
) O O
can O O
be O O
acutely O O
worsened O O
by O O
beta-agonists B-group B-group
, O O
especially O O
when O O
the O O
recommended O O
dose O O
of O O
the O O
beta-agonist B-group B-group
is O O
exceeded O O
. O O

Corticotropin B-drug B-drug
may O O
accentuate O O
the O O
electrolyte O O
loss O O
associated O O
with O O
diuretic B-group B-group
therapy O O
. O O

Given O O
the O O
anticonvulsant O O
properties O O
of O O
carbamazepine B-drug B-drug
, O O
EQUETROTM B-brand B-brand
may O O
reduce O O
the O O
thyroid O O
function O O
as O O
has O O
been O O
reported O O
with O O
other O O
anticonvulsants B-group B-group
. O O

Concomitant O O
single O O
dose O O
administration O O
of O O
valdecoxib B-drug B-drug
20 O O
mg O O
with O O
multiple O O
doses O O
of O O
ketoconazole B-drug B-drug
and O O
fluconazole B-drug B-drug
produced O O
a O O
significant O O
increase O O
in O O
exposure O O
of O O
valdecoxib B-drug B-drug
. O O

Both O O
ibogaine B-drug_n B-drug_n
and O O
18-MC B-drug_n B-drug_n
enhance O O
the O O
locomotor O O
and/or O O
stereotypic O O
effects O O
of O O
stimulants O O
. O O

Protease B-group B-group
inhibitor I-group I-group
: O O
atazanavir B-drug B-drug

T3 O O
resin O O
uptake O O
is O O
decreased O O
, O O
reflecting O O
the O O
elevated O O
TBG O O
. O O

Therefore O O
, O O
patients O O
with O O
COPD O O
should O O
not O O
normally O O
be O O
treated O O
with O O
beta-blockers B-group B-group
. O O

The O O
interaction O O
of O O
intramuscularly O O
injected O O
ketamine B-drug B-drug
and O O
its O O
N-demethylated O O
metabolite O O
( O O
metabolite O O
I O O
) O O
with O O
halothane B-drug B-drug
was O O
evaluated O O
in O O
rats O O
. O O

It O O
is O O
recommended O O
that O O
the O O
dose O O
of O O
rifabutin B-drug B-drug
be O O
reduced O O
to O O
one-half O O
the O O
usual O O
dose O O
when O O
administered O O
with O O
VIRACEPT B-brand B-brand
. O O

however O O
, O O
patients O O
receiving O O
such O O
combined O O
therapy O O
should O O
be O O
monitored O O
closely O O
for O O
early O O
evidence O O
of O O
neurological O O
toxicity O O
and O O
treatment O O
discontinued O O
promptly O O
if O O
such O O
signs O O
appear O O
. O O

During O O
phenytoin B-drug B-drug
and O O
fluvoxamine O B-drug
treatment O O
, O O
ataxia O O
, O O
a O O
typical O O
side O O
effect O O
of O O
phenytoin B-drug B-drug
, O O
was O O
observed O O
. O O

1 O O
. O O

The O O
increased O O
plasma O O
concentration O O
of O O
terfenadine B-drug B-drug
or O O
its O O
metabolite O O
may O O
result O O
in O O
prolonged O O
QT O O
intervals O O
. O O

Phenytoin O B-drug
intoxication O O
induced O O
by O O
fluvoxamine B-drug B-drug
. O O

Clinically O O
significant O O
interactions O O
would O O
not O O
be O O
expected O O
since O O
the O O
NRTIs B-group B-group
are O O
metabolized O O
via O O
a O O
different O O
route O O
than O O
efavirenz B-drug B-drug
and O O
would O O
be O O
unlikely O O
to O O
compete O O
for O O
the O O
same O O
metabolic O O
enzymes O O
and O O
elimination O O
pathways O O
. O O

In O O
a O O
pharmacokinetic O O
interaction O O
study O O
with O O
warfarin B-drug B-drug
, O O
bioavailability O O
parameters O O
, O O
the O O
degree O O
of O O
protein O O
binding O O
, O O
and O O
the O O
anticoagulant O O
effect O O
( O O
measured O O
by O O
prothrombin O O
time O O
) O O
of O O
warfarin B-drug B-drug
were O O
not O O
significantly O O
changed O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
poor O O
metabolizers O O
. O O

A O O
method O O
to O O
maximize O O
the O O
therapeutic O O
benefit O O
of O O
gentamicin B-drug B-drug
while O O
minimizing O O
the O O
risk O O
of O O
nephrotoxicity O O
and O O
the O O
appearance O O
of O O
a O O
hot O O
kidney O O
on O O
scintigraphy O O
is O O
desirable O O
. O O

Drugs O O
which O O
may O O
enhance O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
TRACRIUM B-brand B-brand
include O O
: O O
enflurane B-drug B-drug
; O O

Patients O O
stabilized O O
on O O
oral O O
anticoagulants B-group B-group
who O O
are O O
found O O
to O O
require O O
thyroid B-group O
replacement O O
therapy O O
should O O
be O O
watched O O
very O O
closely O O
when O O
thyroid O O
is O O
started O O
. O O

The O O
second O O
study O O
was O O
identical O O
but O O
endogenous O O
insulin O O
secretion O O
was O O
blocked O O
with O O
somatostatin B-drug B-drug
. O O

If O O
other O O
muscle B-group B-group
relaxants I-group I-group
are O O
used O O
during O O
the O O
same O O
procedure O O
, O O
the O O
possibility O O
of O O
a O O
synergistic O O
or O O
antagonist O O
effect O O
should O O
be O O
considered O O
. O O

Magnesium- B-drug B-drug
and/or O O
aluminum-containing B-drug B-drug
antacids B-group B-group
, O O
products O O
containing O O
ferrous B-drug B-drug
sulfate I-drug I-drug
( O O
iron B-drug B-drug
) O O
, O O
multivitamin B-group B-group
preparations I-group I-group
containing O O
zinc B-drug B-drug
or O O
other O O
metal O O
cations O O
, O O
or O O
Videx B-brand B-brand
( O O
didanosine B-drug B-drug
) O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
should O O
not O O
be O O
taken O O
within O O
3 O O
hours O O
before O O
or O O
2 O O
hours O O
after O O
FACTIVE B-brand B-brand
. O O

The O O
concomitant O O
administration O O
of O O
either O O
cocaine B-drug B-drug
or O O
amphetamine B-drug B-drug
, O O
compounds O O
which O O
inhibit O O
neuronal O O
reuptake O O
of O O
norepinephrine O B-drug
, O O
disrupts O O
the O O
behavioral O O
response O O
of O O
the O O
genetically O O
nervous O O
E-strain O O
subjects O O
to O O
a O O
far O O
greater O O
extent O O
than O O
the O O
stable O O
A-strain O O
subjects O O
. O O

If O O
TYKERB B-brand B-brand
is O O
administered O O
with O O
drugs O O
that O O
inhibit O O
Pgp O O
, O O
increased O O
concentrations O O
of O O
lapatinib B-drug B-drug
are O O
likely O O
, O O
and O O
caution O O
should O O
be O O
exercised O O
. O O

Because O O
changes O O
in O O
glucose O O
concentrations O O
with O O
valdecoxib B-drug B-drug
coadministration O O
were O O
within O O
the O O
normal O O
variability O O
and O O
individual O O
glucose O O
concentrations O O
were O O
above O O
or O O
near O O
70 O O
mg/dL O O
, O O
dose O O
adjustment O O
for O O
glyburide B-drug B-drug
( O O
5 O O
mg O O
QD O O
and O O
10 O O
mg O O
BID O O
) O O
with O O
valdecoxib B-drug B-drug
coadministration O O
( O O
up O O
to O O
40 O O
mg O O
QD O O
) O O
is O O
not O O
indicated O O
. O O

False-positive O O
direct O O
Coombs O O
tests O O
have O O
been O O
reported O O
during O O
treatment O O
with O O
other O O
cephalosporins B-group B-group
. O O

Impaired O O
glucose O O
tolerance O O
. O O

Ketoconazole B-drug B-drug
: O O
When O O
a O O
single O O
125-mg O O
dose O O
of O O
Aprepitant B-drug B-drug
was O O
administered O O
on O O
Day5 O O
of O O
a O O

In O O
four O O
subjects O O
with O O
epilepsy O O
ingesting O O
valproate B-drug B-drug
, O O
the O O
steady-state O O
trough O O
( O O
Cmin O O
) O O
valproate B-drug B-drug
plasma O O
concentration O O
was O O
63 O O
16 O O
micrograms/mL O O
. O O

Anti-HIV B-group B-group
Reverse I-group I-group
Transcriptase I-group I-group
Inhibitors I-group I-group

Clofibric B-drug_n B-drug_n
acid I-drug_n I-drug_n
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
increase O O
the O O
clearance O O
of O O
clofibric B-drug_n B-drug_n
acid I-drug_n I-drug_n
. O O

No O O
specific O O
studies O O
have O O
been O O
performed O O
and O O
caution O O
is O O
recommended O O
. O O

rash O O

Frequent O O
determination O O
of O O
prothrombin O O
time O O
and O O
close O O
monitoring O O
of O O
the O O
patient O O
is O O
essential O O
to O O
ascertain O O
when O O
adjustment O O
of O O
dosage O O
of O O
anticoagulant B-group B-group
may O O
be O O
needed O O
. O O

A O O
21 O O
( O O
17 O O
) O O
% O O
decrease O O
in O O
the O O
steady-state O O
AUC O O
of O O
ganciclovir B-drug B-drug
was O O
observed O O
when O O
VIDEX B-brand B-brand
was O O
administered O O
2 O O
hours O O
prior O O
to O O
ganciclovir B-drug B-drug
, O O
but O O
not O O
when O O
the O O
two O O
drugs O O
were O O
administered O O
simultaneously O O
( O O
n O O
= O O
12 O O
) O O
. O O

Cevimeline B-drug B-drug
might O O
interfere O O
with O O
desirable O O
antimuscarinic O O
effects O O
of O O
drugs O O
used O O
concomitantly O O
. O O

Statistical O O
analysis O O
: O O
Mantel-Haenszel O O
( O O
alpha O O
= O O
0.05 O O
) O O
. O O

Cyclosporine B-drug B-drug
doses O O
, O O
trough O O
concentrations O O
, O O
and O O
AUC O O
exhibited O O
similar O O
temporal O O
patterns O O
during O O
the O O
course O O
of O O
the O O
study O O
regardless O O
of O O
the O O
co-administered O O
everolimus B-drug B-drug
dose O O
level O O
( O O
P O O
= O O
.13 O O
, O O
.82 O O
, O O
and O O
.76 O O
, O O
respectively O O
) O O
. O O

No O O
drug O O
interactions O O
have O O
been O O
observed O O
with O O
the O O
Vitrasert B-brand B-brand
Implant O O
. O O

No O O
interactions O O
were O O
observed O O
. O O

An O O
interaction O O
study O O
with O O
warfarin B-drug B-drug
showed O O
no O O
clinically O O
significant O O
effect O O
of O O
anastrozole B-drug B-drug
on O O
warfarin B-drug B-drug
pharmacokinetics O O
or O O
anticoagulant O B-group
activity O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Naproxen B-drug B-drug
may O O
decrease O O
platelet O O
aggregation O O
and O O
prolong O O
bleeding O O
time O O
. O O

Intestinal O O
absorption O O
of O O
arsenate B-drug_n B-drug_n
in O O
the O O
chick O O
. O O

Ethanol B-drug B-drug
depressed O O
the O O
amplitudes O O
of O O
most O O
evoked O O
potential O O
components O O
in O O
comparison O O
to O O
saline O O
administration O O
. O O

alcohol B-drug B-drug
, O O
barbiturates B-drug B-group
and O O
other O O
CNS B-drug B-group
depressants I-drug I-group
; O O

An O O
immune O O
response O O
to O O
Campath B-brand B-brand
may O O
interfere O O
with O O
subsequent O O
diagnostic O O
serum O O
tests O O
that O O
utilize O O
antibodies B-group O

After O O
one O O
day O O
, O O
fecal O O
as O O
well O O
as O O
urinary O O
excretion O O
of O O
both O O
elements O O
had O O
already O O
responded O O
to O O
the O O
dietary O O
treatments O O
, O O
with O O
constant O O
values O O
being O O
reached O O
after O O
approximately O O
three O O
days O O
. O O

Epinephrine B-drug B-drug
also O O
should O O
be O O
used O O
cautiously O O
with O O
other O O
drugs O O
( O O
e.g. O O
, O O
digitalis B-group B-group
, O O
glycosides B-group B-group
) O O
that O O
sensitize O O
the O O
myocardium O O
to O O
the O O
actions O O
of O O
sympathomimetic B-group B-group
drugs I-group I-group
. O O

Significant O O
increases O O
In O O
AUC O O
( O O
27 O O
% O O
) O O
and O O
Cmax O O
( O O
58 O O
% O O
) O O
and O O
decreases O O
in O O
tmax O O
( O O
23 O O
% O O
) O O
of O O
propranolol B-drug B-drug
were O O
noted O O
in O O
this O O
study O O
. O O

Treatment O O
with O O
PEGASYS B-brand B-brand
once O O
weekly O O
for O O
4 O O
weeks O O
in O O
healthy O O
subjects O O
was O O
associated O O
with O O
an O O
inhibition O O
of O O
P450 O O
1A2 O O
and O O
a O O
25 O O
% O O
increase O O
in O O
theophylline B-drug B-drug
AUC O O
. O O

Itraconazole B-drug B-drug

Clinical O O
Comment O O

The O O
risks O O
of O O
using O O
Anafranil B-brand B-brand
in O O
combination O O
with O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

- O O
Quinidine B-drug B-drug
( O O
e.g. O O
, O O
Quinidex B-brand B-brand
) O O
or O O

Drug/Laboratory O O
Test O O
Interactions O O
Increases O O
in O O
lymphocyte O O
counts O O
related O O
to O O
the O O
pharmacologic O O
mechanism O O
of O O
action O O
are O O
frequently O O
observed O O
during O O
RAPTIVA B-brand B-brand
treatment O O
. O O

Because O O
many O O
drugs O O
are O O
excreted O O
in O O
human O O
milk O O
, O O
and O O
because O O
there O O
exists O O
the O O
potential O O
for O O
serious O O
adverse O O
reactions O O
in O O
nursing O O
infants O O
from O O
AMEVIVE B-brand B-brand
, O O
a O O
decision O O
should O O
be O O
made O O
whether O O
to O O
discontinue O O
nursing O O
while O O
taking O O
the O O
drug O O
or O O
to O O
discontinue O O
the O O
use O O
of O O
the O O
drug O O
, O O
taking O O
into O O
account O O
the O O
importance O O
of O O
the O O
drug O O
to O O
the O O
mother O O
. O O

Both O O
efavirenz B-drug B-drug
and O O
nevirapine B-drug B-drug
have O O
been O O
compared O O
to O O
triple O O
therapy O O
with O O
the O O
PI B-group O
indinavir B-drug B-drug
over O O
48 O O
weeks O O
as O O
initial O O
therapy O O
, O O
with O O
similar O O
responses O O
being O O
observed O O
with O O
nevirapine B-drug B-drug
regimens O O
and O O
superiority O O
observed O O
with O O
efavirenz B-drug B-drug
. O O

Several O O
drug O O
interaction O O
studies O O
have O O
been O O
completed O O
with O O
both O O
INVIRASE B-brand B-brand
and O O
FORTOVASE B-brand B-brand
. O O

Bexarotene B-drug B-drug
oxidative O O
metabolites O O
appear O O
to O O
be O O
formed O O
by O O
cytochrome O O
P450 O O
3A4 O O
. O O

If O O
you O O
think O O
you O O
are O O
taking O O
an O O
MAO B-group B-group
inhibitor I-group I-group
talk O O
to O O
your O O
doctor O O
or O O
pharmacist O O
. O O

The O O
effect O O
of O O
a O O
pulmonary B-group B-group
surfactant I-group I-group
extract O O
from O O
bovine O O
lung O O
, O O
Survanta B-brand B-brand
, O O
on O O
the O O
dissolution O O
rate O O
of O O
aerosol O O
particles O O
of O O
budesonide B-drug B-drug
was O O
determined O O
. O O

In O O
a O O
single O O
study O O
, O O
rats O O
given O O
high O O
intraperitoneal O O
doses O O
of O O
an O O
MAO B-group B-group
inhibitor I-group I-group
plus O O
disulfiram B-drug B-drug
experienced O O
severe O O
toxicity O O
, O O
including O O
convulsions O O
and O O
death O O
. O O

FACTIVE B-brand B-brand
had O O
no O O
significant O O
effect O O
on O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-drug B-drug
in O O
healthy O O
subjects O O
on O O
stable O O
warfarin B-drug B-drug
therapy O O
. O O

The O O
interindividual O O
pharmacokinetic O O
variability O O
for O O
AUC O O
was O O
85.4 O O
% O O
and O O
intraindividual O O
, O O
interoccasion O O
variability O O
was O O
40.8 O O
% O O
. O O

Excretion O O
of O O
thioethers O O
in O O
urine O O
after O O
exposure O O
to O O
electrophilic O O
chemicals O O
. O O

Expected O O
changes O O
in O O
laboratory O O
assessments O O
of O O
PT O O
and O O
INR O O
were O O
observed O O
after O O
warfarin B-drug B-drug
administration O O
, O O
but O O
these O O
changes O O
were O O
not O O
affected O O
by O O
concomitant O O
lenalidomide B-drug B-drug
administration O O
. O O

Propoxyphene B-drug B-drug
: O O
In O O
cases O O
of O O
propoxyphene B-drug B-drug
overdosage O O
, O O
amphetamine B-drug B-drug
CNS O O
stimulation O O
is O O
potentiated O O
and O O
fatal O O
convulsions O O
can O O
occur O O
. O O

Quinolones B-group B-group
have O O
also O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

Caution O O
should O O
be O O
exercised O O
with O O
these O O
drugs O O
when O O
treating O O
patients O O
receiving O O
TAXOTERE B-brand B-brand
as O O
there O O
is O O
a O O
potential O O
for O O
a O O
significant O O
interaction O O
. O O

Except O O
for O O
clindamycin-sensitive B-drug B-drug
isolates O O
, O O
synergy O O
was O O
usually O O
observed O O
only O O
at O O
concentrations O O
of O O
one O O
or O O
both O O
drugs O O
which O O
are O O
not O O
readily O O
obtainable O O
in O O
vivo O O
. O O

- O O
Cholestyramine B-drug B-drug
and O O
colestipol B-drug B-drug
resins B-group B-group
: O O
Cholestytamine B-drug B-drug
and O O
colestipol B-drug B-drug
resins B-group B-group
have O O
the O O
potential O O
of O O
binding O O
thiazide B-group B-group
diuretics I-group I-group
and O O
reducing O O
diuretic B-group B-group
absorption O O
from O O
the O O
gastrointestinal O O
tract O O

This O O
medicine O O
should O O
not O O
be O O
taken O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Patients O O
with O O
a O O
very O O
low O O
cardiac O O
capacity O O
should O O
be O O
advised O O
to O O
refrain O O
from O O
treatment O O
of O O
the O O
erection O O
disorder O O
. O O

As O O
binding O O
of O O
MHD B-drug_n B-drug_n
to O O
plasma O O
proteins O O
is O O
low O O
( O O
40 O O
% O O
) O O
, O O
clinically O O
significant O O
interactions O O
with O O
other O O
drugs O O
through O O
competition O O
for O O
protein O O
binding O O
sites O O
are O O
unlikely O O
. O O

Adverse O O
reactions O O
related O O
to O O
alpha B-drug O
interferons O O
, O O
such O O
as O O
CNS O O
, O O
cardiac O O
, O O
and O O
systemic O O
( O O
eg O O
, O O
flu-like O O
) O O
effects O O
may O O
be O O
more O O
severe O O
in O O
the O O
elderly O O
and O O
caution O O
should O O
be O O
exercised O O
in O O
the O O
use O O
of O O
PEGASYS B-brand B-brand
in O O
this O O
population O O
. O O

In O O
opioid-dependent B-group B-group
patients O O
, O O
mixed B-group B-group
agonist/antagonist I-group I-group
analgesics I-group I-group
may O O
precipitate O O
withdrawal O O
symptoms O O
. O O

Chirocaine B-brand B-drug
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
other O O
local O O
anesthetics B-group B-group
or O O
agents O O
structurally O O
related O O
to O O
amide-type O O
local O O
anesthetics O B-group
since O O
the O O
toxic O O
effects O O
of O O
these O O
drugs O O
could O O
be O O
additive O O
. O O

Misonidazole B-drug_n B-drug_n
reduced O O
the O O
antitumour O O
activity O O
of O O
oral O O
CCNU B-drug B-drug
by O O
dose O O
modifying O O
factors O O
( O O
DMF O O
) O O
of O O
0.58-0.71 O O
. O O

An O O
association O O
between O O
prilocaine B-drug B-drug
and O O
an O O
increased O O
risk O O
of O O
methaemoglobinaemia O O
, O O
particularly O O
in O O
infants O O
, O O
has O O
specifically O O
been O O
described O O
in O O
a O O
literature O O
case O O
report O O
. O O

Fenfluramine B-drug B-drug
may O O
increase O O
slightly O O
the O O
effect O O
of O O
antihypertensive B-group B-group
drugs I-group I-group
, O O
e.g. O O
, O O
guanethidine B-drug B-drug
, O O
methyldopa B-drug B-drug
, O O
reserpine B-drug B-drug
. O O

Cytochrome O O
P450 O O
1A2 O O
( O O
CYP1A2 O O
) O O
is O O
known O O
to O O
be O O
the O O
major O O
enzyme O O
involved O O
in O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

Exposure O O
of O O
the O O
muscle O O
to O O
ouabain B-drug B-drug
( O O
10 O O
( O O
-5 O O
) O O
M O O
) O O
markedly O O
increased O O
the O O
PTX-induced B-drug_n B-drug_n
release O O
. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
with O O
enalapril B-drug B-drug
or O O
enalaprilat B-drug B-drug
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-drug B-group
or O O
increasing O O
the O O
salt O O
intake O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
enalapril B-drug B-drug
or O O
enalaprilat B-drug B-drug
. O O

+15 O O
% O O
+0 O O
% O O
+17 O O
% O O
+13 O O
% O O

When O O
phenobarbital B-drug B-drug
is O O
added O O
to O O
or O O
withdrawn O O
from O O
treatment O O
, O O
dosage O O
adjustment O O
of O O
Nalfon B-brand B-brand
may O O
be O O
required O O
. O O

Digitalis B-group B-group
: O O
Immediate O O
Release O O
Capsules O O
: O O
Since O O
there O O
have O O
been O O
isolated O O
reports O O
of O O
patients O O
with O O
elevated O O
digoxin B-drug B-drug
levels O O
, O O
and O O
there O O
is O O
a O O
possible O O
interaction O O
between O O
digoxin B-drug B-drug
and O O
nifedipine B-drug B-drug
, O O
it O O
is O O
recommended O O
that O O
digoxin B-drug B-drug
levels O O
be O O
monitored O O
when O O
initiating O O
, O O
adjusting O O
, O O
and O O
discontinuing O O
nifedipine B-drug B-drug
to O O
avoid O O
possible O O
over- O O
or O O
under-digitalization O O
. O O

Cyclosporin B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
sirolimus B-drug B-drug

Thus O O
, O O
the O O
selective O O
regulation O O
of O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
subtypes O O
by O O
ginsenosides B-drug_n B-drug_n
in O O
bovine O O
chromaffin O O
cell O O
could O O
be O O
the O O
cellular O O
basis O O
of O O
antistress O O
effects O O
induced O O
by O O
ginseng B-drug B-drug_n
. O O

It O O
has O O
been O O
reported O O
that O O
the O O
addition O O
of O O
triamterene B-drug B-drug
to O O
a O O
maintenance O O
schedule O O
of O O
INDOCIN B-brand B-brand
resulted O O
in O O
reversible O O
acute O O
renal O O
failure O O
in O O
two O O
of O O
four O O
healthy O O
volunteers O O
. O O

As O O
with O O
other O O
drugs O O
primarily O O
being O O
metabolized O O
through O O
CYP3A4 O O
, O O
ingestion O O
of O O
grapefruit O O
or O O
grapefruit O O
juice O O
should O O
be O O
avoided O O
in O O
connection O O
with O O
budesonide B-drug B-drug
administration O O
. O O

. O O

Dexamethasone B-drug B-drug
had O O
a O O
similar O O
effect O O
in O O
the O O
presence O O
of O O
insulin B-drug B-drug
. O O

There O O
is O O
limited O O
experience O O
with O O
use O O
of O O
retinal O O
tamponades O O
in O O
conjunction O O
with O O
the O O
Vitrasert B-brand B-brand
Implant O O
. O O

Drugs O O
which O O
inhibit O O
CYP2D6 O O
and O O
CYP3A3/4 O O
also O O
inhibit O O
the O O
metabolism O O
of O O
cevimeline B-drug B-drug
. O O

Tubocurarine B-drug B-drug

Benzyl B-drug_n B-drug
alcohol I-drug_n I-drug
has O O
been O O
reported O O
to O O
be O O
associated O O
with O O
an O O
increased O O
incidence O O
of O O
neurological O O
and O O
other O O
complications O O
in O O
neonates O O
and O O
infants O O
, O O
which O O
are O O
sometimes O O
fatal O O
. O O

+135 O O
% O O

these O O
may O O
also O O
occur O O
in O O
neonates O O
whose O O
mothers O O
received O O
cephalosporins B-group B-group
before O O
delivery O O
. O O

Blood O O
glucose O O
concentrations O O
should O O
be O O
carefully O O
monitored O O
when O O
Itraconazole B-drug B-drug
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
are O O
coadministered O O
. O O

Prednisolone B-drug B-drug
: O O
Ethinyl B-drug B-drug
estradiol I-drug I-drug
may O O
inhibit O O
the O O
metabolism O O
of O O
prednisolone B-drug B-drug
, O O
leading O O
to O O
increased O O
plasma O O
concentrations O O
. O O

Coadministration O O
of O O
Aprepitant B-drug B-drug
with O O
drugs O O
that O O
induce O O
CYP3A4 O O
activity O O
may O O
result O O
in O O
reduced O O
plasma O O
concentrations O O
and O O
decreased O O
efficacy O O
of O O
Aprepitant B-drug B-drug
. O O

Diagnostic O O
dip-stick O O
methodology O O
, O O
used O O
to O O
detect O O
ketone O O
bodies O O
in O O
urine O O
, O O
has O O
resulted O O
in O O
false-positive O O
findings O O
in O O
some O O
patients O O
treated O O
with O O
Lodine B-brand B-brand
. O O

Concomitant O O
Administration O O
with O O
Racemic O O
Citalopram B-drug B-drug
Citalopram I-drug I-drug
- O O
Since O O
escitalopram B-drug B-drug
is O O
the O O
active O O
isomer O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
Celexa B-brand B-brand
) O O
, O O
the O O
two O O
agents O O
should O O
not O O
be O O
coadministered O O
. O O

Calcium B-group B-group
channel I-group I-group
blockers I-group I-group

Antihypertensive B-group B-group
medications I-group I-group
, O O
other O O
, O O
especially O O
diazoxide B-drug B-drug
, O O
or O O
preanesthetic B-group O
and O O
anesthetic O B-group
agents O I-group
used O O
in O O
surgery O O
or O O
skeletal-muscle B-group B-group
relaxants I-group I-group
, O O
nondepolarizing O O
, O O
used O O
in O O
surgery O O

Clinical O O
Comment O O

Glyburide B-drug B-drug
: O O
The O O
concomitant O O
administration O O
of O O
ciprofloxacin B-drug B-drug
with O O
the O O
sulfonylurea B-group B-group
glyburide B-drug B-drug
has O O
, O O
on O O
rare O O
occasions O O
, O O
resulted O O
in O O
severe O O
hypoglycemia O O
. O O

However O O
, O O
theophylline B-drug B-drug
plasma O O
concentrations O O
should O O
be O O
monitored O O
, O O
with O O
dosage O O
adjustment O O
as O O
appropriate O O
, O O
in O O
patients O O
whose O O
pulmonary O O
disease O O
requires O O
maintaining O O
a O O
given O O
theophylline B-drug B-drug
plasma O O
concentration O O
for O O
optimal O O
pulmonary O O
function O O
or O O
in O O
patients O O
with O O
theophylline B-drug B-drug
concentrations O O
at O O
the O O
higher O O
end O O
of O O
the O O
therapeutic O O
range O O
. O O

Chronic O O
administration O O
of O O
phenobarbital B-drug B-drug
, O O
a O O
known O O
enzyme O O
inducer O O
, O O
may O O
be O O
associated O O
with O O
a O O
decrease O O
in O O
the O O
plasma O O
half-life O O
of O O
fenoprofen B-drug B-drug
. O O

Similarly O O
dialyzed O O
were O O
phenobarbital B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
and O O
theophylline B-drug B-drug
, O O
both O O
alone O O
at O O
therapeutic O O
concentrations O O
in O O
serum O O
and O O
with O O
ethanol B-drug B-drug
at O O
three O O
different O O
concentrations O O
in O O
serum O O
. O O

Do O O
not O O
take O O
this O O
medicine O O
with O O
St. O O
Johns O O
Wort O O
because O O
of O O
the O O
additive O O
effects O O
of O O
sertonin O O
. O O

ATROVENT B-brand B-brand
Inhalation O O
Aerosol O O
has O O
been O O
used O O
concomitantly O O
with O O
other O O
drugs O O
, O O
including O O
sympathomimetic B-group B-group
bronchodilators I-group I-group
, O O
methylxanthines B-group B-group
, O O
and O O
steroids B-group B-group
, O O
commonly O O
used O O
in O O
the O O
treatment O O
of O O
chronic O O
obstructive O O
pulmonary O O
disease O O
. O O

This O O
drug O O
may O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-group B-group
) O O
, O O
anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-group B-group
) O O
, O O
and O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
( O O
concurrent O O
use O O
with O O
antihistamines B-drug B-group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-drug B-group
) O O
. O O

This O O
could O O
lead O O
to O O
decreased O O
salicylate B-group B-group
serum O O
levels O O
or O O
increase O O
the O O
risk O O
of O O
salicylate B-group B-group
toxicity O O
when O O
corticosteroid B-drug B-group
is O O
withdrawn O O
. O O

Oral O O
Hypoglycemics B-group B-group
: O O
Diclofenac B-drug B-drug
does O O
not O O
alter O O
glucose O O
metabolism O O
in O O
normal O O
subjects O O
nor O O
does O O
it O O
alter O O
the O O
effects O O
of O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

After O O
extensive O O
intake O O
of O O
grapefruit O O
juice O O
( O O
which O O
inhibits O O
CYP3A4 O O
activity O O
predominantly O O
in O O
the O O
intestinal O O
mucosa O O
) O O
, O O
the O O
systemic O O
exposure O O
for O O
oral O O
budesonide B-drug B-drug
increased O O
about O O
two O O
times O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Blood O O
Glucose O O
Blood O O
glucose O O
measurement O O
must O O
be O O
done O O
with O O
a O O
glucose-specific O O
method O O
to O O
prevent O O
maltose O O
interference O O
with O O
test O O
results O O
. O O

Interaction O O
with O O
phenytoin B-drug B-drug
, O O
lidocaine B-drug B-drug
and O O
theophylline B-drug B-drug
has O O
also O O
been O O
reported O O
to O O
produce O O
adverse O O
clinical O O
effects O O
. O O

Carbamazepine B-drug B-drug
: O O
Elevated O O
carbamazepine B-drug B-drug
levels O O
have O O
been O O
reported O O
in O O
postmarketing O O
experience O O
when O O
SUPRAX B-brand B-brand
is O O
administered O O
concomitantly O O
. O O

Aspirin B-brand B-brand
increased O O
ulcerogenic O O
effect O O
; O O

Concurrent O O
use O O
of O O
tetracycline B-drug B-drug
may O O
render O O
oral O O
contraceptives B-group B-group
less O O
effective O O
. O O

These O O
results O O
suggest O O
that O O
KRM-1648 B-drug_n B-drug_n
has O O
a O O
great O O
potential O O
in O O
the O O
treatment O O
of O O
M O O
. O O

Two O O
different O O
types O O
of O O
therapy O O
with O O
magnesium B-drug B-drug
are O O
used O O
: O O
physiological O O
oral O O
magnesium B-drug B-drug
supplementation O O
which O O
is O O
totally O O
atoxic O O
since O O
it O O
palliates O O
magnesium B-drug B-drug
deficiencies O O
by O O
simply O O
normalizing O O
the O O
magnesium B-drug B-drug
intake O O
and O O
pharmacological O O
magnesium B-drug B-drug
therapy O O
which O O
may O O
induce O O
toxicity O O
since O O
it O O
creates O O
iatrogenic O O
magnesium B-drug B-drug
overload O O
. O O

No O O
data O O
are O O
available O O
on O O
potential O O
interactions O O
in O O
individuals O O
who O O
consume O O
greater O O
than O O
200 O O
mg O O
of O O
caffeine B-drug B-drug
per O O
day O O
or O O
in O O
those O O
, O O
such O O
as O O
the O O
geriatric O O
population O O
, O O
who O O
are O O
generally O O
believed O O
to O O
be O O
more O O
susceptible O O
to O O
the O O
development O O
of O O
drug-induced O O
CNS-related O O
adverse O O
effects O O
. O O

Theophylline B-drug B-drug
: O O
Twelve O O
healthy O O
male O O
volunteers O O
were O O
administered O O
one O O
200-mg O O
ceftibuten B-drug B-drug
capsule O O
twice O O
daily O O
for O O
6 O O
days O O
. O O

No O O
significant O O
interactions O O
were O O
found O O
between O O
nisoldipine B-drug B-drug
and O O
warfarin B-drug B-drug
or O O
digoxin B-drug B-drug
. O O

It O O
was O O
concluded O O
that O O
oral O O
oxycodone B-drug B-drug
and O O
levofloxacin B-drug B-drug
can O O
be O O
administered O O
concomitantly O O
without O O
a O O
significant O O
decrease O O
in O O
AUC O O
, O O
Cmax O O
, O O
or O O
tmax O O
. O O

The O O
cause O O
of O O
the O O
reported O O
association O O
has O O
not O O
been O O
established O O
. O O

Phosphate-Binding O O
Agents O O
: O O
Since O O
vitamin B-group B-group
D I-group I-group
also O O
has O O
an O O
effect O O
on O O
phosphate O O
transport O O
in O O
the O O
intestine O O
, O O
kidneys O O
and O O
bones O O
, O O
the O O
dosage O O
of O O
phosphate-binding O O
agents O O
must O O
be O O
adjusted O O
in O O
accordance O O
with O O
the O O
serum O O
phosphate O O
concentration O O
. O O

vasculitis O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reaction O O
. O O

Antacids B-group B-group
: O O
Nonclinical O O
data O O
demonstrate O O
that O O
the O O
solubility O O
of O O
dasatinib B-drug B-drug
is O O
pH O O
dependent O O
. O O

It O O
is O O
not O O
known O O
which O O
drug O O
clearance O O
mechanism O O
involved O O
in O O
caspofungin B-drug B-drug
disposition O O
may O O
be O O
inducible O O
. O O

Laboratory O O
Tests O O
Response O O
to O O
Plenaxis B-brand B-brand
should O O
be O O
monitored O O
by O O
measuring O O
serum O O
total O O
testosterone B-drug O
concentrations O O
just O O
prior O O
to O O
administration O O
on O O
Day O O
29 O O
and O O
every O O
8 O O
weeks O O
thereafter O O
. O O

In O O
the O O
present O O
study O O
we O O
evaluated O O
the O O
interference O O
of O O
antidepressants B-group B-group
with O O
blood O O
glucose O O
levels O O
of O O
diabetic O O
and O O
non-diabetic O O
rats O O
. O O

In O O
two O O
clinical O O
studies O O
, O O
cyclosporine B-drug B-drug
( O O
one O O
4 O O
mg/kg O O
dose O O
or O O
two O O
3 O O
mg/kg O O
doses O O
) O O
increased O O
the O O
AUC O O
of O O
caspofungin B-drug B-drug
by O O
approximately O O
35 O O
% O O
. O O

dietary O O
deficiencies O O
; O O

Women O O
should O O
practice O O
additional O O
methods O O
of O O
contraception O O
and O O
not O O
rely O O
on O O
hormonal O O
contraception O O
alone O O
when O O
taking O O
TRACLEER B-brand B-brand
. O O

Concomitant O O
use O O
of O O
barbiturates B-group B-group
usually O O
depresses O O
griseofulvin B-drug B-drug
activity O O
and O O
may O O
necessitate O O
raising O O
the O O
dosage O O
. O O

Tetracycline B-drug B-drug
, O O
a O O
bacteriostatic B-group B-group
antibiotic I-group I-group
, O O
may O O
antagonize O O
the O O
bactericidal O O
effect O O
of O O
penicillin B-drug B-drug
and O O
concurrent O O
use O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

There O O
have O O
been O O
no O O
formal O O
clinical O O
studies O O
to O O
evaluate O O
the O O
drug O O
interactions O O
of O O
TAXOTERE B-brand B-brand
with O O
other O O
medications O O
. O O

Amphetamines B-group B-group
may O O
enhance O O
the O O
effects O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

Immunologic O O

In O O
clinical O O
trials O O
, O O
the O O
concomitant O O
administration O O
of O O
sulfadoxine B-drug B-drug
and O O
pyrimethamine B-drug B-drug
did O O
not O O
alter O O
the O O
adverse O O
reaction O O
profile O O
. O O

Coadministration O O
of O O
VIRACEPT B-brand B-brand
and O O
drugs O O
that O O
induce O O
CYP3A O O
may O O
decrease O O
nelfinavir B-drug B-drug
plasma O O
concentrations O O
and O O
reduce O O
its O O
therapeutic O O
effect O O
. O O

CYP3A4 O O
inhibitors O O
: O O
May O O
increase O O
the O O
levels/effects O O
of O O
chlorpheniramine B-drug B-drug
. O O

Results O O
from O O
human O O
in O O
vitro O O
metabolism O O
studies O O
and O O
nonclinical O O
studies O O
show O O
that O O
REVLIMID B-brand B-brand
( O O
lenalidomide B-drug B-drug
) O O
is O O
neither O O
metabolized O O
by O O
nor O O
inhibits O O
or O O
induces O O
the O O
cytochrome O O
P450 O O
pathway O O
suggesting O O
that O O
lenalidomide B-drug B-drug
is O O
not O O
likely O O
to O O
cause O O
or O O
be O O
subject O O
to O O
P450-based O O
metabolic O O
drug O O
interactions O O
in O O
man O O
. O O

The O O
effects O O
of O O
ketamine B-drug B-drug
and O O
of O O
Innovar B-brand B-brand
anesthesia O O
on O O
digitalis B-group B-group
tolerance O O
in O O
dogs O O
. O O

The O O
potential O O
effects O O
of O O
fulvestrant B-drug B-drug
on O O
the O O
fertility O O
of O O
male O O
animals O O
were O O
not O O
studied O O
but O O
in O O
a O O
6-month O O
toxicology O O
study O O
, O O
male O O
rats O O
treated O O
with O O
intramuscular O O
doses O O
of O O
15 O O
mg/kg/30 O O
days O O
, O O
10 O O
mg/rat/30 O O
days O O
, O O
or O O
10 O O
mg/rat/15 O O
days O O
fulvestrant B-drug B-drug
showed O O
a O O
loss O O
of O O
spermatozoa O O
from O O
the O O
seminiferous O O
tubules O O
, O O
seminiferous O O
tubular O O
atrophy O O
, O O
and O O
degenerative O O
changes O O
in O O
the O O
epididymides O O
. O O

Talk O O
to O O
your O O
doctor O O
and O O
pharmacist O O
before O O
taking O O
any O O
prescription O O
or O O
over-the-counter O O
medicines O O
, O O
including O O
herbal O O
products O O
. O O

If O O
you O O
are O O
taking O O
medications O O
for O O
migraines O O
such O O
as O O
Imitrex B-brand B-brand
, O O
talk O O
to O O
your O O
doctor O O
before O O
starting O O
this O O
medicine O O
. O O

Consequently O O
, O O
it O O
is O O
recommended O O
that O O
fluvoxamine B-drug B-drug
not O O
be O O
used O O
in O O
combination O O
with O O
either O O
terbinafine B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
or O O
cisapride B-drug B-drug
. O O

In O O
a O O
similar O O
study O O
with O O
tamsulosin B-drug B-drug
in O O
healthy O O
volunteers O O
, O O
1 O O
of O O
24 O O
subjects O O
dosed O O
with O O
Vardenafil B-drug B-drug
20 O O
mg O O
and O O
tamsulosin B-drug B-drug
0.4 O O
mg O O
separated O O
by O O
6 O O
hours O O
experienced O O
a O O
standing O O
systolic O O
blood O O
pressure O O
below O O
85 O O
mm O O
Hg O O
. O O

Doses O O
of O O
these O O
and O O
perhaps O O
other O O
medications O O
may O O
need O O
to O O
be O O
adjusted O O
in O O
patients O O
who O O
successfully O O
quit O O
smoking O O
. O O

However O O
, O O
no O O
related O O
changes O O
were O O
noted O O
in O O
the O O
QT0 O O
on O O
ECG O O
taken O O
at O O
2 O O
, O O
6 O O
, O O
and O O
24 O O
hours O O
after O O
the O O
coadministration O O
. O O

The O O
effect O O
of O O
gabapentin B-drug B-drug
on O O
cimetidine B-drug B-drug
was O O
not O O
evaluated O O
. O O

However O O
, O O
in O O
clinical O O
studies O O
the O O
consequences O O
of O O
concomitant O O
irbesartan B-drug B-drug
on O O
the O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
were O O
negligible O O
. O O

When O O
patients O O
have O O
received O O
such O O
drugs O O
, O O
the O O
dose O O
of O O
INAPSINE B-brand B-brand
required O O
will O O
be O O
less O O
than O O
usual O O
. O O

Pyrantel B-drug B-drug
( O O
e.g. O O
, O O
Antiminth B-drug B-brand
) O O
- O O
Taking O O
piperazine B-drug B-drug
and O O
pyrantel B-drug B-drug
together O O
may O O
decrease O O
the O O
effects O O
of O O
piperazine B-drug B-drug
. O O

The O O
clinical O O
significance O O
of O O
this O O
observation O O
is O O
unknown O O
. O O

The O O
administrative O O
arrangements O O
in O O
an O O
area O O
of O O
Scotland O O
were O O
accompanied O O
by O O
a O O
300 O O
% O O
increase O O
in O O
the O O
frequency O O
of O O
admissions O O
for O O
mania O O
, O O
whereas O O
in O O
an O O
area O O
of O O
the O O
West O O
Midlands O O
, O O
a O O
large O O
decrease O O
was O O
achieved O O
. O O

However O O
, O O
it O O
should O O
be O O
noted O O
that O O
both O O
products O O
are O O
capable O O
of O O
producing O O
transient O O
increases O O
in O O
blood O O
pressure O O
. O O

Probenecid B-drug B-drug
given O O
concurrently O O
increases O O
naproxen B-drug B-drug
anion O O
plasma O O
levels O O
and O O
extends O O
its O O
plasma O O
half-life O O
significantly O O
. O O

Concomitant O O
administration O O
of O O
ketoconazole B-drug B-drug
tablets O O
with O O
phenytoin B-drug B-drug
may O O
alter O O
the O O
metabolism O O
of O O
one O O
or O O
both O O
of O O
the O O
drugs O O
. O O

Adrenergic B-group B-group
blockers I-group I-group
Adrenergic I-group I-group
blockers I-group I-group
are O O
inhibited O O
by O O
amphetamines B-group B-group
. O O

Since O O
there O O
have O O
been O O
conflicting O O
results O O
regarding O O
the O O
effect O O
of O O
digoxin B-drug B-drug
levels O O
, O O
it O O
is O O
recommended O O
that O O
digoxin B-drug B-drug
levels O O
be O O
monitored O O
when O O
initiating O O
, O O
adjusting O O
, O O
and O O
discontinuing O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
therapy O O
to O O
avoid O O
possible O O
over- O O
or O O
under-digitalization O O
. O O

However O O
, O O
caution O O
must O O
be O O
exercised O O
in O O
extrapolating O O
these O O
findings O O
to O O
the O O
clinical O O
situation O O
and O O
in O O
the O O
use O O
of O O
glipizide B-drug B-drug
with O O
these O O
drugs O O
. O O

The O O
daily O O
dose O O
of O O
dexamethasone B-drug B-drug
administered O O
in O O
clinical O O
studies O O
with O O
Aprepitant B-drug B-drug
reflects O O
an O O
approximate O O
50 O O
% O O
reduction O O
of O O
the O O
dose O O
of O O
dexamethasone B-drug B-drug
. O O

During O O
controlled O O
hypotensive O O
anesthesia O O
using O O
labetalol B-drug B-drug
HCl I-drug I-drug
in O O
association O O
with O O
halothane B-drug B-drug
, O O
high O O
concentrations O O
( O O
3 O O
% O O
or O O
above O O
) O O
of O O
halothane B-drug B-drug
should O O
not O O
be O O
used O O
because O O
the O O
degree O O
of O O
hypotension O O
will O O
be O O
increased O O
and O O
because O O
of O O
the O O
possibility O O
of O O
a O O
large O O
reduction O O
in O O
cardiac O O
output O O
and O O
an O O
increase O O
in O O
central O O
venous O O
pressure O O
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCA B-group B-group
plasma O O
levels O O
whenever O O
a O O
TCA B-group B-group
is O O
going O O
to O O
be O O
co-administered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
. O O

Formal O O
drug O O
interaction O O
studies O O
with O O
Abciximab B-drug B-drug
have O O
not O O
been O O
conducted O O
. O O

Bosentan B-drug B-drug
had O O
no O O
relevant O O
inhibitory O O
effect O O
on O O
any O O
CYP O O
isoenzymes O O
tested O O
( O O
CYP1A2 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
CYP3A4 O O
) O O
. O O

Therefore O O
, O O
coagulation O O
indices O O
should O O
be O O
monitored O O
frequently O O
to O O
maintain O O
the O O
desired O O
anticoagulant O O
effect O O
. O O

indinavir I-drug B-drug
concentration O O

- O O
Lofexidine B-drug B-drug
may O O
enhance O O
the O O
CNS O O
depressive O O
effects O O
of O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
and O O
other O O
sedatives B-group B-group

When O O
s.c O O
. O O

Population O O
pharmacokinetic O O
analyses O O
revealed O O
that O O
MTX B-drug B-drug
, O O
NSAIDs B-group B-group
, O O
corticosteroids B-group B-group
, O O
and O O
TNF B-group B-group
blocking I-group I-group
agents I-group I-group
did O O
not O O
influence O O
abatacept B-drug B-drug
clearance O O
. O O

Carcinogenesis O O
, O O
Mutagenesis O O
, O O
Impairment O O
of O O
Fertility O O
Carcinogenesis O O
PEGASYS B-brand B-brand
has O O
not O O
been O O
tested O O
for O O
its O O
carcinogenic O O
potential O O
. O O

Alosetron B-drug B-drug
also O O
does O O
not O O
appear O O
to O O
induce O O
CYP O O
enzymes O O
2E1 O O
or O O
2C19 O O
. O O

There O O
is O O
now O O
strong O O
evidence O O
that O O
intensive O O
control O O
of O O
blood O O
glucose O O
can O O
significantly O O
reduce O O
and O O
retard O O
the O O
microvascular O O
complications O O
of O O
retinopathy O O
, O O
nephropathy O O
, O O
and O O
neuropathy O O
. O O

20 O O
mg O O
result O O
in O O
incomplete O O
depletion O O
which O O
becomes O O
complete O O
after O O
a O O
second O O
additional O O
dose O O
. O O

Excessive O O
widening O O
of O O
the O O
QRS O O
complex O O
and/or O O
prolongation O O
of O O
the O O
Q-T O O
interval O O
may O O
occur O O
in O O
these O O
situations O O
. O O

These O O
effects O O
of O O
calcium B-group B-group
blockers I-group I-group
on O O
platelet O O
function O O
and O O
arachidonic O O
acid O O
metabolism O O
could O O
contribute O O
in O O
part O O
to O O
their O O
efficacy O O
in O O
patients O O
with O O
ischemic O O
heart O O
disease O O
. O O

Antithrombotics B-group B-group

pruritus O O

Lovastatin B-drug B-drug

Palytoxin B-drug_n B-drug_n
( O O
PTX B-drug_n B-drug_n
) O O
, O O
C129H223N3O54 O O
, O O
isolated O O
from O O
marine O O
coelenterates O O
of O O
Palythoa O O
tuberculosa O O
, O O
caused O O
a O O
first O O
rapid O O
contraction O O
followed O O
by O O
the O O
slow O O
phasic O O
contraction O O
of O O
guinea-pig O O
vas O O
deferens O O
. O O

If O O
TRANXENE B-brand B-brand
tablets O O
are O O
used O O
to O O
treat O O
anxiety O O
associated O O
with O O
somatic O O
disease O O
states O O
, O O
careful O O
attention O O
must O O
be O O
paid O O
to O O
possible O O
drug O O
interaction O O
with O O
concomitant O O
medication O O
. O O

Cancer O O
chemotherapy O O

Drugs O O
Within O O
Class O O
Not O O
To O O
Be O O
Coadministered O O
With O O
SUSTIVA B-brand B-brand

Every O O
other O O
day O O
dosing O O
with O O
100m O O
g/kg O O
( O O
1200m O O
g/m2 O O
) O O
PEGASYS B-brand B-brand
( O O
equivalent O O
to O O
approximately O O
30 O O
times O O
the O O
recommended O O
human O O
dose O O
) O O
had O O
no O O
effects O O
on O O
cycle O O
duration O O
or O O
reproductive O O
hormone O O
status O O
. O O

Symptoms O O
resolved O O
when O O
clonidine B-drug B-drug
was O O
withdrawn O O
and O O
recurred O O
when O O
the O O
patient O O
was O O
rechallenged O O
with O O
clonidine B-drug B-drug
. O O

Rearrangements O O
of O O
genomes O O
have O O
been O O
found O O
to O O
accompany O O
cellular O O
aging O O
. O O

Anagrelide B-drug B-drug
demonstrates O O
some O O
limited O O
inhibitory O O
activity O O
towards O O
CYP1A2 O O
which O O
may O O
present O O
a O O
theoretical O O
potential O O
for O O
interaction O O
with O O
other O O
coadministered O O
medicinal O O
products O O
sharing O O
that O O
clearance O O
mechanism O O
e.g O O
. O O
theophylline B-drug B-drug
. O O

Cefuroxime B-drug B-drug
does O O
not O O
interfere O O
with O O
the O O
assay O O
of O O
serum O O
and O O
urine O O
creatinine O O
by O O
the O O
alkaline O O
picrate O O
method O O
. O O

Because O O
of O O
the O O
danger O O
of O O
a O O
potentially O O
fatal O O
prolongation O O
of O O
the O O
QTc O O
interval O O
, O O
halofantrine B-drug B-drug
must O O
not O O
be O O
given O O
simultaneously O O
with O O
or O O
subsequent O O
to O O
Mefloquine B-drug B-drug
. O O

He O O
was O O
treated O O
aggressively O O
with O O
intravenous O O
hydration O O
, O O
sodium B-drug B-drug
bicarbonate I-drug I-drug
, O O
and O O
hemodialysis O O
. O O

Alcohol B-drug B-drug
, O O
in O O
particular O O
, O O
has O O
been O O
found O O
to O O
exhibit O O
additive O O
effects O O
of O O
this O O
variety O O
. O O

indinavir I-drug B-drug
concentration O O

Since O O
the O O
pharmacokinetics O O
of O O
BUSULFEX B-brand B-brand
were O O
studied O O
in O O
patients O O
treated O O
with O O
phenytoin B-drug B-drug
, O O
the O O
clearance O O
of O O
BUSULFEX B-brand B-brand
at O O
the O O
recommended O O
dose O O
may O O
be O O
lower O O
and O O
exposure O O
( O O
AUC O O
) O O
higher O O
in O O
patients O O
not O O
treated O O
with O O
phenytoin B-drug B-drug
. O O

Effects O O
of O O
Other O O
Antiepileptic B-group B-group
Drugs I-group I-group
on O O
Felbatol B-brand B-brand
Phenytoin B-drug B-drug
: O O
Phenytoin B-drug B-drug
causes O O
an O O
approximate O O
doubling O O
of O O
the O O
clearance O O
of O O
Felbatol B-brand B-brand
( O O
felbamate B-drug B-drug
) O O
at O O
steady O O
state O O
and O O
, O O
therefore O O
, O O
the O O
addition O O
of O O
phenytoin B-drug B-drug
causes O O
an O O
approximate O O
45 O O
% O O
decrease O O
in O O
the O O
steady-state O O
trough O O
concentrations O O
of O O
Felbatol B-brand B-brand
as O O
compared O O
to O O
the O O
same O O
dose O O
of O O
Felbatol B-brand B-brand
given O O
as O O
monotherapy O O
. O O

[ O O
Pharmacologic O O
interactions O O
in O O
chronic O O
treatments O O
: O O
corrective O O
measures O O
for O O
its O O
prevention O O
in O O
a O O
basic O O
area O O
of O O
rural O O
health O O
] O O
OBJECTIVES O O
: O O
To O O
identify O O
the O O
pharmacological O O
interactions O O
of O O
clinical O O
relevance O O
( O O
PICR O O
) O O
in O O
the O O
medication O O
authorization O O
cards O O
( O O
MAC O O
) O O
of O O
the O O
chronically O O
ill O O
and O O
to O O
establish O O
strategies O O
to O O
minimise O O
their O O
appearance O O
. O O

As O O
a O O
result O O
, O O
drugs O O
that O O
are O O
metabolized O O
by O O
these O O
enzyme O O
systems O O
may O O
have O O
lower O O
than O O
expected O O
plasma O O
levels O O
when O O
coadministered O O
with O O
nevirapine B-drug B-drug
. O O

General O O
: O O
In O O
humans O O
, O O
valdecoxib B-drug B-drug
metabolism O O
is O O
predominantly O O
mediated O O
via O O
CYP O O
3A4 O O
and O O
2C9 O O
with O O
glucuronidation O O
being O O
a O O
further O O
( O O
20 O O
% O O
) O O
route O O
of O O
metabolism O O
. O O

International O O
Normalized O O
Ratio O O
( O O
INR O O
) O O
elevations O O
and/or O O
bleeding O O
events O O
have O O
been O O
reported O O
in O O
some O O
patients O O
taking O O
warfarin B-drug B-drug
while O O
on O O
IRESSA B-brand B-brand
therapy O O
. O O

There O O
have O O
been O O
case O O
reports O O
of O O
increased O O
steady-state O O
levels O O
of O O
quinidine B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
and O O
phenytoin B-drug B-drug
during O O
concomitant O O
therapy O O
with O O
amiodarone B-drug B-drug
. O O

Since O O
1988 O O
, O O
it O O
has O O
been O O
noted O O
that O O
incidence O O
of O O
melarsoprol B-drug B-drug
reaction O O
had O O
increased O O
systematically O O
between O O
June O O
and O O
October O O
of O O
each O O
year O O
, O O
indicating O O
strong O O
seasonal O O
variation O O
. O O

Treatment O O
plans O O
for O O
patients O O
taking O O
anticoagulants B-group B-group
can O O
become O O
complicated O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
( O O
such O O
as O O
CLINISTIX O O
or O O
TES-TAPE O O
) O O
be O O
used O O
. O O

Saquinavir I-drug B-drug

There O O
is O O
no O O
evidence O O
in O O
animal O O
or O O
human O O
studies O O
that O O
TORADOL B-brand B-brand
induces O O
or O O
inhibits O O
hepatic O O
enzymes O O
capable O O
of O O
metabolizing O O
itself O O
or O O
other O O
drugs O O

Coadministration O O
of O O
propoxyphene B-drug B-drug
decreased O O
the O O
maximum O O
plasma O O
concentration O O
of O O
alprazolam B-drug B-drug
by O O
6 O O
% O O
, O O
decreased O O
clearance O O
by O O
38 O O
% O O
, O O
and O O
increased O O
half-life O O
by O O
58 O O
% O O
. O O

No O O
formal O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

A O O
similar O O
association O O
, O O
though O O
less O O
marked O O
, O O
has O O
been O O
suggested O O
with O O
barbiturates B-group B-group
, O O
phenyl-butazone O O
, O O
phenytoin B-drug B-drug
sodium I-drug I-drug
, O O
carbamazepine B-drug B-drug
and O O
possibly O O
with O O
griseofulvin B-drug B-drug
, O O
ampicillin B-drug B-drug
, O O
and O O
tetracyclines B-group B-group
( O O
72 O O
) O O

Pharmacokinetic O O
interaction O O
between O O
single O O
oral O O
doses O O
of O O
diltiazem B-drug B-drug
and O O
sirolimus B-drug B-drug
in O O
healthy O O
volunteers O O
. O O

Resveratrol B-drug_n B-drug_n
( O O
5-35 O O
micromol/l O O
) O O
induced O O
concentration-dependent O O
relaxation O O
of O O
mesenteric O O
arteries O O
preconstricted O O
with O O
noradrenaline B-drug B-drug
( O O
8 O O
micromol/l O O
) O O
or O O
KCl B-drug B-drug
( O O
125 O O
mmol/l O O
) O O
from O O
both O O
lean O O
and O O
dietary-obese O O
rats O O
. O O

When O O
such O O
combined O O
therapy O O
is O O
contemplated O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
significantly O O
reduced O O
. O O

Clinical O O
studies O O
have O O
shown O O
that O O
atorvastatin B-drug B-drug
does O O
not O O
reduce O O
basal O O
plasma O O
cortisol O O
concentration O O
or O O
impair O O
adrenal O O
reserve O O
. O O

CNS-Active O O
Drugs O O
Ethanol B-drug B-drug
An O O
additive O O
effect O O
on O O
psychomotor O O
performance O O
was O O
seen O O
with O O
coadministration O O
of O O
eszopiclone B-drug B-drug
and O O
ethanol B-drug B-drug
0.70 O O
g/kg O O
for O O
up O O
to O O
4 O O
hours O O
after O O
ethanol B-drug B-drug
administration O O
. O O

In O O
response O O
to O O
cocaine B-drug B-drug
, O O
the O O
locomotor O O
activities O O
of O O
the O O
SST O O
were O O
not O O
significantly O O
different O O
from O O
the O O
RBC O O
group O O
. O O

In O O
previous O O
reports O O
we O O
have O O
shown O O
that O O
ginsenosides B-drug_n B-drug_n
inhibit O O
high O O
threshold O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
channels O O
in O O
neuronal O O
cells O O
. O O

oxyphenbutazone B-drug B-drug
; O O

The O O
plasma O O
concentrations O O
of O O
bosentan B-drug B-drug
were O O
not O O
affected O O
. O O

Hypoglycemics B-group B-group
and O O
endocrine O O
drugs O O
. O O

Antiarrhythmics B-group B-group
: O O
Amiodarone B-drug B-drug
, O O
bepridil B-drug B-drug
, O O
flecainide B-drug B-drug
, O O
propafenone B-drug B-drug
, O O
quinidine B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
. O O

H2-Receptor B-group B-group
Antagonists I-group I-group
: O O
Co-administration O O
of O O
a O O
single O O
dose O O
of O O
intravenously O O
administered O O
famotidine B-drug B-drug
( O O
20 O O
mg O O
) O O
reduced O O
the O O
oral O O
absorption O O
of O O
a O O
single O O
400 O O
mg O O
dose O O
of O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
administered O O
following O O
a O O
meal O O
, O O
as O O
evidenced O O
by O O
a O O
27 O O
% O O
decrease O O
in O O
mean O O
Cmax O O
and O O
a O O
22 O O
% O O
decrease O O
in O O
mean O O
AUC O O
. O O

Everolimus B-drug B-drug
exposure-response O O
relationships O O
between O O
area O O
under O O
the O O
blood O O
concentration-time O O
curve O O
( O O
AUC O O
) O O
and O O
changes O O
in O O
platelets O O
, O O
leukocytes O O
, O O
and O O
lipids O O
were O O
explored O O
with O O
the O O
median-effect O O
model O O
. O O

Thus O O
, O O
patients O O
should O O
be O O
cautioned O O
about O O
the O O
use O O
of O O
such O O
drugs O O
concurrently O O
with O O
LEXAPRO B-brand B-brand
. O O

Oils O O
may O O
enhance O O
absorption O O
. O O

Drugs O O
Highly O O
Bound O O
To O O
Plasma O O
Protein O O
Eszopiclone B-drug B-drug
is O O
not O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
52-59 O O
% O O
bound O O
) O O
; O O

however O O
, O O
a O O
comparison O O
of O O
fluvastatin B-drug B-drug
administration O O
with O O
the O O
evening O O
meal O O
or O O
at O O
bedtime O O
has O O
revealed O O
no O O
significant O O
differences O O
in O O
the O O
extent O O
of O O
bioavailability O O
( O O
area O O
under O O
the O O
curve O O
) O O
of O O
these O O
two O O
regimens O O
. O O

Patients O O
receiving O O
catecholamine-depleting O O
drugs O O
, O O
such O O
as O O
reserpine B-drug B-drug
or O O
guanethidine B-drug B-drug
, O O
should O O
be O O
closely O O
monitored O O
, O O
because O O
the O O
added O O
beta-adrenergic O O
blocking O O
action O O
of O O
ZEBETA B-brand B-brand
may O O
produce O O
excessive O O
reduction O O
of O O
sympathetic O O
activity O O
. O O

The O O
benefits O O
and O O
risks O O
of O O
using O O
TRICOR B-brand B-brand
with O O
immunosuppressants B-group B-group
and O O
other O O
potentially O O
nephrotoxic O O
agents O O
should O O
be O O
carefully O O
considered O O
, O O
and O O
the O O
lowest O O
effective O O
dose O O
employed O O

The O O
16,16-dimethylprostaglandin B-drug_n B-drug_n
E2 I-drug_n I-drug_n
( O O
dmPGE2 B-drug_n B-drug_n
) O O
-induced O O
diarrhea O O
was O O
analyzed O O
in O O
cecectomized O O
rats O O
prepared O O
by O O
resecting O O
the O O
cecum O O
and O O
its O O
vasculature O O
without O O
disturbing O O
the O O
ileocecal O O
junction O O
. O O

In O O
vitro O O
studies O O
in O O
human O O
liver O O
microsomes O O
suggest O O
that O O
decitabine B-drug B-drug
is O O
unlikely O O
to O O
inhibit O O
or O O
induce O O
cytochrome O O
P450 O O
enzymes O O
. O O

In O O
one O O
controlled O O
study O O
of O O
175 O O
patients O O
, O O
transient O O
drowsiness O O
was O O
observed O O
in O O
63 O O
% O O
of O O
those O O
receiving O O
baclofen B-drug B-drug
tablets O O
compared O O
to O O
36 O O
% O O
of O O
those O O
in O O
the O O
placebo O O
group O O
. O O

HMG-CoA B-drug B-group
Reductase I-drug I-group
Inhibitors I-drug I-group
: O O
Simvastatin B-drug B-drug
( O O
CYP3A4 B-drug O
substrate O O
) O O
in O O
combination O O
with O O
amiodarone B-drug B-drug
has O O
been O O
associated O O
with O O
reports O O
of O O
myopathy/rhabdomyolysis O O
. O O

The O O
majority O O
of O O
patients O O
in O O
rheumatoid O O
arthritis O O
or O O
Crohn O O
s O O
disease O O
clinical O O
studies O O
received O O
one O O
or O O
more O O
concomitant O O
medications O O
. O O

Danazol B-drug B-drug
: O O
The O O
risk O O
of O O
myopathy/rhabdomyolysis O O
is O O
increased O O
by O O
concomitant O O
administration O O
of O O
danazol B-drug B-drug
particularly O O
with O O
higher O O
doses O O
of O O
lovastatin B-drug B-drug
( O O
see O O
WARNINGS O O
, O O
Myopathy/Rhabdomyolysis O O
) O O
. O O

one-half O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
when O O
administered O O
during O O
the O O
period O O
of O O
organogenesis O O
. O O

Close O O
observation O O
of O O
the O O
patient O O
is O O
recommended O O
when O O
a O O
beta-blocker B-group B-group
is O O
administered O O
to O O
patients O O
receiving O O
catecholamine-depleting O O
drugs O O
such O O
as O O
reserpine B-drug B-drug
, O O
because O O
of O O
possible O O
additive O O
effects O O
and O O
the O O
production O O
of O O
hypotension O O
and/or O O
marked O O
bradycardia O O
, O O
which O O
may O O
produce O O
vertigo O O
, O O
syncope O O
, O O
or O O
postural O O
hypotension O O
. O O

These O O
findings O O
suggest O O
that O O
the O O
phenotype O O
of O O
a O O
tumor O O
that O O
results O O
from O O
a O O
pulse O O
of O O
a O O
chemical O O
carcinogen O O
may O O
depend O O
upon O O
the O O
target O O
cell O O
. O O

Ergot B-group B-group
Derivatives I-group I-group
: O O
Dihydroergotamine B-drug B-drug
, O O
ergonovine B-drug B-drug
, O O
ergotamine B-drug B-drug
, O O
methylergonovine B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and O O
life-threatening O O
reactions O O
such O O
as O O
acute O O
ergot B-group O
toxicity O O
characterized O O
by O O
peripheral O O
vasospasm O O
and O O
ischemia O O
of O O
the O O
extremities O O
and O O
other O O
tissues O O
. O O

Measurement O O
of O O
nociception O O
was O O
performed O O
within O O
2 O O
h O O
after O O
benzodiazepine B-group B-group
administration O O
. O O

Epirubicin B-drug B-drug
is O O
extensively O O
metabolized O O
by O O
the O O
liver O O
. O O

After O O
consumption O O
of O O
alcohol B-drug B-drug
, O O
at O O
least O O
36 O O
hours O O
should O O
elapse O O
before O O
these O O
determinations O O
are O O
made O O
. O O

If O O
it O O
is O O
necessary O O
to O O
continue O O
the O O
diuretic B-group B-group
, O O
provide O O
close O O
medical O O
supervision O O
after O O
the O O
initial O O
dose O O
for O O
at O O
least O O
two O O
hours O O
and O O
until O O
blood O O
pressure O O
has O O
stabilized O O
for O O
at O O
least O O
an O O
additional O O
hour.. O O

The O O
magnitude O O
of O O
these O O
effects O O
may O O
depend O O
on O O
the O O
duration O O
of O O
administration O O
of O O
the O O
volatile O O
agents O O
. O O

Phenytoin B-drug B-drug
: O O
Population O O
pharmacokinetic O O
analyses O O
indicate O O
that O O
tiagabine B-drug B-drug
clearance O O
is O O
60 O O
% O O
greater O O
in O O
patients O O
taking O O
phenytoin B-drug B-drug
with O O
or O O
without O O
other O O
enzyme- O O
inducing O O
AEDs B-group B-group
. O O

In O O
addition O O
, O O
we O O
have O O
shown O O
that O O
RR B-drug_n B-drug_n
is O O
a O O
useful O O
pharmacological O O
tool O O
with O O
which O O
to O O
examine O O
the O O
InsP B-drug_n B-drug_n
( I-drug_n I-drug_n
3 I-drug_n I-drug_n
) I-drug_n I-drug_n
-mediated O O
responses O O
of O O
megakaryocytes O O
. O O

Conversely O O
, O O
the O O
administration O O
of O O
STADOL B-brand B-brand
NS I-brand I-brand
( O O
1 O O
mg O O
butorphanol B-drug B-drug
QID O O
) O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
a O O
300-mg O O
dose O O
of O O
cimetidine B-drug B-drug
. O O

Rifabutin B-drug B-drug

The O O
clinical O O
effects O O
of O O
this O O
combination O O
have O O
not O O
been O O
studied O O
. O O

No O O
drug O O
interactions O O
have O O
been O O
reported O O
. O O

The O O
next O O
chapter O O
presents O O
information O O
on O O
efficacy O O
and O O
pregnancy O O
outcomes O O
in O O
terms O O
of O O
pregnancy O O
rates O O
, O O
compliance O O
and O O
efficacy O O
, O O
ectopic O O
pregnancies O O
, O O
the O O
outcome O O
of O O
pregnancies O O
conceived O O
while O O
using O O
POCs B-group B-group
, O O
and O O
fertility O O
following O O
discontinuation O O
. O O

Interactions O O
between O O
Betaseron B-brand B-brand
and O O
other O O
drugs O O
have O O
not O O
been O O
fully O O
evaluated O O
. O O

There O O
have O O
been O O
no O O
reported O O
cases O O
from O O
spontaneous O O
reports O O
of O O
drug O O
interaction O O
between O O
SSRIs B-group B-group
and O O
D.H.E B-brand B-brand
. I-brand I-brand
45 I-brand I-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
. O O

increased O O
bilirubin O O

A O O
small O O
number O O
of O O
patients O O
received O O
epirubicin-based B-drug B-drug
chemotherapy O O
concomitantly O O
with O O
radiation O O
therapy O O
but O O
had O O
chemotherapy O O
interrupted O O
in O O
order O O
to O O
avoid O O
potential O O
overlapping O O
toxicities O O
. O O

Laboratory O O
Test O O
In O O
clinical O O
trials O O
, O O
no O O
clinically O O
relevant O O
laboratory O O
test O O
abnormalities O O
were O O
identified O O
as O O
causally O O
related O O
to O O
drug O O
during O O
short-term O O
treatment O O
with O O
guanfacine B-drug B-drug
. O O

These O O
reactions O O
consisted O O
of O O
erythema O O
, O O
pruritus O O
, O O
and O O
hypotension O O
and O O
occurred O O
within O O
hours O O
of O O
administration O O
of O O
chemotherapy O O
. O O

Although O O
much O O
statistical O O
work O O
has O O
focused O O
on O O
developing O O
mathematical O O
functions O O
to O O
model O O
the O O
joint O O
dose-response O O
curves O O
, O O
relatively O O
little O O
work O O
exists O O
in O O
regard O O
to O O
designing O O
experiments O O
for O O
assessing O O
joint O O
action O O
. O O

PEGASYS B-brand B-brand
is O O
recommended O O
for O O
use O O
in O O
women O O
of O O
childbearing O O
potential O O
only O O
when O O
they O O
are O O
using O O
effective O O
contraception O O
during O O
therapy O O
. O O

The O O
extent O O
to O O
which O O
SSRI-TCA B-group B-group
interactions O O
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

Lithium B-drug B-drug
carbonate I-drug I-drug
( O O
450 O O
mg O O
BID O O
for O O
7 O O
days O O
) O O
had O O
no O O
effect O O
on O O
valdecoxib B-drug B-drug
pharmacokinetics O O
. O O

Lithium B-drug B-drug
salts O O

therefore O O
, O O
these O O
combinations O O
should O O
be O O
used O O
with O O
caution O O
. O O

Phenobarbital B-drug B-drug

Vasospastic O O
reactions O O
have O O
been O O
reported O O
with O O
therapeutic O O
doses O O
of O O
ergotamine-containing B-drug B-drug
drugs O O
when O O
co-administered O O
with O O
these O O
antibiotics B-group B-group
. O O

Apparent O O
oral O O
clearance O O
and O O
volume O O
of O O
distribution O O
of O O
sirolimus B-drug B-drug
decreased O O
with O O
38 O O
% O O
and O O
45 O O
% O O
, O O
respectively O O
, O O
when O O
sirolimus B-drug B-drug
was O O
given O O
with O O
diltiazem B-drug B-drug
. O O

The O O
interaction O O
of O O
prostaglandin B-drug B-drug
F2alpha I-drug I-drug
and O O
synthetic O O
oxytocin B-drug B-drug
on O O
placental O O
vessels O O
was O O
studied O O
in O O
vitro O O
. O O

Urinary O O
alkalinizing O O
agents O O
increase O O
blood O O
levels O O
and O O
decrease O O
excretion O O
of O O
amphetamines B-group B-group
. O O

( O O
500 O O
mg O O
day O O
1 O O
, O O
250 O O
mg O O
QD O O
4 O O
days O O
) O O

METHODS O O
: O O
Hydrocortisone B-drug B-drug
( O O
100 O O
mg O O
) O O
and O O
d-amphetamine B-drug B-drug
( O O
20 O O
mg O O
) O O
were O O
administered O O
orally O O
to O O
16 O O
healthy O O
male O O
and O O
female O O
volunteers O O
in O O
a O O
four-session O O
, O O
placebo-controlled O O
, O O
within-subject O O
, O O
crossover O O
design O O
. O O

The O O
world O O
medical O O
literature O O
contains O O
43 O O
reports O O
of O O
deaths O O
associated O O
with O O
amphetamines B-drug B-group
in O O
a O O
35-year O O
period O O
. O O

Cardiovasculars O O
: O O
Cardiac B-drug B-group
glycosides I-drug I-group
: O O
In O O
patients O O
receiving O O
digoxin B-drug B-drug
therapy O O
, O O
administration O O
of O O
oral O O
amiodarone B-drug B-drug
regularly O O
results O O
in O O
an O O
increase O O
in O O
serum O O
digoxin B-drug B-drug
concentration O O
that O O
may O O
reach O O
toxic O O
levels O O
with O O
resultant O O
clinical O O
toxicity O O
. O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
: O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
caucasian O O
population O O
( O O
about O O
7 O O
to O O
10 O O
% O O
of O O
caucasians O O
are O O
so O O
called O O
poor O O
metabolizers O O
) O O
; O O

New O O
oral O O
therapies O O
for O O
type O O
2 O O
diabetes O O
mellitus O O
: O O
The O O
glitazones B-group B-group
or O O
insulin O B-drug
sensitizers O O
. O O

CONCLUSIONS O O
: O O
In O O
contrast O O
to O O
the O O
effects O O
of O O
glucocorticoids B-group B-group
in O O
rodent O O
studies O O
, O O
these O O
results O O
indicate O O
that O O
an O O
acute O O
increase O O
in O O
cortisol O O
does O O
not O O
enhance O O
the O O
psychostimulant O O
effects O O
of O O
d-amphetamine B-drug B-drug
in O O
humans O O
. O O

In O O
addition O O
, O O
ketoconazole B-drug B-drug
alone O O
can O O
inhibit O O
adrenal O O
corticosteroid B-drug O
synthesis O O
and O O
may O O
cause O O
adrenal O O
insufficiency O O
during O O
corticosteroid O O
withdrawal O O
. O O

Aspirin B-brand B-brand
: O O
Concomitant O O
administration O O
of O O
diclofenac B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
not O O
recommended O O
because O O
diclofenac B-drug B-drug
is O O
displaced O O
from O O
its O O
binding O O
sites O O
during O O
the O O
concomitant O O
administration O O
of O O
aspirin B-brand B-brand
, O O
resulting O O
in O O
lower O O
plasma O O
concentrations O O
, O O
peak O O
plasma O O
levels O O
, O O
and O O
AUC O O
values O O
. O O

The O O
clearance O O
of O O
benzodiazepines B-group B-group
metabolized O O
by O O
glucuronidation O O
( O O
e. O O
g. O O
, O O
lorazepam B-drug B-drug
, O O
oxazepam B-drug B-drug
, O O
temazepam B-drug B-drug
) O O
is O O
unlikely O O
to O O
be O O
affected O O
by O O
fluvoxamine B-drug B-drug
. O O

The O O
pharmacokinetics O O
of O O
benzodiazepines B-group B-group
are O O
unaltered O O
in O O
the O O
presence O O
of O O
flumazenil B-drug B-drug
and O O
vice O O
versa O O
. O O

however O O
, O O
the O O
clinical O O
significance O O
is O O
unknown O O
. O O

Other O O
: O O
Neither O O
fosinopril B-drug B-drug
sodium I-drug I-drug
nor O O
its O O
metabolites O O
have O O
been O O
found O O
to O O
interact O O
with O O
food O O
. O O

On O O
the O O
basis O O
of O O
this O O
specificity O O
we O O
describe O O
a O O
simple O O
and O O
reliable O O
affinity O O
chromatography O O
procedure O O
for O O
the O O
purification O O
of O O
both O O
human O O
serum O O
and O O
colostrum O O
IgA O O
. O O

and O O
disulfiram B-drug B-drug
When O O
amitriptyline B-drug B-drug
HCl I-drug I-drug
is O O
given O O
with O O
anticholinergic B-drug B-group
agents O I-group
or O O
sympathomimetic B-drug B-group
drugs O I-group
, O O
including O O
epinephrine B-drug B-drug
combined O O
with O O
local O O
anesthetics B-drug B-group
, O O
close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
dosages O O
are O O
required O O
. O O

Rifabutin B-drug B-drug
: O O
Coadministration O O
of O O
rifabutin B-drug B-drug
and O O
VIRACEPT B-brand B-brand
resulted O O
in O O
a O O
32 O O
% O O
decrease O O
in O O
nelfinavir B-drug B-drug
plasma O O
AUC O O
and O O
a O O
207 O O
% O O
increase O O
in O O
rifabutin B-drug B-drug
plasma O O
A.C O O
. O O

while O O
no O O
formal O O
interaction O O
studies O O
have O O
been O O
conducted O O
, O O
no O O
interactions O O
were O O
observed O O
. O O

Food O O
has O O
no O O
clinically O O
significant O O
effect O O
on O O
the O O
bioavailability O O
of O O
anagrelide B-drug B-drug
. O O

Although O O
no O O
studies O O
have O O
been O O
conducted O O
, O O
concomitant O O
administration O O
of O O
Itraconazole B-drug B-drug
and O O
phenytoin B-drug B-drug
may O O
alter O O
the O O
metabolism O O
of O O
phenytoin B-drug B-drug
; O O

Established O O
Drug O O
Interactions O O
( O O
continued O O
) O O

Potassium-sparing B-group B-group
diuretics I-group I-group
( O O
e.g. O O
, O O
spironolactone B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
or O O
amiloride B-drug B-drug
) O O
, O O
potassium B-drug B-drug
supplements O O
, O O
or O O
potassium-containing B-drug O
salt O O
substitutes O O
may O O
lead O O
to O O
significant O O
increases O O
in O O
serum O O
potassium O O
. O O

This O O
observed O O
increase O O
in O O
the O O
bioavailability O O
of O O
fexofenadine B-drug B-drug
may O O
be O O
due O O
to O O
transport-related O O
effects O O
, O O
such O O
as O O
p-glycoprotein O O
. O O
in O O
vivo O O
animal O O
studies O O
also O O
suggest O O
that O O
in O O
addition O O
to O O
enhancing O O
absorption O O
, O O
ketoconazole B-drug B-drug
decreases O O
fexofenadine B-drug B-drug
gastrointestinal O O
secretion O O
, O O
while O O
erythromycin B-drug B-drug
may O O
also O O
decrease O O
biliary O O
excretion O O
. O O

No O O
pharmacokinetic O O
drug-drug O O
interaction O O
studies O O
were O O
conducted O O
with O O
PERSANTINE B-brand B-brand
( O O
dipyridamole B-drug B-drug
USP O O
) O O
Tablets O O
. O O

There O O
is O O
no O O
experience O O
with O O
co-administration O O
of O O
Angiomax B-brand B-brand
and O O
plasma O O
expanders O O
such O O
as O O
dextran B-drug B-drug
. O O

On O O
the O O
ninth O O
day O O
, O O
the O O
rats O O
were O O
sacrificed O O
and O O
aortic O O
rings O O
, O O
with O O
or O O
without O O
endothelium O O
, O O
were O O
used O O
to O O
generate O O
concentration-response O O
curves O O
to O O
noradrenaline B-drug B-drug
. O O

At O O
stable O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
concentrations O O
greater O O
than O O
1 O O
mM O O
, O O
fractional O O
mucosal O O
cell O O
accumulation O O
of O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
remains O O
constant O O
, O O
while O O
fractional O O
transfer O O
to O O
the O O
body O O
declines O O
. O O

Although O O
there O O
is O O
little O O
published O O
information O O
on O O
concomitant O O
administration O O
of O O
lidocaine B-drug B-drug
and O O
Bretylium B-drug B-drug
Tosylate I-drug I-drug
, O O
these O O
drugs O O
are O O
often O O
administered O O
concurrently O O
without O O
any O O
evidence O O
of O O
interactions O O
resulting O O
in O O
adverse O O
effects O O
or O O
diminished O O
efficacy O O
. O O

Plenaxis B-brand B-brand
is O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
96 O O
to O O
99 O O
% O O
) O O
. O O

The O O
concurrent O O
use O O
of O O
tetracycline B-drug B-drug
and O O
Penthrane B-brand B-brand
( O O
methoxyflurane B-drug B-drug
) O O
has O O
been O O
reported O O
to O O
result O O
in O O
fatal O O
renal O O
toxicity O O
. O O

Increased O O
nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
cephalosporins B-group B-group
and O O
aminoglycoside B-group B-group
antibiotics I-group I-group
. O O

with O O
divalent O O
or O O
trivalent O O
cations O O
such O O
as O O
iron B-drug B-drug
; O O

Patients O O
response O O
to O O
oral O O
anticoagulants B-group B-group
may O O
be O O
affected O O
by O O
his/her O O
thyroid O O
and O O
metabolic O O
status O O
. O O

However O O
, O O
the O O
relationship O O
to O O
nifedipine B-drug B-drug
therapy O O
is O O
uncertain O O
. O O

Cimetidine B-drug B-drug
increased O O
AUC O O
by O O
about O O
30 O O
% O O
but O O
caused O O
no O O
change O O
in O O
Cmax O O
. O O

Clinically O O
significant O O
QTc O O
prolongation O O
has O O
not O O
been O O
found O O
with O O
Mefloquineuine O O
alone O O
. O O

Acute O O
effect O O
of O O
different O O
antidepressants B-group B-group
on O O
glycemia O O
in O O
diabetic O O
and O O
non-diabetic O O
rats O O
. O O

In O O
a O O
separate O O
study O O
, O O
baboons O O
given O O
3 O O
doses O O
of O O
alefacept B-drug B-drug
at O O
1 O O
mg/kg O O
every O O
8 O O
weeks O O
were O O
found O O
to O O
have O O
centroblast O O
proliferation O O
in O O
B-cell O O
dependent O O
areas O O
in O O
the O O
germinal O O
centers O O
of O O
the O O
spleen O O
following O O
a O O
116-day O O
washout O O
period O O
. O O

Nevirapine I-drug B-drug

Although O O
there O O
was O O
no O O
effect O O
of O O
Aprepitant B-drug B-drug
on O O
the O O
plasma O O
AUC O O
of O O
R O O
( O O
+ O I-drug
) O I-drug
or O I-drug
S B-drug I-drug
( I-drug I-drug
- I-drug I-drug
) I-drug I-drug
warfarin I-drug I-drug
determined O O
on O O
Day B-drug O
3 I-drug O
, I-drug O
there O O
was O O
a O O
34 O O
% O O
decrease O O
in O O
S B-drug B-drug
( I-drug I-drug
- I-drug I-drug
) I-drug I-drug
warfarin I-drug I-drug
( O O
a O O
CYP2C9 O O
substrate O O
) O O
trough O O
concentration O O
accompanied O O
by O O
a O O
14 O O
% O O
decrease O O
in O O
the O O
prothrombin O O
time O O
( O O
reported O O
as O O
International O O
Normalized O O
Ratio O O
or O O
INR O O
) O O
5 O O
days O O
after O O
completion O O
of O O
dosing O O
with O O
Aprepitant B-drug B-drug
. O O

influenza B-group B-group
virus I-group I-group
vaccine I-group I-group
; O O

This O O
may O O
lead O O
to O O
reduced O O
clearance O O
of O O
caffeine B-drug B-drug
and O O
a O O
prolongation O O
of O O
its O O
plasma O O
half-life O O
. O O

Naproxen B-drug B-drug
and O O
other O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
antihypertensive O O
effect O O
of O O
propranolol B-drug B-drug
and O O
other O O
beta-blockers B-group B-group
. O O

Routine O O
monitoring O O
should O O
be O O
performed O O
when O O
therapy O O
with O O
BEXTRA B-brand B-brand
is O O
either O O
initiated O O
or O O
discontinued O O
in O O
patients O O
on O O
anticonvulsant O B-group
therapy O O
. O O

These O O
cephalosporins B-group B-group
are O O
inhibitors O O
of O O
hepatic O O
vitamin O O
K O O
epoxide O O
reductase O O
. O O

CONCLUSION O O
: O O
Fluvoxamine B-drug B-drug
is O O
a O O
moderate O O
inhibitor O O
of O O
CYP2C9 O O
in O O
vivo O O
. O O

Calcium B-drug B-drug
, O O
particularly O O
if O O
administered O O
rapidly O O
by O O
the O O
intravenous O O
route O O
, O O
may O O
produce O O
serious O O
arrhythmias O O
in O O
digitalized O O
patients O O
. O O

Dextromethorphan B-drug B-drug
: O O
Dextromethorphan B-drug B-drug
is O O
primarily O O
metabolized O O
by O O
CYP O O
2D6 O O
and O O
to O O
a O O
lesser O O
extent O O
by O O
3A4 O O
. O O

Didanosine B-drug B-drug

However O O
, O O
preliminary O O
results O O
from O O
an O O
8-week O O
trial O O
showed O O
comparable O O
cognitive O O
enhancing O O
effects O O
of O O
olanzapine B-drug B-drug
and O O
risperidone B-drug B-drug
treatment O O
in O O
patients O O
with O O
schizophrenia O O
or O O
schizoaffective O O
disorder O O
. O O

The O O
physician O O
should O O
be O O
alert O O
for O O
possible O O
combined O O
drug O O
actions O O
, O O
desirable O O
or O O
undesirable O O
, O O
involving O O
ifosfamide B-drug B-drug
even O O
though O O
ifosfamide B-drug B-drug
has O O
been O O
used O O
successfully O O
concurrently O O
with O O
other O O
drugs O O
, O O
including O O
other O O
cytotoxic O B-group
drugs O I-group
. O O

Population O O
pharmacokinetic O O
studies O O
showed O O
higher O O
concentrations O O
of O O
cilostazol B-drug B-drug
among O O
patients O O
concurrently O O
treated O O
with O O
diltiazem B-drug B-drug
, O O
an O O
inhibitor O O
of O O
C.P.A.. O O

Lithium B-drug B-drug
: O O
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
. O O

Antihistamines B-group B-group
: O O
Benzodiazepines B-group B-group
GI O O
Motility O O
Agents O O
Anti-Migraine B-group B-group
Antifungal I-group I-group

Cimetidine B-drug B-drug
treatment O O
should O O
be O O
stopped O O
during O O
treatment O O
with O O
ELLENCE B-brand B-brand
. O O

Propoxyphene B-drug B-drug
: O O
The O O
concurrent O O
administration O O
of O O
propoxyphene B-drug B-drug
hydrochloride I-drug I-drug
does O O
not O O
affect O O
the O O
bioavailability O O
of O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
. O O

Alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
or O O
narcotics B-group B-group
: O O
potentiation O O
of O O
orthostatic O O
hypotension O O
may O O
occur O O
. O O

. O O

The O O
120 O O
mg/kg O O
dose O O
resulted O O
in O O
a O O
systemic O O
exposure O O
approximately O O
16 O O
times O O
the O O
human O O
plasma O O
area-under-the-curve O O
( O O
AUC O O
, O O
0-24 O O
hours O O
) O O
based O O
on O O
the O O
maximum O O
human O O
dose O O
of O O
80 O O
mg/day O O
. O O

This O O
should O O
be O O
considered O O
whenever O O
these O O
agents O O
are O O
prescribed O O
concomitantly O O
. O O

Effect O O
of O O
rofecoxib B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
in O O
healthy O O
volunteers O O
. O O

Probenecid B-drug B-drug
: O O
As O O
with O O
other O O
b-lactam B-group B-group
antibiotics I-group I-group
, O O
renal O O
excretion O O
of O O
loracarbef B-drug B-drug
is O O
inhibited O O
by O O
probenecid B-drug B-drug
and O O
resulted O O
in O O
an O O
approximate O O
80 O O
% O O
increase O O
in O O
the O O
AUC O O
for O O
loracarbef B-drug B-drug
. O O

Plasma O O
exposure O O
( O O
AUC O O
) O O
to O O
valdecoxib B-drug B-drug
was O O
increased O O
62 O O
% O O
when O O
coadministered O O
with O O
fluconazole B-drug B-drug
and O O
38 O O
% O O
when O O
coadministered O O
with O O
ketoconazole B-drug B-drug
. O O

Cyclosporine B-drug B-drug

vardenafil I-drug B-drug
concentration O O

Interaction O O
with O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
other O O
than O O
benzodiazepines B-group B-group
has O O
not O O
been O O
specifically O O
studied O O
; O O

Ketoconazole B-drug B-drug
did O O
not O O
affect O O
the O O
conversion O O
of O O
losartan B-drug B-drug
to O O
the O O
active O O
metabolite O O
after O O
intravenous O O
administration O O
of O O
losartan B-drug B-drug
, O O
and O O
erythromycin B-drug B-drug
had O O
no O O
clinically O O
significant O O
effect O O
after O O
oral O O
administration O O
. O O

Antidepressants B-group B-group
, O O
tricyclic B-group B-group
: O O
Amphetamines B-group B-group
may O O
enhance O O
the O O
activity O O
of O O
tricyclic B-group B-group
or O O
sympathomimetic B-group B-group
agents I-group I-group
; O O

Anagrelide B-drug B-drug
alone O O
had O O
no O O
effect O O
on O O
platelet O O
aggregation O O
, O O
but O O
did O O
slightly O O
enhance O O
the O O
inhibition O O
of O O
platelet O O
aggregation O O
by O O
aspirin B-brand B-brand
. O O

Substantial O O
intercurrent O O
ethanol B-drug B-drug
use O O
was O O
present O O
in O O
each O O
of O O
these O O
cases O O
, O O
and O O
this O O
may O O
have O O
contributed O O
to O O
the O O
abnormalities O O
seen O O
. O O

Therefore O O
, O O
concurrent O O
use O O
of O O
aspirin B-brand B-brand
and O O
ketoprofen B-drug B-drug
is O O
not O O
recommended O O
. O O

Tablets O O
: O O
The O O
benzodiazepines B-group B-group
, O O
including O O
lorazepam B-drug B-drug
, O O
produce O O
CNS-depressant O O
effects O O
when O O
administered O O
with O O
such O O
medications O O
as O O
barbiturates B-group B-group
or O O
alcohol B-drug B-drug
. O O

The O O
first O O
test O O
is O O
obtained O O
by O O
the O O
prescriber O O
when O O
the O O
decision O O
is O O
made O O
to O O
pursue O O
qualification O O
of O O
the O O
patient O O
for O O
Accutane B-brand B-brand
( O O
a O O
screening O O
test O O
) O O
. O O

High O O
oral O O
magnesium B-drug B-drug
doses O O
besides O O
their O O
laxative O O
action O O
may O O
bring O O
latent O O
complications O O
which O O
may O O
reduce O O
lifespan O O
. O O

phenylbutazone B-drug B-drug
; O O

Drug/Laboratory O O
Test O O
Interaction O O
Because O O
Xigris B-brand B-brand
may O O
affect O O
the O O
APTT O O
assay O O
, O O
Xigris B-brand B-brand
present O O
in O O
plasma O O
samples O O
may O O
interfere O O
with O O
one-stage O O
coagulation O O
assays O O
based O O
on O O
the O O
APTT O O
( O O
such O O
as O O
factor O O
VIII O O
, O O
IX O O
, O O
and O O
XI O O
assays O O
) O O
. O O

Methenamine B-drug B-drug
therapy O O
: O O
Urinary O O
excretion O O
of O O
amphetamines B-group B-group
is O O
increased O O
, O O
and O O
efficacy O O
is O O
reduced O O
, O O
by O O
acidifying B-group B-group
agents I-group I-group
used O O
in O O
methenamine B-drug B-drug
therapy O O
. O O

Rifampin B-drug B-drug
: O O
Rifampin B-drug B-drug
increases O O
the O O
metabolism O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
some O O
progestins B-group B-group
( O O
norethindrone B-drug B-drug
) O O
resulting O O
in O O
decreased O O
contraceptive O O
effectiveness O O
and O O
increased O O
menstrual O O
irregularities O O
. O O

Potentiation O O
of O O
coumarin-type B-group B-group
anticoagulants I-group I-group
has O O
been O O
observed O O
with O O
prolongation O O
of O O
the O O
prothrombin O O
time/INR O O
. O O

Further O O
, O O
misoprostol B-drug B-drug
is O O
reported O O
to O O
have O O
a O O
synergistic O O
effect O O
with O O
this O O
combination O O
in O O
ameliorating O O
intestinal O O
permeability O O
. O O

Phenothiazines B-group B-group
- O O
Taking O O
piperazine B-drug B-drug
and O O
a O O
phenothiazine B-group B-group
together O O
may O O
increase O O
the O O
risk O O
of O O
convulsions O O
( O O
seizures O O
) O O
. O O

However O O
, O O
cohort O O
data O O
and O O
selected O O
patient O O
data O O
from O O
clinical O O
trials O O
suggest O O
comparable O O
activity O O
to O O
PI-based B-group B-group
regimens O O
in O O
these O O
patients O O
. O O

Dicumarol B-drug B-drug
: O O
It O O
has O O
been O O
reported O O
that O O
allopurinol B-drug B-drug
prolongs O O
the O O
half-life O O
of O O
the O O
anticoagulant B-group B-group
, O O
dicumarol B-drug B-drug
. O O

Aspirin B-brand B-brand
: O O
Concomitant O O
administration O O
of O O
aspirin B-brand B-brand
with O O
valdecoxib B-drug B-drug
may O O
result O O
in O O
an O O
increased O O
risk O O
of O O
GI O O
ulceration O O
and O O
complications O O
compared O O
to O O
valdecoxib B-drug B-drug
alone O O
. O O

as O O
such O O
it O O
may O O
impair O O
intestinal O O
absorption O O
of O O
any O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

Taken O O
together O O
, O O
these O O
findings O O
suggest O O
that O O
the O O
changes O O
in O O
the O O
Kd O O
of O O
D2 O O
in O O
the O O
NAC O O
and O O
the O O
Bmax O O
of O O
D2 O O
in O O
the O O
STR O O
may O O
contribute O O
to O O
the O O
differences O O
in O O
locomotor O O
responses O O
to O O
cocaine B-drug B-drug
exposure O O
in O O
these O O
mouse O O
lines O O
. O O

Barbiturates B-group B-group
may O O
decrease O O
the O O
effectiveness O O
of O O
oral O O
contraceptives B-group B-group
, O O
certain O O
antibiotics B-group B-group
, O O
quinidine B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
corticosteroids B-group B-group
, O O
anticoagulants B-group B-group
, O O
and O O
beta B-group B-group
blockers I-group I-group
. O O

Glucose B-drug B-drug
, O O
alone O O
and O O
in O O
the O O
presence O O
of O O
theophylline B-drug B-drug
, O O
caused O O
subnormal O O
insulin O O
release O O
and O O
less O O
suppression O O
of O O
glucagon O O
release O O
in O O
the O O
diabectics O O
than O O
in O O
the O O
normals O O
. O O

Nucleophosmin/B23 O O
in O O
serum-deprived O O
( O O
0 O O
% O O
serum O O
) O O
NIH-3T3 O O
cells O O
was O O
found O O
to O O
be O O
highly O O
unstable O O
with O O
a O O
half-life O O
less O O
than O O
4 O O
h O O
. O O

Although O O
deferasirox B-drug B-drug
has O O
a O O
lower O O
affinity O O
for O O
aluminum B-drug B-drug
than O O
for O O
iron B-drug B-drug
, O O
Exjade B-brand B-brand
should O O
not O O
be O O
taken O O
with O O
aluminum-containing B-drug B-drug
antacid B-group B-group
preparations I-group I-group
. O O

However O O
, O O
under O O
certain O O
circumstances O O
, O O
e.g. O O
, O O
as O O
prophylaxis O O
after O O
myocardial O O
infarction O O
, O O
there O O
may O O
be O O
no O O
acceptable O O
alternatives O O
to O O
the O O
use O O
of O O
beta-blockers B-group B-group
in O O
patients O O
with O O
COPD O O
. O O

Concomitant O O
use O O
of O O
clozapine B-drug B-drug
with O O
other O O
drugs O O
metabolized O O
by O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
clozapine B-drug B-drug
or O O
the O O
other O O
drug O O
. O O

increased O O
serum O O
triglyceride O O
and O O
phospholipid O O
concentration O O
. O O

Digoxin B-drug B-drug
: O O
Digoxin B-drug B-drug
concentrations O O
are O O
increased O O
by O O
about O O
15 O O
% O O
when O O
digoxin B-drug B-drug
and O O
carvedilol B-drug B-drug
are O O
administered O O
concomitantly O O
. O O

This O O
drug O O
may O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-group B-group
) O O
, O O
anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-group B-group
) O O
, O O
and O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
( O O
concurrent O O
use O O
with O O
antihistamines B-group B-group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-group B-group
) O O
. O O

Patients O O
receiving O O
both O O
drugs O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
diuretic O O
and/or O O
antihypertensive O O
effect O O
of O O
furosemide B-drug B-drug
is O O
achieved O O
. O O

Patients O O
should O O
not O O
be O O
re-treated O O
with O O
subsequent O O
cycles O O
of O O
TAXOL B-brand B-brand
until O O
neutrophils O O
recover O O
to O O
a O O
level O O
1500 O O
cells/mm3 O O
and O O
platelets O O
recover O O
to O O
a O O
level O O
100,000 O O
cells/mm3 O O
. O O

Anabolic B-group B-group
steroids I-group I-group
( O O
particularly O O
C-17 O O
alkylated O O
androgens B-group B-group
such O O
as O O
oxymetholone B-drug B-drug
, O O
methandrostenolone B-drug B-drug
, O O
norethandrolone B-drug B-drug
, O O
and O O
similar O O
compounds O O
) O O
enhanced O O
tendency O O
toward O O
edema O O
. O O

Physicians O O
are O O
provided O O
this O O
information O O
to O O
increase O O
awareness O O
of O O
the O O
potential O O
for O O
serious O O
interactions O O
when O O
cinoxacin B-drug B-drug
and O O
certain O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
administered O O
concomitantly O O
. O O

Furthermore O O
, O O
no O O
significant O O
difference O O
in O O
pharmacodynamic O O
effect O O
( O O
reduction O O
in O O
low-density O O
lipoprotein O O
cholesterol O O
levels O O
) O O
could O O
be O O
ascertained O O
between O O
mealtime O O
dosing O O
and O O
bedtime O O
dosing O O
. O O

5 O O
. O O

In O O
diabetic O O
patients O O
, O O
the O O
metabolic O O
effects O O
of O O
androgens B-group B-group
may O O
decrease O O
blood O O
glucose O O
and O O
therefore O O
, O O
insulin B-drug B-drug
requirements O O
. O O

The O O
incidence O O
of O O
hypertriglyceridemia O O
is O O
1 O O
patient O O
in O O
4 O O
on O O
Accutane B-brand B-brand
therapy O O

Dexamethasone B-drug B-drug
and O O
retinyl B-drug B-drug
acetate I-drug I-drug
similarly O O
inhibit O O
and O O
stimulate O O
EGF- B-drug_n B-drug_n
or O O
insulin-induced B-drug B-drug
proliferation O O
of O O
prostatic O O
epithelium O O
. O O

Cold O O
and O O
flu O O
remedies O O
. O O

Diflunisal B-drug B-drug
decreased O O
the O O
hyperuricemic O O
effect O O
of O O
furosemide B-drug B-drug
. O O

No O O
other O O
pharmacokinetic O O
parameters O O
were O O
changed O O
. O O

Use O O
of O O
Antithrombotics B-group B-group
Aspirin B-brand B-brand
and O O
heparin B-drug B-drug
have O O
been O O
administered O O
concomitantly O O
with O O
and O O
following O O
infusions O O
of O O
Activase B-brand B-brand
in O O
the O O
management O O
of O O
acute O O
myocardial O O
infarction O O
or O O
pulmonary O O
embolism O O
. O O

The O O
results O O
from O O
a O O
study O O
in O O
which O O
eight O O
HIV-infected O O
individuals O O
were O O
treated O O
with O O
zidovudine B-drug B-drug
, O O
8 O O
+/- O O
0.4 O O
mg/kg/day O O
, O O
showed O O
that O O
the O O
pharmacokinetics O O
of O O
zidovudine B-drug B-drug
were O O
not O O
affected O O
during O O
concomitant O O
administration O O
of O O
Itraconazole B-drug B-drug
, O O
100 O O
mg O O
b.i.d O O
. O O

The O O
concomitant O O
administration O O
of O O
quinolones B-group B-group
including O O
norfloxacin B-drug B-drug
with O O
glyburide B-drug B-drug
( O O
a O O
sulfonylurea B-group B-group
agent I-group I-group
) O O
has O O
, O O
on O O
rare O O
occasions O O
, O O
resulted O O
in O O
severe O O
hypoglycemia O O
. O O

Phenytoin B-drug B-drug
may O O
also O O
cause O O
increased O O
serum O O
concentrations O O
of O O
glucose O B-drug
, O O
alkaline O O
phosphatase O O
, O O
and O O
gamma O O
glutamyl O O
transpeptidase O O
( O O
GGT O O
) O O
. O O

The O O
risk O O
of O O
metabolic O O
interactions O O
caused O O
by O O
an O O
effect O O
on O O
an O O
individual O O
isoform O O
is O O
therefore O O
minimized O O
. O O

" O O
hippocampal-independent O O
" O O

Repeated O O
doses O O
of O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
given O O
prior O O
to O O
a O O
single O O
dose O O
of O O
propranolol B-drug B-drug
in O O
human O O
trials O O
have O O
been O O
reported O O
to O O
decrease O O
propranolol B-drug B-drug
absorption O O
. O O

Acetaminophen B-drug B-drug
and O O
methotrexate B-drug B-drug
- O O
L-methionine B-drug B-drug
may O O
decrease O O
hepatic O O
toxicity O O
in O O
those O O
with O O
acetaminophen B-drug B-drug
overdosage O O
or O O
in O O
those O O
taking O O
methotrexate B-drug B-drug
. O O

Cholestyramine B-drug B-drug
and O O
Charcoal B-drug B-drug
Administration O O
of O O
cholestyramine B-drug B-drug
or O O
activated B-drug B-drug
charcoal I-drug I-drug
in O O
patients O O
( O O
n=13 O O
) O O
and O O
volunteers O O
( O O
n=96 O O
) O O
resulted O O
in O O
a O O
rapid O O
and O O
significant O O
decrease O O
in O O
plasma O O
M1 O O
( O O
the O O
active O O
metabolite O O
of O O
leflunomide B-drug B-drug
) O O
concentration O O
. O O

In O O
some O O
patients O O
, O O
combined O O
use O O
of O O
INDOCIN B-brand B-brand
and O O
diflunisal B-drug B-drug
has O O
been O O
associated O O
with O O
fatal O O
gastrointestinal O O
hemorrhage O O
. O O

- O O
Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
reduce O O
the O O
efficacy O O
of O O
lofexidine B-drug B-drug
. O O

Furosemide B-drug B-drug
may O O
add O O
to O O
or O O
potentiate O O
the O O
therapeutic O O
effect O O
of O O
other O O
antihypertensive B-group B-group
drugs I-group I-group
. O O

dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O
) O O

Synergism O O
was O O
observed O O
when O O
GL B-drug_n B-drug_n
was O O
combined O O
with O O
cefazolin B-drug B-drug
against O O
Bacillus O O
subtilis O O
and O O
Klebsiella O O
oxytoca O O
. O O

Etonogestrel B-drug B-drug
may O O
interact O O
with O O
the O O
following O O
medications O O
: O O
acetaminophen B-drug B-drug
( O O
Tylenol B-brand B-brand
) O O
, O O
antibiotics B-group B-group
such O O
as O O
ampicillin B-drug B-drug
and O O
tetracycline B-drug B-drug
, O O
anticonvulsants B-group B-group
( O O
Dilantin B-brand B-brand
, O O
Phenobarbital B-drug B-drug
, O O
Tegretol B-brand B-brand
, O O
Trileptal B-brand B-brand
, O O
Topamax B-brand B-brand
, O O
Felbatol B-brand B-brand
) O O
, O O
antifungals B-group B-group
( O O
Gris-PEG B-brand B-brand
, O O
Nizoral B-brand B-brand
, O O
Sporanox B-brand B-brand
) O O
, O O
atorvastatin B-drug B-drug
( O O
Lipitor B-brand B-brand
) O O
, O O
clofibrate B-drug B-drug
( O O
Atromid-S B-brand B-brand
) O O
, O O
cyclosporine B-drug B-drug
( O O
Neoral B-brand B-brand
, O O
Sandimmune B-brand B-brand
) O O
, O O
HIV O O
drugs O O
classified O O
as O O
protease B-group B-group
inhibitors I-group I-group
( O O
Agenerase B-brand B-brand
, O O
Crixivan B-brand B-brand
, O O
Fortovase B-brand B-brand
, O O
Invirase B-brand B-brand
, O O
Kaletra B-brand B-brand
, O O
Norvir B-brand B-brand
, O O
Viracept B-brand B-brand
) O O
, O O
morphine B-drug B-drug
( O O
Astramorph B-brand B-brand
, O O
Kadian B-brand B-brand
, O O
MS B-brand B-brand
Contin I-brand I-brand
) O O
, O O
phenylbutazone B-drug B-drug
, O O
prednisolone B-drug B-drug
( O O
Prelone B-brand B-brand
) O O
, O O
rifadin B-brand B-brand
( O O
rifampin B-drug B-drug
) O O
, O O
St. O O
Johns O O
wort O O
, O O
temazepam B-drug B-drug
, O O
theophylline B-drug B-drug
( O O
Theo-Dur B-brand B-brand
) O O
, O O
and O O
vitamin B-drug B-drug
C I-drug I-drug
. O O

The O O
three O O
study O O
periods O O
were O O
separated O O
by O O
a O O
21-day O O
washout O O
phase O O
. O O

Nephrotoxic O O
agents O O
: O O
Concomitant O O
administration O O
of O O
VISTIDE B-brand B-brand
and O O
agents O O
with O O
nephrotoxic O O
potential O O
[ O O
e.g. O O
, O O
intravenous O O
aminoglycosides B-group B-group
( O O
e.g. O O
, O O
tobramycin B-drug B-drug
, O O
gentamicin B-drug B-drug
, O O
and O O
amikacin B-drug B-drug
) O O
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
foscarnet B-drug B-drug
, O O
intravenous O O
pentamidine B-drug B-drug
, O O
vancomycin B-drug B-drug
, O O
and O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
] O O
is O O
contraindicated O O
. O O

Antacids B-group B-group
: O O
Concomitant O O
administration O O
of O O
aluminum O B-drug
and O O
magnesium B-drug B-drug
hydroxides O O
does O O
not O O
interfere O O
with O O
absorption B-drug O
of O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
. O O

Tell O O
your O O
doctor O O
if O O
you O O
are O O
taking O O
any O O
of O O
the O O
following O O
drugs O O
: O O
blood B-group B-group
thinners O I-group
( O O
Coumadin B-brand B-brand
) O O
other O O
antidepressants B-group B-group
metoprolol B-drug B-drug
antihistamines B-group B-group
carbamazepine B-drug B-drug
( O O
Tegretol B-brand B-brand
) O O
cimetidine B-drug B-drug
( O O
Tagamet B-brand B-brand
) O O
estrogens B-group B-group
fluoxetine B-drug B-drug
( O O
Prozac B-brand B-brand
) O O
intraconazole O O
( O O
Sporanox B-brand B-brand
) O O
ketoconazole B-drug B-drug
( O O
Nizoral B-brand B-brand
) O O
levodopa B-drug B-drug
lithium I-drug I-drug
muscle B-group B-group
relaxants I-group I-group
birth O O
control O O
pills O O
sleeping O O
pills O O
thyroid O O
medications O O

and/or O O
Drug/Laboratory O O
Test O O
Interactions O O
See O O
CLINICAL O O
PHARMACOLOGY O O
, O O
Pharmacokinetics O O
and O O
Drug O O
Interactions O O
. O O

Furosemide B-drug B-drug
should O O
not O O
be O O
used O O
concomitantly O O
with O O
ethacrynic B-drug B-drug
acid I-drug I-drug
because O O
of O O
the O O
possibility O O
of O O
ototoxicity O O
. O O

Vitamin B-group B-group
D I-group I-group
: O O
The O O
coadministration O O
of O O
any O O
of O O
the O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
should O O
be O O
avoided O O
as O O
this O O
could O O
create O O
possible O O
additive O O
effects O O
and O O
hypercalcemia O O
. O O

A O O
variety O O
of O O
neurological O O
toxic O O
effects O O
and O O
malignant O O
hyperpyrexia O O
can O O
occur O O
, O O
sometimes O O
with O O
fatal O O
results O O
. O O

No O O
information O O
is O O
available O O
about O O
the O O
interaction O O
of O O
cephalexin B-drug B-drug
and O O
metformin B-drug B-drug
following O O
multiple O O
doses O O
of O O
either O O
drug O O
. O O

The O O
groups O O
then O O
took O O
500 O O
mg O O
of O O
tolbutamide B-drug B-drug
as O O
a O O
single O O
dose O O
( O O
day O O
0 O O
) O O
. O O

Indinavir B-drug B-drug

When O O
other O O
potent O O
parental O O
antihypertensive B-group B-group
drugs I-group I-group
, O O
such O O
as O O
diazoxide B-drug B-drug
, O O
are O O
used O O
in O O
combination O O
with O O
hydralazine B-drug B-drug
, O O
patients O O
should O O
be O O
continuously O O
observed O O
for O O
several O O
hours O O
for O O
any O O
excessive O O
fall O O
in O O
blood O O
pressure O O
. O O

Agents O O
Increasing O O
Serum O O
Potassium O O
: O O
PRINIVIL B-brand B-brand
attenuates O O
potassium O O
loss O O
caused O O
by O O
thiazide-type B-group B-group
diuretics I-group I-group
. O O

Effects O O
were O O
already O O
seen O O
with O O
doses O O
corresponding O O
to O O
relevant O O
plasma O O
levels O O
in O O
humans O O
, O O
and O O
the O O
intracellular O O
phosphorylation O O
of O O
zalcitabine B-drug B-drug
to O O
its O O
three O O
metabolites O O
( O O
including O O
the O O
active O O
zalcitabine O O
triphosphate O O
metabolite O O
) O O
was O O
significantly O O
inhibited O O
. O O

In O O
the O O
large O O
, O O
placebo-controlled O O
osteoporosis O O
Treatment O O
Study O O
, O O
aspirin B-brand B-brand
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
were O O
taken O O
by O O
62 O O
% O O
of O O
the O O
2946 O O
patients O O
. O O

Certain O O
drugs O O
including O O
thiazides B-group B-group
, O O
corticosteroids B-group B-group
, O O
thyroid B-group B-group
products I-group I-group
, O O
and O O
sympathomimetics B-group B-group
may O O
reduce O O
the O O
hypoglycemic O O
action O O
of O O
Starlix B-brand B-brand
and O O
other O O
oral O O
antidiabetic B-group B-group
drugs I-group I-group
. O O

Neuromuscular B-group B-group
Blockers I-group I-group
: O O
In O O
one O O
study O O
of O O
10 O O
healthy O O
volunteers O O
, O O
administration O O
of O O
PRECEDEX B-brand B-brand
for O O
45 O O
minutes O O
at O O
a O O
plasma O O
concentration O O
of O O
1 O O
( O O
one O O
) O O
ng/mL O O
resulted O O
in O O
no O O
clinically O O
meaningful O O
increases O O
in O O
the O O
magnitude O O
or O O
neuromuscular O O
blockade O O
associated O O
with O O
rocuronium B-drug B-drug
administration O O
. O O

A O O
variety O O
of O O
parametric O O
dose-response O O
models O O
based O O
on O O
either O O
the O O
normal O O
or O O
logistic O O
probability O O
distribution O O
have O O
been O O
proposed O O
in O O
the O O
literature O O
. O O

Drugs O O
with O O
parasympathomimetic O O
effects O O
administered O O
concurrently O O
with O O
cevimeline B-drug B-drug
can O O
be O O
expected O O
to O O
have O O
additive O O
effects O O
. O O

Thus O O
, O O
concomitant O O
therapy O O
with O O
warfarin B-drug B-drug
and O O
Lodine B-brand B-brand
should O O
not O O
require O O
dosage O O
adjustment O O
of O O
either O O
drug O O
. O O

A O O
study O O
in O O
14 O O
normal O O
male O O
and O O
female O O
volunteers O O
suggests O O
that O O
coadministration O O
of O O
cisapride B-drug B-drug
and O O
ketoconazole B-drug B-drug
can O O
result O O
in O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

The O O
IC O O
( O O
50 O O
) O O
was O O
about O O
120 O O
microgram/ml O O
. O O

- O O
Phenothiazines B-group B-group
( O O
acetophenazine B-drug B-drug
[ O O
e.g. O O
, O O
Tindal B-brand B-brand
] O O
, O O
chlorpromazine B-drug B-drug
[ O O
e.g. O O
, O O
Thorazine B-brand B-brand
] O O
, O O
fluphenazine B-drug B-drug
[ O O
e.g. O O
, O O
Prolixin B-brand B-brand
] O O
, O O
mesoridazine B-brand B-brand
[ O O
e.g. O O
, O O
Serentil B-brand B-brand
] O O
, O O
perphenazine B-drug B-drug
[ O O
e.g. O O
, O O
Trilafon B-brand B-brand
] O O
, O O
prochlorperazine B-drug B-drug
[ O O
e.g. O O
, O O
Compazine B-brand B-brand
] O O
, O O
promazine B-drug B-drug
[ O O
e.g. O O
, O O
Sparine B-brand B-brand
] O O
, O O
promethazine B-drug B-drug
[ O O
e.g. O O
, O O
Phenergan B-brand B-brand
] O O
, O O
thioridazine B-drug B-drug
[ O O
e.g. O O
, O O
Mellaril B-brand B-brand
] O O
, O O
trifluoperazine B-drug B-drug
[ O O
e.g. O O
, O O
Stelazine B-brand B-brand
] O O
, O O
triflupromazine B-drug B-drug
[ O O
e.g. O O
, O O
Vesprin B-brand B-brand
] O O
, O O
trimeprazine B-drug B-drug
[ O O
e.g. O O
, O O
Temaril B-brand B-brand
] O O
) O O
or O O

Drug/Laboratory O O
Test O O
Interactions O O
Finasteride B-drug B-drug
had O O
no O O
effect O O
on O O
circulating O O
levels O O
of O O
cortisol O O
, O O
thyroid-stimulating O O
hormone O O
, O O
or O O
thyroxine O O
, O O
nor O O
did O O
it O O
affect O O
the O O
plasma O O
lipid O O
profile O O
( O O
e.g. O O
, O O
total O O
cholesterol O O
, O O
low-density O O
lipoproteins O O
, O O
high-density O O
lipoproteins O O
and O O
triglycerides O O
) O O
or O O
bone O O
mineral O O
density O O
. O O

Some O O
quinolones B-group B-group
, O O
including O O
ciprofloxacin B-drug B-drug
, O O
have O O
also O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

Simultaneous O O
administration O O
of O O
SPRYCEL B-brand B-brand
with O O
antacids B-group B-group
should O O
be O O
avoided O O
. O O

procainamide B-drug B-drug
; O O

Your O O
doctor O O
or O O
pharmacist O O
can O O
give O O
you O O
more O O
information O O
on O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Clonidine B-drug B-drug
hydrochloride I-drug I-drug
may O O
enhance O O
the O O
CNS-depressive O O
effects O O
of O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
or O O
other O O
sedatives B-group B-group
. O O

Warfarin B-drug B-drug
: O O
In O O
a O O
study O O
in O O
healthy O O
volunteers O O
, O O
no O O
clinically O O
relevant O O
pharmacokinetic O O
or O O
pharmacodynamic O O
interaction O O
between O O
isradipine B-drug B-drug
and O O
racemic O O
warfarin B-drug B-drug
was O O
seen O O
when O O
two O O
single O O
oral O O
doses O O
of O O
warfarin B-drug B-drug
( O O
0.7 O O
mg/kg O O
body O O
weight O O
) O O
were O O
administered O O
during O O
11 O O
days O O
of O O
multipledose O O
treatment O O
with O O
5 O O
mg O O
b.i.d O O
. O O
isradipine B-drug B-drug
. O O

These O O
events O O
were O O
also O O
reported O O
to O O
occur O O
when O O
contrast O O
media O O
was O O
given O O
several O O
months O O
after O O
interleukin-2 B-drug O
treatment O O
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

Established O O
and O O
Other O O
Potentially O O
Significant O O
Drug O O
Interactions O O
: O O
Alteration O O
in O O
Dose O O
or O O
Regimen O O
May O O
Be O O
Recommended O O
Based O O
on O O
Drug O O
Interaction O O
Studies O O
or O O
Predicted O O
Interaction O O

. O O

In O O
an O O
in O O
vivo O O
metabolic O O
probe O O
study O O
, O O
alosetron B-drug B-drug
did O O
not O O
inhibit O O
CYP2E1 O O
but O O
did O O
produce O O
30 O O
% O O
inhibition O O
of O O
both O O
CYP1A2 O O
and O O
N-acetyltransferase O O
. O O

2 O O
. O O

Saquinavir B-drug B-drug
: O O
The O O
combination O O
of O O
HIVID B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
and O O
ZDV B-drug B-drug
has O O
been O O
studied O O
( O O
as O O
triple O O
combination O O
) O O
in O O
adults O O
. O O

Serotonergic B-group B-group
Agents I-group I-group
: O O
Co-administration O O
of O O
linezolid B-drug B-drug
and O O
serotonergic B-group B-group
agents I-group I-group
was O O
not O O
associated O O
with O O
serotonin O O
syndrome O O
in O O
Phase O O
1 O O
, O O
2 O O
or O O
3 O O
studies O O
. O O

In O O
an O O
analysis O O
of O O
the O O
supraventricular O O
arrhythmia O O
and O O
DIAMOND O O
patient O O
populations O O
, O O
the O O
concomitant O O
administration O O
of O O
verapamil B-drug B-drug
with O O
dofetilide B-drug B-drug
was O O
associated O O
with O O
a O O
higher O O
occurrence O O
of O O
torsade O O
de O O
pointes O O
. O O

Digoxin B-drug B-drug
, O O
Nimodipine B-drug B-drug
and O O
Losartan B-drug B-drug
: O O
Bosentan B-drug B-drug
has O O
no O O
significant O O
pharmacokinetic O O
interactions O O
with O O
digoxin B-drug B-drug
and O O
nimodipine B-drug B-drug
, O O
and O O
losartan B-drug B-drug
has O O
no O O
significant O O
effect O O
on O O
plasma O O
levels O O
of O O
bosentan B-drug B-drug
. O O

In O O
general O O
, O O
if O O
a O O
patient O O
shows O O
no O O
signs O O
of O O
sedation O O
within O O
2 O O
hours O O
after O O
a O O
1-mg O O
dose O O
of O O
flumazenil B-drug B-drug
, O O
serious O O
resedation O O
at O O
a O O
later O O
time O O
is O O
unlikely O O
. O O

Mice O O
from O O
the O O
20th O O
generation O O
of O O
three O O
lines O O
divergently O O
selected O O
for O O
response O O
to O O
pentobarbital-induced B-drug B-drug
sedation O O
times O O
[ O O
long-sedation O O
time O O
( O O
LST O O
) O O
, O O
short O O
sedation O O
time O O
( O O
SST O O
) O O
, O O
and O O
randomly O O
bred O O
control O O
( O O
RBC O O
) O O
] O O
were O O
used O O
to O O
study O O
cocaine-induced B-drug B-drug
behavioral O O
sensitization O O
. O O

Bosentan B-drug B-drug
is O O
metabolized O O
by O O
CYP2C9 O O
and O O
CYP3A4 O O
. O O

No O O
teratogenic O O
effects O O
were O O
seen O O
in O O
the O O
offspring O O
delivered O O
at O O
term O O
. O O

Valproate B-drug B-drug
: O O
Tiagabine B-drug B-drug
causes O O
a O O
slight O O
decrease O O
( O O
about O O
10 O O
% O O
) O O
in O O
steady-state O O
valproate B-drug B-drug
concentrations O O
. O O

The O O
risks O O
of O O
using O O
Clozapine B-drug B-drug
in O O
combination O O
with O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

when O O
the O O
drugs O O
were O O
administered O O
together O O
, O O
the O O
effects O O
were O O
additive O O
. O O

It O O
is O O
suggested O O
to O O
monitor O O
both O O
ketoconazole B-drug B-drug
and O O
phenytoin B-drug B-drug
. O O

co-administration O O
of O O
phenytoin B-drug B-drug
may O O
produce O O
a O O
synergistic O O
anticonvulsant O O
action O O
. O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

Since O O
caffeine B-drug B-drug
is O O
frequently O O
co-administered O O
with O O
acetaminophen B-drug B-drug
, O O
it O O
is O O
of O O
clinical O O
interest O O
to O O
study O O
the O O
effect O O
of O O
caffeine B-drug B-drug
on O O
the O O
hepatotoxicity O O
of O O
acetaminophen B-drug B-drug
. O O

Phenytoin B-drug B-drug
: O O
No O O
significant O O
differences O O
were O O
observed O O
in O O
mean O O
phenytoin B-drug B-drug
AUC O O
, O O
C O O
max O O
, O O
C O O
min O O
or O O
T O O
max O O
( O O
although O O
C O O
max O O
increased O O
by O O
11 O O
% O O
) O O
when O O
extended O O
phenytoin B-drug B-drug
sodium I-drug I-drug
capsules O O
( O O
100 O O
mg O O
tid O O
) O O
were O O
coadministered O O
with O O
lomefloxacin B-drug B-drug
( O O
400 O O
mg O O
qd O O
) O O
for O O
five O O
days O O
in O O
15 O O
healthy O O
males O O
. O O

These O O
precautions O O
probably O O
should O O
apply O O
to O O
digitoxin B-drug B-drug
administration O O
as O O
well O O
. O O

Phospholine B-drug B-drug
Iodide I-drug I-drug
potentiates O O
other O O
cholinesterase B-group B-group
inhibitors I-group I-group
such O O
as O O
succinylcholine B-drug B-drug
or O O
organophosphate B-drug_n B-drug_n
and O O
carbamate B-drug_n B-group
insecticides O I-group
. O O

Carbamazepine B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
the O O
degree O O
of O O
heart O O
block O O
produced O O
by O O
other O O
agents O O
. O O

Avoid O O
concomitant O O
use O O
unless O O
necessary O O
to O O
control O O
side O O
effects O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
. O O

Monoamine B-group B-group
Oxidase I-group I-group
Inhibitors I-group I-group
( O O
MAOIs B-group B-group
) O O

Fluoxetine B-drug B-drug
, O O
OCs B-group B-group
, O O
sertraline B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
macrolide B-group B-group
antibiotics I-group I-group
( O O
exercise O O
caution O O
) O O
. O O

Powder O O
x-ray O O
diffraction O O
, O O
differential O O
scanning O O
calorimetry O O
, O O
differential O O
thermal O O
analysis O O
, O O
and O O
scanning O O
electron O O
microscopy O O
were O O
used O O
to O O
characterize O O
the O O
aerosol O O
particles O O
and O O
starting O O
material O O
. O O

Probenecid B-drug B-drug
: O O
As O O
with O O
other O O
b-lactam B-group B-group
antibiotics I-group I-group
, O O
co-administration O O
of O O
probenecid B-drug B-drug
with O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
resulted O O
in O O
an O O
increase O O
in O O
the O O
plasma O O
exposure O O
of O O
cefditoren B-drug B-drug
, O O
with O O
a O O
49 O O
% O O
increase O O
in O O
mean O O
Cmax O O
, O O
a O O
122 O O
% O O
increase O O
in O O
mean O O
AUC O O
, O O
and O O
a O O
53 O O
% O O
increase O O
in O O
half-life O O
. O O

The O O
hypoglycemic O O
effect O O
of O O
tolbutamide B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
when O O
Atromid-S B-brand B-brand
is O O
given O O
concurrently O O
. O O

Hepatotoxic O O
medications O O
, O O
such O O
as O O
high-dose O O
methotrexate B-drug B-drug
, O O
may O O
impair O O
liver O O
function O O
and O O
increase O O
the O O
risk O O
of O O
toxicity O O
. O O

It O O
is O O
not O O
clear O O
whether O O
this O O
represents O O
an O O
interaction O O
with O O
TIKOSYN B-brand B-brand
or O O
the O O
presence O O
of O O
more O O
severe O O
structural O O
heart O O
disease O O
in O O
patients O O
on O O
digoxin B-drug B-drug
; O O

Some O O
reports O O
have O O
shown O O
that O O
the O O
concomitant O O
administration O O
of O O
thiazides B-group B-group
with O O
vitamin B-group B-group
D I-group I-group
causes O O
hypercalcemia O O
. O O

In O O
this O O
paper O O
, O O
we O O
show O O
that O O
the O O
precipitate O O
is O O
formed O O
after O O
the O O
interaction O O
of O O
jacalin B-drug_n B-drug_n
and O O
the O O
serum O O
protein O O
added O O
to O O
the O O
culture O O
medium O O
. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-group B-group
or O O
increasing O O
salt O O
intake O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
fosinopril B-drug B-drug
sodium I-drug I-drug
. O O

Several O O
beta-adrenergic O O
neuroeffector O O
defects O O
occur O O
in O O
heart O O
failure O O
. O O

The O O
clinical O O
basis O O
of O O
this O O
drug O O
interaction O O
has O O
not O O
been O O
established O O
but O O
should O O
be O O
noted O O
when O O
allopurinol B-drug B-drug
is O O
given O O
to O O
patients O O
already O O
on O O
dicumarol B-drug B-drug
therapy O O
. O O

Methotrexate B-drug B-drug
: O O
Piperacillin B-drug B-drug
sodium I-drug I-drug
may O O
reduce O O
the O O
excretion O O
of O O
methotrexate B-drug B-drug
. O O

The O O
onset O O
of O O
80 O O
% O O
of O O
those O O
" O O
epidemic O O
" O O

Testicular O O
atrophy O O
was O O
seen O O
with O O
dexrazoxane B-drug B-drug
administration O O
at O O
doses O O
as O O
low O O
as O O
30 O O
mg/kg O O
weekly O O
for O O
6 O O
weeks O O
in O O
rats O O
( O O
1/3 O O
the O O
human O O
dose O O
on O O
a O O
mg/m O O
2 O O
basis O O
) O O
and O O
as O O
low O O
as O O
20 O O
mg/kg O O
weekly O O
for O O
13 O O
weeks O O
in O O
dogs O O
( O O
approximately O O
equal O O
to O O
the O O
human O O
dose O O
on O O
a O O
mg/m O O
2 O O
basis O O
) O O
. O O

Lithium B-drug B-drug
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
because O O
they O O
reduce O O
its O O
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium O B-drug
toxicity O O
. O O

Co-medications O O
that O O
induce O O
CYP3A4 O O
( O O
e.g. O O
, O O
dexamethasone B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
phenobarbital B-drug B-drug
or O O
St O O
. O O

We O O
propose O O
these O O
pharmacokinetic O O
changes O O
to O O
be O O
the O O
underlying O O
mechanism O O
for O O
the O O
reduction O O
of O O
oral O O
CCNU B-drug B-drug
cytotoxicity O O
by O O
misonidazole B-drug_n B-drug_n
. O O

General O O
Interactions O O
: O O
Certain O O
drugs O O
could O O
increase O O
the O O
likelihood O O
of O O
potentially O O
serious O O
adverse O O
effects O O
with O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
. O O

The O O
response O O
to O O
Factrel B-brand B-brand
may O O
be O O
blunted O O
by O O
phenothiazines B-group B-group
and O O
dopamine B-group B-group
antagonists I-group I-group
which O O
cause O O
a O O
rise O O
in O O
prolactin O O
. O O

Caution O O
is O O
advised O O
when O O
beginning O O
, O O
discontinuing O O
, O O
or O O
changing O O
the O O
dose O O
of O O
DIAMOX B-brand B-brand
in O O
patients O O
receiving O O
primidone B-drug B-drug
. O O

Drugs O O
that O O
may O O
have O O
their O O
plasma O O
concentration O O
altered O O
by O O
Gleevec B-brand B-brand
Gleevec I-brand I-brand
increases O O
the O O
mean O O
cmax O O
and O O
AUC O O
of O O
simvastatin B-drug B-drug
( O O
CYP3A4 O O
substrate O O
) O O
2- O O
and O O
3.5-fold O O
, O O
respectively O O
, O O
suggesting O O
an O O
inhibition O O
of O O
the O O
CYP3A4 O O
by O O
Gleevec B-brand B-brand
. O O

While O O
all O O
the O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e.g. O O
, O O
citalopram B-drug B-drug
, O O
escitalopram B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
and O O
paroxetine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

During O O
clinical O O
trials O O
, O O
iloprost B-drug B-drug
was O O
used O O
concurrently O O
with O O
anticoagulants B-group B-group
, O O
diuretics B-group B-group
, O O
cardiac B-group B-group
glycosides I-group I-group
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
analgesics B-group B-group
, O O
antipyretics B-group B-group
, O O
nonsteroidal B-group B-group
antiinflammatories I-group I-group
, O O
corticosteroids B-group B-group
, O O
and O O
other O O
medications O O
. O O

Prolonged O O
daily O O
administration O O
of O O
picrotoxin B-drug_n B-drug_n
in O O
a O O
dose O O
of O O
1 O O
mg/kg O O
results O O
in O O
the O O
development O O
of O O
brain O O
edema O O
. O O

The O O
superiority O O
of O O
efavirenz B-drug B-drug
over O O
indinavir-based B-drug B-drug
regimens O O
has O O
been O O
observed O O
in O O
comparative O O
data O O
in O O
a O O
subset O O
of O O
patients O O
with O O
high O O
viral O O
loads O O
. O O

and O O
by O O
observations O O
now O O
appearing O O
on O O
the O O
relation O O
between O O
plasma O O
drug O O
levels O O
and O O
drug O O
effects O O
, O O
both O O
therapeutic O O
and O O
toxic O O
. O O

Thus O O
, O O
it O O
is O O
recommended O O
not O O
to O O
use O O
such O O
methods O O
for O O
12-24 O O
hours O O
after O O
administration O O
of O O
Omniscan B-brand B-brand
. O O

Cardiovascular O O
: O O
Hypotension O O
, O O
bradycardia O O
, O O
and O O
hypertension O O
have O O
been O O
observed O O
during O O
administration O O
of O O
TAXOL B-brand B-brand
, O O
but O O
generally O O
do O O
not O O
require O O
treatment O O
. O O

Antidiabetic B-group B-group
drugs I-group I-group
( O O
oral O O
agents O O
and O O
insulin B-drug B-drug
) O O
diminished O O
antidiabetic O O
effect O O
. O O

Digitalis B-group B-group
toxicity O O
may O O
be O O
aggravated O O
by O O
the O O
initial O O
release O O
of O O
norepinephrine O O
caused O O
by O O
Bretylium B-drug B-drug
Tosylate I-drug I-drug
Injection O O
. O O

The O O
dissolution O O
rate O O
of O O
the O O
aerosol O O
particles O O
in O O
saline O O
was O O
low O O
and O O
variable O O
. O O

However O O
, O O
because O O
both O O
of O O
these O O
compounds O O
have O O
CNS O O
effects O O
, O O
an O O
additive O O
pharmacodynamic O O
effect O O
is O O
possible O O
. O O

Pediatric O O
Use O O
The O O
safety O O
and O O
efficacy O O
of O O
FASLODEX B-brand B-brand
in O O
pediatric O O
patients O O
have O O
not O O
been O O
established O O
. O O

The O O
steady-state O O
Cmin O O
increased O O
to O O
78 O O
14 O O
micrograms/mL O O
when O O
1200 O O
mg/day O O
of O O
felbamate B-drug B-drug
was O O
coadministered O O
. O O

In O O
order O O
to O O
examine O O
some O O
molecular O O
mechanisms O O
of O O
PCP-induced B-drug_n B-drug_n
behavioral O O
changes O O
, O O
Northern O O
blot O O
analysis O O
of O O
total O O
RNA O O
from O O
prefrontal O O
cortical O O
tissues O O
of O O
mice O O
treated O O
with O O
PCP B-drug_n B-drug_n
, O O
DCG-IV B-drug_n B-drug_n
, O O
and O O
L-CCG-1 B-drug_n B-drug_n
was O O
carried O O
out O O
. O O

Clonidine B-drug B-drug
therapy O O
can O O
then O O
be O O
discontinued O O
several O O
days O O
later O O
by O O
gradually O O
decreasing O O
the O O
dosage O O
. O O

However O O
, O O
administration O O
of O O
4-methylpyrazole B-drug B-drug
( O O
90 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
to O O
rats O O
2 O O
hours O O
prior O O
to O O
1,3-difluoroacetone B-drug_n B-drug_n
( O O
100 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
was O O
ineffective O O
in O O
preventing O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
synthesis O O
and O O
did O O
not O O
diminish O O
fluoride O O
or O O
citrate O O
accumulation O O
in O O
vivo O O
. O O

When O O
Mefloquine B-drug B-drug
is O O
taken O O
concurrently O O
with O O
oral O O
live B-group B-group
typhoid I-group I-group
vaccines I-group I-group
, O O
attenuation O O
of O O
immunization O O
can O O
not O O
be O O
excluded O O
. O O

Therefore O O
, O O
fenofibrate B-drug B-drug
should O O
be O O
taken O O
at O O
least O O
1 O O
hour O O
before O O
or O O
4-6 O O
hours O O
after O O
a O O
bile B-group B-group
acid I-group I-group
binding I-group I-group
resin I-group I-group
to O O
avoid O O
impeding O O
its O O
absorption O O
. O O

no O O
change O O
in O O
pravastatin B-drug B-drug
AUC O O
and O O
Cmax O O
was O O
observed O O
during O O
diltiazem B-drug B-drug
coadministration O O
. O O

The O O
extent O O
to O O
which O O
SSRI-TCA B-group B-group
interactions O O
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
, O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

There O O
is O O
no O O
clinical O O
evidence O O
to O O
suggest O O
that O O
anagrelide B-drug B-drug
interacts O O
with O O
any O O
of O O
these O O
compounds O O
. O O

The O O
affinity O O
( O O
Kd O O
) O O
of O O
D2 O O
in O O
the O O
NAC O O
decreased O O
significantly O O
, O O
without O O
changes O O
in O O
density O O
( O O
Bmax O O
) O O
, O O
in O O
the O O
cocaine-treated B-drug B-drug
SST O O
and O O
RBC O O
mice O O
. O O

angioedema O O

Nonetheless O O
, O O
individual O O
patients O O
may O O
require O O
additional O O
titration O O
of O O
their O O
theophylline B-drug B-drug
dosage O O
when O O
lansoprazole B-drug B-drug
is O O
started O O
or O O
stopped O O
to O O
ensure O O
clinically O O
effective O O
blood O O
levels O O
. O O

Chloramphenicol B-drug B-drug
has O O
been O O
shown O O
to O O
be O O
antagonistic O O
to O O
beta-lactam B-group B-group
antibiotics I-group I-group
, O O
including O O
ceftazidime B-drug B-drug
, O O
based O O
on O O
in O O
vitro O O
studies O O
and O O
time O O
kill O O
curves O O
with O O
enteric O O
gram-negative O O
bacilli O O
. O O

Therefore O O
, O O
co-administration O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isoenzyme O O
, O O
including O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
carbamazepine B-drug B-drug
, O O
and O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
( O O
eg O O
, O O
propafenone B-drug B-drug
, O O
flecainide B-drug B-drug
, O O
and O O
encainide B-drug B-drug
) O O
, O O
or O O
that O O
inhibit O O
this O O
enzyme O O
( O O
eg O O
, O O
quinidine B-drug B-drug
) O O
, O O
should O O
be O O
approached O O
with O O
caution O O
. O O

In O O
another O O
study O O
, O O
TORADOLIV/IM O O
was O O
given O O
with O O
two O O
doses O O
of O O
5000 O O
U O O
of O O
heparin B-drug B-drug
to O O
11 O O
healthy O O
volunteers O O
, O O
resulting O O
in O O
a O O
mean O O
template O O
bleeding O O
time O O
of O O
6.4 O O
minutes O O
( O O
3.2 O O
to O O
11.4 O O
min O O
) O O
compared O O
to O O
a O O
mean O O
of O O
6.0 O O
minutes O O
( O O
3.4 O O
to O O
7.5 O O
min O O
) O O
for O O
heparin B-drug B-drug
alone O O
and O O
5.1 O O
minutes O O
( O O
3.5 O O
to O O
8.5 O O
min O O
) O O
for O O
placebo O O
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
and O O
Ortho-Novum B-brand B-brand
1/35 O O
increased O O
the O O
exposure O O
of O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
by O O
20 O O
% O O
and O O
34 O O
% O O
, O O
respectively O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Corticosteroids B-group B-group
may O O
affect O O
the O O
nitrobluetetrazolium O O
test O O
for O O
bacterial O O
infection O O
and O O
produce O O
false-negative O O
results O O

Ketoconazole B-drug B-drug
is O O
a O O
known O O
strong O O
inhibitor O O
of O O
CYP3A4 O O
. O O

Lithium B-drug B-drug
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
because O O
they O O
reduce O O
lithiums B-drug B-drug
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Thus O O
, O O
careful O O
monitoring O O
of O O
clinical O O
status O O
is O O
warranted O O
when O O
rifampin B-drug B-drug
is O O
administered O O
or O O
discontinued O O
in O O
haloperidol-treated B-drug B-drug
patients O O
. O O

On O O
the O O
other O O
hand O O
, O O
intrathecal O O
naloxone B-drug B-drug
( O O
12-120 O O
micrograms O O
) O O
had O O
only O O
a O O
very O O
weak O O
effect O O
on O O
the O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
morphine B-drug B-drug
( O O
40 O O
micrograms O O
) O O
. O O

The O O
drug O O
interaction O O
data O O
described O O
in O O
this O O
section O O
were O O
obtained O O
from O O
studies O O
involving O O
either O O
healthy O O
subjects O O
or O O
patients O O
with O O
epilepsy O O
. O O

Concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
acetaminophen B-drug B-drug
in O O
dogs O O
, O O
but O O
not O O
in O O
rats O O
, O O
at O O
approximately O O
2 O O
times O O
the O O
recommended O O
maximum O O
human O O
therapeutic O O
dose O O
of O O
each O O
( O O
40 O O
to O O
52 O O
mg/kg/day O O
of O O
diflunisal/acetaminophen B-drug B-drug
) O O
resulted O O
in O O
greater O O
gastrointestinal O O
toxicity O O
than O O
when O O
either O O
drug O O
was O O
administered O O
alone O O
. O O

Co-administration O O
of O O
naltrexone B-drug B-drug
with O O
Acamprosate B-drug B-drug
produced O O
a O O
25 O O
% O O
increase O O
in O O
AUC O O
and O O
a O O
33 O O
% O O
increase O O
in O O
the O O
Cmax O O
of O O
acamprosate B-drug B-drug
. O O

CONCLUSIONS O O
: O O
Everolimus B-drug B-drug
exhibited O O
dose-proportional O O
, O O
stable O O
exposure O O
during O O
the O O
first O O
post-transplant O O
year O O
. O O

Cholestyramine-Concomitant B-drug B-drug
intake O O
of O O
cholestyramine B-drug B-drug
and O O
vitamin B-group B-group
K I-group I-group
may O O
reduce O O
the O O
absorption O O
of O O
vitamin B-group B-group
K I-group I-group
. O O

Morphine B-drug B-drug
: O O
TORADOLIV/IM O O
has O O
been O O
administered O O
concurrently O O
with O O
morphine B-drug B-drug
in O O
several O O
clinical O O
trials O O
of O O
postoperative O O
pain O O
without O O
evidence O O
of O O
adverse O O
interactions O O
. O O

At O O
low-levels O O
of O O
exposure O O
the O O
toxicokinetic O O
interferences O O
between O O
solvents O O
have O O
generally O O
not O O
been O O
observed O O
in O O
man O O
and O O
presumably O O
a O O
threshold O O
limit O O
exists O O
. O O

Antiacid O B-group
, O O
clarithromycin B-drug B-drug
, O O
Didanosine B-drug B-drug
, O O
Fluconazole B-drug B-drug
, O O
Fluoxetine B-drug B-drug
, O O
Indanavir O O
, O O
Ketoconazole B-drug B-drug
, O O
Phenytoin B-drug B-drug
, O O
Phenobarbitol O O
, O O
carbamazepine B-drug B-drug
, O O
Rifabutin B-drug B-drug
, O O
Rifampin B-drug B-drug
, O O
Ritanovir O O
, O O
Saquinavir B-drug B-drug
. O O

disulfiram B-drug B-drug
; O O

Bentiromide B-drug B-drug
may O O
interact O O
with O O
acetaminophen B-drug B-drug
( O O
e.g. O O
, O O
Tylenol B-brand B-brand
) O O
, O O
chloramphenicol B-drug B-drug
( O O
e.g. O O
, O O
Chloromycetin B-brand B-brand
) O O
, O O
local O O
anesthetics B-group B-group
( O O
e.g. O O
, O O
benzocaine B-drug B-drug
and O O
lidocaine B-drug B-drug
) O O
, O O
para-aminobenzoic B-drug_n B-drug_n
acid I-drug_n I-drug_n
( O O
PABA B-drug_n B-drug_n
) O O
-containing O O
preparations O O
( O O
e.g. O O
, O O
sunscreens O O
and O O
some O O
multivitamins B-group B-group
) O O
, O O
procainamide B-drug B-drug
( O O
e.g. O O
, O O
Pronestyl B-brand B-brand
) O O
, O O
sulfonamides B-group B-group
( O O
sulfa O B-group
medicines O I-group
) O O
, O O
thiazide B-group B-group
diuretics I-group I-group
( O O
use O O
of O O
these O O
medicines O O
during O O
the O O
test O O
period O O
will O O
affect O O
the O O
test O O
results O O
) O O
, O O
and O O
pancreatic O O
supplements O O
( O O
use O O
of O O
pancreatic O O
supplements O O
may O O
give O O
false O O
test O O
results O O
) O O
. O O

When O O
used O O
in O O
external O O
subcutaneous O O
infusion O O
pumps O O
for O O
insulin B-drug B-drug
, O O
NovoLog B-brand B-brand
should O O
not O O
be O O
mixed O O
with O O
any O O
other O O
insulins B-group B-group
or O O
diluent O O
. O O

Digitalis B-group B-group
: O O
Vitamin B-group B-group
D I-group I-group
dosage O O
must O O
be O O
determined O O
with O O
care O O
in O O
patients O O
undergoing O O
treatment O O
with O O
digitalis B-group B-group
, O O
as O O
hypercalcemia O O
in O O
such O O
patients O O
may O O
precipitate O O
cardiac O O
arrhythmias O O
. O O

Anticholinergic B-group B-group
agents I-group I-group
may O O
potentially O O
alter O O
the O O
absorption O O
of O O
some O O
concomitantly O O
administered O O
drugs O O
due O O
to O O
effects O O
on O O
gastrointestinal O O
motility O O
. O O

Antacids B-group B-group
or O O
H B-group B-group
2 I-group I-group
receptor I-group I-group
antagonists I-group I-group
: O O
When O O
dirithromycin B-drug B-drug
is O O
administered O O
immediately O O
following O O
antacids B-group B-group
or O O
H B-group B-group
2 I-group I-group
-receptor I-group I-group
antagonists I-group I-group
, O O
the O O
absorption O O
of O O
dirithromycin B-drug B-drug
is O O
slightly O O
enhanced O O
. O O

In O O
particular O O
, O O
convulsions O O
have O O
been O O
reported O O
when O O
ethionamide B-drug B-drug
is O O
administered O O
with O O
cycloserine B-drug B-drug
and O O
special O O
care O O
should O O
be O O
taken O O
when O O
the O O
treatment O O
regimen O O
includes O O
both O O
of O O
these O O
drugs O O
. O O

Because O O
dopamine B-drug B-drug
is O O
metabolized O O
by O O
monoamine O O
oxidase O O
( O O
MAO O O
) O O
, O O
inhibition O O
of O O
this O O
enzyme O O
prolongs O O
and O O
potentiates O O
the O O
effect O O
of O O
dopamine B-drug B-drug
. O O

Also O O
included O O
in O O
this O O
paper O O
is O O
a O O
study O O
which O O
confirms O O
the O O
identity O O
of O O
the O O
HPLC O O
peak O O
as O O
being O O
homocysteine O O
by O O
forming O O
a O O
radioactive O O
derivative O O
of O O
this O O
particular O O
sulphydryl-containing O O
amino O O
acid O O
, O O
and O O
then O O
analysing O O
the O O
resulting O O
mixture O O
by O O
TLC O O
. O O

Digoxin B-drug B-drug
Keppra B-brand B-brand
( O O
1000 O O
mg O O
twice O O
daily O O
) O O
did O O
not O O
influence O O
the O O
pharmacokinetics O O
and O O
pharmacodynamics O O
( O O
ECG O O
) O O
of O O
digoxin B-drug B-drug
given O O
as O O
a O O
0.25 O O
mg O O
dose O O
every O O
day O O
. O O

Azithromycin B-drug B-drug
had O O
no O O
significant O O
effect O O
on O O
dideoxyinosine B-drug B-drug
pharmacokinetics O O
. O O

Macrolide B-group B-group
Antibiotics I-group I-group
( O O
e. O O
g. O O
erythromycin B-drug B-drug
and O O
troleandomycin B-drug B-drug
) O O
: O O
Agents O O
of O O
the O O
ergot B-group B-group
alkaloid I-group I-group
class I-group I-group
, O O
of O O
which O O
D.H.E B-brand B-brand
. I-brand I-brand
45 I-brand I-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
is O O
a O O
member O O
, O O
have O O
been O O
shown O O
to O O
interact O O
with O O
antibiotics B-group B-group
of O O
the O O
macrolide B-group B-group
class I-group I-group
, O O
resulting O O
in O O
increased O O
plasma O O
levels O O
of O O
unchanged O O
alkaloids O O
and O O
peripheral O O
vasoconstriction O O
. O O

Due O O
to O O
their O O
similar O O
mechanism O O
of O O
action O O
, O O
it O O
is O O
expected O O
that O O
the O O
neuromuscular O O
blockade O O
produced O O
by O O
any O O
of O O
the O O
non-depolarizing B-group B-group
muscle I-group I-group
relaxants I-group I-group
could O O
be O O
prolonged O O
in O O
the O O
presence O O
of O O
piperacillin B-drug B-drug
. O O

In O O
the O O
DIAMOND O O
trials O O
, O O
1252 O O
patients O O
were O O
treated O O
with O O
TIKOSYN B-brand B-brand
and O O
diuretics B-group B-group
concomitantly O O
of O O
whom O O
493 O O
died O O
compared O O
to O O
508 O O
deaths O O
among O O
the O O
1248 O O
patients O O
receiving O O
placebo O O
and O O
diuretics B-group B-group
. O O

7 O O
. O O

Increased O O
nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
cephalosporins B-group B-group
and O O
aminoglycoside B-group B-group
antibiotics I-group I-group
. O O

Inhibitors O O
of O O
CYP2D6 O O
; O O

Co-administration O O
of O O
multiple O O
doses O O
of O O
10 O O
mg O O
of O O
lenalidomide B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
single O O
dose O O
pharmacokinetics O O
of O O
R- O O
and O O
S- B-drug O
warfarin I-drug B-drug
. O O

Nimodipine B-drug B-drug
had O O
no O O
effect O O
on O O
ginsenosides B-drug_n B-drug_n
response O O
. O O

Specific O O
drug O O
interaction O O
studies O O
, O O
including O O
interactions O O
with O O
MTX B-drug B-drug
, O O
have O O
not O O
been O O
conducted O O
. O O

Based O O
on O O
these O O
data O O
, O O
Vardenafil B-drug B-drug
should O O
not O O
be O O
used O O
in O O
patients O O
on O O
alpha-blocker B-group B-group
therapy O O
. O O

In O O
a O O
12-month O O
controlled O O
trial O O
that O O
included O O
a O O
50 O O
mcg O O
once O O
daily O O
BROVANA B-brand B-brand
dose O O
, O O
30 O O
of O O
the O O
528 O O
BROVANA B-brand B-brand
-treated O O
subjects O O
received O O
concomitant O O
theophylline B-drug B-drug
at O O
study O O
entry O O
. O O

Fentanyl B-drug B-drug

Phenytoin B-drug B-drug
is O O
metabolized O O
by O O
hepatic O O
cytochrome O O
P450 O O
enzymes O O
and O O
is O O
particularly O O
susceptible O O
to O O
inhibitory O O
drug O O
interactions O O
because O O
it O O
is O O
subject O O
to O O
saturable O O
metabolism O O
. O O

No O O
information O O
provided O O

The O O
literature O O
suggests O O
that O O
more O O
than O O
one O O
mechanism O O
of O O
action O O
exists O O
for O O
them O O
. O O

In O O
view O O
of O O
the O O
long O O
and O O
variable O O
half-life O O
of O O
amiodarone B-drug B-drug
, O O
potential O O
for O O
drug O O
interactions O O
exists O O
not O O
only O O
with O O
concomitant O O
medication O O
but O O
also O O
with O O
drugs O O
administered O O
after O O
discontinuation O O
of O O
amiodarone B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
FACTIVE B-brand B-brand
with O O
probenecid B-drug B-drug
resulted O O
in O O
a O O
45 O O
% O O
increase O O
in O O
systemic O O
exposure O O
to O O
gemifloxacin B-drug B-drug
. O O

Drugs O O
Metabolized O O
by O O
Catechol-O-methyltransferase O O
( O O
COMT O O
) O O
: O O
Hormone O O
levels O O
: O O
Levodopa B-drug B-drug
is O O
known O O
to O O
depress O O
prolactin O O
secretion O O
and O O
increase O O
growth O O
hormone O O
levels O O
. O O

Hepatic O O
: O O
There O O
is O O
limited O O
evidence O O
that O O
the O O
myelotoxicity O O
of O O
TAXOL B-brand B-brand
may O O
be O O
exacerbated O O
in O O
patients O O
with O O
serum O O
total O O
bilirubin O O
2 O O
times O O
ULN O O
. O O

Other O O
antiarrhythmic B-group B-group
drugs I-group I-group
( O O
eg O O
, O O
quinidine B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
propranolol B-drug B-drug
) O O
have O O
occasionally O O
been O O
used O O
concurrently O O
with O O
Norpace B-brand B-brand
. O O

Therefore O O
, O O
the O O
potential O O
exists O O
for O O
interaction O O
between O O
carbamazepine B-drug B-drug
and O O
any O O
agent O O
that O O
inhibits O O
CYP3A4 O O
and/or O O
epoxide O O
hydrolase O O
. O O

Co-administration O O
of O O
MYOBLOC B-brand B-brand
and O O
aminoglycosides B-group B-group
or O O
other O O
agents O O
interfering O O
with O O
neuromuscular O O
transmission O O
( O O
e.g. O O
, O O
curare-like B-group B-group
compounds I-group I-group
) O O
should O O
only O O
be O O
performed O O
with O O
caution O O
as O O
the O O
effect O O
of O O
the O O
toxin B-drug O
may O O
be O O
potentiated O O
. O O

1 O O
mM O O
) O O
was O O
a O O
slight O O
degree O O
of O O
inhibition O O
( O O
14 O O
% O O
-30 O O
% O O
) O O
of O O
isoform O O
CYP2A6 O O
observed O O
. O O

Cimetidine B-drug B-drug
: O O
A O O
study O O
in O O
6 O O
healthy O O
volunteers O O
has O O
shown O O
a O O
significant O O
increase O O
in O O
peak O O
nifedipine B-drug B-drug
plasma O O
levels O O
( O O
80 O O
% O O
) O O
and O O
area-under-the-curve O O
( O O
74 O O
% O O
) O O
after O O
a O O
1 O O
week O O
course O O
of O O
cimetidine B-drug B-drug
at O O
1000 O O
mg O O
per O O
day O O
and O O
nifedipine B-drug B-drug
at O O
40 O O
mg O O
per O O
day O O
. O O

Lipids O O
: O O
In O O
clinical O O
studies O O
, O O
the O O
incidence O O
of O O
hypertriglyceridemia O O
was O O
66 O O
% O O
, O O
hypercholesterolemia O O
was O O
33 O O
% O O
and O O
that O O
of O O
decreased O O
HDL O O
was O O
40 O O
% O O
. O O

Alpha-agonists B-group B-group
, O O
as O O
a O O
class O O
, O O
may O O
reduce O O
pulse O O
and O O
blood O O
pressure O O
. O O

Experience O O
with O O
co-administration O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
and O O
Fentanyl B-drug B-drug
in O O
patients O O
is O O
limited O O
, O O
therefore O O
, O O
consideration O O
should O O
be O O
given O O
to O O
temporarily O O
suspending O O
use O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
in O O
patients O O
receiving O O
Fentanyl B-drug B-drug
. O O

Resistance O O
to O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
nondepolarizing B-group B-group
neuromuscular I-group I-group
blocking I-group I-group
agents I-group I-group
has O O
been O O
demonstrated O O
in O O
patients O O
chronically O O
administered O O
phenytoin B-drug B-drug
or O O
carbamazepine B-drug B-drug
. O O

Drug/ O O
Laboratory O O
Test O O
Interactions O O
AMERGE B-brand B-brand
Tablets O O
are O O
not O O
known O O
to O O
interfere O O
with O O
commonly O O
employed O O
clinical O O
laboratory O O
tests O O
. O O

It O O
is O O
important O O
for O O
older O O
adults O O
to O O
be O O
aware O O
of O O
the O O
relationship O O
between O O
folic B-drug B-drug
acid I-drug I-drug
and O O
vitamin B-drug B-drug
B12 I-drug I-drug
because O O
they O O
are O O
at O O
greater O O
risk O O
of O O
having O O
a O O
vitamin O O
B12 O O
deficiency O O
. O O

Much O O
less O O
caspase-3 O O
activity O O
was O O
noted O O
in O O
the O O
lysate O O
derived O O
from O O
serum-deprived O O
RAS-3T3 O O
cells O O
compared O O
with O O
that O O
in O O
the O O
lysate O O
of O O
serum-deprived O O
NIH-3T3 O O
cells O O
. O O

FORADIL B-brand B-brand
is O O
not O O
meant O O
to O O
relieve O O
acute O O
asthma O O
or O O
COPD O O
symptoms O O
and O O
extra O O
doses O O
should O O
not O O
be O O
used O O
for O O
that O O
purpose O O
. O O

Nevirapine I-drug B-drug
and O O
ketoconazole B-drug B-drug
should O O
not O O
beadministered O O
concomitantly O O
becausedecreases O O
in O O
ketoconazole B-drug B-drug
plasmaconcentrations O O
may O O
reduce O O
the O O
efficacy O O
of O O
the O O
drug O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
A O O
false O O
positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
with O O
Benedicts O O
solution O O
, O O
Fehlings O O
solution O O
or O O
with O O
CLINITEST O O
tablets O O
, O O
but O O
not O O
with O O
enzyme-based O O
tests O O
such O O
as O O
CLINISTIX O O
. O O

Examples O O
of O O
Drugs O O
in O O
Which O O
Plasma O O
Concentrations O O
May O O
Be O O
Increased O O
By O O
Co-administration O O
With O O
Nevirapine B-drug B-drug

Alcohol B-drug B-drug
: O O
There O O
was O O
no O O
significant O O
difference O O
between O O
aripiprazole B-drug B-drug
coadministered O O
with O O
ethanol B-drug B-drug
and O O
placebo O O
coadministered O O
with O O
ethanol B-drug B-drug
on O O
performance O O
of O O
gross O O
motor O O
skills O O
or O O
stimulus O O
response O O
in O O
healthy O O
subjects O O
. O O

Aprepitant B-drug B-drug
is O O
also O O
an O O
inducer O O
of O O
CYP2C9 O O
. O O

. O O

Drug O O
Laboratory O O
Test O O
Interactions O O
None O O
known O O
. O O

Although O O
specific O O
studies O O
have O O
not O O
been O O
performed O O
, O O
coadministration O O
with O O
drugs O O
that O O
are O O
mainly O O
metabolized O O
by O O
CYP3A4 O O
( O O
eg O O
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
dapsone B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
quinine B-drug B-drug
, O O
amiodarone B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
ergot B-group B-group
derivatives I-group I-group
, O O
pimozide B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
fentanyl B-drug B-drug
, O O
alfentanyl B-drug B-drug
, O O
alprazolam B-drug B-drug
, O O
and O O
triazolam B-drug B-drug
) O O
may O O
have O O
elevated O O
plasma O O
concentrations O O
when O O
coadministered O O
with O O
saquinavir B-drug B-drug
; O O

Drug/Laboratory O O
Test O O
Interaction O O
Fosinopril B-drug B-drug
may O O
cause O O
a O O
false O O
low O O
measurement O O
of O O
serum O O
digoxin B-drug B-drug
levels O O
with O O
the O O
Digi- O O
Tab O O
RIA O O
Kit O O
for O O
Digoxin B-drug B-drug
. O O

An O O
encephalopathic O O
syndrome O O
( O O
characterized O O
by O O
weakness O O
, O O
lethargy O O
, O O
fever O O
, O O
tremulousness O O
and O O
confusion O O
, O O
extrapyramidal O O
symptoms O O
, O O
leukocytosis O O
, O O
elevated O O
serum O O
enzymes O O
, O O
BUN O O
, O O
and O O
FBS O O
) O O
followed O O
by O O
irreversible O O
brain O O
damage O O
has O O
occurred O O
in O O
a O O
few O O
patients O O
treated O O
with O O
lithium B-drug B-drug
plus O O
HALDOL B-brand B-brand
. O O

InjectionSite O O
Reaction O O
: O O
Injection O O
site O O
reactions O O
, O O
including O O
reactions O O
secondary O O
to O O
extravasation O O
, O O
were O O
usually O O
mild O O
and O O
consisted O O
of O O
erythema O O
, O O
tenderness O O
, O O
skin O O
discoloration O O
, O O
or O O
swelling O O
at O O
the O O
injection O O
site O O
. O O

In O O
patients O O
receiving O O
treatment O O
with O O
SPRYCEL B-brand B-brand
, O O
close O O
monitoring O O
for O O
toxicity O O
and O O
a O O
SPRYCEL B-brand B-brand
dose O O
reduction O O
should O O
be O O
considered O O
if O O
systemic O O
administration O O
of O O
a O O
potent O O
CYP3A4 O O
inhibitor O O
can O O
not O O
be O O
avoided O O
. O O

Additional O O
dose O O
increases O O
should O O
be O O
based O O
on O O
clinical O O
evaluation O O
. O O

The O O
oral O O
bioavailability O O
of O O
enoxacin B-drug B-drug
is O O
reduced O O
by O O
60 O O
% O O
with O O
coadministration O O
of O O
ranitidine B-drug B-drug
. O O

ranitidine* B-drug B-drug
; O O

Antimicrobial O O
activity O O
of O O
GL B-drug_n B-drug_n
( O O
the O O
aqueous O O
extract O O
from O O
the O O
carpophores O O
of O O
Ganoderma O O
lucidum O O
( O O
FR O O
) O O
KARST O O
) O O
was O O
tested O O
in O O
vitro O O
against O O
Gram O O
positive O O
and O O
Gram O O
negative O O
bacteria O O
by O O
serial O O
broth O O
dilution O O
method O O
, O O
and O O
the O O
antimicrobial O O
activity O O
was O O
expressed O O
by O O
minimal O O
inhibitory O O
concentration O O
( O O
MIC O O
) O O
. O O

Ethanol B-drug B-drug
: O O
Clinical O O
evidence O O
has O O
shown O O
that O O
etretinate B-drug B-drug
can O O
be O O
formed O O
with O O
concurrent O O
ingestion O O
of O O
acitretin B-drug B-drug
and O O
ethanol B-drug B-drug
. O O

INTERVENTIONS O O
: O O
Each O O
subject O O
was O O
treated O O
according O O
to O O
the O O
following O O
sequence O O
: O O
baseline O O
; O O

Cyclosporine B-drug B-drug
: O O
Administration O O
of O O
nonsteroial B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
concomitantly O O
with O O
cyclosporine B-drug B-drug
has O O
been O O
associated O O
with O O
an O O
increase O O
in O O
cyclosporine-induced B-drug B-drug
toxicity O O
, O O
possibly O O
due O O
to O O
decreased O O
synthesis O O
of O O
renal O O
prostacyclin O O
. O O

Co-administration O O
of O O
BOTOX B-brand B-brand
and O O
aminoglycosides B-group B-group
or O O
other O O
agents O O
interfering O O
with O O
neuromuscular O O
transmission O O
( O O
e.g. O O
, O O
curare-like B-group B-group
compounds I-group I-group
) O O
should O O
only O O
be O O
performed O O
with O O
caution O O
as O O
the O O
effect O O
of O O
the O O
toxin B-drug O
may O O
be O O
potentiated O O
. O O

In O O
vitro O O
studies O O
have O O
shown O O
no O O
binding O O
displacement O O
between O O
entacapone B-drug B-drug
and O O
other O O
highly O O
bound O O
drugs O O
, O O
such O O
as O O
warfarin B-drug B-drug
, O O
salicylic B-drug B-drug
acid I-drug I-drug
, O O
phenylbutazone B-drug B-drug
, O O
and O O
diazepam B-drug B-drug
. O O

Compromised O O
norepinephrine B-drug B-drug
uptake-1 O O
in O O
functional O O
class O O
IV O O
can O O
not O O
be O O
further O O
increased O O
by O O
cocaine B-drug B-drug
and O O
desipramine B-drug B-drug
. O O

SINCE O O
CHOLESTYRAMINE B-drug B-drug
RESIN B-group B-group
MAY O O
BIND O O
OTHER O O
DRUGS O O
GIVEN O O
CONCURRENTLY O O
, O O
IT O O
IS O O
RECOMMENDED O O
THAT O O
PATIENTS O O
TAKE O O
OTHER O O
DRUGS O O
AT O O
LEAST O O
1 O O
HOUR O O
BEFORE O O
OR O O
4 O O
TO O O
6 O O
HOURS O O
AFTER O O
CHOLESTYRAMINE B-drug B-drug
RESIN B-group B-group
( O O
OR O O
AT O O
AS O O
GREAT O O
AN O O
INTERVAL O O
AS O O
POSSIBLE O O
) O O
TO O O
AVOID O O
IMPEDING O O
THEIR O O
ABSORPTION O O
. O O

Lansoprazole B-drug B-drug
causes O O
a O O
profound O O
and O O
long O O
lasting O O
inhibition O O
of O O
gastric O O
acid O O
secretion O O
; O O

Therefore O O
, O O
it O O
should O O
be O O
recognized O O
that O O
a O O
positive O O
Coombs O O
test O O
could O O
be O O
due O O
to O O
the O O
drug O O
. O O

Maalox B-brand B-brand
* O O
Coadministration O O
of O O
Maalox B-brand B-brand
TC I-brand I-brand
had O O
no O O
effect O O
on O O
nicardipine B-drug B-drug
HCl I-drug I-drug
absorption O O
. O O

Concomitant O O
use O O
of O O
antihistamines B-group B-group
with O O
alcohol B-drug B-drug
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
barbiturates B-group B-group
, O O
or O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
may O O
have O O
an O O
additive O O
effect O O
. O O

Table O O
8 O O

anabolic B-group B-group
steroids I-group I-group
; O O

adjust O O
dosage O O
of O O
antidiabetic B-group B-group
drug I-group I-group
upward O O
if O O
necessary O O
. O O

Carbamazepine B-drug B-drug
( O O
CBZ B-drug B-drug
) O O

Combinations O O
of O O
these O O
drugs O O
have O O
not O O
been O O
studied O O
and O O
coadministration O O
of O O
CRIXIVAN B-brand B-brand
and O O
atazanavir B-drug B-drug
is O O
not O O
recommended O O
. O O

Amphotericin B-drug B-drug
, O O
Foscarnet B-drug B-drug
, O O
and O O
Aminoglycosides B-group B-group
: O O
Drugs O O
such O O
as O O
amphotericin B-drug B-drug
, O O
foscarnet B-drug B-drug
, O O
and O O
aminoglycosides B-group B-group
may O O
increase O O
the O O
risk O O
of O O
developing O O
peripheral O O
neuropathy O O
or O O
other O O
HIVID-associated B-drug B-drug
adverse O O
events O O
by O O
interfering O O
with O O
the O O
renal O O
clearance O O
of O O
zalcitabine B-drug B-drug
( O O
thereby O O
raising O O
systemic O O
exposure O O
) O O
. O O

Antiepileptic B-group B-group
drugs I-group I-group
: O O
Potential O O
interactions O O
between O O
Trileptal B-brand B-brand
and O O
other O O
AEDs B-group B-group
were O O
assessed O O
in O O
clinical O O
studies O O
. O O

Selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
have O O
been O O
reported O O
, O O
rarely O O
, O O
to O O
cause O O
weakness O O
, O O
hyperreflexia O O
, O O
and O O
incoordination O O
when O O
coadministered O O
with O O
5-HT1 B-group B-group
agonists I-group I-group
. O O

Short-term O O
pharmacokinetic O O
studies O O
have O O
demonstrated O O
that O O
concomitant O O
administration O O
of O O
warfarin B-drug B-drug
and O O
Lodine B-brand B-brand
( O O
etodolac B-drug B-drug
capsules O O
and O O
tablets O O
) O O
results O O
in O O
reduced O O
protein O O
binding O O
of O O
warfarin B-drug B-drug
, O O
but O O
there O O
was O O
no O O
change O O
in O O
the O O
clearance O O
of O O
free O O
warfarin B-drug B-drug
. O O

Antihistamines B-group B-group
may O O
enhance O O
the O O
effects O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
barbiturates B-group B-group
, O O
alcohol B-drug B-drug
, O O
and O O
other O O
CNS B-group B-group
depressants I-group I-group
. O O

Skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
, O O
nondepolarizing O O
( O O
e.g. O O
, O O
tubocurarine B-drug B-drug
) O O
: O O
possible O O
increased O O
responsiveness O O
to O O
the O O
muscle B-group B-group
relaxant I-group I-group
. O O

Videx B-brand B-brand
( O O
Didanosine B-drug B-drug
) O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
, O O
or O O
within O O
2 O O
hours O O
of O O
, O O
the O O
administration O O
of O O
norfloxacin B-drug B-drug
, O O
because O O
these O O
products O O
may O O
interfere O O
with O O
absorption O O
resulting O O
in O O
lower O O
serum O O
and O O
urine O O
levels O O
of O O
norfloxacin B-drug B-drug
. O O

If O O
desipramine B-drug B-drug
hydrochloride I-drug I-drug
is O O
to O O
be O O
combined O O
with O O
other O O
psychotropic B-group B-group
agents I-group I-group
such O O
as O O
tranquilizers B-group B-group
or O O
sedative/hypnotics B-group B-group
, O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
the O O
agents O O
employed O O
since O O
the O O
sedative O O
effects O O
of O O
desipramine B-drug B-drug
and O O
benzodiazepines B-group B-group
( O O
e.g. O O
, O O
chlordiazepoxide B-drug B-drug
or O O
diazepam B-drug B-drug
) O O
are O O
additive O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
co-administration O O
of O O
T.A B-group B-group
. I-group O
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

The O O
results O O
from O O
trials O O
using O O
the O O
intravenous O O
prodrug O O
are O O
reported O O
in O O
this O O
section O O
as O O
they O O
relate O O
to O O
the O O
role O O
of O O
valdecoxib B-drug B-drug
in O O
drug O O
interactions O O
. O O

ACE B-group B-group
Inhibitors I-group I-group
and O O
Angiotensin B-group B-group
II I-group I-group
Receptor I-group I-group
Antagonists I-group I-group
( O O
Congestive O O
Heart O O
Failure O O
Post-Myocardial O O
Infarction O O
) O O
- O O
In O O
EPHESUS O O
, O O
3020 O O
( O O
91 O O
% O O
) O O
patients O O
receiving O O
INSPRA B-brand B-brand
25 O O
to O O
50 O O
mg O O
also O O
received O O
ACE B-group B-group
inhibitors I-group I-group
or O O
angiotensin B-group B-group
II I-group I-group
receptor I-group I-group
antagonists I-group I-group
( O O
ACEI/ARB B-group B-group
) O O
. O O

Furosemide B-drug B-drug
may O O
increase O O
the O O
ototoxic O O
potential O O
of O O
aminoglycoside B-group B-group
antibiotics I-group I-group
, O O
especially O O
in O O
the O O
presence O O
of O O
impaired O O
renal O O
function O O
. O O

therefore O O
, O O
coadministration O O
of O O
Aprepitant B-drug B-drug
with O O
drugs O O
that O O
inhibit O O
CYP3A4 O O
activity O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
aprepitant B-drug B-drug
. O O

. O O

Concurrent O O
use O O
of O O
these O O
agents O O
should O O
generally O O
be O O
avoided O O
. O O

Thiazides B-group B-group
: O O
Thiazides B-group B-group
are O O
known O O
to O O
induce O O
hypercalcemia O O
by O O
the O O
reduction O O
of O O
calcium O O
excretion O O
in O O
urine O O
. O O

Drugs O O
that O O
are O O
known O O
to O O
prolong O O
the O O
QTc O O
interval O O
have O O
an O O
increased O O
risk O O
of O O
ventricular O O
arrhythmias O O
. O O

Exposure O O
from O O
the O O
proposed O O
topical O O
dose O O
is O O
about O O
1 O O
% O O
of O O
that O O
from O O
the O O
100 O O
mg O O
oral O O
dose O O
, O O
even O O
when O O
co-administered O O
with O O
TMP/SMX B-drug B-drug
. O O

Morphine B-drug B-drug
: O O
A O O
literature O O
article O O
reported O O
that O O
when O O
a O O
60-mg O O
controlled-release O O
morphine B-drug B-drug
capsule O O
was O O
administered O O
2 O O
hours O O
prior O O
to O O
a O O
600-mg O O
Neurontin B-brand B-brand
capsule O O
( O O
N=12 O O
) O O
, O O
mean O O
gabapentin B-drug B-drug
AUC O O
increased O O
by O O
44 O O
% O O
compared O O
to O O
gabapentin B-drug B-drug
administered O O
without O O
morphine B-drug B-drug
. O O

The O O
clearance O O
of O O
theophylline B-drug B-drug
was O O
decreased O O
approximately O O
3-fold O O
. O O

phenyramidol B-drug_n B-drug
; O O

Auranofin B-drug B-drug
should O O
be O O
avoided O O
by O O
patients O O
with O O
a O O
history O O
of O O
serious O O
reaction O O
to O O
any O O
gold B-group B-group
medication I-group I-group
, O O
including O O
Solganal B-brand B-brand
and O O
Myochrysine B-brand B-brand
. O O

However O O
, O O
on O O
a O O
body O O
surface O O
area O O
basis O O
, O O
this O O
dose O O
was O O
0.5 O O
times O O
maximum O O
recommended O O
human O O
24-hour O O
dose O O
of O O
ribavirin B-drug B-drug
. O O

ANTACID B-group B-group
( O O
Magnesium-Aluminum B-drug B-drug
Hydroxide I-drug I-drug
) O O
: O O
Cerivastatin B-drug B-drug
plasma O O
concentrations O O
were O O
not O O
affected O O
by O O
co-administration O O
of O O
antacid B-group B-group
. O O

Although O O
no O O
interaction O O
between O O
MAO B-group B-group
inhibitors I-group I-group
and O O
Levo-Dromoran B-brand B-brand
has O O
been O O
observed O O
, O O
it O O
is O O
not O O
recommended O O
for O O
use O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Table O O
1 O O
Changes O O
in O O
Desloratadine B-drug B-drug
and O O
3-Hydroxydesloratadine B-drug_n B-drug_n
Pharmacokinetics O O
in O O
Healthy O O
Male O O
and O O
Female O O
Volunteers O O

If O O
it O O
is O O
necessary O O
to O O
continue O O
the O O
diuretic B-group B-group
, O O
initiate O O
therapy O O
with O O
PRINIVIL B-brand B-brand
at O O
a O O
dose O O
of O O
5 O O
mg O O
daily O O
, O O
and O O
provide O O
close O O
medical O O
supervision O O
after O O
the O O
initial O O
dose O O
until O O
blood O O
pressure O O
has O O
stabilized O O
. O O

Diabetics O O
who O O
take O O
EPA B-drug B-drug
supplements O O
should O O
be O O
monitored O O
by O O
their O O
physicians O O
. O O

if O O
plasma O O
levels O O
are O O
being O O
monitored O O
, O O
they O O
should O O
be O O
reassessed O O
. O O

In O O
adjuvant O O
trials O O
of O O
epirubicin-containing B-drug B-drug
CEF-120 O O
or O O
FEC-100 O O
chemotherapies O O
, O O
breast O O
irradiation O O
was O O
delayed O O
until O O
after O O
chemotherapy O O
was O O
completed O O
. O O

Phenytoin B-drug B-drug
is O O
a O O
potent O O
inducer O O
of O O
hepatic O O
drug-metabolizing O O
enzymes O O
. O O

Caution O O
is O O
warranted O O
and O O
clinical O O
monitoring O O
of O O
patients O O
is O O
recommended O O
. O O

In O O
both O O
species O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
, O O
but O O
not O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
, O O
antagonized O O
the O O
rate-decreasing O O
effects O O
of O O
morphine B-drug B-drug
on O O
FI O O
and O O
FR O O
responding O O
. O O

Glibenclamide B-drug B-drug
: O O
In O O
a O O
study O O
of O O
7 O O
healthy O O
male O O
volunteers O O
, O O
acitretin B-drug B-drug
treatment O O
potentiated O O
the O O
blood O O
glucose O O
lowering O O
effect O O
of O O
glibenclamide B-drug B-drug
( O O
a O O
sulfonylurea B-group B-group
similar O O
to O O
chlorpropamide B-drug B-drug
) O O
in O O
3 O O
of O O
the O O
7 O O
subjects O O
. O O

By O O
this O O
procedure O O
, O O
it O O
was O O
observed O O
that O O
arsenate B-drug_n B-drug_n
is O O
rapidly O O
and O O
essentially O O
completely O O
absorbed O O
( O O
80-95 O O
% O O
) O O
from O O
the O O
lumen O O
at O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
concentrations O O
up O O
to O O
5 O O
mM O O
, O O
declining O O
to O O
about O O
50 O O
% O O
absorption O O
at O O
50 O O
mM O O
. O O

There O O
have O O
been O O
reports O O
of O O
QTc O O
prolongation O O
, O O
with O O
or O O
without O O
TdP O O
, O O
in O O
patients O O
taking O O
amiodarone B-drug B-drug
when O O
fluoroquinolones B-drug B-group
, O O
macrolide B-drug B-group
antibiotics I-drug I-group
, O O
or O O
azoles O O
were O O
administered O O
concomitantly O O
. O O

cinchophen B-drug B-drug
; O O

Cholestyramine B-drug B-drug
resin B-group B-group
may O O
interfere O O
with O O
the O O
pharmacokinetics O O
of O O
drugs O O
that O O
undergo O O
enterohepatic O O
circulation O O
, O O
The O O
discontinuance O O
of O O
cholestyramine B-drug B-drug
resin B-group B-group
could O O
pose O O
a O O
hazard O O
to O O
health O O
if O O
a O O
potentially O O
toxic O O
drug O O
such O O
as O O
digitalis B-group B-group
has O O
been O O
filtrated O O
to O O
a O O
maintenance O O
level O O
while O O
the O O
patient O O
was O O
taking O O
cholestyramine B-drug B-drug
resin B-group B-group
. O O

Ibuprofen B-drug B-drug
- O O
L-arginine B-drug B-drug
may O O
increase O O
the O O
absorption O O
of O O
ibuprofen B-drug B-drug
if O O
taken O O
concomitantly O O
. O O

Prednisone/prednisolone B-drug B-drug
: O O
Rofecoxib B-drug B-drug
did O O
not O O
have O O
any O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
prednisolone B-drug B-drug
or O O
prednisone B-drug B-drug
. O O

Therefore O O
smaller O O
ALFENTA B-brand B-brand
doses O O
will O O
be O O
required O O
with O O
prolonged O O
administration O O
and O O
the O O
duration O O
of O O
action O O
of O O
ALFENTA B-brand B-brand
my O O
be O O
extended O O
. O O

Reductions O O
in O O
serum O O
endogenous O O
vitamin O O
D O O
concentrations O O
have O O
been O O
observed O O
following O O
the O O
administration O O
of O O
300 O O
mg/day O O
to O O
1200 O O
mg/day O O
ketoconazole B-drug B-drug
for O O
a O O
week O O
to O O
healthy O O
men O O
. O O

Methadone B-drug B-drug
dose O O
was O O
increased O O
by O O
a O O
mean O O
of O O
22 O O
% O O
to O O
alleviate O O
withdrawal O O
symptoms O O
. O O

. O O

The O O
concomitant O O
use O O
of O O
ENABLEX B-brand B-brand
with O O
other O O
anticholinergic B-group B-group
agents I-group I-group
may O O
increase O O
the O O
frequency O O
and/or O O
severity O O
of O O
dry O O
mouth O O
, O O
constipation O O
, O O
blurred O O
vision O O
and O O
other O O
anticholinergic O O
pharmacological O O
effects O O
. O O

You O O
may O O
require O O
a O O
dosage O O
adjustment O O
or O O
special O O
monitoring O O
if O O
you O O
are O O
taking O O
any O O
of O O
the O O
medicines O O
listed O O
above O O
. O O

Nateglinide B-drug B-drug
is O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
98 O O
% O O
) O O
, O O
mainly O O
albumin O O
. O O

- O O
Lithium B-drug B-drug
: O O
Generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
. O O

Theophylline B-drug B-drug
: O O
As O O
with O O
some O O
other O O
quinolones B-group B-group
, O O
concurrent O O
administration O O
of O O
ciprofloxacin B-drug B-drug
with O O
theophylline B-drug B-drug
may O O
lead O O
to O O
elevated O O
serum O O
concentrations O O
of O O
theophylline B-drug B-drug
and O O
prolongation O O
of O O
its O O
elimination O O
half-life O O
. O O

This O O
problem O O
has O O
been O O
analysed O O
using O O
two O O
different O O
tasks O O
in O O
mice O O
: O O
a O O
bar-press O O
conditioning O O
and O O
a O O
spatial O O
discrimination O O
task O O
. O O

Patients O O
with O O
Hepatic O O
Impairment O O
In O O
vitro O O
and O O
in O O
vivo O O
evidence O O
suggest O O
that O O
erlotinib B-drug B-drug
is O O
cleared O O
primarily O O
by O O
the O O
liver O O
. O O

Of O O
over O O
3500 O O
patients O O
enrolled O O
in O O
the O O
Ibandronate B-drug B-drug
osteoporosis O O
Treatment O O
and O O
Prevention O O
Studies O O
, O O
15 O O
% O O
used O O
anti-peptic O O
agents O O
( O O
primarily O O
H2 B-group B-group
blockers I-group I-group
and O O
PPIs B-group B-group
) O O
. O O

Desloratadine B-drug B-drug
3-Hydroxydesloratadine B-drug_n I-drug

More O O
importantly O O
, O O
we O O
demonstrate O O
that O O
IgA O O
is O O
probably O O
the O O
major O O
serum O O
constituent O O
precipitated O O
by O O
the O O
lectin O O
and O O
that O O
no O O
IgG O O
or O O
IgM O O
can O O
be O O
detected O O
in O O
the O O
precipitates O O
. O O

The O O
effect O O
on O O
other O O
progestational B-group B-group
contraceptives I-group I-group
( O O
eg O O
, O O
implants O O
, O O
injectables O O
) O O
is O O
unknown O O
. O O

These O O
drugs O O
should O O
be O O
coad-ministered O O
with O O
caution O O
and O O
frequent O O
monitoring O O
of O O
serum O O
lithium B-drug B-drug
levels O O
is O O
recommended O O
. O O

dosage O O
adjustment O O
of O O
antigout B-group B-group
medications I-group I-group
may O O
be O O
necessary O O
to O O
control O O
hyperuricemia O O
and O O
gout O O
. O O
) O O

Drug/Laboratory O O
Test O O
Interactions O O
False O O
elevations O O
of O O
urinary O O
catecholamine O O
levels O O
may O O
occur O O
due O O
to O O
interference O O
with O O
the O O
fluorescence O O
test O O
. O O

In O O
these O O
six O O
cases O O
it O O
was O O
demonstrated O O
that O O
the O O
neuroleptics B-group B-group
dosage O O
was O O
inappropriate O O
, O O
being O O
either O O
too O O
high O O
or O O
too O O
low O O
as O O
judged O O
from O O
the O O
plasma O O
concentrations O O
. O O

This O O
may O O
lead O O
to O O
low O O
amiodarone B-drug B-drug
serum O O
levels O O
and O O
potential O O
decrease O O
in O O
efficacy O O
. O O

Vasopressors B-group B-group
: O O
Thyroxine B-drug B-drug
increases O O
the O O
adrenergic O O
effect O O
of O O
catecholamines O B-group
such O O
as O O
epinephrine B-drug B-drug
and O O
norepinephrine B-drug B-drug
. O O

Drugs O O
which O O
may O O
enhance O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
TRACRIUM B-brand B-brand
include O O
: O O
enflurane B-drug B-drug
; O O
isoflurane B-drug B-drug
; O O
halothane B-drug B-drug
; O O
certain O O
antibiotics B-group B-group
, O O
especially O O
the O O
aminoglycosides B-group B-group
and O O
polymyxins B-group B-group
; O O
lithium B-drug B-drug
; O O
magnesium B-drug B-drug
salts O O
; O O
procainamide B-drug B-drug
; O O
and O O
quinidine B-drug B-drug
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
other O O
drugs O O
is O O
withdrawn O O
from O O
co-therapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
may O O
be O O
required O O
. O O

ACE B-group B-group
Inhibitors I-group I-group
: O O
Concomitant O O
use O O
of O O
ACE B-group B-group
inhibitors I-group I-group
may O O
increase O O
the O O
risk O O
of O O
renal O O
impairment O O
, O O
particularly O O
in O O
volume-depleted O O
patients O O
. O O

barbiturates B-group B-group
; O O

b O O
. O O

Paroxetine B-drug B-drug
: O O
Coadministration O O
of O O
a O O
single O O
dose O O
of O O
Sonata B-brand B-brand
20 O O
mg O O
and O O
paroxetine B-drug B-drug
20 O O
mg O O
daily O O
for O O
7 O O
days O O
did O O
not O O
produce O O
any O O
interaction O O
on O O
psychomotor O O
performance O O
. O O

ulcerans O O
was O O
measured O O
by O O
plate O O
counts O O
and O O
the O O
BACTEC O O
radiometric O O
method O O
. O O

The O O
objective O O
of O O
this O O
study O O
was O O
to O O
determine O O
if O O
there O O
is O O
a O O
pharmacokinetic O O
interaction O O
when O O
amprenavir B-drug B-drug
is O O
given O O
with O O
rifabutin B-drug B-drug
or O O
rifampin B-drug B-drug
and O O
to O O
determine O O
the O O
effects O O
of O O
these O O
drugs O O
on O O
the O O
erythromycin O O
breath O O
test O O
( O O
ERMBT O O
) O O
. O O

Stereoselective O O
behavioral O O
effects O O
of O O
N-allylnormetazocine B-drug_n B-drug_n
in O O
pigeons O O
and O O
squirrel O O
monkeys O O
. O O

The O O
effect O O
on O O
CYP1A2 O O
was O O
explored O O
further O O
in O O
a O O
clinical O O
interaction O O
study O O
with O O
theophylline B-drug B-drug
and O O
no O O
effect O O
on O O
metabolism O O
was O O
observed O O
. O O

Nabilone I-drug B-drug
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
who O O
are O O
taking O O
other O O
psychoactive B-group B-group
drugs I-group I-group
or O O
CNS B-group B-group
depressants I-group I-group
, O O
including O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
and O O
narcotic B-group B-group
analgesics I-group I-group
, O O
or O O
to O O
those O O
with O O
a O O
history O O
of O O
psychiatric O O
disorder O O
( O O
including O O
manic-depressive O O
illness O O
and O O
schizophrenia O O
) O O
. O O

Drug-Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
known O O
interactions O O
between O O
CAMPTOSAR B-brand B-brand
and O O
laboratory O O
tests O O
. O O

Administration O O
of O O
lithium B-drug B-drug
prophylaxis O O
. O O

Sedatives/Hypnotics B-group B-group
: O O
triazolam B-drug B-drug
, O O
midazolam B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
prolonged O O
or O O
increased O O
sedation O O
or O O
respiratory O O
depression O O
. O O

Drug O O
Class O O
Examples O O
of O O
Drugs O O

Dosage O O
adjustment O O
of O O
concomitant O O
medications O O
may O O
be O O
necessary O O
. O O

In O O
the O O
current O O
study O O
, O O
the O O
nonpredisposed O O
strain O O
C57BL/6N O O
was O O
also O O
shown O O
to O O
be O O
highly O O
susceptible O O
to O O
diethylnitrosamine O O
during O O
the O O
neonatal O O
period O O
. O O

Phenobarbital B-drug B-drug
( O O
Primidone B-drug B-drug
) O O
: O O
Population O O
pharmacokinetic O O
analyses O O
indicate O O
that O O
tiagabine B-drug B-drug
clearance O O
is O O
60 O O
% O O
greater O O
in O O
patients O O
taking O O
phenobarbital B-drug B-drug
( O O
primidone B-drug B-drug
) O O
with O O
or O O
without O O
other O O
enzyme-inducing O O
AEDs B-group B-group
. O O

BACKGROUND O O
: O O
Since O O
its O O
approval O O
by O O
the O O
US O O
Food O O
and O O
Drug O O
Administration O O
in O O
March O O
1998 O O
, O O
sildenafil B-drug B-drug
citrate I-drug I-drug
has O O
been O O
used O O
by O O
millions O O
of O O
men O O
for O O
the O O
treatment O O
of O O
erectile O O
dysfunction O O
. O O

unreliable O O
prothrombin O O
time O O
determinations O O
; O O

Additional O O
iron B-drug B-drug
significantly O O
inhibited O O
the O O
absorption O O
of O O
cobalt B-drug B-drug
in O O
both O O
dietary O O
cobalt B-drug B-drug
treatments O O
. O O

It O O
is O O
not O O
clear O O
whether O O
this O O
was O O
due O O
to O O
the O O
combination O O
of O O
therapy O O
. O O

increased O O
creatine O O

A O O
number O O
of O O
substances O O
affect O O
glucose O O
metabolism O O
and O O
may O O
require O O
insulin B-drug O
dose O O
adjustment O O
and O O
particularly O O
close O O
monitoring O O
. O O

Beta-adrenergic B-group B-group
receptor I-group I-group
antagonists I-group I-group
( O O
beta-blockers B-group B-group
) O O
and O O
BROVANA B-brand B-brand
may O O
interfere O O
with O O
the O O
effect O O
of O O
each O O
other O O
when O O
administered O O
concurrently O O
. O O

Based O O
on O O
the O O
chemical O O
resemblance O O
of O O
itraconazole B-drug B-drug
and O O
ketoconazole B-drug B-drug
, O O
coadministration O O
of O O
astemizole B-drug B-drug
with O O
itraconazole B-drug B-drug
is O O
contraindicated O O
. O O

Unless O O
really O O
needed O O
, O O
agents O O
which O O
may O O
enhance O O
the O O
risk O O
of O O
hemorrhage O O
should O O
be O O
discontinued O O
prior O O
to O O
initiation O O
of O O
Lovenox B-brand B-brand
Injection O O
therapy O O
. O O

With O O
the O O
morning O O
dose O O
of O O
ceftibuten B-drug B-drug
on O O
day O O
6 O O
, O O
each O O
volunteer O O
received O O
a O O
single O O
intravenous O O
infusion O O
of O O
theophylline B-drug B-drug
( O O
4 O O
mg/kg O O
) O O
. O O

Ways O O
of O O
improving O O
the O O
adequacy O O
of O O
the O O
treatment O O
of O O
psychotic O O
patients O O
with O O
neuroleptics B-group B-group
are O O
discussed O O
. O O

May O O
interact O O
with O O
wthionamide O B-drug
( O O
Trecator-SC B-brand B-brand
) O O
and O O
isoniazid B-drug B-drug
( O O
Nydrazid B-brand B-brand
) O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

Methadone B-drug B-drug
: O O
Coadministration O O
of O O
amprenavir B-drug B-drug
and O O
methadone B-drug B-drug
can O O
decrease O O
plasma O O
levels O O
of O O
methadone B-drug B-drug
. O O

N-methyllevallorphan B-drug_n B-drug_n
( O O
5 O O
mg/kg O O
, O O
s.c O O
. O O
) O O

Studies O O
showed O O
that O O
diltiazem B-drug B-drug
increased O O
the O O
AUC O O
of O O
midazolam B-drug B-drug
and O O
triazolam B-drug B-drug
by O O
3-4 O O
fold O O
and O O
the O O
Cmax O O
by O O
2-fold O O
, O O
compared O O
to O O
placebo O O
. O O

AMEVIVE B-brand B-brand
is O O
not O O
indicated O O
for O O
pediatric O O
patients O O
. O O

If O O
pregnancy O O
occurs O O
in O O
a O O
patient O O
or O O
partner O O
of O O
a O O
patient O O
during O O
treatment O O
or O O
during O O
the O O
6 O O
months O O
after O O
treatment O O
cessation O O
, O O
such O O
cases O O
should O O
be O O
reported O O
to O O
the O O
COPEGUS B-brand B-brand
Pregnancy O O
Registry O O
at O O
1-800-526-6367 O O
. O O

. O O

Steady-state O O
bosentan B-drug B-drug
plasma O O
concentrations O O
were O O
3- O O
to O O
4-fold O O
higher O O
than O O
in O O
the O O
absence O O
of O O
cyclosporine B-drug B-drug
A I-drug O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

Therefore O O
, O O
it O O
should O O
be O O
used O O
in O O
caution O O
in O O
patients O O
receiving O O
such O O
agents O O
. O O

this O O
did O O
not O O
interfere O O
with O O
its O O
effect O O
. O O

Based O O
on O O
the O O
results O O
of O O
these O O
studies O O
, O O
it O O
is O O
concluded O O
that O O
azithromycin B-drug B-drug
may O O
be O O
safely O O
coadministered O O
with O O
both O O
zidovudine B-drug B-drug
and O O
dideoxyinosine B-drug B-drug
. O O

Hypotension O O
- O O
Patients O O
on O O
Diuretic O B-group
Therapy O O
: O O
Patients O O
on O O
diuretics B-group B-group
, O O
and O O
especially O O
those O O
in O O
whom O O
diuretic O B-group
therapy O O
was O O
recently O O
instituted O O
, O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
PRINIVIL B-brand B-brand
. O O

Metformin B-drug B-drug
: O O
In O O
a O O
single-dose O O
interaction O O
study O O
in O O
NIDDM O O
subjects O O
, O O
decreases O O
in O O
glyburide B-drug B-drug
AUC O O
and O O
Cmax O O
were O O
observed O O
, O O
but O O
were O O
highly O O
variable O O
. O O

. O O

The O O
bioavailability O O
of O O
the O O
capsule O O
formulation O O
of O O
cefprozil B-drug B-drug
was O O
not O O
affected O O
when O O
administered O O
5 O O
minutes O O
following O O
an O O
antacid B-group B-group
. O O

Therefore O O
, O O
when O O
using O O
these O O
blocking O B-group
agents O I-group
to O O
treat O O
hypertension O O
, O O
patients O O
should O O
be O O
observed O O
carefully O O
in O O
order O O
to O O
confirm O O
that O O
the O O
desired O O
therapeutic O O
effect O O
has O O
been O O
obtained O O
. O O

This O O
interaction O O
was O O
not O O
accompanied O O
by O O
ECG O O
changes O O
and O O
its O O
clinical O O
significance O O
is O O
not O O
known O O
. O O

Veratrum B-group B-group
alkaloids I-group I-group
: O O
Amphetamines B-group B-group
inhibit O O
the O O
hypotensive O O
effect O O
of O O
veratrum B-group B-group
alkaloids I-group I-group
. O O

aBased O O
on O O
reports O O
of O O
narcotic O B-group
withdrawal O O
syndrome O O
in O O
patients O O
treated O O
with O O
nevirapine B-drug B-drug
and O O
methadone B-drug B-drug
concurrently O O
, O O
and O O
evidence O O
of O O
decreased O O
plasma O O
concentrations O O
of O O
methadone B-drug B-drug
. O O

The O O
administration O O
of O O
naproxen B-drug B-drug
may O O
result O O
in O O
increased O O
urinary O O
values O O
for O O
17-ketogenic O O
steroids O O
because O O
of O O
an O O
interaction O O
between O O
the O O
drug O O
and/or O O
its O O
metabolites O O
with O O
m-dinitrobenzene O B-drug_n
used O O
in O O
this O O
assay O O
. O O

these O O
enzymes O O
would O O
therefore O O
not O O
be O O
expected O O
to O O
be O O
inhibited O O
in O O
clinical O O
use O O
. O O

The O O
reduced O O
risk O O
of O O
adverse O O
events O O
and O O
therapeutic O O
superiority O O
compared O O
with O O
haloperidol B-drug B-drug
and O O
risperidone B-drug B-drug
in O O
the O O
treatment O O
of O O
negative O O
and O O
depressive O O
symptoms O O
support O O
the O O
choice O O
of O O
olanzapine B-drug B-drug
as O O
a O O
first-line O O
option O O
in O O
the O O
management O O
of O O
schizophrenia O O
in O O
the O O
acute O O
phase O O
and O O
for O O
the O O
maintenance O O
of O O
treatment O O
response O O
. O O

In O O
a O O
study O O
of O O
12 O O
schizophrenic O O
patients O O
coadministered O O
oral O O
haloperidol B-drug B-drug
and O O
rifampin B-drug B-drug
, O O
plasma O O
haloperidol B-drug B-drug
levels O O
were O O
decreased O O
by O O
a O O
mean O O
of O O
70 O O
% O O
and O O
mean O O
scores O O
on O O
the O O
Brief O O
Psychiatric O O
Rating O O
Scale O O
were O O
increased O O
from O O
baseline O O
. O O

Co-administration O O
with O O
antifungal B-group B-group
agents I-group I-group
such O O
as O O
ketoconazole B-drug B-drug
or O O
itraconazole B-drug B-drug
is O O
not O O
recommended O O
. O O

Leucovorin B-drug B-drug
may O O
enhance O O
the O O
toxicity O O
of O O
5-fluorouracil B-drug O
. O O

Laboratory O O
Tests O O
Pregnancy O O
Test O O
Female O O
patients O O
of O O
childbearing O O
potential O O
must O O
have O O
negative O O
results O O
from O O
2 O O
urine O O
or O O
serum O O
pregnancy O O
tests O O
with O O
a O O
sensitivity O O
of O O
at O O
least O O
25 O O
mIU/mL O O
before O O
receiving O O
the O O
initial O O
Accutane B-brand B-brand
prescription O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

Mineral B-drug O
oil I-drug O
interferes O O
with O O
the O O
absorption O O
of O O
fat-soluble B-group B-group
vitamins I-group I-group
, O O
including O O
vitamin B-group B-group
D I-group I-group
preparations I-group I-group
. O O

Digoxin B-drug B-drug
half-life O O
of O O
elimination O O
was O O
prolonged O O
from O O
34 O O
+/- O O
13 O O
to O O
40 O O
+/- O O
16 O O
hours O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
. O O

Therefore O O
, O O
based O O
on O O
these O O
in O O
vitro O O
data O O
, O O
estazolam B-drug B-drug
is O O
very O O
unlikely O O
to O O
inhibit O O
the O O
biotransformation O O
of O O
other O O
drugs O O
metabolized O O
by O O
these O O
CYP O O
isoforms O O

The O O
biochemical O O
toxicology O O
of O O
1,3-difluoroacetone B-drug_n B-drug_n
, O O
a O O
known O O
metabolite O O
of O O
the O O
major O O
ingredient O O
of O O
the O O
pesticide O O
Gliftor B-drug_n B-brand
( O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
) O O
, O O
was O O
investigated O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

No O O
pharmacokinetic O O
interaction O O
was O O
identified O O
. O O

Alprazolam B-drug B-drug
: O O
When O O
fluvoxamine B-drug B-drug
maleate I-drug I-drug
( O O
100 O O
mg O O
qd O O
) O O
and O O
alprazolam B-drug B-drug
( O O
1 O O
mg O O
q.d O O
. O O
were O O
co-administered O O
to O O
steady O O
state O O
, O O
plasma O O
concentration O O
and O O
other O O
pharmacokinetics O O
parameters O O
( O O
AUC O O
, O O
Cmax O O
, O O
T1/2 O O
, O O
) O O
of O O
alprazolam B-drug B-drug
were O O
approximately O O
twice O O
those O O
observed O O
when O O
alprazolam B-drug B-drug
was O O
administered O O
alone O O
; O O

Drug/Laboratory O O
Test O O
Interactions O O
No O O
clinically O O
significant O O
changes O O
in O O
the O O
results O O
of O O
clinical O O
laboratory O O
tests O O
have O O
been O O
observed O O

Certain O O
drugs O O
tend O O
to O O
produce O O
hyperglycemia O O
and O O
may O O
lead O O
to O O
loss O O
of O O
blood O O
glucose O O
control O O
. O O

These O O
compounds O O
are O O
metabolized O O
through O O
various O O
cytochrome O O
P450 O O
isozymes O O
including O O
CYP1A2 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
and O O
CYP3A O O
. O O

Efavirenz B-drug B-drug

The O O
pharmacokinetics O O
of O O
fenofibric B-drug_n B-drug
acid I-drug_n I-drug
were O O
not O O
significantly O O
affected O O
by O O
atorvastatin B-drug B-drug

Acebutolol B-drug B-drug
, O O
atenolol B-drug B-drug
, O O
and O O
nadolol B-drug B-drug
( O O
low O O
hepatic O O
clearance O O
or O O
no O O
first-pass O O
metabolism O O
) O O
are O O
unlikely O O
to O O
be O O
affected O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

Drugs O O
Demonstrated O O
to O O
be O O
CYP O O
3A O O
Inhibitors O O
of O O
Possible O O
Clinical O O
Significance O O
on O O
the O O
Basis O O
of O O
Clinical O O
Studies O O
Involving O O
Alprazolam B-drug B-drug
( O O
caution O O
is O O
recommended O O
during O O
coadministration O O
with O O
alprazolam B-drug B-drug
) O O
: O O
Coadministration O O
of O O
fluoxetine B-drug B-drug
with O O
alprazolam B-drug B-drug
increased O O
the O O
maximum O O
plasma O O
concentration O O
of O O
alprazolam B-drug B-drug
by O O
46 O O
% O O
, O O
decreased O O
clearance O O
by O O
21 O O
% O O
, O O
increased O O
half-life O O
by O O
17 O O
% O O
, O O
and O O
decreased O O
measured O O
psychomotor O O
performance O O
. O O

The O O
serum O O
androgen O O
concentrations O O
of O O
estradiol B-drug B-drug
+ O O
endotoxin-treated B-drug_n O
rats O O
did O O
not O O
change O O
significantly O O
, O O
while O O
those O O
of O O
endotoxin-treated B-drug_n O
rats O O
dropped O O
to O O
30-40 O O
% O O

The O O
mechanism O O
for O O
this O O
interaction O O
is O O
unknown O O
. O O

Sucralfate B-drug B-drug
should O O
not O O
be O O
taken O O
within O O
2 O O
hours O O
of O O
FACTIVE B-brand B-brand
. O O

Diltiazem B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
verapamil B-drug B-drug

In O O
contrast O O
, O O
atropine B-drug B-drug
increased O O
the O O
amplitudes O O
of O O
components O O
P1 O O
and O O
P2 O O
, O O
while O O
decreasing O O
components O O
N1 O O
, O O
N2 O O
and O O
N3 O O
for O O
varying O O
durations O O
of O O
time O O
. O O

Clindamycin B-drug B-drug
has O O
been O O
shown O O
to O O
have O O
neuromuscular O O
blocking O O
properties O O
that O O
may O O
enhance O O
the O O
action O O
of O O
other O O
neuromuscular B-group B-group
blocking I-group I-group
agents I-group I-group
. O O

No O O
drug O O
interactions O O
of O O
clinical O O
importance O O
have O O
been O O
identified O O
. O O

Prior O O
administration O O
of O O
succinylcholine B-drug B-drug
has O O
no O O
clinically O O
important O O
effect O O
on O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
NUROMAX B-brand B-brand
. O O

Imipramine B-drug B-drug
hydrochloride I-drug I-drug
may O O
potentiate O O
the O O
effects O O
of O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
. O O

SUSTIVA B-brand B-brand
has O O
the O O
potential O O
to O O
decrease O O
plasma O O
concentrations O O
of O O
itraconazole B-drug B-drug
and O O
ketoconazole B-drug B-drug
. O O

Since O O
symptoms O O
of O O
anticholinesterase O O
overdose O O
( O O
cholinergic O O
crisis O O
) O O
may O O
mimic O O
underdosage O O
( O O
myasthenic O O
weakness O O
) O O
, O O
their O O
condition O O
may O O
be O O
worsened O O
by O O
the O O
use O O
of O O
this O O
drug O O
. O O

Since O O
the O O
effect O O
of O O
AMEVIVE B-brand B-brand
on O O
pregnancy O O
and O O
fetal O O
development O O
, O O
including O O
immune O O
system O O
development O O
, O O
is O O
not O O
known O O
, O O
health O O
care O O
providers O O
are O O
encouraged O O
to O O
enroll O O
patients O O
currently O O
taking O O
AMEVIVE B-brand B-brand
who O O
become O O
pregnant O O
into O O
the O O
Biogen O B-brand
Pregnancy O O
Registry O O
by O O
calling O O
1-866-AMEVIVE B-brand O
( O O
1-866-263-8483 O O
) O O
. O O

Myocardial O O
injury O O
, O O
including O O
myocardial O O
infarction O O
, O O
myocarditis O O
, O O
ventricular O O
hypokinesia O O
, O O
and O O
severe O O
rhabdomyolysis O O
appear O O
to O O
be O O
increased O O
in O O
patients O O
receiving O O
PROLEUKIN B-brand B-brand
and O O
interferon-alfa B-drug B-drug
concurrently O O
. O O

In O O
comparison O O
to O O
saline O O
values O O
, O O
all O O
three O O
agents O O
produced O O
reliable O O
increases O O
in O O
peak O O
latency O O
for O O
most O O
of O O
the O O
components O O
, O O
with O O
only O O
N3 O O
showing O O
no O O
effects O O
. O O

Understanding O O
the O O
breadth O O
of O O
systemic O O
antimicrobial B-group B-group
agents I-group I-group
available O O
for O O
use O O
by O O
the O O
dermatologist O O
and O O
their O O
associated O O
side-effect O O
profiles O O
and O O
drug O O
interactions O O
allows O O
the O O
clinician O O
to O O
offer O O
patients O O
optimal O O
care O O
in O O
the O O
management O O
of O O
cutaneous O O
infectious O O
disease O O
. O O

Studies O O
in O O
humans O O
show O O
that O O
the O O
absorption O O
of O O
chlorothiazide B-drug B-drug
as O O
reflected O O
in O O
urinary O O
excretion O O
is O O
markedly O O
decreased O O
even O O
when O O
administered O O
one O O
hour O O
before O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
. O O

Anticoagulants B-group B-group
( O O
Oral O O
) O O
: O O
The O O
hypoprothrombinemic O O
effect O O
of O O
anticoagulants B-group B-group
may O O
be O O
potentiated O O
, O O
apparently O O
by O O
increased O O
catabloism O O
of O O
vitamin O O
K-dependent O O
clotting O O
factors O O
. O O

Boric B-drug B-drug
acid I-drug I-drug
may O O
interact O O
with O O
the O O
idoxuridine B-drug B-drug
preparation O O
causing O O
a O O
gritty O O
substance O O
to O O
form O O
or O O
may O O
interact O O
with O O
the O O
preservative O O
in O O
the O O
idoxuridine B-drug B-drug
preparation O O
causing O O
a O O
toxic O O
effect O O
in O O
the O O
eye O O
. O O

Although O O
inhibition O O
of O O
CYP O O
3A4/5 O O
by O O
OXC B-drug B-drug_n
and O O
MHD B-drug_n B-drug_n
did O O
occur O O
at O O
high O O
concentrations O O
, O O
it O O
is O O
not O O
likely O O
to O O
be O O
of O O
clinical O O
significance O O
. O O

The O O
dosage O O
of O O
these O O
drugs O O
or O O
others O O
with O O
a O O
similar O O
metabolism O O
may O O
need O O
to O O
be O O
modified O O
if O O
they O O
are O O
administered O O
concomitantly O O
with O O
nilutamide B-drug B-drug
. O O

Lastly O O
local O O
use O O
of O O
the O O
mucocutaneous O O
and O O
cytoprotective O O
properties O O
of O O
magnesium B-drug B-drug
is O O
still O O
valid O O
, O O
in O O
cardioplegic B-drug O
solutions I-drug O
and O O
for O O
preservation O O
of O O
transplants O O
particularly O O
. O O

Furosemide B-drug B-drug
may O O
decrease O O
arterial O O
responsiveness O O
to O O
norepinephrine B-drug B-drug
. O O

efavirenz I-drug B-drug
concentration O O

In O O
a O O
Phase O O
I O O
trial O O
using O O
escalating O O
doses O O
of O O
TAXOL B-brand B-brand
( O O
110-200 O O
mg/m2 O O
) O O
and O O
cisplatin B-drug B-drug
( O O
50 O O
or O O
75 O O
mg/m2 O O
) O O
given O O
as O O
sequential O O
infusions O O
, O O
myelosuppression O O
was O O
more O O
profound O O
when O O
TAXOL B-brand B-brand
was O O
given O O
after O O
cisplatin B-drug B-drug
than O O
with O O
the O O
alternate O O
sequence O O
( O O
ie O O
, O O
TAXOL B-brand B-brand
before O O
cisplatin B-drug B-drug
) O O
. O O

-adrenergic O B-group
Blockers O I-group
: O O
-adrenergic O B-group
blockers O I-group
may O O
weaken O O
or O O
antagonise O O
the O O
effect O O
of O O
FORADIL B-brand B-brand
. O O

The O O
key O O
to O O
maximizing O O
therapy O O
lies O O
in O O
individualizing O O
it O O
as O O
much O O
as O O
possible O O
. O O

In O O
clinical O O
studies O O
with O O
PROPECIA B-brand B-brand
( O O
finasteride B-drug B-drug
, O O
1 O O
mg O O
) O O
in O O
men O O
18-41 O O
years O O
of O O
age O O
, O O
the O O
mean O O
value O O
of O O
serum O O
prostate-specific O O
antigen O O
( O O
PSA O O
) O O
decreased O O
from O O
0.7 O O
ng/mL O O
at O O
baseline O O
to O O
0.5 O O
ng/mL O O
at O O
Month O O
12 O O
. O O

The O O
patient O O
had O O
been O O
receiving O O
simvastatin B-drug B-drug
for O O
approximately O O
six O O
months O O
. O O

Ergot-containing B-group O
drugs O O
have O O
been O O
reported O O
to O O
cause O O
prolonged O O
vasospastic O O
reactions O O
. O O

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
lasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

The O O
concomitant O O
use O O
of O O
alcohol B-drug B-drug
or O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
may O O
have O O
an O O
additive O O
effect O O
. O O

Antiarrhythmics B-drug B-group
: O O
Other O O
antiarrhythmic B-drug B-group
drugs O I-group
, O O
such O O
as O O
quinidine B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
and O O
phenytoin B-drug B-drug
, O O
have O O
been O O
used O O
concurrently O O
with O O
amiodarone B-drug B-drug
. O O

However O O
, O O
because O O
nafarelin B-drug B-drug
acetate I-drug I-drug
is O O
a O O
peptide O O
that O O
is O O
primarily O O
degraded O O
by O O
peptidase O O
and O O
not O O
by O O
cytochrome O O
P-450 O O
enzymes O O
, O O
and O O
the O O
drug O O
is O O
only O O
about O O
80 O O
% O O
bound O O
to O O
plasma O O
proteins O O
at O O
4 O O
C O O
, O O
drug O O
interactions O O
would O O
not O O
be O O
expected O O
to O O
occur O O
. O O

However O O
, O O
since O O
there O O
is O O
an O O
increased O O
risk O O
of O O
bleeding O O
with O O
Xigris B-brand B-brand
, O O
caution O O
should O O
be O O
employed O O
when O O
Xigris B-brand B-brand
is O O
used O O
with O O
other O O
drugs O O
that O O
affect O O
hemostasis O O
. O O

In O O
addition O O
, O O
new O O
cases O O
of O O
diabetes O O
have O O
been O O
diagnosed O O
during O O
retinoid B-group O
therapy O O
, O O
including O O
diabetic O O
ketoacidosis O O
. O O

On O O
the O O
contrary O O
, O O
neurotensin B-drug_n B-drug_n
and O O
tuftsin B-drug_n O
were O O
agonists O O
in O O
induction O O
of O O
analgesia O O
. O O

A O O
chemically O O
similar O O
drug O O
in O O
this O O
class O O
produced O O
optic O O
nerve O O
degeneration O O
( O O
Wallerian O O
degeneration O O
of O O
retinogeniculate O B-drug
fibers O O
) O O
in O O
clinically O O
normal O O
dogs O O
in O O
a O O
dose-dependent O O
fashion O O
at O O
a O O
dose O O
that O O
produced O O
plasma O O
drug O O
levels O O
about O O
30 O O
times O O
higher O O
than O O
the O O
mean O O
drug O O
level O O
in O O
humans O O
taking O O
the O O
highest O O
recommended O O
dose O O
. O O

- O O
Furazolidone B-drug B-drug
( O O
e.g. O O
, O O
Furoxone B-brand B-brand
) O O
or O O

Concomitant O O
administration O O
of O O
diltiazem B-drug B-drug
with O O
carbamazepine B-drug B-drug
has O O
been O O
reported O O
to O O
result O O
in O O
elevated O O
serum O O
levels O O
of O O
carbamazepine B-drug B-drug
( O O
40 O O
% O O
to O O
72 O O
% O O
increase O O
) O O
, O O
resulting O O
in O O
toxicity O O
in O O
some O O
cases O O
. O O

In O O
single O O
and O O
multiple O O
dose O O
studies O O
in O O
healthy O O
subjects O O
receiving O O
both O O
warfarin B-drug B-drug
and O O
rofecoxib B-drug B-drug
, O O
prothrombin O O
time O O
( O O
measured O O
as O O
INR O O
) O O
was O O
increased O O
by O O
approximately O O
8 O O
% O O
to O O
11 O O
% O O
. O O

Pharmacokinetic O O
studies O O
indicate O O
that O O
administration O O
of O O
disulfiram B-drug B-drug
or O O
diazepam B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
acamprosate B-drug B-drug
. O O

Therefore O O
, O O
agents O O
affecting O O
sympathetic O O
activity O O
( O O
e.g. O O
, O O
ganglionic B-group B-group
blocking I-group I-group
agents I-group I-group
or O O
adrenergic B-group B-group
neuron I-group I-group
blocking I-group I-group
agents I-group I-group
) O O
should O O
be O O
used O O
with O O
caution O O
. O O

Reports O O
in O O
the O O
literature O O
suggest O O
that O O
plasma O O
levels O O
of O O
doxorubicin B-drug B-drug
( O O
and O O
its O O
active O O
metabolite O O
doxorubicinol B-drug_n B-drug
) O O
may O O
be O O
increased O O
when O O
paclitaxel B-drug B-drug
and O O
doxorubicin B-drug B-drug
are O O
used O O
in O O
combination O O
. O O

The O O
concomitant O O
use O O
of O O
H2 B-group B-group
blockers I-group I-group
or O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
with O O
SPRYCEL B-brand B-brand
is O O
not O O
recommended O O
. O O

The O O
results O O
indicate O O
that O O
a O O
statistically O O
significant O O
difference O O
exists O O
between O O
the O O
excreted O O
levels O O
of O O
homocysteine O O
in O O
the O O
urine O O
of O O
both O O
control O O
and O O
levonorgestrel-treated B-drug O
rats O O
and O O
the O O
levels O O
shown O O
by O O
rats O O
treated O O
with O O
ethynyl B-drug B-drug
estradiol I-drug I-drug
. O O

The O O
IV O O
methylprednisolone B-drug B-drug
dose O O
should O O
be O O
reduced O O
by O O
approximately O O
25 O O
% O O
, O O
and O O
the O O
oral O O
methylprednisolone B-drug B-drug
dose O O
should O O
be O O
reduced O O
by O O
approximately O O
50 O O
% O O
when O O
coadministered O O
with O O
Aprepitant B-drug B-drug
to O O
achieve O O
exposures O O
of O O
methylprednisolone B-drug B-drug
similar O O
to O O
those O O
obtained O O
when O O
it O O
is O O
given O O
without O O
Aprepitant B-drug B-drug
. O O

Simultaneous O O
use O O
of O O
activated B-group O
prothrombin I-group O
complex I-group O
concentrates I-group O
or O O
prothrombin B-group O
complex I-group O
concentrates I-group O
should O O
be O O
avoided O O
. O O

Digoxin B-drug B-drug
did O O
not O O
affect O O
BREVIBLOC B-brand B-brand
pharmacokinetics O O
. O O

Urinary B-drug O
acidifying I-drug O
agents O O
decrease O O
blood O O
levels O O
and O O
increase O O
excretion O O
of O O
amphetamines B-group B-group
. O O

Antibiotics B-group B-group
( O O
ampicillin B-drug B-drug
, O O
tetracycline B-drug B-drug
) O O
: O O
Pregnancy O O
has O O
been O O
reported O O
following O O
concomitant O O
use O O
, O O
however O O
, O O
pharmacokinetic O O
studies O O
have O O
not O O
shown O O
consistent O O
effects O O
with O O
these O O
antibiotics B-group B-group
on O O
plasma O O
concentrations O O
of O O
synthetic B-group B-group
steroids I-group I-group
. O O

The O O
second O O
pregnancy O O
test O O
( O O
a O O
confirmation O O
test O O
) O O
should O O
be O O
done O O
during O O
the O O
first O O
5 O O
days O O
of O O
the O O
menstrual O O
period O O
immediately O O
preceding O O
the O O
beginning O O
of O O
Accutane B-brand B-brand
therapy O O
. O O

However O O
, O O
total O O
mucosal O O
accumulation O O
of O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n O
and O O
that O O
transferred O O
to O O
the O O
body O O
increase O O
in O O
a O O
linear O O
logarithmic O O
fashion O O
from O O
0.05 O O
to O O
5 O O
mm O O
As B-drug_n O
( I-drug_n B-drug_n
V I-drug_n I-drug_n
) I-drug_n O
. O O

Information O O
on O O
concurrent O O
usage O O
of O O
atenolol B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
limited O O
. O O

In O O
order O O
to O O
avoid O O
the O O
occurrence O O
of O O
severe O O
hypersensitivity O O
reactions O O
, O O
all O O
patients O O
treated O O
with O O
TAXOL B-brand B-brand
should O O
be O O
premedicated O O
with O O
corticosteroids B-group B-group
( O O
such O O
as O O
dexamethasone B-drug B-drug
) O O
, O O
diphen-hydramine O B-drug
and O O
H2 B-group B-group
antagonists I-group I-group
( O O
such O O
as O O
cimetidine B-drug B-drug
or O O
ranitidine B-drug B-drug
) O O
. O O

Patients O O
in O O
a O O
clinical O O
study O O
who O O
were O O
on O O
established O O
therapy O O
with O O
sulfasalazine B-drug B-drug
, O O
to O O
which O O
ENBREL B-brand B-brand
was O O
added O O
, O O
were O O
noted O O
to O O
develop O O
a O O
mild O O
decrease O O
in O O
mean O O
neutrophil O O
counts O O
in O O
comparison O O
to O O
groups O O
treated O O
with O O
either O O
ENBREL B-brand B-brand
CI O O
or O O
sulfasalazine B-drug B-drug
alone O O
. O O

It O O
is O O
concluded O O
from O O
these O O
results O O
that O O
the O O
modulatory O O
effect O O
of O O
glycine B-drug B-drug
is O O
evidently O O
a O O
later O O
developmental O O
acquisition O O
( O O
after O O
day O O
15 O O
of O O
incubation O O
) O O
in O O
the O O
embryogenesis O O
of O O
NMDA-ergic O O
activation O O
of O O
spontaneous O O
motility O O
in O O
chick O O
embryos O O
similarly O O
as O O
glycinergic O O
inhibition O O
. O O

If O O
TRANXENE B-brand B-brand
is O O
to O O
be O O
combined O O
with O O
other O O
drugs O O
acting O O
on O O
the O O
central O O
nervous O O
system O O
, O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
the O O
agents O O
to O O
be O O
employed O O
. O O

Plasma O O
concentrations O O
of O O
cyclosporine B-drug B-drug
should O O
therefore O O
be O O
closely O O
monitored O O
, O O
and O O
its O O
dosage O O
reduced O O
accordingly O O
, O O
in O O
patients O O
treated O O
with O O
nicardipine B-drug B-drug
. O O

Excessive O O
ethanol B-drug B-drug
ingestion O O
should O O
be O O
avoided O O
because O O
a O O
psychotic O O
reaction O O
has O O
been O O
reported O O
. O O

There O O
is O O
thus O O
an O O
enhancement O O
effect O O
of O O
PGF2alpha B-drug B-drug
upon O O
the O O
reaction O O
of O O
placental O O
vessels O O
to O O
oxytocin B-drug B-drug
in O O
vitro O O
. O O

Azithromycin B-drug B-drug

or O O
- O O
over-the-counter O O
cough O O
, O O
cold O O
, O O
allergy O O
, O O
or O O
weight O O
loss O O
medications O O
. O O

DESIGN O O
: O O
Open-label O O
, O O
three-phase O O
, O O
sequential O O
study O O
. O O

Adenosine B-drug O
effects O O
are O O
potentiated O O
by O O
dipyridamole B-drug B-drug
. O O

Aerosol O O
particles O O
of O O
budesonide B-drug B-drug
were O O
generated O O
from O O
an O O
ethanol B-drug B-drug
solution O O
, O O
dried O O
, O O
and O O
collected O O
by O O
a O O
cascade O O
impactor O O
for O O
characterization O O
or O O
by O O
a O O
liquid O O
impinger O O
for O O
dissolution O O
experiments O O
. O O

Colestipol B-drug B-drug

STUDY O O
OBJECTIVE O O
: O O
To O O
evaluate O O
the O O
effect O O
of O O
fluoxetine B-drug B-drug
on O O
the O O
pharmacokinetics O O
and O O
cardiovascular O O
safety O O
of O O
cisapride B-drug B-drug
at O O
steady O O
state O O
in O O
healthy O O
men O O
. O O

However O O
, O O
current O O
evidence O O
suggests O O
that O O
isoniazid B-drug B-drug
does O O
induce O O
P-450IIE1 O O
, O O
a O O
mixed-function O O
oxidase O O
enzyme O O
that O O
appears O O
to O O
generate O O
the O O
toxic O O
metabolites O O
, O O
in O O
the O O
liver O O
. O O

Nelfinavir B-drug B-drug
is O O
an O O
inhibitor O O
of O O
CYP3A O O
( O O
cytochrome O O
P450 O O
3A O O
) O O
. O O

The O O
vasodilating O O
effects O O
of O O
nitroglycerin B-drug B-drug
may O O
be O O
additive O O
with O O
those O O
of O O
other O O
vasodilators B-group B-group
. O O

The O O
hatching O O
of O O
miracidia O O
from O O
eggs O O
was O O
inhibited O O
by O O
concentrations O O
of O O
1000-10000 O O
microg/l O O
of O O
single O O
metals O O
. O O

Phenytoin B-drug B-drug
decreases O O
serum O O
amiodarone O B-drug
levels O O
. O O

The O O
effect O O
of O O
orally O O
ingested O O
peginterferon B-drug B-drug
or O O
ribavirin B-drug B-drug
from O O
breast O O
milk O O
on O O
the O O
nursing O O
infant O O
has O O
not O O
been O O
evaluated O O
. O O

Vardenafil B-drug B-drug
dose O O
should O O
not O O
exceed O O
a O O
maximum O O
of O O
2.5 O O
mg O O
in O O
a O O
24-hour O O
period O O
in O O
patients O O
receiving O O
concomitant O O
indinavir B-drug B-drug
therapy O O
. O O

therefore O O
, O O
caution O O
should O O
be O O
used O O
when O O
administering O O
CYP3A4 O O
inhibitors O O
with O O
IRESSA B-brand B-brand
. O O

Therefore O O
, O O
the O O
simultaneous O O
administration O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

Non-selective B-group B-group
MAO I-group I-group
inhibitors I-group I-group
including O O
tranylcypromine B-drug B-drug
sulfate I-drug I-drug
, O O
phenelzine B-drug B-drug
sulfate I-drug I-drug
, O O
and O O
pargyline B-drug B-drug
HC1 O O
: O O
Concomitant O O
use O O
of O O
L-tyrosine B-drug B-drug
and O O
non-selective O B-group
MAO B-group I-group
inhibitors I-group I-group
may O O
cause O O
hypertension O O
. O O

Acetaminophen B-drug B-drug
had O O
no O O
effect O O
on O O
plasma O O
levels O O
of O O
diflunisal B-drug B-drug
. O O

However O O
, O O
in O O
patients O O
treated O O
with O O
oral O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitors I-group I-group
, O O
rare O O
instances O O
of O O
drug O O
interactions O O
have O O
occurred O O
with O O
high-dose O O
salicylate B-drug B-group
therapy O O
. O O

Immunosuppressive B-group B-group
Drugs I-group I-group
, O O
Fibric B-group B-group
Acid I-group I-group
Derivatives I-group I-group
, O O
Niacin B-drug B-drug
( O O
Nicotinic B-drug B-drug
Acid I-drug I-drug
, O O
Erythromycin B-drug B-drug
, O O
Azole B-group B-group
Antifungals I-group I-group
: O O
Skeletal O O
Muscle O O
. O O

Further O O
, O O
these O O
results O O
confirm O O
that O O
the O O
diabetic O O
Chinese O O
hamster O O
's O O
alpha O B-drug
and O O
beta O O
cells O O
respond O O
normally O O
to O O
theophylline B-drug B-drug
, O O
but O O
are O O
relatively O O
insensitive O O
to O O
glucose B-drug O
. O O

Patients O O
treated O O
with O O
acebutolol B-drug B-drug
plus O O
catecholamine B-group O
depletors I-group O
should O O
, O O
therefore O O
, O O
be O O
observed O O
closely O O
for O O
evidence O O
of O O
marked O O
bradycardia O O
or O O
hypotension O O
which O O
may O O
present O O
as O O
vertigo O O
, O O
syncope/presyncope O O
, O O
or O O
orthostatic O O
changes O O
in O O
blood O O
pressure O O
without O O
compensatory O O
tachycardia O O
. O O

Thus O O
, O O
the O O
hypothesis O O
of O O
Gibaldi O B-brand
et O O
al O O
. O O

This O O
has O O
been O O
observed O O
with O O
CLINITEST O O
reagent O O
tablets O O

For O O
patients O O
with O O
amenorrhea O O
, O O
the O O
second O O
test O O
should O O
be O O
done O O
at O O
least O O
11 O O
days O O
after O O
the O O
last O O
act O O
of O O
unprotected O O
sexual O O
intercourse O O
( O O
without O O
using O O
2 O O
effective O O
forms O O
of O O
contraception O O
) O O
. O O

No O O
interactions O O
have O O
been O O
observed O O
with O O
beta-receptor B-group B-group
blockers I-group I-group
, O O
calcium B-group B-group
antagonists I-group I-group
, O O
thiazide O B-group
and O O
loop B-group B-group
diuretics I-group I-group
and O O
ACE B-group B-group
inhibitors I-group I-group
. O O

These O O
experiences O O
have O O
been O O
characterized O O
by O O
flushing O O
, O O
rash O O
, O O
peripheral O O
edema O O
, O O
nausea O O
, O O
and O O
headache O O
. O O

Modification O O
of O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
with O O
diethyl B-drug_n B-drug
pyrocarbonate I-drug_n I-drug
abolished O O
both O O
its O O
cytotoxic O O
activity O O
and O O
the O O
ability O O
of O O
the O O
toxin O O
to O O
bind O O
Zn-Sepharose O O
gel O O
. O O

Flurbiprofen B-drug B-drug
pretreatment O O
attenuated O O
the O O
hypotensive O O
effect O O
of O O
a O O
single O O
dose O O
of O O
propranolol B-drug B-drug
but O O
not O O
atenolol B-drug B-drug
. O O

Conclusions O O
and O O
the O O
types O O
of O O
studies O O
which O O
support O O
these O O
conclusions O O
are O O
given O O
for O O
each O O
major O O
section O O
. O O

Thiazide B-group B-group
Diuretics I-group I-group
: O O
The O O
reports O O
that O O
the O O
concomitant O O
use O O
of O O
allopurinol B-drug B-drug
and O O
thiazide B-group B-group
diuretics I-group I-group
may O O
contribute O O
to O O
the O O
enhancement O O
of O O
allopurinol B-drug B-drug
toxicity O O
in O O
some O O
patients O O
have O O
been O O
reviewed O O
in O O
an O O
attempt O O
to O O
establish O O
a O O
cause-and-effect O O
relationship O O
and O O
a O O
mechanism O O
of O O
causation O O
. O O

Concurrent O O
administration O O
of O O
vasopressor B-group B-group
drugs I-group I-group
( O O
for O O
the O O
treatment O O
of O O
hypotension O O
related O O
to O O
obstetric O O
blocks O O
) O O
and O O
ergot-type B-group B-group
oxytocic I-group I-group
drugs I-group I-group
may O O
cause O O
severe O O
, O O
persistent O O
hypertension O O
or O O
cerebrovascular O O
accidents O O
. O O

For O O
example O O
, O O
when O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
are O O
administered O O
concomitantly O O
with O O
nilutamide B-drug B-drug
, O O
prothrombin O O
time O O
should O O
be O O
carefully O O
monitored O O
and O O
if O O
necessary O O
, O O
the O O
dosage O O
of O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
should O O
be O O
reduced O O
. O O

Theophylline B-drug B-drug
: O O
Grepafloxacin B-drug B-drug
is O O
a O O
competitive O O
inhibitor O O
of O O
the O O
metabolism O O
of O O
theophylline B-drug B-drug
. O O

However O O
, O O
the O O
absolute O O
number O O
of O O
alcohol-related B-drug O
deaths O O
is O O
far O O
greater O O
than O O
the O O
number O O
of O O
deaths O O
in O O
amphetamine B-drug B-drug
or O O
heroin B-drug_n B-drug
users O O
. O O

Phenytoin/Phenobarbital B-drug O
: O O
The O O
coadministration O O
of O O
phenytoin B-drug B-drug
or O O
phenobarbital B-drug B-drug
will O O
not O O
affect O O
plasma O O
concentrations O O
of O O
vitamin B-group B-group
D I-group I-group
, O O
but O O
may O O
reduce O O
endogenous O O
plasma O O
levels O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
by O O
accelerating O O
metabolism O O
. O O

In O O
the O O
presence O O
of O O
these O O
methylxanthines B-group B-group
, O O
larger O O
doses O O
of O O
adenosine B-drug B-drug
may O O
be O O
required O O
or O O
adenosine B-drug B-drug
may O O
not O O
be O O
effective O O
. O O

Gastrointestinal O O
: O O
Nausea O O
( O O
4-12 O O
% O O
) O O
, O O
constipation O O
( O O
2-6 O O
% O O
) O O
; O O

If O O
a O O
diuretic B-group B-group
is O O
also O O
used O O
, O O
the O O
risk O O
of O O
lithium O B-drug
toxicity O O
may O O
be O O
increased O O
. O O

The O O
administration O O
of O O
epinephrine B-drug B-drug
should O O
be O O
avoided O O
in O O
the O O
treatment O O
of O O
drug O O
induced O O
hypotension O O
because O O
of O O
a O O
possible O O
reverse O O
epinephrine B-drug O
effect O O
. O O

The O O
blood O O
pressure O O
( O O
carotid O O
cannulation O O
) O O
decreased O O
along O O
with O O
the O O
core O O
temperature O O
. O O

The O O
decrease O O
in O O
temperature O O
began O O
within O O
20 O O
minutes O O
after O O
ethanol B-drug B-drug
administration O O
, O O
reaching O O
a O O
maximal O O
decrease O O
between O O
60 O O
and O O
120 O O
minutes O O
post O O
ethanol B-drug B-drug
. O O

Aripiprazole B-drug B-drug
dose O O
should O O
be O O
reduced O O
to O O
one-half O O
of O O
its O O
normal O O
dose O O
when O O
concomitant O O
administration O O
of O O
quinidine B-drug B-drug
with O O
aripiprazole B-drug B-drug
occurs O O
. O O

Dose O O
adjustment O O
is O O
not O O
recommended.Levetiracetam B-drug O
had O O
no O O
effect O O
on O O
plasma O O
concentrations O O
of O O
carbamazepine B-drug B-drug
, O O
valproate B-drug B-drug
, O O
topiramate B-drug B-drug
, O O
or O O
lamotrigine B-drug B-drug
. O O

Peripheral O O
mononuclear O O
cells O O
were O O
also O O
collected O O
for O O
quantitation O O
of O O
phosphorylated O O
zidovudine B-drug B-drug
. O O

Dose O O
adjustments O O
of O O
either O O
class O O
of O O
agents O O
may O O
be O O
necessary O O
. O O

In O O
the O O
present O O
study O O
, O O
it O O
is O O
proposed O O
that O O
the O O
opioids B-group B-group
applied O O
to O O
supraspinal O O
brain O O
sites O O
produced O O
their O O
analgesic O O
effects O O
by O O
the O O
activation O O
of O O
different O O
descending O O
pain O O
inhibitory O O
systems O O
. O O

Warfarin B-drug B-drug
: O O
The O O
effect O O
of O O
valdecoxib B-drug B-drug
on O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-drug B-drug
( O O
1 O O
- O O
8 O O
mg/day O O
) O O
was O O
studied O O
in O O
healthy O O
subjects O O
by O O
coadministration O O
of O O
BEXTRA B-brand B-brand
40 O O
mg O O
BID O O
for O O
7 O O
days O O
. O O

While O O
mean O O
INR O O
values O O
were O O
only O O
slightly O O
increased O O
with O O
coadministration O O
of O O
valdecoxib B-drug B-drug
, O O
the O O
day-to-day O O
variability O O
in O O
individual O O
INR O O
values O O
was O O
increased O O
. O O

The O O
preservation O O
of O O
the O O
microtubules O O
was O O
improved O O
when O O
D2O O O
was O O
present O O
in O O
the O O
incubation O O
medium O O
. O O

With O O
simultaneous O O
dosing O O
of O O
Vardenafil B-drug B-drug
10 O O
mg O O
and O O
terazosin B-drug B-drug
10 O O
mg O O
, O O
6 O O
of O O
8 O O
subjects O O
experienced O O
a O O
standing O O
systolic O O
blood O O
pressure O O
of O O
less O O
than O O
85 O O
mm O O
Hg O O
. O O

Lithium B-drug B-drug
: O O
Inhibition O O
of O O
renal O O
lithium B-drug B-drug
clearance O O
, O O
leading O O
to O O
an O O
increase O O
in O O
plasma O O
lithium B-drug B-drug
concentration O O
, O O
has O O
been O O
reported O O
with O O
some O O
prostaglandin O B-group
synthesis-inhibiting O I-group
drugs O I-group
. O O

Drugs O O
that O O
reduce O O
the O O
number O O
of O O
blood O O
platelets O O
by O O
causing O O
bone O O
marrow O O
depression O O
( O O
such O O
as O O
antineoplastic B-group B-group
agents I-group I-group
) O O
or O O
drugs O O
which O O
inhibit O O
platelet O O
function O O
( O O
eg O O
, O O
aspirin B-brand B-brand
and O O
other O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
dipyridamole B-drug B-drug
, O O
hydrochloroquine B-drug B-drug
, O O
clofibrate B-drug B-drug
, O O
dextran B-drug B-drug
) O O
may O O
increase O O
the O O
bleeding O O
tendency O O
produced O O
by O O
anticoagulants B-group B-group
without O O
altering O O
prothrombin O O
time O O
determinations O O
. O O

Monitoring O O
for O O
amiodarone B-drug B-drug
toxicity O O
and O O
serial O O
measurement O O
of O O
amiodarone B-drug B-drug
serum O O
concentration O O
during O O
concomitant O O
protease B-group B-group
inhibitor I-group I-group
therapy O O
should O O
be O O
considered O O
. O O

Interactions O O
with O O
Fruit O O
Juices O O
Fruit O O
juices O O
such O O
as O O
grapefruit O O
, O O
orange O O
and O O
apple O O
may O O
reduce O O
the O O
bioavailability O O
and O O
exposure O O
of O O
fexofenadine B-drug B-drug
. O O

The O O
effects O O
of O O
oral O O
neomycin B-drug B-drug
on O O
ACTH B-group B-drug
induced O O
hypertension O O
were O O
examined O O
in O O
conscious O O
sheep O O
. O O

Cardiovascular O O
disease O O
is O O
a O O
common O O
comorbidity O O
and O O
a O O
major O O
cause O O
of O O
mortality O O
in O O
patients O O
with O O
chronic O O
renal O O
disease O O
. O O

Patients O O
taking O O
warfarin B-drug B-drug
or O O
other O O
coumarin-derivative B-group B-group
anticoagulants I-group I-group
should O O
be O O
monitored O O
regularly O O
for O O
changes O O
in O O
prothrombin O O
time O O
or O O
INR O O

Risk O O
of O O
Anaphylactic O O
Reaction O O
: O O
Although O O
it O O
is O O
known O O
that O O
patients O O
on O O
beta-blockers B-group B-group
may O O
be O O
refractory O O
to O O
epinephrine B-drug B-drug
in O O
the O O
treatment O O
of O O
anaphylactic O O
shock O O
, O O
beta-blockers B-group B-group
can O O
, O O
in O O
addition O O
, O O
interfere O O
with O O
the O O
modulation O O
of O O
allergic O O
reaction O O
and O O
lead O O
to O O
an O O
increased O O
severity O O
and/or O O
frequency O O
of O O
attacks O O
. O O

- O O
Increased O O
thyroid-binding O O
globulin O O
( O O
TBG O O
) O O
leading O O
to O O
in-creased O O
circulating O O
total O O
thyroid O O
hormone O O
; O O

Serum O O
digoxin B-drug B-drug
levels O O
using O O
an O O
125I-labelled O O
antigen O O
: O O
Validation O O
of O O
method O O
and O O
observations O O
on O O
cardiac O O
patients O O
. O O

There O O
are O O
no O O
known O O
drug O O
interactions O O
with O O
LEUSTATIN B-brand B-brand
Injection O O
. O O

This O O
cluster O O
of O O
metabolic O O
abnormalities O O
has O O
been O O
termed O O
the O O
insulin O O
resistance O O
or O O
cardiovascular O O
dysmetabolic O O
syndrome O O
. O O

Deferasirox B-drug B-drug
should O O
be O O
taken O O
on O O
an O O
empty O O
stomach O O
30 O O
minutes O O
before O O
eating O O
. O O

As O O
DIFFERIN B-brand B-brand
Gel O O
has O O
the O O
potential O O
to O O
produce O O
local O O
irritation O O
in O O
some O O
patients O O
, O O
concomitant O O
use O O
of O O
other O O
potentially O O
irritating O O
topical O O
products O O
( O O
medicated O O
or O O
abrasive O O
soaps O O
and O O
cleansers O O
, O O
soaps O O
and O O
cosmetics O O
that O O
have O O
a O O
strong O O
drying O O
effect O O
, O O
and O O
products O O
with O O
high O O
concentrations O O
of O O
alcohol O B-drug
, O O
astringents O B-group
, O O
spices O O
or O O
lime O O
) O O
should O O
be O O
approached O O
with O O
caution O O
. O O

To O O
investigate O O
the O O
effects O O
of O O
antimicrobial O O
combinations O O
of O O
GL B-drug_n B-drug_n
with O O
four O O
kinds O O
of O O
antibiotics B-group B-group
( O O
ampicillin B-drug B-drug
, O O
cefazolin B-drug B-drug
, O O
oxytetracycline B-drug B-drug
and O O
chloramphenicol B-drug B-drug
) O O
, O O
the O O
fractional O O
inhibitory O O
concentration O O
index O O
( O O
FICI O O
) O O
was O O
determined O O
by O O
checkerboard O O
assay O O
for O O
each O O
strain O O
. O O

Effect O O
of O O
Clonazepam B-drug B-drug
on O O
the O O
Pharmacokinetics O O
of O O
Other O O
Drugs O O
: O O
Clonazepam B-drug B-drug
does O O
not O O
appear O O
to O O
alter O O
the O O
pharmacokinetics O O
of O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
or O O
phenobarbital B-drug B-drug
. O O

Excystment O O
in O O
vitro O O
was O O
only O O
significantly O O
affected O O
by O O
cercariae O O
exposed O O
to O O
cadmium/zinc O O
mixtures O O
whilst O O
encysting O O
. O O

Hypokalemia O O
may O O
increase O O
susceptibility O O
to O O
cardiac O O
arrhythmias O O
in O O
patients O O
treated O O
with O O
digitalis B-group B-group
. O O

Lamivudine B-drug B-drug
: O O
In O O
vitro O O
studies O O
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
, O O
U937 O O
and O O
Molt-4 O O
cells O O
revealed O O
that O O
lamivudine B-drug B-drug
significantly O O
inhibited O O
zalcitabine B-drug B-drug
phosphorylation O O
in O O
a O O
dose O O
dependent O O
manner O O
. O O

Therefore O O
, O O
precaution O O
should O O
be O O
taken O O
when O O
coadministration O O
is O O
necessary O O
. O O

as O O
judged O O
by O O
increased O O
serum O O
enzyme O O
activities O O
and O O
increased O O
incidence O O
of O O
hepatic O O
necrosis O O
. O O

Caution O O
should O O
be O O
exercised O O
if O O
an O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitor I-group I-group
is O O
administered O O
concomitantly O O
with O O
drugs O O
that O O
may O O
decrease O O
the O O
levels O O
or O O
activity O O
of O O
endogenous O B-group
steroid O I-group
hormones O I-group
, O O
such O O
as O O
ketoconazole B-drug B-drug
, O O
spironolactone B-drug B-drug
, O O
and O O
cimetidine B-drug B-drug
. O O

Inhibitors O O
of O O
CYP2D6 O O
: O O
Because O O
CYP2D6 O O
is O O
involved O O
in O O
duloxetine B-drug B-drug
metabolism O O
, O O
concomitant O O
use O O
of O O
duloxetine B-drug B-drug
with O O
potent O O
inhibitors O O
of O O
CYP2D6 O O
may O O
result O O
in O O
higher O O
concentrations O O
of O O
duloxetine B-drug B-drug
. O O

Ketoconazole B-drug B-drug
: O O
Co-administration O O
of O O
200 O O
mg O O
twice-daily O O
ketoconazole B-drug B-drug
with O O
aliskiren B-drug B-drug
resulted O O
in O O
an O O
approximate O O
80 O O
% O O
increase O O
in O O
plasma O O
levels O O
of O O
aliskiren B-drug B-drug
. O O

The O O
pharmacokinetic O O
variables O O
for O O
digoxin B-drug B-drug
were O O
determined O O
after O O
a O O
1.0 O O
mg O O
intravenous O O
dose O O
of O O
digoxin B-drug B-drug
in O O
each O O
subject O O
, O O
before O O
and O O
after O O
oral O O
amiodarone B-drug B-drug
, O O
400 O O
mg O O
daily O O
for O O
3 O O
weeks O O
. O O

Drugs O O
That O O
Interfere O O
With O O
Hemostasis O O
( O O
NSAIDs B-group B-group
, O O
Aspirin B-brand B-brand
, O O
Warfarin B-drug B-drug
, O O
etc O O
. O O
) O O

Rat O O
kidney O O
homogenates O O
supplemented O O
with O O
coenzyme O O
A O O
, O O
ATP O O
, O O
oxaloacetate O B-drug
, O O
and O O
Mg2+ O O
converted O O
1,3-difluoroacetone B-drug_n B-drug_n
to O I-drug_n
( B-drug_n I-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
in O O
vitro O O
. O O

mefenamic B-drug B-drug
acid I-drug I-drug
; O O

Genitourinary O O
: O O
Urinary O O
frequency O O
( O O
2-6 O O
% O O
) O O
; O O

Human O O
pharmacokinetics O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-drug B-drug
potently O O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
resulting O O
in O O
a O O
mean O O
eight-fold O O
increase O O
in O O
AUC O O
of O O
cisapride B-drug B-drug
. O O

Ketoconazole B-drug B-drug
at O O
400 O O
mg O O
daily O O
( O O
the O O
maximum O O
approved O O
prescription O O
dose O O
) O O
co-administered O O
with O O
TIKOSYN B-brand B-brand
( O O
500 O O
mcg O O
BID O O
) O O
for O O
7 O O
days O O
has O O
been O O
shown O O
to O O
increase O O
dofetilide B-drug B-drug
Cmax O O
by O O
53 O O
% O O
in O O
males O O
and O O
97 O O
% O O
in O O
females O O
, O O
and O O
AUC O O
by O O
41 O O
% O O
in O O
males O O
and O O
69 O O
% O O
in O O
females O O
. O O

Any O O
agent O O
that O O
alters O O
thyroid O O
hormone O O
synthesis O O
, O O
secretion O O
, O O
distribution O O
, O O
effect O O
on O O
target O O
tissues O O
, O O
metabolism O O
, O O
or O O
elimination O O
may O O
alter O O
the O O
optimal O O
therapeutic O O
dose O O
of O O
levothyroxine B-drug B-drug
sodium O I-drug
. O O

Cysteine B-drug B-drug
conjugation O O
at O O
3.6 O O
, O O
5.3 O O
and O O
7.3 O O
% O O
( O O
m/m O O
) O O
resulted O O
in O O
R-values O O
of O O
1.4 O O
, O O
1.7 O O
and O O
1.8 O O
, O O
respectively O O
. O O

Monoamine B-group B-group
Oxidase I-group I-group
Inhibitors I-group I-group
: O O
Coadministration O O
of O O
moclobemide B-drug B-drug
resulted O O
in O O
a O O
27 O O
% O O
decrease O O
in O O
almotriptan B-drug B-drug
clearance O O
and O O
an O O
increase O O
in O O
Cmax O O
of O O
approximately O O
6 O O
% O O
. O O

GI O O
Motility O O
Agent O O
: O O
cisapride* B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
cardiac O O
arrhythmias O O
. O O

However O O
, O O
increasing O O
use O O
of O O
such O O
preparations O O
to O O
control O O
symptoms O O
indicates O O
deterioration O O
of O O
asthma O O
control O O
and O O
the O O
need O O
to O O
reassess O O
the O O
patient O O
s O O
therapy O O
. O O

Concomitant O O
administration O O
of O O
FACTIVE B-brand B-brand
and O O
calcium B-drug B-drug
carbonate I-drug I-drug
, O O
cimetidine B-drug B-drug
, O O
omeprazole B-drug B-drug
, O O
or O O
an O O
estrogen/progesterone B-group B-drug
oral O O
contraceptive B-group B-group
produced O O
minor O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
gemifloxacin B-drug B-drug
, O O
which O O
were O O
considered O O
to O O
be O O
without O O
clinical O O
significance O O
. O O

Interaction O O
with O O
Food O O
See O O
CLINICAL O O
PHARMACOLOGY O O
, O O
Pharmacokinetics O O
and O O
Metabolism O O
. O O

5-HT3 B-group B-group
antagonists I-group I-group
: O O
In O O
clinical O O
drug O O
interaction O O
studies O O
, O O
aprepitant B-drug B-drug
did O O
not O O
have O O
clinically O O
important O O
effects O O
on O O
the O O
pharmacokinetics O O
of O O
ondansetron B-drug B-drug
or O O
granisetron B-drug B-drug
. O O

Use O O
lowest O O
possible O O
dose O O
of O O
atorvastatin B-drug B-drug
with O O
careful O O
monitoring O O
, O O
or O O
consider O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
that O O
are O O
not O O
primarily O O
metabolized O O
by O O
CYP3A4 O O
, O O
such O O
as O O
pravastatin B-drug B-drug
, O O
fluvastatin B-drug B-drug
, O O
or O O
rosuvastatin B-drug B-drug
in O O
combination O O
with O O
CRIXIVAN B-brand B-brand
. O O

Patients O O
who O O
have O O
been O O
treated O O
with O O
MAO B-group B-group
inhibitors I-group I-group
within O O
two O O
to O O
three O O
weeks O O
prior O O
to O O
the O O
administration O O
of O O
dopamine B-drug B-drug
HCl I-drug I-drug
should O O
receive O O
initial O O
doses O O
of O O
dopamine B-drug B-drug
HCl I-drug I-drug
no O O
greater O O
than O O
one-tenth O O
( O O
1/10 O O
) O O
of O O
the O O
usual O O
dose O O
. O O

There O O
is O O
considerable O O
evidence O O
suggesting O O
that O O
histaminergic O O
and O O
serotoninergic O O
central O O
pathways O O
are O O
involved O O
in O O
nociception O O
and O O
that O O
antihistaminic B-group B-group
drugs O I-group
can O O
modulate O O
their O O
responses O O
( O O
1 O O
) O O
. O O

Glyburide B-drug B-drug
: O O
Glyburide B-drug B-drug
is O O
a O O
CYP O O
2C9 O O
substrate O O
. O O

The O O
concomitant O O
use O O
of O O
nitrofurantoin B-drug B-drug
is O O
not O O
recommended O O
since O O
nitrofurantoin B-drug B-drug
may O O
antagonize O O
the O O
antibacterial O O
effect O O
of O O
Norfloxacin B-drug B-drug
in O O
the O O
urinary O O
tract O O
. O O

Use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

The O O
hypotensive O O
effect O O
of O O
sodium B-drug B-drug
nitroprusside I-drug I-drug
is O O
augmented O O
by O O
that O O
of O O
most O O
other O O
hypotensive B-group O
drugs I-group O
, O O
including O O
ganglionic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
negative O O
inotropic O B-group
agents O I-group
, O O
and O O
inhaled O O
anesthetics B-group B-group
. O O

GABITRIL B-brand B-brand
is O O
considered O O
to O O
be O O
a O O
non-enzyme O O
inducing O O
AED B-group B-group
. O O

The O O
following O O
drugs O O
have O O
been O O
coadministered O O
with O O
Kerlone B-brand B-brand
and O O
have O O
not O O
altered O O
its O O
pharmacokinetics O O
: O O
cimetidine B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
chlorthalidone B-drug B-drug
, O O
and O O
hydrochlorothiazide B-drug B-drug
. O O

AUCss O O
( O O
0-12h O O
) O O
( O O
Extent O O
of O O
systemic O O
exposure O O
) O O

Although O O
concomitant O O
use O O
of O O
Clozapine B-drug B-drug
and O O
carbamazepine B-drug B-drug
is O O
not O O
recommended O O
, O O
it O O
should O O
be O O
noted O O
that O O
discontinuation O O
of O O
concomitant O O
carbamazepine B-drug B-drug
administration O O
may O O
result O O
in O O
an O O
increase O O
in O O
Clozapine B-drug B-drug
plasma O O
levels O O
. O O

Sildenafil B-drug B-drug

Therefore O O
, O O
coagulation O O
indices O O
should O O
be O O
monitored O O
to O O
maintain O O
the O O
desired O O
anticoagulant O O
effect O O
. O O

Data O O
from O O
studies O O
to O O
date O O
show O O
that O O
disease O O
states O O
, O O
underlying O O
conditions O O
, O O
and O O
concomitantly O O
administered O O
highly O O
protein-bound O O
drugs O O
have O O
essentially O O
no O O
effect O O
on O O
etodolac B-drug B-drug
pharmacokinetics O O
. O O

Warfarin B-drug B-drug
: O O
Increased O O
INR O O
( O O
International O O
Normalized O O
Ratio O O
) O O
when O O
ARAVA B-brand B-brand
and O O
warfarin B-drug B-drug
were O O
co-administered O O
has O O
been O O
rarely O O
reported O O
. O O

The O O
mechanism O O
for O O
this O O
interaction O O
probably O O
is O O
adsorption O O
of O O
nitrofurantoin B-drug B-drug
onto O O
the O O
surface O O
of O O
magnesium B-drug B-drug
trisilicate I-drug I-drug
. O O

An O O
oral O O
glucose B-drug O
overload O O
of O O
1 O O
ml O O
of O O
a O O
50 O O
% O O
glucose B-drug O
solution O O
was O O
given O O
to O O
rats O O
and O O
blood O O
glucose O O
was O O
determined O O
after O O
30 O O
, O O
60 O O
and O O
90 O O
min O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
imipramine B-drug B-drug
hydrochloride I-drug I-drug
is O O
used O O
with O O
agents O O
that O O
lower O O
blood O O
pressure O O
. O O

Rifampin B-drug B-drug

There O O
is O O
the O O
possibility O O
of O O
precipitating O B-group
anticonvulsant O I-group
drug O I-group
toxicity O O
. O O

Because O O
of O O
possible O O
additive O O
effects O O
with O O
other O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitors I-group I-group
, O O
concomitant O O
use O O
is O O
not O O
advisable O O
. O O

certain O O
tetracyclic B-group B-group
antidepressants I-group I-group
( O O
such O O
as O O
maprotiline B-drug B-drug
) O O
; O O

Nonsteroidal B-drug B-group
Antiinflammatory I-drug I-group
Agents O I-group
: O O
Aspirin B-drug B-brand
is O O
contraindicated O O
in O O
patients O O
who O O
are O O
hypersensitive O O
to O O
nonsteroidal B-drug B-group
anti-inflammatory I-drug I-group
agents O I-group
. O O

There O O
are O O
no O O
data O O
that O O
conclusively O O
establish O O
whether O O
the O O
concomitant O O
administration O O
of O O
Mefloquineuine O O
and O O
the O O
above O O
listed O O
agents O O
has O O
an O O
effect O O
on O O
cardiac O O
function O O
. O O

especially O O
if O O
these O O
patients O O
are O O
extensive O O
metabolizers O O
. O O

These O O
drugs O O
include O O
the O O
thiazides B-group B-group
and O O
other O O
diuretics B-group B-group
, O O
corticosteroids B-group B-group
, O O
phenothiazines B-group B-group
, O O
thyroid B-group B-group
products I-group I-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
, O O
phenytoin B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
, O O
sympathomimetics B-group B-group
, O O
calcium B-group B-group
channel-blocking I-group I-group
drugs I-group I-group
, O O
and O O
isoniazid B-drug B-drug
. O O

Thus O O
, O O
concentrations O O
which O O
have O O
been O O
obtained O O
in O O
vivo O O
clinically O O
in O O
patients O O
with O O
normal O O
renal O O
function O O
are O O
considerably O O
lower O O
than O O
the O O
in O O
vitro O O
concentrations O O
found O O
to O O
induce O O
abnormalities O O
in O O
platelet O O
function O O
tests O O
. O O

In O O
psoriatic O O
arthritis O O
clinical O O
trials O O
, O O
concomitant O O
medications O O
included O O
MTX B-drug B-drug
in O O
approximately O O
half O O
of O O
the O O
patients O O
as O O
well O O
as O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
, O O
folic B-drug B-drug
acid I-drug I-drug
and O O
corticosteroids B-group B-group
. O O

Coadministration O O
with O O
valdecoxib B-drug B-drug
increased O O
exposure O O
of O O
omeprazole B-drug B-drug
( O O
AUC O O
) O O
by O O
46 O O
% O O
. O O

Coadministration O O
in O O
HIV-infected O O
individuals O O
with O O
a O O
history O O
of O O
injection O O
drug O O
use O O
resulted O O
in O O
decreased O O
plasma O O
levels O O
of O O
methadone B-drug B-drug
and O O
signs O O
of O O
opiate B-group B-group
withdrawal O O
. O O

Saquinavir B-drug B-drug

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

Dose O O
reduction O O
of O O
CRIXIVAN B-brand B-brand
to O O
600 O O
mg O O
every O O
8 O O
hours O O
is O O
recommended O O
when O O
administering O O
itraconazole B-drug B-drug
concurrently O O
. O O

Carbamazepine B-drug B-drug
: O O
Felbatol B-brand B-brand
causes O O
a O O
decrease O O
in O O
the O O
steady-state O O
carbamazepine B-drug B-drug
plasma O O
concentrations O O
and O O
an O O
increase O O
in O O
the O O
steady-state O O
carbamazepine B-drug_n B-drug
epoxide I-drug_n O
plasma O O
concentration O O
. O O

Glucose O B-drug
: O O
Some O O
patients O O
receiving O O
Accutane B-brand B-brand
have O O
experienced O O
problems O O
in O O
the O O
control O O
of O O
their O O
blood O O
sugar O O
. O O

Products O O
containing O O
calcium B-drug B-drug
and O O
other O O
multivalent O O
cations O O
( O O
such O O
as O O
aluminum B-drug B-drug
, O O
magnesium B-drug B-drug
, O O
iron B-drug B-drug
) O O
are O O
likely O O
to O O
interfere O O
with O O
absorption O O
of O O
Ibandronate B-drug B-drug
. O O

Antacids B-group B-group
: O O
The O O
concomitant O O
administration O O
of O O
antacids B-group B-group
has O O
no O O
apparent O O
effect O O
on O O
the O O
extent O O
of O O
absorption O O
of O O
Lodine B-brand B-brand
. O O

INDOCIN B-brand B-brand
and O O
triamterene B-drug B-drug
should O O
not O O
be O O
administered O O
together O O
. O O

However O O
, O O
hydrocortisone B-drug B-drug
pretreatment O O
did O O
not O O
affect O O
any O O
of O O
the O O
physiological O O
, O O
behavioral O O
, O O
or O O
subjective O O
effects O O
of O O
d-amphetamine B-drug B-drug
. O O

Depending O O
on O O
the O O
fraction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8-fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA O B-group
) O O
. O O

The O O
resulting O O
increase O O
in O O
nitrofurantoin B-drug B-drug
serum O O
levels O O
may O O
increase O O
toxicity O O
, O O
and O O
the O O
decreased O O
urinary O O
levels O O
could O O
lessen O O
its O O
efficacy O O
as O O
a O O
urinary O O
tract O O
antibacterial B-group B-group
. O O

In O O
pigeons O O
, O O
naloxone B-drug B-drug
did O O
not O O
systematically O O
alter O O
the O O
effects O O
of O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
, O I-drug_n
( B-drug_n I-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
or O O
PCP B-drug_n B-drug_n
. O O

A O O
group O O
of O O
patients O O
who O O
had O O
had O O
a O O
new O O
acute O O
episode O O
despite O O
seemingly O O
adequate O O
treatment O O
were O O
selected O O
. O O

Hypotension O O
was O O
more O O
likely O O
to O O
occur O O
if O O
the O O
calcium B-group B-group
antagonist I-group I-group
were O O
a O O
dihydropyridine B-group O
derivative I-group O
, O O
e.g. O O
, O O
nifedipine B-drug B-drug
, O O
while O O
left O O
ventricular O O
failure O O
and O O
AV O O
conduction O O
disturbances O O
, O O
including O O
complete O O
heart O O
block O O
, O O
were O O
more O O
likely O O
to O O
occur O O
with O O
either O O
verapamil B-drug B-drug
or O O
diltiazem B-drug B-drug
. O O

In O O
the O O
warfarin B-drug B-drug
study O O
, O O
vardenafil B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
prothrombin O O
time O O
or O O
other O O
pharmacodynamic O O
parameters O O
. O O

In O O
a O O
chronic O O
toxicity O O
study O O
, O O
cynomolgus O O
monkeys O O
were O O
dosed O O
weekly O O
for O O
52 O O
weeks O O
with O O
intravenous O O
alefacept B-drug B-drug
at O O
1 O O
mg/kg/dose O O
or O O
20 O O
mg/kg/dose O O
. O O

However O O
, O O
serious O O
opportunistic O O
infections O O
have O O
not O O
been O O
observed O O
, O O
and O O
no O O
complications O O
have O O
specifically O O
been O O
attributed O O
to O O
lymphocytopenia O O
. O O

Adenosine O B-drug
3':5'-cyclic O I-drug
phosphate O I-drug
in O O
turn O O
controls O O
levels O O
of O O
free O O
calcium O O
ions O O
in O O
platelets O O
and O O
regulates O O
calcium-dependent O O
reactions O O
. O O

Accordingly O O
, O O
renal O O
function O O
should O O
be O O
closely O O
monitored O O
in O O
these O O
patients O O
and O O
, O O
in O O
the O O
event O O
of O O
relevant O O
significant O O
changes O O
in O O
laboratory O O
parameters O O
, O O
bezafibrate B-drug B-drug
should O O
, O O
if O O
necessary O O
, O O
be O O
discontinued O O

Aspirin B-brand B-brand
: O O
In O O
normal O O
volunteers O O
, O O
a O O
small O O
decrease O O
in O O
diflunisal B-drug B-drug
levels O O
was O O
observed O O
when O O
multiple O O
doses O O
of O O
diflunisal B-drug B-drug
and O O
aspirin B-brand B-brand
were O O
administered O O
concomitantly O O
. O O

Clonazepam B-drug B-drug
would O O
be O O
useful O O
in O O
cases O O
with O O
potential O O
risk O O
of O O
hypoglycemia O O
. O O

6 O O
. O O

In O O
vitro O O
metabolism O O
studies O O
have O O
demonstrated O O
that O O
tizoxanide B-drug B-drug
has O O
no O O
significant O O
inhibitory O O
effect O O
on O O
cytochrome O O
P450 O O
enzymes O O
. O O

This O O
may O O
indicate O O
that O O
ibuprofen B-drug B-drug
could O O
enhance O O
the O O
toxicity O O
of O O
methotrexate B-drug B-drug
. O O

FLEXERIL B-brand B-brand
may O O
have O O
life-threatening O O
interactions O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

acanthus O O
. O O

0.001 O O
. O O

In O O
an O O
in O O
vitro O O
study O O
, O O
cytochrome O O
P450 O O
isozymes O O
1A2 O O
, O O
2A6 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
2E1 O O
, O O
and O O
3A4 O O
were O O
not O O
inhibited O O
by O O
exposure O O
to O O
cevimeline B-drug B-drug
. O O

ZEBETA B-brand B-brand
should O O
not O O
be O O
combined O O
with O O
other O O
beta-blocking B-group B-group
agents I-group I-group
. O O

The O O
safety O O
and O O
efficacy O O
of O O
PROLEUKIN B-brand B-brand
in O O
combination O O
with O O
any O O
antineoplastic B-group B-group
agents I-group I-group
have O O
not O O
been O O
established O O
. O O

Nevertheless O O
, O O
the O O
effects O O
of O O
Mefloquine B-drug B-drug
on O O
travelers O O
receiving O O
comedication O O
, O O
particularly O O
diabetics O O
or O O
patients O O
using O O
anticoagulants B-group B-group
, O O
should O O
be O O
checked O O
before O O
departure O O
. O O

In O O
contrast O O
, O O
nucleophosmin/B23 O O
in O O
serum-deprived O O
ras-transformed O O
( O O
RAS-3T3 O O
) O O
cells O O
was O O
as O O
stable O O
as O O
that O O
in O O
serum-supplemented O O
NIH-3T3 O O
or O O
RAS-3T3 O O
cells O O
. O O

Patients O O
using O O
CYP3A4 O O
metabolized O O
statins B-group O
should O O
have O O
cholesterol O O
levels O O
monitored O O
after O O
TRACLEER B-brand B-brand
is O O
initiated O O
to O O
see O O
whether O O
the O O
statin B-group O
dose O O
needs O O
adjustment O O
. O O

Due O O
to O O
its O O
nephrotoxicity O O
, O O
gentamicin B-drug B-drug
may O O
cause O O
abnormal O O
renal O O
uptake O O
to O O
be O O
seen O O
on O O
99mTc-MDP B-drug O
bone O O
scintigraphy O O
. O O

Paroxetine B-drug B-drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
eszopiclone B-drug B-drug
3 O I-drug
mg O O
and O O
paroxetine B-drug B-drug
20 O O
mg O O
daily O O
for O O
7 O O
days O O
produced O O
no O O
pharmacokinetic O O
or O O
pharmacodynamic O O
interaction O O
. O O

More O O
than O O
600 O O
Parkinsons O O
disease O O
patients O O
in O O
clinical O O
trials O O
have O O
used O O
selegiline B-drug B-drug
in O O
combination O O
with O O
entacapone B-drug B-drug
and O O
levodopa/dopa B-drug B-group
decarboxylase B-group I-group
inhibitor I-group I-group
. O O

Lincomycin B-drug B-drug
has O O
been O O
shown O O
to O O
have O O
neuromuscular O O
blocking O O
properties O O
that O O
may O O
enhance O O
the O O
action O O
of O O
other O O
neuromuscular B-group B-group
blocking I-group I-group
agents I-group I-group
. O O

Antacids B-group B-group
, O O
Sucralfate B-drug B-drug
, O O
Metal O O
Cations O O
, O O
Multivitamins B-group B-group
Quinolones I-group I-group
form O O
chelates O O
with O O
alkaline O O
earth O O
and O O
transition O O
metal O O
cations O O
. O O

In O O
vitro O O
mixing O O
of O O
an O O
aminoglycoside B-group B-group
with O O
beta-lactamtype O B-group
antibiotics B-group I-group
( O O
penicillins B-group B-group
or O O
cephalosporins B-group B-group
) O O
may O O
result O O
in O O
a O O
significant O O
mutual O O
inactivation O O
. O O

When O O
given O O
in O O
a O O
dose O O
of O O
50 O O
mg/kg O O
, O O
sandimmune B-brand B-brand
produced O O
no O O
statistically O O
significant O O
effect O O
on O O
the O O
duration O O
of O O
hexanal-induced O B-drug
sleep O O
in O O
mice O O
. O O

Although O O
trough O O
citalopram B-drug B-drug
plasma O O
levels O O
were O O
unaffected O O
, O O
given O O
the O O
enzyme-inducing O O
properties O O
of O O
carbamazepine B-drug B-drug
, O O
the O O
possibility O O
that O O
carbamazepine B-drug B-drug
might O O
increase O O
the O O
clearance O O
of O O
escitalopram B-drug B-drug
should O O
be O O
considered O O
if O O
the O O
two O O
drugs O O
are O O
coadministered O O
. O O

BREVIBLOC B-brand B-brand
concentrations O O
were O O
equivocally O O
higher O O
when O O
given O O
with O O
warfarin B-drug B-drug
, O O
but O O
this O O
is O O
not O O
likely O O
to O O
be O O
clinically O O
important O O
. O O

Propranolol B-drug B-drug
: O O
In O O
a O O
single O O
dose O O
study O O
in O O
normal O O
volunteers O O
, O O
coadministration O O
of O O
propranolol B-drug B-drug
had O O
a O O
small O O
effect O O
on O O
the O O
rate O O
but O O
no O O
effect O O
on O O
the O O
extent O O
of O O
isradipine B-drug B-drug
bioavailability O O
. O O

Antipsychotic B-group B-group
drugs I-group I-group
such O O
as O O
phenothiazines B-group B-group
or O O
haloperidol B-drug B-drug
; O O

Sumatriptan B-drug B-drug
and O O
D.H.E B-brand B-brand
. I-brand O
45 I-brand B-drug
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
should O O
not O O
be O O
taken O O
within O O
24 O O
hours O O
of O O
each O O
other.. O O

Use O O
With O O
Ribavirin B-drug B-drug
Ribavirin I-drug I-drug
is O O
genotoxic O O
and O O
mutagenic O O
. O O

Corticosteroids B-group B-group
may O O
also O O
potentiate O O
the O O
replication O O
of O O
some O O
organisms O O
contained O O
in O O
live B-group O
attenuated I-group B-group
vaccines I-group I-group
. O O

If O O
the O O
TARCEVA B-brand B-brand
dose O O
is O O
adjusted O O
upward O O
, O O
the O O
dose O O
will O O
need O O
to O O
be O O
reduced O O
upon O O
discontinuation O O
of O O
rifampicin B-drug B-drug
or O O
other O O
inducers O O
. O O

Dexamethasone B-drug B-drug
: O O
Steady-state O O
trough O O
concentrations O O
of O O
albendazole B-drug B-drug
sulfoxide I-drug I-drug
were O O
about O O
56 O O
% O O
higher O O
when O O
8 O O
mg O O
dexamethasone B-drug B-drug
was O O
coadministered O O
with O O
each O O
dose O O
of O O
albendazole B-drug B-drug
( O O
15 O O
mg/kg/day O O
) O O
in O O
eight O O
neurocysticercosis O O
patients O O
. O O

Dexbrompheniramine B-drug B-drug
can O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-group B-group
) O O
, O O
anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-group B-group
) O O
, O O
and O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
( O O
concurrent O O
use O O
with O O
antihistamines B-group B-group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-group B-group
) O O
. O O

COPEGUS B-brand B-brand
therapy O O
is O O
contraindicated O O
in O O
women O O
who O O
are O O
pregnant O O
and O O
in O O
the O O
male O O
partners O O
of O O
women O O
who O O
are O O
pregnant O O
. O O

A O O
similar O O
association O O
, O O
though O O
less O O
marked O O
, O O
has O O
been O O
suggested O O
with O O
barbiturates B-group B-group
, O O
phenylbutazone B-drug B-drug
, O O
phenytoin B-drug B-drug
sodium I-drug I-drug
, O O
carbamazepine B-drug B-drug
, O O
griseofulvin B-drug B-drug
, O O
topiramate B-drug B-drug
, O O
and O O
possibly O O
with O O
ampicillin B-drug B-drug
and O O
tetracyclines B-group B-group
72 O O
. O O

In O O
a O O
parallel O O
group O O
drug O O
interaction O O
study O O
comparing O O
the O O
intravenous O O
prodrug O O
form O O
of O O
valdecoxib B-drug B-drug
at O O
40 O O
mg O O
BID O O
( O O
n=10 O O
) O O
vs O O
placebo O O
( O O
n=9 O O
) O O
, O O
valdecoxib B-drug B-drug
had O O
no O O
effect O O
on O O
in O O
vitro O O
aspirin-mediated B-brand O
inhibition O O
of O O
arachidonate- O O
or O O
collagen-stimulated O O
platelet O O
aggregation O O
. O O

Protein O O
Binding O O
: O O
Entacapone B-drug B-drug
is O O
highly O O
protein O O
bound O O
( O O
98 O O
% O O
) O O
. O O

Patients O O
taking O O
warfarin B-drug B-drug
should O O
be O O
monitored O O
regularly O O
for O O
changes O O
in O O
prothrombin O O
time O O
or O O
INR O O
. O O

The O O
potential O O
effects O O
of O O
INDOCIN B-brand B-brand
and O O
potassium-sparing B-group B-group
diuretics I-group I-group
on O O
potassium O O
kinetics O O
and O O
renal O O
function O O
should O O
be O O
considered O O
when O O
these O O
agents O O
are O O
administered O O
concurrently O O
. O O

Indinavir B-drug B-drug

Rifampin B-drug B-drug
significantly O O
decreased O O
the O O
AUC O O
( O O
ss O O
) O O
of O O
amprenavir B-drug B-drug
by O O
82 O O
% O O
, O O
but O O
amprenavir B-drug B-drug
had O O
no O O
effect O O
on O O
rifampin B-drug B-drug
pharmacokinetics O O
. O O

Similarly O O
, O O
ethanol B-drug B-drug
decreased O O
the O O
rate O O
of O O
elimination O O
of O O
Antizol B-brand B-brand
( O O
by O O
approximately O O
50 O O
% O O
) O O
by O O
the O O
same O O
mechanism O O
. O O

Monoamine B-group B-group
Oxidase I-group I-group
Inhibitors I-group I-group
and O O
Tricyclic B-group B-group
Antidepressants I-group I-group
: O O
FORADIL B-brand B-brand
should O O
be O O
administered O O
with O O
extreme O O
caution O O
in O O
patients O O
being O O
treated O O
with O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
or O O
tricyclic B-group B-group
antidepressants I-group I-group
because O O
the O O
action O O
of O O
formoterol B-drug B-drug
on O O
the O O
cardiovascular O O
system O O
may O O
be O O
potentiated O O
by O O
these O O
agents O O
. O O

1200-2400 O O
up O O
to O O
40 O O
% O O
increase3 O O
[ O O
CI O O
: O O
12 O O
% O O
increase O O
, O O
60 O O
% O O
increase O O
] O O

Drug O O
interaction O O
studies O O
have O O
not O O
been O O
performed O O
with O O
Soliris B-brand B-brand
. O O

Itraconazole B-drug B-drug

Organic O O
nitrates B-group B-group
- O O
L-arginine B-drug B-drug
supplements O O
theoretically O O
may O O
potentiate O O
the O O
effects O O
of O O
organic O O
nitrates B-drug B-group
if O O
taken O O
concomitantly O O
. O O

However O O
, O O
in O O
vivo O O
drug O O
interaction O O
studies O O
of O O
ketoconazole B-drug B-drug
with O O
vitamin B-group B-group
D I-group I-group
have O O
not O O
been O O
investigated O O
. O O

The O O
tolerability O O
of O O
NNRTIs B-group B-group
appears O O
generally O O
good O O
with O O
few O O
individuals O O
discontinuing O O
in O O
clinical O O
studies O O
as O O
a O O
result O O
of O O
adverse O O
drug O O
events O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
The O O
administration O O
of O O
CEFOTAN B-brand B-brand
may O O
result O O
in O O
a O O
false O O
positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
using O O
Clinitest O O
, O O
Benedicts O O
solution O O
, O O
or O O
Fehlings O O
solution O O
. O O

Coadministration O O
of O O
oral O O
contraceptives B-group B-group
increased O O
the O O
maximum O O
plasma O O
concentration O O
of O O
alprazolam B-drug B-drug
by O O
18 O O
% O O
, O O
decreased O O
clearance O O
by O O
22 O O
% O O
, O O
and O O
increased O O
half-life O O
by O O
29 O O
% O O
. O O

The O O
therapeutic O O
efficacy O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
be O O
compromised O O
in O O
these O O
patients O O
when O O
cimetidine B-drug B-drug
is O O
discontinued O O
. O O

Drugs O O
Metabolized O O
by O O
CYP2D6 O O
: O O
Duloxetine B-drug B-drug
is O O
a O O
moderate O O
inhibitor O O
of O O
CYP2D6 O O
. O O

In O O
renal O O
and O O
cardiac O O
transplant O O
recipients O O
, O O
a O O
reduction O O
of O O
cyclosporine B-drug B-drug
dose O O
ranging O O
from O O
15 O O
% O O
to O O
48 O O
% O O
was O O
necessary O O
to O O
maintain O O
cyclosporine B-drug B-drug
trough O O
concentrations O O
similar O O
to O O
those O O
seen O O
prior O O
to O O
the O O
addition O O
of O O
diltiazem B-drug B-drug
. O O

Catecholamine-depleting O O
drugs O O
( O O
e.g. O O
, O O
reserpine B-drug B-drug
) O O
may O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
beta-blocking B-drug B-group
agents O I-group
. O O

Morphine B-drug B-drug
pharmacokinetic O O
parameter O O
values O O
were O O
not O O
affected O O
by O O
administration O O
of O O
Neurontin B-brand B-brand
2 O O
hours O O
after O O
morphine B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
vasopressor B-group B-group
drugs I-group I-group
and O O
of O O
ergot-type B-group B-group
oxytocic I-group I-group
drugs I-group I-group
may O O
cause O O
severe O O
, O O
persistent O O
hypertension O O
or O O
cerebrovascular O O
accidents O O
. O O

. O O

If O O
phenytoin B-drug B-drug
or O O
other O O
hepatic O O
enzyme O O
inducers O O
are O O
taken O O
concurrently O O
with O O
Norpace B-brand B-brand
or O O
Norpace B-brand B-brand
CR I-brand O
, O O
lower O O
plasma O O
levels O O
of O O
disopyramide B-drug B-drug
may O O
occur O O
. O O

Ketoconazole B-drug B-drug
( O O
200 O O
mg O O
once O O
daily O O
) O O
produced O O
a O O
10-fold O O
increase O O
in O O
vardenafil B-drug B-drug
AUC O O
and O O
a O O
4-fold O O
increase O O
in O O
Cmax O O
when O O
co-administered O O
with O O
Vardenafil B-drug B-drug
( O O
5 O O
mg O O
) O O
in O O
healthy O O
volunteers O O
. O O

As O O
most O O
entacapone B-drug B-drug
excretion O O
is O O
via O O
the O O
bile O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
drugs O O
known O O
to O O
interfere O O
with O O
biliary O O
excretion O O
, O O
glucuronidation O O
, O O
and O O
intestinal O O
beta-glucuronidase O O
are O O
given O O
concurrently O O
with O O
entacapone B-drug B-drug
. O O

Limited O O
PK O O
and/or O O
PD O O
studies O O
investigating O O
possible O O
interactions O O
between O O
anagrelide B-drug B-drug
and O O
other O O
medicinal O O
products O O
have O O
been O O
conducted O O
. O O

Cimetidine B-drug B-drug
( O O
300 O O
mg O O
qid O O
) O O
+103 O O
% O O
+ O O
6 O O
% O O

Nursing O O
Mothers O O

Coadministration O O
of O O
NIZORAL B-brand B-brand
Tablets O O
and O O
drugs O O
primarily O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
drugs O O
that O O
could O O
increase O O
or O O
prolong O O
both O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

CYP2D6 O O
inhibitors O O
- O O
Atomoxetine B-drug B-drug
is O O
primarily O O
metabolized O O
by O O
the O O
CYP2D6 O O
pathway O O
to O O
4-hydroxyatomoxetine B-drug_n B-drug_n
. O O

Antacid B-group B-group
: O O
When O O
atorvastatin B-drug B-drug
and O O
Maalox B-brand B-brand
TC I-brand I-brand
suspension O O
were O O
coadministered O O
, O O
plasma O O
concentrations O O
of O O
atorvastatin B-drug B-drug
decreased O O
approximately O O
35 O O
% O O
. O O

Erythromycin B-drug B-drug
and O O
clarithromycin B-drug B-drug
( O O
and O O
possibly O O
other O O
macrolide B-group B-group
antibiotics I-group I-group
) O O
and O O
tetracycline B-drug B-drug
may O O
increase O O
digoxin B-drug B-drug
absorption O O
in O O
patients O O
who O O
inactivate O O
digoxin B-drug B-drug
by O O
bacterial O O
metabolism O O
in O O
the O O
lower O O
intestine O O
, O O
so O O
that O O
digitalis B-group B-group
intoxication O O
may O O
result O O
. O O

Concurrent O O
administration O O
of O O
a O O
TNF B-group B-group
antagonist I-group I-group
with O O
ORENCIA B-brand B-brand
has O O
been O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
serious O O
infections O O
and O O
no O O
significant O O
additional O O
efficacy O O
over O O
use O O
of O O
the O O
TNF B-group B-group
antagonists I-group I-group
alone O O
. O O

Central B-group B-group
nervous I-group I-group
system I-group I-group
depressant I-group I-group
( O O
CNS O O
) O O
drugs O O
including O O
alcohol B-drug B-drug
, O O
antidepressants B-group B-group
, O O
antihistamines B-group B-group
, O O
antipsychotics B-group B-group
, O O
blood O O
pressure O O
medications O O
( O O
reserpine B-drug B-drug
, O O
methyldopa B-drug B-drug
, O O
beta-blockers B-group B-group
) O O
, O O
motion O O
sickness O O
medications O O
, O O
muscle B-group B-group
relaxants I-group I-group
, O O
narcotics B-group B-group
, O O
sedatives B-group B-group
, O O
sleeping O O
pills O O
and O O
tranquilizers B-group B-group

Magnesium B-drug B-drug
: O O
Magnesium-containing B-drug B-drug
preparations O O
( O O
eg O O
, O O
antacids B-group B-group
) O O
may O O
cause O O
hypermagnesemia O O
and O O
should O O
therefore O O
not O O
be O O
taken O O
during O O
therapy O O
with O O
vitamin B-group B-group
D I-group I-group
by O O
patients O O
on O O
chronic O O
renal O O
dialysis O O
. O O

Patients O O
receiving O O
these O O
drugs O O
concurrently O O
should O O
be O O
monitored O O
for O O
a O O
potential O O
drug O O
interaction O O
. O O

Concomitant O O
use O O
of O O
other O O
5-HT1B/1D O B-group
agonists O I-group
within O O
24 O O
hours O O
of O O
FROVA B-brand B-brand
treatment O O
is O O
not O O
recommended O O
. O O

This O O
change O O
was O O
not O O
considered O O
clinically O O
significant O O
and O O
no O O
dose O O
adjustment O O
is O O
needed O O
when O O
ketoconazole B-drug B-drug
and O O
VIRACEPT B-brand B-brand
are O O
coadministered O O
. O O

Interactions O O
for O O
vitamin B-group B-group
D I-group I-group
analogues O I-group
( O O
Vitamin B-drug B-drug
D2 I-drug I-drug
, O O
Vitamin B-drug B-drug
D3 I-drug I-drug
, O O
Calcitriol B-drug B-drug
, O O
and O O
Calcidiol B-drug B-drug
) O O
: O O
Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
has O O
been O O
reported O O
to O O
reduce O O
intestinal O O
absorption O O
of O O
fat B-group B-group
soluble I-group I-group
vitamins I-group I-group
; O O

Considering O O
that O O
the O O
involvement O O
of O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
has O O
been O O
implicated O O
in O O
the O O
toxicity O O
of O O
various O O
pesticides O O
, O O
this O O
study O O
was O O
designed O O
to O O
investigate O O
the O O
possibility O O
of O O
oxidative O O
stress O O
induction O O
by O O
cypermethrin B-drug B-drug
, O O
a O O
Type B-drug_n B-group
II I-drug_n I-group
pyrethroid I-drug_n I-group
. O O

Digoxin B-drug B-drug
: O O
Rofecoxib B-drug B-drug
75 O O
mg O O
once O O
daily O O
for O O
11 O O
days O O
does O O
not O O
alter O O
the O O
plasma O O
concentration O O
profile O O
or O O
renal O O
elimination O O
of O O
digoxin B-drug B-drug
after O O
a O O
single O O
0.5 O O
mg O O
oral O O
dose O O
. O O

Endocrine O O
Function O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
interfere O O
with O O
cholesterol O O
synthesis O O
and O O
theoretically O O
might O O
blunt O O
adrenal O O
and/or O O
gonadal O O
steroid O O
production O O
. O O

Other O O
Drugs O O
: O O
In O O
small O O
groups O O
of O O
patients O O
( O O
7-10/interaction O O
study O O
) O O
, O O
the O O
concomitant O O
administration O O
of O O
azathioprine B-drug B-drug
, O O
gold B-group B-drug
, O O
chloroquine B-drug B-drug
, O O
D-penicillamine B-drug B-drug
, O O
prednisolone B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
or O O
digitoxin B-drug B-drug
did O O
not O O
significantly O O
affect O O
the O O
peak O O
levels O O
and O O
AUC O O
values O O
of O O
diclofenac B-drug B-drug
. O O

4 O O
. O O

In O O
clinical O O
studies O O
, O O
coadministration O O
of O O
WelChol B-brand B-brand
with O O
atorvastatin B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
or O O
simvastatin B-drug B-drug
did O O
not O O
interfere O O
with O O
the O O
lipid-lowering O O
activity O O
of O O
the O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitor I-group I-group
. O O

The O O
latency O O
to O O
loss O O
of O O
the O O
righting O O
reflex O O
and O O
duration O O
of O O
sleep O O
time O O
were O O
recorded O O
while O O
the O O
rats O O
were O O
kept O O
in O O
sound-attenuating O O
chambers O O
. O O

The O O
concurrent O O
use O O
of O O
these O O
drugs O O
is O O
not O O
recommended O O
. O O

There O O
are O O
no O O
known O O
drug/drug O O
interactions O O
with O O
chlorambucil B-drug B-drug
. O O

In O O
the O O
first O O
study O O
, O O
concomitant O O
administration O O
of O O
0.2 O O
mg O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
and O O
12 O O
g O O
cholestyramine B-drug B-drug
resulted O O
in O O
decreases O O
of O O
more O O
than O O
22 O O
% O O
for O O
AUC O O
and O O
40 O O
% O O
for O O
Cmax O O
when O O
compared O O
to O O
dosing O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
alone O O
. O O

PTX B-drug_n O
caused O O
the O O
release O O
of O O
norepinephrine O B-drug
from O O
the O O
muscle O O
. O O

Although O O
glucocorticoids B-group B-group
have O O
been O O
shown O O
to O O
reduce O O
PROLEUKIN-induced B-brand B-brand
side O O
effects O O
including O O
fever O O
, O O
renal O O
insufficiency O O
, O O
hyperbilirubinemia O O
, O O
confusion O O
, O O
and O O
dyspnea O O
, O O
concomitant O O
administration O O
of O O
these O O
agents O O
with O O
PROLEUKIN B-brand B-brand
may O O
reduce O O
the O O
antitumor O O
effectiveness O O
of O O
PROLEUKIN B-brand B-brand
and O O
thus O O
should O O
be O O
avoided O O
. O O
12 O O
Beta-blockers B-group B-group
and O O
other O O
antihypertensives B-group B-group
may O O
potentiate O O
the O O
hypotension O O
seen O O
with O O
PROLEUKIN B-brand B-brand
. O O

Combination O O
therapy O O
should O O
be O O
administered O O
with O O
caution O O
, O O
especially O O
in O O
immunocompromised O O
patients O O
. O O

CPK O O
: O O
Some O O
patients O O
undergoing O O
vigorous O O
physical O O
activity O O
while O O
on O O
Accutane B-brand B-brand
therapy O O
have O O
experienced O O
elevated O O
CPK O O
levels O O
; O O

We O O
obtained O O
evidence O O
that O O
increased O O
stability O O
of O O
nucleophosmin/B23 O O
is O O
involved O O
in O O
antiapoptotic O O
effect O O
of O O
ras O O
during O O
serum O O
deprivation O O
. O O

In O O
a O O
controlled O O
clinical O O
trial O O
, O O
a O O
20 O O
% O O
reduction O O
of O O
the O O
phenytoin B-drug B-drug
dose O O
at O O
the O O
initiation O O
of O O
Felbatol B-brand B-brand
therapy O O
resulted O O
in O O
phenytoin B-drug B-drug
levels O O
comparable O O
to O O
those O O
prior O O
to O O
Felbatol B-brand B-brand
administration O O
. O O

The O O
percentage O O
of O O
drug O O
binding O O
in O O
each O O
preparation O O
was O O
calculated O O
. O O

Thus O O
, O O
the O O
results O O
suggest O O
that O O
cypermethrin B-drug B-drug
exposure O O
of O O
rats O O
results O O
in O O
free O O
radical-mediated O O
tissue O O
damage O O
, O O
as O O
indicated O O
by O O
elevated O O
cerebral O O
and O O
hepatic O O
lipid O O
peroxidation O O
, O O
which O O
was O O
prevented O O
by O O
allopurinol B-drug B-drug
and O O
Vitamin B-drug B-drug
E I-drug I-drug
. O O

Two O O
retrospective O O
studies O O
were O O
conducted O O
in O O
1992 O O
( O O
75 O O
cases O O
) O O
and O O
in O O
1993 O O
( O O
51 O O
cases O O
) O O
. O O

use O O
potassium B-drug B-drug
supplements O O
if O O
necessary O O
. O O

In O O
addition O O
, O O
the O O
beneficial O O
effects O O
of O O
levodopa B-drug B-drug
in O O
Parkinsons O O
disease O O
have O O
been O O
reported O O
to O O
be O O
reversed O O
by O O
phenytoin B-drug B-drug
and O O
papaverine B-drug B-drug
. O O

No O O
effects O O
were O O
evident O O
on O O
excystment O O
rates O O
of O O
cyst-exposed O O
parasites O O
. O O

These O O
included O O
seven O O
cerebrovascular O O
accidents O O
, O O
six O O
sudden O O
cardiac O O
deaths O O
, O O
three O O
cases O O
of O O
hyperpyrexia O O
, O O
eight O O
poisonings O O
of O O
uncertain O O
mechanism O O
and O O
seven O O
cases O O
of O O
medical O O
complications O O
of O O
intravenous O O
injection O O
; O O

The O O
interval O O
between O O
the O O
administration O O
of O O
COLESTID B-brand B-brand
Tablets O O
and O O
any O O
other O O
medication O O
should O O
be O O
as O O
long O O
as O O
possible O O
. O O

Administration O O
of O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
with O O
digoxin B-drug B-drug
in O O
24 O O
healthy O O
male O O
subjects O O
increased O O
plasma O O
digoxin B-drug B-drug
concentrations O O
approximately O O
20 O O
% O O
. O O

positive O O
antinuclear O O

The O O
atorvastatin B-drug B-drug
Cmax O O
values O O
were O O
not O O
significantly O O
affected O O
by O O
fenofibrate B-drug B-drug
. O O

None O O
Reported O O

one O O
patient O O
died O O
with O O
severe O O
hypocalcemia O O
. O O

DIGOXIN B-drug B-drug
: O O
Plasma O O
digoxin B-drug B-drug
levels O O
and O O
digoxin B-drug B-drug
clearance O O
at O O
steady-state O O
were O O
not O O
affected O O
by O O
co-administration O O
of O O
0.2 O O
mg O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
( O O
amitriptyline B-drug B-drug
, O O
imipramine B-drug B-drug
, O O
nortriptyline B-drug B-drug
) O O
: O O
Metabolism O O
may O O
be O O
inhibited O O
by O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
, O O
increasing O O
plasma O O
levels O O
of O O
antidepressant B-group B-group
; O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
cardiac O O
arrhythmias O O
. O O

Drugs O O
Decreasing O O
Heparin B-drug B-drug
Effect O O
: O O
Digitalis B-group B-group
, O O
tetracyclines B-group B-group
, O O
nicotine B-drug B-drug
, O O
or O O
antihistamines B-group B-group
may O O
partially O O
counteract O O
the O O
anticoagulant O O
action O O
of O O
heparin B-drug B-drug
sodium I-drug I-drug
. O O

Lack O O
of O O
interaction O O
between O O
levofloxacin B-drug B-drug
and O O
oxycodone B-drug B-drug
: O O
pharmacokinetics O O
and O O
drug O O
disposition O O
. O O

substrates O O
, O O
in O O
vitro O O
data O O
suggest O O
similar O O
effects O O
of O O
grepafloxacin B-drug B-drug
in O O
CYP3A4 O O
mediated O O
metabolism O O
and O O
theophylline B-drug B-drug
metabolism O O
. O O

Development O O
and O O
pharmacology O O
of O O
fluvastatin B-drug B-drug
. O O

Choose O O
particular O O
low O O
doses O O
of O O
these O O
drugs O O
. O O

Treatment O O
of O O
both O O
parental O O
and O O
resistant O O
MCF-7 O O
cells O O
with O O
TAM B-drug_n O
induces O O
apoptosis O O
and O O
clusterin O B-drug
. O O

Phenothiazines B-group B-group
and O O
butyrophenones B-group B-group
may O O
reduce O O
or O O
reverse O O
the O O
pressor O O
effect O O
of O O
epinephrine B-drug B-drug
. O O

. O O

No O O
dose O O
adjustment O O
of O O
bosentan B-drug B-drug
is O O
necessary O O
, O O
but O O
increased O O
effects O O
of O O
bosentan B-drug B-drug
should O O
be O O
considered O O
. O O

Urinary O O
alkalinizing O O
agents O O
( O O
acetazolamide B-drug B-drug
, O O
some O O
thiazides B-group B-group
) O O
increase O O
the O O
concentration O O
of O O
the O O
non-ionized O O
species O O
of O O
the O O
amphetamine B-drug B-drug
molecule O O
, O O
thereby O O
decreasing O O
urinary O O
excretion O O
. O O

Cyclophosphamide B-drug B-drug

It O O
is O O
suggested O O
that O O
in O O
patients O O
receiving O O
dopamine B-drug B-drug
HCl I-drug I-drug
, O O
alternatives O O
to O O
phenytoin B-drug B-drug
should O O
be O O
used O O
if O O
anticonvulsant B-group B-group
therapy O O
is O O
needed O O
. O O

Similarly O O
, O O
saquinavir B-drug B-drug
might O O
also O O
modify O O
the O O
pharmacokinetics O O
of O O
other O O
drugs O O
that O O
are O O
substrates O O
for O O
CYP3A4 O O
or O O
Pgp O O
. O O

5 O O
. O O

Hepatotoxicity O O
Asymptomatic O O
increases O O
in O O
liver O O
transaminases O O
have O O
been O O
observed O O
in O O
TARCEVA B-brand B-brand
treated O O
patients O O
; O O

On O O
the O O
other O O
hand O O
, O O
surprisingly O O
, O O
green B-drug O
tea I-drug O
gallocatechins I-drug O
, O O
( O B-drug_n
- O I-drug_n
) O I-drug_n
-epigallocatechin-3-O-gallate O I-drug_n
and O O
theasinensin O B-drug
A O I-drug
, O O
potently O O
enhanced O O
the O O
promoter O O
activity O O
( O O
182 O O
and O O
247 O O
% O O
activity O O
at O O
1 O O
microM O O
, O O
respectively O O
) O O
. O O

N=12 O O
) O O
administration O O
. O O

Appropriate O O
doses O O
for O O
this O O
combination O O
arenot O O
established O O
, O O
but O O
an O O
increase O O
in O O
thedosage O O
of O O
saquinavir B-drug B-drug
may O O
be O O
required O O
. O O

In O O
screening O O
patients O O
suspected O O
of O O
having O O
a O O
pheochromocytoma O O
and O O
being O O
treated O O
with O O
labetalol B-drug B-drug
HCl I-drug I-drug
, O O
a O O
specific O O
method O O
, O O
such O O
as O O
a O O
high O O
performance O O
liquid O O
chromatographic O O
assay O O
with O O
solid O O
phase O O
extraction O O
( O O
e.g. O O
, O O
J O O
Chromatogr O O
385:241,1987 O O
) O O
should O O
be O O
employed O O
in O O
determining O O
levels O O
of O O
catecholamines O O
. O O

MICs O O
of O O
vancomycin B-drug B-drug
against O O
67 O O
% O O
of O O
resistant O O
clinical O O
isolates O O
and O O
a O O
type O O
strain O O
of O O
enterococci O O
were O O
lowered O O
from O O
> O O
250 O O
microg O O
mL O O
( O O
-1 O O
) O O
to O O
1 O O

however O O
, O O
14-OH O O
metabolite O O
concentrations O O
were O O
increased.Because O O
clarithromycin B-drug B-drug
active O O
metabolite O O
has O O
reduced O O
activity O O
against O O
Mycobacteriumavium-intracellulare O O
complex O O
, O O
overallactivity O O
against O O
this O O
pathogen O O
may O O
bealtered O O
. O O

The O O
magnitude O O
of O O
interaction O O
at O O
other O O
doses O O
is O O
not O O
known O O
. O O

Anastrozole B-drug B-drug
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
antipyrine B-drug B-drug
. O O

The O O
results O O
of O O
a O O
study O O
of O O
coadministration O O
of O O
ethambutol B-drug B-drug
( O O
50 O O
mg/kg O O
) O O
with O O
an O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
containing O O
antacid B-group B-group
to O O
13 O O
patients O O
with O O
tuberculosis O O
showed O O
a O O
reduction O O
of O O
mean O O
serum O O
concentrations O O
and O O
urinary O O
excretion O O
of O O
ethambutol B-drug B-drug
of O O
approximately O O
20 O O
% O O
and O O
13 O O
% O O
, O O
respectively O O
, O O
suggesting O O
that O O
the O O
oral O O
absorption O O
of O O
ethambutol B-drug B-drug
may O O
be O O
reduced O O
by O O
these O O
antacid B-group B-group
products I-group O
. O O

No O O
formal O O
studies O O
to O O
evaluate O O
drug O O
interactions O O
with O O
bexarotene B-drug B-drug
have O O
been O O
conducted O O
. O O

However O O
, O O
there O O
has O O
been O O
one O O
report O O
of O O
prolonged O O
prothrombin O O
time O O
when O O
buspirone B-drug B-drug
was O O
added O O
to O O
the O O
regimen O O
of O O
a O O
patient O O
treated O O
with O O
warfarin B-drug B-drug
. O O

Interactions O O
for O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
( O O
Vitamin B-drug B-drug
D2 I-drug I-drug
, O O
Vitamin B-drug B-drug
D3 I-drug I-drug
, O O
Calcitriol B-drug B-drug
, O O
and O O
Calcidiol B-drug B-drug
) O O
: O O
Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
has O O
been O O
reported O O
to O O
reduce O O
intestinal O O
absorption O O
of O O
fat B-group B-group
soluble I-group I-group
vitamins I-group I-group
; O O

- O O
Drug/Laboratory O O
Test O O
Interactions O O
: O O
Thiazides B-group B-group
should O O
be O O
discontinued O O
before O O
carrying O O
out O O
tests O O
for O O
parathyroid O O
function O O
. O O

Conversion O O
could O O
be O O
affected O O
by O O
alterations O O
in O O
the O O
level O O
of O O
phosphatase O O
activity O O
, O O
but O O
given O O
the O O
abundance O O
and O O
wide O O
distribution O O
of O O
phosphatases O O
in O O
the O O
body O O
it O O
is O O
unlikely O O
that O O
drugs O O
would O O
affect O O
this O O
activity O O
enough O O
to O O
affect O O
conversion O O
of O O
fosphenytoin B-drug B-drug
to O O
phenytoin B-drug B-drug
. O O

For O O
example O O
, O O
diuretics B-group B-group
( O O
e.g. O O
, O O
thiazides B-group B-group
) O O
may O O
activate O O
the O O
renin-angiotensin-aldosterone O O
system O O
. O O

Corticosteroids B-group B-group
and O O
Corticotropin B-drug B-drug
( O O
ACTH B-group B-drug
) O O
: O O
may O O
potentiate O O
amphotericin B-drug B-drug
B- O O
induced O O
hypokalemia O O
which O O
may O O
predispose O O
the O O
patient O O
to O O
cardiac O O
dysfunction O O
. O O

Sedatives B-group B-group
and O O
tranquilizers B-group B-group
( O O
e.g. O O
, O O
diazepam B-drug B-drug
) O O
. O O

If O O
these O O
drugs O O
are O O
to O O
be O O
used O O
in O O
the O O
initial O O
treatment O O
of O O
severe O O
malaria O O
, O O
Mefloquine B-drug B-drug
administration O O
should O O
be O O
delayed O O
at O O
least O O
12 O O
hours O O
after O O
the O O
last O O
dose O O
. O O

Drug O O
Name O O

Because O O
antacids B-group B-group
may O O
interfere O O
with O O
the O O
absorption O O
of O O
anticholinergic B-group B-group
agents I-group I-group
, O O
simultaneous O O
use O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

anemia O O

Single O O
doses O O
of O O
either O O
cholestyramine B-drug B-drug
or O O
colestipol B-drug B-drug
resins B-group B-group
bind O O
the O O
hydrochlorothiazide B-drug B-drug
and O O
reduce O O
its O O
absorption O O
from O O
the O O
gastrointestinal O O
tract O O
by O O
up O O
to O O
85 O O
and O O
43 O O
percent O O
, O O
respectively O O
. O O

Differences O O
in O O
iron B-drug B-drug
balance O O
were O O
only O O
observed O O
between O O
both O O
dietary O O
concentrations O O
, O O
showing O O
a O O
higher O O
absolute O O
but O O
a O O
lower O O
relative O O
absorption O O
as O O
well O O
as O O
retention O O
in O O
the O O
groups O O
fed O O
further O O
Fe B-drug B-drug
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Terfenadine B-drug B-drug
: O O
No O O
clinically O O
significant O O
changes O O
occurred O O
in O O
heart O O
rate O O
or O O
corrected O O
QT O O
intervals O O
, O O
or O O
in O O
terfenadine B-drug B-drug
metabolite O O
or O O
lomefloxacin B-drug B-drug
pharmacokinetics O O
, O O
during O O
concurrent O O
administration O O
of O O
lomefloxacin B-drug B-drug
and O O
terfenadine B-drug B-drug
at O O
steady-state O O
in O O
28 O O
healthy O O
males O O
. O O

No O O
other O O
drug O O
interactions O O
are O O
known O O
. O O

Ketorolac B-drug B-drug
is O O
highly O O
bound O O
to O O
human O O
plasma O O
protein O O
( O O
mean O O
99.2 O O
% O O
) O O
. O O

Although O O
BETAGAN B-brand B-brand
used O O
alone O O
has O O
little O O
or O O
no O O
effect O O
on O O
pupil O O
size O O
, O O
mydriasis O O
resulting O O
from O O
concomitant O O
therapy O O
with O O
BETAGAN B-brand B-brand
and O O
epinephrine B-drug B-drug
may O O
occur O O
. O O

Use O O
of O O
PRINIVIL B-brand B-brand
with O O
potassium-sparing B-group B-group
diuretics I-group I-group
( O O
e.g. O O
, O O
spironolactone B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
or O O
amiloride B-drug B-drug
) O O
, O O
potassium B-drug B-drug
supplements O O
, O O
or O O
potassium-containing O B-drug
salt O O
substitutes O O
may O O
lead O O
to O O
significant O O
increases O O
in O O
serum O O
potassium O O
. O O

Ketoconazole I-drug B-drug

Blood O O
sampling O O
for O O
the O O
pharmacokinetics O O
of O O
everolimus B-drug B-drug
and O O
cyclosporine B-drug B-drug
was O O
performed O O
on O O
day O O
1 O O
, O O
on O O
weeks O O
1 O O
, O O
2 O O
, O O
3 O O
, O O
and O O
4 O O
, O O
and O O
on O O
months O O
2 O O
, O O
3 O O
, O O
6 O O
, O O
9 O O
, O O
and O O
12 O O
. O O

No O O
formal O O
clinical O O
studies O O
have O O
been O O
conducted O O
to O O
assess O O
if O O
there O O
is O O
an O O
interactive O O
effect O O
on O O
bone O O
loss O O
between O O
phenytoin B-drug B-drug
and O O
Accutane B-brand B-brand
. O O

Analysis O O
of O O
the O O
concentration O O
of O O
budesonide B-drug B-drug
following O O
ultracentrifugation O O
indicated O O
that O O
there O O
is O O
rapid O O
equilibration O O
of O O
budesonide B-drug B-drug
between O O
the O O
Survanta B-brand B-brand
and O O
aqueous O O
phase O O
. O O

The O O
immediate O O
release O O
, O O
but O O
not O O
the O O
coat-core O O
formulation O O
of O O
nisoldipine B-drug B-drug
increased O O
plasma O O
quinidine B-drug B-drug
concentrations O O
by O O
about O O
20 O O
% O O
. O O

Because O O
busulfan B-drug B-drug
is O O
eliminated O O
from O O
the O O
body O O
via O O
conjugation O O
with O O
glutathione O B-drug
, O O
use O O
of O O
acetaminophen B-drug B-drug
prior O O
to O O
( O O
72 O O
hours O O
) O O
or O O
concurrent O O
with O O
BUSULFEX B-brand B-brand
may O O
result O O
in O O
reduced O O
busulfan B-drug B-drug
clearance O O
based O O
upon O O
the O O
known O O
property O O
of O O
acetaminophen B-drug B-drug
to O O
decrease O O
glutathione O O
levels O O
in O O
the O O
blood O O
and O O
tissues O O
. O O

Response O O
to O O
Treatment O O
for O O
Anaphylactic O O
Reaction O O
: O O
While O O
taking O O
beta-blockers B-group B-group
, O O
patients O O
with O O
a O O
history O O
of O O
severe O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
be O O
more O O
reactive O O
to O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
, O O
or O O
therapeutic O O
. O O

Amphetamines B-group B-group
may O O
interfere O O
with O O
urinary O O
steroid O B-group
determinations O O
. O O

If O O
combination O O
therapy O O
is O O
initiated O O
or O O
withdrawn O O
in O O
conjunction O O
with O O
propranolol B-drug B-drug
, O O
an O O
adjustment O O
in O O
the O O
propranolol B-drug B-drug
dose O O
may O O
be O O
warranted O O
. O O

Other O O
than O O
with O O
probenecid B-drug B-drug
, O O
no O O
specific O O
clinical O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O

Alternate O O
or O O
additional O O
contraceptive O B-group
measures O O
should O O
be O O
used O O
during O O
therapy O O
with O O
VIRACEPT B-brand B-brand

Also O O
, O O
although O O
minimal O O
alterations O O
of O O
fluvastatin B-drug B-drug
clearance O O
in O O
patients O O
with O O
renal O O
insufficiency O O
are O O
anticipated O O
due O O
to O O
limited O O
renal O O
excretion O O
( O O
5 O O
% O O
) O O
, O O
a O O
study O O
in O O
this O O
patient O O
group O O
is O O
currently O O
underway O O
to O O
examine O O
this O O
further O O
. O O

However O O
, O O
neuromuscular O O
paralysis O O
may O O
be O O
potentiated O O
by O O
co-administration O O
or O O
overlapping O O
administration O O
of O O
different O O
botulinum B-group B-group
toxin I-group I-group
serotypes O I-group
. O O

The O O
effects O O
of O O
ruthenium B-drug_n B-drug_n
red I-drug_n I-drug_n
( O I-drug_n
RR B-drug_n I-drug_n
) O I-drug_n
on O O
inositol B-drug_n O
1,4,5-trisphosphate I-drug_n O
( O O
InsP B-drug_n B-drug_n
( I-drug_n I-drug_n
3 I-drug_n I-drug_n
) I-drug_n I-drug_n
) I-drug_n I-drug_n
-induced O O
responses O O
were O O
studied O O
in O O
rat O O
bone O O
marrow O O
megakaryocytes O O
with O O
the O O
patch-clamp O O
whole-cell O O
recording O O
technique O O
in O O
combination O O
with O O
fura-2 O O
microfluorometry O O
. O O

Extended O O
Release O O
Tablets O O
: O O
Administration O O
of O O
nifedipine B-drug B-drug
with O O
digoxin B-drug B-drug
increased O O
digoxin B-drug B-drug
levels O O
in O O
9 O O
of O O
12 O O
normal O O
volunteers O O
. O O

Other O O
antihypertensive B-group B-group
drugs I-group I-group
: O O
additive O O
effect O O
or O O
potentiation O O
. O O

Unfortunately O O
, O O
folic B-drug B-drug
acid I-drug I-drug
will O O
not O O
correct O O
changes O O
in O O
the O O
nervous O O
system O O
that O O
result O O
from O O
vitamin O O
B12 O O
deficiency O O
. O O

These O O
effects O O
not O O
only O O
improve O O
insulin O O
sensitivity O O
and O O
glycemic O O
control O O
with O O
reduced O O
insulin O B-drug
requirements O O
, O O
but O O
also O O
have O O
potentially O O
favorable O O
effects O O
on O O
other O O
components O O
of O O
the O O
cardiovascular O O
dysmetabolic O O
syndrome O O
. O O

= O O
increase O O
; O O

No O O
rashes O O
were O O
reported O O
in O O
these O O
patients O O
. O O

The O O
data O O
presented O O
here O O
demonstrate O O
that O O
with O O
serial O O
pharmacokinetic O O
dosing O O
of O O
gentamicin B-drug B-drug
, O O
the O O
iatrogenic O O
alteration O O
caused O O
by O O
gentamicin B-drug B-drug
therapy O O
can O O
be O O
avoided O O
. O O

Ritonavir B-drug B-drug
and O O
indinavir B-drug B-drug
: O O
Upon O O
concomitant O O
administration O O
of O O
5 O O
mg O O
of O O
Vardenafil B-drug B-drug
with O O
600 O O
mg O O
BID O O
ritonavir B-drug B-drug
, O O
the O O
Cmax O O
and O O
AUC O O
of O O
ritonavir B-drug B-drug
were O O
reduced O O
by O O
approximately O O
20 O O
% O O
. O O

These O O
data O O
raise O O
the O O
question O O
of O O
whether O O
sertraline B-drug B-drug
is O O
the O O
best O O
choice O O
for O O
prolonged O O
use O O
for O O
diabetic O O
individuals O O
, O O
because O O
of O O
its O O
antihyperglycemic O O
effects O O
. O O

Due O O
to O O
the O O
considerable O O
variability O O
of O O
these O O
interactions O O
, O O
the O O
dosage O O
of O O
digoxin B-drug B-drug
should O O
be O O
individualized O O
when O O
patients O O
receive O O
these O O
medications O O
concurrently O O
. O O

increased O O
prothrombin O O
and O O
factors O O
VII O O
, O O
VIII O O
, O O
IX O O
, O O
and O O
X O O
; O O

Tablet O O
If O O
a O O
patient O O
receiving O O
clonidine B-drug B-drug
hydrochloride I-drug I-drug
is O O
also O O
taking O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
the O O
effect O O
of O O
clonidine B-drug B-drug
may O O
be O O
reduced O O
, O O
thus O O
necessitating O O
an O O
increase O O
in O O
dosage O O
. O O

As O O
a O O
consequence O O
, O O
when O O
INDOCIN B-brand B-brand
and O O
lithium B-drug B-drug
are O O
given O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
carefully O O
observed O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Blood O O
Sugar O O
: O O
Some O O
patients O O
receiving O O
retinoids B-group B-group
have O O
experienced O O
problems O O
with O O
blood O O
sugar O O
control O O
. O O

Antifungals B-group B-group

avoid O O
use O O
if O O
possible O O
or O O
closely O O
monitor O O
cardiovascular O O
status O O
at O O
the O O
end O O
of O O
drug O O
interactions O O

Caffeine B-drug B-drug
Theobromine I-drug I-drug
Grepafloxacin I-drug B-drug
, O O
like O O
other O O
quinolones B-group B-group
, O O
may O O
inhibit O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
and O O
theobromine B-drug B-drug
. O O

Clinical O O
studies O O
of O O
PEGASYS B-brand B-brand
alone O O
or O O
in O O
combination O O
with O O
COPEGUS B-brand B-brand
did O O
not O O
include O O
sufficient O O
numbers O O
of O O
subjects O O
aged O O
65 O O
or O O
over O O
to O O
determine O O
whether O O
they O O
respond O O
differently O O
from O O
younger O O
subjects O O
. O O

d-amphetamine B-drug B-drug
with O O
desipramine B-drug B-drug
or O O
protriptyline B-drug B-drug
and O O
possibly O O
other O O
tricyclics B-group B-group
cause O O
striking O O
and O O
sustained O O
increases O O
in O O
the O O
concentration O O
of O O
d-amphetamine B-drug B-drug
in O O
the O O
brain O O
; O O

RESULTS O O
: O O
Insulin B-drug B-drug
increased O O
renal O O
plasma O O
flow O O
and O O
fundus O O
pulsation O O
amplitude O O
but O O
not O O
the O O
glomerular O O
filtration O O
rate O O
. O O

During O O
concomitant O O
therapy O O
with O O
NSAIDs B-group B-group
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
signs O O
of O O
renal O O
failure O O
, O O
as O O
well O O
as O O
to O O
assure O O
diuretic O B-group
efficacy O O
. O O

Mixtures O O
should O O
not O O
be O O
administered O O
intravenously O O
. O O

Magnesium B-drug B-drug
: O O
Magnesium-containing B-drug B-drug
preparations O O
( O O
eg O O
, O O
antacids B-group B-group
) O O
may O O
cause O O
hypermagnesemia O O
and O O
should O O
therefore O O
not O O
be O O
taken O O
during O O
therapy O O
with O O
vitamin B-group B-group
D I-group I-group
by O O
patients O O
on O O
chronic O O
renal O O
dialysis O O
. O O

The O O
safety O O
of O O
using O O
STADOL B-brand B-brand
NS I-brand I-brand
and O O
IMITREX B-brand B-brand
( O O
sumatriptan B-drug B-drug
) O O
Nasal O O
Spray O O
during O O
the O O
same O O
episode O O
of O O
migraine O O
has O O
not O O
been O O
established O O
. O O

Cevimeline B-drug B-drug
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
taking O O
beta B-group B-group
adrenergic I-group I-group
antagonists I-group I-group
, O O
because O O
of O O
the O O
possibility O O
of O O
conduction O O
disturbances O O
. O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCAmay B-group B-group
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Depending O O
on O O
the O O
fraction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8 O O
fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA B-group B-group
) O O
. O O

No O O
interaction O O
with O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
imipramine B-drug B-drug
was O O
shown O O
in O O
a O O
single-dose O O
study O O
with O O
entacapone B-drug B-drug
without O O
coadministered O O
levodopa/dopa-decarboxylase B-drug O
inhibitor B-group O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Effect O O
on O O
Blood O O
Coagulation O O
: O O
Diclofenac B-drug B-drug
increases O O
platelet O O
aggregation O O
time O O
but O O
does O O
not O O
affect O O
bleeding O O
time O O
, O O
plasma O O
thrombin O O
clotting O O
time O O
, O O
plasma O O
fibrinogen O O
, O O
or O O
factors O O
V O O
and O O
VII O O
to O O
XII O O
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
the O O
allergic O O
reaction O O
. O O

This O O
diminution O O
is O O
not O O
sufficient O O
to O O
preclude O O
effectiveness O O
of O O
the O O
pressor O O
agent O O
for O O
therapeutic O O
use O O
. O O
) O O

Morphine B-drug B-drug
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
increase O O
the O O
clearance O O
of O O
morphine B-drug B-drug
. O O

This O O
may O O
potentiate O O
and O O
prolong O O
hypnotic O O
and O O
sedative O O
effects O O
. O O

Ketoconazole B-drug B-drug
is O O
a O O
potent O O
inhibitor O O
of O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
. O O

Each O O
healthy O O
subject O O
( O O
N O O
= O O
10 O O
) O O
received O O
rofecoxib B-drug B-drug
( O O
75 O O
mg O O
once O O
daily O O
) O O
or O O
placebo O O
for O O
11 O O
days O O
in O O
a O O
double-blind O O
, O O
randomized O O
, O O
balanced O O
, O O
two-period O O
crossover O O
study O O
. O O

Since O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
is O O
an O O
anion B-group O
exchange I-group O
resin I-group B-group
, O O
it O O
may O O
have O O
a O O
strong O O
affinity O O
for O O
anions O O
other O O
than O O
the O O
bile O O
acids O O
. O O

In O O
such O O
cases O O
of O O
combined O O
treatment O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

Intracellular O O
resistance O O
to O O
thyroid B-group B-group
hormone I-group I-group
is O O
quite O O
rare O O
. O O

Drugs O O
that O O
suppress O O
the O O
immune O O
system O O
are O O
widely O O
used O O
. O O

Saquinavir B-drug B-drug
steady-state O O
Cmax O O
, O O
A.C. O O
and O O
Cmin O O
were O O
increased O O
21 O O
% O O
, O O
decreased O O
19 O O
% O O
, O O
and O O
decreased O O
48 O O
% O O
, O O
respectively O O
, O O
by O O
concomitant O O
amprenavir B-drug B-drug
. O O

Anticholinergics B-group B-group
antagonize O O
the O O
effects O O
of O O
antiglaucoma B-group B-group
agents I-group I-group
. O O

The O O
intake O O
of O O
furosemide B-drug B-drug
and O O
sucralfate B-drug B-drug
should O O
be O O
separated O O
by O O
at O O
least O O
two O O
hours O O
. O O

Patients O O
taking O O
digoxin B-drug B-drug
should O O
be O O
monitored O O
appropriately O O
. O O

For O O
this O O
reason O O
the O O
dose O O
of O O
adrenaline B-drug B-drug
should O O
be O O
restricted O O
and O O
an O O
antiarrhythmic B-group B-group
agent I-group I-group
administered O O
as O O
appropriate O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
density O O
of O O
D2 O O
binding O O
sites O O
in O O
the O O
SST O O
and O O
the O O
RBC O O
mice O O
in O O
the O O
STR O O
was O O
significantly O O
increased O O
in O O
cocaine-treated B-drug B-drug
groups O O
without O O
change O O
in O O
Kd O O
. O O

This O O
study O O
investigated O O
the O O
role O O
of O O
neuronal O O
uptake O O
of O O
norepinephrine B-drug B-drug
( O O
uptake-1 O O
) O O
in O O
human O O
heart O O
failure O O
as O O
a O O
local O O
factor O O
for O O
altering O O
concentrations O O
of O O
norepinephrine O B-drug
at O O
the O O
cardiac O O
myocyte O O
membranes O O
. O O

In O O
clinical O O
trials O O
, O O
mean O O
decreases O O
of O O
1 O O
to O O
2 O O
mg/dL O O
were O O
observed O O
in O O
arthritic O O
patients O O
receiving O O
etodolac B-drug B-drug
( O O
600 O O
mg O O
to O O
1000 O O
mg/day O O
) O O
after O O
4 O O
weeks O O
of O O
therapy O O
. O O

Breakthrough O O
bleeding O O
has O O
been O O
reported O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

A O O
variety O O
of O O
toxic O O
neurological O O
effects O O
and O O
malignant O O
hyperpyrexia O O
can O O
occur O O
, O O
sometimes O O
with O O
fatal O O
results O O
. O O

Postoperative O O
respiratory O O
depression O O
may O O
be O O
enhanced O O
or O O
prolonged O O
by O O
these O O
agents O O
. O O

Both O O
groups O O
of O O
agents O O
increase O O
blood O O
levels O O
and O O
therefore O O
potentiate O O
the O O
actions O O
of O O
amphetamines B-group B-group
. O O

Therefore O O
, O O
monitoring O O
of O O
blood O O
glucose O O
is O O
recommended O O
when O O
these O O
agents O O
are O O
co-administered O O
. O O

Hypersensitivity O O
reactions O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
combination O O
regimens O O
containing O O
sequential O O
high O O
dose O O
PROLEUKIN B-brand B-brand
and O O
antineoplastic B-group B-group
agents I-group I-group
, O O
specifically O O
, O O
dacarbazine B-drug B-drug
, O O
cis-platinum B-drug B-drug
, O O
tamoxifen B-drug B-drug
and O O
interferon-alfa B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
oxyphenbutazone B-drug B-drug
and O O
androgens B-group B-group
may O O
result O O
in O O
elevated O O
serum O O
levels O O
of O O
oxyphenbutazone B-drug B-drug
. O O

Increased O O
ectopic O O
pacemaker O O
activity O O
can O O
occur O O
when O O
pseudoephedrine B-drug B-drug
is O O
used O O
concomitantly O O
with O O
digitalis B-group B-group
. O O

When O O
concomitant O O
treatment O O
with O O
agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group I-group
and O O
clonidine B-drug B-drug
is O O
to O O
be O O
terminated O O
, O O
the O O
b-blocking B-group B-group
agent I-group I-group
should O O
be O O
discontinued O O
first O O
. O O

Blunting O O
of O O
the O O
antihypertensive O O
effect O O
of O O
beta-adrenoceptor B-group B-group
blocking I-group I-group
agents I-group I-group
by O O
non-steroidal B-group B-group
antiinflammatory I-group I-group
drugs I-group I-group
including O O
INDOCIN B-brand B-brand
has O O
been O O
reported O O
. O O

Serious O O
cardiac O O
dysrhythmias O O
, O O
some O O
resulting O O
in O O
death O O
, O O
have O O
occurred O O
in O O
patients O O
receiving O O
terfenadine B-drug B-drug
concomitantly O O
with O O
other O O
macrolide B-group B-group
antibiotics I-group I-group
. O O

The O O
growth O O
of O O
Pseudomonas O O
aeruginosa O O
, O O
particularly O O
serotype O O
O11 O O
, O O
in O O
pentazocine B-drug B-drug
and O O
tripelennamine B-drug B-drug

There O O
is O O
strong O O
evidence O O
that O O
insulin O B-drug
resistance O O
is O O
involved O O
in O O
the O O
development O O
of O O
not O O
only O O
hyperglycemia O O
, O O
but O O
also O O
dyslipidemia O O
, O O
hypertension O O
, O O
hypercoagulation O O
, O O
vasculopathy O O
, O O
and O O
ultimately O O
atherosclerotic O O
cardiovascular O O
disease O O
. O O

Central B-group B-group
Nervous I-group I-group
System I-group I-group
Depressants I-group I-group
: O O
The O O
concomitant O O
use O O
of O O
DURAGESIC B-brand B-brand
( O O
fentanyl B-drug B-drug
transdermal O O
system O O
) O O
with O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
, O O
including O O
but O O
not O O
limited O O
to O O
other O O
opioids B-group B-group
, O O
sedatives B-group B-group
, O O
hypnotics B-group B-group
, O O
tranquilizers B-group B-group
( O O
e.g. O O
, O O
benzodiazepines B-group B-group
) O O
, O O
general O O
anesthetics B-group B-group
, O O
phenothiazines B-group B-group
, O O
skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
, O O
and O O
alcohol B-drug B-drug
, O O
may O O
cause O O
respiratory O O
depression O O
, O O
hypotension O O
, O O
and O O
profound O O
sedation O O
, O O
or O O
potentially O O
result O O
in O O
coma O O
or O O
death O O
. O O

OBJECTIVE O O
: O O
Our O O
objective O O
was O O
to O O
examine O O
the O O
interaction O O
between O O
fluvoxamine B-drug B-drug
and O O
tolbutamide B-drug B-drug
to O O
confirm O O
that O O
fluvoxamine B-drug B-drug
inhibits O O
CYP2C9 O O
. O O

Abciximab B-drug B-drug
has O O
been O O
administered O O
to O O
patients O O
with O O
ischemic O O
heart O O
disease O O
treated O O
concomitantly O O
with O O
a O O
broad O O
range O O
of O O
medications O O
used O O
in O O
the O O
treatment O O
of O O
angina O O
myocardial O O
infarction O O
and O O
hypertension O O
. O O

Patients O O
receiving O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemics B-group B-group
should O O
be O O
closely O O
watched O O
during O O
initiation O O
of O O
thyroid O O
replacement O O
therapy O O
. O O

No O O
data O O
for O O
saquinavir B-drug B-drug
. O O

N=48 O O
) O O
decreases O O
hydrocodone B-drug B-drug
( O O
10 O O
mg O O
; O O

Appropriate O O
laboratory O O
testing O O
should O O
be O O
considered O O
prior O O
to O O
initiating O O
combination O O
therapy O O
with O O
Amprenavir B-drug B-drug
and O O
ritonavir B-drug B-drug
and O O
at O O
periodic O O
intervals O O
or O O
if O O
any O O
clinical O O
signs O O
or O O
symptoms O O
of O O
hyperlipidemia O O
or O O
elevated O O
liver O O
function O O
tests O O
occur O O
during O O
therapy O O
. O O

Griseofulvin B-drug B-drug
: O O
Griseofulvin B-drug B-drug
may O O
induce O O
the O O
metabolism O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
causing O O
menstrual O O
changes O O
; O O

It O O
is O O
not O O
known O O
whether O O
other O O
progestational B-group B-group
contraceptives I-group I-group
, O O
such O O
as O O
implants O O
and O O
injectables O O
, O O
are O O
adequate O O
methods O O
of O O
contraception O O
during O O
acitretin B-drug B-drug
therapy O O
. O O

Because O O
heparin B-drug B-drug
, O O
aspirin B-brand B-brand
, O O
or O O
Activase B-brand B-brand
may O O
cause O O
bleeding O O
complications O O
, O O
careful O O
monitoring O O
for O O
bleeding O O
is O O
advised O O
, O O
especially O O
at O O
arterial O O
puncture O O
sites O O
. O O

There O O
is O O
no O O
pharmacokinetic O O
interaction O O
between O O
ethanol B-drug B-drug
and O O
flumazenil B-drug B-drug
. O O

This O O
is O O
demonstrated O O
for O O
cigarette O O
smokers O O
and O O
industrial O O
workers O O
involved O O
in O O
chemical O O
waste O O
incineration O O
. O O

Differences O O
in O O
clearance O O
between O O
patients O O
on O O
these O O
medications O O
( O O
at O O
any O O
occasion O O
in O O
the O O
study O O
) O O
and O O
those O O
off O O
medications O O
varied O O
between O O
-16 O O
% O O
and O O
+3 O O
% O O
. O O

The O O
adverse O O
effects O O
of O O
CAMPTOSAR B-brand B-brand
, O O
such O O
as O O
myelosuppression O O
and O O
diarrhea O O
, O O
would O O
be O O
expected O O
to O O
be O O
exacerbated O O
by O O
other O O
antineoplastic B-group B-group
agents I-group I-group
having O O
similar O O
adverse O O
effects O O
. O O

It O O
is O O
, O O
however O O
, O O
possible O O
that O O
concomitant O O
use O O
of O O
other O O
known O O
photosensitizing B-group O
agents I-group O
such O O
as O O
griseofulvin B-drug B-drug
, O O
thiazide B-group B-group
diuretics I-group I-group
, O O
sulfonylureas B-group B-group
, O O
phenothiazines B-group B-group
, O O
sulfonamides B-group B-group
and O O
tetracyclines B-group B-group
might O O
increase O O
the O O
photosensitivity O O
reaction O O
of O O
actinic O O
keratoses O O
treated O O
with O O
the O O
LEVULAN B-brand B-brand
KERASTICK I-brand B-brand
for O O
Topical O O
Solution O O
. O O

No O O
evaluation O O
of O O
EXTRANEALs B-brand B-brand
effects O O
on O O
the O O
cytochrome O O
P450 O O
system O O
was O O
conducted O O
. O O

These O O
increases O O
should O O
be O O
considered O O
when O O
selecting O O
an O O
oral O O
contraceptive B-group B-group
for O O
a O O
woman O O
taking O O
atorvastatin B-drug B-drug
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
has O O
been O O
reported O O
to O O
produce O O
clinically O O
significant O O
fluctuations O O
in O O
steady-state O O
serum O O
concentrations O O
of O O
various O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

In O O
patients O O
on O O
chronic O O
warfarin B-drug B-drug
therapy O O
, O O
the O O
prothrombin O O
time O O
( O O
INR O O
) O O
should O O
be O O
closely O O
monitored O O
in O O
the O O
2-week O O
period O O
, O O
particularly O O
at O O
7 O O
to O O
10 O O
days O O
, O O
following O O
initiation O O
of O O
the O O
3-day O O
regimen O O
of O O
Aprepitant B-drug B-drug
with O O
each O O
chemotherapy O O
cycle O O
. O O

Therefore O O
, O O
a O O
potent O O
effect O O
of O O
etofibrate B-drug B-drug
on O O
both O O
chylomicron O B-drug
lipolysis O O
and O O
remnant O O
removal O O
was O O
achieved O O
, O O
indicating O O
that O O
this O O
drug O O
can O O
be O O
used O O
to O O
improve O O
this O O
metabolism O O
in O O
future O O
prospective O O
studies O O
. O O

Antimycobacterial B-group O
: O O
rifampin B-drug B-drug

Patients O O
already O O
stabilized O O
on O O
valdecoxib B-drug B-drug
should O O
be O O
closely O O
monitored O O
for O O
loss O O
of O O
symptom O O
control O O
with O O
phenytoin B-drug B-drug
coadministration O O
. O O

There O O
were O O
26 O O
PI O O
with O O
drugs O O
of O O
low O O
intrinsic O O
value O O
( O O
7.6 O O
% O O
; O O
95 O O
% O O
CI O O
, O O
+/- O O
2.8 O O
) O O
. O O

Seizures O O
have O O
been O O
reported O O
in O O
patients O O
taking O O
another O O
quinolone B-group B-group
class I-group I-group
antimicrobial I-group I-group
and O O
the O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drug I-group I-group
fenbufen B-drug B-drug
concurrently O O
. O O

Monitoring O O
of O O
disopyramide B-drug B-drug
plasma O O
levels O O
is O O
recommended O O
in O O
such O O
concurrent O O
use O O
to O O
avoid O O
ineffective O O
therapy O O
. O O

Available O O
data O O
are O O
not O O
sufficient O O
, O O
however O O
, O O
to O O
predict O O
the O O
effects O O
of O O
concomitant O O
medication O O
on O O
patients O O
with O O
impaired O O
ventricular O O
function O O
or O O
cardiac O O
conduction O O
abnormalities O O
. O O

Withdrawal O O
of O O
rifampin B-drug B-drug
decreased O O
the O O
warfarin B-drug B-drug
requirement O O
by O O
50 O O
% O O
. O O

In O O
patients O O
who O O
have O O
received O O
general O O
anesthesia O O
utilizing O O
a O O
volatile O O
agent O O
known O O
to O O
sensitize O O
the O O
myocardium O O
to O O
catecholamines O O
, O O
administration O O
of O O
doxapram B-drug B-drug
should O O
be O O
delayed O O
until O O
the O O
volatile O O
agent O O
has O O
been O O
excreted O O
in O O
order O O
to O O
lessen O O
the O O
potential O O
for O O
arrhythmias O O
, O O
including O O
ventricular O O
tachycardia O O
and O O
ventricular O O
fibrillation O O
. O O

This O O
defect O O
in O O
the O O
failing O O
heart O O
can O O
be O O
mimicked O O
by O O
the O O
effects O O
of O O
uptake O O
blocking O O
agents O O
, O O
such O O
as O O
cocaine B-drug B-drug
and O O
desipramine B-drug B-drug
, O O
in O O
the O O
nonfailing O O
heart O O
only O O
. O O

Patients O O
treated O O
with O O
Nalfon B-brand B-brand
may O O
be O O
resistant O O
to O O
the O O
effects O O
of O O
loop B-group B-group
diuretics I-group I-group
. O O

In O O
Europe O O
, O O
Nimotop B-brand B-brand
was O O
observed O O
to O O
occasionally O O
intensify O O
the O O
effect O O
of O O
antihypertensive B-group B-group
compounds I-group I-group
taken O O
concomitantly O O
by O O
patients O O
suffering O O
from O O
hypertension O O
; O O

Inhibits O O
CYP2D6 O O
( O O
weak O O
) O O
. O O

Cholestyramine B-drug B-drug
, O O
an O O
anionic-binding O O
resin O B-group
, O O
has O O
a O O
considerable O O
effect O O
in O O
lowering O O
the O O
rate O O
and O O
extent O O
of O O
fluvastatin B-drug B-drug
bioavailability O O
. O O

Drugs O O
that O O
have O O
been O O
reported O O
to O O
diminish O O
oral O O
anticoagulant B-group B-group
response O O
, O O
ie O O
, O O
decreased O O
prothrom-bin O O
time O O
response O O
, O O
in O O
man O O
significantly O O
include O O
: O O
adrenocortical B-group B-group
steroids I-group I-group
; O O

Certain O O
concomitant O O
medications O O
( O O
such O O
as O O
rifampin B-drug B-drug
, O O
anticonvulsants B-group B-group
, O O
St O O
. O O

The O O
authors O O
investigated O O
the O O
possibility O O
of O O
a O O
similar O O
interaction O O
between O O
oxycodone B-drug B-drug
and O O
levofloxacin B-drug B-drug
. O O

The O O
successive O O
application O O
of O O
glycine B-drug B-drug
( O O
5 O O
or O O
10 O O
mg/kg O O
egg O O
weight O O
( O O
e.w O O
. O O
) O O

Combinations O O
of O O
clindamycin B-drug B-drug
and O O
gentamicin B-drug B-drug
were O O
indifferent O O
for O O
16 O O
and O O
synergistic O O
for O O
11 O O
of O O
the O O
resistant O O
strains O O
. O O

Concurrent O O
use O O
of O O
erythromycin B-drug B-drug
and O O
ergotamine B-drug B-drug
or O O
dihydroergotamine B-drug B-drug
has O O
been O O
associated O O
in O O
some O O
patients O O
with O O
acute O O
ergot O B-group
toxicity O O
characterized O O
by O O
severe O O
peripheral O O
vasospasm O O
and O O
dysesthesia O O
. O O

Triazolam B-drug B-drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
titrated O O
to O O
40 O O
mg/day O O
for O O
28 O O
days O O
) O O
and O O
the O O
CYP3A4 O O
substrate O O
triazolam B-drug B-drug
( O O
single O O
dose O O
of O O
0.25 O O
mg O O
) O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
either O O
citalopram B-drug B-drug
or O O
triazolam B-drug B-drug
. O O

Aprepitant B-drug B-drug
is O O
a O O
substrate O O
, O O
a O O
moderate O O
inhibitor O O
, O O
and O O
an O O
inducer O O
of O O
CYP3A4 O O
. O O

Due O O
to O O
highintersubject O O
variability O O
, O O
however O O
, O O
somepatients O B-group
may O O
experience O O
large O O
increases O O
inrifabutin B-drug B-drug
exposure O O
and O O
may O O
be O O
at O O
higher O O
riskfor O O
rifabutin O B-drug
toxicity O O
. O O

In O O
eight O O
experiments O O
the O O
perfusion O O
medium O O
contained O O
oxytocin B-drug B-drug
. O O

The O O
anticoagulant O O
effect O O
of O O
heparin B-drug B-drug
is O O
enhanced O O
by O O
concurrent O O
treatment O O
with O O
antithrombin B-drug O
III I-drug O
( O O
human O O
) O O
in O O
patients O O
with O O
hereditary O O
antithrombin O O
III O O
deficiency O O
. O O

After O O
multiple O O
dosing O O
, O O
interferon B-drug B-drug
beta-1a I-drug I-drug
( O O
AVONEX B-brand B-brand
30 O O
mcg O O
IM O O
once O O
weekly O O
) O O
reduced O O
TYSABRI B-brand B-brand
clearance O O
by O O
approximately O O
30 O O
% O O
. O O

Drug O O
interactions O O
between O O
NEUPOGEN B-brand B-brand
and O O
other O O
drugs O O
have O O
not O O
been O O
fully O O
evaluated O O
. O O

Fluconazole B-drug B-drug
, O O
an O O
inhibitor O O
of O O
P450 O O
2C9 O O
, O O
decreased O O
active O O
metabolite O O
concentration O O
and O O
increased O O
losartan B-drug B-drug
concentration O O
. O O

A O O
proposed O O
mechanism O O
for O O
the O O
potentiation O O
of O O
cAMP-mediated O O
acid O O
secretion O O
by O O
carbachol B-drug B-drug
. O O

Renal O O
Impairment O O
There O O
are O O
currently O O
no O O
clinical O O
studies O O
with O O
SPRYCEL B-brand B-brand
in O O
patients O O
with O O
impaired O O
renal O O
function O O
( O O
clinical O O
studies O O
have O O
excluded O O
patients O O
with O O
serum O O
creatinine O O
concentration O O
1.5 O O
times O O
the O O
upper O O
limit O O
of O O
the O O
normal O O
range O O
) O O
. O O

Limited O O
clinical O O
data O O
in O O
angina O O
patients O O
receiving O O
concomitant O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
and O O
digoxin B-drug B-drug
therapy O O
indicate O O
no O O
discernible O O
changes O O
in O O
serum O O
digoxin O B-drug
levels O O
. O O

FLEXERIL B-brand B-brand
may O O
enhance O O
the O O
effects O O
of O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
and O O
other O O
CNS B-group B-group
depressants I-group I-group
. O O

Interactions O O
of O O
cobalt B-drug B-drug
and O O
iron B-drug B-drug
in O O
absorption O O
and O O
retention O O
. O O

Adenosine B-drug B-drug
: O O
Dipyridamole B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
the O O
plasma O O
levels O O
and O O
cardiovascular O O
effects O O
of O O
adenosine B-drug B-drug
. O O

Cholestyramine B-drug B-drug
and O O
colestipol B-drug B-drug
resins B-group B-group
: O O
Absorption O O
of O O
hydrochlorothiazide B-drug B-drug
is O O
impaired O O
in O O
the O O
presence O O
of O O
anionic B-group O
exchange I-group O
resins I-group B-group
. O O

Beta-adrenergic B-group B-group
Blocking I-group I-group
Agents I-group I-group
: O O
The O O
effect O O
of O O
flurbiprofen B-drug B-drug
on O O
blood O O
pressure O O
response O O
to O O
propranolol B-drug B-drug
and O O
atenolol B-drug B-drug
was O O
evaluated O O
in O O
men O O
with O O
mild O O
uncomplicated O O
hypertension O O
( O O
n O O
= O O
10 O O
) O O
. O O

methyldopa B-drug B-drug
; O O

Because O O
the O O
nitrosourea B-group B-group
CCNU B-drug B-drug
is O O
given O O
exclusively O O
by O O
the O O
oral O O
route O O
in O O
man O O
, O O
we O O
have O O
carried O O
out O O
studies O O
in O O
mice O O
on O O
the O O
antitumour O O
activity O O
, O O
acute O O
toxicity O O
and O O
pharmacokinetics O O
of O O
oral O O
CCNU B-drug B-drug
, O O
either O O
alone O O
or O O
in O O
combination O O
with O O
the O O
chemosensitizer O O
misonidazole B-drug_n O
. O O

Given O O
the O O
primary O O
CNS O O
effects O O
of O O
Anafranil B-brand B-brand
, O O
caution O O
is O O
advised O O
in O O
using O O
it O O
concomitantly O O
with O O
other O O
CNS-active O O
drugs O O
. O O

This O O
may O O
occur O O
because O O
diflunisal B-drug B-drug
competitively O O
displaces O O
coumarins B-group B-group
from O O
protein O O
binding O O
sites O O
. O O

In O O
vivo O O
studies O O
: O O
Cytochrome O O
P450 O O
Inhibitors O O

These O O
potential O O
drug O O
interactions O O
are O O
listed O O
in O O
Table O O
4 O O
. O O

It O O
is O O
recommended O O
not O O
to O O
exceed O O
a O O
single O O
2.5 O O
mg O O
Vardenafil B-drug B-drug
dose O O
in O O
a O O
24-hour O O
period O O
when O O
used O O
in O O
combination O O
with O O
indinavir B-drug B-drug
. O O

Because O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
oral O O
miconazole B-drug B-drug
( O O
an O O
imidazole B-group B-group
) O O
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
, O O
such O O
a O O
potential O O
interaction O O
involving O O
the O O
latter O O
agents O O
when O O
used O O
concomitantly O O
with O O
ketoconazole B-drug B-drug
tablets O O
( O O
an O O
imidazole B-group B-group
) O O
can O O
not O O
be O O
ruled O O
out O O
. O O

The O O
oral O O
dexamethasone B-drug B-drug
doses O O
should O O
be O O
reduced O O
by O O
approximately O O
50 O O
% O O
when O O
coadministered O O
with O O
Aprepitant B-drug B-drug
, O O
to O O
achieve O O
exposures O O
of O O
dexamethasone B-drug B-drug
similar O O
to O O
those O O
obtained O O
when O O
it O O
is O O
given O O
without O O
Aprepitant B-drug B-drug
. O O

Beta-Blocking O B-group
Agents O I-group
A O O
pharmacokinetic O O
study O O
of O O
felodipine B-drug B-drug
in O O
conjunction O O
with O O
metoprolol B-drug B-drug
demonstrated O O
no O O
significant O O
effects O O
on O O
the O O
pharmacokinetics O O
of O O
felodipine B-drug B-drug
. O O

ROMAZICON B-brand B-brand
blocks O O
the O O
central O O
effects O O
of O O
benzodiazepines B-group B-group
by O O
competitive O O
interaction O O
at O O
the O O
receptor O O
level O O
. O O

Serum O O
Amylase O O
An O O
apparent O O
decrease O O
in O O
serum O O
amylase O O
activity O O
has O O
been O O
observed O O
in O O
patients O O
administered O O
EXTRANEAL B-brand B-brand
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
such O O
agents O O
is O O
indicated O O
, O O
they O O
should O O
be O O
given O O
with O O
caution O O
, O O
and O O
the O O
patient O O
's O O
serum O O
potassium O O
should O O
be O O
monitored O O
frequently O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isozyme O O
, O O
including O O
many O O
antidepressants B-group B-group
( O O
clozapine B-drug B-drug
, O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
, O O
and O O
others O O
) O O
, O O
may O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
, O O
and O O
thus O O
may O O
make O O
normal O O
metabolizers O O
resemble O O
poor O O
metabolizers O O
with O O
regard O O
to O O
concomitant O O
therapy O O
with O O
other O O
drugs O O
metabolized O O
by O O
this O O
enzyme O O
system O O
, O O
leading O O
to O O
drug O O
interaction O O
. O O

increased O O
alkaline O O

Ethanol B-drug B-drug
or O O
Triazolam B-drug B-drug
: O O
No O O
significant O O
differences O O
were O O
observed O O
in O O
the O O
pharmacokinetics O O
of O O
triazolam B-drug B-drug
( O O
0.125 O O
mg O O
) O O
and O O
tiagabine B-drug B-drug
( O O
10 O O
mg O O
) O O
when O O
given O O
together O O
as O O
a O O
single O O
dose O O
. O O

Studies O O
have O O
demonstrated O O
that O O
pretreatment O O
with O O
isoniazid B-drug B-drug
potentiates O O
a O O
cetaminophen O B-drug
hepatoxicity O O
in O O
rats O O
. O O

Ibogaine B-drug_n B-drug_n
attenuates O O
, O O
but O O
18-MC B-drug_n B-drug_n
potentiates O O
, O O
the O O
acute O O
locomotor O O
effects O O
of O O
morphine B-drug B-drug
; O O

The O O
carbamazepine B-drug B-drug
steady-state O O
Cmin O O
decreased O O
31 O O
% O O
to O O
5 O O
1 O O
micrograms/mL O O
when O O
felbamate B-drug B-drug
( O O
3000 O O
mg/day O O
, O O
divided O O
into O O
three O O
doses O O
) O O
was O O
coadministered O O
. O O

Sodium B-drug B-drug
cephalothin I-drug I-drug
may O O
enhance O O
the O O
nephrotoxicity O O
of O O
Coly-Mycin B-brand B-brand
M I-brand O
Parenteral O O
. O O

magnesium B-drug B-drug
salts O O
; O O

The O O
gradual O O
withdrawal O O
of O O
guafacine B-drug B-drug
or O O
a O O
cardioselective B-group B-group
beta-blocker I-group I-group
could O O
be O O
substituted O O
. O O

Refer O O
to O O
the O O
package O O
insert O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
preparations O O
with O O
Hydrochlorothiazide B-drug B-drug
. O O

Therefore O O
, O O
if O O
theophylline B-drug B-drug
is O O
co-administered O O
with O O
fluvoxamine B-drug B-drug
maleate I-drug I-drug
, O O
its O O
dose O O
should O O
be O O
reduced O O
to O O
one O O
third O O
of O O
the O O
usual O O
daily O O
maintenance O O
dose O O
and O O
plasma O O
concentrations O O
of O O
theophylline B-drug B-drug
should O O
to O O
monitored O O
. O O

Caution O O
in O O
using O O
concomitant O O
drugs O O
such O O
as O O
beta-blockers B-group B-group
( O O
ophthalmic O O
and O O
systemic O O
) O O
, O O
anti-hypertensives B-group B-group
and/or O O
cardiac B-group B-group
glycosides I-group I-group
is O O
advised O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
may O O
also O O
interact O O
with O O
sympathomimetics B-group B-group
. O O

EDECRIN B-brand B-brand
may O O
increase O O
the O O
ototoxic O O
potential O O
of O O
other O O
drugs O O
such O O
as O O
aminoglycoside B-group B-group
and O O
some O O
cephalosporin B-group B-group
antibiotics I-group I-group
. O O

A O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
with O O
copper O O
reduction O O
tests O O
( O O
Benedicts O O
or O O
Fehlings O O
solution O O
or O O
with O O
CLINITEST O O
tablets O O
) O O
, O O
but O O
not O O
with O O
enzyme-based O O
tests O O
for O O
glycosuria O O
( O O
e.g. O O
, O O
CLINISTIX O O
, O O
TES-TAPE O O
) O O
. O O

Immunosuppressants B-group B-group
: O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
sirolimus B-drug B-drug

Pentamidine B-drug B-drug
may O O
cause O O
hypoglycemia O O
, O O
which O O
may O O
sometimes O O
be O O
followed O O
by O O
hyperglycemia O O
. O O

quinine B-drug B-drug
; O O

This O O
effect O O
may O O
be O O
mediated O O
by O O
the O O
known O O
inhibition O O
of O O
hepatic O O
cytochrome O O
P- O O
450 O O
by O O
cimetidine B-drug B-drug
, O O
which O O
could O O
decrease O O
first O O
pass O O
metabolism O O
of O O
nimodipine B-drug B-drug
. O O

It O O
is O O
not O O
known O O
whether O O
this O O
potentiation O O
of O O
ampicillin B-drug B-drug
rashes O O
is O O
due O O
to O O
allopurinol B-drug B-drug
or O O
the O O
hyperuricemia O O
present O O
in O O
these O O
patients O O
. O O

Theophylline B-drug B-drug
: O O
Following O O
co-administration O O
of O O
two O O
250-mg O O
dirithromycin B-drug B-drug
tablets O O
administered O O
once O O
daily O O
with O O
200-mg O O
theophylline B-drug B-drug
tablets O O
administered O O
twice O O
daily O O
for O O
10 O O
days O O
to O O
14 O O
healthy O O
subjects O O
, O O
the O O
steady-state O O
plasma O O
concentration O O
of O O
theophylline B-drug B-drug
was O O
not O O
significantly O O
altered O O
. O O

These O O
reactions O O
have O O
also O O
been O O
reported O O
in O O
patients O O
who O O
have O O
discontinued O O
that O O
drug O O
and O O
have O O
been O O
started O O
on O O
a O O
MAOI B-group B-group
. O O

Zidovudine B-drug B-drug
: O O
There O O
is O O
no O O
significant O O
pharmacokinetic O O
interaction O O
between O O
ZDV B-drug B-drug
and O O
zalcitabine B-drug B-drug
which O O
has O O
been O O
confirmed O O
clinically O O
. O O

The O O
concomitant O O
use O O
of O O
transdermal O O
fentanyl B-drug B-drug
with O O
ritonavir B-drug B-drug
or O O
other O O
potent O O
3A4 O O
inhibitors O O
such O O
as O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
troleandomycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
and O O
nefazadone O B-drug
may O O
result O O
in O O
an O O
increase O O
in O O
fentanyl B-drug B-drug
plasma O O
concentrations O O
. O O

Most O O
( O O
98 O O
% O O
) O O
of O O
plasma O O
doxazosin B-drug B-drug
is O O
protein O O
bound O O
. O O

Tetracycline B-drug B-drug
, O O
a O O
bacteriostatic B-group B-group
antibiotic I-group I-group
, O O
may O O
antagonize O O
the O O
bactercidal O O
effect O O
of O O
penicillin B-drug B-drug
and O O
concurrent O O
use O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

Specific O O
interaction O O
studies O O
have O O
demonstrated O O
the O O
following O O
: O O
Cyclosporine B-drug B-drug
A I-drug O
: O O
During O O
the O O
first O O
day O O
of O O
concomitant O O
administration O O
, O O
trough O O
concentrations O O
of O O
bosentan B-drug B-drug
were O O
increased O O
by O O
about O O
30-fold O O
. O O

This O O
has O O
been O O
demonstrated O O
in O O
view O O
, O O
however O O
, O O
the O O
clinical O O
significance O O
of O O
this O O
interaction O O
is O O
not O O
well O O
documented O O
. O O

Ketoconazole B-drug B-drug
( O O
400 O O
mg O O
once O O
daily O O
) O O

Conflicting O O
results O O
have O O
been O O
reported O O
regarding O O
the O O
effects O O
of O O
EPA B-drug B-drug
supplements O O
on O O
glycemic O O
control O O
in O O
non-diabetics O O
with O O
glucose O O
intolerance O O
, O O
and O O
those O O
with O O
type O O
2 O O
diabetes O O
. O O

Hematology O O
: O O
TAXOL B-brand B-brand
therapy O O
should O O
not O O
be O O
administered O O
to O O
patients O O
with O O
baseline O O
neutrophil O O
counts O O
of O O
less O O
than O O
1,500 O O
cells/mm3 O O
. O O

However O O
, O O
another O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitor I-group I-group
has O O
been O O
found O O
to O O
produce O O
a O O
less O O
than O O
two-second O O
increase O O
in O O
prothrombin O O
time O O
in O O
healthy O O
volunteers O O
receiving O O
low O O
doses O O
of O O
warfarin B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
Co-administration O O
of O O
bosentan B-drug B-drug
500 O O
mg O O
b.i.d O O
. O O
for O O
6 O O
days O O
decreased O O
the O O
plasma O O
concentrations O O
of O O
both O O
S-warfarin B-drug B-drug_n
( O O
a O O
CYP2C9 O O
substrate O O
) O O
and O O
R-warfarin B-drug B-drug_n
( O O
a O O
CYP3A4 O O
substrate O O
) O O
by O O
29 O O
and O O
38 O O
% O O
, O O
respectively O O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

The O O
administration O O
of O O
local O O
anesthetic B-group B-group
solutions I-group O
containing O O
epinephrine B-drug B-drug
or O O
norepinephrine B-drug B-drug
to O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
or O O
phenothiazines B-group B-group
may O O
produce O O
severe O O
, O O
prolonged O O
hypotension O O
or O O
hypertension O O
. O O

Acid O O
secretion O O
in O O
isolated O O
rabbit O O
gastric O O
glands O O
was O O
monitored O O
by O O
the O O
accumulation O O
of O O
[ O O
( O O
14 O O
) O O
C O O
] O O
aminopyrine B-drug B-drug
. O O

Antiarrhythmics B-group B-group
: O O
bepridil B-drug B-drug
, O O
lidocaine B-drug B-drug
( O O
systemic O O
) O O
and O O
quinidine B-drug B-drug

Therefore O O
, O O
when O O
INDOCIN B-brand B-brand
and O O
INDOCIN B-brand B-brand
. O O

decreased O O
levels O O
of O O
anti-factor O O
Xa O O
and O O
antithrombin B-drug O
III I-drug O
, O O
decreased O O
antithrombin B-drug O
III I-drug O
activity O O
; O O

Anticoagulant B-brand B-group
therapy O O
should O O
be O O
monitored O O
, O O
particularly O O
during O O
the O O
first O O
few O O
weeks O O
, O O
after O O
initiating O O
therapy O O
with O O
BEXTRA B-brand B-brand
in O O
patients O O
receiving O O
warfarin B-drug B-drug
or O O
similar O O
agents O O
. O O

Based O O
on O O
in O O
vitro O O
data O O
, O O
no O O
interaction O O
would O O
be O O
expected O O
with O O
drugs O O
whose O O
metabolism O O
is O O
dependent O O
upon O O
cytochrome O O
P450 O O
isozymes O O
1A1 O O
, O O
1A2,2A6,2B6,2D6,2E1 O O
, O O
or O O
3A4 O O
. O O

Ketoconazole B-drug B-drug
: O O
Coadministration O O
of O O
ketoconazole B-drug B-drug
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
a O O
35 O O
% O O
increase O O
in O O
nelfinavir B-drug B-drug
plasma O O
A.C O O
. O O

Moreover O O
, O O
additional O O
interaction O O
studies O O
with O O
niacin B-drug B-drug
and O O
propranolol B-drug B-drug
have O O
not O O
demonstrated O O
any O O
effect O O
on O O
fluvastatin B-drug B-drug
plasma O O
levels O O
, O O
and O O
administration O O
to O O
a O O
patient O O
population O O
chronically O O
receiving O O
digoxin B-drug B-drug
resulted O O
in O O
no O O
difference O O
in O O
the O O
extent O O
of O O
bioavailability O O
of O O
digoxin B-drug B-drug
relative O O
to O O
control O O
data O O
. O O

The O O
initiation O O
of O O
alcohol B-drug B-drug
or O O
nicotine B-drug B-drug
use O O
may O O
be O O
precipitated O O
by O O
similar O O
personality O O
characteristics O O
in O O
the O O
user O O
, O O
such O O
as O O
impulsivity O O
and O O
sensation O O
seeking O O
. O O

ZINECARD B-brand B-brand
does O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
doxorubicin B-drug B-drug
. O O

FORADIL B-brand B-brand
should O O
not O O
be O O
used O O
as O O
a O O
substitute O O
for O O
oral O O
or O O
inhaled O O
corticosteroids B-group B-group
. O O

dmPGE2 B-drug_n B-drug_n
( O O
0.1-1.0 O O
mg/kg O O
, O O
p.o O O
. O O
) O O

A O O
subset O O
( O O
3 O O
% O O
-10 O O
% O O
) O O
of O O
the O O
population O O
has O O
reduced O O
activity O O
of O O
certain O O
drug O O
metabolizing O O
enzymes O O
such O O
as O O
the O O
cytochrome O O
P450 O O
isozyme O O
P450 O O
2D6 O O
. O O

It O O
may O O
also O O
produce O O
artifactually O O
low O O
results O O
in O O
dexamethasone O B-drug
or O O
metyrapone O O
tests O O
. O O

- O O
Reduced O O
response O O
to O O
metyrapone O O
test O O

Potential O O
drug O O
interactions O O
for O O
doxylamine B-drug B-drug
include O O
, O O
increased O O
sedation O O
if O O
doxylamine B-drug B-drug
is O O
combined O O
with O O
other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
. O O

Amprenavir B-drug B-drug
plus O O
rifabutin B-drug B-drug
was O O
poorly O O
tolerated O O
, O O
and O O
5 O O
of O O
11 O O
subjects O O
discontinued O O
therapy O O
. O O

Concurrent O O
administration O O
of O O
HEXALEN B-brand B-brand
and O O
antidepressants B-group B-group
of I-group O
the I-group O
MAO I-group B-group
inhibitor I-group I-group
class I-group I-group
may O O
cause O O
severe O O
orthostatic O O
hypotension.Cimetidine B-drug O
, O O
an O O
inhibitor O O
of O O
microsomal O O
drug O O
metabolism O O
, O O
increased O O
altretamines B-drug O
half-life O O
and O O
toxicity O O
in O O
a O O
rat O O
model O O
. O O

Anticholinesterases B-group B-group
: O O
Concomitant O O
use O O
of O O
anticholinesterase B-group B-group
agents I-group I-group
and O O
corticosteroids B-group B-group
may O O
produce O O
severe O O
weakness O O
in O O
patients O O
with O O
myasthenia O O
gravis O O
. O O

Such O O
information O O
assists O O
in O O
development O O
of O O
safe O O
dosing O O
regimens O O
, O O
prediction O O
of O O
abnormal O O
handling O O
of O O
drugs O O
in O O
states O O
of O O
disease O O
and O O
disorder O O
and O O
anticipation O O
of O O
drug O O
interactions O O
. O O

The O O
effect O O
of O O
administering O O
different O O
botulinum B-group B-group
neurotoxin I-group I-group
serotypes O O
at O O
the O O
same O O
time O O
or O O
within O O
several O O
months O O
of O O
each O O
other O O
is O O
unknown O O
. O O

In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
a O O
non- B-group B-group
steroidal I-group I-group
antiinflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic B-group B-group
, I-group O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium- O O
sparing O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Given O O
the O O
primary O O
CNS O O
effects O O
of O O
Clozapine B-drug B-drug
, O O
caution O O
is O O
advised O O
in O O
using O O
it O O
concomitantly O O
with O O
other O O
CNS-active O O
drugs O O
or O O
alcohol B-drug B-drug
. O O

This O O
suggests O O
that O O
an O O
interaction O O
of O O
aripiprazole B-drug B-drug
with O O
inhibitors O O
or O O
inducers O O
of O O
these O O
enzymes O O
, O O
or O O
other O O
factors O O
, O O
like O O
smoking O O
, O O
is O O
unlikely O O
. O O

Animal O O
reproduction O O
studies O O
, O O
however O O
, O O
are O O
not O O
always O O
predictive O O
of O O
human O O
response O O
and O O
there O O
are O O
no O O
adequate O O
and O O
well-controlled O O
studies O O
in O O
pregnant O O
women O O
. O O

Increased O O
plasma O O
HDL O O
and O O
HDL2 O O
cholesterol O O
subfraction O O
concentrations O O
, O O
reduced O O
LDL O O
cholesterol O O
concentration O O
, O O
increased O O
triglyceride O O
levels O O
. O O

The O O
urinary O O
excretion O O
of O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
is O O
unaffected O O
by O O
aspirin B-brand B-brand
, O O
indicating O O
no O O
change O O
in O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
absorption O O
. O O

Renal O O
function O O
should O O
be O O
monitored O O
carefully O O
if O O
high O O
doses O O
of O O
aminoglycosides B-group B-group
are O O
to O O
be O O
administered O O
with O O
MAXIPIME B-brand B-brand
because O O
of O O
the O O
increased O O
potential O O
of O O
nephrotoxicity O O
and O O
ototoxicity O O
of O O
aminoglycoside B-group B-group
antibiotics I-group I-group
. O O

Netilmicin B-drug B-drug
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
potent O O
loop B-group B-group
diuretics I-group I-group
such O O
as O O
furosemide B-drug B-drug
and O O
ethacrynic B-drug B-drug
acid I-drug I-drug
as O O
the O O
potential O O
for O O
ototoxicity O O
is O O
enhanced O O
by O O
the O O
combination O O
. O O

When O O
warfarin B-drug B-drug
is O O
co-administered O O
with O O
nevirapine B-drug B-drug
, O O
anticoagulation O O
levels O O
should O O
be O O
monitored O O
frequently O O
. O O

Sucralfate B-drug B-drug
administered O O
2 O O
hours O O
before O O
lomefloxacin B-drug B-drug
resulted O O
in O O
a O O
slower O O
absorption O O
( O O
mean O O
C O O
max O O
decreased O O
by O O
30 O O
% O O
and O O
mean O O
T O O
max O O
increased O O
by O O
1 O O
hour O O
) O O
and O O
a O O
lesser O O
extent O O
of O O
absorption O O
( O O
mean O O
AUC O O
decreased O O
by O O
approximately O O
25 O O
% O O
) O O
. O O

Medication O O
is O O
rarely O O
needed O O
. O O

Liver O O
Function O O
Tests O O
: O O
Since O O
elevations O O
of O O
liver O O
enzymes O O
have O O
been O O
observed O O
during O O
clinical O O
trials O O
, O O
and O O
hepatitis O O
has O O
been O O
reported O O
, O O
pretreatment O O
and O O
follow-up O O
liver O O
function O O
tests O O
should O O
be O O
performed O O
at O O
weekly O O
or O O
biweekly O O
intervals O O
until O O
the O O
response O O
to O O
Accutane B-brand B-brand
has O O
been O O
established O O

Renal O O
function O O
should O O
be O O
carefully O O
monitored O O
, O O
especially O O
if O O
higher O O
dosages O O
of O O
the O O
aminoglycosides B-group B-group
are O O
to O O
be O O
administered O O
or O O
if O O
therapy O O
is O O
prolonged O O
, O O
because O O
of O O
the O O
potential O O
nephrotoxicity O O
and O O
ototoxicity O O
of O O
aminoglycosidic B-group B-group
antibiotics I-group I-group
. O O

A O O
case O O
report O O
of O O
one O O
patient O O
taking O O
amiodarone B-drug B-drug
200 O O
mg O O
and O O
indinavir B-drug B-drug
800 O O
mg O O
three O O
times O O
a O O
day O O
resulted O O
in O O
increases O O
in O O
amiodarone B-drug B-drug
concentrations O O
from O O
0.9 O O
mg/L O O
to O O
1.3 O O
mg/L O O
. O O

The O O
addition O O
of O O
tiagabine B-drug B-drug
in O O
a O O
limited O O
number O O
of O O
patients O O
in O O
three O O
well-controlled O O
studies O O
caused O O
no O O
systematic O O
changes O O
in O O
phenobarbital B-drug B-drug
or O O
primidone B-drug B-drug
concentrations O O
when O O
compared O O
to O O
placebo O O
. O O

Therefore O O
, O O
injection O O
of O O
these O O
agents O O
into O O
patients O O
receiving O O
thyroid B-group B-group
preparations I-group I-group
increases O O
the O O
risk O O
of O O
precipitating O O
coronary O O
insufficiency O O
especially O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

Here O O
, O O
we O O
have O O
examined O O
whether O O
METH B-drug B-drug
administration O O
affects O O
expression O O
of O O
an O O
effector O O
IEG O O
arc O O
( O O
activity-regulated O O
, O O
cytoskeleton-associated O B-drug_n
) O O
that O O
encodes O O
a O O
protein O O
with O O
homology O O
to O O
spectrin O O
. O O

Lotensin B-brand B-brand
has O O
been O O
used O O
concomitantly O O
with O O
beta-adrenergic-blocking B-group B-group
agents I-group I-group
, O O
calcium-channel-blocking B-group B-group
agents I-group I-group
, O O
diuretics B-group B-group
, O O
digoxin B-drug B-drug
, O O
and O O
hydralazine B-drug B-drug
, O O
without O O
evidence O O
of O O
clinically O O
important O O
adverse O O
interactions O O
. O O

These O O
pharmacokinetic O O
effects O O
seen O O
during O O
diltiazem B-drug B-drug
coadministration O O
can O O
result O O
in O O
increased O O
clinical O O
effects O O
( O O
e.g. O O
, O O
prolonged O O
sodation O O
) O O
of O O
both O O
midazolam B-drug B-drug
and O O
triazolam B-drug B-drug
. O O

Combinations O O
of O O
clozapine B-drug B-drug
and O O
phencyclidine B-drug_n B-drug
: O O
effects O O
on O O
drug O O
discrimination O O
and O O
behavioral O O
inhibition O O
in O O
rats O O
. O O

No O O
drug O O
interaction O O
studies O O
were O O
performed O O
. O O

RESULTS O O
: O O
Everolimus B-drug B-drug
steady O O
state O O
was O O
reached O O
on O O
or O O
before O O
day O O
7 O O
, O O
with O O
a O O
median O O
3-fold O O
accumulation O O
of O O
drug O O
exposure O O
compared O O
with O O
that O O
after O O
the O O
first O O
postoperative O O
dose O O
. O O

The O O
binding O O
of O O
thyroxine O O
by O O
thyroxine-binding O O
prealbumin O O
( O O
TBPA O O
) O O
is O O
inhibited O O
by O O
salicylates B-group B-group

Warfarin B-drug B-drug
: O O
Eszopiclone B-drug B-drug
3 O I-drug
mg O O
administered O O
daily O O
for O O
5 O O
days O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
( O O
R O O
) B-drug O
- I-drug O
or I-drug O
( I-drug B-drug_n
S I-drug I-drug_n
) I-drug I-drug_n
-warfarin I-drug I-drug_n
, O O
nor O O
were O O
there O O
any O O
changes O O
in O O
the O O
pharmacodynamic O O
profile O O
( O O
prothrombin O O
time O O
) O O
following O O
a O O
single O O
25 O O
mg O O
oral O O
dose O O
of O O
warfarin B-drug B-drug

The O O
patient O O
continued O O
to O O
receive O O
intermittent O O
hemodialysis O O
until O O
his O O
death O O
from O O
infectious O O
complications O O
that O O
occurred O O
three O O
months O O
after O O
admission O O
. O O

Pharmacoeconomic O O
analyses O O
indicate O O
that O O
olanzapine B-drug B-drug
does O O
not O O
significantly O O
increase O O
, O O
and O O
may O O
even O O
decrease O O
, O O
the O O
overall O O
direct O O
treatment O O
costs O O
of O O
schizophrenia O O
, O O
compared O O
with O O
haloperidol B-drug B-drug
. O O

In O O
spite O O
of O O
the O O
absence O O
of O O
kidney O O
function O O
, O O
the O O
value O O
of O O
the O O
elimination O O
rate O O
constant O O
was O O
significantly O O
decreased O O
in O O
the O O
presence O O
of O O
probenecid B-drug B-drug
( O O
from O O
0.326 O O
to O O
0.263/h O O
) O O
. O O

Information O O
on O O
precautions O O
and O O
contraindications O O
, O O
indications O O
, O O
use O O
instructions O O
, O O
and O O
instructions O O
for O O
appropriate O O
actions O O
after O O
missing O O
a O O
pill O O
is O O
appended O O
. O O

Alcohol B-drug B-drug
: O O
Has O O
a O O
synergistic O O
effect O O
with O O
aspirin B-brand B-brand
in O O
causing O O
gastrointestinal O O
bleeding O O
. O O

Immunosuppressive B-group B-group
drugs I-group I-group
and O O
their O O
complications O O
. O O

Current O O
immunosuppressive O B-group
therapies O I-group
are O O
effective O O
but O O
can O O
be O O
associated O O
with O O
significant O O
adverse O O
reactions O O
. O O

In O O
addition O O
, O O
there O O
was O O
no O O
pharmacodynamic O O
interaction O O
as O O
a O O
result O O
of O O
coadministration O O
of O O
zaleplon B-drug B-drug
and O O
venlafaxine B-drug B-drug
ER O O
. O O

Increases O O
in O O
plasma O O
levels O O
of O O
tricyclic B-drug B-group
antidepressants I-drug I-group
, O O
and O O
in O O
the O O
frequency O O
and O O
severity O O
of O O
side O O
effects O O
, O O
particularly O O
anticholinergic B-drug O
, O O
have O O
been O O
reported O O
when O O
cimetidine B-drug B-drug
was O O
added O O
to O O
the O O
drug B-drug O
regimen O O
. O O

The O O
mechanism O O
of O O
resveratrol-induced B-drug_n B-drug
vasorelaxation O O
differs O O
in O O
the O O
mesenteric O O
resistance O O
arteries O O
of O O
lean O O
and O O
obese O O
rats O O
. O O

clinical O O
implications O O
are O O
unclear O O
. O O

When O O
the O O
muscle O O
was O O
exposed O O
to O O
the O O
potassium-depleted O O
solution O O
, O O
the O O
first O O
contractile O O
response O O
to O O
PTX B-drug_n B-drug_n
was O O
rather O O
potentiated O O
. O O

Addition O O
or O O
deletion O O
of O O
any O O
drug O O
from O O
the O O
therapeutic O O
regimen O O
of O O
patients O O
receiving O O
oral O O
anticoagulants B-group B-group
may O O
affect O O
patient O O
response O O
to O O
the O O
anticoagulant B-group B-group
. O O

Concomitant O O
use O O
of O O
agents O O
in O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
class I-group I-group
( O O
which O O
includes O O
Anafranil B-brand B-brand
) O O
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
agent I-group I-group
or O O
the O O
other O O
drug O O
. O O

Patients O O
receiving O O
other O O
narcotic B-group B-group
analgesics O I-group
, O O
general O O
anesthetics B-group B-group
, O O
phenothiazines B-group B-group
, O O
tranquilizers B-group B-group
, O O
sedative-hypnotics B-group B-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
including O O
alcohol B-drug B-drug
) O O
concomitantly O O
with O O
DILAUDID B-brand B-brand
may O O
exhibit O O
an O O
additive O O
CNS O O
depression O O
. O O

In O O
vitro O O
studies O O
of O O
human O O
CYP O O
enzymes O O
showed O O
that O O
entacapone B-drug B-drug
inhibited O O
the O O
CYP O O
enzymes O O
1A2 O O
, O O
2A6 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
2E1 O O
and O O
3A O O
only O O
at O O
very O O
high O O
concentrations O O
( O O
IC50 O O
from O O
200 O O
to O O
over O O
1000 O O
uM O O
; O O

900 O O

NSAIDs B-group B-group
: O O
In O O
in O O
vitro O O
studies O O
, O O
M1 O O
was O O
shown O O
to O O
cause O O
increases O O
ranging O O
from O O
13 O O
- O O
50 O O
% O O
in O O
the O O
free O O
fraction O O
of O O
diclofenac B-drug B-drug
and O O
ibuprofen B-drug B-drug
at O O
concentrations O O
in O O
the O O
clinical O O
range O O
. O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

Hydrochlorothiazide B-drug B-drug
: O O
In O O
normal O O
volunteers O O
, O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
hydrochlorothiazide B-drug B-drug
resulted O O
in O O
significantly O O
increased O O
plasma O O
levels O O
of O O
hydrochlorothiazide B-drug B-drug
. O O

Enhanced O O
theophylline B-drug B-drug
clearance O O
secondary O O
to O O
phenytoin B-drug B-drug
therapy O O
. O O

Glyburide B-drug B-drug
: O O
An O O
increased O O
risk O O
of O O
elevated O O
liver O O
aminotransferases O O
was O O
observed O O
in O O
patients O O
receiving O O
concomitant O O
therapy O O
with O O
glyburide B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
an O O
aluminum-containing B-drug B-group
antacid B-group I-group
had O O
no O O
significant O O
effect O O
in O O
the O O
bioavailability O O
of O O
6MNA B-drug_n B-drug_n
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
MICRONASE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Although O O
the O O
interaction O O
between O O
almotriptan B-drug B-drug
and O O
other O O
potent O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
itraconazole B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
and O O
erythromycin B-drug B-drug
) O O
has O O
not O O
been O O
studied O O
, O O
increased O O
exposures O O
to O O
almotriptan B-drug B-drug
may O O
be O O
expected O O
when O O
almotriptan B-drug B-drug
is O O
used O O
concomitantly O O
with O O
these O O
medications O O
. O O

Pretreatment O O
and O O
follow-up O O
measurements O O
should O O
be O O
obtained O O
under O O
fasting O O
conditions O O
. O O

Ergotamine B-drug B-drug
or O O
dihydroergotamine B-drug B-drug
acute O O
ergot O B-group
toxicity O O
characterized O O
by O O
severe O O
peripheral O O
vasospasm O O
and O O
dysesthesia O O
. O O

Interactions O O
with O O
Other O O
CNS O B-group
Agents O I-group
: O O
Concurrent O O
use O O
of O O
Levo-Dromoran B-brand B-brand
with O O
all O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
( O O
eg O O
, O O
alcohol B-drug B-drug
, O O
sedatives B-group B-group
, O O
hypnotics B-group B-group
, O O
other O O
opioids B-group B-group
, O O
general O O
anesthetics B-group B-group
, O O
barbiturates B-group B-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
phenothiazines B-group B-group
, O O
tranquilizers B-group B-group
, O O
skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
and O O
antihistamines B-group B-group
) O O
may O O
result O O
in O O
additive O O
central O O
nervous O O
system O O
depressant O O
effects O O
. O O

Propantheline B-drug B-drug
and O O
diphenoxylate B-drug B-drug
, O O
by O O
decreasing O O
gut O O
motility O O
, O O
may O O
increase O O
digoxin B-drug B-drug
absorption O O
. O O

If O O
taken O O
1 O O
hour O O
before O O
indinavir B-drug B-drug
( O O
IDV B-drug O
) O O
, O O
didanosine B-drug B-drug
does O O
not O O
affect O O
IDV B-drug O
exposure O O
, O O
despite O O
persistent O O
buffering O O
effects O O
. O O

5 O O
. O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
propafenone B-drug B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

The O O
effect O O
of O O
concomitant O O
administration O O
of O O
fluconazole B-drug B-drug
and O O
glipizide B-drug B-drug
has O O
been O O
demonstrated O O
in O O
a O O
placebo-controlled O O
crossover O O
study O O
in O O
normal O O
volunteers O O
. O O

However O O
, O O
in O O
the O O
second O O
study O O
, O O
administration O O
of O O
12 O O
g O O
cholestyramine B-drug B-drug
1 O O
hour O O
before O O
the O O
evening O O
meal O O
and O O
0.3 O O
mg O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
approximately O O
4 O O
hours O O
after O O
the O O
same O O
evening O O
meal O O
resulted O O
in O O
a O O
decrease O O
in O O
the O O
cerivastatin B-drug O
AUC O O
of O O
less O O
than O O
8 O O
% O O
, O O
and O O
a O O
decrease O O
in O O
Cmax O O
of O O
about O O
30 O O
% O O
when O O
compared O O
to O O
dosing O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
alone O O
. O O

These O O
results O O
suggest O O
that O O
the O O
hepatoxicity O O
of O O
ethanol B-drug B-drug
in O O
alcoholic O B-drug
beverages O O
is O O
enhanced O O
by O O
interaction O O
with O O
its O O
congeners O O
and O O
acetaldehyde B-drug_n B-drug
; O O

It O O
is O O
now O O
clear O O
that O O
topoisomerase O O
activity O O
level O O
is O O
an O O
important O O
determinant O O
of O O
sensitivity O O
to O O
topo O O
drugs O O
. O O

( O O
See O O
CLINICAL O O
PHARMACOLOGY O O
) O O
Coadministration O O
of O O
Femara B-brand B-brand
and O O
tamoxifen B-drug B-drug
20 O O
mg O O
daily O O
resulted O O
in O O
a O O
reduction O O
of O O
letrozole B-drug B-drug
plasma O O
levels O O
by O O
38 O O
% O O
on O O
average O O
. O O

however O O
, O O
the O O
total O O
amount O O
of O O
6MNA B-drug_n B-drug_n
in O O
the O O
plasma O O
is O O
unchanged O O
. O O

Therefore O O
, O O
amiodarone B-drug B-drug
has O O
the O O
potential O O
for O O
interactions O O
with O O
drugs O O
or O O
substances O O
that O O
may O O
be O O
substrates O O
, O O
inhibitors O O
or O O
inducers O O
of O O
CYP3A4 O O
. O O

Neither O O
racemic O O
warfarin B-drug B-drug
nor O O
isradipine B-drug B-drug
binding O O
to O O
plasma O O
proteins O O
in O O
vitro O O
was O O
altered O O
by O O
the O O
addition O O
of O O
the O O
other O O
drug O O
. O O

These O O
agents O O
, O O
including O O
norfloxacin B-drug B-drug
, O O
ciprofloxacin B-drug B-drug
, O O
ofloxacin B-drug B-drug
, O O
enoxacin B-drug B-drug
, O O
and O O
lomefloxacin B-drug B-drug
, O O
have O O
been O O
extensively O O
studied O O
and O O
have O O
demonstrated O O
efficacy O O
and O O
safety O O
profiles O O
comparable O O
to O O
those O O
of O O
other O O
traditional O O
agents O O
for O O
the O O
treatment O O
of O O
complicated O O
or O O
uncomplicated O O
urinary O O
tract O O
infections O O
and O O
prostatitis O O
. O O

Furosemide B-drug B-drug
: O O
When O O
aliskiren B-drug B-drug
was O O
co-administered O O
with O O
furosemide B-drug B-drug
, O O
the O O
AUC O O
and O O
Cmax O O
of O O
furosemide B-drug B-drug
were O O
reduced O O
by O O
about O O
30 O O
% O O
and O O
50 O O
% O O
, O O
respectively O O
. O O

Treatment O O
with O O
antidepressant B-group B-group
drugs I-group I-group
can O O
directly O O
interfere O O
with O O
blood O O
glucose O O
levels O O
or O O
may O O
interact O O
with O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

Ethinyl B-drug B-drug
Estradiol I-drug I-drug
and O O
Norethindrone B-drug B-drug
: O O
Coadministration O O
of O O
VIRACEPT B-brand B-brand
with O O
OVCON-35 B-brand B-brand
resulted O O
in O O
a O O
47 O O
% O O
decrease O O
in O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
an O O
18 O O
% O O
decrease O O
in O O
norethindrone B-drug B-drug
plasma O O
concentrations O O
. O O

- O O
Sulfoxone B-drug B-brand
( O O
e.g. O O
, O O
Diasone B-brand B-brand
) O O
or O O

The O O
8.5 O O
% O O
incidence O O
of O O
akathisia O O
, O O
however O O
, O O
is O O
within O O
the O O
range O O
reported O O
for O O
use O O
of O O
prochlorperazine B-drug B-drug
when O O
given O O
as O O
a O O
premedication O O
for O O
other O O
chemotherapies O O
. O O

- O O
a O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drug I-group I-group
( O O
NSAID B-group B-group
) O O
such O O
as O O
ibuprofen B-drug B-drug
( O O
Motrin B-brand B-brand
, O O
Advil B-brand B-brand
, O O
Nuprin B-brand B-brand
, O O
others O O
) O O
, O O
ketoprofen B-drug B-drug
( O O
Orudis B-brand B-brand
, O O
Orudis B-brand B-brand
KT I-brand O
, O O
Oruvail B-brand B-brand
) O O
, O O
diclofenac B-drug B-drug
( O O
Voltaren B-brand B-brand
, O O
Cataflam B-brand B-brand
) O O
, O O
etodolac B-drug B-drug
( O O
Lodine B-brand B-brand
) O O
, O O
indomethacin B-drug B-drug
( O O
Indocin B-brand B-brand
) O O
, O O
nabumetone B-drug B-drug
( O O
Relafen B-brand B-brand
) O O
, O O
oxaprozin B-drug B-drug
( O O
Daypro B-brand B-brand
) O O
, O O
and O O
naproxen B-drug B-drug
( O O
Anaprox B-brand B-brand
, O O
Naprosyn B-brand B-brand
, O O
Aleve B-brand B-brand
) O O
; O O

However O O
, O O
when O O
any O O
additional O O
drug O O
, O O
including O O
INDOCIN B-brand B-brand
, O O
is O O
added O O
to O O
the O O
treatment O O
of O O
patients O O
on O O
anticoagulant B-group B-group
therapy O O
, O O
the O O
patients O O
should O O
be O O
observed O O
for O O
alterations O O
of O O
the O O
prothrombin O O
time O O
. O O

Lorazepam B-drug B-drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
eszopiclone B-drug B-drug
3 O I-drug
mg O O
and O O
lorazepam B-drug B-drug
2 O O
mg O O
did O O
not O O
have O O
clinically O O
relevant O O
effects O O
on O O
the O O
pharmacodynamics O O
or O O
pharmacokinetics O O
of O O
either O O
drug O O
. O O

Drug O O
Interaction O O
During O O
Pregnancy O O
: O O
Cromolyn B-drug B-brand
sodium I-drug I-drug
and O O
isoproterenol B-drug B-drug
were O O
studied O O
following O O
subcutaneous O O
injections O O
in O O
pregnant O O
mice O O
. O O

Symptoms O O
resolved O O
within O O
a O O
few O O
hours O O
. O O

The O O
threohydrobupropion B-drug_n O
metabolite O O
of O O
bupropion B-drug B-drug
does O O
not O O
appear O O
to O O
be O O
produced O O
by O O
the O O
cytochrome O O
P450 O O
isoenzymes O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
DIABINESE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Concurrent O O
use O O
of O O
these O O
agents O O
should O O
generally O O
be O O
avoided O O
. O O

In O O
the O O
case O O
that O O
you O O
are O O
taking O O
digoxin B-drug B-drug
while O O
taking O O
aminosalicylic B-drug B-drug
acid I-drug I-drug
, O O
higher O O
doses O O
of O O
digoxin B-drug B-drug
may O O
be O O
needed O O
. O O

no O O
evidence O O
of O O
mutagenicity O O
was O O
observed O O
. O O

Further O O
, O O
in O O
rabbits O O
dosed O O
at O O
0.25 O O
mg/kg/day O O
( O O
about O O
one-half O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
, O O
increases O O
in O O
placental O O
weight O O
and O O
post-implantation O O
loss O O
were O O
observed O O
but O O
, O O
there O O
were O O
no O O
observed O O
effects O O
on O O
fetal O O
development O O
. O O

The O O
following O O
are O O
examples O O
of O O
substances O O
that O O
may O O
reduce O O
the O O
blood-glucose-lowering O O
effect O O
of O O
insulin B-drug B-drug
: O O
corticosteroids B-group B-group
, O O
danazol B-drug B-drug
, O O
diuretics B-group B-group
, O O
sympathomimetic B-group B-group
agents I-group I-group
( O O
e.g. O O
, O O
epinephrine B-drug B-drug
, O O
albuterol B-drug B-drug
, O O
terbutaline B-drug B-drug
) O O
, O O
isoniazid B-drug B-drug
, O O
phenothiazine B-group B-group
derivatives I-group I-group
, O O
somatropin B-drug B-drug
, O O
thyroid B-group B-group
hormones I-group I-group
, O O
estrogens B-group B-group
, O O
progestogens B-group B-group
( O O
e.g. O O
, O O
in O O
oral O O
contraceptives B-group B-group
) O O
. O O

In O O
order O O
to O O
monitor O O
the O O
occurrence O O
of O O
myelotoxicity O O
, O O
it O O
is O O
recommended O O
that O O
frequent O O
peripheral O O
blood O O
cell O O
counts O O
be O O
performed O O
on O O
all O O
patients O O
receiving O O
TAXOL B-brand B-brand
. O O

Acid-base O O
and O O
electrolyte O O
alterations O O
were O O
not O O
reported O O
in O O
the O O
clinical O O
trials O O
with O O
brinzolamide B-drug B-drug
. O O

. O O

Albendazole B-drug B-drug
sulfoxide I-drug I-drug
plasma O O
concentrations O O
were O O
unchanged O O
4 O O
hours O O
after O O
dosing O O
. O O

HIV B-group B-group
Antiviral I-group I-group
Agents I-group I-group

Drugs O O
that O O
inhibit O O
or O O
Induce O O
CYP O O
2D6 O O
and O O
CYP O O
3A4 O O
may O O
affect O O
the O O
concentration O O
on O O
Aricept B-brand B-brand
. O O

The O O
optimal O O
dosing O O
interval O O
for O O
coadministration O O
with O O
VIDEX B-brand B-brand
should O O
be O O
determined O O
by O O
consulting O O
the O O
appropriate O O
quinolone B-group B-group
package O O
insert O O
. O O

Itraconazole B-drug B-drug
decreases O O
busulfan B-drug B-drug
clearance O O
by O O
up O O
to O O
25 O O
% O O
, O O
and O O
may O O
produce O O
AUCs O O
1500 O O
M O O
min O O
in O O
some O O
patients O O
. O O

Antacids B-group B-group
: O O
Concomitant O O
administration O O
of O O
antacids B-group B-group
containing O O
magnesium B-drug B-drug
or O O
aluminum B-drug B-drug
with O O
VIDEX B-brand B-brand
Chewable/Dispersible O O
Buffered O O
Tablets O O
or O O
Pediatric O O
Powder O O
for O O
Oral O O
Solution O O
may O O
potentiate O O
adverse O O
events O O
associated O O
with O O
the O O
antacid B-group B-group
components O I-group
. O O

This O O
article O O
will O O
describe O O
the O O
escalating O O
use O O
of O O
herbal O O
therapy O O
and O O
the O O
hazards O O
of O O
herbal O O
remedy O O
use O O
among O O
patients O O
. O O

Nelfinavir B-drug B-drug

Interferon O B-drug
induction O O
: O O
tool O O
for O O
establishing O O
interactions O O
among O O
homopolyribonucleotides O O
. O O

- O O
Pressor O B-group
amines O I-group
( O O
e.g. O O
, O O
norepinephrine B-drug B-drug
) O O
: O O
Possible O O
decreased O O
response O O
to O O
pressor O B-group
amines O I-group
but O O
not O O
sufficient O O
to O O
preclude O O
their O O
use O O

This O O
study O O
demonstrated O O
that O O
the O O
potent O O
cytochrome O O
P450 O O
enzyme-inducer O O
phenytoin B-drug B-drug
did O O
indeed O O
have O O
a O O
marked O O
effect O O
on O O
the O O
metabolism O O
of O O
quetiapine B-drug B-drug
, O O
resulting O O
in O O
a O O
5-fold O O
increase O O
in O O
clearance O O
when O O
administered O O
concomitantly O O
to O O
patients O O
with O O
DSM-IV-diagnosed O O
schizophrenia O O
, O O
schizoaffective O O
disorder O O
, O O
or O O
bipolar O O
disorder O O
. O O

Accordingly O O
, O O
when O O
diflunisal B-drug B-drug
is O O
administered O O
with O O
oral O O
anticoagulants B-group B-group
, O O
the O O
prothrombin O O
time O O
should O O
be O O
closely O O
monitored O O
during O O
and O O
for O O
several O O
days O O
after O O
concomitant O O
drug O O
administration O O
. O O

Imidazoles B-group O
( O O
e. O O
g. O O
, O O
ketoconazole B-drug B-drug
, O O
miconazole B-drug B-drug
, O O
clotrimazole B-drug B-drug
, O O
fluconazole B-drug B-drug
, O O
etc O O
. O O
) O O
: O O
in O O
vitro O O
and O O
animal O O
studies O O
with O O
the O O
combination O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
and O O
imidazoles B-group O
suggest O O
that O O
imidazoles B-group O
may O O
induce O O
fungal O O
resistance O O
to O O
amphotericin B-drug B-drug
B I-drug I-drug
. O O

Phenobarbital B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenobarbital B-drug B-drug
; O O

Benzodiazepines B-group B-group

A O O
study O O
in O O
rats O O
to O O
assess O O
the O O
carcinogenic O O
potential O O
of O O
ribavirin B-drug B-drug
is O O
ongoing O O
. O O

Although O O
bupropion B-drug B-drug
is O O
not O O
metabolized O O
by O O
this O O
isoenzyme O O
, O O
bupropion B-drug B-drug
and O O
hydroxybupropion B-drug_n O
are O O
inhibitors O O
of O O
the O O
CYP2D6 O O
isoenzyme O O
in O O
vitro O O
. O O

Although O O
there O O
have O O
been O O
no O O
formal O O
interaction O O
studies O O
other O O
than O O
with O O
antipyrine B-drug B-drug
, O O
based O O
on O O
these O O
in O O
vivo O O
and O O
in O O
vitro O O
studies O O
, O O
it O O
is O O
unlikely O O
that O O
co-administration O O
of O O
a O O
1 O O
mg O O
dose O O
of O O
ARIMIDEX B-brand B-brand
with O O
other O O
drugs O O
will O O
result O O
in O O
clinically O O
significant O O
drug O O
inhibition O O
of O O
cytochrome O O
P450-mediated O O
metabolism O O
of O O
the O O
other O O
drugs O O
. O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
, O O
a O O
renal O O
tubular O O
secretion O O
blocking O O
agent O O
, O O
administered O O
at O O
a O O
dose O O
of O O
500 O O
mg O O
four O O
times O O
a O O
day O O
, O O
did O O
not O O
change O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
1000 O O
mg O O
twice O O
daily O O
. O O

18-MC B-drug_n B-drug_n
does O O
not O O
produce O O
these O O
effects O O
. O O

Plasma O O
levels O O
of O O
flecainide B-drug B-drug
have O O
been O O
reported O O
to O O
increase O O
in O O
the O O
presence O O
of O O
oral O O
amiodarone B-drug B-drug
; O O

No O O
increase O O
in O O
mortality O O
was O O
observed O O
in O O
patients O O
taking O O
digoxin B-drug B-drug
as O O
concomitant O O
medication O O
. O O

However O O
, O O
if O O
the O O
patients O O
thyroid O O
gland O O
has O O
sufficient O O
function O O
, O O
the O O
decreased O O
free O O
thyroxine B-drug B-drug
will O O
result O O
in O O
a O O
compensatory O O
increase O O
in O O
thyroxine O O
output O O
by O O
the O O
thyroid O O
. O O

The O O
drug O O
interaction O O
data O O
described O O
in O O
this O O
section O O
were O O
obtained O O
from O O
studies O O
involving O O
healthy O O
adults O O
and O O
adult O O
patients O O
with O O
epilepsy O O
. O O

Administration O O
of O O
repeat O O
doses O O
of O O
FACTIVE B-brand B-brand
had O O
no O O
effect O O
on O O
the O O
repeat O O
dose O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
, O O
digoxin B-drug B-drug
or O O
an O O
ethinylestradiol/levonorgestrol B-drug B-drug
oral O O
contraceptive B-group B-group
product I-group I-group
in O O
healthy O O
subjects O O
. O O

There O O
was O O
no O O
change O O
after O O
a O O
single O O
dose O O
of O O
PGF2alpha B-drug B-drug
. O O

Studies O O
in O O
vitro O O
show O O
that O O
caspofungin B-drug B-drug
acetate I-drug I-drug
is O O
not O O
an O O
inhibitor O O
of O O
any O O
enzyme O O
in O O
the O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
system O O
. O O

Salicylates-Salicylates B-group B-group
in O O
large O O
doses O O
may O O
inhibit O O
vitamin O O
K O O
epoxide O O
reductase O O
resulting O O
in O O
vitamin O B-group
K O I-group
deficiency O O
. O O

During O O
co-administration O O
, O O
systemic O O
levels O O
of O O
TMP B-drug O
and O O
SMX B-drug B-drug_n
were O O
essentially O O
unchanged O O
. O O

After O O
incubation O O
at O O
0 O O
degrees O O
C O O
for O O
4 O O
h O O
this O O
number O O
fell O O
to O O
2.3 O O
plus O O
or O O
minus O O
0.1 O O
S.E.M O O
. O O

- O O
Valproic B-drug B-drug
acid I-drug I-drug
( O O
e.g. O O
, O O
Depakene B-brand B-brand
) O O
Use O O
of O O
sulfapyridine B-drug B-drug
with O O
these O O
medicines O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O

Ketoconazole B-drug B-drug
tablets O O
may O O
alter O O
the O O
metabolism O O
of O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
and O O
methylprednisolone B-drug B-drug
, O O
resulting O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
the O O
latter O O
drugs O O
. O O

- O O
The O O
action O O
of O O
sulphonylureas B-group B-group
and O O
insulin B-drug B-drug
may O O
be O O
enhanced O O
by O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
. O O

However O O
, O O
these O O
studies O O
did O O
not O O
show O O
whether O O
ginsenosides-induced B-drug_n B-drug
inhibition O O
of O O
Ca O O
( O O
2+ O O
) O O
currents O O
discriminates O O
among O O
the O O
various O O
Ca O O
( O O
2+ O O
) O O
channel O O
subtypes O O
, O O
although O O
it O O
is O O
known O O
that O O
there O O
are O O
at O O
least O O
five O O
different O O
Ca O O
( O O
2+ O O
) O O
channel O O
subtypes O O
in O O
neuronal O O
cells O O
. O O

Concomitant O O
administration O O
of O O
erythromycin B-drug B-drug
and O O
digoxin B-drug B-drug
has O O
been O O
reported O O
to O O
result O O
in O O
elevated O O
digoxin B-drug B-drug
serum O O
levels O O
. O O

Differential O O
actions O O
of O O
intrathecal O O
naloxone B-drug B-drug
on O O
blocking O O
the O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta-endorphin B-drug_n B-drug
and O O
morphine B-drug B-drug
in O O
rats O O
. O O

While O O
taking O O
beta B-group B-group
blockers I-group I-group
, O O
patients O O
with O O
a O O
history O O
of O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
have O O
a O O
more O O
severe O O
reaction O O
on O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
or O O
therapeutic O O
. O O

Q4H O O
, O O
and O O
levofloxacin B-drug B-drug
, O O
500 O O
mg O O
p.o O O
. O O

Nonetheless O O
, O O
their O O
relevance O O
continues O O
to O O
be O O
demonstrated O O
by O O
the O O
dependence O O
of O O
each O O
agent O O
on O O
intact O O
liver O O
blood O O
flow O O
and O O
function O O
for O O
normal O O
rates O O
of O O
elimination O O
; O O

However O O
, O O
in O O
vitro O O
studies O O
have O O
shown O O
that O O
at O O
high O O
concentrations O O
( O O
7.4 O O
mMol/L O O
or O O
0.97 O O
mg/mL O O
and O O
greater O O
) O O
EACA B-drug O
inhibits O O
ADP O O
and O O
collagen-induced O O
platelet O O
aggregation O O
, O O
the O O
release O O
of O O
ATP O O
and O O
serotonin O O
, O O
and O O
the O O
binding O O
of O O
fibrinogen O O
to O O
the O O
platelets O O
in O O
a O O
concentration-response O O
manner O O
. O O

Use O O
with O O
Allopurinol B-drug B-drug
: O O
The O O
principal O O
pathway O O
for O O
detoxification O O
of O O
azathioprine B-drug B-drug
is O O
inhibited O O
by O O
allopurinol B-drug B-drug
. O O

Familial O O
hyper- O O
or O O
hypo-thyroxine-binding-globulinemias O O
have O O
been O O
described O O
. O O

Talk O O
to O O
your O O
doctor O O
if O O
you O O
are O O
taking O O
certain O O
antibiotics B-group B-group
such O O
as O O
erythromycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
or O O
azithromycin B-drug B-drug
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

Guardians O O
of O O
children O O
who O O
have O O
been O O
prescribed O O
FORADIL B-brand B-brand
should O O
be O O
alerted O O
to O O
the O O
general O O
concern O O
regarding O O
asthma O O
therapy O O
compliance O O
, O O
especially O O
neglect O O
of O O
anti-inflammatory O O
therapy O O
and O O
overuse O O
of O O
short-acting B-group B-group
beta2-agonists I-group I-group
. O O

Injection O O
: O O
Lorazepam B-drug B-drug
injection O O
, O O
like O O
other O O
injectable O O
benzodiazepines B-group B-group
, O O
produces O O
depression O O
of O O
the O O
central O O
nervous O O
system O O
when O O
administered O O
with O O
ethyl B-drug B-drug
alcohol I-drug I-drug
, O O
phenothiazines B-group B-group
, O O
barbiturates B-group B-group
, O O
MAO B-group B-group
inhibitors I-group I-group
, O O
and O O
other O O
antidepressants.When B-group B-drug
scopolamine B-drug I-drug
is O O
used O O
concomitantly O O
with O O
injectable O O
lorazepam B-drug B-drug
, O O
an O O
increased O O
incidence O O
of O O
sedation O O
, O O
hallucinations O O
, O O
and O O
irrational O O
behavior O O
has O O
been O O
observed O O
. O O

Acidifying B-group B-group
agents I-group I-group
: O O
Gastrointestinal B-group B-group
acidifying I-group I-group
agents I-group I-group
( O O
guanethidine B-drug B-drug
, O O
reserpine B-drug B-drug
, O O
glutamic B-drug B-drug
acid I-drug I-drug
HCl I-drug I-drug
, O O
ascorbic B-drug B-drug
acid I-drug I-drug
, O O
fruit O O
juices O O
, O O
etc O O
. O O
) O O
lower O O
absorption O O
of O O
amphetamines B-group B-group
. O O

Positive O O
direct O O
and O O
indirect O O
antiglobulin O B-drug
( O O
Coombs O O
) O O
tests O O
have O O
occurred O O
; O O

Drugs O O
highly O O
bound O O
to O O
albumin O O
could O O
increase O O
the O O
unbound O O
fraction O O
of O O
fosphenytoin B-drug B-drug
. O O

The O O
concomitant O O
use O O
of O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
with O O
digitalis B-group B-group
and O O
calcium B-group B-group
antagonists O I-group
may O O
have O O
additive O O
effects O O
on O O
prolonging O O
atrioventricular O O
conduction O O
time O O
. O O

RESULTS O O
: O O
The O O
two O O
treatment O O
groups O O
were O O
well O O
matched O O
with O O
regard O O
to O O
patient O O
demographics O O
, O O
NHL O O
characteristics O O
, O O
HIV O O
status O O
, O O
and O O
treatment O O
, O O
i.e. O O
, O O
the O O
number O O
of O O
cycles O O
and O O
chemotherapy O O
dose O O
. O O

Avoid O O
the O O
concomitant O O
use O O
of O O
chlorprothixene B-drug B-drug
and O O
tramadol B-drug B-drug
( O O
Ultram B-brand B-brand
) O O
. O O

Coadministration O O
of O O
NIZORAL B-brand B-brand
Tablets O O
with O O
midazolam B-drug B-drug
or O O
triazolam B-drug B-drug
has O O
resulted O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
the O O
latter O O
two O O
drugs O O
. O O

This O O
treatment O O
arm O O
was O O
discontinued O O
from O O
the O O
trial O O
. O O

No O O
dose O O
adjustment O O
is O O
necessary O O
. O O

An O O
in O O
vitro O O
effect O O
occurs O O
when O O
the O O
medication O O
interferes O O
with O O
the O O
assay O O
, O O
and O O
the O O
result O O
is O O
erroneous O O
and O O
can O O
not O O
be O O
interpreted O O
. O O

Ironically O O
, O O
benzodiazepines B-group B-group
are O O
often O O
used O O
in O O
the O O
treatment O O
of O O
heroin B-drug B-drug
addiction O O
while O O
they O O
cause O O
much O O
more O O
severe O O
withdrawal O O
symptoms O O
. O O

However O O
, O O
a O O
crossover O O
study O O
in O O
healthy O O
subjects O O
receiving O O
either O O
Tagamet B-brand B-brand
300 O O
mg O O
q.i.d O O
. O O
or O O
800 O O
mg O O
h.s O O
. O O
concomitantly O O
with O O
a O O
300 O O
mg O O
b.i.d O O
. O O
dosage O O
of O O
theophylline B-drug B-drug
( O O
Theo-Dur B-brand B-brand
, O O
Key O O
Pharmaceuticals O O
, O O
Inc. O O
) O O
demonstrated O O
less O O
alteration O O
in O O
steady-state O O
theophylline B-drug B-drug
peak O O
serum O O
levels O O
with O O
the O O
800 O O
mg O O
h.s O O
. O O
regimen O O
, O O
particularly O O
in O O
subjects O O
aged O O
54 O O
years O O
and O O
older O O
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-group B-group
concomitantly O O
with O O
ACE B-group B-group
inhibitors I-group I-group
. O O

cardiac B-group B-group
glycosides I-group I-group
; O O

Specific O O
studies O O
have O O
confirmed O O
these O O
effects O O
with O O
sevoflurane B-drug B-drug
, O O
isoflurane B-drug B-drug
, O O
propofol B-drug B-drug
, O O
alfentanil B-drug B-drug
, O O
and O O
midazolam B-drug B-drug
. O O

Anti-arrhythmics B-group B-group
and O O
tricyclic B-group B-group
anti-depressants I-group I-group
could O O
exaggerate O O
the O O
prolongation O O
of O O
the O O
QT O O
interval O O
observed O O
with O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
. O O

It O O
is O O
assumed O O
that O O
increased O O
interaction O O
between O O
3H-spiroperidol B-drug_n O
and O O
high O O
affinity O O
binding O O
sites O O
for O O
apomorphine B-drug B-drug
on O O
dopamine2- O O
and O O
serotonin2-receptors O O
underlies O O
the O O
antipsychotic O O
action O O
of O O
neuroleptics B-group B-group
after O O
their O O
prolonged O O
administration O O
. O O

The O O
most O O
commonly O O
occurring O O
drug O O
interactions O O
are O O
listed O O
below O O
: O O
- O O
Drugs O O
that O O
may O O
increase O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
include O O
: O O
acute O O
alcohol B-drug B-drug
intake O O
, O O
amiodarone B-drug B-drug
, O O
chboramphenicol O B-drug
, O O
chlordiazepoxide B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
dicumarol B-drug B-drug
, O O
disulfiram B-drug B-drug
, O O
estrogens B-group B-group
, O O
ethosuximide B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
H2-antagonists B-group B-group
, O O
halothane B-drug B-drug
, O O
isoniazid B-drug B-drug
, O O
methylphenidate B-drug B-drug
, O O
phenothiazines B-group B-group
, O O
phenylbutazone B-drug B-drug
, O O
salicylates B-group B-group
, O O
succinimides B-group B-group
, O O
sulfonamides B-group B-group
, O O
tolbutamide B-drug B-drug
, O O
trazodone B-drug B-drug

If O O
they O O
do O O
occur O O
, O O
the O O
EPA B-drug B-drug
dose O O
should O O
be O O
lowered O O
or O O
discontinued O O
. O O

For O O
digoxin B-drug B-drug
AUC O O
( O O
0-infinity O O
) O O
, O O
AUC O O
( O O
0-24 O O
) O O
, O O
and O O
Cmax O O
, O O
the O O
geometric O O
mean O O
ratios O O
( O O
90 O O
% O O
confidence O O
interval O O
) O O
for O O
( O O
rofecoxib B-drug B-drug
+ O I-drug
digoxin/placebo B-drug I-drug
+ O O
digoxin B-drug B-drug
) O O
were O O
1.04 O O
( O O
0.94 O O
, O O
1.14 O O
) O O
, O O
1.02 O O
( O O
0.94 O O
, O O
1.09 O O
) O O
, O O
and O O
1.00 O O
( O O
0.91 O O
, O O
1.10 O O
) O O
, O O
respectively O O
. O O

washout O O
( O O
days O O
7-13 O O
) O O
; O O

In O O
a O O
study O O
in O O
which O O
patients O O
with O O
active O O
RA O O
were O O
treated O O
for O O
up O O
to O O
24 O O
weeks O O
with O O
concurrent O O
Kineret B-brand B-brand
and O O
etanercept B-drug B-drug
therapy O O
, O O
a O O
7 O O
% O O
rate O O
of O O
serious O O
infections O O
was O O
observed O O
, O O
which O O
was O O
higher O O
than O O
that O O
observed O O
with O O
etanercept B-drug B-drug
alone O O
( O O
0 O O
% O O
) O O
. O O

Because O O
Nalfon B-brand B-brand
has O O
not O O
been O O
shown O O
to O O
produce O O
any O O
additional O O
effect O O
beyond O O
that O O
obtained O O
with O O
aspirin B-brand B-brand
alone O O
and O O
because O O
aspirin B-brand B-brand
increases O O
the O O
rate O O
of O O
excretion O O
of O O
Nalfon B-brand B-brand
, O O
the O O
concomitant O O
use O O
of O O
Nalfon B-brand B-brand
and O O
salicylates B-group B-group
is O O
not O O
recommended O O
. O O

In O O
that O O
same O O
study O O
, O O
aspirin B-brand B-brand
alone O O
produced O O
a O O
marked O O
inhibition O O
in O O
platelet O O
aggregation O O
ex O O
vivo O O
. O O

When O O
used O O
concomitantly O O
, O O
anesthetics B-group B-group
and O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
should O O
be O O
titrated O O
carefully O O
. O O

When O O
estrogen B-group B-group
therapy O O
is O O
initiated O O
, O O
a O O
reduction O O
in O O
corticosteroid B-group B-group
dosage O O
may O O
be O O
required O O
, O O
and O O
increased O O
amounts O O
may O O
be O O
required O O
when O O
estrogen B-group B-group
is O O
terminated O O
. O O

In O O
neither O O
case O O
were O O
the O O
pharmacokinetics O O
of O O
sumatriptan B-drug B-drug
affected O O
by O O
coadministration O O
with O O
STADOL B-brand B-brand
NS I-brand I-brand
. O O

Some O O
cases O O
presented O O
with O O
features O O
resembling O O
neuroleptic O O
malignant O O
syndrome O O
. O O

Therefore O O
, O O
intake O O
of O O
supplemental O O
folic B-drug B-drug
acid I-drug I-drug
should O O
not O O
exceed O O
1000 O O
micrograms O O
( O O
g O O
, O O
sometimes O O
mcg O O
) O O
per O O
day O O
to O O
prevent O O
folic B-drug B-drug
acid I-drug I-drug
from O O
masking O O
symptoms O O
of O O
vitamin O O
B12 O O
deficiency O O
. O O

Xigris B-brand B-brand
present O O
in O O
plasma O O
samples O O
does O O
not O O
interfere O O
with O O
one-stage O O
factor O O
assays O O
based O O
on O O
the O O
PT O O
( O O
such O O
as O O
factor O O
II O O
, O O
V O I-drug_n
, O O
VII O O
, O O
and O O
X O O
assays O O
) O O
. O O

These O O
compounds O O
interfere O O
with O O
chemical O O
color O O
development O O
essential O O
to O O
the O O
analytical O O
procedures O O
. O O

GI O O
motility O O
agents O O
: O O
cisapride B-drug B-drug

Amprenavir B-drug B-drug
is O O
metabolized O O
in O O
the O O
liver O O
by O O
the O O
cytochrome O O
P450 O O
enzyme O O
system O O
. O O

At O O
least O O
14 O O
days O O
should O O
elapse O O
between O O
discontinuation O O
of O O
a O O
MAO B-group B-group
inhibitor I-group I-group
and O O
initiation O O
of O O
treatment O O
with O O
dexfenfluramine B-drug B-drug
. O O

Phenytoin B-drug B-drug
is O O
extensively O O
bound O O
to O O
serum O O
plasma O O
proteins O O
and O O
is O O
prone O O
to O O
competitive O O
displacement O O
. O O

the O O
third O O
group O O
( O O
SH/EA O O
) O O
was O O
treated O O
with O O
a O O
hydroalcoholic O B-drug
solution O O
of O O
ethanol B-drug B-drug
; O O

Administration O O
of O O
rifampin B-drug B-drug
concomitantly O O
with O O
oral O O
amiodarone B-drug B-drug
has O O
been O O
shown O O
to O O
result O O
in O O
decreases O O
in O O
serum O O
concentrations O O
of O O
amiodarone B-drug B-drug
and O O
desethylamiodarone B-drug B-drug
. O O

The O O
fluoroquinolones B-group B-group
are O O
also O O
extensively O O
used O O
in O O
urologic O O
surgery O O
. O O

Each O O
serum O O
without O O
the O O
other O O
added O O
drug O O
as O O
well O O
as O O
the O O
serum O O
supplemented O O
with O O
the O O
other O O
drug O O
at O O
the O O
three O O
concentrations O O
was O O
dialyzed O O
against O O
phosphate O O
buffer O O
. O O

endocrine O O
dysfunction O O
; O O

Quinolones B-group B-group
have O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

Therefore O O
, O O
concurrent O O
use O O
of O O
Trileptal B-brand B-brand
with O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
render O O
these O O
contraceptives B-group B-group
less O O
effective O O
. O O

In O O
controlled O O
clinical O O
trials O O
of O O
AUGMENTIN B-brand B-brand
XR I-brand I-brand
, O O
22 O O
patients O O
received O O
concomitant O O
allopurinol B-drug B-drug
and O O
AUGMENTIN B-brand B-brand
XR I-brand I-brand
. O O

Examples O O
of O O
Drugs O O
in O O
Which O O
Plasma O O
Concentrations O O
May O O
Be O O
Decreased O O
By O O
Co-administration O O
With O O
Nevirapine B-drug B-drug

Using O O
calcium B-drug B-drug
acetate I-drug I-drug
with O O
digitalis B-group B-group
glycosides I-group I-group
( O O
heart O O
medicine O O
) O O
may O O
cause O O
hypercalcemia O O
( O O
too O O
much O O
calcium B-drug B-drug
in O O
the O O
blood O O
) O O
, O O
which O O
could O O
increase O O
the O O
chance O O
of O O
developing O O
an O O
irregular O O
heartbeat O O
. O O

Fentanyl B-drug B-drug
Anesthesia O O
: O O
Severe O O
hypotension O O
has O O
been O O
reported O O
during O O
fentanyl B-drug B-drug
anesthesia O O
with O O
concomitant O O
use O O
of O O
a O O
beta B-group B-group
blocker I-group I-group
and O O
a O O
calcium B-group B-group
channel I-group I-group
blocker I-group I-group
. O O

Laboratory O O
Tests O O
If O O
significant O O
abnormal O O
laboratory O O
results O O
are O O
obtained O O
, O O
either O O
dosage O O
reduction O O
with O O
careful O O
monitoring O O
or O O
treatment O O
discontinuation O O
is O O
recommended O O
, O O
depending O O
on O O
clinical O O
judgement O O
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

Although O O
ROMAZICON B-brand B-brand
exerts O O
a O O
slight O O
intrinsic O O
anticonvulsant O O
effect O O
, O O
its O O
abrupt O O
suppression O O
of O O
the O O
protective O O
effect O O
of O O
a O O
benzodiazepine B-group B-group
agonist O I-group
can O O
give O O
rise O O
to O O
convulsions O O
in O O
epileptic O O
patients O O
. O O

In O O
healthy O O
volunteers O O
, O O
the O O
pharmacokinetics O O
of O O
a O O
1-mg O O
dose O O
of O O
butorphanol B-drug B-drug
administered O O
as O O
STADOL B-brand B-brand
NS I-brand I-brand
were O O
not O O
affected O O
by O O
the O O
coadministration O O
of O O
a O O
single O O
6-mg O O
subcutaneous O O
dose O O
of O O
sumatriptan B-drug B-drug
. O O

In O O
post-marketing O O
experience O O
, O O
bleeding O O
has O O
been O O
reported O O
in O O
patients O O
on O O
concomitant O O
treatment O O
with O O
anticoagulants B-group B-group
and O O
INDOCIN B-brand B-brand
. O O

Concurrent O O
administration O O
of O O
low-dose O O
dopamine B-drug B-drug
HCl I-drug I-drug
and O O
diuretic B-group B-group
agents I-group I-group
may O O
produce O O
an O O
additive O O
or O O
potentiating O O
effect O O
on O O
urine O O
flow O O
. O O

Maximal O O
hypotension O O
was O O
found O O
120 O O
minutes O O
post O O
ethanol B-drug B-drug
, O O
and O O
returned O O
to O O
normal O O
300 O O
minutes O O
after O O
ethanol B-drug B-drug
. O O

Since O O
bacteriostatic O B-group
drugs O I-group
, O O
such O O
as O O
the O O
tetracycline B-group B-group
class I-group I-group
of O I-group
antibiotics B-group I-group
, O O
may O O
interfere O O
with O O
the O O
bactericidal O O
action O O
of O O
penicillins B-group B-group
, O O
it O O
is O O
not O O
advisable O O
to O O
administer O O
these O O
drugs O O
concomitantly O O
. O O

In O O
healthy O O
volunteers O O
, O O
Exjade B-brand B-brand
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

Dexfenfluramine B-drug B-drug
should O O
not O O
be O O
administered O O
with O O
other O O
serotoninergic B-group B-group
agents I-group I-group
. O O

Nevirapine I-drug B-drug

To O O
prevent O O
stomach O O
irritation O O
, O O
subjects O O
received O O
rantidine B-drug B-drug
hydrochloride I-drug I-drug
before O O
each O O
experimental O O
session O O
. O O

Amiodarone B-drug B-drug
is O O
known O O
to O O
raise O O
serum O O
digoxin B-drug B-drug
levels O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
of O O
Aranesp B-brand B-brand
have O O
been O O
performed O O
. O O

Deaths O O
from O O
severe O O
enterocolitis O O
, O O
diarrhea O O
, O O
and O O
dehydration O O
have O O
been O O
reported O O
in O O
elderly O O
patients O O
receiving O O
weekly O O
leucovorin B-drug B-drug
and O O
fluorouracil B-drug B-drug
. O O

The O O
response O O
rates O O
were O O
similar O O
between O O
the O O
two O O
groups O O
. O O

Antacids B-group B-group
and O O
kaolin B-drug O
: O O
Antacids B-group B-group
and O O
kaolin B-drug O
can O O
reduce O O
absorption O O
of O O
chloroquine B-drug B-drug
; O O

However O O
, O O
the O O
effects O O
of O O
stress O O
and O O
glucocorticoids B-group B-group
on O O
the O O
subjective O O
and O O
behavioral O O
effects O O
of O O
psychostimulants B-group B-group
have O O
not O O
been O O
well O O
studied O O
in O O
humans O O
. O O

filipin B-drug_n B-drug_n
was O O
more O O
potent O O
in O O
lysing O O
human O O
red O O
blood O O
cells O O
, O O
whereas O O
amphotericin B-drug B-drug
B I-drug I-drug
was O O
more O O
potent O O
in O O
inhibiting O O
yeast O O
cell O O
growth O O
; O O

Oral O O
contraceptives B-group B-group
may O O
be O O
less O O
effective O O
while O O
you O O
are O O
taking O O
lymecycline B-drug B-drug
. O O

AIMS/HYPOTHESIS O O
: O O
There O O
is O O
evidence O O
that O O
insulin B-drug B-drug
and O O
glucose B-drug O
cause O O
renal O O
and O O
ocular O O
vasodilation O O
. O O

Latent O O
LCV O O
infection O O
is O O
generally O O
asymptomatic O O
, O O
but O O
can O O
lead O O
to O O
B-cell O O
lymphomas O O
when O O
animals O O
are O O
immune O O
suppressed O O
. O O

PEGASYS B-brand B-brand
should O O
be O O
assumed O O
to O O
have O O
abortifacient O O
potential O O
. O O

Adrenergic B-group B-group
Agents I-group I-group
: O O
Some O O
individuals O O
receiving O O
ZYVOX B-brand B-brand
may O O
experience O O
a O O
reversible O O
enhancement O O
of O O
the O O
pressor O O
response O O
to O O
indirect-acting O O
sympathomimetic B-group B-group
agents I-group I-group
, O O
vasopressor B-group O
or O O
dopaminergic B-group B-group
agents I-group I-group
. O O

Effect O O
of O O
Other O O
Drugs O O
on O O
the O O
Pharmacokinetics O O
of O O
Clonazepam B-drug B-drug
: O O
Literature O O
reports O O
suggest O O
that O O
ranitidine B-drug B-drug
, O O
an O O
agent O O
that O O
decreases O O
stomach O O
acidity O O
, O O
does O O
not O O
greatly O O
alter O O
clonazepam B-drug B-drug
pharmacokinetics O O
. O O

Substances O O
that O O
inhibit O O
the O O
cytochrome O O
P450 O O
isoenzyme O O
( O O
CYP3A4 O O
) O O
activity O O
may O O
decrease O O
metabolism O O
and O O
increase O O
imatinib B-drug B-drug
concentrations O O
. O O

However O O
, O O
in O O
a O O
well-controlled O O
study O O
of O O
patients O O
with O O
lymphoma O O
on O O
combination O O
therapy O O
, O O
allopurinol B-drug B-drug
did O O
not O O
increase O O
the O O
marrow O O
toxicity O O
of O O
patients O O
treated O O
with O O
cyclophosphamide B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
bleomycin B-drug B-drug
, O O
procarbazine B-drug B-drug
and/or O O
mechlorethamine B-drug B-drug
. O O

Diabetic O O
patients O O
have O O
a O O
20 O O
% O O
higher O O
risk O O
of O O
depression O O
than O O
the O O
general O O
population O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
A O O
false-positive O O
reaction O O
for O O
ketones O O
in O O
the O O
urine O O
may O O
occur O O
with O O
tests O O
using O O
nitroprusside B-drug B-drug
, O O
but O O
not O O
with O O
those O O
using O O
nitroferricyanide B-drug B-drug
. O O

General O O
No O O
clinical O O
drug O O
interaction O O
studies O O
were O O
performed O O
. O O

The O O
interaction O O
between O O
lomefloxacin B-drug B-drug
and O O
cimetidine B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
tests O O
should O O
be O O
closely O O
monitored O O
. O O

Beta B-group B-group
blockers I-group I-group
may O O
exacerbate O O
the O O
hypertensive O O
response O O
seen O O
with O O
clonidine B-drug B-drug
withdrawl O O
. O O

Potential O O
for O O
reduction O O
in O O
anticonvulsant B-group O
and/or O O
efavirenz B-drug B-drug
plasma O O
levels O O
; O O

Beta-blockers B-group B-group
( O O
metoprolol B-drug B-drug
, O O
propranolol B-drug B-drug
) O O
serum O O
concentrations O O
and O O
pharmacologic O O
effects O O
may O O
be O O
increased O O
. O O

Aprepitant B-drug B-drug
is O O
unlikely O O
to O O
interact O O
with O O
drugs O O
that O O
are O O
substrates O O
for O O
the O O
P-glycoprotein O O
transporter O O
, O O
as O O
demonstrated O O
by O O
the O O
lack O O
of O O
interaction O O
of O O
Aprepitant B-drug B-drug
with O O
digoxin B-drug B-drug
in O O
a O O
clinical O O
drug O O
interaction O O
study O O
. O O

Hypotension O O
: O O
Patients O O
on O O
Diuretic O B-group
Therapy O O
: O O
Patients O O
on O O
diuretics B-drug B-group
and O O
especially O O
those O O
in O O
whom O O
diuretic O B-group
therapy O O
was O O
recently O O
instituted O O
, O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
enalapril B-drug B-drug
or O O
enalaprilat B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
No O O
significant O O
differences O O
were O O
observed O O
in O O
the O O
steady-state O O
pharmacokinetics O O
of O O
R-warfarin B-drug B-drug_n
or O O
S-warfarin B-drug B-drug_n
with O O
the O O
addition O O
of O O
tiagabine B-drug B-drug
given O O
as O O
a O O
single O O
dose O O
. O O

In O O
patients O O
receiving O O
FORADIL B-brand B-brand
, O O
other O O
inhaled O O
medications O O
should O O
be O O
used O O
only O O
as O O
directed O O
by O O
the O O
physician O O
. O O

With O O
the O O
exception O O
of O O
albuterol B-drug B-drug
, O O
there O O
are O O
no O O
formal O O
studies O O
fully O O
evaluating O O
the O O
interaction O O
effects O O
of O O
ATROVENT B-brand B-brand
Inhalation O O
Aerosol O O
and O O
these O O
drugs O O
with O O
respect O O
to O O
effectiveness O O
. O O

We O O
demonstrate O O
that O O
the O O
conversion O O
of O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
to O O
1,3-difluoroacetone B-drug_n B-drug_n
by O O
an O O
NAD+-dependent O O
oxidation O O
is O O
the O O
rate-limiting O O
step O O
in O O
the O O
synthesis O O
of O O
the O O
toxic O O
product O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
from O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
. O O

These O O
results O O
suggest O O
that O O
exposure O O
to O O
environmental O O
lead B-drug_n O
may O O
alter O O
the O O
biological O O
and O O
behavioral O O
responsiveness O O
of O O
an O O
animal O O
to O O
alcohol B-drug B-drug
. O O

No O O
drug O O
interactions O O
were O O
detected O O
except O O
for O O
an O O
increase O O
in O O
symptomatic O O
hypotension O O
in O O
patients O O
receiving O O
oral O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Excessive O O
neuromuscular O O
weakness O O
may O O
be O O
exacerbated O O
by O O
administration O O
of O O
another O O
botulinum B-group B-group
toxin I-group I-group
prior O O
to O O
the O O
resolution O O
of O O
the O O
effects O O
of O O
a O O
previously O O
administered O O
botulinum B-group B-group
toxin I-group I-group
. O O

SINCE O O
THE O O
CONCOMITANT O O
ADMINISTRATION O O
OF O O
THESE O O
TWO O O
DRUGS O O
CAN O O
LEAD O O
TO O O
PHENYTOIN B-drug B-drug
INTOXICATION O O
, O O
PRIOR O O
TO O O
ADMINISTERING O O
DISULFIRAM B-drug B-drug
TO O O
A O O
PATIENT O O
ON O O
PHENYTOIN B-drug B-drug
THERAPY O O
, O O
A O O
BASELINE O O
PHENYTOIN B-drug B-drug
SERUM O O
LEVEL O O
SHOULD O O
BE O O
OBTAINED O O
. O O

Other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
taking O O
fenfluramine B-drug B-drug
, O O
since O O
the O O
effects O O
may O O
be O O
additive O O
. O O

When O O
taken O O
concurrently O O
with O O
ethanol B-drug B-drug
, O O
a O O
pharmacological O O
interaction O O
may O O
occur O O
, O O
potentiating O O
the O O
central O O
nervous O O
system O O
depression O O
produced O O
by O O
either O O
drug O O
. O O

Cytochrome O O
P-450 O O
is O O
not O O
known O O
to O O
be O O
involved O O
in O O
the O O
metabolism O O
of O O
Plenaxis B-brand B-brand
. O O

Diuretics B-group B-group
: O O
Patients O O
on O O
diuretics B-group B-group
, O O
especially O O
those O O
with O O
intravascular O O
volume O O
depletion O O
, O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
fosinopril B-drug B-drug
sodium I-drug I-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Acetaminophen B-drug B-drug
may O O
produce O O
false-positive O O
test O O
results O O
for O O
urinary O O
5-hydroxyindoleacetic O O
acid O O
. O O

Some O O
quinolone B-group B-group
antibiotics I-group I-group
would O O
be O O
expected O O
to O O
have O O
similar O O
effects O O
and O O
these O O
combinations O O
should O O
be O O
avoided O O
. O O

Colestipol-Concomitant B-drug O
intake O O
of O O
colestipol B-drug B-drug
and O O
vitamin B-group B-group
K I-group I-group
may O O
reduce O O
the O O
absorption O O
of O O
vitamin B-group B-group
K I-group I-group
. O O

Since O O
fondaparinux B-drug B-drug
does O O
not O O
markedly O O
inhibit O O
CYP450s O O
( O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
or O O
CYP3A4 O O
) O O
in O O
vitro O O
, O O
fondaparinux B-drug B-drug
sodium I-drug I-drug
is O O
not O O
expected O O
to O O
significantly O O
interact O O
with O O
other O O
drugs O O
in O O
vivo O O
by O O
inhibition O O
of O O
metabolism O O
mediated O O
by O O
these O O
isozymes O O
. O O

Several O O
studies O O
indicate O O
that O O
olanzapine B-drug B-drug
has O O
benefits O O
against O O
symptoms O O
of O O
aggression O O
and O O
agitation O O
, O O
while O O
other O O
studies O O
strongly O O
support O O
the O O
effectiveness O O
of O O
olanzapine B-drug B-drug
in O O
the O O
treatment O O
of O O
depressive O O
symptomatology O O
. O O

In O O
view O O
of O O
the O O
potential O O
risk O O
of O O
dehydration O O
secondary O O
to O O
vomiting O O
and/or O O
diarrhea O O
induced O O
by O O
CAMPTOSAR B-brand B-brand
, O O
the O O
physician O O
may O O
wish O O
to O O
withhold O O
diuretics B-group B-group
during O O
dosing O O
with O O
CAMPTOSAR B-brand B-brand
and O O
, O O
certainly O O
, O O
during O O
periods O O
of O O
active O O
vomiting O O
or O O
diarrhea O O
. O O

Co-administration O O
of O O
bosentan B-drug B-drug
decreased O O
the O O
plasma O O
concentrations O O
of O O
glyburide B-drug B-drug
by O O
approximately O O
40 O O
% O O
. O O

Diltiazem B-drug B-drug
: O O
In O O
patients O O
with O O
mild O O
to O O
moderate O O
hypertension O O
, O O
administration O O
of O O
aprepitant B-drug B-drug
once O O
daily O O
, O O
as O O
a O O
tablet O O
formulation O O
comparable O O
to O O
230 O O
mg O O
of O O
the O O
capsule O O
formulation O O
, O O
with O O
diltiazem B-drug B-drug
120 O O
mg O O
3 O O
times O O
daily O O
for O O
5 O O
days O O
, O O
resulted O O
in O O
a O O
2-fold O O
increase O O
of O O
aprepitant B-drug B-drug
AUC O O
and O O
a O O
simultaneous O O
1.7-fold O O
increase O O
of O O
diltiazem B-drug B-drug
AUC O O
. O O

This O O
increase O O
is O O
greatest O O
in O O
the O O
evening O O
. O O

Drugs O O
That O O
Should O O
Not O O
Be O O
Coadministered O O
With O O
INVIRASE/Ritonavir B-brand B-drug_n

Concomitant O O
administration O O
of O O
drugs O O
known O O
to O O
induce O O
cytochrome O O
P450 O O
enzymes O O
may O O
decrease O O
the O O
plasma O O
levels O O
of O O
clozapine B-drug B-drug
. O O

Digoxin B-drug B-drug
is O O
eliminated O O
renally O O
. O O

However O O
, O O
LDL-C O O
reduction O O
was O O
not O O
altered O O
. O O

There O O
was O O
no O O
apparent O O
pharmacokinetic O O
interaction O O
between O O
zaleplon B-drug B-drug
and O O
ibuprofen B-drug B-drug
following O O
single O O
dose O O
administration O O
( O O
10 O O
mg O O
and O O
600 O O
mg O O
, O O
respectively O O
) O O
of O O
each O O
drug O O
. O O

In O O
controlled O O
clinical O O
trials O O
, O O
however O O
, O O
beta B-drug B-group
blockers I-drug I-group
including O O
metoprolol B-drug B-drug
were O O
concurrently O O
administered O O
with O O
felodipine B-drug B-drug
and O O
were O O
well O O
tolerated O O
. O O

When O O
amiodarone B-drug B-drug
is O O
added O O
to O O
flecainide B-drug B-drug
therapy O O
, O O
plasma O O
flecainide B-drug B-drug
levels O O
may O O
increase O O
two-fold O O
or O O
more O O
in O O
some O O
patients O O
, O O
if O O
flecainide B-drug B-drug
dosage O O
is O O
not O O
reduced O O
. O O

Digoxin B-drug B-drug
: O O
Enoxacin B-drug B-drug
may O O
raise O O
serum O O
digoxin B-drug B-drug
levels O O
in O O
some O O
individuals O O
. O O

Cardiovascular O O
collapse O O
in O O
patients O O
treated O O
simultaneously O O
with O O
varapamil O B-drug
and O O
dantrolene B-drug B-drug
sodium I-drug I-drug
is O O
rare O O
. O O

tolbutamide B-drug B-drug
; O O

In O O
such O O
a O O
case O O
, O O
the O O
peripheral O O
vascular O O
resistance O O
may O O
increase O O
. O O

9 O O
. O O

The O O
effects O O
of O O
diethyl B-drug_n B-drug
pyrocarbonate I-drug_n I-drug
could O O
be O O
reversed O O
by O O
hydroxylamine B-drug_n O
treatment O O
. O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

both O O
compounds O O
attenuate O O
morphine-induced B-drug B-drug
locomotion O O
in O O
morphine-experienced B-drug B-drug
rats O O
. O O

ACE B-group B-group
Inhibitors I-group I-group
and O O
Angiotensin B-group B-group
II I-group I-group
Receptor I-group I-group
Antagonists I-group I-group
( O O
Hypertension O O
) O O
- O O
In O O
clinical O O
studies O O
of O O
patients O O
with O O
hypertension O O
, O O
the O O
addition O O
of O O
INSPRA B-brand B-brand
50 O O
to O O
100 O O
mg O O
to O O
ACE B-group B-group
inhibitors I-group I-group
and O O
angiotensin B-group B-group
II I-group I-group
receptor I-group I-group
antagonists I-group I-group
increased O O
mean O O
serum O O
potassium O O
slightly O O
( O O
about O O
0.09-0.13 O O
mEq/L O O
) O O
. O O

Although O O
results O O
have O O
varied O O
from O O
study O O
to O O
study O O
, O O
effects O O
have O O
been O O
shown O O
on O O
furosemide-stimulated B-drug B-drug
diuresis O O
, O O
natriuresis O O
, O O
and O O
kaliuresis O O
. O O

The O O
possibility O O
of O O
reduced O O
statin B-group O
efficacy O O
should O O
be O O
considered O O
. O O

These O O
data O O
indicate O O
that O O
levetiracetam B-drug B-drug
does O O
not O O
influence O O
the O O
plasma O O
concentration O O
of O O
other O O
AEDs B-group B-group
and O O
that O O
these O O
AEDs B-group B-group
do O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
. O O

Multiple-dose O O
administration O O
of O O
the O O
potent O O
CYP3A4 O O
inducer O O
rifampin B-drug B-drug
( O O
600 O O
mg O O
every O O
24 O O
hours O O
, O O
q24h O O
, O O
for O O
14 O O
days O O
) O O
, O O
however O O
, O O
reduced O O
zaleplon B-drug B-drug
Cmax O O
and O O
AUC O O
by O O
approximately O O
80 O O
% O O
. O O

. O O

In O O
vitro O O
studies O O
have O O
indicated O O
that O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
binds O O
a O O
number O O
of O O
drugs O O
. O O

Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
also O O
increase O O
risk O O
of O O
thromboembolic O O
disorders O O
. O O

( O O
1968 O O
, O O
1970 O O
) O O
, O O
the O O
higher O O
serum O O
concentrations O O
of O O
penicillins B-group B-group
and O O
cephaloridine B-drug B-drug
reached O O
after O O
administration O O
of O O
probenecid B-drug B-drug
are O O
due O O
not O O
only O O
to O O
slower O O
renal O O
elimination O O
but O O
also O O
to O O
an O O
altered O O
distribution O O
in O O
the O O
body O O
. O O

Caution O O
should O O
also O O
be O O
applied O O
for O O
other O O
sympathomimetics B-group B-group
, O O
and O O
for O O
aminophylline B-drug B-drug
and O O
theophylline B-drug B-drug
and O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
which O O
may O O
also O O
precipitate O O
arrhythmias O O
. O O

CNS O O
Drugs O O
- O O
Given O O
the O O
primary O O
CNS O O
effects O O
of O O
escitalopram B-drug B-drug
, O O
caution O O
should O O
be O O
used O O
when O O
it O O
is O O
taken O O
in O O
combination O O
with O O
other O O
centrally O O
acting O O
drugs O O
. O O

nc1 O O
40 O O
% O O
decrease O O
[ O O
CI O O
: O O
17 O O
% O O
decrease O O
, O O
57 O O
% O O
decrease O O
] O O

approximately O O
one-hundredth O O
of O O
the O O
human O O
recommended O O
dose O O
based O O
on O O
body O O
surface O O
area O O
[ O O
BSA O O
] O O
) O O
, O O
fulvestrant B-drug B-drug
caused O O
a O O
reversible O O
reduction O O
in O O
female O O
fertility O O
, O O
as O O
well O O
as O O
effects O O
on O O
embryo/fetal O O
development O O
consistent O O
with O O
its O O
anti-estrogenic O O
activity O O
. O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

Morphine B-drug B-drug
analgesia O O
and O O
pupil O O
constriction O O
were O O
unaffected O O
by O O
ADL B-drug B-drug
8-2698 I-drug I-drug
and O O
differed O O
from O O
placebo O O
( O O
P O O
< O O
.002 O O
) O O
. O O

Survanta B-brand B-brand
increased O O
the O O
extent O O
of O O
dissolution O O
of O O
budesonide B-drug B-drug
in O O
proportion O O
to O O
the O O
added O O
concentration O O
, O O
which O O
was O O
also O O
verified O O
by O O
equilibrium O O
solubilization O O
studies O O
. O O

Each O O
volunteer O O
was O O
administered O O
one O O
400-mg O O
ceftibuten B-drug B-drug
capsule O O
. O O

Other O O
drugs O O
have O O
not O O
been O O
studied O O
. O O

Dimenhydrinate B-drug B-drug
may O O
decrease O O
emetic B-group B-group
response O O
to O O
apomorphine B-drug B-drug
. O O

Electrocardiograms O O
were O O
done O O
at O O
baseline O O
and O O
on O O
the O O
last O O
day O O
of O O
the O O
washout O O
period O O
and O O
phase O O
2 O O
. O O

Because O O
of O O
the O O
variability O O
of O O
individual O O
patient O O
response O O
, O O
multiple O O
interacting O O
mechanisms O O
with O O
some O O
drugs O O
, O O
the O O
dependency O O
of O O
the O O
extent O O
of O O
the O O
interaction O O
on O O
the O O
dosage O O
and O O
duration O O
of O O
therapy O O
, O O
and O O
the O O
possible O O
administration O O
of O O
several O O
interacting O O
drugs O O
simultaneously O O
, O O
it O O
is O O
difficult O O
to O O
predict O O
the O O
direction O O
and O O
degree O O
of O O
the O O
ultimate O O
effect O O
of O O
concomitant O O
medications O O
on O O
anticoagulant B-group B-group
response O O
. O O

However O O
, O O
caution O O
should O O
be O O
exercised O O
because O O
there O O
have O O
been O O
a O O
few O O
spontaneous O O
reports O O
of O O
prolonged O O
prothrombin O O
times O O
, O O
with O O
or O O
without O O
bleeding O O
, O O
in O O
etodolac-treated B-drug B-drug
patients O O
receiving O O
concomitant O O
warfarin B-drug B-drug
therapy O O
. O O

Doxepin B-drug B-drug
is O O
primarily O O
metabolized O O
by O O
CYP2D6 O O
( O O
with O O
CYP1A2 O O
and O O
CYP3A4 O O
as O O
minor O O
pathways O O
) O O
. O O

Release O O
of O O
arachidonic O O
acid O O
from O O
membrane O O
phospholipids O O
as O O
well O O
as O O
subsequent O O
synthesis O O
and O O
release O O
of O O
vasoconstrictor O O
thromboxane O O
A2 O O
are O O
also O O
regulated O O
by O O
movement O O
of O O
calcium O O
ions O O
. O O

DESIGN O O
: O O
Cross-sectional O O
descriptive O O
study O O
. O O

Finasteride B-drug B-drug
does O O
not O O
appear O O
to O O
affect O O
the O O
cytochrome O O
P450-linked O O
drug-metabolizing O O
enzyme O O
system O O
. O O

We O O
have O O
shown O O
that O O
MCF-7 O O
cells O O
treated O O
with O O
100 O O
nM O O
1,25 B-drug O
( I-drug O
OH I-drug O
) I-drug O
2D3 I-drug O
exhibit O O
characteristic O O
apoptotic O O
morphology O O
( O O
pyknotic O O
nuclei O O
, O O
chromatin O O
and O O
cytoplasmic O O
condensation O O
, O O
nuclear O O
matrix O O
protein O O
reorganization O O
) O O
within O O
48 O O
h O O
. O O

Therefore O O
, O O
the O O
potential O O
exists O O
for O O
a O O
drug O O
interaction O O
between O O
WELLBUTRIN B-brand B-brand
and O O
drugs O O
that O O
affect O O
the O O
CYP2B6 O O
isoenzyme O O
( O O
e.g. O O
, O O
orphenadrine B-drug B-drug
and O O
cyclophosphamide B-drug B-drug
) O O
. O O

Dose O O
adjustment O O
of O O
Sensipar B-brand B-brand
may O O
be O O
required O O
and O O
PTH O O
and O O
serum O O
calcium O O
concentrations O O
should O O
be O O
closely O O
monitored O O
if O O
a O O
patient O O
initiates O O
or O O
discontinues O O
therapy O O
with O O
a O O
strong O O
CYP3A4 O O
inhibitor O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
itraconazole B-drug B-drug
; O O

There O O
were O O
no O O
significant O O
differences O O
between O O
the O O
two O O
groups O O
, O O
achieving O O
a O O
maximum O O
relaxation O O
of O O
> O O
95 O O
% O O
at O O
a O O
concentration O O
of O O
35 O O
micromol/l O O
. O O

It O O
was O O
concluded O O
that O O
, O O
although O O
gentamycin B-drug B-drug
did O O
augment O O
the O O
neuromuscular O O
blockade O O
of O O
atracurium B-drug B-drug
, O O
the O O
effect O O
was O O
minimal O O
. O O

Whether O O
this O O
interaction O O
also O O
occurs O O
with O O
the O O
intravenous O O
, O O
topical O O
or O O
vaginal O O
preparations O O
of O O
miconazole B-drug B-drug
is O O
not O O
known O O
. O O

The O O
mode O O
of O O
toxic O O
action O O
of O O
the O O
pesticide O B-group
gliftor B-drug_n I-group
: O O
the O O
metabolism O O
of O O
1,3-difluoroacetone B-drug_n B-drug_n
to O I-drug_n
( B-drug_n I-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
. O O

. O O

Rare O O
cases O O
of O O
elevated O O
plasma O O
concentrations O O
of O O
digoxin B-drug B-drug
have O O
been O O
reported O O
. O O

At O O
75 O O
% O O
recovery O O
of O O
fade O O
, O O
hoof O O
twitch O O
was O O
87 O O
+/- O O
3 O O
% O O
for O O
atracurium B-drug B-drug
alone O O
and O O
82 O O
+/- O O
4 O O
% O O
for O O
atracurium B-drug B-drug
plus O O
gentamycin B-drug B-drug
. O O

CYP3A4 B-drug B-drug
Inhibitors O I-drug
Felodipine O B-drug
is O O
metabolized O O
by O O
CYP3A4 B-drug O
. O O

therefore O O
, O O
if O O
glucocorticoid B-group B-group
replacement O O
is O O
needed O O
, O O
hydrocortisone B-drug B-drug
should O O
be O O
prescribed O O
. O O

Hepatic O O
Impairment O O
There O O
are O O
currently O O
no O O
clinical O O
studies O O
with O O
SPRYCEL B-brand B-brand
in O O
patients O O
with O O
impaired O O
liver O O
function O O
( O O
clinical O O
studies O O
have O O
excluded O O
patients O O
with O O
ALT O O
and/or O O
AST O O
2.5 O O
times O O
the O O
upper O O
limit O O
of O O
the O O
normal O O
range O O
and/or O O
total O O
bilirubin O O
2 O O
times O O
the O O
upper O O
limit O O
of O O
the O O
normal O O
range O O
) O O
. O O

Digoxin B-drug B-drug
: O O
Studies O O
of O O
concomitant O O
administration O O
of O O
flurbiprofen B-drug B-drug
and O O
digoxin B-drug B-drug
to O O
healthy O O
men O O
( O O
n= O O
14 O O
) O O
did O O
not O O
show O O
a O O
change O O
in O O
the O O
steady O O
state O O
serum O O
levels O O
of O O
either O O
drug O O
. O O

Thus O O
, O O
when O O
ibuprofen B-drug B-drug
and O O
lithium B-drug B-drug
are O O
administered O O
concurrently O O
, O O
subjects O O
should O O
be O O
observed O O
carefully O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Acarbose B-drug B-drug
may O O
affect O O
digoxin B-drug B-drug
bioavailabillty O O
and O O
may O O
require O O
dose O O
adjustment O O
of O O
digoxin B-drug B-drug
by O O
16 O O
% O O
( O O
90 O O
% O O
confidence O O
interval O O
: O O
8-23 O O
% O O
) O O
, O O
decrease O O
mean O O
C O O
max O O
digoxin B-drug B-drug
by O O
26 O O
% O O
( O O
90 O O
% O O
confidence O O
interval O O
: O O
16-34 O O
% O O
) O O
and O O
decrease O O
mean O O
trough O O
concentrations O O
of O O
digoxin B-drug B-drug
by O O
9 O O
% O O
( O O
90 O O
% O O
confidence O O
limit O O
: O O
19 O O
% O O
decrease O O
to O O
2 O O
% O O
increase O O
) O O
. O O

According O O
to O O
Gibaldi O O
et O O
al O O
. O O

Concurrent O O
use O O
of O O
hydroxyurea B-drug B-drug
and O O
other O O
myelosuppressive O B-group
agents O I-group
or O O
radiation O O
therapy O O
may O O
increase O O
the O O
likelihood O O
of O O
bone O O
marrow O O
depression O O
or O O
other O O
adverse O O
events O O
. O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
may O O
inhibit O O
both O O
synthetic O O
and O O
catabolic O O
enzymes O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

Due O O
to O O
the O O
frequent O O
occurrence O O
of O O
severe O O
and O O
prolonged O O
thrombocytopenia O O
, O O
the O O
potential O O
benefits O O
of O O
medications O O
which O O
interfere O O
with O O
platelet O O
function O O
and/or O O
anticoagulation O O
should O O
be O O
weighed O O
against O O
the O O
potential O O
increased O O
risks O O
of O O
bleeding O O
and O O
hemorrhage O O
. O O

Carbamazepine B-drug_n B-drug
epoxide I-drug_n I-drug
steady-state O O
Cmin O O
concentrations O O
increased O O
57 O O
% O O
from O O
1.0 O O
0.3 O O
to O O
1.6 O O
0.4 O O
micrograms/mL O O
with O O
the O O
addition O O
of O O
felbamate B-drug B-drug
. O O

LABORATORY O O
TEST O O
FINDINGS O O
Asymptomatic O O
, O O
transitory O O
changes O O
in O O
serum O O
iron O B-drug
have O O
been O O
observed O O
. O O

In O O
separate O O
single O O
or O O
multiple O O
dose O O
pharmacokinetic O O
interaction O O
studies O O
with O O
chlorthalidone B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
propanolol B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
metoclopramide B-drug B-drug
, O O
propantheline B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
, O O
the O O
bioavailability O O
of O O
fosinoprilat B-drug_n B-drug
was O O
not O O
altered O O
by O O
coadministration O O
of O O
fosinopril B-drug B-drug
with O O
any O O
one O O
of O O
these O O
drugs O O
. O O

Caution O O
, O O
however O O
, O O
is O O
advised O O
in O O
patients O O
taking O O
tricyclic B-group B-group
antidepressants I-group I-group
which O O
can O O
affect O O
the O O
metabolism O O
and O O
uptake O O
of O O
circulating O O
amines O O
. O O

Caution O O
should O O
be O O
exercised O O
if O O
tacrolimus B-drug B-drug
and O O
bosentan B-drug B-drug
are O O
used O O
together O O
. O O

Patients O O
taking O O
isoniazid B-drug B-drug
when O O
disulfiram B-drug B-drug
is O O
given O O
should O O
be O O
observed O O
for O O
the O O
appearance O O
of O O
unsteady O O
gait O O
or O O
marked O O
changes O O
in O O
mental O O
status O O
; O O

ADL-8-2698 B-drug B-drug_n
is O O
a O O
novel O O
peripherally B-group O
restricted I-group O
opioid I-group B-group
antagonist I-group I-group
that O O
may O O
selectively O O
prevent O O
opioid-induced B-group B-group
gastrointestinal O O
effects O O
without O O
reversing O O
analgesia O O
. O O

This O O
was O O
due O O
to O O
reductions O O
in O O
both O O
renal O O
clearance O O
( O O
from O O
105 O O
+/- O O
39 O O
to O O
84 O O
+/- O O
15 O O
ml/min O O
) O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
and O O
nonrenal O O
clearance O O
( O O
from O O
130 O O
+/- O O
38 O O
to O O
88 O O
+/- O O
20 O O
ml/min O O
) O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
. O O

Use O O
with O O
caution O O
. O O

Diabetics O O
should O O
discuss O O
the O O
use O O
of O O
these O O
supplements O O
with O O
their O O
physicians O O
and O O
note O O
if O O
the O O
supplements O O
affect O O
their O O
glycemic O O
control O O
. O O

Infusion O O
of O O
arginine B-drug B-drug
alone O O
markedly O O
decreased O O
the O O
amount O O
of O O
extractable O O
pancreatic O O
insulin O O
and O O
glucagon O O
. O O

Aspirin B-brand B-brand
: O O
Vardenafil B-drug B-drug
( O O
10 O O
mg O O
and O O
20 O O
mg O O
) O O
did O O
not O O
potentiate O O
the O O
increase O O
in O O
bleeding O O
time O O
caused O O
by O O
aspirin B-brand B-brand
( O O
two O O
81 O O
mg O O
tablets O O
) O O
. O O

In O O
a O O
12-week O O
endoscopy O O
study O O
conducted O O
in O O
OA O O
patients O O
there O O
was O O
no O O
difference O O
in O O
the O O
cumulative O O
incidence O O
of O O
endoscopic O O
gastroduodenal O O
ulcers O O
in O O
patients O O
taking O O
low-dose O O
( O O
81 O O
mg O O
) O O
enteric O O
coated O O
aspirin B-brand B-brand
plus O O
VIOXX B-brand B-brand
25 O O
mg O O
daily O O
, O O
as O O
compared O O
to O O
those O O
taking O O
ibuprofen B-drug B-drug
2400 O O
mg O O
daily O O
alone O O
. O O

Patients O O
receiving O O
both O O
drugs O O
should O O
be O O
under O O
careful O O
observation O O
. O O

Cmax O O
and O O
AUC O O
values O O
are O O
3 O O
% O O
to O O
4 O O
% O O
lower O O
, O O
respectively O O
, O O
after O O
administration O O
of O O
125 O O
mg O O
Neurontin B-brand B-brand
and O O
21 O O
% O O
to O O
22 O O
% O O
lower O O
, O O
respectively O O
, O O
after O O
administration O O
of O O
500 O O
mg O O
Neurontin B-brand B-brand
. O O

The O O
concomitant O O
use O O
of O O
INDOCIN B-brand B-brand
with O O
other O O
NSAIDs B-group B-group
is O O
not O O
recommended O O
due O O
to O O
the O O
increased O O
possibility O O
of O O
gastrointestinal O O
toxicity O O
, O O
with O O
little O O
or O O
no O O
increase O O
in O O
efficacy O O
. O O

Concomitant O O
treatment O O
with O O
coumarin B-group B-group
derivatives I-group I-group
( O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
) O O
and O O
drugs O O
that O O
affect O O
platelet O O
function O O
may O O
also O O
increase O O
the O O
risk O O
of O O
bleeding O O
. O O

1,25-Dihydroxycholecalciferol B-drug B-drug_n
D3 I-drug I-drug_n
( O O
1,25 B-drug O
( I-drug O
OH I-drug O
) I-drug O
2D3 I-drug O
) O O
, O O
the O O
active O O
metabolite O O
of O O
vitamin B-group B-group
D I-group I-group
, O O
is O O
a O O
potent O O
inhibitor O O
of O O
breast O O
cancer O O
cell O O
growth O O
both O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

cmaxSS O O
( O O
Peak O O
plasma O O
concentration O O
) O O

Dexbrompheniramine B-drug B-drug
can O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-group B-group
) O O
, O O
anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-group B-group
) O O
, O O
and O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
( O O
concurrent O O
use O O
with O O
antihistamines B-group B-group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-group B-group
) O O
. O O

These O O
reactions O O
include O O
fever O O
, O O
chills O O
, O O
nausea O O
, O O
vomiting O O
, O O
pruritus O O
, O O
rash O O
, O O
diarrhea O O
, O O
hypotension O O
, O O
edema O O
, O O
and O O
oliguria O O
. O O

Increases O O
of O O
22 O O
% O O
with O O
MHD B-drug_n B-drug_n
and O O
47 O O
% O O
with O O
oxcarbazepine B-drug B-drug
were O O
observed O O
. O O

Interaction O O
of O O
the O O
constituents O O
of O O
alcoholic O B-drug
beverages O O
in O O
the O O
promotion O O
of O O
liver O O
damage O O
. O O

Resistance O O
was O O
measured O O
near O O
the O O
placental O O
margin O O
after O O
spontaneous O O
term O O
delivery O O
. O O

Elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
use O O
of O O
cyclosporine B-drug B-drug
with O O
norfloxacin B-drug B-drug
. O O

Warfarin B-drug B-drug

Geriatric O O
Use O O
Younger O O
patients O O
have O O
higher O O
virologic O O
response O O
rates O O
than O O
older O O
patients O O
. O O

Rifampin B-drug B-drug

The O O
magnitude O O
and O O
relative O O
importance O O
of O O
the O O
effects O O
noted O O
below O O
are O O
likely O O
to O O
be O O
patient O O
specific O O
and O O
may O O
vary O O
by O O
such O O
factors O O
as O O
age O O
, O O
gender O O
, O O
race O O
, O O
intercurrent O O
illnesses O O
, O O
dose O O
of O O
either O O
agent O O
, O O
additional O O
concomitant O O
medications O O
, O O
and O O
timing O O
of O O
drug O O
administration O O
. O O

Phenothiazine-related B-group O
compounds I-group O
and O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
may O O
have O O
additive O O
hypotensite O O
effects O O
due O O
to O O
the O O
inhibition O O
of O O
each O O
other O O
s O O
metabolism O O
. O O

Lethargy O O
and O O
somnolence O O
have O O
been O O
reported O O
following O O
doses O O
of O O
REVIA B-brand B-brand
and O O
thioridazine B-drug B-drug
. O O

Coadministration O O
of O O
amprenavir B-drug B-drug
and O O
methadone B-drug B-drug
as O O
compared O O
to O O
a O O
non-matched O O
historicalcontrol O O
group O O
resulted O O
in O O
a O O
30 O O
% O O
, O O
27 O O
% O O
, O O
and O O
25 O O
% O O
decrease O O
in O O
serum O O
amprenavir B-drug B-drug
AUC O O
, O O
Cmax O O
, O O
andCmin O O
, O O
respectively O O
. O O

MAO B-group B-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
( O O
drying O O
) O O
effects O O
of O O
antihistamines B-group B-group
. O O

In O O
vitro O O
metabolism O O
studies O O
have O O
suggested O O
that O O
decitabine B-drug B-drug
is O O
not O O
a O O
substrate O O
for O O
the O O
human O O
liver O O
cytochrome O O
P450 O O
enzymes O O
. O O

For O O
the O O
identification O O
of O O
" O O
limit O O
values O O
" O O
, O O
it O O
has O O
generally O O
been O O
suggested O O
in O O
the O O
literature O O
that O O
the O O
possible O O
effects O O
deriving O O
from O O
multiple O O
exposure O O
be O O
considered O O
as O O
additive O O
. O O

Cancer O O
in O O
the O O
elderly O O
: O O
basic O O
science O O
and O O
clinical O O
aspects O O
. O O

Rare O O
cases O O
of O O
serious O O
cardiovascular O O
adverse O O
events O O
, O O
including O O
electrocardiographic O O
QT/QTc O O
interval O O
prolongation O O
, O O
cardiac O O
arrest O O
, O O
torsades O O
de O O
pointes O O
, O O
and O O
other O O
ventricular O O
arrhythmias O O
have O O
been O O
observed O O
. O O

Other O O
Agents O O
: O O
PRINIVIL B-brand B-brand
has O O
been O O
used O O
concomitantly O O
with O O
nitrates B-group B-group
and/or O O
digoxin B-drug B-drug
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

Animal O O
studies O O
also O O
suggest O O
an O O
increased O O
potential O O
for O O
seizures O O
when O O
these O O
2 O O
drugs O O
are O O
given O O
concomitantly O O
. O O

It O O
is O O
important O O
that O O
patients O O
understand O O
how O O
to O O
use O O
FORADIL B-brand B-brand
( O O
formoterol B-drug B-drug
fumarate I-drug I-drug
) O O
capsules O O
with O O
the O O
supplied O O
AerolizerTM O O
inhalation O O
device O O
and O O
how O O
it O O
should O O
be O O
used O O
in O O
relation O O
to O O
other O O
asthma O O
or O O
COPD O O
medications O O
they O O
are O O
taking O O
. O O

Coadministration O O
of O O
alosetron B-drug B-drug
and O O
strong O O
CYP3A4 O O
inhibitors O O
, O O
such O O
as O O
clarithromycin B-drug B-drug
, O O
telithromycin B-drug B-drug
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
voriconazole B-drug B-drug
, O O
and O O
itraconazole B-drug B-drug
has O O
not O O
been O O
evaluated O O
but O O
should O O
be O O
undertaken O O
with O O
caution O O
because O O
of O O
similar O O
potential O O
drug O O
interactions O O
. O O

In O O
vitro O O
studies O O
suggest O O
that O O
coadministration O O
of O O
cytochrome O O
P450 O O
inhibitors O O
to O O
PMs O O
will O O
not O O
increase O O
the O O
plasma O O
concentrations O O
of O O
atomoxetine B-drug B-drug
. O O

Effect O O
of O O
dofetillide B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

. O O

miconazole B-drug B-drug
; O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCA B-group B-group
may O O
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
anticoagulants B-group B-group
are O O
given O O
in O O
conjunction O O
with O O
Atromid-S B-brand B-brand
. O O

Because O O
tetracyclines B-group B-group
have O O
been O O
shown O O
to O O
depress O O
plasma O O
prothrombin O O
activity O O
, O O
patients O O
who O O
are O O
on O O
anticoagulant B-group B-group
therapy O O
may O O
require O O
downward O O
adjustment O O
of O O
their O O
anticoagulant B-group B-group
dosage O O
. O O

Caspofungin B-drug B-drug
is O O
not O O
a O O
substrate O O
for O O
P-glycoprotein O O
and O O
is O O
a O O
poor O O
substrate O O
for O O
cytochrome O O
P450 O O
enzymes O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
Acarbose B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
blood O O
glucose O O
control O O
. O O

Antacids B-group B-group
containing O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
and O O
magnesium B-drug B-drug
hydroxide I-drug I-drug
reduce O O
the O O
oral O O
absorption O O
of O O
enoxacin B-drug B-drug
by O O
75 O O
% O O
. O O

Green B-drug O
tea I-drug O
polyphenols I-drug B-group
as O O
potent O O
enhancers B-drug O
of O O
glucocorticoid-induced O O
mouse O O
mammary O O
tumor O O
virus O O
gene O O
expression O O
. O O

1- O O
nc O O
denotes O O
a O O
mean O O
change O O
of O O
less O O
than O O
10 O O
% O O
2- O O
Pediatrics O O
3- O O
Mean O O
increase O O
in O O
adults O O
at O O
high O O
Trileptal B-brand B-brand
doses O O
In O O
vivo O O
, O O
the O O
plasma O O
levels O O
of O O
phenytoin B-drug B-drug
increased O O
by O O
up O O
to O O
40 O O
% O O
, O O
when O O
Trileptal B-brand B-brand
was O O
given O O
at O O
doses O O
above O O
1200 O O
mg/day O O
. O O

- O O
Androgens B-group B-group
( O O
male O O
hormones O O
) O O
or O O

Cimetidine B-drug B-drug
( O O
400 O O
mg O O
b.i.d O O
. O O
) O O
had O O
no O O
effect O O
on O O
vardenafil B-drug B-drug
bioavailability O O
( O O
AUC O O
) O O
and O O
maximum O O
concentration O O
( O O
Cmax O O
) O O
of O O
vardenafil B-drug B-drug
when O O
co-administered O O
with O O
20 O O
mg O O
Vardenafil B-drug B-drug
in O O
healthy O O
volunteers O O
. O O

Furosemide B-drug B-drug
: O O
In O O
normal O O
volunteers O O
, O O
the O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
furosemide B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
diuretic O O
activity O O
of O O
furosemide B-drug B-drug
. O O

While O O
the O O
effects O O
of O O
chronic O O
phenytoin B-drug B-drug
or O O
carbamazepine B-drug B-drug
therapy O O
on O O
the O O
action O O
of O O
NIMBEX B-brand B-brand
are O O
unknown O O
, O O
slightly O O
shorter O O
durations O O
of O O
neuromuscular O O
block O O
may O O
be O O
anticipated O O
and O O
infusion O O
rate O O
requirements O O
may O O
be O O
higher O O
. O O

Animal O O
toxicology O O
studies O O
showed O O
increased O O
DEET B-drug O
toxicity O O
when O O
DEET B-drug O
was O O
included O O
as O O
proof O O
of O O
the O O
formulation O O
. O O

Itraconazole B-drug B-drug
Ketoconazole I-drug B-drug
Erythromycin I-drug I-drug
Clarithromycin I-drug B-drug
Telithromycin I-drug I-drug
HIV B-group B-group
protease I-group I-group
inhibitors I-group I-group
Nefazodone B-drug B-drug
Cyclosporine I-drug I-drug
Large O O
quantities O O
of O O
grapefruit O O
juice O O
( O O
1 O O
quart O O
daily O O
) O O

The O O
fluoroquinolones B-group B-group
for O O
urinary O O
tract O O
infections O O
: O O
a O O
review O O
. O O

A O O
clinical O O
study O O
in O O
healthy O O
male O O
volunteers O O
( O O
n=24 O O
) O O
demonstrated O O
that O O
mixing O O
NovoLog B-brand B-brand
with O O
NPH B-drug O
human I-drug O
insulin I-drug B-drug
immediately O O
before O O
injection O O
produced O O
some O O
attenuation O O
in O O
the O O
peak O O
concentration O O
of O O
NovoLog B-brand B-brand
, O O
but O O
that O O
the O O
time O O
to O O
peak O O
and O O
the O O
total O O
bioavailability O O
of O O
NovoLog B-brand B-brand
were O O
not O O
significantly O O
affected O O
. O O

Therefore O O
, O O
when O O
INDOCIN B-brand B-brand
and O O
digoxin B-drug B-drug
are O O
used O O
concomitantly O O
, O O
serum O O
digoxin B-drug B-drug
levels O O
should O O
be O O
closely O O
monitored O O
. O O

Hyperglycaemia O O
increased O O
all O O
the O O
renal O O
and O O
ocular O O
parameters O O
studied O O
. O O

Increase O O
daily O O
dose O O
of O O
rifabutin B-drug B-drug
by O O
50 O O
% O O
. O O

After O O
30 O O
min O O
, O O
fasting O O
glycemia O O
was O O
measured O O
. O O

Co-administration O O
of O O
celecoxib B-drug B-drug
with O O
drugs O O
that O O
are O O
known O O
to O O
inhibit O O
2C9 O O
should O O
be O O
done O O
with O O
caution O O
. O O

Potassium B-drug O
Supplements O O
and O O
Potassium-Sparing B-group B-group
Diuretics I-group I-group
Lotensin O B-brand
can O O
attenuate O O
potassium O O
loss O O
caused O O
by O O
thiazide B-group B-group
diuretics I-group I-group
. O O

In O O
case O O
of O O
theophylline B-drug B-drug
toxicity O O
and/or O O
elevated O O
serum O O
theophylline B-drug B-drug
levels O O
, O O
the O O
dose O O
of O O
theophylline B-drug B-drug
should O O
be O O
reduced O O
while O O
the O O
patient O O
is O O
receiving O O
concomitant O O
erythromycin B-drug B-drug
therapy O O
. O O

Phenytoin B-drug B-drug
: O O
In O O
post-marketing O O
experience O O
, O O
there O O
have O O
been O O
reports O O
of O O
both O O
increases O O
and O O
decreases O O
in O O
phenytoin B-drug B-drug
levels O O
with O O
dexamethasone B-drug B-drug
co-administration O O
, O O
leading O O
to O O
alterations O O
in O O
seizure O O
control O O
. O O

In O O
vitro O O
binding O O
studies O O
with O O
human O O
serum O O
proteins O O
indicate O O
that O O
glipizide B-drug B-drug
binds O O
differently O O
than O O
tolbutamide B-drug B-drug
and O O
does O O
not O O
interact O O
with O O
salicylate B-group B-group
or O O
dicumarol B-drug B-drug
. O O

It O O
is O O
not O O
known O O
if O O
hormonal B-group B-group
contraceptives I-group I-group
differ O O
in O O
their O O
effectiveness O O
when O O
used O O
with O O
Accutane B-brand B-brand
. O O

Administration O O
of O O
dantrolene B-drug B-drug
may O O
potentiate O O
vecuronium-induced B-drug B-drug
neuromuscular O O
block O O
. O O

This O O
decrease O O
in O O
bioavailability O O
was O O
about O O
5 O O
% O O
when O O
gabapentin B-drug B-drug
was O O
administered O O
2 O O
hours O O
after O O
Maalox B-brand B-brand
. O O

Folic B-drug B-drug
acid I-drug I-drug
supplements O O
can O O
correct O O
the O O
anemia O O
associated O O
with O O
vitamin O B-drug
B12 O O
deficiency O O
. O O

Taking O O
amyl B-drug B-drug
nitrite I-drug I-drug
after O O
drinking O O
alcohol B-drug B-drug
may O O
worsen O O
side O O
effects O O
and O O
may O O
cause O O
severe O O
hypotension O O
and O O
cardiovascular O O
collapse O O
. O O

Indomethacin B-drug B-drug
was O O
also O O
ineffective O O
in O O
altering O O
resveratrol B-drug_n O
activity O O
in O O
arteries O O
from O O
both O O
lean O O
and O O
dietary-obese O O
rats O O
. O O

INDOCIN B-brand B-brand
given O O
concomitantly O O
with O O
digoxin B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
the O O
serum O O
concentration O O
and O O
prolong O O
the O O
half-life O O
of O O
digoxin B-drug B-drug
. O O

Considerable O O
caution O O
should O O
be O O
exercised O O
if O O
PEGANONE B-brand B-brand
is O O
administered O O
concurrently O O
with O O
Phenurone B-brand B-brand
( O O
phenacemide B-drug B-drug
) O O
since O O
paranoid O O
symptoms O O
have O O
been O O
reported O O
during O O
therapy O O
with O O
this O O
combination O O
. O O

Paroxetine B-drug B-drug
produced O O
only O O
minor O O
changes O O
in O O
the O O
levels O O
of O O
clozapine B-drug B-drug
and O O
its O O
metabolites O O
. O O

Formulation O O
of O O
fluorescence O O
labelled O O
bacitracin B-drug B-drug
and O O
insulin B-drug B-drug
in O O
unconjugated O O
NaCMC B-drug_n B-drug_n
( O O
1 O O
% O O
m/v O O
) O O
did O O
not O O
significantly O O
improve O O
the O O
permeation O O
, O O
however O O
in O O
the O O
presence O O
of O O
1 O O
% O O
( O O
m/v O O
) O O
CMC-Cys7.3 B-drug_n O
a O O
significantly O O
improved O O
permeation O O
was O O
observed O O
( O O
R= O O
1.3 O O
) O O
. O O

Interaction O O
of O O
ketamine B-drug B-drug
and O O
halothane B-drug B-drug
in O O
rats O O
. O O

Thus O O
, O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
on O O
one O O
of O O
the O O
agents O O
in O O
this O O
category O O
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
treatment O O
with O O
EQUETROTM B-brand B-brand
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
increase O O
for O O
the O O
concomitant O O
agent O O
may O O
be O O
necessary O O
. O O

PEGASYS B-brand B-brand
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
with O O
creatinine O O
clearance O O
50 O O
mL/min O O
and O O
COPEGUS B-brand B-brand
should O O
not O O
be O O
administered O O
to O O
patients O O
with O O
creatinine O O
clearance O O
50 O O
mL/min O O

Other O O
binding O O
proteins O O
may O O
be O O
elevated O O
in O O
serum O O
, O O
( O O
i.e. O O
, O O
corticosteroid O O
binding O O
globulin O O
( O O
CBG O O
) O O
, O O
sex O O
hormone O O
binding O O
globulin O O
( O O
SHBG O O
) O O
) O O
leading O O
to O O
increased O O
total O O
circulating O O
corticosteroids B-group B-group
and O O
sex B-group B-group
steroids I-group I-group
, O O
respectively O O
. O O

Decreases O O
in O O
TBg O O
concentrations O O
are O O
observed O O
in O O
nephrosis O O
, O O
acromegaly O O
and O O
after O O
androgen B-group O
or O O
corticosteroid B-group B-group
therapy O O
. O O

Concomitant O O
administration O O
of O O
clarithromycin B-drug B-drug
with O O
pimozide B-drug B-drug
is O O
contraindicated O O
. O O

In O O
comparison O O
with O O
haloperidol B-drug B-drug
, O O
the O O
adverse O O
events O O
reported O O
significantly O O
more O O
frequently O O
with O O
olanzapine B-drug B-drug
in O O
> O O
or O O
= O O
3.5 O O
% O O
of O O
patients O O
were O O
dry O O
mouth O O
, O O
bodyweight O O
gain O O
and O O
increased O O
appetite O O
and O O
compared O O
with O O
risperidone B-drug B-drug
, O O
only O O
bodyweight O O
gain O O
occurred O O
significantly O O
more O O
frequently O O
with O O
olanzapine B-drug B-drug
. O O

These O O
medications O O
have O O
included O O
heparin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
beta-adrenergic B-group B-group
receptor I-group I-group
blockers I-group I-group
, O O
calcium B-group B-group
channel I-group I-group
antagonists I-group I-group
, O O
angiotensin B-group B-group
converting I-group I-group
enzyme I-group I-group
inhibitors I-group I-group
, O O
intravenous O O
and O O
oral O O
nitrates B-group B-group
, O O
ticlopidine B-drug B-drug
, O O
and O O
aspirin B-brand B-brand
. O O

Pretreatment O O
of O O
rats O O
with O O
allopurinol B-drug B-drug
( O O
100 O O
mg/kg O O
, O O
ip O O
) O O
or O O
Vitamin B-drug B-drug
E I-drug I-drug
( O O
100 O O
mg/kg O O
per O O
day O O
, O O
ig O O
, O O
for O O
3 O O
days O O
and O O
a O O
dose O O
of O O
40 O O
mg/kg O O
on O O
the O O
4th O O
day O O
) O O
provided O O
significant O O
protection O O
against O O
the O O
elevation O O
of O O
TBARS O B-brand
levels O O
in O O
cerebral O O
and O O
hepatic O O
tissues O O
, O O
induced O O
by O O
single O O
high O O
dose O O
of O O
oral O O
cypermethrin B-drug B-drug
administration O O
within O O
4 O O
h O O
. O O

These O O
would O O
include O O
a O O
variety O O
of O O
preparations O O
which O O
contain O O
androgens B-group B-group
, O O
estrogens B-group B-group
, O O
progestins B-group B-group
, O O
or O O
glucocorticoids B-group B-group
. O O

Theophylline B-drug B-drug
: O O
Theophylline B-drug B-drug
clearance O O
may O O
decrease O O
in O O
hypothyroid O O
patients O O
and O O
return O O
toward O O
normal O O
when O O
a O O
euthyroid O O
state O O
is O O
achieved O O
. O O

These O O
data O O
suggest O O
that O O
rofecoxib B-drug B-drug
may O O
produce O O
a O O
modest O O
inhibition O O
of O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
1A2 O O
. O O

Because O O
many O O
drugs O O
are O O
excreted O O
in O O
human O O
milk O O
, O O
and O O
because O O
of O O
the O O
potential O O
for O O
serious O O
adverse O O
reactions O O
from O O
FASLODEX B-brand B-brand
in O O
nursing O O
infants O O
, O O
a O O
decision O O
should O O
be O O
made O O
whether O O
to O O
discontinue O O
nursing O O
or O O
to O O
discontinue O O
the O O
drug O O
taking O O
into O O
account O O
the O O
importance O O
of O O
the O O
drug O O
to O O
the O O
mother O O
. O O

A O O
return O O
to O O
normal O O
menstrual O O
rhythm O O
followed O O
cessation O O
of O O
treatment O O
. O O

The O O
higher O O
verografine B-drug B-drug
and O O
iodamide B-drug B-drug
excretion O O
was O O
due O O
to O O
their O O
increased O O
renal O O
tubular O O
secretion O O
. O O

Opioids B-group B-group
are O O
strong O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
, O O
but O O
regular O O
users O O
develop O O
physiological O O
tolerance O O
allowing O O
gradually O O
increased O O
dosages O O
. O O

Calcium B-group B-group
Channel I-group I-group
Blockers I-group I-group
, O O
Dihydropyridine B-group B-drug
: O O
e.g. O O
, O O
felodipine B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
nicardipine B-drug B-drug

Additionally O O
, O O
paroxetine B-drug B-drug
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
Sonata B-brand B-brand
, O O
reflecting O O
the O O
absence O O
of O O
a O O
role O O
of O O
CYP2D6 O O
in O O
zaleplon B-drug B-drug
s O O
metabolism O O
. O O

Therefore O O
, O O
monitoring O O
of O O
plasma O O
digoxin B-drug B-drug
levels O O
may O O
be O O
indicated O O
in O O
patients O O
receiving O O
similar O O
combination O O
chemotherapy O O
regimens O O
. O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

Dolasetron B-drug B-drug
has O O
been O O
safely O O
coadministered O O
with O O
drugs O O
used O O
in O O
chemotherapy O O
and O O
surgery O O
. O O

Phenobarbital B-drug B-drug
: O O
Coadministration O O
of O O
felbamate B-drug B-drug
with O O
phenobarbital B-drug B-drug
causes O O
an O O
increase O O
in O O
phenobarbital B-drug B-drug
plasma O O
concentrations O O
, O O
In O O
12 O O
otherwise O O
healthy O O
male O O
volunteers O O
ingesting O O
phenobarbital B-drug B-drug
, O O
the O O
steady-state O O
trough O O
( O O
Cmin O O
) O O
phenobarbital B-drug B-drug
concentration O O
was O O
14.2 O O
micrograms/mL O O
. O O

Antihypertensives B-group B-group
: O O
Amphetamines B-group B-group
may O O
antagonize O O
the O O
hypotensive O O
effects O O
of O O
antihypertensives B-drug B-group
. O O

In O O
these O O
subjects O O
, O O
celecoxib B-drug B-drug
did O O
not O O
alter O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-drug B-drug
as O O
determined O O
by O O
prothrombin O O
time O O
. O O

Repeating O O
the O O
study O O
with O O
6 O O
healthy O O
male O O
volunteers O O
in O O
the O O
absence O O
of O O
glibenclamide B-drug B-drug
did O O
not O O
detect O O
an O O
effect O O
of O O
acitretin B-drug B-drug
on O O
glucose O O
tolerance O O
. O O

Two O O
weeks O O
after O O
bilateral O O
ovariectomy O O
, O O
female O O
rats O O
received O O
a O O
s.c O O
. O O

( O O
Effectiveness O O
may O O
be O O
decreased O O
when O O
used O O
concurrently O O
with O O
thiazide B-group B-group
diuretics I-group I-group
because O O
of O O
alkalinization O O
of O O
the O O
urine O O
. O O
) O O

Although O O
not O O
studied O O
with O O
alosetron B-drug B-drug
, O O
inhibition O O
of O O
N-acetyltransferase O O
may O O
have O O
clinically O O
relevant O O
consequences O O
for O O
drugs O O
such O O
as O O
isoniazid B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
and O O
hydralazine B-drug B-drug
. O O

However O O
, O O
if O O
Argatroban B-drug B-drug
is O O
to O O
be O O
initiated O O
after O O
cessation O O
of O O
heparin B-drug B-drug
therapy O O
, O O
allow O O
sufficient O O
time O O
for O O
heparins O O
effect O O
on O O
the O O
aPTT O O
to O O
decrease O O
prior O O
to O O
initiation O O
of O O
Argatroban B-drug B-drug
therapy O O
. O O

- O O
Antidiabetics B-group B-group
, O O
oral O O
( O O
diabetes O O
medicine O O
you O O
take O O
by O O
mouth O O
) O O
Use O O
of O O
oral O O
antidiabetics B-group B-group
with O O
sulfapyridine B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
blood O O
and/or O O
the O O
side O O
effects O O
or O O
oral O O
antidiabetics B-group B-group

Data O O
suggest O O
that O O
coadministration O O
of O O
oral O O
ketoconazole B-drug B-drug
and O O
cisapride B-drug B-drug
can O O
result O O
in O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

If O O
you O O
are O O
taking O O
a O O
tricyclic B-group B-group
antidepressant I-group I-group
, O O
talk O O
to O O
your O O
doctor O O
before O O
taking O O
this O O
medicine O O
. O O

Carbamazepine B-drug B-drug
: O O
Isoniazid B-drug B-drug
is O O
known O O
to O O
slow O O
the O O
metabolism O O
of O O
carbamazepine B-drug B-drug
and O O
increase O O
its O O
serum O O
levels O O
Carbamazepine B-drug B-drug
levels O O
should O O
be O O
determined O O
prior O O
to O O
concurrent O O
administration O O
with O O
isoniazid B-drug B-drug
, O O
signs O O
and O O
symptoms O O
of O O
carbamazepine B-drug B-drug
toxicity O O
should O O
be O O
monitored O O
closely O O
, O O
and O O
appropriate O O
dosage O O
adjustment O O
of O O
the O O
anticonvulsant B-group B-group
should O O
be O O
made O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
post O O
marketing O O
observations O O
, O O
have O O
shown O O
that O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

Butyrophenones B-group B-group
( O O
such O O
as O O
haloperidol B-drug B-drug
) O O
and O O
phenothiazines B-group B-group
can O O
suppress O O
the O O
dopaminergic B-drug O
renal O O
and O O
mesenteric O O
vasodilation O O
induced O O
with O O
low O O
dose O O
dopamine O O
infusion O O
. O O

Erythromycin I-drug B-drug
( O O
500 O O
mg O O
q8h O O
) O O
+ O O
40 O O
% O O
+46 O O
% O O

Also O O
, O O
due O O
to O O
the O O
potential O O
for O O
additive O O
effects O O
such O O
as O O
bradycardia O O
and O O
AV O O
block O O
, O O
caution O O
is O O
warranted O O
in O O
patients O O
receiving O O
clonidine B-drug B-drug
with O O
agents O O
known O O
to O O
affect O O
sinus O O
node O O
function O O
or O O
AV O O
nodal O O
conduction O O
( O O
e.g. O O
, O O
digitalis B-group B-group
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
and O O
beta-blockers B-group B-group
. O O
) O O

The O O
size O O
of O O
wheal O O
and O O
flare O O
were O O
significantly O O
larger O O
when O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
was O O
administered O O
with O O
either O O
grapefruit O O
or O O
orange O O
juices O O
compared O O
to O O
water O O
. O O

Effects O O
of O O
Lapatinib B-drug B-drug
on O O
Drug O O
Metabolizing O O
Enzymes O O
and O O
Drug O O
Transport O O
Systems O O
Lapatinib B-drug B-drug
inhibits O O
CYP3A4 O O
and O O
CYP2C8 O O
in O O
vitro O O
at O O
clinically O O
relevant O O
concentrations O O
. O O

Certain O O
drugs O O
tend O O
to O O
produce O O
hyperglycemia O O
and O O
may O O
lead O O
to O O
loss O O
of O O
control O O
. O O

Administration O O
of O O
epinephrine B-drug B-drug
to O O
patients O O
receiving O O
cyclopropane B-drug B-drug
or O O
halogenated B-group B-group
hydrocarbon I-group I-group
general I-group O
anesthetics I-group B-group
such O O
as O O
halothane B-drug B-drug
which O O
sensitize O O
the O O
myocardium O O
, O O
may O O
induce O O
cardiac O O
arrhythmia.. O O

AZOPT B-brand B-brand
( O O
brinzolamide B-drug B-drug
ophthalmic O O
suspension O O
) O O
1 O O
% O O
contains O O
a O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitor I-group I-group
. O O

All O O
20 O O
strains O O
of O O
enterococcus O O
, O O
three O O
strains O O
of O O
Clostridium O B-drug_n
, O O
three O O
strains O O
of O O
Escherichia O O
coli O O
, O O
and O O
one O O
strain O O
of O O
Proteus O O
rettgeri O O
were O O
resistant O O
to O O
both O O
clindamycin B-drug B-drug
( O O
minimal O O
inhibitory O O
concentration O O
greater O O
than O O
3.1 O O
mug/ml O O
) O O
and O O
gentamicin B-drug B-drug
( O O
minimal O O
inhibitory O O
concentration O O
greater O O
than O O
6.2 O O
mug/ml O O
) O O
. O O

In O O
combination O O
with O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
, O O
heroin B-drug_n B-drug
may O O
still O O
kill O O
even O O
experienced O O
users O O
, O O
particularly O O
if O O
their O O
tolerance O O
to O O
the O O
drug O O
has O O
reduced O O
or O O
the O O
strength O O
of O O
their O O
usual O O
dose O O
has O O
increased O O
. O O

Caution O O
is O O
advised O O
when O O
TRISENOX B-brand B-brand
is O O
coadministered O O
with O O
other O O
medications O O
that O O
can O O
prolong O O
the O O
QT O O
interval O O
( O O
e.g O O
. O O
certain O O
antiarrhythmics B-group B-group
or O O
thioridazine B-drug B-drug
) O O
or O O
lead O O
to O O
electrolyte O O
abnormalities O O
( O O
such O O
as O O
diuretics B-group B-group
or O O
amphotericin B-drug B-drug
B I-drug I-drug
) O O
. O O

Available O O
data O O
indicate O O
that O O
platelet O O
function O O
and O O
arachidonic O O
acid O O
metabolism O O
are O O
important O O
factors O O
in O O
hemostasis O O
and O O
regulation O O
of O O
vascular O O
tone O O
. O O

All O O
patients O O
in O O
whom O O
this O O
effect O O
was O O
observed O O
remained O O
asymptomatic O O
. O O

Combination O O
of O O
amiodarone B-drug B-drug
with O O
other O O
antiarrhythmic B-drug B-drug
therapy O O
should O O
be O O
reserved O O
for O O
patients O O
with O O
life-threatening O O
ventricular O O
arrhythmias O O
who O O
are O O
incompletely O O
responsive O O
to O O
a O O
single O O
agent O O
or O O
incompletely O O
responsive O O
to O O
amiodarone B-drug B-drug
. O O

RESULTS O O
: O O
During O O
treatment O O
with O O
fluvoxamine B-drug B-drug
, O O
there O O
was O O
a O O
statistically O O
significant O O
decrease O O
in O O
the O O
median O O
of O O
the O O
total O O
clearance O O
of O O
tolbutamide B-drug B-drug
, O O
from O O
845 O O
mL/h O O
to O O
688 O O
mL/h O O
, O O
among O O
the O O
volunteers O O
who O O
received O O
75 O O
mg/d O O
. O O

Disopyramide B-drug B-drug
increases O O
QT O O
prolongation O O
which O O
could O O
cause O O
arrhythmia O O
. O O

When O O
combined O O
with O O
ofloxacin B-drug B-drug
, O O
KRM-1648 B-drug_n B-drug_n
exhibited O O
strong O O
synergistic O O
activity O O
while O O
only O O
additive O O
effects O O
were O O
observed O O
with O O
the O O
combination O O
of O O
rifampicin B-drug B-drug
( O O
or O O
rifabutin B-drug B-drug
) O O
and O O
ofloxacin B-drug B-drug
. O O

Clarithromycin B-drug B-drug
exposure O O
was O O
significantly O O
decreased O O
by O O
nevirapine B-drug B-drug
; O O

Pregnancies O O
have O O
been O O
reported O O
by O O
users O O
of O O
combined B-group O
hormonal I-group B-group
contraceptives I-group I-group
who O O
also O O
used O O
some O O
form O O
of O O
St. O O
Johns O O
Wort O O
. O O

Patients O O
currently O O
receiving O O
diltiazem B-drug B-drug
therapy O O
should O O
be O O
carefully O O
monitored O O
for O O
a O O
change O O
in O O
pharmacological O O
effect O O
when O O
initiating O O
and O O
discontinuing O O
therapy O O
with O O
cimetidine B-drug B-drug
. O O

Anticoagulants B-group B-group
, O O
oral O O
: O O
Co-administration O O
of O O
corticosteroids B-group B-group
and O O
warfarin B-drug B-drug
usually O O
results O O
in O O
inhibition O O
of O O
response O O
to O O
warfarin B-drug B-drug
, O O
although O O
there O O
have O O
been O O
some O O
conflicting O O
reports O O
. O O

- O O
a O O
phenothiazine B-group B-group
such O O
as O O
chlorpromazine B-drug B-drug
( O O
Thorazine B-brand B-brand
) O O
, O O
fluphenazine B-drug B-drug
( O O
Prolixin B-brand B-brand
, O O
Permitil B-brand B-brand
) O O
, O O
prochlorperazine B-drug B-drug
( O O
Compazine B-brand B-brand
) O O
, O O
promethazine B-drug B-drug
( O O
Phenergan B-brand B-brand
) O O
, O O
and O O
others O O
; O O

Rifampin B-drug B-drug
: O O
Following O O
concomitant O O
administration O O
of O O
a O O
single O O
dose O O
of O O
ARAVA B-brand B-brand
to O O
subjects O O
receiving O O
multiple O O
doses O O
of O O
rifampin B-drug B-drug
, O O
M1 O O
peak O O
levels O O
were O O
increased O O
( O O
~40 O O
% O O
) O O
over O O
those O O
seen O O
when O O
ARAVA B-brand B-brand
was O O
given O O
alone O O
. O O

sulfonamides B-group B-group
, O O
long O O
acting O O
; O O

In O O
both O O
plasma O O
and O O
KHT O O
tumour O O
the O O
peak O O
concentration O O
and O O
" O O
early O O
" O O

The O O
monoamine O O
oxidase O O
inhibitory O O
effects O O
of O O
Isocarboxazid B-drug B-drug
may O O
persist O O
for O O
a O O
substantial O O
period O O
after O O
discontinuation O O
of O O
the O O
drug O O
, O O
and O O
this O O
should O O
be O O
borne O O
in O O
mind O O
when O O
another O O
drug O O
is O O
prescribed O O
following O O
Isocarboxazid B-drug B-drug
. O O

When O O
cholestyramine B-drug B-drug
resin B-group B-group
is O O
given O O
for O O
long O O
periods O O
of O O
time O O
, O O
concomitant O O
supplementation O O
with O O
water-miscible O O
( O O
or O O
parenteral O O
) O O
forms O O
of O O
fat-soluble B-group B-group
vitamins I-group I-group
should O O
be O O
considered O O
. O O

Drugs O O
That O O
Induce O O
CYP3A4 O O
( O O
Rifampicin B-drug B-drug
) O O
Racemic O O
zopiclone B-drug B-drug
exposure O O
was O O
decreased O O
80 O O
% O O
by O O
concomitant O O
useof O O
rifampicin B-drug B-drug
, O O
a O O
potent O O
inducer O O
of O O
CYP3A4 O O
. O O

Prothrombin O O
time O O
was O O
not O O
affected O O
. O O

400-2000 O O

The O O
concomitant O O
administration O O
of O O
rifampin B-drug B-drug
and O O
warfarin B-drug B-drug
resulted O O
in O O
the O O
need O O
for O O
an O O
unusually O O
high O O
maintenance O O
dose O O
of O O
warfarin B-drug B-drug
( O O
20 O O
mg O O
per O O
day O O
) O O
in O O
order O O
to O O
produce O O
a O O
therapeutic O O
effect O O
. O O

Cyclosporin B-drug B-drug
: O O
After O O
introduction O O
of O O
chloroquine B-drug B-drug
( O O
oral O O
form O O
) O O
, O O
a O O
sudden O O
increase O O
in O O
serum O O
cyclosporin B-drug B-drug
level O O
has O O
been O O
reported O O
. O O

Although O O
a O O
dose O O
adjustment O O
of O O
azithromycin B-drug B-drug
is O O
not O O
recommended O O
when O O
administered O O
in O O
combination O O
with O O
nelfinavir B-drug B-drug
, O O
close O O
monitoring O O
for O O
known O O
side O O
effects O O
of O O
azithromycin B-drug B-drug
, O O
such O O
as O O
liver O O
enzyme O O
abnormalities O O
and O O
hearing O O
impairment O O
, O O
is O O
warranted O O
. O O

Special O O
consideration O O
should O O
be O O
given O O
to O O
the O O
administration O O
of O O
ETHYOL B-brand B-brand
in O O
patients O O
receiving O O
antihypertensive B-group B-group
medications I-group I-group
or O O
other O O
drugs O O
that O O
could O O
cause O O
or O O
potentiate O O
hypotension O O
. O O

Synergism O O
between O O
xanthine B-group B-group
bronchodilators I-group I-group
( O O
e.g. O O
, O O
theophylline B-drug B-drug
) O O
, O O
ephedrine B-drug B-drug
, O O
and O O
other O O
sympathomimetic B-group B-group
bronchodilators I-group I-group
has O O
been O O
reported O O
. O O

Promethazine B-drug B-drug
: O O
Coadministration O O
of O O
a O O
single O O
dose O O
of O O
zaleplon B-drug B-drug
and O O
promethazine B-drug B-drug
( O O
10 O O
and O O
25 O O
mg O O
, O O
respectively O O
) O O
resulted O O
in O O
a O O
15 O O
% O O
decrease O O
in O O
maximal O O
plasma O O
concentrations O O
of O O
zaleplon B-drug B-drug
, O O
but O O
no O O
change O O
in O O
the O O
area O O
under O O
the O O
plasma O O
concentration-time O O
curve O O
. O O

Although O O
no O O
specific O O
drug O O
interactions O O
with O O
topical O O
glaucoma O O
drugs O O
or O O
systemic O O
medications O O
were O O
identified O O
in O O
clinical O O
studies O O
of O O
IOPIDINE B-brand B-brand
0.5 O O
% O O
Ophthalmic O O
Solution O O
, O O
the O O
possibility O O
of O O
an O O
additive O O
or O O
potentiating O O
effect O O
with O O
CNS B-group B-group
depressants I-group I-group
( O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
opiates B-group B-group
, O O
sedatives B-group B-group
, O O
anesthetics B-group B-group
) O O
should O O
be O O
considered O O
. O O

CONCLUSIONS O O
: O O
It O O
is O O
important O O
to O O
identify O O
the O O
medications O O
most O O
commonly O O
involved O O
in O O
the O O
PICR O O
so O O
as O O
to O O
establish O O
corrective O O
measures O O
to O O
minimise O O
the O O
risks O O
arising O O
from O O
multiple O O
medication O O
. O O

Lithium B-drug B-drug
: O O
Lithium B-drug B-drug
toxicity O O
has O O
been O O
reported O O
in O O
patients O O
receiving O O
lithium B-drug B-drug
concomitantly O O
with O O
drugs O O
which O O
cause O O
elimination O O
of O O
sodium O B-drug
, O O
including O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Effect O O
on O O
Concentration O O
of O O
Nevirapine B-drug B-drug
or O O
Concomitant O O
Drug O O

Additionally O O
, O O
higher O O
than O O
expected O O
tricyclic B-group B-group
antidepressant I-group I-group
levels O O
have O O
been O O
observed O O
when O O
they O O
are O O
begun O O
in O O
patients O O
already O O
taking O O
cimetidine B-drug B-drug
. O O

Interactions O O
may O O
occur O O
between O O
EPA B-drug B-drug
supplements O O
and O O
aspirin B-brand B-brand
and O O
other O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
and O O
herbs O O
such O O
as O O
garlic O O
( O O
Allium O B-brand
sativum O I-brand
) O O
and O O
ginkgo B-drug O
( O O
Ginkgo B-drug O
biloba I-drug O
) O O
. O O

Theoretically O O
, O O
it O O
may O O
decrease O O
hepatic O O
toxicity O O
in O O
the O O
case O O
of O O
other O O
potential O O
hepatotoxic O O
drugs O O
, O O
as O O
well O O
. O O

On O O
the O O
basis O O
of O O
the O O
principles O O
observed O O
the O O
concentrations O O
fo O O
these O O
hormones O O
were O O
investigated O O
in O O
the O O
plasma O O
of O O
dogs O O
deprived O O
of O O
water O O
for O O
3 O O
days O O
and O O
then O O
allowed O O
to O O
drink O O
. O O

Ocupress B-brand O
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
who O O
are O O
receiving O O
a O O
beta-adrenergic B-group B-group
blocking I-group I-group
agent I-group I-group
orally O O
because O O
of O O
the O O
potential O O
for O O
additive O O
effects O O
on O O
systemic O O
beta-blockade O O
. O O

In O O
diabetics O O
, O O
blood-sugar O O
levels O O
should O O
be O O
monitored O O
very O O
carefully O O
. O O

Ketoconazole B-drug B-drug
: O O
Co-administration O O
of O O
bosentan B-drug B-drug
125 O O
mg O O
b.i.d O O
. O O
and O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
CYP3A4 O O
inhibitor O O
, O O
increased O O
the O O
plasma O O
concentrations O O
of O O
bosentan B-drug B-drug
by O O
approximately O O
2-fold O O
. O O

clarithromycin I-drug B-drug
concentration O O
indinavir B-drug B-drug
concentration O O

Further O O
, O O
no O O
effects O O
on O O
either O O
warfarin B-drug B-drug
levels O O
or O O
prothrombin O O
times O O
were O O
observed O O
in O O
a O O
study O O
involving O O
concomitant O O
administration O O
of O O
warfarin B-drug B-drug
and O O
fluvastatin B-drug B-drug
. O O

The O O
amplitude O O
data O O
from O O
this O O
study O O
suggest O O
that O O
ethanol B-drug B-drug
's O O
augmentation O O
of O O
component O O
P2 O O
may O O
result O O
, O O
at O O
least O O
in O O
part O O
, O O
from O O
alterations O O
in O O
cholinergic O O
functions O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
DOXIL B-brand B-brand
. O O

The O O
effect O O
may O O
be O O
mediated O O
by O O
cimetidines B-drug O
known O O
inhibition O O
of O O
hepatic O O
cytochrome O O
P-450 O O
, O O
the O O
enzyme O O
system O O
responsible O O
for O O
the O O
first-pass O O
metabolism O O
of O O
diltiazem B-drug B-drug
. O O

Therefore O O
, O O
a O O
lower O O
total O O
daily O O
dosage O O
of O O
INDOCIN B-brand B-brand
may O O
produce O O
a O O
satisfactory O O
therapeutic O O
effect O O
. O O

Drug O O
interaction O O
studies O O
with O O
decitabine B-drug B-drug
have O O
not O O
been O O
conducted O O
. O O

It O O
is O O
recommended O O
not O O
to O O
exceed O O
a O O
single O O
5 O O
mg O O
dose O O
of O O
Vardenafil B-drug B-drug
in O O
a O O
24-hour O O
period O O
when O O
used O O
in O O
combination O O
with O O
erythromycin B-drug B-drug
. O O

The O O
concomitant O O
administration O O
of O O
griseofulvin B-drug B-drug
has O O
been O O
reported O O
to O O
reduce O O
the O O
efficacy O O
of O O
oral O O
contraceptives B-group B-group
and O O
to O O
increase O O
the O O
incidence O O
of O O
breakthrough O O
bleeding O O
. O O

Fluvoxamine B-drug B-drug
is O O
a O O
known O O
strong O O
inhibitor O O
of O O
CYP1A2 O O
and O O
also O O
inhibits O O
CYP3A4 O O
, O O
CYP2C9 O O
, O O
and O O
CYP2C19 O O
. O O

No O O
information O O
is O O
available O O
. O O

Greater O O
fecal O O
blood O O
loss O O
results O O
from O O
concomitant O O
administration O O
of O O
both O O
drugs O O
than O O
from O O
either O O
drug O O
alone O O
. O O

Concomitant O O
use O O
with O O
other O O
oxytocic B-group B-group
agents I-group I-group
is O O
not O O
recommended O O

Data O O
from O O
in O O
vitro O O
studies O O
of O O
alprazolam B-drug B-drug
suggest O O
a O O
possible O O
drug O O
interaction O O
with O O
alprazolam B-drug B-drug
for O O
the O O
following O O
: O O
sertraline B-drug B-drug
and O O
paroxetine B-drug B-drug
. O O

Concurrent O O
use O O
of O O
rifampin B-drug B-drug
increases O O
the O O
metabolic O O
clearance O O
of O O
ZEBETA B-brand B-brand
, O O
resulting O O
in O O
a O O
shortened O O
elimination O O
half-life O O
of O O
ZEBETA B-brand B-brand
. O O

Urinary O O
Alkalinizers O O
: O O
Decrease O O
aspirin B-brand B-brand
effectiveness O O
by O O
increasing O O
the O O
rate O O
of O O
salicylate B-group B-group
renal O O
excretion O O
. O O

When O O
concomitant O O
administration O O
of O O
ketoconazole B-drug B-drug
with O O
aripiprazole B-drug B-drug
occurs O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
be O O
reduced O O
to O O
one-half O O
of O O
its O O
normal O O
dose O O
. O O

Therefore O O
, O O
the O O
dose O O
of O O
corticosteroid B-group B-group
should O O
be O O
titrated O O
to O O
avoid O O
steroid O B-group
toxicity O O
. O O

In O O
patients O O
taking O O
an O O
anticonvulsant B-group B-group
( O O
eg O O
, O O
valproic B-drug B-drug
acid I-drug I-drug
, O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
or O O
phenytoin B-drug B-drug
) O O
, O O
the O O
concomitant O O
use O O
of O O
Mefloquine B-drug B-drug
may O O
reduce O O
seizure O O
control O O
by O O
lowering O O
the O O
plasma O O
levels O O
of O O
the O O
anticonvulsant B-group B-group
. O O

Moreover O O
, O O
the O O
mechanisms O O
underlying O O
the O O
development O O
of O O
dependence O O
may O O
be O O
similar O O
for O O
alcohol B-drug B-drug
and O O
nicotine B-drug B-drug
. O O

May O O
interact O O
with O O
cefamandole B-drug B-drug
naftate I-drug I-drug
, O O
cephalothin B-drug B-drug
sodium I-drug I-drug
, O O
magnesium B-drug B-drug
sulfate I-drug I-drug
, O O
prednisolone B-drug B-drug
sodium I-drug I-drug
succinate I-drug I-drug
, O O
and O O
prochlorperazine B-drug B-drug
edisylate I-drug I-drug
. O O

- O O
Etretinate B-drug B-drug
( O O
e.g. O O
, O O
Tegison B-brand B-brand
) O O
or O O

In O O
patients O O
taking O O
furosemide B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
ACE B-group B-group
inhibitors I-group I-group
, O O
verapamil B-drug B-drug
, O O
glyburide B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
and O O
various O O
chemotherapy O O
agents O O
, O O
no O O
effect O O
was O O
shown O O
on O O
the O O
clearance O O
of O O
hydrodolasetron B-drug_n B-drug_n
. O O

The O O
depression O O
of O O
cardiac O O
contractility O O
, O O
conductivity O O
, O O
and O O
automaticity O O
as O O
well O O
as O O
the O O
vascular O O
dilation O O
associated O O
with O O
anesthetics B-group B-group
may O O
be O O
potentiated O O
by O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
. O O

Nifedipine B-drug B-drug
did O O
not O O
alter O O
the O O
plasma O O
levels O O
of O O
Vardenafil B-drug B-drug
when O O
taken O O
in O O
combination O O
. O O

No O O
evidence O O
of O O
interaction O O
of O O
PROCRIT B-brand B-brand
with O O
other O O
drugs O O
was O O
observed O O
in O O
the O O
course O O
of O O
clinical O O
trials O O
. O O

The O O
drug O O
interaction O O
between O O
warfarin B-drug B-drug
and O O
rifampin B-drug B-drug
is O O
not O O
well O O
known O O
. O O

However O O
, O O
due O O
to O O
possible O O
pharmacodynamic O O
interactions O O
, O O
when O O
co-administered O O
with O O
PRECEDEX B-brand B-brand
, O O
a O O
reduction O O
in O O
dosage O O
of O O
PRECEDEX B-brand B-brand
on O O
the O O
concomitant O O
anesthetic B-group B-group
, O O
sedative B-group B-group
, O O
hypnotic B-group B-group
or O O
opioid B-group B-group
may O O
be O O
required O O
. O O

Drugs O O
which O O
inhibit O O
this O O
metabolic O O
pathway O O
may O O
have O O
a O O
profound O O
effect O O
on O O
the O O
clearance O O
of O O
alprazolam B-drug B-drug
. O O

Enoxacin B-drug B-drug
does O O
not O O
affect O O
the O O
clearance O O
of O O
the O O
active O O
S-isomer O O
, O O
and O O
changes O O
in O O
clotting O O
time O O
have O O
not O O
been O O
observed O O
when O O
enoxacin B-drug B-drug
and O O
warfarin B-drug B-drug
were O O
coadministered O O
. O O

Anticoagulants B-group B-group
( O O
Oral O O
) O O
: O O
In O O
patients O O
receiving O O
oral O O
anticoagulants B-group B-group
, O O
the O O
coagulation O O
times O O
were O O
increased O O
in O O
some O O
cases O O
. O O

AUC O O
for O O
total O O
nitrosoureas B-group B-group
were O O
about O O
1.4-1.5 O O
fold O O
greater O O
for O O
the O O
oral O O
compared O O
to O O
the O O
i.p O O
. O O

Because O O
the O O
tetracyclines B-group B-group
have O O
been O O
shown O O
to O O
depress O O
plasma O O
prothrombin O O
activity O O
, O O
patients O O
who O O
are O O
on O O
anticoagulant B-group B-group
therapy O O
may O O
require O O
downward O O
adjustment O O
of O O
their O O
anticoagulant B-group B-group
dosage O O
. O O

Oxytocin B-drug B-drug
or O O
other O O
oxytocics B-group B-group
( O O
concurrent O O
use O O
with O O
dinoprost B-drug B-drug
may O O
result O O
in O O
uterine O O
hypertonus O O
, O O
possibly O O
causing O O
uterine O O
rupture O O
or O O
cervical O O
laceration O O
, O O
especially O O
in O O
the O O
absence O O
of O O
adequate O O
cervical O O
dilatation O O
; O O

The O O
single-dose O O
nature O O
of O O
this O O
study O O
and O O
the O O
lack O O
of O O
correlation O O
between O O
glyburide B-drug B-drug
blood O O
levels O O
and O O
pharmaco-dynamic O O
effects O O
, O O
makes O O
the O O
clinical O O
significance O O
of O O
this O O
interaction O O
uncertain O O
. O O

The O O
incidence O O
of O O
TBg O O
deficiency O O
approximates O O
1 O O
in O O
9000 O O
. O O

If O O
midazolam B-drug B-drug
is O O
administered O O
parenterally O O
, O O
special O O
precaution O O
is O O
required O O
since O O
the O O
sedative O O
effect O O
may O O
be O O
prolonged O O
. O O

Caffeine B-drug B-drug
: O O
Enoxacin B-drug B-drug
is O O
a O O
potent O O
inhibitor O O
of O O
the O O
cytochrome O O
P-450 O O
isozymes O O
responsible O O
for O O
the O O
metabolism O O
of O O
methylxanthines B-group B-group
. O O

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

Dexamethasone O B-drug
suppression O O
test O O
( O O
DST O O
) O O
: O O
False-negative O O
results O O
in O O
the O O
dexamethasone O B-drug
suppression O O
test O O
( O O
DST O O
) O O
in O O
patients O O
being O O
treated O O
with O O
indomethacin B-drug B-drug
have O O
been O O
reported O O
. O O

Use O O
with O O
Angiotensln B-group B-group
Converting I-group I-group
Enzyme I-group I-group
Inhibitors I-group I-group
: O O
The O O
use O O
of O O
angiotensin B-group B-group
converting I-group I-group
enzyme I-group I-group
inhibitors I-group I-group
to O O
control O O
hypertension O O
in O O
patients O O
on O O
azathioprine B-drug B-drug
has O O
been O O
reported O O
to O O
induce O O
severe O O
leukopenia O O
. O O

In O O
addition O O
, O O
other O O
quinolones B-group B-group
have O O
been O O
reported O O
to O O
decrease O O
the O O
CYP3A4-mediated O O
metabolism O O
of O O
cyclosporine B-drug B-drug
. O O

Imipramine B-drug B-drug
and O O
clonazepam B-drug B-drug
did O O
not O O
change O O
fasting O O
or O O
overload O O
glycemia O O
. O O

The O O
concurrent O O
administration O O
of O O
allopurinol B-drug B-drug
and O O
ampicillin B-drug B-drug
increases O O
substantially O O
the O O
incidence O O
of O O
rashes O O
in O O
patients O O
receiving O O
both O O
drugs O O
as O O
compared O O
to O O
patients O O
receiving O O
ampicillin B-drug B-drug
alone O O
. O O

The O O
initial O O
dose O O
of O O
levorphanol B-drug B-drug
should O O
be O O
reduced O O
by O O
approximately O O
50 O O
% O O
or O O
more O O
when O O
it O O
is O O
given O O
to O O
patients O O
along O O
with O O
another O O
drug O O
affecting O O
respiration O O
. O O

Cerivastatin B-drug B-drug
plasma O O
concentrations O O
were O O
also O O
not O O
affected O O
by O O
co-administration O O
of O O
digoxin B-drug B-drug
. O O

Betaseron B-brand B-brand
administration O O
to O O
three O O
cancer O O
patients O O
over O O
a O O
dose O O
range O O
of O O
0.025 O O
mg O O
to O O
2.2 O O
mg O O
led O O
to O O
a O O
dose-dependent O O
inhibition O O
of O O
antipyrine B-drug B-drug
elimination.14 O O
The O O
effect O O
of O O
alternate-day O O
administration O O
of O O
0.25 O O
mg O O
of O O
Betaseron B-brand B-brand
on O O
drug O O
metabolism O O
in O O
MS O O
patients O O
is O O
unknown O O
. O O

- O O
Acetohydroxamic B-drug B-drug
acid I-drug I-drug
( O O
e.g. O O
, O O
Lithostat B-brand B-brand
) O O
or O O

Indinavir B-drug B-drug
is O O
metabolized O O
by O O
CYP3A4 O O
. O O

Plasma O O
was O O
analyzed O O
for O O
tolbutamide B-drug B-drug
, O O
and O O
urine O O
was O O
analyzed O O
for O O
tolbutamide B-drug B-drug
and O O
its O O
two O O
metabolites O O
, O O
4-hydroxytolbutamide B-drug_n B-drug_n
and O O
carboxytolbutamide B-drug_n B-drug
by O O
means O O
of O O
HPLC O O
. O O

No O O
clinically O O
relevant O O
drug-drug O O
interactions O O
have O O
been O O
observed O O
with O O
drugs O O
likely O O
to O O
be O O
co-administered O O
with O O
anidulafungin B-drug B-drug
. O O

Nelfinavir B-drug B-drug
is O O
metabolized O O
in O O
proof O O
by O O
C.P.A O O
. O O

. O O

Curariform B-brand B-group
muscle I-brand I-group
relaxants I-brand I-group
( O O
eg O O
, O O
tubocurarine B-drug B-drug
) O O
and O O
other O O
drugs O O
, O O
including O O
ether O B-drug
, O O
succinylcholine B-drug B-drug
, O O
gallamine B-drug B-drug
, O O
decamethonium B-drug B-drug
and O O
sodium B-drug B-drug
citrate I-drug I-drug
, O O
potentiate O O
the O O
neuromuscular O O
blocking O O
effect O O
and O O
should O O
be O O
used O O
with O O
extreme O O
caution O O
in O O
patients O O
being O O
treated O O
with O O
Coly-Mycin B-brand B-brand
M I-brand O
Parenteral O O
. O O

The O O
MPTP-induced B-drug B-drug_n
neuronal O O
damage O O
produced O O
a O O
tolerance O O
to O O
the O O
disruptive O O
effects O O
of O O
amphetamine B-drug B-drug
and O O
a O O
supersensitivity O O
to O O
the O O
disruptive O O
effects O O
of O O
apomorphine B-drug B-drug
in O O
rats O O
responding O O
in O O
a O O
schedule O O
controlled O O
paradigm O O
. O O

Since O O
chronic O O
dosing O O
is O O
required O O
for O O
therapeutic O O
efficacy O O
of O O
antipsychotics B-group B-group
, O O
future O O
studies O O
should O O
focus O O
on O O
investigation O O
of O O
chronic O O
dosing O O
effects O O
of O O
these O O
drugs O O
in O O
combination O O
with O O
PCP B-drug_n B-drug_n
. O O

When O O
carbamazepine B-drug B-drug
is O O
added O O
to O O
aripiprazole B-drug B-drug
therapy O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
be O O
doubled O O
. O O

Effect O O
of O O
Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
is O O
a O O
blocker O O
of O O
renal O O
tubular O O
secretion O O
. O O

Post-marketing O O
reports O O
of O O
changes O O
in O O
prothrombin O O
measures O O
have O O
been O O
received O O
among O O
patients O O
on O O
concomitant O O
warfarin B-drug B-drug
and O O
esomeprazole B-drug B-drug
therapy O O
. O O

To O O
determine O O
whether O O
probenecid B-drug B-drug
has O O
a O O
direct O O
effect O O
on O O
the O O
distribution O O
of O O
cloxacillin B-drug B-drug
, O O
the O O
elimination O O
and O O
distribution O O
of O O
cloxacillin B-drug B-drug
was O O
studied O O
in O O
six O O
patients O O
, O O
five O O
lacking O O
kidney O O
function O O
and O O
one O O
with O O
a O O
partially O O
impaired O O
renal O O
function O O
, O O
in O O
the O O
presence O O
or O O
absence O O
of O O
probenecid B-drug B-drug
. O O

Accordingly O O
, O O
diazepam B-drug B-drug
and O O
fluvoxamine B-drug B-drug
should O O
not O O
ordinarily O O
be O O
co-administered O O
. O O

A O O
potential O O
interaction O O
between O O
oral O O
miconazole B-drug B-drug
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
leading O O
to O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
. O O

Calcium B-drug B-group
Supplements/Antacids B-group I-group

Fluoxetine B-drug B-drug
and O O
its O O
active O O
metabolite O O
, O O
norfluoxe-tine O B-drug
, O O
have O O
long O O
half-lives O B-group
( O O
4 O O
to O O
16 O O
days O O
for O O
norfluoxetine B-drug_n B-drug
) O O
, O O
that O O
may O O
affect O O
strategies O O
during O O
conversion O O
from O O
one O O
drug O O
to O O
the O O
other O O
. O O

In O O
vitro O O
displacement O O
studies O O
with O O
highly O O
protein-bound O O
drugs O O
such O O
as O O
furosemide B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
captopril B-drug B-drug
, O O
nicardipine B-drug B-drug
, O O
pravastatin B-drug B-drug
, O O
glyburide B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
tolbutamide B-drug B-drug
, O O
and O O
metformin B-drug B-drug
showed O O
no O O
influence O O
on O O
the O O
extent O O
of O O
nateglinide B-drug B-drug
protein O O
binding O O
. O O

In O O
those O O
patients O O
in O O
whom O O
renal O O
insufficiency O O
was O O
documented O O
, O O
however O O
, O O
the O O
recommendation O O
to O O
lower O O
the O O
dose O O
of O O
allopurinol B-drug B-drug
was O O
not O O
followed O O
. O O

Serum O O
potassium O O
levels O O
and O O
cardiac O O
function O O
should O O
be O O
closely O O
monitored O O
and O O
any O O
deficit O O
promptly O O
corrected O O
. O O

More O O
specific O O
applications O O
of O O
the O O
assay O O
of O O
thio O O
compounds O O
in O O
urine O O
allow O O
development O O
of O O
selective O O
methods O O
that O O
may O O
be O O
useful O O
for O O
biological O O
monitoring O O
. O O

. O O

In O O
a O O
small O O
( O O
n=30 O O
) O O
combination O O
study O O
of O O
ARAVA B-brand B-brand
with O O
methotrexate B-drug B-drug
, O O
a O O
2- O O
to O O
3-fold O O
elevation O O
in O O
liver O O
enzymes O O
was O O
seen O O
in O O
5 O O
of O O
30 O O
patients O O
. O O

In O O
the O O
absence O O
of O O
formal O O
clinical O O
drug O O
interaction O O
studies O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
administering O O
TAXOL B-brand B-brand
concomitantly O O
with O O
known O O
substrates O O
or O O
inhibitors O O
of O O
the O O
cytochrome O O
P450 O O
isoenzymes O O
CYP2C8 O O
and O O
CYP3A4 O O
. O O

pentoxifylline B-drug B-drug
; O O

and O O
clinical O O
implications O O
. O O

Sedative/hypnotics B-group B-group
: O O
midazolam B-drug B-drug
, O O
triazolam B-drug B-drug

Other O O
kits O O
, O O
such O O
as O O
the O O
Coat-A-Count O O
RIA O O
Kit O O
, O O
may O O
be O O
used O O
. O O

The O O
effects O O
, O O
if O O
any O O
, O O
on O O
the O O
pituitary-gonadal O O
axis O O
in O O
premenopausal O O
women O O
are O O
unknown O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
increase O O
in O O
doxazosin B-drug B-drug
AUC O O
is O O
unknown O O
. O O

Ketoconazole B-drug B-drug
: O O
Potential O O
interaction O O
of O O
Ketoconazole B-drug B-drug
and O O
Isoniazid B-drug B-drug
may O O
exist O O
. O O

Close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
dosage O O
are O O
required O O
when O O
Anafranil B-brand B-brand
is O O
administered O O
with O O
anticholinergic B-group B-group
or O O
sympathomimetic B-group B-group
drugs I-group I-group
. O O

Prolonged O O
recovery O O
time O O
may O O
occur O O
if O O
barbiturates B-group B-group
and/or O O
narcotics B-group B-group
are O O
used O O
concurrently O O
with O O
ketamine B-drug B-drug
. O O

It O O
was O O
observed O O
that O O
contortrostatin B-drug_n B-drug_n
had O O
a O O
dramatic O O
effect O O
on O O
the O O
tyrosine O O
phosphorylation O O
status O O
of O O
several O O
proteins O O
in O O
T24 O O
human O O
bladder O O
cancer O O
cells O O
, O O
including O O
robust O O
induction O O
of O O
phosphorylation O O
of O O
proteins O O
in O O
the O O
range O O
of O O
120-140 O O
kDa O O
. O O

The O O
safety O O
and O O
efficacy O O
of O O
AMEVIVE B-brand B-brand
in O O
pediatric O O
patients O O
have O O
not O O
been O O
studied O O
. O O

Coadministration O O
of O O
glyburide B-drug B-drug
with O O
doses O O
higher O O
than O O
40 O O
mg O O
valdecoxib B-drug B-drug
( O O
e.g. O O
, O O
40 O O
mg O O
BID O O
) O O
have O O
not O O
been O O
studied O O
. O O

The O O
dextrorotatory O O
isomer O O
, O O
on O O
the O O
other O O
hand O O
, O O
had O O
effects O O
similar O O
to O O
those O O
of O O
PCP B-drug_n B-drug_n
in O O
both O O
species O O
. O O

Antacids B-group B-group
increase O O
the O O
rate O O
of O O
absorption O O
of O O
pseudoephedrine B-drug B-drug
, O O
while O O
kaolin B-drug O
decreases O O
it O O
. O O

Thyroid B-group O
hormone I-group O
activity O O
may O O
also O O
be O O
enhanced O O
. O O

Ritonavir B-drug B-drug

Methotrexate B-drug B-drug
Renal O O
tubular O O
transport O O
of O O
methotrexate B-drug B-drug
may O O
be O O
inhibited O O
by O O
concomitant O O
administration O O
of O O
ciprofloxacin B-drug B-drug
, O O
potentially O O
leading O O
to O O
increased O O
plasma O O
levels O O
of O O
methotrexate B-drug B-drug
. O O

A O O
number O O
of O O
drugs O O
, O O
including O O
ethacrynic B-drug B-drug
acid I-drug I-drug
, O O
have O O
been O O
shown O O
to O O
displace O O
warfarin B-drug B-drug
from O O
plasma O O
protein O O
; O O

Milk O O
, O O
milk O O
products O O
, O O
and O O
calcium-rich B-drug O
foods O O
or O O
drugs O O
may O O
impair O O
the O O
absorption O O
of O O
EMCYT B-brand B-brand
. O O

Anticoagulants B-group B-group
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
increase O O
or O O
decrease O O
the O O
effects O O
of O O
coumarin B-group B-group
derivatives I-group I-group
. O O

Concomitant O O
administration O O
of O O
gemfibrozil B-drug B-drug
with O O
Targretin B-brand B-drug
capsules O O
is O O
not O O
recommended O O
. O O

No O O
formal O O
drug-drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

Therefore O O
, O O
indomethacin B-drug B-drug
and O O
diflunisal B-drug B-drug
should O O
not O O
be O O
used O O
concomitantly O O
. O O

Drug O O
interaction O O
studies O O
with O O
SUSTIVA B-brand B-brand
and O O
these O O
imidazole O B-group
and O O
triazole B-group B-group
antifungals I-group I-group
have O O
not O O
been O O
conducted B-group O
. I-group O

In O O
addition O O
, O O
administration O O
of O O
Sonata B-brand B-brand
to O O
a O O
patient O O
taking O O
another O O
drug O O
that O O
is O O
highly O O
protein O O
bound O O
should O O
not O O
cause O O
transient O O
increase O O
in O O
free O O
concentrations O O
of O O
the O O
other O O
drug O O
. O O

When O O
taken O O
orally O O
, O O
imidazole B-group B-group
compounds I-group I-group
like O O
ketoconazole B-drug B-drug
may O O
enhance O O
the O O
anticoagulant O O
effect O O
of O O
coumarin-like B-group B-group
drugs O I-group
. O O

Anticholinergic B-group B-group
agents I-group I-group
may O O
affect O O
gastrointestinal O O
absorption O O
of O O
various O O
drugs O O
, O O
such O O
as O O
slowly O O
dissolving O O
dosage O O
forms O O
of O O
digoxin B-drug B-drug
; O O

However O O
, O O
no O O
clinically O O
or O O
statistically O O
significant O O
differences O O
in O O
prothrombin O O
time O O
ratio O O
or O O
warfarin B-drug B-drug
enantiomer O I-drug
pharmacokinetics O O
were O O
observed O O
in O O
a O O
small O O
study O O
of O O
7 O O
healthy O O
males O O
who O O
received O O
both O O
warfarin B-drug B-drug
and O O
lomefloxacin B-drug B-drug
under O O
steady-state O O
conditions O O
. O O

All O O
of O O
these O O
also O O
resolved O O
, O O
2 O O
with O O
continuation O O
of O O
both O O
drugs O O
and O O
3 O O
after O O
discontinuation O O
of O O
leflunomide B-drug B-drug
. O O

Optimal O O
designs O O
for O O
the O O
individual O O
and O O
joint O O
exposure O O
general O O
logistic O O
regression O O
models O O
. O O

The O O
following O O
drug O O
interactions O O
have O O
been O O
reported O O
with O O
etomidate B-drug B-drug
. O O

The O O
renal O O
plasma O O
flow O O
, O O
glomerular O O
filtration O O
rate O O
and O O
pulsatile O B-drug
choroidal O O
blood O O
flow O O
were O O
measured O O
using O O
the O O
paraaminohippurate O O
method O O
, O O
the O O
inulin O O
method O O
and O O
a O O
laser O O
interferometric O O
measurement O O
of O O
fundus O O
pulsation O O
amplitude O O
, O O
respectively O O
. O O

Potassium-sparing B-group B-group
diuretics I-group I-group
such O O
as O O
spironolactone B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
or O O
amiloride B-drug B-drug
, O O
or O O
potassium B-drug B-drug
supplements O O
should O O
be O O
given O O
only O O
for O O
documented O O
hypokalemia O O
, O O
and O O
then O O
with O O
caution O O
, O O
since O O
they O O
may O O
lead O O
to O O
a O O
significant O O
increase O O
of O O
serum O O
potassium O O
. O O

Optimal O O
conditions O O
, O O
kinetics O O
, O O
equilibrium O O
, O O
and O O
the O O
mechanism O O
of O O
this O O
acid-catalyzed O O
ethanolysis O O
are O O
reported O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
. O O

Dosage O O
of O O
the O O
anticoagulant B-group B-group
may O O
require O O
reduction O O
in O O
order O O
to O O
maintain O O
satisfactory O O
therapeutic O O
hypoprothrombinemia O O
. O O

The O O
histology O O
of O O
the O O
liver O O
was O O
altered O O
in O O
the O O
three O O
groups O O
which O O
were O O
submitted O O
to O O
treatment O O
with O O
the O O
hydroalcoholic O B-drug
solutions O O
, O O
with O O
quantitative O O
and O O
qualitative O O
differences O O
between O O
the O O
groups O O
. O O

The O O
following O O
laboratory O O
tests O O
have O O
been O O
found O O
to O O
be O O
abnormal O O
in O O
a O O
few O O
patients O O
receiving O O
baclofen B-drug B-drug
: O O
increased O O
SGOT O O
, O O
elevated O O
alkaline O O
phosphatase O O
, O O
and O O
elevation O O
of O O
blood O O
sugar O O
. O O

Analgesic O O
effects O O
of O O
antihistaminics B-group B-group
. O O

Combined O O
effects O O
may O O
induce O O
serious O O
cardiac O O
arrhythmias O O
. O O

Oral O O
Hypoglycemic B-group B-group
Agents I-group I-group
: O O
In O O
one O O
study O O
, O O
flurbiprofen B-drug B-drug
was O O
given O O
to O O
adult O O
diabetics O O
who O O
were O O
already O O
receiving O O
glyburide B-drug B-drug
( O O
n=4 O O
) O O
, O O
metformin B-drug B-drug
( O O
n=2 O B-drug
) O O
chlorpropamide B-drug B-drug
with O O
phenformin B-drug B-drug
( O O
n= O B-brand
3 O I-brand
) O O
or O O
glyburide B-drug B-drug
with O O
phenformin B-drug B-drug
( O O
n=6 O O
) O O
. O O

CELEBREX B-brand B-brand
should O O
be O O
introduced O O
at O O
the O O
lowest O O
recommended O O
dose O O
in O O
patients O O
receiving O O
fluconazole B-drug B-drug
. O O

The O O
incidence O O
of O O
akathisia O O
in O O
clinical O O
trials O O
of O O
the O O
weekly O O
dosage O O
schedule O O
was O O
greater O O
( O O
8.5 O O
% O O
, O O
4/47 O O
patients O O
) O O
when O O
prochlorperazine B-drug B-drug
was O O
administered O O
on O O
the O O
same O O
day O O
as O O
CAMPTOSAR B-brand B-brand
than O O
when O O
these O O
drugs O O
were O O
given O O
on O O
separate O O
days O O
( O O
1.3 O O
% O O
, O O
1/80 O O
patients O O
) O O
. O O

To O O
avoid O O
phenytoin B-drug B-drug
intoxication O O
, O O
appropriate O O
adjustment O O
of O O
the O O
anticonvulsant B-group B-group
should O O
be O O
made O O
. O O

however O O
, O O
no O O
significant O O
difference O O
in O O
the O O
maximum O O
concentration O O
in O O
plasma O O
or O O
the O O
area O O
under O O
the O O
concentration-time O O
curve O O
from O O
time O O
zero O O
to O O
8 O O
h O O
was O O
observed O O
. O O

Orlistat-Orlistat B-drug O
may O O
decrease O O
the O O
absorption O O
of O O
vitamin B-group B-group
K I-group I-group
. O O

However O O
, O O
in O O
vivo O O
drug O O
interaction O O
studies O O
of O O
ketoconazole B-drug B-drug
with O O
vitamin B-group B-group
D I-group I-group
have O O
not O O
been O O
investigated O O
. O O

Clinical O O
Comment O O

When O O
used O O
in O O
therapeutic O O
doses O O
, O O
azithromycin B-drug B-drug
had O O
a O O
modest O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
atorvastatin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
cetirizine B-drug B-drug
, O O
didanosine B-drug B-drug
, O O
efavirenz B-drug B-drug
, O O
fluconazole B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
midazolam B-drug B-drug
, O O
rifabutin B-drug B-drug
, O O
sildenafil B-drug B-drug
, O O
theophylline B-drug B-drug
( O O
intravenous O O
and O O
oral O O
) O O
, O O
triazolam B-drug B-drug
, O O
trimethoprim/sulfamethoxazole B-drug B-drug
or O O
zidovudine B-drug B-drug
. O O

HMG-CoA B-group B-group
Reductase I-group I-group
Inhibitors I-group I-group
: O O
lovastatin B-drug B-drug
, O O
simvastatin B-drug B-drug
WARNING O O
potential O O
for O O
serious O O
reactions O O
such O O
as O O
risk O O
of O O
myopathy O O
including O O
rhabdomyolysis O O
. O O

In O O
addition O O
to O O
established O O
drug O O
interactions O O
, O O
there O O
may O O
be O O
potential O O
pharmacokinetic O O
interactions O O
between O O
nevirapine B-drug B-drug
and O O
other O O
drug O O
classes O O
that O O
are O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
. O O

Drug/Laboratory O O
Test O O
Interaction O O
After O O
treatment O O
with O O
ampicillin B-drug B-drug
, O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
with O O
copper B-drug_n O
sulfate I-drug_n O
tests O O
( O O
Benedicts O O
solution O O
, O O
Fehlings O O
solution O O
, O O
or O O
Clinitest O O
tablets O O
) O O
but O O
not O O
with O O
enzyme O O
based O O
tests O O
such O O
as O O
Clinistix O O
and O O
Glucose O O
Enzymatic O O
Test O O
Strip O O
USP O O
. O O

Lovastatin B-drug B-drug
therapy O O
has O O
not O O
been O O
associated O O
with O O
bleeding O O
or O O
with O O
changes O O
in O O
prothrombin O O
time O O
in O O
patients O O
not O O
taking O O
anticoagulants B-group B-group
. O O

. O O

Note O O
: O O

Olanzapine B-drug B-drug
, O O
a O O
thienobenzodiazepine B-group O
derivative I-group O
, O O
is O O
a O O
second B-group O
generation I-group O
( I-group O
atypical I-group B-group
) I-group I-group
antipsychotic I-group I-group
agent I-group I-group
which O O
has O O
proven O O
efficacy O O
against O O
the O O
positive O O
and O O
negative O O
symptoms O O
of O O
schizophrenia O O
. O O

Other O O
Drug O O
Interaction O O
Information O O
Digoxin B-drug B-drug
: O O
Studies O O
in O O
healthy O O
volunteers O O
have O O
shown O O
that O O
TIKOSYN B-brand B-brand
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

Caution O O
, O O
however O O
, O O
is O O
advised O O
in O O
patients O O
taking O O
tricyclic B-group B-group
antidepressants I-group I-group
which O O
can O O
affect O O
the O O
metabolism O O
and O O
uptake O O
of O O
circulating O O
amines O O
. O O

Propanolol B-drug B-drug
: O O
The O O
pharmacokinetics O O
of O O
almotriptan B-drug B-drug
were O O
not O O
affected O O
by O O
coadministration O O
of O O
propranolol B-drug B-drug
. O O

phase O O
1 O O
( O O
days O O
1-6 O O
) O O
: O O
cisapride B-drug B-drug
10 O O
mg O O
4 O O
times/day O O
; O O

Compared O O
with O O
risperidone B-drug B-drug
, O O
olanzapine B-drug B-drug
has O O
also O O
been O O
reported O O
to O O
decrease O O
overall O O
treatment O O
costs O O
, O O
despite O O
the O O
several-fold O O
higher O O
daily O O
acquisition O O
cost O O
of O O
the O O
drug O O
. O O

Alcohol B-drug B-drug
- O O
Although O O
LEXAPRO B-brand B-brand
did O O
not O O
potentiate O O
the O O
cognitive O O
and O O
motor O O
effects O O
of O O
alcohol B-drug B-drug
in O O
a O O
clinical O O
trial O O
, O O
as O O
with O O
other O O
psychotropic B-group B-group
medications I-group I-group
, O O
the O O
use O O
of O O
alcohol B-drug B-drug
by O O
patients O O
taking O O
LEXAPRO B-brand B-brand
is O O
not O O
recommended O O
. O O

- O O
When O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
is O O
used O O
concurrently O O
with O O
anion-exchange B-group B-group
resins I-group I-group
( O O
e.g O O
. O O
cholestryramine B-drug B-drug
) O O
, O O
an O O
interval O O
of O O
at O O
least O O
2 O O
hours O O
should O O
be O O
maintained O O
between O O
the O O
two O O
medicines O O
, O O
since O O
the O O
absorption O O
of O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
is O O
impaired O O

However O O
, O O
initial O O
dose O O
modification O O
is O O
generally O O
not O O
necessary O O
. O O

4 O O
. O O

These O O
behavioral O O
changes O O
may O O
be O O
related O O
with O O
the O O
negative O O
symptoms O O
of O O
schizophrenia O O
. O O

metronidazole B-drug B-drug
; O O

Other O O
quinolones B-group B-group
have O O
demonstrated O O
moderate O O
to O O
marked O O
interference O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
, O O
resulting O O
in O O
a O O
reduced O O
clearance O O
, O O
a O O
prolongation O O
of O O
plasma O O
half-life O O
, O O
and O O
an O O
increase O O
in O O
symptoms O O
that O O
accompany O O
high O O
levels O O
of O O
caffeine B-drug B-drug
. O O

METHODS O O
: O O
From O O
the O O
beginning O O
of O O
the O O
experiment O O
, O O
rats O O
were O O
given O O
10 O O
weekly O O
subcutaneous O O
injections O O
of O O
AOM B-drug_n B-drug_n
( O O
7.4 O O
mg/kg O O
body O O
weight O O
) O O
and O O
subcutaneous O O
injections O O
of O O
bombesin B-drug_n B-drug_n
( O O
40 O O
microg/kg O O
body O O
weight O O
) O O
every O O
other O O
day O O
, O O
and O O
from O O
week O O
16 O O
, O O
intraperitoneal O O
injections O O
of O O
verapamil B-drug B-drug
( O O
10 O O
or O O
20 O O
mg/kg O O
body O O
weight O O
) O O
every O O
other O O
day O O
until O O
the O O
end O O
fo O O
the O O
experiment O O
in O O
week O O
45 O O
. O O

The O O
exact O O
length O O
of O O
time O O
may O O
vary O O
and O O
is O O
dependent O O
upon O O
the O O
particular O O
MAO B-group B-group
inhibitor I-group I-group
being O O
used O O
, O O
the O O
length O O
of O O
time O O
it O O
has O O
been O O
administered O O
, O O
and O O
the O O
dosage O O
involved O O
. O O

Saquinavir B-drug B-drug

Interaction O O
between O O
lomefloxacin B-drug B-drug
and O O
cyclosporine B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

this O O
effect O O
is O O
at O O
least O O
balanced O O
by O O
decreased O O
metabolism O O
of O O
corticosteroids B-group B-group
. O O

Although O O
metoclopramide B-drug B-drug
may O O
increase O O
the O O
bioavailability O O
of O O
levodopa B-drug B-drug
by O O
increasing O O
gastric O O
emptying O O
, O O
metoclopramide B-drug B-drug
may O O
also O O
adversely O O
affect O O
disease O O
control O O
by O O
its O O
dopamine O O
receptor O O
antagonistic O O
properties O O
. O O

This O O
increase O O
may O O
be O O
clinically O O
relevant O O
as O O
adverse O O
experiences O O
are O O
related O O
to O O
dose O O
and O O
exposure O O
; O O

Increasing O O
the O O
indinavir B-drug B-drug
dose O O
to O O
1000 O O
mg O O
every O O
8 O O
hours O O
does O O
not O O
compensate O O
for O O
the O O
increased O O
indinavir B-drug B-drug
metabolism O O
due O O
to O O
efavirenz B-drug B-drug
. O O

Internal O O
application O O
of O O
InsP B-drug_n B-drug_n
( I-drug_n I-drug_n
3 I-drug_n I-drug_n
) I-drug_n O
( O O
100 O O
microM O O
) O O
increased O O
intracellular O O
Ca O O
( O O
2+ O O
) O O
concentration O O
( O O
[ O O
Ca O O
( O O
2+ O O
) O O
] O O
( O O
i O O
) O O
) O O
and O O
activated O O
the O O
Ca O O
( O O
2+ O O
) O O
-dependent O O
K O O
( O O
+ O O
) O O
current O O
. O O

If O O
treatment O O
with O O
inhibitors O O
of O O
CYP3A4 O O
activity O O
( O O
such O O
as O O
ketoconazole B-drug B-drug
, O O
intraconazole B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
etc O O
. O O
) O O
is O O
indicated O O
, O O
reduction O O
of O O
the O O
budesonide B-drug B-drug
dose O O
should O O
be O O
considered O O
. O O

The O O
core O O
temperature O O
returned O O
to O O
normal O O
300 O O
minutes O O
after O O
ethanol B-drug B-drug
. O O

St. O O
Johns O O
wort O O
( O O
Hypericum O O
perforatum O O
) O O
may O O
decrease O O
SPRYCEL B-brand B-brand
plasma O O
concentrations O O
unpredictably O O
. O O

In O O
a O O
multiple O O
dose O O
study O O
of O O
theophylline B-drug B-drug
( O O
400 O O
mg O O
once O O
daily O O
for O O
3 O O
days O O
) O O
and O O
cetirizine B-drug B-drug
( O O
20 O O
mg O O
once O O
daily O O
for O O
3 O O
days O O
) O O
, O O
a O O
16 O O
% O O
decrease O O
in O O
the O O
clearance O O
of O O
cetirizine B-drug B-drug
was O O
observed O O
. O O

Patients O O
taking O O
low-dose O O
aspirin B-brand B-brand
plus O O
ibuprofen B-drug B-drug
were O O
not O O
studied O O
. O O

These O O
drugs O O
include O O
the O O
thiazides B-group B-group
and O O
other O O
diuretics B-group B-group
, O O
corticosteroids B-group B-group
, O O
phenothiazines B-group B-group
, O O
thyroid B-group B-group
products I-group I-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
, O O
phenytoin B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
, O O
sympathomimetics B-group B-group
, O O
calcium B-group B-group
channel I-group I-group
blocking I-group I-group
drugs I-group I-group
, O O
and O O
isoniazid B-drug B-drug
. O O

However O O
, O O
iloprost B-drug B-drug
has O O
the O O
potential O O
to O O
increase O O
the O O
hypotensive O O
effect O O
of O O
vasodilators B-group B-group
and O O
antihypertensive B-group B-group
agents I-group I-group
. O O

Specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
Levofloxacin B-drug B-drug
. O O

These O O
reports O O
are O O
more O O
frequent O O
for O O
women O O
who O O
use O O
only O O
a O O
single O O
method O O
of O O
contraception O O
. O O

Other O O
medicines O O
- O O
Although O O
certain O O
medicines O O
should O O
not O O
be O O
used O O
together O O
at O O
all O O
, O O
in O O
other O O
cases O O
two O O
different O O
medicines O O
may O O
be O O
used O O
together O O
even O O
if O O
an O O
interaction O O
might O O
occur O O
. O O

Most O O
cases O O
of O O
serious O O
or O O
fatal O O
adverse O O
events O O
involving O O
Levo-Dromoran B-brand B-brand
reported O O
to O O
the O O
manufacturer O O
or O O
the O O
FDA O O
have O O
involved O O
either O O
the O O
administration O O
of O O
large O O
initial O O
doses O O
or O O
too O O
frequent O O
doses O O
of O O
the O O
drug O O
to O O
nonopioid O O
tolerant O O
patients O O
, O O
or O O
the O O
simultaneous O O
administration O O
of O O
levorphanol B-drug B-drug
with O O
other O O
drugs O O
affecting O O
respiration O O
. O O

The O O
results O O
demonstrate O O
a O O
high O O
degree O O
of O O
stereoselectivity O O
in O O
the O O
behavioral O O
effects O O
of O O
NANM B-drug_n B-drug_n
. O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type O B-group
1C O I-group
antiarrhythrnics O I-group
propatenone O B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

The O O
effect O O
of O O
ceftibuten B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
administered O O
orally O O
has O O
not O O
been O O
investigated O O
. O O

Cimetidine B-drug B-drug

As O O
a O O
precursor O O
to O O
this O O
effort O O
, O O
optimal O O
and O O
minimal O O
experimental O O
designs O O
for O O
the O O
case O O
in O O
which O O
a O O
single O O
compound O O
is O O
administered O O
have O O
also O O
been O O
developed O O
. O O

co-administration O O
of O O
phenobarbital B-drug B-drug
may O O
produce O O
a O O
synergistic O O
anticonvulsant O O
action O O
. O O

If O O
used O O
in O O
combination O O
with O O
saquinavir B-drug B-drug
hard O O
gelatin O B-drug
capsules O O
at O O
the O O
recommended O O
dose O O
of O O
600 O O
mg O O
tid O O
, O O
no O O
dose O O
adjustments O O
are O O
needed O O
. O O

It O O
is O O
not O O
known O O
if O O
REGRANEX B-brand B-brand
Gel O O
interacts O O
with O O
other O O
topical O O
medications O O
applied O O
to O O
the O O
ulcer O O
site O O
. O O

. O O

Possible O O
extrarenal O O
mechanisms O O
of O O
action O O
of O O
cimetidine B-drug B-drug
on O O
verografine B-drug B-drug
and O O
iodamide B-drug B-drug
transport O O
were O O
also O O
examined O O
. O O

[ O O
Hippocampus O O
as O O
interaction O O
sites O O
between O O
cerebral O O
memory O O
systems O O
] O O
Most O O
of O O
the O O
current O O
theories O O
assume O O
that O O
there O O
are O O
multiple O O
forms O O
of O O
memory O O
that O O
are O O
supported O O
by O O
separate O O
brain O O
systems O O
and O O
have O O
different O O
characteristics O O
. O O

Concomitant O O
medications O O
should O O
be O O
carefully O O
assessed O O
. O O

Periodic O O
measurement O O
of O O
serum O O
PSA O O
levels O O
may O O
also O O
be O O
considered O O
. O O

Recovery O O
of O O
hoof O O
twitch O O
from O O
50 O O
% O O
to O O
75 O O
% O O
took O O
7.7 O O
+/- O O
0.7 O O
min O O
for O O
atracurium B-drug B-drug
alone O O
and O O
11.5 O O
+/- O O
2.7 O O
min O O
for O O
atracurium B-drug B-drug
plus O O
gentamycin B-drug B-drug
( O O
P O O
= O O
0.03 O O
) O O
. O O

Inducers O O
and O O
Inhibitors O O
of O O
Hepatic O O
Metabolism O O
: O O
Rifampin B-drug B-drug
reduced O O
plasma O O
concentrations O O
of O O
carvedilol B-drug B-drug
by O O
about O O
70 O O
% O O
. O O

The O O
fluoroquinolones B-group B-group
are O O
a O O
rapidly O O
growing O O
class O O
of O O
antibiotics B-group B-group
with O O
a O O
broad O O
spectrum O O
of O O
activity O O
against O O
gram-negative O O
and O O
some O O
gram-positive O O
aerobic O O
bacteria O O
. O O

The O O
mean O O
minimum O O
lithium B-drug B-drug
concentration O O
increased O O
15 O O
% O O
and O O
the O O
renal O O
clearance O O
of O O
lithium B-drug B-drug
was O O
decreased O O
by O O
19 O O
% O O
during O O
this O O
period O O
of O O
concomitant O O
drug O O
administration O O
. O O

Because O O
escitalopram B-drug B-drug
is O O
metabolized O O
by O O
multiple O O
enzyme O O
systems O O
, O O
inhibition O O
of O O
a O O
single O O
enzyme O O
may O O
not O O
appreciably O O
decrease O O
escitalopram B-drug B-drug
clearance O O
. O O

Some O O
drugs/substances B-drug O
are O O
known O O
to O O
accelerate O O
the O O
metabolism O O
of O O
amiodarone B-drug B-drug
by O O
stimulating O O
the O O
synthesis O O
of O O
CYP3A4 B-drug O
( O O
enzyme O O
induction O O
) O O
. O O

Methotrexate B-drug B-drug
: O O
HUMIRA B-brand B-brand
has O O
been O O
studied O O
in O O
rheumatoid O O
arthritis O O
patients O O
taking O O
concomitant O O
MTX B-drug B-drug
. O O

Some O O
disorders O O
unrelated O O
to O O
sexual O O
dysfunction O O
( O O
eg O O
, O O
esophageal O O
motility O O
dysfunction O O
) O O
may O O
also O O
respond O O
to O O
sildenafil B-drug B-drug
. O O

Co-administration O O
of O O
irbesartan B-drug B-drug
reduced O O
aliskiren B-drug B-drug
Cmax O O
up O O
to O O
50 O O
% O O
after O O
multiple O O
dosing O O
. O O

Disulfiram B-drug B-drug
alone O O
in O O
the O O
rat O O
s O O
diet O O
did O O
not O O
lead O O
to O O
such O O
tumors O O
. O O

Platelet O O
function O O
studies O O
in O O
these O O
patients O O
have O O
not O O
demonstrated O O
any O O
significant O O
platelet O O
dysfunction O O
. O O

Paclitaxel B-drug B-drug
- O O
In O O
one O O
report O O
, O O
L-glutamine B-drug B-drug
at O O
a O O
dose O O
of O O
10 O O
grams O O
three O O
times O O
daily O O
, O O
given O O
24 O O
hours O O
after O O
receiving O O
paclitaxel B-drug B-drug
, O O
appeared O O
to O O
prevent O O
the O O
development O O
of O O
myalgia O O
and O O
arthralgia O O
, O O
adverse O O
reactions O O
of O O
paclitaxel B-drug B-drug
. O O

METH B-drug B-drug
induced O O
arc O O
mRNA O O
in O O
layers O O
IV O O
and O O
VI O O
of O O
the O O
cortex O O
which O O
dopamine O O
receptor O O
are O O
localized O O
to O O
. O O

Carbamazepine B-drug B-drug
: O O
Tiagabine B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
steady-state O O
plasma O O
concentrations O O
of O O
carbamazepine B-drug B-drug
or O O
its O O
epoxide O O
metabolite O O
in O O
patients O O
with O O
epilepsy O O
. O O

Table O O
4 O O
Potential O O
Drug O O
Interactions O O
: O O
Use O O
With O O
Caution O O
, O O
Dose O O
Adjustment O O
of O O
Co-administered O O
Drug O O
May O O
Be O O
Needed O O
due O O
to O O
Possible O O
Decrease O O
in O O
Clinical O O
Effect O O

Other O O
concomitant O O
therapies O O
: O O
In O O
clinical O O
trials O O
, O O
the O O
safety O O
profile O O
in O O
subjects O O
treated O O
with O O
Acamprosate B-drug B-drug
concomitantly O O
with O O
anxiolytics B-group B-group
, O O
hypnotics B-group B-group
and O O
sedatives B-group B-group
( O O
including O O
benzodiazepines B-group B-group
) O O
, O O
or O O
non-opioid B-group B-group
analgesics I-group I-group
was O O
similar O O
to O O
that O O
of O O
subjects O O
taking O O
placebo O O
with O O
these O O
concomitant O O
medications O O
. O O

could O O
not O O
be O O
confirmed O O
for O O
cloxacillin B-drug B-drug
in O O
patients O O
lacking O O
kidney O O
function O O
. O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
- O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
caucasian O O
population O O
( O O
about O O
7-10 O O
% O O
of O O
caucasians O O
are O O
so O O
called O O
poor O O
metabolizers O O
) O O
; O O

Chapter O O
3 O O
covers O O
pharmacology O O
( O O
pharmacokinetics O O
, O O
pharmacodynamics O O
and O O
potency O O
, O O
and O O
clinical O O
implications O O
) O O
. O O

Slow-channel B-group B-group
calcium I-group I-group
blockers I-group I-group
, O O
such O O
as O O
verapamil B-drug B-drug
, O O
diltiazem B-drug B-drug
and O O
nifedipine B-drug B-drug
, O O
inhibit O O
platelet O O
activation O O
in O O
vitro O O
, O O
and O O
decrease O O
platelet O O
adhesion O O
intravascularly O O
. O O

Magnesium- B-drug B-drug
and O O
aluminum-containing B-drug B-drug
antacids B-group B-group
, O O
administered O O
concomitantly O O
with O O
lomefloxacin B-drug B-drug
, O O
significantly O O
decreased O O
the O O
bioavailability O O
( O O
48 O O
% O O
) O O
of O O
lomefloxacin B-drug B-drug
. O O

The O O
regulation O O
of O O
topoisomerases O O
is O O
no O O
doubt O O
complex O O
and O O
multifaceted O O
and O O
is O O
probably O O
accomplished O O
through O O
redundancy O O
at O O
many O O
control O O
levels O O
. O O

clinical O O
significance O O
unknown O O
. O O

Narcotic B-group B-group
analgesics I-group I-group
may O O
potentiate O O
the O O
hypotensive O O
effects O O
of O O
clonidine B-drug B-drug
. O O

Lithium B-drug B-drug
: O O
Valdecoxib B-drug B-drug
40 O O
mg O O
BID O O
for O O
7 O O
days O O
produced O O
significant O O
decreases O O
in O O
lithium B-drug B-drug
serum O O
clearance O O
( O O
25 O O
% O O
) O O
and O O
renal O O
clearance O O
( O O
30 O O
% O O
) O O
with O O
a O O
34 O O
% O O
higher O O
serum O O
exposure O O
compared O O
to O O
lithium B-drug B-drug
alone O O
. O O

Clidinium B-drug B-drug
may O O
decrease O O
the O O
effect O O
of O O
phenothiazines B-group B-group
, O O
levodopa B-drug B-drug
, O O
and O O
ketoconazole B-drug B-drug
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
( O O
day O O
1 O O
) O O
and O O
40 O O
mg O O
QD O O
( O O
days O O
2-7 O O
) O O
) O O
with O O
glyburide B-drug B-drug
( O O
10 O O
mg O O
glyburide B-drug B-drug
BID O O
) O O
resulted O O
in O O
21 O O
% O O
increase O O
in O O
glyburide B-drug B-drug
AUC0-12 O O
and O O
a O O
16 O O
% O O
increase O O
in O O
glyburide B-drug B-drug
Cmax O O
leading O O
to O O
a O O
16 O O
% O O
decrease O O
in O O
glucose O O
AUC0-24 O O
. O O

Nursing O O
Mothers O O
Fulvestrant B-drug B-drug
is O O
found O O
in O O
rat O O
milk O O
at O O
levels O O
significantly O O
higher O O
( O O
approximately O O
12-fold O O
) O O
than O O
plasma O O
after O O
administration O O
of O O
2 O O
mg/kg O O
. O O

dose-dependently O O
increased O O
the O O
number O O
of O O
defecation O O
episodes O O
and O O
induced O O
a O O
soft O O
and O O
watery O O
stool O O
in O O
cecectomized O O
rats O O
. O O

Intermediate O O
doses O O
of O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
or O O
PCP B-drug_n B-drug_n
produced O O
transient O O
increases O O
in O O
FI O O
responding O O
in O O
monkeys O O
and O O
sustained O O
increases O O
in O O
FI O O
responding O O
in O O
pigeons O O
; O O

The O O
basal O O
colonic O O
fluid O O
contents O O
and O O
transits O O
were O O
the O O
same O O
in O O
cecectomized O O
and O O
in O O
control O O
rats O O
. O O

Co-administration O O
of O O
nelfinavir B-drug B-drug
at O O
steady-state O O
with O O
a O O
single O O
dose O O
of O O
azithromycin B-drug B-drug
( O O
2 O O
x O O
600 O O
mg O O
tablets O O
) O O
results O O
in O O
increased O O
azithromycin B-drug B-drug
serum O O
concentrations O O
. O O

Drug O O
monitoring O O
may O O
be O O
of O O
assistance O O
in O O
detecting O O
alterations O O
in O O
carbamazepine B-drug B-drug
plasma O O
concentrations O O
. O O

Pharmacological/Pharmacodynamic O O
Interactions O O
with O O
Carbamazepine B-drug B-drug
Concomitant O O
administration O O
of O O
carbamazepine B-drug B-drug
and O O
lithium B-drug B-drug
may O O
increase O O
the O O
risk O O
of O O
neurotoxic O O
side O O
effects O O
. O O

The O O
reaction O O
after O O
norepinephrine B-drug B-drug
remained O O
the O O
same O O
in O O
both O O
groups O O
of O O
experiments O O
. O O

CONCLUSIONS O O
: O O
Olanzapine B-drug B-drug
demonstrated O O
superior O O
antipsychotic O O
efficacy O O
compared O O
with O O
haloperidol B-drug B-drug
in O O
the O O
treatment O O
of O O
acute O O
phase O O
schizophrenia O O
, O O
and O O
in O O
the O O
treatment O O
of O O
some O O
patients O O
with O O
first-episode O O
or O O
treatment-resistant O O
schizophrenia O O
. O O

In O O
clinical O O
studies O O
where O O
patients O O
were O O
on O O
chronic O O
theophylline B-drug B-drug
therapy O O
, O O
lomefloxacin B-drug B-drug
had O O
no O O
measurable O O
effect O O
on O O
the O O
mean O O
distribution O O
of O O
theophylline B-drug B-drug
concentrations O O
or O O
the O O
mean O O
estimates O O
of O O
theophylline B-drug B-drug
clearance O O
. O O

No O O
cases O O
of O O
rhabdomyolysis O O
were O O
reported O O
in O O
this O O
trial O O
. O O

No O O
information O O
is O O
available O O
about O O
the O O
use O O
of O O
butorphanol B-drug B-drug
concurrently O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Cromolyn B-drug B-drug
sodium I-drug I-drug
alone O O
in O O
doses O O
up O O
to O O
540 O O
mg/kg/day O O
( O O
approximately O O
340 O O
times O O
the O O
maximum O O
recommended O O
daily O O
inhalation O O
dose O O
in O O
adults O O
on O O
a O O
mg/m2 O O
basis O O
) O O
did O O
not O O
cause O O
significant O O
increases O O
in O O
resorptions O O
or O O
major O O
malformations O O
. O O

Caution O O
is O O
advised O O
in O O
patients O O
receiving O O
chronic O O
concomitant O O
therapy O O
. O O

Methamphetamine B-drug B-drug
, O O
like O O
MPTP B-drug_n B-drug_n
, O O
produced O O
depletions O O
of O O
striatal O O
dopamine O O
but O O
these O O
actions O O
were O O
potentiated O O
by O O
pargyline B-drug B-drug
pretreatment O O
. O O

Amiodarone B-drug B-drug
is O O
metabolized O O
to O O
desethylamiodarone B-drug O
by O O
the O O
cytochrome O O
P450 O O
( O O
CYP450 O O
) O O
enzyme O O
group O O
, O O
specifically O O
cytochromes O O
P450 O O
3A4 O O
( O O
CYP3A4 O O
) O O
and O O
CYP2C8 O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
to O O
blunt O O
the O O
hypotensive O O
effect O O
of O O
systemic O O
clonidine B-drug B-drug
. O O

Antagonism O O
was O O
never O O
observed O O
. O O

When O O
coadministered O O
with O O
SUSTIVA B-brand B-brand
in O O
treatment-naive O O
patients O O
, O O
the O O
recommended O O
dose O O
of O O
atazanavir B-drug B-drug
is O O
300 O O
mg O O
with O O
ritonavir B-drug B-drug
100 O O
mg O O
and O O
SUSTIVA B-brand B-brand
600 O O
mg O O
( O O
all O O
once O O
daily O O
) O O
. O O

Vaccines B-group B-group
: O O
Patients O O
on O O
corticosteroid B-group B-group
therapy O O
may O O
exhibit O O
a O O
diminished O O
response O O
to O O
toxoids O B-group
and O O
live O O
or B-group O
inactivated I-group B-group
vaccines I-group I-group
due O O
to O O
inhibition O O
of O O
antibody O O
response O O
. O O

In O O
rats O O
, O O
simultaneous O O
ingestion O O
of O O
disulfiram B-drug B-drug
and O O
nitrite B-drug O
in O O
the O O
diet O O
for O O
78 O O
weeks O O
has O O
been O O
reported O O
to O O
cause O O
tumors O O
, O O
and O O
it O O
has O O
been O O
suggested O O
that O O
disulfiram B-drug B-drug
may O O
react O O
with O O
nitrites B-group B-group
in O O
the O O
rat O O
stomach O O
to O O
form O O
a O O
nitrosamine O B-drug
, O O
which O O
is O O
tumorigenic O O
. O O

Therophylline O B-drug
: O O
A O O
recent O O
study O O
has O O
shown O O
that O O
concomitan O B-drug
administration O O
of O O
isoniazid B-drug B-drug
and O O
theophylline B-drug B-drug
may O O
cause O O
elevated O O
plasma O O
levels O O
of O O
theophylline B-drug B-drug
, O O
and O O
in O O
some O O
instances O O
a O O
slight O O
decrease O O
in O O
the O O
elimination O O
of O O
isoniazid B-drug B-drug
. O O

and O O
( O O
ii O O
) O O
the O O
effects O O
of O O
filipin B-drug_n B-drug_n
were O O
more O O
efficiently O O
inhibited O O
by O O
added O O
cholesterol O O
, O O
the O O
major O O
membrane O O
sterol O O
in O O
human O O
cells O O
, O O
whereas O O
the O O
effects O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
were O O
more O O
efficiently O O
inhibited O O
by O O
ergosterol O B-drug
, O O
the O O
major O O
membrane O O
sterol O O
in O O
yeast O O
. O O

Some O O
of O O
the O O
cases O O
of O O
collapse/respiratory O O
arrest/cardiac O O
arrest O O
during O O
initial O O
treatment O O
occurred O O
in O O
patients O O
who O O
were O O
being O O
administered O O
benzodiazepines B-group B-group
; O O

For O O
comprehensive O O
information O O
concerning O O
laboratory O O
test O O
alterations O O
associated O O
with O O
ritonavir B-drug B-drug
, O O
physicians O O
should O O
refer O O
to O O
the O O
complete O O
prescribing O O
information O O
for O O
NORVIR B-brand B-brand
( O O
ritonavir B-drug B-drug
) O O
. O O

The O O
effects O O
of O O
ERGOMAR B-brand B-brand
may O O
be O O
potentiated O O
by O O
triacetyloleandomycin B-drug B-drug
which O O
inhibits O O
the O O
metabolism O O
of O O
ergotamine B-drug B-drug
. O O

In O O
2 O O
separate O O
studies O O
, O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
120 O O
mg O O
twice O O
daily O O
( O O
240 O O
mg O O
total O O
daily O O
dose O O
) O O
was O O
co-administered O O
with O O
either O O
erythromycin B-drug B-drug
500 O O
mg O O
every O O
8 O O
hours O O
or O O
ketoconazole B-drug B-drug
400 O O
mg O O
once O O
daily O O
under O O
steady-state O O
conditions O O
to O O
healthy O O
volunteers O O
( O O
n=24 O O
, O O
each O O
study O O
) O O
. O O

HMG-CoA B-group B-group
Reductase I-group I-group
inhibitors I-group I-group
: O O
lovastatin B-drug B-drug
, O O
simvastatin B-drug B-drug

Oral O O
Anticoagulants B-group B-group
CAUTION O O
SHOULD O O
BE O O
EXERCISED O O
WHEN O O
COUMARIN B-group B-brand
ANTICOAGULANTS I-group B-group
ARE O O
GIVEN O O
IN O O
CONJUNCTION O O
WITH O O
TRICOR B-brand B-brand
. O O

High-dose O O
cisplatin B-drug B-drug
with O O
sodium B-drug B-drug
thiosulfate I-drug I-drug
protection O O
. O O

There O O
have O O
been O O
rare O O
reports O O
of O O
significant O O
respiratory O O
depression O O
, O O
stupor O O
and/or O O
hypotension O O
with O O
the O O
concomitant O O
use O O
of O O
loxapine B-drug B-drug
and O O
lorazepam B-drug B-drug
. O O

The O O
latter O O
might O O
arise O O
from O O
a O O
hit O O
in O O
a O O
genetically O O
initiated O O
cell O O
, O O
the O O
result O O
of O O
which O O
is O O
a O O
more O O
rapid O O
progression O O
in O O
tumor O O
type O O
. O O

Coadministration O O
of O O
CRIXIVAN B-brand B-brand
and O O
other O O
drugs O O
that O O
inhibit O O
CYP3A4 O O
may O O
decrease O O
the O O
clearance O O
of O O
indinavir B-drug B-drug
and O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
indinavir B-drug B-drug
. O O

Probenecid B-drug B-drug
: O O
As O O
with O O
other O O
b-lactams B-group O
, O O
the O O
renal O O
excretion O O
of O O
cephalexin B-drug B-drug
is O O
inhibited O O
by O O
probenecid B-drug B-drug
. O O

Therefore O O
, O O
when O O
using O O
doses O O
of O O
Trileptal B-brand B-brand
greater O O
than O O
1200 O O
mg/day O O
during O O
adjunctive O O
therapy O O
, O O
a O O
decrease O O
in O O
the O O
dose O O
of O O
phenytoin B-drug B-drug
may O O
be O O
required O O
. O O

oxolinic B-drug B-drug
acid I-drug I-drug
; O O

Cimetidine B-drug B-drug
: O O
In O O
the O O
presence O O
of O O
cimetidine B-drug B-drug
at O O
300 O O
mg O O
QID O O
( O O
N=12 O O
) O O
the O O
mean O O
apparent O O
oral O O
clearance O O
of O O
gabapentin B-drug B-drug
fell O O
by O O
14 O O
% O O
and O O
creatinine O O
clearance O O
fell O O
by O O
10 O O
% O O
. O O

The O O
toxicity O O
of O O
cadmium O O
, O O
zinc B-drug B-drug
, O O
and O O
cadmium/zinc O O
mixtures O O
at O O
concentrations O O
ranging O O
from O O
10000 O O
to O O
10 O O
microg/l O O
was O O
investigated O O
. O O

Vecuronium B-drug B-drug
: O O
When O O
used O O
in O O
the O O
perioperative O O
period O O
, O O
piperacillin B-drug B-drug
has O O
been O O
implicated O O
in O O
the O O
prolongation O O
of O O
the O O
neuromuscular O O
blockade O O
of O O
vecuronium B-drug B-drug
. O O

The O O
agent O O
was O O
found O O
to O O
produce O O
some O O
inhibiting O O
activity O O
against O O
hepatic O O
microsomal O O
7-ethoxycoumarine O O
deethylase O O
in O O
male O O
Wistar O O
rats O O
in O O
vitro O O
and O O
in O O
vivo O O
experiments O O
. O O

Other O O
strong O O
inhibitors O O
of O O
CYP3A4 O O
( O O
itraconazole B-drug B-drug
) O O
would O O
be O O
expected O O
to O O
have O O
similar O O
effects O O
and O O
need O O
similar O O
dose O O
reductions O O
; O O

- O O
a O O
monoamine B-group B-group
oxidase I-group I-group
inhibitor I-group I-group
( O O
MAOI B-group B-group
) O O
such O O
as O O
isocarboxazid B-drug B-drug
( O O
Marplan B-brand B-brand
) O O
, O O
tranylcypromine B-drug B-drug
( O O
Parnate B-brand B-brand
) O O
, O O
or O O
phenelzine B-drug B-drug
( O O
Nardil B-brand B-brand
) O O
; O O

The O O
mean O O
percentage O O
increase O O
in O O
the O O
glipizide B-drug B-drug
AUC O O
after O O
fluconazole B-drug B-drug
administration O O
was O O
56.9 O O
% O O
( O O
range O O
: O O
35 O O
to O O
81 O O
) O O
. O O

A O O
potential O O
interaction O O
between O O
oral O O
miconazole B-drug B-drug
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
leading O O
to O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
. O O

Additive O O
adverse O O
effects O O
resulting O O
from O O
cholinergic O O
blockade O O
may O O
occur O O
when O O
LEVSIN B-brand B-brand
is O O
administered O O
concomitantly O O
with O O
other O O
antimuscarinics B-group B-group
, O O
amantadine B-drug B-drug
, O O
haloperidol B-drug B-drug
, O O
phenothiazines B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
or O O
some O O
antihistamines B-group B-group
. O O

Additional O O
drugs O O
that O O
are O O
not O O
recommended O O
for O O
coadministration O O
with O O
INVIRASE B-brand B-brand
and O O
ritonavir B-drug B-drug
are O O
included O O
below O O
. O O

The O O
physician O O
is O O
advised O O
to O O
monitor O O
plasma O O
levels O O
of O O
phenytoin B-drug B-drug
and O O
to O O
decrease O O
the O O
dose O O
if O O
necessary O O
. O O

Benazepril B-drug B-drug
, O O
like O O
other O O
ACE B-group B-group
inhibitors I-group I-group
, O O
has O O
had O O
less O O
than O O
additive O O
effects O O
with O O
beta-adrenergic B-group B-group
blockers I-group I-group
, O O
presumably O O
because O O
both O O
drugs O O
lower O O
blood O O
pressure O O
by O O
inhibiting O O
parts O O
of O O
the O O
renin-angiotensin O O
system O O

Fifteen O O
to O O
30 O O
minutes O O
of O O
exposure O O
to O O
1.25 O O
MAC O O
isoflurane B-drug B-drug
or O O
enflurane B-drug B-drug
had O O
minimal O O
effects O O
on O O
the O O
duration O O
of O O
action O O
of O O
initial O O
doses O O
of O O
NIMBEX B-brand B-brand
and O O
therefore O O
, O O
no O O
adjustment O O
to O O
the O O
initial O O
dose O O
should O O
be O O
necessary O O
when O O
NIMBEX B-brand B-brand
is O O
administered O O
shortly O O
after O O
initiation O O
of O O
volatile O O
agents O O
. O O

In O O
vitro O O
studies O O
with O O
several O O
drugs O O
which O O
may O O
be O O
administered O O
concomitantly O O
showed O O
that O O
the O O
extent O O
of O O
flecainide B-drug B-drug
binding O O
to O O
human O O
plasma O O
proteins O O
is O O
either O O
unchanged O O
or O O
only O O
slightly O O
less O O
. O O

N-methyllevallorphan B-drug_n B-drug_n
( O O
5 O O
mg/kg O O
, O O
s.c. O O
) O O
completely O O
antagonized O O
the O O
inhibitory O O
effect O O
of O O
loperamide B-drug B-drug
and O O
partly O O
antagonized O O
the O O
effect O O
of O O
morphine B-drug B-drug
. O O

At O O
a O O
median O O
follow-up O O
of O O
33 O O
months O O
, O O
the O O
combination O O
of O O
ARIMIDEX B-brand B-brand
and O O
tamoxifen B-drug B-drug
did O O
not O O
demonstrate O O
any O O
efficacy O O
benefit O O
when O O
compared O O
with O O
tamoxifen B-drug B-drug
in O O
all O O
patients O O
as O O
well O O
as O O
in O O
the O O
hormone O O
receptor-positive O O
subpopulation O O
. O O

The O O
effect O O
of O O
dofetilide B-drug B-drug
on O O
the O O
steady-state O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
was O O
evaluated O O
in O O
a O O
randomized O O
, O O
double-blind O O
study O O
. O O

increased O O
platelet O O
count O O
; O O

The O O
effects O O
of O O
DCG-IV B-drug_n B-drug_n
and O O
L-CCG-1 B-drug_n B-drug_n
upon O O
phencyclidine B-drug_n B-drug_n
( O O
PCP B-drug_n B-drug_n
) O O
-induced O O
locomotion O O
and O O
behavioral O O
changes O O
in O O
mice O O
. O O

Serious O O
anticholinergic O O
symptoms O O
( O O
severe O O
dry O O
mouth O O
, O O
urinary O O
retention O O
, O O
blurred O O
vision O O
) O O
have O O
been O O
associated O O
with O O
elevations O O
in O O
the O O
serum O O
levels O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
when O O
cimetidine B-drug B-drug
is O O
added O O
to O O
the O O
drug O O
regimen O O
. O O

Concurrent O O
use O O
of O O
butorphanol B-drug B-drug
with O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
( O O
e.g. O O
, O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
and O O
antihistamines B-group B-group
) O O
may O O
result O O
in O O
increased O O
central B-group O
nervous I-group O
system I-group O
depressant I-group O
effects O O
. O O

Atromid-S B-brand B-brand
may O O
displace O O
acidic O O
drugs O O
such O O
as O O
phenytoin B-drug B-drug
or O O
tolbutamide B-drug B-drug
from O O
their O O
binding O O
sites O O
. O O

- O O
Corticosteroids B-group B-group
, O O
ACTH B-drug B-drug
: O O
Intensified O O
electrolyte O O
depletion O O
, O O
particularly O O
hypokalemia O O

Because O O
of O O
the O O
risk O O
of O O
serious O O
ventricular O O
arrhythmias O O
and O O
sudden O O
death O O
potentially O O
associated O O
with O O
elevated O O
plasma O O
levels O O
of O O
thioridazine B-drug B-drug
, O O
Duloxetine B-drug B-drug
and O O
thioridazine B-drug B-drug
should O O
not O O
be O O
co-administered O O
. O O

It O O
is O O
essentially O O
completely O O
metabolised O O
, O O
therefore O O
little O O
is O O
excreted O O
unchanged O O
. O O

Atazanavir B-drug B-drug

Alcohol B-drug B-drug
: O O
In O O
post-marketing O O
experience O O
, O O
there O O
have O O
been O O
rare O O
reports O O
of O O
adverse O O
neuropsychiatric O O
events O O
or O O
reduced O O
alcohol B-drug B-drug
tolerance O O
in O O
patients O O
who O O
were O O
drinking O O
alcohol B-drug B-drug
during O O
treatment O O
with O O
WELLBUTRIN B-brand B-brand
. O O

Such O O
an O O
interaction O O
can O O
potentially O O
lead O O
to O O
higher O O
free O O
fractions O O
of O O
either O O
tiagabine B-drug B-drug
or O O
the O O
competing O O
drug O O
. O O

PROSTIN B-brand B-brand
E2 I-brand I-brand
may O O
augment O O
the O O
activity O O
of O O
other O O
oxytocic B-group B-group
drugs I-group I-group
. O O

Single O O
dose O O
bioavailability O O
studies O O
in O O
normal O O
volunteers O O
have O O
failed O O
to O O
wshow O O
an O O
effect O O
of O O
aspirin B-brand B-brand
on O O
ibuprofen B-drug B-drug
blood O O
levels O O
. O O

Ergot O B-group
derivatives O I-group
: O O
dihydroergotamine B-drug B-drug
, O O
ergonovine B-drug B-drug
, O O
ergotamine B-drug B-drug
, O O
methylergonovine B-drug B-drug

fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
. O O

In O O
vitro O O
studies O O
show O O
significant O O
inhibition O O
of O O
the O O
formation O O
of O O
oxidized O O
irbesartan O B-drug
metabolites O O
with O O
the O O
known O O
cytochrome O O
CYP O O
2C9 O O
substrates/inhibitors O O
sulphenazole B-drug B-drug
, O O
tolbutamide B-drug B-drug
and O O
nifedipine B-drug B-drug
. O O

Other O O
drugs O O
that O O
are O O
specific O O
substrates O O
, O O
inhibitors O O
, O O
or O O
inducers O O
of O O
the O O
enzyme O O
system O O
may O O
have O O
a O O
significant O O
impact O O
on O O
the O O
efficacy O O
and O O
side O O
effect O O
profile O O
of O O
diltiazem B-drug B-drug
. O O

[ O O
Quantitative O O
approach O O
to O O
treatment O O
with O O
incisive O O
neuroleptics B-group B-group
by O O
therapeutic O O
monitoring O O
] O O
; O O
The O O
problems O O
encountered O O
during O O
the O O
longterm O O
treatment O O
of O O
psychotic O O
patients O O
with O O
neuroleptics B-group B-group
are O O
illustrated O O
by O O
six O O
typical O O
case O O
reports O O
. O O

The O O
effect O O
of O O
BREVIBLOC B-drug B-brand
on O O
the O O
duration O O
of O O
succinylcholine-induced B-drug B-drug
neuromuscular O O
blockade O O
was O O
studied O O
in O O
patients O O
undergoing O O
surgery O O
. O O

In O O
treatment-experienced O O
patients O O
, O O
available O O
uncontrolled O O
data O O
suggest O O
these O O
agents O O
contribute O O
to O O
regimen O O
efficacy O O
in O O
NNRTI-na B-group O
ve O O
, O O
treatment-experienced O O
patients O O
. O O

While O O
all O O
the O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
and O O
fluvoxamine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

Haloperidol B-drug B-drug
: O O
Haloperidol B-drug B-drug
blocks O O
dopamine O O
receptors O O
, O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-group B-group
. O O

No O O
drug O O
interactions O O
have O O
been O O
reported O O
between O O
Prostin B-brand B-brand
VR I-brand I-brand
Pediatric I-brand O
and O O
the O O
therapy O O
standard O O
in O O
neonates O O
with O O
restricted O O
pulmonary O O
or O O
systemic O O
blood O O
flow O O
. O O

Amiodarone B-drug B-drug
taken O O
concomitantly O O
with O O
procainamide B-drug B-drug
for O O
less O O
than O O
seven O O
days O O
increases O O
plasma O O
concentrations O O
of O O
procainamide B-drug B-drug
and O O
n-acetyl O B-drug_n
procainamide B-drug B-drug
by O O
55 O O
% O O
and O O
33 O O
% O O
, O O
respectively O O
. O O

In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
INDOCIN B-brand B-brand
can O O
reduce O O
the O O
diuretic O B-group
, O O
natriuretic O O
, O O
and O O
antihypertensive B-group O
effects O O
of O O
loop O O
, O O
potassium-sparing O O
, O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Improvements O O
in O O
general O O
cognitive O O
function O O
seen O O
with O O
olanzapine B-drug B-drug
treatment O O
in O O
a O O
1-year O O
controlled O O
study O O
of O O
patients O O
with O O
early-phase O O
schizophrenia O O
, O O
were O O
significantly O O
greater O O
than O O
changes O O
seen O O
with O O
either O O
risperidone B-drug B-drug
or O O
haloperidol B-drug B-drug
. O O

Intravenous O O
Pentamidine B-drug B-drug
: O O
Treatment O O
with O O
HIVID B-drug B-drug
should O O
be O O
interrupted O O
when O O
the O O
use O O
of O O
a O O
drug O O
that O O
has O O
the O O
potential O O
to O O
cause O O
pancreatitis O O
is O O
required O O
. O O

Studies O O
to O O
evaluate O O
possible O O
interactions O O
between O O
REVIA B-brand B-brand
and O O
drugs O O
other O O
than O O
opiates B-group B-group
have O O
not O O
been O O
performed O O
. O O

nalidixic B-drug O
acid I-drug O
; O O

The O O
findings O O
suggest O O
that O O
the O O
agent O O
has O O
slight O O
effects O O
on O O
the O O
tested O O
activities O O
. O O

Drug O O
Effect O O

Aminosalicylic B-drug B-drug
acid I-drug I-drug
may O O
decrease O O
the O O
amount O O
of O O
digoxin B-drug B-drug
( O O
Lanoxin B-brand B-brand
, O O
Lanoxicaps B-drug B-drug
) O O
that O O
gets O O
absorbed O O
into O O
your O O
body O O
. O O

Clinical O O
Comment O O

Quinidine B-drug B-drug
and O O
procainamide O B-drug
doses O O
should O O
be O O
reduced O O
by O O
one-third O O
when O O
either O O
is O O
administered O O
with O O
amiodarone B-drug B-drug
. O O

However O O
, O O
halothane B-drug B-drug
anesthetic O O
requirement O O
( O O
i.e. O O
, O O
MAC O O
) O O
was O O
depressed O O
in O O
a O O
dose-dependent O O
fashion O O
as O O
much O O
as O O
56 O O
% O O
1-2 O O
hours O O
and O O
as O O
much O O
as O O
14 O O
% O O
5-6 O O
hours O O
after O O
injection O O
of O O
ketamine B-drug B-drug
, O O
50 O O
mg/kg O O
, O O
im O O
. O O

CONCLUSIONS O O
: O O
The O O
combination O O
of O O
CHOP O O
plus O O
HAART O O
is O O
feasible O O
and O O
may O O
reduce O O
the O O
morbidity O O
from O O
OIs O O
in O O
HIV-NHL O O
patients O O
. O O

The O O
administration O O
of O O
local O O
anesthetic B-group B-group
solutions I-group O
containing O O
epinephrine B-drug B-drug
or O O
norepinephrine B-drug B-drug
to O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
or O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
produce O O
severe O O
, O O
prolonged O O
hypertension O O
. O O

Phenobarbital B-drug B-drug
: O O
Decreases O O
aspirin B-brand B-brand
effectiveness O O
by O O
enzyme O O
induction O O
. O O

Orthostatic O O
hypotension O O
in O O
patients O O
taking O O
clozapine B-drug B-drug
can O O
, O O
in O O
rare O O
cases O O
( O O
approximately O O
1 O O
case O O
per O O
3,000 O O
patients O O
) O O
, O O
be O O
accompanied O O
by O O
profound O O
collapse O O
and O O
respiratory O O
and/or O O
cardiac O O
arrest O O
. O O

The O O
use O O
of O O
dextromethorphan B-drug B-drug
hydrobromide I-drug I-drug
may O O
result O O
in O O
additive O O
CNS O O
depressant O O
effects O O
when O O
coadministered O O
with O O
alcohol B-drug B-drug
, O O
antihistamines B-group B-group
, O O
psychotropics B-group B-group
or O O
other O O
drugs O O
that O O
produce O O
CNS O O
depression O O
. O O

However O O
, O O
in O O
vivo O O
drug O O
interaction O O
studies O O
of O O
ketoconazole B-drug B-drug
with O O
vitamin B-group B-group
D I-group I-group
have O O
not O O
been O O
investigated O O
. O O

No O O
inhibition O O
of O O
any O O
of O O
the O O
other O O
isoforms O O
tested O O
was O O
observed O O
at O O
gabapentin B-drug B-drug
concentrations O O
up O O
to O O
171 O O
mg/mL O O
( O O
approximately O O
15 O O
times O O
the O O
Cmax O O
at O O
3600 O O
mg/day O O
) O O
. O O

Dose O O
modification O O
is O O
recommended O O
for O O
patients O O
who O O
are O O
also O O
receiving O O
a O O
potent O O
CYP O O
3A4 O O
inducer O O
. O O

Following O O
a O O
10 O O
g O O
bolus O O
of O O
AMICAR B-brand B-brand
, O O
transient O O
peak O O
plasma O O
concentrations O O
of O O
4.6 O O
mMol/L O O
or O O
0.60 O O
mg/mL O O
have O O
been O O
obtained O O
. O O

Butalbital B-drug B-drug
, O O
acetaminophen B-drug B-drug
and O O
caffeine B-drug B-drug
may O O
enhance O O
the O O
effects O O
of O O
: O O
other O O
narcotic B-group B-group
analgesics O I-group
, O O
alcohol B-drug B-drug
, O O
general O O
anesthetics B-group B-group
, O O
tranquilizers B-group B-group
such O O
as O O
chlordiazepoxide B-drug B-drug
, O O
sedative-hypnotics B-group B-group
, O O
or O O
other O O
CNS B-group B-group
depressants I-group I-group
, O O
causing O O
increased O O
CNS O O
depression O O
. O O

Reduced O O
efficacy O O
and O O
increased O O
incidence O O
of O O
breakthrough O O
bleeding O O
and O O
menstrual O O
irregularities O O
have O O
been O O
associated O O
with O O
concomitant O O
use O O
of O O
rifampin B-drug B-drug
. O O

Discontinuation O O
of O O
cimetidine B-drug B-drug
in O O
well-controlled O O
patients O O
receiving O O
tricyclic B-drug B-group
antidepressants I-drug I-group
and O O
cimetidine B-drug B-drug
may O O
decrease O O
the O O
plasma O O
levels O O
and O O
efficacy O O
of O O
the O O
antidepressants B-drug B-group
. O O

Nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
have O O
been O O
reported O O
to O O
decrease O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-drug B-drug
and O O
to O O
potentiate O O
its O O
toxicity O O
. O O

Pharmacokinetic O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-drug B-drug
inhibits O O
the O O
metabolism O O
of O O
astemizole B-drug B-drug
, O O
resulting O O
in O O
elevated O O
plasma O O
levels O O
of O O
astemizole B-drug B-drug
and O O
its O O
active O O
metabolite O O
desmethylastemizole B-drug_n O
which O O
may O O
prolong O O
QT O O
intervals O O
. O O

Flurbiprofen B-drug B-drug
did O O
not O O
appear O O
to O O
affect O O
the O O
beta-blocker-mediated O O
reduction O O
in O O
heart O O
rate O O
. O O

In O O
patients O O
receiving O O
HCTZ B-drug B-drug
alone O O
, O O
dofetilide B-drug B-drug
AUC O O
increased O O
by O O
27 O O
% O O
and O O
Cmax O O
by O O
21 O O
% O O
. O O

descending O O
epsilon O O
and O O
mu O O
systems O O
for O O
beta-endorphin B-drug_n B-drug
and O O
morphine B-drug B-drug
, O O
respectively O O
, O O
are O O
proposed O O
. O O

Both O O
steady-state O O
maximum O O
concentration O O
and O O
AUC O O
were O O
dose O O
proportional O O
over O O
the O O
full O O
dose O O
range O O
when O O
assessed O O
on O O
day O O
1 O O
, O O
as O O
well O O
as O O
for O O
the O O
full O O
duration O O
of O O
the O O
study O O
at O O
steady O O
state O O
. O O

Non-steroidal B-group B-group
Anti-inflammatory I-group I-group
Agents I-group I-group
: O O
In O O
some O O
patients O O
with O O
compromised O O
renal O O
function O O
who O O
are O O
being O O
treated O O
with O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
the O O
co-administration O O
of O O
lisinopril B-drug B-drug
may O O
result O O
in O O
a O O
further O O
deterioration O O
of O O
renal O O
function O O
. O O

Drugs O O
which O O
may O O
potentiate O O
the O O
release O O
of O O
neutrophils O O
, O O
such O O
as O O
lithium B-drug B-drug
, O O
should O O
be O O
used O O
with O O
caution O O
. O O

bone O O
density O O
; O O

Treatment O O
with O O
entacapone B-drug B-drug
coadministered O O
with O O
levodopa/dopa B-drug B-drug
decarboxylase B-group B-group
inhibitor I-group I-group
does O O
not O O
change O O
these O O
effects O O
. O O

Pimozide B-drug B-drug
and O O
Celexa B-brand B-brand
- O O
In O O
a O O
controlled O O
study O O
, O O
a O O
single O O
dose O O
of O O
pimozide B-drug B-drug
2 O O
mg O O
co-administered O O
with O O
racemic O O
citalopram B-drug B-drug
40 O O
mg O O
given O O
once O O
daily O O
for O O
11 O O
days O O
was O O
associated O O
with O O
a O O
mean O O
increase O O
in O O
QTc O O
values O O
of O O
approximately O O
10 O O
msec O O
compared O O
to O O
pimozide B-drug B-drug
given O O
alone O O
. O O

Oral O O
Contraceptives B-group B-group
: O O
Multiple O O
dose O O
administration O O
of O O
tiagabine B-drug B-drug
( O O
8 O O
mg/day O O
monotherapy O O
) O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
oral O O
contraceptives B-group B-group
in O O
healthy O O
women O O
of O O
childbearing O O
age O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
property O O
is O O
unknown O O
. O O

Cephalosporins B-group B-group
are O O
known O O
to O O
occasionally O O
induce O O
a O O
positive O O
direct O O
Coombs O O
test O O
. O O

Loperamide B-drug B-drug
and O O
morphine B-drug B-drug
( O O
0.1 O O
and O O
1.0 O O
mg/kg O O
, O O
s.c O O
. O O
) O O

As O O
with O O
other O O
cephalosporins B-group B-group
, O O
high O O
concentrations O O
of O O
cefotetan B-drug B-drug
may O O
interfere O O
with O O
measurement O O
of O O
serum O O
and O O
urine O O
creatinine O O
levels O O
by O O
Jaffe O O
reaction O O
and O O
produce O O
false O O
increases O O
in O O
the O O
levels O O
of O O
creatinine O O
reported O O
. O O

Profound O O
hypotensive O O
episodes O O
may O O
occur O O
when O O
diazoxide B-drug B-drug
infection O O
and O O
hydralazine B-drug B-drug
are O O
used O O
concomitantly O O
. O O

However O O
, O O
concomitant O O
administration O O
of O O
5 O O
mg O O
b.i.d O O
. O O
isradipine B-drug B-drug
and O O
40 O O
mg O O
b.i.d O O
. O O

Two O O
groups O O
( O O
SH/DA O O
; O O
SH/FA O B-brand
) O O
were O O
submitted O O
to O O
daily O O
treatment O O
with O O
synthetic O B-group
hydroalcoholic O B-drug
solutions O O
containing O O
ethanol B-drug B-drug
, O O
methanol B-drug_n B-drug
, O O
higher O O
alcohols B-drug_n B-drug
and O O
acetaldehyde B-drug_n B-drug
in O O
the O O
same O O
proportions O O
as O O
those O O
found O O
in O O
most O O
common O O
distilled O O
and O O
fermented O O
alcoholic O B-drug
beverages O O
; O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
VIOXX B-brand B-brand
concomitantly O O
with O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Esomeprazole B-drug B-drug
inhibits O O
gastric O O
acid O O
secretion O O
. O O

Antihistamines B-group B-group

Anesthetics B-group B-group

Acetaminophen B-drug B-drug
: O O
A O O
report O O
of O O
severe O O
acetaminophen B-drug B-drug
toxicity O O
was O O
reported O O
in O O
a O O
patient O O
receiving O O
Isoniazid B-drug B-drug
. O O

Interaction O O
between O O
glycine B-drug B-drug
and O O
glutamate B-drug B-drug
in O O
the O O
development O O
of O O
spontaneous O O
motility O O
in O O
chick O O
embryos O O
. O O

The O O
interaction O O
was O O
pharmacodynamic O O
with O O
no O O
alteration O O
of O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
. O O

The O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
were O O
not O O
altered O O
. O O

b O O
This O O
table O O
is O O
not O O
all-inclusive O O
. O O

Wait O O
5 O O
weeks O O
after O O
stopping O O
escitalopram B-drug B-drug
before O O
starting O O
a O O
non-selective B-group B-group
MAO I-group I-group
inhibitor I-group I-group
. O O

However O O
, O O
coadministration O O
of O O
escitalopram B-drug B-drug
( O O
20 O O
mg O O
) O O
and O O
ritonavir B-drug B-drug
( O O
600 O O
mg O O
) O O
, O O
a O O
potent O O
inhibitor O O
of O O
CYP3A4 O O
, O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
escitalopram B-drug B-drug
. O O

This O O
loss O O
of O O
microtubules O O
on O O
cooling O O
the O O
nerves O O
and O O
their O O
reappearance O O
on O O
rewarming O O
was O O
a O O
rapid O O
process O O
; O O

The O O
potential O O
for O O
increased O O
sedation O O
when O O
guanfacine B-drug B-drug
is O O
given O O
with O O
other O O
CNS-depressant B-group O
drug I-group O
should O O
be O O
appreciated O O
. O O

The O O
potential O O
effects O O
of O O
increased O O
plasma O O
concentrations O O
of O O
midazolam B-drug B-drug
or O O
other O O
benzodiazepines B-group B-group
metabolized O O
via O O
CYP3A4 O O
( O O
alprazolam B-drug B-drug
, O O
triazolam B-drug B-drug
) O O
should O O
be O O
considered O O
when O O
coadministering O O
these O O
agents O O
with O O
Aprepitant B-drug B-drug
. O O

Oral O O
anticoagulant B-group B-group
agents I-group I-group
: O O
Pharmacokinetic O O
drug-drug O O
interactions O O
between O O
Argatroban B-drug B-drug
and O O
warfarin B-drug B-drug
( O O
7.5 O O
mg O O
single O O
oral O O
dose O O
) O O
have O O
not O O
been O O
demonstrated O O
. O O

Drug/Laboratory O O
Test-Interactions O O
None O O
observed O O
. O O

The O O
ratios O O
of O O
the O O
AUCs O O
of O O
unbound O O
valproate B-drug B-drug
to O O
the O O
AUCs O O
of O O
the O O
total O O
valproate B-drug B-drug
were O O
11.1 O O
% O O
, O O
13.0 O O
% O O
, O O
and O O
11.5 O O
% O O
, O O
with O O
coadministration O O
of O O
0 O O
, O O
1200 O O
, O O
and O O
2400 O O
mg/day O O
of O O
Felbatol B-brand B-brand
, O O
respectively O O
. O O

The O O
results O O
of O O
the O O
ERMBT O O
after O O
2 O O
weeks O O
of O O
rifabutin B-drug B-drug
and O O
rifampin B-drug B-drug
therapy O O
were O O
increased O O
187 O O
and O O
156 O O
% O O
, O O
respectively O O
. O O

Interations O O

CANCIDAS B-brand B-brand
reduced O O
the O O
blood O O
AUC0-12 O O
of O O
tacrolimus B-drug B-drug
by O O
approximately O O
20 O O
% O O
, O O
peak O O
blood O O
concentration O O
( O O
Cmax O O
) O O
by O O
16 O O
% O O
, O O
and O O
12-hour O O
blood O O
concentration O O
( O O
C12hr O O
) O O
by O O
26 O O
% O O
in O O
healthy O O
subjects O O
when O O
tacrolimus B-drug B-drug
( O O
2 O O
doses O O
of O O
0.1 O O
mg/kg O O
12 O O
hours O O
apart O O
) O O
was O O
administered O O
on O O
the O O
10th O O
day O O
of O O
CANCIDAS B-brand B-brand
70 O O
mg O O
daily O O
, O O
as O O
compared O O
to O O
results O O
from O O
a O O
control O O
period O O
in O O
which O O
tacrolimus B-drug B-drug
was O O
administered O O
alone O O
. O O

This O O
combinational O O
action O O
in O O
reversing O O
vancomycin O B-drug
resistance O O
of O O
enterococci O O
highlights O O
novel O O
drug O O
targets O O
and O O
has O O
importance O O
in O O
the O O
design O O
of O O
new O O
therapeutic O O
regimes O O
against O O
resistant O O
pathogens O O
. O O

Concurrent O O
use O O
of O O
macrolides B-group B-group
and O O
warfarin B-drug B-drug
in O O
clinical O O
practice O O
has O O
been O O
associated O O
with O O
increased O O
anticoagulant O O
effects O O
. O O

Serial O O
plasma O O
and O O
urine O O
samples O O
for O O
measurement O O
of O O
amprenavir B-drug B-drug
, O O
rifabutin B-drug B-drug
, O O
and O O
rifampin B-drug B-drug
and O O
their O O
25-O-desacetyl B-drug_n O
metabolites I-drug_n O
, O O
were O O
measured O O
by O O
high-performance O O
liquid O O
chromatography O O
. O O

Nevirapine I-drug B-drug
and O O
rifampin B-drug B-drug
should O O
not O O
beadministered O O
concomitantly O O
becausedecreases O O
in O O
nevirapine B-drug B-drug
plasmaconcentrations O O
may O O
reduce O O
the O O
efficacy O O
ofthe O O
drug O O
. O O

Antibiotics B-group B-group
: O O
In O O
vitro O O
and/or O O
in O O
vivo O O
data O O
show O O
that O O
clarithromycin B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
and O O
troleandomycin B-drug B-drug
markedly O O
inhibit O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
, O O
which O O
can O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
cisapride B-drug B-drug
levels O O
and O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

The O O
treatment O O
of O O
ewes O O
with O O
an O O
intravenous O O
( O O
IV O O
) O O
injection O O
of O O
trichlorfon B-drug_n B-drug
, O O
insufficient O O
to O O
produce O O
significant O O
inhibition O O
of O O
erythrocyte O O
acetylcholinesterase O O
( O O
AChE O O
) O O
activity O O
, O O
appeared O O
to O O
produce O O
additive O O
effects O O
with O O
those O O
produced O O
by O O
subsequent O O
treatment O O
with O O
4 O O
mg O O
of O O
coumaphos/kg/day B-drug_n O
. O O

Consequently O O
, O O
it O O
is O O
recommended O O
not O O
to O O
exceed O O
a O O
single O O
2.5 O O
mg O O
Vardenafil B-drug B-drug
dose O O
in O O
a O O
72-hour O O
period O O
when O O
used O O
in O O
combination O O
with O O
ritonavir B-drug B-drug
. O O

Castor B-drug O
oil I-drug O
( O O
4 O O
ml/kg O O
, O O
p.o O O
. O O
) O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
increases O O
both O O
free O O
and O O
bound O O
ketoprofen B-drug B-drug
by O O
reducing O O
the O O
plasma O O
clearance O O
of O O
ketoprofen B-drug B-drug
to O O
about O O
one-third O O
, O O
as O O
well O O
as O O
decreasing O O
its O O
protein O O
binding O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
coadministration O O
of O O
escitalopram B-drug B-drug
and O O
drugs O O
metabolized O O
by O O
CYP2D6 O O
. O O

Capsules O O
INDOCIN B-brand B-brand
50 O O
mg O O
t.i.d O O
. O O
produced O O
a O O
clinically O O
relevant O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
and O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
in O O
psychiatric O O
patients O O
and O O
normal O O
subjects O O
with O O
steady O O
state O O
plasma O O
lithium B-drug B-drug
concentrations O O
. O O

Therefore O O
, O O
increased O O
monitoring O O
of O O
digoxin B-drug B-drug
is O O
recommended O O
when O O
initiating O O
, O O
adjusting O O
, O O
or O O
discontinuing O O
COREG B-brand B-brand
. O O

Cimetidine B-drug B-drug
, O O
caffeine B-drug B-drug
, O O
and O O
erythromycin B-drug B-drug
may O O
increase O O
plasma O O
levels O O
of O O
Clozapine B-drug B-drug
, O O
potentially O O
resulting O O
in O O
adverse O O
effects O O
. O O

Analysis O O
of O O
16,16-dimethylprostaglandin B-drug_n B-drug_n
E2-induced O I-drug_n
diarrhea O O
in O O
cecectomized O O
rats O O
. O O

Response O O
to O O
sympathomimetic B-group B-group
agents I-group I-group
may O O
be O O
enhanced O O
by O O
colchicine B-drug B-drug
. O O

Therefore O O
, O O
digoxin B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
. O O

The O O
clinical O O
significance O O
of O O
these O O
findings O O
is O O
unknown O O
. O O

Increases O O
in O O
prothrombin O O
time O O
have O O
been O O
noted O O
in O O
patients O O
receiving O O
long- O B-group
term O O
warfarin B-drug B-drug
therapy O O
after O O
flutamide B-drug B-drug
was O O
initiated O O
. O O

. O O

Methotrexate B-drug B-drug
: O O
Caution O O
should O O
be O O
used O O
if O O
diflunisal B-drug B-drug
is O O
administered O O
concomitantly O O
with O O
methotrexate B-drug B-drug
. O O

dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O
) O O

While O O
all O O
the O O
selective O B-group
serotonin B-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
and O O
paroxetine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

Fulvestrant B-drug B-drug
was O O
not O O
mutagenic O O
or O O
clastogenic O O
in O O
multiple O O
in O O
vitro O O
tests O O
with O O
and O O
without O O
the O O
addition O O
of O O
a O O
mammalian O O
liver O O
metabolic O O
activation O O
factor O O
( O O
bacterial O O
mutation O O
assay O O
in O O
strains O O
of O O
Salmonella O O
typhimurium O O
and O O
Escherichia O O
coli O O
, O O
in O O
vitro O O
cytogenetics O O
study O O
in O O
human O O
lymphocytes O O
, O O
mammalian O O
cell O O
mutation O O
assay O O
in O O
mouse O O
lymphoma O O
cells O O
and O O
in O O
vivo O O
micronucleus O O
test O O
in O O
rat O O
. O O

Concomitantly O O
given O O
thiazide B-group B-group
diuretics I-group I-group
did O O
not O O
interfere O O
with O O
the O O
absorption O O
of O O
a O O
tablet O O
of O O
digoxin B-drug B-drug
. O O

After O O
1 O O
h O O
, O O
atracurium B-drug B-drug
was O O
discontinued O O
and O O
hoof O O
twitch O O
allowed O O
to O O
recover O O
to O O
75 O O
% O O
. O O

Depression O O
is O O
reaching O O
epidemic O O
proportions O O
in O O
the O O
western O O
world O O
. O O

When O O
these O O
drugs O O
are O O
administered O O
to O O
or O O
withdrawn O O
from O O
patients O O
receiving O O
Starlix B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
changes O O
in O O
glycemic O O
control O O
. O O

When O O
amiloride B-drug B-drug
HCl O I-drug
is O O
administered O O
concomitantly O O
with O O
an O O
angiotensin-converting B-group B-group
enzyme I-group I-group
inhibitor I-group I-group
, O O
the O O
risk O O
of O O
hyperkalemia O O
may O O
be O O
increased O O
. O O

No O O
interactions O O
have O O
been O O
observed O O
between O O
nizatidine B-drug B-drug
and O O
theophylline B-drug B-drug
, O O
chlordiazepoxide B-drug B-drug
, O O
lorazepam B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
with O O
doses O O
higher O O
than O O
40 O O
mg O O
QD O O
omeprazole B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

In O O
the O O
second O O
experiment O O
, O O
non-diabetic O O
and O O
streptozotocin-induced O O
diabetic O O
rats O O
were O O
fasted O O
, O O
and O O
the O O
same O O
procedures O O
were O O
followed O O
for O O
estimation O O
of O O
glucose B-drug O
tolerance O O
30 O O
min O O
after O O
glucose B-drug O
overload O O
. O O

Digoxin B-drug B-drug
, O O
Methotrexate B-drug B-drug
, O O
Cyclosporine B-drug B-drug
: O O
Diclofenac B-drug B-drug
, O O
like O O
other O O
NSAIDs B-group B-group
, O O
may O O
affect O O
renal O O
prostaglandins O O
and O O
increase O O
the O O
toxicity O O
of O O
certain O O
drugs O O
. O O

Studies O O
have O O
shown O O
that O O
the O O
bioavailability O O
of O O
isoniazid B-drug B-drug
is O O
reduced O O
significantly O O
when O O
administered O O
with O O
food O O
. O O

Drug-Drug O O
Interactions O O
Albuterol B-drug B-drug
- O O
STRATTERA B-brand B-brand
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
being O O
treated O O
with O O
systemically-administered O O
( O O
oral O O
or O O
intravenous O O
) O O
albuterol B-drug B-drug
( O O
or O O
other O O
beta2 B-group B-group
agonists I-group I-group
) O O
because O O
the O O
action O O
of O O
albuterol B-drug B-drug
on O O
the O O
cardiovascular O O
system O O
can O O
be O O
potentiated O O
resulting O O
in O O
increases O O
in O O
heart O O
rate O O
and O O
blood O O
pressure O O
. O O

Drugs O O
Which O O
Require O O
a O O
Dose O O
Reduction O O
When O O
Coadminstered O O
With O O
VIRACEPT B-brand B-brand
Antimycobacterial B-group B-group
agents I-group I-group
: O O
rifabutin B-drug B-drug

phosphokinase O O

Acetaminophen B-drug B-drug
: O O
In O O
normal O O
volunteers O O
, O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
acetaminophen B-drug B-drug
resulted O O
in O O
an O O
approximate O O
50 O O
% O O
increase O O
in O O
plasma O O
levels O O
of O O
acetaminophen B-drug B-drug
. O O

In O O
a O O
single-dose O O
crossover O O
study O O
examining O O
lansoprazole B-drug B-drug
30 O O
mg O O
and O O
omeprazole B-drug B-drug
20 O O
mg O O
each O O
administered O O
alone O O
and O O
concomitantly O O
with O O
sucralfate B-drug B-drug
1 O O
gram O O
, O O
absorption O O
of O O
the O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
was O O
delayed O O
and O O
their O O
bioavailability O O
was O O
reduced O O
by O O
17 O O
% O O
and O O
16 O O
% O O
, O O
respectively O O
, O O
when O O
administered O O
concomitantly O O
with O O
sucralfate B-drug B-drug
. O O

Pharmacokinetics O O
. O O

Saquinavir B-drug B-drug
: O O
Coadministration O O
of O O
saquinavir B-drug B-drug
( O O
using O O
an O O
experimental O O
soft-gelatin O B-drug
capsule O O
formulation O O
of O O
saquinavir B-drug B-drug
1200mg O O
) O O
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
an O O
18 O O
% O O
increase O O
in O O
nelfinavir B-drug B-drug
plasma O O
AUC O O
and O O
a O O
4-fold O O
increase O O
in O O
saquinavir B-drug B-drug
plasma O O
A.C O O
. O O

This O O
is O O
based O O
on O O
the O O
results O O
from O O
3 O O
clinical O O
studies O O
using O O
histamine B-drug O
induced O O
skin O O
wheals O O
and O O
flares O O
coupled O O
with O O
population O O
pharmacokinetic O O
analysis O O
. O O

CONCLUSIONS O O
. O O

Other O O
: O O
There O O
appears O O
to O O
be O O
no O O
pharmacokinetic O O
interaction O O
between O O
acitretin B-drug B-drug
and O O
cimetidine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
or O O
glyburide B-drug B-drug
. O O

While O O
all O O
the O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e. O O
g. O O
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
and O O
paroxetine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

Substrate O O
of O O
CYP2D6 O O
( O O
minor O O
) O O
, O O
3A4 O O
( O O
major O O
) O O
; O O

this O O
interaction O O
is O O
not O O
expected O O
to O O
be O O
of O O
clinical O O
importance O O
. O O

Other O O
TNFa-blocking B-group B-group
agents I-group I-group
( O O
including O O
REMICADE B-brand B-brand
) O O
used O O
in O O
combination O O
with O O
anakinra B-drug B-drug
may O O
also O O
result O O
in O O
similar O O
toxicities O O
. O O

There O O
have O O
been O O
reports O O
of O O
positive O O
test O O
results O O
using O O
the O O
Bio-Rad O O
Laboratories O O
Platelia O O
Aspergillus O O
EIA O O
test O O
in O O
patients O O
receiving O O
piperacillin/tazobactam B-drug B-drug
injection O O
who O O
were O O
subsequently O O
found O O
to O O
be O O
free O O
of O O
Aspergillus O O
infection O O
. O O

MAO B-group B-group
Inhibitors I-group I-group
: O O
DURAGESIC B-brand B-brand
is O O
not O O
recommended O O
for O O
use O O
in O O
patients O O
who O O
have O O
received O O
MAOI B-group B-group
within O O
14 O O
days O O
because O O
severe O O
and O O
unpredictable O O
potentiation O O
by O O
MAO B-group B-group
inhibitors I-group I-group
has O O
been O O
reported O O
with O O
opioid B-group B-group
analgesics I-group I-group

INDOCIN B-brand B-brand
reduces O O
basal O O
plasma O O
renin O O
activity O O
( O O
PRA O O
) O O
, O O
as O O
well O O
as O O
those O O
elevations O O
of O O
PRA O O
induced O O
by O O
furosemide B-drug B-drug
administration O O
, O O
or O O
salt O O
or O O
volume O O
depletion O O
. O O

In O O
a O O
study O O
in O O
which O O
patients O O
with O O
active O O
RA O O
were O O
treated O O
for O O
up O O
to O O
24 O O
weeks O O
with O O
concurrent O O
ENBREL B-brand B-brand
and O O
anakinra B-drug B-drug
therapy O O
, O O
a O O
7 O O
% O O
rate O O
of O O
serious O O
infections O O
was O O
observed O O
, O O
which O O
was O O
higher O O
than O O
that O O
observed O O
with O O
ENBREL B-brand B-brand
alone O O
( O O
0 O O
% O O
) O O
. O O

The O O
antimicrobial O O
effect O O
of O O
a O O
benzoxazinorifamycin B-drug_n B-drug
, O O
KRM-1648 B-drug_n B-drug_n
, O O
either O O
alone O O
or O O
in O O
combination O O
with O O
ofloxacin B-drug B-drug
, O O
was O O
evaluated O O
in O O
vitro O O
against O O
two O O
type O O
strains O O
and O O
six O O
clinical O O
isolates O O
of O O
Mycobacterium O O
ulcerans O O
. O O

The O O
combination O O
of O O
therapeutic O O
doses O O
of O O
intravenous O O
dantrolene B-drug B-drug
sodium I-drug I-drug
and O O
verapamil B-drug B-drug
in O O
halothane B-drug B-drug
a-chloralose O O
anesthetized O O
swine O O
has O O
resulted O O
in O O
ventricular O O
fibrillation O O
and O O
cardiovascular O O
collapse O O
in O O
association O O
with O O
marked O O
hyperkalemia O O
. O O

Phenylbutazone B-drug B-drug
: O O
Phenylbutazone B-drug B-drug
causes O O
increase O O
( O O
by O O
about O O
80 O O
% O O
) O O
in O O
the O O
free O O
fraction O O
of O O
etodolac B-drug B-drug
. O O

These O O
drugs O O
include O O
the O O
thiazides B-group B-group
and O O
other O O
diuretics B-group B-group
, O O
corticosteroids B-group B-group
, O O
phe-nothiazines O B-group
, O O
thyroid B-group B-group
products I-group I-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
, O O
phenytoin B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
, O O
sympathomimet-ics O B-group
, O O
calcium B-group B-group
channel I-group I-group
blocking I-group I-group
drugs I-group I-group
, O O
and O O
isoniazid B-drug B-drug
. O O

Fulvestrant B-drug B-drug
caused O O
an O O
increased O O
incidence O O
of O O
fetal O O
abnormalities O O
in O O
rats O O
( O O
tarsal O O
flexure O O
of O O
the O O
hind O O
paw O O
at O O
2 O O
mg/kg/day O O
IM O O
; O O

CIMETlDINE B-drug B-drug
: O O
Cerivastatin B-drug B-drug
plasma O O
concentrations O O
were O O
not O O
affected O O
by O O
co-administration O O
of O O
cimetidine B-drug B-drug
. O O

DIAMOX B-brand B-brand
modifies O O
phenytoin B-drug B-drug
metabolism O O
with O O
increased O O
serum O O
levels O O
of O O
phenytoin B-drug B-drug
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
, O O
at O O
therapeutic O O
concentrations O O
of O O
salicylate B-group B-drug
( O O
300 O O
m O O
g/mL O O
) O O
, O O
the O O
binding O O
of O O
ketorolac B-drug B-drug
was O O
reduced O O
from O O
approximately O O
99.2 O O
% O O
to O O
97.5 O O
% O O
, O O
representing O O
a O O
potential O O
twofold O O
increase O O
in O O
unbound O O
ketorolac B-drug B-drug
plasma O O
levels O O
. O O

increased O O
norepinephrine-induced O O
platelet O O
aggregability O O

Ergot-containing O O
drugs O O
have O O
been O O
reported O O
to O O
cause O O
prolonged O O
vasospastic O O
reactions O O
. O O

No O O
formal O O
clinical O O
studies O O
have O O
been O O
conducted O O
to O O
assess O O
if O O
there O O
is O O
an O O
interactive O O
effect O O
on O O
bone O O
loss O O
between O O
systemic B-group O
corticosteroids I-group B-group
and O O
Accutane B-brand B-brand
. O O

Erythromycin B-drug B-drug
: O O
In O O
healthy O O
individuals O O
, O O
plasma O O
concentrations O O
of O O
atorvastatin B-drug B-drug
increased O O
approximately O O
40 O O
% O O
with O O
coadministration O O
of O O
atorvastatin B-drug B-drug
and O O
erythromycin B-drug B-drug
, O O
a O O
known O O
inhibitor O O
of O O
cytochrome O O
P450 O O
3A4 O O
. O O

to O O
contend O O
with O O
. O O

Cysteine B-drug B-drug
was O O
covalently O O
linked O O
to O O
carbodiimide O B-drug
activated O O
NaCMC B-drug_n B-drug_n
. O O

Warfarin B-drug B-drug
: O O
Meclofenamate B-drug B-drug
sodium I-drug I-drug
enhances O O
the O O
effect O O
of O O
warfarin B-drug B-drug
. O O

The O O
mean O O
changes O O
were O O
observed O O
to O O
be O O
less O O
than O O
1 O O
second O O
in O O
both O O
instances O O
, O O
however O O
, O O
and O O
are O O
unlikely O O
to O O
be O O
clinically O O
important O O
. O O

SUBJECTS O O
: O O
Twelve O O
healthy O O
male O O
volunteers O O
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
test O O
should O O
be O O
closely O O
monitored O O
. O O

Angiomax B-brand B-brand
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
with O O
disease O O
states O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
bleeding O O
. O O

The O O
syndrome O O
requires O O
immediate O O
medical O O
attention O O
and O O
may O O
include O O
one O O
or O O
more O O
of O O
the O O
following O O
symptoms O O
: O O
excitement O O
, O O
hypomania O O
, O O
restlessness O O
, O O
loss O O
of O O
consciousness O O
, O O
confusion O O
, O O
disorientation O O
, O O
anxiety O O
, O O
agitation O O
, O O
motor O O
weakness O O
, O O
myoclonus O O
, O O
tremor O O
, O O
hemiballismus O O
, O O
hyperreflexia O O
, O O
ataxia O O
, O O
dysarthria O O
, O O
incoordination O O
, O O
hyperthermia O O
, O O
shivering O O
, O O
pupillary O O
dilation O O
, O O
diaphoresis O O
, O O
emesis O O
, O O
and O O
tachycardia O O
. O O

Probenecid B-drug B-drug
: O O
As O O
with O O
other O O
b-lactam B-group B-group
antibiotics I-group I-group
, O O
probenecid B-drug B-drug
inhibits O O
the O O
renal O O
excretion O O
of O O
cefdinir B-drug B-drug
, O O
resulting O O
in O O
an O O
approximate O O
doubling O O
in O O
A.C. O O
a O O
54 O O
% O O
increase O O
in O O
peak O O
cefdinir B-drug B-drug
plasma O O
levels O O
, O O
and O O
a O O
50 O O
% O O
prolongation O O
in O O
the O O
apparent O O
elimination O O
half-life O O
. O O

Future O O
trends O O
are O O
also O O
predicted O O
. O O

Coadministration O O
of O O
Aprepitant B-drug B-drug
with O O
these O O
drugs O O
or O O
other O O
drugs O O
that O O
are O O
known O O
to O O
be O O
metabolized O O
by O O
CYP2C9 O O
, O O
such O O
as O O
phenytoin B-drug B-drug
, O O
may O O
result O O
in O O
lower O O
plasma O O
concentrations O O
of O O
these O O
drugs O O
. O O

efavirenz B-drug B-drug
concentration O O

Indinavir I-drug B-drug

Lack O O
of O O
an O O
effect O O
of O O
azithromycin B-drug B-drug
on O O
the O O
disposition O O
of O O
zidovudine B-drug B-drug
and O O
dideoxyinosine B-drug B-drug
in O O
HIV-infected O O
patients O O
. O O

Although O O
increased O O
plasma O O
concentrations O O
( O O
AUC O O
0-24 O O
hrs O O
) O O
of O O
loratadine B-drug B-drug
and/or O O
descarboethoxyloratadine B-drug B-drug
were O O
observed O O
following O O
coadministration O O
of O O
loratadine B-drug B-drug
with O O
each O O
of O O
these O O
drugs O O
in O O
normal O O
volunteers O O
( O O
n O O
= O O
24 O O
in O O
each O O
study O O
) O O
, O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
safety O O
profile O O
of O O
loratadine B-drug B-drug
, O O
as O O
assessed O O
by O O
electrocardiographic O O
parameters O O
, O O
clinical O O
laboratory O O
tests O O
, O O
vital O O
signs O O
, O O
and O O
adverse O O
events O O
. O O

The O O
conjugates O O
so O O
formed O O
often O O
appear O O
in O O
the O O
urine O O
as O O
mercapturic O O
acids O O
or O O
other O O
thioether O O
products O O
. O O

Agents O O
that O O
have O O
been O O
found O O
, O O
or O O
are O O
expected O O
to O O
have O O
decreased O O
plasma O O
levels O O
in O O
the O O
presence O O
of O O
EQUETROTM B-brand B-brand
due O O
to O O
induction O O
of O O
CYP O O
enzymes O O
are O O
the O O
following O O
: O O
Acetaminophen B-drug B-drug
, O O
alprazolam B-drug B-drug
, O O
amitriptyline B-drug B-drug
, O O
bupropion B-drug B-drug
, O O
buspirone B-drug B-drug
, O O
citalopram B-drug B-drug
, O O
clobazam B-drug B-drug
, O O
clonazepam B-drug B-drug
, O O
clozapine B-drug B-drug
, O O
cyclosporin B-drug B-drug
, O O
delavirdine B-drug B-drug
, O O
desipramine B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
dicumarol B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
ethosuximide B-drug B-drug
, O O
felbamate B-drug B-drug
, O O
felodipine B-drug B-drug
, O O
glucocorticoids B-group B-group
, O O
haloperidol B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
lamotrigine B-drug B-drug
, O O
levothyroxine B-drug B-drug
, O O
lorazepam B-drug B-drug
, O O
methadone B-drug B-drug
, O O
midazolam B-drug B-drug
, O O
mirtazapine B-drug B-drug
, O O
nortriptyline B-drug B-drug
, O O
olanzapine B-drug B-drug
, O O
oral O O
contraceptives B-group B-group
( O O
3 O O
) O O
, O O
oxcarbazepine B-drug B-drug
, O O
Phenytoin B-drug B-drug
( O O
4 O O
) O O
, O O
praziquantel B-drug B-drug
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
quetiapine B-drug B-drug
, O O
risperidone B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
topiramate B-drug B-drug
, O O
tiagabine B-drug B-drug
, O O
tramadol B-drug B-drug
, O O
triazolam B-drug B-drug
, O O
valproate B-drug B-drug
, O O
warfarin B-drug B-drug
( O O
5 O O
) O O
, O O
ziprasidone B-drug B-drug
, O O
and O O
zonisamide B-drug B-drug
. O O

The O O
pharmacokinetics O O
of O O
nelfinavir B-drug B-drug
are O O
not O O
altered O O
to O O
a O O
clinically O O
significant O O
degree O O
when O O
it O O
is O O
administered O O
with O O
a O O
light O O
meal O O
1 O O
hour O O
after O O
VIDEX B-brand B-brand
. O O

. O O

Caution O O
should O O
be O O
used O O
if O O
naproxen B-drug B-drug
is O O
administered O O
concomitantly O O
with O O
methotrexate B-drug B-drug
. O O

It O O
is O O
recommended O O
to O O
avoid O O
concurrent O O
administration O O
of O O
ethambutol B-drug B-drug
with O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
containing O O
antacids B-group B-group
for O O
at O O
least O O
4 O O
hours O O
following O O
ethambutol B-drug B-drug
administration O O
. O O

*Increased O O
and O O
decreased O O
prothrombin O O
time O O
responses O O
have O O
been O O
reported O O
. O O

Epinephrine B-drug B-drug
should O O
be O O
used O O
cautiously O O
in O O
patients O O
with O O
hyperthyroidism O O
, O O
hypertension O O
and O O
cardiac O O
arrhythmias O O
. O O

Atracurium B-drug B-drug
infusion O O
was O O
continued O O
for O O
a O O
third O O
hour O O
, O O
and O O
then O O
hoof O O
twitch O O
was O O
again O O
allowed O O
to O O
recover O O
spontaneously O O
to O O
75 O O
% O O
. O O

Patients O O
should O O
report O O
to O O
their O O
practitioners O O
any O O
new O O
rashes O O
, O O
itching O O
, O O
mouth O O
sores O O
, O O
or O O
unusual O O
taste O O
while O O
taking O O
auranofin B-drug B-drug
. O O

and O O
the O O
remaining O O
25.9 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
9.3 O O
) O O
by O O
monitoring O O
and O O
follow-up O O
of O O
patients O O
. O O

immunosuppressant B-group B-group
agents I-group I-group
concentration O O

MAO B-group B-group
inhibitors I-group I-group
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
hydralazine B-drug B-drug
. O O

In O O
vitro O O
studies O O
have O O
shown O O
CASODEX B-brand B-brand
can O O
displace O O
coumarin B-group B-group
anticoagulants O I-group
, O O
such O O
as O O
warfarin B-drug B-drug
, O O
from O O
their O O
protein-binding O O
sites O O
. O O

chlorpropamide B-drug B-drug
; O O

The O O
benzodiazepines B-group B-group
, O O
including O O
alprazolam B-drug B-drug
, O O
produce O O
additive O O
CNS O O
depressant O O
effects O O
when O O
co-administered O O
with O O
other O O
psychotropic B-group B-group
medications I-group I-group
, O O
anticonvulsants B-group B-group
, O O
antihistaminics B-group B-group
, O O
ethanol B-drug B-drug
, O O
and O O
other O O
drugs O O
which O O
themselves O O
produce O O
CNS O O
depression O O
. O O

Digitalis B-group B-group
glycosides I-group I-group
enhanced O O
possibility O O
of O O
arrhythmias O O
or O O
digitalis B-group B-group
toxicity O O
associated O O
with O O
hypokalemia O O
. O O

In O O
the O O
presence O O
of O O
ouabain B-drug B-drug
( O O
10 O O
( O O
-5 O O
) O O
M O O
) O O
, O O
PTX B-drug_n B-drug_n
( O O
10 O O
( O O
-8 O O
) O O
M O O
) O O
failed O O
to O O
cause O O
the O O
first O O
contraction O O
; O O

no O O
other O O
specific O O
drug O O
interaction O O
studies O O
were O O
performed O O
. O O

INFORMATION O O
TO O O
BE O O
PROVIDED O O
TO O O
THE O O
PATIENT O O
OR O O
GUARDIAN O O
See O O
illustrated O O
Information O O
For O O
The O O
Patient O O
or O O
Guardian O O
section O O
. O O

Therefore O O
, O O
to O O
maximize O O
the O O
effects O O
of O O
fexofenadine B-drug B-drug
, O O
it O O
is O O
recommended O O
that O O
ALLEGRA B-brand B-brand
should O O
be O O
taken O O
with O O
water O O

Patients O O
were O O
intravenously O O
injected O O
a O O
chylomicron-like O O
emulsion O O
doubly O O
labeled O O
with O O
14C-cholesteryl O O
oleate O O
and O O
3H-triolein O O
at O O
baseline O O
and O O
after O O
treatments O O
. O O

increased O O
levels O O
of O O
fibrinogen B-drug O
and O O
fibrinogen B-drug O
activity O O
; O O

Warfarin B-drug B-drug
: O O
The O O
effects O O
of O O
warfarin B-drug B-drug
and O O
NSAIDs B-group B-group
on O O
GI O O
bleeding O O
are O O
synergistic O O
, O O
such O O
that O O
users O O
of O O
both O O
drugs O O
together O O
have O O
a O O
risk O O
of O O
serious O O
GI O O
bleeding O O
higher O O
than O O
users O O
of O O
either O O
drug O O
alone O O
. O O

A O O
greater O O
understanding O O
of O O
pain O O
mechanisms O O
will O O
aid O O
in O O
elucidating O O
the O O
role O O
of O O
antihistaminics B-group B-group
in O O
analgesia O O
. O O

In O O
vitro O O
, O O
propranolol B-drug B-drug
appears O O
to O O
be O O
displaced O O
from O O
its O O
binding O O
sites O O
by O O
diltiazem B-drug B-drug
. O O

For O O
example O O
, O O
the O O
plasma O O
nitrosourea B-group B-group
AUC O O
was O O
reduced O O
by O O
factors O O
of O O
1.05 O O
and O O
9.6 O O
for O O
MEC O O
values O O
of O O
1 O O
and O O
2 O O
micrograms O O
ml-1 O O
respectively O O
. O O

Proquin B-brand B-brand
XR I-brand I-brand
should O O
be O O
administered O O
at O O
least O O
4 O O
hours O O
before O O
or O O
2 O O
hours O O
after O O
these O O
products O O
. O O

Rifampin B-drug B-drug
markedly O O
increases O O
the O O
metabolic O O
clearance O O
of O O
amprenavir B-drug B-drug
, O O
and O O
coadministration O O
is O O
contraindicated O O
. O O

CNS-Active O O
Drugs O O
Ethanol B-drug B-drug
: O O
Sonata B-brand B-brand
10 O O
mg O O
potentiated O O
the O O
CNS-impairing O O
effects O O
of O O
ethanol B-drug B-drug
0.75 O O
g/kg O O
on O O
balance O O
testing O O
and O O
reaction O O
time O O
for O O
1 O O
hour O O
after O O
ethanol B-drug B-drug
administration O O
and O O
on O O
the O O
digit O O
symbol O O
substitution O O
test O O
( O O
DSST O O
) O O
, O O
symbol O O
copying O O
test O O
, O O
and O O
the O O
variability O O
component O O
of O O
the O O
divided O O
attention O O
test O O
for O O
2.5 O O
hours O O
after O O
ethanol B-drug B-drug
administration O O
. O O

Additionally O O
, O O
BREVIBLOC B-brand B-brand
should O O
not O O
be O O
used O O
to O O
control O O
supraventricular O O
tachycardia O O
in O O
the O O
presence O O
of O O
agents O O
which O O
are O O
vasoconstrictive O O
and O O
inotropic O O
such O O
as O O
dopamine B-drug B-drug
, O O
epinephrine B-drug B-drug
, O O
and O O
norepinephrine B-drug B-drug
because O O
of O O
the O O
danger O O
of O O
blocking O O
cardiac O O
contractility O O
when O O
systemic O O
vascular O O
resistance O O
is O O
high O O
. O O

Digoxin B-drug B-drug
: O O
The O O
concomitant O O
administration O O
of O O
DynaCirc B-brand B-brand
( O O
isradipine B-drug B-drug
) O O
and O O
digoxin B-drug B-drug
in O O
a O O
single-dose O O
pharmacokinetic O O
study O O
did O O
not O O
affect O O
renal O O
, O O
nonrenal O O
and O O
total O O
body O O
clearance O O
of O O
digoxin B-drug B-drug
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
valdecoxib B-drug B-drug
is O O
a O O
moderate O O
inhibitor O O
of O O
CYP O O
2C19 O O
( O O
IC50 O O
= O O
6 O O
g/mL O O
or O O
19 O O
M O O
) O O
and O O
2C9 O O
( O O
IC50 O O
= O O
13 O O
g/mL O O
or O O
41 O O
M O O
) O O
, O O
and O O
a O O
weak O O
inhibitor O O
of O O
CYP O O
2D6 O O
( O O
IC50 O O
= O O
31 O O
g/mL O O
or O O
100 O O
M O O
) O O
and O O
3A4 O O
( O O
IC50 O O
= O O
44 O O
g/mL O O
or O O
141 O O
M O O
) O O
.. O O

If O O
the O O
drugs O O
are O O
used O O
together O O
, O O
caution O O
should O O
be O O
exercised O O
because O O
unexpected O O
hypotension O O
could O O
result O O
from O O
beta-blocker O O
inhibition O O
of O O
the O O
sympathetic O O
reflex O O
response O O
to O O
fenoldopam B-drug B-drug
. O O

Because O O
cholestyramine B-drug B-drug
binds O O
bile O O
acids O O
, O O
cholestyramine B-drug B-drug
resin B-group B-group
may O O
interfere O O
with O O
normal O O
fat O O
digestion O O
and O O
absorption O O
and O O
thus O O
may O O
prevent O O
absorption O O
of O O
fat B-group B-group
soluble I-group I-group
vitamins I-group I-group
such O O
as O O
A O O
, O O
D O O
, O O
E O O
, O O
and O O
K O O
. O O

. O O

Chapter O O
5 O O
focuses O O
on O O
metabolic O O
effects O O
, O O
specifically O O
lipid O O
metabolism O O
, O O
carbohydrate O O
metabolism O O
and O O
diabetes O O
, O O
coagulation O O
factors O O
, O O
and O O
blood O O
pressure O O
. O O

Therapeutic O O
concentrations O O
of O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
ibuprofen B-drug B-drug
, O O
naproxen B-drug B-drug
, O O
piroxicam B-drug B-drug
, O O
acetaminophen B-drug B-drug
, O O
phenytoin B-drug B-drug
andtolbutamide O I-drug
did O O
not O O
alter O O
ketorolac B-drug B-drug
tromethamine I-drug I-drug
protein O O
binding O O
. O O

6 O O
. O O

[ O O
Importance O O
of O O
pharmacogenetics O O
] O O
; O O
Pharmacogenetics O O
deals O O
with O O
the O O
differences O O
in O O
effect O O
of O O
drugs O O
caused O O
by O O
genetic O O
variation O O
. O O

INSPRA B-brand B-brand
should O O
not O O
be O O
used O O
with O O
drugs O O
described O O
as O O
strong O O
inhibitors O O
of O O
CYP3A4 O O
in O O
their O O
labeling O O
. O O

* O O
No O O
longer O O
marketed O O
in O O
the O O
US O O
. O O

The O O
peripheral O O
vasoconstriction O O
caused O O
by O O
high O O
doses O O
of O O
dopamine B-drug B-drug
HCl I-drug I-drug
is O O
antagonized O O
by O O
alpha-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
. O O

Dosage O O
reduction O O
of O O
Cerubidine B-brand B-drug
may O O
be O O
required O O
when O O
used O O
concurrently O O
with O O
other O O
myelosuppressive O O
agents O O
. O O

In O O
amiodarone-treated B-drug O
patients O O
who O O
require O O
additional O O
antiarrhythmic B-drug B-drug
therapy O O
, O O
the O O
initial O O
dose O O
of O O
such O O
agents O O
should O O
be O O
approximately O O
half O O
of O O
the O O
usual O O
recommended O O
dose O O
. O O

Increased O O
thyroid-binding O O
globulin O O
( O O
TBG O O
) O O
leading O O
to O O
increased O O
circulating O O
total O O
thyroid O O
hormone O O
levels O O
, O O
as O O
measured O O
by O O
protein-bound O O
iodine O O
( O O
PBI O O
) O O
, O O
T4 O O
levels O O
( O O
by O O
column O O
or O O
by O O
radioimmunoassay O O
) O O
or O O
T3 O O
levels O O
by O O
radioimmunoassay O O
. O O

Drug O O
Interactions O O
, O O
General O O
: O O
Although O O
there O O
have O O
been O O
no O O
formal O O
interaction O O
studies O O
, O O
intravenous O O
fenoldopam B-drug B-drug
has O O
been O O
administered O O
safely O O
with O O
drugs O O
such O O
as O O
digitalis B-group B-group
and O O
sublingual O O
nitroglycerin B-drug B-drug
. O O

The O O
AUC O O
of O O
ciprofloxacin B-drug B-drug
was O O
decreased O O
an O O
average O O
of O O
15-fold O O
in O O
12 O O
healthy O O
subjects O O
given O O
ciprofloxacin B-drug B-drug
and O O
didanosine-placebo B-drug B-drug
tablets O O
concurrently O O
. O O

Allopurinol B-drug B-drug
: O O
The O O
AUC O O
of O O
didanosine B-drug B-drug
was O O
increased O O
about O O
4-fold O O
when O O
allopurinol B-drug B-drug
at O O
300 O O
mg/day O O
was O O
coadministered O O
with O O
a O O
single O O
200-mg O O
dose O O
of O O
VIDEX B-brand B-brand
to O O
two O O
patients O O
with O O
renal O O
impairment O O
( O O
CLcr=15 O O
and O O
18 O O
mL/min O O
) O O
. O O

ulcerans O O
was O O
between O O
0.012 O O
and O O
0.025 O O
mg/l O O
, O O
while O O
corresponding O O
values O O
for O O
rifampicin B-drug B-drug
and O O
rifabutin B-drug B-drug
were O O
in O O
the O O
range O O
of O O
0.1-0.8 O O
mg/l O O
and O O
0.1-0.4 O O
mg/l O O
respectively O O
. O O

Antibiotics B-group B-group
( O O
e.g. O O
, O O
erythromycin B-drug B-drug
, O O
trimethoprim B-drug B-drug
and O O
sulfamethoxazole B-drug B-drug
, O O
amoxicillin B-drug B-drug
) O O
. O O

If O O
such O O
measurements O O
are O O
necessary O O
, O O
the O O
use O O
of O O
other O O
methods O O
is O O
recommended O O
. O O

The O O
following O O
information O O
was O O
obtained O O
from O O
studies O O
in O O
normal O O
volunteers O O
. O O

. O O

Few O O
systemic O O
data O O
have O O
been O O
collected O O
on O O
the O O
metabolism O O
of O O
WELLBUTRIN B-brand B-brand
following O O
concomitant O O
administration O O
with O O
other O O
drugs O O
or O O
, O O
alternatively O O
, O O
the O O
effect O O
of O O
concomitant O O
administration O O
of O O
WELLBUTRIN B-brand B-brand
on O O
the O O
metabolism O O
of O O
other O O
drugs O O
. O O

While O O
the O O
recognition O O
of O O
drug O O
toxicity O O
resulting O O
from O O
interactions O O
is O O
of O O
importance O O
to O O
all O O
physciains O B-group
, O O
it O O
is O O
especially O O
so O O
for O O
the O O
clinician O O
responsible O O
for O O
the O O
welfare O O
of O O
those O O
in O O
the O O
aerospace O O
environment O O
. O O

The O O
serum O O
estrogen O O
concentrations O O
of O O
estradiol B-drug B-drug
+ O O
endotoxin-treated B-drug_n O
rats O O
decreased O O
by O O
50 O O
% O O
, O O
while O O
those O O
of O O
the O O
endotoxin-treated B-drug_n O
rats O O
increased O O
( O O
2- O O
to O O
5-fold O O
) O O
. O O

however O O
, O O
in O O
a O O
study O O
of O O
12 O O
normal O O
subjects O O
, O O
concurrent O O
administration O O
of O O
aspirin B-brand B-brand
decreased O O
ketoprofen B-drug B-drug
protein O O
binding O O
and O O
increased O O
ketoprofen B-drug B-drug
plasma O O
clearance O O
from O O
0.07 O O
L/kg/h O O
without O O
aspirin B-brand B-brand
to O O
0.11 O O
L/kg/h O O
with O O
aspirin B-brand B-brand
. O O

Everolimus B-drug B-drug
dose-proportionality O O
and O O
stability O O
over O O
time O O
were O O
assessed O O
in O O
the O O
context O O
of O O
linear O O
regression O O
and O O
ANOVA O O
models O O
. O O

Based O O
on O O
in O O
vitro O O
studies O O
in O O
human O O
liver O O
microsomes O O
, O O
des-ciclesonide B-drug B-drug
appears O O
to O O
have O O
no O O
inhibitory O O
or O O
induction O O
potential O O
on O O
the O O
metabolism O O
of O O
other O O
drugs O O
metabolized O O
by O O
CYP O O
450 O O
enzymes O O
. O O

Thiazides B-group B-group
: O O
Thiazides B-group B-group
are O O
known O O
to O O
induce O O
hypercalcemia O O
by O O
the O O
reduction O O
of O O
calcium O B-drug
excretion O O
in O O
urine O O
. O O

Cssmax O O
of O O
the O O
metabolite O O
, O O
ucb O O
L057 O O
, O O
was O O
approximately O O
doubled O O
in O O
the O O
presence O O
of O O
probenecid B-drug B-drug
while O O
the O O
fraction O O
of O O
drug O O
excreted O O
unchanged O O
in O O
the O O
urine O O
remained O O
the O O
same O O
. O O

Severe O O
hypoglycemia O O
has O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
azole B-group B-group
antifungal I-group I-group
agents I-group I-group
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

Corticosteroids B-group B-group
may O O
increase O O
the O O
clearance O O
of O O
chronic O O
high O O
dose O O
aspirin B-brand B-brand
. O O

adjust O O
salicylate B-group B-group
dosage O O
accordingly O O
if O O
effect O O
is O O
altered O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
co-administration O O
of O O
TCAs B-group B-group
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

Chapter O O
2 O O
considers O O
the O O
mode O O
of O O
action O O
, O O
including O O
ovulation O O
prevention O O
; O O

Diuretics B-group B-group
: O O
Patients O O
on O O
diuretics B-group B-group
, O O
especially O O
those O O
in O O
whom O O
diuretic O B-group
therapy O O
was O O
recently O O
instituted O O
, O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
Lotensin B-brand B-brand
. O O

Because O O
of O O
the O O
increased O O
risk O O
of O O
adverse O O
reactions O O
in O O
patients O O
who O O
have O O
been O O
taking O O
benzodiazepines B-group B-group
on O O
a O O
regular O O
basis O O
, O O
it O O
is O O
particularly O O
important O O
that O O
physicians O O
query O O
patients O O
or O O
their O O
guardians O O
carefully O O
about O O
benzodiazepine B-group B-group
, O O
alcohol B-drug B-drug
and O O
sedative B-group B-group
use O O
as O O
part O O
of O O
the O O
history O O
prior O O
to O O
any O O
procedure O O
in O O
which O O
the O O
use O O
of O O
ROMAZICON B-brand B-brand
is O O
planned O O
. O O

+15 O O
% O O
+5 O O
% O O
+15 O O
% O O
+4 O O
% O O

the O O
doses O O
of O O
naloxone B-drug B-drug
required O O
to O O
antagonize O O
the O O
effects O O
of O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
were O O
more O O
than O O
100 O O
times O O
higher O O
than O O
those O O
required O O
to O O
antagonize O O
the O O
effects O O
of O O
morphine B-drug B-drug
. O O

Among O O
aspirin B-brand B-brand
or O O
NSAID B-group B-group
users O O
, O O
the O O
incidence O O
of O O
upper O O
gastrointestinal O O
adverse O O
events O O
in O O
patients O O
treated O O
with O O
ibandronate B-drug B-drug
2.5 O O
mg O O
daily O O
( O O
28.9 O O
% O O
) O O
was O O
similar O O
to O O
that O O
in O O
placebo-treated O O
patients O O
( O O
30.7 O O
% O O
) O O
. O O

Warfarin B-drug B-drug
: O O
The O O
effect O O
of O O
celecoxib B-drug B-drug
on O O
the O O
anti-coagulant O O
effect O O
of O O
warfarin B-drug B-drug
was O O
studied O O
in O O
a O O
group O O
of O O
healthy O O
subjects O O
receiving O O
daily O O
doses O O
of O O
2-5 O O
mg O O
of O O
warfarin B-drug B-drug
. O O

4 O O
. O O

Increased O O
anticoagulation O O
effects O O
due O O
to O O
interactions O O
of O O
erythromycin B-drug B-drug
with O O
various O O
oral O O
anticoagulents O B-group
may O O
be O O
more O O
pronounced O O
in O O
the O O
elderly O O
. O O

Colchicine B-drug B-drug
may O O
increase O O
sensitivity O O
to O O
the O O
CNS B-group B-group
depressants I-group I-group
. O O

Phenytoin B-drug B-drug
increases O O
the O O
clearance O O
of O O
busulfan B-drug B-drug
by O O
15 O O
% O O
or O O
more O O
, O O
possibly O O
due O O
to O O
the O O
induction O O
of O O
glutathione-S-transferase O O
. O O

In O O
clinical O O
trials O O
, O O
doxazosin B-drug B-drug
mesylate I-drug I-drug
tablets O O
have O O
been O O
administered O O
to O O
patients O O
on O O
a O O
variety O O
of O O
concomitant O O
medications O O
; O O

The O O
evidence O O
for O O
a O O
role O O
for O O
norepinephrine O B-drug
and O O
dopamine O B-drug
and O O
the O O
effects O O
of O O
antihistaminics B-group B-group
on O O
them O O
are O O
less O O
well O O
established O O
. O O

H2 B-group B-group
Blockers/Proton I-group I-group
Pump I-group I-group
Inhibitors I-group I-group
: O O
Long-term O O
suppression O O
of O O
gastric O O
acid O O
secretion O O
by O O
H2 B-group B-group
blockers I-group I-group
or O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
( O O
eg O O
, O O
famotidine B-drug B-drug
and O O
omeprazole B-drug B-drug
) O O
is O O
likely O O
to O O
reduce O O
dasatinib B-drug B-drug
exposure O O
. O O

abnormal O O
vaginal O O
bleeding O O
; O O

Inhibitors O O
or O O
substrates O O
of O O
CYP2D6 O O
( O O
i.e. O O
, O O
quinidine B-drug B-drug
, O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
[ O O
SSRIs B-group B-group
] O O
) O O
may O O
increase O O
the O O
plasma O O
concentration O O
of O O
doxepin B-drug B-drug
when O O
administered O O
concomitantly O O
. O O

No O O
volunteer O O
showed O O
hormonal O O
evidence O O
of O O
ovulation O O
, O O
but O O
one O O
volunteer O O
reported O O
intermenstrual O O
bleeding O O
during O O
felbamate B-drug B-drug
treatment O O
. O O

Paralytic O O
ileus O O
may O O
occur O O
in O O
patients O O
taking O O
tricyclic B-drug B-group
antidepressants I-drug I-group
in O O
combination O O
with O O
anticholinergic-type B-drug B-group
drugs O I-group
. O O

Repeat O O
Treatment O O
Studies O O
evaluating O O
the O O
use O O
of O O
repeated O O
courses O O
of O O
Zmax B-brand O
have O O
not O O
been O O
conducted O O
. O O

The O O
extent O O
to O O
which O O
SSRI-TCA B-group B-group
interactions O O
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

this O O
can O O
cause O O
headaches O O
and O O
other O O
signs O O
of O O
hypertensive O O
crisis O O
. O O

chloral B-drug B-drug
hydrate* O O
; O O

Chlorpropamide B-drug B-drug
: O O
Chlorpropamides B-drug B-group
plasma O O
half-life O O
may O O
be O O
prolonged O O
by O O
allopurinol B-drug B-drug
, O O
since O O
allopurinol B-drug B-drug
and O O
chlorpropamide B-drug B-drug
may O O
compete O O
for O O
excretion O O
in O O
the O O
renal O O
tubule O O
. O O

This O O
is O O
especially O O
true O O
in O O
patients O O
who O O
may O O
subject O O
themselves O O
to O O
an O O
overdosage O O
of O O
drugs O O
. O O

Colchicine B-drug B-drug
para-aminosalicylic I-drug I-drug
acid I-drug I-drug
and O O
heavy O O
alcohol B-drug B-drug
intake O O
for O O
longer O O
than O O
2 O O
weeks O O
may O O
produce O O
malabsorption O O
of O O
vitamin B-drug B-drug
B12 I-drug I-drug
. O O

When O O
administered O O
concurrently O O
, O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
beta-adrenergic B-group B-group
receptor I-group I-group
blocking I-group I-group
agents I-group I-group
: O O
Anesthetics B-group B-group
, O O
general O O
: O O
exaggeration O O
of O O
the O O
hypotension O O
induced O O
by O O
general O O
anesthetics B-group B-group
. O O

It O O
has O O
been O O
reported O O
that O O
Itraconazole B-drug B-drug
enhances O O
the O O
anticoagulant O O
effect O O
of O O
coumarin-like B-group B-group
drugs O I-group
. O O

Cimetidine B-drug B-drug
at O O
400 O O
mg O O
BID O O
( O O
the O O
usual O O
prescription O O
dose O O
) O O
co-administered O O
with O O
TIKOSYN B-brand B-brand
( O O
500 O O
mcg O O
BID O O
) O O
for O O
7 O O
days O O
has O O
been O O
shown O O
to O O
increase O O
dofetilide B-drug B-drug
plasma O O
levels O O
by O O
58 O O
% O O
. O O

. O O

Integumentary O O

341 O O
PI O O
affecting O O
197 O O
patients O O
( O O
31.5 O O
% O O
, O O
95 O O
% O O
CI O O
, O O
+/- O O
3.6 O O
) O O
were O O
identified O O
. O O

Because O O
bupropion B-drug B-drug
is O O
extensively O O
metabolized O O
, O O
the O O
coadministration O O
of O O
other O O
drugs O O
may O O
affect O O
its O O
clinical O O
activity O O
. O O

Nonsteroidal B-group B-group
Anti-Inflammatory I-group I-group
Drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
-A O O
drug O O
interaction O O
study O O
of O O
eplerenone B-drug B-drug
with O O
an O O
NSAID B-group B-group
has O O
not O O
been O O
conducted O O
. O O

Steroids B-group B-group
enhance O O
the O O
renal O O
toxicity O O
of O O
edetate B-drug B-drug
calcium I-drug I-drug
disodium I-drug I-drug
in O O
animals O O
. O O
7 O O
Edetate B-drug B-drug
calcium I-drug I-drug
disodium I-drug I-drug
interferes O O
with O O
the O O
action O O
of O O
zinc B-drug B-drug
insulin I-drug I-drug
preparations O O
by O O
chelating O O
the O O
zinc B-drug B-drug
. O O
7 O O

These O O
effects O O
are O O
usually O O
reversible O O
. O O

Vitamin B-group B-group
D I-group I-group
: O O
The O O
coadministration O O
of O O
any O O
of O O
the O O
vitamin B-group B-group
D I-group I-group
analogues O I-group
should O O
be O O
avoided O O
as O O
this O O
could O O
create O O
possible O O
additive O O
effects O O
and O O
hypercalcemia O O
. O O

H1 O O
and O O
H2 B-group B-group
Blockers I-group I-group
- O O
Although O O
not O O
reported O O
, O O
L-histidine B-drug B-drug
, O O
via O O
its O O
metabolism O O
to O O
histamine O O
, O O
might O O
decrease B-group O
the I-group O
efficacy O O
of O O
H1 O O
and O O
H2 B-group B-group
blockers I-group I-group
. O O

Serious O O
toxicity O O
may O O
result O O
if O O
dextromethorphan B-drug B-drug
is O O
coadministered O O
with O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
( O O
MAOIs B-group B-group
) O O
. O O

Human O O
pharmacokinetic O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-drug B-drug
markedly O O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
, O O
resulting O O
in O O
a O O
mean O O
eight-fold O O
increase O O
in O O
AUC O O
of O O
cisapride B-drug B-drug
. O O

Growth O O
of O O
M O O
. O O

Opiate B-group B-group
agonists I-group I-group

Maximum O O
calculated O O
theophylline B-drug B-drug
clearance O O
ranged O O
from O O
2 O O
1/2 O O
to O O
3 O O
1/2 O O
times O O
baseline O O
. O O

Interactions O O
may O O
also O O
occur O O
with O O
the O O
following O O
: O O
anti-depressants/anti-anxiety B-group B-group
drugs I-group I-group
, O O
drugs O O
used O O
to O O
treat O O
an O O
overactive O O
thyroid O O
, O O
beta-blockers B-group B-group
( O O
e.g. O O
, O O
propranolol B-drug B-drug
) O O
, O O
sparfloxacin B-drug B-drug
, O O
grepafloxacin B-drug B-drug
, O O
guanethidine B-drug B-drug
, O O
guanadrel B-drug B-drug
, O O
metrizamide B-drug B-drug
, O O
cabergoline B-drug B-drug
, O O
lithium B-drug B-drug
, O O
narcotic B-group B-group
pain O O
medication O O
( O O
e.g. O O
, O O
codeine B-drug B-drug
) O O
, O O
drugs O O
used O O
to O O
aid O O
sleep O O
, O O
drowsiness-causing O O
antihistamines B-group B-group
( O O
e.g. O O
, O O
diphenhydramine B-drug B-drug
) O O
, O O
any O O
other O O
drugs O O
that O O
may O O
make O O
you O O
drowsy O O
. O O

however O O
, O O
there O O
was O O
extensive O O
concomitant O O
use O O
of O O
NSAIDs B-group B-group
in O O
clinical O O
studies O O
and O O
no O O
differential O O
effect O O
was O O
observed O O
. O O

however O O
, O O
at O O
lower O O
concentrations O O
only O O
zinc B-drug B-drug
demonstrated O O
toxicity O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
DIABINESE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Drugs O O
that O O
may O O
decrease O O
dasatinib B-drug B-drug
plasma O O
concentrations O O
CYP3A4 O O
Inducers O O
: O O
Drugs O O
that O O
induce O O
CYP3A4 O O
activity O O
may O O
decrease O O
dasatinib B-drug B-drug
plasma O O
concentrations O O
. O O

Valproate I-drug B-drug
** O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
precipitation O O
occurs O O
when O O
eye O O
drops O O
containing O O
thimerosal B-drug_n B-drug
are O O
mixed O O
with O O
latanoprost B-drug B-drug
. O O

plasma O O
levels O O
of O O
several O O
closely O O
related O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
to O O
be O O
increased O O
by O O
the O O
concomitant O O
administration O O
of O O
methylphenidate B-drug B-drug
or O O
hepatic O O
enzyme O O
inhibitors O O
( O O
e.g. O O
, O O
cimetidine B-drug B-drug
, O O
fluoxetine B-drug B-drug
) O O
and O O
decreased O O
by O O
the O O
concomitant O O
administration O O
of O O
hepatic O O
enzyme O O
inducers O O
( O O
e.g. O O
, O O
barbiturates B-group B-group
, O O
phenytoin B-drug B-drug
) O O
, O O
and O O
such O O
an O O
effect O O
may O O
be O O
anticipated O O
with O O
CMI B-drug O
as O O
well O O
. O O

Therefore O O
, O O
interactions O O
could O O
occur O O
following O O
concomitant O O
administration O O
of O O
psychotropic B-group B-group
drugs I-group I-group
( O O
e.g. O O
, O O
narcotics B-group B-group
, O O
analgesics B-group B-group
, O O
antiemetics B-group B-group
, O O
sedatives B-group B-group
, O O
tranquilizers B-group B-group
) O O
. O O

Although O O
no O O
clinical O O
drug-drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
to O O
date O O
, O O
on O O
the O O
basis O O
of O O
the O O
in O O
vitro O O
studies O O
, O O
cytochrome O O
p450 O O
inhibitors O O
and O O
inducers O O
are O O
unlikely O O
to O O
affect O O
the O O
metabolism O O
of O O
clofarabine B-drug B-drug
. O O

ACE B-group B-group
inhibitors I-group I-group
: O O
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Due O O
to O O
its O O

This O O
conference O O
reviews O O
recent O O
developments O O
in O O
these O O
areas O O
, O O
examines O O
the O O
effects O O
of O O
drug O O
use O O
in O O
the O O
elderly O O
and O O
implications O O
for O O
management O O
, O O
and O O
discusses O O
current O O
information O O
on O O
how O O
age O O
may O O
influence O O
the O O
response O O
of O O
cancer O O
to O O
therapy O O
. O O

We O O
incorporate O O
the O O
principles O O
of O O
recovery O O
and O O
define O O
positive O O
and O O
constructive O O
alternatives O O
in O O
dealing O O
with O O
cocaine O B-drug
hunger O O
. O O

Although O O
a O O
causal O O
mechanism O O
and O O
a O O
cause-and-effect O O
relationship O O
have O O
not O O
been O O
established O O
, O O
current O O
evidence O O
suggests O O
that O O
renal O O
function O O
should O O
be O O
monitored O O
in O O
patients O O
on O O
thiazide B-group B-group
diuretics I-group I-group
and O O
allopurinol B-drug B-drug
even O O
in O O
the O O
absence O O
of O O
renal O O
failure O O
, O O
and O O
dosage O O
levels O O
should O O
be O O
even O O
more O O
conservatively O O
adjusted O O
in O O
those O O
patients O O
on O O
such O O
combined O O
therapy O O
if O O
diminished O O
renal O O
function O O
is O O
detected.. O O

These O O
effects O O
were O O
not O O
considered O O
clinically O O
important O O
. O O

Drugs O O
that O O
have O O
been O O
associated O O
with O O
peripheral O O
neuropathy O O
include O O
antiretroviral B-drug B-group
nucleoside I-drug I-group
analogues I-drug I-group
, O O
chloramphenicol B-drug B-drug
, O O
cisplatin B-drug B-drug
, O O
dapsone B-drug B-drug
, O O
disulfiram B-drug B-drug
, O O
ethionamide B-drug B-drug
, O O
glutethimide B-drug B-drug
, O O
gold B-drug B-drug
, O O
hydralazine B-drug B-drug
, O O
iodoquinol B-drug B-drug
, O O
isoniazid B-drug B-drug
, O O
metronidazole B-drug B-drug
, O O
nitrofurantoin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
ribavirin B-drug B-drug
, O O
and O O
vincristine B-drug B-drug
. O O

. O O

Concurrent O O
use O O
of O O
phenothiazines B-group B-group
may O O
antagonize O O
the O O
anorectic O O
effect O O
of O O
diethylpropion B-drug B-drug
. O O

It O O
is O O
extensively O O
metabolized O O
, O O
predominantly O O
by O O
cytochrome O O
P450 O O
3A4 O O
. O O

There O O
are O O
other O O
agents O O
that O O
may O O
result O O
in O O
serious O O
and/or O O
life-threatening O O
drug O O
interactions O O
. O O

In O O
another O O
report O O
, O O
nine O O
patients O O
with O O
breast O O
cancer O O
were O O
reported O O
to O O
have O O
decreased O O
symptoms O O
of O O
methotrexate-related B-drug B-drug
toxicity O O
when O O
given O O
supplemental O O
L-glutamine B-drug B-drug
at O O
a O O
dose O O
of O O
0.5 O O
gram/kilogram/day O O
. O O

Other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
that O O
inhibit O O
prostaglandin O O
synthesis O O
have O O
been O O
shown O O
to O O
interfere O O
with O O
thiazide B-group B-group
diuretics I-group I-group
in O O
some O O
studies O O
and O O
with O O
potassium-sparing B-group B-group
diuretics I-group I-group
. O O

Both O O
groups O O
of O O
agents O O
lower O O
blood O O
levels O O
and O O
efficacy O O
of O O
amphetamines B-group B-group
. O O

- O O
Carmustine B-drug B-drug
( O O
e.g. O O
, O O
BiCNU B-brand B-drug
) O O
or O O

The O O
mechanism O O
of O O
these O O
interactions O O
has O O
been O O
evaluated O O
in O O
in O O
vitro O O
, O O
in O O
situ O O
, O O
and O O
in O O
vivo O O
animal O O
models O O
. O O

Concomitant O O
use O O
of O O
L-phenylalanine B-drug B-drug
and O O
non-selective B-group B-group
MAO I-group I-group
inhibitors I-group I-group
may O O
cause O O
hypertension O O
. O O

The O O
safety O O
of O O
such O O
concomitant O O
use O O
with O O
Activase B-brand B-brand
for O O
the O O
management O O
of O O
acute O O
ischemic O O
stroke O O
is O O
unknown O O
. O O

Veratrum B-group B-group
alkaloids I-group I-group
: O O
Amphetamines B-group B-group
inhibit O O
the O O
hypotensive O O
effect O O
of O O
veratrum B-group B-group
alkaloids I-group I-group
. O O

Rarely O O
salicylate B-group B-group
toxicity O O
may O O
occur O O
in O O
patients O O
who O O
discontinue O O
steroids B-group O
after O O
concurrent O O
high-dose O O
aspirin B-brand B-brand
therapy O O
. O O

Since O O
amiodarone B-drug B-drug
is O O
a O O
substrate O O
for O O
CYP3A4 O O
and O O
CYP2C8 O O
, O O
drugs/substances O O
that O O
inhibit O O
these O O
isoenzymes O O
may O O
decrease O O
the O O
metabolism O O
and O O
increase O O
serum O O
concentration O O
of O O
amiodarone B-drug B-drug
. O O

. O O

the O O
dose O O
of O O
Prostigmin B-brand B-drug
may O O
have O O
to O O
be O O
increased O O
accordingly O O
. O O

Accelerated O O
prothrombin O O
time O O
, O O
partial O O
thromboplastin O O
time O O
, O O
and O O
platelet O O
aggregation O O
time O O
; O O

Concomitant O O
administration O O
of O O
probenecid B-drug B-drug
doubled O O
the O O
AUC O O
for O O
cefprozil B-drug B-drug
. O O

Therefore O O
, O O
the O O
potential O O
exists O O
for O O
interaction O O
between O O
carbamazepine B-drug B-drug
and O O
any O O
agent O O
that O O
induces O O
CYP3A4 O O
. O O

Digoxin B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
erythromycin B-drug B-drug
and O O
digoxin B-drug B-drug
has O O
been O O
reported O O
to O O
result O O
in O O
elevated O O
digoxin B-drug B-drug
serum O O
levels O O
. O O

The O O
effect O O
of O O
TORADOL B-brand B-brand
on O O
plasma O O
lithium B-drug B-drug
has O O
not O O
been O O
studied O O
, O O
but O O
cases O O
of O O
increased O O
lithium B-drug B-drug
plasma O O
levels O O
during O O
TORADOL B-brand B-brand
therapy O O
have O O
been O O
reported O O
. O O

These O O
studies O O
indicate O O
that O O
ketoconazole B-drug B-drug
or O O
erythromycin B-drug B-drug
co-administration O O
enhances O O
fexofenadine B-drug B-drug
gastrointestinal O O
absorption O O
. O O

Because O O
prostaglandina O O
play O O
an O O
important O O
role O O
in O O
hemostasis O O
and O O
ketoprofen B-drug B-drug
has O O
an O O
effect O O
on O O
platelet O O
function O O
as O O
well O O
, O O
concurent O O
therapy O O
with O O
ketoprofen B-drug B-drug
and O O
warfarin B-drug B-drug
requires O O
close O O
monitoring O O
of O O
patients O O
on O O
both O O
drugs O O
. O O

Initial O O
doses O O
of O O
adrenergic B-group B-group
agents I-group I-group
, O O
such O O
as O O
dopamine B-drug B-drug
or O O
epinephrine B-drug B-drug
, O O
should O O
be O O
reduced O O
and O O
titrated O O
to O O
achieve O O
the O O
desired O O
response O O
. O O

But O O
it O O
is O O
now O O
difficult O O
to O O
situate O O
the O O
exact O O
place O O
of O O
the O O
pharmacological O O
indications O O
of O O
magnesium B-drug B-drug
. O O

In O O
the O O
experiments O O
reported O O
here O O
, O O
we O O
examined O O
the O O
interactions O O
between O O
1,25 B-drug B-drug_n
( I-drug I-drug_n
OH I-drug I-drug_n
) I-drug I-drug_n
2D3 I-drug I-drug_n
and O O
the O O
antiestrogen B-group B-drug_n
4-hydroxytamoxifen B-drug_n B-drug_n
( O O
TAM B-drug_n B-drug_n
) O O
, O O
which O O
also O O
induces O O
apoptosis O O
in O O
MCF-7 O O
cells O O
. O O

Anti-HIV B-group B-group
protease I-group I-group
inhibitors I-group I-group
: O O
Saquinavir/ritonavir B-drug B-drug
combination O O

Diethyl B-drug_n B-drug_n
pyrocarbonate I-drug_n I-drug_n
, O O
at O O
pH O O
7.0 O O
, O O
was O O
used O O
to O O
chemically O O
modify O O
exposed O O
histidine O O
residues O O
on O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
. O O

in O O
vitro O O
data O O
on O O
metabolic O O
interactions O O
indicate O O
that O O
Keppra B-brand B-brand
is O O
unlikely O O
to O O
produce O O
, O O
or O O
be O O
subject O O
to O O
, O O
pharmacokinetic O O
interactions O O
. O O

Estrogen B-group O
increased O O
levels O O
of O O
corticosteroid-binding O O
globulin O O
, O O
thereby O O
increasing O O
the O O
bound O O
( O O
inactive O O
) O O
fraction O O
; O O

AMEVIVE B-brand B-brand
underwent O O
trans-placental O B-drug
passage O O
and O O
produced O O
in O O
utero O O
exposure O O
in O O
the O O
developing O O
monkeys O O
. O O

No O O
special O O
precautions O O
appear O O
to O O
be O O
necessary O O
when O O
oral O O
anticoagulant O B-group
therapy O O
is O O
begun O O
in O O
a O O
patient O O
already O O
stabilized O O
on O O
maintenance O O
thyroid O O
replacement O O
therapy O O
. O O

Diagnostic O O
, O O
treatment O O
and O O
aftercare O O
approaches O O
to O O
cocaine B-drug B-drug
abuse O O
. O O

Antidiabetic B-group B-group
drugs I-group I-group
: O O
( O O
oral O O
agents O O
and O O
insulin B-drug B-drug
) O O
- O O
dosage O O
adjustment O O
of O O
the O O
antidiabetic B-group B-group
drug I-group I-group
may O O
be O O
required O O
. O O

Although O O
studies O O
designed O O
to O O
examine O O
drug O O
interactions O O
have O O
not O O
been O O
done O O
, O O
it O O
was O O
noted O O
that O O
corticosteroid B-group B-group
or O O
ACTH B-drug B-group
treatment O O
of O O
relapses O O
for O O
periods O O
of O O
up O O
to O O
28 O O
days O O
has O O
been O O
administered O O
to O O
patients O O
( O O
N=180 O O
) O O
receiving O O
Betaseron B-brand B-brand
. O O

Indinavir I-drug B-drug
and O O
didanosine B-drug B-drug
formulations O O
containing O O
buffer O O
should O O
be O O
administered O O
at O O
least O O
one O O
hour O O
apart O O
on O O
an O O
empty O O
stomach O O
. O O

OBJECTIVES O O
: O O
To O O
examine O O
the O O
effects O O
of O O
acute O O
hydrocortisone B-drug B-drug
pretreatment O O
on O O
the O O
subjective O O
and O O
behavioral O O
effects O O
of O O
d-amphetamine B-drug B-drug
. O O

Efavirenz B-drug B-drug
has O O
been O O
shown O O
in O O
vivo O O
to O O
induce O O
CYP3A4 O O
. O O

The O O
beta-blocker B-group B-group
should O O
be O O
withdrawn O O
first O O
. O O

Although O O
this O O
interaction O O
has O O
not O O
been O O
reported O O
with O O
cinoxacin B-drug B-drug
, O O
caution O O
should O O
be O O
exercised O O
when O O
cinoxacin B-drug B-drug
is O O
given O O
concomitantly O O
with O O
caffeine-containing B-drug B-drug
products O O
. O O

It O O
is O O
probable O O
that O O
dexamethasone B-drug B-drug
, O O
given O O
as O O
antiemetic O O
prophylaxis O O
, O O
contributed O O
to O O
hyperglycemia O O
in O O
some O O
patients O O
. O O

[ O O
Drug O O
treatment O O
of O O
erection O O
disorders O O
in O O
patients O O
with O O
cardiovascular O O
disease O O
] O O
Erectile O O
dysfunction O O
is O O
a O O
frequent O O
condition O O
in O O
cardiovascular O O
patients O O
. O O

Physostigmine B-drug B-drug
briefly O O
reduced O O
the O O
amplitude O O
of O O
most O O
components O O
, O O
including O O
P2 O O
. O O

No O O
specific O O
studies O O
in O O
humans O O
have O O
been O O
performed O O
and O O
caution O O
is O O
recommended O O
. O O

Coadministered O O
Concentration O O
Concentration O O

Co-administration O O
of O O
lovastatin B-drug B-drug
, O O
atenolol B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
celecoxib B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
ramipril B-drug B-drug
, O O
valsartan B-drug B-drug
, O O
metformin B-drug B-drug
and O O
amlodipine B-drug B-drug
did O O
not O O
result O O
in O O
clinically O O
significant O O
increases O O
in O O
aliskiren B-drug B-drug
exposure O O
. O O

During O O
administration O O
of O O
multiple O O
oral O O
doses O O
of O O
TAMBOCOR B-brand B-brand
to O O
healthy O O
subjects O O
stabilized O O
on O O
a O O
maintenance O O
dose O O
of O O
digoxin B-drug B-drug
, O O
a O O
13 O O
% O O
-19 O O
% O O
increase O O
in O O
plasma O O
digoxin B-drug B-drug
levels O O
occurred O O
at O O
six O O
hours O O
postdose O O
. O O

Some O O
reports O O
have O O
shown O O
that O O
the O O
concomitant O O
administration O O
of O O
thiazides B-group B-group
with O O
vitamin B-group B-group
D I-group I-group
causes O O
hypercalcemia O O
. O O

This O O
report O O
describes O O
a O O
recently O O
identified O O
case O O
of O O
interference O O
of O O
acetylcysteine B-drug B-drug
with O O
the O O
urine O O
test O O
for O O
ketones O O
and O O
demonstrates O O
the O O
importance O O
of O O
a O O
thorough O O
medication O O
review O O
in O O
evaluating O O
abnormal O O
laboratory O O
tests O O
. O O

Nondepolarizing B-group B-group
Muscle I-group I-group
Relaxants I-group I-group
: O O
In O O
postmarketing O O
experience O O
there O O
have O O
been O O
reports O O
of O O
a O O
possible O O
interaction O O
between O O
TORADOLIV/IM O O
and O O
nondepolarizing B-group B-group
muscle I-group I-group
relaxants I-group I-group
that O O
resulted O O
in O O
apnea O O
. O O

Phenytoin B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenytoin B-drug B-drug
; O O

faecalis O O
ATCC O O
51299 O O
showed O O
the O O
flavonoids O O
alone O O
significantly O O
lowered O O
numbers O O
of O O
colony O O
forming O O
units O O
( O O
CFUs O O
) O O
. O O

Catecholamine-depleting O O
drugs O O
( O O
eg O O
, O O
reserpine B-drug B-drug
) O O
may O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
beta-blocking B-group B-group
agents O I-group
. O O

in O O
vitro O O
, O O
Gleevec B-brand O
inhibits O O
the O O
cytochrome O O
P450 O O
isoenzyme O O
CYP2D6 O O
activity O O
at O O
similar O O
concentrations O O
that O O
affect O O
CYP3A4 O O
activity O O
. O O

When O O
the O O
STADOL B-brand B-brand
NS I-brand I-brand
was O O
administered O O
30 O O
minutes O O
after O O
the O O
sumatriptan B-drug B-drug
nasal O O
spray O O
, O O
the O O
AUC O O
of O O
butorphanol B-drug B-drug
increased O O
11 O O
% O O
and O O
Cmax O O
decreased O O
18 O O
% O O
. O O

Dosage O O
adjustments O O
of O O
BROVANA B-brand B-brand
are O O
not O O
necessary O O
when O O
the O O
drug O O
is O O
given O O
concomitantly O O
with O O
potent O O
CYP2D6 O O
inhibitors O O
. O O

Other O O
drugs O O
Drug O O
interactions O O
have O O
been O O
reported O O
with O O
concomitant O O
administration O O
of O O
erythromycin B-drug B-drug
and O O
other O O
medications O O
, O O
including O O
cyclosporine B-drug B-drug
, O O
hexobarbital B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
alfentanil B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
bromocriptine B-drug B-drug
, O O
valproate B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
and O O
lovastatin B-drug B-drug
. O O

Drug/Laboratory O O
Test O O
Interferences O O
: O O
Dicumarol B-drug B-drug
and O O
indanedione B-group B-drug
anticoagulants I-group B-group
, O O
including O O
anisindione B-drug B-drug
, O O
or O O
their O O
metabolites O O
may O O
color O O
alkaline O O
urine O O
red-orange O O
, O O
which O O
may O O
interfere O O
with O O
spectrophotometrically O O
determined O O
urinary O O
laboratory O O
tests O O
. O O

. O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCA B-group B-group
may O O
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Antacids B-group B-group
: O O
In O O
a O O
single O O
dose O O
study O O
( O O
n=6 O O
) O O
, O O
ingestion O O
of O O
an O O
antacid B-group B-group
containing O O
1.7-gram O O
of O O
magnesium B-drug B-drug
hydroxide I-drug I-drug
with O O
500-mg O O
of O O
mefenamic B-drug B-drug
acid I-drug I-drug
increased O O
the O O
Cmax O O
and O O
AUC O O
of O O
mefenamic B-drug B-drug
acid I-drug I-drug
by O O
125 O O
% O O
and O O
36 O O
% O O
, O O
respectively O O
. O O
A O O
number O O
of O O
compounds O O
are O O
inhibitors O O
of O O
CYP2C9 O O
including O O
fluconazole B-drug B-drug
, O O
lovastatin B-drug B-drug
and O O
trimethoprim B-drug B-drug
. O O

When O O
ouabain B-drug B-drug
was O O
applied O O
to O O
the O O
muscle O O
in O O
the O O
presence O O
of O O
phentolamine B-drug B-drug
, O O
both O O
first O O
and O O
second O O
contractile O O
responses O O
to O O
PTX B-drug_n B-drug_n
were O O
abolished O O
. O O

Studies O O
in O O
rats O O
have O O
shown O O
that O O
neomycin B-drug B-drug
administration O O
attenuates O O
certain O O
types O O
of O O
adrenocortical B-group O
steroid I-group O
dependent O O
hypertension O O
, O O
including O O
ACTH B-drug B-group
hypertension O O
. O O

If O O
these O O
agents O O
are O O
to O O
be O O
administered O O
concurrently O O
, O O
cyclosporine B-drug B-drug
concentrations O O
should O O
be O O
monitored O O
, O O
especially O O
when O O
diltiazem B-drug B-drug
therapy O O
is O O
initiated O O
, O O
adjusted O O
, O O
or O O
discontinued O O
. O O

We O O
conclude O O
that O O
ADL B-drug B-drug
8-2698 I-drug I-drug
prevents O O
morphine-induced B-drug B-drug
increases O O
in O O
gastrointestinal O O
transit O O
time O O
by O O
means O O
of O O
selective O B-group
peripheral O I-group
opioid O I-group
anitagonism O I-group
without O O
affecting O O
central O O
opioid O B-group
analgesia O O
. O O

Dose O O
reduction O O
of O O
CRIXIVAN B-brand B-brand
to O O
600 O O
mg O O
every O O
8 O O
hours O O
should O O
be O O
considered O O
when O O
taking O O
delavirdine B-drug B-drug
400 O O
mg O O
three O O
times O O
a O O
day O O
. O O

As O O
with O O
other O O
drugs O O
that O O
block O O
angiotensin O B-group
II O I-group
or O O
its O O
effects O O
, O O
concomitant O O
use O O
of O O
potassium-sparing B-group B-group
diuretics I-group I-group
( O O
e.g. O O
, O O
spironolactone B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
amiloride B-drug B-drug
) O O
, O O
potassium B-drug B-drug
supplements O O
, O O
or O O
salt O O
substitutes O O
containing O O
potassium O B-drug
may O O
lead O O
to O O
increases O O
in O O
serum O O
potassium O O
. O O

In O O
healthy O O
subjects O O
, O O
no O O
significant O O
drug-drug O O
interaction O O
was O O
observed O O
when O O
Norpace B-brand B-brand
was O O
coadministered O O
with O O
either O O
propranolol B-drug B-drug
or O O
diazepam B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
alosetron B-drug B-drug
and O O
fluvoxamine B-drug B-drug
is O O
contraindicated O O
. O O

Interaction O O
of O O
GABITRIL B-brand B-brand
with O O
Highly O O
Protein O O
Bound O O
Drugs O O
: O O
In O O
vitro O O
data O O
showed O O
that O O
tiagabine B-drug B-drug
is O O
96 O O
% O O
bound O O
to O O
human O O
plasma O O
protein O O
and O O
therefore O O
has O O
the O O
potential O O
to O O
interact O O
with O O
other O O
highly O O
protein O O
bound O O
compounds O O
. O O

Alternate O O
treatments O O
lacking O O
CYP3A4 O O
inducing O O
activity O O
should O O
be O O
considered O O
. O O

In O O
many O O
of O O
these O O
cases O O
, O O
buprenorphine B-drug B-drug
was O O
misused O O
by O O
self-injection O O
of O O
crushed O O
SUBUTEX B-brand B-brand
tablets O O
. O O

Sildenafil B-drug B-drug
citrate I-drug I-drug
- O O
Theoretically O O
, O O
L-arginine B-drug B-drug
supplements O O
taken O O
concomitantly O O
with O O
sildenafil B-drug B-drug
citrate I-drug I-drug
, O O
may O O
potentiate O O
the O O
effects O O
of O O
the O O
drug O O
. O O

. O O

Agents O O
Having O O
Vasodilator O O
Activity O O
: O O
Data O O
on O O
the O O
effect O O
of O O
concomitant O O
use O O
of O O
other O O
vasodilators B-group B-group
in O O
patients O O
receiving O O
captopril B-drug B-drug
for O O
heart O O
failure O O
are O O
not O O
available O O
; O O

The O O
coadministration O O
of O O
a O O
potent O O
CYP3A4 O O
enzyme O O
inducer O O
, O O
although O O
not O O
posing O O
a O O
safety O O
concern O O
, O O
thus O O
could O O
lead O O
to O O
ineffectiveness O O
of O O
zaleplon B-drug B-drug
. O O

Lithium B-drug B-drug
serum O O
concentrations O O
should O O
be O O
monitored O O
closely O O
when O O
initiating O O
or O O
changing O O
therapy O O
with O O
BEXTRA B-brand B-brand
in O O
patients O O
receiving O O
lithium B-drug B-drug
. O O

Five O O
, O O
10 O O
, O O
20 O O
, O O
or O O
50 O O
mg/kg O O
of O O
ketamine B-drug B-drug
alone O O
or O O
20 O O
, O O
50 O O
, O O
or O O
100 O O
mg/kg O O
of O O
metabolite O O
I O O
alone O O
produced O O
less O O
than O O
10 O O
minutes O O
of O O
hypnosis O O
. O O

Fluoxetine B-drug B-drug

Theophylline B-drug B-drug
alone O O
caused O O
identical O O
insulin O B-drug
and O O
glucagon O O
release O O
in O O
diabetics O O
and O O
normals O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
be O O
used O O
. O O

However O O
, O O
neither O O
phenobarbital B-drug B-drug
nor O O
diazepam B-drug B-drug
appears O O
to O O
affect O O
Dantrium B-brand B-drug
metabolism O O
. O O

Bile B-group B-group
acid I-group I-group
binding I-group I-group
resins I-group I-group
may O O
also O O
interfere O O
with O O
the O O
absorption O O
of O O
oral O O
phosphate B-drug B-drug
supplements O O
and O O
hydrocortisone B-drug B-drug
. O O

Cyclosporine B-drug B-drug
: O O
Because O O
cyclosporine B-drug B-drug
can O O
produce O O
nephrotoxicity O O
with O O
decreases O O
in O O
creatinine O O
clearance O O
and O O
rises O O
in O O
serum O O
creatinine O O
, O O
and O O
because O O
renal O O
excretion O O
is O O
the O O
primary O O
elimination O O
route O O
of O O
fibrate B-group B-group
drugs I-group I-group
including O O
TRICOR B-brand B-brand
, O O
there O O
is O O
a O O
risk O O
that O O
an O O
interaction O O
will O O
lead O O
to O O
deterioration O O
. O O

- O O
Antithyroid B-group B-group
agents I-group I-group
( O O
medicine O O
for O O
overactive O O
thyroid O O
) O O
or O O

In O O
the O O
digitalized O O
patient O O
, O O
slow O O
alterations O O
in O O
serum O O
levels O O
after O O
oral O O
administration O O
appeared O O
well O O
correlated O O
with O O
, O O
at O O
least O O
, O O
the O O
negative O O
chronotropic O O
effects O O
of O O
the O O
drug O O
. O O

Potential O O
for O O
Other O O
Drugs O O
to O O
Affect O O
ABILIFY B-brand B-brand
Aripiprazole I-brand B-drug
is O O
not O O
a O O
substrate O O
of O O
CYP1A1 O O
, O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2B6 O O
, O O
CYP2C8 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
or O O
CYP2E1 O O
enzymes O O
. O O

Coadministration O O
of O O
oral O O
contraceptives B-group B-group
, O O
diazepam B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
or O O
quinidine B-drug B-drug
did O O
not O O
seem O O
to O O
change O O
the O O
pharmacokinetic O O
profile O O
of O O
esomeprazole B-drug B-drug
. O O

DRUG/LABORATORY O O
TEST O O
INTERACTIONS O O
1 O O
. O O

In O O
several O O
well-controlled O O
studies O O
, O O
guanfacine B-drug B-drug
was O O
administered O O
together O O
with O O
diuretics B-group B-group
with O O
no O O
drug O O
interactions O O
reported O O
. O O

Spermine B-drug B-drug
( O O
0.5-2 O O
mM O O
) O O
promoted O O
the O O
translocation O O
of O O
phosphatidate O O
phosphohydrolase O O
from O O
the O O
soluble O O
to O O
the O O
microsomal O O
fraction O O
in O O
a O O
cell-free O O
system O O
derived O O
from O O
rat O O
liver O O
. O O

Ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
Norethindrone B-drug B-drug

Due O O
to O O
the O O
potential O O
for O O
additive O O
effects O O
, O O
caution O O
and O O
careful O O
titration O O
are O O
warranted O O
in O O
patients O O
receiving O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
concomitantly O O
with O O
other O O
agents O O
known O O
to O O
affect O O
cardiac O O
contractility O O
and/or O O
conduction O O
. O O

laryngeal O O
edema O O

Since O O
Zarontin B-brand B-brand
( O O
ethosuximide B-drug B-drug
) O O
may O O
interact O O
with O O
concurrently O O
administered O O
antiepileptic B-group B-group
drugs I-group I-group
, O O
periodic O O
serum O O
level O O
determinations O O
of O O
these O O
drugs O O
may O O
be O O
necessary O O
( O O
eg O O
, O O
ethosuximide B-drug B-drug
may O O
elevate O O
phenytoin B-drug B-drug
serum O O
levels O O
and O O
valproic B-drug B-drug
acid I-drug I-drug
has O O
been O O
reported O O
to O O
both O O
increase O O
and O O
decrease O O
ethosuximide B-drug B-drug
levels O O
) O O
. O O

Interactions O O
with O O
Mixed B-group O
Agonist/Antagonist I-group B-group
Opioid I-group I-group
Analgesics I-group I-group
: O O
Agonist/antagonist B-group B-group
analgesics I-group I-group
( O O
eg O O
, O O
pentazocine B-drug B-drug
, O O
nalbuphine B-drug B-drug
, O O
butorphanol B-drug B-drug
, O O
dezocine B-drug B-drug
and O O
buprenorphine B-drug B-drug
) O O
should O O
NOT O O
be O O
administered O O
to O O
a O O
patient O O
who O O
has O O
received O O
or O O
is O O
receiving O O
a O O
course O O
of O O
therapy O O
with O O
a O O
pure B-group O
agonist I-group B-group
opioid I-group I-group
analgesic I-group I-group
such O O
as O O
Levo-Dromoran B-brand B-brand
. O O

Amphotericin B-drug B-drug
B I-drug I-drug
or O O
Corticosteroids B-group B-group
or O O
Corticotropin B-drug B-drug
( O O
ACTH B-drug B-drug
) O O

If O O
oral O O
anticoagulants B-group B-group
are O O
also O O
being O O
given O O
, O O
compensatory O O
increases O O
in O O
clotting O O
factor O O
synthesis O O
are O O
impaired O O
. O O

Because O O
efficient O O
labeling O O
can O O
be O O
achieved O O
with O O
0.1 O O
% O O
biocytin O O
with O O
whole-cell O O
recording O O
, O O
higher O O
concentrations O O
are O O
contraindicated O O
. O O

Nevertheless O O
, O O
the O O
possibility O O
of O O
additive O O
negative O O
inotropic O O
effects O O
of O O
beta B-group B-group
blockers I-group I-group
and O O
flecainide B-drug B-drug
should O O
be O O
recognized O O
. O O

Caution O O
should O O
be O O
taken O O
when O O
ENABLEX B-brand B-brand
is O O
used O O
concomitantly O O
with O O
medications O O
that O O
are O O
predominantly O O
metabolized O O
by O O
CYP2D6 O O
and O O
which O O
have O O
a O O
narrow O O
therapeutic O O
window O O
, O O
such O O
as O O
flecainide B-drug B-drug
, O O
thioridazine B-drug B-drug
and O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
see O O
CLINICAL O O
PHARMACOLOGY O O
) O O
. O O

These O O
results O O
show O O
that O O
lung B-group B-group
surfactant I-group I-group
has O O
the O O
potential O O
of O O
enhancing O O
the O O
rate O O
and O O
extent O O
of O O
dissolution O O
of O O
drugs O O
administered O O
to O O
the O O
lung O O
. O O

Inhibition O O
of O O
renal O O
lithium B-drug B-drug
clearance O O
leading O O
to O O
increases O O
in O O
plasma O O
lithium B-drug B-drug
concentrations O O
has O O
also O O
been O O
reported O O
. O O

Effects O O
of O O
low O O
temperatures O O
on O O
microtubules O O
in O O
the O O
non-myelinated O O
axons O O
of O O
post-ganglionic O O
sympathetic O O
nerves O O
. O O

However O O
, O O
LDL-C O O
reduction O O
was O O
greater O O
when O O
atorvastatin B-drug B-drug
and O O
colestipol B-drug B-drug
were O O
coadministered O O
than O O
when O O
either O O
drug O O
was O O
given O O
alone O O
. O O

therefore O O
, O O
VIRACEPT B-brand B-brand
should O O
not O O
be O O
administered O O
concurrently O O
with O O
terfenadine B-drug B-drug
because O O
of O O
the O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
cardiac O O
arrhythmias O O
. O O

Results O O
with O O
warfarin B-drug B-drug
wshow O O
no O O
evidence O O
of O O
interaction O O
with O O
either O O
single O O
or O O
repeated O O
doses O O
of O O
Trileptal B-brand B-brand
. O O

The O O
magnitude O O
of O O
interaction O O
with O O
multiple O O
doses O O
of O O
erythromycin B-drug B-drug
is O O
unknown O O
. O O

In O O
general O O
, O O
most O O
patients O O
treated O O
with O O
dirithromycin B-drug B-drug
who O O
are O O
receiving O O
concomitant O O
theophylline B-drug B-drug
therapy O O
may O O
not O O
require O O
empiric O O
adjustment O O
of O O
theophylline B-drug B-drug
dosage O O
or O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
concentrations O O
. O O

and O O
glutamate B-drug B-drug
( O O
15 O O
mg/kg O O
e.w O O
. O O
) O O

Other O O
drugs O O
which O O
may O O
enhance O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
nondepolarizing B-group O
agents I-group O
such O O
as O O
NIMBEX B-brand B-brand
include O O
certain O O
antibiotics B-group B-group
( O O
e. O O
g. O O
, O O
aminoglycosides B-group B-group
, O O
tetracyclines B-group B-group
, O O
bacitracin B-drug B-drug
, O O
polymyxins B-group B-group
, O O
lincomycin B-drug B-drug
, O O
clindamycin B-drug B-drug
, O O
colistin B-drug B-drug
, O O
and O O
sodium B-drug B-drug
colistemethate I-drug I-drug
) O O
, O O
magnesium B-group B-drug
salts O O
, O O
lithium B-drug B-drug
, O O
local O O
anesthetics B-group B-group
, O O
procainamide B-drug B-drug
, O O
and O O
quinidine B-drug B-drug
. O O

diseases O O
of O O
the O O
liver O O
, O O
gallbladder O O
, O O
and O O
bowel O O
; O O

In O O
in O O
vivo O O
studies O O
, O O
10- O O
to O O
30-mg/day O O
doses O O
of O O
aripiprazole B-drug B-drug
had O O
no O O
significant O O
effect O O
on O O
metabolism O O
by O O
CYP2D6 O O
( O O
dextromethorphan B-drug B-drug
) O O
, O O
CYP2C9 O O
( O O
warfarin B-drug B-drug
) O O
, O O
CYP2C19 O O
( O O
omeprazole B-drug B-drug
, O O
warfarin B-drug B-drug
) O O
, O O
and O O
CYP3A4 O O
( O O
dextromethorphan B-drug B-drug
) O O
substrates O O
. O O

Lapatinib B-drug B-drug
did O O
not O O
significantly O O
inhibit O O
the O O
following O O
enzymes O O
in O O
human O O
liver O O
microsomes O O
: O O
CYP1A2 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
and O O
CYP2D6 O O
or O O
UGT O O
enzymes O O
in O O
vitro O O
, O O
however O O
, O O
the O O
clinical O O
significance O O
is O O
unknown O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
enhanced O O
secretion O O
of O O
colonic O O
fluid O O
by O O
dmPGE2 B-drug_n B-drug_n
, O O
given O O
intraluminally O O
, O O
was O O
only O O
half O O
of O O
that O O
in O O
control O O
rats O O
, O O
whereas O O
the O O
colonic O O
transit-enhancing O O
effect O O
of O O
dmPGE2 B-drug_n B-drug_n
in O O
cecectomized O O
rats O O
was O O
more O O
pronounced O O
than O O
in O O
control O O
rats O O
at O O
15 O O
but O O
not O O
at O O
30 O O
min O O
after O O
its O O
administration O O
. O O

Increases O O
in O O
INR O O
and O O
prothrombin O O
time O O
may O O
lead O O
to O O
abnormal O O
bleeding O O
and O O
even O O
death O O
. O O

A O O
5-mg O O
Vardenafil B-drug B-drug
dose O O
should O O
not O O
be O O
exceeded O O
when O O
used O O
in O O
combination O O
with O O
200 O O
mg O O
once O O
daily O O
ketoconazole B-drug B-drug
. O O

Fluvoxamine B-drug B-drug
increased O O
mean O O
alosetron B-drug B-drug
plasma O O
concentrations O O
( O O
AUC O O
) O O
approximately O O
6-fold O O
and O O
prolonged O O
the O O
half-life O O
by O O
approximately O O
3-fold O O
. O O

[ O O
Stimulation O O
by O O
cerulein B-drug_n O
-- O O
an O O
analog O O
of O O
the O O
octapeptide O O
cholecystokinin O O
-- O O
of O O
3H-spiroperidol B-drug_n O
binding O O
after O O
the O O
long-term O O
administration O O
of O O
neuroleptics B-group B-group
] O O
It O O
has O O
been O O
established O O
in O O
experiments O O
on O O
white O O
male O O
rats O O
that O O
prolonged O O
administration O O
( O O
twice O O
a O O
day O O
for O O
14 O O
days O O
) O O
of O O
haloperidol B-drug B-drug
( O O
0.25 O O
mg/kg O O
) O O
and O O
pyreneperone B-drug_n B-drug
( O O
0.25 O O
mg/kg O O
) O O
resulted O O
in O O
the O O
reduced O O
interaction O O
between O O
3H-spiroperidol B-drug_n B-drug_n
and O O
low O O
affinity O O
binding O O
sites O O
for O O
apomorphine B-drug B-drug
in O O
subcortical O O
structures O O
, O O
whereas O O
3H-spiroperidol B-drug_n O
binding O O
with O O
high O O
affinity O O
binding O O
sites O O
for O O
apomorphine B-drug B-drug
increased O O
both O O
in O O
the O O
frontal O O
cortex O O
and O O
subcortical O O
structures O O
of O O
the O O
forebrain O O
. O O

Pulmonary O O
granulomata O O
, O O
subacute O O
hepatitis O O
and O O
other O O
lesions O O
resulting O O
from O O
intravenous O O
drug O O
use O O
were O O
common O O
findings O O
at O O
autopsy O O
. O O

Blunting O O
of O O
the O O
antihypertensive O O
effect O O
of O O
beta-adrenoceptor B-group B-group
blocking I-group I-group
agents I-group I-group
by O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
has O O
been O O
reported O O
. O O

Therefore O O
, O O
when O O
heparin B-drug B-drug
sodium I-drug I-drug
is O O
given O O
with O O
dicumarol B-drug B-drug
or O O
warfarin B-drug B-drug
sodium I-drug I-drug
, O O
a O O
period O O
of O O
at O O
least O O
5 O O
hours O O
after O O
the O O
last O O
intravenous O O
dose O O
or O O
24 O O
hours O O
after O O
the O O
last O O
subcutaneous O O
dose O O
should O O
elapse O O
before O O
blood O O
is O O
drawn O O
if O O
a O O
valid O O
prothrombin O O
time O O
is O O
to O O
be O O
obtained O O
. O O

The O O
concurrent O O
use O O
of O O
TORADOL B-brand B-brand
with O O
muscle B-group B-group
relaxants I-group I-group
has O O
not O O
been O O
formally O O
studied O O
. O O

When O O
increases O O
in O O
the O O
dose O O
of O O
INDOCIN B-brand B-brand
are O O
made O O
, O O
they O O
should O O
be O O
made O O
carefully O O
and O O
in O O
small O O
increments O O
. O O

In O O
some O O
patients O O
, O O
a O O
disulfiram-like B-drug O
reaction O O
may O O
be O O
produced O O
by O O
the O O
ingestion O O
of O O
alcohol B-drug B-drug
. O O

+12 O O
% O O
+19 O O
% O O
-11 O O
% O O
-3 O O
% O O

Because O O
both O O
of O O
these O O
drugs O O
have O O
negative O O
inotropic O O
properties O O
and O O
the O O
effects O O
of O O
coadministration O O
with O O
TAMBOCOR B-brand B-brand
are O O
unknown O O
, O O
neither O O
disopyramide B-drug B-drug
nor O O
verapamil B-drug B-drug
should O O
be O O
administered O O
concurrently O O
with O O
TAMBOCOR B-brand B-brand
unless O O
, O O
in O O
the O O
judgment O O
of O O
the O O
physician O O
, O O
the O O
benefits O O
of O O
this O O
combination O O
outweigh O O
the O O
risks O O
. O O

The O O
20 O O
% O O
v/v O O
solution O O
of O O
alcohol B-drug B-drug
was O O
prepared O O
in O O
water O O
from O O
a O O
stock O O
solution O O
of O O
95 O O
% O O
ethanol B-drug B-drug
. O O

The O O
clinical O O
significance O O
of O O
this O O
interaction O O
in O O
preterm O O
neonates O O
is O O
not O O
known O O
. O O

Retrospective O O
analysis O O
of O O
side O O
effects O O
in O O
clinical O O
trials O O
showed O O
that O O
poor O O
2D6 O O
metabolizers O O
had O O
a O O
higher O O
rate O O
of O O
dizziness O O
during O O
up-titration O O
, O O
presumably O O
resulting O O
from O O
vasodilating O O
effects O O
of O O
the O O
higher O O
concentrations O O
of O O
the O O
a-blocking O O
R O O
( O O
+ O O
) O O
enantiomer O O
. O O

asthma O O
drugs O O
and O O
antipsychotics B-group B-group
. O O

bone O O
marrow O O
hypoplasia O O

( O O
20 O O
mg O O
QD O O
) O O

Coadministration O O
of O O
entecavir B-drug B-drug
with O O
lamivudine B-drug B-drug
, O O
adefovir B-drug B-drug
dipivoxil I-drug I-drug
, O O
or O O
tenofovir B-drug B-drug
disoproxil I-drug I-drug
fumarate I-drug I-drug
did O O
not O O
result O O
in O O
significant O O
drug O O
interactions O O
. O O

Because O O
of O O
the O O
possible O O
additive O O
effects O O
of O O
drugs O O
that O O
may O O
depress O O
the O O
nervous O O
system O O
, O O
ethanol B-drug B-drug
or O O
triazolam B-drug B-drug
should O O
be O O
used O O
cautiously O O
in O O
combination O O
with O O
tiagabine B-drug B-drug
. O O

Aminoglutethimide B-drug B-drug
: O O
Aminoglutethimide B-drug B-drug
may O O
diminish O O
adrenal O O
suppression O O
by O O
corticosteroids B-group B-group
. O O

Atropine B-drug B-drug
, O O
either O O
alone O O
or O O
in O O
combination O O
with O O
alcohol B-drug B-drug
, O O
produced O O
approximately O O
the O O
same O O
degree O O
of O O
enhancement O O
of O O
component O O
P2 O O
. O O

Animals O O
studies O O
on O O
the O O
various O O
dual-memory O O
theories O O
have O O
been O O
carried O O
out O O
mainly O O
on O O
the O O
basis O O
of O O
hippocampal O O
system O O
function O O
. O O

Sertraline B-drug B-drug

Potential O O
Drug O O
Interactions O O
Dofetilide B-drug B-drug
is O O
eliminated O O
in O O
the O O
kidney O O
by O O
cationic O O
secretion O O
. O O

was O O
evaluated O O
as O O
a O O
possible O O
explanation O O
for O O
the O O
association O O
of O O
deep-seated O O
infection O O
with O O
this O O
organism O O
and O O
abuse O O
of O O
these O O
drugs O O
. O O

When O O
Vardenafil B-drug B-drug
dosing O O
was O O
separated O O
from O O
terazosin B-drug B-drug
10 O O
mg O O
by O O
6 O O
hours O O
, O O
7 O O
of O O
28 O O
subjects O O
who O O
received O O
20 O O
mg O O
of O O
Vardenafil B-drug B-drug
experienced O O
a O O
decrease O O
in O O
standing O O
systolic O O
blood O O
pressure O O
below O O
85 O O
mm O O
Hg O O
. O O

However O O
, O O
reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE B-group B-group
inhibitors I-group I-group
. O O

The O O
neurochemical O O
and O O
functional O O
consequences O O
following O O
MPTP B-drug_n B-drug_n
administration O O
to O O
the O O
rat O O
were O O
evaluated O O
and O O
compared O O
to O O
similar O O
effects O O
following O O
methamphetamine B-drug B-drug
administration O O
. O O

Caffeine B-drug B-drug
administered O O
concurrently O O
with O O
ketoprofen B-drug B-drug
reduced O O
the O O
urine O O
volume O O
in O O
4 O O
healthy O O
volunteers O O
. O O

There O O
have O O
been O O
reports O O
of O O
theophylline-related B-drug B-drug
side-effects O O
in O O
patients O O
on O O
concomitant O O
theophylline-quinolone B-drug O
therapy O O
. O O

Non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
( O O
but O O
not O O
aspirin B-brand B-brand
) O O
: O O
These O O
drugs O O
in O O
combination O O
with O O
very O O
high O O
doses O O
of O O
quinolones B-group B-group
have O O
been O O
shown O O
to O O
provoke O O
convulsions O O
in O O
pre-clinical O O
studies O O
. O O

In O O
vitro O O
human O O
liver O O
microsome O O
studies O O
and O O
an O O
in O O
vivo O O
metabolic O O
probe O O
study O O
demonstrated O O
that O O
alosetron B-drug B-drug
did O O
not O O
inhibit O O
CYP O O
enzymes O O
2D6 O O
, O O
3A4 O O
, O O
2C9 O O
, O O
or O O
2C19 O O
. O O

In O O
contrast O O
to O O
its O O
enantiomer O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
failed O O
to O O
increase O O
FI O O
responding O O
significantly O O
in O O
either O O
species O O
; O O

The O O
extent O O
to O O
which O O
SSRI-TCAinteractions B-group B-group
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

Thus O O
, O O
in O O
addition O O
to O O
its O O
proposed O O
specific O O
information O O
processing O O
functions O O
( O O
i.e. O O
, O O
relational O O
) O O
, O O
the O O
hippocampus O O
would O O
play O O
a O O
role O O
in O O
addressing O O
information O O
to O O
the O O
brain O O
memory O O
system O O
that O O
, O O
in O O
a O O
given O O
situation O O
, O O
has O O
the O O
best O O
adaptive O O
value O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

When O O
INDOCIN B-brand B-brand
is O O
given O O
to O O
patients O O
receiving O O
probenecid B-drug B-drug
, O O
the O O
plasma O O
levels O O
of O O
indomethacin B-drug B-drug
are O O
likely O O
to O O
be O O
increased O O
. O O

Antihistamines B-group B-group
: O O
Amphetamines B-group B-group
may O O
counteract O O
the O O
sedative O O
effect O O
of O O
antihistamines B-group B-group
. O O

Mixing O O
of O O
Insulins B-group B-group

There O O
was O O
not O O
a O O
significant O O
difference O O
( O O
p O O
> O O
0.05 O O
) O O
in O O
AUC O O
( O O
48.59 O O
+/- O O
8.52 O O
vs. O O
49.9 O O
+/- O O
9.93 O O
) O O
, O O
Cmax O O
( O O
7.73 O O
+/- O O
2.6 O O
vs. O O
6.6 O O
+/- O O
2.0 O O
) O O
, O O
and O O
tmax O O
( O O
1.1 O O
+/- O O
0.6 O O
vs. O O
1.6 O O
+/- O O
1.1 O O
) O O
for O O
levofloxacin B-drug B-drug
versus O O
levofloxacin/oxycodone B-drug B-drug
regimens O O
. O O

The O O
thiazolidinediones B-group B-group
( O O
rosiglitazone B-drug B-drug
and O O
pioglitazone B-drug B-drug
) O O
, O O
a O O
new O O
class O O
of O O
oral O O
antidiabetic B-group B-group
agents I-group I-group
, O O
are O O
" O O
insulin O O
sensitizers O O
" O O

Although O O
specific O O
drug O O
interaction O O
studies O O
in O O
HIV-1 O O
seropositive O O
subjects O O
have O O
not O O
been O O
conducted O O
for O O
the O O
classes O O
of O O
drugs O O
listed O O
in O O
Table O O
4 O O
, O O
additional O O
clinical O O
monitoring O O
may O O
be O O
warranted O O
when O O
co-administering O O
these O O
drugs O O
. O O

In O O
this O O
situation O O
, O O
special O O
patient O O
care O O
and O O
observation O O
are O O
appropriate O O
. O O

Labetalol B-drug B-drug
HCl I-drug I-drug
has O O
also O O
been O O
reported O O
to O O
produce O O
a O O
false O O
positive O O
test O O
for O O
amphetamine B-drug B-drug
when O O
screening O O
urine O O
for O O
the O O
presence O O
of O O
drugs O O
using O O
the O O
commercially O O
available O O
assay O O
methods O O
Toxi-Lab O O
A O O
( O O
thin-layer O O
chromatographic O O
assay O O
) O O
and O O
Emit-d.a.u O O
. O O
( O O
radioenzymatic O O
assay O O
) O O
. O O

Therefore O O
, O O
close O O
monitoring O O
of O O
prothrombin O O
time O O
is O O
recommended O O
and O O
adjustment O O
of O O
the O O
anticoagulant B-group B-group
dose O O
may O O
be O O
necessary O O
when O O
EULEXIN B-brand B-brand
Capsules O O
are O O
administered O O
concomitantly O O
with O O
warfarin B-drug B-drug
. O O

The O O
data O O
inTables O O
1 O O
and O O
3 O O
are O O
based O O
on O O
the O O
results O O
of O O
drug O O
interaction O O
studies O O
conducted O O
in O O
HIV-1 O O
seropositive O O
subjects O O
unless O O
otherwise O O
indicated O O
. O O

Phenobarbital B-drug B-drug
toxicity O O
has O O
been O O
reported O O
to O O
have O O
occurred O O
in O O
a O O
patient O O
on O O
chronic O O
phenobarbital B-drug B-drug
treatment O O
following O O
the O O
initiation O O
of O O
diclofenac B-drug B-drug
therapy O O
. O O

Hydrochlorothiazide B-drug B-drug
: O O
A O O
study O O
in O O
normal O O
healthy O O
volunteers O O
has O O
shown O O
that O O
concomitant O O
administration O O
of O O
DynaCirc B-brand B-brand
( O O
isradipine B-drug B-drug
) O O
and O O
hydrochlorothiazide B-drug B-drug
does O O
not O O
result O O
in O O
altered O O
pharmacoktnetics O O
of O O
either O O
drug O O
. O O

CANCIDAS B-brand B-brand
has O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
itraconazole B-drug B-drug
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
or O O
the O O
active O O
metabolite O O
of O O
mycophenolate O B-drug
. O O

Antidepressants B-group B-group
( O O
tricyclic B-group B-group
) O O
, O O
atropine B-drug B-drug
or O O
other O O
anticholinergic B-group B-group
agents I-group I-group
, O O
or O O
digitalis B-group B-group
glycosides I-group I-group
: O O
concurrent O O
use O O
with O O
arbutamine B-drug B-drug
may O O
produce O O
additive O O
inotropic O O
and/or O O
chronotropic O O
effects O O
. O O

This O O
interaction O O
appears O O
to O O
be O O
clinically O O
significant O O
. O O

Since O O
bacteriostatic O O
drugs O O
may O O
interfere O O
with O O
the O O
bactericidal O O
action O O
of O O
penicillin B-drug B-drug
, O O
it O O
is O O
advisable O O
to O O
avoid O O
giving O O
tetracyclines B-group B-group
in O O
conjunction O O
with O O
penicillin B-group B-drug
. O O

The O O
mean O O
reduction O O
of O O
growth O O
caused O O
by O O
the O O
drugs O O
was O O
1,000-fold O O
greater O O
for O O
49 O O
Pseudomonas O O
strains O O
from O O
normal O O
subjects O O
than O O
for O O
32 O O
strains O O
from O O
drug O O
addicts O O
( O O
4.2 O O
vs. O O
1.3 O O
logs O O
of O O
reduction O O
at O O
2 O O
hr O O
, O O
P O O
less O O
than O O
.0005 O O
) O O
. O O

Diazepam B-drug B-drug
: O O
Diazepam B-drug B-drug
( O O
Valium B-brand B-brand
) O O
is O O
a O O
CYP O O
3A4 O O
and O O
CYP O O
2C19 O O
substrate O O
. O O

INCREASED O O
PHENYTOIN B-drug B-drug
LEVELS O O
SHOULD O O
BE O O
TREATED O O
WITH O O
APPROPRIATE O O
DOSAGE O O
ADJUSTMENT O O
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
these O O
agents O O
is O O
indicated O O
because O O
of O O
demonstrated O O
hypokalemia O O
, O O
they O O
should O O
be O O
used O O
with O O
caution O O
and O O
with O O
frequent O O
monitoring O O
of O O
serum O O
potassium O O
. O O

Drugs O O
Metabolized O O
by O O
Cytochrome O O
P4502D6 O O
- O O
In O O
vitro O O
studies O O
did O O
not O O
reveal O O
an O O
inhibitory O O
effect O O
of O O
escitalopram B-drug B-drug
on O O
CYP2D6 O O
. O O

The O O
concomitant O O
administration O O
of O O
macrolide B-group B-group
antibiotics I-group I-group
and O O
other O O
hydroxymethylglutaryl B-group B-group
coenzyme I-group I-group
A I-group I-group
( I-group I-group
HMG-CoA I-group I-group
) I-group I-group
reductase I-group I-group
inhibitors I-group I-group
have O O
resulted O O
in O O
previous O O
reports O O
of O O
rhabdomyolysis O O
. O O

The O O
pressor O O
effects O O
of O O
ERGOMAR B-brand B-brand
and O O
other O O
vasoconstrictor B-group B-group
drugs I-group I-group
can O O
combine O O
to O O
cause O O
dangerous O O
hypertension O O
. O O

A O O
causal O O
relationship O O
between O O
these O O
events O O
and O O
the O O
concomitant O O
administration O O
of O O
lithium B-drug B-drug
and O O
HALDOL B-brand B-brand
has O O
not O O
been O O
established O O
; O O

Aortic O O
rings O O
with O O
intact O O
endothelium O O
from O O
the O O
high-dose O O
( O O
4 O O
mg/kg/day O O
) O O
estradiol B-drug B-drug
group O O
were O O
supersensitive O O
to O O
noradrenaline B-drug B-drug
compared O O
to O O
the O O
vehicle O O
or O O
low-dose O O
( O O
10 O O
microg/kg/day O O
) O O
estradiol O B-drug
groups O O
( O O
pD2 O O
values O O
= O O
7.86+/-0.09 O O
, O O
7.30+/-0.11 O O
and O O
7.35+/-0.04 O O
, O O
respectively O O
) O O
. O O

The O O
concurrent O O
use O O
of O O
two O O
or O O
more O O
drugs O O
with O O
anticholinergic O O
activity O O
-- O O
such O O
as O O
an O O
antipsychotic B-group B-group
drug I-group I-group
( O O
eg O O
, O O
chlorpromazine B-drug B-drug
) O O
, O O
an O O
antiparkinsonian B-group O
drug I-group O
( O O
eg O O
, O O
trihexyphenidyl B-drug O
) O O
, O O
and/or O O
a O O
tricyclic B-group B-group
antidepressant I-group I-group
( O O
eg O O
, O O
amitriptyline B-drug B-drug
) O O
-- O O
commonly O O
results O O
in O O
excessive O O
anticholinergic O O
effects O O
, O O
including O O
dry O O
mouth O O
and O O
associated O O
dental O O
complications O O
, O O
blurred O O
vision O O
, O O
and O O
, O O
in O O
patients O O
exposed O O
to O O
high O O
temperature O O
and O O
humidity O O
, O O
hyperpyrexia O O
. O O

Although O O
the O O
pattern O O
of O O
use O O
for O O
oral O O
allopurinol B-drug B-drug
includes O O
longer O O
term O O
therapy O O
, O O
particularly O O
for O O
gout O O
and O O
renal O O
calculi O O
, O O
the O O
experience O O
gained O O
may O O
be O O
relevant O O
. O O

Similarly O O
, O O
in O O
the O O
1-year O O
monthly O O
comparison O O
study O O
, O O
aspirin B-brand B-brand
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
were O O
taken O O
by O O
39 O O
% O O
of O O
the O O
1602 O O
patients O O
. O O

These O O
factors O O
, O O
in O O
concert O O
with O O
age-dependent O O
alterations O O
in O O
immune O O
function O O
and O O
host O O
defense O O
, O O
may O O
help O O
to O O
explain O O
the O O
increased O O
risk O O
of O O
malignant O O
disease O O
in O O
aged O O
persons O O
. O O

Although O O
there O O
was O O
a O O
slight O O
reduction O O
in O O
blood O O
sugar O O
concentrations O O
during O O
concomitant O O
administration O O
of O O
flurbiprofen B-drug B-drug
and O O
hypoglycemic B-group B-group
agents I-group I-group
, O O
there O O
were O O
no O O
signs O O
or O O
symptoms O O
of O O
hypoglycemia O O
. O O

Survival O O
of O O
miracidia O O
was O O
reduced O O
by O O
increasing O O
metal O O
concentration O O
except O O
at O O
concentrations O O
of O O
10 O O
microg/l O O
for O O
single O O
metal O O
toxicity O O
where O O
survival O O
was O O
increased O O
above O O
the O O
control O O
. O O

- O O
Antihypertensives B-group B-group
: O O
Bumetanide B-drug B-drug
may O O
potentiate O O
the O O
effect O O
of O O
various O O
antihypertensive B-group B-group
drugs I-group I-group
, O O
necessitating O O
a O O
reduction O O
in O O
the O O
dosage O O
of O O
these O O
drugs O O
. O O

acetaminophen/theophylline B-drug B-drug
, O O
lidocaine/quinidine B-drug B-drug
, O O
phenobarbital/acetaminophen B-drug B-drug
, O O
phenobarbital/valproic B-drug B-drug
acid I-drug I-drug
, O O
quinidine/lidocaine B-drug B-drug
, O O
theophylline/acetaminophen B-drug B-drug
, O O
and O O
valproic B-drug B-drug
acid/phenobarbital I-drug I-drug
. O O

- O O
Increased O O
prothrombin O O
and O O
factors O O
VII O O
, O O
VIII O O
, O O
IX O O
, O O
and O O
X O O
; O O

Enalapril B-drug B-drug
IV O O
has O O
been O O
used O O
concomitantly O O
with O O
digitalis B-group B-group
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
reactions O O
. O O

Administration O O
of O O
CMI B-drug O
has O O
been O O
reported O O
to O O
increase O O
the O O
plasma O O
levels O O
of O O
phenobarbital B-drug B-drug
, O O
if O O
given O O
concomitantly O O
. O O

eosinophilia O O

Presumably O O
, O O
phenytoin B-drug B-drug
acts O O
as O O
a O O
stimulator O O
of O O
coumarin B-group B-group
metabolism O O
and O O
has O O
been O O
reported O O
to O O
cause O O
decreased O O
serum O O
levels O O
of O O
the O O
coumarin B-group B-group
anticoagulants I-group I-group
and O O
increased O O
prothrombin-proconvertin O B-drug
concentrations O O
. O O

Johns O O
Wort O O
) O O
may O O
significantly O O
reduce O O
exposure O O
to O O
Gleevec B-brand B-brand
. O O

( O O
Read O O
circulars O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
concomitant O O
therapy O O
. O O
) O O

The O O
results O O
indicate O O
that O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
readily O O
penetrates O O
both O O
the O O
mucosal O O
and O O
serosal O O
surfaces O O
of O O
the O O
epithelial O O
membrane O O
. O O

Clarithromycin B-drug B-drug

Aspirin/Nonsteroidal B-brand B-group
Antiinflammatory B-group I-group
Drugs O I-group
( O O
NSAIDs B-group B-group
) O O

thyroid B-drug B-group
medication O I-group
; O O

Pharmacokinetic O O
interaction O O
studies O O
with O O
cetirizine B-drug B-drug
in O O
adults O O
were O O
conducted O O
with O O
pseudoephedrine B-drug B-drug
, O O
antipyrine B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
and O O
azithromycin B-drug B-drug
. O O

When O O
given O O
i.p. O O
, O O
dmPGE2 B-drug_n B-drug_n
( O O
0.3 O O
mg/kg O O
) O O
induced O O
a O O
watery O O
stool O O
in O O
cecectomized O O
and O O
control O O
rats O O
with O O
the O O
same O O
efficacy O O
, O O
although O O
these O O
effects O O
were O O
short-lasting O O
as O O
compared O O
to O O
oral O O
administration O O
. O O

Prior O O
administration O O
of O O
4-methylpyrazole B-drug B-drug
( O O
90 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
was O O
shown O O
to O O
prevent O O
the O O
conversion O O
of O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
( O O
100 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
to O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
in O O
vivo O O
and O O
to O O
eliminate O O
the O O
fluoride O B-drug
and O O
citrate O O
elevations O O
seen O O
in O O
1,3-difluoro-2-propanol-intoxicated B-drug_n O
animals O O
. O O

Therefore O O
, O O
use O O
of O O
lamivudine B-drug B-drug
in O O
combination O O
with O O
zalcitabine B-drug B-drug
is O O
not O O
recommended O O

Echistatin B-drug_n B-drug
alone O O
had O O
no O O
effect O O
on O O
tyrosine O O
phosphorylation O O
in O O
T24 O O
cells O O
, O O
but O O
dose-dependently O O
inhibits O O
the O O
effects O O
of O O
contortrostatin B-drug_n B-drug_n
when O O
both O O
are O O
added O O
simultaneously O O
. O O

Patients O O
taking O O
diuretics B-group B-group
are O O
at O O
a O O
greater O O
risk O O
of O O
developing O O
renal O O
failure O O
secondary O O
to O O
a O O
decrease O O
in O O
renal O O
blood O O
flow O O
caused O O
by O O
prostaglandin O O
inhibition O O
. O O

Heparin B-drug B-drug
, O O
other O O
anticoagulants B-group B-group
, O O
thrombolytics B-group B-group
, O O
and O O
anti B-group B-group
platelet I-group I-group
agents I-group I-group
are O O
associated O O
with O O
an O O
increase O O
in O O
bleeding O O
. O O

- O O
Ethotoin B-drug B-drug
( O O
e.g. O O
, O O
Peganone B-brand B-brand
) O O
or O O

Further O O
, O O
they O O
bring O O
into O O
question O O
the O O
utility O O
of O O
using O O
PCP B-drug_n B-drug_n
combination O O
procedures O O
in O O
animals O O
to O O
screen O O
for O O
antipsychotic O O
potential O O
. O O

chloral B-drug B-drug
hydrate* O O
; O O

clofibrate B-drug B-drug
; O O

Caution O O
should O O
be O O
taken O O
in O O
concurrent O O
or O O
serial O O
use O O
of O O
other O O
neurotoxic O O
and/ O O
or O O
nephrotoxic O O
drugs O O
because O O
of O O
possible O O
enhancement O O
of O O
the O O
nephrotoxicity O O
and/or O O
ototoxicity O O
of O O
neomycin B-drug B-drug
. O O

Lithium B-drug B-drug
: O O
Ibuprofen B-drug B-drug
produced O O
an O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
levels O O
and O O
a O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
in O O
a O O
study O O
of O O
eleven O O
normal O O
volunteers O O
. O O

fenoprofen B-drug B-drug
; O O

The O O
genotypes O O
of O O
CYP2C9 B-drug O
and O O
2C19 O O
, O O
the O O
enzymes O O
responsible O O
for O O
phenytoin O B-drug
metabolism O O
, O O
were O O
homozygous O O
for O O
the O O
wild-type O O
alleles O O
( O O
CYP2C9*1/*1 B-drug O
and O O
2C19*1/ O O
*1 O O
) O O
. O O

Gabapentin B-drug B-drug
had O O
no O O
effect O O
on O O
naproxen B-drug B-drug
pharmacokinetic O O
parameters O O
. O O

Coadministration O O
with O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
for O O
7 O O
days O O
) O O
resulted O O
in O O
a O O
significant O O
increase O O
in O O
dextromethorphan B-drug B-drug
plasma O O
levels O O
suggesting O O
that O O
, O O
at O O
these O O
doses O O
, O O
valdecoxib B-drug B-drug
is O O
a O O
weak O O
inhibitor O O
of O O
2D6 O O
. O O

- O O
Lofexidine B-drug B-drug
may O O
enhance O O
the O O
effects O O
of O O
anti-hypertensive B-group B-group
drug I-group I-group
therapy O O

Drug O O
Interactions O O
: O O
The O O
central O O
anticholinergic B-group O
syndrome O O
can O O
occur O O
when O O
anticholinergic O B-group
agents O I-group
such O O
as O O
AKINETON B-brand B-brand
are O O
administered O O
concomitantly O O
with O O
drugs O O
that O O
have O O
secondary O O
anticholinergic O O
actions O O
, O O
e.g. O O
, O O
certain O O
narcotic B-group B-group
analgesics I-group I-group
such O O
as O O
meperidine B-drug B-drug
, O O
the O O
phenothiazines B-group B-group
and O O
other O O
antipsychotics B-group B-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
certain O O
antiarrhythmics B-group B-group
such O O
as O O
the O O
quinidine B-drug B-drug
salts O O
, O O
and O O
antihistamines B-group B-group
. O O

unlike O O
ibogaine B-drug_n B-drug_n
, O O
18-MC B-drug_n B-drug_n
does O O
not O O
affect O O
responding O O
for O O
a O O
nondrug O O
reinforcer O O
( O O
water O O
) O O
. O O

INOmax B-brand O
has O O
been O O
administered O O
with O O
tolazoline B-drug B-drug
, O O
dopamine B-drug B-drug
, O O
dobutamine B-drug B-drug
, O O
steroids B-group B-group
, O O
surfactant B-drug B-group
, O O
and O O
high-frequency O O
ventilation O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
interaction O O
with O O
doxepin B-drug B-drug
has O O
not O O
been O O
systematically O O
evaluated O O
. O O

in O O
vitro O O
, O O
Gleevec B-brand B-brand
inhibits O O
acetaminophen O B-drug
O-glucuronidation O O
( O O
Ki O O
value O O
of O O
58.5 O O
M O O
) O O
at O O
therapeutic O O
levels O O
. O O

There O O
were O O
several O O
factors O O
that O O
could O O
have O O
increased O O
his O O
risk O O
for O O
developing O O
rhabdomyolysis O O
, O O
including O O
chronic O O
renal O O
failure O O
. O O

These O O
small O O
changes O O
are O O
not O O
clinically O O
significant O O
and O O
no O O
dose O O
adjustment O O
is O O
necessary O O
. O O

and O O
diuretics B-group B-group
, O O
such O O
as O O
furosemide B-drug B-drug
. O O

D O I-group
. O O

NovoSeven B-brand B-brand
should O O
not O O
be O O
mixed O O
with O O
infusion O O
solutions O O
until O O
clinical O O
data O O
are O O
available O O
to O O
direct O O
this O O
use O O
. O O

Therefore O O
, O O
the O O
combined O O
use O O
of O O
lovastatin B-drug B-drug
with O O
fibrates B-group B-group
should O O
generally O O
be O O
avoided O O
. O O

Gentamycin B-drug B-drug
reduced O O
twitch O O
strength O O
from O O
40 O O
+/- O O
1 O O
% O O
( O O
mean O O
+/- O O
sem O O
) O O
to O O
29 O O
+/- O O
4 O O
% O O
within O O
7.0 O O
+/- O O
1.5 O O
min O O
( O O
P O O
= O O
0.02 O O
) O O
. O O

Therefore O O
, O O
co-administration O O
of O O
bupropion B-drug B-drug
with O O
drugs O O
that O O
are O O
metabolized O O
by O O
CYP2D6 O O
isoenzyme O O
including O O
certain O O
antidepressants B-group B-group
( O O
e.g. O O
, O O
nortriptyline B-drug B-drug
, O O
imipramine B-drug B-drug
, O O
desipramine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
, O O
antipsychotics B-group B-group
( O O
e.g. O O
, O O
haloperidol B-drug B-drug
, O O
risperidone B-drug B-drug
, O O
thioridazine B-drug B-drug
) O O
, O O
beta-blockers B-group B-group
( O O
e.g. O O
, O O
metoprolol B-drug B-drug
) O O
, O O
and O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
( O O
e.g. O O
, O O
propafenone B-drug B-drug
, O O
flecainide B-drug B-drug
) O O
, O O
should O O
be O O
approached O O
with O O
caution O O
and O O
should O O
be O O
initiated O O
at O O
the O O
lower O O
end O O
of O O
the O O
dose O O
range O O
of O O
the O O
concomitant O O
medication O O
. O O

The O O
plasma O O
and O O
tumour O O
total O O
nitrosourea B-group B-drug
peak O O
concentrations O O
were O O
reduced O O
by O O
1.5 O O
and O O
1.7 O O
fold O O
respectively O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
reduction O O
is O O
not O O
known O O
, O O
hence O O
zalcitabine B-drug B-drug
is O O
not O O
recommended O O
to O O
be O O
ingested O O
simultaneously O O
with O O
magnesium/aluminum-containing B-drug B-group
antacids B-group I-group
. O O

phophatase O O

Therefore O O
, O O
hormonal B-group B-group
contraceptives I-group I-group
, O O
including O O
oral O O
, O O
injectable O O
, O O
transdermal O O
, O O
and O O
implantable O O
forms O O
, O O
may O O
not O O
be O O
reliable O O
when O O
TRACLEER B-brand B-brand
is O O
co-administered O O
. O O

Calcium B-drug B-drug
Supplements O O
: O O
Uncontrolled O O
intake O O
of O O
additional O O
calcium-containing B-drug O
preparations O O
should O O
be O O
avoided O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
( O O
such O O
as O O
Clinistix O O
or O O
Tes-Tape O O
) O O
be O O
used O O
. O O

Corticosteroids B-group B-group
: O O
A O O
relationship O O
of O O
functional O O
antagonism O O
exists O O
between O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
, O O
which O O
promote O O
calcium O O
absorption O O
, O O
and O O
corticosteroids B-group B-group
, O O
which O O
inhibit O O
calcium O O
absorption O O
. O O

Infusion O O
requirements O O
of O O
NIMBEX B-brand B-brand
in O O
patients O O
administered O O
succinylcholine B-drug B-drug
prior O O
to O O
infusions O O
of O O
NIMBEX B-brand B-brand
were O O
comparable O O
to O O
or O O
slightly O O
greater O O
than O O
when O O
succinylcholine B-drug B-drug
was O O
not O O
administered O O
. O O

The O O
potentiation O O
resulted O O
from O O
a O O
CNS O O
pharmacodynamic O O
interaction O O
; O O

Since O O
fondaparinux B-drug B-drug
sodium I-drug I-drug
does O O
not O O
bind O O
significantly O O
to O O
plasma O O
proteins O O
other O O
than O O
ATIII O B-brand
, O O
no O O
drug O O
interactions O O
by O O
protein-binding O O
displacement O O
are O O
expected O O
. O O

Adjustment O O
of O O
dosage O O
of O O
oral O O
anticoagulants B-group B-group
may O O
be O O
required O O
. O O

However O O
, O O
because O O
bleeding O O
has O O
been O O
reported O O
when O O
ibuprofen B-drug B-drug
and O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
have O O
been O O
administered O O
to O O
patients O O
on O O
coumarin-type B-group B-group
anticoagulants I-group I-group
, O O
the O O
physician O O
should O O
be O O
cautious O O
when O O
administering O O
ibuprofen B-drug B-drug
to O O
patients O O
on O O
anticoagulants B-group B-group
. O O

In O O
vitro O O
data O O
suggest O O
that O O
itraconazole B-drug B-drug
also O O
markedly O O
inhibits O O
the O O
biotransformation O O
system O O
mainly O O
responsible O O
for O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
; O O

fecal O O
excretion O O
, O O
too O O
, O O
was O O
increased O O
by O O
supplementary O O
iron B-drug B-drug
; O O

No O O
statistically O O
significant O O
differences O O
between O O
treatment O O
groups O O
were O O
observed O O
for O O
any O O
of O O
the O O
calculated O O
digoxin B-drug B-drug
pharmacokinetic O O
parameters O O
. O O

Medications O O
can O O
cause O O
in O O
vivo O O
effects O O
when O O
the O O
concentration O O
or O O
activity O O
of O O
the O O
analyte O O
is O O
altered O O
before O O
the O O
analysis O O
and O O
therefore O O
the O O
assay O O
result O O
is O O
true O O
and O O
accurate O O
. O O

tadalafil I-drug B-drug
concentration O O

Neomycin B-drug B-drug
has O O
no O O
effect O O
on O O
the O O
blood O O
pressure O O
or O O
metabolic O O
responses O O
to O O
ACTH B-group B-drug
in O O
sheep O O
. O O

The O O
concurrent O O
use O O
of O O
anticholinergics B-group B-group
with O O
hydrocodone B-drug B-drug
may O O
produce O O
paralytic O O
ileus O O
. O O

Modification O O
of O O
surface O O
histidine O O
residues O O
abolishes O O
the O O
cytotoxic O O
activity O O
of O O
Clostridium B-drug_n B-drug_n
difficile I-drug_n I-drug_n
toxin I-drug_n I-drug_n
A I-drug_n I-drug_n
. O O

Induction O O
of O O
apoptosis O O
in O O
breast O O
cancer O O
cells O O
in O O
response O O
to O O
vitamin B-group B-group
D I-group I-group
and O O
antiestrogens B-group B-group
. O O

These O O
six O O
volunteers O O
received O O
terfenadine B-drug B-drug
alone O O
( O O
60 O O
mg O O
twice O O
daily O O
) O O
for O O
8 O O
days O O
, O O
followed O O
by O O
terfenadine B-drug B-drug
in O O
combination O O
with O O
dirithromycin B-drug B-drug
( O O
500 O O
mg O O
once O O
daily O O
) O O
for O O
10 O O
days O O
. O O

However O O
, O O
there O O
are O O
limited O O
in O O
vivo O O
data O O
suggesting O O
a O O
modest O O
CYP2D6 O O
inhibitory O O
effect O O
for O O
escitalopram B-drug B-drug
, O O
i.e. O O
, O O
coadministration O O
of O O
escitalopram B-drug B-drug
( O O
20 O O
mg/day O O
for O O
21 O O
days O O
) O O
with O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
desipramine B-drug B-drug
( O O
single O O
dose O O
of O O
50 O O
mg O O
) O O
, O O
a O O
substrate O O
for O O
CYP2D6 O O
, O O
resulted O O
in O O
a O O
40 O O
% O O
increase O O
in O O
Cmax O O
and O O
a O O
100 O O
% O O
increase O O
in O O
AUC O O
of O O
desipramine B-drug B-drug
. O O

Ketoconazole/Itraconazole B-drug B-drug
, O O
Macrolides B-group B-group
, O O
Including O O
Erythromycin B-drug B-drug

Transient O O
and O O
minor O O
adverse O O
events O O
occurred O O
with O O
similar O O
frequency O O
on O O
placebo O O
and O O
rofecoxib B-drug B-drug
treatments O O
, O O
and O O
no O O
treatment-related O O
pattern O O
was O O
apparent O O
. O O

The O O
following O O
drug O O
interactions O O
were O O
observed O O
in O O
some O O
patients O O
undergoing O O
treatment O O
with O O
oral O O
allopurinol B-drug B-drug
. O O

. O O

INDOCIN B-brand B-brand
and O O
potassium-sparing B-group B-group
diuretics I-group I-group
each O O
may O O
be O O
associated O O
with O O
increased O O
serum O O
potassium O O
levels O O
. O O

Potassium-sparing B-group B-group
diuretics I-group I-group
( O O
spironolactone B-drug B-drug
, O O
amiloride B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
and O O
others O O
) O O
or O O
potassium B-drug B-drug
supplements O O
can O O
increase O O
the O O
risk O O
of O O
hyperkalemia O O
. O O

Therefore O O
, O O
erlotinib B-drug B-drug
exposure O O
may O O
be O O
increased O O
in O O
patients O O
with O O
hepatic O O
dysfunction O O
. O O

alone O O
. O O

Pregnancy O O
Pregnancy O O
Category O O
D O O
: O O
. O O

Nevirapine B-drug B-drug
is O O
known O O
to O O
be O O
an O O
inducer O O
of O O
these O O
enzymes O O
. O O

Therefore O O
, O O
in O O
patients O O
taking O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemics B-group B-group
, O O
regular O O
monitoring O O
of O O
blood O O
glucose O B-drug
is O O
recommended O O
. O O

It O O
is O O
recommended O O
that O O
in O O
patients O O
taking O O
anticoagulants B-group B-group
, O O
prothrombin O O
time O O
be O O
determined O O
before O O
starting O O
lovastatin B-drug B-drug
and O O
frequently O O
enough O O
during O O
early O O
therapy O O
to O O
insure O O
that O O
no O O
significant O O
alteration O O
of O O
prothrombin O O
time O O
occurs O O
. O O

Similarly O O
, O O
there O O
is O O
currently O O
little O O
adequate O O
evidence O O
on O O
either O O
the O O
presence O O
or O O
the O O
absence O O
of O O
serious O O
adverse O O
reactions O O
to O O
such O O
doses O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
, O O
although O O
many O O
such O O
reactions O O
have O O
been O O
hypothesized O O
. O O

These O O
agents O O
include O O
medications O O
such O O
as O O
: O O
anticoagulants B-group B-group
, O O
platelet B-group B-group
inhibitors I-group I-group
including O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
sali-cylates O B-group
, O O
NSAIDs B-group B-group
( O O
including O O
ketorolac B-drug B-drug
tromethamine I-drug I-drug
) O O
, O O
dipyridamole B-drug B-drug
, O O
or O O
sulfinpyrazone B-drug B-drug
. O O

Diminished O O
urinary O O
excretion O O
of O O
norfloxacin B-drug B-drug
has O O
been O O
reported O O
during O O
the O O
concomitant O O
administration O O
of O O
probenecid B-drug B-drug
and O O
norfloxacin B-drug B-drug
. O O

Retention O O
was O O
calculated O O
by O O
the O O
balance O O
technique O O
and O O
by O O
the O O
comparative O O
slaughter O O
technique O O
. O O

St. O O
John O O
s O O
wort O O
( O O
Hypericum O O
perforatum O O
) O O

Either O O
single O O
( O O
170 O O
mg/kg O O
) O O
or O O
repeated O O
( O O
75 O O
mg/kg O O
per O O
day O O
for O O
5 O O
days O O
) O O
oral O O
administration O O
of O O
cypermethrin B-drug B-drug
was O O
found O O
to O O
produce O O
significant O O
oxidative O O
stress O O
in O O
cerebral O O
and O O
hepatic O O
tissues O O
of O O
rats O O
, O O
as O O
was O O
evident O O
by O O
the O O
elevation O O
of O O
the O O
level O O
of O O
thiobarbituric O O
acid O O
reactive O O
substances O O
( O O
TBARS O O
) O O
in O O
both O O
tissues O O
, O O
either O O
4 O O
or O O
24 O O
h O O
after O O
treatment O O
. O O

The O O
use O O
of O O
REGRANEX B-brand B-brand
Gel O O
with O O
other O O
topical O O
drugs O O
has O O
not O O
been O O
studied O O
. O O

Histidine O B-drug
modification O O
had O O
no O O
effect O O
on O O
the O O
glucosyl O O
transferase O O
enzyme O O
activity O O
of O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
. O O

Hypotension O O
, O O
AV O O
conduction O O
disturbances O O
, O O
and O O
left O O
ventricular O O
failure O O
have O O
been O O
reported O O
in O O
some O O
patients O O
receiving O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
when O O
an O O
oral O O
calcium B-group B-group
antagonist I-group I-group
was O O
added O O
to O O
the O O
treatment O O
regimen O O
. O O

When O O
a O O
diuretic B-group B-group
is O O
added O O
to O O
the O O
therapy O O
of O O
a O O
patient O O
receiving O O
PRINIVIL B-brand B-brand
, O O
an O O
additional O O
antihypertensive O O
effect O O
is O O
usually O O
observed O O
. O O

METHODS O O
. O O

These O O
recommendations O O
are O O
based O O
on O O
either O O
drug O O
interaction O O
studies O O
or O O
predicted O O
interactions O O
due O O
to O O
the O O
expected O O
magnitude O O
of O O
interaction O O
and O O
potential O O
for O O
serious O O
events O O
or O O
loss O O
of O O
efficacy O O
. O O

free O O
T4 O O
concentration O O
is O O
unaltered O O
: O O
impaired O O
glucose O O
tolerance O O
; O O

The O O
inhibition O O
of O O
CYP-2C19 O O
by O O
OXC B-drug B-drug
and O O
MHD B-drug_n B-drug_n
, O O
however O O
, O O
is O O
clinically O O
relevant O O
. O O

anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
- O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
diphenidol B-drug B-drug
; O O

Lopinavir/Ritonavir B-drug B-drug

Other O O
factors O O
may O O
increase O O
the O O
risk O O
of O O
this O O
drug O O
interaction O O
, O O
including O O
the O O
administration O O
of O O
other O O
medications O O
that O O
are O O
associated O O
with O O
myopathy O O
, O O
underlying O O
renal O O
insufficiency O O
, O O
and O O
administration O O
of O O
high O O
doses O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
MICRONASE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Other O O
Drug O O
Interactions O O
Oral O O
Contraceptives B-group B-group
Keppra B-brand B-brand
( O O
500 O O
mg O O
twice O O
daily O O
) O O
did O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
an O O
oral O O
contraceptive B-group B-group
containing O O
0.03 O O
mg O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
0.15 O O
mg O O
levonorgestrel B-drug B-drug
, O O
or O O
of O O
the O O
luteinizing O B-drug
hormone O I-drug
and O O
progesterone O B-drug
levels O O
, O O
indicating O O
that O O
impairment O O
of O O
contraceptive O O
efficacy O O
is O O
unlikely O O
. O O

Amitriptyline B-drug B-drug
: O O
Concurrent O O
administration O O
of O O
25 O O
mg O O
or O O
100 O O
mg O O
cinacalcet B-drug B-drug
with O O
50 O O
mg O O
amitriptyline B-drug B-drug
increased O O
amitriptyline B-drug B-drug
exposure O O
and O O
nortriptyline B-drug_n B-drug
( O O
active O O
metabolite O O
) O O
exposure O O
by O O
approximately O O
20 O O
% O O
in O O
CYP2D6 O O
extensive O O
metabolizers O O
. O O

When O O
patients O O
being O O
treated O O
with O O
labetalol B-drug B-drug
have O O
a O O
positive O O
urine O O
test O O
for O O
amphetamine B-drug B-drug
using O O
these O O
techniques O O
confirmation O O
should O O
be O O
made O O
by O O
using O O
more O O
specific O O
methods O O
such O O
as O O
a O O
gas O O
chromatographic-mass O O
spectrometer O O
technique O O
. O O

Cyclosporine B-drug B-drug
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
inhibit O O
the O O
metabolism O O
of O O
cyclosporine B-drug B-drug
, O O
leading O O
to O O
increased O O
plasma O O
concentrations O O
; O O

Since O O
indomethacin B-drug B-drug
and O O
potassium-sparing B-group B-group
diuretics I-group I-group
, O O
including O O
MIDAMOR B-brand B-brand
, O O
may O O
each O O
be O O
associated O O
with O O
increased O O
serum O O
potassium O O
levels O O
, O O
the O O
potential O O
effects O O
on O O
potassium O O
kinetics O O
and O O
renal O O
function O O
should O O
be O O
considered O O
when O O
these O O
agents O O
are O O
administered O O
concurrently O O
. O O

Some O O
preliminary O O
data O O
suggest O O
that O O
calcium B-group B-group
blockers I-group I-group
also O O
increase O O
generation O O
of O O
vasodilator O O
and O O
platelet O O
antiaggregant O O
prostacyclin O B-drug
, O O
which O O
could O O
contribute O O
to O O
decrease O O
in O O
platelet O O
function O O
. O O

Hypotension O O
Patients O O
on O O
Diuretic B-group O
Therapy O O
: O O
Patients O O
on O O
diuretics B-group B-group
and O O
especially O O
those O O
in O O
whom O O
diuretic B-group B-group
therapy O O
was O O
recently O O
instituted O O
, O O
as O O
well O O
as O O
those O O
on O O
severe O O
dietary O O
salt O O
restriction O O
or O O
dialysis O O
, O O
may O O
occasionally O O
experience O O
a O O
precipitous O O
reduction O O
of O O
blood O O
pressure O O
usually O O
within O O
the O O
first O O
hour O O
after O O
receiving O O
the O O
initial O O
dose O O
of O O
captopril B-drug B-drug
. O O

Theophylline B-drug B-drug
: O O
Ethinyl B-drug B-drug
estradiol I-drug I-drug
may O O
inhibit O O
the O O
metabolism O O
of O O
theophylline B-drug B-drug
, O O
leading O O
to O O
increased O O
plasma O O
concentrations O O
. O O

by O O
the O O
nonlinear O O
kinetic O O
characteristics O O
for O O
verapamil B-drug B-drug
and O O
diltiazem B-drug B-drug
( O O
and O O
probably O O
for O O
nifedipine B-drug B-drug
, O O
as O O
well O O
) O O
and O O
the O O
derivative O O
implications O O
for O O
decreased O O
dosing O O
frequency O O
requirements O O
; O O

In O O
eight O O
HIV-infected O O
patients O O
, O O
the O O
steady-state O O
AUC O O
of O O
ciprofloxacin B-drug B-drug
was O O
decreased O O
an O O
average O O
of O O
26 O O
% O O
( O O
95 O O
% O O
CI O O
= O O
14 O O
% O O
, O O
37 O O
% O O
) O O
when O O
ciprofloxacin B-drug B-drug
was O O
administered O O
2 O O
hours O O
prior O O
to O O
a O O
marketed O O
chewable/dispersible O O
tablet O O
formulation O O
of O O
VIDEX B-brand B-brand
. O O

Coadministration O O
of O O
gly-buride O B-drug
and O O
metformin B-drug B-drug
did O O
not O O
result O O
in O O
any O O
changes O O
in O O
either O O
metformin B-drug B-drug
pharmacokinetics O O
or O O
pharmaco-dynamics O O
. O O

Patients O O
who O O
begin O O
taking O O
diclofenac B-drug B-drug
or O O
who O O
increase O O
their O O
diclofenac B-drug B-drug
dose O O
or O O
any O O
other O O
NSAID B-group B-group
while O O
taking O O
digoxin B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
or O O
cyclosporine B-drug B-drug
may O O
develop O O
toxicity O O
characteristics O O
for O O
these O O
drugs O O
. O O

Mercaptopurine/Azathioprine B-drug B-drug
: O O
Allopurinol B-drug B-drug
inhibits O O
the O O
enzymatic O O
oxidation O O
of O O
mercaptopurine B-drug B-drug
and O O
azathioprine B-drug B-drug
to O O
6-thiouric B-drug B-drug_n
acid I-drug I-drug_n
. O O

There O O
was O O
a O O
small O O
increase O O
in O O
plasma O O
concentrations O O
of O O
capecitabine B-drug B-drug
and O O
one O O
metabolite O O
( O O
5-DFCR B-drug_n O
) O O
; O O

Concomitant O O
oral O O
administration O O
of O O
ketoconazole B-drug B-drug
( O O
a O O
known O O
inhibitor O O
of O O
CYP3A4 O O
activity O O
in O O
the O O
liver O O
and O O
in O O
the O O
intestinal O O
mucosa O O
) O O
caused O O
an O O
eight-fold O O
increase O O
of O O
the O O
systemic O O
exposure O O
to O O
oral O O
budesonide B-drug B-drug
. O O

Probenecid B-drug B-drug
or O O
Cimetidine B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
probenecid B-drug B-drug
or O O
cimetidine B-drug B-drug
decreases O O
the O O
elimination O O
of O O
zalcitabine B-drug B-drug
, O O
most O O
likely O O
by O O
inhibition O O
of O O
renal O O
tubular O O
secretion O O
of O O
zalcitabine B-drug B-drug
. O O

There O O
is O O
no O O
information O O
on O O
the O O
effect O O
of O O
other O O
highly O O
plasma O O
protein O O
bound O O
drugs O O
on O O
doxazosin B-drug B-drug
binding O O
. O O

sickle O O
cell O O
disease O O
; O O

Buprenorphine B-drug B-drug
is O O
metabolized O O
to O O
norbuprenorphine B-drug_n B-drug
by O O
cytochrome O O
CYP O O
3A4 O O
. O O

Patients O O
receiving O O
other O O
narcotic B-group B-group
analgesics I-group I-group
, O O
antipsychotics B-group B-group
, O O
antianxiety B-group B-group
agents I-group I-group
, O O
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
including O O
alcohol B-drug B-drug
) O O
concomitantly O O
with O O
hydrocodone B-drug B-drug
and O O
acetaminophen B-drug B-drug
tablets O O
may O O
exhibit O O
an O O
additive O O
CNS O O
depression O O
. O O

Depending O O
on O O
the O O
traction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8 O O
fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA B-group B-group
) O O
. O O

Isoproterenol B-drug B-drug
alone O O
at O O
a O O
dose O O
of O O
2.7 O O
mg/kg/day O O
( O O
approximately O O
7 O O
times O O
the O O
maximum O O
recommended O O
daily O O
inhalation O O
dose O O
in O O
adults O O
on O O
a O O
mg/m2 O O
basis O O
) O O
increased O O
both O O
resorptions O O
and O O
malformations O O
. O O

This O O
could O O
facilitate O O
the O O
action O O
of O O
fatty O O
acids O O
and O O
enable O O
cells O O
to O O
increase O O
their O O
capacity O O
for O O
triacylglycerol O O
synthesis O O
to O O
match O O
an O O
increased O O
availability O O
of O O
fatty O O
acids O O
. O O

Formal O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
ORENCIA B-brand B-brand
. O O

Benzylpenicillin B-drug B-drug
, O O
ampicillin B-drug B-drug
, O O
oxacillin B-drug B-drug
, O O
chlortetracycline B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
cephalothin B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
and O O
sulfamethoxazole B-drug B-drug
have O O
no O O
influence O O
in O O
vitro O O
on O O
the O O
protein O O
binding O O
of O O
diclofenac B-drug B-drug
in O O
human O O
serum O O
. O O

Cyclosporine B-drug B-drug
, O O
hexobarbital B-drug B-drug
and O O
phenytoin B-drug B-drug
concentrations O O
. O O

Anticholinergic B-group B-group
agents I-group I-group
: O O
Although O O
ipratropium B-drug B-drug
bromide I-drug I-drug
is O O
minimally O O
absorbed O O
into O O
the O O
systemic O O
circulation O O
, O O
there O O
is O O
some O O
potential O O
for O O
an O O
additive O O
interaction O O
with O O
concomitantly O O
used O O
anticholinergic B-group B-group
medications I-group I-group
. O O

Preliminary O O
animal O O
and O O
human O O
studies O O
have O O
shown O O
that O O
small O O
quantities O O
of O O
systemically O O
administered O O
leucovorin B-drug B-drug
enter O O
the O O
CSF O O
primarily O O
as O O
5-methyltetrahydro-folate O O
and O O
, O O
in O O
humans O O
, O O
remain O O
1 O O
to O O
3 O O
orders O O
of O O
magnitude O O
lower O O
than O O
the O O
usual O O
methotrexate B-drug B-drug
concentrations O O
following O O
intrathecal O O
administration O O
. O O

THE O O
POTENTIATING O O
ACTION O O
OF O O
HYDROXYZINE B-drug B-drug
MUST O O
BE O O
CONSIDERED O O
WHEN O O
THE O O
DRUG O O
IS O O
USED O O
IN O O
CONJUNCTION O O
WITH O O
CENTRAL B-group B-group
NERVOUS I-group I-group
SYSTEM I-group I-group
DEPRESSANTS I-group I-group
SUCH O O
AS O O
NARCOTICS B-group O
, O O
NON-NARCOTIC B-group B-group
ANALGESICS I-group I-group
AND O O
BARBITURATES B-group B-group
. O O

Cholestyramine B-drug B-drug
increases O O
enterohepatic O O
elimination O O
of O O
amiodarone B-drug B-drug
and O O
may O O
reduce O O
its O O
serum O O
levels O O
and O O
t1/2 B-drug O
. O O

Patients O O
receiving O O
these O O
drugs O O
in O O
combination O O
with O O
zalcitabine B-drug B-drug
should O O
be O O
monitored O O
for O O
signs O O
of O O
toxicity O O
and O O
the O O
dose O O
of O O
zalcitabine B-drug B-drug
reduced O O
if O O
warranted O O
. O O

. O O

Thiazides B-group B-group
: O O
Thiazides B-group B-group
are O O
known O O
to O O
induce O O
hypercalcemia O O
by O O
the O O
reduction O O
of O O
calcium B-drug B-drug
excretion O O
in O O
urine O O
. O O

The O O
drugs O O
may O O
, O O
however O O
, O O
be O O
administered O O
alternately O O
provided O O
a O O
proper O O
interval O O
has O O
elapsed O O
between O O
doses O O
. O O

Data O O
suggest O O
that O O
coadministration O O
of O O
oral O O
ketoconazole B-drug B-drug
and O O
cisapride B-drug B-drug
can O O
result O O
in O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

. O O

The O O
plasma O O
concentration O O
of O O
CMI B-drug O
has O O
been O O
reported O O
to O O
be O O
increased O O
by O O
the O O
concomitant O O
administration O O
of O O
haloperidol B-drug B-drug
; O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
naproxen B-drug B-drug
anion O O
, O O
because O O
of O O
its O O
affinity O O
for O O
protein O O
, O O
may O O
displace O O
from O O
their O O
binding O O
sites O O
other O O
drugs O O
which O O
are O O
also O O
albumin-bound O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
these O O
2 O O
agents O O
are O O
coadministered O O
. O O

In O O
the O O
case O O
of O O
digoxin B-drug B-drug
, O O
serum O O
levels O O
should O O
be O O
monitored O O
. O O

Ranitidine B-drug B-drug
150 O O
mg O O
twice O O
daily O O
did O O
not O O
interact O O
significantly O O
with O O
nisoldipine B-drug B-drug
( O O
AUC O O
was O O
decreased O O
by O O
15-20 O O
% O O
) O O
. O O

Therefore O O
, O O
in O O
patients O O
taking O O
VIOXX B-brand B-brand
, O O
antiplatelet O O
therapies O O
should O O
not O O
be O O
discontinued O O
and O O
should O O
be O O
considered O O
in O O
patients O O
with O O
an O O
indication O O
for O O
cardiovascular O O
prophylaxis O O
. O O

Co-administration O O
of O O
bosentan B-drug B-drug
decreased O O
the O O
plasma O O
concentrations O O
of O O
cyclosporine B-drug B-drug
A I-drug O
( O O
a O O
CYP3A4 O O
substrate O O
) O O
by O O
approximately O O
50 O O
% O O
. O O

Diuretics B-group B-group
: O O
Diclofenac B-drug B-drug
and O O
other O O
NSAIDs B-group B-group
can O O
inhibit O O
the O O
activity O O
of O O
diuretics B-group B-group
. O O

Clinical O O
experience O O
with O O
concomitant O O
administration O O
of O O
bosentan B-drug B-drug
and O O
warfarin B-drug B-drug
in O O
patients O O
with O O
pulmonary O O
arterial O O
hypertension O O
did O O
not O O
show O O
clinically O O
relevant O O
changes O O
in O O
INR O O
or O O
warfarin B-drug B-drug
dose O O
( O O
baseline O O
vs. O O
end O O
of O O
the O O
clinical O O
studies O O
) O O
, O O
and O O
the O O
need O O
to O O
change O O
the O O
warfarin B-drug B-drug
dose O O
during O O
the O O
trials O O
due O O
to O O
changes O O
in O O
INR O O
or O O
due O O
to O O
adverse O O
events O O
was O O
similar O O
among O O
bosentan- B-drug O
and O O
placebo-treated O O
patients O O
. O O

This O O
included O O
post O O
myocardial O O
infarction O O
patients O O
who O O
were O O
receiving O O
intravenous O O
or O O
transdermal O O
nitroglycerin B-drug B-drug
. O O

Potentiation O O
of O O
the O O
hypotensive O O
effects O O
of O O
nitrates B-group B-group
for O O
patients O O
with O O
ischemic O O
heart O O
disease O O
has O O
not O O
been O O
evaluated O O
, O O
and O O
concomitant O O
use O O
of O O
Vardenafil B-drug B-drug
and O O
nitrates B-group B-group
is O O
contraindicated O O
. O O

sulindac B-drug B-drug
; O O

. O O

No O O
differences O O
in O O
safety O O
or O O
efficacy O O
were O O
observed O O
between O O
older O O
and O O
younger O O
patients O O
, O O
but O O
there O O
were O O
not O O
sufficient O O
data O O
to O O
exclude O O
important O O
differences O O
. O O

Increased O O
thyroid-binding O O
globulin O O
( O O
TBG O O
) O O
levels O O
leading O O
to O O
increased O O
circulating O O
total O O
thyroid O O
hormone O O
levels O O
as O O
measured O O
by O O
protein-bound O O
iodine B-drug O
( O O
PBI O O
) O O
, O O
T4 O O
levels O O
( O O
by O O
column O O
or O O
by O O
radioimmunoassay O O
) O O
or O O
T3 O O
levels O O
by O O
radioimmunoassay O O
. O O

Bosentan B-drug B-drug
is O O
also O O
expected O O
to O O
reduce O O
plasma O O
concentrations O O
of O O
other O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
that O O
are O O
predominantly O O
metabolized O O
by O O
CYP2C9 O O
or O O
CYP3A4 O O
. O O

2 O O
. O O

In O O
vitro O O
data O O
suggest O O
that O O
itraconazole B-drug B-drug
, O O
when O O
compared O O
to O O
ketoconazole B-drug B-drug
, O O
has O O
a O O
less O O
pronounced O O
effect O O
on O O
the O O
biotransformation O O
system O O
responsible O O
for O O
the O O
metabolism O O
of O O
astemizole B-drug B-drug
. O O

These O O
data O O
suggest O O
the O O
modified O O
histidine O O
residues O O
on O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
are O O
critical O O
to O O
its O O
cytotoxic O O
activity O O
. O O

Misonidazole B-drug_n B-drug
has O O
a O O
complex O O
effect O O
on O O
oral O O
CCNU B-drug B-drug
pharmacokinetics O O
. O O

Free O O
T4 O O
and O O
free O O
T3 O O
concentrations O O
are O O
unaltered O O
. O O

Alcohol B-drug B-drug
: O O
It O O
should O O
be O O
borne O O
in O O
mind O O
that O O
alcohol B-drug B-drug
ingestion O O
may O O
increase O O
the O O
danger O O
inherent O O
in O O
any O O
intentional O O
or O O
unintentional O O
SINEQUAN B-brand B-brand
overdosage O O
. O O

A O O
similar O O
effect O O
would O O
be O O
expected O O
with O O
eszopiclone B-drug B-drug
. O O

Plasma O O
concentrations O O
decreased O O
by O O
SUSTIVA B-brand B-brand
; O O

The O O
effect O O
may O O
be O O
mediated O O
by O O
the O O
known O O
inhibition O O
of O O
cimetidine B-drug B-drug
on O O
hepatic O O
cytochrome O O
P-450 O O
, O O
the O O
enzyme O O
system O O
probably O O
responsible O O
for O O
the O O
first-pass O O
metabolism O O
of O O
nifedipine B-drug B-drug
. O O

No O O
formal O O
drug-interaction O O
studies O O
have O O
been O O
performed O O
, O O
and O O
a O O
clinically O O
significant O O
interaction O O
with O O
other O O
medications O O
used O O
in O O
the O O
treatment O O
of O O
hypoxic O O
respiratory O O
failure O O
can O O
not O O
be O O
excluded O O
based O O
on O O
the O O
available O O
data O O
. O O

unreliable O O
prothrombin O O
time O O
determinations O O
; O O

Since O O
etodolac B-drug B-drug
has O O
a O O
well-defined O O
pharmacokinetic-pharmacodynamic O O
relationship O O
, O O
measurement O O
of O O
pharmacokinetic O O
parameters O O
is O O
clinically O O
relevant O O
. O O

Core O O
temperature O O
was O O
decreased O O
in O O
rats O O
in O O
a O O
dose-dependent O O
manner O O
when O O
ethanol B-drug B-drug
was O O
administered O O
to O O
rats O O
treated O O
with O O
disulfiram B-drug B-drug
8 O O
hours O O
before O O
the O O
ethanol B-drug B-drug
challenge O O
. O O

Other O O
drug O O
interactions O O

These O O
drugs O O
include O O
the O O
thiazides B-group B-group
and O O
other O O
diuretics B-group B-group
, O O
corticosteroids B-group B-group
, O O
phenothiazines B-group B-group
, O O
thyroid O B-group
products O I-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
, O O
phenytoin B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
, O O
sympathomimetics B-group B-group
, O O
calcium B-group B-group
channel I-group I-group
blocking I-group I-group
drugs I-group I-group
, O O
and O O
isoniazid B-drug B-drug
. O O

When O O
you O O
are O O
using O O
idoxuridine B-drug B-drug
, O O
it O O
is O O
especially O O
important O O
that O O
your O O
health O O
care O O
professional O O
know O O
if O O
you O O
are O O
using O O
the O O
following O O
: O O
Eye O O
product O O
containing O O
boric B-drug B-drug
acid I-drug I-drug
. O O

Rifabutin B-drug B-drug
did O O
not O O
significantly O O
affect O O
amprenavir B-drug B-drug
's O O
pharmacokinetics O O
. O O

an O O
oral O O
200 O O
mg O O
dose O O
achieves O O
a O O
highest O O
level O O
of O O
approximately O O
5 O O
uM O O
in O O
people O O
) O O
; O O

These O O
drugs O O
should O O
not O O
be O O
given O O
concomitantly O O
. O O

The O O
mechanisms O O
of O O
metal O O
toxicity O O
to O O
miracidia O O
are O O
briefly O O
discussed O O
. O O

Dolasetron B-drug B-drug
does O O
not O O
influence O O
anesthesia O O
recovery O O
time O O
in O O
patients O O
. O O

Co-administration O O
of O O
TIKOSYN B-brand B-brand
with O O
verapamil B-drug B-drug
resulted O O
in O O
increases O O
in O O
dofetilide B-drug B-drug
peak O O
plasma O O
levels O O
of O O
42 O O
% O O
, O O
although O O
overall O O
exposure O O
to O O
dofetilide B-drug B-drug
was O O
not O O
significantly O O
increased O O
. O O

Theophylline B-drug B-drug
decreased O O
the O O
binding O O
of O O
acetaminophen B-drug B-drug
by O O
a O O
net O O
change O O
of O O
6.8 O O
% O O
( O O
percentage O O
increase O O
in O O
FDF O O
, O O
8.8 O O
% O O
) O O
at O O
277.5 O O
micromol/L O O
; O O

This O O
small O O
decrease O O
in O O
excretion O O
of O O
gabapentin B-drug B-drug
by O O
cimetidine B-drug B-drug
is O O
not O O
expected O O
to O O
be O O
of O O
clinical O O
importance O O
. O O

The O O
average O O
infusion O O
rate O O
requirement O O
may O O
be O O
decreased O O
by O O
as O O
much O O
as O O
30 O O
% O O
to O O
40 O O
% O O
. O O

This O O
report O O
describes O O
two O O
cases O O
in O O
which O O
theophylline B-drug B-drug
clearance O O
accelerated O O
markedly O O
with O O
concomitant O O
phenytoin B-drug B-drug
administration O O
. O O

Minimum O O
inhibitory O O
concentrations O O
( O O
MICs O O
) O O
and O O
viable O O
counts O O
were O O
determined O O
in O O
Iso-sensitest O O
broth O O
using O O
a O O
microtitre O O
method O O
. O O

Consequently O O
, O O
caution O O
is O O
advised O O
if O O
the O O
concomitant O O
administration O O
of O O
REVIA B-brand B-brand
and O O
other O O
drugs O O
is O O
required O O
. O O

Sinus O O
bradycardia O O
has O O
been O O
reported O O
with O O
oral O O
amiodarone B-drug B-drug
in O O
combination O O
with O O
lidocaine B-drug B-drug
( O O
CYP3A4 B-drug O
substrate O O
) O O
given O O
for O O
local O O
anesthesia B-drug O
. O O

Need O O
for O O
more O O
inhalations O O
than O O
usual O O
of O O
short-acting B-group O
, I-group O
inhaled I-group O
beta2-agonists I-group B-group
. O O

The O O
clinical O O
significance O O
of O O
these O O
changes O O
is O O
unknown O O
. O O

Cimetidine B-drug B-drug
at O O
doses O O
of O O
100 O O
mg O O
BID O O
( O O
OTC O O
dose O O
) O O
resulted O O
in O O
a O O
13 O O
% O O
increase O O
in O O
dofetilide B-drug B-drug
plasma O O
levels O O
( O O
500 O O
mcg O O
single O O
dose O O
) O O
. O O

Blood O O
levels O O
of O O
hydrodolasetron B-drug_n B-drug
increased O O
24 O O
% O O
when O O
dolasetron B-drug B-drug
was O O
coadministered O O
with O O
cimetidine B-drug B-drug
( O O
nonselective O O
inhibitor O O
of O O
cytochrome O O
P-450 O O
) O O
for O O
7 O O
days O O
, O O
and O O
decreased O O
28 O O
% O O
with O O
coadministration O O
of O O
rifampin B-drug B-drug
( O O
potent O O
inducer O O
of O O
cytochrome O O
P-450 O O
) O O
for O O
7 O O
days O O
. O O

Rifabutin B-drug B-drug
, O O
another O O
rifamycin B-drug B-drug
, O O
is O O
structurally O O
similar O O
to O O
rifampin B-drug B-drug
and O O
may O O
possibly O O
have O O
some O O
of O O
the O O
same O O
drug O O
interactions O O
as O O
rifampin B-drug B-drug
. O O

Binding O O
to O O
plasma O O
proteins O O
is O O
reduced O O
by O O
warfarin B-drug B-drug
and O O
clotibrate O B-drug
and O O
increased O O
by O O
tolbutamide B-drug B-drug
. O O

( O O
600 O O
mg O O
Q12h O O
) O O

Cisapride B-drug B-drug
is O O
metabolized O O
mainly O O
via O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
increased O O
bioavailability O O
and O O
whether O O
similar O O
increases O O
will O O
occur O O
in O O
patients O O
given O O
oral O O
H2-antagonists B-group B-group
is O O
unknown O O
; O O

The O O
clinical O O
significance O O
of O O
this O O
interaction O O
is O O
not O O
known O O
; O O

Literature O O
reports O O
indicate O O
that O O
coadministration O O
of O O
indomethacin B-drug B-drug
may O O
reduce O O
the O O
natriuretic O O
and O O
antihypertensive O O
effects O O
of O O
furosemide B-drug B-drug
in O O
some O O
patients O O
by O O
inhibiting O O
prostaglandin O O
synthesis O O
. O O

Drug O O
regimens O O
in O O
patients O O
with O O
cardiovascular O O
disease O O
are O O
frequently O O
complex O O
and O O
can O O
be O O
significantly O O
affected O O
by O O
alterations O O
in O O
renal O O
function O O
. O O

SUBUTEX B-brand B-brand
and O O
SUBOXONE B-brand B-brand
should O O
be O O
prescribed O O
with O O
caution O O
to O O
patients O O
on O O
benzodiazepines B-group B-group
or O O
other O O
drugs O O
that O O
act O O
on O O
the O O
central O O
nervous O O
system O O
, O O
regardless O O
of O O
whether O O
these O O
drugs O O
are O O
taken O O
on O O
the O O
advice O O
of O O
a O O
physician O O
or O O
are O O
taken O O
as O O
drugs O O
of O O
abuse O O
. O O

The O O
effect O O
of O O
digoxin B-drug B-drug
on O O
Exjade B-brand B-brand
pharmacokinetics O O
has O O
not O O
been O O
studied O O
. O O

The O O
antimicrobial O O
combinations O O
of O O
GL B-drug_n B-drug_n
with O O
four O O
antibiotics B-group B-group
resulted O O
in O O
additive O O
effect O O
in O O
most O O
instances O O
, O O
synergism O O
in O O
two O O
instances O O
, O O
and O O
antagonism O O
in O O
two O O
instances O O
. O O

The O O
pharmacokinetics O O
of O O
a O O
1-mg O O
dose O O
of O O
butorphanol B-drug B-drug
administered O O
as O O
STADOL B-brand B-brand
NS I-brand I-brand
were O O
not O O
affected O O
by O O
the O O
coadministration O O
of O O
cimetidine B-drug B-drug
( O O
300 O O
mg O O
QID O O
) O O
. O O

In O O
post-marketing O O
experience O O
, O O
bleeding O O
events O O
have O O
been O O
reported O O
, O O
predominantly O O
in O O
the O O
elderly O O
, O O
in O O
association O O
with O O
increases O O
in O O
prothrombin O O
time O O
in O O
patients O O
receiving O O
VIOXX B-brand B-brand
concurrently O O
with O O
warfarin B-drug B-drug
. O O

Interactions O O
between O O
treatments O O
with O O
coumaphos B-drug_n O
, O O
bishydroxycoumarin B-drug B-drug
( O O
an O O
anticoagulant B-group B-group
) O O
, O O
trichlorfon B-drug_n B-drug
( O O
an O O
organophosphorous B-group O
compound I-group O
) O O
, O O
and O O
phenobarbital B-drug B-drug
sodium I-drug I-drug
( O O
an O O
inducer O O
of O O
microsomal O O
enzymes O O
) O O
were O O
investigated O O
in O O
sheep O O
. O O

Clinical O O
comments O O
about O O
possible O O
dosage O O
modifications O O
based O O
on O O
these O O
pharmacokinetic O O
changes O O
are O O
listed O O
in O O
Table O O
3 O O
. O O

In O O
contrast O O
, O O
in O O
isolated O O
single O O
pancreatic O O
acinar O O
cells O O
, O O
RR B-drug_n B-drug_n
had O O
no O O
effect O O
on O O
InsP B-drug_n B-drug_n
( I-drug_n O
3 I-drug_n O
) I-drug_n O
-induced O O
responses O O
. O O

Other O O
No O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
occurred O O
when O O
Lotensin B-brand B-brand
was O O
administered O O
concomitantly O O
with O O
hydrochlorothiazide B-drug B-drug
, O O
chlorthalidone B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
atenolol B-drug B-drug
, O O
naproxen B-drug B-drug
, O O
or O O
cimetidine B-drug B-drug
. O O

These O O
differences O O
were O O
reflected O O
in O O
the O O
roughly O O
twofold O O
greater O O
antitumour O O
activity O O
for O O
the O O
oral O O
route O O
. O O

ISUPREL B-brand B-brand
should O O
be O O
used O O
with O O
caution O O
, O O
if O O
at O O
all O O
, O O
when O O
potent O O
inhalational O O
anesthetics B-group B-group
such O O
as O O
halothane B-drug B-drug
are O O
employed O O
because O O
of O O
potential O O
to O O
sensitize O O
the O O
myocardium O O
to O O
effects O O
of O O
sympathomimetic B-group B-group
amines I-group I-group
. O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
caucasian O O
population O O
( O O
about O O
7 O O
to O O
10 O O
% O O
of O O
caucasians O O
are O O
so O O
called O O
poor O O
metabolizers O O
) O O
; O O

Conversely O O
, O O
the O O
coumarin B-group B-group
anticoagulants I-group I-group
have O O
been O O
reported O O
to O O
increase O O
the O O
serum O O
levels O O
and O O
prolong O O
the O O
serum O O
half-life O O
of O O
phenytoin B-drug B-drug
by O O
inhibiting O O
its O O
metabolism O O
. O O

Antinociception O O
was O O
measured O O
by O O
the O O
hot-plate O O
method O O
. O O

The O O
possibility O O
of O O
worsened O O
glucose O O
control O O
in O O
patients O O
using O O
these O O
agents O O
should O O
be O O
considered O O
. O O

Catecholamine-depleting B-group O
drugs I-group O
, O O
such O O
as O O
reserpine B-drug B-drug
, O O
may O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
beta-blocking B-group B-group
agents I-group I-group
. O O

Antacids B-group B-group
or O O
H B-group B-group
2 I-group I-group
-receptor I-group I-group
antagonists I-group I-group
: O O
The O O
effect O O
of O O
increased O O
gastric O O
pH O O
on O O
the O O
bioavailability O O
of O O
ceftibuten B-drug B-drug
was O O
evaluated O O
in O O
18 O O
healthy O O
adult O O
volunteers O O
. O O

In O O
vitro O O
and O O
in O O
vivo O O
studies O O
have O O
shown O O
that O O
esomeprazole B-drug B-drug
is O O
not O O
likely O O
to O O
inhibit O O
CYPs O O
1A2 O O
, O O
2A6 O O
, O O
2C9 O O
, O O
2D6 O O
, O O
2E1 O O
and O O
3A4 O O
. O O

The O O
use O O
of O O
antacids B-group B-group
should O O
be O O
considered O O
in O O
place O O
of O O
H2 B-group B-group
blockers I-group I-group
or O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
in O O
patients O O
receiving O O
SPRYCEL B-brand B-brand
therapy O O
. O O

No O O
significant O O
drug O O
interactions O O
have O O
been O O
reported O O
in O O
studies O O
of O O
candesartan B-drug B-drug
cilexetil I-drug I-drug
given O O
with O O
other O O
drugs O O
such O O
as O O
glyburide B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
and O O
oral O O
contraceptives B-group B-group
in O O
healthy O O
volunteers O O
, O O
or O O
given O O
with O O
enalapril B-drug B-drug
to O O
patients O O
with O O
heart O O
failure O O
( O O
NYHA O O
class O O
II O O
and O O
III O O
) O O
. O O

Potential O O
pharmacokinetic O O
interactions O O
were O O
assessed O O
in O O
clinical O O
pharmacokinetic O O
studies O O
( O O
phenytoin B-drug B-drug
, O O
valproate B-drug B-drug
, O O
oral O O
contraceptive B-group B-group
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
probenecid B-drug B-drug
) O O
and O O
through O O
pharmacokinetic O O
screening O O
in O O
the O O
placebo-controlled O O
clinical O O
studies O O
in O O
epilepsy O O
patients O O
. O O

N=13 O O
) O O
. O O

Concomitant O O
use O O
of O O
bupropion B-drug B-drug
with O O
other O O
drugs O O
metabolized O O
by O O
CYP2D6 O O
has O O
not O O
been O O
formally O O
studied O O
. O O

Warfarin B-drug B-drug
: O O
The O O
effects O O
of O O
warfarin B-drug B-drug
and O O
NSAIDs B-group B-group
on O O
GI O O
bleeding O O
are O O
synergistic O O
, O O
such O O
that O O
users O O
of O O
both O O
drugs O O
together O O
have O O
a O O
risk O O
of O O
serious O O
GI O O
bleeding O O
higher O O
than O O
that O O
of O O
users O O
of O O
either O O
drug O O
alone O O
. O O

Systemic O O
exposure O O
to O O
acetaminophen B-drug B-drug
is O O
expected O O
to O O
be O O
increased O O
when O O
coadministered O O
with O O
Gleevec B-brand B-brand
. O O

If O O
such O O
drugs O O
are O O
used O O
they O O
should O O
be O O
administered O O
with O O
an O O
interval O O
of O O
at O O
least O O
5 O O
minutes O O
between O O
applications O O
. O O

Others O O
reported O O
: O O
Neuropsychiatric O O
: O O
Confusion O O
( O O
1-11 O O
% O O
) O O
, O O
headache O O
( O O
4-8 O O
% O O
) O O
, O O
insomnia O O
( O O
2-7 O O
% O O
) O O
; O O

Effects O O
of O O
sympathomimetics B-group B-group
are O O
increased O O
with O O
MAO B-group B-group
inhibitors I-group I-group
and O O
beta B-group B-group
adrenergic I-group I-group
blockers I-group I-group
. O O

Other O O
Cardiovascular O O
Agents O O
: O O
Enalapril B-drug B-drug
and O O
enalapril B-drug B-drug
IV O O
have O O
been O O
used O O
concomitantly O O
with O O
beta B-group B-group
adrenergic-blocking I-group I-group
agents I-group I-group
, O O
methyldopa B-drug B-drug
, O O
nitrates B-group B-group
, O O
calcium-blocking B-group B-group
agents I-group I-group
, O O
hydralazine B-drug B-drug
, O O
prazosin B-drug B-drug
and O O
digoxin B-drug B-drug
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

The O O
co-administration O O
of O O
Natrecor B-brand B-brand
with O O
IV O O
vasodilators B-group B-group
such O O
as O O
nitroglycerin B-drug B-drug
, O O
nitroprusside B-drug B-drug
, O O
milrinone B-drug B-drug
, O O
or O O
IV O O
ACE B-group B-group
inhibitors I-group I-group
has O O
not O O
been O O
evaluated O O
( O O
these O O
drugs O O
were O O
not O O
co-administered O O
with O O
Natrecor B-brand B-brand
in O O
clinical O O
trials O O
) O O
. O O

Ketoconazole B-drug B-drug

The O O
contribution O O
of O O
each O O
of O O
the O O
treatments O O
to O O
this O O
adverse O O
reaction O O
is O O
unknown O O
but O O
the O O
possibility O O
of O O
a O O
drug O O
interaction O O
can O O
not O O
be O O
excluded O O
. O O

v. O O
Patients O O
should O O
be O O
cautioned O O
regarding O O
potential O O
adverse O O
cardiovascular O O
effects O O
, O O
such O O
as O O
palpitations O O
or O O
chest O O
pain O O
. O O

Research O O
has O O
shown O O
that O O
herbal O O
remedy O O
use O O
may O O
be O O
associated O O
with O O
acute O O
renal O O
failure O O
. O O

Because O O
oral O O
anticoagulants B-group B-group
may O O
interfere O O
with O O
the O O
hepatic O O
metabolism O O
of O O
phenytoin B-drug B-drug
, O O
toxic O O
levels O O
of O O
the O O
anticonvulsant B-group B-group
may O O
occur O O
when O O
an O O
oral O O
anticoagulant B-group B-group
and O O
phenytoin B-drug B-drug
are O O
administered O O
concurrently O O
. O O

Irinotecan B-drug B-drug
concentrations O O
were O O
similar O O
in O O
patients O O
receiving O O
bolus-IFL O O
alone O O
and O O
in O O
combination O O
with O O
AVASTIN B-brand B-brand
. O O

Possible O O
drug O O
interactions O O
of O O
HUMORSOL B-brand B-brand
with O O
succinylcholine B-drug B-drug
or O O
with O O
other O O
anticholinesterase B-group B-group
agents I-group I-group
. O O

The O O
interaction O O
of O O
Activase B-brand B-brand
with O O
other O O
cardioactive O O
or O O
cerebroactive O O
drugs O O
has O O
not O O
been O O
studied O O
. O O

Concurrent O O
use O O
of O O
tetracyclines B-group B-group
with O O
oral O O
contraceptives B-group B-group
may O O
render O O
oral O O
contraceptives B-group B-group
less O O
effective O O
. O O

600-1800 O O

Insulin B-drug B-drug
: O O
A O O
clinical O O
study O O
in O O
6 O O
insulin-dependent O O
diabetic O O
patients O O
demonstrated O O
no O O
effect O O
of O O
EXTRANEAL B-brand B-brand
on O O
insulin B-drug B-drug
absorption O O
from O O
the O O
peritoneal O O
cavity O O
or O O
on O O
insulins B-drug B-group
ability O O
to O O
control O O
blood O O
glucose O O
when O O
insulin B-drug B-drug
was O O
administered O O
intraperitoneally O O
with O O
EXTRANEAL B-brand B-brand
. O O

indinavir I-drug B-drug
concentration O O

Imipramine B-drug B-drug
( O O
5 O O
mg/kg O O
) O O
, O O
moclobemide B-drug B-drug
( O O
30 O O
mg/kg O O
) O O
, O O
clonazepam B-drug B-drug
( O O
0.25 O O
mg/kg O O
) O O
, O O
fluoxetine B-drug B-drug
( O O
20 O O
mg/kg O O
) O O
sertraline B-drug B-drug
( O O
30 O O
mg/kg O O
) O O
or O O
vehicle O O
was O O
administered O O
. O O

The O O
LST O O
mice O O
did O O
not O O
show O O
any O O
changes O O
in O O
the O O
Kd O O
and O O
Bmax O O
in O O
either O O
the O O
STR O O
or O O
the O O
NAC O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
MICRONASE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
loss O O
of O O
control O O
. O O

There O O
is O O
evidence O O
that O O
the O O
use O O
of O O
halofantrine B-drug B-drug
after O O
Mefloquineuine O O
causes O O
a O O
significant O O
lengthening O O
of O O
the O O
QTc O O
interval O O
. O O

Systemic O O
clonidine B-drug B-drug
may O O
inhibit O O
the O O
production O O
of O O
catecholamines O O
in O O
response O O
to O O
insulin-induced O B-drug
hypoglycemia O O
and O O
mask O O
the O O
signs O O
and O O
symptoms O O
of O O
hypoglycemia O O
. O O

therefore O O
, O O
plasma O O
concentrations O O
of O O
phenytoin B-drug B-drug
should O O
also O O
be O O
monitored O O
when O O
it O O
is O O
given O O
concurrently O O
with O O
Itraconazole B-drug B-drug
. O O

While O O
18-MC B-drug_n B-drug_n
and O O
ibogaine B-drug_n B-drug_n
have O O
similar O O
affinities O O
for O O
kappa O O
opioid O B-group
and O O
possibly O O
nicotinic O O
receptors O O
, O O
18-MC B-drug_n B-drug_n
has O O
much O O
lower O O
affinities O O
than O O
ibogaine B-drug_n B-drug_n
for O O
NMDA O O
and O O
sigma-2 O O
receptors O O
, O O
sodium O O
channels O O
, O O
and O O
the O O
5-HT O O
transporter O O
. O O

The O O
specific O O
objectives O O
of O O
this O O
study O O
were O O
to O O
elucidate O O
metal O O
toxicity O O
to O O
hatching O O
, O O
survival O O
and O O
avoidance O O
behaviour O O
of O O
Schistosoma O O
mansoni O O
miracidia O O
. O O

Although O O
the O O
relevance O O
of O O
these O O
reports O O
and O O
any O O
mechanism O O
of O O
coagulation O O
alterations O O
is O O
unclear O O
, O O
patients O O
on O O
warfarin B-drug B-drug
should O O
have O O
their O O
prothrombin O O
time O O
monitored O O
. O O

( O O
Thiazide B-group B-group
diuretics I-group I-group
may O O
raise O O
the O O
level O O
of O O
blood O O
uric O O
acid O O
; O O

A O O
conservative O O
approach O O
to O O
dosing O O
felodipine B-drug B-drug
should O O
be O O
taken O O
. O O

the O O
disulfiram B-drug B-drug
should O O
be O O
discontinued O O
if O O
such O O
signs O O
appear O O
. O O

This O O
may O O
increase O O
or O O
enhance O O
the O O
occurrence O O
of O O
osteomalacia O O
in O O
some O O
patients O O
receiving O O
chronic O O
phenytoin B-drug B-drug
therapy O O
. O O

Glucose B-drug B-drug
and O O
insulin B-drug B-drug
exert O O
additive O O
ocular O O
and O O
renal O O
vasodilator O O
effects O O
on O O
healthy O O
humans O O
. O O

The O O
rate O O
of O O
metabolism O O
and O O
the O O
leukopenic O O
activity O O
of O O
cyclophosphamide B-drug B-drug
reportedly O O
are O O
increased O O
by O O
chronic O O
administration O O
of O O
high O O
doses O O
of O O
phenobarbital B-drug B-drug
. O O

Exjade B-brand B-brand
should O O
not O O
be O O
combined O O
with O O
other O O
iron O B-drug
chelator O O
therapies O O
, O O
as O O
safety O O
of O O
such O O
combinations O O
has O O
not O O
been O O
established O O
. O O

the O O
remainder O O
were O O
of O O
uncertain O O
cause O O
. O O

In O O
occasional O O
susceptible O O
patients O O
or O O
in O O
those O O
receiving O O
anticholinergic B-group B-group
drugs I-group I-group
( O O
including O O
antiparkinsonism O B-group
agents O I-group
) O O
in O O
addition O O
, O O
the O O
atropine-like O O
effects O O
may O O
become O O
more O O
pronounced O O
( O O
e.g. O O
, O O
paralytic O O
ileus O O
) O O
. O O

Thioridazine B-drug B-drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
Sonata B-brand B-brand
20 O O
mg O O
and O O
thioridazine B-drug B-drug
50 O O
mg O O
produced O O
additive O O
effects O O
on O O
decreased O O
alertness O O
and O O
impaired O O
psychomotor O O
performance O O
for O O
2 O O
to O O
4 O O
hours O O
after O O
administration O O
. O O

Pharmacology O O
and O O
pharmacotherapy O O
of O O
cardiovascular O O
drugs O O
in O O
patients O O
with O O
chronic O O
renal O O
disease O O
. O O

No O O
drug O O
interactions O O
have O O
been O O
identified O O
. O O

Motility O O
agents O O

No O O
Important O O
Interactions O O
To O O
Date O O
Levosimendan B-drug B-drug
does O O
not O O
have O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
with O O
captopril B-drug B-drug
, O O
beta-blockers B-group B-group
, O O
felodipine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
isosorbide B-drug B-drug
mononitrate I-drug I-drug
, O O
carvedilol B-drug B-drug
, O O
ethanol B-drug B-drug
or O O
itraconazole B-drug B-drug
. O O

Selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
have O O
been O O
reported O O
, O O
rarely O O
, O O
to O O
cause O O
weakness O O
, O O
hyperreflexia O O
, O O
and O O
incoordination O O
when O O
coadministered O O
with O O
5-HTv O B-group
agonists O I-group
. O O

1 O O
hour O O
after O O
starting O O
the O O
oxycodone B-drug B-drug
or O O
levofloxacin B-drug B-drug
500 O O
mg O O
p.o O O
. O O

Vitamin B-group B-drug
A I-group I-drug
and O O
oral O O
retinoids B-group B-group
: O O
Concomitant O O
administration O O
of O O
vitamin B-group B-drug
A I-group O
and/or O O
other O O
oral O O
retinoids B-group B-group
with O O
acitretin B-drug B-drug
must O O
be O O
avoided O O
because O O
of O O
the O O
risk O O
of O O
hypervitaminosis O O
A O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
Amphetamines B-group B-group
can O O
cause O O
a O O
significant O O
elevation O O
in O O
plasma O O
corticosteroid O O
levels O O
. O O

In O O
addition O O
, O O
higher-than O B-drug
expected O O
steady-state O O
serum O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
observed O O
when O O
therapy O O
is O O
initiated O O
in O O
patients O O
already O O
taking O O
cimetidine B-drug B-drug
. O O

However O O
, O O
higher O O
plasma O O
concentrations O O
of O O
AMICAR B-brand B-brand
may O O
occur O O
in O O
patients O O
with O O
severe O O
renal O O
failure O O
. O O

During O O
concomitant O O
therapy O O
with O O
ibuprofen B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
signs O O
of O O
renal O O
failure O O
, O O
as O O
well O O
as O O
to O O
assure O O
diuretic B-group O
efficacy O O
. O O

Antifungal B-group B-group
Agents I-group I-group

Cisapride B-drug B-drug
should O O
not O O
be O O
used O O
concomitantly O O
with O O
other O O
drugs O O
known O O
to O O
prolong O O
the O O
QT O O
interval O O
: O O
certain O O
antiarrhythmics B-group B-group
, O O
including O O
those O O
of O O
Class O O
IA O O
( O O
such O O
as O O
quinidine B-drug B-drug
and O O
procainamide B-drug B-drug
) O O
and O O
Class O B-drug
III O I-drug
( O O
such O O
as O O
sotalol B-drug B-drug
) O O
; O O

therefore O O
, O O
coadministration O O
of O O
Aprepitant B-drug B-drug
with O O
drugs O O
that O O
strongly O O
induce O O
CYP3A4 O O
activity O O
( O O
e.g. O O
, O O
rifampin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
phenytoin B-drug B-drug
) O O
may O O
result O O
in O O
reduced O O
plasma O O
concentrations O O
of O O
aprepitant B-drug B-drug
that O O
may O O
result O O
in O O
decreased O O
efficacy O O
of O O
Aprepitant B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
Anticoagulant O B-group
activity O O
should O O
be O O
monitored O O
, O O
particularly O O
in O O
the O O
first O O
few O O
days O O
after O O
initiating O O
or O O
changing O O
VIOXX B-brand B-brand
therapy O O
in O O
patients O O
receiving O O
warfarin B-drug B-drug
or O O
similar O O
agents O O
, O O
since O O
these O O
patients O O
are O O
at O O
an O O
increased O O
risk O O
of O O
bleeding O O
complications O O
. O O

Although O O
beta-adrenergic B-group B-group
blockers I-group I-group
or O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
and O O
digoxin B-drug B-drug
may O O
be O O
useful O O
in O O
combination O O
to O O
control O O
atrial O O
fibrillation O O
, O O
their O O
additive O O
effects O O
on O O
AV O O
node O O
conduction O O
can O O
result O O
in O O
advanced O O
or O O
complete O O
heart O O
block O O
. O O

subjects O O
. O O

No O O
specific O O
information O O
available O O

It O O
is O O
proposed O O
that O O
the O O
phosphohydrolase O O
becomes O O
metabolically O O
active O O
when O O
it O O
combines O O
with O O
membranes O O
and O O
that O O
polyamines O B-group
might O O
help O O
to O O
regulate O O
this O O
interaction O O
. O O

These O O
results O O
suggest O O
that O O
both O O
dexamethasone B-drug B-drug
and O O
retinyl B-drug B-drug
acetate I-drug I-drug
, O O
and O O
possibly O O
other O O
glucocorticoids B-group B-group
and O O
retinoids B-group B-group
, O O
may O O
regulate O O
the O O
proliferation O O
of O O
prostate O O
epithelium O O
by O O
a O O
dose-dependent O O
modification O O
of O O
the O O
activity O O
of O O
insulin B-drug B-drug
and O O
EGF B-drug_n B-drug_n
. O O

Neurochemical O O
and O O
functional O O
consequences O O
following O O
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine B-drug_n B-drug_n
( O O
MPTP B-drug_n B-drug_n
) O O
and O O
methamphetamine B-drug B-drug
. O O

There O O
are O O
few O O
data O O
regarding O O
the O O
coadministration O O
of O O
radiation O O
therapy O O
and O O
epirubicin B-drug B-drug
. O O

Cimetidine B-drug B-drug
increased O O
the O O
AUC O O
of O O
epirubicin B-drug B-drug
by O O
50 O O
% O O
. O O

TRACRIUM B-brand B-brand
should O O
not O O
be O O
administered O O
until O O
a O O
patient O O
has O O
recovered O O
from O O
succinylcholine-induced B-drug B-drug
neuromuscular O O
block O O
. O O

We O O
conclude O O
that O O
the O O
prophylactic O O
and O O
antidotal O O
properties O O
of O O
4-methylpyrazole B-drug B-drug_n
seen O O
in O O
animals O O
treated O O
with O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
derive O O
from O O
its O O
capacity O O
to O O
inhibit O O
the O O
NAD+-dependent O O
oxidation O O
responsible O O
for O O
converting O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
to O O
1,3-difluoroacetone B-drug_n B-drug_n
in O O
the O O
committed O O
step O O
of O O
the O O
toxic O O
pathway O O
. O O

No O O
drugs O O
are O O
known O O
to O O
interfere O O
with O O
the O O
conversion O O
of O O
fosphenytoin B-drug B-drug
to O O
phenytoin B-drug B-drug
. O O

Patients O O
receiving O O
concomitant O O
lovastatin B-drug B-drug
and O O
erythromycin B-drug B-drug
should O O
be O O
carefully O O
monitored O O
; O O

Combination O O
Therapy O O
: O O
Any O O
form O O
of O O
therapy O O
which O O
adds O O
to O O
the O O
stress O O
of O O
the O O
patient O O
, O O
interferes O O
with O O
nutrition O O
or O O
depresses O O
bone O O
marrow O O
function O O
will O O
increase O O
the O O
toxicity O O
of O O
Floxuridine B-drug B-drug
. O O

The O O
1-year O O
risk O O
of O O
relapse O O
( O O
rehospitalisation O O
) O O
was O O
significantly O O
lower O O
with O O
olanzapine B-drug B-drug
than O O
with O O
haloperidol B-drug B-drug
treatment O O
. O O

Vitamin B-group B-drug
A I-group I-drug
: O O
Because O O
of O O
the O O
relationship O O
of O O
Accutane B-brand B-brand
to O O
vitamin B-group B-drug
A I-group O
, O O
patients O O
should O O
be O O
advised O O
against O O
taking O O
vitamin B-group B-drug
supplements I-group O
containing O O
vitamin B-group B-drug
A I-group O
to O O
avoid O O
additive O O
toxic O O
effects O O

similar O O
events O O
have O O
been O O
reported O O
in O O
patients O O
taking O O
other O O
psychotropic B-group B-group
drugs I-group I-group
or O O
even O O
Clozapine B-drug B-drug
by O O
itself O O
. O O

In O O
EM O O
individuals O O
treated O O
with O O
paroxetine B-drug B-drug
or O O
fluoxetine B-drug B-drug
, O O
the O O
AUC O O
of O O
atomoxetine B-drug B-drug
is O O
approximately O O
6- O O
to O O
8-fold O O
and O O
Css O O
, O O
max O O
is O O
about O O
3- O O
to O O
4-fold O O
greater O O
than O O
atomoxetine B-drug B-drug
alone O O
. O O

The O O
risk O O
of O O
using O O
bromocriptine B-drug B-drug
mesylate I-drug I-drug
in O O
combination O O
with O O
other O O
drugs O O
has O O
not O O
been O O
systematically O O
evaluated O O
, O O
but O O
alcohol B-drug B-drug
may O O
potentiate O O
the O O
side O O
effects O O
of O O
bromocriptine B-drug B-drug
mesylate I-drug I-drug
. O O

Fatalities O O
have O O
been O O
reported O O
. O O

However O O
, O O
retinyl B-drug B-drug
acetate I-drug I-drug
stimulated O O
, O O
but O O
did O O
not O O
significantly O O
inhibit O O
, O O
proliferation O O
in O O
the O O
presence O O
of O O
insulin B-drug B-drug
. O O

In O O
a O O
study O O
in O O
which O O
the O O
2 O O
mg O O
clonazepam B-drug B-drug
orally O O
disintegrating O O
tablet O O
was O O
administered O O
with O O
and O O
without O O
propantheline B-drug B-drug
( O O
an O O
anticholinergic B-group B-group
agent I-group I-group
with O O
multiple O O
effects O O
on O O
the O O
GI O O
tract O O
) O O
to O O
healthy O O
volunteers O O
, O O
the O O
AUC O O
of O O
clonazepam B-drug B-drug
was O O
10 O O
% O O
lower O O
and O O
the O O
Cmax O O
of O O
clonazepam B-drug B-drug
was O O
20 O O
% O O
lower O O
when O O
the O O
orally O O
disintegrating O O
tablet O O
was O O
given O O
with O O
propantheline B-drug B-drug
compared O O
to O O
when O O
it O O
was O O
given O O
alone O O
. O O

Agents O O
Increasing O O
Serum O O
Potassium O O
: O O
Enalapril B-drug B-drug
and O O
enalapril B-drug B-drug
IV O O
attenuate O O
potassium O O
loss O O
caused O O
by O O
thiazide-type B-group B-group
diuretics I-group I-group
. O O

4 O O
. O O

Protease B-group B-group
inhibitors I-group I-group
: O O
Amprenavir B-drug B-drug
, O O
lopinavir B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
and O O
ritonavir B-drug B-drug
have O O
been O O
shown O O
to O O
decrease O O
plasma O O
levels O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
; O O

The O O
effect O O
of O O
a O O
higher O O
ketoconazole B-drug B-drug
dose O O
( O O
400 O O
mg/day O O
) O O
has O O
not O O
been O O
studied O O
. O O

Although O O
clinical O O
studies O O
have O O
not O O
been O O
performed O O
, O O
based O O
on O O
the O O
involvement O O
of O O
the O O
cytochrome O O
P-450 O O
3A O O
family O O
in O O
clonazepam B-drug B-drug
metabolism O O
, O O
inhibitors O O
of O O
this O O
enzyme O O
system O O
, O O
notably O O
oral O O
antifungal B-group B-group
agents I-group I-group
, O O
should O O
be O O
used O O
cautiously O O
in O O
patients O O
receiving O O
clonazepam B-drug B-drug
. O O

Carbamazepine B-drug B-drug
, O O
clonazepam B-drug B-drug
, O O
ethosuximide B-drug B-drug

As O O
a O O
result O O
, O O
when O O
giving O O
these O O
drugs O O
concomitantly O O
, O O
plasma O O
warfarin B-drug B-drug
levels O O
may O O
change O O
with O O
the O O
potential O O
for O O
increases O O
in O O
coagulation O O
time O O
. O O

Ritonavir B-drug B-drug
: O O
Coadministration O O
of O O
ritonavir B-drug B-drug
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
a O O
152 O O
% O O
increase O O
in O O
nelfinavir B-drug B-drug
plasma O O
AUC O O
and O O
very O O
little O O
change O O
in O O
ritonavir B-drug B-drug
plasma O O
A.C O O
. O O

These O O
usually O O
clear O O
within O O
a O O
week O O
, O O
leaving O O
only O O
the O O
" O O
drug O O
hunger O O
" O O

- O O
Although O O
not O O
a O O
true O O
drug O O
interaction O O
, O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
precipitate O O
seizures O O
in O O
susceptible O O
patients O O
and O O
Cerebyx B-brand B-brand
dosage O O
may O O
need O O
to O O
be O O
adjusted O O

Selective B-group B-group
Serotonin I-group I-group
Reuptake I-group I-group
Inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
: O O
SSRIs B-group B-group
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
have O O
been O O
rarely O O
reported O O
to O O
cause O O
weakness O O
, O O
hyperreflexia O O
, O O
and O O
incoordination O O
when O O
coadministered O O
with O O
5-HT1 B-group B-group
agonists I-group I-group
. O O

Lamivudine B-drug B-drug
is O O
predominantly O O
eliminated O O
in O O
the O O
urine O O
by O O
active O O
organic O O
cationic O O
secretion O O
. O O

Because O O
prostaglandins O B-group
play O O
an O O
important O O
role O O
in O O
hemostasis O O
, O O
and O O
NSAIDs B-group B-group
affect O O
platelet O O
function O O
as O O
well O O
, O O
concurrent O O
therapy O O
with O O
all O O
NSAIDs B-group B-group
, O O
including O O
diclofenac B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
requires O O
close O O
monitoring O O
of O O
patients O O
to O O
be O O
certain O O
that O O
no O O
change O O
in O O
their O O
anticoagulant B-group B-group
dosage O O
is O O
required O O
. O O

Cytosine B-drug B-drug
arabinoside I-drug O
, O O
a O O
cytostatic B-group O
agent I-group O
, O O
has O O
been O O
reported O O
to O O
inactivate O O
the O O
antifungal O O
activity O O
of O O
flucytosine B-drug B-drug
by O O
competitive O O
inhibition O O
. O O

Administration O O
of O O
eszopiclone B-drug B-drug
3 O O
mg O O
to O O
a O O
patient O O
taking O O
another O O
drug O O
that O O
is O O
highly O O
protein-bound O O
would O O
not O O
be O O
expected O O
to O O
cause O O
an O O
alteration O O
in O O
the O O
free O O
concentration O O
of O O
either O O
drug O O
. O O

Pyrazolone B-group B-drug
Derivatives I-group I-drug
( O O
phenylbutazone B-drug B-drug
, O O
oxyphenbutazone B-drug B-drug
, O O
and O O
possibly O O
dipyrone B-drug B-drug
) O O
: O O
Concomitant O O
administration O O
with O O
aspirin B-drug B-brand
may O O
increase O O
the O O
risk O O
of O O
gastrointestinal O O
ulceration O O
. O O

18-MC B-drug_n B-drug_n
, O O
a O O
novel O O
iboga O O
alkaloid O O
congener O O
, O O
is O O
being O O
developed O O
as O O
a O O
potential O O
treatment O O
for O O
multiple O O
forms O O
of O O
drug O O
abuse O O
. O O

Drugs O O
With O O
A O O
Narrow O O
Therapeutic O O
Index O O
Digoxin B-drug B-drug
A O O
single O O
dose O O
of O O
eszopiclone B-drug B-drug
3 O O
mg O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
measured O O
at O O
steady O O
state O O
following O O
dosing O O
of O O
0.5 O O
mg O O
twice O O
daily O O
for O O
one O O
day O O
and O O
0.25 O O
mg O O
daily O O
for O O
the O O
next O O
6 O O
days O O
. O O

Mineral B-drug_n B-drug
Oil-Concomitant O O
intake O O
of O O
mineral B-drug_n O
oil I-drug_n O
and O O
vitamin B-group B-group
K I-group I-group
may O O
reduce O O
the O O
absorption O O
of O O
vitamin B-group B-group
K I-group I-group
. O O

Lithium B-drug B-drug
carbonate I-drug I-drug
: O O
The O O
anorectic O O
and O O
stimulatory O O
effects O O
of O O
amphetamines B-group B-group
may O O
be O O
inhibited O O
by O O
lithium B-drug B-drug
carbonate I-drug I-drug
. O O

400-2800 O O

Studies O O
with O O
famotidine B-drug B-drug
in O O
man O O
, O O
in O O
animal O O
models O O
, O O
and O O
in O O
vitro O O
have O O
shown O O
no O O
significant O O
interference O O
with O O
the O O
disposition O O
of O O
compounds O O
metabolized O O
by O O
the O O
hepatic O O
microsomal O O
enzymes O O
, O O
e.g. O O
, O O
cytochrome O O
P450 O O
system O O
. O O

Agents O O
with O O
Increased O O
Levels O O
in O O
the O O
Presence O O
of O O
Carbamazepine B-drug B-drug
: O O
EQUETROTM B-brand B-brand
increases O O
the O O
plasma O O
levels O O
of O O
the O O
following O O
agents O O
: O O
Clomipramine B-drug B-drug
HCl I-drug I-drug
, O O
Phenytoin B-drug B-drug
( O O
6 O O
) O O
, O O
and O O
primidone B-drug B-drug
Thus O O
, O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
on O O
one O O
of O O
the O O
agents O O
in O O
this O O
category O O
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
the O O
treatment O O
with O O
EQUETROTM B-brand B-brand
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
decrease O O
for O O
the O O
concomitant O O
agent O O
may O O
be O O
necessary O O
. O O

These O O
doses O O
were O O
6 O O
to O O
11 O O
times O O
( O O
mouse O O
) O O
and O O
8 O O
to O O
16 O O
times O O
( O O
rat O O
) O O
the O O
human O O
AUC O O
( O O
0-24 O O
) O O
based O O
on O O
the O O
maximum O O
recommended O O
human O O
dose O O
of O O
80 O O
mg/day O O
. O O

In O O
some O O
patients O O
the O O
combined O O
use O O
of O O
indomethacin B-drug B-drug
and O O
diflunisal B-drug B-drug
has O O
been O O
associated O O
with O O
fatal O O
gastrointestinal O O
hemorrhage O O
. O O

FLUOTHANE B-brand B-brand
may O O
augment O O
the O O
hypotension O O
caused O O
by O O
the O O
ganglionic-blocking O O
effect O O
of O O
tubocurarine B-drug B-drug
. O O

Specific O O
studies O O
with O O
ibandronate B-drug B-drug
have O O
not O O
been O O
performed O O
. O O

Acetazolamide B-drug B-drug
may O O
elevate O O
cyclosporine B-drug B-drug
levels O O
. O O

Similarly O O
, O O
of O O
over O O
1600 O O
patients O O
enrolled O O
in O O
a O O
study O O
comparing O O
once-monthly O B-drug
with O O
daily O O
dosing O O
regimens O O
of O O
ibandronate B-drug B-drug
, O O
14 O O
% O O
of O O
patients O O
used O O
anti-peptic O O
agents O O
. O O

In O O
vitro O O
interaction O O
of O O
prostaglandin B-drug B-drug
F2alpha I-drug I-drug
and O O
oxytocin B-drug B-drug
in O O
placental O O
vessels O O
. O O

These O O
effects O O
may O O
be O O
due O O
to O O
a O O
relatively O O
specific O O
blockade O O
of O O
diverse O O
potassium O O
channel O O
types O O
. O O

250-500 O O

Patients O O
taking O O
both O O
flurbiprofen B-drug B-drug
and O O
a O O
beta-blocker B-group B-group
should O O
be O O
monitored O O
to O O
ensure O O
that O O
a O O
satisfactory O O
hypotensive O O
effect O O
is O O
achieved O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
DIABINESE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
loss O O
of O O
control O O
. O O

In O O
patients O O
receiving O O
mercaptopurine B-drug B-drug
( O O
Purinethol B-brand B-drug
) O O
or O O
azathioprine B-drug B-drug
( O O
Imuran B-brand B-brand
) O O
, O O
the O O
concomitant O O
administration O O
of O O
300-600 O O
mg O O
of O O
allopurinol B-drug B-drug
per O O
day O O
will O O
require O O
a O O
reduction O O
in O O
dose O O
to O O
approximately O O
one-third O O
to O O
one-fourth O O
of O O
the O O
usual O O
dose O O
of O O
mercaptopurine B-drug B-drug
or O O
azathioprine B-drug B-drug
. O O

In O O
a O O
study O O
of O O
schizophrenic O O
patients O O
who O O
received O O
clozapine B-drug B-drug
under O O
steady O O
state O O
conditions O O
, O O
fluvoxamine B-drug B-drug
or O O
paroxetine B-drug B-drug
was O O
added O O
in O O
16 O O
and O O
14 O O
patients O O
, O O
respectively O O
. O O

Longitudinal O O
assessment O O
of O O
everolimus B-drug B-drug
in O O
de O O
novo O O
renal O O
transplant O O
recipients O O
over O O
the O O
first O O
post-transplant O O
year O O
: O O
pharmacokinetics O O
, O O
exposure-response O O
relationships O O
, O O
and O O
influence O O
on O O
cyclosporine B-drug B-drug
. O O

Nevertheless O O
, O O
plasma O O
lithium B-drug B-drug
levels O O
should O O
be O O
monitored O O
with O O
appropriate O O
adjustment O O
to O O
the O O
lithium B-drug B-drug
dose O O
in O O
accordance O O
with O O
standard O O
clinical O O
practice O O
. O O

Because O O
the O O
small O O
magnitude O O
and O O
the O O
direction O O
of O O
the O O
effect O O
on O O
theophylline B-drug B-drug
clearance O O
, O O
this O O
interaction O O
is O O
unlikely O O
to O O
be O O
clinical O O
concern O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
MICRONASE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
control O O
. O O

No O O
drug-drug O O
interaction O O
studies O O
in O O
human O O
subjects O O
have O O
been O O
conducted O O
. O O

Depending O O
on O O
the O O
fraction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8-fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA B-group B-group
) O O
. O O

With O O
combined O O
use O O
, O O
clinicians O O
should O O
be O O
aware O O
, O O
when O O
phenytoin B-drug B-drug
is O O
added O O
, O O
of O O
the O O
potential O O
for O O
reexacerbation O O
of O O
pulmonary O O
symptomatology O O
due O O
to O O
lowered O O
serum O O
theophylline B-drug B-drug
concentrations O O
. O O

There O O
is O O
one O O
reported O O
case O O
of O O
a O O
patient O O
with O O
acute O O
delirium O O
associated O O
with O O
the O O
simultaneous O O
use O O
of O O
fluphenazine B-drug B-drug
and O O
oral O O
clonidine B-drug B-drug
. O O

Sublingual O O
nitroglycerin B-drug B-drug
may O O
be O O
taken O O
if O O
necessary O O
for O O
the O O
control O O
of O O
acute O O
angina O O
attacks O O
during O O
Bepridil B-drug B-drug
therapy O O
. O O

Ketoconazole B-drug B-drug
( O O
200 O O
mg O O
q12h O O
) O O
+307 O O
% O O
+73 O O
% O O

Studies O O
with O O
other O O
oral O O
or O O
implant O O
contraceptives B-group B-group
have O O
not O O
been O O
conducted O O
. O O

Effect O O
of O O
coadministered O O
drugs O O
and O O
ethanol B-drug B-drug
on O O
the O O
binding O O
of O O
therapeutic O O
drugs O O
to O O
human O O
serum O O
in O O
vitro O O
. O O

A O O
possible O O
drug O O
interaction O O
of O O
FOSCAVIR B-brand B-brand
and O O
intravenous O O
pentamidine B-drug B-drug
has O O
been O O
described O O
. O O

Caution O O
should O O
also O O
be O O
taken O O
in O O
concurrent O O
or O O
serial O O
use O O
of O O
other O O
aminoglycosides B-group B-group
and O O
polymyxins B-group B-group
because O O
they O O
may O O
enhance O O
neomycin O B-drug
s O O
nephrotoxicity O O
and/or O O
ototoxicity O O
and O O
potentiate O O
neomycin B-drug B-drug
sulfate I-drug I-drug
neuromuscular O O
blocking O O
effects O O
. O O

In O O
nine O O
otherwise O O
healthy O O
subjects O O
with O O
epilepsy O O
ingesting O O
carbamazepine B-drug B-drug
, O O
the O O
steady-state O O
trough O O
( O O
Cmin O O
) O O
carbamazepine B-drug B-drug
concentration O O
was O O
8 O O
2 O O
micrograms/mL O O
. O O

The O O
mean O O
AUC O O
values O O
of O O
EE O O
were O O
decreased O O
by O O
48 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
22-65 O O
] O O
in O O
one O O
study O O
and O O
52 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
38-52 O O
] O O
in O O
another O O
study O O
[ O O
1,2 O O
] O O
. O O

Barbiturates B-group B-group
, O O
phenytoin B-drug B-drug
, O O
or O O
rifampin B-drug B-drug
increased O O
metabolic O O
clearance O O
of O O
fludrocortisone B-drug B-drug
acetate I-drug I-drug
because O O
of O O
the O O
induction O O
of O O
hepatic O O
enzymes O O
. O O

There O O
have O O
been O O
rare O O
reports O O
of O O
reddish O O
stools O O
in O O
patients O O
who O O
have O O
received O O
cefdinir B-drug B-drug
in O O
Japan O O
. O O

Beta-blockers B-group B-group
, O O
clonidine B-drug B-drug
, O O
lithium B-drug B-drug
salts O O
, O O
and O O
alcohol B-drug B-drug
may O O
either O O
potentiate O O
or O O
weaken O O
the O O
blood-glucose-lowering O O
effect O O
of O O
insulin B-drug B-drug
. O O

Aspirin B-brand B-brand
: O O
When O O
Lodine B-brand B-brand
is O O
administered O O
with O O
aspirin B-brand B-brand
, O O
its O O
protein O O
binding O O
is O O
reduced O O
, O O
although O O
the O O
clearance O O
of O O
free O O
etodolac B-drug B-drug
is O O
not O O
altered O O
. O O

The O O
behavioral O O
effects O O
of O O
these O O
two O O
drugs O O
differ O O
, O O
and O O
they O O
do O O
not O O
act O O
on O O
the O O
same O O
target O O
sites O O
in O O
the O O
brain O O
, O O
although O O
they O O
may O O
share O O
, O O
or O O
partly O O
share O O
, O O
certain O O
properties O O
. O O

The O O
extent O O
of O O
plasma O O
protein O O
binding O O
of O O
atovaquone B-drug B-drug
in O O
human O O
plasma O O
is O O
not O O
affected O O
by O O
the O O
presence O O
of O O
therapeutic O O
concentrations O O
of O O
phenytoin B-drug B-drug
( O O
15 O O
mcg/ O O
mL O O
) O O
, O O
nor O O
is O O
the O O
binding O O
of O O
phenytoin B-drug B-drug
affected O O
by O O
the O O
presence O O
of O O
atovaquone B-drug B-drug
. O O

Inhibitors O O
of O O
renal O O
cationic O O
secretion O O
are O O
contraindicated O O
with O O
TIKOSYN B-brand B-brand
. O O

Nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
( O O
NSAIDS B-group B-group
) O O
: O O
Concomitant O O
use O O
of O O
aspirin B-brand B-brand
( O O
or O O
other O O
nonsteroidal B-group B-group
antiinflammatory I-group I-group
agents I-group I-group
) O O
and O O
corticosteroids B-group B-group
increases O O
the O O
risk O O
of O O
gastrointestinal O O
side O O
effects O O
. O O

Consider O O
doubling O O
the O O
rifabutin B-drug B-drug
dose O O
in O O
regimens O O
where O O
rifabutin B-drug B-drug
is O O
given O O
2 O O
or O O
3 O O
times O O
a O O
week O O
. O O

Diflunisal B-drug B-drug
decreased O O
the O O
hyperuricemic O O
effect O O
of O O
hydrochlorothiazide B-drug B-drug
. O O

Patients O O
who O O
are O O
concomitantly O O
receiving O O
VELCADE B-brand B-brand
and O O
drugs O O
that O O
are O O
inhibitors O O
or O O
inducers O O
of O O
cytochrome O O
P450 O O
3A4 O O
should O O
be O O
closely O O
monitored O O
for O O
either O O
toxicities O O
or O O
reduced O O
efficacy O O
. O O

Bosentan B-drug B-drug
is O O
an O O
inducer O O
of O O
CYP3A4 O O
and O O
CYP2C9 O O
. O O

therefore O O
, O O
the O O
efficacy O O
of O O
oral O O
contraceptives B-group B-group
during O O
administration O O
of O O
Aprepitant B-drug B-drug
may O O
be O O
reduced O O
. O O

The O O
effects O O
of O O
concomitant O O
phenytoin B-drug B-drug
administration O O
on O O
the O O
steady-state O O
pharmacokinetics O O
of O O
quetiapine B-drug B-drug
. O O

It O O
is O O
unknown O O
whether O O
the O O
concomitant O O
administration O O
of O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
affects O O
duloxetine B-drug B-drug
absorption O O
. O O

Routine O O
administration O O
of O O
vaccines B-group B-group
or O O
toxoids O B-group
should O O
be O O
deferred O O
until O O
corticosteroid B-group B-group
therapy O O
is O O
discontinued O O
if O O
possible O O
. O O

While O O
it O O
is O O
not O O
known O O
whether O O
this O O
interaction O O
occurs O O
with O O
fibrates B-group B-group
other O O
than O O
gemfibrozil B-drug B-drug
, O O
myopathy O O
and O O
rhabdomyolysis O O
have O O
occasionally O O
been O O
associated O O
with O O
the O O
use O O
of O O
fibrates B-group B-group
alone O O
, O O
including O O
clofibrate B-drug B-drug
. O O

Clarithromycin B-drug B-drug

The O O
minimal O O
inhibitory O O
concentration O O
as O O
well O O
as O O
minimal O O
bactericidal O O
concentration O O
of O O
KRM-1648 B-drug_n B-drug_n
against O O
M O O
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
the O O
binding O O
is O O
not O O
easily O O
removed O O
. O O

There O O
are O O
rare O O
reports O O
, O O
however O O
, O O
from O O
marketing O O
experiences O O
, O O
of O O
changes O O
in O O
effects O O
of O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
in O O
the O O
presence O O
of O O
diclofenac B-drug B-drug
that O O
necessitated O O
changes O O
in O O
the O O
doses O O
of O O
such O O
agents O O
. O O

Consequently O O
, O O
interactions O O
with O O
other O O
drugs O O
which O O
are O O
highly O O
protein O O
bound O O
( O O
e.g. O O
, O O
anticoagulants B-group B-group
) O O
would O O
not O O
be O O
expected O O
. O O

No O O
significant O O
drug-drug O O
pharmacokinetic O O
interactions O O
have O O
been O O
found O O
in O O
interaction O O
studies O O
with O O
hydrochlorothiazide B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
cimetidine B-drug B-drug
and O O
phenobarbital B-drug B-drug
. O O

Calcium B-drug B-drug
Supplements O O
: O O
Uncontrolled O O
intake O O
of O O
additional O O
calcium-containing B-drug O
preparations O O
should O O
be O O
avoided O O
. O O

DOSTINEX B-brand B-brand
should O O
not O O
be O O
administered O O
concurrently O O
with O O
D2-antagonists O B-group
, O O
such O O
as O O
phenothiazines B-group B-group
, O O
butyrophenones B-group B-group
, O O
thioxanthines B-group B-group
, O O
or O O
metoclopramide B-drug B-drug
. O O

Interference O O
with O O
the O O
absorption O O
of O O
oral O O
phosphate B-drug_n B-drug
supplements O O
has O O
been O O
observed O O
with O O
another O O
positively-charged O B-group
bile O I-group
acid O I-group
sequestrant O I-group
. O O

Warfarin B-drug B-drug
: O O
In O O
a O O
short-term O O
controlled O O
study O O
in O O
14 O O
normal O O
volunteers O O
, O O
ketoprofen B-drug B-drug
did O O
not O O
significantly O O
interfere O O
with O O
the O O
effect O O
of O O
warfarin B-drug B-drug
on O O
prothrombin O O
time O O
. O O

Co-administration O O
: O O
Concomitant O O
use O O
of O O
Argatroban B-drug B-drug
with O O
antiplatelet B-group B-group
agents I-group I-group
, O O
thrombolytics B-group B-group
, O O
and O O
other O O
anticoagulants B-group B-group
may O O
increase O O
the O O
risk O O
of O O
bleeding O O
. O O

Corresponding O O
values O O
for O O
free O O
valproate B-drug B-drug
Cmin O O
concentrations O O
were O O
7 O O
3 O O
, O O
9 O O
4 O O
, O O
and O O
11 O O
6 O O
micrograms/mL O O
for O O
0 O O
, O O
1200 O O
, O O
and O O
2400 O O
mg/day O O
Felbatol B-brand B-brand
, O O
respectively O O
. O O

Indinavir B-drug B-drug
is O O
an O O
inhibitor O O
of O O
the O O
cytochrome O O
P450 O O
isoform O O
CYP3A4 O O
. O O

Currently O O
, O O
there O O
are O O
no O O
safety O O
and O O
efficacy O O
data O O
available O O
from O O
the O O
use O O
of O O
this O O
combination O O
. O O

structural O O
heart O O
disease O O
is O O
a O O
known O O
risk O O
factor O O
for O O
arrhythmia O O
. O O

Ergot B-group B-group
alkaloids I-group I-group

Magnesium/Aluminum-containing B-drug B-drug
Antacid B-group B-group
Products I-group O
: O O
Absorption O O
of O O
zalcitabine B-drug B-drug
is O O
moderately O O
reduced O O
( O O
approximately O O
25 O O
% O O
) O O
when O O
coadministered O O
with O O
magnesium/aluminum-containing B-drug B-drug
antacid B-group B-group
products I-group O
. O O

This O O
increase O O
is O O
greatest O O
in O O
the O O
evening O O
. O O

Pressor O O
amines O O
( O O
e.g. O O
, O O
norepinephrine B-drug B-drug
) O O
: O O
possible O O
decreased O O
response O O
to O O
pressor O O
amines O O
but O O
not O O
sufficient O O
to O O
preclude O O
their O O
use O O
. O O

Antihistamines B-group B-group
( O O
e.g. O O
, O O
chlorpheniramine B-group B-drug
) O O
. O O

Ranitidine B-drug B-drug
produced O O
smaller O O
, O O
non-significant O O
increases O O
. O O

Increased O O
plasma O O
concentrations O O
of O O
terfenadine B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
and O O
cisapride B-drug B-drug
cause O O
QT O O
prolongation O O
and O O
have O O
been O O
associated O O
with O O
torsades O O
de O O
pointes-type O O
ventricular O O
tachycardia O O
, O O
sometimes O O
fatal O O
. O O

Aspirin B-brand B-brand
: O O
Animal O O
studies O O
wshow O O
that O O
aspirin B-brand B-brand
given O O
with O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
, O O
including O O
ibuprofen B-drug B-drug
, O O
yields O O
a O O
net O O
decrease O O
in O O
anti-inflammatory O O
activity O O
with O O
lowered O O
blood O O
levels O O
of O O
the O O
non-aspirin O B-group
drug O I-group
. O O

Furthermore O O
, O O
rifampin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
and O O
other O O
inducers O O
of O O
cytochrome O O
P450 O O
3A4 O O
may O O
cause O O
a O O
reduction O O
in O O
plasma O O
bexarotene B-drug B-drug
concentrations O O
. O O

Reduced O O
levels O O
( O O
up O O
to O O
20 O O
% O O
) O O
of O O
total O O
glutathione O B-drug
( O O
total O O
GSH O O
) O O
, O O
and O O
elevation O O
of O O
conjugated O O
dienes O O
( O O
approximately O O
60 O O
% O O
in O O
liver O O
by O O
single O O
dose O O
at O O
4 O O
h O O
) O O
also O O
indicated O O
the O O
presence O O
of O O
an O O
oxidative O O
insult O O
. O O

General O O
In O O
vitro O O
studies O O
in O O
human O O
liver O O
microsomes O O
demonstrated O O
no O O
evidence O O
of O O
cytochrome O O
P450-mediated O O
drug O O
interactions O O
that O O
are O O
likely O O
to O O
be O O
of O O
clinical O O
relevance O O
. O O

Correlative O O
clinical O O
studies O O
have O O
not O O
been O O
performed O O
. O O

This O O
interaction O O
, O O
which O O
has O O
not O O
been O O
investigated O O
using O O
higher O O
doses O O
of O O
fluvoxamine B-drug B-drug
, O O
may O O
be O O
more O O
pronounced O O
if O O
a O O
300 O O
mg O O
daily O O
dose O O
is O O
co-administered O O
, O O
particularly O O
since O O
fluvoxamine B-drug B-drug
exhibits O O
non-linear O O
pharmacokinetics O O
over O O
the O O
dosage O O
range O O
100-300 O O
mg O O
. O O
If O O
alprazolam B-drug B-drug
is O O
co-administered O O
with O O
Fluvoxamine B-drug B-drug
Tablets O O
, O O
the O O
initial O O
alprazolam B-drug B-drug
dosage O O
should O O
be O O
at O O
least O O
halved O O
and O O
titration O O
to O O
the O O
lowest O O
effective O O
dose O O
is O O
recommended O O
. O O

Both O O
of O O
these O O
strategies O O
will O O
become O O
more O O
feasible O O
as O O
specific O O
molecular O O
differences O O
between O O
tumor O O
and O O
normal O O
cells O O
are O O
being O O
rapidly O O
identified O O
and O O
new O O
combination O O
therapies O O
that O O
take O O
advantage O O
of O O
these O O
differences O O
are O O
being O O
designed O O
and O O
tested O O
. O O

Hypothermia O O
as O O
an O O
index O O
of O O
the O O
disulfiram-ethanol B-drug B-drug
reaction O O
in O O
the O O
rat O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
post-marketing O O
observations O O
, O O
have O O
shown O O
that O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

In O O
dogs O O
, O O
cimetidine B-drug B-drug
unchanged O O
the O O
secretion O O
of O O
cardiotrast B-drug O
, O O
a O O
test O O
agent O O
for O O
anionic O O
transport O O
. O O

This O O
effect O O
of O O
aspirin B-brand B-brand
( O O
which O O
also O O
lowers O O
serum O O
concentrations O O
of O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
given O O
with O O
it O O
) O O
has O O
been O O
demonstrated O O
in O O
patients O O
with O O
rheumatoid O O
arthritis O O
( O O
n= O O
15 O O
) O O
as O O
well O O
as O O
normal O O
volunteers O O
( O O
n= O O
16 O O
) O O
. O O

In O O
extremely O O
acidic O O
conditions O O
, O O
Duloxetine B-drug B-drug
, O O
unprotected O O
by O O
the O O
enteric O O
coating O O
, O O
may O O
undergo O O
hydrolysis O O
to O O
form O O
naphthol O B-drug
. O O

Amprenavir B-drug B-drug
inhibits O O
CYP3A4 O O
. O O

Anticoagulants B-group B-group
: O O
There O O
have O O
been O O
reports O O
of O O
increased O O
anticoagulant O O
effects O O
when O O
erythromycin B-drug B-drug
and O O
oral O O
anticoagulants B-group B-group
were O O
used O O
concomitantly O O
. O O

Oral O O
neomycin B-drug B-drug
sulfate I-drug I-drug
may O O
enhance O O
the O O
effect O O
of O O
coumarin B-group B-group
in O O
anticoagulants B-group B-group
by O O
decreasing O O
vitamin O B-group
K O I-group
availability O O
. O O

The O O
physician O O
should O O
be O O
alert O O
for O O
possible O O
combined O O
drug O O
actions O O
, O O
desirable O O
or O O
undesirable O O
, O O
involving O O
cyclophosphamide B-drug B-drug
even O O
though O O
cyclophosphamide B-drug B-drug
has O O
been O O
used O O
successfully O O
concurrently O O
with O O
other O O
drugs O O
, O O
including O O
other O O
cytotoxic O B-group
drugs O I-group
. O O

Among O O
fifteen O O
species O O
of O O
bacteria O O
tested O O
, O O
the O O
antimicrobial O O
activity O O
of O O
GL B-drug_n B-drug_n
was O O
the O O
most O O
potent O O
against O O
Micrococcus O O
luteus O O
( O O
MIC O O
, O O
0.75 O O
mg/ml O O
) O O
. O O

Aprepitant I-drug B-drug
is O O
a O O
substrate O O
for O O
CYP3A4 O O
; O O

This O O
may O O
lead O O
to O O
reduced O O
clearance O O
of O O
caffeine B-drug B-drug
and O O
a O O
prolongation O O
of O O
its O O
plasma O O
half-life O O
. O O

Aripiprazole B-drug B-drug
also O O
does O O
not O O
undergo O O
direct O O
glucuronidation O O
. O O

Alcohol B-drug B-drug
, O O
in O O
particular O O
, O O
has O O
been O O
found O O
to O O
exhibit O O
additive O O
effects O O
of O O
this O O
variety O O
. O O

Vitamin B-drug B-drug
D3 I-drug I-drug
administration O O
to O O
rachitic O O
chicks O O
was O O
effective O O
in O O
significantly O O
elevating O O
duodenal O O
arsenate B-drug_n O
absorption O O
, O O
acting O O
primarily O O
to O O
enhance O O
serosal O O
transport O O
. O O

TBg O O
may O O
also O O
be O O
increased O O
during O O
infectious O O
hepatitis O O
. O O

. O O

The O O
plasma O O
concentrations O O
of O O
bosentan B-drug B-drug
were O O
also O O
decreased O O
by O O
approximately O O
30 O O
% O O
. O O

Drugs O O
that O O
induce O O
hepatic O O
enzymes O O
such O O
as O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
and O O
rifampin B-drug B-drug
may O O
increase O O
the O O
clearance O O
of O O
corticosteroids B-group B-group
and O O
may O O
require O O
increases O O
in O O
corticosteroid B-group B-group
dose O O
to O O
achieve O O
the O O
desired O O
response O O
. O O

Amiodarone B-drug B-drug
: O O
Amiodarone B-drug B-drug
therapy O O
alone O O
can O O
cause O O
hypothyroidism O O
or O O
hyperthyroidism O O
. O O

Higher O O
concentrations O O
of O O
dexamethasone B-drug B-drug
( O O
10 O O
( O O
-8 O O
) O O
- O O
10 O O
( O O
-6 O O
) O O
M O O
) O O
or O O
retinyl B-drug B-drug
acetate I-drug I-drug
( O O
3 O O
X O O
10 O O
( O O
-8 O O
) O O
- O O
10 O O
( O O
-7 O O
) O O
M O O
) O O
enhance O O
the O O
mitogenic O O
activity O O
of O O
EGF B-drug_n B-drug_n
. O O

Certain O O
drugs O O
tend O O
to O O
produce O O
hyperglycemia O O
and O O
may O O
lead O O
to O O
loss O O
of O O
control O O
. O O

Recent O O
studies O O
and O O
consensus O O
reports O O
have O O
expanded O O
our O O
understanding O O
of O O
its O O
efficacy O O
, O O
safety O O
, O O
contraindications O O
, O O
and O O
drug O O
interactions O O
. O O

Drugs O O
That O O
Inhibit O O
CYP3A4 O O
( O O
Ketoconazole B-drug B-drug
) O O
CYP3A4 O O
is O O
a O O
major O O
metabolic O O
pathway O O
for O O
elimination O O
of O O
eszopiclone B-drug B-drug
. O O

A O O
pharmacokinetic O O
study O O
evaluating O O
the O O
administration O O
of O O
a O O
single O O
dose O O
of O O
INSPRA B-brand B-brand
100 O O
mg O O
with O O
ketoconazole B-drug B-drug
200 O O
mg O O
BID O O
, O O
a O O
potent O O
inhibitor O O
of O O
the O O
CYP3A4 O O
pathway O O
, O O
showed O O
a O O
1.7-fold O O
increase O O
in O O
Cmax O O
of O O
eplerenone B-drug B-drug
and O O
a O O
5.4-fold O O
increase O O
in O O
AUC O O
of O O
eplerenone B-drug B-drug
. O O

Caution O O
should O O
be O O
exercised O O
and O O
dose O O
reduction O O
of O O
the O O
concomitant O O
substrate O O
drug O O
should O O
be O O
considered O O
when O O
dosing O O
lapatinib B-drug B-drug
concurrently O O
with O O
medications O O
with O O
narrow O O
therapeutic O O
windows O O
that O O
are O O
substrates O O
of O O
CYP3A4 O O
or O O
CYP2C8 O O
. O O

As O O
with O O
other O O
agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group O
, O O
if O O
COREG B-brand B-brand
is O O
to O O
be O O
administered O O
orally O O
with O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
of O O
the O O
verapamil B-drug B-drug
or O O
diltiazem B-drug B-drug
type O O
, O O
it O O
is O O
recommended O O
that O O
ECG O O
and O O
blood O O
pressure O O
be O O
monitored O O
. O O

No O O
formal O O
assessments O O
of O O
drug-drug O O
interactions O O
between O O
Vidaza B-brand B-brand
and O O
other O O
agents O O
have O O
been O O
conducted O O

Pregnancies O O
have O O
been O O
reported O O
by O O
users O O
of O O
combined B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
who O O
also O O
used O O
some O O
form O O
of O O
St. O O
Johns O O
Wort O O
. O O

Phenobarbital B-drug B-drug

Specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
performed O O
with O O
SUSTIVA B-brand B-brand
and O O
NRTIs B-group B-group
other O O
than O O
lamivudine B-drug B-drug
and O O
zidovudine B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
Norpace B-brand B-brand
and O O
quinidine B-drug B-drug
resulted O O
in O O
slight O O
increases O O
in O O
plasma O O
disopyramide B-drug B-drug
levels O O
and O O
slight O O
decreases O O
in O O
plasma O O
quinidine B-drug B-drug
levels O O
. O O

OBJECTIVE O O
: O O
To O O
report O O
a O O
case O O
of O O
rhabdomyolysis O O
resulting O O
from O O
concomitant O O
use O O
of O O
clarithromycin B-drug B-drug
and O O
simvastatin B-drug B-drug
. O O

Drugs O O
with O O
a O O
Narrow O O
Therapeutic O O
Index O O
Digoxin B-drug B-drug
: O O
Sonata B-brand B-brand
( O O
10 O O
mg O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetic O O
or O O
pharmacodynamic O O
profile O O
of O O
digoxin B-drug B-drug
( O O
0.375 O O
mg O O
q24h O O
for O O
8 O O
days O O
) O O
. O O

Coadministration O O
with O O
compounds O O
that O O
are O O
potent O O
inducers O O
of O O
CYP3A4 O O
( O O
eg O O
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
dexamethasone B-drug B-drug
, O O
carbamazepine B-drug B-drug
) O O
may O O
result O O
in O O
decreased O O
plasma O O
levels O O
of O O
saquinavir B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
Quinolones B-group B-group
, O O
including O O
enoxacin B-drug B-drug
, O O
decrease O O
the O O
clearance O O
of O O
R-warfarin B-drug B-drug
, O O
the O O
less O O
active O O
isomer O O
of O O
racemic O O
warfarin B-drug B-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Phenytoin B-drug B-drug
may O O
decrease O O
serum O O
concentrations O O
of O O
14 O O
. O O

Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
also O O
decrease O O
the O O
plasma O O
concentration O O
of O O
acetaminophen B-drug B-drug
. O O

Digoxin B-drug B-drug
: O O
When O O
multiple O O
doses O O
of O O
atorvastatin B-drug B-drug
and O O
digoxin B-drug B-drug
were O O
coadministered O O
, O O
steady-state O O
plasma O O
digoxin B-drug B-drug
concentrations O O
increased O O
by O O
approximately O O
20 O O
% O O
. O O

Oxcarbazepine B-drug B-drug
was O O
evaluated O O
in O O
human O O
liver O O
microsomes O O
to O O
determine O O
its O O
capacity O O
to O O
inhibit O O
the O O
major O O
cytochrome O O
P450 O O
enzymes O O
responsible O O
for O O
the O O
metabolism O O
of O O
other O O
drugs O O
. O O

In O O
studies O O
with O O
finasteride B-drug B-drug
, O O
no O O
clinically O O
meaningful O O
changes O O
in O O
luteinizing O B-drug
hormone O I-drug
( O O
LH O O
) O O
, O O
follicle-stimulating O B-drug
hormone O I-drug
( O O
FSH O B-drug
) O O
or O O
prolactin O B-drug
were O O
detected O O
. O O

Phenytoin B-drug B-drug

Amiodarone B-drug B-drug
caused O O
a O O
three- O O
to O O
fivefold O O
increase O O
in O O
serum O O
reverse O O
triiodothyronine O O
levels O O
, O O
but O O
changes O O
in O O
thyroid O O
function O O
were O O
not O O
quantitatively O O
related O O
to O O
the O O
changes O O
in O O
digoxin B-drug B-drug
pharmacokinetics O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unknown O O
; O O

Additive O O
CNS O O
depression O O
may O O
occur O O
when O O
antihistamines B-group B-group
are O O
administered O O
concomitantly O O
with O O
other O O
CNS B-group B-group
depressants I-group I-group
including O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
and O O
alcohol B-drug B-drug
. O O

This O O
article O O
looks O O
at O O
five O O
commonly O O
used O O
immunosuppressive B-group B-group
drugs I-group I-group
in O O
turn O O
( O O
corticosteroids B-group B-group
, O O
cyclosporin B-drug B-drug
, O O
azathioprine B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
cyclophosphamide B-drug B-drug
) O O
, O O
discussing O O
the O O
main O O
, O O
non-infection O O
, O O
unwanted O O
effects O O
, O O
ways O O
to O O
avoid O O
them O O
and O O
what O O
to O O
do O O
if O O
problems O O
arise O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
co-administration O O
of O O
TCAs B-group B-group
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

No O O
pharmacokinetic-based O O
drug-drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
SYNAREL B-brand B-brand
. O O

Prescribers O O
are O O
advised O O
to O O
consult O O
the O O
package O O
insert O O
of O O
medication O O
administered O O
concomitantly O O
with O O
hormonal B-group B-group
contraceptives I-group I-group
, O O
since O O
some O O
medications O O
may O O
decrease O O
the O O
effectiveness O O
of O O
these O O
birth O O
control O O
products O O
. O O

Co-administration O O
of O O
anastrozole B-drug B-drug
and O O
tamoxifen B-drug B-drug
resulted O O
in O O
a O O
reduction O O
of O O
anastrozole B-drug B-drug
plasma O O
levels O O
by O O
27 O O
% O O
compared O O
with O O
those O O
achieved O O
with O O
anastrozole B-drug B-drug
alone O O
. O O

The O O
mechanism O O
of O O
this O O
pharmacodynamic O O
interaction O O
is O O
not O O
known O O
. O O

Patients O O
receiving O O
high O O
doses O O
of O O
salicylates B-group B-group
concomitantly O O
with O O
furosemide B-drug B-drug
, O O
as O O
in O O
rheumatic O O
disease O O
, O O
may O O
experience O O
salicylate B-group B-group
toxicity O O
at O O
lower O O
doses O O
because O O
of O O
competitive O O
renal O O
excretory O O
sites O O
. O O

When O O
lansoprazole B-drug B-drug
was O O
administered O O
concomitantly O O
with O O
theophylline B-drug B-drug
( O O
CYP1A2 O O
, O O
CYP3A O O
) O O
, O O
a O O
minor O O
increase O O
( O O
10 O O
% O O
) O O
in O O
the O O
clearance O O
of O O
theophylline B-drug B-drug
was O O
seen O O
. O O

Caution O O
is O O
advised O O
in O O
using O O
Duloxetine B-drug B-drug
in O O
patients O O
with O O
conditions O O
that O O
may O O
slow O O
gastric O O
emptying O O
( O O
e.g. O O
, O O
some O O
diabetics O O
) O O
. O O

Diuretic B-group B-group
agents I-group I-group
reduce O O
the O O
renal O O
clearance O O
of O O
lithium B-drug B-drug
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

MAO B-group B-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
effects O O
of O O
antihistamines B-group B-group
. O O

These O O
cells O O
express O O
the O O
vitamin O B-group
D O I-group
receptor O O
and O O
exhibit O O
doubling O O
times O O
comparable O O
to O O
the O O
parental O O
MCF-7 O O
cells O O
, O O
even O O
when O O
grown O O
in O O
100 O O
mM O O
1,25 B-drug B-drug
( I-drug I-drug
OH I-drug I-drug
) I-drug I-drug
2D3 I-drug I-drug
. O O

Some O O
reports O O
have O O
shown O O
that O O
the O O
concomitant O O
administration O O
of O O
thiazides B-group B-group
with O O
vitamin B-group B-group
D I-group I-group
causes O O
hypercalcemia O O
. O O

The O O
concomitant O O
administration O O
of O O
uricosuric B-group B-group
agents I-group I-group
and O O
allopurinol B-drug B-drug
has O O
been O O
associated O O
with O O
a O O
decrease O O
in O O
the O O
excretion O O
of O O
oxypurines O B-drug
( O O
hypoxanthine O B-drug
and O O
xanthine O B-drug
) O O
and O O
an O O
increase O O
in O O
urinary O O
uric O O
acid O O
excretion O O
compared O O
with O O
that O O
observed O O
with O O
allopurinol B-drug B-drug
alone O O
. O O

TAMBOCOR B-brand B-brand
has O O
been O O
used O O
in O O
a O O
large O O
number O O
of O O
patients O O
receiving O O
diuretics B-group B-group
without O O
apparent O O
interaction O O
. O O

Drugs O O
That O O
Inhibit O O
Aldehyde O O
Oxidase O O
The O O
aldehyde O O
oxidase O O
enzyme O O
system O O
is O O
less O O
well O O
studied O O
than O O
the O O
cytochrome O O
P450 O O
enzyme O O
system O O
. O O

A O O
study O O
in O O
eight O O
healthy O O
volunteers O O
has O O
shown O O
a O O
50 O O
% O O
increase O O
in O O
mean O O
peak O O
nimodipine B-drug B-drug
plasma O O
concentrations O O
and O O
a O O
90 O O
% O O
increase O O
in O O
mean O O
area O O
under O O
the O O
curve O O
, O O
after O O
a O O
one O O
week O O
course O O
of O O
cimetidine B-drug B-drug
at O O
1,000 O O
mg/day O O
and O O
nimodipine B-drug B-drug
at O O
90 O O
mg/day O O
. O O

We O O
have O O
selected O O
a O O
subclone O O
of O O
MCF-7 O O
cells O O
resistant O O
to O O
1,25 B-drug B-drug
( I-drug I-drug
OH I-drug I-drug
) I-drug I-drug
2D3 I-drug I-drug
( O O
MCF-7D3Res O O
) O O
. O O

Antagonism O O
between O O
lincomycin B-drug B-drug
and O O
erythromycin B-drug B-drug
in O O
vitro O O
has O O
been O O
demonstrated O O
. O O

The O O
data O O
suggest O O
that O O
the O O
histidine O O
residues O O
may O O
be O O
crucial O O
to O O
the O O
receptor-binding O O
activity O O
of O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
. O O

The O O
following O O
precautions O O
should O O
be O O
kept O O
in O O
mind O O
in O O
the O O
treatment O O
of O O
anticholinesterase O O
poisoning O O
although O O
they O O
do O O
not O O
bear O O
directly O O
on O O
the O O
use O O
of O O
atropine B-drug B-drug
and O O
pralidoxime B-drug B-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
None O O
known O O
. O O

Other O O
Chemotherapy O O
Agents O O
In O O
a O O
separate O O
study O O
, O O
concomitant O O
administration O O
of O O
lapatinib B-drug B-drug
with O O
capecitabine B-drug B-drug
did O O
not O O
meaningfully O O
alter O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
( O O
or O O
the O O
metabolites O O
of O O
capecitabine B-drug B-drug
) O O
. O O

Labetalol B-drug B-drug
HCl I-drug I-drug
blunts O O
the O O
reflex O O
tachycardia O O
produced O O
by O O
nitroglycerin B-drug B-drug
without O O
preventing O O
its O O
hypotensive O O
effect O O
. O O

It O O
is O O
advisable O O
to O O
check O O
coagulation O O
time O O
within O O
the O O
first O O
few O O
days O O
after O O
the O O
start O O
and O O
discontinuation O O
of O O
cisapride B-drug B-drug
therapy O O
, O O
with O O
an O O
appropriate O O
adjustment O O
of O O
the O O
anticoagulant B-group B-group
dose O O
, O O
if O O
necessary O O
. O O

This O O
is O O
especially O O
important O O
in O O
patients O O
who O O
may O O
use O O
alcohol B-drug B-drug
excessively O O
. O O

It O O
is O O
likely O O
that O O
use O O
of O O
epirubicin B-drug B-drug
with O O
radiotherapy O O
may O O
sensitize O O
tissues O O
to O O
the O O
cytotoxic O O
actions O O
of O O
irradiation O O
. O O

Carbamazepine B-drug B-drug
overdose O O
recognized O O
by O O
a O O
tricyclic B-group B-group
antidepressant I-group I-group
assay O O
. O O

The O O
concomitant O O
use O O
of O O
vasopressors B-group B-group
, O O
vasoconstricting O B-group
agents O I-group
( O O
such O O
as O O
ergonovine B-drug B-drug
) O O
and O O
some O O
oxytocic B-group B-group
drugs I-group I-group
may O O
result O O
in O O
severe O O
hypertension O O
. O O

Concurrent O O
use O O
with O O
general O O
anesthetics B-group B-group
may O O
result O O
in O O
arrhythmias O O
. O O

Thrombolytic B-group B-group
agents I-group I-group
: O O
The O O
safety O O
and O O
effectiveness O O
of O O
Argatroban B-drug B-drug
with O O
thrombolytic B-group B-group
agents I-group I-group
have O O
not O O
been O O
established O O
. O O

Non-steroidal B-group B-group
Anti-inflammatory I-group I-group
Agents I-group I-group
: O O
In O O
some O O
patients O O
with O O
compromised O O
renal O O
function O O
who O O
are O O
being O O
treated O O
with O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
the O O
co-administration O O
of O O
enalapril B-drug B-drug
may O O
result O O
in O O
a O O
further O O
deterioration O O
of O O
renal O O
function O O
. O O

This O O
indicates O O
that O O
tiagabine B-drug B-drug
does O O
not O O
cause O O
induction O O
or O O
inhibition O O
of O O
the O O
hepatic O O
microsomal O O
enzyme O O
systems O O
responsible O O
for O O
the O O
metabolism O O
of O O
antipyrine B-drug B-drug
. O O

indinavir I-drug B-drug
concentration O O

Cimetidine B-drug B-drug
: O O
Co-administration O O
with O O
high O O
doses O O
of O O
cimetidine B-drug B-drug
[ O O
800 O O
mg O O
twice O O
daily O O
] O O
increased O O
the O O
Cmax O O
of O O
rofecoxib B-drug B-drug
by O O
21 O O
% O O
, O O
the O O
AUC0-120hr O O
by O O
23 O O
% O O
and O O
the O O
t1/2 O O
by O O
15 O O
% O O
. O O

Other O O
drug O O
interactions O O
Cimetidine B-drug B-drug
, O O
erythromycin B-drug B-drug
and O O
dextropropoxyphene B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
MHD B-drug_n B-drug_n
. O O

Standard O O
monitoring O O
of O O
methotrexate-related B-drug B-drug
toxicity O O
should O O
be O O
continued O O
if O O
VIOXX B-brand B-brand
and O O
methotrexate B-drug B-drug
are O O
administered O O
concomitantly O O
. O O

Risk O O
of O O
Anaphylactic O O
Reaction O O
While O O
taking O O
beta-blockers B-group B-group
, O O
patients O O
with O O
a O O
history O O
of O O
severe O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
be O O
more O O
reactive O O
to O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
, O O
or O O
therapeutic O O
. O O

In O O
healthy O O
volunteers O O
, O O
treatment O O
with O O
finasteride B-drug B-drug
did O O
not O O
alter O O
the O O
response O O
of O O
LH O B-drug
and O O
FSH O O
to O O
gonadotropin-releasing O O
hormone O O
indicating O O
that O O
the O O
hypothalamic-pituitary-testicular O O
axis O O
was O O
not O O
affected O O
. O O

Rifabutin I-drug B-drug

The O O
prior O O
administration O O
of O O
succinylcholine B-drug B-drug
does O O
not O O
enhance O O
the O O
duration O O
, O O
but O O
quickens O O
the O O
onset O O
and O O
may O O
increase O O
the O O
depth O O
, O O
of O O
neuromuscular O O
block O O
induced O O
by O O
TRACRIUM B-brand B-brand
. O O

ranitidine* B-drug B-drug
; O O

The O O
appropriate O O
interval O O
between O O
administration O O
of O O
these O O
agents O O
and O O
dexfenfluramine B-drug B-drug
has O O
not O O
been O O
established O O
. O O

The O O
half-life O O
increased O O
from O O
4.0 O O
to O O
4.8 O O
hours O O
. O O

There O O
is O O
no O O
pharmacokinetic O O
interaction O O
between O O
zaleplon B-drug B-drug
and O O
diphenhydramine B-drug B-drug
following O O
the O O
administration O O
of O O
a O O
single O O
dose O O
( O O
10 O O
mg O O
and O O
50 O O
mg O O
, O O
respectively O O
) O O
of O O
each O O
drug O O
. O O

saquinavir I-drug B-drug
concentration O O

The O O
adverse O O
experience O O
profile O O
seen O O
with O O
KEMSTROTM B-brand B-brand
was O O
similar O O
to O O
that O O
seen O O
with O O
baclofen B-drug B-drug
tablets O O
. O O

Agents O O
that O O
are O O
CYP3A4 O O
inhibitors O O
that O O
have O O
been O O
found O O
, O O
or O O
are O O
expected O O
, O O
to O O
increase O O
plasma O O
levels O O
of O O
EQUETROTM B-brand B-brand
are O O
the O O
following O O
: O O
Acetazolamide B-drug B-drug
, O O
azole B-group B-group
antifungals I-group I-group
, O O
cimetidine B-drug B-drug
, O O
clarithromycin B-drug B-drug
( O O
1 O O
) O O
, O O
dalfopristin B-drug B-drug
, O O
danazol B-drug B-drug
, O O
delavirdine B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
erythromycin B-drug B-drug
( O O
1 O O
) O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
grapefruit O O
juice O O
, O O
isoniazid B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
loratadine B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
niacinamide B-drug B-drug
, O O
nicotinamide B-drug B-drug
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
propoxyphene B-drug B-drug
, O O
quinine B-drug B-drug
, O O
quinupristin B-drug B-drug
, O O
troleandomycin B-drug B-drug
, O O
valproate B-drug B-drug
( O O
1 O O
) O O
, O O
verapamil B-drug B-drug
, O O
zileuton B-drug B-drug
. O O

In O O
three O O
separate O O
controlled O O
, O O
parallel O O
group O O
clinical O O
pharmacology O O
studies O O
, O O
desloratadine B-drug B-drug
at O O
the O O
clinical O O
dose O O
of O O
5 O O
mg O O
has O O
been O O
coadministered O O
with O O
azithromycin B-drug B-drug
500 O O
mg O O
followed O O
by O O
250 O O
mg O O
once O O
daily O O
for O O
4 O O
days O O
( O O
n=18 O O
) O O
or O O
with O O
fluoxetine B-drug B-drug
20 O O
mg O O
once O O
daily O O
for O O
7 O O
days O O
after O O
a O O
23 O O
day O O
pretreatment O O
period O O
with O O
fluoxetine B-drug B-drug
( O O
n=18 O O
) O O
or O O
with O O
cimetidine B-drug B-drug
600 O O
mg O O
every O O
12 O O
hours O O
for O O
14 O O
days O O
( O O
n=18 O O
) O O
under O O
steady O O
state O O
conditions O O
to O O
normal O O
healthy O O
male O O
and O O
female O O
volunteers O O
. O O

Concomitant O O
use O O
of O O
digoxin B-drug B-drug
and O O
sympathomimetics B-group B-group
increases O O
the O O
risk O O
of O O
cardiac O O
arrhythmias O O
. O O

Olanzapine B-drug B-drug
is O O
associated O O
with O O
significantly O O
fewer O O
extrapyramidal O O
symptoms O O
than O O
haloperidol B-drug B-drug
and O O
risperidone B-drug B-drug
. O O

lithium B-drug B-drug
; O O

Drugs O O
which O O
impair O O
glomerular O O
filtration O O
may O O
prolong O O
the O O
biological O O
half-life O O
of O O
flucytosine B-drug B-drug
. O O

Meperidine B-drug B-drug
: O O
Amphetamines B-group B-group
potentiate O O
the O O
analgesic O O
effect O O
of O O
meperidine B-drug B-drug
. O O

- O O
Dantrolene B-drug B-drug
( O O
e.g. O O
, O O
Dantrium B-brand B-brand
) O O
or O O

Drug-Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
reported O O
drug-laboratory O O
test O O
interactions O O
. O O

Lodine B-brand B-brand
treatment O O
is O O
associated O O
with O O
a O O
small O O
decrease O O
in O O
serum O O
uric O O
acid O O
levels O O
. O O

Immediate O O
and O O
Extended O O
Release O O
Tablets O O
The O O
hypoglycemic O O
action O O
of O O
sulfonylureas B-group B-group
may O O
be O O
potentiated O O
by O O
certain O O
drugs O O
including O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
, O O
some O O
azoles B-group O
and O O
other O O
drugs O O
that O O
are O O
highly O O
protein O O
bound O O
, O O
salicylates B-group B-group
, O O
sulfonamides B-group B-group
, O O
chloramphenicol B-drug B-drug
, O O
probenecid B-drug B-drug
, O O
coumarins B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
and O O
beta B-group B-group
adrenergic I-group I-group
blocking I-group I-group
agents I-group I-group
. O O

CYP3A4 O O
inducers O O
: O O
CYP3A4 O O
inducers O O
may O O
decrease O O
the O O
levels/effects O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
. O O

Aprepitant I-drug B-drug
, O O
when O O
given O O
as O O
a O O
regimen O O
of O O
125 O O
mg O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
and O O
3 O O
, O O
increased O O
the O O
AUC O O
of O O
methylprednisolone B-drug B-drug
, O O
a O O
CYP3A4 O O
substrate O O
, O O
by O O
1.34-fold O O
on O O
Day O O
1 O O
and O O
by O O
2.5-fold O O
on O O
Day O O
3 O O
, O O
when O O
methylprednisolone B-drug B-drug
was O O
coadministered O O
intravenously O O
as O O
125 O O
mg O O
on O O
Day O O
1 O O
and O O
orally O O
as O O
40 O O
mg O O
on O O
Days O O
2 O O
and O O
3 O O
. O O

Catecholamine-depleting O O
drugs O O
( O O
e.g. O O
, O O
reserpine B-drug B-drug
) O O
: O O
additive O O
effect O O
; O O

Doxazosin B-drug B-drug
mesylate I-drug I-drug
tablets O O
have O O
been O O
used O O
with O O
the O O
following O O
drugs O O
or O O
drug O O
classes O O
: O O
1 O O
. O O

Because O O
there O O
is O O
a O O
theoretical O O
basis O O
that O O
these O O
effects O O
may O O
be O O
additive O O
, O O
use O O
of O O
ergotamine-containing B-drug B-drug
or O O
ergot-type B-group B-group
medications I-group I-group
( O O
like O O
dihydroergotamine B-drug B-drug
or O O
methysergide B-drug B-drug
) O O
and O O
AXERT B-brand B-brand
within O O
24 O O
hours O O
of O O
each O O
other O O
should O O
be O O
avoided O O
. O O

Miracidia O O
demonstrated O O
a O O
rapid O O
avoidance O O
behaviour O O
when O O
briefly O O
exposed O O
to O O
heavy O O
metals O O
. O O

Carbamazepine B-drug B-drug
: O O
In O O
healthy O O
subjects O O
receiving O O
the O O
CYP3A4 O O
inducer O O
, O O
carbamazepine B-drug B-drug
, O O
at O O
100 O O
mg O O
twice O O
daily O O
for O O
3 O O
days O O
and O O
200 O O
mg O O
twice O O
daily O O
for O O
17 O O
days O O
, O O
systemic O O
exposure O O
( O O
AUC O O
) O O
to O O
lapatinib B-drug B-drug
was O O
decreased O O
approximately O O
72 O O
% O O
. O O

The O O
aim O O
of O O
this O O
paper O O
was O O
to O O
study O O
the O O
interaction O O
between O O
neurotensin B-drug_n B-drug
and O O
both O O
enkephalins B-drug_n B-group
or O O
its O O
synthetic O O
analogue O O
D-Ala2-metenkephalinamide B-drug_n B-drug
, O O
or O O
tuftsin B-drug_n B-drug_n
, O O
on O O
the O O
antinonciceptive O O
effect O O
of O O
these O O
peptides O O
in O O
mice O O
after O O
intracisternal O O
injection O O
. O O

Coadministration O O
of O O
this O O
oral O O
contraceptive B-group B-group
did O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
. O O

The O O
magnitude O O
of O O
interaction O O
within O O
the O O
recommended O O
dose O O
ranges O O
of O O
either O O
drug O O
is O O
not O O
known O O
. O O

Treatment O O
of O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
with O O
[ O O
( O O
14 O O
) O O
C O O
] O O
-diethyl B-drug_n O
pyrocarbonate I-drug_n O
revealed O O
concentration O O
dependent O O
labelling O O
of O O
histidine O O
residues O O
on O O
the O O
toxin O O
molecules O O
. O O

Cross-reactions O O
with O O
non-Aspergillus O O
polysaccharides O B-group
and O O
polyfuranoses O B-group
with O O
the O O
Bio-Rad O O
Laboratories O O
Platelia O O
Aspergillus O O
EIA O O
test O O
have O O
been O O
reported O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
A O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
with O O
copper O O
reduction O O
tests O O
( O O
Benedict O O
s O O
or O O
Fehling O O
s O O
solution O O
or O O
with O O
Clinitest O O
tablets O O
) O O
but O O
not O O
with O O
enzyme-based O O
tests O O
for O O
glycosuria O O
. O O

Grapefruit O O
juice O O
should O O
not O O
be O O
taken O O
during O O
treatment O O
with O O
oral O O
amiodarone O B-drug
. O O

monitor O O
cyclosporine B-drug B-drug
levels O O
. O O

Table O O
3 O O
Established O O
Drug O O
Interactions O O
: O O
Alteration O O
in O O
Dose O O
or O O
Regimen O O
May O O
Be O O
Recommended O O
Based O O
on O O
Drug O O
Interaction O O
Studies O O

Anagrelide B-drug B-drug
is O O
an O O
inhibitor O O
of O O
cyclic O O
AMP O O
PDE O O
III O O
. O O

Cyclosporine B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
nicardipine B-drug B-drug
and O O
cyclosporine B-drug B-drug
levels O O
. O O

This O O
interaction O O
may O O
result O O
in O O
myopathy O O
and O O
rhabdomyolysis O O
, O O
particularly O O
in O O
patients O O
with O O
renal O O
insufficiency O O
or O O
those O O
who O O
are O O
concurrently O O
taking O O
medications O O
associated O O
with O O
myopathy O O
. O O

FLUOTHANE B-brand B-brand
augments O O
the O O
action O O
of O O
non-depolarising B-group B-group
muscle I-group I-group
relaxants O I-group
and O O
the O O
muscle O O
relaxant O O
effects O O
of O O
aminoglycosides B-group B-group
. O O

Twelve O O
strains O O
of O O
Staphylococcus O O
aureus O O
( O O
a O O
frequent O O
cause O O
of O O
infection O O
in O O
heroin B-drug_n B-drug_n
, O O
but O O
not O O
in O O
pentazocine B-drug B-drug
and O O
tripelennamine B-drug B-drug
, O O
addicts O O
) O O
were O O
completely O O
inhibited O O
by O O
the O O
drug O O
combination O O
. O O

Recovery O O
programs O O
should O O
be O O
flexible O O
and O O
involve O O
individual O O
and O O
family O O
education O O
on O O
recovery O O
and O O
the O O
nature O O
of O O
addictive O O
disease O O
. O O

- O O
Skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
, O O
nondepolarizing O O
( O O
e.g. O O
, O O
tubocurarine B-drug B-drug
) O O
: O O
Possible O O
increased O O
responsiveness O O
to O O
the O O
muscle B-group B-group
relaxant I-group I-group

Continued O O
admistration O O
of O O
the O O
drug O O
is O O
required O O
to O O
maintain O O
barpress O O
response O O
in O O
this O O
strain O O
of O O
dogs O O
. O O

A O O
dose O O
increase O O
of O O
lopinavir/ritonavir B-drug B-drug
to O O
533/133 O O
mg O O
twice O O
daily O O
with O O
food O O
isrecommended O O
in O O
combination O O
with O O
nevirapine B-drug B-drug
. O O

Nevertheless O O
, O O
caution O O
should O O
be O O
used O O
in O O
patients O O
receiving O O
concomitant O O
treatment O O
with O O
other O O
drugs O O
that O O
are O O
either O O
inhibitors O O
or O O
inducers O O
of O O
these O O
enzymes O O
. O O

Permanent O O
nerve O O
damage O O
could O O
theoretically O O
occur O O
if O O
vitamin O O
B12 O O
deficiency O O
is O O
not O O
treated O O
. O O

- O O
Carbamazepine B-drug B-drug
( O O
e.g. O O
, O O
Tegretol B-brand B-brand
) O O
or O O

Anagrelide B-drug B-drug
is O O
metabolized O O
at O O
least O O
in O O
part O O
by O O
CYP1A2 O O
. O O

If O O
the O O
usual O O
amounts O O
of O O
nondepolarizing O B-group
relaxants O I-group
are O O
given O O
, O O
the O O
time O O
for O O
recovery O O
from O O
neuromuscular O O
blockade O O
will O O
be O O
longer O O
in O O
the O O
presence O O
of O O
Enflurane B-drug B-drug
than O O
when O O
halothane B-drug B-drug
or O O
nitrous B-drug B-drug
oxide I-drug I-drug
with O O
a O O
balanced O O
technique O O
are O O
used O O
. O O

Although O O
not O O
studied O O
systematically O O
in O O
clinical O O
trials O O
, O O
no O O
drug O O
interactions O O
were O O
observed O O
when O O
vecuronium B-drug B-drug
, O O
pancuronium B-drug B-drug
, O O
or O O
atracurium B-drug B-drug
were O O
administered O O
following O O
varying O O
degrees O O
of O O
recovery O O
from O O
single O O
doses O O
or O O
infusions O O
of O O
NIMBEX B-brand B-brand
. O O

Free O O
T3 O O
resin O O
uptake O O
is O O
decreased O O
, O O
reflecting O O
the O O
elevated O O
TBG O O
; O O

In O O
both O O
periods O O
, O O
blood O O
and O O
urine O O
were O O
sampled O O
at O O
regular O O
intervals O O
. O O

Interest O O
in O O
administering O O
compounds O O
in O O
combination O O
lies O O
both O O
in O O
enhancing O O
efficacious O O
effects O O
and O O
in O O
limiting O O
adverse O O
effects O O
. O O

May O O
interact O O
with O O
addictive O O
medications O O
, O O
especially O O
central B-group B-group
nervous I-group I-group
system I-group I-group
( I-group I-group
CNS I-group I-group
) I-group I-group
depressants I-group I-group
with O O
habituating O O
potential O O
( O O
prolonged O O
concurrent O O
use O O
may O O
increase O O
the O O
risk O O
of O O
habituation O O
) O O
, O O
alcohol B-drug B-drug
or O O
CNS O O
depression O O
producing O O
medications O O
( O O
concurrent O O
use O O
may O O
increase O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
ethinamate B-drug B-drug
) O O
. O O

There O O
were O O
no O O
significant O O
differences O O
among O O
the O O
pD2 O O
values O O
for O O
noradrenaline B-drug B-drug
in O O
aortic O O
rings O O
without O O
endothelium O O
. O O

Consequently O O
, O O
concomitant O O
administration O O
of O O
Aprepitant B-drug B-drug
with O O
strong O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
troleandomycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
nelfinavir B-drug B-drug
) O O
should O O
be O O
approached O O
with O O
caution O O
. O O

Additional O O
animals O O
in O O
both O O
dose O O
groups O O
developed O O
B-cell O O
hyperplasia O O
of O O
the O O
spleen O O
and O O
lymph O O
nodes O O
. O O

When O O
the O O
CYP2D6 O O
inhibitor O O
is O O
withdrawn O O
from O O
the O O
combination O O
therapy O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
then O O
be O O
increased O O
. O O

( O O
Indomethacin B-drug B-drug
) O O
diuretics B-group B-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O

Preliminary O O
studies O O
indicate O O
that O O
the O O
concomitant O O
use O O
of O O
dobutamine B-drug B-drug
and O O
nitroprusside B-drug B-drug
results O O
in O O
a O O
higher O O
cardiac O O
output O O
and O O
, O O
usually O O
, O O
a O O
lower O O
pulmonary O O
wedge O O
pressure O O
than O O
when O O
either O O
drug O O
is O O
used O O
alone O O
. O O

In O O
order O O
to O O
use O O
the O O
pharmacological O O
properties O O
of O O
induced O O
therapeutic O O
hypermagnesaemia O O
, O O
high O O
oral O O
doses O O
of O O
magnesium B-drug B-drug
( O O
> O O
10 O O
mg/kg/day O O
) O O
are O O
advisable O O
for O O
chronic O O
indications O O
and O O
the O O
parenteral O O
route O O
is O O
suitable O O
for O O
acute O O
indications O O
. O O

insulin B-drug B-drug
requirements O O
may O O
be O O
increased O O
, O O
decreased O O
, O O
or O O
unchanged O O
. O O
) O O

The O O
CYP3A4 O O
isoenzyme O O
is O O
present O O
in O O
both O O
the O O
liver O O
and O O
intestines O O
. O O

No O O
information O O
available O O

DIDREX B-brand B-brand
should O O
not O O
be O O
used O O
concomitantly O O
with O O
other O O
CNS B-group B-group
stimulants I-group I-group
. O O

however O O
, O O
as O O
with O O
other O O
NSAIDs B-group B-group
, O O
concomitant O O
administration O O
of O O
Lodine B-brand B-brand
and O O
aspirin B-brand B-brand
is O O
not O O
generally O O
recommended O O
because O O
of O O
the O O
potential O O
of O O
increased O O
adverse O O
effects O O
. O O

Therefore O O
, O O
when O O
hydroflumethiazide B-drug B-drug
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O
) O O

In O O
such O O
cases O O
, O O
therefore O O
, O O
more O O
frequent O O
dosing O O
may O O
be O O
required O O
to O O
achieve O O
or O O
maintain O O
the O O
desired O O
hypotensive O O
response O O
. O O

Gabapentin B-drug B-drug
is O O
not O O
appreciably O O
metabolized O O
nor O O
does O O
it O O
interfere O O
with O O
the O O
metabolism O O
of O O
commonly O O
coadministered O O
antiepileptic B-group B-group
drugs I-group I-group
. O O

Drugs O O
that O O
Inhibit O O
or O O
Induce O O
Cytochrome O O
P450 O O
3A4 O O
Enzymes O O
Lapatinib B-drug B-drug
undergoes O O
extensive O O
metabolism O O
by O O
CYP3A4 O O
, O O
and O O
concomitant O O
administration O O
of O O
strong O O
inhibitors O O
or O O
inducers O O
of O O
CYP3A4 O O
alter O O
lapatinib B-drug B-drug
concentrations O O
significantly O O
. O O

When O O
initiating O O
a O O
multi-day O O
course O O
of O O
grepafloxacin B-drug B-drug
in O O
a O O
patient O O
maintained O O
on O O
theophylline B-drug B-drug
, O O
the O O
theophylline B-drug B-drug
maintenance O O
dose O O
should O O
be O O
halved O O
for O O
the O O
period O O
of O O
concurrent O O
use O O
of O O
grepafloxacin B-drug B-drug
and O O
monitoring O O
of O O
serum O O
theophylline B-drug B-drug
concentrations O O
should O O
be O O
initiated O O
as O O
a O O
guide O O
to O O
further O O
dosage O O
adjustments O O
. O O

ZEBETA B-brand B-brand
should O O
be O O
used O O
with O O
care O O
when O O
myocardial B-group B-group
depressants I-group I-group
or O O
inhibitors O O
of O O
AV O O
conduction O O
, O O
such O O
as O O
certain O O
calcium B-group B-group
antagonists I-group I-group
( O O
particularly O O
of O O
the O O
phenylalkylamine B-group B-drug
[ O O
verapamil B-drug B-drug
] O O
and O O
benzothiazepine B-group B-drug
[ O O
diltiazem B-drug B-drug
] O O
classes O O
) O O
, O O
or O O
antiarrhythmic B-group B-drug
agents I-group I-drug
, O O
such O O
as O O
disopyramide B-drug B-drug
, O O
are O O
used O O
concurrently O O
. O O

Elevated O O
cyclosporine B-drug B-drug
serum O O
levels O O
have O O
been O O
reported O O
with O O
the O O
concomitant O O
use O O
of O O
quinolones B-group B-group
and O O
cyclosporine B-drug B-drug
. O O

Cytotoxic B-group B-group
Agents I-group I-group
: O O
Enhanced O O
bone O O
marrow O O
suppression O O
by O O
cyclophosphamide B-drug B-drug
and O O
other O O
cytotoxic B-group B-group
agents I-group I-group
has O O
been O O
reported O O
among O O
patients O O
with O O
neoplastic O O
disease O O
, O O
except O O
leukemia O O
, O O
in O O
the O O
presence O O
of O O
allopurinol B-drug B-drug
. O O

100-150 O O

Once O O
a O O
stable O O
prothrombin O O
time O O
has O O
been O O
documented O O
, O O
prothrombin O O
times O O
can O O
be O O
monitored O O
at O O
the O O
intervals O O
usually O O
recommended O O
for O O
patients O O
on O O
coumarin B-group B-group
anticoagulants I-group I-group
. O O

It O O
is O O
recommended O O
that O O
serum O O
lithium B-drug B-drug
levels O O
be O O
monitored O O
frequently O O
if O O
enalapril B-drug B-drug
is O O
administered O O
concomitantly O O
with O O
lithium B-drug B-drug
. O O

- O O
Non-steroidal B-group B-group
Anti-inflammatory I-group I-group
Drugs I-group I-group
: O O
In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
a O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic O B-group
, O O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium-sparing O O
and O O
thiazide B-drug B-group
diuretics I-drug I-group
. O O

The O O
reluctance O O
to O O
treat O O
aggressively O O
is O O
understandable O O
because O O
the O O
geriatric O O
population O O
is O O
susceptible O O
to O O
adverse O O
drug O O
reactions O O
. O O

Leukocyte B-drug_n O
transfusions I-drug_n O
: O O
acute O O
pulmonary O O
toxicity O O
has O O
been O O
reported O O
in O O
patients O O
receiving O O
intravenous O O
amphotericin B-drug B-drug
B I-drug I-drug
and O O
leukocyte B-drug_n O
transfusions I-drug_n O
. O O

The O O
effect O O
of O O
corticosteroids B-group B-group
on O O
oral O O
anticoagulants B-group B-group
is O O
variable O O
. O O

The O O
levorotatory O O
isomer O O
had O O
opioid-antagonist O B-group
and O O
non-opioid O O
agonist O O
effects O O
in O O
pigeons O O
and O O
mixed O O
opioid O O
agonist-antagonist O O
effects O O
in O O
monkeys O O
. O O

The O O
interaction O O
is O O
a O O
consequence O O
of O O
blocking O O
hepatic O O
metabolism O O
of O O
vardenafil B-drug B-drug
by O O
ritonavir B-drug B-drug
, O O
a O O
highly O O
potent O O
CYP3A4 O O
inhibitor O O
, O O
which O O
also O O
inhibits O O
CYP2C9 O O
. O O

Samples O O
for O O
plasma O O
and O O
urine O O
immunoreactive O O
digoxin B-drug B-drug
concentrations O O
were O O
collected O O
through O O
120 O O
hours O O
following O O
the O O
digoxin B-drug B-drug
dose O O
. O O

. O O

The O O
pharmacokinetics O O
of O O
irbesartan B-drug B-drug
were O O
not O O
affected O O
by O O
coadministration O O
of O O
nifedipine B-drug B-drug
or O O
hydrochlorothiazide B-drug B-drug

griseofulvin B-drug B-drug
; O O

Praziquantel B-drug B-drug
: O O
In O O
the O O
fed O O
state O O
, O O
praziquantel B-drug B-drug
( O O
40 O O
mg/kg O O
) O O
increased O O
mean O O
maximum O O
plasma O O
concentration O O
and O O
area O O
under O O
the O O
curve O O
of O O
albendazole B-drug B-drug
sulfoxide I-drug I-drug
by O O
about O O
50 O O
% O O
in O O
healthy O O
subjects O O
( O O
n=10 O O
) O O
compared O O
with O O
a O O
separate O O
group O O
of O O
subjects O O
( O O
n=6 O O
) O O
given O O
albendazole B-drug B-drug
alone O O
. O O

Such O O
individuals O O
are O O
referred O O
to O O
as O O
poor O O
metabolizers O O
of O O
drugs O O
such O O
as O O
debrisoquin B-drug B-drug
, O O
dextromethorphan B-drug B-drug
, O O
and O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
tests O O
should O O
be O O
monitored O O
. O O

- O O
Anticoagulants B-group B-group
: O O
Interaction O O
studies O O
in O O
humans O O
have O O
shown O O
bumetanide B-drug B-drug
to O O
have O O
no O O
effect O O
on O O
warfarin B-drug B-drug
metabolism O O
or O O
on O O
plasma O O
prothrombin O O
activity O O
. O O

Both O O
studies O O
used O O
12 O O
subjects O O
. O O

Lithium B-drug B-drug
: O O
Nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
have O O
been O O
reported O O
to O O
increase O O
steadystate O O
plasma O O
lithium B-drug B-drug
levels O O
. O O

After O O
etofibrate B-drug B-drug
treatment O O
, O O
there O O
was O O
decrease O O
of O O
total O O
cholesterol O B-drug
and O O
triglyceride O B-drug
plasma O O
levels O O
and O O
a O O
trend O O
to O O
increase O O
high-density O O
lipoprotein O O
cholesterol O O
plasma O O
levels O O
. O O

nc1,2 O O
30 O O
% O O
decrease O O
[ O O
CI O O
: O O
3 O O
% O O
decrease O O
, O O
48 O O
% O O
decrease O O
] O O

Patients O O
receiving O O
hydantoins B-group B-group
, O O
sulfonamides B-group B-group
, O O
or O O
sulfonylureas B-group B-group
should O O
be O O
observed O O
for O O
increased O O
activity O O
of O O
these O O
drugs O O
and O O
, O O
therefore O O
, O O
signs O O
of O O
toxicity O O
from O O
these O O
drugs O O
. O O

In O O
vitro O O
drug O O
metabolism O O
studies O O
indicate O O
that O O
Starlix B-brand B-brand
is O O
predominantly O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
isozyme O O
CYP2C9 O O
( O O
70 O O
% O O
) O O
and O O
to O O
a O O
lesser O O
extent O O
CYP3A4 O O
( O O
30 O O
% O O
) O O
. O O

zaleplon B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
ethanol B-drug B-drug
. O O

Dofetilide B-drug B-drug
is O O
not O O
an O O
inhibitor O O
of O O
CYP3A4 O O
nor O O
of O O
other O O
cytochrome O O
P450 O O
isoenzymes O O
( O O
e.g. O O
, O O
CYP2C9 O O
, O O
CYP2D6 O O
) O O
and O O
is O O
not O O
expected O O
to O O
increase O O
levels O O
of O O
drugs O O
metabolized O O
by O O
CYP3A4 O O
. O O

Reductions O O
in O O
serum O O
endogenous O O
vitamin O O
D O O
concentrations O O
have O O
been O O
observed O O
following O O
the O O
administration O O
of O O
300 O O
mg/day O O
to O O
1200 O O
mg/day O O
ketoconazole B-drug B-drug
for O O
a O O
week O O
to O O
healthy O O
men O O
. O O

n-Octyl O B-drug_n
and O O
n-cetyl O O
gallate O B-drug
also O O
showed O O
good O O
inhibition O O
, O O
while O O
gallic O B-drug
acid O I-drug
itself O O
was O O
not O O
so O O
active O O
, O O
suggesting O O
that O O
the O O
presence O O
of O O
hydrophobic O O
side O O
chain O O
is O O
important O O
for O O
the O O
suppressive O O
effect O O
. O O

These O O
agents O O
should O O
not O O
be O O
used O O
in O O
patients O O
treated O O
with O O
Itraconazole B-drug B-drug
. O O

18-Methoxycoronaridine B-drug_n B-drug_n
( O O
18-MC B-drug_n B-drug_n
) O O
and O O
ibogaine B-drug_n B-drug_n
: O O
comparison O O
of O O
antiaddictive O O
efficacy O O
, O O
toxicity O O
, O O
and O O
mechanisms O O
of O O
action O O
. O O

Conjugation O O
at O O
NaCMC B-drug_n B-drug_n
with O O
cysteine B-drug B-drug
moieties O O
significantly O O
improves O O
the O O
intestinal O O
permeation O O
of O O
the O O
hydrophilic O O
molecule O O
NaFlu B-drug B-drug
and O O
the O O
model O O
peptide O O
drugs O O
bacitracin B-drug B-drug
and O O
insulin B-drug B-drug
in O O
vitro O O
, O O
therefore O O
this O O
conjugated O O
system O O
maybe O O
useful O O
for O O
peroral O O
administration O O
of O O
peptide O B-group
drugs O I-group
in O O
the O O
future O O
. O O

Reproductive O O
toxicology O O
studies O O
have O O
been O O
performed O O
in O O
cynomolgus O O
monkeys O O
at O O
doses O O
up O O
to O O
5 O O
mg/kg/week O O
( O O
about O O
62 O O
times O O
the O O
human O O
dose O O
based O O
on O O
body O O
weight O O
) O O
and O O
have O O
revealed O O
no O O
evidence O O
of O O
impaired O O
fertility O O
or O O
harm O O
to O O
the O O
fetus O O
due O O
to O O
AMEVIVE B-brand B-brand
. O O

Since O O
both O O
alcohol B-drug B-drug
and O O
organoleads O O
are O O
present O O
in O O
the O O
environment O O
and O O
seem O O
to O O
influence O O
limbic O O
integration O O
, O O
the O O
interaction O O
of O O
these O O
two O O
compounds O O
was O O
assessed O O
in O O
the O O
present O O
experiment O O
. O O

Interactions O O
between O O
theraputic O O
agents O O
have O O
been O O
recognized O O
as O O
increasingly O O
important O O
causes O O
of O O
drug O O
at O O
their O O
usual O O
recommended O O
dose O O
may O O
, O O
under O O
certain O O
conditions O O
, O O
produce O O
toxicity O O
of O O
life-endangering O O
proportions O O
. O O

We O O
examined O O
the O O
effect O O
of O O
exogenous O O
estradiol B-drug B-drug
on O O
the O O
changes O O
in O O
serum O O
steroid O O
hormone O O
levels O O
induced O O
by O O
a O O
nonlethal O O
dose O O
of O O
Escherichia O O
coli O O
endotoxin B-drug_n O
in O O
male O O
rats O O
and O O
the O O
deaths O O
due O O
to O O
nonlethal O O
and O O
lethal O O
doses O O
of O O
endotoxin B-drug_n B-drug
. O O

Therefore O O
, O O
it O O
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
such O O
agents O O
. O O

Meperidine B-drug B-drug
: O O
Amphetamines B-group B-group
potentiate O O
the O O
analgesic O O
effect O O
of O O
meperidine B-drug B-drug
. O O

A O O
direct O O
causal O O
relationship O O
has O O
not O O
been O O
established O O
, O O
but O O
physicians O O
should O O
consider O O
the O O
possibility O O
that O O
diclofenac B-drug B-drug
may O O
alter O O
a O O
diabetic O O
patient O O
s O O
response O O
to O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

Both O O
ibogaine B-drug_n B-drug_n
and O O
18-MC B-drug_n B-drug_n
decrease O O
extracellular O O
levels O O
of O O
dopamine O B-drug
in O O
the O O
nucleus O O
accumbens O O
, O O
but O O
only O O
ibogaine B-drug_n B-drug_n
increases O O
extracellular O O
levels O O
of O O
serotonin O O
in O O
the O O
nucleus O O
accumbens O O
. O O

Before O O
prescribing O O
a O O
symptomatic O O
( O O
pharmaceutical O O
) O O
treatment O O
for O O
patients O O
with O O
an O O
erection O O
disorder O O
, O O
attention O O
should O O
be O O
given O O
tot O O
the O O
sexological O O
, O O
psychological O O
and O O
medical O O
backgrounds O O
of O O
the O O
disorder O O
. O O

In O O
a O O
study O O
in O O
36 O O
patients O O
with O O
mild O O
to O O
moderate O O
hypertension O O
where O O
the O O
antihypertensive O O
effects O O
of O O
PRINIVIL B-brand B-brand
alone O O
were O O
compared O O
to O O
PRINIVIL B-brand B-brand
given O O
concomitantly O O
with O O
indomethacin B-drug B-drug
, O O
the O O
use O O
of O O
indomethacin B-drug B-drug
was O O
associated O O
with O O
a O O
reduced O O
antihypertensive O O
effect O O
, O O
although O O
the O O
difference O O
between O O
the O O
two O O
regimens O O
was O O
not O O
significant O O
. O O

In O O
this O O
study O O
we O O
investigated O O
the O O
effect O O
of O O
ginsenosides B-drug_n B-drug_n
on O O
high O O
threshold O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
channel O O
subtypes O O
using O O
their O O
selective B-group O
Ca I-group O
( I-group O
2+ I-group O
) I-group O
channel I-group O
blockers I-group O
nimodipine B-drug B-drug
( O O
L-type O O
) O O
, O O
omega-conotoxin B-drug_n B-drug_n
GVIA I-drug_n I-drug_n
( O O
N-type O O
) O O
, O O
or O O
omega-agatoxin B-drug_n B-drug
IVA I-drug_n O
( O O
P-type O O
) O O
in O O
bovine O O
chromaffin O O
cells O O
. O O

Dose O O
reduction O O
or O O
interruption O O
of O O
TARCEVA B-brand B-brand
should O O
be O O
considered O O
if O O
changes O O
in O O
liver O O
function O O
are O O
severe O O
. O O

Trimethoprim B-drug B-drug
Alone O O
or O O
in O O
Combination O O
with O O
Sulfamethoxazole B-drug B-drug
: O O
Concomitant O O
use O O
of O O
trimethoprim B-drug B-drug
alone O O
or O O
in O O
combination O O
with O O
sulfamethoxazole B-drug B-drug
is O O
contraindicated O O
. O O

This O O
paper O O
critically O O
reviews O O
the O O
suitability O O
of O O
the O O
urinary O O
thioether O O
assay O O
as O O
a O O
method O O
for O O
the O O
detection O O
of O O
exposure O O
to O O
electrophilic O O
agents O O
or O O
their O O
precursors O O
. O O

clinical O O
implications O O
are O O
unclear O O
. O O

Nabilone B-drug B-drug
has O O
been O O
shown O O
to O O
have O O
an O O
additive O O
CNS O O
depressant O O
effect O O
when O O
given O O
with O O
either O O
diazepam B-drug B-drug
, O O
secobarbitone B-brand B-drug
sodium I-brand I-drug
, O O
alcohol B-drug B-drug
or O O
codeine B-drug B-drug
. O O

The O O
interaction O O
may O O
be O O
a O O
result O O
of O O
inhibition O O
of O O
both O O
CYP2C9 B-drug O
and O O
2C19 O O
by O O
fluvoxamine B-drug B-drug
. O O

Other O O
nephrotoxic O O
medications O O
: O O
agents O O
such O O
as O O
aminoglycosides B-group B-group
, O O
cyclosporine B-drug B-drug
, O O
and O O
pentamidine B-drug B-drug
may O O
enhance O O
the O O
potential O O
for O O
drug-induced O O
renal O O
toxicity O O
, O O
and O O
should O O
be O O
used O O
concomitantly O O
only O O
with O O
great O O
caution O O
. O O

Methotrexate B-drug B-drug
: O O
An O O
increased O O
risk O O
of O O
hepatitis O O
has O O
been O O
reported O O
to O O
result O O
from O O
combined O O
use O O
of O O
methotrexate B-drug B-drug
and O O
etretinate B-drug B-drug
. O O

certain O O
antipsychotic B-group B-group
medications I-group I-group
( O O
such O O
as O O
sertindole B-drug O
) O O
; O O

Phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
and O O
carbamazepine B-drug B-drug
are O O
ge O O
nerally O O
classified O O
as O O
enzyme O O
inducers O O
; O O

Sertraline B-drug B-drug
neutralized O O
the O O
increase O O
of O O
glycemia O O
induced O O
by O O
oral O O
glucose B-drug B-drug
overload O O
. O O

Drug/ O O
Laboratory O O
Test O O
Interactions O O
Certain O O
endocrine O O
and O O
liver O O
function O O
tests O O
may O O
be O O
affected O O
by O O
estrogen-containing B-group B-group
oral O O
contraceptives B-group B-group
. O O

- O O
Divalproex B-drug B-drug
( O O
e.g. O O
, O O
Depakote B-brand B-brand
) O O
or O O

This O O
is O O
especially O O
important O O
for O O
drugs O O
associated O O
with O O
serious O O
toxicity O O
, O O
such O O
as O O
other O O
antiarrhythmics B-group B-group
. O O

In O O
a O O
study O O
in O O
hypertensive O O
patients O O
, O O
addition O O
of O O
isradipine B-drug B-drug
to O O
existing O O
hydrochlorothiazide B-drug B-drug
therapy O O
did O O
not O O
result O O
in O O
any O O
unexpected O O
adverse O O
effects O O
, O O
and O O
isradipine B-drug B-drug
had O O
an O O
additional O O
antihypertensive O O
effect O O
. O O

Acarbose B-drug B-drug
did O O
not O O
interfere O O
with O O
the O O
absorption O O
or O O
disposition O O
of O O
the O O
sulfonylurea B-drug B-group
glyburide I-drug B-drug
in O O
diabetic O O
patients O O
. O O

These O O
effects O O
are O O
usually O O
reversible O O
. O O

Inhibitors O O
Of O O
Endogenous O O
Prostaglandin O O
Synthesis O O
It O O
has O O
been O O
reported O O
that O O
indomethacin B-drug B-drug
may O O
reduce O O
the O O
antihypertensive O O
effect O O
of O O
captopril B-drug B-drug
, O O
especially O O
in O O
cases O O
of O O
low O O
renin O O
hypertension O O
. O O

Pregnancy O O
( O O
Category O O
B O B-drug
) O O

Therefore O O
, O O
diflunisal B-drug B-drug
and O O
INDOCIN B-brand B-brand
should O O
not O O
be O O
used O O
concomitantly O O
. O O

Therefore O O
, O O
unless O O
otherwise O O
specified O O
, O O
appropriate O O
dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O

Drug-Drug O O
Interactions O O
Between O O
Keppra B-brand B-brand
And O O
Other O O
Antiepileptic B-group B-group
Drugs I-group I-group
( O O
AEDs B-group B-group
) O O
Phenytoin B-drug B-drug
Keppra B-brand B-brand
( O O
3000 O O
mg O O
daily O O
) O O
had O O
no O O
effect O O
on O O
the O O
pharmacokinetic O O
disposition O O
of O O
phenytoin B-drug B-drug
in O O
patients O O
with O O
refractory O O
epilepsy O O
. O O

The O O
benefits O O
of O O
Mefloquine B-drug B-drug
therapy O O
should O O
be O O
weighed O O
against O O
the O O
possibility O O
of O O
adverse O O
effects O O
in O O
patients O O
with O O
cardiac O O
disease O O
. O O

Each O O
treatment O O
period O O
was O O
separated O O
by O O
14 O O
to O O
21 O O
days O O
. O O

Zimelidine B-drug_n B-drug
etomidate B-drug I-drug
antagonism O O

In O O
these O O
cases O O
, O O
your O O
doctor O O
may O O
want O O
to O O
change O O
the O O
dose O O
, O O
or O O
other O O
precautions O O
may O O
be O O
necessary O O
. O O

Other O O
significant O O
inhibitors O O
of O O
CYP2D6 O O
, O O
such O O
as O O
fluoxetine B-drug B-drug
or O O
paroxetine B-drug B-drug
, O O
would O O
be O O
expected O O
to O O
have O O
similar O O
effects O O
and O O
, O O
therefore O O
, O O
should O O
be O O
accompanied O O
by O O
similar O O
dose O O
reductions O O
. O O

Patients O O
with O O
major O O
psychotic O O
disorders O O
, O O
treated O O
with O O
neuroleptics B-group B-group
, O O
should O O
be O O
treated O O
with O O
dopamine B-group B-group
agonists I-group I-group
only O O
if O O
the O O
potential O O
benefits O O
outweigh O O
the O O
risks O O
. O O

Nine O O
additional O O
patients O O
who O O
had O O
initial O O
positive O O
tests O O
were O O
negative O O
on O O
repeat O O
testing O O
. O O

Antiepileptic B-group B-group
Drugs I-group I-group
: O O
Sporadic O O
cases O O
of O O
seizures O O
have O O
been O O
reported O O
during O O
concomitant O O
use O O
of O O
TORADOL B-brand B-brand
and O O
antiepileptic B-group B-group
drugs I-group I-group
( O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
) O O
. O O

Concomitant O O
Drug O O

- O O
Plicamycin B-drug B-drug
( O O
e.g. O O
, O O
Mithracin B-brand B-drug
) O O
or O O

Digoxin B-drug B-drug
: O O
When O O
Starlix B-brand B-brand
120 O O
mg O O
before O O
meals O O
was O O
administered O O
in O O
combination O O
with O O
a O O
single O O
1-mg O O
dose O O
of O O
digoxin B-drug B-drug
to O O
healthy O O
volunteers O O
, O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

Additional O O
interactions O O

Therefore O O
, O O
inhibitors O O
of O O
these O O
enzymes O O
are O O
expected O O
to O O
reduce O O
vardenafil B-drug B-drug
clearance O O
. O O

Ketoconazole B-drug B-drug
: O O
In O O
healthy O O
subjects O O
receiving O O
ketoconazole B-drug B-drug
, O O
a O O
CYP3A4 O O
inhibitor O O
, O O
at O O
200 O O
mg O O
twice O O
daily O O
for O O
7 O O
days O O
, O O
systemic O O
exposure O O
( O O
AUC O O
) O O
to O O
lapatinib B-drug B-drug
was O O
increased O O
to O O
approximately O O
3.6-fold O O
of O O
control O O
and O O
half-life O O
increased O O
to O O
1.7-fold O O
of O O
control O O
. O O

Guidelines O O
are O O
provided O O
to O O
assist O O
the O O
clinician O O
in O O
his O O
logical O O
approach O O
to O O
the O O
identification O O
of O O
drug O O
interactions O O
when O O
serious O O
drug O O
toxicity O O
is O O
encountered O O
in O O
a O O
pateint O O
. O O

Because O O
of O O
foscarnets B-drug O
tendency O O
to O O
cause O O
renal O O
impairment O O
, O O
the O O
use O O
of O O
FOSCAVIR B-brand B-brand
should O O
be O O
avoided O O
in O O
combination O O
with O O
potentially O O
nephrotoxic O O
drugs O O
such O O
as O O
aminoglycosides B-group B-group
, O O
amphotericin B-drug B-drug
B I-drug I-drug
and O O
intravenous O O
pentamidine B-drug B-drug
unless O O
the O O
potential O O
benefits O O
outweigh O O
the O O
risks O O
to O O
the O O
patient O O
. O O

Epinephrine B-drug B-drug
may O O
antagonize O O
the O O
neuron O O
blockade O O
produced O O
by O O
guanethidine B-drug B-drug
resulting O O
in O O
decreased O O
antihypertensive O O
effect O O
and O O
requiring O O
increased O O
dosage O O
of O O
the O O
latter O O
. O O

Because O O
CYP O O
3A4 O O
inhibitors O O
may O O
increase O O
plasma O O
concentrations O O
of O O
buprenorphine B-drug B-drug
, O O
patients O O
already O O
on O O
CYP O O
3A4 O O
inhibitors O O
such O O
as O O
azole B-group B-group
antifungals I-group I-group
( O O
e.g O O
. O O

With O O
each O O
successive O O
generation O O
more O O
people O O
are O O
becoming O O
more O O
severely O O
depressed O O
at O O
a O O
younger O O
age O O
. O O

saquinavir I-drug B-drug
concentration O O

Marked O O
symptomatic O O
orthostatic O O
hypotension O O
has O O
been O O
reported O O
when O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
and O O
organic B-group O
nitrates I-group B-group
were O O
used O O
in O O
combination O O
. O O

Thus O O
no O O
dosing O O
adjustments O O
are O O
necessary O O
during O O
concomitant O O
use O O
with O O
these O O
agents O O
. O O

Concomitant O O
administration O O
of O O
Sonata B-brand B-brand
( O O
10 O O
mg O O
) O O
and O O
cimetidine B-drug B-drug
( O O
800 O O
mg O O
) O O
produced O O
an O O
85 O O
% O O
increase O O
in O O
the O O
mean O O
Cmax O O
and O O
AUC O O
of O O
zaleplon B-drug B-drug
. O O

This O O
antagonistic O O
effect O O
of O O
probenecid B-drug B-drug
on O O
bumetanide B-drug B-drug
natriuresis O O
is O O
not O O
due O O
to O O
a O O
direct O O
action O O
on O O
sodium O O
excretion O O
but O O
is O O
probably O O
secondary O O
to O O
its O O
inhibitory O O
effect O O
on O O
renal O O
tubular O O
secretion O O
of O O
bumetanide B-drug B-drug
. O O

For O O
information O O
on O O
the O O
pharmacokinetics O O
of O O
Gemzar B-brand B-brand
and O O
cisplatin B-drug B-drug
in O O
combination O O
, O O
see O O
Drug O O
Interactions O O
under O O
CLINICAL O O
PHARMACOLOGY O O
section O O
. O O

Caffeine-related B-drug O
adverse O O
effects O O
have O O
occurred O O
in O O
patients O O
consuming O O
caffeine B-drug B-drug
while O O
on O O
therapy O O
with O O
enoxacin B-drug B-drug
. O O

Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
may O O
increase O O
the O O
clearance O O
of O O
corticosteroids B-group B-group
. O O

Among O O
these O O
patients O O
, O O
the O O
incidence O O
of O O
upper O O
gastrointestinal O O
adverse O O
experiences O O
in O O
the O O
patients O O
treated O O
with O O
Ibandronate B-drug B-drug
150 O O
mg O O
once O O
monthly O O
was O O
similar O O
to O O
that O O
in O O
patients O O
treated O O
with O O
Ibandronate B-drug B-drug
2.5 O O
mg O O
once O O
daily O O
. O O

Ampicillin B-drug B-drug
: O O
In O O
a O O
study O O
of O O
healthy O O
volunteers O O
, O O
chloroquine B-drug B-drug
significantly O O
reduced O O
the O O
bioavailability O O
of O O
ampicillin B-drug B-drug
. O O

Metal O O
mixtures O O
had O O
no O O
effect O O
on O O
egg B-drug O
hatching O O
. O O

Because O O
of O O
its O O
primary O O
CNS O O
effect O O
, O O
caution O O
should O O
be O O
used O O
when O O
EQUETROTM B-brand B-brand
is O O
taken O O
with O O
other O O
centrally B-group O
acting I-group O
drugs I-group O
and O O
alcohol B-drug B-drug
. O O

Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE B-group B-group
inhibitors I-group I-group
, O O
including O O
lisinopril B-drug B-drug
. O O

Thus O O
agents O O
likely O O
to O O
be O O
concomitantly O O
administered O O
with O O
Chirocaine B-brand B-drug
that O O
are O O
metabolized O O
by O O
this O O
isoenzyme O O
family O O
may O O
potentially O O
interact O O
with O O
Chirocaine B-brand B-drug
. O O

These O O
individuals O O
may O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
when O O
given O O
usual O O
doses O O
. O O

In O O
order O O
to O O
approximate O O
the O O
steady O O
state O O
level O O
, O O
serum O O
digoxin B-drug B-drug
levels O O
should O O
be O O
drawn O O
either O O
before O O
or O O
at O O
least O O
six O O
hours O O
following O O
the O O
administration O O
of O O
an O O
oral O O
tablet O O
. O O

The O O
use O O
of O O
herbal O O
remedies O O
is O O
becoming O O
increasingly O O
popular O O
in O O
the O O
United O O
States O O
. O O

Drugs O O
that O O
may O O
decrease O O
imatinib B-drug B-drug
plasma O O
concentrations O O
: O O
Substances O O
that O O
are O O
inducers O O
of O O
CYP3A4 O O
activity O O
may O O
increase O O
metabolism O O
and O O
decrease O O
imatinib B-drug B-drug
plasma O O
concentrations O O
. O O

This O O
inhibition O O
can O O
result O O
in O O
unexpectedly O O
high O O
plasma O O
levels O O
of O O
other O O
drugs B-drug O
which O O
are O O
metabolized O O
by O O
those O O
CYP450 O O
enzymes O O
. O O

In O O
a O O
study O O
in O O
diabetics O O
with O O
microalbuminuria O O
INSPRA B-brand B-brand
200 O O
mg O O
combined O O
with O O
the O O
ACE B-group B-group
inhibitor I-group I-group
enalapril B-drug B-drug
10 O O
mg O O
increased O O
the O O
frequency O O
of O O
hyperkalemia O O
( O O
serum O O
potassium O O
5.5 O O
mEq/L O O
) O O
from O O
17 O O
% O O
on O O
enalapril B-drug B-drug
alone O O
to O O
38 O O
% O O
. O O

Tumor O O
phenotype O O
and O O
susceptibility O O
to O O
progression O O
as O O
an O O
expression O O
of O O
subpopulations O O
of O O
initiated O O
murine O O
cells O O
. O O

Rifampin B-drug B-drug
and O O
warfarin B-drug B-drug
: O O
a O O
drug O O
interaction O O
. O O

When O O
catecholamines B-group B-group
are O O
administered O O
, O O
dilute O O
solutions O O
should O O
be O O
used O O
and O O
blood O O
pressure O O
should O O
be O O
monitored O O
closely O O
. O O

Iodine B-drug B-drug
or O O
iodine B-drug B-drug
excess O O
may O O
decrease O O
the O O
effect O O
of O O
Carbimazole B-drug B-drug
, O O
and O O
an O O
iodine B-drug O
deficiency O O
can O O
increase O O
the O O
effect O O
of O O
Carbimazole B-drug B-drug
. O O

Elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
have O O
been O O
reported O O
with O O
the O O
concomitant O O
use O O
of O O
some O O
quinolones B-group B-group
and O O
cyclosporine B-drug B-drug
. O O

See O O
WARNINGS O O
, O O
Myopathy/Rhabdomyolysis O O
. O O

Acetazolamide B-drug B-drug
increases O O
lithium B-drug B-drug
excretion O O
and O O
the O O
lithium B-drug B-drug
may O O
be O O
decreased O O
. O O

Drugs O O
that O O
may O O
increase O O
dasatinib B-drug B-drug
plasma O O
concentrations O O
CYP3A4 O O
Inhibitors O O
: O O
Dasatinib B-drug B-drug
is O O
a O O
CYP3A4 O O
substrate O O
. O O

No O O
significant O O
interaction O O
has O O
been O O
found O O
with O O
broad-spectrum O B-group
antibiotics B-group I-group
. O O

Magnesium B-drug B-drug
: O O
Magnesium-containing B-drug B-drug
preparations O O
( O O
eg O O
, O O
antacids B-group B-group
) O O
may O O
cause O O
hypermagnesemia O O
and O O
should O O
therefore O O
not O O
be O O
taken O O
during O O
therapy O O
with O O
vitamin B-group B-group
D I-group I-group
by O O
patients O O
on O O
chronic O O
renal O O
dialysis O O
. O O

Currently O O
, O O
there O O
are O O
no O O
safety O O
and O O
efficacy O O
data O O
available O O
from O O
the O O
use O O
of O O
this O O
combination O O
. O O

Differential O O
regulation O O
of O O
tyrosine O O
phosphorylation O O
in O O
tumor O O
cells O O
by O O
contortrostatin B-drug_n B-drug_n
, O O
a O O
homodimeric O O
disintegrin O O
, O O
and O O
monomeric O O
disintegrins O O
echistatin B-drug_n O
and O O
flavoridin B-drug_n O
. O O

Usually O O
, O O
this O O
has O O
been O O
observed O O
in O O
patients O O
with O O
a O O
history O O
of O O
diabetes O O
mellitus O O
or O O
evidence O O
of O O
glucose O O
intolerance O O
prior O O
to O O
administration O O
of O O
CAMPTOSAR B-brand B-brand
. O O

. O O

Salt O O
substitutes O O
containing O O
potassium B-drug B-drug
should O O
also O O
be O O
used O O
with O O
caution O O
. O O

In O O
TAMBOCOR B-brand B-brand
clinical O O
trials O O
, O O
patients O O
who O O
were O O
receiving O O
beta B-group B-group
blockers I-group I-group
concurrently O O
did O O
not O O
experience O O
an O O
increased O O
incidence O O
of O O
side O O
effects O O
. O O

Benzodiazepines B-group B-group
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
decrease O O
the O O
clearance O O
of O O
some O O
benzodiazepines B-group B-group
( O O
alprazolam B-drug B-drug
, O O
chlordiazepoxide B-drug B-drug
, O O
diazepam B-drug B-drug
) O O
and O O
increase O O
the O O
clearance O O
of O O
others O O
( O O
lorazepam B-drug B-drug
, O O
oxazepam B-drug B-drug
, O O
temazepam B-drug B-drug
) O O
. O O

All O O
animals O O
in O O
the O O
study O O
were O O
positive O O
for O O
an O O
endemic O O
primate O O
gammaherpes O O
virus O O
also O O
known O O
as O O
lymphocryptovirus O O
( O O
LCV O O
) O O
. O O

Cyclosporine B-drug B-drug
- O O
L-arginine B-drug B-drug
may O O
counteract O O
the O O
antinaturetic O O
effect O O
of O O
cyclosporin B-drug B-drug
. O O

Although O O
, O O
it O O
is O O
unknown O O
whether O O
this O O
could O O
result O O
in O O
clinically O O
significant O O
effects O O
, O O
caution O O
is O O
advised O O
when O O
administering O O
Cerebyx B-brand B-brand
with O O
other O O
drugs O O
that O O
significantly O O
bind O O
to O O
serum O O
albumin O O
. O O

Coingestion O O
of O O
acetaminophen B-drug B-drug
with O O
theophylline B-drug B-drug
, O O
phenobarbital B-drug B-drug
with O O
acetaminophen B-drug B-drug
, O O
and O O
valproic B-drug B-drug
acid I-drug I-drug
with O O
phenobarbital B-drug B-drug
at O O
high O O
to O O
toxic O O
concentrations O O
decreases O O
the O O
binding O O
of O O
the O O
target O O
drug O O
. O O

Alosetron B-drug B-drug
does O O
not O O
appear O O
to O O
induce O O
the O O
major O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
drug O O
metabolizing O O
enzyme O O
3A O O
. O O

3 O O
. O O

antacids B-group B-group
; O O

N=12 O O
) O O
are O O
identical O O
whether O O
the O O
drugs O O
are O O
administered O O
alone O O
or O O
together O O
. O O

Erythromycin B-drug B-drug
( O O
500 O O
mg O O
t.i.d O O
) O O
produced O O
a O O
4-fold O O
increase O O
in O O
vardenafil B-drug B-drug
AUC O O
and O O
a O O
3-fold O O
increase O O
in O O
Cmax O O
when O O
co-administered O O
with O O
Vardenafil B-drug B-drug
5 O O
mg O O
in O O
healthy O O
volunteers O O
. O O

HMG-CoA B-group B-group
Reductase I-group I-group
Inhibitor I-group I-group
: O O
atorvastatin B-drug B-drug

These O O
results O O
would O O
seem O O
to O O
dictate O O
against O O
the O O
clinical O O
use O O
of O O
methotrexate B-drug B-drug
with O O
ELSPAR B-brand B-brand
, O O
or O O
during O O
the O O
period O O
following O O
ELSPAR B-brand B-brand
therapy O O
when O O
plasma O O
asparagine O B-drug
levels O O
are O O
below O O
normal O O
. O O

Gastrointestinal O O
transit O O
time O O
( O O
lactulose O O
hydrogen O O
breath O O
test O O
) O O
was O O
measured O O
in O O
14 O O
volunteers O O
with O O
oral O O
and O O
intravenous O O
placebo O O
, O O
oral O O
placebo O O
and O O
intravenous O O
morphine B-drug B-drug
( O O
0.05 O O
mg O O
x O O
kg O O
( O O
-1 O O
) O O
) O O
, O O
and O O
oral O O
ADL B-drug B-drug
8-2698 I-drug I-drug
( O O
4 O O
mg O O
) O O
and O O
intravenous O O
morphine B-drug B-drug
( O O
0.05 O O
mg O O
x O O
kg O O
( O O
-1 O O
) O O
) O O
in O O
a O O
double O O
blind O O
, O O
cross-over O O
study O O
. O O

Also O O
, O O
bleeding O O
and/or O O
increased O O
prothrombin O O
time O O
have O O
been O O
reported O O
in O O
a O O
few O O
patients O O
taking O O
coumarin B-group B-group
anticoagulants O I-group
concomitantly O O
with O O
lovastatin B-drug B-drug
. O O

The O O
acceleration O O
of O O
gastric O O
emptying O O
by O O
cisapride B-drug B-drug
could O O
affect O O
the O O
rate O O
of O O
absorption O O
of O O
other O O
drugs O O
. O O

In O O
a O O
study O O
of O O
15 O O
male O O
subjects O O
( O O
ages O O
19 O O
to O O
35 O O
years O O
) O O
who O O
were O O
extensive O O
metabolizers O O
of O O
the O O
CYP2D6 O O
isoenzyme O O
, O O
daily O O
doses O O
of O O
bupropion B-drug B-drug
given O O
as O O
150 O O
mg O O
twice O O
daily O O
followed O O
by O O
a O O
single O O
dose O O
of O O
50 O O
mg O O
desipramine B-drug B-drug
increased O O
the O O
Cmax O O
, O O
AUC O O
, O O
and O O
t1/2 O O
of O O
desipramine B-drug B-drug
by O O
an O O
average O O
of O O
approximately O O
2- O O
, O O
5- O O
and O O
2-fold O O
, O O
respectively O O
. O O

Quinolones B-group B-group
, O O
including O O
cinoxacin B-drug B-drug
, O O
may O O
enhance O O
the O O
effects O O
of O O
oral O O
anticoagulants B-group B-group
, O O
such O O
as O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

The O O
selection O O
of O O
drugs O O
and O O
their O O
dosages O O
may O O
be O O
improved O O
, O O
and O O
the O O
number O O
of O O
adverse O O
effects O O
reduced O O
by O O
pharmacogenetic O O
investigations O O
. O O

Chlorthalidone B-drug B-drug
and O O
related O O
drugs O O
may O O
increase O O
the O O
responsiveness O O
to O O
tubocurarine B-drug B-drug
. O O

Although O O
a O O
3-day O O
regimen O O
of O O
Aprepitant B-drug B-drug
given O O
concomitantly O O
with O O
oral O O
contraceptives B-group B-group
has O O
not O O
been O O
studied O O
, O O
alternative O O
or O O
back-up O O
methods O O
of O O
contraception O O
should O O
be O O
used O O
. O O

Caffeine B-drug B-drug
: O O
Two O O
hundred O O
mg O O
of O O
caffeine B-drug B-drug
( O O
equivalent O O
to O O
1 O O
to O O
3 O O
cups O O
of O O
American O O
coffee O O
) O O
was O O
administered O O
to O O
16 O O
normal O O
, O O
healthy O O
volunteers O O
who O O
had O O
achieved O O
steady-state O O
blood O O
concentrations O O
of O O
lomefloxacin B-drug B-drug
after O O
being O O
dosed O O
at O O
400 O O
mg O O
qd O O
. O O

Their O O
concurrent O O
use O O
should O O
be O O
avoided O O
. O O

Metoclopramide B-drug B-drug
: O O
When O O
coadministered O O
with O O
MONUROL B-brand B-brand
, O O
metoclopramide B-drug B-drug
, O O
a O O
drug O O
which O O
increases O O
gastrointestinal O O
motility O O
, O O
lowers O O
the O O
serum O O
concentration O O
and O O
urinary O O
excretion O O
of O O
fosfomycin B-drug B-drug
. O O

Dosage O O
of O O
the O O
anticoagulant B-group B-group
may O O
require O O
reduction O O
in O O
order O O
to O O
maintain O O
satisfactory O O
therapeutic O O
hypoprothrombinemia O O
. O O

Among O O
the O O
proteins O O
that O O
undergo O O
tyrosine O O
phosphorylation O O
in O O
response O O
to O O
contortrostatin B-drug_n O
treatment O O
is O O
CAS O O
, O O
a O O
130 O O
kDa O O
adapter O O
protein O O
involved O O
in O O
integrin O O
signaling O O
. O O

Careful O O
observation O O
is O O
required O O
. O O

The O O
presence O O
of O O
food O O
in O O
the O O
stomach O O
does O O
not O O
alter O O
the O O
bioavailability O O
of O O
PRINIVIL B-brand B-brand
. O O

Epidural O B-group
clonidine B-drug B-drug
may O O
prolong O O
the O O
duration O O
of O O
pharmacologic O O
effects O O
of O O
epidural O B-drug
local O O
anesthetics B-group B-group
, O O
including O O
both O O
sensory O O
and O O
motor O O
blockade O O
. O O

Esomeprazole B-drug B-drug
is O O
extensively O O
metabolized O O
in O O
the O O
liver O O
by O O
CYP2C19 O O
and O O
CYP3A4 O O
. O O

also O O
induced O O
diarrhea O O
, O O
but O O
did O O
not O O
produce O O
a O O
watery O O
stool O O
in O O
cecectomized O O
rats O O
. O O

( O O
Concurrent O O
use O O
with O O
thiazide B-group B-group
diuretics I-group I-group
is O O
not O O
recommended O O
, O O
as O O
they O O
may O O
provoke O O
lithium B-drug B-drug
toxicity O O
because O O
of O O
reduced O O
renal O O
clearance O O
. O O
) O O

Coadministration O O
of O O
astemizole B-drug B-drug
with O O
ketoconazole B-drug B-drug
tablets O O
is O O
therefore O O
contraindicated O O
. O O

Based O O
on O O
the O O
literature O O
reports O O
, O O
the O O
same O O
effects O O
may O O
be O O
extrapolated O O
to O O
other O O
fruit O O
juices O O
such O O
as O O
apple O O
juice O O
. O O

Drugs O O
possessing O O
beta-blocking O O
properties O O
can O O
blunt O O
the O O
bronchodilator O O
effect O O
of O O
beta-receptor B-group B-group
agonist I-group I-group
drugs I-group I-group
in O O
patients O O
with O O
bronchospasm O O
; O O

Ritonavir B-drug B-drug

- O O
Dapsone B-drug B-drug
or O O

A O O
study O O
in O O
six O O
healthy O O
volunteers O O
has O O
shown O O
a O O
significant O O
increase O O
in O O
peak O O
diltiazem B-drug B-drug
plasma O O
levels O O
( O O
58 O O
% O O
) O O
and O O
AUC O O
( O O
53 O O
% O O
) O O
after O O
a O O
1-week O O
course O O
of O O
cimetidine B-drug B-drug
1200 O O
mg/day O O
and O O
a O O
single O O
dose O O
of O O
diltiazem B-drug B-drug
60mg O O
. O O

The O O
pathophysiologic O O
consequences O O
could O O
be O O
an O O
increased O O
synaptic O O
concentration O O
of O O
norepinephrine B-drug O
predisposing O O
to O O
adenylyl O O
cyclase O O
desensitization O O
. O O

However O O
, O O
a O O
significantly O O
higher O O
proportion O O
of O O
neurons O O
fired O O
spontaneous O O
action O O
potentials O O
with O O
either O O
0.05-0.2 O O
or O O
1 O O
% O O
biocytin O O
compared O O
to O O
no O O
biocytin O O
. O O

The O O
Factrel B-brand B-brand
test O O
should O O
be O O
conducted O O
in O O
the O O
absence O O
of O O
other O O
drugs O O
which O O
directly O O
affect O O
the O O
pituitary O O
secretion O O
of O O
the O O
gonadotropins O O
. O O

Cimetidine O B-drug
Co-administration O O
of O O
felodipine B-drug B-drug
with O O
cimetidine B-drug B-drug
( O O
a O O
non-specific O O
CYP-450 O O
inhibitor O O
) O O
resulted O O
in O O
an O O
increase O O
of O O
approximately O O
50 O O
% O O
in O O
the O O
AUC O O
and O O
the O O
Cmax O O
, O O
of O O
felodipine B-drug B-drug
. O O

triclofos B-drug B-drug
sodium I-drug I-drug
; O O

Metal O O
mixture O O
toxicity O O
investigation O O
was O O
undertaken O O
with O O
equal O O
concentrations O O
of O O
the O O
metals O O
. O O

A O O
pharmacokinetic O O
interaction O O
between O O
diltiazem B-drug B-drug
and O O
cyclosporine B-drug B-drug
has O O
been O O
observed O O
during O O
studies O O
involving O O
renal O O
and O O
cardiac O O
transplant O O
patients O O
. O O

Reversal O O
of O O
the O O
block O O
with O O
edrophonium B-drug B-drug
and O O
subsequent O O
recovery O O
of O O
the O O
horses O O
from O O
anaesthesia O O
were O O
uneventful O O
. O O

Mean O O
number O O
of O O
drugs O O
per O O
MAC O O
was O O
4 O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
0.2 O O
) O O
. O O

The O O
mean O O
minimum O O
lithium B-drug B-drug
concentration O O
increased O O
15 O O
% O O
and O O
the O O
renal O O
clearance O O
was O O
decreased O O
by O O
approximately O O
20 O O
% O O
. O O

Patients O O
undergoing O O
systemic O O
anticholinesterase O O
treatment O O
should O O
be O O
warned O O
of O O
the O O
possible O O
additive O O
effects O O
of O O
Phospholine B-drug B-drug
Iodide I-drug I-drug
. O O

The O O
presence O O
of O O
the O O
radiopharmaceutical B-group O
in O O
the O O
kidneys O O
, O O
along O O
with O O
an O O
increase O O
in O O
renal O O
retention O O
, O O
tend O O
to O O
produce O O
scintigraphic O O
results O O
that O O
falsely O O
identify O O
characteristics O O
related O O
to O O
diseases O O
such O O
as O O
renal O O
vascular O O
, O O
or O O
urinary O O
tract O O
obstruction O O
, O O
and O O
even O O
renal O O
cancer O O
. O O

When O O
given O O
concurrently O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Concomitant O O
use O O
with O O
other O O
oxytocic B-group B-group
agents I-group I-group
is O O
not O O
recommended O O
. O O

Anticonvulsants B-group B-group
: O O
Phenytoin B-drug B-drug
Phenobarbital I-drug I-drug
Carbamazepine I-drug I-drug

decreased O O
pharmacologic O O
effect O O
of O O
aspirin B-brand B-brand
. O O

The O O
inhibiting O O
effects O O
of O O
anticholinergic B-group B-group
drugs I-group I-group
on O O
gastric O O
hydrochloric O O
acid O O
secretion O O
are O O
antagonized O O
by O O
agents O O
used O O
to O O
treat O O
achlorhydria O O
and O O
those O O
used O O
to O O
test O O
gastric O O
secretion O O
. O O

The O O
possibility O O
of O O
interactions O O
with O O
other O O
drugs O O
administered O O
concurrently O O
should O O
be O O
considered O O
, O O
particularly O O
when O O
their O O
main O O
route O O
of O O
elimination O O
is O O
active O O
renal O O
secretion O O
via O O
the O O
organic O O
cationic O O
transport O O
system O O
( O O
e.g. O O
, O O
trimethoprim B-drug B-drug
) O O
. O O

The O O
following O O
information O O
was O O
obtained O O
from O O
the O O
literature O O
. O O

Co-administration O O
of O O
warfarin B-drug B-drug
and O O
cerivastatin B-drug B-drug
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
. O O

However O O
, O O
the O O
antagonism O O
of O O
the O O
theophylline-induced B-drug B-drug
anxiogenic O O
effects O O
by O O
CGS21680 B-drug_n B-drug_n
was O O
only O O
observed O O
in O O
the O O
time O O
spent O O
in O O
the O O
light O O
zone O O
, O O
and O O
DPCPX-induced B-drug_n B-drug_n
anxiogenic O O
effects O O
were O O
neither O O
reversed O O
by O O
CGS B-drug B-drug_n
21680 I-drug I-drug_n
nor O O
by O O
CPA B-drug_n B-drug_n
. O O

No O O
clinical O O
or O O
drug O O
interaction O O
study O O
was O O
conducted O O
with O O
dolasetron B-drug B-drug
. O O

Although O O
other O O
hormonal B-group B-group
contraceptives I-group I-group
are O O
highly O O
effective O O
, O O
there O O
have O O
been O O
reports O O
of O O
pregnancy O O
from O O
women O O
who O O
have O O
used O O
combined B-group O
oral I-group O
contraceptives I-group B-group
, O O
as O O
well O O
as O O
topical/injectable/implantable/insertable O O
hormonal O O
birth O O
control O O
products O O
. O O

Anticoagulants B-group B-group
: O O
Warfarin B-drug B-drug

METHODS O O
: O O
The O O
study O O
was O O
carried O O
out O O
as O O
an O O
open O O
, O O
randomized O O
, O O
crossover O O
design O O
with O O
14 O O
healthy O O
participants O O
. O O

7 O O
. O O

However O O
, O O
in O O
a O O
single O O
in O O
vivo O O
rodent O O
study O O
denileukin B-drug O
diftitox I-drug O
had O O
no O O
effect O O
on O O
P450 O O
levels O O
. O O

If O O
hypotension O O
occurs O O
, O O
the O O
patient O O
should O O
be O O
placed O O
in O O
a O O
supine O O
position O O
and O O
, O O
if O O
necessary O O
, O O
receive O O
an O O
intravenous O O
infusion O O
of O O
normal O O
saline O O
. O O

There O O
have O O
been O O
no O O
formal O O
studies O O
of O O
the O O
interaction O O
of O O
LEVULAN B-brand B-brand
KERASTICK I-brand B-brand
for O O
Topical O O
Solution O O
with O O
any O O
other O O
drugs O O
, O O
and O O
no O O
drug-specific O O
interactions O O
were O O
noted O O
during O O
any O O
of O O
the O O
controlled O O
clinical O O
trials O O
. O O

In O O
addition O O
, O O
the O O
use O O
of O O
herbal O O
remedies O O
may O O
be O O
detrimental O O
for O O
the O O
patient O O
with O O
compromised O O
renal O O
function O O
. O O

This O O
may O O
result O O
in O O
increased O O
risk O O
of O O
theophylline-related B-drug B-drug
adverse O O
reactions O O
. O O

The O O
pharmacokinetics O O
of O O
estazolam B-drug B-drug
( O O
Cmax O O
and O O
AUC O O
) O O
were O O
not O O
affected O O
during O O
multiple-dose O O
fluoxetine B-drug B-drug
, O O
suggesting O O
no O O
clinically O O
significant O O
pharmacokinetic O O
interaction O O
. O O

Even O O
so O O
dextromethorphan B-drug B-drug
plasma O O
concentrations O O
in O O
the O O
presence O O
of O O
high O O
doses O O
of O O
valdecoxib B-drug B-drug
were O O
almost O O
5-fold O O
lower O O
than O O
those O O
seen O O
in O O
CYP O O
2D6 O O
poor O O
metabolizers O O
suggesting O O
that O O
dose O O
adjustment O O
is O O
not O O
necessary O O
. O O

CNS O O
Acting O O
Drugs O O
: O O
Given O O
the O O
primary O O
CNS O O
effects O O
of O O
Duloxetine B-drug B-drug
, O O
it O O
should O O
be O O
used O O
with O O
caution O O
when O O
it O O
is O O
taken O O
in O O
combination O O
with O O
or O O
substituted O O
for O O
other O O
centrally O O
acting O O
drugs O O
, O O
including O O
those O O
with O O
a O O
similar O O
mechanism O O
of O O
action O O
. O O

Slow O O
chylomicron O O
intravascular O O
catabolism O O
has O O
been O O
associated O O
with O O
coronary O O
artery O O
disease O O
and O O
screening O O
for O O
drugs O O
that O O
can O O
speed-up O O
this O O
process O O
can O O
be O O
important O O
. O O

Pretreatment O O
of O O
healthy O O
volunteers O O
with O O
multiple O O
doses O O
of O O
rifampin B-drug B-drug
followed O O
by O O
a O O
single O O
dose O O
of O O
Gleevec B-brand B-brand
, O O
increased O O
Gleevec B-brand B-brand
oral-dose O O
clearance O O
by O O
3.8-fold O O
, O O
which O O
significantly O O
( O O
p O O
0.05 O O
) O O
decreased O O
mean O O
cmax O O
and O O
AUC O O
( O O
0-8 O O
) O O
. O O

sertraline I-drug B-drug
concentration O O

Coadministration O O
of O O
almotriptan B-drug B-drug
and O O
the O O
potent O O
CYP3A4 O O
inhibitor O O
ketoconazole B-drug B-drug
( O O
400 O O
mg O O
q.d O O
. O O
for O O
3 O O
days O O
) O O
resulted O O
in O O
an O O
approximately O O
60 O O
% O O
increase O O
in O O
the O O
area O O
under O O
the O O
plasma O O
concentration-time O O
curve O O
and O O
maximal O O
plasma O O
concentrations O O
of O O
almotriptan B-drug B-drug
. O O

Delavirdine B-drug B-drug

Because O O
pregnancy O O
could O O
not O O
be O O
maintained O O
in O O
the O O
rabbit O O
following O O
doses O O
of O O
fulvestrant B-drug B-drug
of O O
1 O O
mg/kg/day O O
and O O
above O O
, O O
this O O
study O O
was O O
inadequate O O
to O O
fully O O
define O O
the O O
possible O O
adverse O O
effects O O
on O O
fetal O O
development O O
at O O
clinically O O
relevant O O
exposures O O
. O O

HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
: O O
The O O
combined O O
use O O
of O O
TRICOR B-brand B-brand
and O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
should O O
be O O
avoided O O
unless O O
the O O
benefit O O
of O O
further O O
alterations O O
in O O
lipid O O
levels O O
is O O
likely O O
to O O
outweigh O O
the O O
increased O O
risk O O
of O O
this O O
drug O O
combination O O
. O O

Coadministration O O
of O O
diltiazem B-drug B-drug
with O O
rifampin B-drug B-drug
or O O
any O O
known O O
CYP3A4 O O
inducer O O
should O O
be O O
avoided O O
when O O
possible O O
, O O
and O O
alternative O O
therapy O O
considered O O
. O O

Acellular O B-drug
, O O
live O O
and O O
live-attenuated B-group B-group
vaccines I-group I-group
should O O
not O O
be O O
administered O O
during O O
RAPTIVA B-brand B-brand
treatment O O
. O O

Drugs O O
Highly O O
Bound O O
to O O
Plasma O O
Protein O O
Zaleplon B-drug B-drug
is O O
not O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
fraction O O
bound O O
60 O O
% O O
15 O O
% O O
) O O
; O O

The O O
administration O O
of O O
local O O
anesthetic B-group B-group
solutions I-group I-group
containing O O
epinephrine B-drug B-drug
or O O
norepinephrine B-drug B-drug
to O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
or O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
produce O O
severe O O
, O O
prolonged O O
hypertension O O
. O O

Skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
: O O
amphotericin B-drug B-drug
B-induced O O
hypokalemia O O
may O O
enhance O O
the O O
curariform O O
effect O O
of O O
skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
( O O
e.g. O O
, O O
tubocurarine B-drug B-drug
) O O
. O O

[ O O
2 O O
epidemics O O
of O O
arsenical O O
encephalopathy O O
in O O
the O O
treatment O O
of O O
trypanosomiasis O O
, O O
Uganda O O
, O O
1992-1993 O O
] O O
Since O O
1988 O O
, O O
the O O
french O O
non-governmental O O
organisation O O
M O O
decins O O
Sans O O
Fronti O O
res O O
is O O
running O O
a O O
control O O
program O O
of O O
human O O
african O O
trypanosomiasis O O
in O O
the O O
district O O
of O O
Moyo O O
, O O
North-Uganda O B-drug_n
. O O

There O O
have O O
been O O
reports O O
of O O
increased O O
anticoagulant O O
effects O O
when O O
erythromycin B-drug B-drug
and O O
oral O O
anticoagulants B-group B-group
were O O
used O O
concomitantly O O
. O O

Verapamil B-drug B-drug
also O O
significantly O O
decreased O O
the O O
incidence O O
of O O
lymphatic O O
invasion O O
of O O
adenocarcinomas O O
, O O
which O O
was O O
enhanced O O
by O O
bombesin B-drug_n B-drug_n
. O O

However O O
, O O
high O O
doses O O
of O O
leucovorin B-drug B-drug
may O O
reduce O O
the O O
efficacy O O
of O O
intrathecally O O
administered O O
methotrexate B-drug B-drug
. O O

Other O O
factors O O
, O O
such O O
as O O
tolerance O O
and O O
sensitization O O
to O O
the O O
drugs O O
' O O
actions O O
and O O
the O O
development O O
of O O
withdrawal O O
symptoms O O
, O O
may O O
also O O
contribute O O
to O O
dependence O O
. O O

epilepsy O O
; O O

Cisplatin B-drug B-drug
was O O
administered O O
over O O
the O O
last O O
two O O
hours O O
of O O
the O O
thiosulfate B-drug B-drug
infusion O O
. O O

Determinants O O
of O O
cellular O O
sensitivity O O
to O O
topoisomerase-targeting B-group O
antitumor I-group O
drugs I-group O
. O O

Care O O
should O O
be O O
given O O
when O O
administering O O
this O O
drug O O
to O O
patients O O
with O O
symptoms O O
of O O
myasthenic O O
weakness O O
who O O
are O O
also O O
on O O
anticholinesterase B-group B-group
drugs I-group I-group
. O O

The O O
concomitant O O
administration O O
of O O
Exjade B-brand B-brand
and O O
vitamin B-drug B-drug
C I-drug I-drug
has O O
not O O
been O O
formally O O
studied O O
. O O

it O O
was O O
independent O O
of O O
the O O
influence O O
of O O
the O O
nueronal O O
cell O O
body O O
and O O
of O O
protein O O
synthesis O O
within O O
the O O
axon O O
. O O

An O O
altered O O
biodistribution O O
may O O
provide O O
misleading O O
information O O
that O O
can O O
either O O
mask O O
or O O
mimic O O
certain O O
disease O O
symptoms O O
. O O

Such O O
data O O
are O O
discussed O O
herein O O
, O O
with O O
emphasis O O
on O O
those O O
aspects O O
that O O
impact O O
on O O
the O O
clinical O O
use O O
of O O
the O O
calcium-entry B-group B-group
antagonists I-group I-group
. O O

Anticoagulants B-group B-group
: O O
Ten O O
patients O O
who O O
were O O
stabilized O O
on O O
oral O O
anticoagulants B-group B-group
were O O
given O O
guanfacine B-drug B-drug
, O O
1-2 O O
mg/day O O
, O O
for O O
4 O O
weeks O O
. O O

Concurrent O O
use O O
with O O
probenecid B-drug B-drug
or O O
other O O
drugs O O
significantly O O
eliminated O O
by O O
active O O
renal O O
tubular O O
secretion O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
penciclovir B-drug B-drug
. O O

Fenbufen B-drug B-drug
is O O
not O O
approved O O
in O O
the O O
United O O
States O O
at O O
this O O
time O O
. O O

TAXOL B-brand B-brand
contains O O
dehydrated O O
alcohol O B-drug
USP O O
, O O
396 O O
mg/mL O O
; O O

Another O O
oral O O
azole B-group B-group
antifungal I-group I-group
, O O
ketoconazole B-drug B-drug
, O O
inhibits O O
the O O
metabolism O O
of O O
astemizole B-drug B-drug
, O O
resulting O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
astemizole B-drug B-drug
and O O
its O O
active O O
metabolite O O
desmethylastermizole B-drug_n B-drug
which O O
may O O
prolong O O
QT O O
intervals O O
. O O

Lansoprazole B-drug B-drug
has O O
also O O
been O O
shown O O
to O O
have O O
no O O
clinically O O
significant O O
interaction O O
with O O
amoxicillin B-drug B-drug
. O O

Potential O O
drug O O
interactions O O
between O O
Keppra B-brand B-brand
and O O
other O O
AEDs B-group B-group
( O O
carbamazepine B-drug B-drug
, O O
gabapentin B-drug B-drug
, O O
lamotrigine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
primidone B-drug B-drug
and O O
valproate B-drug B-drug
) O O
were O O
also O O
assessed O O
by O O
evaluating O O
the O O
serum O O
concentrations O O
of O O
levetiracetam B-drug B-drug
and O O
these O O
AEDs B-group B-group
during O O
placebo-controlled O O
clinical O O
studies O O
. O O

These O O
data O O
suggest O O
that O O
ginsenosides B-drug_n B-drug_n
are O O
negatively O O
coupled O O
to O O
three O O
types O O
of O O
calcium O O
channels O O
in O O
bovine O O
chromaffin O O
cell O O
, O O
including O O
an O O
omega-conotoxin B-drug_n B-drug_n
GVIA-sensitive O I-drug_n
( O O
N-type O O
) O O
channel O O
, O O
an O O
omega-agatoxin B-drug_n O
IVA-sensitive O O
( O O
P-type O O
) O O
channel O O
and O O
nimodipine/omega-conotoxin B-drug O
GVIA/omega-agatoxin B-drug_n O
VIA-resistant O O
( O O
presumptive O O
Q-type O O
) O O
channel O O
. O O

Drug O O
Interactions O O
with O O
Beta-Blockers B-group B-group
: O O
Concomitant O O
use O O
of O O
fenoldopam B-drug B-drug
with O O
beta-blockers B-group B-group
should O O
be O O
avoided O O
. O O

Morphine B-drug B-drug
prolonged O O
gastrointestinal O O
transit O O
time O O
from O O
69 O O
to O O
103 O O
minutes O O
( O O
P O O
= O O
.005 O O
) O O
; O O
this O O
was O O
prevented O O
by O O
ADL B-drug B-drug
8-2698 I-drug I-drug
( O O
P O O
= O O
.004 O O
) O O
. O O

Oral O O
Contraceptives B-group B-group
: O O
Coadministration O O
of O O
atorvastatin B-drug B-drug
and O O
an O O
oral O O
contraceptive B-group B-group
increased O O
AUC O O
values O O
for O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
by O O
approximately O O
30 O O
% O O
and O O
20 O O
% O O
. O O

Caution O O
should O O
be O O
used O O
if O O
INDOCIN B-brand B-brand
is O O
administered O O
simultaneously O O
with O O
methotrexate B-drug B-drug
. O O

exfoliative O O
dermatitis O O

Therefore O O
, O O
it O O
would O O
be O O
expected O O
that O O
a O O
dosing O O
schedule O O
of O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
given O O
at O O
bedtime O O
and O O
cholestyramine B-drug B-drug
given O O
before O O
the O O
evening O O
meal O O
would O O
not O O
result O O
in O O
a O O
significant O O
decrease O O
in O O
the O O
clinical O O
effect O O
of O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
. O O

However O O
, O O
there O O
were O O
16 O O
% O O
and O O
32 O O
% O O
increases O O
in O O
the O O
AUC O O
and O O
Cmax O O
, O O
respectively O O
, O O
of O O
the O O
combined O O
moieties O O
of O O
threohydrobupropion B-drug_n O
and O O
erythrohydrobupropion B-drug_n O
. O O

The O O
permeability O O
of O O
the O O
cell O O
membrane O O
was O O
changed O O
as O O
evidenced O O
by O O
the O O
leakage O O
of O O
260-nm O O
absorbing O O
materials O O
, O O
amino O O
acids O O
, O O
proteins O O
, O O
and O O
inorganic O O
cations O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
used O O
when O O
administering O O
nitazoxanide B-drug B-drug
concurrently O O
with O O
other O O
highly O O
plasma O O
protein-bound O O
drugs O O
with O O
narrow O O
therapeutic O O
indices O O
, O O
as O O
competition O O
for O O
binding O O
sites O O
may O O
occur O O
( O O
e.g. O O
, O O
warfarin B-drug B-drug
) O O
. O O

The O O
plasma O O
maximum O O
concentration O O
and O O
area O O
under O O
the O O
plasma O O
concentration-time O O
curve O O
of O O
diltiazem B-drug B-drug
, O O
desacetyldiltiazem B-drug_n B-drug
, O O
and O O
desmethyldiltiazem B-drug_n B-drug
were O O
unchanged O O
after O O
coadministration O O
of O O
sirolimus B-drug B-drug
, O O
and O O
no O O
potentiation O O
of O O
the O O
effects O O
of O O
diltiazem B-drug B-drug
on O O
diastolic O O
or O O
systolic O O
blood O O
pressure O O
or O O
on O O
the O O
electrocardiographic O O
parameters O O
was O O
seen O O
. O O

Prothrombin O O
time O O
was O O
not O O
affected O O
by O O
levetiracetam B-drug B-drug
. O O

Noncardioselective B-group B-group
beta-blockers I-group I-group
( O O
nadolol B-drug B-drug
, O O
porpranolol O B-drug
, O O
timolol B-drug B-drug
) O O
may O O
exacerbate O O
rebound O O
hypertension O O
when O O
guanfacine B-drug B-drug
is O O
withdrawn O O
. O O

**No O O
significant O O
effect O O
. O O

Data O O
from O O
in O O
vitro O O
studies O O
of O O
benzodiazepines B-group B-group
other O O
than O O
alprazolam B-drug B-drug
suggest O O
a O O
possible O O
drug O O
interaction O O
for O O
the O O
following O O
: O O
ergotamine B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
amiodarone B-drug B-drug
, O O
nicardipine B-drug B-drug
, O O
and O O
nifedipine B-drug B-drug
. O O

An O O
interacting O O
drug O O
which O O
leads O O
to O O
a O O
decrease O O
in O O
prothrombin O O
time O O
necessitating O O
an O O
increased O O
dose O O
of O O
oral O O
anticoagulant B-group B-group
to O O
maintain O O
an O O
adequate O O
degree O O
of O O
anticoagulation O O
may O O
, O O
if O O
abruptly O O
discontinued O O
, O O
increase O O
the O O
risk O O
of O O
subsequent O O
bleeding O O
. O O

Among O O
these O O
patients O O
, O O
the O O
incidence O O
of O O
upper O O
gastrointestinal O O
adverse O O
experiences O O
in O O
the O O
patients O O
treated O O
with O O
Ibandronate B-drug B-drug
was O O
similar O O
to O O
that O O
in O O
placebo-treated O O
patients O O
. O O

Corticosteroids B-group B-group
, O O
Methylxanthines B-group B-group
and O O
Diuretics B-group B-group
: O O
Concomitant O O
treatment O O
with O O
xanthine B-group B-group
derivatives I-group I-group
, O O
steroids B-group B-group
, O O
or O O
diuretics B-group B-group
may O O
potentiate O O
a O O
possible O O
hypokalemic O O
effect O O
of O O
beta2-agonists B-group B-group
. I-group O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
presence O O
of O O
labetalol O B-drug
metabolites O O
in O O
the O O
urine O O
may O O
result O O
in O O
falsely O O
elevated O O
levels O O
of O O
urinary O O
catecholamines O O
, O O
metanephrine O B-drug
, O O
normetanephrine O B-drug
and O O
vanillylmandelic O B-drug
acid O I-drug
when O O
measured O O
by O O
fluorimetric O O
or O O
photometric O O
methods O O
. O O

Eight O O
healthy O O
volunteers O O
were O O
randomized O O
in O O
an O O
open-label O O
, O O
two-way O O
crossover O O
study O O
to O O
receive O O
oxycodone B-drug B-drug
, O O
5 O O
mg O O
p.o O O
. O O

Patients O O
taking O O
coumarin-derivative B-group B-group
anticoagulants I-group I-group
concomitantly O O
with O O
capecitabine B-drug B-drug
should O O
be O O
monitored O O
regularly O O
for O O
alterations O O
in O O
their O O
coagulation O O
parameters O O
( O O
PT O O
or O O
INR O O
) O O
. O O

Cytokines B-group O
( O O
interferon B-group B-drug
, O O
interleukin B-group O
) O O
: O O
Cytokines B-group B-group
have O O
been O O
reported O O
to O O
induce O O
both O O
hyperthyroidism O O
and O O
hypothyroidism O O
. O O

Corticotropin B-drug B-drug
may O O
accentuate O O
the O O
electrolyte O O
loss O O
associated O O
with O O
diuretic B-drug B-group
therapy O O
. O O

Because O O
of O O
the O O
low O O
dietary O O
cobalt B-drug B-drug
concentration O O
as O O
compared O O
to O O
the O O
iron B-drug B-drug
contents O O
of O O
the O O
diets O O
, O O
no O O
effect O O
of O O
cobalt B-drug B-drug
on O O
iron B-drug B-drug
absorption O O
and O O
excretion O O
occurred O O
. O O

Tricyclic B-group B-group
Antidepressants I-group I-group
: O O
Concurrent O O
use O O
may O O
increase O O
the O O
therapeutic O O
and O O
toxic O O
effects O O
of O O
both O O
drugs O O
, O O
possibly O O
due O O
to O O
increased O O
catecholamine O O
sensitivity O O
. O O

Drug-Drug O O
Interactions O O
: O O
The O O
pharmacokinetic O O
and O O
pharmacodynamic O O
interactions O O
between O O
UROXATRAL B-brand B-brand
and O O
other O O
alpha-blockers B-group B-group
have O O
not O O
been O O
determined O O
. O O

The O O
administration O O
of O O
SUPRAX B-brand B-brand
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
using O O
Clinitest O O
** O O
, O O
Benedict O O
s O O
solution O O
, O O
or O O
Fehling O O
s O O
solution O O
. O O

thyroid B-group B-group
drugs I-group I-group
; O O

No O O
formal O O
drug-drug O O
interaction O O
studies O O
, O O
however O O
, O O
have O O
been O O
conducted O O
. O O

The O O
reduction O O
in O O
MAC O O
was O O
correlated O O
with O O
brain O O
levels O O
of O O
ketamine B-drug B-drug
or O O
metabolite O O
I O O
, O O
suggesting O O
a O O
ketamine B-drug B-drug
: O O
metabolite O O
I O O
potency O O
ration O O
of O O
3:1 O O
. O O

In O O
vitro O O
studies O O
demonstrated O O
no O O
evidence O O
of O O
incompatibility O O
of O O
heparin B-drug B-drug
with O O
EXTRANEAL B-brand B-brand
. O O

The O O
action O O
of O O
colchicine B-drug B-drug
is O O
potentiated O O
by O O
alkalinizing B-group O
agents I-group O
. O O

In O O
male O O
Sprague-Dawley O O
rats O O
fasted O O
for O O
18 O O
h O O
, O O
concomitant O O
administration O O
of O O
caffeine B-drug B-drug
( O O
0.1 O O
g/kg O O
, O O
i.p O O
. O O
) O O

If O O
combination O O
therapy O O
is O O
needed O O
, O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
all O O
agents O O
to O O
be O O
used O O
. O O

Zalcitabine B-drug B-drug
inhibited O O
lamivudine B-drug B-drug
phosphorylation O O
at O O
high O O
concentration O O
ratios O O
( O O
10 O O
and O O
100 O O
) O O
; O O

Lithium B-drug B-drug
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
because O O
they O O
reduce O O
its O O
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Valdecoxib B-drug B-drug
caused O O
a O O
statistically O O
significant O O
increase O O
in O O
plasma O O
exposures O O
of O O
R-warfarin B-drug B-drug
and O O
S-warfarin B-drug B-drug
( O O
12 O O
% O O
and O O
15 O O
% O O
, O O
respectively O O
) O O
, O O
and O O
in O O
the O O
pharmacodynamic O O
effects O O
( O O
prothrombin O O
time O O
, O O
measured O O
as O O
INR O O
) O O
of O O
warfarin B-drug B-drug
. O O

Lithium B-drug B-drug
: O O
NSAIDs B-group B-group
have O O
produced O O
an O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
levels O O
and O O
a O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
. O O

Mutagenicity O O
studies O O
were O O
conducted O O
in O O
vitro O O
and O O
in O O
vivo O O
; O O

The O O
relative O O
risk O O
of O O
myocardial O O
infarction O O
during O O
sexual O O
activity O O
is O O
not O O
significantly O O
higher O O
than O O
for O O
healthy O O
persons O O
. O O

Those O O
for O O
which O O
effectiveness O O
is O O
reported O O
includes O O
diphenhydramine B-drug B-drug
, O O
hydroxyzine B-drug B-drug
, O O
orphenadrine B-drug B-drug
, O O
pyrilamine B-drug B-drug
, O O
phenyltoloxamine B-drug_n B-drug
, O O
promethazine B-drug B-drug
, O O
methdilazine B-drug B-drug
, O O
and O O
tripelennamine B-drug B-drug
. O O

Heart O O
rate O O
increased O O
initially O O
and O O
returned O O
to O O
normal O O
40 O O
minutes O O
after O O
ethanol B-drug B-drug
challenge O O
. O O

The O O
concentration O O
of O O
AMICAR B-brand B-brand
necessary O O
to O O
maintain O O
inhibition O O
of O O
fibrinolysis O O
is O O
0.99 O O
mMol/L O O
or O O
0.13 O O
mg/mL O O
. O O

Therefore O O
, O O
unless O O
otherwise O O
specified O O
, O O
appropriate O O
dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O

Pharmacokinetic O O
data O O
suggest O O
that O O
absorption O O
, O O
metabolism O O
, O O
and O O
elimination O O
of O O
each O O
of O O
these O O
drugs O O
are O O
unchanged O O
when O O
they O O
are O O
used O O
together O O
. O O

Short-Acting B-group B-group
beta2-agonists I-group I-group
: O O
Aerosol O O
bronchodilators B-group B-group
of O O
the O O
short-acting O B-group
adrenergic O I-group
stimulant O I-group
type O I-group
may O O
be O O
used O O
for O O
relief O O
of O O
breakthrough O O
symptoms O O
while O O
using O O
formoterol B-drug B-drug
. O O

It O O
is O O
recommended O O
that O O
gabapentin B-drug B-drug
be O O
taken O O
at O O
least O O
2 O O
hours O O
following O O
Maalox B-brand B-brand
administration O O
. O O

ethacrynic B-drug B-drug
acid I-drug I-drug
; O O

Warfarin B-drug B-drug
: O O
When O O
healthy O O
subjects O O
were O O
administered O O
Starlix B-brand B-brand
120 O O
mg O O
three O O
times O O
daily O O
before O O
meals O O
for O O
four O O
days O O
in O O
combination O O
with O O
a O O
single O O
dose O O
of O O
warfarin B-drug B-drug
30 O O
mg O O
on O O
day O O
2 O O
, O O
there O O
were O O
no O O
alterations O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

Cerubidine B-brand B-drug
should O O
not O O
be O O
used O O
in O O
patients O O
who O O
have O O
previously O O
received O O
the O O
recommended O O
maximum O O
cumulative O O
doses O O
of O O
doxorubicin B-drug B-drug
or O O
Cerubidine B-brand B-drug
. O O

However O O
, O O
L-NAME B-drug_n B-brand
( O O
100 O O
and O O
300 O O
micromol/l O O
) O O
did O O
not O O
alter O O
the O O
effects O O
of O O
reseveratrol B-drug_n B-brand
on O O
arteries O O
from O O
dietary-obese O O
rats O O
, O O
giving O O
superimposed O O
concentration-responses O O
curves O O
. O O

- O O
a O O
sulfa-based O O
drug O O
such O O
as O O
sulfamethoxazole-trimethoprim B-drug B-drug
( O O
Bactrim B-brand B-brand
, O O
Septra B-brand B-brand
) O O
, O O
sulfisoxazole B-drug B-drug
( O O
Gantrisin B-brand B-brand
) O O
, O O
or O O
sulfasalazine B-drug B-drug
( O O
Azulfidine B-brand B-drug
) O O
; O O

Concomitant O O
use O O
of O O
SPRYCEL B-brand B-brand
and O O
drugs O O
that O O
inhibit O O
CYP3A4 O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
atazanavir B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
telithromycin B-drug B-drug
) O O
may O O
increase O O
exposure O O
to O O
dasatinib B-drug B-drug
and O O
should O O
be O O
avoided O O
. O O

Patients O O
should O O
be O O
cautioned O O
against O O
engaging O O
in O O
hazardous O O
activities O O
requiring O O
complete O O
mental O O
alertness O O
such O O
as O O
operating O O
machinery O O
or O O
driving O O
a O O
motor O O
vehicle O O
. O O

If O O
a O O
diuretic B-group B-group
is O O
also O O
used O O
, O O
the O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
may O O
be O O
increased O O
. O O

Insulin B-drug B-drug
or O O
Oral O O
Hypoglycemics B-group B-group
: O O
Agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group O
may O O
enhance O O
the O O
blood-sugar-reducing O O
effect O O
of O O
insulin B-drug B-drug
and O O
oral O O
hypoglycemics B-group B-group
. O O

The O O
following O O
drug O O
interactions O O
were O O
studied O O
with O O
ketoprofen B-drug B-drug
doses O O
of O O
200 O O
mg/day O O
. O O

The O O
gonadotropin O O
levels O O
may O O
be O O
transiently O O
elevated O O
by O O
spironolactone B-drug B-drug
, O O
minimally O O
elevated O O
by O O
levodopa B-drug B-drug
, O O
and O O
suppressed O O
by O O
oral O O
contraceptives B-group B-group
and O O
digoxin B-drug B-drug
. O O

Careful O O
observations O O
on O O
hepatotoxicity O O
are O O
suggested O O
when O O
acetaminophen B-drug B-drug
is O O
prescribed O O
with O O
caffeine B-drug B-drug
. O O

Lipids O O
: O O
Pretreatment O O
and O O
follow-up O O
blood O O
lipids O O
should O O
be O O
obtained O O
under O O
fasting O O
conditions O O
. O O

This O O
effect O O
should O O
be O O
kept O O
in O O
mind O O
when O O
bleeding O O
times O O
are O O
determined O O
. O O

Trecator B-brand B-brand
may O O
potentiate O O
the O O
adverse O O
effects O O
of O O
other O O
antituberculous B-group O
drugs I-group O
administered O O
concomitantly O O
. O O

Immunodeficiency-associated O O
lymphocyte O O
disorders O O
( O O
plasmacytic O O
hyperplasia O O
, O O
polymorphic O O
proliferation O O
, O O
and O O
B-cell O O
lymphomas O O
) O O
occur O O
in O O
patients O O
who O O
have O O
congenital O O
or O O
acquired O O
immunodeficiencies O O
including O O
those O O
resulting O O
from O O
immunosuppressive B-group B-group
therapy O O
. O O

Prescribing O O
. O O

- O O
Hydroxychloroquine B-drug B-drug
( O O
e.g. O O
, O O
Plaquenil B-brand B-brand
) O O
or O O

The O O
risk O O
of O O
myopathy O O
is O O
also O O
increased O O
by O O
the O O
following O O
lipid-lowering O O
drugs O O
that O O
are O O
not O O
potent O O
CYP3A4 O O
inhibitors O O
, O O
but O O
which O O
can O O
cause O O
myopathy O O
when O O
given O O
alone O O
. O O

Codeine B-drug B-drug
in O O
combination O O
with O O
other O O
narcotic B-group B-group
analgesics I-group I-group
, O O
general O O
anesthetics B-group B-group
, O O
phenothiazines B-group B-group
, O O
tranquilizers B-group B-group
, O O
sedative-hypnotics B-group B-group
, O O
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
including O O
alcohol B-drug B-drug
) O O
has O O
additive O O
depressant O O
effects O O
. O O

Potential O O
for O O
serious O O
reactions O O
such O O
as O O
risk O O
of O O
myopathy O O
including O O
rhabdomyolysis O O
. O O

Heparin B-drug B-drug
: O O
Since O O
heparin B-drug B-drug
is O O
contraindicated O O
in O O
patients O O
with O O
heparin-induced B-drug O
thrombocytopenia O O
, O O
the O O
co-administration O O
of O O
Argatroban B-drug B-drug
and O O
heparin B-drug B-drug
is O O
unlikely O O
for O O
this O O
indication O O
. O O

If O O
these O O
products O O
are O O
needed O O
, O O
they O O
should O O
be O O
given O O
at O O
least O O
2 O O
hours O O
before O O
cimetidine B-drug B-drug
administration O O
. O O

Terfenadine B-drug B-drug
: O O
Administration O O
of O O
terfenadine B-drug B-drug
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
the O O
appearance O O
of O O
unchanged O O
terfenadine B-drug B-drug
in O O
plasma O O
; O O

increased O O
levels O O
of O O
fibrinogen O O
and O O
fibrinogen O O
activity O O
; O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
is O O
known O O
to O O
interact O O
with O O
the O O
metabolism O O
or O O
renal O O
tubular O O
excretion O O
of O O
many O O
drugs O O
( O O
e.g. O O
, O O
acetaminophen B-drug B-drug
, O O
acyclovir B-drug B-drug
, O O
angiotensin-converting B-group B-group
enzyme I-group I-group
inhibitors I-group I-group
, O O
aminosalicylic B-drug B-drug
acid I-drug I-drug
, O O
barbiturates B-group B-group
, O O
benzodiazepines B-group B-group
, O O
bumetanide B-drug B-drug
, O O
clofibrate B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
famotidine B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents O I-group
, O O
theophylline B-drug B-drug
, O O
and O O
zidovudine B-drug B-drug
) O O
. O O

The O O
data O O
suggest O O
that O O
18-MC B-drug_n B-drug_n
has O O
a O O
narrower O O
spectrum O O
of O O
actions O O
and O O
will O O
have O O
a O O
substantially O O
greater O O
therapeutic O O
index O O
than O O
ibogaine B-drug_n B-drug_n
. O O

Cyclopentolate B-drug B-drug
may O O
interfere O O
with O O
the O O
anti-glaucoma O O
action O O
of O O
carbachol B-drug B-drug
or O O
pilocarpine B-drug B-drug
; O O

Anticonvulsants B-group B-group
( O O
carbamazepine B-drug B-drug
, O O
felbamate B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
topiramate B-drug B-drug
) O O
: O O
Increase O O
the O O
metabolism O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and/or O O
some O O
progestins B-group B-group
, O O
leading O O
to O O
possible O O
decrease O O
in O O
contraceptive O O
effectiveness O O
. O O

Anticoagulants B-group B-group
: O O
While O O
studies O O
have O O
not O O
shown O O
diclofenac B-drug B-drug
to O O
interact O O
with O O
anticoagulants B-group B-group
of I-group O
the I-group O
warfarin I-group B-drug
type I-group O
, O O
caution O O
should O O
be O O
exercised O O
, O O
nonetheless O O
, O O
since O O
interactions O O
have O O
been O O
seen O O
with O O
other O O
NSAIDs B-group B-group
. O O

Methenamine B-drug B-drug
therapy O O
Urinary O O
excretion O O
of O O
amphetamines B-group B-group
is O O
increased O O
, O O
and O O
efficacy O O
is O O
reduced O O
by O O
acidifying O B-group
agents O I-group
used O O
in O O
methenamine B-drug B-drug
therapy O O
. O O

Dose O O
adjustment O O
of O O
lapatinib B-drug B-drug
should O O
be O O
considered O O
for O O
patients O O
who O O
must O O
receive O O
concomitant O O
strong O O
inhibitors O O
or O O
concomitant O O
strong O O
inducers O O
of O O
CYP3A4 O O
enzymes O O
. O O

Short-term O O
controlled O O
studies O O
failed O O
to O O
show O O
that O O
taking O O
the O O
drug O O
significantly O O
affects O O
prothrombin O O
times O O
when O O
administered O O
to O O
individuals O O
on O O
coumarin-type B-group B-group
anticoagulants I-group I-group
. O O

Monitoring O O
of O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
may O O
be O O
helpful O O
when O O
possible O O
drug O O
interactions O O
are O O
suspected O O
. O O

SUSTIVAhas O O
the O O
potential O O
to O O
decrease O O
serum O O
concentrations O O
of O O
amprenavir B-drug B-drug
. O O

Interaction O O
of O O
gentamycin B-drug B-drug
and O O
atracurium B-drug B-drug
in O O
anaesthetised O O
horses O O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

Although O O
not O O
observed O O
in O O
this O O
study O O
, O O
adverse O O
effects O O
could O O
potentially O O
arise O O
from O O
co-administration O O
of O O
cephalexin B-drug B-drug
and O O
metformin B-drug B-drug
by O O
inhibition O O
of O O
tubular O O
secretion O O
via O O
organic O O
cationic O O
transporter O O
systems O O
. O O

In O O
bioavailability O O
studies O O
with O O
normal O O
subjects O O
, O O
the O O
concurrent O O
administration O O
of O O
antacids B-group B-group
at O O
therapeutic O O
levels O O
did O O
not O O
significantly O O
influence O O
the O O
bioavailability O O
of O O
TRANXENE B-brand B-brand
tablets O O
. O O

Nitroglycerin B-drug B-drug
: O O
DynaCirc B-brand B-drug
( O O
isradipine B-drug B-drug
) O O
has O O
been O O
safely O O
coadministered O O
with O O
nitroglycerin B-drug B-drug
. O O

Even O O
though O O
such O O
interactions O O
were O O
not O O
seen O O
during O O
clinical O O
studies O O
with O O
nicardipine B-drug B-drug
HCl I-drug I-drug
, O O
an O O
increased O O
volume O O
of O O
circulating O O
fluids O O
might O O
be O O
required O O
if O O
such O O
an O O
interaction O O
were O O
to O O
occur O O
. O O

Patients O O
receiving O O
concurrent O O
administration O O
of O O
substrates O O
of O O
C.P.A O O
. O O
were O O
not O O
excluded O O
from O O
clinical O O
trials O O
of O O
grepafloxacin B-drug B-drug
. O O

Warfarin B-drug B-drug
Keppra B-brand B-brand
( O O
1000 O O
mg O O
twice O O
daily O O
) O O
did O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
R O O
and O O
S B-drug B-drug
warfarin I-drug I-drug
. O O

Hepatotoxic O O
Drugs O O
Increased O O
side O O
effects O O
may O O
occur O O
when O O
leflunomide B-drug B-drug
is O O
given O O
concomitantly O O
with O O
hepatotoxic O O
substances O O
. O O

Physicians O O
needing O O
to O O
treatpatients O O
co-infected O O
with O O
tuberculosis O O
andusing O O
a O O
nevirapine B-drug B-drug
containing O O
regimen O O
mayuse O O
rifabutin B-drug B-drug
instead O O
. O O

In O O
a O O
pharmacokinetic O O
study O O
, O O
38 O O
healthy O O
female O O
subjects O O
received O O
ketoconazole B-drug B-drug
200 O O
mg O O
twice O O
daily O O
for O O
7 O O
days O O
, O O
with O O
coadministration O O
of O O
alosetron B-drug B-drug
1 O O
mg O O
on O O
the O O
last O O
day O O
. O O

ketoconazole B-drug B-drug
) O O
, O O
macrolide B-group B-group
antibiotics I-group I-group
( O O
e.g O O
. O O
erythromycin B-drug B-drug
) O O
, O O
and O O
HIV B-group B-group
protease I-group I-group
inhibitors I-group I-group
( O O
e.g O O
. O O
ritonavir B-drug B-drug
, O O
indinavir B-drug B-drug
and O O
saquinavir B-drug B-drug
) O O
should O O
have O O
their O O
dose O O
of O O
SUBUTEX B-brand B-brand
or O O
SUBOXONE B-brand B-brand
adjusted O O
. O O

It O O
may O O
be O O
necessary O O
to O O
adjust O O
the O O
dosage O O
of O O
oral O O
anticoagulants B-group B-group
upon O O
beginning O O
or O O
stopping O O
disulfiram B-drug B-drug
. O O
since O O
disulfiram B-drug B-drug
may O O
prolong O O
prothrombin O O
time O O
. O O

Caution O O
is O O
advised O O
nonetheless O O
, O O
since O O
interactions O O
have O O
been O O
seen O O
with O O
other O O
nonsteroidal O B-group
agents O I-group
of O O
this O O
class O O
. O O

The O O
simplest O O
inference O O
is O O
that O O
the O O
toxicity O O
and O O
effectiveness O O
of O O
polyenes O B-group
are O O
determined O O
by O O
their O O
relative O O
avidities O O
for O O
the O O
predominant O O
sterol O O
in O O
cell O O
membranes O O
. O O

In O O
Study O O
1 O O
, O O
patients O O
receiving O O
bolus-IFL O O
plus O O
AVASTIN B-brand B-brand
had O O
a O O
higher O O
incidence O O
of O O
Grade O O
3-4 O O
diarrhea O O
and O O
neutropenia O O
. O O

Plasma O O
TCA B-group B-group
concentrations O O
may O O
need O O
to O O
be O O
monitored O O
and O O
the O O
dose O O
of O O
the O O
TCA B-group B-group
may O O
need O O
to O O
be O O
reduced O O
if O O
a O O
TCA B-group B-group
is O O
co-administered O O
with O O
Duloxetine B-drug B-drug
. O O

Although O O
there O O
is O O
little O O
risk O O
for O O
loss O O
of O O
contraceptive O O
efficacy O O
, O O
the O O
clinical O O
significance O O
of O O
these O O
increased O O
exposures O O
in O O
terms O O
of O O
safety O O
is O O
not O O
known O O
. O O

Additional O O
clinical O O
experience O O
may O O
reveal O O
other O O
drugs O O
affected O O
by O O
the O O
concomitant O O
administration O O
of O O
Tagamet B-brand B-brand
. O O

Tricyclic B-group B-group
Antidepressants I-group I-group
: O O
Use O O
of O O
thyroid B-group O
products I-group O
with O O
imipramine B-drug B-drug
and O O
other O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
increase O O
receptor O O
sensitivity O O
and O O
enhance O O
antidepressant O O
activity O O
transient O O
cardiac O O
arrhythmias O O
have O O
been O O
observed O O
. O O

Effects O O
of O O
Felbatol B-brand B-brand
on O O
Low-Dose O O
Combination B-group O
Oral I-group O
Contraceptives I-group B-group
A O O
group O O
of O O
24 O O
nonsmoking O O
, O O
healthy O O
white O O
female O O
volunteers O O
established O O
on O O
an O O
oral O O
contraceptive B-group B-group
regimen O O
containing O O
30 O O
mg O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
75 O O
mg O O
gestodene B-drug B-drug
for O O
at O O
least O O
3 O O
months O O
received O O
2400 O O
mg/day O O
of O O
felbamate B-drug B-drug
from O O
midcycle O O
( O O
day O O
15 O O
) O O
to O O
midcycle O O
( O O
day O O
14 O O
) O O
of O O
two O O
consecutive O O
oral O O
contraceptive B-group B-group
cycles O O
. O O

The O O
median O O
survival O O
for O O
CHOP-HAART O O
patients O O
was O O
not O O
reached O O
, O O
whereas O O
the O O
medial O O
survival O O
of O O
CHOP O O
patients O O
was O O
7 O O
months O O
( O O
P O O
= O O
0.03 O O
) O O
. O O

increased O O
platelet O O
count O O
; O O

Tadalafil B-drug B-drug

Cisapride B-drug B-drug
was O O
well O O
tolerated O O
when O O
administered O O
alone O O
or O O
with O O
fluoxetine B-drug B-drug
. O O

H2 B-group B-group
Blockers I-group I-group
and O O
Proton B-group B-group
Pump I-group I-group
Inhibitors I-group I-group
( O O
PPIs B-group B-group
) O O

Antihistamines B-group B-group
may O O
partially O O
counteract O O
the O O
anticoagulation O O
effects O O
of O O
heparin B-drug B-drug
or O O
warfarin B-drug B-drug
. O O

Since O O
FOSCAVIR B-brand B-brand
decreases O O
serum O O
concentrations O O
of O O
ionized O O
calcium O O
, O O
concurrent O O
treatment O O
with O O
other O O
drugs O O
known O O
to O O
influence O O
serum O O
calcium O O
concentrations O O
should O O
be O O
used O O
with O O
particular O O
caution O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
drugs I-group I-group
add O O
some O O
further O O
antihypertensive O O
effect O O
to O O
captopril B-drug B-drug
, O O
but O O
the O O
overall O O
response O O
is O O
less O O
than O O
additive O O
. O O

chymotrypsin B-drug O
; O O

In O O
vitro O O
studies O O
in O O
human O O
liver O O
microsomes O O
indicate O O
that O O
ertapenem B-drug B-drug
does O O
not O O
inhibit O O
metabolism O O
mediated O O
by O O
any O O
of O O
the O O
following O O
six O O
cytochrome O O
p450 O O
( O O
CYP O O
) O O
isoforms O O
: O O
1A2 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
2E1 O O
and O O
3A4 O O
. O O

These O O
events O O
required O O
medical O O
intervention O O
in O O
some O O
patients O O
. O O

- O O
Digoxin B-drug B-drug
: O O
Interaction O O
studies O O
in O O
humans O O
have O O
shown O O
no O O
effect O O
on O O
digoxin B-drug B-drug
blood O O
levels O O
. O O

Potassium-depleting B-group B-group
diuretics I-group I-group
are O O
a O O
major O O
contributing O O
factor O O
to O O
digitalis B-group B-group
toxicity O O
. O O

Rhabdomyolysis O O
has O O
been O O
observed O O
in O O
patients O O
receiving O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
administered O O
alone O O
( O O
at O O
recommended O O
dosages O O
) O O
or O O
concomitantly O O
with O O
immunosuppressive B-group B-group
drugs I-group I-group
including O O
cyclosporine B-drug B-drug
. O O

Magnesium B-drug B-drug
and O O
therapeutics O O
. O O

Interactions O O
with O O
lipid-lowering O O
drugs O O
that O O
can O O
cause O O
myopathy O O
when O O
given O O
alone O O
. O O

Geriatric O O
Use O O

Quetiapine B-drug B-drug
fumarate I-drug I-drug
( O O
'Seroquel B-brand B-brand
' O O
) O O
is O O
a O O
newly O O
introduced O O
atypical B-group B-group
antipsychotic I-group I-group
with O O
demonstrated O O
efficacy O O
in O O
the O O
treatment O O
of O O
positive O O
and O O
negative O O
symptoms O O
of O O
schizophrenia O O
. O O

glucagon B-drug O
; O O

In O O
the O O
case O O
of O O
severe O O
neutropenia O O
( O O
500 O O
cells/mm3 O O
for O O
seven O O
days O O
or O O
more O O
) O O
during O O
a O O
course O O
of O O
TAXOL B-brand B-brand
therapy O O
, O O
a O O
20 O O
% O O
reduction O O
in O O
dose O O
for O O
subsequent O O
courses O O
of O O
therapy O O
is O O
recommended O O
. O O

Based O O
on O O
adult O O
data O O
, O O
lower O O
doses O O
of O O
caffeine B-drug B-drug
may O O
be O O
needed O O
following O O
coadministration O O
of O O
drugs O O
which O O
are O O
reported O O
to O O
decrease O O
caffeine B-drug B-drug
elimination O O
( O O
e.g. O O
, O O
cimetidine B-drug B-drug
and O O
ketoconazole B-drug B-drug
) O O
and O O
higher O O
caffeine B-drug B-drug
doses O O
may O O
be O O
needed O O
following O O
coadministration O O
of O O
drugs O O
that O O
increase O O
caffeine B-drug B-drug
elimination O O
( O O
e.g. O O
, O O
phenobarbital B-drug B-drug
and O O
phenytoin B-drug B-drug
) O O
. O O

- O O
Disulfiram B-drug B-drug
( O O
e.g. O O
, O O
Antabuse B-brand B-brand
) O O
or O O

Rifampin B-drug B-drug
: O O
Coadministration O O
of O O
rifampin B-drug B-drug
and O O
MEPRON B-brand B-brand
Suspension O O
results O O
in O O
a O O
significant O O
decrease O O
in O O
average O O
steady- O O
state O O
plasma O O
atovaquone B-drug B-drug
concentrations O O
. O O

When O O
digoxin B-drug B-drug
and O O
BREVIBLOC B-brand B-brand
were O O
concomitantly O O
administered O O
intravenously O O
to O O
normal O O
volunteers O O
, O O
there O O
was O O
a O O
10-20 O O
% O O
increase O O
in O O
digoxin B-drug B-drug
blood O O
levels O O
at O O
some O O
time O O
points O O
. O O

Grapefruit O O
juice O O
increases O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
concentrations O O
and O O
would O O
be O O
expected O O
to O O
increase O O
progesterone B-drug B-drug
serum O O
levels O O
as O O
well O O
; O O

Rifabutin B-drug B-drug

Acetazolamide B-drug B-drug
and O O
sodium B-drug B-drug
bicarbonate I-drug I-drug
used O O
concurrently O O
increases O O
the O O
risk O O
of O O
renal O O
calculus O O
formation O O
. O O

Efavirenz I-drug B-drug

Moreover O O
, O O
the O O
basal O O
and O O
dmPGE2-induced B-drug_n B-drug_n
jejunal O I-drug_n
net O O
fluid O O
transfers O O
were O O
the O O
same O O
in O O
cecectomized O O
and O O
in O O
control O O
rats O O
. O O

Antacids B-group B-group
: O O
In O O
a O O
clinical O O
pharmacology O O
study O O
, O O
coadministration O O
of O O
an O O
antacid B-group B-group
( O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
, O O
magnesium B-drug B-drug
hydroxide I-drug I-drug
, O O
and O O
simethicone B-drug B-drug
) O O
with O O
fosinopril B-drug B-drug
reduced O O
serum O O
levels O O
and O O
urinary O O
excretion O O
of O O
fosinoprilat B-drug_n B-drug
as O O
compared O O
with O O
fosinopril B-drug B-drug
administered O O
alone O O
, O O
suggesting O O
that O O
antacids B-group B-group
may O O
impair O O
absorption O O
of O O
fosinopril B-drug B-drug
. O O

The O O
renal O O
effects O O
of O O
nephrotoxic O O
compounds O O
may O O
be O O
potentiated O O
by O O
Carboplatin B-drug B-drug
. O O

Further O O
, O O
in O O
clinical O O
studies O O
with O O
PROSCAR B-brand B-brand
( O O
finasteride B-drug B-drug
, O O
5 O O
mg O O
) O O
when O O
used O O
in O O
older O O
men O O
who O O
have O O
benign O O
prostatic O O
hyperplasia O O
( O O
BPH O O
) O O
, O O
PSA O O
levels O O
are O O
decreased O O
by O O
approximately O O
50 O O
% O O
. O O

Amiodarone B-drug B-drug
may O O
suppress O O
certain O O
CYP450 O O
enzymes O O
, O O
including O O
CYP1A2 B-drug O
, O O
CYP2C9 B-drug O
, O O
CYP2D6 B-drug O
, O O
and O O
CYP3A4 B-drug O
. O O

Influence O O
of O O
estradiol B-drug B-drug
and O O
progesterone B-drug B-drug
on O O
the O O
sensitivity O O
of O O
rat O O
thoracic O O
aorta O O
to O O
noradrenaline B-drug B-drug
. O O

Use O O
of O O
Cerubidine B-brand B-drug
in O O
a O O
patient O O
who O O
has O O
previously O O
received O O
doxorubicin B-drug B-drug
increases O O
the O O
risk O O
of O O
cardiotoxicity O O
. O O

Because O O
Anafranil B-brand B-brand
is O O
highly O O
bound O O
to O O
serum O O
protein O O
, O O
the O O
administration O O
of O O
Anafranil B-brand B-brand
to O O
patients O O
taking O O
other O O
drugs O O
that O O
are O O
highly O O
bound O O
to O O
protein O O
( O O
e.g. O O
, O O
warfarin B-drug B-drug
, O O
digoxin B-drug B-drug
) O O
may O O
cause O O
an O O
increase O O
in O O
plasma O O
concentrations O O
of O O
these O O
drugs O O
, O O
potentially O O
resulting O O
in O O
adverse O O
effects O O
. O O

Olanzapine B-drug B-drug
: O O
Coadministration O O
of O O
eszopiclone B-drug B-drug
3 O O
mg O O
and O O
olanzapine B-drug B-drug
10 O O
mg O O
produced O O
a O O
decrease O O
in O O
DSST O O
scores O O
. O O

METHOD O O
: O O
This O O
study O O
was O O
a O O
multicenter O O
randomized O O
double-blind O O
study O O
of O O
101 O O
patients O O
who O O
were O O
randomly O O
assigned O O
1:1:1 O O
to O O
receive O O
everolimus B-drug B-drug
tablets O O
at O O
doses O O
of O O
0.5 O O
mg O O
, O O
1 O O
mg O O
, O O
or O O
2 O O
mg O O
twice O O
daily O O
with O O
cyclosporine B-drug B-drug
and O O
prednisone B-drug B-drug
. O O

The O O
onset O O
of O O
symptoms O O
usually O O
occurred O O
within O O
hours O O
( O O
most O O
commonly O O
1 O O
to O O
4 O O
hours O O
) O O
following O O
the O O
administration O O
of O O
contrast O O
media O O
. O O

The O O
coadministration O O
of O O
aspirin B-brand B-brand
decreases O O
the O O
biologic O O
half-life O O
of O O
fenoprofen B-drug B-drug
because O O
of O O
an O O
increase O O
in O O
metabolic O O
clearance O O
that O O
results O O
in O O
a O O
greater O O
amount O O
of O O
hydroxylated B-drug_n O
fenoprofen I-drug_n B-drug
in O O
the O O
urine O O
. O O

If O O
NovoLog B-brand B-brand
is O O
mixed O O
with O O
NPH B-drug B-drug
human I-drug I-drug
insulin I-drug I-drug
, O O
NovoLog B-brand B-brand
should O O
be O O
drawn O O
into O O
the O O
syringe O O
first O O
. O O

The O O
fraction O O
of O O
STADOL B-brand B-brand
NS I-brand I-brand
absorbed O O
is O O
unaffected O O
by O O
the O O
concomitant O O
administration O O
of O O
a O O
nasal B-group B-group
vasoconstrictor I-group I-group
( O O
oxymetazoline B-drug B-drug
) O O
, O O
but O O
the O O
rate O O
of O O
absorption O O
is O O
decreased O O
. O O

Minor O O
symptoms O O
such O O
as O O
flushing O O
, O O
skin O O
reactions O O
, O O
dyspnea O O
, O O
hypotension O O
, O O
or O O
tachycardia O O
do O O
not O O
require O O
interruption O O
of O O
therapy O O
. O O

Spermine B-drug B-drug
, O O
and O O
to O O
a O O
lesser O O
extent O O
, O O
spermidine B-drug_n B-drug
, O O
enhanced O O
the O O
translocating O O
action O O
of O O
oleate O O
and O O
increased O O
its O O
effectiveness O O
in O O
transferring O O
the O O
phosphohydrolase O O
from O O
the O O
soluble O O
to O O
the O O
microsomal O O
fraction O O
. O O

Carcinogenesis O O
, O O
Mutagenesis O O
and O O
Impairment O O
of O O
Fertility O O
A O O
two-year O O
carcinogenesis O O
study O O
was O O
conducted O O
in O O
female O O
and O O
male O O
rats O O
, O O
at O O
intramuscular O O
doses O O
of O O
15 O O
mg/kg/30 O O
days O O
, O O
10 O O
mg/rat/30 O O
days O O
and O O
10 O O
mg/rat/15 O O
days O O
. O O

Although O O
in O O
vivo O O
studies O O
have O O
not O O
been O O
done O O
to O O
see O O
if O O
etodolac B-drug B-drug
clearance O O
is O O
changed O O
by O O
coadministration O O
of O O
phenylbutazone B-drug B-drug
, O O
it O O
is O O
not O O
recommended O O
that O O
they O O
be O O
coadministered O O
. O O

Products O O
containing O O
calcium B-drug B-drug
and O O
other O O
multivalent B-drug O
cations I-drug O
likely O O
will O O
interfere O O
with O O
absorption O O
of O O
alendronate B-drug B-drug
. O O

Enoxaparin B-drug B-drug
dosed O O
as O O
a O O
1.0 O O
mg/kg O O
subcutaneous O O
injection O O
q12h O O
for O O
four O O
doses O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
eptifibatide B-drug B-drug
or O O
the O O
level O O
of O O
platelet O O
aggregation O O
in O O
healthy O O
adults O O
. O O

These O O
results O O
indicate O O
that O O
the O O
pancreatic O O
alpha O O
cell O O
of O O
the O O
diabetic O O
Chinese O O
hamster O O
responds O O
excessively O O
to O O
arginine B-drug B-drug
, O O
as O O
is O O
seen O O
in O O
the O O
human O O
diabetic O O
. O O

The O O
mean O O
AUC O O
values O O
of O O
LNG O O
were O O
decreased O O
by O O
32 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
20-45 O O
] O O
in O O
one O O
study O O
and O O
52 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
42-52 O O
] O O
in O O
another O O
study O O
. O O

Cohort O O
1 O O
then O O
received O O
amprenavir B-drug B-drug
plus O O
rifabutin B-drug B-drug
for O O
10 O O
days O O
, O O
and O O
cohort O O
2 O O
received O O
amprenavir B-drug B-drug
plus O O
rifampin B-drug B-drug
for O O
4 O O
days O O
. O O

Protease B-group B-group
Inhibitors I-group I-group
: O O
In O O
vitro O O
data O O
indicate O O
that O O
indinavir B-drug B-drug
and O O
ritonavir B-drug B-drug
markedly O O
inhibit O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
which O O
can O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
cisapride B-drug B-drug
levels O O
and O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

Death O O
due O O
to O O
fulminant O B-drug
pancreatitis O O
possibly O O
related O O
to O O
intravenous O O
pentamidine B-drug B-drug
and O O
HIVID B-drug B-drug
has O O
been O O
reported O O
. O O

These O O
findings O O
should O O
be O O
taken O O
into O O
account O O
for O O
proper O O
interpretation O O
of O O
serum O O
PSA O O
when O O
evaluating O O
men O O
treated O O
with O O
finasteride B-drug B-drug
. O O

The O O
dosage O O
of O O
these O O
medications O O
should O O
not O O
be O O
changed O O
and O O
they O O
should O O
not O O
be O O
stopped O O
without O O
consulting O O
the O O
physician O O
, O O
even O O
if O O
the O O
patient O O
feels O O
better O O
after O O
initiating O O
treatment O O
with O O
FORADIL B-brand B-brand
. O O

Diuretic B-group B-group
agents I-group I-group
reduce O O
the O O
renal O O
clearance O O
of O O
lithium B-drug B-drug
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

The O O
action O O
of O O
the O O
benzodiazepines B-group B-group
may O O
be O O
potentiated O O
by O O
anticonvulsants B-group B-group
, O O
antihistamines B-group B-group
, O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
narcotics B-group B-group
, O O
phenothiazines B-group B-group
, O O
psychotropic B-group B-group
medications I-group I-group
, O O
or O O
other O O
drugs O O
that O O
produce O O
CNS O O
depression O O
. O O

Although O O
there O O
is O O
no O O
documentation O O
of O O
such O O
, O O
a O O
similar O O
interaction O O
between O O
ethotoin B-drug B-drug
and O O
the O O
coumarin B-group B-group
anticoagulants I-group I-group
may O O
occur O O
. O O

if O O
necessary O O
, O O
amiodarone B-drug B-drug
can O O
continue O O
to O O
be O O
used O O
after O O
insertion O O
of O O
a O O
pacemaker O O
in O O
patients O O
with O O
severe O O
bradycardia O O
or O O
sinus O O
arrest O O
. O O

Although O O
neither O O
dexamethasone B-drug B-drug
nor O O
retinyl B-drug B-drug
acetate I-drug I-drug
affected O O
the O O
proliferation O O
of O O
prostatic O O
epithelium O O
in O O
RPMI1640 O O
containing O O
transferrin B-drug_n B-drug
alone O O
, O O
they O O
modify O O
the O O
mitogenic O O
effect O O
of O O
EGF B-drug_n B-drug_n
and O O
insulin B-drug B-drug
. O O

Barbiturates B-group B-group
and O O
glutethimide B-drug B-drug
should O O
not O O
be O O
administered O O
to O O
patients O O
receiving O O
coumarin B-group B-group
drugs I-group I-group
. O O

If O O
pregnancy O O
occurs O O
while O O
taking O O
AMEVIVE B-brand B-brand
, O O
continued O O
use O O
of O O
the O O
drug O O
should O O
be O O
assessed O O
. O O

drugs O O
affecting O O
blood O O
elements O O
; O O

Electrolyte O O
Disturbances O O
Patients O O
with O O
hypokalemia O O
or O O
hypomagnesemia O O
should O O
have O O
the O O
condition O O
corrected O O
whenever O O
possible O O
before O O
being O O
treated O O
with O O
Cordarone B-drug B-brand
I.V. I-drug O
, O O
as O O
these O O
disorders O O
can O O
exaggerate O O
the O O
degree O O
of O O
QTc O O
prolongation O O
and O O
increase O O
the O O
potential O O
for O O
TdP O O
. O O

Potentially O O
fatal O O
drug O O
interactions O O
may O O
occur O O
when O O
coadministered O O
with O O
digoxin B-drug B-drug
, O O
as O O
this O O
may O O
enhance O O
cardiovascular O O
depression O O
and O O
bradyarrhythmias O O
may O O
occur O O
. O O

Interacts O O
with O O
valproic B-drug B-drug
acid I-drug I-drug

Furthermore O O
, O O
arsenate B-drug_n B-drug
and O O
phosphate B-drug B-drug
do O O
not O O
appear O O
to O O
share O O
a O O
common O O
transport O O
pathway O O
in O O
the O O
duodenum O O
and O O
no O O
evidence O O
was O O
obtained O O
for O O
any O O
interaction O O
between O O
the O O
two O O
at O O
this O O
level O O
. O O

Ingestion O O
of O O
diclofenac B-drug B-drug
may O O
increase O O
serum O O
concentrations O O
of O O
digoxin B-drug B-drug
and O O
methotrexate B-drug B-drug
and O O
increase O O
cyclosporine B-drug B-drug
s O O
nephrotoxicity O O
. O O

No O O
dose O O
adjustment O O
is O O
necessary O O
when O O
Simulect B-brand B-brand
is O O
added O O
to O O
triple-immunosuppression O O
regimens O O
including O O
cyclosporine B-drug B-drug
, O O
corticosteroids B-group B-group
, O O
and O O
either O O
azathioprine B-drug B-drug
or O O
mycophenolate B-drug B-drug
mofetil I-drug I-drug
. O O

Inhibition O O
of O O
the O O
other O O
isozymes O O
evaluated O O
( O O
CYPs O O
2A1 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
3A4 O O
, O O
and O O
3E1 O O
) O O
was O O
0-16 O O
% O O
. O O

Taken O O
together O O
, O O
these O O
results O O
suggest O O
that O O
the O O
site O O
of O O
the O O
inhibitory O O
action O O
of O O
RR B-drug_n B-drug_n
is O O
at O O
the O O
InsP O B-drug_n
( O O
3 O O
) O O
receptor O O
, O O
or O O
its O O
closely O O
associated O O
proteins O O
. O O

Iodometric O O
titration O O
of O O
the O O
polymer O O
conjugates O O
was O O
used O O
to O O
determine O O
the O O
extent O O
of O O
immobilised O O
cysteine B-drug B-drug
. O O

The O O
duration O O
of O O
the O O
period O O
following O O
treatment O O
with O O
AMEVIVE B-brand B-brand
before O O
one O O
should O O
consider O O
starting O O
other O O
immunosuppressive B-group B-group
therapy O O
has O O
not O O
been O O
evaluated O O
. O O

Plasma O O
membrane O O
and O O
intracellular O O
mobilization O O
of O O
calcium O B-drug
ions O O
are O O
intimately O O
related O O
to O O
platelet O O
activation O O
and O O
release O O
of O O
platelet O O
contents O O
. O O

Prior O O
administration O O
of O O
succinylcholine B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
duration O O
of O O
neuromuscular O O
block O O
following O O
initial O O
or O O
maintenance O O
bolus O O
doses O O
of O O
NIMBEX B-brand B-brand
. O O

- O O
Increased O O
serum O O
triglyceride O O
and O O
phospholipid O O
concentration O O
. O O

Patients O O
receiving O O
flurbiprofen B-drug B-drug
and O O
furosemide B-drug B-drug
or O O
other O O
diuretics B-group B-group
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
is O O
obtained O O
. O O

Quinolones B-group B-group
, O O
including O O
nalidixic B-drug B-drug
acid I-drug I-drug
, O O
may O O
enhance O O
the O O
effects O O
of O O
the O O
oral O O
anticoagulant B-group B-group
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

Coadministration O O
of O O
Itraconazole B-drug B-drug
and O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
or O O
digoxin B-drug B-drug
has O O
led O O
to O O
increased O O
plasma O O
concentrations O O
of O O
the O O
latter O O
three O O
drugs O O
. O O

The O O
administration O O
of O O
other O O
potassium-sparing B-group O
antihypertensives I-group B-group
with O O
NSAIDs B-group B-group
has O O
been O O
shown O O
to O O
reduce O O
the O O
antihypertensive O O
effect O O
in O O
some O O
patients O O
and O O
result O O
in O O
severe O O
hyperkalemia O O
in O O
patients O O
with O O
impaired O O
renal O O
function O O
. O O

Anastrozole B-drug B-drug
inhibited O O
in O O
vitro O O
metabolic O O
reactions O O
catalyzed O O
by O O
cytochromes O O
P450 O O
1A2 O O
, O O
2C8/9 O O
, O O
and O O
3A4 O O
but O O
only O O
at O O
relatively O O
high O O
concentrations O O
. O O

( O O
Effects O O
may O O
be O O
decreased O O
when O O
used O O
concurrently O O
with O O
thiazide B-group B-group
diuretics I-group I-group
; O O

Chloral B-drug B-drug
hydrate I-drug I-drug
and O O
methaqualone B-drug B-drug
interact O O
pharmacologically O O
with O O
orally O O
administered O O
anticoagulant B-group B-group
agents I-group I-group
, O O
but O O
the O O
effect O O
is O O
not O O
clinically O O
significant O O
. O O

Standard O O
therapy O O
includes O O
antibiotics B-group B-group
, O O
such O O
as O O
penicillin B-drug B-drug
and O O
gentamicin B-drug B-drug
; O O

This O O
effect O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
. O O

Leucovorin B-drug B-drug
: O O
The O O
concentration O O
of O O
5-fluorouracil B-drug B-drug
is O O
increased O O
and O O
its O O
toxicity O O
may O O
be O O
enhanced O O
by O O
leucovorin B-drug B-drug
. O O

Caution O O
is O O
warranted O O
and O O
therapeutic O O
concentration O O
monitoring O O
is O O
recommended O O
for O O
antiarrhythmics B-group B-group
when O O
coadministered O O
with O O
CRIXIVAN B-brand B-brand
. O O

This O O
slowing O O
potentiates O O
amphetamines B-group B-group
, O O
increasing O O
their O O
effect O O
on O O
the O O
release O O
of O O
norepinephrine O B-drug
and O O
other O O
monoamines O O
from O O
adrenergic O O
nerve O O
endings O O
; O O

The O O
majority O O
of O O
these O O
reports O O
concerned O O
variable O O
elevations O O
in O O
prothrombin O O
times O O
without O O
clinically O O
significant O O
sequelae O O
. O O

Effects O O
of O O
Antacids B-group B-group
on O O
Felbatol B-brand B-brand
The O O
rate O O
and O O
extent O O
of O O
absorption O O
of O O
a O O
2400 O O
mg O O
dose O O
of O O
Felbatol B-brand B-brand
as O O
monotherapy O O
given O O
as O O
tablets O O
was O O
not O O
affected O O
when O O
coadministered O O
with O O
antacids B-group B-group
. O O

There O O
has O O
been O O
too O O
little O O
experience O O
with O O
the O O
coadministration O O
of O O
TAMBOCOR B-brand B-brand
with O O
nifedipine B-drug B-drug
or O O
diltiazem B-drug B-drug
to O O
recommend O O
concomitant O O
use O O
. O O

Because O O
of O O
the O O
risk O O
of O O
increased O O
exposure O O
tonevirapine B-drug B-drug
, O O
caution O O
should O O
be O O
used O O
inconcomitant O O
administration O O
, O O
and O O
patients O O
should O O
be O O
monitored O O
closely O O
for O O
nevirapine-associated O B-drug
adverse O O
events O O
. O O

Cardiac B-group B-group
Glycosides I-group I-group
: O O
In O O
a O O
study O O
of O O
young O O
healthy O O
male O O
subjects O O
no O O
evidence O O
of O O
a O O
direct O O
pharmacokinetic O O
captopril-digoxin B-drug O
interaction O O
could O O
be O O
found O O
. O O

Monitor O O
cardiovascular O O
status O O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

methadone I-drug B-drug
concentration O O

There O O
is O O
no O O
information O O
regarding O O
the O O
effect O O
on O O
lamivudine B-drug B-drug
pharmacokinetics O O
of O O
higher O O
doses O O
of O O
TMP/SMX B-drug B-drug
such O O
as O O
those O O
used O O
to O O
treat O O
Pneumocystis O O
carinii O O
pneumonia O O
. O O

Based O O
on O O
known O O
metabolic O O
profiles O O
, O O
clinically O O
significant O O
drug O O
interactions O O
are O O
not O O
expected O O
between O O
VIRACEPT B-brand B-brand
and O O
dapsone B-drug B-drug
, O O
trimethoprim/sulfamethoxazole B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
itraconazole B-drug B-drug
or O O
fluconazole B-drug B-drug
. O O

Therefore O O
, O O
close O O
monitoring O O
of O O
serum O O
cyclosporin B-drug B-drug
level O O
is O O
recommended O O
and O O
, O O
if O O
necessary O O
, O O
chloroquine B-drug B-drug
should O O
be O O
discontinued O O
. O O

Lapatinib B-drug B-drug
inhibits O O
human O O
P-glycoprotein O O
. O O

Oral O O
anticoagulants B-group B-group
may O O
potentiate O O
the O O
hypoglycemic O O
action O O
of O O
hypoglycemic B-group B-group
agents I-group I-group
, O O
eg O O
, O O
tolbutamide B-drug B-drug
and O O
chlorpropamide B-drug B-drug
, O O
by O O
inhibiting O O
their O O
metabolism O O
in O O
the O O
liver O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

No O O
formal O O
drug/drug O O
interaction O O
studies O O
with O O
Plenaxis B-brand B-brand
were O O
performed O O
. O O

Coadministration O O
of O O
warfarin B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
. O O

All O O
antagonists O B-group
decreased O O
the O O
time O O
spent O O
in O O
the O O
light O O
zone O O
in O O
this O O
test O O
, O O
which O O
suggested O O
that O O
these O O
compounds O O
have O O
anxiogenic O O
effects O O
. O O

iv O O
. O O

Nucleoside O B-group
Analogues O O
Didanosine B-drug O
Co-administration O O
of O O
COPEGUS B-brand B-brand
and O O
didanosine B-drug B-drug
is O O
not O O
recommended O O
. O O

Glutathione-S-transferase O O
( O O
GST O O
) O O
activity O O
, O O
however O O
, O O
did O O
not O O
differ O O
from O O
control O O
values O O
for O O
any O O
dose O O
or O O
at O O
any O O
time O O
point O O
in O O
cerebral O O
and O O
hepatic O O
tissues O O
. O O

Thus O O
, O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
of O O
EQUETROTM B-brand B-brand
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
treatment O O
with O O
one O O
of O O
these O O
CYP3A4 O O
or O O
epoxide O O
hydrolase O O
inhibitors O O
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
reduction O O
for O O
EQUETROTM B-brand B-brand
may O O
be O O
necessary O O
. O O

In O O
a O O
ten-subject O O
study O O
, O O
coadministration O O
of O O
diltiazem B-drug B-drug
( O O
120 O O
mg O O
bid O O
) O O
with O O
lovastatin B-drug B-drug
resulted O O
in O O
a O O
3-4 O O
times O O
increase O O
in O O
mean O O
lovastatin B-drug B-drug
AUC O O
and O O
Cmax O O
vs. O O
lovastatin B-drug B-drug
alone O O
; O O

. O O

In O O
clinical O O
trials O O
in O O
patients O O
undergoing O O
PTCA/PCI O O
, O O
co-administration O O
of O O
Angiomax B-brand B-brand
with O O
heparin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
thrombolytics B-group B-group
or O O
glycoprotein O B-group
IIb/IIIa O I-group
inhibitors O I-group
was O O
associated O O
with O O
increased O O
risks O O
of O O
major O O
bleeding O O
events O O
compared O O
to O O
patients O O
not O O
receiving O O
these O O
concomitant O O
medications O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
urine O O
of O O
patients O O
who O O
take O O
Lodine B-brand B-brand
can O O
give O O
a O O
false-positive O O
reaction O O
for O O
urinary O O
bilirubin O O
( O O
urobilin O O
) O O
due O O
to O O
the O O
presence O O
of O O
phenolic O O
metabolites O O
of O O
etodolac B-drug B-drug
. O O

Hormonal B-group B-group
Contraceptives I-group I-group
: O O
It O O
has O O
not O O
been O O
established O O
if O O
there O O
is O O
a O O
pharmacokinetic O O
interaction O O
between O O
acitretin B-drug B-drug
and O O
combined B-group O
oral I-group O
contraceptives I-group B-group
. O O

Beta-blockers B-group B-group
not O O
only O O
block O O
the O O
therapeutic O O
effects O O
of O O
beta-agonists B-group B-group
, O O
but O O
may O O
produce O O
severe O O
bronchospasm O O
in O O
COPD O O
patients O O
. O O

A O O
smaller O O
24-week O O
study O O
has O O
suggested O O
nevirapine B-drug B-drug
may O O
be O O
superior O O
to O O
the O O
PI B-group O
nelfinavir B-drug B-drug
. O O

Therefore O O
, O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
levels O O
should O O
be O O
considered O O
and O O
dosage O O
of O O
theophylline B-drug B-drug
adjusted O O
as O O
required O O
. O O

Tablets O O
, O O
Injection O O
, O O
and O O
Oral O O
Solution O O
One O O
study O O
in O O
six O O
subjects O O
demonstrated O O
that O O
the O O
combination O O
of O O
furosemide B-drug B-drug
and O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
temporarily O O
reduced O O
creatinine O O
clearance O O
in O O
patients O O
with O O
chronic O O
renal O O
insufficiency O O
. O O

Because O O
the O O
potential O O
interaction O O
of O O
efavirenz B-drug B-drug
with O O
oral O O
contraceptives B-group B-group
has O O
not O O
been O O
fully O O
characterized O O
, O O
a O O
reliable O O
method O O
of O O
barrier O O
contraception O O
should O O
be O O
used O O
in O O
addition O O
to O O
oral O O
contraceptives B-group B-group
. O O

and O O
exert O O
direct O O
effects O O
on O O
the O O
mechanisms O O
of O O
insulin O B-drug
resistance O O
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
drugs O O
is O O
withdrawn O O
from O O
co-therapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
agent I-group I-group
may O O
be O O
required O O
. O O

use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

Transfer O O
from O O
the O O
intestinal O O
lumen O O
to O O
the O O
mucosal O O
cells O O
at O O
low O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
concentration O O
( O O
0.1 O O
mM O O
) O O
is O O
rapid O O
, O O
while O O
transfer O O
from O O
the O O
mucosal O O
cells O O
to O O
the O O
body O O
occurs O O
more O O
slowly O O
. O O

Increased O O
metoprolol B-drug B-drug
plasma O O
levels O O
have O O
been O O
associated O O
with O O
decreased O O
cardioselectivity O O
. O O

Bacteriostatic B-group B-group
Antibiotics I-group I-group
: O O
Chloramphenicol B-drug B-drug
, O O
erythromycins B-drug B-group
, O O
sulfonamides B-group B-group
, O O
or O O
tetracyclines B-group B-group
may O O
interfere O O
with O O
the O O
bactericidal O O
effect O O
of O O
penicillins B-group B-group
. O O

It O O
is O O
possible O O
that O O
the O O
cardiovascular O O
action O O
of O O
other O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
could O O
be O O
enhanced O O
by O O
the O O
addition O O
of O O
Nimotop B-brand B-brand
. O O

Free O O
T4 O O
and O O
T3 O O
concentrations O O
are O O
unaltered O O
. O O

uterine O B-group
fibroids O I-group
; O O

Co-administration O O
of O O
tacrolimus B-drug B-drug
and O O
bosentan B-drug B-drug
resulted O O
in O O
markedly O O
increased O O
plasma O O
concentrations O O
of O O
bosentan B-drug B-drug
in O O
animals O O
. O O

sucralfate B-drug B-drug
or O O
divalent O O
or O O
trivalent O O
cations O O
such O O
as O O
iron B-drug B-drug
; O O

Indocyanine B-drug_n O
green I-drug_n O
as O O
an O O
index O O
of O O
hepatic O O
drug O O
extraction O O
has O O
been O O
tested O O
and O O
no O O
significant O O
effects O O
have O O
been O O
found O O
. O O

Tumors O O
of O O
more O O
malignant O O
phenotype O O
were O O
demonstrated O O
only O O
in O O
genetically O O
predisposed O O
mice O O
( O O
C57BL/6N O O
X O O
C3H/HeN O O
F1 O O
) O O
that O O
received O O
one O O
dose O O
of O O
carcinogen O O
. O O

use O O
potassium B-drug B-drug
supplements O O
if O O
necessary O O
. O O

It O O
is O O
recommended O O
that O O
plasma O O
lithium B-drug B-drug
levels O O
be O O
monitored O O
when O O
ketoprofen B-drug B-drug
is O O
coadministered O O
with O O
lithium B-drug B-drug
. O O

Tagamet B-brand B-brand
, O O
apparently O O
through O O
an O O
effect O O
on O O
certain O O
microsomal O O
enzyme O O
systems O O
, O O
has O O
been O O
reported O O
to O O
reduce O O
the O O
hepatic O O
metabolism O O
of O O
warfarin-type B-group B-group
anticoagulants I-group I-group
, O O
phenytoin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
chlordiazepoxide B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
certain O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
lidocaine B-drug B-drug
, O O
theophylline B-drug B-drug
and O O
metronidazole B-drug B-drug
, O O
thereby O O
delaying O O
elimination O O
and O O
increasing O O
blood O O
levels O O
of O O
these O O
drugs O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
A O O
false-positive O O
reaction O O
for O O
ketones O O
in O O
the O O
urine O O
may O O
occur O O
with O O
tests O O
using O O
nitroprusside B-drug B-drug
but O O
not O O
with O O
those O O
using O O
nitroferricyanide B-drug B-drug
. O O

Because O O
of O O
the O O
potential O O
for O O
adverse O O
reactions O O
from O O
the O O
drugs O O
in O O
nursing O O
infants O O
, O O
a O O
decision O O
must O O
be O O
made O O
whether O O
to O O
discontinue O O
nursing O O
or O O
discontinue O O
PEGASYS B-brand B-brand
and O O
COPEGUS B-brand B-brand
treatment O O
. O O

Several O O
classes O O
of O O
cardiovascular O O
drugs O O
are O O
also O O
discussed O O
in O O
relationship O O
to O O
their O O
differential O O
effects O O
on O O
the O O
management O O
and O O
progression O O
of O O
renal O O
disease O O
. O O

Exercise O O
that O O
produces O O
cardiopulmonary O O
stimulation O O
is O O
a O O
helpful O O
means O O
of O O
reducing O O
drug O O
hunger O O
and O O
anxiety O O
during O O
recovery O O
therapy O O
. O O

There O O
has O O
been O O
little O O
experience O O
with O O
the O O
coadministration O O
of O O
TAMBOCOR B-brand B-brand
and O O
either O O
disopyramide B-drug B-drug
or O O
verapamil B-drug B-drug
. O O

The O O
administration O O
of O O
cefdinir B-drug B-drug
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
urine O O
using O O
Clinitest O O
, O O
Benedict O O
s O O
solution O O
, O O
or O O
Fehlings O O
solution O O
. O O

Anaesthesia O O
and O O
the O O
epileptic O O
pateint O O
. O O

. O O

therefore O O
, O O
nelfinavir B-drug B-drug
should O O
be O O
administered O O
( O O
with O O
food O O
) O O
one O O
hour O O
after O O
or O O
more O O
than O O
two O O
hours O O
before O O
didanosine B-drug B-drug
. O O

Dose O O
reduction O O
of O O
rifabutin B-drug B-drug
to O O
half O O
the O O
standard O O
dose O O
and O O
a O O
dose O O
increase O O
of O O
CRIXIVAN B-brand B-brand
to O O
1000 O O
mg O O
( O O
three O O
333-mg O O
capsules O O
) O O
every O O
8 O O
hours O O
are O O
recommended O O
when O O
rifabutin B-drug B-drug
and O O
CRIXIVAN B-brand B-brand
are O O
coadministered O O
. O O

Succinylcholine B-drug B-drug
may O O
cause O O
a O O
sudden O O
extrusion O O
of O O
potassium O O
from O O
muscle O O
cells O O
, O O
and O O
may O O
thereby O O
cause O O
arrhythmias O O
in O O
digitalized O O
patients O O
. O O

dextrothyroxine B-drug B-drug
; O O

Cardiac O O
effects O O
of O O
dopamine B-drug B-drug
are O O
antagonized O O
by O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
such O O
as O O
propranolol B-drug B-drug
and O O
metoprolol B-drug B-drug
. O O

The O O
principal O O
drugs O O
given O O
( O O
number O O
of O O
patients O O
in O O
parentheses O O
) O O
were O O
: O O
cardiac B-group B-group
glycosides I-group I-group
( O O
115 O O
) O O
, O O
sedatives B-group B-group
and O O
hypnotics B-group B-group
( O O
103 O O
) O O
, O O
coronary B-group B-group
vasodilators I-group I-group
( O O
52 O O
) O O
, O O
oral O O
hypoglycemics B-group B-group
( O O
45 O O
) O O
, O O
cough O O
and O O
cold O O
preparations O O
( O O
45 O O
) O O
, O O
NSAIDs B-group B-group
( O O
38 O O
) O O
, O O
antihyperlipidemics B-group B-group
( O O
29 O O
) O O
, O O
antigout B-group B-group
drugs I-group I-group
( O O
24 O O
) O O
, O O
oral O O
contraceptives B-group B-group
( O O
18 O O
) O O
, O O
bronchodilators B-group B-group
( O O
13 O O
) O O
, O O
insulin B-drug B-drug
( O O
10 O O
) O O
, O O
and O O
beta B-group B-group
blockers I-group I-group
( O O
10 O O
) O O
. O O

Phenobarbital B-drug B-drug
: O O
Estimates O O
of O O
steady-state O O
pharmacokinetic O O
parameters O O
for O O
phenobarbital B-drug B-drug
or O O
gabapentin B-drug B-drug
( O O
300 O O
mg O O
TID O O
; O O

It O O
is O O
concluded O O
that O O
chloral B-drug B-drug
hydrate I-drug I-drug
and O O
methaqualone B-drug B-drug
may O O
be O O
administered O O
safely O O
without O O
additional O O
caution O O
in O O
prothrombin O O
test O O
monitoring O O
during O O
oral O O
anticoagulant B-group B-group
therapy O O
. O O

Based O O
on O O
anecdotal O O
reports O O
, O O
there O O
may O O
be O O
an O O
interaction O O
between O O
buprenorphine B-drug B-drug
and O O
benzodiazepines B-group B-group
. O O

Unlike O O
nucleolin/C23 O O
, O O
down-regulation O O
of O O
nucleophosmin/B23 O O
was O O
thus O O
not O O
proliferation-dependent O O
but O O
caspase-3- O O
and O O
apoptosis-dependent O O
. O O

Buforin B-drug_n B-brand
II I-drug_n O
showed O O
moderate O O
activity O O
, O O
which O O
increased O O
with O O
increasing O O
concentration O O
to O O
55.7 O O
% O O
suppression O O
of O O
growth O O
at O O
20 O O
microM O O
. O O

To O O
avoid O O
this O O
interaction O O
, O O
delavirdine B-drug B-drug
or O O
indinavir B-drug B-drug
should O O
be O O
given O O
1 O O
hour O O
prior O O
to O O
dosing O O
with O O
VIDEX B-brand B-brand
. O O

Drug O O
interactions O O
with O O
clomiphene B-drug B-drug
citrate I-drug I-drug
tablets O O
USP O O
have O O
not O O
been O O
documented O O
. O O

Drug O O
Name O O

In O O
the O O
general O O
population O O
, O O
sildenafil B-drug B-drug
is O O
considered O O
to O O
have O O
an O O
acceptable O O
tolerability O O
profile O O
; O O

The O O
incidence O O
of O O
cancer O O
increases O O
progressively O O
with O O
age O O
. O O

Absorption O O
of O O
tetracycline B-drug B-drug
is O O
impaired O O
by O O
bismuth B-drug B-drug
subsalicylate I-drug I-drug
. O O

increased O O
factors O O
II O O
, O O
VII O O
antigen O O
, O O
VIII O O
antigen O O
, O O
VIII O O
coagulant O O
activity O O
, O O
IX O O
, O O
X O O
, O O
XII O O
, O O
VII-X O O
complex O O
, O O
II-VII-X O O
complex O O
, O O
and O O
beta-thromboglobulin O B-drug_n
; O O

If O O
labetalol B-drug B-drug
HCl I-drug I-drug
is O O
used O O
with O O
nitroglycerin B-drug B-drug
in O O
patients O O
with O O
angina O O
pectoris O O
, O O
additional O O
antihypertensive O O
effects O O
may O O
occur O O
. O O

Oxcarbazepine B-drug B-drug
can O O
inhibit O O
CYP2C19 O O
and O O
induce O O
CYP3A4/5 O O
with O O
potentially O O
important O O
effects O O
on O O
plasma O O
concentrations O O
of O O
other O O
drugs O O
. O O

Thus O O
, O O
results O O
of O O
the O O
DST O O
should O O
be O O
interpreted O O
with O O
caution O O
in O O
these O O
patients O O
. O O

Broad-Spectrum B-group B-group
Antibiotics-Broad-spectrum I-group I-group
antibiotics I-group I-group
may O O
sterilize O O
the O O
bowel O O
and O O
decrease O O
the O O
vitamin B-group B-group
K I-group I-group
contribution O O
to O O
the O O
body O O
by O O
the O O
intestinal O O
microflora O O
. O O

The O O
effect O O
of O O
TORADOL B-brand B-brand
on O O
methotrexate B-drug B-drug
clearance O O
has O O
not O O
been O O
studied O O
. O O

Exaggerated O O
hypertensive O O
responses O O
have O O
been O O
reported O O
from O O
the O O
combined O O
use O O
of O O
beta-adrenergic B-group B-group
antagonists I-group I-group
and O O
alpha-adrenergic B-group B-group
stimulants I-group I-group
, O O
including O O
those O O
contained O O
in O O
proprietary O O
cold O O
remedies O O
and O O
vasoconstrictive O O
nasal O O
drops O O
. O O

TAMBOCOR B-brand B-brand
has O O
been O O
administered O O
to O O
patients O O
receiving O O
digitalis B-group B-group
preparations I-group I-group
or O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
without O O
adverse O O
effects O O
. O O

Pharmacological O O
treatment O O
of O O
depression O O
: O O
the O O
role O O
of O O
paroxetine B-drug B-drug
. O O

Anticoagulant O O
inhibition O O
was O O
observed O O
during O O
the O O
administration O O
of O O
phenobarbital B-drug B-drug
, O O
secobarbital B-drug B-drug
and O O
glutethimide B-drug B-drug
; O O

Hypertensive O O
crises O O
have O O
resulted O O
when O O
sympathomimetic B-group B-group
amines I-group I-group
have O O
been O O
used O O
concomitantly O O
within14 O O
days O O
following O O
use O O
of O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
. O O

Systemic O O
exposure O O
is O O
limited O O
, O O
as O O
fluvastatin B-drug B-drug
is O O
subject O O
to O O
first-pass O O
metabolism O O
, O O
and O O
the O O
plasma O O
half-life O O
of O O
the O O
drug O O
is O O
approximately O O
30 O O
minutes O O
. O O

In O O
these O O
subjects O O
( O O
R= O O
B O O
) O O
, O O
the O O
clearance O O
of O O
diazepam B-drug B-drug
was O O
reduced O O
by O O
65 O O
% O O
and O O
that O O
of O O
N-desmethyldiazepam B-drug_n B-drug_n
to O O
a O O
level O O
that O O
was O O
too O O
low O O
to O O
measure O O
over O O
the O O
course O O
of O O
the O O
2 O O
week O O
long O O
study O O
. O O

an O O
interval O O
of O O
at O O
least O O
4 O O
hours O O
between O O
intake O O
of O O
these O O
agents O O
and O O
chloroquine B-drug B-drug
should O O
be O O
observed O O
. O O

Following O O
the O O
administration O O
of O O
INAPSINE B-brand B-brand
, O O
the O O
dose O O
of O O
other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
should O O
be O O
reduced O O
. O O

PROLEUKIN B-brand B-brand
may O O
affect O O
central O O
nervous O O
function O O
. O O

In O O
another O O
study O O
with O O
intravenous O O
administration O O
of O O
midazolam B-drug B-drug
, O O
Aprepitant B-drug B-drug
was O O
given O O
as O O
125 O O
mg O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
and O O
3 O O
, O O
and O O
midazolam B-drug B-drug
2 O O
mg O O
IV O O
was O O
given O O
prior O O
to O O
the O O
administration O O
of O O
the O O
3-day O O
regimen O O
of O O
Aprepitant B-drug B-drug
and O O
on O O
Days O O
4 O O
, O O
8 O O
, O O
and O O
15 O O
. O O

The O O
impact O O
of O O
the O O
combined O O
chemotherapy O O
plus O O
HAART O O
treatment O O
on O O
patient O O
survival O O
needs O O
urgently O O
to O O
be O O
evaluated O O
in O O
prospective O O
studies O O
. O O

In O O
clinical O O
studies O O
, O O
caspofungin B-drug B-drug
did O O
not O O
induce O O
the O O
CYP3A4 O O
metabolism O O
of O O
other O O
drugs O O
. O O

Physostigmine B-drug B-drug
pretreatment O O
augmented O O
the O O
depressant O O
effect O O
of O O
alcohol B-drug B-drug
on O O
the O O
early O O
components O O
P1 O O
and O O
N1 O O
, O O
while O O
attenuating O O
alcohol B-drug B-drug
's O O
influence O O
on O O
components O O
P2 O O
and O O
P3 O O
. O O

Concomitant O O
use O O
with O O
iron B-group B-drug
supplements O O
may O O
result O O
in O O
the O O
reduced O O
absorption O O
of O O
iron B-drug B-drug
. O O

Skin O O
tests O O
: O O
Corticosteroids B-group B-group
may O O
suppress O O
reactions O O
to O O
skin O O
tests O O
. O O

If O O
digitalis B-drug B-group
treatment O O
is O O
continued O O
, O O
serum O O
levels O O
should O O
be O O
closely O O
monitored O O
and O O
patients O O
observed O O
for O O
clinical O O
evidence O O
of O O
toxicity O O
. O O

Dexamethasone B-drug B-drug
is O O
a O O
moderate O O
inducer O O
of O O
CYP O O
3A4 O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
the O O
following O O
drugs O O
are O O
administered O O
concomitantly O O
with O O
LODOSYN B-brand B-brand
( O O
Carbidopa B-drug B-drug
) O O
given O O
with O O
levodopa B-drug B-drug
or O O
carbidopa-levodopa B-drug B-drug
combination O O
products O O
. O O

In O O
patients O O
, O O
the O O
concomitant O O
administration O O
of O O
digoxin B-drug B-drug
with O O
dofetilide B-drug B-drug
was O O
associated O O
with O O
a O O
higher O O
occurrence O O
of O O
torsade O O
de O O
pointes O O
. O O

Chlorthalidone B-drug B-drug
and O O
related O O
drugs O O
may O O
decrease O O
arterial O O
responsiveness O O
to O O
norepinephrine B-drug B-drug
. O O

Anticholinergic B-group B-group
drugs I-group I-group
in O O
the O O
presence O O
of O O
increased O O
intraocular O O
pressure O O
may O O
be O O
hazardous O O
when O O
taken O O
concurrently O O
with O O
agents O O
such O O
as O O
corti O O
costeroids.. O O

Although O O
there O O
may O O
be O O
decreased O O
zalcitabine B-drug B-drug
activity O O
because O O
of O O
lessened O O
active O O
metabolite O O
formation O O
, O O
the O O
clinical O O
relevance O O
of O O
these O O
in O O
vitro O O
results O O
are O O
not O O
known O O
. O O

Phenytoin/Phenobarbital B-drug B-drug
: O O
The O O
coadministration O O
of O O
phenytoin B-drug B-drug
or O O
phenobarbital B-drug B-drug
will O O
not O O
affect O O
plasma O O
concentrations O O
of O O
vitamin B-group B-group
D I-group I-group
, O O
but O O
may O O
reduce O O
endogenous O O
plasma O O
levels O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
by O O
accelerating O O
metabolism O O
. O O

Because O O
the O O
incidence O O
of O O
infections O O
and O O
certain O O
malignancies O O
is O O
higher O O
in O O
the O O
elderly O O
population O O
, O O
in O O
general O O
, O O
caution O O
should O O
be O O
used O O
in O O
treating O O
the O O
elderly O O
. O O

An O O
increase O O
of O O
63 O O
% O O
in O O
the O O
mean O O
AUC O O
and O O
increases O O
of O O
50 O O
% O O
and O O
4 O O
% O O
, O O
respectively O O
, O O
in O O
the O O
mean O O
T O O
max O O
and O O
mean O O
C O O
max O O
were O O
noted O O
in O O
1 O O
study O O
of O O
6 O O
individuals O O
. O O

- O O
Anticoagulants B-group B-group
( O O
blood B-group B-group
thinners O I-group
) O O
or O O

The O O
use O O
of O O
erythromycin B-drug B-drug
in O O
patients O O
concurrently O O
taking O O
drugs O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
may O O
be O O
associated O O
with O O
elevations O O
in O O
serum O O
levels O O
of O O
these O O
other O O
drugs O O
. O O

Results O O
demonstrate O O
that O O
oxcarbazepine B-drug B-drug
and O O
its O O
pharmacologically O O
active O O
10-monohydroxy O O
metabolite O O
( O O
MHD B-drug_n B-drug_n
) O O
have O O
little O O
or O O
no O O
capacity O O
to O O
function O O
as O O
inhibitors O O
for O O
most O O
of O O
the O O
human O O
cytochrome O O
P450 O O
enzymes O O
evaluated O O
( O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2C9 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
CYP4A9 O O
and O O
CYP4A11 O O
) O O
with O O
the O O
exception O O
of O O
CYP2C19 O O
and O O
CYP3A4/5 O O
. O O

The O O
use O O
of O O
codeine B-drug B-drug
may O O
result O O
in O O
additive O O
CNS O O
depressant O O
effects O O
when O O
coadministered O O
with O O
alcohol B-drug B-drug
, O O
antihistamines B-group B-group
, O O
psychotropics B-group B-group
or O O
other O O
drugs O O
that O O
produce O O
CNS O O
depression O O
. O O

Concomitant O O
administration O O
of O O
Targretin B-brand B-brand
capsules O O
and O O
gemfibrozil B-drug B-drug
resulted O O
in O O
substantial O O
increases O O
in O O
plasma O O
concentrations O O
of O O
bexarotene B-drug B-drug
, O O
probably O O
at O O
least O O
partially O O
related O O
to O O
cytochrome O O
P450 O O
3A4 O O
inhibition O O
by O O
gemfibrozil B-drug B-drug
. O O

It O O
is O O
recommended O O
that O O
GABA-positive O B-group
drugs O I-group
be O O
included O O
into O O
a O O
complex O O
of O O
treatment O O
measures O O
for O O
edema O O
. O O

The O O
effects O O
of O O
coadministered O O
drugs O O
and O O
ethanol B-drug B-drug
on O O
the O O
binding O O
of O O
therapeutic O O
drugs O O
to O O
human O O
serum O O
in O O
vitro O O
was O O
investigated O O
. O O

Oral O O
Contraceptives B-group B-group
: O O
May O O
be O O
less O O
effective O O
and O O
increased O O
breakthrough O O
bleeding O O
may O O
occur O O
. O O

rifampin B-drug B-drug
; O O

Specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
ENBREL B-brand B-brand
. O O

However O O
, O O
patients O O
on O O
digoxin B-drug B-drug
may O O
show O O
elevations O O
of O O
digoxin B-drug B-drug
concentrations O O
after O O
initiation O O
of O O
therapy O O
with O O
FLOLAN B-brand B-brand
, O O
which O O
may O O
be O O
clinically O O
significant O O
in O O
patients O O
prone O O
to O O
digoxin B-drug B-drug
toxicity O O
. O O

A O O
number O O
of O O
substances O O
affect O O
glucose O O
metabolism O O
and O O
may O O
require O O
insulin B-drug B-drug
dose O O
adjustment O O
and O O
particularly O O
close O O
monitoring O O
. O O

While O O
no O O
clinical O O
studies O O
have O O
been O O
conducted O O
to O O
evaluate O O
the O O
effect O O
of O O
grepafloxacin B-drug B-drug
on O O
the O O
metabolism O O
of O O
C.P.A O O
. O O

Alternatives O O
to O O
clarithromycin B-drug B-drug
, O O
such O O
as O O
azithromycin B-drug B-drug
, O O
should O O
be O O
considered O O
. O O

Drugs O O
that O O
raise O O
the O O
gastrointestinal O O
pH O O
may O O
lead O O
to O O
an O O
earlier O O
release O O
of O O
duloxetine B-drug B-drug
. O O

indinavir I-drug B-drug
concentration O O
rifabutin B-drug B-drug
concentration O O

Coumarin B-group B-group
Anticoagulants I-group I-group
Altered O O
coagulation O O
parameters O O
and/or O O
bleeding O O
have O O
been O O
reported O O
in O O
patients O O
taking O O
capecitabine B-drug B-drug
concomitantly O O
with O O
coumarin-derivative B-group B-group
anticoagulants I-group I-group
such O O
as O O
warfarin B-drug B-drug
and O O
phenprocoumon B-drug B-drug
. O O

Fluconazole B-drug B-drug
, O O
and O O
the O O
5-HT3 B-group B-group
antiemetics I-group I-group
ondansetron B-drug B-drug
( O O
Zofran B-brand B-brand
) O O
and O O
granisetron B-drug B-drug
( O O
Kytril B-brand B-brand
) O O
have O O
all O O
been O O
used O O
with O O
BUSULFEX B-brand B-brand
. O O

Though O O
individual O O
theophylline B-drug B-drug
levels O O
fluctuated O O
, O O
there O O
were O O
no O O
clinically O O
significant O O
symptoms O O
of O O
drug O O
inter-action O O
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
other O O
drugs O O
is O O
withdrawn O O
from O O
co-therapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
may O O
be O O
required O O
. O O

Serum O O
potassium O O
levels O O
should O O
be O O
monitored O O
and O O
deficiencies O O
corrected O O
. O O

These O O
effects O O
were O O
not O O
observed O O
when O O
Vardenafil B-drug B-drug
20 O O
mg O O
was O O
taken O O
24 O O
hours O O
before O O
the O O
NTG B-drug O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
INDOCIN B-brand B-brand
and O O
anticoagulants B-group B-group
are O O
administered O O
concomitantly O O
. O O

Administration O O
of O O
quinolones B-group B-group
with O O
antacids B-group B-group
containing O O
aluminum B-drug B-drug
, O O
magnesium B-drug B-drug
, O O
or O O
calcium B-drug B-drug
, O O
with O O
sucralfate B-drug B-drug
, O O
with O O
metal O O
cations O O
such O O
as O O
iron B-drug B-drug
, O O
or O O
with O O
multivitamins B-group B-group
containing O O
iron B-drug B-drug
or O O
zinc B-drug B-drug
, O O
or O O
with O O
formulations O O
containing O O
divalent O O
and O O
trivalent O O
cations O O
such O O
as O O
VIDEX B-brand B-brand
( O O
didanosine B-drug B-drug
) O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
, O O
may O O
substantially O O
interfere O O
with O O
the O O
absorption O O
of O O
quinolones B-group B-group
, O O
resulting O O
in O O
systemic O O
concentrations O O
considerably O O
lower O O
than O O
desired O O
. O O

Steady-state O O
serum O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
are O O
reported O O
to O O
fluctuate O O
significantly O O
when O O
cimetidine B-drug B-drug
is O O
either O O
added O O
or O O
deleted O O
from O O
the O O
drug O O
regimen O O
. O O

Concurrent O O
therapy O O
with O O
bumetanide B-drug B-drug
is O O
thus O O
not O O
recommended O O
. O O

Drug O O
Laboratory O O
Test O O
Interactions O O
: O O
Prolongation O O
of O O
the O O
template O O
bleeding O O
time O O
has O O
been O O
reported O O
during O O
continuous O O
intravenous O O
infusion O O
of O O
AMICAR B-brand B-brand
at O O
dosages O O
exceeding O O
24 O O
g/day O O
. O O

Diazepam B-drug B-drug
: O O
The O O
co-administration O O
of O O
Fluvoxamine B-drug B-drug
Tablets O O
and O O
diazepam B-drug B-drug
is O O
generally O O
not O O
advisable O O
. O O

Anti-HIV B-group B-group
Protease I-group I-group
Inhibitors I-group I-group

Although O O
verapamil B-drug B-drug
administered O O
at O O
either O O
dose O O
had O O
little O O
or O O
no O O
effect O O
on O O
the O O
enhancement O O
of O O
intestinal O O
carcinogenesis O O
by O O
bombesin B-drug_n B-drug_n
or O O
on O O
the O O
location O O
, O O
histologic O O
type O O
, O O
depth O O
of O O
involvement O O
, O O
labeling O O
index O O
, O O
apoptotic O O
index O O
or O O
tumor O O
vascularity O O
of O O
intestinal O O
cancers O O
, O O
it O O
significantly O O
decreased O O
the O O
incidence O O
of O O
cancer O O
metastasis O O
. O O

The O O
following O O
are O O
examples O O
of O O
drugs O O
known O O
to O O
inhibit O O
the O O
metabolism O O
of O O
other O O
related O O
benzodiazepines B-group B-group
, O O
presumably O O
through O O
inhibition O O
of O O
CYP3A O O
: O O
nefazodone B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
isoniazide B-drug B-drug
, O O
and O O
some O O
macrolide B-group B-group
antibiotics I-group I-group
. O O

There O O
have O O
been O O
no O O
formal O O
drug-interaction O O
studies O O
performed O O
with O O
Mylotarg B-brand B-brand
. O O

Vasoconstrictors B-group B-group
: O O
D.H.E B-brand B-brand
. I-brand O
45 I-brand B-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
should O O
not O O
be O O
used O O
with O O
peripheral B-group B-group
vasoconstrictors I-group I-group
because O O
the O O
combination O O
may O O
cause O O
synergistic O O
elevation O O
of O O
blood O O
pressure O O
. O O

Valproate B-drug B-drug
: O O
A O O
recent O O
case O O
study O O
has O O
shown O O
a O O
possible O O
increase O O
in O O
the O O
plasma O O
level O O
of O O
valproate B-drug B-drug
when O O
co O O
administered O O
with O O
isoniazid B-drug B-drug
. O O

This O O
did O O
not O O
result O O
in O O
any O O
statistically O O
or O O
clinically O O
relevant O O
changes O O
in O O
the O O
pharmacokinetic O O
parameters O O
of O O
either O O
caffeine B-drug B-drug
or O O
its O O
major O O
metabolite O O
, O O
paraxanthine B-drug_n B-drug
. O O

Leukopenia O O
was O O
similar O O
between O O
the O O
two O O
groups O O
, O O
but O O
colony O O
stimulating O O
factor O O
support O O
was O O
significantly O O
greater O O
in O O
the O O
CHOP-HAART O O
group O O
than O O
in O O
the O O
control O O
group O O
( O O
92 O O
% O O
vs. O O
66 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
0.03 O O
) O O
. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
with O O
PRINIVIL B-brand B-brand
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-group B-group
or O O
increasing O O
the O O
salt O O
intake O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
PRINIVIL B-brand B-brand
. O O

When O O
other O O
antiplatelet B-group B-group
agents I-group I-group
or O O
anticoagulants B-group B-group
are O O
used O O
concomitantly O O
, O O
there O O
is O O
the O O
potential O O
for O O
FLOLAN B-brand B-brand
to O O
increase O O
the O O
risk O O
of O O
bleeding O O
. O O

Taking O O
a O O
rauwolfia B-group B-drug
alkaloid I-group I-drug
while O O
you O O
are O O
taking O O
or O O
within O O
2 O O
weeks O O
of O O
taking O O
MAO B-group B-group
inhibitors I-group I-group
may O O
increase O O
the O O
risk O O
of O O
central O O
nervous O O
system O O
depression O O
or O O
may O O
cause O O
a O O
severe O O
high O O
blood O O
pressure O O
reaction O O
. O O

No O O
autoinduction O O
has O O
been O O
observed O O
with O O
Trileptal B-brand B-brand
. O O

Latent O O
diabetes O O
mellitus O O
may O O
become O O
manifest O O
during O O
chlorthalidone B-drug B-drug
administration O O
. O O

Repeated O O
oral O O
administration O O
of O O
coumaphos B-drug_n B-drug_n
in O O
sheep O O
: O O
interactions O O
of O O
coumaphos B-drug_n B-group
with O O
bishydroxycoumarin B-drug B-drug
, O O
trichlorfon B-drug_n B-drug
, O O
and O O
phenobarbital B-drug B-drug
sodium I-drug I-drug
. O O

surgery O O
; O O

In O O
another O O
drug O O
interaction O O
study O O
, O O
co-administration O O
of O O
orally O O
inhaled O O
ciclesonide B-drug B-drug
and O O
oral O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
cytochrome O O
P450 O O
3A4 O O
, O O
increased O O
the O O
exposure O O
( O O
AUC O O
) O O
of O O
des-ciclesonide B-drug B-drug
by O O
approximately O O
3.6-fold O O
at O O
steady O O
state O O
, O O
while O O
levels O O
of O O
ciclesonide B-drug B-drug
remained O O
unchanged O O
. O O

rifabutin I-drug B-drug
concentration O O

The O O
percentage O O
of O O
neurons O O
hyperpolarized O O
by O O
mu- B-group O
, O O
delta O O
( O O
1 O O
) O O
- O O
, O O
and O O
kappa-selective B-group O
opioids I-group B-group
was O O
significantly O O
reduced O O
when O O
1 O O
% O O
but O O
not O O
< O O

antacids B-group B-group
after O O
meals O O
. O O

Coadministration O O
of O O
rifampin B-drug B-drug
with O O
diltiazem B-drug B-drug
lowered O O
the O O
diltiazem B-drug B-drug
plasma O O
concentrations O O
to O O
undetectable O O
levels O O
. O O

Laboratory O O
Tests O O
: O O
The O O
combination O O
of O O
Amprenavir B-drug B-drug
and O O
low-dose O O
ritonavir B-drug B-drug
has O O
been O O
associated O O
with O O
elevations O O
of O O
cholesterol O O
and O O
triglycerides O O
, O O
SGOT O O
( O O
AST O O
) O O
, O O
and O O
SGPT O O
( O O
ALT O O
) O O
in O O
some O O
patients O O
. O O

The O O
elimination O O
half O O
life O O
of O O
midazolam B-drug B-drug
and O O
triazolam B-drug B-drug
also O O
increased O O
( O O
1.5-2.5 O O
fold O O
) O O
during O O
coadministration O O
with O O
diltiazem B-drug B-drug
. O O

These O O
effects O O
have O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
by O O
the O O
NSAID B-group B-group
. O O

If O O
possible O O
, O O
anticholinesterase B-group B-group
agents I-group I-group
should O O
be O O
withdrawn O O
at O O
least O O
24 O O
hours O O
before O O
initiating O O
corticosteroid B-group B-group
therapy O O
. O O

Potential O O
for O O
Interaction O O
with O O
Monoamine B-group B-group
Oxidase I-group I-group
Inhibitors I-group I-group

Therefore O O
, O O
the O O
combination O O
of O O
ketoprofen B-drug B-drug
and O O
probenecid B-drug B-drug
is O O
not O O
recommended O O
. O O

Eprosartan B-drug B-drug
doses O O
of O O
up O O
to O O
300 O O
mg O O
b.i.d O O
. O O
have O O
been O O
safely O O
used O O
concomitantly O O
with O O
sustained-release O B-group
calcium B-group I-group
channel I-group I-group
blockers I-group I-group
( O O
sustained-release O O
nifedipine B-drug B-drug
) O O
with O O
no O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

there O O
was O O
no O O
effect O O
on O O
the O O
3 O O
major O O
metabolites O O
( O O
5-DFUR B-drug_n O
, O O
5-FU B-drug_n O
and O O
FBAL B-drug_n O
) O O
. O O

Concomitant O O
use O O
of O O
ELLENCE B-brand B-brand
with O O
other O O
cardioactive O B-group
compounds O I-group
that O O
could O O
cause O O
heart O O
failure O O
( O O
e.g. O O
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
) O O
, O O
requires O O
close O O
monitoring O O
of O O
cardiac O O
function O O
throughout O O
treatment O O
. O O

Clearance O O
of O O
hydrodolasetron B-drug_n B-drug
decreased O O
by O O
about O O
27 O O
% O O
when O O
dolasetron B-drug B-drug
mesylate I-drug I-drug
was O O
administered O O
intravenously O O
concomitantly O O
with O O
atenolol B-drug B-drug
. O O

The O O
blockade O O
of O O
the O O
spinal O O
endorphinergic O O
system O O
by O O
intrathecal O O
naloxone B-drug B-drug
on O O
the O O
production O O
of O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta-endorphin B-drug_n B-drug_n
and O O
morphine B-drug B-drug
was O O
then O O
studied O O
. O O

The O O
time O O
to O O
onset O O
of O O
maximum O O
block O O
following O O
NIMBEX B-brand B-brand
is O O
approximately O O
2 O O
minutes O O
faster O O
with O O
prior O O
administration O O
of O O
succinylcholine B-drug B-drug
. O O

There O O
is O O
no O O
significant O O
change O O
in O O
platelet O O
count O O
, O O
prothrombin O O
time O O
, O O
partial O O
thromboplastin O O
time O O
, O O
or O O
thrombin O O
time O O
. O O

Serum O O
transaminase O O
levels O O
should O O
be O O
obtained O O
before O O
starting O O
treatment O O
with O O
Plenaxis B-brand B-brand
and O O
periodically O O
during O O
treatment O O
. O O

Benzthiazide B-drug B-drug
may O O
interact O O
with O O
alcohol B-drug B-drug
, O O
blood B-group B-group
thinners O I-group
, O O
decongestant B-group B-group
drugs I-group I-group
( O O
allergy O O
, O O
cold O O
, O O
and O O
sinus O O
medicines O O
) O O
, O O
diabetic O O
drugs O O
, O O
lithium B-drug B-drug
, O O
norepinephrine B-drug B-drug
, O O
NSAIDs B-group B-group
like O O
Aleve B-brand B-brand
or O O
Ibuprofen B-drug B-drug
, O O
and O O
high O O
blood O O
pressure O O
medications O O
. O O

Concomitant O O
use O O
of O O
prostaglandin O B-group
synthase O I-group
inhibiting O I-group
drugs O I-group
, O O
eg O O
, O O
indomethacin B-drug B-drug
, O O
may O O
decrease O O
the O O
hypotensive O O
effects O O
of O O
beta B-group B-group
blockers I-group I-group
. O O

Therefore O O
when O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
are O O
administered O O
concomitantly O O
with O O
hydroxyzine B-drug B-drug
their O O
dosage O O
should O O
be O O
reduced O O
. O O

- O O
The O O
persistence O O
of O O
clinical O O
and O O
laboratory O O
evidence O O
of O O
hypothyroidism O O
in O O
spite O O
of O O
adequate O O
dosage O O
replacement O O
indicates O O
either O O
poor O O
patient O O
compliance O O
, O O
poor O O
absorption O O
, O O
excessive O O
fecal O O
loss O O
, O O
or O O
inactivity O O
of O O
the O O
preparation O O
. O O

. O O

Diclofenac B-drug B-drug
: O O
Administration O O
of O O
morning O O
and O O
lunch O O
doses O O
of O O
Starlix B-brand B-brand
120 O O
mg O O
in O O
combination O O
with O O
a O O
single O O
75-mg O O
dose O O
of O O
diclofenac B-drug B-drug
in O O
healthy O O
volunteers O O
resulted O O
in O O
no O O
significant O O
changes O O
to O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

Loratadine B-drug B-drug
( O O
10 O O
mg O O
once O O
daily O O
) O O
has O O
been O O
coadministered O O
with O O
therapeutic O O
doses O O
of O O
erythromycin B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
and O O
ketoconazole B-drug B-drug
in O O
controlled O O
clinical O O
pharmacology O O
studies O O
in O O
adult O O
volunteers O O
. O O

No O O
data O O
on O O
the O O
level O O
of O O
circulating O O
catecholamines O O
after O O
ALPHAGAN B-brand B-brand
P I-brand O
administration O O
are O O
available O O
. O O

Amitriptyline B-drug B-drug
in O O
combination O O
with O O
clonidine B-drug B-drug
enhances O O
the O O
manifestation O O
of O O
corneal O O
lesions O O
in O O
rats O O
Epidural O O
Injection O O
Clonidine B-drug B-drug
may O O
potentiate O O
the O O
CNS-depressive O O
effect O O
of O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
or O O
other O O
sedating B-group B-group
drugs I-group I-group
. O O

Other O O
substances O O
, O O
including O O
herbal O O
preparations O O
: O O
St. O O
John O O
s O O
Wort O O
( O O
Hypericum O O
perforatum O O
) O O
induces O O
CYP3A4 O O
. O O

In O O
normal O O
volunteers O O
receiving O O
indomethacin B-drug B-drug
, O O
the O O
administration O O
of O O
diflunisal B-drug B-drug
decreased O O
the O O
renal O O
clearance O O
and O O
significantly O O
increased O O
the O O
plasma O O
levels O O
of O O
indomethacin B-drug B-drug
. O O

Valproate B-drug B-drug
: O O
Felbatol B-brand B-brand
causes O O
an O O
increase O O
in O O
steady-state O O
valproate B-drug B-drug
concentrations O O
. O O

APRD00513_IN O O
, O O
txt O O

These O O
agents O O
should O O
not O O
be O O
taken O O
within O O
the O O
two O O
hour O O
period O O
before O O
or O O
within O O
the O O
two-hour O O
period O O
after O O
nalidixic B-drug B-drug
acid I-drug I-drug
administration O O
. O O

Intrathecal O O
injection O O
of O O
naloxone B-drug B-drug
at O O
doses O O
of O O
0.4 O O
to O O
40 O O
micrograms O O
caused O O
a O O
dose-related O O
blockade O O
of O O
the O O
inhibition O O
of O O
the O O
tail-flick O O
response O O
induced O O
by O O
intraventricular O O
injection O O
of O O
beta-endorphin B-drug_n B-drug_n
, O O
and O O
a O O
high O O
dose O O
of O O
naloxone B-drug B-drug
( O O
40 O O
micrograms O O
) O O
completely O O
blocked O O
the O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta-endorphin B-drug_n B-drug_n
( O O
16 O O
micrograms O O
) O O
. O O

In O O
one O O
survey O O
, O O
2.3 O O
% O O
of O O
patients O O
taking O O
labetalol B-drug B-drug
HCl I-drug I-drug
in O O
combination O O
with O O
tricyclic B-group B-group
antidepressants I-group I-group
experienced O O
tremor O O
, O O
as O O
compared O O
to O O
0.7 O O
% O O
reported O O
to O O
occur O O
with O O
labetalol B-drug B-drug
HCl I-drug I-drug
alone O O
. O O

When O O
sympathomimetic B-group B-group
drugs I-group I-group
are O O
given O O
to O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
hypertensive O O
reactions O O
, O O
including O O
hypertensive O O
crises O O
, O O
may O O
occur O O
. O O

Resins B-group B-group
: O O
Since O O
bile B-group B-group
acid I-group I-group
sequestrants I-group I-group
may O O
bind O O
other O O
drugs O O
given O O
concurrently O O
, O O
patients O O
should O O
take O O
TRICOR B-brand B-brand
at O O
least O O
1 O O
hour O O
before O O
or O O
4-6 O O
hours O O
after O O
a O O
bile B-group B-group
acid I-group I-group
binding I-group I-group
resin I-group I-group
to O O
avoid O O
impeding O O
its O O
absorption O O
. O O

No O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

In O O
common O O
with O O
other O O
broad-spectrum B-group B-group
antibiotics I-group I-group
, O O
AUGMENTIN B-brand B-brand
XR I-brand I-brand
may O O
reduce O O
the O O
efficacy O O
of O O
oral O O
contraceptives B-group B-group

Antimycobacterial B-group B-group
Agents I-group I-group

Valdecoxib B-drug B-drug
steady O O
state O O
plasma O O
concentrations O O
( O O
40 O O
mg O O
BID O O
) O O
were O O
not O O
affected O O
significantly O O
with O O
multiple O O
doses O O
of O O
omeprazole B-drug B-drug
( O O
40 O O
mg O O
QD O O
) O O
. O O

lopinavir I-drug B-drug
concentration O O

3 O O
. O O

Warfarin B-drug B-drug
and O O
Anticoagulants B-group B-group
: O O
Increased O O
prothrombin O O
time O O
, O O
with O O
or O O
without O O
clinical O O
bleeding O O
, O O
has O O
been O O
reported O O
when O O
cefixime B-drug B-drug
is O O
administered O O
concomitantly O O
. O O

Drugs O O
that O O
Lower O O
Seizure O O
Threshold O O
: O O
Concurrent O O
administration O O
of O O
WELLBUTRIN B-brand B-brand
and O O
agents O O
( O O
e.g. O O
, O O
antipsychotics B-group B-group
, O O
other O O
antidepressants B-group B-group
, O O
theophylline B-drug B-drug
, O O
systemic O B-group
steroids B-group I-group
, O O
etc O O
. O O
) O O
that O O
lower O O
seizure O O
threshold O O
should O O
be O O
undertaken O O
only O O
with O O
extreme O O
caution O O
. O O

Drug O O
Name O O

A O O
single O O
0.5 O O
mg O O
oral O O
dose O O
of O O
digoxin B-drug B-drug
elixir O O
was O O
administered O O
on O O
the O O
7th O O
day O O
of O O
each O O
11-day O O
period O O
. O O

HCTZ B-drug B-drug
50 O O
mg O O
QD O O
or O O
HCTZ/triamterene B-drug B-drug
50/100 O O
mg O O
QD O O
was O O
co-administered O O
with O O
TIKOSYN B-brand B-brand
( O O
500 O O
mcg O O
BID O O
) O O
for O O
5 O O
days O O
( O O
following O O
2 O O
days O O
of O O
diuretic B-group B-group
use O O
at O O
half O O
dose O O
) O O
. O O

Results O O
from O O
existing O O
clinical O O
trials O O
suggest O O
no O O
significant O O
interactions O O
between O O
COPAXONE B-brand B-brand
and O O
other O O
therapies O O
commonly O O
used O O
in O O
MS O O
patients O O
, O O
including O O
the O O
concurrent O O
use O O
of O O
corticosteroids B-group B-group
for O O
up O O
to O O
28 O O
days O O
. O O

Antacids B-group B-group
may O O
interfere O O
with O O
the O O
absorption O O
of O O
LEVSIN B-brand B-brand
. O O

The O O
zidovudine B-drug B-drug
study O O
dosed O O
subjects O O
with O O
1200 O O
mg/day O O
of O O
azithromycin B-drug B-drug
( O O
n O O
= O O
7 O O
) O O
( O O
later O O
changed O O
to O O
600 O O
mg/day O O
[ O O
n O O
= O O
5 O O
] O O
) O O
for O O
Days O O
8 O O
to O O
21 O O
of O O
a O O
21-day O O
course O O
of O O
100 O O
mg O O
, O O
five O O
times/day O O
of O O
zidovudine B-drug B-drug
. O O

Sulindac B-drug B-drug
: O O
The O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
sulindac B-drug B-drug
in O O
normal O O
volunteers O O
resulted O O
in O O
lowering O O
of O O
the O O
plasma O O
levels O O
of O O
the O O
active O O
sulindac O B-drug
sulfide O I-drug
metabolite O O
by O O
approximately O O
one-third O O
. O O

Thus O O
, O O
concomitant O O
administration O O
of O O
enoxacin B-drug B-drug
and O O
bismuth B-drug B-drug
subsalicylate I-drug I-drug
should O O
be O O
avoided O O
. O O

CRIXIVAN B-brand B-brand
may O O
not O O
be O O
effective O O
due O O
to O O
decreased O O
indinavir B-drug B-drug
concentrations O O
in O O
patients O O
taking O O
these O O
agents O O
concomitantly O O
. O O

Nifedipine B-drug B-drug
: O O
Vardenafil B-drug B-drug
20 O O
mg O O
, O O
when O O
co-administered O O
with O O
slow-release O O
nifedipine B-drug B-drug
30 O O
mg O O
or O O
60 O O
mg O O
once O O
daily O O
, O O
did O O
not O O
affect O O
the O O
relative O O
bioavailability O O
( O O
AUC O O
) O O
or O O
maximum O O
concentration O O
( O O
Cmax O O
) O O
of O O
nifedipine B-drug B-drug
, O O
a O O
drug O O
that O O
is O O
metabolized O O
via O O
CYP3A4 O O
. O O

Isoflurane B-drug B-drug
, O O
enflurane B-drug B-drug
, O O
and O O
halothane B-drug B-drug
decrease O O
the O O
ED50 O O
of O O
NUROMAX B-brand B-brand
by O O
30 O O
% O O
to O O
45 O O
% O O
. O O

Since O O
photic O O
evoked O O
potential O O
components O O
are O O
representations O O
of O O
neural O O
pathways O O
which O O
are O O
activated O O
during O O
photic O O
stimulation O O
, O O
study O O
of O O
the O O
effects O O
of O O
alcohol B-drug B-drug
on O O
these O O
components O O
may O O
help O O
to O O
trace O O
pathways O O
which O O
are O O
affected O O
by O O
alcohol B-drug B-drug
. O O

While O O
all O O
the O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
seriraline O B-drug
, O O
and O O
paroxetine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
mechanism O O
( O O
s O O
) O O
of O O
resveratrol-induced B-drug_n B-drug_n
vasorelaxation O O
in O O
resistance O O
mesenteric O O
arteries O O
from O O
male O O
lean O O
and O O
dietary-induced O B-drug
obese O O
rats O O
. O O

Coadministration O O
of O O
VIDEX B-brand B-brand
with O O
drugs O O
that O O
are O O
known O O
to O O
cause O O
pancreatitis O O
may O O
increase O O
the O O
risk O O
of O O
this O O
toxicity O O
( O O
see O O
WARNINGS O O
) O O
and O O
should O O
be O O
done O O
with O O
extreme O O
caution O O
, O O
only O O
if O O
other O O
alternatives O O
are O O
not O O
available O O
, O O
and O O
only O O
if O O
clearly O O
indicated O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
glipizide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

The O O
in O O
vitro O O
interaction O O
between O O
nevirapine B-drug B-drug
and O O
the O O
antithrombotic B-group B-group
agent I-group I-group
warfarin B-drug B-drug
is O O
complex O O
. O O

In O O
addition O O
, O O
neuromuscular O O
blocking O O
action O O
is O O
enhanced O O
by O O
general O O
anesthetics B-group B-group
, O O
local O O
anesthetics B-group B-group
like O O
lidocaine B-drug B-drug
, O O
procaine B-drug B-drug
, O O
beta-blockers B-group B-group
, O O
metaclopramide B-drug B-drug
, O O
lithium B-drug B-drug
carbonate I-drug I-drug
, O O
and O O
terbutaline B-drug B-drug
. O O

The O O
optimal O O
dose O O
of O O
indinavir B-drug B-drug
, O O
when O O
given O O
in O O
combination O O
with O O
efavirenz B-drug B-drug
, O O
is O O
not O O
known O O
. O O

Example O O
inducers O O
include O O
aminoglutethimide B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
nafcillin B-drug B-drug
, O O
nevirapine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
and O O
rifamycins B-group B-group
. O O

Cobalt B-drug B-drug
excretion O O
was O O
enhanced O O
by O O
supplementary O O
cobalt B-drug B-drug
; O O

This O O
effect O O
is O O
small O O
with O O
occasional O O
doses O O
of O O
antacids B-group B-group
, O O
but O O
may O O
be O O
clinically O O
significant O O
when O O
antacids B-group B-group
are O O
used O O
on O O
a O O
continuous O O
schedule O O
. O O

Toxicologic O O
and O O
toxicokinetic O O
studies O O
in O O
rats O O
did O O
not O O
demonstrate O O
any O O
alterations O O
in O O
the O O
clearance O O
or O O
toxicologic O O
profile O O
of O O
either O O
methotrexate B-drug B-drug
or O O
Kineret B-brand B-brand
when O O
the O O
two O O
agents O O
were O O
administered O O
together O O
. O O

Whether O O
this O O
interaction O O
also O O
occurs O O
with O O
the O O
intravenous O O
, O O
topical O O
, O O
or O O
vaginal O O
preparations O O
of O O
miconazole B-drug B-drug
is O O
not O O
known O O
. O O

Concomitant O O
administration O O
of O O
Aprepitant B-drug B-drug
with O O
strong O O
CYP3A4 O O
inhibitors O O
should O O
be O O
approached O O
cautiously O O
. O O

Dosage O O
adjustment O O
may O O
be O O
warranted O O
when O O
levobupivacaine B-drug B-drug
is O O
concurrently O O
administered O O
with O O
CYP3A4 O O
inhibitors O O
and O O
CYP1A2 O O
inhibitors O O
as O O
systemic O O
levobupivacaine B-drug B-drug
levels O O
may O O
rise O O
resulting O O
in O O
toxicity O O
. O O

Microdosed O O
minipill O B-drug
progestin B-drug I-drug
preparations O O
are O O
not O O
recommended O O
for O O
use O O
with O O
Soriatane B-drug B-brand
. O O

An O O
in O O
vivo O O
interaction O O
study O O
in O O
humans O O
demonstrated O O
that O O
a O O
single O O
1mg O O
dose O O
of O O
anagrelide B-drug B-drug
administered O O
concomitantly O O
with O O
a O O
single O O
900 O O
mg O O
dose O O
of O O
aspirin B-brand B-brand
was O O
generally O O
well O O
tolerated O O
. O O

N=50 O O
) O O
Cmax O O
and O O
AUC O O
values O O
in O O
a O O
dose-dependent O O
manner O O
relative O O
to O O
administration O O
of O O
hydrocodone B-drug B-drug
alone O O
; O O

INDOCIN B-brand B-brand
can O O
reduce O O
the O O
antihypertensive O O
effects O O
of O O
captopril B-drug B-drug
and O O
losartan B-drug B-drug
. O O

The O O
general O O
public O O
feels O O
that O O
cocaine B-drug B-drug
is O O
not O O
particularly O O
dangerous O O
because O O
it O O
does O O
not O O
produce O O
a O O
well O O
defined O O
physical O O
dependency O O
and O O
abstinence O O
syndrome O O
. O O

It O O
should O O
also O O
be O O
avoided O O
in O O
patients O O
with O O
blood O O
, O O
liver O O
or O O
kidney O O
diseases O O
, O O
recent O O
radiation O O
treatment O O
, O O
or O O
uncontrolled O O
diabetes O O
. O O

A O O
decrease O O
of O O
the O O
dosage O O
may O O
be O O
necessary O O
when O O
patient O O
becomes O O
euthyroid O O
. O O

dihydropyridine B-group B-group
calcium I-group I-group
channel I-group I-group
blockers I-group I-group
concentration O O

The O O
clinical O O
relevance O O
of O O
the O O
potential O O
effect O O
of O O
grepafloxacin B-drug B-drug
on O O
the O O
metabolism O O
of O O
C.P.A O O
. O O
substrates O O
is O O
not O O
known O O
. O O

Acute O O
hydrocortisone B-drug B-drug
administration O O
does O O
not O O
affect O O
subjective O O
responses O O
to O O
d-amphetamine B-drug B-drug
in O O
humans O O
. O O

Acetaminophen B-drug B-drug
: O O
May O O
increase O O
plasma O O
concentration O O
of O O
synthetic B-group B-group
estrogens I-group I-group
, O O
possibly O O
by O O
inhibiting O O
conjugation O O
. O O

Concomitant O O
Crohn O O
s O O
disease O O
medications O O
were O O
antibiotics B-group B-group
, O O
antivirals B-group B-group
, O O
corticosteroids B-group B-group
, O O
6-MP/AZA B-drug O
and O O
aminosalicylates O B-group
. O O

Serum O O
concentrations O O
of O O
drugs O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
should O O
be O O
monitored O O
closely O O
in O O
patients O O
concurrently O O
receiving O O
erythromycin B-drug B-drug
. O O

Interaction O O
between O O
oxytocin B-drug B-drug
and O O
antidiuretic O B-group
hormone O I-group
and O O
its O O
effect O O
on O O
the O O
milk O O
secretion O O
by O O
alveoli O O
of O O
the O O
mammary O O
gland O O
of O O
lactating O O
rats O O
. O O

The O O
following O O
eight O O
target O O
drug/added O O
drug O O
combinations O O
were O O
studied O O
: O O
acetaminophen/phenobarbital B-drug B-drug
. O O

The O O
antifungal B-group B-group
drug I-group I-group
, O O
miconazole B-drug B-drug
nitrate I-drug I-drug
, O O
inhibits O O
the O O
growth O O
of O O
several O O
species O O
of O O
Candida O O
. O O

No O O
dosage O O
adjustment O O
is O O
required O O
for O O
Fluvoxamine B-drug B-drug
Tablets O O
. O O

Fluoroquinolones B-drug B-group
, O O
macrolide B-drug B-group
antibiotics I-drug I-group
, O O
and O O
azoles O B-group
are O O
known O O
to O O
cause O O
QTc O O
prolongation O O
. O O

Concomitant O O
use O O
with O O
other O O
calcium-containing B-drug B-group
medicines O I-group
( O O
including O O
antacids B-group B-group
) O O
may O O
cause O O
too O O
much O O
calcium B-drug B-drug
in O O
the O O
blood O O
or O O
urine O O
, O O
which O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
. O O

These O O
individuals O O
may O O
develop O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
clozapine B-drug B-drug
when O O
given O O
usual O O
doses O O
. O O

Other O O
reported O O
interactions O O
with O O
amiodarone B-drug B-drug
: O O
Fentanyl B-drug B-drug
( O O
CYP3A4 B-drug O
substrate O O
) O O
in O O
combination O O
with O O
amiodarone B-drug B-drug
may O O
cause O O
hypotension O O
, O O
bradycardia O O
, O O
and O O
decreased O O
cardiac O O
output O O
. O O

Finally O O
, O O
it O O
is O O
notable O O
that O O
xanthine-derived O O
adenosine O O
antagonists O O
tested O O
here O O
commonly O O
showed O O
anxiogenic O O
effects O O
in O O
the O O
light/dark O O
test O O
in O O
mice O O
. O O

Theophylline B-drug B-drug
: O O
The O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
( O O
aminophylline B-drug B-drug
5.8 O O
mg/kg O O
infused O O
over O O
20 O O
minutes O O
) O O
were O O
unchanged O O
following O O
a O O
single O O
oral O O
dose O O
of O O
albendazole B-drug B-drug
( O O
400 O O
mg O O
) O O
in O O
6 O O
healthy O O
subjects O O
. O O

Drug/Laboratory O O
Tests O O
Interactions O O
Because O O
false O O
positive O O
readings O O
were O O
reported O O
with O O
the O O
Ames O O
N-Multistix O O
SG O O
dipstick O O
test O O
for O O
urinary O O
protein O O
when O O
gabapentin B-drug B-drug
was O O
added O O
to O O
other O O
antiepileptic B-group B-group
drugs I-group I-group
, O O
the O O
more O O
specific O O
sulfosalicylic O B-drug
acid O I-drug
precipitation O O
procedure O O
is O O
recommended O O
to O O
determine O O
the O O
presence O O
of O O
urine O O
protein O O

Thus O O
, O O
certain O O
factors O O
, O O
such O O
as O O
reinforcing O O
drug O O
effects O O
, O O
conditioning O O
processes O O
, O O
automatic O O
behavior O O
, O O
and O O
stress O O
, O O
may O O
influence O O
the O O
development O O
of O O
dependence O O
on O O
both O O
drugs O O
. O O

. O O

This O O
risk O O
is O O
present O O
whether O O
the O O
drugs O O
are O O
administered O O
as O O
oral O O
, O O
parenteral O O
, O O
or O O
topical O O
formulations O O
. O O

Successful O O
prophylaxis O O
of O O
manic-depressive O O
disorder O O
requires O O
more O O
than O O
the O O
prescription O O
of O O
lithium B-drug B-drug
carbonate I-drug I-drug
. O O

Dependent O O
measures O O
included O O
self-reported O O
mood O O
and O O
subjective O O
effects O O
( O O
Addiction O O
Research O O
Center O O
inventory O O
, O O
the O O
profile O O
of O O
mood O O
states O O
, O O
and O O
a O O
series O O
of O O
visual O O
analogue O O
scales O O
) O O
, O O
vital O O
signs O O
, O O
salivary O O
cortisol O O
, O O
and O O
psychomotor O O
performance O O
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
or O O
other O O
suitable O O
coagulation O O
tests O O
should O O
be O O
monitored O O
closely O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
Cyanokit B-brand B-brand
. O O

vitamin B-drug B-drug
C I-drug I-drug
; O O

Meclofenamate B-drug B-drug
sodium I-drug I-drug
does O O
not O O
affect O O
serum O O
salicylate B-group O
levels O O
. O O

The O O
use O O
of O O
NSAIDs B-group B-group
in O O
patients O O
who O O
are O O
receiving O O
ACE B-group B-group
inhibitors I-group I-group
may O O
potentiate O O
renal O O
disease O O
states O O
. O O

Therapeutic O O
drug O O
monitoring O O
can O O
avoid O O
iatrogenic O O
alterations O O
caused O O
by O O
99mTc-methylene B-drug B-drug
diphosphonate I-drug I-drug
( O O
MDP O B-drug
) O O
-gentamicin B-drug B-drug
interaction O O
. O O

Consequently O O
, O O
prothrombin O O
time O O
should O O
be O O
reassessed O O
periodically O O
in O O
patients O O
receiving O O
both O O
drugs O O
. O O

Rifampin B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
the O O
warfarin B-drug B-drug
requirements O O
in O O
human O O
subjects O O
ingesting O O
these O O
agents O O
simultaneously O O
. O O

This O O
appears O O
to O O
be O O
the O O
only O O
clinically O O
relevant O O
interaction O O
of O O
this O O
kind O O
with O O
Mefloquine B-drug B-drug
, O O
although O O
theoretically O O
, O O
coadministration O O
of O O
other O O
drugs O O
known O O
to O O
alter O O
cardiac O O
conduction O O
( O O
eg O O
, O O
anti-arrhythmic B-drug O
or O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
antihistamines B-group B-group
or O O
H1-blocking B-group B-group
agents I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
and O O
phenothiazines B-group B-group
) O O
might O O
also O O
contribute O O
to O O
a O O
prolongation O O
of O O
the O O
QTc O O
interval O O
. O O

The O O
effect O O
was O O
present O O
for O O
at O O
least O O
7 O O
days O O
after O O
the O O
last O O
dose O O
of O O
bupropion B-drug B-drug
. O O

Barbiturates B-group B-group
, O O
carbamazepine B-drug B-drug
, O O
and O O
phenytoin B-drug B-drug
decrease O O
the O O
half-life O O
of O O
doxycycline B-drug B-drug
. O O

If O O
nifedipine B-drug B-drug
therapy O O
is O O
initiated O O
in O O
a O O
patient O O
currently O O
receiving O O
cimetidine B-drug B-drug
, O O
cautious O O
titration O O
is O O
advised O O
. O O

During O O
concomitant O O
therapy O O
of O O
Ponstel B-brand B-brand
with O O
furosemide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
signs O O
of O O
renal O O
failure O O
, O O
as O O
well O O
as O O
to O O
assure O O
diuretic O O
efficacy O O
. O O

However O O
, O O
appropriate O O
monitoring O O
of O O
blood O O
glucose O B-drug
should O O
be O O
performed O O
when O O
initiating O O
EXTRANEAL B-brand B-brand
in O O
diabetic O O
patients O O
and O O
insulin B-drug B-drug
dosage O O
should O O
be O O
adjusted O O
if O O
needed O O
. O O

Depending O O
on O O
the O O
fraction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8-fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA B-group B-group
) O O
. O O

An O O
alternative O O
non-CYP3A4 O O
substrate O O
hypnotic B-group O
agent I-group O
may O O
be O O
considered O O
in O O
patients O O
taking O O
CYP3A4 O O
inducers O O
such O O
as O O
rifampin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
and O O
phenobarbital B-drug B-drug
. O O

Antidiabetic B-group B-group
Agents I-group I-group
: O O
Disturbances O O
of O O
blood O O
glucose O O
, O O
including O O
hyperglycemia O O
and O O
hypoglycemia O O
, O O
have O O
been O O
reported O O
in O O
patients O O
treated O O
concomitantly O O
with O O
quinolones B-group B-group
and O O
an O O
antidiabetic B-group B-group
agent I-group I-group
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
the O O
effect O O
of O O
sodium B-drug_n B-drug
carboxymethylcellulose I-drug_n I-drug
( O O
NaCMC B-drug_n B-drug_n
) O O
and O O
carboxymethylcellulose-cysteine B-drug_n B-drug_n
( O O
CMC-Cys B-drug_n B-drug_n
) O O
conjugates O O
on O O
the O O
intestinal O O
permeation O O
of O O
sodium B-drug O
fluorescein I-drug O
( O O
NaFlu B-drug B-drug
) O O
and O O
model O O
peptide O O
drugs O O
, O O
bacitracin B-drug B-drug
and O O
insulin B-drug B-drug
. O O

Uricosuric B-group B-group
Agents I-group I-group
: O O
Aspirin B-brand B-brand
may O O
decrease O O
the O O
effects O O
of O O
probenecid B-drug B-drug
, O O
sulfinpyrazone B-drug B-drug
, O O
and O O
phenylbutazone B-drug B-drug
. O O

The O O
effects O O
of O O
fulvestrant B-drug B-drug
on O O
the O O
fertility O O
of O O
female O O
rats O O
appear O O
to O O
be O O
consistent O O
with O O
its O O
anti-estrogenic O O
activity O O
. O O

The O O
availability O O
of O O
potent O O
non-nucleoside B-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitor I-group I-group
( O O
NNRTI B-group B-group
) O O
-based O O
regimens O O
for O O
antiretroviral B-group B-group
therapy O O
and O O
concerns O O
regarding O O
protease B-group B-group
inhibitor I-group I-group
( O O
PI B-group O
) O O
-related O O
metabolic O O
disturbances O O
have O O
led O O
to O O
significant O O
shifts O O
in O O
treatment O O
practices O O
in O O
HIV O O
infection O O
. O O

- O O
Antidiabetic B-group B-group
drugs I-group I-group
: O O
( O O
Oral O O
agents O O
and O O
insulin B-drug B-drug
) O O
Dosage O O
adjustment O O
of O O
the O O
antidiabetic B-group B-group
drug I-group I-group
may O O
be O O
required O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
has O O
been O O
reported O O
to O O
decrease O O
the O O
metabolism O O
of O O
certain O O
corticosteroids B-group B-group
by O O
up O O
to O O
60 O O
% O O
, O O
leading O O
to O O
increased O O
risk O O
of O O
corticosteroid B-group B-group
side O O
effects O O
. O O

a O O
See O O
Tables O O
1 O O
and O O
2 O O
. O O

NSAIDs B-group B-group
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
taking O O
cyclosporine B-drug B-drug
, O O
and O O
renal O O
function O O
should O O
be O O
carefully O O
monitored O O
. O O

Electrophilic O O
agents O O
-- O O
a O O
class O O
of O O
chemicals O O
that O O
includes O O
most O O
genotoxic O B-group
compounds O I-group
-- O O
can O O
be O O
inactivated O O
by O O
reaction O O
with O O
glutathione O B-drug
or O O
other O O
SH-bearing O O
molecules O O
. O O

Theophylline B-drug B-drug
: O O
In O O
three O O
pharmacokinetic O O
studies O O
including O O
46 O O
normal O O
, O O
healthy O O
subjects O O
, O O
theophylline B-drug B-drug
clearance O O
and O O
concentration O O
were O O
not O O
significantly O O
altered O O
by O O
the O O
addition O O
of O O
lomefloxacin B-drug B-drug
. O O

Concurrent O O
therapy O O
with O O
ORENCIA B-brand B-brand
and O O
TNF B-group B-group
antagonists I-group I-group
is O O
not O O
recommended O O
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
can O O
inhibit O O
the O O
metabolism O O
of O O
chloroquine B-drug B-drug
, O O
increasing O O
its O O
plasma O O
level O O
. O O

the O O
time O O
to O O
reach O O
maximum O O
concentration O O
was O O
delayed O O
approximately O O
30 O O
minutes O O
. O O

It O O
is O O
also O O
shown O O
that O O
after O O
14 O O
days O O
of O O
daily O O
administration O O
of O O
chlordiazepoxide B-drug B-drug
, O O
withdrawal O O
of O O
the O O
drug O O
not O O
only O O
re-results O O
in O O
almost O O
complete O O
loss O O
of O O
bar-press O O
response O O
in O O
the O O
E-strain O O
subjects O O
but O O
also O O
results O O
in O O
a O O
temporary O O
decrease O O
in O O
the O O
acquired O O
behavioral O O
response O O
of O O
the O O
stable O O
A-strain O O
subjects O O
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
CELEBREX B-brand B-brand
concomitantly O O
with O O
ACE-inhibitors B-group B-group
. O O

Lithium B-drug B-drug
: O O
Lithium B-drug B-drug
toxicity O O
has O O
been O O
reported O O
in O O
patients O O
receiving O O
lithium B-drug B-drug
concomitantly O O
with O O
drugs O O
which O O
cause O O
elimination O O
of O O
sodium O B-drug
, O O
including O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Reciprocal O O
interactions O O
may O O
occur O O
with O O
concomitant O O
use O O
of O O
Antizol B-brand B-brand
and O O
drugs O O
that O O
increase O O
or O O
inhibit O O
the O O
cytochrome O O
P450 O O
system O O
( O O
e.g. O O
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
cimetidine B-drug B-drug
, O O
ketoconazole B-drug B-drug
) O O
, O O
though O O
this O O
has O O
not O O
been O O
studied O O

Ranitidine B-drug B-drug
also O O
has O O
no O O
effect O O
on O O
eprosartan B-drug B-drug
pharmacokinetics O O
. O O

multivitamins B-group B-group
containing O O
zinc B-drug B-drug
; O O

The O O
benzodiazepines B-group B-group
are O O
a O O
family O O
of O O
anxiolytic B-group B-group
and O O
hypnotic B-group B-group
drugs I-group I-group
. O O

Warfarin B-drug B-drug
: O O
The O O
effects O O
of O O
aliskiren B-drug B-drug
on O O
warfarin B-drug B-drug
pharmacokinetics O O
have O O
not O O
been O O
evaluated O O
in O O
a O O
well-controlled O O
clinical O O
trial O O
. O O

Phenobarbital B-drug B-drug
: O O
It O O
appears O O
that O O
phenobarbital B-drug B-drug
may O O
reduce O O
plasma O O
felbamate B-drug B-drug
concentrations O O
. O O

False-negative O O
results O O
in O O
the O O
dexamethasone O O
suppression O O
test O O
( O O
DST O O
) O O
in O O
patients O O
being O O
treated O O
with O O
INDOCIN B-brand B-brand
have O O
been O O
reported O O
. O O

The O O
EC50 O O
values O O
for O O
isoproterenol B-drug B-drug
, O O
which O O
is O O
not O O
a O O
substrate O O
for O O
norepinephrine B-drug B-drug
uptake-1 O O
, O O
were O O
reduced O O
in O O
myocardium O O
in O O
functional O O
classes O O
II O O
to O O
III O O
and O O
IV O O
compared O O
with O O
those O O
in O O
nonfailing O O
myocardium O O
. O O

HIV B-group B-group
Protease I-group I-group
Inhibitors I-group I-group
: O O
The O O
effect O O
of O O
amprenavir B-drug B-drug
on O O
total O O
drug O O
concentrations O O
of O O
other O O
HIV B-group B-group
protease I-group I-group
inhibitors I-group I-group
in O O
subjects O O
receiving O O
both O O
agents O O
was O O
evaluated O O
using O O
comparisons O O
to O O
historical O O
data O O
. O O

A O O
false-positive O O
direct O O
Coombs O O
test O O
has O O
been O O
reported O O
during O O
treatment O O
with O O
other O O
cephalosporin B-group B-group
antibiotics I-group I-group
; O O

Another O O
study O O
showed O O
that O O
alosetron B-drug B-drug
had O O
no O O
clinically O O
significant O O
effect O O
on O O
plasma O O
concentrations O O
of O O
the O O
oral O O
contraceptive B-group B-group
agents I-group I-group
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
levonorgestrel B-drug B-drug
( O O
CYP3A4 O O
substrates O O
) O O
. O O

Cytadren B-brand B-drug
accelerates O O
the O O
metabolism O O
of O O
dexamethasone B-drug B-drug
; O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
acute O O
ergot O O
toxicity O O
characterized O O
by O O
peripheral O O
vasospasm O O
and O O
ischemia O O
of O O
the O O
extremities O O
and O O
other O O
tissues O O
. O O

Anticholinergics B-group B-group
: O O
Concurrent O O
administration O O
of O O
certain O O
anticholinergic B-group B-group
compounds I-group I-group
, O O
such O O
as O O
belladonna B-group B-group
alkaloids I-group I-group
and O O
dicyclomine B-drug B-drug
, O O
would O O
be O O
expected O O
to O O
compromise O O
the O O
beneficial O O
effects O O
of O O
cisapride B-drug B-drug
. O O

Use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

Phenytoin B-drug B-drug
: O O
Isoniazid B-drug B-drug
may O O
increase O O
serum O O
levels O O
of O O
phenytoin B-drug B-drug
. O O

Non-nucleoside B-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitors I-group I-group
( O O
NNRTIs B-group B-group
) O O
: O O
Nevirapine B-drug B-drug
may O O
decrease O O
plasma O O
levels O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
; O O

PEGASYS B-brand B-brand
contains O O
benzyl B-drug_n B-drug
alcohol I-drug_n I-drug
. O O

because O O
of O O
this O O
, O O
the O O
dosage O O
of O O
flecainide B-drug B-drug
should O O
be O O
adjusted O O
when O O
these O O
drugs B-drug O
are O O
administered O O
concomitantly O O
. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
with O O
Lotensin B-brand B-brand
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-group B-group
or O O
increasing O O
the O O
salt O O
intake O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
Lotensin B-brand B-brand
. O O

these O O
drugs O O
were O O
not O O
tested O O
to O O
determine O O
the O O
effect O O
of O O
administration O O
one O O
hour O O
before O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
. O O

Patients O O
receiving O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
along O O
with O O
either O O
oral O O
or O O
intravenous O O
calcium B-group B-group
antagonists I-group I-group
should O O
be O O
monitored O O
for O O
possible O O
atrioventricular O O
conduction O O
disturbances O O
, O O
left O O
ventricular O O
failure O O
and O O
hypotension O O
. O O

Nitrofurantoin B-drug B-drug
interferes O O
with O O
the O O
therapeutic O O
action O O
of O O
nalidixic B-drug B-drug
acid I-drug I-drug
. O O

In O O
vitro O O
, O O
at O O
total O O
drug O O
concentrations O O
27-fold O O
higher O O
than O O
peak O O
plasma O O
concentrations O O
observed O O
with O O
the O O
1-mg O O
dosage O O
, O O
alosetron B-drug B-drug
inhibited O O
CYP O O
enzymes O O
1A2 O O
( O O
60 O O
% O O
) O O
and O O
2E1 O O
( O O
50 O O
% O O
) O O
. O O

Activity O O
of O O
buforin B-drug_n B-drug_n
II I-drug_n I-drug_n
alone O O
and O O
in O O
combination O O
with O O
azithromycin B-drug B-drug
and O O
minocycline B-drug B-drug
against O O
Cryptosporidium O B-drug_n
parvum O O
in O O
cell O O
culture O O
. O O

In O O
patients O O
using O O
cardiac B-group B-group
glycosides I-group I-group
( O O
digoxin B-drug B-drug
and O O
others O O
) O O
, O O
plasma O O
levels O O
of O O
calcium O B-drug
, O O
potassium O B-drug
and O O
magnesium O B-drug
must O O
be O O
carefully O O
monitored O O
. O O

This O O
study O O
indicates O O
that O O
: O O
( O O
a O O
) O O
the O O
maximal O O
effects O O
of O O
resveratrol B-drug_n B-drug_n
on O O
resistance O O
arteries O O
from O O
lean O O
and O O
dietary-obese O O
rats O O
are O O
not O O
effected O O
by O O
endothelial O O
dysfunction O O
, O O
and O O
( O O
b O O
) O O
the O O
effects O O
of O O
resveratrol B-drug_n B-drug_n
in O O
lean O O
animals O O
( O O
where O O
endothelial O O
function O O
is O O
not O O
impaired O O
) O O
, O O
but O O
not O O
in O O
dietary-obese O O
rats O O
, O O
are O O
mediated O O
via O O
NO O O
. O O

In O O
period O O
B O O
, O O
the O O
volunteers O O
were O O
randomly O O
assigned O O
to O O
one O O
of O O
two O O
groups O O
. O O

However O O
, O O
there O O
are O O
several O O
instances O O
in O O
the O O
animal O O
literature O O
showing O O
that O O
hippocampal O O
lesions O O
actually O O
produced O O
enhanced O O
learning O O
and O O
memory O O
function O O
. O O

This O O
secretory O O
diarrhea O O
model O O
is O O
suitable O O
for O O
evaluating O O
the O O
antidiarrheal O O
activity O O
of O O
drugs O O
. O O

In O O
addition O O
, O O
there O O
have O O
been O O
cases O O
reported O O
in O O
which O O
concomitant O O
use O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
and O O
hydrocortisone B-drug B-drug
was O O
followed O O
by O O
cardiac O O
enlargement O O
and O O
congestive O O
heart O O
failure O O
. O O

Cyclosporine B-drug B-drug
: O O
Increased O O
activity O O
of O O
both O O
cyclosporine B-drug B-drug
and O O
corticosteroids B-group B-group
may O O
occur O O
when O O
the O O
two O O
are O O
used O O
concurrently O O
. O O

Phenytoin/Phenobarbital B-drug B-drug
: O O
The O O
coadministration O O
of O O
phenytoin B-drug B-drug
or O O
phenobarbital B-drug B-drug
will O O
not O O
affect O O
plasma O O
concentrations O O
of O O
vitamin B-group B-group
D I-group I-group
, O O
but O O
may O O
reduce O O
endogenous O O
plasma O O
levels O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
by O O
accelerating O O
metabolism O O
. O O

Clinical O O
studies O O
in O O
healthy O O
volunteers O O
show O O
that O O
the O O
pharmacokinetics O O
of O O
CANCIDAS B-brand B-brand
are O O
not O O
altered O O
by O O
itraconazole B-drug B-drug
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
mycophenolate B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
or O O
tacrolimus B-drug B-drug
. O O

The O O
implications O O
of O O
these O O
results O O
are O O
discussed O O
, O O
especially O O
with O O
respect O O
to O O
observations O O
which O O
indicate O O
that O O
homocysteine O O
may O O
be O O
a O O
precipitating O O
factor O O
in O O
the O O
development O O
of O O
thrombosis O O
. O O

Calcium B-drug B-drug
Supplements O O
: O O
Uncontrolled O O
intake O O
of O O
additional O O
calcium-containing B-drug B-drug
preparations O O
should O O
be O O
avoided O O
. O O

Available O O
data O O
are O O
neither O O
sufficient O O
to O O
rule O O
out O O
possible O O
increases O O
in O O
serum O O
digoxin B-drug B-drug
with O O
concomitant O O
treatment O O
in O O
some O O
patients O O
, O O
nor O O
other O O
possible O O
interactions O O
, O O
particularly O O
in O O
patients O O
with O O
cardiac O O
conduction O O
abnormalities O O
( O O
Also O O
see O O
WARNINGS O O
Congestive O O
Heart O O
Failure O O
) O O
. O O

6 O O
. O O

In O O
clinical O O
studies O O
propofol B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
duration O O
of O O
action O O
or O O
dosing O O
requirements O O
for O O
NIMBEX B-brand B-brand
. O O

The O O
pharmacodynamic O O
consequences O O
of O O
concomitant O O
use O O
of O O
losartan B-drug B-drug
and O O
inhibitors O O
of O O
P450 O O
2C9 O O
have O O
not O O
been O O
examined O O
. O O

this O O
was O O
seen O O
in O O
studies O O
with O O
estazolam B-drug B-drug
. O O

In O O
some O O
cases O O
the O O
onset O O
of O O
the O O
injection O O
site O O
reaction O O
either O O
occurred O O
during O O
a O O
prolonged O O
infusion O O
or O O
was O O
delayed O O
by O O
a O O
week O O
to O O
ten O O
days O O
. O O

Free O O
T3 O O
resin O O
uptake O O
is O O
decreased O O
, O O
reflecting O O
the O O
elevated O O
TBG O O
; O O

Anticonvulsants B-group B-group
: O O
In O O
a O O
pharmacokinetic O O
study O O
, O O
maximum O O
plasma O O
concentrations O O
of O O
felodipine B-drug B-drug
were O O
considerably O O
lower O O
in O O
epileptic O O
patients O O
on O O
long-term O O
anticonvulsant B-group B-group
therapy O O
( O O
eg O O
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
or O O
phenobarbital B-drug B-drug
) O O
than O O
in O O
healthy O O
volunteers O O
. O O

The O O
injection O O
should O O
be O O
made O O
immediately O O
after O O
mixing O O
. O O

Patients O O
using O O
cardiovascular O O
drugs O O
concurrently O O
with O O
IOPIDINE B-brand B-brand
0.5 O O
% O O
Ophthalmic O O
Solution O O
should O O
have O O
pulse O O
and O O
blood O O
pressures O O
frequently O O
monitored O O
. O O

Because O O
of O O
the O O
potential O O
for O O
ARAVA B-brand B-brand
levels O O
to O O
continue O O
to O O
increase O O
with O O
multiple O O
dosing O O
, O O
caution O O
should O O
be O O
used O O
if O O
patients O O
are O O
to O O
be O O
receiving O O
both O O
ARAVA B-brand B-brand
and O O
rifampin B-drug B-drug
. O O

Frequent O O
vital O O
sign O O
monitoring O O
, O O
particularly O O
during O O
the O O
first O O
hour O O
of O O
TAXOL B-brand B-brand
infusion O O
, O O
is O O
recommended O O
. O O

tricyclic B-group B-group
antidepressants I-group I-group
( O O
such O O
as O O
amitriptyline B-drug B-drug
) O O
; O O

Numerous O O
drug O O
interactions O O
are O O
possible O O
with O O
some O O
anticonvulsant B-group B-group
agents I-group I-group
, O O
such O O
as O O
phenobarbitone B-drug B-drug
and O O
phenytoin B-drug B-drug
, O O
which O O
affect O O
hepatic O O
microsomal O O
enzyme O O
systems O O
. O O

Therefore O O
, O O
cyclosporine B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
and O O
appropriate O O
cyclosporine B-drug B-drug
dosage O O
adjustments O O
made O O
when O O
these O O
drugs O O
are O O
used O O
concomitantly O O
. O O

Amprenavir B-drug B-drug
decreased O O
the O O
results O O
of O O
the O O
ERMBT O O
by O O
83 O O
% O O
. O O

There O O
was O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
representative O O
drugs O O
metabolized O O
by O O
CYP O O
2C9 O O
, O O
CYP O O
2C19 O O
, O O
CYP O O
2D6 O O
or O O
CYP O O
3A4 O O
. O O

Systemic B-group O
Corticosteroids I-group B-group
: O O
Systemic B-group O
corticosteroids I-group B-group
are O O
known O O
to O O
cause O O
osteoporosis O O
. O O

The O O
influence O O
of O O
midazolam B-drug B-drug
and O O
diazepam B-drug B-drug
on O O
antinociceptive O O
effect O O
of O O
morphine B-drug B-drug
( O O
10 O O
mg/kg O O
) O O
, O O
metamizol B-drug B-drug
( O O
500 O O
mg/kg O O
) O O
and O O
indomethacin B-drug B-drug
( O O
10 O O
mg/kg O O
) O O
was O O
investigated O O
in O O
a O O
mouse O O
model O O
using O O
the O O
tail-flick O O
and O O
hot-plate O O
tests O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
There O O
have O O
been O O
no O O
chemical O O
or O O
laboratory O O
test O O
interactions O O
with O O
ceftibuten B-drug B-drug
noted O O
to O O
date O O
. O O

incomplete O O
data O O
for O O
efavirenz B-drug B-drug
. O O

Preliminary O O
clinical O O
data O O
suggest O O
that O O
the O O
incidence O O
of O O
nephrolithiasis O O
is O O
higher O O
in O O
patients O O
receiving O O
indinavir B-drug B-drug
in O O
combination O O
with O O
ritonavir B-drug B-drug
than O O
those O O
receiving O O
CRIXIVAN B-brand B-brand
800 O O
mg O O
q8h O O
. O O

Propranolol B-drug B-drug
: O O
In O O
normal O O
volunteers O O
, O O
there O O
was O O
no O O
clinically O O
significant O O
pharmacokinetic O O
or O O
pharmacodynamic O O
interaction O O
with O O
concomitant O O
administration O O
of O O
single O O
doses O O
of O O
lovastatin B-drug B-drug
and O O
propranolol B-drug B-drug
. O O

cases O O
, O O
occurred O O
between O O
the O O
5th O O
and O O
the O O
11th O O
day O O
of O O
treatment O O
. O O

Arginine B-drug B-drug
, O O
in O O
the O O
presence O O
of O O
glucose B-drug B-drug
and O O
theophylline B-drug B-drug
, O O
caused O O
excessive O O
glucagon O O
release O O
but O O
nearly O O
normal O O
insulin O O
release O O
in O O
the O O
diabetics O O
. O O

A O O
routine O O
dosage O O
adjustment O O
of O O
zaleplon B-drug B-drug
is O O
not O O
considered O O
necessary O O
. O O

Sirolimus B-drug B-drug
: O O
mammalian O O
target O O
of O O
rapamycin B-drug B-drug
inhibitor O I-drug
to O O
prevent O O
kidney O O
rejection O O
. O O

Serum O O
theophylline B-drug B-drug
concentrations O O
increase O O
when O O
grepafloxacin B-drug B-drug
is O O
initiated O O
in O O
a O O
patient O O
maintained O O
on O O
theophylline B-drug B-drug
. O O

Amprenavir B-drug B-drug
is O O
an O O
inhibitor O O
of O O
cytochrome O O
P450 O O
C.P.A O O
. O O
metabolism O O
and O O
therefore O O
should O O
not O O
be O O
administered O O
concurrently O O
with O O
medications O O
with O O
narrow O O
therapeutic O O
windows O O
that O O
are O O
substrates O O
of O O
CYP3A4 O O
. O O

Colestipol B-drug B-drug
: O O
Plasma O O
concentrations O O
of O O
atorvastatin B-drug B-drug
decreased O O
approximately O O
25 O O
% O O
when O O
colestipol B-drug B-drug
and O O
atorvastatin B-drug B-drug
were O O
coadministered O O
. O O

Although O O
the O O
clinical O O
significance O O
is O O
not O O
known O O
, O O
it O O
is O O
not O O
recommended O O
that O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
be O O
taken O O
concomitantly O O
with O O
antacids B-group B-group
. O O

Maprotiline B-drug B-drug
: O O
Risk O O
of O O
cardiac O O
arrhythmias O O
may O O
increase O O
. O O

Effects O O
of O O
Aliskiren B-drug B-drug
on O O
Other O O
Drugs O O
Aliskiren B-drug B-drug
does O O
not O O
inhibit O O
the O O
CYP450 O O
isoenzymes O O
( O O
CYP1A2 O O
, O O
2C8 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
2E1 O O
, O O
and O O
CYP O O
3A O O
) O O
or O O
induce O O
CYP O O
3A4 O O
. O O

Clinical O O
interaction O O
studies O O
with O O
cimetidine B-drug B-drug
and O O
warfarin B-drug B-drug
indicated O O
that O O
the O O
coadministration O O
of O O
Femara B-brand B-brand
with O O
these O O
drugs O O
does O O
not O O
result O O
in O O
clinically- O O
significant O O
drug O O
interactions O O
. O O

This O O
may O O
lead O O
to O O
reduced O O
clearance O O
of O O
caffeine B-drug B-drug
and O O
a O O
prolongation O O
of O O
its O O
serum O O
half-life O O
. O O

Ganciclovir B-drug B-drug
: O O
The O O
pharmacokinetics O O
of O O
foscarnet B-drug B-drug
and O O
ganciclovir B-drug B-drug
were O O
not O O
altered O O
in O O
13 O O
patients O O
receiving O O
either O O
concomitant O O
therapy O O
or O O
daily O O
alternating O O
therapy O O
for O O
maintenance O O
of O O
CMV O O
disease O O
. O O

Drug/Laboratory O O
Tests O O
Interactions O O
No O O
clinically O O
relevant O O
changes O O
in O O
the O O
results O O
of O O
clinical O O
laboratory O O
tests O O
have O O
been O O
observed O O
. O O

Pretreatment O O
with O O
atropine B-drug B-drug
likewise O O
further O O
reduced O O
the O O
amplitudes O O
of O O
components O O
P1 O O
and O O
N1 O O
, O O
and O O
produced O O
a O O
similar O O
effect O O
on O O
component O O
N3 O O
. O O

naproxen B-drug B-drug
; O O

Pharmacodynamic-related O O
Interactions O O
: O O
The O O
mechanism O O
of O O
Clozapine B-drug B-drug
induced O O
agranulocytosis O O
is O O
unknown O O
; O O

Consequently O O
, O O
the O O
effect O O
of O O
iron B-drug B-drug
on O O
the O O
retention O O
of O O
cobalt B-drug B-drug
was O O
lower O O
than O O
on O O
absorption O O
. O O

Dextromethorphan B-drug B-drug
is O O
a O O
substrate O O
for O O
both O O
CYP2D6 B-drug O
and O O
CYP3A4 B-drug O
. O O

The O O
AUC O O
and O O
Cmax O O
of O O
metoprolol B-drug B-drug
, O O
however O O
, O O
were O O
increased O O
approximately O O
31 O O
and O O
38 O O
% O O
, O O
respectively O O
. O O

Patients O O
receiving O O
antihistamines B-group B-group
should O O
be O O
advised O O
against O O
the O O
concurrent O O
use O O
of O O
other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
. O O

Fourteen O O
days O O
later O O
, O O
all O O
animals O O
were O O
challenged O O
with O O
a O O
single O O
hypnotic O O
dose O O
of O O
ethanol B-drug B-drug
( O O
3.5 O O
g/kg O O
IP O O
) O O
. O O

Quinidine B-drug B-drug
at O O
648 O O
mg O O
bid O O
decreased O O
the O O
bioavailability O O
( O O
AUC O O
) O O
of O O
nisoldipine B-drug B-drug
by O O
26 O O
% O O
, O O
but O O
not O O
the O O
peak O O
concentration O O
. O O

Dopamine B-group B-group
D2 I-group I-group
receptor I-group I-group
antagonists I-group I-group
( O O
e.g. O O
, O O
phenothiazines B-group B-group
, O O
butyrophenones B-group B-group
, O O
risperidone B-drug B-drug
) O O
and O O
isoniazid B-drug B-drug
may O O
reduce O O
the O O
therapeutic O O
effects O O
of O O
levodopa B-drug B-drug
. O O

or O O
=0.2 O O
% O O
biocytin O O
was O O
included O O
in O O
the O O
recording O O
pipette O O
, O O
compared O O
with O O
neurons O O
recorded O O
without O O
biocytin O O
. O O

Whenever O O
increased O O
thioether O O
excretion O O
is O O
observed O O
, O O
it O O
is O O
likely O O
to O O
be O O
due O O
to O O
exposure O O
to O O
one O O
or O O
more O O
suspect O O
compounds O O
. O O

Two O O
studies O O
were O O
conducted O O
in O O
HIV-infected O O
subjects O O
to O O
assess O O
the O O
potential O O
for O O
azithromycin B-drug B-drug
to O O
interact O O
with O O
zidovudine B-drug B-drug
and O O
dideoxyinosine B-drug B-drug
. O O

Comparative O O
analysis O O
of O O
the O O
effects O O
of O O
stimulation O O
and O O
inhibition O O
of O O
cholino- O B-drug_n
and O O
adrenoreceptors O B-drug_n
on O O
this O O
inhibitory O O
action O O
of O O
angiotensins B-drug_n B-group
suggested O O
the O O
mediation O O
of O O
angiotensin B-drug_n B-drug_n
influence O O
through O O
the O O
modulation O O
of O O
cholinergic O O
reactions O O
of O O
parietal O O
cells O O
in O O
the O O
stomach O O
. O O

Cimetidine B-drug B-drug
reduces O O
the O O
clearance O O
of O O
ALFENTA B-brand B-brand
. O O

Drugs O O
that O O
cause O O
significant O O
sustained O O
elevation O O
in O O
gastric O O
pH O O
( O O
histamine B-group B-group
H2-receptor I-group I-group
antagonists I-group I-group
such O O
as O O
ranitidine B-drug B-drug
or O O
cimetidine B-drug B-drug
) O O
may O O
reduce O O
plasma O O
concentrations O O
of O O
IRESSA B-brand B-brand
and O O
therefore O O
potentially O O
may O O
reduce O O
efficacy O O
. O O

Therefore O O
, O O
linezolid B-drug B-drug
has O O
the O O
potential O O
for O O
interaction O O
with O O
adrenergic B-group O
and O O
serotonergic B-group B-group
agents I-group I-group
. O O

Phencyclidine B-drug_n B-drug_n
( O O
PCP B-drug_n B-drug_n
) O O
produces O O
psychotomimetic O O
effects O O
in O O
humans O O
that O O
resemble O O
schizophrenia O O
symptoms O O
. O O

Simvastatin B-drug B-drug
and O O
Other O O
Statins B-group B-group
: O O
Co-administration O O
of O O
bosentan B-drug B-drug
decreased O O
the O O
plasma O O
concentrations O O
of O O
simvastatin B-drug B-drug
( O O
a O O
CYP3A4 O O
substrate O O
) O O
, O O
and O O
its O O
active O O
-hydroxy O O
acid O O
metabolite O O
, O O
by O O
approximately O O
50 O O
% O O
. O O

After O O
prolonged O O
administration O O
of O O
neuroleptics B-group B-group
the O O
displacing O O
effect O O
of O O
cerulein B-drug_n O
, O O
an O O
analog O O
of O O
cholecystokinin O O
octapeptide O O
, O O
was O O
replaced O O
by O O
the O O
stimulant O O
action O O
on O O
3H-spiroperidol B-drug_n B-drug_n
binding O O
. O O

therefore O O
, O O
administration O O
of O O
EQUETROTM B-brand B-brand
to O O
a O O
patient O O
taking O O
another O O
drug O O
that O O
is O O
highly O O
protein O O
bound O O
should O O
not O O
cause O O
increased O O
free O O
concentrations O O
of O O
the O O
other O O
drug O O
. O O

Medication O O
such O O
as O O
digitalis B-group B-group
may O O
also O O
influence O O
serum O O
electrolytes O O
. O O

Antidiabetic B-group B-group
drug I-group I-group
requirements O O
( O O
i.e. O O
, O O
insulin B-drug B-drug
) O O
may O O
be O O
altered O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
As O O
a O O
result O O
of O O
the O O
presence O O
of O O
nitrofurantoin B-drug B-drug
, O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
. O O

Urinary B-group O
acidifying I-group O
agents I-group O
( O O
ammonium B-drug B-drug
chloride I-drug I-drug
, O O
sodium B-drug B-drug
acid I-drug I-drug
phosphate I-drug I-drug
, O O
etc O O
. O O
) O O
increase O O
the O O
concentration O O
of O O
the O O
ionized O O
species O O
of O O
the O O
amphetamine B-drug B-drug
molecule O O
, O O
thereby O O
increasing O O
urinary O O
excretion O O
. O O

Responses O O
to O O
arginine B-drug B-drug
of O O
the O O
perfused O O
pancreas O O
of O O
the O O
genetically O O
diabetic O O
Chinese O O
hamster O O
. O O

A O O
two-way O O
interaction O O
between O O
the O O
hydantoin B-group B-group
antiepileptic I-group I-group
, O O
phenytoin B-drug B-drug
, O O
and O O
the O O
coumarin B-group B-group
anticoagulants O I-group
has O O
been O O
suggested O O
. O O

Amprenavir B-drug B-drug
plus O O
rifampin B-drug B-drug
was O O
well O O
tolerated O O
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
these O O
agents O O
is O O
indicated O O
because O O
of O O
demonstrated O O
hypokalemia O O
, O O
they O O
should O O
be O O
used O O
with O O
caution O O
and O O
with O O
frequent O O
monitoring O O
of O O
serum O O
potassium O O
. O O

Lithium B-drug B-drug
: O O
Increased O O
serum O O
lithium B-drug B-drug
levels O O
and O O
symptoms O O
of O O
lithium B-drug B-drug
toxicity O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
concomitant O O
lithium B-drug B-drug
and O O
ACE B-group B-group
inhibitor I-group I-group
therapy O O
. O O

Patients O O
who O O
have O O
developed O O
severe O O
hypersensitivity O O
reactions O O
should O O
not O O
be O O
rechallenged O O
with O O
TAXOL B-brand B-brand
. O O

and O O
, O O
rarely O O
, O O
enuresis O O
, O O
urinary O O
retention O O
, O O
dysuria O O
, O O
impotence O O
, O O
inability O O
to O O
ejaculate O O
, O O
nocturia O O
, O O
hematuria O O
. O O

A O O
single O O
dose O O
of O O
liquid O O
antacid B-group B-group
did O O
not O O
affect O O
the O O
C O O
max O O
or O O
AUC O O
of O O
ceftibuten B-drug B-drug
; O O

An O O
evaluation O O
of O O
prothrombin O O
time O O
and O O
an O O
adjustment O O
of O O
anticoagulant B-group B-group
dosage O O
are O O
recommended O O

For O O
this O O
reason O O
, O O
the O O
dose O O
of O O
the O O
anticoagulant B-drug B-group
should O O
be O O
reduced O O
by O O
30 O O
- O O
50 O O
% O O
at O O
the O O
start O O
of O O
treatment O O
with O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard O I-brand
and O O
then O O
titrated O O
according O O
to O O
the O O
blood O O
clotting O O
parameters O O

ibuprofen B-drug B-drug
; O O

The O O
appropriate O O
dose O O
for O O
nelfinavir B-drug B-drug
incombination O O
with O O
nevirapine B-drug B-drug
, O O
with O O
respectto O O
safety O O
and O O
efficacy O O
, O O
has O O
not O O
been O O
established O O
. O O

Concomitant O O
administration O O
of O O
fenofibrate B-drug B-drug
( O O
equivalent O O
to O O
145mg O O
TRICOR B-brand B-brand
) O O
with O O
pravastatin B-drug B-drug
( O O
40 O O
mg O O
) O O
once O O
daily O O
for O O
10 O O
days O O
has O O
been O O
shown O O
to O O
increase O O
the O O
mean O O
Cmax O O
and O O
AUC O O
values O O
for O O
pravastatin B-drug B-drug
by O O
36 O O
% O O
( O O
range O O
from O O
69 O O
% O O
decrease O O
to O O
321 O O
% O O
increase O O
) O O
and O O
28 O O
% O O
( O O
range O O
from O O
54 O O
% O O
decrease O O
to O O
128 O O
% O O
increase O O
) O O
, O O
respectively O O
, O O
and O O
for O O
3 O O
-hydroxy-iso-pravastatin O O
by O O
55 O O
% O O
( O O
range O O
from O O
32 O O
% O O
decrease O O
to O O
314 O O
% O O
increase O O
) O O
and O O
39 O O
% O O
( O O
range O O
from O O
24 O O
% O O
decrease O O
to O O
261 O O
% O O
increase O O
) O O
, O O
respectively O O
in O O
23 O O
healthy O O
adults O O
. O O

Data O O
from O O
several O O
studies O O
, O O
ie O O
, O O
TIMI-II O O
, O O
ISIS-2 O O
, O O
currently O O
do O O
not O O
suggest O O
any O O
clinical O O
interaction O O
between O O
aspirin B-brand B-brand
and O O
beta B-group B-group
blockers I-group I-group
in O O
the O O
acute O O
myocardial O O
infarction O O
setting O O
. O O

chlordiazepoxide B-drug B-drug
; O O

Treatment O O
with O O
daily O O
doses O O
of O O
2 O O
mg O O
of O O
coumaphos/kg B-drug_n B-drug_n
for O O
6 O O
days O O
did O O
not O O
modify O O
the O O
anticholinesterase O O
effect O O
of O O
a O O
2nd O O
series O O
of O O
treatments O O
given O O
6 O O
weeks O O
later O O
. O O

Effects O O
of O O
Vardenafil B-drug B-drug
on O O
other O O
drugs O O

Doxorubicin B-drug B-drug
: O O
Doxorubicin B-drug B-drug
caused O O
a O O
decrease O O
in O O
zalcitabine B-drug B-drug
phosphorylation O O
( O O
50 O O
% O O
inhibition O O
of O O
total O O
phosphate O O
formation O O
) O O
in O O
U937/Molt O O
4 O O
cells O O
. O O

it O O
is O O
possible O O
that O O
larger O O
theophylline B-drug B-drug
doses O O
could O O
have O O
a O O
greater O O
effect O O
. O O

Progestin-only O B-group
oral O O
contraception O O
: O O
a O O
comprehensive O O
review O O
. O O

Although O O
the O O
magnitude O O
of O O
changes O O
in O O
diazepam B-drug B-drug
plasma O O
exposure O O
when O O
coadministered O O
with O O
valdecoxib B-drug B-drug
were O O
not O O
sufficient O O
to O O
warrant O O
dosage O O
adjustments O O
, O O
patients O O
may O O
experience O O
enhanced O O
sedative O B-group
side O O
effects O O
caused O O
by O O
increased O O
exposure O O
of O O
diazepam B-drug B-drug
under O O
this O O
circumstance O O
. O O

cardiovascular O O
effects O O
can O O
be O O
potentiated O O
. O O

However O O
, O O
interactions O O
may O O
be O O
expected O O
, O O
and O O
UROXATRAL B-brand B-brand
should O O
NOT O O
be O O
used O O
in O O
combination O O
with O O
other O O
alpha-blockers B-group B-group
. O O

The O O
addition O O
of O O
540 O O
mg/kg/day O O
of O O
cromolyn B-drug B-drug
sodium I-drug I-drug
( O O
approximately O O
340 O O
times O O
the O O
maximum O O
recommended O O
daily O O
inhalation O O
dose O O
in O O
adults O O
on O O
a O O
mg/m2 O O
basis O O
) O O
to O O
2.7 O O
mg/kg/day O O
of O O
isoproterenol B-drug B-drug
( O O
approximately O O
7 O O
times O O
the O O
maximum O O
recommended O O
daily O O
inhalation O O
dose O O
in O O
adults O O
on O O
a O O
mg/m2 O O
basis O O
) O O
appears O O
to O O
have O O
increased O O
the O O
incidence O O
of O O
both O O
resorptions O O
and O O
malformations O O
. O O

Agents O O
with O O
Decreased O O
Levels O O
in O O
the O O
Presence O O
of O O
Carbamazepine B-drug B-drug
due O O
to O O
Induction O O
of O O
Cytochrome O O
P450 O O
Enzymes O O
Carbamazepine B-drug B-drug
is O O
known O O
to O O
induce O O
CYP1A2 O O
and O O
CYP3A4 O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
As O O
with O O
other O O
penicillins B-drug B-group
, O O
the O O
administration O O
of O O
PIPRACIL B-brand B-brand
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
using O O
a O O
copper-reduction O O
method O O
. O O

The O O
total O O
drug O O
exposure O O
for O O
the O O
plasma O O
was O O
approximately O O
twofold O O
at O O
the O O
higher O O
cisplatin B-drug B-drug
dose O O
. O O

The O O
patient O O
should O O
be O O
informed O O
that O O
the O O
response O O
to O O
alcohol B-drug B-drug
may O O
be O O
exaggerated O O
. O O

Drug O O
Interaction O O
with O O
Fluoxetine B-drug B-drug
: O O
A O O
multiple-dose O O
study O O
was O O
conducted O O
to O O
assess O O
the O O
effect O O
of O O
fluoxetine B-drug B-drug
20 O O
mg O O
BID O O
on O O
the O O
pharmacokinetics O O
of O O
estazolam B-drug B-drug
2 O O
mg O O
QHS O O
after O O
seven O O
days O O
. O O

Reductions O O
in O O
serum O O
endogenous O O
vitamin O O
D O O
concentrations O O
have O O
been O O
observed O O
following O O
the O O
administration O O
of O O
300 O O
mg/day O O
to O O
1200 O O
mg/day O O
ketoconazole B-drug B-drug
for O O
a O O
week O O
to O O
healthy O O
men O O
. O O

+45 O O
% O O
+39 O O
% O O
+43 O O
% O O
+72 O O
% O O

Geocillin B-brand B-drug
( O O
carbenicillin B-drug B-drug
indanyl I-drug I-drug
sodium I-drug I-drug
) O O
blood O O
levels O O
may O O
be O O
increased O O
and O O
prolonged O O
by O O
concurrent O O
administration O O
of O O
probenecid B-drug B-drug
. O O

It O O
may O O
increase O O
excretion O O
of O O
barbiturates B-group B-group
, O O
lithium B-drug B-drug
, O O
and O O
ASA B-drug O
and O O
may O O
also O O
increase O O
the O O
toxicity O O
of O O
salicylates B-group B-group
. O O

Do O O
not O O
mix O O
TORADOL B-brand B-brand
and O O
morphine B-drug B-drug
in O O
the O O
same O O
syringe O O
. O O

The O O
steady-state O O
Cmin O O
increased O O
to O O
21 O O
5 O O
micrograms/mL O O
when O O
1200 O O
mg/day O O
of O O
felbamate B-drug B-drug
was O O
coadministered O O
. O O

Isoflurane B-drug B-drug
or O O
enflurane B-drug B-drug
administered O O
with O O
nitrous B-drug B-group
oxide/oxygen I-drug I-group
to O O
achieve O O
1.25 O O
MAC O O
[ O O
Minimum O O
Alveolar O O
Concentration O O
] O O
may O O
prolong O O
the O O
clinically O O
effective O O
duration O O
of O O
action O O
of O O
initial O O
and O O
maintenance O O
doses O O
of O O
NIMBEX B-brand B-brand
and O O
decrease O O
the O O
required O O
infusion O O
rate O O
of O O
NIMBEX B-brand B-brand
. O O

It O O
is O O
, O O
therefore O O
, O O
advisable O O
to O O
monitor O O
digoxin B-drug B-drug
concentrations O O
in O O
patients O O
receiving O O
ketoconazole B-drug B-drug
. O O

- O O
Vitamin B-group B-group
K I-group I-group
( O O
e.g. O O
, O O
AquaMEPHYTON B-brand B-brand
, O O
Synkayvite B-brand B-brand
) O O
Use O O
of O O
sulfapyridine B-drug B-drug
with O O
these O O
medicines O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
blood O O

No O O
information O O
provided O O

Patients O O
receiving O O
the O O
two O O
drugs O O
concomitantly O O
should O O
be O O
carefully O O
monitored O O
. O O

Notably O O
, O O
systemic O O
exposure O O
( O O
AUC0-12 O O
) O O
of O O
dapsone B-drug_n B-drug
hydroxylamine I-drug_n I-drug
( O O
DHA B-drug_n O
) O O
was O O
more O O
than O O
doubled O O
in O O
the O O
presence O O
of O O
TMP/SMX B-drug B-drug
. O O

If O O
the O O
two O O
drugs O O
are O O
coadministered O O
, O O
the O O
beta B-group B-group
blocker I-group I-group
should O O
be O O
withdrawn O O
several O O
days O O
before O O
the O O
gradual O O
withdrawal O O
of O O
clonidine B-drug B-drug
. O O

Therefore O O
concomitant O O
administration O O
of O O
ketoconazole B-drug B-drug
tablets O O
with O O
cisapride B-drug B-drug
is O O
contraindicated O O
. O O

benign O O
breast O O
disease O O
; O O

Colchicine B-drug B-drug
is O O
inhibited O O
by O O
acidifying B-group B-group
agents I-group I-group
. O O

Co-administration O O
with O O
efavirenz B-drug B-drug
or O O
fluconazole B-drug B-drug
had O O
a O O
modest O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
azithromycin B-drug B-drug
. O O

Oral O O
Hypoglycemic B-group B-group
Agents I-group I-group
: O O
In O O
pharmacokinetic O O
studies O O
of O O
MEVACOR B-brand B-brand
in O O
hypercholesterolemic O O
noninsulin O O
dependent O O
diabetic O O
patients O O
, O O
there O O
was O O
no O O
drug O O
interaction O O
with O O
glipizide B-drug B-drug
or O O
with O O
chlorpropamide B-drug B-drug

Comparison O O
of O O
cisplatin B-drug B-drug
pharmacokinetics O O
in O O
patients O O
treated O O
with O O
202.5 O O
mg/m2 O O
plus O O
thiosulfate B-drug B-drug
to O O
those O O
in O O
patients O O
treated O O
with O O
100 O O
mg/m2 O O
without O O
thiosulfate B-drug B-drug
indicated O O
that O O
there O O
were O O
no O O
changes O O
in O O
the O O
elimination O O
rate O O
constant O O
, O O
volume O O
of O O
distribution O O
, O O
or O O
total O O
body O O
clearance O O
of O O
cisplatin B-drug B-drug
. O O

Dosage O O
adjustment O O
may O O
be O O
required O O
if O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
or O O
methylprednisolone B-drug B-drug
are O O
given O O
concomitantly O O
with O O
NIZORAL B-brand B-brand
Tablets O O
. O O

No O O
depressant O O
effect O O
on O O
blood O O
levels O O
in O O
humans O O
was O O
noted O O
when O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
was O O
administered O O
with O O
any O O
of O O
the O O
following O O
drugs O O
: O O
aspirin B-brand B-brand
, O O
clindamycin B-brand B-drug
, O O
clofibrate B-drug B-drug
, O O
methyldopa B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
( O O
niacin B-drug B-drug
) O O
, O O
tolbutamide B-drug B-drug
, O O
phenytoin B-drug B-drug
or O O
warfarin B-drug B-drug
. O O

- O O
phenytoin B-drug B-drug
( O O
Dilantin B-brand B-brand
) O O
; O O

Withdrawal O O
from O O
cocaine B-drug B-drug
dependence O O
usually O O
involves O O
depression O O
, O O
anxiety O O
and O O
lethargy O O
. O O

Therapeutic O O
drug O O
monitoring O O
( O O
TDM O O
) O O
of O O
gentamicin B-drug B-drug
therapy O O
, O O
and O O
bone O O
scintigraphy O O
employing O O
99mTc-MDP B-drug B-drug
as O O
the O O
radiopharmaceutical B-group O
was O O
carried O O
out O O
in O O
22 O O
patients O O
. O O

Refer O O
to O O
the O O
package O O
insert O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
preparations O O
with O O
chlorothiazide B-drug B-drug

Drug O O
Interaction O O
with O O
Erythromycin B-drug B-drug
and O O
Ketoconazole B-drug B-drug
Fexofenadine I-drug I-drug
has O O
been O O
shown O O
to O O
exhibit O O
minimal O O
( O O
ca O O
. O O
5 O O
% O O
) O O
metabolism O O
. O O

Because O O
eprosartan B-drug B-drug
is O O
not O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
, O O
inhibitors O O
of O O
CYP450 O O
enzyme O O
would O O
not O O
be O O
expected O O
to O O
affect O O
its O O
metabolism O O
, O O
and O O
ketoconazole B-drug B-drug
and O O
fluconazole B-drug B-drug
, O O
potent O O
inhibitors O O
of O O
CYP3A O O
and O O
2C9 O O
, O O
respectively O O
, O O
have O O
been O O
shown O O
to O O
have O O
no O O
effect O O
on O O
eprosartan B-drug B-drug
pharmacokinetics O O
. O O

The O O
concomitant O O
intake O O
of O O
alcohol B-drug B-drug
and O O
Acamprosate B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
either O O
alcohol B-drug B-drug
or O O
acamprosate B-drug B-drug
. O O

The O O
following O O
specific O O
interactions O O
have O O
been O O
reported O O
: O O
Itraconazole O B-drug
Co-administration O O
of O O
another O O
extended O O
release O O
formulation O O
of O O
felodipine B-drug B-drug
with O O
itraconazole B-drug B-drug
resulted O O
in O O
approximately O O
8-fold O O
increase O O
in O O
the O O
AUC O O
, O O
more O O
than O O
6- O O
fold O O
increase O O
in O O
the O O
Cmax O O
, O O
and O O
2-fold O O
prolongation O O
in O O
the O O
half- O O
life O O
of O O
felodipine B-drug B-drug
. O O

Erythromycin B-drug B-drug
has O O
been O O
reported O O
to O O
significantly O O
alter O O
the O O
metabolism O O
of O O
nonsedating O B-group
antihistamines B-group I-group
terfenadine B-drug B-drug
and O O
astemizole B-drug B-drug
when O O
taken O O
concomitantly O O
. O O

Mixtures O O
of O O
cadmium O O
and O O
zinc B-drug B-drug
had O O
a O O
synergistic O O
effect O O
compared O O
with O O
single O O
metal O O
toxicity O O
but O O
only O O
at O O
50000 O O
microg/l O O
. O O

ALLEGRA B-brand B-brand
should O O
not O O
be O O
taken O O
closely O O
in O O
time O O
with O O
aluminum B-drug B-drug
and O O
magnesium B-drug B-drug
containing O O
antacids B-group B-group
. O O

No O O
interaction O O
was O O
noted O O
with O O
the O O
MAO-B B-group B-group
inhibitor I-group I-group
selegiline B-drug B-drug
in O O
two O O
multiple-dose O O
interaction O O
studies O O
when O O
entacapone B-drug B-drug
was O O
coadministered O O
with O O
a O O
levodopa/dopa B-drug B-drug
decarboxylase B-group B-group
inhibitor I-group I-group
( O O
n=29 O O
) O O
. O O

There O O
is O O
the O O
risk O O
of O O
convulsions O O
occurring O O
in O O
susceptible O O
patients O O
following O O
the O O
use O O
of O O
the O O
new O O
anaesthetic B-group B-group
agents I-group I-group
which O O
are O O
capable O O
of O O
inducing O O
CNS O O
excitability O O
. O O

RESULTS O O
: O O
Hydrocortisone B-drug B-drug
elevated O O
salivary O O
cortisol O O
levels O O
, O O
produced O O
modest O O
dysphoria O O
, O O
and O O
reduced O O
subjects O O
' O O
reports O O
of O O
wanting O O
more O O
drug O O
. O O

Clarithromycin I-drug B-drug
14OH- O O
clarithromycin O B-drug

Caution O O
should O O
be O O
exercised O O
during O O
the O O
administration O O
of O O
adrenaline B-drug B-drug
to O O
patients O O
anaesthetised O O
with O O
FLUOTHANE B-brand B-brand
as O O
arrhythmias O O
may O O
be O O
precipitated O O
. O O

Probenecid B-drug B-drug
: O O
The O O
oral O O
combination O O
of O O
probenecid B-drug B-drug
before O O
intramuscular O O
injection O O
of O O
PIPRACIL B-brand B-brand
produces O O
an O O
increase O O
in O O
piperacillin B-drug B-drug
peak O O
serum O O
level O O
of O O
about O O
30 O O
% O O
. O O

A O O
review O O
. O O

The O O
effects O O
of O O
medicinal O O
products O O
with O O
similar O O
properties O O
such O O
as O O
inotropes O O
milrinone B-drug B-drug
, O O
enoximone B-drug B-drug
, O O
amrinone B-drug B-drug
, O O
olprinone B-drug_n B-drug
and O O
cilostazol B-drug B-drug
may O O
be O O
exacerbated O O
by O O
anagrelide B-drug B-drug
. O O

Our O O
data O O
suggest O O
that O O
TAM B-drug_n B-drug_n
significantly O O
potentiates O O
the O O
reduction O O
in O O
cell O O
number O O
induced O O
by O O
1,25 B-drug B-drug
( I-drug I-drug
OH I-drug I-drug
) I-drug I-drug
2D3 I-drug I-drug
alone O O
. O O

Determinants O O
downstream O O
of O O
cleavable O O
complex O O
formation O O
that O O
affect O O
the O O
sensitivity O O
of O O
tumor O O
versus O O
normal O O
cells O O
to O O
topo O O
drugs O O
in O O
particular O O
and O O
DNA-damaging O O
agents O O
in O O
general O O
are O O
little O O
known O O
. O O

ethchlorvynol B-drug B-drug
; O O

Injection O O
of O O
estradiol B-drug B-drug
5 O O
min O O
before O O
a O O
nonlethal O O
dose O O
of O O
endotoxin B-drug_n B-drug_n
changed O O
the O O
serum O O
sex O O
steroid O O
hormone O O
response O O
of O O
male O O
rats O O
to O O
endotoxin B-drug_n B-drug_n
. O O

Additive O O
depressant O O
effect O O
when O O
used O O
with O O
general O O
anesthetics B-group B-group
, O O
sedatives B-group B-group
, O O
antianxiety B-group B-group
drugs I-group I-group
, O O
hypnotics B-group B-group
, O O
alcohol B-drug B-drug
, O O
and O O
other O O
opiate B-group B-group
analgesics I-group I-group
. O O

Antagonism O O
has O O
been O O
demonstrated O O
between O O
clindamycin B-drug B-drug
and O O
erythromycin B-drug B-drug
in O O
vitro O O
. O O

It O O
may O O
also O O
interact O O
with O O
amantadine B-drug B-drug
or O O
other O O
anticholinergic B-group B-group
drugs I-group I-group
or O O
MAOIs B-group B-group
, O O
which O O
may O O
intensify O O
the O O
anticholinergic O O
action O O
. O O

Oral O O
Anticoagulants B-group B-group
: O O
In O O
some O O
normal O O
volunteers O O
, O O
the O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
warfarin B-drug B-drug
, O O
acenocoumarol B-drug B-drug
, O O
or O O
phenprocoumon B-drug B-drug
resulted O O
in O O
prolongation O O
of O O
prothrombin O O
time O O
. O O

Rifabutin I-drug B-drug
and O O
its O O
metabolite O O
concentrationswere O O
moderately O O
increased O O
. O O

The O O
concomitant O O
use O O
of O O
sodium B-drug B-drug
cephalothin I-drug I-drug
and O O
Coly-Mycin B-brand B-brand
M I-brand I-brand
Parenteral O O
should O O
be O O
avoided O O
. O O

for O O
some O O
strains O O
combinations O O
were O O
synergistic O O
. O O

The O O
absorption O O
of O O
tetracycline B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
penicillin B-drug B-drug
G I-drug I-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
and O O
gemfibrozil B-drug B-drug
was O O
significantly O O
decreased O O
when O O
given O O
simultaneously O O
with O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
; O O

The O O
results O O
indicate O O
that O O
a O O
spinal O O
naloxone-sensitive B-drug O
endorphinergic O O
system O O
is O O
involved O O
in O O
the O O
production O O
of O O
beta-endorphin B-drug_n B-drug_n
but O O
not O O
morphine-induced B-drug B-drug
tail-flick O O
inhibition O O
, O O
and O O
suggest O O
that O O
intraventricular O O
beta-endorphin B-drug_n B-drug_n
and O O
morphine B-drug B-drug
elicit O O
their O O
pharmacological O O
actions O O
via O O
the O O
activation O O
of O O
different O O
descending O O
pain O O
inhibitory O O
systems O O
; O O

Effects O O
of O O
Other O O
Drugs O O
on O O
Aliskiren B-drug B-drug
Based O O
on O O
in-vitro O O
studies O O
, O O
aliskiren B-drug B-drug
is O O
metabolized O O
by O O
CYP O O
3A4 O O
. O O

Combined O O
treatment O O
with O O
1,25 B-drug B-drug
( I-drug I-drug
OH I-drug I-drug
) I-drug I-drug
2D3 I-drug I-drug
and O O
TAM B-drug_n B-drug
enhances O O
the O O
degree O O
of O O
apoptosis O O
assessed O O
using O O
morphological O O
markers O O
that O O
identify O O
chromatin O O
and O O
nuclear O O
matrix O O
protein O O
condensation O O
. O O

At O O
0.3 O O
mg/kg O O
, O O
the O O
diarrhea-inducing O O
effects O O
of O O
dmPGE2 B-drug_n B-drug_n
were O O
more O O
pronounced O O
in O O
cecectomized O O
than O O
in O O
control O O
rats O O
. O O

Tissue O O
culture O O
and O O
animal O O
studies O O
indicate O O
that O O
ELSPAR B-brand B-brand
can O O
diminish O O
or O O
abolish O O
the O O
effect O O
of O O
methotrexate B-drug B-drug
on O O
malignant O O
cells.14 O O
This O O
effect O O
on O O
methotrexate B-drug B-drug
activity O O
persists O O
as O O
long O O
as O O
plasma O O
asparagine O B-drug
levels O O
are O O
suppressed O O
. O O

Therefore O O
, O O
the O O
use O O
of O O
genetic O O
data O O
in O O
these O O
instances O O
has O O
to O O
be O O
regulated O O
. O O

- O O
Quinine B-drug B-drug
( O O
e.g. O O
, O O
Quinamm B-brand B-brand
) O O
or O O

Drug-drug O O
interactions O O
have O O
not O O
been O O
observed O O
between O O
Argatroban B-drug B-drug
and O O
digoxin B-drug B-drug
or O O
erythromycin B-drug B-drug
. O O

Probenecid B-drug B-drug
depresses O O
tubular O O
secretion O O
of O O
certain O O
weak O O
acids O O
such O O
as O O
PAH B-drug B-drug
. O O

Particular O O
caution O O
should O O
be O O
observed O O
with O O
digitalis B-group B-group
preparations I-group I-group
since O O
there O O
are O O
conflicting O O
results O O
for O O
the O O
effect O O
of O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
on O O
the O O
availability O O
of O O
digoxin B-drug B-drug
and O O
digitoxin B-drug B-drug
. O O

While O O
taking O O
beta B-group B-group
blockers I-group I-group
, O O
patients O O
with O O
a O O
history O O
of O O
severe O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
be O O
more O O
reactive O O
to O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
, O O
or O O
therapeutic O O
. O O

Rifampin B-drug B-drug
: O O
When O O
a O O
single O O
375-mg O O
dose O O
of O O
Aprepitant B-drug B-drug
was O O
administered O O
on O O
Day9 O O
of O O
a O O
14-day O O
regimen O O
of O O
600 O O
mg/day O O
of O O
rifampin B-drug B-drug
, O O
a O O
strong O O
CYP3A4 O O
inducer O O
, O O
the O O
AUC O O
of O O
aprepitant B-drug B-drug
decreased O O
approximately O O
11-fold O O
and O O
the O O
mean O O
terminal O O
half-life O O
decreased O O
approximately O O
3-fold O O
. O O

For O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
see O O
CONTRAINDICATIONS O O
. O O

If O O
used O O
concomitantly O O
, O O
closely O O
monitor O O
serum O O
electrolytes O O
and O O
cardiac O O
function O O
. O O

Interactions O O
with O O
the O O
drugs O O
listed O O
below O O
have O O
not O O
been O O
reported O O
in O O
clinical O O
trials O O
with O O
azithromycin B-drug B-drug
; O O

Propranolol B-drug B-drug
attenuated O O
the O O
heart O O
rate O O
increase O O
following O O
administration O O
of O O
immediate O O
release O O
nisoldipine B-drug B-drug
. O O

Ethinyl B-drug B-drug
estradiol I-drug I-drug

ELLENCE B-brand B-brand
when O O
used O O
in O O
combination O O
with O O
other O O
cytotoxic O B-group
drugs O I-group
may O O
show O O
on-treatment O O
additive O O
toxicity O O
, O O
especially O O
hematologic O O
and O O
gastrointestinal O O
effects O O
. O O

poor O O
metabolizers O O
of O O
debrisoquin B-drug B-drug
: O O
Interactions O O
of O O
carvedilol B-drug B-drug
with O O
strong O O
inhibitors O O
of O O
CYP2D6 O O
( O O
such O O
as O O
quinidine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
and O O
propafenone B-drug B-drug
) O O
have O O
not O O
been O O
studied O O
, O O
but O O
these O O
drugs O O
would O O
be O O
expected O O
to O O
increase O O
blood O O
levels O O
of O O
the O O
R O O
( O O
+ O O
) O O
enantiomer O O
of O O
carvedilol B-drug B-drug
. O O

- O O
Indomethacin B-drug B-drug
: O O
Indomethacin B-drug B-drug
blunts O O
the O O
increases O O
in O O
urine O O
volume O O
and O O
sodium O O
excretion O O
seen O O
during O O
bumetanide B-drug B-drug
treatment O O
and O O
inhibits O O
the O O
bumetanide-induced B-drug B-drug
increase O O
in O O
plasma O O
renin O O
activity O O
. O O

anaphylaxis O O

It O O
has O O
been O O
reported O O
that O O
results O O
of O O
studies O O
in O O
animals O O
indicate O O
that O O
dopamine-induced B-drug B-drug
ventricular O O
arrhythmias O O
during O O
anesthesia O O
can O O
be O O
reversed O O
by O O
propranolol B-drug B-drug
. O O

Calcium B-group B-group
Channel I-group I-group
Blockers I-group I-group
: O O
Isolated O O
cases O O
of O O
conduction O O
disturbance O O
( O O
rarely O O
with O O
hemodynamic O O
compromise O O
) O O
have O O
been O O
observed O O
when O O
COREG B-brand B-brand
is O O
co-administered O O
with O O
diltiazem B-drug B-drug
. O O

Verapamil B-drug B-drug
: O O
Coadministration O O
of O O
almotriptan B-drug B-drug
and O O
verapamil B-drug B-drug
resulted O O
in O O
a O O
24 O O
% O O
increase O O
in O O
plasma O O
concentrations O O
of O O
almotriptan B-drug B-drug
. O O

The O O
elevated O O
plasma O O
alprazolam B-drug B-drug
concentrations O O
resulted O O
in O O
decreased O O
psychomotor O O
performance O O
and O O
memory O O
. O O

The O O
potential O O
for O O
binding O O
of O O
these O O
drugs O O
if O O
given O O
concomitantly O O
is O O
present O O
. O O

Intraventricular O O
injection O O
of O O
naloxone B-drug B-drug
at O O
doses O O
of O O
1.2 O O
to O O
12 O O
micrograms O O
equally O O
antagonized O O
in O O
a O O
dose-dependent O O
manner O O
the O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta-endorphin B-drug_n B-drug
and O O
morphine B-drug B-drug
. O O

Lamivudine B-drug B-drug
and O O
zalcitabine B-drug B-drug
may O O
inhibit O O
the O O
intracellular O O
phosphorylation O O
of O O
one O O
another O O
. O O

Coadministration O O
of O O
fluoxetine B-drug B-drug
significantly O O
decreased O O
cisapride B-drug B-drug
plasma O O
concentrations O O
. O O

decreased O O
levels O O
of O O
anti-factor O O
Xa O O
and O O
antithrombin O B-drug
III O I-drug
, O O
decreased O O
antithrombin O O
III O O
activity O O
; O O

Some O O
95 O O
% O O
of O O
a O O
single O O
dosage O O
of O O
fluvastatin B-drug B-drug
is O O
excreted O O
via O O
the O O
biliary O O
route O O
, O O
with O O
less O O
than O O
2 O O
% O O
of O O
this O O
being O O
the O O
parent O O
compound O O
. O O

. O O

higher O O
doses O O
decreased O O
FI O O
and O O
FR O O
responding O O
in O O
both O O
species O O
. O O

ERYTHROMYCIN B-drug B-drug
: O O
In O O
hypercholesterolemic O O
patients O O
, O O
steady-state O O
cerivastatin B-drug B-drug
AUC O O
and O O
Cmax O O
increased O O
approximately O O
50 O O
% O O
and O O
24 O O
% O O
respectively O O
after O O
10 O O
days O O
with O O
co-administration O O
of O O
erythromycin B-drug B-drug
, O O
a O O
known O O
inhibitor O O
of O O
cytochrome O O
P450 O O
3A4 O O
. O O

As O O
a O O
false-negative O O
result O O
may O O
occur O O
in O O
the O O
ferricyanide O O
test O O
, O O
it O O
is O O
recommended O O
that O O
either O O
the O O
glucose O O
oxidase O O
or O O
hexokinase O O
method O O
be O O
used O O
to O O
determine O O
blood O O
plasma O O
glucose O O
levels O O
in O O
patients O O
receiving O O
cefuroxime B-drug B-drug
. O O

Norpace B-brand B-brand
does O O
not O O
increase O O
serum O O
digoxin B-drug B-drug
levels O O
. O O

Although O O
the O O
interactions O O
observed O O
in O O
these O O
studies O O
do O O
not O O
appear O O
to O O
be O O
of O O
major O O
clinical O O
importance O O
, O O
BREVIBLOC B-brand B-brand
should O O
be O O
titrated O O
with O O
caution O O
in O O
patients O O
being O O
treated O O
concurrently O O
with O O
digoxin B-drug B-drug
, O O
morphine B-drug B-drug
, O O
succinylcholine B-drug B-drug
or O O
warfarin B-drug B-drug
. O O

Carcinogenesis O O
, O O
Mutagenesis O O
, O O
and O O
Fertility O O

[ O O
Dose-time O O
effects O O
of O O
competitive O O
displacement O O
of O O
radiopertechnetate B-drug B-drug
by O O
sodium B-drug_n B-drug
perchlorate I-drug_n I-drug
following O O
oral O O
and O O
intravenous O O
administration O O
] O O
The O O
effect O O
of O O
various O O
doses O O
of O O
sodium B-drug_n B-drug
perchlorate I-drug_n I-drug
in O O
several O O
dose O O
fractions O O
on O O
the O O
extent O O
and O O
the O O
time O O
scale O O
of O O
displacement O O
of O O
radiopertechnetate B-drug B-drug
, O O
in O O
dependence O O
on O O
application O O
mode O O
, O O
was O O
studied O O
. O O

oral O O
contraceptives B-group B-group
; O O

CONCLUSIONS O O
: O O
Single-dose O O
diltiazem B-drug B-drug
coadministration O O
leads O O
to O O
higher O O
sirolimus B-drug B-drug
exposure O O
, O O
presumably O O
by O O
inhibition O O
of O O
the O O
first-pass O O
metabolism O O
of O O
sirolimus B-drug B-drug
. O O

methylphenidate B-drug B-drug
; O O

Diuretic B-group B-group
: O O
Hydrochlorothiazide B-drug B-drug
, O O
given O O
concomitantly O O
with O O
ketoprofen B-drug B-drug
, O O
produces O O
a O O
reduction O O
in O O
urinary O O
potassium O O
and O O
chloride O B-drug
excretion O O
compared O O
to O O
hydrochlorothiazide B-drug B-drug
alone O O
. O O

Drugs O O
Metabolized O O
by O O
Cytochrome O O
P450 O O
Enzymes O O
The O O
drug O O
interaction O O
study O O
evaluating O O
the O O
effect O O
of O O
grepafloxacin B-drug B-drug
on O O
theophylline B-drug B-drug
indicates O O
that O O
grepafloxacin B-drug B-drug
inhibits O O
theophylline B-drug B-drug
metabolism O O
, O O
which O O
is O O
mediated O O
by O O
CYP1A2 O O
. O O

When O O
such O O
combined O O
therapy O O
is O O
contemplated O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

Serum O O
digitalis B-group B-group
levels O O
may O O
be O O
decreased O O
in O O
hyperthyroidism O O
or O O
when O O
a O O
hypothyroid O O
patient O O
becomes O O
euthyroid O O
. O O

Nafazodone B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
cimetidine B-drug B-drug
( O O
consider O O
Xanax B-brand B-brand
dose O O
reduction O O
) O O
. O O

When O O
the O O
CYP3A4 O O
inhibitor O O
is O O
withdrawn O O
from O O
the O O
combination O O
therapy O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
then O O
be O O
increased O O
. O O

Sildenafil B-drug B-drug
is O O
contraindicated O O
in O O
patients O O
using O O
long-acting B-group B-group
nitrates I-group I-group
or O O
who O O
may O O
need O O
to O O
use O O
short-acting B-group B-group
nitrates I-group I-group
, O O
because O O
the O O
combination O O
may O O
cause O O
a O O
sharp O O
fall O O
of O O
the O O
blood O O
pressure O O
. O O

In O O
patients O O
with O O
mild O O
to O O
moderate O O
hypertension O O
, O O
administration O O
of O O
25 O O
mg O O
daily O O
of O O
VIOXX B-brand B-brand
with O O
the O O
ACE B-group B-group
inhibitor I-group I-group
benazepril B-drug B-drug
, O O
10 O O
to O O
40 O O
mg O O
for O O
4 O O
weeks O O
, O O
was O O
associated O O
with O O
an O O
average O O
increase O O
in O O
mean O O
arterial O O
pressure O O
of O O
about O O
3 O O
mm O O
Hg O O
compared O O
to O O
ACE B-group B-group
inhibitor I-group I-group
alone O O
. O O

The O O
effects O O
seen O O
are O O
poorly O O
understood O O
and O O
depend O O
upon O O
a O O
variety O O
of O O
factors O O
such O O
as O O
dose O O
and O O
type O O
of O O
thyroid B-group O
preparations I-group O
and O O
endocrine O O
status O O
of O O
the O O
patient O O
. O O

Midazolam B-drug B-drug
Synergism O O

Moreover O O
, O O
the O O
acquisition O O
of O O
tasks O O
that O O
are O O
facilitated O O
by O O
hippocampal O O
lesions O O
( O O
or O O
dysfunction O O
) O O
is O O
nevertheless O O
associated O O
, O O
in O O
intact O O
subjects O O
, O O
with O O
specific O O
neurobiological O O
alterations O O
in O O
the O O
hippocampus O O
. O O

Tolazamide B-drug B-drug
: O O
A O O
case O O
of O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
in O O
a O O
type O O
II O O
diabetic O O
patient O O
maintained O O
on O O
tolazamide B-drug B-drug
( O O
1 O O
gm/day O O
) O O
11 O O
days O O
after O O
the O O
addition O O
of O O
doxepin B-drug B-drug
( O O
75 O O
mg/day O O
) O O
. O O

In O O
situations O O
when O O
concurrent O O
therapy O O
is O O
necessary O O
, O O
careful O O
patient O O
monitoring O O
is O O
essential O O
. O O

Oral O O
Anticoagulants B-group B-group
Interaction O O
studies O O
with O O
warfarin B-drug B-drug
and O O
acenocoumarol B-drug B-drug
failed O O
to O O
identify O O
any O O
clinically O O
important O O
effects O O
on O O
the O O
serum O O
concentrations O O
or O O
clinical O O
effects O O
of O O
these O O
anticoagulants B-group B-group
. O O

( O O
Cancer O O
Res. O O
, O O
38 O O
: O O
2003-2010 O O
, O O
1978 O O
) O O
have O O
reported O O
that O O
a O O
single O O
, O O
small O O
pulse O O
of O O
carcinogen O O
can O O
induce O O
early O O
and O O
numerous O O
liver O O
tumors O O
when O O
administered O O
neonatally O O
to O O
mice O O
with O O
a O O
genetic O O
predisposition O O
to O O
hepatotumorigenesis O O
. O O

As O O
with O O
most O O
psychoactive O B-group
medications O I-group
, O O
patients O O
should O O
be O O
advised O O
to O O
avoid O O
alcohol B-drug B-drug
while O O
taking O O
ABILIFY B-brand B-brand

This O O
decrease O O
in O O
absorption O O
results O O
in O O
a O O
36 O O
% O O
and O O
50 O O
% O O
lower O O
AUC O O
for O O
trovafloxacin B-drug B-drug
and O O
ciprofloxacin B-drug B-drug
, O O
respectively O O
, O O
which O O
could O O
cause O O
clinical O O
failures O O
. O O

A O O
pregnancy O O
test O O
must O O
be O O
repeated O O
each O O
month O O
prior O O
to O O
the O O
female O O
patient O O
receiving O O
each O O
prescription O O

The O O
interaction O O
of O O
Exjade B-brand B-brand
with O O
hydroxyurea B-drug B-drug
has O O
not O O
been O O
formally O O
studied O O
. O O

In O O
addition O O
to O O
bleeding O O
associated O O
with O O
heparin B-drug B-drug
and O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
, O O
drugs O O
that O O
alter O O
platelet O O
function O O
( O O
such O O
as O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
dipyridamole B-drug B-drug
and O O
Abciximab B-drug B-drug
) O O
may O O
increase O O
the O O
risk O O
of O O
bleeding O O
if O O
administered O O
prior O O
to O O
, O O
during O O
, O O
or O O
after O O
Activase B-brand B-brand
therapy O O
. O O

Although O O
the O O
pressor O O
activity O O
of O O
Desmopressin B-drug B-drug
is O O
very O O
low O O
compared O O
to O O
its O O
antidiuretic O O
activity O O
, O O
large O O
doses O O
of O O
Desmopressin B-drug B-drug
Tablets O O
should O O
be O O
used O O
with O O
other O O
pressor O B-group
agents O I-group
only O O
with O O
careful O O
patient O O
monitoring O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
with O O
anti-neoplastic B-group B-group
agents I-group I-group
have O O
been O O
conducted O O
. O O

Digoxin B-drug B-drug
: O O
Coadministration O O
of O O
digoxin B-drug B-drug
, O O
a O O
P-glycoprotein O O
substrate O O
, O O
with O O
oral O O
conivaptan B-drug B-drug
resulted O O
in O O
a O O
reduction O O
in O O
clearance O O
and O O
an O O
increase O O
in O O
digoxin B-drug B-drug
Cmax O O
and O O
AUC O O
values O O
. O O

Cephalosporins-Cephalosporins B-group B-group
containing O O
side O O
chains O O
of O O
N-methylthiotetrazole O B-drug_n
( O O
cefmenoxime B-drug B-drug
, O O
cefoperazone B-drug B-drug
, O O
cefotetan B-drug B-drug
, O O
cefamandole B-drug B-drug
, O O
latamoxef B-drug B-drug
) O O
or O O
methylthiadiazole O B-drug
( O O
cefazolin B-drug B-drug
) O O
can O O
cause O O
vitamin O B-group
K O I-group
deficiency O O
and O O
hypoprothrombinemia O O
. O O

May O O
interact O O
with O O
the O O
following O O
: O O
cholestyramine B-drug B-drug
, O O
colestipol B-drug B-drug
( O O
use O O
with O O
thiazide B-group B-group
diuretics I-group I-group
may O O
prevent O O
the O O
diuretic B-group B-group
from O O
working O O
properly O O
; O O

although O O
combinations O O
are O O
sometimes O O
used O O
for O O
therapeutic O O
advantage O O
, O O
when O O
used O O
concurrently O O
, O O
patient O O
should O O
be O O
closely O O
monitored O O
. O O

It O O
is O O
concluded O O
that O O
neurotensin B-drug_n B-drug_n
modulates O O
in O O
an O O
opposite O O
way O O
the O O
function O O
of O O
the O O
enkephalinergic O O
neurons O O
and O O
the O O
central O O
action O O
of O O
tuftsin B-drug_n B-drug_n
. O O

Intensive O O
monitoring O O
of O O
renal O O
function O O
is O O
recommended O O
in O O
patients O O
requiring O O
any O O
combination O O
of O O
nephrotoxic O O
medications O O
. O O

Thus O O
cimetidine B-drug B-drug
appeared O O
to O O
alter O O
the O O
renal O O
excretion O O
of O O
both O O
gabapentin B-drug B-drug
and O O
creatinine O O
, O O
an O O
endogenous O O
marker O O
of O O
renal O O
function O O
. O O

May O O
interact O O
with O O
other O O
creams O O
, O O
lotions O O
, O O
or O O
skin O O
medicines O O
when O O
placed O O
on O O
the O O
same O O
areas O O
of O O
your O O
skin O O
that O O
you O O
are O O
using O O
bentoquatam B-drug_n B-drug
. O O

Neuroleptic B-group B-group
Drugs I-group I-group
- O O
L-phenylalanine B-drug B-drug
may O O
potentiate O O
the O O
tardive O O
dyskinesia O O
side O O
reactions O O
of O O
neuroleptic B-group B-group
drugs I-group I-group
if O O
used O O
concomitantly O O
with O O
them O O
. O O

Beta B-group B-group
blockers I-group I-group
may O O
exacerbate O O
the O O
rebound O O
hypertension O O
which O O
can O O
follow O O
the O O
withdrawal O O
of O O
clonidine B-drug B-drug
. O O

MAO B-group B-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
effects O O
of O O
antihistamines B-group B-group
. O O

Other O O
5-HT1B/1D B-group O
Agonists I-group O
Concomitant O O
use O O
of O O
other O O
5-HT1B/1D B-group B-group
agonists I-group I-group
within O O
24 O O
hours O O
of O O
treatment O O
with O O
AXERT B-brand B-brand
is O O
contraindicated O O
. O O

The O O
following O O
agents O O
may O O
increase O O
certain O O
actions O O
or O O
side O O
effects O O
of O O
anticholinergic B-group B-group
drugs I-group I-group
. O O
amantadine B-drug B-group
antiarrhythmic B-group I-group
agents I-group I-group
of O I-group
class O I-group
( O O
e.g O O
. O O
quinidine B-drug B-drug
) O O
, O O
antihistamines B-group B-group
antipsychotic I-group I-group
agents I-group I-group
( O O
e.g O O
. O O
phenothiazines B-group B-group
) O O
, O O
benzodiazepines B-group B-group
. O O

Effect O O

The O O
utilization O O
of O O
digitoxin B-drug B-drug
for O O
such O O
patients O O
may O O
be O O
considered O O
as O O
an O O
alternative O O
. O O

Type O O
2 O O
diabetes O O
mellitus O O
is O O
a O O
growing O O
problem O O
not O O
only O O
in O O
the O O
United O O
States O O
but O O
also O O
across O O
the O O
world O O
. O O

No O O
pharmacodynamic O O
effects O O
of O O
either O O
histamine B-group B-group
H2 I-group I-group
receptor I-group I-group
antagonist I-group I-group
were O O
observed O O
. O O

BACKGROUND O O
. O O

Neuroleptic B-group O
: O O
pimozide B-drug B-drug

These O O
results O O
indicate O O
that O O
dosage O O
adjustment O O
of O O
quetiapine B-drug B-drug
may O O
be O O
necessary O O
when O O
the O O
two O O
drugs O O
are O O
given O O
concurrently O O
and O O
that O O
caution O O
may O O
be O O
required O O
when O O
administering O O
other O O
drugs O O
that O O
inhibit O O
or O O
induce O O
cytochromes O O
, O O
particularly O O
P450 O O
3A4 O O
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
these O O
agents O O
is O O
indicated O O
because O O
of O O
demonstrated O O
hypokalemia O O
, O O
they O O
should O O
be O O
used O O
with O O
caution O O
and O O
with O O
frequent O O
monitoring O O
of O O
serum O O
potassium O O
. O O

Aspirin B-brand B-brand
: O O
Ketoprofen B-drug B-drug
does O O
not O O
alter O O
aspirin B-brand B-brand
absorption O O
; O O

Other O O
strong O O
inhibitors O O
of O O
CYP3A4 O O
( O O
e.g. O O
, O O
itraconazole B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
troleandomycin B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
nelfinavir B-drug B-drug
) O O
would O O
be O O
expected O O
to O O
behave O O
similarly O O
. O O

Effect O O
of O O
other O O
drugs O O
on O O
Vardenafil B-drug B-drug

No O O
specific O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
. O O

Because O O
of O O
possible O O
clinical O O
significance O O
, O O
the O O
two O O
drugs O O
should O O
not O O
be O O
administered O O
concurrently O O
. O O

These O O
agents O O
may O O
also O O
prolong O O
the O O
clinically O O
effective O O
duration O O
of O O
action O O
by O O
up O O
to O O
25 O O
% O O
. O O

Since O O
this O O
could O O
be O O
explained O O
either O O
by O O
enhanced O O
absorption O O
or O O
by O O
an O O
alteration O O
of O O
hepatic O O
metabolism O O
of O O
labetalol B-drug B-drug
HCl I-drug I-drug
, O O
special O O
care O O
should O O
be O O
used O O
in O O
establishing O O
the O O
dose O O
required O O
for O O
blood O O
pressure O O
control O O
in O O
such O O
patients O O
. O O

Rifampin B-drug B-drug
may O O
decrease O O
serum O O
digoxin B-drug B-drug
concentration O O
, O O
especially O O
in O O
patients O O
with O O
renal O O
dysfunction O O
, O O
by O O
increasing O O
the O O
non-renal O O
clearance O O
of O O
digoxin B-drug B-drug
. O O

Drug O O
interaction O O
studies O O
have O O
shown O O
that O O
esomeprazole B-drug B-drug
does O O
not O O
have O O
any O O
clinically O O
significant O O
interactions O O
with O O
phenytoin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
clarithromycin B-drug B-drug
or O O
amoxicillin B-drug B-drug
. O O

In O O
patients O O
receiving O O
concurrent O O
therapy O O
with O O
clonidine B-drug B-drug
, O O
if O O
therapy O O
is O O
to O O
be O O
discontinued O O
, O O
it O O
is O O
suggested O O
that O O
ZEBETA B-brand B-brand
be O O
discontinued O O
for O O
several O O
days O O
before O O
the O O
withdrawal O O
of O O
clonidine B-drug B-drug
. O O

Both O O
groups O O
of O O
agents O O
lower O O
blood O O
levels O O
and O O
efficacy O O
of O O
amphetamines B-group B-group
. O O

METHODS O O
: O O
Clinical O O
studies O O
, O O
case O O
reports O O
, O O
and O O
commentaries O O
and O O
editorials O O
concerning O O
sildenafil B-drug B-drug
published O O
in O O
the O O
international O O
literature O O
between O O
January O O
1999 O O
and O O
August O O
2000 O O
were O O
identified O O
through O O
searches O O
of O O
MEDLINE O B-brand
, O O
PREMEDLINE O B-brand
, O O
and O O
International O O
Pharmaceutical O O
Abstracts O O
, O O
using O O
the O O
terms O O
sildenafil B-drug B-drug
, O O
Viagra B-brand B-brand
, O O
and O O
erectile O O
dysfunction O O
. O O

Therefore O O
, O O
if O O
digoxin B-drug B-drug
is O O
administered O O
with O O
VAPRISOL B-brand B-brand
, O O
the O O
clinician O O
should O O
be O O
alert O O
to O O
the O O
possibility O O
of O O
increases O O
in O O
digoxin B-drug B-drug
levels O O
. O O

While O O
no O O
in O O
vivo O O
drug-drug O O
interaction O O
studies O O
were O O
conducted O O
between O O
estazolam B-drug B-drug
and O O
inducers O O
of O O
CYP3A O O
, O O
compounds O O
that O O
are O O
potent O O
CYP3A O O
inducers O O
( O O
such O O
as O O
carbamazepine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
and O O
barbiturates B-group B-group
) O O
would O O
be O O
expected O O
to O O
decrease O O
estazolam B-drug B-drug
concentrations O O
. O O

Compounds O O
in O O
these O O
categories O O
result O O
in O O
a O O
decreased O O
efficacy O O
of O O
bromocriptine B-drug B-drug
mesylate I-drug I-drug
: O O
phenothiazines B-group B-group
, O O
haloperidol B-drug B-drug
, O O
metoclopramide B-drug B-drug
, O O
pimozide B-drug B-drug
. O O

Both O O
the O O
sedative O O
and O O
anticholinergic O O
effects O O
of O O
the O O
major B-group O
tranquilizers I-group B-group
are O O
also O O
additive O O
to O O
those O O
of O O
desipramine B-drug B-drug
. O O

The O O
intravenous O O
application O O
of O O
perchlorate B-drug_n B-drug
offers O O
advantages O O
in O O
clinical O O
use O O
. O O

therefore O O
, O O
the O O
disposition O O
of O O
eszopiclone B-drug B-drug
is O O
not O O
expected O O
to O O
be O O
sensitive O O
to O O
alterations O O
in O O
protein O O
binding O O
. O O

Three O O
patients O O
met O O
ACR O O
criteria O O
for O O
liver O O
biopsy O O
( O O
1 O O
: O O
Roegnik O B-brand
Grade O O
I O O
, O O
2 O O
: O O
Roegnik O B-brand
Grade O O
IIIa O O
) O O
. O O

Nervous O O
System O O
: O O
Although O O
the O O
occurrence O O
of O O
peripheral O O
neuropathy O O
is O O
frequent O O
, O O
the O O
development O O
of O O
severe O O
symptomatology O O
is O O
unusual O O
and O O
requires O O
a O O
dose O O
reduction O O
of O O
20 O O
% O O
for O O
all O O
subsequentcourses O O
of O O
TAXOL B-brand B-brand
. O O

Effect O O
of O O
ginsenosides B-drug_n B-drug_n
on O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
channel O O
subtypes O O
in O O
bovine O O
chromaffin O O
cells O O
. O O

antiarrhythmic B-group B-group
agents I-group I-group
concentration O O

Agents O O
that O O
induce O O
CYP3A4 O O
( O O
eg O O
, O O
carbamazepine B-drug B-drug
) O O
could O O
cause O O
an O O
increase O O
in O O
aripiprazole B-drug B-drug
clearance O O
and O O
lower O O
blood O O
levels O O
. O O

Do O O
not O O
take O O
this O O
medicine O O
with O O
thioridizine O B-drug
, O O
or O O
within O O
5 O O
weeks O O
of O O
taking O O
fluoxetine B-drug B-drug
. O O

The O O
magnitude O O
of O O
interaction O O
at O O
other O O
doses O O
is O O
not O O
known O O
. O O

However O O
, O O
the O O
peak O O
plasma O O
level O O
of O O
metformin B-drug B-drug
was O O
reduced O O
by O O
approximately O O
20 O O
% O O
when O O
taking O O
Acarbose B-drug B-drug
due O O
to O O
a O O
slight O O
delay O O
in O O
the O O
absorption O O
of O O
metformin B-drug B-drug
. O O

However O O
, O O
the O O
concomitant O O
use O O
of O O
Argatroban B-drug B-drug
and O O
warfarin B-drug B-drug
( O O
5-7.5 O O
mg O O
initial O O
oral O O
dose O O
followed O O
by O O
2.5-6 O O
mg/day O O
orally O O
for O O
6-10 O O
days O O
) O O
results O O
in O O
prolongation O O
of O O
the O O
prothrombin O O
time O O
( O O
PT O O
) O O
and O O
International O O
Normalized O O
Ratio O O
( O O
INR O O
) O O
. O O

Little O O
has O O
been O O
studied O O
of O O
the O O
adverse O O
effects O O
of O O
the O O
exposure O O
of O O
the O O
liver O O
to O O
the O O
interaction O O
of O O
ethanol B-drug B-drug
with O O
its O O
congeners O O
and O O
acetaldehyde B-drug_n B-drug_n
, O O
coexisting O O
in O O
the O O
contents O O
of O O
alcoholic O O
beverages O O
. O O

Other O O
Drugs O O
: O O
In O O
healthy O O
volunteers O O
, O O
amlodipine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
glyburide B-drug B-drug
, O O
ranitidine B-drug B-drug
, O O
omeprazole B-drug B-drug
, O O
hormone B-drug O
replacement O O
therapy O O
( O O
a O O
combination O O
of O O
conjugated O B-group
estrogens B-group I-group
and O O
medroxyprogesterone B-drug B-drug
) O O
, O O
antacid B-group B-group
( O O
aluminum O B-drug
and O O
magnesium B-drug B-drug
hydroxides O I-drug
) O O
and O O
theophylline B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
TIKOSYN B-brand B-brand
. O O

Anticoagulants B-group B-group
, O O
oral O O

Although O O
there O O
are O O
no O O
study O O
data O O
to O O
evaluate O O
the O O
possibility O O
, O O
nitric B-group B-group
oxide I-group I-group
donor I-group I-group
compounds I-group I-group
, O O
including O O
sodium B-drug B-drug
nitroprusside I-drug I-drug
and O O
nitroglycerin B-drug B-drug
, O O
may O O
have O O
an O O
additive O O
effect O O
with O O
INOmax B-brand B-brand
on O O
the O O
risk O O
of O O
developing O O
methemoglobinemia O O
. O O

n-dodecyl B-drug O
gallate I-drug O
showed O O
the O O
most O O
potent O O
inhibition O O
( O O
66 O O
% O O
inhibition O O
at O O
10 O O
microM O O
) O O
, O O
which O O
was O O
far O O
more O O
potent O O
than O O
that O O
of O O
crude O O
tannic B-drug O
acid I-drug O
. O O

Inhibitors O O
of O O
this O O
isoenzyme O O
( O O
e.g. O O
, O O
macrolide B-group B-group
antibiotics I-group I-group
, O O
azole B-group B-group
antifungal I-group I-group
agents I-group I-group
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
serotonin B-group B-group
reuptake I-group I-group
inhibitors I-group I-group
, O O
amiodarone B-drug B-drug
, O O
cannabinoids B-group B-group
, O O
diltiazem B-drug B-drug
, O O
grapefruit O O
juice O O
, O O
nefazadone B-drug B-drug
, O O
norfloxacin B-drug B-drug
, O O
quinine B-drug B-drug
, O O
zafirlukast B-drug B-drug
) O O
should O O
be O O
cautiously O O
coadministered O O
with O O
TIKOSYN B-brand B-brand
as O O
they O O
can O O
potentially O O
increase O O
dofetilide B-drug B-drug
levels O O
. O O

Electroconvulsive O O
Therapy O O
( O O
ECT O O
) O O
- O O
There O O
are O O
no O O
clinical O O
studies O O
of O O
the O O
combined O O
use O O
of O O
ECT O O
and O O
escitalopram B-drug B-drug
. O O

Midazolam B-drug B-drug
: O O
Aprepitant B-drug B-drug
increased O O
the O O
AUC O O
of O O
midazolam B-drug B-drug
, O O
a O O
sensitive O O
CYP3A4 O O
substrate O O
, O O
by O O
2.3-fold O O
on O O
Day O O
1 O O
and O O
3.3-fold O O
on O O
Day O O
5 O O
, O O
when O O
a O O
single O O
oral O O
dose O O
of O O
midazolam B-drug B-drug
2 O O
mg O O
was O O
coadministered O O
on O O
Day O O
1 O O
and O O
Day O O
5 O O
of O O
a O O
regimen O O
of O O
Aprepitant B-drug B-drug
125 O O
mg O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
through O O
5 O O
. O O

NNRTI-based B-group B-group
regimens O O
may O O
have O O
several O O
advantages O O
over O O
PI-based B-group O
therapy O O
for O O
initial O O
or O O
prolonged O O
therapy O O
, O O
including O O
more O O
convenient O O
administration O O
regimens O O
, O O
lower O O
tablet O O
volume O O
, O O
fewer O O
drug O O
interactions O O
, O O
and O O
central O O
nervous O O
system O O
penetration O O
. O O

The O O
clearance O O
of O O
salicylates B-group B-group
may O O
be O O
increased O O
with O O
concurrent O O
use O O
of O O
corticosteroids B-group B-group
. O O

As O O
with O O
all O O
drugs O O
, O O
care O O
should O O
be O O
exercised O O
when O O
treating O O
patients O O
with O O
multiple O O
medications O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
considering O O
the O O
use O O
of O O
BREVIBLOC B-brand B-brand
and O O
verapamil B-drug B-drug
in O O
patients O O
with O O
depressed O O
myocardial O O
function O O
. O O

For O O
a O O
4-fold O O
range O O
of O O
everolimus B-drug B-drug
doses O O
there O O
were O O
no O O
differential O O
effects O O
on O O
cyclosporine B-drug B-drug
dosing O O
or O O
pharmacokinetics O O
. O O

An O O
increase O O
in O O
serum O O
lithium B-drug B-drug
concentration O O
has O O
been O O
reported O O
during O O
concomitant O O
administration O O
of O O
lithium B-drug B-drug
with O O
ATACAND B-brand B-brand
, O O
so O O
careful O O
monitoring O O
of O O
serum O O
lithium B-drug B-drug
levels O O
is O O
recommended O O
during O O
concomitant O O
use O O
. O O

Neuropathy O O
has O O
occurred O O
more O O
frequently O O
in O O
patients O O
with O O
a O O
history O O
of O O
neuropathy O O
or O O
neurotoxic O O
drug O O
therapy O O
, O O
including O O
stavudine B-drug B-drug
, O O
and O O
these O O
patients O O
may O O
be O O
at O O
increased O O
risk O O
of O O
neuropathy O O
during O O
VIDEX B-brand B-brand
therapy O O
( O O
see O O
ADVERSE O O
REACTIONS O O
) O O
. O O

This O O
interference O O
may O O
result O O
in O O
an O O
apparent O O
factor O O
concentration O O
that O O
is O O
lower O O
than O O
the O O
true O O
concentration O O
. O O

oral O O
clearance O O
was O O
reduced O O
by O O
about O O
50 O O
% O O
. O O

Antacids B-group B-group
containing O O
magnesium B-drug B-drug
trisilicate I-drug I-drug
, O O
when O O
administered O O
concomitantly O O
with O O
nitrofurantoin B-drug B-drug
, O O
reduce O O
both O O
the O O
rate O O
and O O
extent O O
of O O
absorption O O
. O O

An O O
initial O O
dose O O
of O O
5 O O
mg O O
should O O
be O O
given O O
to O O
patients O O
who O O
are O O
concomitantly O O
being O O
treated O O
with O O
cimetidine B-drug B-drug
. O O

there O O
was O O
no O O
significant O O
change O O
in O O
prothrombin O O
test O O
results O O
during O O
the O O
trials O O
of O O
chloral B-drug B-drug
hydrate I-drug I-drug
and O O
methaqualone B-drug B-drug
. O O

Patients O O
treated O O
with O O
a O O
beta-adrenergic B-group B-group
receptor I-group I-group
blocking I-group I-group
agent I-group I-group
plus O O
a O O
catecholamine O B-group
depletor O I-group
should O O
therefore O O
be O O
closely O O
observed O O
for O O
evidence O O
of O O
hypotension O O
or O O
marked O O
bradycardia O O
, O O
which O O
may O O
produce O O
vertigo O O
, O O
syncope O O
, O O
or O O
postural O O
hypotension O O
. O O

Diuretics B-group B-group
: O O
Studies O O
in O O
normal O O
volunteers O O
have O O
shown O O
that O O
flurbiprofen B-drug B-drug
like O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
can O O
interfere O O
with O O
the O O
effects O O
of O O
furosemide B-drug B-drug
. O O

Usually O O
, O O
the O O
dosage O O
of O O
the O O
anticoagulant B-group B-group
should O O
be O O
reduced O O
by O O
one-half O O
( O O
depending O O
on O O
the O O
individual O O
case O O
) O O
to O O
maintain O O
the O O
prothrombin O O
time O O
at O O
the O O
desired O O
level O O
to O O
prevent O O
bleeding O O
complications O O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

A O O
1-month O O
washout O O
period O O
was O O
inserted O O
between O O
the O O
treatment O O
periods O O
. O O

The O O
pharmacokinetics O O
of O O
naltrexone B-drug B-drug
and O O
its O O
major O O
metabolite O O
6-beta-naltrexol B-drug_n O
were O O
unaffected O O
following O O
co-administration O O
with O O
Acamprosate B-drug B-drug
. O O

cimetidine B-drug B-drug
; O O

they O O
also O O
suggest O O
that O O
alcoholic O O
beverages O O
are O O
not O O
equivalent O O
in O O
their O O
potential O O
to O O
cause O O
liver O O
damage O O
. O O

Results O O
of O O
preliminary O O
studies O O
in O O
humans O O
and O O
rats O O
suggest O O
that O O
nonabsorbable O O
antacids B-group B-group
given O O
concurrently O O
with O O
lactulose B-drug B-drug
may O O
inhibit O O
the O O
desired O O
lactulose-induced B-drug B-drug
drop O O
in O O
colonic O O
pH O O
. O O

Histamine B-group B-group
H2 I-group I-group
antagonists I-group I-group
: O O
Cimetidine B-drug B-drug
inhibits O O
CYP3A4 O O
and O O
can O O
increase O O
serum O O
amiodarone B-drug B-drug
levels O O
. O O

Cyclosporine B-drug B-drug
: O O
Modest O O
increases O O
in O O
mean O O
trough O O
cyclosporine B-drug B-drug
concentrations O O
were O O
observed O O
following O O
initiation O O
of O O
carvedilol B-drug B-drug
treatment O O
in O O
21 O O
renal O O
transplant O O
patients O O
suffering O O
from O O
chronic O O
vascular O O
rejection O O
. O O

. O O

These O O
reactions O O
have O O
been O O
observed O O
more O O
frequently O O
with O O
the O O
24-hour O O
infusion O O
than O O
with O O
the O O
3-hour O O
infusion O O
. O O

Altered O O
responsiveness O O
to O O
alcohol B-drug B-drug
after O O
exposure O O
to O O
organic O O
lead O O
. O O

At O O
37 O O
degrees O O
C O O
the O O
non-myelinated O O
axons O O
contained O O
28.4 O O
plus O O
or O O
minus O O
0.8 O O
S.E.M O O
. O O

Drugs O O
that O O
may O O
alter O O
imatinib B-drug B-drug
plasma O O
concentrations O O
Drugs O O
that O O
may O O
increase O O
imatinib B-drug B-drug
plasma O O
concentrations O O
: O O
Caution O O
is O O
recommended O O
when O O
administering O O
Gleevec B-brand B-brand
with O O
inhibitors O O
of O O
the O O
CYP3A4 O O
family O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
) O O
. O O

Indinavir B-drug B-drug
concentrations O O
may O O
be O O
decreased O O
in O O
the O O
presence O O
of O O
nevirapine B-drug B-drug
. O O

Trileptal B-brand B-brand
dose O O
( O O
mg/day O O
) O O

It O O
is O O
recommended O O
that O O
these O O
tests O O
be O O
performed O O
at O O
weekly O O
or O O
biweekly O O
intervals O O
until O O
the O O
lipid O O
response O O
to O O
Accutane B-brand B-brand
is O O
established O O
. O O

Untreated O O
hypothyroidism O O
may O O
interfere O O
with O O
the O O
growth O O
response O O
to O O
somatrem B-drug O
or O O
somatropin B-drug B-drug
. O O

In O O
patients O O
receiving O O
a O O
potent O O
CYP3A4 O O
inducer O O
such O O
as O O
rifampicin B-drug B-drug
or O O
phenytoin B-drug B-drug
, O O
a O O
dose O O
increase O O
to O O
500 O O
mg O O
daily O O
should O O
be O O
considered O O
in O O
the O O
absence O O
of O O
severe O O
adverse O O
drug O O
reaction O O
, O O
and O O
clinical O O
response O O
and O O
adverse O O
events O O
should O O
be O O
carefully O O
monitored O O
( O O
see O O
CLINICAL O O
PHARMACOLOGY-Pharmacokinetics-Drug-Drug O O
Interactions O O
and O O
DOSAGE O O
AND O O
ADMINISTRATION-Dosage O O
Adjustment O O
sections O O
) O O
. O O

These O O
pharmacokinetic O O
effects O O
did O O
not O O
result O O
in O O
clinically O O
meaningful O O
changes O O
in O O
ECG O O
, O O
heart O O
rate O O
or O O
blood O O
pressure O O
beyond O O
those O O
changes O O
induced O O
by O O
diltiazem B-drug B-drug
alone O O
. O O

Agents O O
that O O
Inhibit O O
Cytochrome O O
P450 O O
Isoenzymes O O
and/or O O
Epoxide O O
Hydrolase O O
Carbamazepine B-drug B-drug
is O O
metabolized O O
mainly O O
by O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
3A4 O O
to O O
the O O
active O O
carbamazepine B-drug B-drug
10,11-epoxide I-drug I-drug
, O O
which O O
is O O
further O O
metabolized O O
to O O
the O O
trans-diol O O
by O O
epoxide O O
hydrolase O O
. O O

leukopenia O O

Drugs O O
That O O
Alter O O
Renal O O
Excretion O O
Ibuprofen B-drug B-drug
: O O
Ibuprofen B-drug B-drug
is O O
known O O
to O O
affect O O
renal O O
function O O
and O O
, O O
consequently O O
, O O
alter O O
the O O
renal O O
excretion O O
of O O
other O O
drugs O O
. O O

Misonidazole B-drug_n B-drug_n
also O O
reduced O O
the O O
" O O
early O O
" O O

. O O

There O O
was O O
no O O
evidence O O
of O O
any O O
pharmacokinetic O O
interactions O O
between O O
ERBITUX B-brand B-brand
and O O
irinotecan B-drug B-drug
. O O

Drug-Drug O O
Interactions O O
Cimetidine B-drug B-drug
: O O
Concomitant O O
use O O
of O O
cimetidine B-drug B-drug
is O O
contraindicated O O
. O O

. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
with O O
captopril B-drug B-drug
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-group B-group
or O O
increasing O O
the O O
salt O O
intake O O
approximately O O
one O O
week O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
captopril B-drug B-drug
( O O
captopril B-drug B-drug
tablets O O
, O O
USP O O
) O O
or O O
initiating O O
therapy O O
with O O
small O O
doses O O
( O O
6.25 O O
or O O
12.5 O O
mg O O
) O O
. O O

Two O O
percent O O
of O O
patients O O
treated O O
concurrently O O
with O O
Kineret B-brand B-brand
and O O
etanercept B-drug B-drug
developed O O
neutropenia O O
( O O
ANC O O
1 O O
x O O
109/L O O
) O O
. O O

COPAXONE B-brand B-brand
has O O
not O O
been O O
formally O O
evaluated O O
in O O
combination O O
with O O
Interferon B-drug B-drug
beta I-drug I-drug
. O O

Estrogens B-group B-group
, O O
including O O
oral O O
contraceptives B-group B-group
: O O
Estrogens B-group B-group
may O O
decrease O O
the O O
hepatic O O
metabolism O O
of O O
certain O O
corticosteroids B-group B-group
, O O
thereby O O
increasing O O
their O O
effect O O
. O O

Potential O O
differences O O
in O O
cyclosporine B-drug B-drug
dosing O O
and O O
pharmacokinetics O O
at O O
different O O
levels O O
of O O
everolimus B-drug B-drug
exposure O O
were O O
assessed O O
in O O
the O O
context O O
of O O
ANOVA O O
. O O

Monitoring O O
of O O
anticoagulation O O
levels O O
is O O
recommended O O
. O O

These O O
data O O
emphasize O O
that O O
apoptosis O O
can O O
be O O
induced O O
in O O
MCF-7 O O
cells O O
either O O
by O O
activation O O
of O O
vitamin-D-mediated B-group O
signalling O O
or O O
disruption O O
of O O
estrogen-dependent B-group O
signalling O O
. O O

Antithyroid B-group B-group
agents I-group I-group
may O O
decrease O O
thyroidal O O
uptake O O
of O O
sodium B-drug B-drug
iodide I-drug I-drug
I131 I-drug O
, O O
a O O
rebound O O
in O O
uptake O O
may O O
occur O O
up O O
to O O
5 O O
days O O
after O O
sudden O O
withdrawal O O
of O O
Carbimazole B-drug B-drug
. O O

5HT3 B-group B-group
Antagonists I-group I-group
: O O
Based O O
on O O
reports O O
of O O
profound O O
hypotension O O
and O O
loss O O
of O O
consciousness O O
when O O
apomorphine B-drug B-drug
was O O
administered O O
with O O
ondansetron B-drug B-drug
, O O
the O O
concomitant O O
use O O
of O O
apomorphine B-drug B-drug
with O O
drugs O O
of O O
the O O
5HT3 B-group B-group
antagonist I-group I-group
class I-group I-group
( O O
including O O
, O O
for O O
example O O
, O O
ondansetron B-drug B-drug
, O O
granisetron B-drug B-drug
, O O
dolasetron B-drug B-drug
, O O
palonosetron B-drug B-drug
, O O
and O O
alosetron B-drug B-drug
) O O
is O O
contraindicated O O
. O O

Severe O O
anemia O O
( O O
Grade O O
3-4 O O
according O O
to O O
the O O
World O O
Health O O
Organization O O
criteria O O
) O O
was O O
significantly O O
greater O O
in O O
the O O
patients O O
who O O
received O O
CHOP-HAART O O
compared O O
with O O
the O O
patients O O
who O O
received O O
CHOP O O
alone O O
( O O
33 O O
% O O
vs. O O
7 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
0.001 O O
) O O
. O O

atazanavir I-drug B-drug

Magnesium B-drug B-drug
infusions O O
can O O
only O O
be O O
envisaged O O
in O O
intensive O O
care O O
units O O
with O O
careful O O
monitoring O O
of O O
pulse O O
, O O
arterial O O
pressure O O
, O O
deep O O
tendon O O
reflexes O O
, O O
hourly O O
diuresis O O
, O O
electrocardiogram O O
and O O
respiratory O O
recordings O O
. O O

As O O
MHD B-drug_n B-drug_n
, O O
the O O
predominant O O
plasma O O
substrate O O
, O O
is O O
only O O
a O O
weak O O
inducer O O
of O O
UDP-glucuronyl O O
transferase O O
, O O
it O O
is O O
unlikely O O
to O O
have O O
an O O
effect O O
on O O
drugs O O
that O O
are O O
mainly O O
eliminated O O
by O O
conjugation O O
through O O
UDP-glucuronyl O O
transferase O O
( O O
e.g. O O
, O O
valproic B-drug B-drug
acid I-drug I-drug
, O O
lamotrigine B-drug B-drug
) O O
. O O

Other O O
concomitant O O
therapy O O
Although O O
specific O O
interaction O O
studies O O
were O O
not O O
performed O O
, O O
finasteride B-drug B-drug
doses O O
of O O
1 O O
mg O O
or O O
more O O
were O O
concomitantly O O
used O O
in O O
clinical O O
studies O O
with O O
acetaminophen B-drug B-drug
, O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
a-blockers O B-group
, O O
analgesics B-group B-group
, O O
angiotensin-converting B-group B-group
enzyme I-group I-group
( I-group O
ACE I-group B-group
) I-group I-group
inhibitors I-group I-group
, O O
anticonvulsants B-group B-group
, O O
benzodiazepines B-group B-group
, O O
beta B-group B-group
blockers I-group I-group
, O O
calcium-channel B-group B-group
blockers I-group I-group
, O O
cardiac O B-group
nitrates B-group I-group
, O O
diuretics B-group B-group
, O O
H2 B-group B-group
antagonists I-group I-group
, O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
, O O
prostaglandin B-group B-group
synthetase I-group I-group
inhibitors I-group I-group
( O O
also O O
referred O O
to O O
as O O
NSAIDs B-group B-group
) O O
, O O
and O O
quinolone B-group B-group
anti-infectives I-group I-group
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

however O O
, O O
it O O
is O O
not O O
known O O
if O O
other O O
phenothiazines B-group B-group
produce O O
a O O
similar O O
response O O
. O O

Inhibition O O
of O O
CYP3A4 O O
metabolic O O
reactions O O
was O O
not O O
detected O O
in O O
in O O
vitro O O
experiments O O
. O O

Patients O O
should O O
take O O
other O O
drugs O O
at O O
least O O
one O O
hour O O
before O O
or O O
four O O
hours O O
after O O
COLESTID B-brand B-brand
Tablets O O
to O O
avoid O O
impeding O O
their O O
absorption O O
. O O

Nevertheless O O
, O O
there O O
may O O
be O O
the O O
potential O O
for O O
clinically O O
important O O
alterations O O
of O O
blood O O
levels O O
of O O
coadministered O O
drugs O O
. O O

Injection O O
There O O
is O O
inadequate O O
systematic O O
experience O O
with O O
the O O
use O O
of O O
baclofen B-drug B-drug
injection O O
in O O
combination O O
with O O
other O O
medications O O
to O O
predict O O
specific O O
drug-drug O O
interactions O O
. O O

N=17 O O
) O O
were O O
not O O
different O O
and O O
neither O O
were O O
gabapentin B-drug B-drug
pharmacokinetic O O
parameters O O
affected O O
by O O
valproic B-drug B-drug
acid I-drug I-drug
. O O

Other O O
depressasnts O B-group
such O O
as O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
and O O
MAOIs B-group B-group
may O O
enhance O O
CNS O O
depression O O
when O O
administered O O
with O O
ethchlorvynol B-drug B-drug
. O O

Ketoconazole B-drug B-drug
: O O
Concomitant O O
use O O
of O O
ketoconazole B-drug B-drug
is O O
contraindicated O O
. O O

reduced O O
serum O O
folate O O
concentration O O
; O O

One O O
animal O O
in O O
the O O
high O O
dose O O
group O O
developed O O
a O O
B-cell O O
lymphoma O O
that O O
was O O
detected O O
after O O
28 O O
weeks O O
of O O
dosing O O
. O O

Clozapine B-drug B-drug
may O O
potentiate O O
the O O
hypotensive O O
effects O O
of O O
antihypertensive B-group B-group
drugs I-group I-group
and O O
the O O
anticholinergic O O
effects O O
of O O
atropine-type B-drug B-group
drugs O I-group
. O O

Drug O O
Laboratory O O
Test O O
Interactions O O
Interactions O O
between O O
darifenacin B-drug B-drug
and O O
laboratory O O
tests O O
have O O
not O O
been O O
studied O O
. O O

Ketoconazole B-drug B-drug

Increases O O
in O O
serum O O
creatinine O O
have O O
occurred O O
when O O
CEFOTAN B-brand B-brand
was O O
given O O
alone O O
. O O

Therefore O O
, O O
when O O
chlorothiazide B-drug B-drug
and O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O

Although O O
the O O
proposed O O
methodology O O
for O O
deriving O O
experimental O O
designs O O
can O O
be O O
applied O O
to O O
any O O
nonlinear O O
regression O O
model O O
, O O
primary O O
focus O O
is O O
given O O
to O O
the O O
additive O O
and O O
nonadditive O O
independent O O
joint O O
action O O
( O O
IJA O O
) O O
models O O
for O O
individual O O
and O O
combined O O
exposures O O
proposed O O
by O O
Barton O B-brand
, O O
Braunberg O O
, O O
and O O
Friedman O B-drug
( O O
1 O O
) O O
. O O

diflunisal B-drug B-drug
; O O

Potassium B-drug B-drug
Supplements O O
and O O
Potassium-Sparing B-group B-group
Diuretics I-group I-group
: O O
Fosinopril B-drug B-drug
sodium I-drug I-drug
can O O
attenuate O O
potassium O O
loss O O
caused O O
by O O
thiazide B-group B-group
diuretics I-group I-group
. O O

a O O
reduction O O
in O O
the O O
usual O O
anticoagulant B-group B-group
dosage O O
may O O
be O O
required O O
in O O
patients O O
receiving O O
both O O
drugs O O
. O O

Delayed O O
Adverse O O
Reactions O O
to O O
Iodinated B-group O
Contrast I-group O
Media I-group O
: O O
A O O
review O O
of O O
the O O
literature O O
revealed O O
that O O
12.6 O O
% O O
( O O
range O O
11-28 O O
% O O
) O O
of O O
501 O O
patients O O
treated O O
with O O
various O O
interleukin-2 B-drug B-drug
containing O O
regimens O O
who O O
were O O
subsequently O O
administered O O
radiographic B-group O
iodinated I-group B-drug
contrast I-group O
media I-group O
experienced O O
acute O O
, O O
atypical O O
adverse O O
reactions O O
. O O

Ketoconazole B-drug B-drug
: O O
When O O
a O O
single O O
125-mg O O
dose O O
of O O
Aprepitant B-drug B-drug
was O O
administered O O
on O O
Day5 O O
of O O
a O O
10-day O O
regimen O O
of O O
400 O O
mg/day O O
of O O
ketoconazole B-drug B-drug
, O O
a O O
strong O O
CYP3A4 O O
inhibitor O O
, O O
the O O
AUC O O
of O O
aprepitant B-drug B-drug
increased O O
approximately O O
5-fold O O
and O O
the O O
mean O O
terminal O O
half-life O O
of O O
aprepitant B-drug B-drug
increased O O
approximately O O
3-fold O O
. O O

At O O
a O O
low O O
cocaine B-drug B-drug
dose O O
and O O
long O O
withdrawal O O
period O O
( O O
10 O O
mg/kg O O
, O O
twice O O
a O O
day O O
for O O
5 O O
days O O
followed O O
by O O
a O O
14-day O O
withdrawal O O
) O O
, O O
the O O
LST O O
mice O O
showed O O
tolerance O O
development O O
. O O

CONCLUSION O O
: O O
These O O
findings O O
indicate O O
that O O
verapamil B-drug B-drug
inhibits O O
cancer O O
metastasis O O
through O O
actions O O
that O O
do O O
not O O
affect O O
the O O
growth O O
of O O
intestinal O O
cancers O O
. O O

It O O
is O O
recommended O O
that O O
serum O O
lithium B-drug B-drug
levels O O
be O O
monitored O O
frequently O O
if O O
PRINIVIL B-brand B-brand
is O O
administered O O
concomitantly O O
with O O
lithium B-drug B-drug
. O O

Similarly O O
, O O
the O O
effects O O
of O O
phenytoin B-drug B-drug
on O O
phenobarbital B-drug B-drug
, O O
valproic B-drug B-drug
acid I-drug I-drug
and O O
sodium O B-drug
plasma O O
valproate B-drug B-drug
concentrations O O
are O O
unpredictable O O

Potential O O
for O O
Other O O
Drugs O O
to O O
Affect O O
Duloxetine B-drug B-drug
: O O
Both O O
CYP1A2 O O
and O O
CYP2D6 O O
are O O
responsible O O
for O O
duloxetine B-drug B-drug
metabolism O O
. O O

This O O
medication O O
should O O
not O O
be O O
taken O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Substances O O
that O O
are O O
inducers O O
of O O
CYP3A4 O O
activity O O
increase O O
the O O
metabolism O O
of O O
gefitinib B-drug B-drug
and O O
decrease O O
its O O
plasma O O
concentrations O O
. O O

In O O
addition O O
, O O
patients O O
taking O O
drugs O O
that O O
inhibit O O
the O O
cytochrome O O
P450 O O
3A4 O O
isozyme O O
, O O
which O O
metabolizes O O
sildenafil B-drug B-drug
, O O
may O O
experience O O
increased O O
drug O O
concentrations O O
and O O
possible O O
toxicity O O
from O O
normal O O
doses O O
of O O
sildenafil B-drug B-drug
. O O

Alpha-blockers B-group B-group
: O O
When O O
Vardenafil B-drug B-drug
10 O O
or O O
20 O O
mg O O
was O O
given O O
to O O
healthy O O
volunteers O O
either O O
simultaneously O O
or O O
6 O O
hours O O
after O O
a O O
10 O O
mg O O
dose O O
of O O
terazosin B-drug B-drug
, O O
significant O O
hypotension O O
developed O O
in O O
a O O
substantial O O
number O O
of O O
subjects O O
. O O

Drug O O
Interactions O O
: O O
Flupenthixol B-drug B-drug
may O O
interact O O
with O O
some O O
drugs O O
, O O
like O O
Monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
( O O
MAOI B-group B-group
) O O
: O O
MAOI B-group B-group
could O O
theoretically O O
affect O O
flupenthixol B-drug B-drug
pharmacodynamics O O
- O O
Arecoline B-drug_n B-brand
- O O
Eproxindine O B-drug
- O O
Ethanol B-drug B-drug
: O O
Flupenthixol B-drug B-drug
and O O
Ethanol B-drug B-drug
cause O O
additive O O
CNS O O
depression O O
- O O
Tricyclic B-group B-group
antidepressants I-group I-group
: O O
Flupenthixol B-drug B-drug
increases O O
the O O
effect O O
of O O
Tricyclic B-group B-group
antidepressants I-group I-group

Hepatic O O
Enzyme O O
Inducers O O
, O O
Inhibitors O O
and O O
Substrates O O
: O O
Drugs O O
which O O
induce O O
cytochrome O O
P450 O O
3A4 O O
( O O
CYP O O
3A4 O O
) O O
enzyme O O
activity O O
( O O
e.g. O O
, O O
barbiturates B-group B-group
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
rifampin B-drug B-drug
) O O
may O O
enhance O O
the O O
metabolism O O
of O O
corticosteroids B-group B-group
and O O
require O O
that O O
the O O
dosage O O
of O O
the O O
corticosteroid B-group B-group
be O O
increased O O
. O O

In O O
addition O O
, O O
the O O
transfusion O O
practices O O
for O O
such O O
patients O O
may O O
need O O
to O O
be O O
modified O O
given O O
the O O
increased O O
risk O O
of O O
bleeding O O
. O O

600-1800 O O

See O O

If O O
this O O
is O O
not O O
possible O O
, O O
the O O
starting O O
dose O O
should O O
be O O
reduced O O
. O O

Until O O
data O O
on O O
possible O O
interactions O O
between O O
verapamil B-drug B-drug
and O O
disopyramide B-drug B-drug
phosphate I-drug I-drug
are O O
obtained O O
, O O
disopyramide B-drug B-drug
should O O
not O O
be O O
administered O O
within O O
48 O O
hours O O
before O O
or O O
24 O O
hours O O
after O O
verapamil B-drug B-drug
administration O O
. O O

Interaction O O
on O O
the O O
antinociceptive O O
effect O O
between O O
neurotensin B-drug_n B-drug
and O O
enkephalins B-drug_n B-group
or O O
tuftsin B-drug_n B-drug_n
. O O

It O O
is O O
recommended O O
that O O
these O O
tests O O
be O O
performed O O
weekly O O
or O O
every O O
other O O
week O O
until O O
the O O
lipid O O
response O O
to O O
Soriatane B-brand B-brand
has O O
stabilized O O
. O O

Decreased O O
core O O
temperature O O
in O O
female O O
rats O O
was O O
investigated O O
as O O
one O O
possible O O
index O O
of O O
the O O
disulfiram-ethanol B-drug B-drug
reaction O O
( O O
DER O O
) O O
. O O

There O O
were O O
transient O O
increases O O
in O O
liver O O
ALT O O
and O O
AST O O
when O O
CANCIDAS B-brand B-brand
and O O
cyclosporine B-drug B-drug
were O O
co-administered O O
. O O

Analyses O O
of O O
this O O
sequence O O
, O O
however O O
, O O
usually O O
give O O
little O O
consideration O O
to O O
the O O
nature O O
of O O
the O O
target O O
cell O O
or O O
to O O
the O O
characteristics O O
of O O
the O O
resultant O O
tumors O O
. O O

To O O
evaluate O O
the O O
impact O O
of O O
chemotherapy O O
plus O O
HAART O O
on O O
the O O
clinical O O
course O O
of O O
patients O O
with O O
HIV-related O O
, O O
systemic O O
, O O
non-Hodgkin O O
lymphoma O O
( O O
HIV-NHL O O
) O O
, O O
the O O
authors O O
compared O O
retrospectively O O
a O O
group O O
of O O
24 O O
patients O O
with O O
HIV-NHL O B-drug
who O O
were O O
treated O O
with O O
the O O
cyclophosphamide B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
vincristine B-drug B-drug
, O O
and O O
prednisone B-drug B-drug
( O O
CHOP O O
) O O
chemotherapy O O
regimen O O
plus O O
HAART O O
with O O
a O O
group O O
of O O
80 O O
patients O O
who O O
were O O
treated O O
with O O
CHOP O O
chemotherapy O O
or O O
a O O
CHOP-like O O
regimen O O
( O O
i.e. O O
, O O
cyclophosphamide B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
teniposide B-drug B-drug
, O O
and O O
prednisone B-drug B-drug
with O O
vincristine B-drug B-drug
plus O O
bleomycin B-drug B-drug
) O O
without O O
receiving O O
antiretroviral B-group B-group
therapy O O
. O O

indinavir I-drug B-drug
concentration O O

DRUG O O
INTERACTIONS O O

Changes O O
in O O
omeprazole B-drug B-drug
pharmacokinetics O O
were O O
not O O
studied O O
. O O

In O O
general O O
, O O
these O O
are O O
drugs O O
that O O
have O O
one O O
or O O
more O O
pharmacologic O O
activities O O
similar O O
to O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
, O O
including O O
anti-arrhythmic B-group B-group
agents I-group I-group
such O O
as O O
quinidine B-drug B-drug
and O O
procainamide B-drug B-drug
, O O
cardiac B-group B-group
glycosides I-group I-group
and O O
tricyclic B-group B-group
anti-depressants I-group I-group
. O O

Ranitidine B-drug B-drug
produced O O
smaller O O
, O O
nonsignificant O O
increases O O
. O O

Anesthetics/Sedatives/Hypnotics/Opioids B-group B-group
: O O
Co-administration O O
of O O
PRECEDEX B-brand B-brand
with O O
anesthetics B-group B-group
, O O
sedatives B-group B-group
, O O
hypnotics B-group B-group
, O O
and O O
opioids B-group B-group
is O O
likely O O
to O O
lead O O
to O O
an O O
enhancement O O
of O O
effects O O
. O O

Drug-Drug O O
Interactions O O
Given O O
the O O
primary O O
CNS O O
effects O O
of O O
aripiprazole B-drug B-drug
, O O
caution O O
should O O
be O O
used O O
when O O
ABILIFY B-brand B-brand
is O O
taken O O
in O O
combination O O
with O O
other O O
centrally B-group O
acting I-group O
drugs I-group O
and O O
alcohol B-drug B-drug
. O O

Rhabdomyolysis O O
secondary O O
to O O
a O O
drug O O
interaction O O
between O O
simvastatin B-drug B-drug
and O O
clarithromycin B-drug B-drug
. O O

Phenytoin B-drug B-drug
: O O
If O O
acitretin B-drug B-drug
is O O
given O O
concurrently O O
with O O
phenytoin B-drug B-drug
, O O
the O O
protein O O
binding O O
of O O
phenytoin B-drug B-drug
may O O
be O O
reduced O O
. O O

A O O
patient O O
had O O
phenytoin O B-drug
intoxication O O
after O O
administration O O
of O O
fluvoxamine B-drug B-drug
, O O
a O O
selective O B-group
serotonin O I-group
reuptake O I-group
inhibitor O I-group
. O O

There O O
were O O
no O O
differences O O
between O O
cecectomized O O
and O O
control O O
rats O O
in O O
basal O O
small O O
intestinal O O
transits O O
or O O
in O O
dmPGE2 B-drug_n B-drug_n
( O O
0.3 O O
mg/kg O O
, O O
p.o O O
. O O
) O O
-induced O O
enhancements O O
. O O

MAO B-group B-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
effects O O
of O O
antihistamines B-group B-group
. O O

Agents O O
Affecting O O
Sympathetic O O
Activity O O
The O O
sympathetic O O
nervous O O
system O O
may O O
be O O
especially O O
important O O
in O O
supporting O O
blood O O
pressure O O
in O O
patients O O
receiving O O
captopril B-drug B-drug
alone O O
or O O
with O O
diuretics B-group B-group
. O O

Concurrent O O
use O O
of O O
flurbiprofen B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
therefore O O
not O O
recommended O O
. O O

Coadministration O O
of O O
VIRACEPT B-brand B-brand
and O O
drugs O O
primarily O O
metabolized O O
by O O
CYP3A O O
( O O
e.g. O O
, O O
dihydropyridine B-group B-group
calcium I-group I-group
channel I-group I-group
blockers I-group I-group
) O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
other O O
drug O O
that O O
could O O
increase O O
or O O
prolong O O
both O O
its O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

( O O
Note O O
: O O
All O O
patients O O
receiving O O
theophylline B-drug B-drug
should O O
be O O
monitored O O
appropriately O O
, O O
regardless O O
of O O
concomitant O O
drug O O
therapy O O
. O O
) O O

valproate B-drug B-drug
and O O
gabapentin B-drug B-drug
are O O
not O O
. O O

Therefore O O
, O O
when O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
is O O
given O O
to O O
a O O
patient O O
receiving O O
warfarin B-drug B-drug
, O O
the O O
dosage O O
of O O
warfarin B-drug B-drug
should O O
be O O
reduced O O
to O O
prevent O O
excessive O O
prolongation O O
of O O
the O O
prothrombin O O
time O O
. O O

Lithium B-drug B-drug
: O O
NSAIDs B-group B-group
have O O
produced O O
an O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
levels O O
and O O
a O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
. O O

65 O O
years O O
of O O
age O O
and O O
13 O O
patients O O
were O O

The O O
minimal O O
inhibitory O O
concentrations O O
of O O
clindamycin B-drug B-drug
and O O
gentamicin B-drug B-drug
alone O O
and O O
in O O
combinations O O
were O O
determined O O
by O O
a O O
microdilution O O
method O O
for O O
163 O O
aerobic O O
, O O
facultative O O
, O O
and O O
anaerobic O O
clinical O O
isolates O O
. O O

As O O
with O O
other O O
dialysis B-group O
solutions I-group O
, O O
blood O O
concentrations O O
of O O
dialyzable O O
drugs O O
may O O
be O O
reduced O O
by O O
dialysis O O
. O O

therefore O O
concomitant O O
administration O O
of O O
Itraconazole B-drug B-drug
with O O
cisapride B-drug B-drug
is O O
contraindicated O O
. O O

Particular O O
caution O O
is O O
recommended O O
when O O
administering O O
Gleevec B-brand B-brand
with O O
CYP3A4 O O
substrates O O
that O O
have O O
a O O
narrow O O
therapeutic O O
window O O
( O O
e.g. O O
, O O
cyclosporine B-drug B-drug
or O O
pimozide B-drug B-drug
) O O
. O O

Potassium O B-group
sparing O I-group
agents O I-group
should O O
generally O O
not O O
be O O
used O O
in O O
patients O O
with O O
heart O O
failure O O
receiving O O
enalapril B-drug B-drug
. O O

clinically O O
significant O O
interactions O O
with O O
other O O
drugs O O
through O O
competition O O
for O O
protein O O
binding O O
sites O O
are O O
therefore O O
unlikely O O
. O O

This O O
was O O
expected O O
because O O
zaleplon B-drug B-drug
is O O
primarily O O
metabolized O O
and O O
renal O O
excretion O O
of O O
unchanged O O
zaleplon B-drug B-drug
accounts O O
for O O
less O O
than O O
1 O O
% O O
of O O
the O O
administered O O
dose O O
. O O

A O O
muscle O O
biopsy O O
revealed O O
necrotizing O O
myopathy O O
secondary O O
to O O
a O O
toxin O O
. O O

Cyclosporine B-drug B-drug
: O O
Elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
use O O
of O O
cyclosporine B-drug B-drug
with O O
other O O
members O O
of O O
the O O
quinolone B-group B-group
class I-group I-group
. O O

The O O
gastrointestinal O O
absorption O O
of O O
cimetidine B-drug B-drug
and O O
ranitidine B-drug B-drug
is O O
accelerated O O
when O O
they O O
are O O
coadministered O O
with O O
cisapride B-drug B-drug
. O O

Amprenavir B-drug B-drug
significantly O O
decreases O O
clearance O O
of O O
rifabutin B-drug B-drug
and O O
25-O-desacetylrifabutin B-drug_n B-drug_n
, O O
and O O
the O O
combination O O
is O O
poorly O O
tolerated O O
. O O

ACE-inhibitors B-group B-group
: O O
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE-inhibitors B-group B-group
. O O

Therefore O O
, O O
CYP3A4 O O
substrates O O
known O O
to O O
have O O
a O O
narrow O O
therapeutic O O
index O O
such O O
as O O
alfentanil B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
terfenadine B-drug B-drug
, O O
cisapride B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
fentanyl B-drug B-drug
, O O
pimozide B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
sirolimus B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
or O O
ergot B-group B-group
alkaloids I-group I-group
( O O
ergotamine B-drug B-drug
, O O
dihydroergotamine B-drug B-drug
) O O
should O O
be O O
administered O O
with O O
caution O O
in O O
patients O O
receiving O O
SPRYCEL B-brand B-brand
. O O

Thus O O
, O O
when O O
VIOXX B-brand B-brand
and O O
lithium B-drug B-drug
are O O
administered O O
concurrently O O
, O O
subjects O O
should O O
be O O
observed O O
carefully O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

aminosalicylic B-drug B-drug
acid I-drug I-drug
; O O

Drug/Laboratory O O
Test O O
Interactions O O
Positive O O
direct O O
Coombs O O
tests O O
have O O
been O O
reported O O
during O O
treatment O O
with O O
the O O
cephalosporin B-group B-group
antibiotics I-group I-group
. O O

Cimetidine B-drug B-drug
: O O
In O O
a O O
study O O
in O O
healthy O O
volunteers O O
, O O
a O O
one-week O O
course O O
of O O
cimetidine B-drug B-drug
at O O
400 O O
mg O O
b.i.d O O
. O O
with O O
a O O
single O O
5 O O
mg O O
dose O O
of O O
isradipine B-drug B-drug
on O O
the O O
sixth O O
day O O
showed O O
an O O
increase O O
in O O
isradipine B-drug B-drug
mean O O
peak O O
plasma O O
concentrations O O
( O O
36 O O
% O O
) O O
and O O
significant O O
increase O O
in O O
area O O
under O O
the O O
curve O O
( O O
50 O O
% O O
) O O
. O O

Synergism O O
has O O
been O O
shown O O
between O O
halothane B-drug B-drug
anesthesia O O
and O O
intravenously O O
administered O O
labetalol B-drug B-drug
HCl I-drug I-drug
. O O

Methotrexate B-drug B-drug
: O O
In O O
an O O
interaction O O
study O O
of O O
rheumatoid O O
arthritis O O
patients O O
taking O O
methotrexate B-drug B-drug
, O O
CELEBREX B-brand B-brand
did O O
not O O
have O O
a O O
significant O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
methotrexate B-drug B-drug
. O O

Even O O
though O O
such O O
interactions O O
have O O
not O O
been O O
seen O O
in O O
clinical O O
studies O O
with O O
DynaCirc B-brand B-brand
( O O
isradipine B-drug B-drug
) O O
, O O
an O O
increased O O
volume O O
of O O
circulating O O
fluids O O
might O O
be O O
required O O
if O O
such O O
an O O
interaction O O
were O O
to O O
occur O O
. O O

Methadone B-drug B-drug
levels O O
may O O
be O O
decreased O O
; O O
increased O O
dosages O O
may O O
be O O
required O O
to O O
prevent O O
symptoms O O
of O O
opiate B-group B-group
withdrawal O O
. O O
Methadone B-drug B-drug
maintained O O
patients O O
beginning O O
nevirapine B-drug B-drug
therapy O O
should O O
be O O
monitored O O
forevidence O O
of O O
withdrawal O O
and O O
methadone B-drug B-drug
dose O O
should O O
be O O
adjusted O O
accordingly O O
. O O

Diazoxide I-drug B-drug
Hypotension O O

However O O
, O O
prudent O O
medical O O
practice O O
dictates O O
careful O O
monitoring O O
of O O
prothrombin O O
time O O
in O O
all O O
patients O O
treated O O
with O O
azithromycin B-drug B-drug
and O O
warfarin B-drug B-drug
concomitantly O O
. O O

The O O
preceding O O
lists O O
of O O
drugs O O
are O O
not O O
comprehensive O O
. O O

In O O
an O O
in O O
vitro O O
study O O
in O O
human O O
liver O O
microsomes O O
, O O
inhibition O O
of O O
CYP2A6 O O
hydroxylation O O
of O O
coumarin B-group B-drug_n
by O O
fondaparinux B-drug B-drug
( O O
200 O O
m O O
m O O
M O O
i.e. O O
, O O
350 O O
mg/L O O
) O O
was O O
17-28 O O
% O O
. O O

Chlorpromazine B-drug B-drug
: O O
Chlorpromazine B-drug B-drug
blocks O O
dopamine O B-drug
and O O
norepinephrine O B-drug
reuptake O O
, O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-group B-group
, O O
and O O
can O O
be O O
used O O
to O O
treat O O
amphetamine B-group B-drug
poisoning O O
. O O

In O O
this O O
study O O
, O O
the O O
effects O O
of O O
etofibrate B-drug B-drug
upon O O
chylomicron O B-drug
metabolism O O
was O O
tested O O
by O O
determination O O
of O O
the O O
plasma O O
kinetics O O
of O O
a O O
chylomicron-like O O
emulsion O O
model O O
in O O
12 O O
patients O O
with O O
coronary O O
artery O O
disease O O
, O O
aged O O
59+/-11 O O
years O O
, O O
( O O
total O O
cholesterol O O
: O O
240+/-41 O O
mg/dl O O
; O O
triglycerides O O
: O O
188+/-42 O O
mg/dl O O
) O O
submitted O O
to O O
a O O
randomized O O
, O O
crossover O O
, O O
double-blind O O
, O O
placebo-controlled O O
study O O
with O O
administration O O
of O O
1 O O
g O O
per O O
day O O
etofibrate B-drug B-drug
or O O
placebo O O
for O O
1-month O O
. O O

When O O
indinavir B-drug B-drug
at O O
an O O
increased O O
dose O O
( O O
1000 O O
mg O O
every O O
8 O O
hours O O
) O O
was O O
given O O
with O O
SUSTIVA B-brand B-brand
( O O
600 O O
mg O O
once O O
daily O O
) O O
, O O
the O O
indinavir B-drug B-drug
AUC O O
and O O
Cmin O O
were O O
decreased O O
on O O
average O O
by O O
33-46 O O
% O O
and O O
39-57 O O
% O O
, O O
respectively O O
, O O
compared O O
to O O
when O O
indinavir B-drug B-drug
( O O
800 O O
mg O O
every O O
8 O O
hours O O
) O O
was O O
given O O
alone O O
. O O

Onset O O
of O O
action O O
of O O
tricyclics B-group B-group
may O O
be O O
accelerated O O
. O O

Fatal O O
cardiac O O
arrests O O
have O O
occurred O O
in O O
patients O O
receiving O O
both O O
drugs O O
. O O

Drug-Laboratory O O
Test O O
Interactions O O
: O O
There O O
are O O
no O O
reported O O
drug-laboratory O O
test O O
interactions O O
. O O

HEMABATE B-brand B-brand
may O O
augment O O
the O O
activity O O
of O O
other O O
oxytocic B-group B-group
agents I-group I-group
. O O

Dexrazoxane B-drug B-drug
was O O
not O O
mutagenic O O
in O O
the O O
Ames O O
test O O
but O O
was O O
found O O
to O O
be O O
clastogenic O O
to O O
human O O
lymphocytes O O
in O O
vitro O O
and O O
to O O
mouse O O
bone O O
marrow O O
erythrocytes O O
in O O
vivo O O
( O O
micronucleus O O
test O O
) O O
. O O

Special O O
attention O O
should O O
be O O
given O O
to O O
electrolyte O O
and O O
acid-base O O
balance O O
in O O
patients O O
experiencing O O
severe O O
or O O
prolonged O O
diarrhea O O
or O O
in O O
patients O O
receiving O O
concomitant O O
diuretics B-drug B-group
. O O

Many O O
other O O
medicines O O
may O O
increase O O
or O O
decrease O O
the O O
effects O O
of O O
glimepiride B-drug B-drug
or O O
affect O O
your O O
condition O O
. O O

- O O
Drugs O O
that O O
may O O
either O O
increase O O
or O O
decrease O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
include O O
: O O
phenobarbital B-drug B-drug
, O O
vaiproic O B-drug
acid O I-drug
, O O
and O O
sodium B-drug B-drug
valproate I-drug I-drug
. O O

We O O
reviewed O O
the O O
clinical O O
data O O
relating O O
to O O
the O O
efficacy O O
and O O
safety O O
of O O
pharmacologic O O
doses O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
in O O
the O O
prevention O O
and O O
treatment O O
of O O
the O O
common O O
cold O O
. O O

Concomitant O O
administration O O
of O O
naproxen B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
not O O
recommended O O
because O O
naproxen B-drug B-drug
is O O
displaced O O
from O O
its O O
binding O O
sites O O
during O O
the O O
concomitant O O
administration O O
of O O
aspirin B-brand B-brand
, O O
resulting O O
in O O
lower O O
plasma O O
concentrations O O
and O O
peak O O
plasma O O
levels O O
. O O

Although O O
it O O
has O O
not O O
been O O
established O O
that O O
there O O
is O O
an O O
interaction O O
between O O
Clozapine B-drug B-drug
and O O
benzodiazepines B-group B-group
or O O
other O O
psychotropics B-group B-group
, O O
caution O O
is O O
advised O O
when O O
clozapine B-drug B-drug
is O O
initiated O O
in O O
patients O O
taking O O
a O O
benzodiazepine B-group B-group
or O O
any O O
other O O
psychotropic B-group B-group
drug I-group I-group
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
poor O O
metabolizers O O
. O O

Aprepitant B-drug B-drug
is O O
a O O
substrate O O
for O O
CYP3A4 O O
; O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-group B-group
concomitantly O O
with O O
ACE-inhibitors B-group B-group
. O O

No O O
formal O O
assessments O O
of O O
pharmacokinetic O O
drug-drug O O
interactions O O
between O O
TRISENOX B-brand B-brand
and O O
other O O
agents O O
have O O
been O O
conducted O O
. O O

Studies O O
on O O
two O O
strains O O
of O O
pointer O O
dogs O O
have O O
demonstrated O O
that O O
administration O O
of O O
a O O
benzodiazepine B-group B-group
( O O
chlordiazepoxide B-drug B-drug
) O O
facilitates O O
acquisition O O
of O O
goal-directed O O
behavior O O
in O O
" O O
genetically O O
nervous O O
" O O

+24 O O
% O O
+14 O O
% O O
+43 O O
% O O
+40 O O
% O O

Non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
: O O
Seizures O O
have O O
been O O
reported O O
in O O
patients O O
taking O O
enoxacin B-drug B-drug
concomitantly O O
with O O
the O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drug I-group I-group
fenbufen B-drug B-drug
. O O

In O O
humans O O
, O O
two O O
inhibitors O O
of O O
P450 O O
3A4 O O
have O O
been O O
studied O O
. O O

However O O
, O O
it O O
may O O
be O O
important O O
also O O
in O O
case O O
of O O
medical O O
examinations O O
for O O
insurances O O
and O O
job O O
appointments O O
, O O
since O O
some O O
patients O O
may O O
turn O O
out O O
to O O
need O O
expensive O O
drugs O O
or O O
to O O
be O O
susceptible O O
to O O
a O O
certain O O
disease O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
may O O
antagonize O O
the O O
hypotensive O O
effects O O
of O O
clonidine B-drug B-drug
. O O

Flurbiprofen B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetic O O
profile O O
of O O
either O O
drug O O
, O O
and O O
the O O
mechanism O O
under O O
lying O O
the O O
interference O O
with O O
propranolols B-drug B-drug
hypotensive O O
effect O O
is O O
unknown O O
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
In O O
December O O
1998 O O
, O O
the O O
following O O
was O O
gathered O O
for O O
every O O
MAC O O
with O O
more O O
than O O
one O O
drug O O
treatment O O
: O O
age O O
, O O
sex O O
, O O
number O O
of O O
drugs O O
, O O
intrinsic O O
value O O
, O O
drugs O O
prescribed O O
, O O
daily O O
dose O O
and O O
pharmacological O O
interactions O O
( O O
PI O O
) O O
, O O
classified O O
( O O
using O O
the O O
scale O O
of O O
Hansten O B-brand
1996 O O
) O O
into O O
light O O
and O O
clinically O O
relevant O O
. O O

Drugs O O
Metabolized O O
by O O
P450IID6 O O
A O O
subset O O
( O O
3 O O
% O O
to O O
10 O O
% O O
) O O
of O O
the O O
population O O
has O O
reduced O O
activity O O
of O O
certain O O
drug O O
metabolizing O O
enzymes O O
such O O
as O O
the O O
cytochrome O O
P450 O O
isoenzyme O O
P450IID6 O O
. O O

( O O
Concurrent O O
use O O
with O O
thiazide B-group B-group
diuretics I-group I-group
may O O
enhance O O
the O O
possibility O O
of O O
digitalis B-group B-group
toxicity O O
associated O O
with O O
hypokalemia O O
. O O
) O O

14 O O
% O O
increase O O
[ O O
CI O O
: O O
2 O O
% O O
increase O O
, O O
24 O O
% O O
increase O O
] O O
25 O O
% O O
decrease O O
[ O O
CI O O
: O O
12 O O
% O O
decrease O O
, O O
51 O O
% O O
decrease O O
] O O

Thus O O
, O O
results O O
of O O
the O O
DST O O
should O O
be O O
interpreted O O
with O O
caution O O
in O O
these O O
patients O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
post-marketing O O
observations O O
, O O
have O O
shown O O
that O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

Folic B-drug B-drug
acid I-drug I-drug
in O O
large O O
amounts O O
may O O
counteract O O
the O O
antiepileptic O O
effect O O
of O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
and O O
primidone B-drug B-drug
, O O
and O O
increase O O
the O O
frequency O O
of O O
seizures O O
in O O
susceptible O O
pediatric O O
patients O O
. O O

It O O
is O O
important O O
that O O
health O O
care O O
professionals O O
be O O
aware O O
of O O
the O O
potential O O
for O O
medications O O
to O O
interfere O O
with O O
clinical O O
laboratory O O
tests O O
. O O

Antidiabetic B-group B-group
Agents I-group I-group
( O O
Insulin B-drug B-drug
, O O
Sulfonylureas B-group B-group
) O O
: O O
Requirements O O
for O O
insulin B-drug B-drug
or O O
oral O O
antidiabetic B-group B-group
agents I-group I-group
may O O
be O O
reduced O O
in O O
hypothyroid O O
patients O O
with O O
diabetes O O
mellitus O O
and O O
may O O
subsequently O O
increase O O
with O O
the O O
initiation O O
of O O
thyroid O B-group
hormone O I-group
replacement O O
therapy O O
. O O

Antihypertensives B-drug B-group
: O O
Amiodarone B-drug B-drug
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
-receptor B-drug B-group
blocking O I-group
agents O I-group
( O O
e.g. O O
, O O
propranolol B-drug B-drug
, O O
a O O
CYP3A4 B-drug O
inhibitor O O
) O O
or O O
calcium B-drug B-group
channel I-drug I-group
antagonists O I-group
( O O
e.g. O O
, O O
verapamil B-drug B-drug
, O O
a O O
CYP3A4 B-drug O
substrate O O
, O O
and O O
diltiazem B-drug B-drug
, O O
a O O
CYP3A4 B-drug O
inhibitor O O
) O O
because O O
of O O
the O O
possible O O
potentiation O O
of O O
bradycardia O O
, O O
sinus O O
arrest O O
, O O
and O O
AV O O
block O O
; O O

Carcinogenesis O O
, O O
Mutagenesis O O
, O O
Impairment O O
of O O
Fertility O O
No O O
long-term O O
carcinogenicity O O
studies O O
have O O
been O O
carried O O
out O O
with O O
dexrazoxane B-drug B-drug
in O O
animals O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
Rebif B-brand B-brand
. O O

Recurrence O O
of O O
skin O O
reactions O O
at O O
a O O
site O O
of O O
previous O O
extravasation O O
following O O
administration O O
of O O
TAXOL B-brand B-brand
at O O
a O O
different O O
site O O
, O O
ie O O
, O O
recall O O
, O O
has O O
been O O
reported O O
rarely O O
. O O

Pharmacokinetic O O
studies O O
document O O
no O O
clinically O O
relevant O O
interactions O O
with O O
other O O
agents O O
given O O
concomitantly O O
, O O
including O O
thiazide B-group B-group
diuretics I-group I-group
, O O
digoxin B-drug B-drug
, O O
and O O
cimetidine B-drug B-drug
. O O

When O O
therapeutic O O
concentrations O O
of O O
furosemide B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
dipyridamole B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
or O O
naproxen B-drug B-drug
were O O
added O O
to O O
human O O
plasma O O
( O O
in O O
vitro O O
) O O
, O O
the O O
plasma O O
protein O O
binding O O
of O O
nicardipine B-drug B-drug
HCl I-drug I-drug
was O O
not O O
altered O O
. O O

Drugs O O
which O O
inhibit O O
CYP O O
3A4 O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
macrolide B-group B-group
antibiotics I-group I-group
such O O
as O O
erythromycin B-drug B-drug
) O O
have O O
the O O
potential O O
to O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
corticosteroids B-group B-group
. O O

No O O
dosage O O
adjustment O O
is O O
required O O
for O O
Fluvoxamine B-drug B-drug
Tablets O O
. O O

Antimycobacterial B-group B-group
Agents I-group I-group
: O O
rifampin B-drug B-drug
CONTRAINDICATED O O
since O O
the O O
coadministration O O
of O O
this O O
product O O
with O O
saquinavir B-drug B-drug
in O O
an O O
antiretroviral B-group B-group
regimen O O
reduces O O
the O O
plasma O O
concentrations O O
of O O
saquinavir B-drug B-drug
. O O

Ethyl B-drug B-drug
alcohol I-drug I-drug
is O O
known O O
to O O
effect O O
the O O
functional O O
integrity O O
of O O
the O O
limbic O O
system O O
, O O
particularly O O
the O O
hippocampus O O
, O O
and O O
to O O
alter O O
behaviors O O
which O O
are O O
thought O O
to O O
be O O
mediated O O
through O O
limbic O O
function O O
. O O

Prothrombin O O
times O O
were O O
not O O
affected O O
by O O
tiagabine B-drug B-drug
. O O

The O O
specific O O
pharmacokinetic O O
changes O O
that O O
occur O O
with O O
co-administration O O
of O O
nevirapine B-drug B-drug
and O O
other O O
drugs O O
are O O
listed O O
in O O
CLINICAL O O
PHARMACOLOGY O O
, O O
Table O O
1 O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
RAPTIVA B-brand B-brand
. O O

The O O
disposition O O
of O O
theophylline B-drug B-drug
was O O
not O O
altered O O
by O O
concomitant O O
cetirizine B-drug B-drug
administration O O
. O O

. O O

Toxicodynamic O O
interference O O
between O O
solvents O B-group
can O O
give O O
rise O O
to O O
additive O O
, O O
potentiation O O
, O O
synergistic O O
, O O
antagonistic O O
effects O O
. O O

Similarly O O
, O O
nateglinide B-drug B-drug
had O O
no O O
influence O O
on O O
the O O
serum O O
protein O O
binding O O
of O O
propranolol B-drug B-drug
, O O
glyburide B-drug B-drug
, O O
nicardipine B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
and O O
tolbutamide B-drug B-drug
in O O
vitro O O
. O O

Dantrium B-brand B-drug
is O O
metabolized O O
by O O
the O O
liver O O
, O O
and O O
it O O
is O O
theoretically O O
possible O O
that O O
its O O
metabolism O O
may O O
be O O
enhanced O O
by O O
drugs O O
known O O
to O O
induce O O
hepatic O O
microsomal O O
enzymes O O
. O O

Oral O O
neomycin B-drug B-drug
inhibits O O
the O O
gastrointestinal O O
absorption O O
of O O
penicillin B-drug B-drug
V I-drug I-drug
, O O
oral O O
vitamin B-drug B-group
B-12 I-drug I-group
, O O
methotrexate B-drug B-drug
and O O
5-fluorouracil B-drug B-drug
. O O

If O O
concomitant O O
treatment O O
with O O
sumatriptan B-drug B-drug
and O O
an O O
SSRI B-group B-group
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
citalopram B-drug B-drug
, O O
escitalopram B-drug B-drug
) O O
is O O
clinically O O
warranted O O
, O O
appropriate O O
observation O O
of O O
the O O
patient O O
is O O
advised O O
. O O

however O O
, O O
the O O
second O O
contraction O O
was O O
potentiated O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
co-administration O O
of O O
TCA5 O B-group
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

- O O
a O O
beta-blocker B-group B-group
such O O
as O O
propranolol B-drug B-drug
( O O
Inderal B-brand B-brand
) O O
, O O
atenolol B-drug B-drug
( O O
Tenormin B-brand B-brand
) O O
, O O
acebutolol B-drug B-drug
( O O
Sectral B-brand B-brand
) O O
, O O
metoprolol B-drug B-drug
( O O
Lopressor B-brand B-brand
) O O
, O O
and O O
others O O
; O O

Caution O O
is O O
recommended O O
in O O
patients O O
with O O
hepatic O O
impairment O O
. O O

transaminases O O
( O O
AST O O

In O O
this O O
study O O
there O O
was O O
no O O
evidence O O
of O O
a O O
blunting O O
of O O
the O O
antihypertensive O O
action O O
of O O
VASOTEC B-brand B-brand
. O O

The O O
effects O O
of O O
DCG-IV B-drug_n B-drug_n
were O O
very O O
strong O O
and O O
completely O O
depressed O O
the O O
PCP-induced B-drug_n B-drug_n
hyperlocomotion O O
. O O

Carbamazepine B-drug B-drug

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
( O O
such O O
as O O
Clinistix O O
** O O
or O O
Tes-Tape O O
** O O
) O O
be O O
used O O
. O O

Therefore O O
, O O
concomitant O O
use O O
of O O
ribavirin B-drug B-drug
with O O
either O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

No O O
trials O O
specifically O O
examining O O
potential O O
drug O O
interactions O O
with O O
Natrecor B-brand B-brand
were O O
conducted O O
, O O
although O O
many O O
concomitant O O
drugs O O
were O O
used O O
in O O
clinical O O
trials O O
. O O

Theophylline B-drug B-drug
: O O
A O O
single O O
10 O O
mg O O
dose O O
of O O
tiagabine B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
at O O
steady O O
state O O
. O O

Valproic B-drug B-drug
acid I-drug I-drug
diminished O O
binding O O
of O O
phenobarbital B-drug B-drug
by O O
a O O
net O O
change O O
of O O
9.9 O O
% O O
( O O
percentage O O
increase O O
in O O
FDF O O
, O O
21.2 O O
% O O
) O O
at O O
1732 O O
micromol/L O O
. O O

Ibogaine B-drug_n B-drug_n
produces O O
whole O O
body O O
tremors O O
and O O
, O O
at O O
high O O
doses O O
( O O
> O O
or O O
= O O
100 O O
mg/kg O O
) O O
, O O
cerebellar O O
damage O O
; O O

The O O
use O O
of O O
NIMBEX B-brand B-brand
before O O
succinylcholine B-drug B-drug
to O O
attenuate O O
some O O
of O O
the O O
side O O
effects O O
of O O
succinylcholine B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

Additionally O O
, O O
saquinavir B-drug B-drug
is O O
a O O
substrate O O
for O O
P-Glycoprotein O O
( O O
Pgp O O
) O O
. O O

[ O O
The O O
GABA-ergic O O
system O O
and O O
brain O O
edema O O
] O O
It O O
has O O
been O O
shown O O
in O O
rats O O
with O O
experimental O O
toxic O O
and O O
traumatic O O
edemas O O
that O O
picrotoxin B-drug_n B-drug_n
( O O
1 O O
mg/kg O O
) O O
removes O O
the O O
antiedematous O O
action O O
of O O
diazepam B-drug B-drug
, O O
phenazepam B-drug_n B-drug
, O O
phenibut B-drug_n B-drug_n
and O O
amizyl B-drug_n O
and O O
reduces O O
the O O
action O O
of O O
phentolamine B-drug B-drug
. O O

Patients O O
on O O
warfarin-type B-group B-group
anticoagulant I-group I-group
therapy O O
may O O
require O O
dosage O O
adjustment O O
of O O
the O O
anticoagulant O B-group
during O O
and O O
after O O
griseofulvin B-drug B-drug
therapy O O
. O O

Concomitant O O
administration O O
of O O
rifampin B-drug B-drug
with O O
ketoconazole B-drug B-drug
tablets O O
reduces O O
the O O
blood O O
levels O O
of O O
the O O
latter O O
. O O

No O O
data O O
are O O
available O O
regarding O O
interactions O O
with O O
other O O
drugs O O
that O O
have O O
renal O O
clearance O O
mechanisms O O
similar O O
to O O
that O O
of O O
lamivudine B-drug B-drug
. O O

In O O
13-day-old O O
embryos O O
, O O
glycine B-drug B-drug
was O O
ineffective O O
in O O
both O O
doses O O
. O O

Triazolam B-drug B-drug
: O O
Erythromycin B-drug B-drug
has O O
been O O
reported O O
to O O
decrease O O
the O O
clearance O O
of O O
triazolam B-drug B-drug
and O O
, O O
thus O O
, O O
may O O
increase O O
the O O
pharmacologic O O
effect O O
of O O
triazolam B-drug B-drug
. O O

( O O
Thiazide B-group B-group
diuretics I-group I-group
may O O
raise O O
blood O O
glucose O O
levels O O
; O O

Consequently O O
, O O
the O O
combination O O
of O O
methotrexate B-drug B-drug
with O O
acitretin B-drug B-drug
is O O
also O O
contraindicated O O
. O O

The O O
role O O
of O O
norepinephrine B-drug B-drug
uptake-1 O O
was O O
studied O O
in O O
electrically O O
stimulated O O
( O O
1 O O
Hz O O
, O O
37 O O
degrees O O
C O O
) O O
human O O
ventricular O O
cardiac O O
preparations O O
and O O
isolated O O
myocardial O O
membranes O O
. O O

Drugs O O
that O O
induce O O
CYP3A4 O O
activity O O
would O O
be O O
expected O O
to O O
increase O O
the O O
clearance O O
of O O
indinavir B-drug B-drug
, O O
resulting O O
in O O
lowered O O
plasma O O
concentrations O O
of O O
indinavir B-drug B-drug
. O O

Fluconazole B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
fluconazole B-drug B-drug
at O O
200 O O
mg O O
QD O O
resulted O O
in O O
a O O
two-fold O O
increase O O
in O O
celecoxib B-drug B-drug
plasma O O
concentration O O
. O O

Starlix B-brand B-brand
is O O
a O O
potential O O
inhibitor O O
of O O
the O O
CYP2C9 O O
isoenzyme O O
in O O
vivo O O
as O O
indicated O O
by O O
its O O
ability O O
to O O
inhibit O O
the O O
in O O
vitro O O
metabolism O O
of O O
tolbutamide B-drug B-drug
. O O

Healthcare O O
prescribers O O
are O O
advised O O
to O O
consult O O
the O O
package O O
inserts O O
of O O
medication O O
administered O O
concomitantly O O
with O O
oral O O
contraceptives B-group B-group
. O O

Catecholamine-depleting O B-group
Agents O I-group
: O O
Patients O O
taking O O
both O O
agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group I-group
and O O
a O O
drug O O
that O O
can O O
deplete O O
catecholamines O O
( O O
e.g. O O
, O O
reserpine B-drug B-drug
and O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
) O O
should O O
be O O
observed O O
closely O O
for O O
signs O O
of O O
hypotension O O
and/or O O
severe O O
bradycardia O O
. O O

Drugs O O
Metabolized O O
by O O
CYP3A O O
: O O
Results O O
of O O
in O O
vitro O O
studies O O
demonstrate O O
that O O
duloxetine B-drug B-drug
does O O
not O O
inhibit O O
or O O
induce O O
CYP3A O O
activity O O
. O O

astemizole B-drug B-drug
, O O
bepridil B-drug B-drug
, O O
sparfloxacin B-drug B-drug
, O O
and O O
terodiline B-drug B-drug
. O O

for O O
adult-onset O O
diabetics O O
, O O
dosage O O
adjustment O O
of O O
hypoglycemic B-group B-group
medications I-group I-group
may O O
be O O
necessary O O
during O O
and O O
after O O
thiazide B-group B-group
diuretic I-group I-group
therapy O O
; O O

Beta B-group B-group
Blockers I-group I-group
: O O
Although O O
the O O
results O O
of O O
a O O
clinical O O
study O O
did O O
not O O
indicate O O
a O O
safe O O
problem O O
associated O O
with O O
the O O
administration O O
of O O
D.H.E B-brand B-brand
. I-brand O
45 I-brand B-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
to O O
subjects O O
already O O
receiving O O
propranolol B-drug B-drug
, O O
there O O
have O O
been O O
reports O O
that O O
propranolol B-drug B-drug
may O O
potentiate O O
the O O
vasoconstrictive O O
action O O
of O O
ergotamine B-drug B-drug
by O O
blocking O O
the O O
vasodilating O O
property O O
of O O
epinephrine O B-drug
. O O

May O O
interact O O
with O O
skin O O
products O O
or O O
shampoos O O
for O O
dandruff O O
or O O
psoriasis O O
. O O

No O O
data O O
are O O
available O O
for O O
the O O
coadministration O O
of O O
INVIRASE/ritonavir B-brand B-brand
or O O
FORTOVASE/ritonavir B-brand B-brand
and O O
garlic O O
capsules O O
. O O

There O O
was O O
no O O
evidence O O
of O O
toxicity O O
. O O

BROVANA B-brand B-brand
, O O
as O O
with O O
other O O
beta2-agonists B-group B-group
, O O
should O O
be O O
administered O O
with O O
extreme O O
caution O O
to O O
patients O O
being O O
treated O O
with O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
or O O
drugs O O
known O O
to O O
prolong O O
the O O
QTc O O
interval O O
because O O
the O O
action O O
of O O
adrenergic B-group B-group
agonists I-group I-group
on O O
the O O
cardiovascular O O
system O O
may O O
be O O
potentiated O O
by O O
these O O
agents O O
. O O

Drug O O
laboratory O O
Test O O
Interactions O O
Serum O O
Salicylate O B-group
Assays O O
: O O
Caution O O
should O O
be O O
used O O
in O O
interpreting O O
the O O
results O O
of O O
serum O O
salicylate O O
assays O O
when O O
diflunisal B-drug B-drug
is O O
present O O
. O O

CANCIDAS B-brand B-brand
did O O
not O O
increase O O
the O O
plasma O O
levels O O
of O O
cyclosporine B-drug B-drug
. O O

Levetiracetam B-drug B-drug
and O O
its O O
major O O
metabolite O O
, O O
at O O
concentrations O O
well O O
above O O
cmax O O
levels O O
achieved O O
within O O
the O O
therapeutic O O
dose O O
range O O
, O O
are O O
neither O O
inhibitors O O
of O O
nor O O
high O O
affinity O O
substrates O O
for O O
human O O
liver O O
cytochrome O O
P450 O O
isoforms O O
, O O
epoxide O O
hydrolase O O
or O O
UDP-glucuronidation O O
enzymes O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
: O O
Coadministration O O
of O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
did O O
not O O
have O O
any O O
effect O O
on O O
either O O
the O O
safety O O
or O O
efficacy O O
of O O
ibutilide B-drug B-drug
in O O
the O O
clinical O O
trials O O
. O O

co-administration O O
of O O
phenytoin B-drug B-drug
may O O
produce O O
a O O
synergistic O O
anticonvulsant O O
action O O
. O O

whereas O O
urinary O O
excretion O O
was O O
decreased O O
in O O
both O O
cases O O
. O O

A O O
drug-drug O O
interaction O O
study O O
evaluated O O
the O O
effect O O
of O O
the O O
use O O
of O O
ACZONE B-brand B-brand
Gel O O
, O O
5 O O
% O O
, O O
in O O
combination O O
with O O
double O O
strength O O
( O O
160 O O
mg/800 O O
mg O O
) O O
trimethoprim/sulfamethoxazole B-drug B-drug
( O O
TMP/SMX B-drug B-drug
) O O
. O O

An O O
intravenous O O
dose O O
of O O
50 O O
mg O O
perchlorate B-drug_n B-drug
was O O
in O O
respect O O
of O O
competitive O O
suppression O O
of O O
organs O O
actively O O
concentrating O O
pertechnetate B-drug B-drug
as O O
effective O O
as O O
intravenous O O
1000 O O
mg O O
ClO-4- O O
simultaneously O O
or O O
1000 O O
mg O O
orally O O
30 O O
min O O
before O O
the O O
injection O O
of O O
radiopertechnetate B-drug B-drug
. O O

The O O
glucocorticoid-induced O O
gene O O
transcription O O
was O O
strongly O O
suppressed O O
by O O
synthetic O B-group
alkyl O I-group
esters O I-group
; O O

Administration O O
of O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
concomitantly O O
with O O
propranolol B-drug B-drug
in O O
five O O
normal O O
volunteers O O
resulted O O
in O O
increased O O
propranolol B-drug B-drug
levels O O
in O O
all O O
subjects O O
and O O
bioavailability O O
of O O
propranolol B-drug B-drug
was O O
increased O O
approximately O O
50 O O
% O O
. O O

In O O
patients O O
in O O
whom O O
CYP3A4 O O
inducers O O
( O O
eg O O
, O O
dexamethasone B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
rifampicin B-drug B-drug
, O O
phenobarbital B-drug B-drug
) O O
are O O
indicated O O
, O O
alternative O O
agents O O
with O O
less O O
enzyme O O
induction O O
potential O O
should O O
be O O
used O O
. O O

There O O
is O O
no O O
evidence O O
that O O
EPA B-drug B-drug
supplements O O
have O O
detrimental O O
effects O O
on O O
glucose O B-drug
tolerance O O
, O O
insulin O B-drug
secretion O O
or O O
insulin O B-drug
resistance O O
in O O
non-diabetic O O
subjects O O
. O O

The O O
behavioral O O
effects O O
of O O
the O O
stereoisomers O O
of O O
N-allylnormetazocine B-drug_n B-drug_n
( O O
NANM B-drug_n B-drug_n
) O O
were O O
compared O O
with O O
those O O
of O O
phencyclidine B-drug_n B-drug_n
( O O
PCP B-drug_n B-drug_n
) O O
in O O
pigeons O O
and O O
squirrel O O
monkeys O O
responding O O
under O O
a O O
multiple O O
fixed-interval O O
fixed-ratio O O
( O O
FI O O
FR O O
) O O
schedule O O
of O O
food O O
presentation O O
. O O

The O O
pharmacokinetics O O
and O O
protein O O
binding O O
of O O
fosphenytoin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
and O O
diazepam B-drug B-drug
were O O
not O O
altered O O
when O O
diazepam B-drug B-drug
and O O
Cerebyx B-brand B-brand
were O O
concurrently O O
administered O O
in O O
single O O
submaximal O O
doses O O
. O O

Since O O
higher O O
doses O O
of O O
ketoconazole B-drug B-drug
( O O
400 O O
mg O O
daily O O
) O O
may O O
result O O
in O O
higher O O
increases O O
in O O
Cmax O O
and O O
AUC O O
, O O
a O O
single O O
2.5 O O
mg O O
dose O O
of O O
Vardenafil B-drug B-drug
should O O
not O O
be O O
exceeded O O
in O O
a O O
24-hour O O
period O O
when O O
used O O
in O O
combination O O
with O O
ketoconazole B-drug B-drug
400 O O
mg O O
daily O O
. O O

Also O O
, O O
concomitant O O
administration O O
of O O
quinolones B-group B-group
with O O
products O O
containing O O
iron B-drug B-drug
, O O
multivitamins B-group B-group
containing O O
zinc B-drug B-drug
, O O
or O O
Videx B-brand B-brand
( O O
didanosine B-drug B-drug
) O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
may O O
result O O
in O O
low O O
urine O O
levels O O
. O O

The O O
risk O O
of O O
this O O
interaction O O
may O O
be O O
reduced O O
if O O
digoxin B-drug B-drug
is O O
given O O
as O O
capsules O O
. O O

CHOLESTYRAMINE B-drug B-drug
: O O
The O O
influence O O
of O O
the O O
bile-acidsequestering O O
agent O O
cholestyramine B-drug B-drug
on O O
the O O
pharmacokinetits O O
of O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
was O O
evaluated O O
in O O
12 O O
healthy O O
males O O
in O O
2 O O
separate O O
randomized O O
crossover O O
studies O O
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
increases O O
nicardipine B-drug B-drug
HCl I-drug I-drug
plasma O O
levels O O
. O O

Catecholamine-depleting O O
drugs O O
, O O
e.g. O O
, O O
reserpine B-drug B-drug
, O O
may O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
beta B-group B-group
blocking I-group I-group
agents I-group I-group
. O O

Higher O O
dosage O O
of O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
may O O
be O O
required O O
. O O

( O O
In O O
some O O
patients O O
, O O
the O O
steroidal B-group B-group
anti-inflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic O B-group
, O O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium O B-drug
sparing O O
, O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Care O O
should O O
be O O
taken O O
if O O
labetalol B-drug B-drug
is O O
used O O
concomitantly O O
with O O
calcium B-group B-group
antagonists O I-group
of O O
the O O
verapamil B-drug B-drug
type O O
. O O

There O O
are O O
reports O O
of O O
enhanced O O
as O O
well O O
as O O
diminished O O
effects O O
of O O
anticoagulants B-group B-group
when O O
given O O
concurrently O O
with O O
corticosteroids B-group B-group
. O O

Effect O O
of O O
probenecid B-drug B-drug
on O O
the O O
apparent O O
volume O O
of O O
distribution O O
and O O
elimination O O
of O O
cloxacillin B-drug B-drug
. O O

They O O
may O O
be O O
administered O O
alternately O O
when O O
the O O
preceding O O
effect O O
of O O
other O O
such O O
drug O O
has O O
subsided O O
. O O

The O O
role O O
of O O
AMEVIVE B-brand B-brand
in O O
the O O
development O O
of O O
the O O
lymphoid O O
malignancy O O
and O O
the O O
hyperplasia O O
observed O O
in O O
non-human O O
primates O O
and O O
the O O
relevance O O
to O O
humans O O
is O O
unknown O O
. O O

Impaired O O
glucose O O
tolerance O O
. O O

ethinyl I-drug B-drug
estradiol I-drug I-drug
concentration O O

There O O
was O O
a O O
small O O
decrease O O
in O O
the O O
clearance O O
of O O
cetirizine B-drug B-drug
caused O O
by O O
a O O
400-mg O O
dose O O
of O O
theophylline B-drug B-drug
; O O

These O O
drugs O O
should O O
be O O
coadministered O O
with O O
caution O O
, O O
and O O
frequent O O
monitoring O O
of O O
serum O O
lithium B-drug B-drug
levels O O
is O O
recommended O O
. O O

Alcohol B-drug B-drug
( O O
increases O O
bioavailability O O
by O O
50 O O
% O O
) O O
, O O
cimetidine B-drug B-drug
, O O
and O O
valproates O B-group
. O O

Other O O
: O O
Instances O O
of O O
rash O O
, O O
pruritus O O
, O O
ankle O O
edema O O
, O O
excessive O O
perspiration O O
, O O
weight O O
gain O O
, O O
nasal O O
congestion O O
. O O

Therefore O O
, O O
MAO B-group B-group
inhibitors I-group I-group
should O O
be O O
discontinued O O
at O O
least O O
two O O
weeks O O
prior O O
to O O
the O O
cautious O O
initiation O O
of O O
therapy O O
with O O
SINEQUAN B-brand B-brand
. O O

Cimetidine B-drug B-drug

ADL B-drug B-drug
8-2698 I-drug I-drug
, O O
a O O
trans-3,4-dimethyl-4- O O
( O O
3-hydroxyphenyl O B-drug
) O O
piperidine O B-drug
, O O
prevents O O
gastrointestinal O O
effects O O
of O O
intravenous O O
morphine B-drug B-drug
without O O
affecting O O
analgesia O O
. O O

The O O
change O O
in O O
furosemide B-drug B-drug
clearance O O
value O O
is O O
not O O
likely O O
to O O
be O O
clinically O O
significant O O
. O O

Methotrexate B-drug B-drug
- O O
There O O
is O O
one O O
report O O
that O O
methotrexate B-drug B-drug
may O O
decrease O O
the O O
possible O O
effectiveness O O
of O O
supplemental O O
L-glutamine B-drug B-drug
for O O
chemotherapy-induced O O
mucositis O O
. O O

Methadone B-drug B-drug

Plasma O O
concentrations O O
and O O
effects O O
potentially O O
increased O O
or O O
decreased O O
by O O
SUSTIVA B-brand B-brand
. O O

The O O
clearance O O
by O O
means O O
of O O
4-hydroxytolbutamide B-drug_n B-drug_n
and O O
carboxytolbutamide B-drug_n B-drug_n
was O O
significantly O O
reduced O O
in O O
both O O
groups O O
( O O
ie O O
, O O
from O O
901 O O
mL/h O O
to O O
318 O O
mL/h O O
in O O
the O O
group O O
that O O
received O O
150 O O
mg O O
of O O
tolbutamide B-drug B-drug
per O O
day O O
and O O
from O O
723 O O
mL/h O O
to O O
457 O O
mL/h O O
in O O
the O O
group O O
that O O
received O O
75 O O
mg O O
of O O
tolbutamide B-drug B-drug
per O O
day O O
) O O
. O O

Aspirin B-brand B-brand
: O O
Concurrent O O
administration O O
of O O
aspirin B-brand B-brand
and O O
flurbiprofen B-drug B-drug
resulted O O
in O O
50 O O
% O O
lower O O
serum O O
flurbiprofen B-drug B-drug
concentrations O O
. O O

Therefore O O
, O O
simultaneous O O
use O O
of O O
creams O O
, O O
ointments O B-group
or O O
oils O O
should O O
be O O
avoided O O
. O O

Aspirin B-brand B-brand
, O O
warfarin B-drug B-drug
, O O
heparin B-drug B-drug
, O O
NSAIDs B-group B-group

Approximately O O
2/3 O O
of O O
the O O
patients O O
in O O
the O O
Phase O O
3 O O
study O O
received O O
either O O
prophylactic O O
low O O
dose O O
heparin B-drug B-drug
( O O
unfractionated B-drug B-drug
heparin I-drug I-drug
up O O
to O O
15,000 O O
units/day O O
) O O
or O O
prophylactic O O
doses O O
of O O
low B-group O
molecular I-group O
weight I-group O
heparins I-group O
as O O
indicated O O
in O O
the O O
prescribing O O
information O O
for O O
the O O
specific O O
products O O
. O O

Patients O O
receiving O O
SPRYCEL B-brand B-brand
should O O
not O O
take O O
St. O O
Johns O O
wort O O
. O O

Alternatively O O
, O O
provide O O
medical O O
supervision O O
for O O
at O O
least O O
one O O
hour O O
after O O
the O O
initial O O
dose O O
. O O

The O O
effects O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
on O O
male O O
fertility O O
have O O
not O O
been O O
studied O O
in O O
adequate O O
numbers O O
of O O
patients O O
. O O

No O O
drug O O
, O O
nutritional O O
supplement O O
, O O
food O O
or O O
herb O O
interactions O O
are O O
known O O
. O O

In O O
long O O
surgical O O
procedures O O
during O O
enflurane B-drug B-drug
or O O
isoflurane B-drug B-drug
anesthesia O O
, O O
less O O
frequent O O
maintenance O O
dosing O O
, O O
lower O O
maintenance O O
doses O O
, O O
or O O
reduced O O
infusion O O
rates O O
of O O
NIMBEX B-brand B-brand
may O O
be O O
necessary O O
. O O

Other O O
substances O O
: O O
Grapefruit O O
juice O O
given O O
to O O
healthy O O
volunteers O O
increased O O
amiodarone B-drug B-drug
AUC O O
by O O
50 O O
% O O
and O O
Cmax O O
by O O
84 O O
% O O
, O O
resulting O O
in O O
increased O O
plasma O O
levels O O
of O O
amiodarone B-drug B-drug
. O O

With O O
simultaneous O O
dosing O O
of O O
Vardenafil B-drug B-drug
20 O O
mg O O
and O O
terazosin B-drug B-drug
10 O O
mg O O
, O O
2 O O
of O O
9 O O
subjects O O
experienced O O
a O O
standing O O
systolic O O
blood O O
pressure O O
of O O
less O O
than O O
85 O O
mm O O
Hg O O
. O O

Auranofin B-drug B-drug
should O O
not O O
be O O
used O O
together O O
with O O
penicillamine B-drug B-drug
( O O
Depen B-brand B-brand
, O O
Cuprimine B-brand B-brand
) O O
, O O
another O O
arthritis O O
medication O O
. O O

This O O
practice O O
resulted O O
in O O
no O O
apparent O O
increase O O
in O O
local O O
breast O O
cancer O O
recurrence O O
relative O O
to O O
published O O
accounts O O
in O O
the O O
literature O O
. O O

Continuous O O
cardiac O O
monitoring O O
is O O
not O O
required O O
except O O
for O O
patients O O
with O O
serious O O
conduction O O
abnormalities O O
. O O

Agents O O
Affecting O O
Cytochrome O O
P450 O O
3A4 O O
Isoenzyme O O
System O O
Fentanyl B-drug B-drug
is O O
metabolized O O
mainly O O
via O O
the O O
human O O
cytochrome O O
P450 O O
3A4 O O
isoenzyme O O
system O O
( O O
CYP3A4 O O
) O O
, O O
therefore O O
potential O O
interactions O O
may O O
occur O O
when O O
DURAGESIC B-brand B-brand
is O O
given O O
concurrently O O
with O O
agents O O
that O O
affect O O
CYP3A4 O O
activity O O
. O O

Thiolated B-drug_n B-drug_n
carboxymethylcellulose I-drug_n I-drug_n
: O O
in O O
vitro O O
evaluation O O
of O O
its O O
permeation O O
enhancing O O
effect O O
on O O
peptide O B-group
drugs O I-group
. O O

Ethoxzolamide B-drug B-drug
may O O
increase O O
the O O
action O O
of O O
tricyclics B-group B-group
, O O
amphetamines B-group B-group
, O O
procainamide B-drug B-drug
, O O
and O O
quinidine B-drug B-drug
. O O

General O O
: O O
Significant O O
interactions O O
may O O
occur O O
when O O
celecoxib B-drug B-drug
is O O
administered O O
together O O
with O O
drugs O O
that O O
inhibit O O
P450 O O
2C9 O O
. O O

Commonly O O
used O O
drugs O O
such O O
as O O
phenylpropanolamine B-drug B-drug
and O O
pseudoephedrine B-drug B-drug
have O O
been O O
specifically O O
studied O O
. O O

May O O
interact O O
with O O
the O O
following O O
: O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
( O O
these O O
medicines O O
may O O
make O O
your O O
condition O O
worse O O
and O O
prevent O O
the O O
adrenergic B-group B-group
bronchodilators I-group I-group
from O O
working O O
properly O O
) O O
and O O
disopyramide B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
phenothiazines B-group B-group
, O O
and O O
procainamide B-drug B-drug
( O O
these O O
medicines O O
may O O
increase O O
the O O
risk O O
of O O
heart O O
problems O O
) O O
. O O

However O O
, O O
in O O
another O O
study O O
in O O
healthy O O
volunteers O O
, O O
the O O
pharmacokinetics O O
of O O
butorphanol B-drug B-drug
were O O
significantly O O
altered O O
( O O
29 O O
% O O
decrease O O
in O O
AUC O O
and O O
38 O O
% O O
decrease O O
in O O
Cmax O O
) O O
when O O
a O O
1-mg O O
dose O O
of O O
STADOL B-brand B-brand
NS I-brand I-brand
was O O
administered O O
1 O O
minute O O
after O O
a O O
20-mg O O
dose O O
of O O
sumatriptan B-drug B-drug
nasal O I-drug
spray O O
. O O

( O O
The O O
two O O
drugs O O
were O O
administered O O
in O O
opposite O O
nostrils O O
. O O
) O O

Limited O O
data O O
in O O
patients O O
receiving O O
known O O
enzyme O O
inducers O O
( O O
phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
carbamazepine B-drug B-drug
) O O
indicate O O
only O O
a O O
30 O O
% O O
increase O O
in O O
the O O
rate O O
of O O
flecainide B-drug B-drug
elimination O O
. O O

Dosage O O
of O O
the O O
drugs O O
mentioned O O
above O O
and O O
other O O
similarly O O
metabolized O O
drugs O O
, O O
particularly O O
those O O
of O O
low O O
therapeutic O O
ratio O O
or O O
in O O
patients O O
with O O
renal O O
and/or O O
hepatic O O
impairment O O
, O O
may O O
require O O
adjustment O O
when O O
starting O O
or O O
stopping O O
concomitantly O O
administered O O
Tagamet B-brand B-brand
to O O
maintain O O
optimum O O
therapeutic O O
blood O O
levels O O
. O O

However O O
, O O
because O O
some O O
quinolones B-group B-group
have O O
been O O
reported O O
to O O
enhance O O
the O O
effects O O
of O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
anticoagulation O O
test O O
should O O
be O O
monitored O O
closely O O
if O O
a O O
quinolone B-group B-group
antimicrobial I-group I-group
is O O
administered O O
with O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

In O O
five O O
men O O
, O O
terfenadine B-drug B-drug
levels O O
were O O
undetectable O O
( O O
5 O O
ng/mL O O
) O O
throughout O O
the O O
study O O
; O O

Therefore O O
, O O
chloroprocaine B-drug B-drug
should O O
not O O
be O O
used O O
in O O
any O O
condition O O
in O O
which O O
a O O
sulfonamide B-group B-group
drug I-group I-group
is O O
being O O
employed O O
. O O

Pletal B-brand B-brand
does O O
not O O
, O O
however O O
, O O
appear O O
to O O
cause O O
increased O O
blood O O
levels O O
of O O
drugs O O
metabolized O O
by O O
CYP3A4 O O
, O O
as O O
it O O
had O O
no O O
effect O O
on O O
lovastatin B-drug B-drug
, O O
a O O
drug O O
with O O
metabolism O O
very O O
sensitive O O
to O O
C.P.A O O
. O O
inhibition O O
. O O

When O O
administering O O
other O O
drugs O O
for O O
which O O
alterations O O
in O O
blood O O
levels O O
could O O
have O O
a O O
clinically O O
significant O O
effect O O
on O O
safety O O
or O O
efficacy O O
, O O
physicians O O
should O O
consider O O
monitoring O O
drug O O
levels O O
or O O
effects O O
. O O

Tacrolimus O B-drug
Felodipine B-drug I-drug
may O O
increase O O
the O O
blood O O
concentration O O
of O O
tacrolimus B-drug B-drug
. O O

Drugs O O
That O O
Inhibit O O
Alprazolam B-drug B-drug
Metabolism O O
Via O O
Cytochrome O O
P450 O O
3A O O
: O O
The O O
initial O O
step O O
in O O
alprazolam B-drug B-drug
metabolism O O
is O O
hydroxylation O O
catalyzed O O
by O O
cytochrome O O
P450 O O
3A O O
( O O
CYP O O
3A O O
) O O
. O O

In O O
patients O O
who O O
have O O
received O O
muscle B-group B-group
relaxants I-group I-group
, O O
doxapram B-drug B-drug
may O O
temporarily O O
mask O O
the O O
residual O O
effects O O
of O O
muscle B-group B-group
relaxant I-group I-group
drugs I-group I-group
. O O

Co-administration O O
of O O
probenecid B-drug B-drug
with O O
acyclovir B-drug B-drug
has O O
been O O
shown O O
to O O
increase O O
the O O
mean O O
half-life O O
and O O
the O O
area O O
under O O
the O O
concentration-time O O
curve O O
. O O

Pressor O O
agents O O
- O O
Because O O
of O O
possible O O
effects O O
on O O
blood O O
pressure O O
, O O
STRATTERA B-brand B-brand
should O O
be O O
used O O
cautiously O O
with O O
pressor O O
agents O O
. O O

Increased O O
plasma O O
HDL O O
and O O
HDL2 O O
cholesterol O O
subfraction O O
concentrations O O
, O O
reduced O O
LDL O O
cholesterol O O
concentration O O
, O O
increased O O
triglyceride O O
levels O O
. O O

Iron B-group B-drug
Supplements I-group O
and O O
Foods O O
Fortified O O
With O O
Iron B-drug B-drug
Concomitant O O
administration O O
of O O
cefdinir B-drug B-drug
with O O
a O O
therapeutic O O
iron B-group B-drug
supplement I-group O
containing O O
60 O O
mg O O
of O O
elemental O O
iron B-drug B-drug
( O O
as O O
FeSO4 O B-brand
) O O
or O O
vitamins B-group B-group
supplemented O O
with O O
10 O O
mg O O
of O O
elemental O O
iron B-drug B-drug
reduced O O
extent O O
of O O
absorption O O
by O O
80 O O
% O O
and O O
31 O O
% O O
, O O
respectively O O
. O O

Use O O
in O O
Conjunction O O
with O O
Other O O
Antiepileptic B-group B-group
Drugs I-group I-group
: O O
The O O
addition O O
of O O
Felbatol B-brand B-brand
to O O
antiepileptic B-group B-group
drugs I-group I-group
( O O
AEDs B-group B-group
) O O
affects O O
the O O
steady-state O O
plasma O O
concentrations O O
of O O
AEDs B-group B-group
. O O

- O O
isoniazid B-drug B-drug
( O O
Nydrazid B-brand B-brand
) O O
; O O

Specific O O
Effects O O
of O O
Felbatol B-brand B-brand
on O O
Other O O
Antiepileptic B-group B-group
Drugs I-group I-group
Phenytoin B-drug B-drug
: O O
Felbatol B-brand B-brand
causes O O
an O O
increase O O
in O O
steady-state O O
phenytoin B-drug B-drug
plasma O O
concentrations O O
. O O

There O O
were O O
no O O
significant O O
effects O O
on O O
QTc O O
intervals O O
, O O
and O O
no O O
reports O O
of O O
sedation O O
or O O
syncope O O
. O O

monitor O O
closely O O
for O O
evidence O O
of O O
hypotension O O
and/or O O
excessive O O
bradycardia O O
( O O
e.g. O O
, O O
vertigo O O
, O O
syncope O O
, O O
postural O O
hypotension O O
) O O
. O O

Unmodified O O
NaCMC B-drug_n B-drug_n
( O O
1 O O
% O O
m/v O O
) O O
significantly O O
improved O O
the O O
transport O O
ratio O O
( O O
R= O O
P O O
( O O
app O O
) O O
polymer/ O O
P O O
( O O
app O O
) O O
control O O
) O O
of O O
NaFlu B-drug B-drug
to O O
1.3 O O
and O O
1 O O
% O O
( O O
m/v O O
) O O
NaCMC B-drug_n O
conjugated O O
with O O
cysteine B-drug B-drug
further O O
enhanced O O
the O O
permeation O O
. O O

To O O
each O O
preparation O O
was O O
added O O
one O O
additional O O
drug O O
at O O
three O O
concentrations O O
ranging O O
from O O
therapeutic O O
to O O
toxic O O
. O O

To O O
investigate O O
the O O
effect O O
of O O
disease O O
states O O
or O O
concomitant O O
drug O O
administration O O
on O O
a O O
patient O O
's O O
response O O
to O O
etodolac B-drug B-drug
, O O
additional O O
pharmacokinetic O O
studies O O
were O O
carried O O
out O O
in O O
special O O
populations O O
. O O

No O O
clinical O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
. O O

Ergotamine B-drug B-drug
: O O
Concurrent O O
use O O
of O O
erythromycin B-drug B-drug
and O O
ergotamine B-drug B-drug
or O O
dihydroergotamine B-drug B-drug
has O O
been O O
associated O O
in O O
some O O
patients O O
with O O
acute O O
ergot O O
toxicity O O
characterized O O
by O O
severe O O
peripheral O O
vasospasm O O
and O O
dysesthesia O O
. O O

Herbal O O
remedies O O
, O O
nephropathies O O
, O O
and O O
renal O O
disease O O
. O O

Diclofenac B-drug B-drug
is O O
a O O
prostaglandin O B-group
synthetase O I-group
inhibitor O I-group
, O O
however O O
, O O
and O O
all O O
drugs O O
that O O
inhibit O O
prostaglandin O O
synthesis O O
interfere O O
with O O
platelet O O
function O O
to O O
some O O
degree O O
; O O

nonetheless O O
, O O
the O O
possibility O O
that O O
causative O O
factors O O
may O O
interact O O
synergistically O O
to O O
increase O O
the O O
risk O O
and/or O O
severity O O
of O O
bone O O
marrow O O
suppression O O
warrants O O
consideration O O
. O O

In O O
studies O O
in O O
female O O
rats O O
at O O
doses O O
0.01 O O
mg/kg/day O O
( O O
IM O O
; O O

Mean O O
T O O
max O O
and O O
mean O O
plasma O O
elimination O O
half-life O O
of O O
albendazole B-drug B-drug
sulfoxide I-drug I-drug
were O O
unchanged O O
. O O

Sildenafil B-drug B-drug
dose O O
should O O
not O O
exceed O O
a O O
maximum O O
of O O
25 O O
mg O O
in O O
a O O
48- O O
hour O O
period O O
in O O
patients O O
receiving O O
concomitant O O
indinavir B-drug B-drug
therapy O O
. O O

Herb/Nutraceutical O O
: O O
St O O
Johns O O
wort O O
may O O
decrease O O
the O O
effectiveness O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
by O O
inducing O O
hepatic O O
enzymes O O
. O O

urticaria O O

Caverject B-brand O
: O O
The O O
potential O O
for O O
pharmacokinetic O O
drug-drug O O
interactions O O
between O O
alprostadil B-drug B-drug
and O O
other O O
agents O O
has O O
not O O
been O O
formally O O
studied O O
. O O

therefore O O
, O O
it O O
should O O
be O O
recognized O O
that O O
a O O
positive O O
Coombs O O
test O O
may O O
be O O
due O O
to O O
the O O
drug O O
. O O

Although O O
no O O
drug-drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
in O O
vivo O O
, O O
it O O
is O O
expected O O
that O O
no O O
significant O O
interaction O O
would O O
occur O O
when O O
nitazoxanide B-drug B-drug
is O O
co-administered O O
with O O
drugs O O
that O O
either O O
are O O
metabolized O O
by O O
or O O
inhibit O O
cytochrome O O
P450 O O
enzymes O O
. O O

There O O
are O O
no O O
clinical O O
data O O
on O O
concomitant O O
use O O
of O O
NUROMAX B-brand B-brand
and O O
other O O
nondepolarizing O B-group
neuromuscular B-group I-group
blocking I-group I-group
agents I-group I-group
. O O

Administration O O
of O O
thiazide B-group B-group
diuretics I-group I-group
to O O
hypoparathyroid O O
patients O O
who O O
are O O
concurrently O O
being O O
treated O O
with O O
dihydrotachysterol B-drug B-drug
may O O
cause O O
hypercalcemia O O
. O O

antibiotics B-group B-group
; O O

These O O
agents O O
should O O
not O O
be O O
used O O
in O O
patients O O
treated O O
with O O
NIZORAL B-brand B-brand
Tablets O O
. O O

Amiodarone B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
lidocaine B-drug B-drug

The O O
pharmacokinetics O O
of O O
ethanol B-drug B-drug
were O O
not O O
affected O O
by O O
multiple-dose O O
administration O O
of O O
tiagabine B-drug B-drug
. O O

The O O
CNS O O
effects O O
of O O
butalbital B-drug B-drug
may O O
be O O
enhanced O O
by O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
. O O

Indinavir B-drug B-drug
may O O
be O O
taken O O
with O O
a O O
light O O
meal O O
1 O O
h O O
following O O
the O O
administration O O
of O O
400 O O
mg O O
of O O
didanosine B-drug B-drug
. O O

Nitrates B-group B-group
: O O
The O O
concomitant O O
use O O
of O O
Bepridil B-drug B-drug
with O O
long- O B-group
and O O
short-acting O B-group
nitrates B-group I-group
has O O
been O O
safely O O
tolerated O O
in O O
patients O O
with O O
stable O O
angina O O
pectoris O O
. O O

The O O
results O O
we O O
present O O
clearly O O
show O O
that O O
the O O
drug O O
alters O O
the O O
cellular O O
permeability O O
, O O
and O O
thus O O
the O O
exogenous O O
respiration O O
becomes O O
sensitive O O
to O O
the O O
drug O O
. O O

Vardenafil B-drug B-drug
( O O
20 O O
mg O O
) O O
did O O
not O O
potentiate O O
the O O
hypotensive O O
effects O O
of O O
alcohol B-drug B-drug
during O O
the O O
4-hour O O
observation O O
period O O
in O O
healthy O O
volunteers O O
when O O
administered O O
with O O
alcohol B-drug B-drug
( O O
0.5 O O
g/kg O O
body O O
weight O O
) O O
. O O

In O O
addition O O
to O O
this O O
pharmacological O O
interaction O O
, O O
this O O
report O O
describes O O
a O O
novel O O
chemical O O
reaction O O
between O O
temazepam B-drug B-drug
( O O
a O O
benzodiazepine B-group B-group
) O O
and O O
ethanol B-drug B-drug
under O O
acidic O O
conditions O O
similar O O
to O O
those O O
found O O
in O O
vivo O O
, O O
resulting O O
in O O
a O O
3-ethoxylated O O
product O O
. O O

MEASUREMENTS O O
and O O
MAIN O O
RESULTS O O
: O O
Blood O O
samples O O
were O O
drawn O O
and O O
12-lead O O
electrocardiograms O O
performed O O
at O O
specified O O
time O O
points O O
after O O
the O O
last O O
morning O O
dose O O
of O O
cisapride B-drug B-drug
in O O
phases O O
1 O O
and O O
3 O O
. O O

increased O O
liver O O

Still O O
other O O
pathways O O
have O O
been O O
proposed O O
. O O

Sympathomimetic B-group B-group
Agents I-group I-group
: O O
Possible O O
increased O O
risk O O
of O O
coronary O O
insufficiency O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

In O O
addition O O
, O O
new O O
cases O O
of O O
diabetes O O
have O O
been O O
diagnosed O O
during O O
Accutane B-brand B-brand
therapy O O
, O O
although O O
no O O
causal O O
relationship O O
has O O
been O O
established O O

This O O
may O O
potentiate O O
and O O
prolong O O
hypnotic O O
and O O
sedative O O
effects O O
, O O
especially O O
with O O
repeated O O
dosing O O
or O O
chronic O O
administration O O
of O O
these O O
agents O O
. O O

Several O O
of O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
cited O O
in O O
these O O
reports O O
. O O

Bleeding O O
from O O
a O O
number O O
of O O
sites O O
may O O
be O O
a O O
complication O O
of O O
warfarin B-drug B-drug
treatment O O
and O O
GI O O
bleeding O O
a O O
complication O O
of O O
ketoprofen B-drug B-drug
treatment O O
. O O

. O O

Between O O
1988 O O
and O O
1993 O O
, O O
more O O
than O O
7,000 O O
patients O O
were O O
diagnosed O O
and O O
treated O O
. O O

Therefore O O
, O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
levels O O
should O O
be O O
considered O O
and O O
dosage O O
of O O
theophylline B-drug B-drug
adjusted O O
, O O
as O O
required O O
. O O

Both O O
CYP3A4 O O
and O O
CYP2D6 O O
are O O
responsible O O
for O O
aripiprazole B-drug B-drug
metabolism O O
. O O

Separating O O
the O O
doses O O
of O O
antacid B-group B-group
and O O
lomefloxacin B-drug B-drug
minimizes O O
this O O
decrease O O
in O O
bioavailability O O
; O O

TCAs B-group B-group
decrease O O
the O O
hypotensive O O
effect O O
of O O
guanfacine B-drug B-drug
. O O

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

Non-selective B-group B-group
monoamine I-group I-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
- O O
including O O
phenelzine B-drug B-drug
sulfate I-drug I-drug
, O O
tranylcypromine B-drug B-drug
sulfate I-drug I-drug
and O O
pargyline B-drug B-drug
HC1 O O
. O O

However O O
, O O
this O O
sample O O
size O O
is O O
too O O
small O O
to O O
allow O O
for O O
any O O
conclusions O O
to O O
be O O
drawn O O
regarding O O
the O O
risk O O
of O O
rashes O O
with O O
concomitant O O
AUGMENTIN B-brand B-brand
XR I-brand I-brand
and O O
allopurinol B-drug B-drug
use O O
. O O

The O O
introductory O O
chapter O O
discusses O O
the O O
advantages O O
and O O
disadvantages O O
of O O
POCs B-group B-group
and O O
the O O
magnitude O O
and O O
prevalence O O
of O O
their O O
use O O
. O O

Theophylline B-drug B-drug
: O O
The O O
effect O O
of O O
steady-state O O
fluvoxamine B-drug B-drug
l50 O O
mg O O
bid O O
on O O
the O O
pharmacokinetics O O
of O O
a O O
single O O
dose O O
of O O
Theophylline B-drug B-drug
( O O
375 O O
mg O O
) O O
as O O
442 O O
mg O O
aminophylline B-drug B-drug
was O O
evaluated O O
in O O
12 O O
healthy O O
non-smoking O O
, O O
male O O
volunteers O O
. O O

The O O
effects O O
of O O
supplementary O O
oral O O
cobalt B-drug B-drug
and O O
iron B-drug B-drug
, O O
as O O
well O O
as O O
the O O
interaction O O
between O O
both O O
at O O
the O O
absorption O O
site O O
, O O
fecal O O
and O O
urinary O O
excretion O O
as O O
well O O
as O O
the O O
retention O O
of O O
these O O
trace O O
elements O O
were O O
determined O O
by O O
using O O
four O O
diets O O
containing O O
either O O
9 O O
or O O
63 O O
micrograms/kg O O
of O O
Co B-drug O
and O O
48 O O
or O O
446 O O
mg/kg O O
of O O
Fe B-drug B-drug
over O O
a O O
period O O
of O O
19 O O
days O O
in O O
a O O
total O O
of O O
24 O O
rats O O
. O O

These O O
fulvestrant B-drug B-drug
doses O O
correspond O O
to O O
approximately O O
2- O O
, O O
3- O O
, O O
and O O
3-fold O O
the O O
systemic O O
exposure O O
[ O O
AUC0-30 O O
days O O
] O O
achieved O O
in O O
women O O
. O O

This O O
review O O
discusses O O
the O O
actions O O
of O O
the O O
two O O
drugs O O
on O O
certain O O
brain O O
chemical O O
( O O
i.e. O O
, O O
neurotransmitter O O
) O O
systems O O
and O O
the O O
extent O O
to O O
which O O
the O O
effects O O
of O O
the O O
two O O
drugs O O
may O O
interact O O
. O O

Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
binds O O
both O O
T4 B-drug O
and O O
T3 B-drug O
in O O
the O O
intestine O O
, O O
thus O O
impairing O O
absorption O O
of O O
these O O
thyroid B-group B-group
hormones I-group I-group
. O O

The O O
use O O
of O O
Adenocard B-brand B-brand
in O O
patients O O
receiving O O
digitalis B-group B-group
may O O
be O O
rarely O O
associated O O
with O O
ventricular O O
fibrillation O O
. O O

Cisapride B-drug B-drug

The O O
patient O O
was O O
also O O
chronically O O
receiving O O
phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
and O O
levothyroxine B-drug B-drug
sodium I-drug I-drug
. O O

Pregnancy O O
: O O
Category O O
X O O
: O O
Use O O
With O O
Ribavirin B-drug B-drug
( O O
see O O
CONTRAINDICATIONS O O
) O O
Significant O O
teratogenic O O
and/or O O
embryocidal O O
effects O O
have O O
been O O
demonstrated O O
in O O
all O O
animal O O
species O O
exposed O O
to O O
ribavirin B-drug B-drug
. O O

When O O
Itraconazole B-drug B-drug
was O O
coadministered O O
with O O
phenytoin B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
or O O
H2antagonists O B-group
, O O
reduced O O
plasma O O
concentrations O O
of O O
itraconazole B-drug B-drug
were O O
reported O O
. O O

. O O

phenytoin B-drug B-drug
; O O

Azithromycin B-drug B-drug
had O O
no O O
significant O O
impact O O
on O O
the O O
Cmax O O
and O O
AUC O O
of O O
zidovudine B-drug B-drug
, O O
although O O
it O O
significantly O O
decreased O O
the O O
zidovudine B-drug B-drug
tmax O O
by O O
44 O O
% O O
and O O
increased O O
the O O
intracellular O O
exposure O O
to O O
phosphorylated O O
zidovudine B-drug B-drug
by O O
110 O O
% O O
. O O

At O O
similar O O
median O O
follow-up O O
, O O
opportunistic O O
infection O O
( O O
OI O O
) O O
rates O O
and O O
mortality O O
were O O
significantly O O
lower O O
in O O
the O O
CHOP-HAART O O
patients O O
than O O
in O O
the O O
CHOP O O
patients O O
( O O
18 O O
% O O
vs. O O
52 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
0.05 O O
; O O
and O O
38 O O
% O O
vs. O O
85 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
0.001 O O
) O O
. O O

If O O
ProSom B-brand B-brand
is O O
given O O
concomitantly O O
with O O
other O O
drugs O O
acting O O
on O O
the O O
central O O
nervous O O
system O O
, O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
all O O
agents O O
. O O

Patients O O
taking O O
Acamprosate B-drug B-drug
concomitantly O O
with O O
antidepressants B-group B-group
more O O
commonly O O
reported O O
both O O
weight O O
gain O O
and O O
weight O O
loss O O
, O O
compared O O
with O O
patients O O
taking O O
either O O
medication O O
alone O O
. O O

however O O
, O O
no O O
specific O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
to O O
evaluate O O
potential O O
drug-drug O O
interaction O O
. O O

No O O
well-known O O
drug O O
interactions O O
with O O
glutamic B-drug B-drug
acid I-drug I-drug

It O O
was O O
established O O
that O O
both O O
angiotensins O B-group
inhibited O O
gastric O O
acid O O
secretion O O
stimulated O O
by O O
pentagastrin B-drug B-drug
but O O
not O O
by O O
histamine B-drug B-drug
. O O

As O O
with O O
other O O
agents O O
which O O
prolong O O
ECG O O
intervals O O
, O O
caution O O
should O O
be O O
exercised O O
in O O
patients O O
taking O O
drugs O O
which O O
prolong O O
ECG O O
intervals O O
, O O
particularly O O
QTc O O
. O O

Other O O
interactions O O
: O O
Vardenafil B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacodynamics O O
of O O
glyburide B-drug B-drug
( O O
glucose O B-drug
and O O
insulin O B-drug
concentrations O O
) O O
and O O
warfarin B-drug B-drug
( O O
prothrombin O O
time O O
or O O
other O O
pharmacodynamic O O
parameters O O
) O O
. O O

Patients O O
treated O O
with O O
TENORMIN B-brand B-brand
plus O O
a O O
catecholamine O B-group
depletor O I-group
should O O
therefore O O
be O O
closely O O
observed O O
for O O
evidence O O
of O O
hypotension O O
and/or O O
marked O O
bradycardia O O
which O O
may O O
produce O O
vertigo O O
, O O
syncope O O
, O O
or O O
postural O O
hypotension O O
. O O

diazoxide B-drug B-drug
; O O

Aspirin B-brand B-brand
: O O
Concurrent O O
administration O O
of O O
aspirin B-brand B-brand
may O O
lower O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
plasma O O
levels O O
, O O
possibly O O
by O O
competing O O
for O O
protein-binding O O
sites O O
. O O

Gentamicin B-drug B-drug
is O O
an O O
aminoglycoside B-group B-group
antibiotic I-group I-group
used O O
to O O
treat O O
a O O
wide O O
variety O O
of O O
infections O O
caused O O
by O O
gram-negative O O
organisms O O
, O O
but O O
it O O
is O O
potentially O O
toxic O O
to O O
the O O
kidneys O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
None O O
known O O
. O O

Interactions O O
attributed O O
to O O
the O O
combined O O
use O O
of O O
baclofen B-drug B-drug
injection O O
and O O
epidural O O
morphine B-drug B-drug
include O O
hypotension O O
and O O
dyspnea O O
. O O

Antiarrhythmics B-group B-group

Isocarboxazid B-drug B-drug
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
receiving O O
Antabuse B-brand B-brand
( O O
disulfiram B-drug B-drug
, O O
Wyeth-Ayerst O O
Laboratories O O
) O O
. O O

Since O O
acetaminophen B-drug B-drug
in O O
high O O
doses O O
has O O
been O O
associated O O
with O O
hepatotoxicity O O
, O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
acetaminophen B-drug B-drug
should O O
be O O
used O O
cautiously O O
, O O
with O O
careful O O
monitoring O O
of O O
patients O O
. O O

The O O
appropriate O O
doses O O
for O O
this O O
combination O O
, O O
with O O
respect O O
to O O
efficacy O O
and O O
safety O O
, O O
have O O
not O O
been O O
established O O
. O O

These O O
observations O O
are O O
discussed O O
in O O
reference O O
to O O
possible O O
deleterious O O
effects O O
following O O
the O O
administration O O
of O O
pargyline B-drug B-drug
to O O
patients O O
with O O
Parkinson O O
's O O
Disease O O
. O O

There O O
was O O
evidence O O
for O O
longitudinal O O
stability O O
in O O
AUC O O
of O O
everolimus B-drug B-drug
during O O
the O O
course O O
of O O
the O O
study O O
. O O

It O O
is O O
recommended O O
that O O
the O O
combination O O
of O O
intravenous O O
dantrolene B-drug B-drug
sodium I-drug I-drug
and O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
such O O
as O O
verapamil B-drug B-drug
, O O
not O O
be O O
used O O
together O O
during O O
the O O
management O O
of O O
malignant O O
hyperthermia O O
crisis O O
until O O
the O O
relevance O O
of O O
these O O
findings O O
to O O
humans O O
is O O
established O O
. O O

L-glutamine B-drug B-drug
has O O
orphan O O
drug O O
status O O
for O O
this O O
indication O O
. O O

BACKGROUND O O
: O O
The O O
feasibility O O
and O O
efficacy O O
of O O
concomitant O O
chemotherapy O O
and O O
highly B-group B-group
active I-group I-group
antiretroviral I-group I-group
therapy O O
( O O
HAART O O
) O O
is O O
still O O
unknown O O
in O O
patients O O
with O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
-related O O
malignancies O O
. O O

Coadministration O O
of O O
SULAR B-brand B-brand
with O O
phenytoin B-drug B-drug
or O O
any O O
known O O
CYP3A4 O O
inducer O O
should O O
be O O
avoided O O
and O O
alternative O O
antihypertensive B-group B-group
therapy O O
should O O
be O O
considered O O
. O O

The O O
concomitant O O
use O O
of O O
other O O
CYP3A4 O O
inhibitors O O
such O O
as O O
diltiazem B-drug B-drug
and O O
erythromycin B-drug B-drug
with O O
transdermal O O
fentanyl B-drug B-drug
may O O
also O O
result O O
in O O
an O O
increase O O
in O O
fentanyl B-drug B-drug
plasma O O
concentrations O O
, O O
which O O
could O O
increase O O
or O O
prolong O O
adverse O O
drug O O
effects O O
and O O
may O O
cause O O
serious O O
respiratory O O
depression O O
. O O

This O O
information O O
should O O
be O O
considered O O
when O O
changing O O
from O O
intravenous O O
amiodarone B-drug B-drug
to O O
oral O O
amiodarone B-drug B-drug
. O O

Alcohol B-drug B-drug
: O O
Alcohol B-drug B-drug
( O O
0.5 O O
g/kg O O
body O O
weight O O
: O O
approximately O O
40 O O
mL O O
of O O
absolute O O
alcohol O B-drug
in O O
a O O
70 O O
kg O O
person O O
) O O
and O O
vardenafil B-drug B-drug
plasma O O
levels O O
were O O
not O O
altered O O
when O O
dosed O O
simultaneously O O
. O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
may O O
inhibit O O
both O O
synthetic O O
and O O
catabolic O O
enzymes O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

Although O O
the O O
mechanism O O
of O O
interaction O O
between O O
fenoprofen B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
not O O
totally O O
known O O
, O O
enzyme O O
induction O O
and O O
displacement O O
of O O
fenoprofen B-drug B-drug
from O O
plasma O O
albumin O O
binding O O
sites O O
are O O
possibilities O O
. O O

In O O
evaluating O O
the O O
potential O O
for O O
interactions O O
among O O
co-administered O O
antiepilepsy O O
drugs O O
( O O
AEDs B-group B-group
) O O
, O O
whether O O
or O O
not O O
an O O
AED B-group B-group
induces O O
or O O
does O O
not O O
induce O O
metabolic O O
enzymes O O
is O O
an O O
important O O
consideration O O
. O O

Other O O
drugs O O
that O O
increase O O
gastrointestinal O O
motility O O
may O O
produce O O
similar O O
effects O O
. O O

Bromocriptine B-drug B-drug
mesylate I-drug I-drug
may O O
interact O O
with O O
dopamine B-group B-group
antagonists I-group I-group
, O O
butyrophenones B-group B-group
, O O
and O O
certain O O
other O O
agents O O
. O O

Inhibition O O
and O O
stimulation O O
of O O
the O O
effect O O
of O O
oxytocin B-drug B-drug
on O O
milk O O
ejection O O
by O O
vasopressin O B-drug
was O O
demonstrated O O
. O O

Accelerated O O
prothrombin O O
time O O
, O O
partial O O
thromboplastin O O
time O O
, O O
and O O
platelet O O
aggregation O O
time O O
; O O

Care O O
should O O
be O O
taken O O
when O O
using O O
immunoanalytical O O
methods O O
to O O
measure O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
following O O
Cerebyx B-brand B-brand
administration O O
. O O

Organometals O O
also O O
compromise O O
the O O
limbic O O
system O O
and O O
result O O
in O O
deficits O O
in O O
learning O O
and O O
memory O O
. O O

Furthermore O O
it O O
has O O
been O O
proposed O O
that O O
isoniazid B-drug B-drug
resulted O O
In O O
induction O O
of O O
P-450IIE1 O O
in O O
the O O
patients O O
liver O O
which O O
, O O
in O O
turn O O
, O O
resulted O O
in O O
a O O
greater O O
proportion O O
of O O
the O O
ingested O O
acetaminophen B-drug B-drug
being O O
converted O O
to O O
the O O
toxic O O
metabolites O O
. O O

Based O O
on O O
the O O
above O O
data O O
from O O
in O O
vitro O O
and O O
in O O
vivo O O
studies O O
, O O
it O O
is O O
unlikely O O
that O O
alosetron B-drug B-drug
will O O
inhibit O O
the O O
hepatic O O
metabolic O O
clearance O O
of O O
drugs O O
metabolized O O
by O O
the O O
major O O
CYP O O
enzyme O O
3A4 O O
, O O
as O O
well O O
as O O
the O O
CYP O O
enzymes O O
2D6 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2E1 O O
, O O
or O O
1A2 O O
. O O

This O O
may O O
lead O O
to O O
reduced O O
clearance O O
of O O
caffeine B-drug B-drug
and O O
the O O
prolongation O O
of O O
its O O
plasma O O
half-life O O
. O O

Cimetidine B-drug B-drug
- O O
In O O
subjects O O
who O O
had O O
received O O
21 O O
days O O
of O O
40 O O
mg/day O O
racemic O O
citalopram B-drug B-drug
, O O
combined O O
administration O O
of O O
400 O O
mg/day O O
cimetidine B-drug B-drug
for O O
8 O O
days O O
resulted O O
in O O
an O O
increase O O
in O O
citalopram B-drug B-drug
AUC O O
and O O
Cmax O O
of O O
43 O O
% O O
and O O
39 O O
% O O
, O O
respectively O O
. O O

- O O
Methotrexate B-drug B-drug
( O O
e.g. O O
, O O
Mexate B-brand B-brand
) O O
Use O O
of O O
methotrexate B-drug B-drug
with O O
sulfapyridine B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O
and/or O O
the O O
side O O
effects O O
of O O
methotrexate B-drug B-drug

Norepinephrine B-drug B-drug
: O O
Amphetamines B-group B-group
enhance O O
the O O
adrenergic O O
effect O O
of O O
norepinephrine B-drug B-drug
. O O

A O O
possible O O
interaction O O
has O O
been O O
suggested O O
with O O
hormonal B-group B-group
contraceptives I-group I-group
and O O
the O O
herbal O O
supplement O O
St. O O
Johns O O
Wort O O
based O O
on O O
some O O
reports O O
of O O
oral O O
contraceptive B-group B-group
users O O
experiencing O O
breakthrough O O
bleeding O O
shortly O O
after O O
starting O O
St. O O
Johns O O
Wort O O
. O O

In O O
an O O
emergency O O
situation O O
when O O
opioid O B-group
analgesia O I-group
must O O
be O O
administered O O
to O O
a O O
patient O O
receiving O O
REVIA B-brand B-brand
, O O
the O O
amount O O
of O O
opioid B-group B-group
required O O
may O O
be O O
greater O O
than O O
usual O O
, O O
and O O
the O O
resulting O O
respiratory O O
depression O O
may O O
be O O
deeper O O
and O O
more O O
prolonged O O
. O O

The O O
net O O
effect O O
of O O
these O O
interactions O O
is O O
summarized O O
in O O
the O O
following O O
table O O
: O O
AED B-group B-group
AED I-group I-group
Felbatol B-brand B-brand

In O O
these O O
patients O O
, O O
approximately O O
half O O
of O O
the O O
CPK O O
elevations O O
returned O O
to O O
normal O O
within O O
2 O O
weeks O O
and O O
half O O
returned O O
to O O
normal O O
within O O
4 O O
weeks O O
. O O

Studies O O
on O O
the O O
mechanism O O
of O O
action O O
of O O
miconazole B-drug B-drug
: O O
effect O O
of O O
miconazole B-drug B-drug
on O O
respiration O O
and O O
cell O O
permeability O O
of O O
Candida O O
albicans O O
. O O

Concurrent O O
use O O
of O O
these O O
agents O O
should O O
generally O O
be O O
avoided O O
. O O

- O O
Mephenytoin B-drug B-drug
( O O
e.g. O O
, O O
Mesantoin B-brand B-brand
) O O
Use O O
of O O
sulfapyridine B-drug B-drug
with O O
these O O
medicines O O
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
of O O
these O O
medicines O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reaction O O
. O O

1- O O
adrenergic O O
receptor O O
antagonism O O
, O O
aripiprazole B-drug B-drug
has O O
the O O
potential O O
to O O
enhance O O
the O O
effect O O
of O O
certain O O
antihypertensive B-group B-group
agents I-group I-group
. O O

Nephrotoxicity O O
and O O
ototoxicity O O
were O O
not O O
noted O O
when O O
ceftazidime B-drug B-drug
was O O
given O O
alone O O
in O O
clinical O O
trials O O
. O O

Median O O
gastric O O
pH O O
was O O
significantly O O
higher O O
when O O
indinavir B-drug B-drug
was O O
taken O O
after O O
didanosine B-drug B-drug
administration O O
; O O

carbamazepine B-drug B-drug
; O O

Patients O O
taking O O
other O O
drugs O O
that O O
are O O
substrates O O
of O O
CYP450 O O
3A4 O O
, O O
especially O O
patients O O
with O O
renal O O
and/or O O
hepatic O O
impairment O O
, O O
may O O
require O O
dosage O O
adjustment O O
when O O
starting O O
or O O
stopping O O
concomitantly O O
administered O O
diltiazem B-drug B-drug
in O O
order O O
to O O
maintain O O
optimum O O
therapeutic O O
blood O O
levels O O
. O O

The O O
initiated O O
cells O O
that O O
result O O
from O O
this O O
hit O O
may O O
vary O O
from O O
those O O
that O O
demonstrate O O
very O O
little O O
progression O O
in O O
cell O O
type O O
and O O
may O O
or O O
may O O
not O O
require O O
exogenous O O
enhancement O O
of O O
growth O O
to O O
those O O
that O O
can O O
progress O O
very O O
rapidly O O
to O O
fully O O
malignant O O
behavior O O
. O O

Exert O O
particular O O
caution O O
in O O
combining O O
chlorprothixene B-drug B-drug
with O O
other O O
anticholinergic B-group B-group
drugs I-group I-group
( O O
tricyclic B-group B-group
antidepressants I-group I-group
and O O
antiparkinsonian B-group B-group
agents I-group I-group
) O O
: O O
Particularly O O
the O O
elderly O O
may O O
develop O O
delirium O O
, O O
high O O
fever O O
, O O
severe O O
obstipation O O
, O O
even O O
ileus O O
and O O
glaucoma O O
. O O

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

14C-cholesterol O O
ester O O
fractional O O
clearance O O
rate O O
was O O
260 O O
% O O
greater O O
after O O
etofibrate B-drug B-drug
than O O
after O O
placebo O O
. O O

The O O
mean O O
( O O
SD O O
) O O
cumulative O O
urinary O O
excretion O O
of O O
immunoreactive O O
digoxin B-drug B-drug
after O O
concurrent O O
treatment O O
with O O
rofecoxib B-drug B-drug
or O O
placebo O O
was O O
228.2 O O
( O O
+/- O O
30.8 O O
) O O
and O O
235.1 O O
( O O
+/- O O
39.1 O O
) O O
micrograms/120 O O
hours O O
, O O
respectively O O
. O O

Therefore O O
, O O
ketoconazole B-drug B-drug
should O O
be O O
administered O O
with O O
caution O O
with O O
intranasal O O
ciclesonide B-drug B-drug
. O O

Since O O
the O O
renal O O
excretion O O
of O O
unchanged O O
dasatinib B-drug B-drug
and O O
its O O
metabolites O O
is O O
4 O O
% O O
, O O
a O O
decrease O O
in O O
total O O
body O O
clearance O O
is O O
not O O
expected O O
in O O
patients O O
with O O
renal O O
insufficiency O O
. O O

Estrogen B-group B-group
, O O
Oral O O
Contraceptives B-group B-group
: O O
Estrogens B-group B-group
tend O O
to O O
increase O O
serum O O
thyroxine-binding O O
globulin O O
( O O
TBg O O
) O O
. O O

Although O O
acid-base O O
and O O
electrolyte O O
disturbances O O
were O O
not O O
reported O O
in O O
the O O
clinical O O
trials O O
with O O
dorzolamide B-drug B-drug
, O O
these O O
disturbances O O
have O O
been O O
reported O O
with O O
oral O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitors I-group I-group
and O O
have O O
, O O
in O O
some O O
instances O O
, O O
resulted O O
in O O
drug O O
interactions O O
( O O
e.g. O O
, O O
toxicity O O
associated O O
with O O
high-dose O O
salicylate B-group B-group
therapy O O
) O O
. O O

This O O
is O O
also O O
to O O
be O O
considered O O
when O O
leflunomide B-drug B-drug
treatment O O
is O O
followed O O
by O O
such O O
drugs O O
without O O
a O O
drug O O
elimination O O
procedure O O
. O O

Consequently O O
, O O
plasma O O
concentrations O O
of O O
drugs O O
metabolized O O
by O O
these O O
two O O
isoenzymes O O
will O O
be O O
decreased O O
when O O
TRACLEER B-brand B-brand
is O O
co-administered O O
. O O

Heparin B-drug B-drug
: O O
No O O
human O O
drug O O
interaction O O
studies O O
with O O
heparin B-drug B-drug
were O O
conducted O O
. O O

The O O
effects O O
of O O
mixing O O
NovoLog B-brand B-brand
with O O
insulins B-group O
of O O
animal O O
source O O
or O O
insulin B-drug B-drug
preparations O O
produced O O
by O O
other O O
manufacturers O O
have O O
not O O
been O O
studied O O
. O O

astemizole B-drug B-drug
midazolam I-drug I-drug
, O O
triazolam B-drug B-drug
cisapride I-drug I-drug
ergot O I-drug
derivatives O I-drug
voriconazole B-drug I-drug

In O O
a O O
study O O
in O O
normal O O
volunteers O O
, O O
concomitant O O
administration O O
of O O
buspirone B-drug B-drug
HCl I-drug I-drug
and O O
haloperidol B-drug B-drug
resulted O O
in O O
increased O O
serum O O
haloperidol B-drug B-drug
concentrations O O
. O O

The O O
inhibitory O O
potential O O
of O O
ciclesonide B-drug B-drug
on O O
CYP450 O O
isoenzymes O O
has O O
not O O
been O O
studied O O
. O O

prolonged O O
hot O O
weather O O
; O O

Thus O O
, O O
smaller O O
doses O O
of O O
adenosine B-drug B-drug
may O O
be O O
effective O O
in O O
the O O
presence O O
of O O
dipyridamole B-drug B-drug
. O O

Drugs O O
Prolonging O O
the O O
QT/QTc O O
Interval O O
Caution O O
should O O
be O O
exercised O O
when O O
prescribing O O
apomorphine B-drug B-drug
concomitantly O O
with O O
drugs O O
that O O
prolong O O
the O O
QT/QTc O O
interval O O
. O O

In O O
healthy O O
subjects O O
receiving O O
cimetidine B-drug B-drug
( O O
1 O O
gm O O
daily O O
) O O
for O O
one O O
week O O
, O O
plasma O O
flecainide B-drug B-drug
levels O O
increased O O
by O O
about O O
30 O O
% O O
and O O
half-life O O
increased O O
by O O
about O O
10 O O
% O O
. O O

The O O
effects O O
celecoxib B-drug B-drug
on O O
the O O
pharmacokinetics O O
and/or O O
pharmacodynamics O O
of O O
glyburide B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
tolbutamide B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
have O O
been O O
studied O O
in O O
vivo O O
and O O
clinically O O
important O O
interactions O O
have O O
not O O
been O O
found O O
. O O

Albuterol B-drug B-drug
, O O
Antihistamines B-group B-group
, O O
antidiabetic B-group B-group
drugs I-group I-group
, O O
diuretics B-group B-group
, O O
digitalis B-group B-group
. O O

Animal O O
data O O
indicated O O
that O O
bupropion B-drug B-drug
may O O
be O O
an O O
inducer O O
of O O
drug-metabolizing O O
enzymes O O
in O O
humans O O
. O O

600-1800 O O

Age O O
( O O
range O O
, O O
17-69 O O
years O O
) O O
, O O
weight O O
( O O
range O O
, O O
49-106 O O
kg O O
) O O
, O O
and O O
sex O O
( O O
65 O O
men O O
and O O
36 O O
women O O
) O O
were O O
not O O
significant O O
contributors O O
to O O
variability O O
. O O

Therefore O O
, O O
if O O
concomitant O O
administration O O
of O O
these O O
agents O O
is O O
indicated O O
, O O
dosing O O
should O O
be O O
separated O O
by O O
2 O O
hours O O
. O O

No O O
separate O O
information O O
available O O

Therefore O O
the O O
, O O
combination O O
of O O
anakinra B-drug B-drug
with O O
other O O
TNF-blocking B-group B-group
agents I-group I-group
, O O
including O O
HUMIRA B-brand B-brand
, O O
may O O
also O O
result O O
i O O
n O O
similar O O
toxicities O O
. O O

Co-administration O O
of O O
aliskiren B-drug B-drug
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
lovastatin B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
valsartan B-drug B-drug
, O O
amlodipine B-drug B-drug
, O O
metformin B-drug B-drug
, O O
celecoxib B-drug B-drug
, O O
atenolol B-drug B-drug
, O O
atorvastatin B-drug B-drug
, O O
ramipril B-drug B-drug
or O O
hydrochlorothiazide B-drug B-drug
. O O

The O O
onset O O
of O O
neuromuscular O O
blockade O O
by O O
succinylcholine B-drug B-drug
was O O
unaffected O O
by O O
BREVIBLOC B-brand B-brand
, O O
but O O
the O O
duration O O
of O O
neuromuscular O O
blockade O O
was O O
prolonged O O
from O O
5 O O
minutes O O
to O O
8 O O
minutes O O
. O O

Therefore O O
, O O
patients O O
concurrently O O
taking O O
antiseizure O B-group
medication O I-group
and O O
Mefloquine B-drug B-drug
should O O
have O O
the O O
blood O O
level O O
of O O
their O O
antiseizure O B-group
medication O I-group
monitored O O
and O O
the O O
dosage O O
adjusted O O
appropriately O O
. O O

Therefore O O
, O O
drugs O O
that O O
affect O O
CYP3A4 O O
and/or O O
Pgp O O
, O O
may O O
modify O O
the O O
pharmacokinetics O O
of O O
saquinavir B-drug B-drug
. O O

There O O
is O O
no O O
clinical O O
experience O O
to O O
date O O
on O O
the O O
use O O
of O O
Femara B-brand B-brand
in O O
combination O O
with O O
other O O
anticancer O B-group
agents O I-group
. O O

Due O O
to O O
wide O O
interindividual O O
variability O O
in O O
the O O
dose O O
adjustment O O
required O O
, O O
it O O
is O O
recommended O O
that O O
cyclosporine B-drug B-drug
concentrations O O
be O O
monitored O O
closely O O
after O O
initiation O O
of O O
carvedilol B-drug B-drug
therapy O O
and O O
that O O
the O O
dose O O
of O O
cyclosporine B-drug B-drug
be O O
adjusted O O
as O O
appropriate O O
. O O

Patients O O
who O O
are O O
treated O O
with O O
ZYVOX B-brand B-brand
and O O
concomitant O O
serotonergic B-group B-group
agents I-group I-group
should O O
be O O
closely O O
observed O O
for O O
signs O O
and O O
symptoms O O
of O O
serotonin O O
syndrome O O
( O O
e.g. O O
, O O
cognitive O O
dysfunction O O
, O O
hyperpyrexia O O
, O O
hyperreflexia O O
, O O
incoordination O O
) O O
. O O

Misonidazole B-drug_n B-drug_n
protects O O
mouse O O
tumour O O
and O O
normal O O
tissues O O
from O O
the O O
toxicity O O
of O O
oral O O
CCNU B-drug B-drug
. O O

Serial O O
pharmacokinetic O O
dosing O O
has O O
been O O
proposed O O
as O O
a O O
method O O
to O O
accomplish O O
this O O
goal O O
. O O

clarithromycin I-drug B-drug
concentration O O

Among O O
494 O O
subjects O O
who O O
received O O
Angiomax B-brand B-brand
in O O
clinical O O
trials O O
and O O
were O O
tested O O
for O O
antibodies O O
, O O
2 O O
subjects O O
had O O
treatment-emergent O O
positive O O
bivalirudin B-drug O
antibody O O
tests O O
. O O

The O O
effect O O
of O O
theophylline B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
citalopram B-drug B-drug
was O O
not O O
evaluated O O
. O O

Safety O O
and O O
effectiveness O O
in O O
children O O
has O O
not O O
been O O
established O O
. O O

Except O O
in O O
life-threatening O O
situations O O
, O O
avoid O O
this O O
combination O O
. O O

Evoked O O
hind O O
limb O O
digital O O
extensor O O
tension O O
( O O
hoof O O
twitch O O
) O O
was O O
maintained O O
at O O
40 O O
% O O
of O O
baseline O O
for O O
1 O O
h O O
by O O
atracurium B-drug B-drug
infusion O O
in O O
7 O O
horses O O
anaesthetised O O
with O O
halothane B-drug B-drug
. O O

Ritonavir B-drug B-drug
- O O
Combined O O
administration O O
of O O
a O O
single O O
dose O O
of O O
ritonavir B-drug B-drug
( O O
600 O O
mg O O
) O O
, O O
both O O
a O O
CYP3A4 O O
substrate O O
and O O
a O O
potent O O
inhibitor O O
of O O
CYP3A4 O O
, O O
and O O
escitalopram B-drug B-drug
( O O
20 O O
mg O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
either O O
ritonavir B-drug B-drug
or O O
escitalopram B-drug B-drug
. O O

We O O
investigated O O
the O O
effects O O
of O O
adenosine O B-group
receptor O I-group
antagonists O I-group
, O O
caffeine B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
8-phenyltheophylline B-drug_n B-drug
, O O
and O O
8-cyclopentyl-1,3-dipropylxanthine B-drug_n B-drug
( O O
DPCPX B-drug_n B-brand
) O O
, O O
in O O
a O O
light/dark O O
test O O
in O O
mice O O
. O O

b-Adrenergic B-group B-group
Blocking I-group I-group
Agents I-group I-group
: O O
Actions O O
of O O
some O O
of O O
beta-blocking B-group B-group
agents I-group I-group
may O O
be O O
impaired O O
when O O
hypothyroid O O
patients O O
become O O
euthyroid O O
. O O

In O O
these O O
trials O O
, O O
heart O O
rate O O
and O O
systolic O O
blood O O
pressure O O
were O O
approximately O O
2-3 O O
bpm O O
and O O
6-8 O O
mm O O
Hg O O
higher O O
, O O
respectively O O
, O O
in O O
subjects O O
on O O
concomitant O O
theophylline B-drug B-drug
compared O O
with O O
the O O
overall O O
population O O
. O O

( O O
Both O O
drugs O O
were O O
thus O O
dosed O O
to O O
steady O O
state O O
. O O
) O O

Efavirenz B-drug B-drug

Concomitant O O
treatment O O
with O O
thrombolytics B-group B-group
( O O
eg O O
, O O
rt-PA O O
or O O
streptokinase B-drug O
) O O
may O O
: O O
- O O
increase O O
the O O
risk O O
of O O
bleeding O O
complications O O
- O O
considerably O O
enhance O O
the O O
effect O O
of O O
REFLUDAN B-brand B-brand
on O O
aPTT O O
prolongation O O

When O O
duloxetine B-drug B-drug
was O O
administered O O
( O O
at O O
a O O
dose O O
of O O
60 O O
mg O O
BID O O
) O O
in O O
conjunction O O
with O O
a O O
single O O
50-mg O O
dose O O
of O O
desipramine B-drug B-drug
, O O
a O O
CYP2D6 O O
substrate O O
, O O
the O O
AUC O O
of O O
desipramine B-drug B-drug
increased O O
3-fold O O
. O O

WARFARIN B-drug B-brand
: O O
Co- O O
administration O O
of O O
warfarin B-drug B-drug
and O O
cerivastatin B-drug B-drug
to O O
healthy O O
volunteers O O
did O O
not O O
result O O
in O O
any O O
changes O O
in O O
prothrombin O O
time O O
or O O
clotting O O
factor O O
VII O O
when O O
compared O O
to O O
co-administration O O
of O O
warfarin B-drug B-drug
and O O
placebo O O
. O O

It O O
would O O
be O O
expected O O
that O O
laxative B-group O
use O O
during O O
therapy O O
with O O
CAMPTOSAR B-brand B-brand
would O O
worsen O O
the O O
incidence O O
or O O
severity O O
of O O
diarrhea O O
, O O
but O O
this O O
has O O
not O O
been O O
studied O O
. O O

Pharmacokinetic O O
evaluation O O
of O O
the O O
digoxin-amiodarone B-drug B-drug
interaction O O
. O O

Increasing O O
the O O
indinavir B-drug B-drug
dose O O
to O O
1000 O O
mg O O
every O O
8 O O
hours O O
does O O
not O O
compensate O O
for O O
the O O
increased O O
indinavir B-drug B-drug
metabolism O O
due O O
to O O
SUSTIVA B-brand B-brand
. O O

Convulsions O O
have O O
been O O
reported O O
with O O
this O O
concurrent O O
use O O
. O O

The O O
effect O O
of O O
desflurane B-drug B-drug
on O O
the O O
disposition O O
of O O
other O O
drugs O O
has O O
not O O
been O O
determined O O
. O O

Hormonal O B-group
contraceptives B-group I-group
Co-administration O O
of O O
Trileptal B-brand B-brand
with O O
an O O
oral O O
contraceptive B-group B-group
has O O
been O O
shown O O
to O O
influence O O
the O O
plasma O O
concentrations O O
of O O
the O O
two O O
hormonal O O
components O O
, O O
ethinylestradiol B-drug B-drug
( O O
EE O O
) O O
and O O
levonorgestrel B-drug B-drug
( O O
LNG O O
) O O
. O O

RAPTIVA B-brand B-brand
should O O
not O O
be O O
used O O
with O O
other O O
immunosuppressive B-group B-group
drugs I-group I-group
. O O

In O O
5 O O
other O O
schizophrenic O O
patients O O
treated O O
with O O
oral O O
haloperidol B-drug B-drug
and O O
rifampin B-drug B-drug
, O O
discontinuation O O
of O O
rifampin B-drug B-drug
produced O O
a O O
mean O O
3.3-fold O O
increase O O
in O O
haloperidol B-drug B-drug
concentrations O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
glipizide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
loss O O
of O O
control O O
. O O

This O O
may O O
be O O
due O O
to O O
an O O
improved O O
glucose O O
utilization O O
with O O
simultaneous O O
reduction O O
in O O
insulin B-drug B-drug
requirement O O

Cyclopropane B-drug B-drug
or O O
halogenated B-group B-group
hydrocarbon I-group I-group
anesthetics I-group I-group
increase O O
cardiac O O
autonomic O O
irritability O O
and O O
may O O
sensitize O O
the O O
myocardium O O
to O O
the O O
action O O
of O O
certain O O
intravenously O O
administered O O
catecholamines B-group B-group
, O O
such O O
as O O
dopamine B-drug B-drug
. O O

Esomeprazole B-drug B-drug
may O O
potentially O O
interfere O O
with O O
CYP2C19 O O
, O O
the O O
major O O
esomeprazole B-drug B-drug
metabolizing O O
enzyme O O
. O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
may O O
inhibit O O
both O O
synthetic O O
and O O
catabolic O O
enzymes O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

* O O
This O O
table O O
is O O
not O O
all O O
inclusive O O
** O O
VIRACEPT B-brand B-brand
may O O
not O O
be O O
effective O O
due O O
to O O
decreased O O
nelfinavir B-drug B-drug
plasma O O
concentrations O O
in O O
patients O O
taking O O
these O O
agents O O
concomitantly O O

The O O
effects O O
of O O
allopurinol B-drug B-drug
on O O
didanosine B-drug B-drug
pharmacokinetics O O
in O O
subjects O O
with O O
normal O O
renal O O
function O O
are O O
not O O
known O O
. O O

Therefore O O
, O O
diphenoxylate B-drug B-drug
has O O
the O O
potential O O
to O O
prolong O O
the O O
biological O O
half-lives O O
of O O
drugs O O
for O O
which O O
the O O
rate O O
of O O
elimination O O
is O O
dependent O O
on O O
the O O
microsomal O O
drug O O
metabolizing O O
enzyme O O
system O O
. O O

Digoxin B-drug B-drug
- O O
In O O
subjects O O
who O O
had O O
received O O
21 O O
days O O
of O O
40 O O
mg/day O O
racemic O O
citalopram B-drug B-drug
, O O
combined O O
administration O O
of O O
citalopram B-drug B-drug
and O O
digoxin B-drug B-drug
( O O
single O O
dose O O
of O O
1 O O
mg O O
) O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
either O O
citalopram B-drug B-drug
or O O
digoxin B-drug B-drug
. O O

Valproic B-drug B-drug
Acid I-drug I-drug
: O O
The O O
mean O O
steady-state O O
trough O O
serum O O
valproic B-drug B-drug
acid I-drug I-drug
concentrations O O
prior O O
to O O
and O O
during O O
concomitant O O
gabapentin B-drug B-drug
administration O O
( O O
400 O O
mg O O
TID O O
; O O

Tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
to O O
blunt O O
the O O
hypotensive O O
effect O O
of O O
systemic O O
clonidine.It B-drug O
is O O
not O O
known O O
whether O O
the O O
concurrent O O
use O O
of O O
these O O
agents O O
with O O
ALPHAGAN B-brand B-brand
P I-brand O
in O O
humans O O
can O O
lead O O
to O O
resulting O O
interference O O
with O O
the O O
IOP O O
lowering O O
effect O O
. O O

DIAGNOSTIC O O
INTERFERENCE O O
With O O
expected O O
physiologic O O
effects O O
: O O
Blood O O
and O O
urine O O
glucose O O
levels O O
( O O
usually O O
only O O
in O O
patients O O
with O O
a O O
predisposition O O
for O O
glucose O O
intolerance O O
) O O
and O O
Serum O O
bilirubin O O
levels O O
( O O
by O O
displacement O O
from O O
albumin O O
binding O O
) O O
and O O
Serum O O
calcium O O
levels O O
( O O
thiazide B-group B-group
diuretics I-group I-group
should O O
be O O
discontinued O O
before O O
parathyroid-function O O
tests O O
are O O
carried O O
out O O
) O O
and O O
Serum O O
uric O O
acid O O
levels O O
( O O
may O O
be O O
increased O O
) O O
Serum O O
magnesium O B-drug
, O O
potassium O O
, O O
and O O
sodium O O
levels O O
( O O
may O O
be O O
decreased O O
; O O

Anastrozole B-drug B-drug
did O O
not O O
inhibit O O
P450 O O
2A6 O O
or O O
the O O
polymorphic O O
P450 O O
2D6 O O
in O O
human O O
liver O O
microsomes O O
. O O

In O O
addition O O
, O O
oxcarbazepine B-drug B-drug
and O O
MHD B-drug_n B-drug_n
induce O O
a O O
subgroup O O
of O O
the O O
cytochrome O O
P450 O O
3A O O
family O O
( O O
CYP3A4 O O
and O O
CYP3A5 O O
) O O
responsible O O
for O O
the O O
metabolism O O
of O O
dihydropyridine B-group B-group
calcium I-group I-group
antagonists I-group I-group
and O O
oral O O
contraceptives B-group B-group
, O O
resulting O O
in O O
a O O
lower O O
plasma O O
concentration O O
of O O
these O O
drugs O O
. O O

Gentamicin B-drug B-drug
did O O
not O O
interfere O O
with O O
the O O
activity O O
of O O
clindamycin B-drug B-drug
within O O
the O O
range O O
of O O
concentrations O O
tested O O
( O O
0.1 O O
to O O
100 O O
mug/ml O O
) O O
; O O

Plasma O O
concentrations O O
may O O
be O O
increased O O
by O O
CRIXIVAN B-brand B-brand
. O O

Intraventricular O O
injection O O
of O O
beta-endorphin B-drug_n B-drug_n
and O O
morphine B-drug B-drug
produced O O
an O O
inhibition O O
of O O
the O O
tail-flick O O
response O O
to O O
the O O
heat O O
stimulus O O
in O O
rats O O
. O O

Interaction O O
of O O
GABITRIL B-brand B-brand
with O O
Other O O
Drugs O O
: O O
Cimetidine B-drug B-drug
: O O
Co-administration O O
of O O
cimetidine B-drug B-drug
( O O
800 O O
mg/day O O
) O O
to O O
patients O O
taking O O
tiagabine B-drug B-drug
chronically O O
had O O
no O O
effect O O
on O O
tiagabine B-drug B-drug
pharmacokinetics O O
. O O

The O O
following O O
are O O
examples O O
of O O
substances O O
that O O
may O O
increase O O
the O O
blood-glucose-lowering O O
effect O O
and O O
susceptibility O O
to O O
hypoglycemia O O
: O O
oral O O
antidiabetic B-group B-group
products I-group I-group
, O O
ACE B-group B-group
inhibitors I-group I-group
, O O
disopyramide B-drug B-drug
, O O
fibrates B-group B-group
, O O
fluoxetine B-drug B-drug
, O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
, O O
propoxyphene B-drug B-drug
, O O
salicylates B-group B-group
, O O
somatostatin B-group B-group
analog I-group I-group
( O O
e.g. O O
, O O
octreotide B-drug B-drug
) O O
, O O
sulfonamide B-group B-group
antibiotics I-group I-group
. O O

However O O
, O O
the O O
pharmacodynamic O O
effect O O
increased O O
by O O
190 O O
% O O
( O O
QTc O O
increase O O
over O O
time O O
) O O
and O O
by O O
84 O O
% O O
( O O
Maximum O O
QTc O O
increase O O
) O O
. O O

Mutagenesis O O
PEGASYS B-brand B-brand
did O O
not O O
cause O O
DNA O O
damage O O
when O O
tested O O
in O O
the O O
Ames O O
bacterial O O
mutagenicity O O
assay O O
and O O
in O O
the O O
in O O
vitro O O
chromosomal O O
aberration O O
assay O O
in O O
human O O
lymphocytes O O
, O O
either O O
in O O
the O O
presence O O
or O O
absence O O
of O O
metabolic O O
activation O O
. O O

Ganciclovir B-drug B-drug
: O O
Administration O O
of O O
VIDEX B-brand B-brand
2 O O
hours O O
prior O O
to O O
or O O
concurrent O O
with O O
oral O O
ganciclovir B-drug B-drug
was O O
associated O O
with O O
a O O
111 O O
( O O
114 O O
) O O
% O O
increase O O
in O O
the O O
steady-state O O
AUC O O
of O O
didanosine B-drug B-drug
( O O
n O O
= O O
12 O O
) O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isoenzyme O O
, O O
including O O
many O O
antidepressants B-group B-group
( O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
, O O
and O O
others O O
) O O
, O O
may O O
inhibit O O
the O O
activity O O
of O O
this O O
isoenzyme O O
, O O
and O O
thus O O
may O O
make O O
normal O O
metab-olizers O O
resemble O O
poor O O
metabolizers O O
with O O
regard O O
to O O
concomitant O O
therapy O O
with O O
other O O
drugs O O
metabolized O O
by O O
this O O
enzyme O O
system O O
, O O
leading O O
to O O
drug O O
interactions O O
. O O

in O O
one O O
man O O
, O O
the O O
C O O
max O O
of O O
terfenadine B-drug B-drug
was O O
8.1 O O
ng/mL O O
with O O
terfenadine B-drug B-drug
alone O O
and O O
7.2 O O
ng/mL O O
with O O
terfenadine B-drug B-drug
plus O O
dirithromycin B-drug B-drug
. O O

The O O
mechanism O O
( O O
s O O
) O O
of O O
altered O O
topo O O
I O O
expression O O
in O O
certain O O
tumor O O
types O O
is O O
unknown O O
, O O
but O O
may O O
be O O
related O O
to O O
the O O
central O O
importance O O
of O O
topoisomerases O O
in O O
proliferating O O
cell O O
functions O O
( O O
transcription O O
, O O
replication O O
, O O
etc O O
. O O
) O O
, O O
and O O
the O O
aberrant O O
and O O
chronic O O
activation O O
of O O
these O O
functions O O
as O O
a O O
result O O
of O O
specific O O
tumorigenic O O
alterations O O
. O O

All O O
subjects O O
received O O
amprenavir B-drug B-drug
( O O
1,200 O O
mg O O
twice O O
a O O
day O O
) O O
for O O
4 O O
days O O
, O O
followed O O
by O O
a O O
7-day O O
washout O O
period O O
, O O
followed O O
by O O
either O O
rifabutin B-drug B-drug
( O O
300 O O
mg O O
once O O
a O O
day O O
[ O O
QD O O
] O O
) O O
( O O
cohort O O
1 O O
) O O
or O O
rifampin B-drug B-drug
( O O
600 O O
mg O O
QD O O
) O O
( O O
cohort O O
2 O O
) O O
for O O
14 O O
days O O
. O O

Prospective O O
, O O
long-term O O
studies O O
on O O
concomitant O O
administration O O
of O O
VIOXX B-brand B-brand
and O O
aspirin B-brand B-brand
have O O
not O O
been O O
conducted O O
. O O

therefore O O
, O O
it O O
is O O
theoretically O O
possible O O
that O O
lansoprazole B-drug B-drug
may O O
interfere O O
with O O
the O O
absorption O O
of O O
drugs O O
where O O
gastric O O
pH O O
is O O
an O O
important O O
determinant O O
of O O
bioavailability O O
( O O
e.g O O
. O O
ketoconazole B-drug B-drug
, O O
ampicillin B-drug B-drug
esters O I-drug
, O O
iron B-drug B-drug
salts O O
, O O
digoxin B-drug B-drug
) O O
. O O

Use O O
of O O
MAO B-group B-group
inhibitors I-group I-group
may O O
cause O O
an O O
excessive O O
increase O O
in O O
blood O O
pressure O O
and O O
heart O O
stimulation O O
. O O

Dosage O O
adjustment O O
of O O
STRATTERA B-brand B-brand
may O O
be O O
necessary O O
when O O
coadministered O O
with O O
CYP2D6 O O
inhibitors O O
, O O
e.g. O O
, O O
paroxetine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
and O O
quinidine B-drug B-drug
. O O

Data O O
from O O
a O O
randomized O O
trial O O
of O O
HEXALEN B-brand B-brand
and O O
cisplatin B-drug B-drug
plus O O
or O O
minus O O
pyridoxine B-drug B-drug
in O O
ovarian O O
cancer O O
indicated O O
that O O
pyridoxine B-drug B-drug
significantly O O
reduced O O
neurotoxicity O O
; O O

May O O
lead O O
to O O
loss O O
of O O
virologic O O
response O O
and O O
possible O O
resistance O O
to O O
CRIXIVAN B-brand B-brand
or O O
to O O
the O O
class O O
of O O
protease B-group B-group
inhibitors I-group I-group
. O O

Antineoplastic B-group B-group
agents I-group I-group
( O O
e. O O
g. O O
, O O
nitrogen B-drug B-drug
mustard I-drug I-drug
, O O
etc O O
. O O
) O O
should O O
be O O
given O O
concomitantly O O
only O O
with O O
great O O
caution O O
. O O

These O O
observations O O
suggest O O
that O O
exogenous O O
co-factors O O
could O O
be O O
involved O O
in O O
the O O
occurrence O O
of O O
ARE O O
. O O

bromelains B-drug B-group
; O O

Anticholinesterases B-group B-group
( O O
neostgmine O B-drug
, O O
physostigmine B-drug B-drug
) O O
, O O
lignocaine B-drug B-drug
, O O
quinine B-drug B-drug
, O O
procainamide B-drug B-drug
can O O
enhance O O
toxicity O O
and O O
cause O O
cardio O O
respiratory O O
depression O O
. O O

increased O O
norepinephrine-induced O O
platel O O
et O O
aggregation O O
; O O

Vardenafil B-drug B-drug

Binding O O
to O O
Serum O O
Proteins O O
: O O
The O O
following O O
agents O O
may O O
either O O
inhibit O O
levothyroxine B-drug B-drug
sodium I-drug I-drug
binding O O
to O O
serum O O
proteins O O
or O O
alter O O
the O O
concentrations O O
of O O
serum O O
binding O O
proteins O O
: O O
androgens B-group B-group
and O O
related O O
anabolic B-group B-group
hormones I-group I-group
, O O
asparaginase B-drug O
, O O
clofibrate B-drug B-drug
, O O
estrogens B-group B-group
and O O
estrogen-containing B-group B-group
compounds I-group I-group
, O O
5-fluorouracil B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
glucocorticoids B-group B-group
, O O
meclofenamic B-drug B-drug
acid I-drug I-drug
, O O
mefenamic B-drug B-drug
acid I-drug I-drug
, O O
methadone B-drug B-drug
, O O
perphenazine B-drug B-drug
, O O
phenylbutazone B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
salicylates B-group B-group
, O O
tamoxifen B-drug B-drug
. O O

Paroxetine B-drug B-drug
: O O
Coadministration O O
of O O
once O O
daily O O
doses O O
of O O
aprepitant B-drug B-drug
, O O
as O O
a O O
tablet O O
formulation O O
comparable O O
to O O
85 O O
mg O O
or O O
170 O O
mg O O
of O O
the O O
capsule O O
formulation O O
, O O
with O O
paroxetine B-drug B-drug
20 O O
mg O O
once O O
daily O O
, O O
resulted O O
in O O
a O O
decrease O O
in O O
AUC O O
by O O
approximately O O
25 O O
% O O
and O O
Cmax O O
, O O
by O O
approximately O O
20 O O
% O O
of O O
both O O
aprepitant B-drug B-drug
and O O
paroxetine B-drug B-drug
. O O

Sumatriptan B-drug B-drug
: O O
Sumatriptan B-drug B-drug
has O O
been O O
reported O O
to O O
cause O O
coronary O O
artery O O
vasospasm O O
, O O
and O O
its O O
effect O O
could O O
be O O
additive O O
with O O
D.H.E B-brand B-brand
. I-brand O
45 I-brand B-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
. O O

It O O
was O O
shown O O
that O O
neurotensin B-drug_n B-drug_n
antagonized O O
evidently O O
the O O
antinociceptive O O
effect O O
of O O
enkephalins B-drug_n B-group
and O O
their O O
analogue O O
. O O

If O O
signs O O
and O O
symptoms O O
suggestive O O
of O O
digoxin B-drug B-drug
toxicity O O
occur O O
when O O
enoxacin B-drug B-drug
and O O
digoxin B-drug B-drug
are O O
given O O
concomitantly O O
, O O
physicians O O
are O O
advised O O
to O O
obtain O O
serum O O
digoxin B-drug B-drug
levels O O
and O O
adjust O O
digoxin B-drug B-drug
doses O O
appropriately O O
. O O

Antidiabetic B-group B-group
drugs I-group I-group
( O O
oral O O
agents O O
and O O
insulin B-drug B-drug
) O O
: O O
hypoglycemia O O
or O O
hyperglycemia O O
; O O

The O O
effect O O
of O O
rifampin B-drug B-drug
on O O
the O O
warfarin B-drug B-drug
requirement O O
of O O
our O O
patient O O
appeared O O
to O O
be O O
maximal O O
5 O O
to O O
7 O O
days O O
after O O
the O O
initiation O O
of O O
rifampin B-drug B-drug
and O O
extended O O
a O O
similar O O
length O O
of O O
time O O
after O O
rifampin B-drug B-drug
withdrawal O O
. O O

The O O
ratio O O
between O O
the O O
liver O O
weight O O
and O O
body O O
weight O O
was O O
found O O
to O O
be O O
lower O O
in O O
the O O
treated O O
animals O O
than O O
in O O
the O O
control O O
group O O
. O O

Other O O
Potentially O O
Clinically O O
Significant O O
Drug O O
or O O
Herbal O O
Product O O
Interactions O O
With O O
SUSTIVAb O B-brand

With O O
oral O O
dapsone B-drug B-drug
treatment O O
, O O
folic B-group B-group
acid I-group I-group
antagonists I-group I-group
such O O
as O O
pyrimethamine B-drug B-drug
have O O
been O O
noted O O
to O O
possibly O O
increase O O
the O O
likelihood O O
of O O
hematologic O O
reactions O O

Ketoconazole B-drug B-drug
increased O O
mean O O
alosetron B-drug B-drug
plasma O O
concentrations O O
( O O
AUC O O
) O O
by O O
29 O O
% O O
. O O

Although O O
the O O
specific O O
drug O O
interaction O O
was O O
not O O
studied O O
in O O
a O O
clinical O O
trial O O
, O O
there O O
have O O
been O O
more O O
than O O
50 O O
episodes O O
of O O
concomitant O O
use O O
of O O
antifibrinolytic O B-group
therapies O I-group
( O O
i.e. O O
, O O
tranexamic B-drug B-drug
acid I-drug I-drug
, O O
aminocaproic B-drug B-drug
acid I-drug I-drug
) O O
and O O
NovoSeven B-brand B-brand
. O O

Urinary O O
excretion O O
and O O
renal O O
clearance O O
were O O
correspondingly O O
reduced O O
. O O

During O O
transfer O O
to O O
oral O O
amiodarone B-drug B-drug
, O O
the O O
dose O O
levels O O
of O O
previously O O
administered O O
agents O O
should O O
be O O
reduced O O
by O O
30 O O
to O O
50 O O
% O O
several O O
days O O
after O O
the O O
addition O O
of O O
oral O O
amiodarone B-drug B-drug
. O O

Ketoconazole B-drug B-drug
: O O
Coadministration O O
of O O
ketoconazole B-drug B-drug
( O O
200 O O
mg/day O O
for O O
14 O O
days O O
) O O
with O O
a O O
15-mg O O
single O O
dose O O
of O O
aripiprazole B-drug B-drug
increased O O
the O O
AUC O O
of O O
aripiprazole B-drug B-drug
and O O
its O O
active O O
metabolite O O
by O O
63 O O
% O O
and O O
77 O O
% O O
, O O
respectively O O
. O O

Survanta B-brand B-brand
also O O
increased O O
rate O O
of O O
dissolution O O
, O O
in O O
a O O
manner O O
similar O O
to O O
sodium B-drug_n B-drug
dodecyl I-drug_n I-drug
sulfate I-drug_n I-drug
. O O

Since O O
drowsiness O O
may O O
occur O O
with O O
use O O
of O O
this O O
drug O O
, O O
patients O O
should O O
be O O
warned O O
of O O
this O O
possibility O O
and O O
cautioned O O
against O O
driving O O
a O O
car O O
or O O
operating O O
dangerous O O
machinery O O
while O O
taking O O
Atarax B-brand B-brand
. O O

Dolasetron B-drug B-drug
mesylate I-drug I-drug
did O O
not O O
inhibit O O
the O O
antitumor O O
activity O O
of O O
four O O
chemotherapeutic B-group B-group
agents I-group I-group
( O O
cisplatin B-drug B-drug
, O O
5-fluorouracil B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
cyclophosphamide B-drug B-drug
) O O
in O O
four O O
murine O O
models O O
. O O

Bisphosphonates B-group B-group
are O O
known O O
to O O
interfere O O
with O O
the O O
use O O
of O O
bone-imaging O B-group
agents O I-group
. O O

An O O
additive O O
hypotensive O O
effect O O
has O O
been O O
reported O O
with O O
the O O
combination O O
of O O
systemic O O
clonidine B-drug B-drug
and O O
neuroleptic B-group O
therapy O O
. O O

Nizatidine B-drug B-drug
does O O
not O O
inhibit O O
the O O
cytochrome O O
P-450-linked O O
drug-metabolizing O O
enzyme O O
system O O
; O O

Aspirin B-brand B-brand
should O O
be O O
used O O
cautiously O O
in O O
conjunction O O
with O O
cortico-steroids B-group B-group
in O O
patients O O
suffering O O
from O O
hypopro-thrombinemia O O
. O O

RATIONALE O O
: O O
Stress O O
and O O
glucocorticoids B-group B-group
facilitate O O
and O O
reinstate O O
psychostimulant O B-drug
self-administration O O
in O O
rodents O O
. O O

Methotrexate B-drug B-drug
: O O
NSAIDs B-group B-group
have O O
been O O
reported O O
to O O
competitively O O
inhibit O O
methotrexate B-drug B-drug
accumulation O O
in O O
rabbit O O
kidney O O
slices O O
. O O

However O O
, O O
co-administration O O
of O O
Duloxetine B-drug B-drug
with O O
aluminum- B-drug B-drug
and O O
magnesium-containing B-drug B-drug
antacids B-group B-group
( O O
51 O O
mEq O O
) O O
or O O
Duloxetine B-drug B-drug
with O O
famotidine B-drug B-drug
, O O
had O O
no O O
significant O O
effect O O
on O O
the O O
rate O O
or O O
extent O O
of O O
duloxetine B-drug B-drug
absorption O O
after O O
administration O O
of O O
a O O
40-mg O O
oral O O
dose O O
. O O

It O O
is O O
indicated O O
that O O
the O O
first O O
and O O
second O O
contractile O O
responses O O
to O O
PTX B-drug_n B-drug_n
have O O
entirely O O
different O O
properties O O
. O O

Dopamine O B-drug
( O O
DA O O
) O O
levels O O
did O O
not O O
differ O O
significantly O O
in O O
either O O
striatum O O
( O O
STR O O
) O O
or O O
nucleus O O
accumbens O O
( O O
NAC O O
) O O
for O O
the O O
cocaine-treated B-drug B-drug
animals O O
to O O
their O O
corresponding O O
saline-treated O O
controls O O
. O O

Other O O
: O O
Coadministration O O
of O O
grapefruit O O
juice O O
with O O
cisapride B-drug B-drug
increases O O
the O O
bioavailability O O
of O O
cisapride B-drug B-drug
and O O
concomitant O O
use O O
should O O
be O O
avoided O O
. O O

ACE B-group B-group
inhibitors I-group I-group
: O O
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
Angiotensin B-group B-group
Converting I-group I-group
Enzyme I-group I-group
( I-group I-group
ACE I-group I-group
) I-group I-group
inhibitors I-group I-group
. O O

Similarly O O
, O O
the O O
acute O O
toxicity O O
was O O
also O O
diminished O O
by O O
a O O
DMF O O
of O O
0.74 O O
. O O

Therefore O O
, O O
careful O O
monitoring O O
of O O
blood O O
glucose O O
is O O
recommended O O
when O O
these O O
agents O O
are O O
coadministered O O
. O O

Drug-drug O O
interactions O O
In O O
vitro O O
studies O O
using O O
human O O
liver O O
microsomes O O
indicate O O
that O O
fenofibrate B-drug B-drug
and O O
fenofibric B-drug_n B-drug
acid I-drug_n I-drug
are O O
not O O
inhibitors O O
of O O
cytochrome O O
( O O
CYP O O
) O O
P450 O O
isoforms O O
CYP3A4 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
or O O
CYP1A2 O O
. O O

Drugs O O
that O O
may O O
have O O
their O O
plasma O O
concentration O O
altered O O
by O O
dasatinib B-drug B-drug
CYP3A4 O O
Substrates O O
: O O
Dasatinib B-drug B-drug
is O O
a O O
time-dependent O O
inhibitor O O
of O O
CYP3A4 O O
. O O

Evidence O O
for O O
reduction O O
of O O
norepinephrine B-drug B-drug
uptake O O
sites O O
in O O
the O O
failing O O
human O O
heart O O
. O O

metabolizers O O
. O O

The O O
effects O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
on O O
clonidines B-drug B-group
analgesic O I-group
actions O O
are O O
not O O
known O O
. O O

All O O
subjects O O
received O O
glipizide B-drug B-drug
alone O O
and O O
following O O
treatment O O
with O O
100 O O
mg O O
of O O
fluconazole B-drug B-drug
as O O
a O O
single O O
daily O O
oral O O
dose O O
for O O
seven O O
days O O
. O O

Therefore O O
FORADIL B-brand B-brand
should O O
not O O
be O O
given O O
together O O
with O O
-adrenergic O B-group
blockers O I-group
( O O
including O O
eye O O
drops O O
) O O
unless O O
there O O
are O O
compelling O O
reasons O O
for O O
their O O
use O O
. O O

In O O
addition O O
, O O
deaths O O
have O O
been O O
reported O O
rarely O O
with O O
concomitant O O
administration O O
of O O
terfenadine B-drug B-drug
and O O
erythromycin B-drug B-drug
. O O

It O O
reduced O O
the O O
number O O
of O O
deaths O O
induced O O
by O O
nonlethal O O
( O O
2 O O
mg/kg O O
) O O
dose O O
of O O
endotoxin B-drug_n B-drug_n
but O O
increased O O
the O O
number O O
of O O
deaths O O
induced O O
by O O
a O O
highly O O
lethal O O
dose O O
( O O
8 O O
mg/kg O O
) O O
. O O

and O O
phase O O
3 O O
( O O
days O O
45-52 O O
) O O
: O O
cisapride B-drug B-drug
10 O O
mg O O
4 O O
times/day O O
( O O
days O O
45-51 O O
) O O
plus O O
fluoxetine B-drug B-drug
20 O O
mg/day O O
( O O
days O O
45-52 O O
) O O
. O O

Digoxin B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
tiagabine B-drug B-drug
did O O
not O O
affect O O
the O O
steady-state O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
or O O
the O O
mean O O
daily O O
trough O O
serum O O
level O O
of O O
digoxin B-drug B-drug
. O O

No O O
dose O O
relationship O O
has O O
been O O
observed O O
. O O

Acetazolamide B-drug B-drug
may O O
prevent O O
the O O
urinary O O
antiseptic O O
effect O O
of O O
methenamine B-drug B-drug
. O O

When O O
administered O O
concurrently O O
, O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
amphotericin B-drug B-drug
B I-drug I-drug
: O O
Antineoplastic B-group B-group
agents I-group I-group
: O O
may O O
enhance O O
the O O
potential O O
for O O
renal O O
toxicity O O
, O O
bronchospasm O O
and O O
hypotension O O
. O O

The O O
last O O
4 O O
chapters O O
cover O O
interactions O O
with O O
drugs O O
and O O
laboratory O O
tests O O
, O O
common O O
side O O
effects O O
, O O
breast O O
feeding O O
, O O
and O O
effective O O
use O O
of O O
POCs B-group B-group
. O O

Patients O O
who O O
have O O
previously O O
received O O
pelvic/ O O
abdominal O O
irradiation O O
are O O
at O O
increased O O
risk O O
of O O
severe O O
myelosuppression O O
following O O
the O O
administration O O
of O O
CAMPTOSAR B-brand B-brand
. O O

Five O O
days O O
of O O
dofetilide B-drug B-drug
treatment O O
did O O
not O O
significantly O O
affect O O
steady-state O O
pharmacokinetic O O
variables O O
of O O
digoxin B-drug B-drug
compared O O
with O O
placebo O O
; O O

For O O
patients O O
with O O
advanced O O
HIV O O
disease O O
and O O
poor-risk O O
AIDS-related O O
Kaposi O O
s O O
sarcoma O O
, O O
TAXOL B-brand B-brand
, O O
at O O
the O O
recommended O O
dose O O
for O O
this O O
disease O O
, O O
can O O
be O O
initiated O O
and O O
repeated O O
if O O
the O O
neutrophil O O
count O O
is O O
at O O
least O O
1000 O O
cells/mm3 O O
. O O

If O O
co-administration O O
is O O
essential O O
, O O
close O O
monitoring O O
may O O
be O O
appropriate O O
. O O

These O O
results O O
suggest O O
that O O
the O O
analgesic O O
effect O O
of O O
STADOL B-brand B-brand
NS I-brand I-brand
may O O
be O O
diminished O O
when O O
it O O
is O O
administered O O
shortly O O
after O O
sumatriptan B-drug B-drug
nasal O I-drug
spray O O
, O O
but O O
by O O
30 O O
minutes O O
any O O
such O O
reduction O O
in O O
effect O O
should O O
be O O
minimal O O
. O O

Clinical O O
significance O O
of O O
reduced O O
efavirenz B-drug B-drug
concentrations O O
unknown O O
. O O

Acetylsalicylic B-drug B-drug
acid I-drug I-drug
did O O
not O O
alter O O
the O O
clearance O O
( O O
pharmacokinetics O O
) O O
of O O
iloprost B-drug B-drug
. O O

Anticoagulants B-group B-group
predispose O O
a O O
patient O O
to O O
bleeding O O
problems O O
. O O

Review O O
of O O
these O O
case O O
reports O O
indicates O O
that O O
the O O
patients O O
were O O
mainly O O
receiving O O
thiazide B-group B-group
diuretics I-group I-group
for O O
hypertension O O
and O O
that O O
tests O O
to O O
rule O O
out O O
decreased O O
renal O O
function O O
secondary O O
to O O
hypertensive O O
nephropathy O O
were O O
not O O
often O O
performed O O
. O O

Inhibitors O O
of O O
CYP1A2 O O
: O O
Concomitant O O
use O O
of O O
duloxetine B-drug B-drug
with O O
fluvoxamine B-drug B-drug
, O O
an O O
inhibitor O O
of O O
CYP1A2 O O
, O O
results O O
in O O
approximately O O
a O O
6-fold O O
increase O O
in O O
AUC O O
and O O
about O O
a O O
2.5-fold O O
increase O O
in O O
Cmax O O
of O O
duloxetine B-drug B-drug
. O O

Benzodiazepines B-group B-group
were O O
administered O O
to O O
mice O O
30 O O
min O O
before O O
applying O O
the O O
analgesic B-group B-group
drugs I-group I-group
. O O

We O O
previously O O
reported O O
that O O
seeds O O
of O O
Artocarpus O O
integrifolia O O
( O O
jackfruit O O
) O O
contain O O
a O O
lectin O O
, O O
which O O
we O O
call O O
jacalin B-drug_n B-drug_n
, O O
that O O
is O O
both O O
a O O
potent O O
T O O
cell O O
mitogen O O
and O O
an O O
apparently O O
T O O
cell-independent O O
activator O O
of O O
human O O
B O O
cells O O
for O O
the O O
secretion O O
of O O
immunoglobulins O B-group
. O O

Thus O O
in O O
order O O
to O O
avoid O O
bleeding O O
, O O
reduced O O
dosage O O
of O O
heparin B-drug B-drug
is O O
recommended O O
during O O
treatment O O
with O O
antithrombin B-drug B-drug
III I-drug I-drug
( O O
human O O
) O O
. O O

Phosphate-Binding O O
Agents O O
: O O
Since O O
vitamin B-group B-group
D I-group I-group
also O O
has O O
an O O
effect O O
on O O
phosphate O O
transport O O
in O O
the O O
intestine O O
, O O
kidneys O O
and O O
bones O O
, O O
the O O
dosage O O
of O O
phosphate-binding O O
agents O O
must O O
be O O
adjusted O O
in O O
accordance O O
with O O
the O O
serum O O
phosphate O O
concentration O O
. O O

Limited O O
clinical O O
experience O O
indicates O O
that O O
requirements O O
for O O
volatile B-group O
inhalation I-group O
anesthetics I-group B-group
are O O
reduced O O
by O O
30 O O
to O O
50 O O
% O O
for O O
the O O
first O O
sixty O O
( O O
60 O O
) O O
minutes O O
following O O
ALFENTA B-brand B-brand
induction O O
The O O
concomitant O O
use O O
of O O
erythromycin B-drug B-drug
with O O
ALFENTA B-brand B-brand
can O O
significantly O O
inhibit O O
ALFENTA B-brand B-brand
clearance O O
and O O
may O O
increase O O
the O O
risk O O
of O O
prolonged O O
or O O
delayed O O
respiratory O O
depression O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unknown O O
. O O

When O O
paroxetine B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
CYP2D6 O O
, O O
was O O
co-administered O O
with O O
BROVANA B-brand B-brand
at O O
steady-state O O
, O O
exposure O O
to O O
either O O
drug O O
was O O
not O O
altered O O
. O O

This O O
effect O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
by O O
ibuprofen B-drug B-drug
. O O

While O O
additional O O
research O O
is O O
needed O O
, O O
the O O
initial O O
clinical O O
data O O
in O O
kidney O O
recipients O O
suggest O O
that O O
sirolimus B-drug B-drug
, O O
in O O
combination O O
with O O
cyclosporine B-drug B-drug
or O O
tacrolimus B-drug B-drug
, O O
might O O
have O O
the O O
potential O O
to O O
reduce O O
the O O
frequency O O
of O O
rejection O O
episodes O O
, O O
permit O O
reductions O O
in O O
cyclosporine B-drug B-drug
or O O
tacrolimus B-drug B-drug
dosage O O
, O O
and O O
permit O O
steroid O B-group
withdrawal O O
( O O
Kelly O O
, O O
1999 O O
) O O
. O O

The O O
findings O O
of O O
these O O
studies O O
are O O
summarized O O
in O O
the O O
following O O
table O O
: O O
Effects O O
on O O
steady-state O O
fexofenadine B-drug B-drug
pharmacokinetics O O
after O O
7 O O
days O O
of O O
co-administration O O
with O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
120 O O
mg O O
every O O
12 O O
hours O O
( O O
two O O
times O O
the O O
recommended O O
twice O O
daily O O
dose O O
) O O
in O O
healthy O O
volunteers O O
( O O
n=24 O O
) O O

Apraclonidine B-drug B-drug
should O O
not O O
be O O
used O O
in O O
patients O O
receiving O O
MAO B-group B-group
inhibitors.. O I-group

Corticosteroids B-group B-group
: O O
A O O
relationship O O
of O O
functional O O
antagonism O O
exists O O
between O O
vitamin B-group B-group
D I-group I-group
analogues O I-group
, O O
which O O
promote O O
calcium O O
absorption O O
, O O
and O O
corticosteroids B-group B-group
, O O
which O O
inhibit O O
calcium O O
absorption O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
ZEVALIN B-brand B-brand
. O O

In O O
patients O O
receiving O O
nonselective O B-group
monoamine B-group I-group
oxidase I-group I-group
inhibitors I-group I-group
( O O
MAOIs B-group B-group
) O O
( O O
e.g. O O
, O O
selegiline B-drug B-drug
hydrochloride I-drug I-drug
) O O
in O O
combination O O
with O O
serotoninergic B-group B-group
agents I-group I-group
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
venlafaxine B-drug B-drug
) O O
, O O
there O O
have O O
been O O
reports O O
of O O
serious O O
, O O
sometimes O O
fatal O O
, O O
reactions O O
. O O

In O O
a O O
first O O
experiment O O
, O O
male O O
adult O O
Wistar O O
rats O O
were O O
fasted O O
for O O
12 O O
h O O
. O O

In O O
a O O
study O O
with O O
concomitant O O
administration O O
of O O
aspirin B-brand B-brand
and O O
fosinopril B-drug B-drug
sodium I-drug I-drug
, O O
the O O
bioavailability O O
of O O
unbound O O
fosinoprilat B-drug_n B-drug
was O O
not O O
altered O O
. O O

The O O
toxicity O O
of O O
cadmium O O
, O O
zinc B-drug B-drug
and O O
cadmium/zinc O O
mixtures O O
at O O
concentrations O O
ranging O O
from O O
1000 O O
to O O
50000 O O
microg/l O O
were O O
investigated O O
against O O
cercariae O O
and O O
metacercariae O O
of O O
Parorchis O O
acanthus O O
obtained O O
from O O
the O O
dog O O
whelk O O
Nucella O O
lapillus O O
. O O

The O O
emerging O O
roles O O
of O O
non-nucleoside B-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitors I-group I-group
in O O
antiretroviral B-group B-group
therapy O O
. O O

The O O
safety O O
and O O
efficacy O O
of O O
anakinra B-drug B-drug
used O O
in O O
combination O O
with O O
HUMIRA B-brand B-brand
has O O
not O O
been O O
studied O O
. O O

Both O O
ibogaine B-drug_n B-drug_n
and O O
18-MC B-drug_n B-drug_n
ameliorate O O
opioid B-group O
withdrawal O O
signs O O
. O O

Rofecoxib B-drug B-drug
did O O
not O O
influence O O
the O O
plasma O O
pharmacokinetics O O
or O O
renal O O
elimination O O
of O O
a O O
single O O
oral O O
dose O O
of O O
digoxin B-drug B-drug
. O O

Resting O O
membrane O O
potential O O
, O O
input O O
impedance O O
and O O
the O O
proportion O O
of O O
neurons O O
displaying O O
transient O O
outward O O
rectification O O
were O O
each O O
significantly O O
altered O O
for O O
neurons O O
recorded O O
with O O
1 O O
% O O
but O O
not O O
0.05-0.2 O O
% O O
biocytin O O
. O O

Anticholinergic B-group B-group
drugs I-group I-group
may O O
antagonize O O
the O O
effects O O
of O O
the O O
drugs O O
that O O
alter O O
gastrointestinal O O
motility O O
, O O
such O O
as O O
metoclopramide B-drug B-drug
. O O

In O O
clinical O O
trials O O
, O O
FLOLAN B-brand B-brand
was O O
used O O
with O O
digoxin B-drug B-drug
, O O
diuretics B-group B-group
, O O
anticoagulants B-group B-group
, O O
oral O O
vasodilators B-group B-group
, O O
and O O
supplemental O O
oxygen.In B-drug B-drug
a O O
pharmacokinetic O O
substudy O O
in O O
patients O O
with O O
congestive O O
heart O O
failure O O
receiving O O
furosemide B-drug B-drug
or O O
digoxin B-drug B-drug
in O O
whom O O
therapy O O
with O O
FLOLAN B-brand B-brand
was O O
initiated O O
, O O
apparent O O
oral O O
clearance O O
values O O
for O O
furosemide B-drug B-drug
( O O
n O O
= O O
23 O O
) O O
and O O
digoxin B-drug B-drug
( O O
n O O
= O O
30 O O
) O O
were O O
decreased O O
by O O
13 O O
% O O
and O O
15 O O
% O O
, O O
respectively O O
, O O
on O O
the O O
second O O
day O O
of O O
therapy O O
and O O
had O O
returned O O
to O O
baseline O O
values O O
by O O
day O O
87 O O
. O O

The O O
changes O O
in O O
plasma O O
levels O O
were O O
within O O
the O O
range O O
of O O
plasma O O
levels O O
achieved O O
in O O
adequate O O
and O O
well-controlled O O
clinical O O
trials O O
. O O

. O O

In O O
an O O
uncontrolled O O
study O O
of O O
over O O
200 O O
patients O O
with O O
congestive O O
heart O O
failure O O
during O O
which O O
digoxin B-drug B-drug
blood O O
levels O O
were O O
not O O
measured O O
, O O
digitalis O B-group
toxicity O O
was O O
not O O
observed O O
. O O

Cyclophosphamide B-drug B-drug
used O O
concurrently O O
with O O
Cerubidine B-brand B-brand
may O O
also O O
result O O
in O O
increased O O
cardiotoxicity O O
. O O

Naproxen B-drug B-drug
: O O
The O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
naproxen B-drug B-drug
in O O
normal O O
volunteers O O
had O O
no O O
effect O O
on O O
the O O
plasma O O
levels O O
of O O
naproxen B-drug B-drug
, O O
but O O
significantly O O
decreased O O
the O O
urinary O O
excretion O O
of O O
naproxen B-drug B-drug
and O O
its O O
glucuronide O B-drug
metabolite O O
. O O

Drug O O
Class O O
: O O
Drug O O
Name O O
Clinical O O
Comment O O

phenobarbital B-drug B-drug
reduced O O
it O O
by O O
a O O
net O O
change O O
of O O
6.6 O O
% O O
( O O
percentage O O
increase O O
in O O
FDF O O
, O O
8.5 O O
% O O
) O O
at O O
431 O O
micromol/L O O
. O O

No O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
occurred O O
when O O
PRINIVIL B-brand B-brand
was O O
used O O
concomitantly O O
with O O
propranolol B-drug B-drug
or O O
hydrochlorothiazide B-drug B-drug
. O O

Experience O O
with O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
suggests O O
the O O
potential O O
for O O
interactions O O
with O O
furosemide B-drug B-drug
and O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
administration O O
of O O
cefepime B-drug B-drug
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
when O O
using O O
Clinitest O O
tablets O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
random O O
observations O O
, O O
have O O
shown O O
that O O
ibuprofen B-drug B-drug
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

Aminoglutethimide B-drug B-drug
diminishes O O
the O O
effect O O
of O O
coumarin B-group B-group
and O O
warfarin B-drug B-drug
. O O

There O O
was O O
no O O
effect O O
of O O
ZEBETA B-brand B-brand
on O O
prothrombin O O
time O O
in O O
patients O O
on O O
stable O O
doses O O
of O O
warfarin B-drug B-drug
. O O

To O O
avoid O O
potentiation O O
, O O
the O O
physician O O
wishing O O
to O O
terminate O O
treatment O O
with O O
Isocarboxazid B-drug B-drug
and O O
begin O O
therapy O O
with O O
another O O
agent O O
should O O
allow O O
for O O
an O O
interval O O
of O O
10 O O
days O O
. O O

Studies O O
in O O
healthy O O
volunteers O O
have O O
shown O O
that O O
Acarbose B-drug B-drug
has O O
no O O
effect O O
on O O
either O O
the O O
pharmacokinetics O O
or O O
pharmacodynamics O O
of O O
digoxin B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
or O O
ranitidine B-drug B-drug
. O O

CONCLUSIONS O O
: O O
Sildenafil B-drug B-drug
is O O
an O O
effective O O
first-line O O
therapy O O
for O O
erectile O O
dysfunction O O
in O O
men O O
. O O

Monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
such O O
as O O
isocarboxazid B-drug B-drug
( O O
e.g. O O
, O O
Marplan B-brand B-brand
) O O
, O O
phenelzine B-drug B-drug
( O O
e.g. O O
, O O
Nardil B-brand B-brand
) O O
, O O
procarbazine B-drug B-drug
( O O
e.g. O O
, O O
Matulane B-brand B-brand
) O O
, O O
selegiline B-drug B-drug
( O O
e.g. O O
, O O
Eldepryl B-brand B-brand
) O O
, O O
and O O
tranylcypromine B-drug B-drug
( O O
e.g. O O
, O O
Parnate B-brand B-brand
) O O
: O O
Using O O
these O O
medicines O O
with O O
L-tryptophan B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
other O O
drugs O O
is O O
withdrawn O O
from O O
co-therapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-drug B-group
antidepressant I-drug I-group
may O O
be O O
required O O
. O O

These O O
in O O
vitro O O
studies O O
suggest O O
that O O
concomitant O O
administration O O
of O O
zalcitabine B-drug B-drug
and O O
lamivudine B-drug B-drug
in O O
humans O O
may O O
result O O
in O O
sub-therapeutic O O
concentrations O O
of O O
active O O
phosphorylated O O
zalcitabine B-drug B-drug
, O O
which O O
may O O
lead O O
to O O
a O O
decreased O O
antiretroviral B-group O
effect O O
of O O
zalcitabine B-drug B-drug
. O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
prolonged O O
or O O
increased O O
sedation O O
or O O
respiratory O O
depression O O
. O O

Pancreatic O O
content O O
after O O
perfusion O O
did O O
not O O
correlate O O
with O O
release O O
during O O
perfusion O O
. O O

Patients/Guardians O O
should O O
be O O
given O O
the O O
following O O
information O O
: O O
i O O
. O O

Epidemiological O O
studies O O
of O O
the O O
case-control O O
and O O
cohort O O
design O O
that O O
have O O
demonstrated O O
an O O
association O O
between O O
use O O
of O O
psychotropic B-group B-group
drugs I-group I-group
that O O
interfere O O
with O O
serotonin O O
reuptake O O
and O O
the O O
occurrence O O
of O O
upper O O
gastrointestinal O O
bleeding O O
have O O
also O O
shown O O
that O O
concurrent O O
use O O
of O O
an O O
NSAID B-group B-group
or O O
aspirin B-brand B-brand
potentiated O O
the O O
risk O O
of O O
bleeding O O
. O O

Carbamazepine B-drug B-drug

Plasma O O
concentrations O O
( O O
AUC O O
0-24 O O
hrs O O
) O O
of O O
erythromycin B-drug B-drug
decreased O O
15 O O
% O O
with O O
coadministration O O
of O O
loratadine B-drug B-drug
relative O O
to O O
that O O
observed O O
with O O
erythromycin B-drug B-drug
alone O O
. O O

Relative O O
to O O
the O O
general O O
population O O
, O O
plasma O O
concentrations O O
of O O
fluvastatin B-drug B-drug
do O O
not O O
vary O O
as O O
a O O
function O O
of O O
either O O
age O O
or O O
gender O O
. O O

Patients O O
who O O
are O O
applying O O
Panretin B-brand B-brand
gel O O
should O O
not O O
concurrently O O
use O O
products O O
that O O
contain O O
DEET B-drug B-drug
( O O
N O O
, O O
N-diethyl-m-toluamide B-drug B-drug_n
) O O
, O O
a O O
common O O
component O O
of O O
insect O O
repellent O O
products O O
. O O

- O O
Alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
or O O
narcotics B-group B-group
: O O
Potentiation O O
of O O
otthostatic O O
hypotension O O
may O O
occur O O

The O O
concomitant O O
use O O
of O O
alcohol B-drug B-drug
or O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
may O O
have O O
an O O
additive O O
effect O O
. O O

Fluconazole B-drug B-drug

Therefore O O
, O O
serum O O
levels O O
of O O
methotrexate B-drug B-drug
should O O
be O O
monitored O O
in O O
patients O O
to O O
avoid O O
drug O O
toxicity O O
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
such O O
agents O O
is O O
indicated O O
, O O
they O O
should O O
be O O
given O O
with O O
caution O O
, O O
and O O
the O O
patients O O
serum O O
potassium O O
should O O
be O O
monitored O O
frequently O O
. O O

Nelfinavir B-drug B-drug

The O O
results O O
generated O O
to O O
date O O
in O O
clinical O O
pharmacokinetic O O
studies O O
with O O
fluvastatin B-drug B-drug
thus O O
support O O
its O O
use O O
in O O
a O O
broad O O
population O O
of O O
hypercholesterolaemic O O
patients O O
. O O

Ritonavir B-drug B-drug
significantly O O
prolonged O O
the O O
half-life O O
of O O
vardenafil B-drug B-drug
to O O
26 O O
hours O O
. O O

In O O
separate O O
studies O O
of O O
patients O O
receiving O O
maintenance O O
doses O O
of O O
warfarin B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
or O O
digoxin B-drug B-drug
, O O
irbesartan B-drug B-drug
administration O O
for O O
7 O O
days O O
had O O
no O O
effect O O
on O O
the O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
( O O
prothrombin O O
time O O
) O O
or O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
oxyphenbutazone B-drug B-drug
and O O
androgens B-group B-group
may O O
result O O
in O O
elevated O O
serum O O
levels O O
of O O
oxyphenbutazone B-drug B-drug
. O O

Potentiation O O
occurs O O
with O O
ganglionic O B-drug
or O O
peripheral B-group B-group
adrenergic I-group I-group
blocking I-group I-group
drugs I-group I-group
. O O

The O O
metabolism O O
of O O
saquinavir B-drug B-drug
is O O
mediated O O
by O O
cytochrome O O
P450 O O
, O O
with O O
the O O
specific O O
isoenzyme O O
CYP3A4 O O
responsible O O
for O O
90 O O
% O O
of O O
the O O
hepatic O O
metabolism O O
. O O

Inhibitors O O
of O O
CYP3A4-Eplerenone B-drug B-drug
metabolism O O
is O O
predominantly O O
mediated O O
via O O
CYP3A4 O O
. O O

Like O O
isoflurane B-drug B-drug
, O O
desflurane B-drug B-drug
does O O
not O O
predispose O O
to O O
premature O O
ventricular O O
arrhythmias O O
in O O
the O O
presence O O
of O O
exogenously O O
infused O O
epinephrine B-drug B-drug
in O O
swine O O
. O O

( O O
May O O
inhibit O O
gastrointestinal O O
absorption O O
of O O
the O O
thiazide B-group B-group
diuretics I-group I-group
; O O

No O O
dose O O
adjustment O O
of O O
SUSTIVA B-brand B-brand
is O O
recommended O O
when O O
given O O
with O O
clarithromycin B-drug B-drug
. O O

By O O
contrast O O
, O O
spermidine B-drug_n B-drug
( O O
1 O O
mM O O
) O O
and O O
putrescine B-drug_n B-drug
( O O
1 O O
mM O O
) O O
had O O
no O O
significant O O
effect O O
on O O
the O O
translocation O O
when O O
added O O
alone O O
. O O

Antidepressants B-group B-group
: O O
In O O
vitro O O
data O O
indicate O O
that O O
nefazodone B-drug O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
, O O
which O O
can O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
cisapride B-drug B-drug
levels O O
and O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

In O O
this O O
study O O
we O O
investigated O O
whether O O
also O O
glycine B-drug B-drug
fulfils O O
the O O
function O O
as O O
co-activator O O
in O O
glutamatergic O O
activation O O
of O O
NMDA O O
receptors O O
in O O
the O O
neuronal O O
apparatus O O
of O O
spontaneous O O
motility O O
in O O
chick O O
embryos O O
. O O

Treatment O O
of O O
RAS-3T3 O O
cells O O
with O O
nucleophosmin/B23 O O
antisense O O
oligomer O O
significantly O O
potentiated O O
the O O
apoptosis O O
induced O O
by O O
serum O O
deprivation O O
. O O

However O O
, O O
when O O
addiction O O
is O O
defined O O
as O O
compulsion O O
, O O
loss O O
of O O
control O O
and O O
continued O O
use O O
in O O
spite O O
of O O
adverse O O
consequences O O
, O O
cocaine B-drug B-drug
drug O O
hunger O O
can O O
be O O
seen O O
as O O
an O O
agent O O
of O O
addictive O O
disease O O
. O O

Micro-dosed O O
Progesterone B-drug B-drug
Preparations O O
: O O
Micro-dosed O O
progesterone B-drug B-drug
preparations O O
( O O
minipills O O
that O O
do O O
not O O
contain O O
an O O
estrogen B-group B-group
) O O
may O O
be O O
an O O
inadequate O O
method O O
of O O
contraception O O
during O O
Accutane B-brand B-brand
therapy O O
. O O

. O O

The O O
use O O
of O O
NUROMAX B-brand B-brand
before O O
succinylcholine B-drug B-drug
to O O
attenuate O O
some O O
of O O
the O O
side O O
effects O O
of O O
succinylcholine B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

Drug-drug O O
interactions O O
with O O
Mefloquine B-drug B-drug
have O O
not O O
been O O
explored O O
in O O
detail O O
. O O

indinavir I-drug B-drug
concentration O O

Dopamine-induced B-drug B-drug
renal O O
and O O
mesenteric O O
vasodilation O O
is O O
not O O
antagonized O O
by O O
either O O
alpha- O B-drug
or O O
beta-adrenergic B-group B-group
blocking B-drug I-group
agents I-drug I-group
. O O

These O O
results O O
suggest O O
that O O
acute O O
dosing O O
with O O
clozapine B-drug B-drug
would O O
not O O
affect O O
behaviors O O
most O O
closely O O
associated O O
with O O
PCP B-drug_n B-drug_n
intoxication O O
. O O

In O O
clinical O O
trials O O
, O O
similar O O
changes O O
in O O
carbamazepine B-drug B-drug
and O O
carbamazepine B-drug_n B-drug
epoxide I-drug_n I-drug
were O O
seen O O
. O O

However O O
, O O
it O O
has O O
been O O
established O O
that O O
acitretin B-drug B-drug
interferes O O
with O O
the O O
contraceptive O O
effect O O
of O O
microdosed O B-drug
progestin B-drug I-drug
minipill O O
preparations O O
. O O

quinidine B-drug B-drug
; O O

Statistically O O
significant O O
changes O O
in O O
prothrombin O O
and O O
partial O O
thromboplastin O O
times O O
have O O
been O O
reported O O
in O O
normal O O
volunteers O O
. O O

Persons O O
taking O O
most O O
antibiotics B-group B-group
, O O
methotrexate B-drug B-drug
and O O
pyrimethamine B-drug B-drug
invalidate O O
folic B-drug B-drug
acid I-drug I-drug
and O O
vitamin B-drug B-drug
B12 I-drug I-drug
diagnostic O O
blood O O
assays O O
. O O

Other O O
plasma O O
proteins O O
may O O
be O O
increased O O
( O O
angiotensinogen/renin O O
substrate O O
, O O
alpha-1-antitrypsin O B-drug_n
, O O
ceruloplasmin O B-drug
) O O
. O O

use O O
caution O O
. O O

DRUG/LABORATORY O O
TEST O O
INTERACTIONS O O
: O O
EFFECT O O
ON O O
BLOOD O O
COAGULATION O O
Ketoprofen B-drug B-drug
decreases O O
platelet O O
adhesion O O
and O O
aggregation O O
. O O

Even O O
when O O
an O O
aminoglycoside B-group B-group
and O O
a O O
penicillin-type B-group B-group
drug O I-group
are O O
administered O O
separately O O
by O O
different O O
routes O O
, O O
a O O
reduction O O
in O O
aminoglycoside B-group B-group
serum O O
half-life O O
or O O
serum O O
levels O O
has O O
been O O
reported O O
in O O
patients O O
with O O
impaired O O
renal O O
function O O
and O O
in O O
some O O
patients O O
with O O
normal O O
renal O O
function O O
. O O

Therefore O O
, O O
administration O O
of O O
quinolones B-group B-group
with O O
antacids B-group B-group
containing O O
calcium B-drug B-drug
, O O
magnesium B-drug B-drug
, O O
or O O
aluminum B-drug B-drug
; O O

Substances O O
that O O
are O O
potent O O
inhibitors O O
of O O
CYP3A4 O O
activity O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
and O O
itraconazole B-drug B-drug
) O O
decrease O O
gefitinib B-drug B-drug
metabolism O O
and O O
increase O O
gefitinib B-drug B-drug
plasma O O
concentrations O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
: O O
concurrent O O
use O O
may O O
blunt O O
the O O
response O O
to O O
arbutamine B-drug B-drug
. O O

2 O O
. O O

Rifampin B-drug B-drug
: O O
Co-administration O O
of O O
VIOXX B-brand B-brand
with O O
rifampin B-drug B-drug
600 O O
mg O O
daily O O
, O O
a O O
potent O O
inducer O O
of O O
hepatic O O
metabolism O O
, O O
produced O O
an O O
approximate O O
50 O O
% O O
decrease O O
in O O
rofecoxib B-drug B-drug
plasma O O
concentrations O O
. O O

Certain O O
endocrine O O
and O O
liver O O
function O O
tests O O
may O O
be O O
affected O O
by O O
estrogen-containing B-group B-group
oral O I-group
contraceptives B-group I-group
. O O

Caution O O
should O O
be O O
exercised O O
with O O
simultaneous O O
use O O
of O O
clonidine B-drug B-drug
and O O
other O O
similar O O
pharmacologic O O
agents O O

Aspirin B-brand B-brand
: O O
Concomitant O O
administration O O
of O O
low-dose O O
aspirin B-brand B-brand
with O O
VIOXX B-brand B-brand
may O O
result O O
in O O
an O O
increased O O
rate O O
of O O
GI O O
ulceration O O
or O O
other O O
complications O O
, O O
compared O O
to O O
use O O
of O O
VIOXX B-brand B-brand
alone O O
. O O

Although O O
additional O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
, O O
the O O
most O O
common O O
medications O O
used O O
concomitantly O O
with O O
anagrelide B-drug B-drug
in O O
clinical O O
trials O O
were O O
aspirin B-brand B-brand
, O O
acetaminophen B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
iron B-drug B-drug
, O O
ranitidine B-drug B-drug
, O O
hydroxyurea B-drug B-drug
, O O
and O O
allopurinol B-drug B-drug
. O O

Drug O O
Class O O
: O O
Drug O O
Name O O
Clinical O O
Comment O O

VIRACEPT B-brand B-brand
and O O
rifampin B-drug B-drug
should O O
not O O
be O O
coadministered O O
. O O

Potential O O
Terfenadine B-drug B-drug
, O O
Astemizole B-drug B-drug
, O O
and O O
Cisapride B-drug B-drug
Interactions O O

The O O
pharmacokinetics O O
of O O
praziquantel B-drug B-drug
were O O
unchanged O O
following O O
coadministration O O
with O O
albendazole B-drug B-drug
( O O
400 O O
mg O O
) O O
. O O

- O O
Reduced O O
serum O O
folate O O
concentration O O

Concurrent O O
administration O O
of O O
dyphylline B-drug B-drug
and O O
probenecid B-drug B-drug
, O O
which O O
competes O O
for O O
tubular O O
secretion O O
, O O
has O O
been O O
shown O O
to O O
increase O O
the O O
plasma O O
half-life O O
of O O
dyphylline B-drug B-drug
. O O

H-2 O B-group
Antagonists O I-group
: O O
In O O
studies O O
with O O
human O O
volunteers O O
, O O
co-administration O O
of O O
cimetidine B-drug B-drug
or O O
ranitidine B-drug B-drug
with O O
ibuprofen B-drug B-drug
had O O
no O O
substantive O O
effect O O
on O O
ibuprofen B-drug B-drug
serum O O
concentrations O O
. O O

dextran B-drug B-drug
; O O

Caution O O
should O O
be O O
exercised O O
when O O
administering O O
nabumetone B-drug B-drug
with O O
warfarin B-drug B-drug
since O O
interactions O O
have O O
been O O
seen O O
with O O
other O O
NSAIDs B-group B-group
. O O

Drugs O O
that O O
reportedly O O
may O O
increase O O
oral O O
anticoagulant B-group B-group
response O O
, O O
ie O O
, O O
increased O O
prothrombin O O
response O O
, O O
in O O
man O O
include O O
: O O
alcohol* B-drug B-drug
; O O
allopurinol B-drug B-drug
; O O
aminosalicylic B-drug B-drug
acid I-drug I-drug
; O O
amiodarone B-drug B-drug
; O O
anabolic B-group B-group
steroids I-group I-group
; O O
antibiotics B-group B-group
; O O
bromelains B-drug B-group
; O O
chloral B-drug B-drug
hydrate* O O
; O O
chlorpropamide B-drug B-drug
; O O
chymotrypsin B-drug B-drug
; O O
cimetidine B-drug B-drug
; O O
cinchophen B-drug B-drug
; O O
clofibrate B-drug B-drug
; O O
dextran B-drug B-drug
; O O
dextrothyroxine B-drug B-drug
; O O
diazoxide B-drug B-drug
; O O
dietary O O
deficiencies O O
; O O
diflunisal B-drug B-drug
; O O
disulfiram B-drug B-drug
; O O
drugs O O
affecting O O
blood O O
elements O O
; O O
ethacrynic B-drug B-drug
acid I-drug I-drug
; O O
fenoprofen B-drug B-drug
; O O
glucagon B-drug B-drug
; O O
hepatotoxic O O
drugs O O
; O O
ibuprofen B-drug B-drug
; O O
indomethacin B-drug B-drug
; O O
influenza B-group B-group
virus I-group I-group
vaccine I-group I-group
; O O
inhalation O O
anesthetics B-group B-group
; O O
mefenamic B-drug B-drug
acid I-drug I-drug
; O O
methyldopa B-drug B-drug
; O O
methylphenidate B-drug B-drug
; O O
metronidazole B-drug B-drug
; O O
miconazole B-drug B-drug
; O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
; O O
nalidixic B-drug B-drug
acid I-drug I-drug
; O O
naproxen B-drug B-drug
; O O
oxolinic B-drug B-drug
acid I-drug I-drug
; O O
oxyphenbutazone B-drug B-drug
; O O
pentoxifylline B-drug B-drug
; O O
phenylbutazone B-drug B-drug
; O O
phenyramidol B-drug_n B-drug
; O O
phenytoin B-drug B-drug
; O O
prolonged O O
hot O O
weather O O
; O O
prolonged B-group B-group
narcotics I-group I-group
; O O
pyrazolones B-group B-group
; O O
quinidine B-drug B-drug
; O O
quinine B-drug B-drug
; O O
ranitidine* B-drug B-drug
; O O
salicylates B-group B-group
; O O
sulfinpyrazone B-drug B-drug
; O O
sulfonamides B-group B-group
, O O
long O O
acting O O
; O O
sulindac B-drug B-drug
; O O
thyroid B-group B-group
drugs I-group I-group
; O O
tolbutamide B-drug B-drug
; O O
triclofos B-drug B-drug
sodium I-drug I-drug
; O O
trimethoprim/sulfamethoxazole B-drug B-drug
; O O
unreliable O O
prothrombin O O
time O O
determinations O O
; O O
warfarin B-drug B-drug
sodium I-drug I-drug
overdosage O O
. O O

Nephrotoxicity O O
frequently O O
limits O O
the O O
dose O O
of O O
cisplatin B-drug B-drug
to O O
less O O
than O O
120 O O
mg/m2 O O
per O O
injection O O
. O O

If O O
isradipine B-drug B-drug
therapy O O
is O O
initiated O O
in O O
a O O
patient O O
currently O O
receiving O O
cimetidine B-drug B-drug
careful O O
monitoring O O
for O O
adverse O O
reactions O O
is O O
advised O O
and O O
downward O O
dose O O
adjustment O O
may O O
be O O
required O O
. O O

Long O O
Acting O O
Nitrates B-group B-group
: O O
Nifedipine B-drug B-drug
may O O
be O O
safely O O
co-administered O O
with O O
nitrates B-group B-group
, O O
but O O
there O O
have O O
been O O
no O O
controlled O O
studies O O
to O O
evaluate O O
the O O
antianginal O O
effectiveness O O
of O O
this O O
combination O O
. O O

These O O
steps O O
include O O
regular O O
reevaluations O O
of O O
dosages O O
and O O
plasma O O
drug O O
concentrations O O
, O O
recognition O O
and O O
understanding O O
of O O
drug O O
side O O
effects O O
, O O
and O O
avoidance O O
of O O
certain O O
agents O O
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-group B-group
concomitantly O O
with O O
ACE B-group B-group
inhibitors I-group I-group
. O O

In O O
addition O O
, O O
based O O
on O O
the O O
population O O
pharmacokinetics O O
analysis O O
of O O
the O O
combined O O
data O O
from O O
grapefruit O O
and O O
orange O O
juices O O
studies O O
with O O
the O O
data O O
from O O
a O O
bioequivalence O O
study O O
, O O
the O O
bioavailability O O
of O O
fexofenadine B-drug B-drug
was O O
reduced O O
by O O
36 O O
% O O
. O O

Agents O O
that O O
Induce O O
Cytochrome O O
P450 O O
Isoenzymes O O
Carbamazepine B-drug B-drug
is O O
metabolized O O
by O O
CYP3A4 O O
. O O

All O O
77 O O
strains O O
of O O
Staphylococcus O O
aureus O O
, O O
Diplococcus O O
pneumoniae O O
, O O
Streptococcus O O
pyogenes O O
, O O
and O O
anaerobic O O
bacteria O O
( O O
except O O
for O O
three O O
strains O O
of O O
Clostridium O B-drug_n
) O O
were O O
inhibited O O
by O O
1.6 O O
mug O O
or O O
less O O
of O O
clindamycin B-drug B-drug
per O O
ml O O
. O O

Several O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
to O O
block O O
the O O
pharmacologic O O
effects O O
of O O
guanethidine B-drug B-drug
, O O
clonidine B-drug B-drug
, O O
or O O
similar O O
agents O O
, O O
and O O
such O O
an O O
effect O O
may O O
be O O
anticipated O O
with O O
CMI B-drug B-drug
because O O
of O O
its O O
structural O O
similarity O O
to O O
other O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

The O O
consumption O O
of O O
alcohol B-drug B-drug
during O O
treatment O O
with O O
WELLBUTRIN B-brand B-brand
should O O
be O O
minimized O O
or O O
avoided O O
( O O
also O O
see O O
a O O
href= O O
bupropz_od.htm O O
# O O
CI O O
CONTRAINDICATIONS O O
) O O

Intravenous O O
infusion O O
of O O
iloprost B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

Zalcitabine B-drug B-drug
also O O
has O O
no O O
significant O O
effect O O
on O O
the O O
intracellular O O
phosphorylation O O
of O O
ZDV B-drug B-drug_n
, O O
as O O
shown O O
in O O
vitro O O
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
or O O
in O O
two O O
other O O
cell O O
lines O O
( O O
U937 O O
and O O
Molt-4 O O
) O O
. O O

- O O
Mercaptopurine B-drug B-drug
( O O
e.g. O O
, O O
Purinethol B-brand B-brand
) O O
or O O

Therefore O O
, O O
patients O O
under O O
methotrexate B-drug B-drug
therapy O O
should O O
be O O
carefully O O
monitored O O
when O O
concomitant O O
ciprofloxacin B-drug B-drug
therapy O O
is O O
indicated O O
. O O

Additionally O O
, O O
aripiprazole B-drug B-drug
and O O
dehydroaripiprazole B-drug_n B-drug
did O O
not O O
show O O
potential O O
for O O
altering O O
CYP1A2-mediated O O
metabolism O O
in O O
vitro O O
. O O

75 O O
years O O
of O O
age O O
. O O

The O O
use O O
of O O
FLUDARA B-brand B-brand
FOR O O
INJECTION O O
in O O
combination O O
with O O
pentostatin B-drug B-drug
is O O
not O O
recommended O O
due O O
to O O
the O O
risk O O
of O O
severe O O
pulmonary O O
toxicity O O
. O O

The O O
homodimeric O O
disintegrin O O
contortrostatin B-drug_n B-drug_n
was O O
compared O O
directly O O
to O O
the O O
monomeric O O
disintegrins O O
echistatin B-drug_n B-drug_n
and O O
flavoridin B-drug_n B-drug_n
for O O
the O O
ability O O
to O O
affect O O
protein O O
tyrosine O O
phosphorylation O O
in O O
tumor O O
cells O O
. O O

Extreme O O
caution O O
should O O
be O O
exercised O O
when O O
administering O O
TAXOL B-brand B-brand
to O O
such O O
patients O O
, O O
with O O
dose O O
reduction O O
as O O
recommended O O
in O O
DOSAGE O O
AND O O
ADMINISTRATION O O
, O O
Table O O
17 O O
. O O

The O O
carcinogenic O O
potential O O
of O O
ribavirin B-drug B-drug
has O O
not O O
been O O
fully O O
determined O O
. O O

Warfarin B-drug B-drug
: O O
Quinolones B-group B-group
may O O
enhance O O
the O O
effects O O
of O O
the O O
oral O O
anticoagulant B-group B-group
, O O
warfarin B-drug B-drug
, O O
or O O
its O O
derivatives O O
. O O

however O O
, O O
it O O
is O O
considered O O
to O O
be O O
unlikely O O
that O O
this O O
decrease O O
of O O
phosphorylated O O
lamivudine B-drug B-drug
concentration O O
is O O
of O O
clinical O O
significance O O
, O O
as O O
lamivudine B-drug B-drug
is O O
a O O
more O O
efficient O O
substrate O O
for O O
deoxycytidine O O
kinase O O
than O O
zalcitabine B-drug B-drug
. O O

Therefore O O
, O O
when O O
EDECRIN B-brand B-brand
and O O
non- B-group B-group
steroidal I-group I-group
anti- I-group I-group
inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O

Cardiovascular O O
disease O O
is O O
considered O O
in O O
the O O
next O O
chapter O O
, O O
and O O
chapter O O
7 O O
presents O O
findings O O
on O O
endometrial O O
, O O
ovarian O O
, O O
cervical O O
, O O
breast O O
, O O
and O O
other O O
cancers O O
. O O

aeruginosa O O
as O O
common O O
pathogens O O
of O O
drug O O
addicts O O
in O O
areas O O
where O O
abuse O O
of O O
this O O
combination O O
of O O
drugs O O
has O O
increased O O
. O O

Antihypertensive B-group B-group
Medications O I-group
and O O
Vasodilators B-group B-group
: O O
The O O
following O O
adverse O O
events O O
were O O
experienced O O
more O O
commonly O O
in O O
patients O O
receiving O O
concomitant O O
antihypertensive B-group B-group
medications I-group I-group
or O O
vasodilators B-group B-group
( O O
n O O
= O O
94 O O
) O O
compared O O
to O O
patients O O
not O O
receiving O O
these O O
concomitant O O
drugs O O
( O O
n O O
= O O
456 O O
) O O
: O O
hypotension O O
10 O O
% O O
vs O O
4 O O
% O O
, O O
myocardial O O
infarction O O
3 O O
% O O
vs O O
1 O O
% O O
, O O
serious O O
pneumonia O O
5 O O
% O O
vs O O
3 O O
% O O
, O O
serious O O
falls O O
9 O O
% O O
vs O O
3 O O
% O O
, O O
and O O
bone O O
and O O
joint O O
injuries O O
6 O O
% O O
vs O O
2 O O
% O O
. O O

Antacids B-group B-group
( O O
aluminum- B-drug B-drug
or O O
magnesium-containing B-drug B-drug
) O O
: O O
Concomitant O O
administration O O
of O O
300-mg O O
cefdinir B-drug B-drug
capsules O O
with O O
30 O O
mL O O
Maalox B-brand B-brand
TC I-brand I-brand
suspension O O
reduces O O
the O O
rate O O
( O O
Cmax O O
) O O
and O O
extent O O
( O O
AUC O O
) O O
of O O
absorption O O
by O O
approximately O O
40 O O
% O O
. O O

Acetazolamide B-drug B-drug
may O O
increase O O
or O O
decrease O O
blood O O
glucose O O
levels O O
. O O

Etodolac B-drug B-drug
is O O
characterised O O
by O O
a O O
high O O
oral O O
bioavailability O O
, O O
low O O
clearance O O
, O O
a O O
small O O
volume O O
of O O
distribution O O
, O O
and O O
a O O
7-hour O O
half-life O O
. O O

Antacids B-group B-group
or O O
sucralfate B-drug B-drug
substantially O O
interfere O O
with O O
the O O
absorption O O
of O O
some O O
quinolones B-group B-group
, O O
resulting O O
in O O
low O O
urine O O
levels O O
. O O

amiodarone B-drug B-drug
; O O

Effects O O
of O O
GABITRIL B-brand B-brand
on O O
other O O
Antiepilepsy O B-group
Drugs O I-group
( O O
AEDs B-group B-group
) O O
: O O
Phenytoin B-drug B-drug
: O O
Tiagabine B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
steady-state O O
plasma O O
concentrations O O
of O O
phenytoin B-drug B-drug
in O O
patients O O
with O O
epilepsy O O
. O O

It O O
is O O
not O O
known O O
whether O O
AMEVIVE B-brand B-brand
is O O
excreted O O
in O O
human O O
milk O O
. O O

When O O
prescribing O O
for O O
older O O
patients O O
, O O
some O O
physicians O O
are O O
overly O O
cautious O O
, O O
and O O
this O O
strategy O O
can O O
result O O
in O O
a O O
less O O
than O O
optimal O O
treatment O O
outcome O O
. O O

Long-term O O
studies O O
are O O
needed O O
to O O
determine O O
whether O O
the O O
insulin-sensitizing O O
effects O O
of O O
the O O
glitazones B-group B-group
can O O
prevent O O
or O O
delay O O
premature O O
atherosclerotic O O
cardiovascular O O
disease O O
, O O
morbidity O O
, O O
and O O
death O O
. O O

. O O

Low O O
initial O O
dosing O O
and O O
small O O
gradual O O
dose O O
increases O O
should O O
be O O
employed O O
. O O

Etodolac B-drug B-drug
is O O
highly O O
protein O O
bound O O
. O O

Caution O O
should O O
be O O
used O O
when O O
coadministering O O
medications O O
that O O
are O O
substrates O O
, O O
inhibitors O O
, O O
or O O
inducers O O
of O O
CYP3A4 O O
, O O
or O O
potentially O O
toxic O O
medications O O
that O O
are O O
metabolized O O
by O O
CYP3A4 O O
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCAtreatment B-group B-brand
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

In O O
some O O
cases O O
where O O
serious O O
ventricular O O
arrhythmias O O
, O O
QT O O
prolongation O O
, O O
and O O
torsades O O
de O O
pointes O O
have O O
occurred O O
when O O
cisapride B-drug B-drug
was O O
taken O O
in O O
conjunction O O
with O O
one O O
of O O
the O O
cytochrome O O
P450 O O
3A4 O O
inhibitors O O
, O O
elevated O O
blood O O
cisapride B-drug B-drug
levels O O
were O O
noted O O
at O O
the O O
time O O
of O O
the O O
QT O O
prolongation O O
. O O

After O O
stopping O O
Fluvoxamine B-drug B-drug
Tablets O O
, O O
at O O
least O O
2 O O
weeks O O
should O O
be O O
allowed O O
before O O
starting O O
a O O
MAOI B-group B-group
. O O

cardiovascular O O
effects O O
can O O
be O O
potentiated O O
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
tests O O
should O O
be O O
closely O O
monitored O O
. O O

These O O
results O O
, O O
together O O
with O O
the O O
known O O
relationships O O
between O O
estrogen B-group B-group
and O O
the O O
immune O O
response O O
, O O
suggest O O
that O O
estrogens B-group B-group
affect O O
the O O
course O O
of O O
septic O O
shock O O
in O O
a O O
complex O O
fashion O O
and O O
may O O
have O O
either O O
protective O O
or O O
deleterious O O
effect O O
. O O

Warfarin B-drug B-drug
: O O
When O O
fluvoxamine B-drug B-drug
maleate I-drug I-drug
( O O
50 O O
mg O O
tid O O
) O O
was O O
administered O O
concomitantly O O
with O O
warfarin B-drug B-drug
for O O
two O O
weeks O O
, O O
warfarin B-drug B-drug
plasma O O
concentrations O O
increased O O
by O O
98 O O
% O O
and O O
prothrombin O O
times O O
were O O
prolonged O O
. O O

Nonketotic O B-group
, O O
genetically O O
diabetic O O
Cinese O O
hamsters O O
show O O
subnormal O O
pancreatic O O
insulin O O
release O O
and O O
impaired O O
suppression O O
of O O
glucagon O O
in O O
response O O
to O O
glucose O B-drug
. O O

If O O
a O O
patient O O
requires O O
TIKOSYN B-brand B-brand
and O O
anti-ulcer B-group O
therapy O O
, O O
it O O
is O O
suggested O O
that O O
omeprazole B-drug B-drug
, O O
ranitidine B-drug B-drug
, O O
or B-drug O
antacids B-group B-group
( O O
aluminum O B-drug
and O O
magnesium B-drug B-drug
hydroxides O I-drug
) O O
be O O
used O O
as O O
alternatives O O
to O O
cimetidine B-drug B-drug
, O O
as O O
these O O
agents O O
have O O
no O O
effect O O
on O O
the O O
pharmacokinetic O O
profile O O
of O O
TIKOSYN B-brand B-brand
. O O

Altered O O
mental O O
status O O
in O O
an O O
adolescent O O
presents O O
a O O
diagnostic O O
challenge O O
, O O
and O O
the O O
clinician O O
depends O O
on O O
clinical O O
evaluation O O
and O O
laboratory O O
studies O O
to O O
determine O O
therapy O O
and O O
prognosis O O
. O O

This O O
increased O O
incidence O O
of O O
atherosclerotic O O
disease O O
is O O
intricately O O
associated O O
with O O
insulin O B-drug
resistance O O
, O O
which O O
is O O
a O O
major O O
pathophysiologic O O
abnormality O O
in O O
type O O
2 O O
diabetes O O
. O O

Twenty-four O O
h O O
exposures O O
of O O
fully O O
formed O O
cysts O O
had O O
no O O
effect O O
on O O
excystment O O
in O O
vitro O O
. O O

Co-administration O O
of O O
atorvastatin B-drug B-drug
resulted O O
in O O
about O O
a O O
50 O O
% O O
increase O O
in O O
aliskiren B-drug B-drug
Cmax O O
and O O
AUC O O
after O O
multiple O O
dosing O O
. O O

The O O
clinical O O
relevance O O
of O O
this O O
in O O
vitro O O
finding O O
is O O
unknown O O
. O O

As O O
with O O
other O O
antipsychotic B-group B-group
agents I-group I-group
, O O
it O O
should O O
be O O
noted O O
that O O
HALDOL B-brand B-brand
may O O
be O O
capable O O
of O O
potentiating O B-group
CNS B-group I-group
depressants I-group I-group
such O O
as O O
anesthetics B-group B-group
, O O
opiates B-group B-group
, O O
and O O
alcohol B-drug B-drug
. O O

Clinical O O
trials O O
of O O
such O O
combinations O O
should O O
be O O
accompanied O O
by O O
detailed O O
pharmacokinetic O O
evaluation O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
should O O
be O O
withdrawn O O
at O O
least O O
48 O O
hours O O
before O O
conducting O O
an O O
arbutamine-mediated B-drug O
stress O O
test O O
. O O

Of O O
the O O
remaining O O
cases O O
, O O
two O O
were O O
cardiac O O
, O O
two O O
hepatic O O
and O O
the O O
rest O O
were O O
mixed O O
drug O O
overdose O O
. O O

Loop B-group B-group
Diuretics I-group I-group
: O O
Furosemide B-drug B-drug
administered O O
concurrently O O
with O O
captopril B-drug B-drug
does O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
captopril B-drug B-drug
in O O
renally O O
impaired O O
hypertensive O O
patients O O
. O O

Preliminary O O
data O O
which O O
suggest O O
that O O
dapsone B-drug B-drug
may O O
inhibit O O
the O O
anti-inflammatory O O
activity O O
of O O
Lamprene B-brand B-brand
have O O
not O O
been O O
confirmed O O
. O O

Other O O
drugs O O
which O O
may O O
enhance O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
nondepolarizing O B-group
agents O I-group
such O O
as O O
NUROMAX B-brand B-brand
include O O
certain O O
antibiotics B-group B-group
( O O
e. O O
g. O O
, O O
aminoglycosides B-group B-group
, O O
tetracyclines B-group B-group
, O O
bacitracin B-group B-drug
, O O
polymyxins B-group B-group
, O O
lincomycin B-drug B-drug
, O O
clindamycin B-drug B-drug
, O O
colistin B-drug B-drug
, O O
and O O
sodium B-drug B-drug
colistimethate I-drug I-drug
) O O
, O O
magnesium B-drug B-drug
salts O O
, O O
lithium B-drug B-drug
, O O
local O O
anesthetics B-group B-group
, O O
procainamide B-drug B-drug
, O O
and O O
quinidine B-drug B-drug
. O O

No O O
differences O O
in O O
adverse O O
events O O
or O O
QTc O O
interval O O
were O O
observed O O
when O O
subjects O O
were O O
administered O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
alone O O
or O O
in O O
combination O O
with O O
either O O
erythromycin B-drug B-drug
or O O
ketoconazole B-drug B-drug
. O O

Ergotamine B-drug B-drug

Aminosalicylic B-drug B-drug
acid I-drug I-drug
may O O
also O O
decrease O O
the O O
absorption O O
of O O
vitamin B-drug B-drug
B12 I-drug I-drug
, O O
which O O
can O O
lead O O
to O O
a O O
deficiency O O
. O O

Increasing O O
the O O
felbamate B-drug B-drug
dose O O
to O O
2400 O O
mg/day O O
increased O O
the O O
steadystate O O
valproate B-drug B-drug
Cmin O O
to O O
96 O O
25 O O
micrograms/mL O O
. O O

St. O O
John O O
s O O
Wort O O
should O O
be O O
avoided O O
while O O
taking O O
this O O
medicine O O
due O O
to O O
the O O
additive O O
effects O O
of O O
serotonin O O
. O O

Accordingly O O
, O O
careful O O
patient O O
monitoring O O
and O O
dose O O
adjustment O O
of O O
metformin B-drug B-drug
is O O
recommended O O
in O O
patients O O
concomitantly O O
taking O O
cephalexin B-drug B-drug
and O O
metformin B-drug B-drug
. O O

Read O O
circulars O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
concomitant O O
therapy O O
. O O

In O O
two O O
controlled O O
crossover O O
clinical O O
pharmacology O O
studies O O
in O O
healthy O O
male O O
( O O
n=12 O O
in O O
each O O
study O O
) O O
a O O
nd O O
female O O
( O O
n=12 O O
in O O
each O O
study O O
) O O
volunteers O O
, O O
desloratadine B-drug B-drug
7.5 O O
mg O O
( O O
1.5 O O
times O O
the O O
daily O O
dose O O
) O O
once O O
daily O O
was O O
coadministered O O
with O O
erythromycin B-drug B-drug
500 O O
mg O O
every O O
8 O O
hours O O
or O O
ketoconazole B-drug B-drug
200 O O
mg O O
every O O
12 O O
hours O O
for O O
10 O O
days O O
. O O

reproductive O O
tract O O
infections O O
; O O

If O O
iron B-group B-drug
supplements I-group O
are O O
required O O
during O O
OMNICEF B-brand B-brand
therapy O O
, O O
OMNICEF B-brand B-brand
should O O
be O O
taken O O
at O O
least O O
2 O O
hours O O
before O O
or O O
after O O
the O O
supplement O O
. O O

Women O O
of O O
childbearing O O
potential O O
make O O
up O O
a O O
considerable O O
segment O O
of O O
the O O
patient O O
population O O
affected O O
by O O
psoriasis O O
. O O

Generally O O
, O O
this O O
phenomenon O O
has O O
not O O
been O O
associated O O
with O O
other O O
clinically O O
significant O O
events O O
. O O

. O O

Methotrexate B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
methotrexate B-drug B-drug
and O O
some O O
NSAIDs B-group B-group
has O O
been O O
reported O O
to O O
reduce O O
the O O
clearance O O
of O O
methotrexate B-drug B-drug
, O O
enhancing O O
the O O
toxicity O O
of O O
methotrexate B-drug B-drug
. O O

Digitalis B-group B-group
: O O
Vitamin B-group B-group
D I-group I-group
dosage O O
must O O
be O O
determined O O
with O O
care O O
in O O
patients O O
undergoing O O
treatment O O
with O O
digitalis B-group B-group
, O O
as O O
hypercalcemia O O
in O O
such O O
patients O O
may O O
precipitate O O
cardiac O O
arrhythmias O O
. O O

include O O
terfenadine B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
cisapride B-drug B-drug
, O O
midazolam B-drug B-drug
, O O
and O O
triazolam B-drug B-drug
. O O

Stimulation O O
of O O
the O O
glands O O
with O O
carbachol B-drug B-drug
synergistically O O
augmented O O
the O O
response O O
to O O
dibutyryl O O
cAMP O O
. O O

There O O
were O O
no O O
clinically O O
significant O O
drug O O
interactions O O
for O O
any O O
of O O
these O O
drugs O O

Caution O O
should O O
be O O
observed O O
when O O
anileridine B-drug B-drug
is O O
coadministered O O
with O O
other O O
opioids B-group B-group
, O O
sedatives B-group B-group
, O O
phenothiazines B-group B-group
, O O
or O O
anesthetics B-group B-group
, O O
as O O
these O O
agents O O
may O O
increase O O
respiratory O O
and O O
circulatory O O
depression O O
. O O

However O O
, O O
no O O
adverse O O
effects O O
on O O
fertility O O
were O O
observed O O
in O O
male O O
Rhesus O O
monkeys O O
treated O O
with O O
non-pegylated B-drug O
interferon I-drug B-drug
alfa-2a I-drug I-drug
for O O
5 O O
months O O
at O O
doses O O
up O O
to O O
25 O O
x O O
106 O O
IU/kg/day O O
. O O

The O O
most O O
potent O O
inhibitory O O
activity O O
was O O
observed O O
for O O
vardenafil O B-drug
metabolite O O
M1 O O
, O O
which O O
had O O
a O O
Ki O O
of O O
1.4 O O
uM O O
toward O O
CYP3A4 O O
, O O
which O O
is O O
about O O
20 O O
times O O
higher O O
than O O
the O O
M1 O O
Cmax O O
values O O
after O O
an O O
80 O O
mg O O
Vardenafil B-drug B-drug
dose O O
. O O

This O O
effect O O
did O O
not O O
depend O O
on O O
the O O
order O O
of O O
application O O
of O O
the O O
drugs O O
. O O

Tizoxanide B-drug B-drug
is O O
highly O O
bound O O
to O O
plasma O O
protein O O
( O O
99.9 O O
% O O
) O O
. O O

combination O O
therapy O O
is O O
contemplated O O
, O O
the O O
dosage O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

There O O
was O O
no O O
significant O O
difference O O
in O O
the O O
pharmacodynamic O O
effect O O
of O O
warfarin B-drug B-drug
administered O O
alone O O
and O O
warfarin B-drug B-drug
administered O O
with O O
Lodine B-brand B-brand
as O O
measured O O
by O O
prothrombin O O
time O O
. O O

Since O O
the O O
concomitant O O
administration O O
of O O
warfarin B-drug B-drug
with O O
amiodarone B-drug B-drug
increases O O
the O O
prothrombin O O
time O O
by O O
100 O O
% O O
after O O
3 O O
to O O
4 O O
days O O
, O O
the O O
dose O O
of O O
the O O
anticoagulant B-drug B-group
should O O
be O O
reduced O O
by O O
one-third O O
to O O
one-half O O
, O O
and O O
prothrombin O O
times O O
should O O
be O O
monitored O O
closely O O
. O O

The O O
clinical O O
presentation O O
and O O
natural O O
history O O
of O O
neoplasia O O
are O O
also O O
affected O O
by O O
aging O O
. O O

In O O
period O O
A O O
, O O
all O O
volunteers O O
took O O
500 O O
mg O O
of O O
tolbutamide B-drug B-drug
orally O O
. O O

Warfarin B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
daptomycin B-drug B-drug
( O O
6 O O
mg/kg O O
once O O
every O O
24 O O
hours O O
for O O
5 O O
days O O
) O O
and O O
warfarin B-drug B-drug
( O O
25 O O
mg O O
single O O
oral O O
dose O O
) O O
had O O
no O O
significant O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
, O O
and O O
the O O
INR O O
was O O
not O O
significantly O O
altered O O
. O O

ACE-inhibitors B-group B-group
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE-inhibitors B-group B-group
. O O

Caution O O
is O O
recommended O O
during O O
the O O
coadministration O O
of O O
any O O
of O O
these O O
with O O
alprazolam B-drug B-drug
. O O

Metformin B-drug B-drug
: O O
When O O
Starlix B-brand B-brand
120 O O
mg O O
three O O
times O O
daily O O
before O O
meals O O
was O O
administered O O
in O O
combination O O
with O O
metformin B-drug B-drug
500 O O
mg O O
three O O
times O O
daily O O
to O O
patients O O
with O O
Type O O
2 O O
diabetes O O
, O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

. O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
: O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
aucasian O O
population O O
( O O
about O O
7 O O
% O O
-10 O O
% O O
of O O
Caucasians O O
are O O
so-called O O
poor O O
metabolizers O O
) O O
; O O

The O O
clinical O O
significance O O
of O O
these O O
findings O O
has O O
not O O
been O O
established O O
. O O

Administration O O
of O O
1,3-difluoroacetone B-drug_n B-drug_n
( O O
100 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
to O O
rats O O
in O O
vivo O O
resulted O O
in O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
synthesis O O
in O O
the O O
kidney O O
, O O
which O O
was O O
preceded O O
by O O
an O O
elevation O O
in O O
fluoride O O
levels O O
and O O
followed O O
by O O
citrate O O
accumulation O O
. O O

The O O
following O O
are O O
examples O O
of O O
substances O O
that O O
may O O
reduce O O
the O O
blood-glucose-lowering O O
effect O O
: O O
corticosteroids B-group B-group
, O O
niacin B-drug B-drug
, O O
danazol B-drug B-drug
, O O
diuretics B-group B-group
, O O
sympathomimetic B-group B-group
agents I-group I-group
( O O
e.g. O O
, O O
epinephrine B-drug B-drug
, O O
salbutamol B-drug B-drug
, O O
terbutaline B-drug B-drug
) O O
, O O
isoniazid B-drug B-drug
, O O
phenothiazine B-group B-group
derivatives I-group I-group
, O O
somatropin B-drug B-drug
, O O
thyroid B-group B-group
hormones I-group I-group
, O O
estrogens B-group B-group
, O O
progestogens B-group B-group
( O O
e.g. O O
, O O
in O O
oral O O
contraceptives B-group B-group
) O O
. O O

In O O
EMs O O
, O O
selective O O
inhibitors O O
of O O
CYP2D6 O O
increase O O
atomoxetine B-drug B-drug
steady-state O O
plasma O O
concentrations O O
to O O
exposures O O
similar O O
to O O
those O O
observed O O
in O O
PMs O O
. O O

If O O
these O O
preparations O O
have O O
been O O
used O O
it O O
is O O
advisable O O
not O O
to O O
start O O
therapy O O
with O O
DIFFERIN B-brand B-brand
Gel O O
until O O
the O O
effects O O
of O O
such O O
preparations O O
in O O
the O O
skin O O
have O O
subsided O O
. O O

Based O O
on O O
clinical O O
and O O
pharmacokinetic O O
results O O
from O O
the O O
ATAC O O
trial O O
, O O
tamoxifen B-drug B-drug
should O O
not O O
be O O
administered O O
with O O
anastrozole B-drug B-drug
( O O
see O O
CLINICAL O O
PHARMACOLOGY O O
Drug O O
Interactions O O
and O O
CLINICAL O O
PHARMACOLOGY O O
- O O
Clinical O O
Studies O O
- O O
Adjuvant O O
Treatment O O
of O O
Breast O O
Cancer O O
in O O
Postmenopausal O O
Women O O
subsections O O
) O O
. O O

Naproxen B-drug B-drug
may O O
interfere O O
with O O
some O O
urinary O O
assays O O
of O O
5-hydroxy O O
indoleacetic O O
acid O O
( O O
5HIAA O O
) O O
. O O

Chlorpromazine B-drug B-drug
: O O
Chlorpromazine B-drug B-drug
blocks O O
dopamine O B-drug
and O O
norepinephrine O B-drug
receptors O O
, O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-group B-group
and O O
can O O
be O O
used O O
to O O
treat O O
amphetamine B-group B-drug
poisoning O O
. O O

The O O
pharmacokinetic O O
interactions O O
listed O O
below O O
are O O
potentially O O
clinically O O
important O O
. O O

Quinidine B-drug B-drug
: O O
Coadministration O O
of O O
a O O
10-mg O O
single O O
dose O O
of O O
aripiprazole B-drug B-drug
with O O
quinidine B-drug B-drug
( O O
166 O O
mg/day O O
for O O
13 O O
days O O
) O O
, O O
a O O
potent O O
inhibitor O O
of O O
CYP2D6 O O
, O O
increased O O
the O O
AUC O O
of O O
aripiprazole B-drug B-drug
by O O
112 O O
% O O
but O O
decreased O O
the O O
AUC O O
of O O
its O O
active O O
metabolite O O
, O O
dehydroaripiprazole B-drug_n B-drug_n
, O O
by O O
35 O O
% O O
. O O

The O O
effect O O
of O O
clonazepam B-drug B-drug
on O O
the O O
metabolism O O
of O O
other O O
drugs O O
has O O
not O O
been O O
investigated O O
. O O

Patients O O
receiving O O
these O O
drugs O O
who O O
are O O
given O O
Lodine B-brand B-brand
, O O
or O O
any O O
other O O
NSAID B-group B-group
, O O
and O O
particularly O O
those O O
patients O O
with O O
altered O O
renal O O
function O O
, O O
should O O
be O O
observed O O
for O O
the O O
development O O
of O O
the O O
specific O O
toxicities O O
of O O
these O O
drugs O O
. O O

RESULTS O O
: O O
The O O
geometric O O
mean O O
( O O
90 O O
% O O
confidence O O
interval O O
) O O
whole O O
blood O O
sirolimus B-drug B-drug
area O O
under O O
the O O
plasma O O
concentration O O
time-curve O O
increased O O
60 O O
% O O
( O O
35 O O
% O O
-90 O O
% O O
) O O
, O O
from O O
736 O O
to O O
1178 O O
ng O O
x O O
h/mL O O
, O O
and O O
maximum O O
concentration O O
increased O O
43 O O
% O O
( O O
14 O O
% O O
-81 O O
% O O
) O O
, O O
from O O
67 O O
to O O
96 O O
ng/mL O O
, O O
with O O
diltiazem B-drug B-drug
coadministration O O
, O O
whereas O O
the O O
mean O O
elimination O O
half-life O O
of O O
sirolimus B-drug B-drug
decreased O O
slightly O O
, O O
from O O
79 O O
to O O
67 O O
hours O O
. O O

This O O
might O O
be O O
explained O O
by O O
a O O
blockade O O
by O O
probenecid B-drug B-drug
of O O
the O O
elimination O O
of O O
cloxacillin B-drug B-drug
by O O
the O O
liver O O
. O O

*CBZ O B-drug_n
epoxide O I-drug_n

Levothyroxine B-drug B-drug
Sodium I-drug I-drug
Absorption O O
: O O
The O O
following O O
agents O O
may O O
bind O O
and O O
decrease O O
absorption O O
of O O
levothyroxine B-drug B-drug
sodium I-drug I-drug
from O O
the O O
gastrointestinal O O
tract O O
: O O
aluminum B-drug B-drug
hydoxide I-drug I-drug
, O O
cholestyramine B-drug B-drug
resin O I-drug
, O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
, O O
ferrous B-drug B-drug
sulfate I-drug I-drug
, O O
sodium B-drug B-drug
polystyrene I-drug I-drug
sulfonate I-drug I-drug
, O O
soybean O O
flour O O
( O O
e.g. O O
, O O
infant O O
formula O O
) O O
, O O
sucralfate B-drug B-drug
. O O

Fulvestrant B-drug B-drug
was O O
associated O O
with O O
an O O
increased O O
incidence O O
of O O
fetal O O
variations O O
in O O
rabbits O O
( O O
backwards O O
displacement O O
of O O
the O O
pelvic O O
girdle O O
, O O
and O O
27 O O
pre-sacral O O
vertebrae O O
at O O
0.25 O O
mg/kg/day O O
IM O O
; O O

Didanosine B-drug B-drug
: O O
It O O
is O O
recommended O O
that O O
didanosine B-drug B-drug
be O O
administered O O
on O O
an O O
empty O O
stomach O O
; O O

While O O
not O O
systematically O O
studied O O
, O O
certain O O
drugs O O
may O O
induce O O
the O O
metabolism O O
of O O
bupropion B-drug B-drug
( O O
e.g. O O
, O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
) O O
. O O

Changes O O
in O O
the O O
testes O O
and O O
epididymides O O
had O O
not O O
recovered O O
20 O O
weeks O O
after O O
cessation O O
of O O
dosing O O
. O O

The O O
incidence O O
of O O
ARE O O
suddenly O O
exceeded O O
10 O O
% O O
of O O
the O O
patients O O
treated O O
by O O
melarsoprol B-drug B-drug
during O O
August O O
1992 O O
and O O
September O O
1993 O O
. O O

Monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
effects O O
of O O
antihistamines B-group B-group
. O O

Potential O O
for O O
Duloxetine B-drug B-drug
to O O
Affect O O
Other O O
Drugs O O
: O O
Drugs O O
Metabolized O O
by O O
CYP1A2 O O
: O O
In O O
vitro O O
drug O O
interaction O O
studies O O
demonstrate O O
that O O
duloxetine B-drug B-drug
does O O
not O O
induce O O
CYP1A2 O O
activity O O
, O O
and O O
it O O
is O O
unlikely O O
to O O
have O O
a O O
clinically O O
significant O O
effect O O
on O O
the O O
metabolism O O
of O O
CYP1A2 O O
substrates O O
. O O

In O O
a O O
comparison O O
of O O
digitalis B-group B-group
tolerance O O
in O O
dogs O O
anesthetized O O
with O O
ketamine B-drug B-drug
, O O
Innovar B-brand B-brand
Vet I-brand O
, O O
or O O
pentobarbital B-drug B-drug
, O O
the O O
dosage O O
of O O
ouabain B-drug B-drug
needed O O
to O O
cause O O
ventricular O O
tachycardia O O
was O O
significantly O O
higher O O
, O O
as O O
was O O
the O O
LD50 O O
of O O
ouabain B-drug B-drug
, O O
with O O
ketamine B-drug B-drug
or O O
Innovar B-brand B-brand
than O O
with O O
pentobarbital B-drug B-drug
. O O

Should O O
it O O
be O O
decided O O
to O O
discontinue O O
therapy O O
in O O
patients O O
receiving O O
beta-blockers B-group B-group
and O O
clonidine B-drug B-drug
concurrently O O
, O O
the O O
beta-blocker B-group B-group
should O O
be O O
discontinued O O
slowly O O
over O O
several O O
days O O
before O O
the O O
gradual O O
withdrawal O O
of O O
clonidine B-drug B-drug
. O O

Therefore O O
, O O
prothrombin O O
time O O
should O O
be O O
carefully O O
monitored O O
in O O
patients O O
receiving O O
Itraconazole B-drug B-drug
and O O
coumarin-like B-group B-group
drugs O I-group
simultaneously O O
. O O

Few O O
data O O
exist O O
on O O
drug O O
interactions O O
with O O
caffeine B-drug B-drug
in O O
preterm O O
neonates O O
. O O

Ethosuximide B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
ethosuximide B-drug B-drug
. O O

Selective O O
survival O O
in O O
pentazocine B-drug B-drug
and O O
tripelennamine B-drug B-drug
of O O
Pseudomonas O O
aeruginosa O O
serotype O O
O11 O O
from O O
drug O O
addicts O O
. O O

A O O
reduced O O
Clozapine B-drug B-drug
dose O O
should O O
be O O
considered O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
coadministration O O
of O O
TCAs B-group B-group
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

Ergot-Containing B-group O
Drugs I-group O
: O O
These O O
drugs O O
have O O
been O O
reported O O
to O O
cause O O
prolonged O O
vasospastic O O
reactions O O
. O O

Observations O O
from O O
drug O O
interaction O O
studies O O
with O O
FORTOVASE B-brand B-brand
may O O
not O O
be O O
predictive O O
for O O
INVIRASE B-brand B-brand
. O O

Antihistamines B-drug B-group
: O O
astemizole* B-drug B-drug
, O O
terfenadine* B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
cardiac O O
arrhythmias O O
. O O

indinavir I-drug B-drug
concentration O O
ritonavir B-drug B-drug
concentration O O

No O O
data O O
on O O
the O O
level O O
of O O
circulating O O
catecholamines O O
after O O
apraclonidine B-drug B-drug
withdrawal O O
are O O
available O O
. O O

Amiodarone B-drug B-drug
inhibits O O
CYP2D6 B-drug O
. O O

No O O
CNS O O
lesions O O
have O O
been O O
observed O O
in O O
mice O O
after O O
chronic O O
treatment O O
for O O
up O O
to O O
2 O O
years O O
at O O
doses O O
up O O
to O O
400 O O
mg/kg/day O O
or O O
in O O
rats O O
at O O
doses O O
up O O
to O O
100 O O
mg/kg/day O O
. O O

Coadministration O O
of O O
efavirenz B-drug B-drug
with O O
drugs O O
primarily O O
metabolized O O
by O O
these O O
isozymes O O
may O O
result O O
in O O
altered O O
plasma O O
concentrations O O
of O O
the O O
coadministered O O
drug O O
. O O

. O O

Coadministration O O
of O O
VIRACEPT B-brand B-brand
and O O
drugs O O
that O O
inhibit O O
CYP3A O O
may O O
increase O O
nelfinavir B-drug B-drug
plasma O O
concentrations O O
. O O

Changes O O
in O O
hepatic O O
function O O
induced O O
by O O
concomitant O O
therapies O O
may O O
affect O O
epirubicin B-drug B-drug
metabolism O O
, O O
pharmacokinetics O O
, O O
therapeutic O O
efficacy O O
, O O
and/or O O
toxicity O O
. O O

Twitch O O
gradually O O
returned O O
to O O
pre-gentamycin B-drug O
strength O O
over O O
the O O
course O O
of O O
the O O
next O O
hour O O
. O O

